<?xml version="1.0" encoding="UTF-8"?>
<projectSnippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC2386848/results/search/disease/results.xml">
   <result pre="received: 2007-11-27 rev-recd: 2008-3-7 accepted: 2008-3-10 (C) , Abstract Pediatric" exact="migraine" post="is a disabling condition, which can cause a significant"/>
   <result pre="efficacy and tolerability of topiramate in the prophylactic treatment of" exact="migraine" post="in children and adolescents. A total of five papers"/>
   <result pre="we strongly recommend to assess the disability caused by the" exact="migraine" post="episodes before deciding to initiate a prophylactic treatment. Nevertheless,"/>
   <result pre="very low. Keywords Migraine Headache Children Pediatric Topiramate Introduction Pediatric" exact="migraine" post="is a disabling condition, which can cause a significant"/>
   <result pre="10% [ 1]. About 3–5% of school-aged children suffer from" exact="migraine" post="and this proportion gradually increases to 20% through adolescence."/>
   <result pre="which remains through adulthood [ 2, 3]. Management of pediatric" exact="migraine" post="includes lifestyle changes (in order to avoid foods, habits"/>
   <result pre="avoid foods, habits or enviromental factors that may trigger a" exact="migraine" post="attack), the use of abortive medications and preventive measures,"/>
   <result pre="social functioning (including sports) [ 7, 8]. The assessment of" exact="migraine" post="disability is particularly important in children to correctly evaluate"/>
   <result pre="and in many other countries for the preventive treatment of" exact="migraine" post="in adults and for the treatment of partial-onset seizures"/>
   <result pre="efficacy and tolerability of topiramate in the prophylactic treatment of" exact="migraine" post="in children and adolescents. Materials and methods We searched"/>
   <result pre="had been enrolled in three pivotal RCTs of topiramate for" exact="migraine" post="prophylaxis in adults and two open studies. In a"/>
   <result pre="a day) for 12 weeks. Participants had a diagnosis of" exact="migraine" post="without aura (according to 2004 International Headache Society criteria)"/>
   <result pre="Children with comorbid medical associations or who were already on" exact="migraine" post="prophylaxis were excluded. Primary outcome measures were the reduction"/>
   <result pre="prophylaxis were excluded. Primary outcome measures were the reduction in" exact="migraine" post="frequency and severity; secondary outcome measures included number of"/>
   <result pre="The percentage of topiramate-treated subjects showing &amp;gt;50% reduction in monthly" exact="migraine" post="days during the double-blind phase was 95.2% as opposed"/>
   <result pre="This seems a well-performed trial in which the mean monthly" exact="migraine" post="frequency reduction is clearly evident in the topiramate-treated group."/>
   <result pre="household or social activities to a lesser extent than the" exact="migraine" post="episodes. The other Class I, randomized, double-blind, placebo-controlled trial"/>
   <result pre="12 weeks) or placebo. Eligible criteria were the children with" exact="migraine" post="with or without aura, weighing more than 20 kg,"/>
   <result pre="without aura, weighing more than 20 kg, who experienced 3–10" exact="migraine" post="days/month for the 3 months prior to the screening"/>
   <result pre="migraine, analgesic overuse and previous failure of ≥2 adequately dosed" exact="migraine" post="preventive medications. One hundred and fifty-seven subjects were included"/>
   <result pre="treated with topiramate. Primary outcome measure was the reduction of" exact="migraine" post="days per month in each treatment group of the"/>
   <result pre="baseline phase, there was a reduction of 2.6 ± 2.6" exact="migraine" post="days per month in the topiramate group compared with"/>
   <result pre="group compared with a mean reduction of 2.0 ± 3.1" exact="migraine" post="days per month in the placebo group ( P"/>
   <result pre="= 0.061). In the per-protocol population, the reduction in monthly" exact="migraine" post="days (2.8 ± 2.4 as opposed to 2.2 ±"/>
   <result pre="last 28 days of treatment, the mean number of monthly" exact="migraine" post="was reduced by 3.1 ± 2.6, as opposed to"/>
   <result pre="32% of patients experienced a ≥75% reduction in mean monthly" exact="migraine" post="days compared with a 14% reduction in the placebo"/>
   <result pre="topiramate-treated patients and included infection ( n = 2), severe" exact="migraine" post="( n = 1) and suicidal ideation ( n"/>
   <result pre="( n = 1). In this study, the mean monthly" exact="migraine" post="frequency reduction seems less evident when compared to the"/>
   <result pre="when compared to the previous study [ 10], probably because" exact="migraine" post="frequency at baseline was lower (range 2–9 in the"/>
   <result pre="2–9 in the ITT topiramate population) and children with chronic" exact="migraine" post="were excluded. An important aspect is that the reduction"/>
   <result pre="had been enrolled in three pivotal trials of topiramate for" exact="migraine" post="prophylaxis in adults. Patients were to have had between"/>
   <result pre="adults. Patients were to have had between 3 and 12" exact="migraine" post="attacks, and no more than 14 headache days per"/>
   <result pre="weeks. When compared to baseline, there was a mean monthly" exact="migraine" post="frequency reduction of 46, 63 and 65%, respectively, as"/>
   <result pre="all studies. Furthermore, the degree of disability caused by the" exact="migraine" post="episodes, which is essential in the decision to initiate"/>
   <result pre="was not assessed in all studies. Discussion Management of pediatric" exact="migraine" post="can be tricky, seeing as no pharmacological treatment is"/>
   <result pre="is formally approved or indicated in the prophylactic treatment of" exact="migraine" post="in children and adolescents. A recent review of the"/>
   <result pre="A recent review of the pharmacological treatment options in pediatric" exact="migraine" post="[ 16] found only flunarizine, which is not available"/>
   <result pre="placebo-controlled trials evaluating topiramate in the preventive treatment of pediatric" exact="migraine" post="have been carried out [ 10, 12]. Taken together,"/>
   <result pre="dosages, which seem to be effective in the treatment of" exact="migraine" post="in children and adolescents (2–3 mg/kg/day) are much lower"/>
   <result pre="much lower than those indicated for the adjunctive treatment of" exact="epilepsy" post="(5–9 mg/kg/day) in children as young as 2 years."/>
   <result pre="and should take the degree of disability caused by the" exact="migraine" post="episodes into account. An important aspect, which emerged from"/>
   <result pre="studies, is a significant decrease in school absenteeism due to" exact="migraine" post="[ 10] and a reduction in the disability caused"/>
   <result pre="[ 10] and a reduction in the disability caused by" exact="migraine" post="(as assessed by PedMIDAS), leading to an improvement in"/>
   <result pre="References 1. Abu-Arefeh I Russell G Prevalence of headache and" exact="migraine" post="in schoolchildren Br Med J 1994 309 765 769"/>
   <result pre="Silberstein SD Stewart WF An update on the epidemiology of" exact="migraine" post="Headache 1994 34 319 328 10.1111/j.1526-4610.1994.hed3406319.x 7928310 3. Stewart"/>
   <result pre="Natta M Ziegler D Age and sex-specific incidence rates of" exact="migraine" post="with and without aura Am J Epidemiol 1991 134"/>
   <result pre="RB Kolodner K Liberman J Sawyer J Reliability of the" exact="migraine" post="disability assessment score in a population-based sample of headache"/>
   <result pre="of the Child Neurology Society Practice parameter: pharmacological treatment of" exact="migraine" post="headache in children and adolescents: report of the American"/>
   <result pre="Linder SL Jordan DM Fisher AC Hulihan J Topiramate for" exact="migraine" post="prevention in children: a randomized, double-blind, placebo-controlled trial Headache"/>
   <result pre="Wang S Yuen E Battisti W Nye JS Topiramate for" exact="migraine" post="prevention in adolescents: a pooled analysis of efficacy and"/>
   <result pre="Casas C Herranz JL Topiramate in the prophylactic treatment of" exact="migraine" post="in children J Child Neurol 2005 20 251 253"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC2778404/results/search/disease/results.xml">
   <result pre="secondary causes. The role of new drugs in treatment of" exact="migraine" post="is discussed and trials are quoted from literature. Indications"/>
   <result pre="on quality of life. For management of acute attacks of" exact="migraine" post="both acetaminophen and ibuprofen are recommended for use in"/>
   <result pre="channel blockers, and antidepressants have been used for prophylaxis of" exact="migraine" post="in children. The data for use of newer drugs"/>
   <result pre="in children. The data for use of newer drugs for" exact="migraine" post="in children is limited, though AEDs are emerging a"/>
   <result pre="used with promising results. 1. Introduction Headache is a disabling" exact="neurological disorder" post="of varied etiologies and a frequent health problem in"/>
   <result pre="[ 4]. With such a high prevalence in school-aged children," exact="migraine" post="has significant effect on school attendance and family dynamics"/>
   <result pre="parents [ 5]. 2. Diagnostic Criteria of Pediatric Migraine Pediatric" exact="migraine" post="differs from adult migraine in presentation and response to"/>
   <result pre="Diagnostic Criteria of Pediatric Migraine Pediatric migraine differs from adult" exact="migraine" post="in presentation and response to treatment. It tends to"/>
   <result pre="( Table 1), the two most important of which are" exact="migraine" post="without aura ( Table 2) and migraine with aura."/>
   <result pre="of which are migraine without aura ( Table 2) and" exact="migraine" post="with aura. Under the new classification of 2004 ["/>
   <result pre="(one hour instead of two hours) are currently modified for" exact="migraine" post="diagnosis in children. The criteria for ophthalmoplegic &quot;migraine&quot; now"/>
   <result pre="and central causes of facial pain,&quot; and criteria for chronic" exact="migraine" post="have been added. If a patient fulfils the criteria"/>
   <result pre="be diagnosed. 3. Pathophysiology of Migraine The pathophysiological concepts of" exact="migraine" post="have advanced considerably over the last 20 years. The"/>
   <result pre="the last 20 years. The much popular vascular theory of" exact="migraine" post="by Wolff has been undermined by phase model of"/>
   <result pre="migraine by Wolff has been undermined by phase model of" exact="migraine" post="by Blau [ 6] and cerebral Doppler flow studies"/>
   <result pre="vascular disease. According to this neurogenic theory the genetically sensitive" exact="migraine" post="brain when exposed to a migraine-inducing environment undergoes neurochemical"/>
   <result pre="and demonstration of unique changes of brain blood flow during" exact="migraine" post="auras suggest that the underlying mechanism is the spreading"/>
   <result pre="which may be a key to an understanding of the" exact="migraine" post="attack, is a short-lasting depolarization wave that moves across"/>
   <result pre="correspondence with the 4- to 72-hour duration of a typical" exact="migraine" post="episode. The increased CGRP synthesis and release might be"/>
   <result pre="as sumatriptan. It is now widely accepted that children with" exact="migraine" post="have a genetic predisposition that is in some way"/>
   <result pre="forth. Major breakthrough was an identification of gene locus for" exact="familial hemiplegic migraine" post="in the Cav2.1 subunit of the gene for the"/>
   <result pre="breakthrough was an identification of gene locus for familial hemiplegic" exact="migraine" post="in the Cav2.1 subunit of the gene for the"/>
   <result pre="then many gene mutations have been identified in cases of" exact="familial hemiplegic migraine." post="4. Evaluation of a Child with Headache A detailed"/>
   <result pre="headaches&quot; should be questioned for possible trauma, symptoms suggestive of" exact="meningitis" post="like fever, phono-photophobia, and stiffness of neck. In &quot;chronic"/>
   <result pre="intracranial pressure slowly cause macrocrania. Examine for neurocutaneous syndrome, particularly" exact="neurofibromatosis" post="and tuberous sclerosis, which are highly associated with intracranial"/>
   <result pre="slowly cause macrocrania. Examine for neurocutaneous syndrome, particularly neurofibromatosis and" exact="tuberous sclerosis," post="which are highly associated with intracranial neoplasms. A detailed"/>
   <result pre="abdominal migraine, and benign paroxysmal vertigo. Very often, children with" exact="migraine" post="frequently suffer from travel sickness and giddiness. Other strong"/>
   <result pre="unlikely to provide an etiology, improve diagnostic yield, or distinguish" exact="migraine" post="from other types of headaches. Pooled data indicates that"/>
   <result pre="data does not suggest differences in EEG between children with" exact="migraine" post="and nonmigraine type headaches which may be diagnostically helpful."/>
   <result pre="and nonmigraine type headaches which may be diagnostically helpful. Hemiplegic" exact="migraine" post="has shown the most definite abnormal EEGs with a"/>
   <result pre="of meningeal irritation or if there is high suspicion of" exact="meningitis" post="on clinical grounds. 10. Treatment of Migraine Treatment of"/>
   <result pre="on clinical grounds. 10. Treatment of Migraine Treatment of pediatric" exact="migraine" post="includes an individually tailored regimen for acute attack and"/>
   <result pre="an individually tailored regimen for acute attack and prophylaxis of" exact="migraine" post="using both nonpharmacologic and pharmacologic measures. The successful treatment"/>
   <result pre="effective and widely used for treatment of acute attacks of" exact="migraine" post="in children. The current evidence in literature shows that"/>
   <result pre="are safe and effective in aborting the acute attack of" exact="migraine" post="in children. Comparison of efficacy and safety at doses"/>
   <result pre="The triptans, selective serotonin 5-HT1B/1D agonists, are very effective acute" exact="migraine" post="drugs. They are widely used in treatment of migraine"/>
   <result pre="acute migraine drugs. They are widely used in treatment of" exact="migraine" post="attacks in adults and are very effective. However, children"/>
   <result pre="Attacks Other class of drugs used widely for treatment of" exact="migraine" post="attacks is ergot groups but current evidence finds no"/>
   <result pre="13. Prevention of Migraine Attacks The indications for use of" exact="migraine" post="prophylaxis in children include missing more than 3 days"/>
   <result pre="to improve headache frequency, and/or presence of basilar or hemiplegic" exact="migraine" post="are also appropriate indications for preventive therapy [ 25]."/>
   <result pre="their use in general. Commonly used drugs for prevention of" exact="migraine" post="attacks are tabulated in Table 6. 14. Beta Blockers"/>
   <result pre="review found propranolol to be effective for prophylaxis of pediatric" exact="migraine" post="[ 27]. The side effects of propranolol including insomnia,"/>
   <result pre="shown consistent efficacy and safety as prophylactic agent for paediatric" exact="migraine" post="[ 27]. American academy of neurology's recommendations concluded that"/>
   <result pre="of 2-3 mg/kg/day (maximum dose 200 mg) with reduced mean monthly" exact="migraine" post="frequency from 5.4 days per month to 1.9 days"/>
   <result pre="study assessed the efficacy and safety of levetiracetam for pediatric" exact="migraine" post="at doses of 125–250 mg twice daily and found"/>
   <result pre="6.3 to 1.7/month and 52% of patients experienced elimination of" exact="migraine" post="attacks during treatment. No side effects were reported in"/>
   <result pre="concluded that anticonvulsants appear to be both effective in reducing" exact="migraine" post="frequency and reasonably well tolerated. There was noticeable variation"/>
   <result pre="an antihistamine with serotonine blocking properties, has been used for" exact="migraine" post="prophylaxis in children in doses of 2 to 4 mg/day"/>
   <result pre="the nature of the disease or disorder under treatment. For" exact="migraine" post="headaches, EMG measuring contraction of the frontalis muscle and"/>
   <result pre="biofeedback). Thermal biofeedback is an effective technique used by many" exact="migraine" post="patients to reduce the pain intensity and frequency of"/>
   <result pre="biofeedback have proven to be promising treatments for children with" exact="migraine" post="headaches. Feedback training was accompanied by significant reduction of"/>
   <result pre="efficacy of the training; a significant reduction of days with" exact="migraine" post="and other headache parameters was observed. It is suggested"/>
   <result pre="160 14979299 3 Sillanpaa M Changes in the prevalence of" exact="migraine" post="and other headaches during the first seven school years"/>
   <result pre="USA J. B. Lippincott 2136 5 Sillanpaa M Prevalence of" exact="migraine" post="and other headache in Finnish children starting school Headache"/>
   <result pre="and topography of cerebral blood flow, aura, and headache during" exact="migraine" post="attacks Annals of Neurology 1990 28 6 791 798"/>
   <result pre="6 791 798 2285266 8 Lauritzen M Pathophysiology of the" exact="migraine" post="aura: the spreading depression theory Brain 1994 117, part"/>
   <result pre="Ramesh V Birchall D Serial MRI in a case of" exact="familial hemiplegic migraine" post="Neuroradiology 2003 45 5 300 303 12669159 13 Hämäläinen"/>
   <result pre="Birchall D Serial MRI in a case of familial hemiplegic" exact="migraine" post="Neuroradiology 2003 45 5 300 303 12669159 13 Hämäläinen"/>
   <result pre="Santavuori P Ibuprofen or acetaminophen for the acute treatment of" exact="migraine" post="in children: a double-blind, randomized, placebo-controlled, crossover study Neurology"/>
   <result pre="236 15 Hämäläinen ML Hoppu K Santavuori P Sumatriptan for" exact="migraine" post="attacks in children: a randomized placebo-controlled study. Do children"/>
   <result pre="attacks in children: a randomized placebo-controlled study. Do children with" exact="migraine" post="respond to oral sumatriptan differently from adults? Neurology 1997"/>
   <result pre="Evans JK Rizatriptan 5 mg for the acute treatment of" exact="migraine" post="in adolescents: a randomized, double-blind, placebo-controlled study Headache 2002"/>
   <result pre="Winner P Lewis D Stankowski J Zolmitriptan oral tablet in" exact="migraine" post="treatment: high placebo responses in adolescents Headache 2006 46"/>
   <result pre="S Rahmann A Kraemer C et al. Treatment of childhood" exact="migraine" post="attacks with oral zolmitriptan and ibuprofen Neurology 2006 67"/>
   <result pre="D Yonker M Silberstein S Practice parameter: pharmacological treatment of" exact="migraine" post="headache in children and adolescents: report of the American"/>
   <result pre="AD Wasiewski WW Efficacy of zolmitriptan nasal spray in adolescent" exact="migraine" post="Pediatrics 2007 120 2 390 396 17671066 23 Hämäläinen"/>
   <result pre="Hämäläinen ML Hoppu K Santavuori PR Oral dihydroergotamine for therapy-resistant" exact="migraine" post="attacks in children Pediatric Neurology 1997 16 2 114"/>
   <result pre="AP Berger MY Passchier J Koes BW Symptomatic treatment of" exact="migraine" post="in children: a systematic review of medication trials Pediatrics"/>
   <result pre="2001 3 1 26 Linde K Rossnagel K Propranolol for" exact="migraine" post="prophylaxis Cochrane Database of Systematic Reviews 2004 2 Article"/>
   <result pre="ID CD003225. 27 Victor S Ryan S Drugs for preventing" exact="migraine" post="headaches in children Cochrane Database of Systematic Reviews 2003"/>
   <result pre="of divalproex sodium in the prophylactic treatment of children with" exact="migraine" post="Headache 2000 40 8 672 676 10971664 29 Serdaroglu"/>
   <result pre="E Tekgul H et al. Sodium valproate prophylaxis in childhood" exact="migraine" post="Headache 2002 42 8 819 822 12390647 30 Winner"/>
   <result pre="p. 481 31 Chronicle EP Mulleners WM Anticonvulsant drugs for" exact="migraine" post="prophylaxis Cochrane Database of Systematic Reviews 2004 3 Article"/>
   <result pre="Diamond S Scott D Jones V Prophylactic treatment of oediatric" exact="migraine" post="Headache 2004 44 3 230 237 15012660 33 Powers"/>
   <result pre="with aura Childhood periodic syndromes that are commonly precursors of" exact="migraine" post="Retinal migraine Complications of migraine Probable migraine Tension-type headache"/>
   <result pre="Childhood periodic syndromes that are commonly precursors of migraine Retinal" exact="migraine" post="Complications of migraine Probable migraine Tension-type headache (TTH) Infrequent"/>
   <result pre="that are commonly precursors of migraine Retinal migraine Complications of" exact="migraine" post="Probable migraine Tension-type headache (TTH) Infrequent episodic tension-type headache"/>
   <result pre="commonly precursors of migraine Retinal migraine Complications of migraine Probable" exact="migraine" post="Tension-type headache (TTH) Infrequent episodic tension-type headache Frequent episodic"/>
   <result pre="New daily-persistent headache (NDPH) Table 2 Diagnostic criteria for Pediatric" exact="migraine" post="without aura. A ≥5 attacks fulfilling features B to"/>
   <result pre="is superior to IV ketorolac in the acute treatment of" exact="migraine" post="headaches in emergency department prochlorperazine IV (0.15 mg/kg; maximum 10"/>
   <result pre="maximum 10 mg) Table 6 Drugs used for prevention of" exact="migraine" post="attacks. Class Drug &amp;amp; dosage Comments Beta blockers Propranolol"/>
   <result pre="available in US Nimodipine Not recommended for use in pediatric" exact="migraine" post="Anticonvulsants Valproate 15–45 mg/kg/day, PO Drowsiness, weight gain, tremor, hair"/>
   <result pre="loss, and sensory symptoms Levetiracetam 250–500 mg Evaluated in pediatric" exact="migraine" post="and found to be effective. About 10% children report"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC3451993/results/search/disease/results.xml">
   <result pre="doi: 10.1007/s10194-009-0111-9 : Original Article Study on management of pediatric" exact="migraine" post="by general practitioners in northern France Cuvellier Jean-Christophe +33-320-444057"/>
   <result pre="Haute Autorité de Santé (High Health Authority, HAS) guidelines for" exact="migraine" post="management in children among a random sample of 100"/>
   <result pre="questionnaire conducted by phone included questions on knowledge of pediatric" exact="migraine" post="acute treatment and preventive therapy, referral to a child"/>
   <result pre="preventive therapy. Continuing educational programmes on the implementation of pediatric" exact="migraine" post="guidelines is strongly needed. Electronic supplementary material The online"/>
   <result pre="General practice Guidelines Migraine Children Introduction The estimated prevalence of" exact="migraine" post="in the adolescent population ranges from 8% to 28%"/>
   <result pre="this high prevalence, however, clinicians may not readily recognize childhood" exact="migraine" post="[ 6] and treatment appears even less satisfactory. There"/>
   <result pre="children, and in particular, their awareness of HAS guidelines for" exact="migraine" post="management in children. Methods From 1 August 2007 to"/>
   <result pre="The interviewed GPs were informed that the study concerned pediatric" exact="migraine" post="but they were unaware of the precise study subject,"/>
   <result pre="on GPs’ behavior in terms of the management of pediatric" exact="migraine" post="in their daily practice and their knowledge of HAS"/>
   <result pre="b What is your first intention acute medication for a" exact="migraine" post="attack (in children and adolescents 15 or younger)? 1."/>
   <result pre="b What is your second intention acute medication for a" exact="migraine" post="attack (in children and adolescents 15 or younger)? 1."/>
   <result pre="Aspirin Question 3 b When you prescribe ibuprofen for a" exact="migraine" post="attack, which dose of ibuprofen do you prescribe? 1."/>
   <result pre="Other Question 4 b When you prescribe ibuprofen for a" exact="migraine" post="attack, which number of ibuprofen doses do you prescribe"/>
   <result pre="number of ibuprofen doses do you prescribe for a single" exact="migraine" post="attack? 1. 1–2 doses 2. &amp;gt; 2 doses Question"/>
   <result pre="not prescribe ibuprofen as first intention acute medication for a" exact="migraine" post="attack, why? 1. Ibuprofen is not the reference medication"/>
   <result pre="3. Adverse effects/toxicity 4. Not indicated and/or ineffective in pediatric" exact="migraine" post="attack 5. No answer 6. Free answer Question 6"/>
   <result pre="take into account to start preventive treatment? 1. Frequency of" exact="migraine" post="attacks 2. Intensity of migraine attacks 3. Functional disability"/>
   <result pre="preventive treatment? 1. Frequency of migraine attacks 2. Intensity of" exact="migraine" post="attacks 3. Functional disability 4. Failure and/or poor tolerance"/>
   <result pre="None Question 8 a When do you refer a pediatric" exact="migraine" post="patient to a specialist? 1. Failure of abortive drugs"/>
   <result pre="a specialist? 1. Failure of abortive drugs of first intention" exact="migraine" post="attacks 2. Failure of abortive drugs of second intention"/>
   <result pre="of abortive drugs of second intention 3. Frequent and/or disabling" exact="migraine" post="attacks 4. To start preventive treatment 5. As a"/>
   <result pre="or they had no interest for the issue of pediatric" exact="migraine" post="( n = 12, 8%). The mean age of"/>
   <result pre="men 98%]. Table 2 shows the respondents’ behavior about pediatric" exact="migraine" post="patient management and awareness of HAS recommendations. Table 2"/>
   <result pre="recommendations. Table 2 Awareness of respondents about management of pediatric" exact="migraine" post="Total Urban Rural OR [CI] Question 1. Medication of"/>
   <result pre="Question 6. Criteria to start preventive treatment 1. Frequency of" exact="migraine" post="attacks 76 64 88 0.3 [0.1–0.7] * 2. Intensity"/>
   <result pre="attacks 76 64 88 0.3 [0.1–0.7] * 2. Intensity of" exact="migraine" post="attacks 27 28 26 1.1 [0.5–2.7] 3. Functional disability"/>
   <result pre="0 – Question 9. Knowledge of HAS guidelines for pediatric" exact="migraine" post="1. Yes 54 48 60 0.6 [0.3–1.3] 2. No"/>
   <result pre="1.6 [0.7–3.5] Question 10. Reading of HAS guidelines for pediatric" exact="migraine" post="1. Yes 24 24 24 1 [0.4–2.5] 2. No"/>
   <result pre="44 GPs argued they were prescribing ibuprofen as second-line intention" exact="migraine" post="abortive drug. The second most frequently prescribed medication was"/>
   <result pre="a maximum of one to two doses for a single" exact="migraine" post="attack by 44 GPs. Reasons for refusing to prescribe"/>
   <result pre="mind that ibuprofen was not the reference medication of pediatric" exact="migraine" post="attack, 8 (15%) were unaccustomed to prescribe ibuprofen in"/>
   <result pre="and 7) Reasons for starting preventive treatment Preventive therapy for" exact="migraine" post="was considered by 76 GPs when migraine attacks were"/>
   <result pre="Preventive therapy for migraine was considered by 76 GPs when" exact="migraine" post="attacks were frequent, by 55 GPs when the headache"/>
   <result pre="treatment, and by 27 GPs because of severity of the" exact="migraine" post="attacks. Type of preventive treatment Forty-eight GPs were agreeing"/>
   <result pre="when second-line acute treatment was ineffective, by 56 GPs when" exact="migraine" post="attacks were frequent and/or disabling, and by 6 GPs"/>
   <result pre="Awareness of HAS guidelines for the therapeutic management of pediatric" exact="migraine" post="(Questions 9 and 10) Knowledge of the HAS guidelines"/>
   <result pre="of the HAS guidelines for the therapeutic management of pediatric" exact="migraine" post="Fifty GPs stated that they knew HAS guidelines for"/>
   <result pre="0.31). Reading HAS guidelines for the therapeutic management of pediatric" exact="migraine" post="Twenty-four percent of GPs stated that they had read"/>
   <result pre="urban GPs. Figure analyzes knowledge of reference treatment of pediatric" exact="migraine" post="by the GPs according to knowledge of the HAS"/>
   <result pre="had read HAS guidelines for the therapeutic management of pediatric" exact="migraine" post="(Fig. 1). Among the 54 GPs stating being aware"/>
   <result pre="(61%) were prescribing ibuprofen as first-line acute drug for pediatric" exact="migraine" post="(Fig. 1). Forty-six GPs stated that they did not"/>
   <result pre="Few well-designed trials have evaluated the acute pharmacologic management of" exact="migraine" post="in children [ 9, 10]. In 1997, the study"/>
   <result pre="showed that both drugs were well-tolerated and effective in relieving" exact="migraine" post="attacks. Another study showed that a lower ibuprofen dosage"/>
   <result pre="h [ 13]. The HAS guidelines for the treatment of" exact="migraine" post="in adults and children were issued in October 2002"/>
   <result pre="The HAS recommended ibuprofen as the mainstay drug for acute" exact="migraine" post="attacks in children aged 6 months or older. It"/>
   <result pre="use of paracetamol in its guidelines for the treatment of" exact="migraine" post="in adults and children, paracetamol was the drug of"/>
   <result pre="the GPs would prescribe ibuprofen as first intention drug for" exact="migraine" post="attack, only 3% of the GPs interviewed knew the"/>
   <result pre="(MO) which has been proposed as a risk factor for" exact="migraine" post="transformation. The pediatric prevalence of MO is much variable"/>
   <result pre="25]. Whereas all drugs used in the acute treatment of" exact="migraine" post="bear the risk of MO, &quot;simple&quot; analgesics seem wrongly"/>
   <result pre="an increased risk of invasive group A streptococcal infection after" exact="chickenpox" post="and of acute renal failure in case of hypovolemia"/>
   <result pre="recommended for the treatment of fever or moderate pain during" exact="chickenpox" post="or during a disease with a risk of dehydration,"/>
   <result pre="consequence, fearing of GPs appears excessive as most of pediatric" exact="migraine" post="attacks may not occur during chickenpox or during a"/>
   <result pre="as most of pediatric migraine attacks may not occur during" exact="chickenpox" post="or during a disease with a risk of dehydration."/>
   <result pre="a basis for decisions about preventive therapy [ 31]. Uncommon" exact="migraine" post="conditions such as basilar or hemiplegic migraines [ 32],"/>
   <result pre="initiated, was provided to 22.3% of the children diagnosed with" exact="migraine" post="by their GPs. Behavioral headache treatments include relaxation training,"/>
   <result pre="an adult study, variables such as pain intensity, number of" exact="migraine" post="symptoms, attack duration and disability were associated with increased"/>
   <result pre="already cited survey from our hospital, reasons of referral of" exact="migraine" post="pediatric patients to our out-patient neuropaediatric department were failure"/>
   <result pre="awareness of HAS guidelines and behavior in management of pediatric" exact="migraine" post="patients may have implications regarding the interpretation of the"/>
   <result pre="GPs should also be considered. Conclusion Given the prevalence of" exact="migraine" post="in the pediatric population, children with migraines suffer if"/>
   <result pre="References 1. Abu-Arefah I Russell G Prevalence of headache and" exact="migraine" post="in schoolchildren Br Med J 1994 309 765 769"/>
   <result pre="Natta M Ziegler D Age- and sex-specific incidence rates of" exact="migraine" post="with and without visual aura Am J Epidemiol 1991"/>
   <result pre="1111 1120 1746521 3. Split W Neuman W Epidemiology of" exact="migraine" post="among students from randomly selected secondary schools in Lodz"/>
   <result pre="501 10.1046/j.1526-4610.1999.3907494.x 11279934 4. Stang PE Osterhaus JT Impact of" exact="migraine" post="in the United States: data from the national health"/>
   <result pre="pratique clinique Prise en charge diagnostique et thérapeutique de la" exact="migraine" post="chez l’adulte et l’enfant. Rev Neurol 2003 159 126"/>
   <result pre="Cuisset JM Vallée L French general practitioners’ management of children’s" exact="migraine" post="headaches Headache 2007 47 1282 1292 10.1111/j.1526-4610.2006.00720.x 17927644 9."/>
   <result pre="AP Berger MY Passchier J Koes BW Symptomatic treatment of" exact="migraine" post="in children: a systematic review of medication trials Pediatrics"/>
   <result pre="of the Child Neurology Society Practice parameter: pharmacological treatment of" exact="migraine" post="headache in children and adolescents: report of the American"/>
   <result pre="Santavuori P Ibuprofen or acetaminophen for the acute treatment of" exact="migraine" post="in children: a double-blind, randomized, placebo-controlled, crossover study Neurology"/>
   <result pre="DW Children’s ibuprofen suspension for the acute treatment of pediatric" exact="migraine" post="Headache 2002 42 780 786 10.1046/j.1526-4610.2002.02180.x 12390641 13. Evers"/>
   <result pre="G Debus O Husstedt IW Frese A Treatment of childhood" exact="migraine" post="attacks with oral zolmitriptan and ibuprofen Neurology 2006 67"/>
   <result pre="Diamond S Scott D Jones V Prophylactic treatment of pediatric" exact="migraine" post="Headache 2004 44 230 237 10.1111/j.1526-4610.2004.04052.x 15012660 31. Hämäläinen"/>
   <result pre="16999452 32. Silberstein SD (2000) Practice parameter: evidence-based guidelines for" exact="migraine" post="headache (an evidence-based review): report of the Quality Standards"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC3602609/results/search/disease/results.xml">
   <result pre="AG Cham pmcid: 3602609 148 doi: 10.1186/2193-1801-2-77 : Research Brief" exact="migraine" post="episodes in children and adolescents-a modification to International Headache"/>
   <result pre="in children and adolescents-a modification to International Headache Society pediatric" exact="migraine" post="(without aura) diagnostic criteria Francis Muttamthottil Varghese mvfrancis@rediffmail.com [],"/>
   <result pre="for headache in children and adults improved the accuracy of" exact="migraine" post="diagnoses. However many short duration headaches in children, receive"/>
   <result pre="However many short duration headaches in children, receive an atypical" exact="migraine" post="diagnosis. This study is to diagnose children and adolescents"/>
   <result pre="brief activity affected head pain, were studied. Known and common" exact="migraine" post="triggers and family history of migraine were recorded in"/>
   <result pre="studied. Known and common migraine triggers and family history of" exact="migraine" post="were recorded in all. All the children studied had"/>
   <result pre="diagnostic pain features). At least one of the ICHD2 pediatric" exact="migraine" post="diagnostic symptoms (nausea / vomiting / photophobia / phonophobia)"/>
   <result pre="or siblings was a migrainer and one of the common" exact="migraine" post="triggers as a precipitating factor. This study concludes that"/>
   <result pre="hour ,two additional features to be included to diagnose definitive" exact="migraine" post="in children and adolescents - one migraine parent or"/>
   <result pre="to diagnose definitive migraine in children and adolescents - one" exact="migraine" post="parent or sibling and one of the migraine triggers"/>
   <result pre="- one migraine parent or sibling and one of the" exact="migraine" post="triggers precipitating the head pain. Keywords Brief migraines ICHD2"/>
   <result pre="precipitating the head pain. Keywords Brief migraines ICHD2 Modification Common" exact="migraine" post="triggers family history Introduction Prior to the publication of"/>
   <result pre="used for headache diagnosis in children. These dealt mainly with" exact="migraine" post="and included the criteria established by Vahlquist ( 1955"/>
   <result pre="The major suggestions were to shorten the duration of the" exact="migraine" post="attack to one hour and to remove hemicrania as"/>
   <result pre="with migrainous features fail to fully meet I H S" exact="migraine" post="criteria and thus they receive an atypical migraine diagnosis"/>
   <result pre="H S migraine criteria and thus they receive an atypical" exact="migraine" post="diagnosis ( probable migraine according to ICHD 2 2004"/>
   <result pre="and thus they receive an atypical migraine diagnosis ( probable" exact="migraine" post="according to ICHD 2 2004 ). Many children report"/>
   <result pre="Many children report brief episodes of head pain which resemble" exact="migraine" post="but these migraine episodes of less than one hour"/>
   <result pre="brief episodes of head pain which resemble migraine but these" exact="migraine" post="episodes of less than one hour duration are not"/>
   <result pre="Moreover there are overlapping statements in the diagnostic criteria of" exact="migraine" post="and tension type headaches- number of episodes, duration of"/>
   <result pre="making both diagnoses. Present study is undertaken to document brief" exact="migraine" post="episodes lasting less than one hour duration in children"/>
   <result pre="duration in children and to suggest additional features to distinguish" exact="migraine" post="from tension type headaches and to propose a modification"/>
   <result pre="tension type headaches and to propose a modification to pediatric" exact="migraine" post="(without aura) diagnostic criteria. Methods 9620 children and adolescents"/>
   <result pre="/ vomiting / phonophobia / and or photophobia), one common" exact="migraine" post="trigger precipitating the attacks and one parent or sibling"/>
   <result pre="children and adolescents fulfilled the inclusion criteria to diagnose brief" exact="migraine" post="episodes of less than one hour duration (5 minutes"/>
   <result pre="were 842 girls and 560 boys. The headache characteristics, common" exact="migraine" post="triggers and family history of 1402 children are given"/>
   <result pre="252(18%), vomiting 196 (14%), phonophobia 883(63%) and photophobia 798(57%). Common" exact="migraine" post="triggers exposure to sunlight 1290(92%), travelling by bus 673(46%),"/>
   <result pre="history mother-1148 (82%) father-155 (11%) siblings-99 (7%) DIAGNOSTIC CRITERIA of" exact="migraine" post="without aura ICHD 2 5 attacks  Duration 1 to"/>
   <result pre="or photophobia Discussion Studies show that in children and adolescents," exact="migraine" post="tends to be of shorter duration. The duration of"/>
   <result pre="when duration was omitted as a criterion the prevalence of" exact="migraine" post="increased by 25.9%. In fact Gherpelli and colleagues ("/>
   <result pre="criterion increased the sensitivity without decreasing the specificity of pediatric" exact="migraine" post="diagnosis. This study supports the suggestion of decreasing the"/>
   <result pre="duration of head pain to less than one hour for" exact="migraine" post="without aura in children. In this study, 1402 children"/>
   <result pre="5 to 45 minutes with one of the associated diagnostic" exact="migraine" post="features of nausea / vomiting / phonophobia / and or"/>
   <result pre="attacks when exposed to one or more of the common" exact="migraine" post="triggers ( Francis 2002 , 2004 , 2009 )"/>
   <result pre="triggers. Mortimer et al. ( 1992b ) reported that a" exact="migraine" post="trigger could be identified in 44.4% of the children"/>
   <result pre="noise, glaring light, missing a meal were all reported as" exact="migraine" post="precipitants by different studies. Rossi et al. ( 1989"/>
   <result pre="childhood migraines. This is the first study to document common" exact="migraine" post="triggers in a region to aid in the migraine"/>
   <result pre="common migraine triggers in a region to aid in the" exact="migraine" post="without aura diagnostic work up. Majority of the children"/>
   <result pre="parents reported same common triggers with exposure to sunlight precipitating" exact="migraine" post="in nearly 90% of them. Trigger factors are less"/>
   <result pre=") and menstruation can trigger or aggravate both TTH and" exact="migraine" post="but activity getting affected, other common migraine triggers precipitating"/>
   <result pre="both TTH and migraine but activity getting affected, other common" exact="migraine" post="triggers precipitating pain and family history will favour a"/>
   <result pre="precipitating pain and family history will favour a diagnosis of" exact="migraine" post="in such clinically confusing scenario ( Francis 2009 )."/>
   <result pre="to be one of the very common triggers for ICHD2" exact="migraine" post="in this region of India. Family history revealed mother"/>
   <result pre="history revealed mother (82%), father or sibling suffering from ICHD2" exact="migraine" post="with or without aura. Migraine is a familial disorder,"/>
   <result pre="migraine. Parents must be questioned in detail to find out" exact="migraine" post="symptoms. Most of them considered their headaches are different"/>
   <result pre="exposed to sunlight, bus traveling or other known or common" exact="migraine" post="triggers must be specifically asked to unravel migraine symptomatology."/>
   <result pre="or common migraine triggers must be specifically asked to unravel" exact="migraine" post="symptomatology. It was indeed surprising to find out that"/>
   <result pre="the doctor. When details of these headaches were asked typical" exact="migraine" post="features were revealed. This study shows that reducing the"/>
   <result pre="reduction might increase the overlap between the diagnostic criteria of" exact="migraine" post="and tension type headaches but it can be easily"/>
   <result pre="but it can be easily overcome by adding one common/known" exact="migraine" post="trigger and one family member suffering from ICHD2 migraine"/>
   <result pre="common/known migraine trigger and one family member suffering from ICHD2" exact="migraine" post="to the present diagnostic features. One cannot consider any"/>
   <result pre="diagnose clinically and was not a problem differentiating from brief" exact="migraine" post="without aura episodes. Children and adolescents complaining of aura"/>
   <result pre="A critical analysis of the I CHD2 diagnostic criteria for" exact="migraine" post="and tension, exposes more than one overlapping statements. In"/>
   <result pre="in these children (missing two criteria to diagnose ICHD 2" exact="migraine" post="without aura). At the same time probable migraine (missing"/>
   <result pre="ICHD 2 migraine without aura). At the same time probable" exact="migraine" post="(missing duration criterion) ( Granella et al. 1994 ;"/>
   <result pre="these clinically confusing situations the following three features clearly differentiate" exact="migraine" post="from tension type headaches. 1) activity affected head pain"/>
   <result pre="1) activity affected head pain (motionless) 2)one common / known" exact="migraine" post="trigger precipitating pain 3)one family member suffering from I"/>
   <result pre="precipitating pain 3)one family member suffering from I CHD 2" exact="migraine" post="(definite or probable). The problem in diagnosing probable migraine"/>
   <result pre="2 migraine (definite or probable). The problem in diagnosing probable" exact="migraine" post="is that, most of the parents are concerned about"/>
   <result pre="that what their children are getting is nothing but brief" exact="migraine" post="attacks. Pointing out the triggers and family history with"/>
   <result pre="both children and family. Thus this study shows that both" exact="migraine" post="and tension can be distinguished easily from a thorough"/>
   <result pre="a thorough clinical history. Therefore it is proposed that brief" exact="migraine" post="attacks to be diagnosed in children and adolescents with"/>
   <result pre="one hour, two additional features to be added to diagnose" exact="migraine" post="without aura in children. one common/known migraine trigger precipitating"/>
   <result pre="added to diagnose migraine without aura in children. one common/known" exact="migraine" post="trigger precipitating the attacks. one parent or sibling suffering"/>
   <result pre="the attacks. one parent or sibling suffering from I CHD2" exact="migraine" post="(definite or probable). Ethics This study proposal was approved"/>
   <result pre="to share. Design Prospective cohort study. Setting: Teresa Eye and" exact="migraine" post="centre, Cherthala and St Sebastians Visitation Hospital, Arthunkal, Kerala."/>
   <result pre="funded by any group or institution. Objective To diagnose brief" exact="migraine" post="episodes in children and adolescents and to propose a"/>
   <result pre="children and adolescents and to propose a modification to pediatric" exact="migraine" post="without aura diagnostic criteria of the International headache society."/>
   <result pre="157 160 10.1046/j.1468-2982.1990.1004157.x 2245462 Deubner DC An epidemiologic study of" exact="migraine" post="and headache in 10–20 year olds Headache 1977 17"/>
   <result pre="17 173 180 10.1111/j.1526-4610.1977.hed1704173.x 893091 Francis MV Early or brief" exact="migraine" post="episodes in children and adolescents - a modification to"/>
   <result pre="Francis MV Episodic tension type headaches or mild to moderate" exact="migraine" post="attacks - learning from triggers and family history Cephalalgia"/>
   <result pre="15595991 Maytal J Young M Schecter A Lipton RB Pediatric" exact="migraine" post="and the international headache society criteria Neurology 1997 48"/>
   <result pre="J Kay J Jaron A Epidemiology of headache and childhood" exact="migraine" post="in an urban general practice using ad hoc, Vahlquist"/>
   <result pre="1101 10.1111/j.1469-8749.1992.tb11423.x 1451940 Mortimer MJ Kay J Jaron A Childhood" exact="migraine" post="in general practice. Clinical features and charecteristics Cephalalgia 1992"/>
   <result pre="10.1046/j.1468-2982.1992.1204238.x 1525799 Prensky AL Sommer D Diagnosis and treatment of" exact="migraine" post="in children Neurology 1979 29 506 510 10.1212/WNL.29.4.506 571549"/>
   <result pre="Wober C Wagner Ennsgraber C I H S criteria for" exact="migraine" post="and tension type headaches in children and adolescents Headache"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC3611901/results/search/disease/results.xml">
   <result pre="10.4103/1817-1745.106470 : Original Article Effective dose of topiramate in pediatric" exact="migraine" post="prophylaxis Abbaskhanian Ali Sadeghi Hamid Reza Erfani Ali Rezai"/>
   <result pre="work is properly cited. Abstract Objective: Migraine is a common" exact="neurological disorder" post="in childhood and adolescence. Topiramate is a new anticonvulsant"/>
   <result pre="Topiramate is a new anticonvulsant drug, recently being used in" exact="migraine" post="prophylaxis in adults, although it is not approved by"/>
   <result pre="performed to evaluate the efficacy of low-dose topiramate in pediatric" exact="migraine" post="prophylaxis. Materials and Methods: A prospective study, including 60"/>
   <result pre="Materials and Methods: A prospective study, including 60 patients with" exact="migraine" post="headaches was performed for a period of two months."/>
   <result pre="0.7 mg/kg/day) showed a reduction in the mean (±SD) of" exact="migraine" post="frequency from 6.2 (±2.4) to 3.0 (±1.8) episodes per"/>
   <result pre="suggested as an alternative prophylactic treatment for pediatric migraine. Pediatric" exact="migraine" post="prophylaxis topiramate Introduction Migraine is a common neurological disorder"/>
   <result pre="migraine. Pediatric migraine prophylaxis topiramate Introduction Migraine is a common" exact="neurological disorder" post="in childhood and adolescence. It has a prevalence of"/>
   <result pre="times more common in girls.[ 1 2] Management of pediatric" exact="migraine" post="includes lifestyle changes (in order to avoid foods, habits"/>
   <result pre="avoid foods, habits or environmental factors that may trigger a" exact="migraine" post="attack), the use of abortive medications, and preventive measures,"/>
   <result pre="3 4] Topiramate has been shown to be effective for" exact="migraine" post="prevention in adults. Limited data is available for the"/>
   <result pre="mechanism of topiramate is unknown.[ 6] It is proposed that" exact="epilepsy" post="and migraine share some of the same pathophysiological mechanisms,"/>
   <result pre="topiramate is unknown.[ 6] It is proposed that epilepsy and" exact="migraine" post="share some of the same pathophysiological mechanisms, including abnormal"/>
   <result pre="uncontrolled studies done to evaluate the efficacy of topiramate in" exact="migraine" post="prophylaxis especially in refractory causes confirmed that it could"/>
   <result pre="causes confirmed that it could be effective in prophylaxis of" exact="migraine" post="headache.[ 5 9] Data to support the effectiveness, tolerability,"/>
   <result pre="performed to evaluate the efficacy of low-dose topiramate in pediatric" exact="migraine" post="prophylaxis. Materials and Methods The study was designed as"/>
   <result pre="15 years of age) treated with topiramate for prevention of" exact="migraine" post="headaches, at a pediatric neurology clinic in north of"/>
   <result pre="from March 2011 through September of 2011. The diagnosis of" exact="migraine" post="was based on 2005 definition by the International Headache"/>
   <result pre="and patients were asked baseline laboratory screening tests and a" exact="migraine" post="checklist, including demographic and clinical details of the patients"/>
   <result pre="criteria were as follows: Prior or current prophylactic treatment for" exact="migraine" post="in the last two months Persistent increasing headache Change"/>
   <result pre="adverse effects, using the Student′s t test. The incidence of" exact="migraine" post="attacks and adverse effects before and after treatment was"/>
   <result pre="are recorded [ Table 1]. Frequency intensity and duration of" exact="migraine" post="headache decreased significantly between repeated follow-up visits of each"/>
   <result pre="migraines require prophylactic therapy.[ 14] The successful treatment of pediatric" exact="migraine" post="includes an individually tailored regimen of both non pharmacologic"/>
   <result pre="recommended, if possible.[ 14] Many treatments are currently used for" exact="migraine" post="prophylaxis, including β-blockers, calcium channel antagonists, serotonin antagonists, antidepressants"/>
   <result pre="and performed to compare different dosage of topiramate in pediatric" exact="migraine" post="prophylaxis. In our study, the mean dose in patients"/>
   <result pre="al.[ 21] evaluated the efficacy and safety of topiramate for" exact="migraine" post="prevention in pediatric subjects aged 12-17 years. They found"/>
   <result pre="mg/day, resulted in a statistically significant reduction in the monthly" exact="migraine" post="attack rate from baseline versus placebo (median, 72.2% vs."/>
   <result pre="22] presented that effective mean dose of topiramate in pediatric" exact="migraine" post="prophylaxis is 3.5 ± 1.7 mg/kg/day. The results of"/>
   <result pre="with topiramate for 4 months. And recorded a reduction in" exact="migraine" post="frequency but this was not significantly different from baseline"/>
   <result pre="was not significantly different from baseline and significant differences in" exact="migraine" post="severity and duration of the episodes. Our study revealed"/>
   <result pre="et al.[ 9] reported that 28 (76%) of children with" exact="migraine" post="had an excellent or good response to topiramate. Topiramate"/>
   <result pre="RB Validity of family history data on severe headache and" exact="migraine" post="Neurology 1993 43 1954 60 8413952 3 Hershey AD"/>
   <result pre="efficacy of its use in the prevention and treatment of" exact="migraine" post="J Cent Nerv Syst Dis 2011 3 155 68"/>
   <result pre="S et al. Efficacy and tolerability of topiramate in pediatric" exact="migraine" post="Pediatr Neurol 2009 41 167 70 19664530 10 Olesen"/>
   <result pre="and a clinical, psychological and encephalographic comparison between children with" exact="migraine" post="and matched control Acta Paediatr Suppl 1962 51 1"/>
   <result pre="1962 51 1 151 13869189 12 Sillanpaa M Prevalence of" exact="migraine" post="and other headache in finnish children starting scho Headache"/>
   <result pre="14 Eiland LS Anticonvulsant use for prophylaxis of the pediatric" exact="migraine" post="J Pediatr Health Care 2007 21 392 5 17980806"/>
   <result pre="Diamond S Scott D Jones V Prophylactic treatment of pediatric" exact="migraine" post="Headache 2004 44 230 7 15012660 16 French JA"/>
   <result pre="Silberstein SD Neto W Schmitt J Jacobs D Topiramate in" exact="migraine" post="prevention: Results of a large controlled trial Arch Neurol"/>
   <result pre="Seggern RL Mannix LK Adelman JU Efficacy of topiramate in" exact="migraine" post="prophylaxis: A retrospective chart analysis Headache 2002 42 804"/>
   <result pre="Wang S Yuen E Battisti WP et al. Topiramate for" exact="migraine" post="prevention in adolescents: A pooled analysis of efficacy and"/>
   <result pre="study to evaluate the efficacy and safety of topiramate for" exact="migraine" post="prevention in pediatric subjects 12-17 years of age Pediatrics"/>
   <result pre="Casas C Herranz JL Topiramate in the prophylactic treatment of" exact="migraine" post="in children J Child Neurol 2005 20 251 3"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC3899919/results/search/disease/results.xml">
   <result pre="doi: 10.1186/1824-7288-40-6 : Research Psychotherapy versus usual care in pediatric" exact="migraine" post="and tension-type headache: a single-blind controlled pilot study Balottin"/>
   <result pre="[ 7]. In a meta-analytic study, children and adolescents with" exact="migraine" post="and tension-type headache showed more psychopathological symptoms than did"/>
   <result pre="years; diagnosis of idiopathic headache (migraine without aura - MO," exact="migraine" post="with aura - MA, tension-type headache - TTH) according"/>
   <result pre="M Peres MF Vilanova LC Masruha MR Adolescents with chronic" exact="migraine" post="commonly exhibit depressive symptoms Acta Neurol Belg 2013 113"/>
   <result pre="Molteni S Galli F Psychopathological symptoms in child and adolescent" exact="migraine" post="and tension-type headache: a meta-analysis Cephalalgia 2013 33 112"/>
   <result pre="G Balottin U Gamba N Fazzi E Psychological aspects of" exact="migraine" post="in childhood Cephalalgia 1983 3 Suppl 1 218 220"/>
   <result pre="Sperling M A further contribution to the psycho-analytic study of" exact="migraine" post="and psychogenic headaches. The relation of migraine to depression,"/>
   <result pre="psycho-analytic study of migraine and psychogenic headaches. The relation of" exact="migraine" post="to depression, states of withdrawal, petit mal, and epilepsy"/>
   <result pre="of migraine to depression, states of withdrawal, petit mal, and" exact="epilepsy" post="Int J Psychoanal 1964 45 549 557 14236193 Vincent"/>
   <result pre="2012 38 3 10.1186/1824-7288-38-3 22281207 Mannarini S Boffo M Assessing" exact="mental disorder" post="causal beliefs: a latent dimension identification Community Ment Health"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC3996073/results/search/disease/results.xml">
   <result pre="24580721 doi: 10.1186/1129-2377-15-12 : Research Article Headstrong intervention for pediatric" exact="migraine" post="headache: a randomized clinical trial Rapoff Michael A 1"/>
   <result pre="life. Methods Participants were 35 children ages 7–12 years with" exact="migraine" post="recruited from one university medical center and two children’s"/>
   <result pre="has been estimated to be as high as 58.4%, with" exact="migraine" post="occurring in up to 10% of young children ["/>
   <result pre="is regarded as the optimal standard of care for pediatric" exact="migraine" post="[ 6, 7]. Traditional biobehavioral interventions include relaxation, biofeedback,"/>
   <result pre="have been developed and tested with children and adolescents with" exact="migraine" post="[ 12- 14] and other recurrent or persistent pain"/>
   <result pre="pediatric headache [ 18, 19]. We hypothesized that children with" exact="migraine" post="headaches who received the Headstrong program would demonstrate greater"/>
   <result pre="following inclusion criteria: (a) 7–12 years of age; (b) having" exact="migraine" post="occurring on the average at least once per week"/>
   <result pre="symptom-free periods; and (c) having a board-certified neurologist's diagnosis of" exact="migraine" post="with or without aura, using International Classification of Headache"/>
   <result pre="30] and it can reliably document the effects of pediatric" exact="migraine" post="on QOL [ 3, 31]. The Total Scale Score"/>
   <result pre="71%, fathers 68%), and the children diagnosed most frequently with" exact="migraine" post="headache (94%) and treated with prescribed ibuprofen (57%) and/or"/>
   <result pre="of these findings is also limited for the broader pediatric" exact="migraine" post="population because of our exclusion of children with headaches"/>
   <result pre="Razak S Sivaraman B Graham C Prevalence of headache and" exact="migraine" post="in children and adolescents: a systematic review of population-based"/>
   <result pre="study of a minimal-contact thermal biofeedback treatment in children with" exact="migraine" post="J Pediatr Psychol 2002 15 109 119 10.1093/jpepsy/27.2.109 11821495"/>
   <result pre="Weert E Bouma J Promoting physical activity in children with" exact="juvenile idiopathic arthritis" post="through an internet-based program: Results of a pilot randomized"/>
   <result pre="Bouma J Promoting physical activity in children with juvenile idiopathic" exact="arthritis" post="through an internet-based program: Results of a pilot randomized"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC4239406/results/search/disease/results.xml">
   <result pre="pmcid: 4239406 pmid: 25928129 92 doi: 10.1186/s13052-014-0092-4 : Review Pediatric" exact="migraine" post="and episodic syndromes that may be associated with migraine"/>
   <result pre="Pediatric migraine and episodic syndromes that may be associated with" exact="migraine" post="Spiri Daniele danielespiri@libero.it Rinaldi Victoria Elisa victoria.rinaldi87@gmail.com Titomanlio Luigi"/>
   <result pre="common precursors of migraine. Objective To review current knowledge on" exact="migraine" post="and childhood episodic syndromes, and to discuss future directions"/>
   <result pre="photophobia and phonophobia that must be inferred from behaviour. Classical" exact="migraine" post="features are rare before the age of 6 years,"/>
   <result pre="benign paroxysmal vertigo of childhood, cyclic vomiting syndrome and abdominal" exact="migraine" post="are currently classified as childhood episodic syndromes, and therefore"/>
   <result pre="precursors of migraine. A strong association between infantile colic and" exact="migraine" post="has recently been reported. There are similarities between children"/>
   <result pre="gastrointestinal, neurologic, and vasomotor features. The real pathophysiological mechanisms of" exact="migraine" post="are not fully understood. Current data obtained through molecular"/>
   <result pre="which vascular and neurologic events cooperate in the pathogenesis of" exact="migraine" post="attacks. Genetic factors causing disturbances in neuronal ion channels,"/>
   <result pre="factors that activate the nociception cascade. The expanding knowledge on" exact="migraine" post="genetics and pathophysiology may be applicable to childhood episodic"/>
   <result pre="found to be effective also in the treatment of acute" exact="migraine" post="attacks. Triptans are the specific fist-line drugs for acute"/>
   <result pre="migraine attacks. Triptans are the specific fist-line drugs for acute" exact="migraine" post="treatment. Conclusions and relevance Migraine phenotype differs somewhat in"/>
   <result pre="developing brain, and childhood episodic syndromes may arise before typical" exact="migraine" post="headache. Diagnosing pediatric migraine may be difficult because of"/>
   <result pre="episodic syndromes may arise before typical migraine headache. Diagnosing pediatric" exact="migraine" post="may be difficult because of children’s language and cognitive"/>
   <result pre="of children’s language and cognitive abilities. The risk of underestimating" exact="migraine" post="in pediatric age is high. An adequate diagnosis is"/>
   <result pre="in children and adolescents visiting a pediatrician [ 1] and" exact="migraine" post="is one of the most common causes of primary"/>
   <result pre="associated agents [ 4]. First degree relatives of subjects with" exact="migraine" post="have a 1.9 times higher risk of developing migraine"/>
   <result pre="with migraine have a 1.9 times higher risk of developing" exact="migraine" post="compared to the general population [ 5, 6] and"/>
   <result pre="general population [ 5, 6] and the concordance rate for" exact="migraine" post="with aura in monozygotic twins is 34% compared to"/>
   <result pre="twins [ 7], suggesting the importance of genetic factors in" exact="migraine" post="development. Migraine is disabling at all ages; in children"/>
   <result pre="10]. We aimed at reviewing current knowledge and concerns on" exact="migraine" post="and related episodic syndromes. To identify articles a literature"/>
   <result pre="is available [ 12]. Diagnostic International Headache Society criteria for" exact="migraine" post="without aura and migraine with aura Migraine without aura"/>
   <result pre="Diagnostic International Headache Society criteria for migraine without aura and" exact="migraine" post="with aura Migraine without aura A. At least 5"/>
   <result pre="for the classification work. Already in the ICHD-II, criteria for" exact="migraine" post="had been specifically adopted for use in children allowing"/>
   <result pre="patients to be classified. The two most frequent subtypes of" exact="migraine" post="in pediatric population are respectively migraine without aura and"/>
   <result pre="most frequent subtypes of migraine in pediatric population are respectively" exact="migraine" post="without aura and migraine with aura. Aura is defined"/>
   <result pre="migraine in pediatric population are respectively migraine without aura and" exact="migraine" post="with aura. Aura is defined as a transient focal"/>
   <result pre="a specific primary headache diagnosis [ 14- 16]. Criteria for" exact="migraine" post="diagnosis in children and adolescents are confirmed in ICHD-III"/>
   <result pre="beta except for duration of attacks. For the ICHD-II classification" exact="migraine" post="may last as little as 1 hour whereas in"/>
   <result pre="minimum of 4 hours in adults): the evidence for untreated" exact="migraine" post="with a duration inferior than 2 hours in children"/>
   <result pre="periodic occurrence is observed as the outstanding feature in all" exact="migraine" post="manifestations at this age [ 17]. Children often experience"/>
   <result pre="leading to a misdiagnosis of sinus headache and delaying appropriate" exact="migraine" post="therapy [ 19]. In children, migraine with aura is"/>
   <result pre="headache and delaying appropriate migraine therapy [ 19]. In children," exact="migraine" post="with aura is less frequent than migraine without aura."/>
   <result pre="19]. In children, migraine with aura is less frequent than" exact="migraine" post="without aura. The most common aura symptoms in children"/>
   <result pre="decades, modifications of ICHD criteria permitted to improve sensitivity of" exact="migraine" post="diagnosis in children up to 84.4% [ 20, 21]"/>
   <result pre="study conducted by De Carlo found that 34.6% of pediatric" exact="migraine" post="patients have osmophobia and when this symptom was utilized"/>
   <result pre="was an increase in the percentage of subjects with a" exact="migraine" post="diagnosis [ 23]. Migraine pathogenetic hypothesis Eight genes have"/>
   <result pre="have been so far identified as being associated with common" exact="migraine" post="(i.e. with and without aura) [ 24, 25]. MTDH,"/>
   <result pre="signalling pathways [ 26]. Many advances in the understanding of" exact="migraine" post="pathophysiology have been possible through to the study of"/>
   <result pre="to the study of the rare autosominal dominant Familial hemiplegic" exact="migraine" post="(FHM). Gene mutations in membrane ion channel transport proteins,"/>
   <result pre="transient unilateral motor weakness that characterizes this rare type of" exact="migraine" post="usually lasts for a few hours and neuroimaging abnormalities"/>
   <result pre="the attack onset [ 29]. The real pathophysiological mechanisms of" exact="migraine" post="are not fully understood. For decades, the throbbing pain"/>
   <result pre="are not fully understood. For decades, the throbbing pain during" exact="migraine" post="headache was thought to originate from dilated cranial arteries:"/>
   <result pre="diminished and neuronal mechanisms have been suggested as generators of" exact="migraine" post="headache, without abnormal activation of perivascular sensory fibers ["/>
   <result pre="which vascular and neurologic events cooperate in the pathogenesis of" exact="migraine" post="attacks without aura [ 32]. Afferent innervations of intracranial"/>
   <result pre="forming the Trigemino-Vascular System (TVS), are the essential substrate for" exact="migraine" post="pain in this intricate network [ 33] (Figure 1)."/>
   <result pre="in a recent study conducted using MRA during spontaneous unilateral" exact="migraine" post="attacks, demonstrates that migraine pain is not accompanied by"/>
   <result pre="conducted using MRA during spontaneous unilateral migraine attacks, demonstrates that" exact="migraine" post="pain is not accompanied by extracranial arterial dilatation but"/>
   <result pre="to days in correspondence with the duration of a typical" exact="migraine" post="episode. The cortical spreading depression (CSD) theory is thought"/>
   <result pre="spreading depression (CSD) theory is thought to explain generation of" exact="migraine" post="attacks with aura. Transcranial magnetic stimulation and functional MRI"/>
   <result pre="occipital region. This suggests that the initial phase of a" exact="migraine" post="attack with aura is a wave of cortical spreading"/>
   <result pre="wave of cortical spreading depression which is associated with the" exact="suppression" post="of spontaneous EEG activity and regional oligemia. CSD begins"/>
   <result pre="[ 37]. Recent studies have suggested that some types of" exact="migraine" post="may be related to a mitochondrial dysfunction [ 38]."/>
   <result pre="energy failure in neurons and astrocytes. These events can trigger" exact="migraine" post="mechanisms ultimately causing CSD. Further studies are required to"/>
   <result pre="migraineur more sensitive to multiple trigger factors. The generation of" exact="migraine" post="pain is probably a consequence of multiple pathophysiological changes"/>
   <result pre="as the thalamus and the cortex [ 39]. Treatment of" exact="migraine" post="An appropriate migraine management requires filling in a diary"/>
   <result pre="and the cortex [ 39]. Treatment of migraine An appropriate" exact="migraine" post="management requires filling in a diary for at least"/>
   <result pre="and could be beneficial in childhood episodic syndromes. Prevention of" exact="migraine" post="attacks includes trigger management and adequate pharmacologic treatments, when"/>
   <result pre="includes trigger management and adequate pharmacologic treatments, when needed. Frequent" exact="migraine" post="triggers, such as physical and mental stress, school problems,"/>
   <result pre="activity are the first steps to achieve a high quality" exact="migraine" post="therapy. Distraction techniques, relaxation and biofeedback are also valuable"/>
   <result pre="valuable tools that pediatricians must take into account in managing" exact="migraine" post="[ 41- 44]. Acute pharmacological treatment consists in using"/>
   <result pre="Acute pharmacological treatment consists in using drugs only during a" exact="migraine" post="attack. Its goal is to completely eliminate pain and"/>
   <result pre="found to be effective also in the treatment of acute" exact="migraine" post="attacks [ 45, 46]. Triptans are the specific fist-line"/>
   <result pre="45, 46]. Triptans are the specific fist-line drugs for acute" exact="migraine" post="treatment [ 47, 48]. Although nasal spray sumatriptan ["/>
   <result pre="56] and opioids are not considered first-line treatment of acute" exact="migraine" post="in children and adolescents because of their potential side-effects"/>
   <result pre="opioids, because of their association with the development of chronic" exact="migraine" post="and medication overuse headache [ 57, 58]. Sheridan et"/>
   <result pre="evidence based clinical guidelines, a large number of children with" exact="migraine" post="continued to receive opioids as acute treatment. Pharmacologic preventive"/>
   <result pre="as acute treatment. Pharmacologic preventive treatment is generally proposed when" exact="migraine" post="attacks occur once a week or whenever the attacks"/>
   <result pre="the attacks are particularly long and debilitating [ 60]. Among" exact="migraine" post="preventives, topiramate [ 61- 63], flunarizine [ 64], amitriptyline"/>
   <result pre="and sensorimotor disturbances, anorexia, recurrent abdominal pain, nausea and vomiting," exact="motion sickness," post="sleep and behavioural disorders) may occur in children in"/>
   <result pre="absence of headache and may precede the development of typical" exact="migraine" post="manifestations by several years [ 69, 70]. Benign paroxysmal"/>
   <result pre="paroxysmal torticollis, benign paroxysmal vertigo, cyclic vomiting syndrome and abdominal" exact="migraine" post="are defined as &quot;episodic syndromes that may be associated"/>
   <result pre="In 2001, Jan documented a relationship between infantile colic and" exact="migraine" post="[ 71]. His data suggested that children with migraine"/>
   <result pre="and migraine [ 71]. His data suggested that children with" exact="migraine" post="were more likely to have a personal history of"/>
   <result pre="infantile colic and a family history of infantile colic or" exact="migraine" post="in any of the first-degree relatives. Children with a"/>
   <result pre="some genetically predisposed infants could represent a form of infantile" exact="migraine" post="with an age specific expression. We recently confirmed the"/>
   <result pre="an age specific expression. We recently confirmed the association between" exact="migraine" post="and infantile colic with a multicenter case-control study ["/>
   <result pre="colic may represent one of the earliest clinical manifestations of" exact="migraine" post="such as the episodic syndromes included in ICHD-III beta"/>
   <result pre="tonic up gaze [ 73], recurrent abdominal pain [ 74]," exact="motion sickness" post="[ 75], recurrent limb pain [ 76], and parasomnias"/>
   <result pre="76], and parasomnias [ 77] are not clearly associated with" exact="migraine" post="and are not yet universally accepted as precursors of"/>
   <result pre="with episodic syndromes often have a positive family history for" exact="migraine" post="and those with earlier-onset episodic syndromes may eventually develop"/>
   <result pre="migraine and those with earlier-onset episodic syndromes may eventually develop" exact="migraine" post="in adolescence or adult age [ 81]. The clinical"/>
   <result pre="to observe pallor, photophobia, ataxia, drowsiness and headache which resemble" exact="migraine" post="features. The episodes often last from several hours to"/>
   <result pre="from benign paroxysmal vertigo have a positive family history for" exact="migraine" post="and a positive family and personal history for motion"/>
   <result pre="for migraine and a positive family and personal history for" exact="motion sickness." post="Some patients may develop other childhood episodic syndromes such"/>
   <result pre="benign paroxysmal vertigo may constitute an early-onset variant of basilar-type" exact="migraine" post="[ 90]. Cyclic vomiting syndrome (ICHD III beta 1.6.1.1)"/>
   <result pre="is 10 years and 75% of affected children will develop" exact="migraine" post="by the age of 18 years [ 94]. Abdominal"/>
   <result pre="migraine by the age of 18 years [ 94]. Abdominal" exact="migraine" post="(ICHD III beta 1.6.1.2) Abdominal migraine is characterized by"/>
   <result pre="years [ 94]. Abdominal migraine (ICHD III beta 1.6.1.2) Abdominal" exact="migraine" post="is characterized by recurrent, acute-onset abdominal pain lasting for"/>
   <result pre="children are completely healthy [ 96]. The onset of abdominal" exact="migraine" post="occurs at the age of 7 years with a"/>
   <result pre="years of age [ 97]. Some studies suggest that abdominal" exact="migraine" post="could persist into adult life and 70% of affected"/>
   <result pre="persist into adult life and 70% of affected children develop" exact="migraine" post="as they grow older. There are similarities between affected"/>
   <result pre="older. There are similarities between affected children and children with" exact="migraine" post="regarding demographic, social, clinical and familial features. Moreover, children"/>
   <result pre="demographic, social, clinical and familial features. Moreover, children with abdominal" exact="migraine" post="manifest similar triggering events such as psychological stress, physical"/>
   <result pre="similar triggering events such as psychological stress, physical exhaustion and" exact="motion sickness" post="[ 93]. Sometimes, a preceding aura occurs with visual"/>
   <result pre="weakness. Childhood episodic syndromes pathogenetic hypothesis The expanding knowledge on" exact="migraine" post="genetics and pathophysiology may be applicable to childhood episodic"/>
   <result pre="[ 98], it has been hypothesized that pathogenesis of abdominal" exact="migraine" post="consists in an increased arousal in the CNS in"/>
   <result pre="in the gut, as happens in the brain during a" exact="migraine" post="attack [ 72]. The potential role of molecules as"/>
   <result pre="colic symptoms, as it is often observed in patients with" exact="migraine" post="[ 100]. Cyclic vomiting syndrome is also believed to"/>
   <result pre="The same dysregulated pathways may be involved in symptoms accompanying" exact="migraine" post="attacks as nausea and vomiting [ 103]. Mutations in"/>
   <result pre="another argument in favour of a relationship with migraine. Abdominal" exact="migraine" post="generally responds to triptans [ 106]. Preventive treatment with"/>
   <result pre="or long-lasting [ 107]. Remaining concerns and future directions for" exact="migraine" post="and related syndromes ICHD criteria are useful to simplify"/>
   <result pre="to primary headache, and represent the gold standard for diagnosing" exact="migraine" post="and childhood episodic syndromes. However, applying diagnostic criteria to"/>
   <result pre="considered respectively as a precursor and an alternative symptom of" exact="migraine" post="in future revisions, because of the strong association observed."/>
   <result pre="pulsating nature, worsening or limiting physical activity, improved accuracy of" exact="migraine" post="diagnosis in children [ 20, 22]. Indeed, when migraine"/>
   <result pre="of migraine diagnosis in children [ 20, 22]. Indeed, when" exact="migraine" post="is under-diagnosed the risk is of an immoderate use"/>
   <result pre="genetics have advanced our understanding of the genetic basis of" exact="migraine" post="and related syndromes, also revealing promising treatment targets for"/>
   <result pre="have revealed ion channels and transporter mutations as causative of" exact="migraine" post="[ 111], which seems to be related to ionic"/>
   <result pre="and promote the research for the missing heritability of common" exact="migraine" post="[ 112]. These platforms are able to generate more"/>
   <result pre="expensive and could help us in finding answers to how" exact="migraine" post="attacks start [ 113] and what the links with"/>
   <result pre="next future how non-genetic triggers may modulate attack frequency of" exact="migraine" post="[ 114]. It is realistic to imagine that further"/>
   <result pre="targets, and this will also help in the understanding of" exact="migraine" post="pathogenic process, which is essential for a rational development"/>
   <result pre="attacks are often debilitating and can last for days. When" exact="migraine" post="attacks are too frequent, too long, or too painful,"/>
   <result pre="life quality by validated scores [ 121], not only in" exact="migraine" post="but also in episodic syndromes, when possible. Performing a"/>
   <result pre="between psychiatric and psychological co morbidities in children suffering from" exact="migraine" post="and cyclic vomiting. Whether these comorbidities are triggers or"/>
   <result pre="the care of children and adolescents with headache. Diagnosing pediatric" exact="migraine" post="may be difficult because of children’s language and cognitive"/>
   <result pre="from behaviour. The risk of underestimating the real prevalence of" exact="migraine" post="in pediatric age is high and an adequate diagnosis"/>
   <result pre="developing brain, and childhood episodic syndromes may arise before typical" exact="migraine" post="headache. Being familiar with the characteristics and evolution of"/>
   <result pre="EEG Electroencephalogram FDA Food and Drugs Administration FHM Familial hemiplegic" exact="migraine" post="ICHD Criteria of the International Classification of Headache Disorders"/>
   <result pre="J Increased familial risk and evidence of genetic factor in" exact="migraine" post="BMJ 1995 311 541 544 10.1136/bmj.311.7004.541 7663209 6. Bener"/>
   <result pre="Kilpelainen H Obineche E Genetic and environmental factors associated with" exact="migraine" post="in schoolchildren Headache 2000 40 152 157 10.1046/j.1526-4610.2000.00021.x 10759915"/>
   <result pre="Olesen J Russell MB Evidence of a genetic factor in" exact="migraine" post="with aura: a population-based Danish twin study Ann Neurol"/>
   <result pre="in a clinical population of patients with episodic and chronic" exact="migraine" post="Headache 2005 45 561 570 10.1111/j.1526-4610.2005.05110.x 15953275 9. Jacobs"/>
   <result pre="339 10.1111/j.1526-4610.2011.02086.x 22288433 10. Arruda MA Bigal ME Migraine and" exact="migraine" post="subtypes in preadolescent children: association with school performance Neurology"/>
   <result pre="AA Reider AC Goadsby PJ Cranial autonomic symptoms in pediatric" exact="migraine" post="are the rule, not the exception Neurology 2013 81"/>
   <result pre="Use of the ICHD-II criteria in the diagnosis of pediatric" exact="migraine" post="Headache 2005 45 1288 1297 10.1111/j.1526-4610.2005.00260.x 16324160 22. Balottin"/>
   <result pre="Tozzi E Vecchio A Zanchin G Battistella PA Osmophobia in" exact="migraine" post="classification: a multicentre study in juvenile patients Cephalalgia 2010"/>
   <result pre="Hauge A Werge T et al. Genome-wide association study of" exact="migraine" post="implicates a common susceptibility variant on 8q22.1 Nat Genet"/>
   <result pre="T Genome-wide association study reveals three susceptibility loci for common" exact="migraine" post="in the general population Nat Genet 2011 43 695"/>
   <result pre="695 698 10.1038/ng.856 21666692 26. Ferrari MD Headache: the changing" exact="migraine" post="brain Lancet Neurol 2013 12 6 8 10.1016/S1474-4422(12)70290-9 23237889"/>
   <result pre="expression of the Na(+)-HCO(3)(-) cotransporter NBCe1 is associated with familial" exact="migraine" post="Proc Natl Acad Sci U S A 2010 107"/>
   <result pre="the cranial arteries in subjects with vascular headache of the" exact="migraine" post="type AMA Arch Neurol Psychiatry 1953 70 551 557"/>
   <result pre="angiography of intracranial and extracranial arteries in patients with spontaneous" exact="migraine" post="without aura: a cross-sectional study Lancet Neurol 2013 12"/>
   <result pre="10.1016/S1474-4422(13)70067-X 23578775 36. Durham PL Calcitonin gene-related peptide (CGRP) and" exact="migraine" post="Headache 2006 46 Suppl 1 S3 S8 10.1111/j.1526-4610.2006.00483.x 16927957"/>
   <result pre="S8 10.1111/j.1526-4610.2006.00483.x 16927957 37. Ayata C Cortical spreading depression triggers" exact="migraine" post="attack: pro Headache 2010 50 725 730 10.1111/j.1526-4610.2010.01647.x 20456160"/>
   <result pre="20456160 38. Yorns WR Jr Hardison HH Mitochondrial dysfunction in" exact="migraine" post="Semin Pediatr Neurol 2013 20 188 193 10.1016/j.spen.2013.09.002 24331360"/>
   <result pre="Vasoactive peptide release in the extracerebral circulation of humans during" exact="migraine" post="headache Ann Neurol 1990 28 183 187 10.1002/ana.410280213 1699472"/>
   <result pre="SL Segers A Manning P Powers SW Hershey AD Menstrual" exact="migraine" post="in adolescents Headache 2009 49 341 347 10.1111/j.1526-4610.2009.01347.x 19220498"/>
   <result pre="Varkey E Cider A Carlsson J Linde M Exercise as" exact="migraine" post="prophylaxis: a randomized study using relaxation and topiramate as"/>
   <result pre="Evans RW A rational approach to the management of chronic" exact="migraine" post="Headache 2013 53 168 176 10.1111/head.12014 23293866 44. Bromberg"/>
   <result pre="EJ A randomized trial of a web-based intervention to improve" exact="migraine" post="self-management and coping Headache 2012 52 244 261 10.1111/j.1526-4610.2011.02031.x"/>
   <result pre="L Children’s ibuprofen suspension for the acute treatment of pediatric" exact="migraine" post="Headache 2002 42 780 786 10.1046/j.1526-4610.2002.02180.x 12390641 46. Hamalainen"/>
   <result pre="Santavuori P Ibuprofen or acetaminophen for the acute treatment of" exact="migraine" post="in children: a double-blind, randomized, placebo-controlled, crossover study Neurology"/>
   <result pre="H Hoppu K Nasal sumatriptan is effective in treatment of" exact="migraine" post="attacks in children: A randomized trial Neurology 2004 62"/>
   <result pre="study of sumatriptan nasal spray in the treatment of acute" exact="migraine" post="in adolescents Pediatrics 2000 106 989 997 10.1542/peds.106.5.989 11061765"/>
   <result pre="AD Wasiewski WW Efficacy of zolmitriptan nasal spray in adolescent" exact="migraine" post="Pediatrics 2007 120 390 396 10.1542/peds.2007-0085 17671066 50. Linder"/>
   <result pre="Eerola M Hoppu K A randomized trial of rizatriptan in" exact="migraine" post="attacks in children Neurology 2006 67 1135 1140 10.1212/01.wnl.0000238179.79888.44"/>
   <result pre="Pharmacology of dihydroergotamine and evidence for efficacy and safety in" exact="migraine" post="Headache 2006 46 Suppl 4 S171 S181 10.1111/j.1526-4610.2006.00601.x 17078849"/>
   <result pre="D Buse D Scher A Stewart WF Lipton RB Acute" exact="migraine" post="medications and evolution from episodic to chronic migraine: a"/>
   <result pre="AD Current approaches to the diagnosis and management of pediatric" exact="migraine" post="Lancet Neurol 2010 9 190 204 10.1016/S1474-4422(09)70303-5 20129168 57."/>
   <result pre="study to evaluate the efficacy and safety of topiramate for" exact="migraine" post="prevention in pediatric subjects 12 to 17 years of"/>
   <result pre="double-blind, dose comparison study of topiramate for prophylaxis of basilar-type" exact="migraine" post="in children: a pilot study Headache 2007 47 1409"/>
   <result pre="Diamond S Scott D Jones V Prophylactic treatment of pediatric" exact="migraine" post="Headache 2004 44 230 237 10.1111/j.1526-4610.2004.04052.x 15012660 64. Apostol"/>
   <result pre="and tolerability of divalproex sodium extended-release in the prophylaxis of" exact="migraine" post="headaches: results of an open-label extension trial in adolescents"/>
   <result pre="WM Saltarelli MD Divalproex sodium extended-release for the prophylaxis of" exact="migraine" post="headache in adolescents: results of a stand-alone, long-term open-label"/>
   <result pre="MJ Kay J Jaron A Clinical epidemiology of childhood abdominal" exact="migraine" post="in an urban general practice Dev Med Child Neurol"/>
   <result pre="EEG changes in a case of cyclic vomiting: evidence for" exact="migraine" post="equivalent Dev Med Child Neurol 1991 33 80 85"/>
   <result pre="GV Crichiutti G Alberti C Titomanlio L Association between childhood" exact="migraine" post="and history of infantile colic JAMA 2013 309 1607"/>
   <result pre="the headache: infant colic as an early life expression of" exact="migraine" post="Neurology 2012 79 1392 1396 10.1212/WNL.0b013e31826c1b7b 22972642 81. Cuenca-Leon"/>
   <result pre="Genetic analysis of 27 Spanish patients with hemiplegic migraine, basilar-type" exact="migraine" post="and childhood periodic syndromes Cephalalgia 2008 28 1039 1047"/>
   <result pre="Abu-Arafeh I Russell G Prevalence and clinical features of abdominal" exact="migraine" post="compared with those of migraine headache Arch Dis Child"/>
   <result pre="and clinical features of abdominal migraine compared with those of" exact="migraine" post="headache Arch Dis Child 1995 72 413 417 10.1136/adc.72.5.413"/>
   <result pre="96. Tan V Sahami AR Peebles R Shaw RJ Abdominal" exact="migraine" post="and treatment with intravenous valproic Acid Psychosomatics 2006 47"/>
   <result pre="10.1002/ibd.21422 20722067 100. Epstein LG Zee PC Infantile colic and" exact="migraine" post="JAMA 2013 309 1636 1637 10.1001/jama.2013.3873 23592110 101. Abell"/>
   <result pre="mutation with heterogeneous paroxysmal disorders including paroxysmal torticollis and hemiplegic" exact="migraine" post="Dev Med Child Neurol 2012 54 958 960 10.1111/j.1469-8749.2012.04394.x"/>
   <result pre="flunarizine in the prophylaxis of cyclical vomiting syndrome and abdominal" exact="migraine" post="Eur J Paediatr Neurol 2005 9 23 26 10.1016/j.ejpn.2004.11.002"/>
   <result pre="headache disorders diagnostic criteria (ICHD I-1988) and (ICHD II-2004), for" exact="migraine" post="in children and adolescents Cephalalgia 2005 25 1042 1047"/>
   <result pre="10.1002/pds.1748 19358227 111. Weir GA Cader MZ New directions in" exact="migraine" post="BMC Med 2011 9 116 10.1186/1741-7015-9-116 22027350 112. Eising"/>
   <result pre="den Maagdenberg AM Pearls and pitfalls in genetic studies of" exact="migraine" post="Cephalalgia 2013 33 614 625 10.1177/0333102413484988 23671257 113. Di"/>
   <result pre="disability, and illness attribution in adolescents with chronic fatigue or" exact="migraine" post="Pediatrics 2003 111 e376 e381 10.1542/peds.111.4.e376 12671155 118. Milde-Busch"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC4759342/results/search/disease/results.xml">
   <result pre=": Poster Presentation P072. The visual cortical excitability in pediatric" exact="migraine" post="as tested by sound-induced flash illusions Di Marco Salvatore"/>
   <result pre="we used SIFI to evaluate V1 excitability in children with" exact="migraine" post="assessing also age-related differences in cross-modal audio-visual perception. Materials"/>
   <result pre="cross-modal audio-visual perception. Materials Twelve children (7 females) affected by" exact="migraine" post="without aura: mean age: 10.17±2.76 years, disease duration: 2.91±2.34"/>
   <result pre="(fusions p &amp;lt; .005, fissions p &amp;lt; .00001). Children with" exact="migraine" post="did not differ from age matched controls in the"/>
   <result pre="percept between controls and patients emerged, the increased ability of" exact="migraine" post="children to perceive flashes, even outside migraine attack, reveals"/>
   <result pre="increased ability of migraine children to perceive flashes, even outside" exact="migraine" post="attack, reveals a hyper-functional visual cortex in migraine also"/>
   <result pre="even outside migraine attack, reveals a hyper-functional visual cortex in" exact="migraine" post="also in pediatric age. The sound-induced flash illusions proved"/>
   <result pre="Paladino P Baschi R Fierro B Visual cortex hyperexcitability in" exact="migraine" post="in response to sound-induced flash illusions Neurology 2015 84"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5449358/results/search/disease/results.xml">
   <result pre="Research Article Symptoms of central sensitization and comorbidity for juvenile" exact="fibromyalgia" post="in childhood migraine: an observational study in a tertiary"/>
   <result pre="migraine, clinically expressed by allodynia, pericranial tenderness and comorbidity for" exact="fibromyalgia" post="in a relevant number of patients. This study aimed"/>
   <result pre="and comorbidity for Juvenile Fibromialgia (JFM) in a cohort of" exact="migraine" post="children selected in a tertiary headache center. Methods This"/>
   <result pre="This was an observational cross-sectional study on 8–15 years old" exact="migraine" post="patients. Allodynia was assessed by a questionnaire. Pericranial tenderness"/>
   <result pre="as their possible association with poor quality of life and" exact="migraine" post="related disability, and with other clinical symptoms as anxiety,"/>
   <result pre="One hundred and fifty one patients were selected, including chronic" exact="migraine" post="(n°47), migraine without aura (n° 92) and migraine with"/>
   <result pre="and fifty one patients were selected, including chronic migraine (n°47)," exact="migraine" post="without aura (n° 92) and migraine with aura (n°"/>
   <result pre="including chronic migraine (n°47), migraine without aura (n° 92) and" exact="migraine" post="with aura (n° 12) sufferers. Allodynia was reported in"/>
   <result pre="Pericranial tenderness was more severe in patients with more frequent" exact="migraine" post="and shorter sleep duration. Allodynia seemed associated with anxiety,"/>
   <result pre="Studi di Bari Aldo Moro Background Migraine is a chronic" exact="neurological disorder," post="with an early onset in childhood and juvenile age."/>
   <result pre="Classification of Headache Disorders, 3rd beta edition, includes footnotes for" exact="migraine" post="diagnostic criteria in childhood [ 3, 4]. Central sensitization"/>
   <result pre="3, 4]. Central sensitization is an important epiphenomenon of the" exact="migraine" post="attack. It is caused by functional modifications of the"/>
   <result pre="5]. It was described in almost the 70% of episodic" exact="migraine" post="patients and in the 90% of chronic migraine sufferers,"/>
   <result pre="of episodic migraine patients and in the 90% of chronic" exact="migraine" post="sufferers, as a factor predicting the chronic evolution of"/>
   <result pre="patients, allodynia was more represented in the group of chronic" exact="migraine" post="patients, with a positive correlation with anxiety, depression and"/>
   <result pre="in large samples of patients in adult age, affected by" exact="migraine" post="and other primary headaches [ 9, 10]. Pericranial tenderness"/>
   <result pre="the presence of symptoms of central sensitization even in childhood" exact="migraine" post="[ 13, 14]. In those studies, allodynia was retrospectively"/>
   <result pre="that this symptom was present in a large number of" exact="migraine" post="children [ 14]. Other signs of central sensitization, as"/>
   <result pre="diffusion of pain symptoms outside the trigemino-cervical districts, as for" exact="fibromyalgia" post="comorbidity, were rarely assessed in childhood migraine [ 15,"/>
   <result pre="districts, as for fibromyalgia comorbidity, were rarely assessed in childhood" exact="migraine" post="[ 15, 16] In addition, children with migraine are"/>
   <result pre="in childhood migraine [ 15, 16] In addition, children with" exact="migraine" post="are frequently characterized by psychopathological traits which may facilitate"/>
   <result pre="almost all patients, suggesting a higher representation in the juvenile" exact="migraine" post="than in the adult form [ 16]. Fibromyalgia (FM)"/>
   <result pre="the impact of FM on the global burden of adult" exact="migraine" post="[ 24, 25], the assessment of frequency and clinical"/>
   <result pre="pericranial tenderness and JFM in a population of children with" exact="migraine" post="selected in a tertiary headache center. 2) assess if"/>
   <result pre="center. 2) assess if the severity of allodynia,pericranial tenderness and" exact="fibromyalgia" post="might be associated a) with the headache-related disability and"/>
   <result pre="on distinct days. The inclusion criteria were a diagnosis of" exact="migraine" post="without aura (MA cod. 1.1), migraine with aura (MWA"/>
   <result pre="were a diagnosis of migraine without aura (MA cod. 1.1)," exact="migraine" post="with aura (MWA cod 1.2.1) and chronic migraine (CM"/>
   <result pre="cod. 1.1), migraine with aura (MWA cod 1.2.1) and chronic" exact="migraine" post="(CM 1.3), according to the International Classification of Headache"/>
   <result pre="diseases and with any other neurologic condition. The diagnosis of" exact="migraine" post="was confirmed on the basis of at least 3"/>
   <result pre="1 Flow chart reporting main study design Clinical assessment All" exact="migraine" post="patients and their parents were carefully interviewed by the"/>
   <result pre="11, 16]. Allodynia Mothers were requested to interview children during" exact="migraine" post="attack, in order to help them in filling the"/>
   <result pre="to help them in filling the allodynia questionnaire for each" exact="migraine" post="attack. We proposed the same questionnaires employed for adults"/>
   <result pre="headache episodes. Juvenile Fibromyalgia comorbidity In order to individuate the" exact="migraine" post="children with the comorbidity for JFM, we applied the"/>
   <result pre="22], recently validated also in adolescents [ 23]. Symptoms of" exact="fibromyalgia" post="were examined using the Widespread Pain Index (WPI) and"/>
   <result pre="for FM [ 22] and designed to gather information on" exact="fibromyalgia" post="symptoms through the children and parents reports. Migraine disability"/>
   <result pre="were summarized using means and standard deviation, taking into consideration" exact="migraine" post="subgroups. The allodynia and pericranial tenderness were compared among"/>
   <result pre="migraine subgroups. The allodynia and pericranial tenderness were compared among" exact="migraine" post="groups by means of the Chi-square test and ANOVA"/>
   <result pre="depression, pain catastrophizing and sleep disorders, with the frequency of" exact="migraine" post="as covariate. A value of alpha 0.008 was used"/>
   <result pre="and standard deviations and compared with those of patients without" exact="fibromyalgia" post="by means of one-way ANOVA analysis. Results Among 225"/>
   <result pre="were lost to the first visit. We finally selected 151" exact="migraine" post="patients (Fig. 1; Table 1). Table 1 Mean (M)"/>
   <result pre="and Standard Deviations (SD) of demographic and clinical features of" exact="migraine" post="patients Sex Age (years) Migraine onset (months) Frequency of"/>
   <result pre="Intervals are reported in brackets Demographic and clinical characteristics of" exact="migraine" post="patients. Patients with Chronic Migraine (CM), Migraine without Aura"/>
   <result pre="the CM group (Table 1). Migraine disability prevailed in chronic" exact="migraine" post="children, as compared to the other groups (Table 1)."/>
   <result pre="the other groups (Table 1). Symptoms of central sensitization in" exact="migraine" post="groups- Pericranial tenderness-The most of migraine children presented with"/>
   <result pre="of central sensitization in migraine groups- Pericranial tenderness-The most of" exact="migraine" post="children presented with signs of pericranial tenderness. In fact,"/>
   <result pre="fact, it was present on average in the 68.38% of" exact="migraine" post="patients (66 MA, 30 CM and 10 MWA, chi"/>
   <result pre="The TTS score was not associated to the disability of" exact="migraine" post="and to the quality of life. (Table 2 a),"/>
   <result pre="of symptoms of central sensitization (TTS, Total Tenderness Score) in" exact="migraine" post="children. Divided Into headache diagnosis groups (MA Migraine Without"/>
   <result pre="151). The prevalence of allodynic patients was relevant in all" exact="migraine" post="groups, though in reduced proportion in MWA patients (90"/>
   <result pre="was similar among groups, considering both diagnosis and frequency of" exact="migraine" post="(Fig. 2). Linear regression analysis showed a significant relationship"/>
   <result pre="0.11 2.59 0.01 −0.01 0.04 Comorbidity for Juvenile Fibromyalgia Five" exact="migraine" post="patients fulfilled the criteria for JFM (0.03%). They were"/>
   <result pre="both physical and psychical functions, as compared to the other" exact="migraine" post="patients (Fig. 3). Table 4 Juvenile Fibromyalgia (JFM) comorbidity"/>
   <result pre="(Fig. 3). Table 4 Juvenile Fibromyalgia (JFM) comorbidity in young" exact="migraine" post="Age Frequency Ped MIDAS TTS ALL SAFAA-T SAFAA-D SDSC"/>
   <result pre="pericranial tenderness and allodynia in a population of children with" exact="migraine" post="selected in a tertiary headache center. While pericranial tenderness"/>
   <result pre="next paragraphs, the single results are commented. Clinical characteristics of" exact="migraine" post="We found a large group of young patients with"/>
   <result pre="hypothesis that may be confirmed by the high scores of" exact="migraine" post="disability reported by these patients. These data seem worthy"/>
   <result pre="children [ 34– 36]. As expected, the disability linked with" exact="migraine" post="prevailed in the CM group. In general, in patients"/>
   <result pre="the CM patients [ 37]. Symptoms of central sensitization in" exact="migraine" post="and correlation with clinical and psychopathological features –Pericranial tenderness"/>
   <result pre="with clinical and psychopathological features –Pericranial tenderness The most of" exact="migraine" post="patients presented pericranial tenderness, independently of the type of"/>
   <result pre="pericranial muscle pain was significantly higher in patients with chronic" exact="migraine" post="as compared to those with episodic migraine. The comparison"/>
   <result pre="by hyperalgesia, for the persistence of central sensitization between the" exact="migraine" post="attacks. The close relation between an increase in pain"/>
   <result pre="sleep difficulties, including insufficient sleep time, frequently caused by nocturnal" exact="migraine" post="onset [ 38, 39]. The presence of a self-sustained"/>
   <result pre="of sleep reduction, central sensitization and possible evolution into chronic" exact="migraine" post="[ 8], might be supposed even in juvenile age."/>
   <result pre="consequence of the chronic headache. Allodynia In the most of" exact="migraine" post="attacks, children presented allodynia. Its prevalence among migraine patients"/>
   <result pre="most of migraine attacks, children presented allodynia. Its prevalence among" exact="migraine" post="patients was even higher than that reported in previous"/>
   <result pre="prevalence of allodynia in adults approaches the 70% in large" exact="migraine" post="populations, selected by mailing questionnaires [ 10]. In our"/>
   <result pre="sensitive than the retrospective assessment in detecting symptoms associated to" exact="migraine" post="attack. The six items selected by children to describe"/>
   <result pre="migraine. The presence of allodynia seemed reduced in patients with" exact="migraine" post="with aura, though this was a too small group"/>
   <result pre="number of patients rather than be a feature of juvenile" exact="migraine" post="with aura. Allodynia may be confirmed as a common"/>
   <result pre="reported allodynia symptoms appeared similar to that described in adult" exact="migraine" post="[ 8], though it was computed on a reduced"/>
   <result pre="number of allodynia symptoms seemed similar between episodic and chronic" exact="migraine" post="[ 8], a finding that may be confirmed also"/>
   <result pre="of allodynia questionnaire in the routine assessment of children with" exact="migraine" post="may be also suggested by its association with the"/>
   <result pre="allodynia would be a cause of disability of each single" exact="migraine" post="attack, worsening its evolution and hampering child’s ability in"/>
   <result pre="The number of allodynia symptoms reported on average in the" exact="migraine" post="attacks, appeared significantly correlated to anxiety, which would enhance"/>
   <result pre="allodynia was correlated with anxiety and depression in patients with" exact="migraine" post="and tenson type headaches, both chronic and episodic. There"/>
   <result pre="the descendant control for to pain modulation [ 40]. Child" exact="migraine" post="is frequently associated with anxiety and depression [ 41]."/>
   <result pre="anxiety, more than depression, would be predictive of the long-term" exact="migraine" post="persistence and the headache-related disability [ 42– 44], for"/>
   <result pre="might probable enable significant correlations with the single scores. Juvenile" exact="fibromyalgia" post="comorbidity in migraine children Few children among our migraine"/>
   <result pre="significant correlations with the single scores. Juvenile fibromyalgia comorbidity in" exact="migraine" post="children Few children among our migraine population presented comorbidity"/>
   <result pre="Juvenile fibromyalgia comorbidity in migraine children Few children among our" exact="migraine" post="population presented comorbidity for JFM. At the best of"/>
   <result pre="is the first study assessing this comorbidity in children with" exact="migraine" post="and its low frequency in respect to adult migraine"/>
   <result pre="with migraine and its low frequency in respect to adult" exact="migraine" post="[ 2, 8, 24, 25]. Juvenile Fibromyalgia is currently"/>
   <result pre="reduction of quality of life as compared to the other" exact="migraine" post="children. In accord with adult populations [ 8, 24,"/>
   <result pre="disturbances and pain catastrophizing, seemed not to prevail in this" exact="migraine" post="subgroup, though these aspects would deserve further assessment in"/>
   <result pre="in adult studies, with over 75% of cases with an" exact="anxiety disorder" post="and at least one episode of major mood disorder"/>
   <result pre="an anxiety disorder and at least one episode of major" exact="mood disorder" post="(typically major depressive disorder) [ 49]. More cases are"/>
   <result pre="is the utility of clinical follow-up, in order to confirm" exact="migraine" post="diagnosis and the significance of symptoms of central sensitization"/>
   <result pre="into severe disability. Clinical implications The majority of children with" exact="migraine" post="are characterized by allodynia and pericranial tenderness. The comorbidity"/>
   <result pre="their routine assessment in children with migraine. Abbreviations CM Chronic" exact="migraine" post="JFM Juvenile Fibromyalgia MA Migraine without aura MWA Migraine"/>
   <result pre="MWA Migraine with aura PCS-S Total pain catastrophizing PedMIDAS Pediatric" exact="migraine" post="disability PedPa QL-T Total pediatric quality of life-parent PedPar-QLPHY"/>
   <result pre="23771276 4. Winner P Hershey AD Epidemiology and diagnosis of" exact="migraine" post="in children Curr Pain Headache Rep 2007 11 375"/>
   <result pre="Burstein R Yarnitsky D Goor et al. An association between" exact="migraine" post="and cutaneous allodynia Ann Neurol 2000 2000 47 614"/>
   <result pre="Oosterhout WP et al. Cutaneous allodynia as a predictor of" exact="migraine" post="chronification Brain 2013 136 3489 3496 10.1093/brain/awt251 24080152 8."/>
   <result pre="S, Jakubowski M, et al. (2007) Improved identification of allodynic" exact="migraine" post="patients using a questionnaire.Cephalalgia 27: 325–329. 10. Lipton RB"/>
   <result pre="American Migraine Prevalence Prevention Advisory Group. Cutaneous allodynia in the" exact="migraine" post="population Ann Neurol 2008 63 2 148 158 10.1002/ana.21211"/>
   <result pre="14. Raieli V Trapolino D Giordano G et al. Juvenile" exact="migraine" post="and allodynia: results of a retrospective study Headache 2015"/>
   <result pre="pain threshold in pericranial and extracephalic regions in children with" exact="migraine" post="Pain Med 2014 15 702 709 10.1111/pme.12353 24576109 16."/>
   <result pre="al. Laser-evoked potential habituation and central sensitization symptoms in childhood" exact="migraine" post="Cephalalgia 2016 36 5 463 473 10.1177/0333102415597527 26232104 17."/>
   <result pre="M et al. Assessment of nonarticular tenderness and prevalence of" exact="fibromyalgia" post="in children J Rheumatol 1993 20 2 368 370"/>
   <result pre="Burgos-Vargas R Medina-Palma C Lavielle P Marina FF Prevalence of" exact="fibromyalgia" post="in children: a clinical study of Mexican children J"/>
   <result pre="al. The American College of Rheumatology preliminary diagnostic criteria for" exact="fibromyalgia" post="and measurement of symptom severity Arthritis Care Res (Hoboken)"/>
   <result pre="Henrickson M Kashikar-Zuck S 2010 American College of Rheumatology adult" exact="fibromyalgia" post="criteria for use in an adolescent female population with"/>
   <result pre="criteria for use in an adolescent female population with juvenile" exact="fibromyalgia" post="J Pediatr 2016 169 181 187 10.1016/j.jpeds.2015.10.011 26545727 24."/>
   <result pre="de Tommaso M Prevalence, clinical features and potential therapies for" exact="fibromyalgia" post="in primary headaches Expert Rev Neurother 2012 12 3"/>
   <result pre="Serpino C et al. Clinical features of headache patients with" exact="fibromyalgia" post="comorbidity J Headache Pain 2011 12 6 629 638"/>
   <result pre="52 64 10.1097/00002508-200103000-00008 11289089 33. Özge A Yalin OÖ Chronic" exact="migraine" post="in children and adolescents Curr Pain Headache Rep 2016"/>
   <result pre="7034491 35. Waters WE O'Connor PJ Epidemiology of headache and" exact="migraine" post="in women J Neurol Neurosurg Psychiatry 1971 34 2"/>
   <result pre="D Erpelding N Lebel A et al. Sex and the" exact="migraine" post="brain Neurobiol Dis 2014 68 200 214 10.1016/j.nbd.2014.03.008 24662368"/>
   <result pre="41. Cahill CM Cannon M The longitudinal relationship between comorbid" exact="migraine" post="and psychiatric disorder Cephalalgia 2005 25 1099 1100 10.1111/j.1468-2982.2005.00982.x"/>
   <result pre="Lucas C Anxiety and depression associated with migraine: Influence on" exact="migraine" post="subjects’ disability and quality of life, and acute migraine"/>
   <result pre="on migraine subjects’ disability and quality of life, and acute" exact="migraine" post="management Pain 2005 118 319 332 10.1016/j.pain.2005.09.010 16289799 45."/>
   <result pre="Fantini F Assessment of nonarticular tenderness and prevalence of primary" exact="fibromyalgia" post="syndrome in healthy Italian schoolchildren Arthritis Rheum 1998 41"/>
   <result pre="et al. Psychiatric disorders in young adults diagnosed with juvenile" exact="fibromyalgia" post="in adolescence J Rheumatol 2015 42 12 2427 2433"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5515721/results/search/disease/results.xml">
   <result pre="776 doi: 10.1186/s10194-017-0776-4 : Research Article Is topiramate effective for" exact="migraine" post="prevention in patients less than 18 years of age?"/>
   <result pre="used to prevent pediatric migraines. Topiramate has been approved for" exact="migraine" post="prevention in children as young as 12 years of"/>
   <result pre="currently published data pertaining to the efficacy of topiramate for" exact="migraine" post="prevention in patients less than 18 years of age."/>
   <result pre="it has been recognized as one of the most prevalent" exact="neurological disorder" post="in children and adolescents worldwide, affecting 5–10% of the"/>
   <result pre="harmony [ 1, 2]. The mean age of onset of" exact="migraine" post="is 7.2 years in boys and 10.9 years in"/>
   <result pre="10.9 years in girls [ 3], and the prevalence of" exact="migraine" post="increases with age, as demonstrated by clinical studies. The"/>
   <result pre="age, as demonstrated by clinical studies. The diagnostic criteria for" exact="migraine" post="headaches have developed over time; modern migraine classification includes"/>
   <result pre="diagnostic criteria for migraine headaches have developed over time; modern" exact="migraine" post="classification includes frequency as a criterion, with episodic headaches"/>
   <result pre="headaches occurring up to 14 days per month, and chronic" exact="migraine" post="is defined as the persistence of headache without aura"/>
   <result pre="to the harm caused by migraines, reducing the number of" exact="migraine" post="attacks to the greatest extent possible should be a"/>
   <result pre="positive efficacy and safety for older children and adults with" exact="epilepsy" post="[ 6], and it has been approved for migraine"/>
   <result pre="with epilepsy [ 6], and it has been approved for" exact="migraine" post="prevention in adults in Europe since 2003 and in"/>
   <result pre="7]. The exact mechanism of topiramate in the treatment of" exact="migraine" post="is unknown, although it may be associated with the"/>
   <result pre="to evaluate the efficacy of topiramate for the prevention of" exact="migraine" post="in patients less than 18 years of age. Methods"/>
   <result pre="to April 2017) to retrieve the RCTs of topiramate in" exact="migraine" post="prevention for patients less than 18 years of age."/>
   <result pre="the study was a trial comparing topiramate with placebo in" exact="migraine" post="patients, (2) the study had similar diagnostic criteria for"/>
   <result pre="migraine patients, (2) the study had similar diagnostic criteria for" exact="migraine" post="or definition of migraine, (3) the age of the"/>
   <result pre="employed the International Headache Society (IHS) diagnostic criteria for pediatric" exact="migraine" post="and 3 trials [ 14, 18, 19] used the"/>
   <result pre="Paul Winner,2005 International Headache Society (IHS) diagnostic criteria for pediatric" exact="migraine" post="108 11.3 ± 2.5 50.9:49.1 8-week: Week 1 ="/>
   <result pre="2 weeks 16-week: average 1.93 ± 0.40 mg mg/Kg.d aphasia," exact="cognitive disorder," post="dizziness, memory impairment, paresthesia, general: fatigue, dry mouth, intussusception,"/>
   <result pre="all 4 included trials investigated the effects of topiramate on" exact="migraine" post="prevention via the numbers of patients experiencing a ≥"/>
   <result pre="fatigue, injury, upper respiratory tract infection, dizziness, fever, nausea, pharyngitis," exact="sinusitis" post="and somnolence) of topiramate versus placebo(*There was a significant"/>
   <result pre="trials indicate that a clinically meaningful end point in a" exact="migraine" post="prevention trial is usually defined by a reduction in"/>
   <result pre="the U.S. Food and Drug Administration (FDA) approved topiramate for" exact="migraine" post="prevention in the population aged 12 to 17 ["/>
   <result pre="the first and only medication currently approved for use in" exact="migraine" post="patients 12 years and over. Nevertheless, neither the primary"/>
   <result pre="age-dependent placebo response has ranged from 30% to 70% in" exact="migraine" post="studies in general [ 24– 27]. The outcome of"/>
   <result pre="the rates reported in previous studies of topiramate preventing adult" exact="migraine" post="(0–34.2%) [ 28– 31]. Rothner et al. [ 32]"/>
   <result pre="neurotransmitter systems may explain the differences. 2. The characteristics of" exact="migraine" post="attacks are different [ 34]: migraine headaches in children"/>
   <result pre="2. The characteristics of migraine attacks are different [ 34]:" exact="migraine" post="headaches in children and adolescents are often bilateral and"/>
   <result pre="minimum age at which topiramate was approved for treatment of" exact="migraine" post="was 12 years old, but the minimum age of"/>
   <result pre="Our included patients included those with either episodic or chronic" exact="migraine" post="[ 14], which may influence the results of our"/>
   <result pre="of our meta-analysis is that topiramate decreased PedMIDAS scores in" exact="migraine" post="patients. PedMIDAS is often used to measure disability related"/>
   <result pre="placebo in our included trials. It has been reported that" exact="metabolic acidosis," post="renal calculi and nervous system effects, such as fatigue"/>
   <result pre="system effects, such as fatigue or somnolence, paresthesia, dizziness and" exact="cognitive disorder" post="or aphasia, occurred in adults and pediatric patients taking"/>
   <result pre="drugs, including topiramate [ 39]. Thus, while the pathomechanism of" exact="migraine" post="is not completely understood, the choice of medication for"/>
   <result pre="limitations. Conclusions This is the first meta-analysis of topiramate for" exact="migraine" post="prevention in patients less than 18 years of age."/>
   <result pre="effective clinical trial endpoint than placebo in the prevention of" exact="migraine" post="in patients less than 18 years of age, and"/>
   <result pre="response rate can be beneficial for children and adolescents with" exact="migraine" post="and that drugs used to prevent pediatric migraine might"/>
   <result pre="adolescents with migraine and that drugs used to prevent pediatric" exact="migraine" post="might be reconsidered. Because there was a significant placebo"/>
   <result pre="a significant placebo response, more placebo-controlled trials in the younger" exact="migraine" post="population less than 12 years of age are needed."/>
   <result pre="affiliations. References References 1. Split W Neuman W Epidemiology of" exact="migraine" post="among students from randomly selected secondary schools in Lodz"/>
   <result pre="7 494 501 10.1046/j.1526-4610.1999.3907494.x 11279934 2. Kacperski J Prophylaxis of" exact="migraine" post="in children and adolescents Paediatr Drugs 2015 17 3"/>
   <result pre="D Yonker M Silberstein S Practice parameter: pharmacological treatment of" exact="migraine" post="headache in children and adolescents: report of the American"/>
   <result pre="Bolzonella B Sartori S Battistella PA The pharmacological treatment of" exact="migraine" post="in children and adolescents: an overview Expert Rev Neurother"/>
   <result pre="Schmitt J Neto W Schwabe S Jacobs D Topiramate for" exact="migraine" post="prevention: a randomized controlled trial JAMA 2004 291 8"/>
   <result pre="S Goadsby PJ Efficacy and mechanism of anticonvulsant drugs in" exact="migraine" post="Expert Rev Clin Pharmacol 2014 7 2 191 201"/>
   <result pre="Casas C Herranz JL Topiramate in the prophylactic treatment of" exact="migraine" post="in children J Child Neurol 2005 20 3 251"/>
   <result pre="15832623 10. Anand KS Dhikav V Aggarwal J Topiramate for" exact="migraine" post="prophylaxis Indian Pediatr 2012 49 4 329 330 10.1007/s13312-012-0040-6"/>
   <result pre="22565082 11. Abbaskhanian ASHREAMS Effective dose of topiramate in pediatric" exact="migraine" post="prophylaxis In J Pediatr Neurosci 2012 7 171 174"/>
   <result pre="Mirouliaei M Shamszadeh A Topiramate and propranolol for prophylaxis of" exact="migraine" post="Indian J Pediatr 2013 80 11 920 924 10.1007/s12098-013-0976-0"/>
   <result pre="Hershey AD Trial of Amitriptyline, Topiramate, and placebo for pediatric" exact="migraine" post="N Engl J Med 2017 376 2 115 124"/>
   <result pre="study to evaluate the efficacy and safety of topiramate for" exact="migraine" post="prevention in pediatric subjects 12 to 17 years of"/>
   <result pre="Linder SL Jordan DM Fisher AC Hulihan J Topiramate for" exact="migraine" post="prevention in children: a randomized, double-blind, placebo-controlled trial Headache"/>
   <result pre="1 6 38 10.1177/0333102411430849 23. 2014) FDA approves Topamax for" exact="migraine" post="prevention in adolescents. J Pain Palliat Care Pharmacother, 28(2):191"/>
   <result pre="AD Current approaches to the diagnosis and management of paediatric" exact="migraine" post="Lancet Neurol 2010 9 2 190 204 10.1016/S1474-4422(09)70303-5 20129168"/>
   <result pre="K Hamalainen M Hoppu K Children’s response to placebo in" exact="migraine" post="attacks Cephalalgia Int J Headache 2000 20 385 10.1046/j.1468-2982.2000.00089.x"/>
   <result pre="RB Placebo response in clinical randomized trials of analgesics in" exact="migraine" post="Cephalalgia An Int J Headache 2003 23 7 487"/>
   <result pre="Lebel A Borsook D Harnessing the placebo effect in pediatric" exact="migraine" post="clinic J Pediatr 2014 165 4 659 665 10.1016/j.jpeds.2014.06.040"/>
   <result pre="and tolerability of topiramate 200 mg/d in the prevention of" exact="migraine" post="with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week"/>
   <result pre="trials on the efficacy of topiramate in the prevention of" exact="migraine" post="J Am Osteopath Assoc 2007 107 7 251 258"/>
   <result pre="V Shukla G Behari M Low-dose topiramate versus lamotrigine in" exact="migraine" post="prophylaxis (the Lotolamp study) Headache 2007 47 3 402"/>
   <result pre="Winner P Lewis D Stankowski J Zolmitriptan oral tablet in" exact="migraine" post="treatment: high placebo responses in adolescents Headache 2006 46"/>
   <result pre="HC Sances G Bono G Lessons from placebo effects in" exact="migraine" post="treatment J Headache Pain 2007 8 1 63 66"/>
   <result pre="200 10.1016/S1364-6613(03)00061-5 12757820 37. Oakley CB Kossoff EH Migraine and" exact="epilepsy" post="in the pediatric population Curr Pain Headache Rep 2014"/>
   <result pre="M Bilder RM Ford L Cognitive effects of topiramate in" exact="migraine" post="patients aged 12 through 17 years Pediatr Neurol 2010"/>
   <result pre="Szok D Csáti A Vécsei L Prophylactic drug treatment of" exact="migraine" post="in children and adolescents: an update Curr Pain Headache"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5532325/results/search/disease/results.xml">
   <result pre="are few studies that have investigated predictive factors related to" exact="migraine" post="prophylaxis of which produced inconsistent results. The aim of"/>
   <result pre="a reduction of more than 50% in the number of" exact="migraine" post="episodes after topiramate treatment. Proposed predictive factors such as"/>
   <result pre="migraine episodes after topiramate treatment. Proposed predictive factors such as" exact="migraine" post="characteristics including severity and frequency were assessed, as were"/>
   <result pre="treatment ( p=0.004). Sex, the severity, frequency, and duration of" exact="migraine" post="episodes, disease duration, treatment duration, age at onset, and"/>
   <result pre="topiramate treatment should be strongly encouraged in this patient group." exact="migraine" post="predictive factor prophylaxis topiramate INTRODUCTION Headache is one of"/>
   <result pre="females when reaching adolescence. 2 3 4 The prevalence of" exact="migraine" post="among school children was reported to be 8.7% in"/>
   <result pre="with their academic achievement and social interaction. 6 Treatment of" exact="migraine" post="includes lifestyle modification and acute abortive or prophylactic treatment"/>
   <result pre="on this background, the present study investigated the characteristics of" exact="migraine" post="and associated symptoms with the aim of identifying the"/>
   <result pre="University Bundang Hospital (SNUBH) (IRB No. B-1511-324-11). Patients diagnosed with" exact="migraine" post="at SNUBH between January 2005 and December 2014 were"/>
   <result pre="reasons other than a headache, 3) receiving additional medication for" exact="migraine" post="prophylaxis within 3 months after starting topiramate prophylaxis, and"/>
   <result pre="associated symptoms) in any first-degree relative was consistent with a" exact="migraine" post="diagnosis. The associated symptoms taken into account included nausea,"/>
   <result pre="being present when the patient complained about dizziness associated with" exact="migraine" post="and when there was no vertigo or other neurological"/>
   <result pre="recommendations. 16 17 18 Patients who experienced fewer than 10" exact="migraine" post="episodes per month but still suffered from severe disturbance"/>
   <result pre="in increments of 50% of the previous dosage if the" exact="migraine" post="frequency was not reduced by 50%. Any increase in"/>
   <result pre="duration was longer in the nonresponder group (20.3±18.2 months) before" exact="migraine" post="prophylaxis than in the responder group (15.5±14.0 months), but"/>
   <result pre="the nonresponder group (72.9% vs. 53.5%, p=0.035). Family history of" exact="migraine" post="was not significantly different between the two groups [nonresponder"/>
   <result pre="( p=0.004) ( Table 2). DISCUSSION We analyzed demographic features," exact="migraine" post="characteristics, and associated symptoms with the aim of determining"/>
   <result pre="these factors were associated with topiramate prophylaxis response in pediatric" exact="migraine" post="patients. The presence of associated symptoms such as nausea,"/>
   <result pre="different studies. However, most studies found no significant relationship with" exact="migraine" post="prophylaxis. Impairment of daily activities was significantly more common"/>
   <result pre="lack of clarity of the relationship between predictive factors of" exact="migraine" post="and response to prophylaxis, with most factors not being"/>
   <result pre="being related to the treatment response. We also confirmed that" exact="migraine" post="characteristics and associated symptoms individually were not related to"/>
   <result pre="patients with severe headache and many associated symptoms perceive their" exact="migraine" post="as being more severe. Therefore, these patients and even"/>
   <result pre="these findings could even improve their treatment compliance. Characteristics of" exact="migraine" post="such as duration and location differ between children and"/>
   <result pre="children and adults. 25 26 In addition, symptoms associated with" exact="migraine" post="experienced by children can differ between different age groups."/>
   <result pre="different age groups. 27 Therefore, applying study results for adult" exact="migraine" post="to the pediatric population has limitations. To the best"/>
   <result pre="often not been considered. Dizziness is experienced by 50–60% of" exact="migraine" post="patients, and hence is one of the most common"/>
   <result pre="that the findings might not be applicable to all pediatric" exact="migraine" post="patients. In addition, only the associated symptoms included in"/>
   <result pre="for elucidating predictive factors more precisely. This study found that" exact="migraine" post="characteristics and associated symptoms were not related to the"/>
   <result pre="and a clinical, psychological and electroencephalographic comparison between children with" exact="migraine" post="and matched controls Acta Paediatr Suppl 1962 136 1"/>
   <result pre="Headache 2012 52 327 332 22288386 3 Lewis DW Pediatric" exact="migraine" post="Neurol Clin 2009 27 481 501 19289227 4 Abu-Arefeh"/>
   <result pre="19289227 4 Abu-Arefeh I Russell G Prevalence of headache and" exact="migraine" post="in schoolchildren BMJ 1994 309 765 769 7950559 5"/>
   <result pre="592 599 21929660 6 Stang PE Osterhaus JT Impact of" exact="migraine" post="in the United States: data from the National Health"/>
   <result pre="29 35 8436495 7 Wasiewski WW Preventive therapy in pediatric" exact="migraine" post="J Child Neurol 2001 16 71 78 11292228 8"/>
   <result pre="trial of propranolol versus sodium valproate for the prophylaxis of" exact="migraine" post="in pediatric patients Paediatr Drugs 2010 12 269 275"/>
   <result pre="S Uyar M et al. Sodium valproate prophylaxis in childhood" exact="migraine" post="Headache 2002 42 819 822 12390647 12 Winner P"/>
   <result pre="Hulihan J collab: Topiramate Pediatric Migraine Study Investigators Topiramate for" exact="migraine" post="prevention in children: a randomized, double-blind, placebo-controlled trial Headache"/>
   <result pre="study to evaluate the efficacy and safety of topiramate for" exact="migraine" post="prevention in pediatric subjects 12 to 17 years of"/>
   <result pre="M Christie SN et al. Canadian Headache Society guideline for" exact="migraine" post="prophylaxis Can J Neurol Sci 2012 39 2 Suppl"/>
   <result pre="39 2 Suppl 2 S1 S59 18 Silberstein SD Preventive" exact="migraine" post="treatment Continuum (Minneap Minn) 2015 21 973 989 26252585"/>
   <result pre="Pavese N Gambaccini G Rossi G Bonuccelli U Flunarizine in" exact="migraine" post="prophylaxis: predictive factors for a positive response Cephalalgia 1998"/>
   <result pre="9731940 20 Rossi P Fiermonte G Pierelli F Cinnarizine in" exact="migraine" post="prophylaxis: efficacy, tolerability and predictive factors for therapeutic responsiveness."/>
   <result pre="C Wöber-Bingöl C Koch G Wessely P Long-term results of" exact="migraine" post="prophylaxis with flunarizine and beta-blockers Cephalalgia 1991 11 251"/>
   <result pre="trial of acupuncture versus topiramate treatment in patients with chronic" exact="migraine" post="Clin J Pain 2013 29 982 987 23370087 24"/>
   <result pre="Caers LI Aerts TJ Flunarizine, a calcium entry blocker in" exact="migraine" post="prophylaxis Headache 1985 25 249 254 3897128 25 Raieli"/>
   <result pre="Eidlitz-Markus T Gorali O Haimi-Cohen Y Zeharia A Symptoms of" exact="migraine" post="in the paediatric population by age group Cephalalgia 2008"/>
   <result pre="Prevalence of vertigo, dizziness, and migrainous vertigo in patients with" exact="migraine" post="Headache 2007 47 1427 1435 18052952 30 Noseda R"/>
   <result pre="Diamond S Diamond ML Reed M Prevalence and burden of" exact="migraine" post="in the United States: data from the American Migraine"/>
   <result pre="Koerte I Straube A et al. Associations between stress and" exact="migraine" post="and tension-type headache: results from a school-based study in"/>
   <result pre="Sostak P Reinisch VM Noachtar S et al. Headache in" exact="juvenile myoclonic epilepsy" post="J Headache Pain 2011 12 227 233 21437711 37"/>
   <result pre="Reinisch VM Noachtar S et al. Headache in juvenile myoclonic" exact="epilepsy" post="J Headache Pain 2011 12 227 233 21437711 37"/>
   <result pre="Sartori S Salviati L et al. Comorbidity between headache and" exact="epilepsy" post="in a pediatric headache center J Headache Pain 2010"/>
   <result pre="and clinical characteristics as predictive factors of the response to" exact="migraine" post="prophylaxis using topiramate Total ( n=113) Responders ( n=70)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5548702/results/search/disease/results.xml">
   <result pre="Abstract Background The available data on gender differences in clinical" exact="migraine" post="parameters among pediatric patients are based on relatively few"/>
   <result pre="clinic was searched for all children and adolescents diagnosed with" exact="migraine" post="headaches in 2010–2016. Data on demographics, symptoms, and headache-related"/>
   <result pre="Migraine without aura was documented in 313 patients (66.9%), and" exact="migraine" post="with aura in 127 (27.1%); 28 patients (6.0%) had"/>
   <result pre="= 0.042, Cohen’s d 0.8303, 95% CI 0.614–0.992); age at" exact="migraine" post="onset ( p = 0.021, Cohen’s d 0.211, 95%"/>
   <result pre="= 0.021, Cohen’s d 0.211, 95% CI 0.029–0.394); rate of" exact="migraine" post="with aura (OR 2.01, 95% CI 1.29–3.16, p ="/>
   <result pre="0.0149, Cohen’s d 0.211, 95% CI 0.029–0.3940); rate of chronic" exact="migraine" post="( p = 0.036, OR 1.54, 95% CI 1.02–2.34);"/>
   <result pre="but not prepubertal females, had a significantly higher rate of" exact="migraine" post="with aura than did males (41.1% versus 28.9%; OR"/>
   <result pre="0.85–2.37, p = 0.039). Conclusion Female children and adolescents with" exact="migraine" post="treated in a tertiary pediatric headache clinic were characterized"/>
   <result pre="headache clinic were characterized by a higher rate of chronic" exact="migraine" post="and migraine with aura, a lower rate of vomiting,"/>
   <result pre="were characterized by a higher rate of chronic migraine and" exact="migraine" post="with aura, a lower rate of vomiting, and older"/>
   <result pre="These findings might be influenced by the better description of" exact="migraine" post="symptoms by females owing to their better verbal ability."/>
   <result pre="better verbal ability. Keywords Female Males Migraine Pediatric Adolescent Chronic" exact="migraine" post="Age onset Migraine with aura Puberty Background Worldwide data"/>
   <result pre="in men [ 1]. In addition, clinical symptoms of adult" exact="migraine" post="differ by gender, with women having a longer attack"/>
   <result pre="high-field magnetic resonance imaging studies of children and adolescents with" exact="migraine" post="showed both gender and developmental differences in brain anatomy"/>
   <result pre="all children and adolescents diagnosed at ages 3–18 years with" exact="migraine" post="headache during 2010–2016. The diagnosis was re-evaluated in all"/>
   <result pre="were admitted before 2013, their medical files were reviewed and" exact="migraine" post="was diagnosed according to the ICHD-III criteria [ 9]."/>
   <result pre="Migraine without aura was documented in 313 patients (66.9%), and" exact="migraine" post="with aura, in 127 (27.1%); the remaining 28 patients"/>
   <result pre="= 0.042; Cohen’s d 0.8303, 95% CI 0.614–0.992), age at" exact="migraine" post="onset ( p = 0.021; Cohen’s d 0.211, 95%"/>
   <result pre="= 0.021; Cohen’s d 0.211, 95% CI 0.029–0.394), rate of" exact="migraine" post="with aura ( p = 0.0056; OR 2.01, 95%"/>
   <result pre="0.0149; Cohen’s d 0.211, 95% CI 0.029–0.3940); rate of chronic" exact="migraine" post="( p = 0.036; Cohen’s d 1.54, 95% CI"/>
   <result pre="0.62, 95% CI 0.41–0.93). Further comparison of the rate of" exact="migraine" post="with aura by pubertal stage yielded a significantly higher"/>
   <result pre="Table 1 Demographic and clinical parameters of pediatric patients with" exact="migraine" post="(468 patients) Parameter Males ( N = 215) Females"/>
   <result pre="(61.7%) 0.0056  Migraine with aura 43 (20%) 84 (33.2)  probable" exact="migraine" post="15 (7%) 13 (5.1%) Headache frequency (mos) 12.2 ±"/>
   <result pre="frequency (mos) 12.2 ± 11.2 14.6 ± 11.5 0.0149 Chronic" exact="migraine" post="61(29.8%) 94 (39.5%) 0.036 Migraine duration  Months 27.4 ±"/>
   <result pre="64 (38.3%) 0.098 Puberty 45 (20.9%) 112 (44.2%) &amp;lt;0.001 Parental" exact="migraine" post="history  Negative paternal migraine 105(48.8%) 133(52.6%) 0.188  Paternal only"/>
   <result pre="45 (20.9%) 112 (44.2%) &amp;lt;0.001 Parental migraine history  Negative paternal" exact="migraine" post="105(48.8%) 133(52.6%) 0.188  Paternal only 26 (12.0) 18 (7.1%)"/>
   <result pre="± 11.1, P = 0.01; and a higher rate of" exact="migraine" post="with aura, 30.9% for patients with psychiatric comorbidity vs"/>
   <result pre="at both time points; and had a higher rate of" exact="migraine" post="with aura, greater migraine frequency, more chronic migraine, and"/>
   <result pre="and had a higher rate of migraine with aura, greater" exact="migraine" post="frequency, more chronic migraine, and a lower rate of"/>
   <result pre="Wöber-Bingöl et al. [ 7] reported on the prevalence of" exact="migraine" post="headache symptoms in children by gender and found that"/>
   <result pre="found that the female patients had a higher frequency of" exact="migraine" post="with aura, as in our study, and a higher"/>
   <result pre="3.8–18 years. The differences observed in the current study in" exact="migraine" post="parameters and in symptom frequency between males and females"/>
   <result pre="12] and of disease-related pain perception during acute attacks of" exact="sickle cell anemia" post="in adolescents (median age 14.8 years) [ 13]. By"/>
   <result pre="of disease-related pain perception during acute attacks of sickle cell" exact="anemia" post="in adolescents (median age 14.8 years) [ 13]. By"/>
   <result pre="with higher headache frequency and with a higher rate of" exact="migraine" post="with aura. Gender differences in response to pain were"/>
   <result pre="of pain-related psychological variables [ 16]. Age of onset of" exact="migraine" post="Estrogen per se is not a cause of migraine,"/>
   <result pre="17]. Nevertheless, our finding that male patients presented earlier with" exact="migraine" post="symptoms than did female patients is in line with"/>
   <result pre="peripheral (neuro) vascular level, may act as a trigger for" exact="migraine" post="presentation in females [ 4]. For example, female sex"/>
   <result pre="may be related to the beginning of estrogen release and" exact="migraine" post="modulation in girls. Migraine diagnosis We found that migraine"/>
   <result pre="and migraine modulation in girls. Migraine diagnosis We found that" exact="migraine" post="with aura was significantly associated with female gender, and"/>
   <result pre="migraine with aura was significantly associated with female gender, and" exact="migraine" post="without aura, with male gender. Similar results were reported"/>
   <result pre="patients, would have made it easier for them to describe" exact="migraine" post="aura. Aura may also be influenced by sex hormones."/>
   <result pre="sex hormones. Studies of male and female mouse models of" exact="familial hemiplegic migraine" post="type 1 suggest that estrogens increase susceptibility to cortical"/>
   <result pre="Studies of male and female mouse models of familial hemiplegic" exact="migraine" post="type 1 suggest that estrogens increase susceptibility to cortical"/>
   <result pre="increase susceptibility to cortical spreading depression, the pathophysiological mechanism underlying" exact="migraine" post="aura [ 20]. These findings correspond to reports of"/>
   <result pre="These findings correspond to reports of an increased prevalence of" exact="migraine" post="with aura in high estrogen states, such as during"/>
   <result pre="which occurs perimenstrually, is associated with a higher prevalence of" exact="migraine" post="without aura [ 21]. Accordingly, in our cohort, the"/>
   <result pre="aura [ 21]. Accordingly, in our cohort, the rate of" exact="migraine" post="with aura was significantly higher in pubertal females than"/>
   <result pre="males. This finding was not true for prepubertal males/females. Chronic" exact="migraine" post="and headache frequency In our study, adolescent females had"/>
   <result pre="a significantly higher headache frequency and higher rate of chronic" exact="migraine" post="than did adolescent males. Similarly, studies of adults reported"/>
   <result pre="[ 3], and an almost threefold higher prevalence of chronic" exact="migraine" post="[ 23]. Vomiting Vomiting in our pediatric cohort was"/>
   <result pre="worse autonomic dysfunction contributed to this difference [ 25]. Parental" exact="migraine" post="Goodman and McGrath [ 26] showed that maternal modeling"/>
   <result pre="conditions, we found no difference in the rate of paternal" exact="migraine" post="between male and female patients. This could explain the"/>
   <result pre="reliance on self- and parental reports of clinical parameters of" exact="migraine" post="for young patients. Furthermore, the sample was restricted to"/>
   <result pre="the general population. This might explain the high frequency of" exact="migraine" post="attacks and high rate of chronic migraine. Moreover, the"/>
   <result pre="significantly higher rate of chronic migraine, a higher frequency of" exact="migraine" post="with aura, older age of onset, a higher rate"/>
   <result pre="et al. Gender influences headache characteristics with increasing age in" exact="migraine" post="patients Cephalalgia 2015 35 792 800 10.1177/0333102414559735 25424708 3."/>
   <result pre="Sex differences in the epidemiology, clinical features, and pathophysiology of" exact="migraine" post="Lancet Neurol 2017 16 76 874 10.1016/S1474-4422(16)30293-9 27836433 4."/>
   <result pre="MJ Kay J Jaron A Epidemiology of headache and childhood" exact="migraine" post="in an urban general practice using ad hoc, Vahlquist"/>
   <result pre="6. Faria V Erpelding N Lebel A et al. The" exact="migraine" post="brain in transition: girls vs boys Pain 2015 156"/>
   <result pre="C Wöber C Wagner-Ennsgraber C et al. IHS criteria for" exact="migraine" post="and tension-type headache in children and adolescents Headache 1996"/>
   <result pre="Jakubowski M Silberstein S Ashkenazi A et al. Can allodynic" exact="migraine" post="patients be identified interictally using a questionnaire? Neurology 2005"/>
   <result pre="K, Inagaki M, Kitamura S et al (2016) Changes in" exact="migraine" post="before and after menopause in Japanese climacteric. Cephalalgia. [Epub"/>
   <result pre="Potential role of female sex hormones in the pathophysiology of" exact="migraine" post="Pharmacol Ther 2007 113 321 340 10.1016/j.pharmthera.2006.08.009 17069890 19."/>
   <result pre="modulate spreading depression and transient hemiparesis in mouse models of" exact="familial hemiplegic migraine" post="type 1 J Clin Invest 2009 119 99 109"/>
   <result pre="depression and transient hemiparesis in mouse models of familial hemiplegic" exact="migraine" post="type 1 J Clin Invest 2009 119 99 109"/>
   <result pre="99 109 19104150 21. MacGregor EA Oestrogen and attacks of" exact="migraine" post="with and without aura Lancet Neurol 2004 3 354"/>
   <result pre="MacGregor EA Frith A Ellis J et al. Incidence of" exact="migraine" post="relative to menstrual cycle phases of rising and falling"/>
   <result pre="YW Lee JH Min BH et al. Clinical predictors for" exact="migraine" post="in patients presenting with nausea and/or vomiting J Neurogastroenterol"/>
   <result pre="Y Zeharia A Vomiting and migraine-related clinical parameters in pediatric" exact="migraine" post="Headache 2017 57 6 899 907 10.1111/head.13109 28480554 26."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5573746/results/search/disease/results.xml">
   <result pre="Effects of low-dose topiramate on language function in children with" exact="migraine" post="Han Seung-A MD 1 Yang Eu Jeen MD 2"/>
   <result pre="patients with migraine. Methods Thirty newly diagnosed pediatric patients with" exact="migraine" post="who needed topiramate were enrolled and assessed twice with"/>
   <result pre="peers, and family dynamics 2 3). Therefore, many children with" exact="migraine" post="who do not tolerate to conservative treatments or to"/>
   <result pre="antidepressants, antihistamine mimetics, and antiepileptic drugs have been prescribed for" exact="migraine" post="prophylaxis. Among these drugs, antiepileptic drugs, especially topiramate (TPM),"/>
   <result pre="can cause cognitive dysfunction, including language disturbances in patients with" exact="epilepsy" post="when administered at the recommended dose 4 5 6"/>
   <result pre="TPM may lead to language disturbances in adult patients with" exact="migraine" post="9 10 11). However, there are no published reports"/>
   <result pre="are no published reports investigating the effects of TPM on" exact="migraine" post="in children. Therefore, this study aimed to verify the"/>
   <result pre="Materials and methods 1. Patients Ninety-six pediatric patients diagnosed with" exact="migraine" post="who needed TPM for migraine prevention because of the"/>
   <result pre="Ninety-six pediatric patients diagnosed with migraine who needed TPM for" exact="migraine" post="prevention because of the frequency more than 4 times"/>
   <result pre="data and eight patients who needed other prophylactic medications for" exact="migraine" post="were excluded. Bilingual patients were not included. 2. Methods"/>
   <result pre="period. Twenty patients responded well to the treatment, and patients'" exact="migraine" post="was reduced after taking TPM. There were 5 patients"/>
   <result pre="in headache frequency or headache-related disability. In 5 patients, the" exact="migraine" post="was aggravated. Among of these 5 patients, 3 patients"/>
   <result pre="20. The mean score of 11.5±4.5 was obtained for pediatric" exact="migraine" post="patients before TPM treatment, which increased to 12.3±4.0 after"/>
   <result pre="mean score of 97.8±22.1 was obtained for patients with pediatric" exact="migraine" post="before TPM treatment, which decreased to 96.3±20.0 after taking"/>
   <result pre="mean score of 58.6±7.4 was obtained for pediatric patients with" exact="migraine" post="before TPM treatment, which increased to 59.5±6.6 after taking"/>
   <result pre="developed for the treatment of epilepsy, it is an effective" exact="migraine" post="preventive therapy in adults, as demonstrated in several studies"/>
   <result pre="studies 16 17). The doses of TPM required to treat" exact="migraine" post="are lower than those needed to treat epilepsy, resulting"/>
   <result pre="lower prevalence of adverse effects 18). Treatment options for pediatric" exact="migraine" post="are particularly limited, and there are few migraine preventive"/>
   <result pre="for pediatric migraine are particularly limited, and there are few" exact="migraine" post="preventive agents approved for use in children 19 20)."/>
   <result pre="use in children 19 20). Thus, preventive pharmacologic treatments for" exact="migraine" post="in children need to be based on efficacy and"/>
   <result pre="be based on efficacy and safety. Precisely how TPM prevents" exact="migraine" post="is unclear; however, generally, it appears to reduce the"/>
   <result pre="generally, it appears to reduce the genetically-derived headache that provokes" exact="migraine" post="attacks in susceptible individuals. Fallah et al. 21) showed"/>
   <result pre="showed TPM as a safe and effective drug for pediatric" exact="migraine" post="prophylaxis, which reduces monthly frequency, severity, duration, and disability"/>
   <result pre="prophylaxis, which reduces monthly frequency, severity, duration, and disability of" exact="migraine" post="in children. Other studies have shown that TPM at"/>
   <result pre="TPM at 100 mg/day is effective in the prevention of" exact="migraine" post="headaches and in reducing the severity of the attack"/>
   <result pre="a set of specific language evaluation tools. Pediatric patients with" exact="migraine" post="with no history of anticonvulsant medication were evaluated on"/>
   <result pre="that attention is required when TPM is used in pediatric" exact="migraine" post="patients. The REVT was used as a tool for"/>
   <result pre="considered with positive effects of language development after reductions in" exact="migraine" post="headache. In conclusion, our results show that TPM is"/>
   <result pre="results show that TPM is effective in the prevention of" exact="migraine" post="headache and in reducing the severity of the attack."/>
   <result pre="considering the side effects of language in pediatric patients with" exact="migraine" post="even at low doses. Conflict of interest: No potential"/>
   <result pre="2011 2040 2045 2 Split W Neuman W Epidemiology of" exact="migraine" post="among students from randomly selected secondary schools in Lodz"/>
   <result pre="3 Lee LH Olness KN Clinical and demographic characteristics of" exact="migraine" post="in urban children Headache 1997 37 269 276 9195764"/>
   <result pre="GW et al. Topiramate placebo-controlled dose-ranging trial in refractory partial" exact="epilepsy" post="using 200-, 400-, and 600-mg daily dosages. Topiramate YD"/>
   <result pre="G et al. Topiramate placebo-controlled dose-ranging trial in refractory partial" exact="epilepsy" post="using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE"/>
   <result pre="Double-blind, placebo-controlled study of topiramate in patients with refractory partial" exact="epilepsy" post="Epilepsy Res 1996 25 217 224 8956919 8 Tassinari"/>
   <result pre="topiramate (600 mg daily) for the treatment of refractory partial" exact="epilepsy" post="Epilepsia 1996 37 763 768 8764816 9 Fritz N"/>
   <result pre="cognitive side effects of tiagabine and topiramate in patients with" exact="epilepsy" post="Epilepsy Behav 2005 6 373 381 15820346 10 Tang"/>
   <result pre="activity associated with topiramate and its withdrawal in patients with" exact="epilepsy" post="with language impairment: an fMRI study using the verb"/>
   <result pre="Language disturbances as a side effect of prophylactic treatment of" exact="migraine" post="Headache 2008 48 86 94 18184290 12 Bae SY"/>
   <result pre="Phonology (U-TAP) Seoul Hakjisa 2004 16 Silberstein SD Topiramate in" exact="migraine" post="prevention Headache 2005 45 Suppl 1 S57 S65 15833091"/>
   <result pre="Storey JR Calder CS Hart DE Potter DL Topiramate in" exact="migraine" post="prevention: a double-blind, placebo-controlled study Headache 2001 41 968"/>
   <result pre="975 11903524 18 Brandes JL Practical use of topiramate for" exact="migraine" post="prevention Headache 2005 45 Suppl 1 S66 S73 15833092"/>
   <result pre="Jordan DM Fisher AC Hulihan J et al. Topiramate for" exact="migraine" post="prevention in children: a randomized, double-blind, placebo-controlled trial Headache"/>
   <result pre="M The efficacy and safety of topiramate for prophylaxis of" exact="migraine" post="in children Iran J Child Neurol 2013 7 7"/>
   <result pre="Topiramate improves health-related quality of life when used to prevent" exact="migraine" post="Headache 2005 45 1023 1030 16109116 23 Bussone G"/>
   <result pre="Diener HC Pfeil J Schwalen S Topiramate 100 mg/day in" exact="migraine" post="prevention: a pooled analysis of double-blind randomised controlled trials"/>
   <result pre="Comparison of the effect of topiramate and sodium valporate in" exact="migraine" post="prevention: a randomized blinded crossover study Headache 2006 46"/>
   <result pre="effects of therapy with topiramate in patients with refractory partial" exact="epilepsy" post="Rev Neurol 2002 34 737 741 12080493 28 de"/>
   <result pre="K Sousa PS Yacubian EM Neuropsychiatric profiles of patients with" exact="juvenile myoclonic epilepsy" post="treated with valproate or topiramate Epilepsy Behav 2006 8"/>
   <result pre="PS Yacubian EM Neuropsychiatric profiles of patients with juvenile myoclonic" exact="epilepsy" post="treated with valproate or topiramate Epilepsy Behav 2006 8"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5720689/results/search/disease/results.xml">
   <result pre="Sciences : Pharmacology : Drugs: Antipsychotics Migraine and risk of" exact="narcolepsy" post="in children: A nationwide longitudinal study Migraine and narcolepsy"/>
   <result pre="of narcolepsy in children: A nationwide longitudinal study Migraine and" exact="narcolepsy" post="in children Yang Chun-Pai Conceptualization Supervision Writing – original"/>
   <result pre="and source are credited. pone.0189231.pdf Abstract Background The association between" exact="migraine" post="and narcolepsy remains controversial. We aim to investigate whether"/>
   <result pre="are credited. pone.0189231.pdf Abstract Background The association between migraine and" exact="narcolepsy" post="remains controversial. We aim to investigate whether migraine is"/>
   <result pre="migraine and narcolepsy remains controversial. We aim to investigate whether" exact="migraine" post="is associated with an increased risk of developing narcolepsy"/>
   <result pre="whether migraine is associated with an increased risk of developing" exact="narcolepsy" post="in children. Methods In this longitudinal study, nationwide medical-claims"/>
   <result pre="longitudinal study, nationwide medical-claims data of pediatric patients (0-17y) with" exact="migraine" post="are identified using the National Health Insurance Research Database"/>
   <result pre="between 1997 and 2010 in Taiwan. Two cohorts are selected:" exact="migraine" post="cases (n = 8,923) and propensity score-matched non-migraine controls"/>
   <result pre="non-migraine controls (n = 35,692). Children with previous history of" exact="narcolepsy" post="or headache before the index date are excluded. Cohorts"/>
   <result pre="2012, their withdrawal from the NHI program, or incidence of" exact="narcolepsy" post="(ICD-9-CM: 347). Cox proportional hazards regression models are used"/>
   <result pre="estimate hazard ratios (HRs) and 95% confidence intervals of developing" exact="narcolepsy" post="in children with migraine compared to their non-migraine controls."/>
   <result pre="and 95% confidence intervals of developing narcolepsy in children with" exact="migraine" post="compared to their non-migraine controls. Results A total of"/>
   <result pre="non-migraine controls. Results A total of 13 incident cases with" exact="narcolepsy" post="are observed during follow-up, with incidence rates of 0.1915"/>
   <result pre="incidence rates of 0.1915 and 0.0278 per 1,000 person-years in" exact="migraine" post="and non-migraine children, respectively. After a mean follow-up period"/>
   <result pre="cohort, respectively, the former exhibited a greater risk of developing" exact="narcolepsy" post="compared to the latter (adjusted hazard ratio (aHR) ="/>
   <result pre="comorbidities and concurrent medication uptake, and in our analyses with" exact="migraine" post="subtypes. Conclusions Migraine is an independent risk factor for"/>
   <result pre="migraine subtypes. Conclusions Migraine is an independent risk factor for" exact="narcolepsy" post="development in children. Further studies are needed to validate"/>
   <result pre="our findings and to explore the exact pathophysiological mechanisms linking" exact="migraine" post="and narcolepsy. Funding This study is supported in part"/>
   <result pre="relevant data are within the paper. Introduction The association between" exact="migraine" post="and narcolepsy has been evaluated in several hospital-based studies"/>
   <result pre="are within the paper. Introduction The association between migraine and" exact="narcolepsy" post="has been evaluated in several hospital-based studies and still"/>
   <result pre="not allow us to firmly establish a causal relationship between" exact="migraine" post="and narcolepsy, or suggest a mechanism that could explain"/>
   <result pre="an increasing level of attention given on the development of" exact="narcolepsy" post="early in life [ 4]. Unfortunately, whether migraine is"/>
   <result pre="development of narcolepsy early in life [ 4]. Unfortunately, whether" exact="migraine" post="is associated with increased risk of narcolepsy in children"/>
   <result pre="4]. Unfortunately, whether migraine is associated with increased risk of" exact="narcolepsy" post="in children has not been explored in a large-scale"/>
   <result pre="networks [ 7]. The destruction of orexinergic system results in" exact="narcolepsy" post="as well as altered pain processing including migraine ["/>
   <result pre="results in narcolepsy as well as altered pain processing including" exact="migraine" post="[ 8]. Given that migraine may share with narcolepsy"/>
   <result pre="as altered pain processing including migraine [ 8]. Given that" exact="migraine" post="may share with narcolepsy in distinct brain areas especially"/>
   <result pre="including migraine [ 8]. Given that migraine may share with" exact="narcolepsy" post="in distinct brain areas especially in hypothalamus and neurotransmitter"/>
   <result pre="in hypothalamus and neurotransmitter systems or both, we hypothesize that" exact="migraine" post="can be linked to narcolepsy, particularly in children whose"/>
   <result pre="Taiwan National Health Insurance Research Database (NHIRD) to investigate whether" exact="migraine" post="is associated with an elevated risk of developing narcolepsy"/>
   <result pre="whether migraine is associated with an elevated risk of developing" exact="narcolepsy" post="in children less than 18 years of age. Materials"/>
   <result pre="years from the random, national-representative sample who have newly diagnosed" exact="migraine" post="between 1997 and 2010 (n = 38,284). We included"/>
   <result pre="and 2010 (n = 38,284). We included different types of" exact="migraine" post="including migraine with aura (ICD-9-CM: 346.0x), migraine without aura"/>
   <result pre="(n = 38,284). We included different types of migraine including" exact="migraine" post="with aura (ICD-9-CM: 346.0x), migraine without aura (ICD-9-CM: 346.1x)"/>
   <result pre="different types of migraine including migraine with aura (ICD-9-CM: 346.0x)," exact="migraine" post="without aura (ICD-9-CM: 346.1x) and unspecified migraine (ICD-9-CM: 346.9x)."/>
   <result pre="aura (ICD-9-CM: 346.0x), migraine without aura (ICD-9-CM: 346.1x) and unspecified" exact="migraine" post="(ICD-9-CM: 346.9x). For ascertainment of cases, any identified subject"/>
   <result pre="have at least two ambulatory care and/or inpatient visits with" exact="migraine" post="diagnosis during the study period. We excluded those diagnosed"/>
   <result pre="missing information regarding subject’s sex and birthday, their date of" exact="narcolepsy" post="diagnosis (n = 22,651), or those who had withdrawn"/>
   <result pre="or those who had withdrawn from the NHI program before" exact="migraine" post="diagnosis (n = 4,620) ( Fig 1). A sum"/>
   <result pre="Fig 1). A sum of 10,127 subjects resulted in the" exact="migraine" post="cohort. For these children, their first date of migraine"/>
   <result pre="the migraine cohort. For these children, their first date of" exact="migraine" post="diagnosis became their index date of observation. In a"/>
   <result pre="date of observation. In a similar manner, children without any" exact="migraine" post="diagnosis from the random sample were identified during the"/>
   <result pre="the comparison (non-migraine) cohort. They were subsequently propensity-score-matched with the" exact="migraine" post="children by age, sex, urbanization level, comorbidities, and index"/>
   <result pre="flowchart. Outcome variable Our primary outcome was the occurrence of" exact="narcolepsy" post="(ICD-9-CM: 347), defined as the initial outpatient visit or"/>
   <result pre="defined as the initial outpatient visit or hospital admission for" exact="narcolepsy" post="during the follow-up period. Both cohorts were followed up"/>
   <result pre="could potentially influence our outcome were also considered. They included" exact="schizophrenia" post="and organic psychosis (ICD-9-CM: 293–295), affective psychoses (ICD-9-CM: 296),"/>
   <result pre="psychoses (ICD-9-CM: 296), neurotic disorders (ICD-9-CM: 300), depression (ICD-9-CM: 311)," exact="learning disability" post="and developmental delay (ICD-9-CM: 315), mental retardation (ICD-9-CM: 317–319),"/>
   <result pre="retardation (ICD-9-CM: 317–319), central nervous system (CNS) infection (ICD-9-CM: 320–326)," exact="cerebral palsy" post="(ICD-9-CM: 342–344), cerebral vascular disorder (ICD-9-CM:430–438), head injury with"/>
   <result pre="(%). We compared baseline characteristics between children with and without" exact="migraine" post="using standardized mean difference (SMD). SMD of less than"/>
   <result pre="calculated for each cohort based on their incident events of" exact="narcolepsy" post="and were expressed as per 1,000 person-years. Using log-rank"/>
   <result pre="log-rank test, the statistical difference in the cumulative incidence of" exact="narcolepsy" post="between migraine and non-migraine cohorts was tested, and the"/>
   <result pre="the statistical difference in the cumulative incidence of narcolepsy between" exact="migraine" post="and non-migraine cohorts was tested, and the Kaplan-Meier method"/>
   <result pre="and their 95% confidence intervals (CIs) for the development of" exact="narcolepsy" post="in the study cohort compared to the matched comparison"/>
   <result pre="USA). Results After propensity-score matching, we selected 8,923 children with" exact="migraine" post="and 35,692 control children without migraine for analysis. Table"/>
   <result pre="selected 8,923 children with migraine and 35,692 control children without" exact="migraine" post="for analysis. Table 1 describes the baseline characteristics of"/>
   <result pre="the baseline characteristics of these identified subjects according to their" exact="migraine" post="status (yes or no). As expected, subjects from both"/>
   <result pre="and comorbidities. Mean age was 11.58±3.88 and 11.02±3.94 years for" exact="migraine" post="and non-migraine children, respectively, with a SMD of 0.145."/>
   <result pre="terms of baseline comorbidities and concurrent medication use, proportions of" exact="schizophrenia" post="and organic psychosis, affective psychoses, neurotic disorders, depression, learning"/>
   <result pre="of schizophrenia and organic psychosis, affective psychoses, neurotic disorders, depression," exact="learning disability" post="and developmental delay, mental retardation, CNS infection, cerebral palsy,"/>
   <result pre="depression, learning disability and developmental delay, mental retardation, CNS infection," exact="cerebral palsy," post="cerebral vascular disorder, head injury with skull fracture, vision"/>
   <result pre="of NSAIDs, ergotamine, acetaminophen, triptans and sedative-hypnotics are similar in" exact="migraine" post="and non-migraine subjects. Concomitant use of antiepileptics and antipsychotics,"/>
   <result pre="they were further adjusted for in the multivariate analyses. Among" exact="migraine" post="children, most belonged to the unspecified migraine type (71.75%,"/>
   <result pre="multivariate analyses. Among migraine children, most belonged to the unspecified" exact="migraine" post="type (71.75%, n = 6,402). As a part of"/>
   <result pre="such as hyperactivity, infectious diseases of the upper respiratory tract," exact="influenza" post="and epilepsy between our matched children. 10.1371/journal.pone.0189231.t001 Table 1"/>
   <result pre="hyperactivity, infectious diseases of the upper respiratory tract, influenza and" exact="epilepsy" post="between our matched children. 10.1371/journal.pone.0189231.t001 Table 1 Descriptive profile"/>
   <result pre="1049 11.76 Migraine without aura . . 1869 20.95 Unspecified" exact="migraine" post=". . 6402 71.75 Chi-Square Test a t-test SD:"/>
   <result pre="drugs A total of 13 subjects were newly diagnosed with" exact="narcolepsy" post="during the follow-up period, with incidence rates of 0.1915"/>
   <result pre="rates of 0.1915 and 0.0278 per 1,000 person-years in the" exact="migraine" post="and non-migraine cohorts, respectively. Table 2 displays results from"/>
   <result pre="(aHR: 5.30, 95% CI: 1.61, 17.4, p = 0.006) of" exact="narcolepsy" post="was observed in migraine children compared to non-migraine children."/>
   <result pre="1.61, 17.4, p = 0.006) of narcolepsy was observed in" exact="migraine" post="children compared to non-migraine children. The Kaplan-Meier survival curve"/>
   <result pre="curve with log-rank test also showed higher cumulative incidence of" exact="narcolepsy" post="in children with migraine (p = 0.0007) ( Fig"/>
   <result pre="also showed higher cumulative incidence of narcolepsy in children with" exact="migraine" post="(p = 0.0007) ( Fig 2). Fig 2 Cumulative"/>
   <result pre="= 0.0007) ( Fig 2). Fig 2 Cumulative incidence of" exact="narcolepsy" post="in children diagnosed with migraine versus children without migraine."/>
   <result pre="Fig 2 Cumulative incidence of narcolepsy in children diagnosed with" exact="migraine" post="versus children without migraine. (dotted line) Incidence of narcolepsy"/>
   <result pre="with migraine versus children without migraine. (dotted line) Incidence of" exact="narcolepsy" post="in children of the migraine cohort in the observation"/>
   <result pre="migraine. (dotted line) Incidence of narcolepsy in children of the" exact="migraine" post="cohort in the observation period. (solid line) Incidence of"/>
   <result pre="migraine cohort in the observation period. (solid line) Incidence of" exact="narcolepsy" post="in children of the non-migraine (reference) cohort. 10.1371/journal.pone.0189231.t002 Table"/>
   <result pre="Results from Cox proportional hazards model for the association between" exact="narcolepsy" post="and migraine in pediatric subjects (hazard ratios and 95%"/>
   <result pre="Cox proportional hazards model for the association between narcolepsy and" exact="migraine" post="in pediatric subjects (hazard ratios and 95% confidence intervals)."/>
   <result pre="proportional hazards regression. Stratified by sex, the incidence rates of" exact="narcolepsy" post="in girls and boys with migraine were 0.1382 and"/>
   <result pre="the incidence rates of narcolepsy in girls and boys with" exact="migraine" post="were 0.1382 and 0.2492 per 1,000 person-years, respectively; higher"/>
   <result pre="and 0.0268 per 1,000 person-years) ( Table 3). In addition," exact="migraine" post="boys showed 6.68-fold (95% CI: 1.17, 38.1, p&amp;lt;0.05) higher"/>
   <result pre="(95% CI: 1.17, 38.1, p&amp;lt;0.05) higher adjusted risk of developing" exact="narcolepsy" post="than the non-migraine cohort. Also observed with a statistically"/>
   <result pre="non-migraine cohort. Also observed with a statistically elevated risk of" exact="narcolepsy" post="were migraine children belonging to age group of 12–17"/>
   <result pre="Also observed with a statistically elevated risk of narcolepsy were" exact="migraine" post="children belonging to age group of 12–17 years old"/>
   <result pre="in cells for controls, we observed that there was higher" exact="narcolepsy" post="incidence in the migraine group compared to the non-migraine"/>
   <result pre="we observed that there was higher narcolepsy incidence in the" exact="migraine" post="group compared to the non-migraine group: 3 events in"/>
   <result pre="Furthermore, among children without any concurrent antiepileptic or antipsychotic uptake," exact="migraine" post="children were observed with statistically higher risk of narcolepsy:"/>
   <result pre="4 gives the results of our sensitivity analysis with different" exact="migraine" post="subtypes. The risk of narcolepsy is consistently higher in"/>
   <result pre="our sensitivity analysis with different migraine subtypes. The risk of" exact="narcolepsy" post="is consistently higher in the migraine children when compared"/>
   <result pre="subtypes. The risk of narcolepsy is consistently higher in the" exact="migraine" post="children when compared to non-migraine counterparts except for unspecified"/>
   <result pre="compared to non-migraine counterparts except for unspecified migraine: highest in" exact="migraine" post="with aura (aHR: 9.03, 95% CI: 2.34, 34.8, p&amp;lt;0.01),"/>
   <result pre="aura (aHR: 9.03, 95% CI: 2.34, 34.8, p&amp;lt;0.01), followed by" exact="migraine" post="without aura (aHR: 5.76, 95% CI: 1.48, 22.5, p&amp;lt;0.05)."/>
   <result pre="Table 3 Incidence rates, hazard ratios and confidence intervals of" exact="narcolepsy" post="for children patients with and without migraine stratified by"/>
   <result pre="confidence intervals of narcolepsy for children patients with and without" exact="migraine" post="stratified by demographic attribute, comorbidity and concomitant medication. Variables"/>
   <result pre="p&amp;lt;0.001 10.1371/journal.pone.0189231.t004 Table 4 Incidence rates and hazard ratios of" exact="narcolepsy" post="in different migraine subtypes. Migraine type Event no. Person-years"/>
   <result pre="4 Incidence rates and hazard ratios of narcolepsy in different" exact="migraine" post="subtypes. Migraine type Event no. Person-years Incidence rate per"/>
   <result pre="3 7821 0.38 7.39 (2.03–28.9) ** 5.76 (1.48–22.45) * Unspecified" exact="migraine" post="(346.9x) No 8 190672 0.04 1.00 (reference) 1.00 (reference)"/>
   <result pre="*** p&amp;lt;0.001 Discussion This nationwide, population-based cohort study demonstrated that" exact="migraine" post="in children less than 18 years of age was"/>
   <result pre="comorbidities and concurrent medication uptake. Furthermore, the elevated risk in" exact="migraine" post="children was consistently detected in migraine with aura and"/>
   <result pre="the elevated risk in migraine children was consistently detected in" exact="migraine" post="with aura and migraine without aura subtypes, indicating that"/>
   <result pre="migraine children was consistently detected in migraine with aura and" exact="migraine" post="without aura subtypes, indicating that the study results were"/>
   <result pre="influence of medical care-seeking behavior, thus reinforcing our conclusions that" exact="migraine" post="increased the risk of narcolepsy in children. Although not"/>
   <result pre="thus reinforcing our conclusions that migraine increased the risk of" exact="narcolepsy" post="in children. Although not many population-based estimates of narcolepsy"/>
   <result pre="of narcolepsy in children. Although not many population-based estimates of" exact="narcolepsy" post="in children are available, a European study has indicated"/>
   <result pre="further validated since a statistically significant higher hazard ratio of" exact="narcolepsy" post="is shown in the migraine children despite our comparatively"/>
   <result pre="significant higher hazard ratio of narcolepsy is shown in the" exact="migraine" post="children despite our comparatively higher observed incidence in the"/>
   <result pre="tract and influenza) or other illnesses such as hyperactivity and" exact="epilepsy" post="which could be capable of triggering narcolepsy onset were"/>
   <result pre="as hyperactivity and epilepsy which could be capable of triggering" exact="narcolepsy" post="onset were also found analogous between our two study"/>
   <result pre="two study cohorts, further confirming the relatively increased risk of" exact="narcolepsy" post="attributed to migraine. Still, even after controlled for the"/>
   <result pre="for the effects of other central nervous system conditions like" exact="schizophrenia" post="and organic psychosis, affective psychoses, neurotic disorders and others"/>
   <result pre="narcoleptic syndrome not confounded with idiopathic narcolepsy. The association between" exact="migraine" post="and narcolepsy was inconclusive. In the first hospital-based observational"/>
   <result pre="not confounded with idiopathic narcolepsy. The association between migraine and" exact="narcolepsy" post="was inconclusive. In the first hospital-based observational study, migraine"/>
   <result pre="and narcolepsy was inconclusive. In the first hospital-based observational study," exact="migraine" post="showed a 2-fold to 4-fold increase in patients with"/>
   <result pre="migraine showed a 2-fold to 4-fold increase in patients with" exact="narcolepsy" post="[ 2]. This data supported their previous findings that"/>
   <result pre="supported their previous findings that half of narcoleptic patients reported" exact="migraine" post="in a clinical sample. Nevertheless, a multi-centre case-control study"/>
   <result pre="96 narcoleptics did not find a significant higher prevalence of" exact="narcolepsy" post="with migraine [ 3]. In contrast to these small"/>
   <result pre="did not find a significant higher prevalence of narcolepsy with" exact="migraine" post="[ 3]. In contrast to these small sample size"/>
   <result pre="design, our study included a relatively large number of population-based" exact="migraine" post="pediatric cases, and a retrospective cohort study design with"/>
   <result pre="a sufficiently long follow-up period. Moreover, we focused on pediatric" exact="migraine" post="cases, not adults like those addressed in previous studies"/>
   <result pre="2, 3]. Thus, our results support the emerging notion that" exact="migraine" post="is associated with the risk of narcolepsy development in"/>
   <result pre="emerging notion that migraine is associated with the risk of" exact="narcolepsy" post="development in children. This association suggests a plausible pathophysiological"/>
   <result pre="needs to be further investigated. The exact pathophysiologic mechanisms linking" exact="migraine" post="and narcolepsy are unknown. Loss of orexinergic neurons in"/>
   <result pre="be further investigated. The exact pathophysiologic mechanisms linking migraine and" exact="narcolepsy" post="are unknown. Loss of orexinergic neurons in the hypothalamus"/>
   <result pre="the hypothalamus has been considered playing a causative role in" exact="narcolepsy" post="with cataplexy. There is evidence that dysfunctional hypothalamic activity"/>
   <result pre="cataplexy. There is evidence that dysfunctional hypothalamic activity contributes to" exact="narcolepsy" post="as well as altered pain processing via hypothalamic orexinergic"/>
   <result pre="has been demonstrated in functional and structural brain imaging for" exact="migraine" post="[ 12– 15]. On other aspects, hypothalamic orexinergic neurons"/>
   <result pre="hypothalamic orexinergic system is both involved in trigeminovascular nociception and" exact="narcolepsy" post="developing that predispose some patients to migraine and narcolepsy."/>
   <result pre="trigeminovascular nociception and narcolepsy developing that predispose some patients to" exact="migraine" post="and narcolepsy. Clinical evidence for the role of hypothalamic"/>
   <result pre="the role of hypothalamic orexinergic system in the modulation of" exact="migraine" post="has not yet clearly identified and warrants further research."/>
   <result pre="are associated with the present study. First, the diagnoses of" exact="migraine" post="and narcolepsy were entirely identified on the basis of"/>
   <result pre="with the present study. First, the diagnoses of migraine and" exact="narcolepsy" post="were entirely identified on the basis of ICD-9-CM codes,"/>
   <result pre="every contracted medical institution [ 16]. Ideally, the diagnosis of" exact="narcolepsy" post="should be based on the International Classification of Sleep"/>
   <result pre="(PSG). However, from our data, a lot of children with" exact="narcolepsy" post="may not be diagnosed with the ICSD-2 or -3"/>
   <result pre="disorder did not exhibit much medical attention previously. However, since" exact="narcolepsy" post="is a rare disease, with the diagnosis large restricted"/>
   <result pre="failsafe. Furthermore, since many clinicians were unfamiliar with this disorder," exact="narcolepsy" post="remained under-diagnosed, potentially leading to underestimation of the risk"/>
   <result pre="remained under-diagnosed, potentially leading to underestimation of the risk of" exact="narcolepsy" post="in the migraine cohort. Even so, there still exists"/>
   <result pre="leading to underestimation of the risk of narcolepsy in the" exact="migraine" post="cohort. Even so, there still exists the possibility that"/>
   <result pre="still exists the possibility that there are differential diagnoses of" exact="narcolepsy" post="in the pediatric population such as delayed circadian phase"/>
   <result pre="the pediatric population such as delayed circadian phase syndrome or" exact="attention deficit hyperactivity disorder." post="In addition, the diagnosis of migraine was validated previously"/>
   <result pre="or attention deficit hyperactivity disorder. In addition, the diagnosis of" exact="migraine" post="was validated previously [ 17]. Nevertheless, a more definite"/>
   <result pre="validated previously [ 17]. Nevertheless, a more definite diagnosis of" exact="migraine" post="as a primary neurological disorder (versus unspecified migraine; with"/>
   <result pre="Nevertheless, a more definite diagnosis of migraine as a primary" exact="neurological disorder" post="(versus unspecified migraine; with and without aura) is required"/>
   <result pre="and without aura) is required to solidify the association between" exact="migraine" post="and narcolepsy. Second, headache could potentially be a sign"/>
   <result pre="of results. Also, the frequency and severity of narcoleptic or" exact="migraine" post="symptoms could not be precisely extracted from ICD codes,"/>
   <result pre="codes, and this prevented further analysis. Third, patients in our" exact="migraine" post="cohort were considered &quot;active&quot; migraineurs. Patients whose migraine became"/>
   <result pre="in our migraine cohort were considered &quot;active&quot; migraineurs. Patients whose" exact="migraine" post="became inactive may have been excluded from the migraine"/>
   <result pre="whose migraine became inactive may have been excluded from the" exact="migraine" post="cohort and misclassified as controls. Under these conditions, the"/>
   <result pre="misclassified as controls. Under these conditions, the risk of developing" exact="narcolepsy" post="among patients with migraine might have been underestimated. Fourth,"/>
   <result pre="these conditions, the risk of developing narcolepsy among patients with" exact="migraine" post="might have been underestimated. Fourth, the NHIRD is an"/>
   <result pre="a result, our results merely showed the increased associations of" exact="narcolepsy" post="in patients with migraine, which may not allow a"/>
   <result pre="further confirmed. Conclusion This population-based longitudinal study provides evidence that" exact="migraine" post="diagnosis is associated with an increased risk of narcolepsy"/>
   <result pre="that migraine diagnosis is associated with an increased risk of" exact="narcolepsy" post="in children. The higher narcolepsy incidence in the pediatric"/>
   <result pre="with an increased risk of narcolepsy in children. The higher" exact="narcolepsy" post="incidence in the pediatric migraine population may indicate a"/>
   <result pre="narcolepsy in children. The higher narcolepsy incidence in the pediatric" exact="migraine" post="population may indicate a common pathway of pathophysiology relevant"/>
   <result pre="research is warranted to describe the exact pathophysiological mechanisms linking" exact="migraine" post="and narcolepsy. Public health relevance The association between migraine"/>
   <result pre="linking migraine and narcolepsy. Public health relevance The association between" exact="migraine" post="and narcolepsy in children has not been explored in"/>
   <result pre="and narcolepsy. Public health relevance The association between migraine and" exact="narcolepsy" post="in children has not been explored in a large-scale"/>
   <result pre="explored in a large-scale longitudinal study. As almost one-third of" exact="migraine" post="patients become symptomatic before reaching the age of 15,"/>
   <result pre="an increasing level of attention given on the development of" exact="narcolepsy" post="early in life. Using a nationwide population-based study approach,"/>
   <result pre="population-based study approach, our results support the emerging notion that" exact="migraine" post="is associated with the risk of developing narcolepsy in"/>
   <result pre="notion that migraine is associated with the risk of developing" exact="narcolepsy" post="in children. This derived association suggests a plausible pathophysiological"/>
   <result pre=", Grü B and Bierbrauer J . Increased frequency of" exact="migraine" post="in narcoleptic patients. Neurology . 1999; 52: 1291– 1293."/>
   <result pre=", Epplen JT and Ullrich B . Increased frequency of" exact="migraine" post="in narcoleptic patients: a confirmatory study. Cephalalgia . 2003;"/>
   <result pre="C , Hviid A , et al. The incidence of" exact="narcolepsy" post="in Europe: before, during, and after the influenza A(H1N1)pdm09"/>
   <result pre="incidence of narcolepsy in Europe: before, during, and after the" exact="influenza" post="A(H1N1)pdm09 pandemic and vaccination campaigns . Vaccine . 2013;"/>
   <result pre=", et al. Diagnosis and development of screening items for" exact="migraine" post="in neurological practice in Taiwan . J Formos Med"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5723388/results/search/disease/results.xml">
   <result pre="diagnosis (female n = 62), aged 6–17 years, were included. Children with primary" exact="migraine" post="were recruited from mainstream schools while children with concussion"/>
   <result pre="which require specific management incorporating exposure to optokinetic stimuli. concussion" exact="migraine" post="vestibular disorders motion sickness environmental dizziness triggers fig-count: table-count:"/>
   <result pre="management incorporating exposure to optokinetic stimuli. concussion migraine vestibular disorders" exact="motion sickness" post="environmental dizziness triggers fig-count: table-count: equation-count: ref-count: page-count: word-count:"/>
   <result pre="The most common causes of childhood vertigo and dizziness are" exact="migraine" post="and migraine variants including vestibular migraine, peripheral vestibular syndromes,"/>
   <result pre="common causes of childhood vertigo and dizziness are migraine and" exact="migraine" post="variants including vestibular migraine, peripheral vestibular syndromes, and head"/>
   <result pre="outcome in adults with vestibular dysfunction ( 19) including vestibular" exact="migraine" post="( 20). Children may be more susceptible to ViD"/>
   <result pre="criteria included children with (a) central nervous system involvement excluding" exact="migraine" post="or concussion; (b) significant learning difficulties; or (c) orthopedic"/>
   <result pre="– n = 58 identified on the question set as diagnosed with" exact="migraine" post="from their primary care physician comprised the migraine group."/>
   <result pre="diagnosed with migraine from their primary care physician comprised the" exact="migraine" post="group. – n = 169 comprised the healthy control group. –"/>
   <result pre="n = 169 comprised the healthy control group. – Children with a" exact="migraine" post="diagnosis ( n = 58), frequent dizzy spells ( n = 27), vomiting,"/>
   <result pre="( n = 2) or orthopedic diagnosis, human immunodeficiency virus ( n = 1)," exact="substance abuse" post="history ( n = 2), abnormal SDQ scores ( n = 14) or"/>
   <result pre="and PVSQ scores, age, gender, binocular vision, hearing difficulty, and" exact="migraine" post="history; only significant correlations are reported. Significant results were"/>
   <result pre="SNHL, sensory neural hearing loss; PVD, peripheral vestibular disorder; OM," exact="otitis media" post=". *Indicates a significant p ≤ 0.01 between-group difference between healthy"/>
   <result pre="groups [χ 2(2) = 11.014; p = 0.004], whereby scores increased from a primary" exact="migraine" post="(mean rank = 49.92) to concussion (mean rank = 59.76) to vestibular (mean"/>
   <result pre="and 72% of children with a primary vestibular, concussion, or" exact="migraine" post="diagnosis, respectively. Mean number ViD triggers per person were"/>
   <result pre="and 86.2% of children with a primary vestibular, concussion, or" exact="migraine" post="diagnosis, respectively, had abnormal PVSQ scores ( 13). Strength"/>
   <result pre="r = 0.69, p = 0.001), PVSQ (total: r = 0.60, p = 0.004; emotional: r = 0.55, p = 0.01), and" exact="migraine" post="(total: r = 0.74, p = 0.01; emotional: r = 0.55, p = 0.01), whereby higher SDQ"/>
   <result pre="higher SDQ scores were associated with higher questionnaire scores and" exact="migraine" post="history. Discussion This is the first study to provide"/>
   <result pre="highly. The main triggers endorsed by children with concussion and/or" exact="migraine" post="were also diverse, with computer use and doing schoolwork"/>
   <result pre="concussion in their natural environments ( 45). The relationship between" exact="motion sickness" post="and increased visual dependence also exists with a stronger"/>
   <result pre="symptom triggers in healthy children were those specifically relating to" exact="motion sickness," post="including computer use, with the percentage similar to that"/>
   <result pre="with age and gender, rather than individual items relating to" exact="motion sickness." post="No relationship was noted between the presence of a"/>
   <result pre="the environmental triggers of these symptoms. Children with a primary" exact="migraine" post="diagnosis had been diagnosed by their primary care physician."/>
   <result pre="trigger. Vestibular symptoms of dizziness and ViD may indicate vestibular" exact="migraine" post="( 20), which may occur at any age and"/>
   <result pre="is widely underdiagnosed ( 51, 52). In one study, vestibular" exact="migraine" post="accounted for 20.2% of the diagnoses, but was suspected"/>
   <result pre="1.8% ( 53). Dizziness/vertigo are common symptoms in children with" exact="migraine" post="( 54) and require a comprehensive neuro-otological assessment for"/>
   <result pre="symptoms ( 20). However, none of the children in the" exact="migraine" post="group had been referred for a neuro-otological assessment. Children"/>
   <result pre="self- and informant-rated versions. Significant correlations were noted between questionnaires," exact="migraine" post="history, and SDQ for the informant-rated version in patients,"/>
   <result pre="pediatric population. It is unknown if any children in the" exact="migraine" post="group may have been provided with an additional diagnosis"/>
   <result pre="No neuro-otological assessment was completed for children with a primary" exact="migraine" post="diagnosis as they were recruited from mainstream schools and"/>
   <result pre="recruited from mainstream schools and no information was collected about" exact="migraine" post="characteristics, academic performance, and QOL, which may have provided"/>
   <result pre="Cusick BA Zhou G . Evaluation and management of vestibular" exact="migraine" post="in children: experience from a pediatric vestibular clinic ."/>
   <result pre="Cherkas LF Spector TD MacGregor AJ . Genetic influences on" exact="motion sickness" post="susceptibility in adult women: a classical twin study ."/>
   <result pre="psychopathology and quality of life in children and adolescents with" exact="migraine" post=". J Child Neurol ( 2016) 31( 7): 837–"/>
   <result pre="61 Maizels M Aurora S Heinricher M . Beyond neurovascular:" exact="migraine" post="as a dysfunctional neurolimbic pain network. Headache ( 2012)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5745369/results/search/disease/results.xml">
   <result pre="patients with headache, or with a family history of early" exact="stroke" post="or dementia or mood changes [ 11– 15]. Since"/>
   <result pre="headache, or with a family history of early stroke or" exact="dementia" post="or mood changes [ 11– 15]. Since few pediatric"/>
   <result pre="have been reported those with presenting symptoms of headache had" exact="migraine" post="with or without aura or atypical migraine. In a"/>
   <result pre="disease are caused mainly by cerebral sinus venous thrombosis or" exact="idiopathic intracranial hypertension" post="and symptoms are related to this entity or due"/>
   <result pre="brain involvement [ 17, 18]. Intracranial hemorrhage and arterial ischemic" exact="stroke" post="prevalence is 74% and 21% in pediatric population. However,"/>
   <result pre="of focal signs and papilledema; and positive family history of" exact="stroke" post="or dementia [ 21]. Headache prevalence in pediatric patients"/>
   <result pre="signs and papilledema; and positive family history of stroke or" exact="dementia" post="[ 21]. Headache prevalence in pediatric patients with arteriovenous"/>
   <result pre="changes Headache attributed to non-vascualar intracranial disorder Headache attributed to" exact="idiopathic intracranial hypertension" post="(IIH) The course of pediatric IIH varies, and a"/>
   <result pre="they may only reflect those of generalized intracranial hypertension of" exact="papilledema" post="with normal mental status. Documented elevated intracranial pressure ("/>
   <result pre="posturography etc), radicular features (pain, dermatomal hypoesthesia, radicular weakness, etc)," exact="cerebellar ataxia," post="and encephalopathy. Children show these values approximately 20 to"/>
   <result pre="much more common conditions such as complicated or hemiplegic migraine," exact="aseptic meningitis," post="meningoencephalitis, or stroke. This clinical syndrome is under recognized"/>
   <result pre="have any recommendation for this title. Headache attributed to intracranial" exact="neoplasm" post="Comments Brain tumors are rare in children, with an"/>
   <result pre="associated with endocrine alterations showing visual disturbance unrelated to the" exact="migraine" post="persistent localized pain Headache attributed to epileptic seizures Since"/>
   <result pre="Most cases describe headaches similar to primary headache disorders like" exact="migraine" post="or tension-type headaches. Only 6% of patients reported of"/>
   <result pre="no specific report has been published regarding the relation between" exact="substance abuse" post="and headache disorders in children and adolescents. Illicit drug"/>
   <result pre="headache [ 35, 36]. Alcohol induced headache reported to have" exact="migraine" post="like headache tension cluster headache and triggers of less"/>
   <result pre="triggers of less frequent types of primary headache such as" exact="familial hemiplegic migraine," post="hemicrania continua, and paroxysmal hemicrania with no specific reports"/>
   <result pre="effect can be used for pediatric patients. Headache attributed to" exact="bacterial meningitis" post="or meningoencephalitis It is known that nearly 24.9% of"/>
   <result pre="can be used for pediatric patients. Headache attributed to bacterial" exact="meningitis" post="or meningoencephalitis It is known that nearly 24.9% of"/>
   <result pre="used for pediatric patients. Headache attributed to bacterial meningitis or" exact="meningoencephalitis" post="It is known that nearly 24.9% of the patients"/>
   <result pre="were less than 20% [ 39]. On the other side," exact="bacterial meningitis" post="is present in 30% of children with signs of"/>
   <result pre="less than 20% [ 39]. On the other side, bacterial" exact="meningitis" post="is present in 30% of children with signs of"/>
   <result pre="of meningeal irritation assessed by the pediatrician is related to" exact="bacterial meningitis" post="in 39%. The meningoencephalitis seldom affected children absent fever"/>
   <result pre="meningeal irritation assessed by the pediatrician is related to bacterial" exact="meningitis" post="in 39%. The meningoencephalitis seldom affected children absent fever"/>
   <result pre="the pediatrician is related to bacterial meningitis in 39%. The" exact="meningoencephalitis" post="seldom affected children absent fever and neck stiffness. The"/>
   <result pre="41]. Some cases of children and infants, immunosuppressed patients present" exact="meningoencephalitis" post="absent neck stiffness or any other signs of meningeal"/>
   <result pre="the ICHD-3B criteria for the diagnosis of Headache attributed to" exact="bacterial meningitis" post="or meningoencephalitis; some cases of meningoencephalitis could be presented"/>
   <result pre="ICHD-3B criteria for the diagnosis of Headache attributed to bacterial" exact="meningitis" post="or meningoencephalitis; some cases of meningoencephalitis could be presented"/>
   <result pre="Headache attributed to bacterial meningitis or meningoencephalitis; some cases of" exact="meningoencephalitis" post="could be presented without meningeal irritation signs. ICHD-3B Headache"/>
   <result pre="children and adolescents . The main predisposing factor is cyanotic" exact="congenital heart disease," post="sinusitis, otitis, or dental infections. Because of this, the"/>
   <result pre="and adolescents . The main predisposing factor is cyanotic congenital" exact="heart disease," post="sinusitis, otitis, or dental infections. Because of this, the"/>
   <result pre="have an increased risk for brain abscess in case of" exact="patent foramen ovale" post="[ 42, 43]. Comment regard the sections &quot;Headache attributed"/>
   <result pre="have an increased risk for brain abscess in case of" exact="patent foramen ovale." post="Headache attributed to disorders of homeostasis Comments These criteria"/>
   <result pre="may be associated with physiologic changes such as vasogenic edema," exact="pulmonary edema," post="and hematologic disorders. Therefore, since headache is a nonspecific"/>
   <result pre="sickness, manifested by physical and mental tiredness, feeling of sadness," exact="shortness" post="of breath upon awakening, palpitations, muscle and/or joint pains,"/>
   <result pre="toddlers, adolescents). There are few reports of the characteristics of" exact="sleep apnea" post="headache in pediatric patients [ 52]. As opposed to"/>
   <result pre="opposed to adults, the most common pathophysiologic factor associated with" exact="obstructive sleep apnea" post="in pediatric patients is adenoid hypertrophy in young children"/>
   <result pre="to adults, the most common pathophysiologic factor associated with obstructive" exact="sleep apnea" post="in pediatric patients is adenoid hypertrophy in young children"/>
   <result pre="factor associated with obstructive sleep apnea in pediatric patients is" exact="adenoid hypertrophy" post="in young children and obesity in adolescents [ 51–"/>
   <result pre="in pediatric patients is adenoid hypertrophy in young children and" exact="obesity" post="in adolescents [ 51– 53]. Recommendations Criteria B should"/>
   <result pre="normal age- related polysomnographic respiratory values. The pathophysiologic factors of" exact="adenoid hypertrophy" post="in children and obesity in adolescents should be added"/>
   <result pre="values. The pathophysiologic factors of adenoid hypertrophy in children and" exact="obesity" post="in adolescents should be added to the ICHD-3 criteria."/>
   <result pre="be added to the ICHD-3 criteria. Key point: Usually, if" exact="adenoid hypertrophy" post="or obesity is diagnosed as a cause of sleep"/>
   <result pre="the ICHD-3 criteria. Key point: Usually, if adenoid hypertrophy or" exact="obesity" post="is diagnosed as a cause of sleep apnea, the"/>
   <result pre="adenoid hypertrophy or obesity is diagnosed as a cause of" exact="sleep apnea," post="the headache is significantly alleviated or eliminated after adenoidectomy,"/>
   <result pre="older children, in whom there is a higher incidence of" exact="essential hypertension," post="but moderately reliable in young children, in whom arterial"/>
   <result pre="implied for pediatric patients. Headache attributed to hypertensive crisis without" exact="hypertensive encephalopathy" post="Comments The ICHD-3 beta criteria have high reliability but"/>
   <result pre="for pediatric patients. Headache attributed to hypertensive crisis without hypertensive" exact="encephalopathy" post="Comments The ICHD-3 beta criteria have high reliability but"/>
   <result pre="better accounted for by an underlying disease. Headache attributed to" exact="hypertensive encephalopathy" post="Comments Most studies describe the same symptoms as described"/>
   <result pre="accounted for by an underlying disease. Headache attributed to hypertensive" exact="encephalopathy" post="Comments Most studies describe the same symptoms as described"/>
   <result pre="quality aggravated by physical activity Headache attributed to pre-eclampsia or" exact="eclampsia" post="Comments The ICHD-3 beta criteria for pre-eclampsia/eclampsia-associated headache have"/>
   <result pre="children and adolescents to make good recommendations. Headache attributed to" exact="hypothyroidism" post="Comments The ICHD-3 beta criteria for hypothyroidism-associated headache have"/>
   <result pre="symptoms. The only report regarding hypotyroidism in pediatric patients described" exact="migraine" post="feature of hypothroidsm [ 74, 75]. Recommendation We need"/>
   <result pre="described in the literatures regarding fasting headache is Tension-type headache," exact="migraine" post="and cluster headache [ 76– 78]. The ICHD-3 beta"/>
   <result pre="tension-type headache) are often comorbid with psychiatric disorder. Sleep disorders," exact="post-traumatic stress disorder," post="social anxiety disorder (school phobia) attention-deficit/hyperactivity disorder (ADHD), conduct"/>
   <result pre="comorbid with psychiatric disorder. Sleep disorders, post-traumatic stress disorder, social" exact="anxiety disorder" post="(school phobia) attention-deficit/hyperactivity disorder (ADHD), conduct disorder, learning disorder,"/>
   <result pre="stress disorder, social anxiety disorder (school phobia) attention-deficit/hyperactivity disorder (ADHD)," exact="conduct disorder," post="learning disorder, enuresis, encopresis and tic disorder should be"/>
   <result pre="attention-deficit/hyperactivity disorder (ADHD), conduct disorder, learning disorder, enuresis, encopresis and" exact="tic disorder" post="should be carefully looked for and treated when found,"/>
   <result pre="these cases present clinical pictures of primary headache disorders like" exact="migraine" post="or TTH. Painful cranial neuropathies and other facial pains"/>
   <result pre="or TTH. Painful cranial neuropathies and other facial pains Classical" exact="trigeminal neuralgia" post="(TGN) There are very few reports of TGN in"/>
   <result pre="reports of TGN in the pediatric literature. The symptoms of" exact="trigeminal neuralgia" post="in the few s cases described in the literature"/>
   <result pre="and/or the submaxillary or submandibular regions commonly presented as a" exact="neuropathy" post="[ 91]. Limitations of the paper In pediatric medicine,"/>
   <result pre="A Landgraf MN et al. High diagnostic stability of confirmed" exact="migraine" post="and confirmed tension-type headache according to the ICHD-3 Beta"/>
   <result pre="autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy resulting in" exact="stroke" post="in an 11-year-old male Dev Med Child Neurol 2009"/>
   <result pre="W et al. Risk factors and imaging characteristics of childhood" exact="stroke" post="in china J Child Neurol 2015 30 3 339"/>
   <result pre="Ishii S et al. Characteristics of headache in children with" exact="epilepsy" post="Seizure 2013 22 647 650 10.1016/j.seizure.2013.04.022 23702024 29. Lieba-Samal"/>
   <result pre="ICHD-3 beta criteria of periictal headaches in patients with focal" exact="epilepsy" post="- a prospective diary study. Cephalalgia 0(0):1–6. doi:10.1177/0333102416684343. Available"/>
   <result pre="F Lugaresi E Hemicrania epileptica: synchronous ipsilateral ictal headache with" exact="migraine" post="features Migraine and epilepsy 1987 Boston Butterworth 249 263"/>
   <result pre="epileptica: synchronous ipsilateral ictal headache with migraine features Migraine and" exact="epilepsy" post="1987 Boston Butterworth 249 263 32. Aitken LA Lindan"/>
   <result pre="454 33. Patra KC Kirtane AP Not all cases of" exact="nyctalopia" post="are benign: unusual and serendipitous presentation of Arnold-Chiari type"/>
   <result pre="features, outcomes and molecular profiles of drug resistance in Tuberculous" exact="meningitis" post="in non-HIV patients Sci Rep 2016 7 6 19072"/>
   <result pre="E Irina T Manciuc C Vâţă LG Dorobăţ C Viral" exact="meningitis" post="admitted to an infectious diseases hospital: a retrospective case"/>
   <result pre="41. Michos AG Syriopoulou VP Hadjichristodoulou C et al. Aseptic" exact="meningitis" post="in children: analysis of 506 cases PLoS One 2007"/>
   <result pre="associated with hypertension as unique clinical presentation of posterior reversible" exact="encephalopathy" post="syndrome BMC Pediatr 2014 14 190 10.1186/1471-2431-14-190 25062701 68."/>
   <result pre="B Cebeci AN The debate on the link between subclinical" exact="hypothyroidism" post="and childhood migraine: is initial endocrinological evaluation necessary for"/>
   <result pre="R Mirouliaei M Bashardoost N et al. Frequency of subclinical" exact="hypothyroidism" post="in 5- to 15-year-old children with migraine headache J"/>
   <result pre="Frequency of subclinical hypothyroidism in 5- to 15-year-old children with" exact="migraine" post="headache J Pediatr Endocrinol Metab 2012 25 859 862"/>
   <result pre="Skull involvement in a pediatric case of chronic recurrent multifocal" exact="osteomyelitis" post="Nagoya J Med Sci 2015 77 3 493 500"/>
   <result pre="206 213 10.1046/j.1468-2982.2003.00486.x 12662188 90. Al-Twaijri WA Shevell MI Pediatric" exact="migraine" post="equivalents: occurrence and clinical features in practice Pediatr Neurol"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5745373/results/search/disease/results.xml">
   <result pre="of this paper. Migraine Comments Migraine in children differs from" exact="migraine" post="in adults with regard to its duration, location, and"/>
   <result pre="A significant body of literature has revealed high prevalence of" exact="migraine" post="in the pediatric age group [ 3– 7]. Up"/>
   <result pre="pediatric age group [ 3– 7]. Up to age 7," exact="migraine" post="prevalence of both genders is almost equal, and after"/>
   <result pre="more frequently [ 9]. Overall, the estimated reported prevalence of" exact="migraine" post="in the pediatric age group (3 to 18 years"/>
   <result pre="males [ 10– 12]. The clinical presentation of infants with" exact="migraine" post="can be non-specific and the symptoms may be vague."/>
   <result pre="and irritability [ 13]. Migraine without aura Comments Attacks of" exact="migraine" post="without aura in children are often shorter than in"/>
   <result pre="neurologic findings as elevated intracranial pressure, tumors, benign cysts, or" exact="sinusitis" post="on imaging [ 21– 24]. In very young children,"/>
   <result pre="[ 21– 24]. In very young children, the diagnosis of" exact="migraine" post="can be particularly challenging due to their inability to"/>
   <result pre="at the core of diagnosis. The proposed diagnostic criteria for" exact="migraine" post="in younger children, which emphasize behavioral cues rather than"/>
   <result pre="the current authors [ 3]. Table 1 Proposed criteria for" exact="migraine" post="in children age 5 years and younger A. At"/>
   <result pre="by other diagnoses Recommendations Recognition of the short duration of" exact="migraine" post="attacks should be emphasized and highlighted. Frontal Headache is"/>
   <result pre="emphasized and highlighted. Frontal Headache is common in children with" exact="migraine" post="without aura and should be acknowledged. Severity of headache"/>
   <result pre="cause. It should be emphasized that the character of pediatric" exact="migraine" post="changes over time. The distinction between migraine and tension-type"/>
   <result pre="character of pediatric migraine changes over time. The distinction between" exact="migraine" post="and tension-type headache is far less sharp in children"/>
   <result pre="adults. Additional criteria may be needed, such as presence of" exact="motion sickness" post="or osmophobia. Vertiginous symptoms and motion sickness seem to"/>
   <result pre="as presence of motion sickness or osmophobia. Vertiginous symptoms and" exact="motion sickness" post="seem to be supporting features of pediatric migraine. A"/>
   <result pre="hard to categorize. Prognostically, 50% to 60% of adolescents with" exact="migraine" post="with aura are still symptomatic at the 5- to"/>
   <result pre="of patients in pediatric/adolescent neurology or specialty headache practices with" exact="migraine" post="have accompanying cranial autonomic symptom. By contrast to adults,"/>
   <result pre="they are usually bilateral. Clinicians should be careful to consider" exact="migraine" post="when evaluating a child with headache and associated ocular"/>
   <result pre="28]. Recommendations The autonomic symptoms associated with children and adolescent" exact="migraine" post="should not be considered as exceptions because there are"/>
   <result pre="reported aura or without aura symptoms, on its own. Chronic" exact="migraine" post="Comments Chronic migraine (CM) occurs in 1.7% of children,"/>
   <result pre="without aura symptoms, on its own. Chronic migraine Comments Chronic" exact="migraine" post="(CM) occurs in 1.7% of children, with an increase"/>
   <result pre="and adolescents with chronic headache (73.2% with migraine) revealed that" exact="migraine" post="equivalents (abdominal migraine, cyclical vomiting, benign paroxysmal vertigo, and"/>
   <result pre="that these should potentially be considered as part of the" exact="migraine" post="syndrome. The ICHD-3rd beta version lists these equivalents as"/>
   <result pre="revealed by physicians. Episodic syndromes that may be associated with" exact="migraine" post="Comments There are several episodic syndromes in children and"/>
   <result pre="the prognostic importance. On the other hand, some symptoms like" exact="motion sickness" post="or vertigo, associated with headache disorders, are still debated"/>
   <result pre="is difficult. Often, there is a positive family history of" exact="migraine" post="and evidence suggesting that RAP is a precursor of"/>
   <result pre="migraine and evidence suggesting that RAP is a precursor of" exact="migraine" post="headache, and primarily a comorbid pain disorder in preadolescent"/>
   <result pre="is a precursor of migraine headache, and primarily a comorbid" exact="pain disorder" post="in preadolescent patients [ 37]. Benign paroxysmal vertigo of"/>
   <result pre="at age 5 (about 40% rate of headache); and abdominal" exact="migraine" post="usually begins latest, at school-age. Children with periodic syndromes"/>
   <result pre="earlier-onset syndromes may have later-onset types of periodic syndromes or" exact="migraine" post="headaches later in childhood, and even in adulthood ["/>
   <result pre="There is some supporting evidence linking colic in infancy to" exact="migraine" post="headaches in adulthood. Recent studies showed that mothers with"/>
   <result pre="migraine headaches in adulthood. Recent studies showed that mothers with" exact="migraine" post="are more than twice as likely to have an"/>
   <result pre="the developing brain and childhood periodic syndromes may present before" exact="migraine" post="headache. The definition of benign paroxysmal torticollis should include"/>
   <result pre="final version. Familiarity with these disorders and their association with" exact="migraine" post="headache may help clinicians reach the correct diagnosis and"/>
   <result pre="found. Key point 2: In young children the diagnosis of" exact="migraine" post="can be particularly challenging due to their inability to"/>
   <result pre="and any associated symptoms. The overlap of some symptoms between" exact="migraine" post="and tension-type headache may make it difficult for clinicians"/>
   <result pre="headache The symptoms of tension-type headache may also overlap with" exact="migraine" post="and a diagnosis of migraine can change to episodic"/>
   <result pre="headache may also overlap with migraine and a diagnosis of" exact="migraine" post="can change to episodic tension-type headache over time ["/>
   <result pre="patients from childhood to adulthood. Diagnostic changes of TTH or" exact="migraine" post="may sometimes occur more rapidly. The overlap between the"/>
   <result pre="is greater in children than in adults. Indeed, given that" exact="migraine" post="in children may be characterized by non-pulsating (not a"/>
   <result pre="more important than words. The best diagnostic clinical characteristics of" exact="migraine" post="are pain of moderate or severe intensity, pain aggravated"/>
   <result pre="in intensity and non-pulsating. Thus, the most specific features distinguishing" exact="migraine" post="from tension-type headache are improvement after sleep, presence of"/>
   <result pre="children move through adolescence that their migraines begin to resemble" exact="migraine" post="in adults, owing to the process of cerebral maturation"/>
   <result pre="findings that suggest that tension-type headache in childhood may become" exact="migraine" post="later in life. This suggests that migraine and tension-type"/>
   <result pre="childhood may become migraine later in life. This suggests that" exact="migraine" post="and tension-type headache may not be distinct entities, but"/>
   <result pre="of benign headache [ 55]; alternatively as the brain matures" exact="migraine" post="biology is more readily expressed and the conditions are"/>
   <result pre="in approximately 10% of pediatric cases compared to 25% for" exact="migraine" post="[ 57, 58]. The clinical features of pediatric-onset cluster"/>
   <result pre="Restlessness may not be severe and difficult to characterize. Like" exact="migraine" post="attacks, observation of the behavior is more important than"/>
   <result pre="indomethacin is not always universal (as in adults). Finally, some" exact="migraine" post="features, including vomiting, throbbing nature of the pain, photophobia,"/>
   <result pre="exertional headache and primary sex headache. Others found that comorbid" exact="migraine" post="occurs in about 50% of individuals with primary sex"/>
   <result pre="with primary sex headache, perhaps explaining why sex headache has" exact="migraine" post="features in some cases [ 67]. Recommendations The following"/>
   <result pre="&quot;There is a phenomenological association between primary exertion headache and" exact="migraine" post="attacks&quot;. Primary stabbing or &quot;ice-pick&quot; headache Comments The estimated"/>
   <result pre="note duration of up to 15 min. An association with" exact="migraine" post="is noted by the ICHD-3 beta version. Also, extra-cephalic"/>
   <result pre="has been many secondary cause associated with NDPH such as" exact="cerebral venous sinus thrombosis," post="low or high cerebrospinal fluid pressure syndrome, carotid/vertebral dissection,"/>
   <result pre="and neoplasms. The authors supported that there were too many" exact="migraine" post="features to fulfill ICHD-II criteria for NDPH, a feature"/>
   <result pre="a feature now noted in ICHD-3 which permits TTH and/or" exact="migraine" post="symptoms [ 1, 3, 70– 74]. The phenotypic similarities"/>
   <result pre="1, 3, 70– 74]. The phenotypic similarities between NPDH and" exact="migraine" post="should be noted in the ICHD-3. Nummular headache Comments"/>
   <result pre="disorders, depression and sleep disorders [ 76]. Also, children with" exact="migraine" post="seem to have lower attachment security than children without"/>
   <result pre="et al. (2017) [ 77] found a complex pathway from" exact="migraine" post="to anxiety symptoms mediated by perceived insecurity of paternal"/>
   <result pre="al. (2016) found that both adolescents and mothers suffering from" exact="migraine" post="appear to experience greater level of alexithymia than the"/>
   <result pre="of alexithymia than the control group and the co-occurrence of" exact="migraine" post="and alexithymia increases the risk of psychopathology [ 78]."/>
   <result pre="subtopics of pediatric headaches. Abbreviations CH Cluster headache CM Chronic" exact="migraine" post="HC Hemicrania continua HH Hypnic headache ICDH-3 International classification"/>
   <result pre="Celentano DD et al. Age- and sex-specific incidence rates of" exact="migraine" post="with and without visual aura Am J Epidemiol 1991"/>
   <result pre="Razak S Sivaraman B et al. Prevalence of headache and" exact="migraine" post="in children and adolescents: a systematic review of population-based"/>
   <result pre="Zesch HE et al. Clinical features, classification and prognosis of" exact="migraine" post="and tension-type headache in children and adolescents: a long-term"/>
   <result pre="Hershey AD Coffey CS et al. The childhood and adolescent" exact="migraine" post="prevention (CHAMP) study: a report on baseline characteristics of"/>
   <result pre="30 2 182 186 10.1177/0883073814535494 24846900 17. Lewis DW Pediatric" exact="migraine" post="Neurol Clin 2009 27 481 501 10.1016/j.ncl.2008.11.003 19289227 18."/>
   <result pre="Grauw TJ Hershey AD Powers SW et al. Diagnosis of" exact="migraine" post="in children attending a pediatric headache clinic Headache 1999"/>
   <result pre="Evaluation of diagnostic and prognostic value of clinical characteristics of" exact="migraine" post="and tension type headache included in the diagnostic criteria"/>
   <result pre="Occipital and craniocervical pain and brain MRI in children with" exact="migraine" post="Pediatr Neurol 2014 50 347 352 10.1016/j.pediatrneurol.2013.11.004 24485928 25."/>
   <result pre="G Versace A et al. Epidemiological and clinical features of" exact="migraine" post="in the pediatric population of Northern Italy Cephalalgia 2016"/>
   <result pre="Khourieh Matar A Zelnik N et al. Frequency of pediatric" exact="migraine" post="with aura in a clinic-based sample Headache 2016 56"/>
   <result pre="LL Olesen J The visual Aura rating scale (VARS) for" exact="migraine" post="aura diagnosis Cephalalgia 2005 25 10 801 810 10.1111/j.1468-2982.2005.00955.x"/>
   <result pre="AA Reider AC Goadsby PJ Cranial autonomic symptoms in pediatric" exact="migraine" post="are the rule, not the exception Neurology 2013 81"/>
   <result pre="401 406 10.1177/0333102412438975 22407655 31. Özge A Yalin OÖ Chronic" exact="migraine" post="in children and adolescents Curr Pain Headache Rep 2016"/>
   <result pre="2008 28 1145 1153 10.1111/j.1468-2982.2008.01656.x 18644034 33. Francis MV Brief" exact="migraine" post="episodes in children and adolescents—a modification to international headache"/>
   <result pre="in children and adolescents—a modification to international headache society pediatric" exact="migraine" post="(without aura) diagnostic criteria Springer Plus 2013 2 77"/>
   <result pre="Özge A Ergör G Vestibular symptoms are more frequent in" exact="migraine" post="than in tension type headache patients J Neurol Sci"/>
   <result pre="297 10.1177/000992280104000512 42. Gelfand AA Thomas KC Goadsby PJ Maternal" exact="migraine" post="is associated with increased risk of infant colic. Colic"/>
   <result pre="infant colic. Colic may be an early life manifestation of" exact="migraine" post="Neurology 2012 79 1392 1396 10.1212/WNL.0b013e31826c1b7b 22972642 43. Gelfand"/>
   <result pre="43. Gelfand AA Goadsby PJ Allen IE The relationship between" exact="migraine" post="and infant colic: a systematic review and meta-analysis Cephalalgia"/>
   <result pre="14 1246 1251 10.1177/0333102415576225 25754178 46. Wöber-Bingöl C Epidemiology of" exact="migraine" post="and headache in children and adolescents Curr Pain Headache"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5760673/results/search/disease/results.xml">
   <result pre="the effectiveness and tolerability of melatonin and amitriptyline in pediatric" exact="migraine" post="prevention. Materials &amp;amp; Methods: In a parallel single-blinded randomized"/>
   <result pre="randomized clinical trial, 5-15 yr old children with diagnosis of" exact="migraine" post="that preventive therapy was indicated in whom and were"/>
   <result pre="in 22.5% of amitriptyline group including daily sleepiness in four," exact="constipation" post="in three and fatigue in two children and melatonin"/>
   <result pre="Conclusion: Amitriptyline and melatonin are effective and safe in pediatric" exact="migraine" post="prophylaxis but amitriptyline can be considered as a more"/>
   <result pre="of children and up to 28% of older teenagers have" exact="migraine" post="headache ( 1). Up to one-third of migraineurs children"/>
   <result pre="antihypertensive, antidepressants and antiepileptic drugs have been consumed in pediatric" exact="migraine" post="prophylaxis. However, a standardized and unique guideline for migraine"/>
   <result pre="pediatric migraine prophylaxis. However, a standardized and unique guideline for" exact="migraine" post="prevention in children does not exist and flunarizine and"/>
   <result pre="randomized clinical trials for the use of preventive drugs in" exact="migraine" post="of children are fiercely needed ( 2, 3). Amitriptyline"/>
   <result pre="tricyclic antidepressants with minimal side effects is the most common" exact="migraine" post="preventive drug in children, but amitriptyline should not be"/>
   <result pre="of sleep .The level of melatonin might be decreased in" exact="migraine" post="headaches and it may play an important role in"/>
   <result pre="migraine headaches and it may play an important role in" exact="migraine" post="pathogenesis. This chronobiotic agent has been used as an"/>
   <result pre="has been used as an effective drug in treatment of" exact="migraine" post="headaches. Possible mechanisms of melatonin in treatment of headache"/>
   <result pre="three-milligram oral melatonin at bedtime in 14 children with recurrent" exact="migraine" post="headache, aged 6-16 yr, is reported ( 6). We"/>
   <result pre="that whether or not melatonin was superior to amitriptyline for" exact="migraine" post="prophylaxis in 5-15 yr-old children suffer frequent or disabling"/>
   <result pre="the effectiveness and tolerability of amitriptyline and melatonin for pediatric" exact="migraine" post="prevention. Materials and Methods In a randomized single-blind clinical,"/>
   <result pre="group study, effectiveness and tolerability of amitriptyline and melatonin for" exact="migraine" post="prophylaxis in 5-15 yr old children who had migraines"/>
   <result pre="number: IRCT201305292639N12. Inclusion criteria included children aged 5-15 yr, having" exact="migraine" post="headache (with or without aura) based on second edition"/>
   <result pre="headache disability PedMIDAS more than 20, and not used any" exact="migraine" post="preventive therapy. The children with secondary headaches or systemic"/>
   <result pre="and excitability, mood and behavioral changes, severe skin eruptions, severe" exact="constipation" post="and hypothermia would happen. Laboratory assessment (hepatic, renal, hematologic"/>
   <result pre="of headache, number of analgesics usage, sex distribution, type of" exact="migraine" post="and positive family history of migraine were not statistically"/>
   <result pre="sex distribution, type of migraine and positive family history of" exact="migraine" post="were not statistically significant different in both groups. After"/>
   <result pre="group, adverse events were seen including daily sleepiness in four," exact="constipation" post="in three and fatigue and malaise in two children."/>
   <result pre="of medications have been used for treatment and prevention of" exact="migraine" post="in pediatric population. In the present research, effectiveness and"/>
   <result pre="research, effectiveness and tolerability of amitriptyline and melatonin for pediatric" exact="migraine" post="prophylaxis in 5-15 yr old children were compared. The"/>
   <result pre="2.44 10.11 ± 2.13 0.4 Independent t-test Onset age of" exact="migraine" post="(mean ± SD) 8.59 ± 1.56 8.34 ± 2.45"/>
   <result pre="22 19 0.5 Chi-square test Boy 18 21 Type of" exact="migraine" post="Without aura 23 29 0.2 Chi-square test With aura"/>
   <result pre="Chi-square test With aura 17 11 Positive family history of" exact="migraine" post="Yes 35 33 0.9 Chi-square test No 5 7"/>
   <result pre="Brazil, melatonin and amitriptyline in comparison with placebo-decreased frequency of" exact="migraine" post="headache and tolerability of melatonin was more than amitriptyline"/>
   <result pre="in reduction of monthly frequency, severity, duration and disability of" exact="migraine" post="headache of children in present research was in compliance"/>
   <result pre="interdependently, lack of sleep and excessive sleep can both cause" exact="migraine" post="( 12) and melatonin irregular production has some links"/>
   <result pre="and daytime drowsiness and effectiveness of melatonin in control of" exact="migraine" post="headache might be related to normalization and adjustment of"/>
   <result pre="was effective and with minimal side effects in prevention of" exact="migraine" post="( 21). However, in the USA, amitriptyline was more"/>
   <result pre="USA, amitriptyline was more effective than placebo in prevention of" exact="migraine" post="in 8 weeks but not in 12, 16, or"/>
   <result pre="lightheadedness and cardiac arrhythmia have been reported ( 23). Prophylactic" exact="migraine" post="therapy should be considered in children with frequent and"/>
   <result pre="headaches. Parents and caregivers must learn about different options of" exact="migraine" post="prophylaxis including pharmacologic and non-pharmacological behavioral techniques. In infants"/>
   <result pre="been used as an effective drug for the prevention of" exact="migraine" post="headache in children since 1970 and is preferable because"/>
   <result pre="dosing and minimal side effects. In comorbid situations such as" exact="migraine" post="and depression, amitriptyline might be more beneficial and abundance"/>
   <result pre="melatonin are effective and without life-threatening adverse events in pediatric" exact="migraine" post="prophylaxis but amitriptyline was superior to melatonin and melatonin"/>
   <result pre="27503180 3 Victor S Ryan S WITHDRAWN: Drugs for preventing" exact="migraine" post="headaches in children Cochrane Database Syst Rev 2014 7"/>
   <result pre="Primary headache in children and adolescents: update on pharmacotherapy of" exact="migraine" post="and tension-typeheadache Neuropediatrics 2013 44 1 3 19 23303551"/>
   <result pre="FF Ferdosian F Safety and efficacy of melatonin in pediatric" exact="migraine" post="prophylaxis Curr Drug Saf 2015 10 2 132 5"/>
   <result pre="A Luchetti A Paolino MC Villa MP Melatonin to prevent" exact="migraine" post="or tension-type headache in children Neurol Sci 2008 29"/>
   <result pre="Mirouliaei M Shamszadeh A Topiramate and propranolol for prophylaxis of" exact="migraine" post="Indian J Pediatr 2013 80 11 920 4 23412986"/>
   <result pre="comparing melatonin 3 mg, amitriptyline 25 mg and placebo for" exact="migraine" post="prevention Neurology February 2013 80 (Meeting Abstracts 1).(Epub ahead"/>
   <result pre="Alstadhaug KB Odeh F Salvesen R Bekkelund SI Prophylaxis of" exact="migraine" post="with melatonin: a randomized controlled trial 2010 Neurology 1527"/>
   <result pre="trial 2010 Neurology 1527 32 14 Peres MF Melatonin for" exact="migraine" post="prevention Curr Pain Headache Rep 2011 15 334 5"/>
   <result pre="E Jędrych M Borowicz KK Melatonin in experimental seizures and" exact="epilepsy" post="Pharmacol Rep 2011 63 1 1 11 21441606 18"/>
   <result pre="Diamond S Scott D Jones V Prophylactic treatment of pediatric" exact="migraine" post="Headache 2004 44 3 230 7 15012660 19 Hershey"/>
   <result pre="Kalita J Bhoi SK Misra UK Amitriptyline vs divalproate in" exact="migraine" post="prophylaxis: a randomized controlled trial Acta Neurol Scand 2013"/>
   <result pre="Efficacy of amitriptyline, pizotifen and propranolol in the prevention of" exact="migraine" post="Mymensingh Med J 2013 22 1 93 100 23416816"/>
   <result pre="Versus Placebo Study Group Amitriptyline in the prophylactic treatment of" exact="migraine" post="and chronic daily headache Headache 2011 51 1 33"/>
   <result pre="13 7 959 66 22500646 25 Nagata E Antidepressants in" exact="migraine" post="prophylaxis Brain Nerve 2009 61 10 1131 4 19882939"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5770345/results/search/disease/results.xml">
   <result pre="side effects. Keywords Pediatric headache Greater occipital nerve injection Chronic" exact="migraine" post="Trigeminal autonomic cephalalgia Cluster headache New daily persistent headache"/>
   <result pre="and adolescents can be extremely disabling. The one-year prevalence of" exact="migraine" post="in children between the ages of 5 and 15"/>
   <result pre="around 10% depending on the study [ 2], while chronic" exact="migraine" post="affects between 0.8% and 1.7% of adolescents [ 3]"/>
   <result pre="[ 12], while avoiding the common side effects of classic" exact="migraine" post="preventives or more invasive treatments [ 13]. The mechanism"/>
   <result pre="108:50; 68% - 32% Headache diagnosis ( n; %)  Chronic" exact="migraine" post="without aura (CM) 102 64%  Chronic migraine with aura"/>
   <result pre="n; %)  Chronic migraine without aura (CM) 102 64%  Chronic" exact="migraine" post="with aura (CMwA) 24 15%  Total chronic migraine 126"/>
   <result pre="64%  Chronic migraine with aura (CMwA) 24 15%  Total chronic" exact="migraine" post="126 79%  NDPH 22 14%  CH 3 2%  HC"/>
   <result pre="( n; %)  CM 70 69%  CMwA 15 63%  Total" exact="migraine" post="85 68%  NDPH 13 59%  CH 3 100%  HC"/>
   <result pre="16%  CM 11 16%  CMwA 2 (one brainstem) 13%  Total" exact="migraine" post="13 10% of total migraine  NDPH 2 15%, 9%"/>
   <result pre="2 (one brainstem) 13%  Total migraine 13 10% of total" exact="migraine" post=" NDPH 2 15%, 9% of total NDPH  CH 1"/>
   <result pre="sedative 1 Improvement was seen in 68% of the chronic" exact="migraine" post="population ( n = 85) and 59% ( n = 13)"/>
   <result pre="for significantly predicting a positive outcome, although a diagnosis of" exact="migraine" post="and a trigeminal autonomic cephalalgia increased the odds of"/>
   <result pre="years) 0.38 1.2 0.8–1.8 Gender (female) 0.74 1.2 0.4–3.6 Chronic" exact="migraine" post="diagnosis 0.32 4.0 0.3–62.2 TAC diagnosis 0.45 3.0 0.2–50.6"/>
   <result pre="injections is stronger in cluster headache [ 10, 17] than" exact="migraine" post="[ 18]. Our results are quite encouraging, as it"/>
   <result pre="disorders in children. They appear especially beneficial in patients with" exact="migraine" post="and trigeminal autonomic cephalalgias, although phenotypical diagnosis is not"/>
   <result pre="often more side-effect prone. Abbreviations CH Cluster headache CM Chronic" exact="migraine" post="without aura CMwA Chronic migraine with aura GON Greater"/>
   <result pre="CH Cluster headache CM Chronic migraine without aura CMwA Chronic" exact="migraine" post="with aura GON Greater occipital nerve HA Headache HC"/>
   <result pre="Razak S Sivaraman B Graham C Prevalence of headache and" exact="migraine" post="in children and adolescents: a systematic review of population-based"/>
   <result pre="E Turkel CC Winner P Prevalence and burden of chronic" exact="migraine" post="in adolescents: results of the chronic daily headache in"/>
   <result pre="5 693 706 10.1111/j.1526-4610.2011.01885.x 21521206 4. Wober-Bingol C Epidemiology of" exact="migraine" post="and headache in children and adolescents Curr Pain Headache"/>
   <result pre="et al. Trial of Amitriptyline, Topiramate, and placebo for Pediatric" exact="migraine" post="N Engl J Med 2017 376 2 115 124"/>
   <result pre="16. Evans RW Linde M Expert opinion: adherence to prophylactic" exact="migraine" post="medication Headache 2009 49 7 1054 1058 10.1111/j.1526-4610.2009.01471.x 19583596"/>
   <result pre="32 5 289 297 10.1097/EJA.0000000000000239 25693139 23. Schulman E Refractory" exact="migraine" post="- a review Headache 2013 53 4 599 613"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5799825/results/search/disease/results.xml">
   <result pre="review analyzing the relation between alexithymia and primary headache (e.g.," exact="migraine" post="and tension type headache) in children and adolescents by"/>
   <result pre="alexithymia. There seems to be also differences between children with" exact="migraine" post="compared to those with tension type headache (TTH). Conclusion:"/>
   <result pre="There are some studies on adults suffering from headache or" exact="migraine" post="and alexithymia, but there is only a moderate amount"/>
   <result pre="help children to reduce headache and improve emotional consciousness. headache" exact="migraine" post="tension type headache alexithymia children adolescents fig-count: table-count: equation-count:"/>
   <result pre="are the most frequent complaints among the pediatric population with" exact="migraine" post="and tension type headache (TTH) being the most common"/>
   <result pre="(Mark, 2015). In the pediatric population, tension type headache, and" exact="migraine" post="are commonly associated with various diseases. For instance, psychiatric"/>
   <result pre="and neurological comorbidity, in particular sleep disorders, anxiety and depression," exact="epilepsy" post="and ADHD (Bellini et al., 2013). It has also"/>
   <result pre="been shown an association with medical disorders such as atopy," exact="cardiovascular disease," post="especially ischemic stroke and Patent Foramen Ovale (PFO) (Bellini"/>
   <result pre="with medical disorders such as atopy, cardiovascular disease, especially ischemic" exact="stroke" post="and Patent Foramen Ovale (PFO) (Bellini et al., 2013)."/>
   <result pre="In some studies, it has been shown that children with" exact="migraine" post="had significantly higher levels of internalizing and somatic symptoms,"/>
   <result pre="study conducted by Burba et al. ( 2006), adolescents with" exact="somatoform disorder" post="had higher levels of alexithymia and anxiety than healthy"/>
   <result pre="populations. For example, it has been observed that adults with" exact="migraine" post="or TTH had a higher alexithymia level, compared to"/>
   <result pre="with TTH had major alexithymic problems compared to children with" exact="migraine" post="and the control group. Two dimensions were particularly compromised"/>
   <result pre="alexithymic features in children and adolescents with primary headache (both" exact="migraine" post="and tension type headache) and in their mothers, in"/>
   <result pre="and alexithymia. They assumed that the differences between TTH and" exact="migraine" post="may be due to different pathogenesis of the two"/>
   <result pre="the two disorders. Genetic factors may underline the etiology of" exact="migraine" post="more than TTH, while TTH has a more complex"/>
   <result pre="study, Cerutti et al. ( 2016) examined the association between" exact="migraine" post="and alexithymia, exploring the hypothesis of alexithymia predicting psychopathological"/>
   <result pre="determining any differences between adolescents and their mothers suffering from" exact="migraine" post="vs. adolescents and mothers in the control groups (and"/>
   <result pre="Gatta's results, they discovered that adolescents and their mothers with" exact="migraine" post="had higher rates of alexithymia. Additionally, they demonstrated that"/>
   <result pre="style and alexithymia. It has been observed a connection between" exact="migraine" post="features (high attack frequency and severe pain intensity) and"/>
   <result pre="the ambivalent one (Tarantino et al., 2017). Moreover, children with" exact="migraine" post="and with ambivalent attachment style report higher symptoms of"/>
   <result pre="(Williams et al., 2017) showed that the somatic condition of" exact="migraine" post="acted as a stressor, reducing children's perception of the"/>
   <result pre="security of their parental attachments. It seems that children with" exact="migraine" post="exhibit a significantly higher prevalence of avoidant attachment and"/>
   <result pre="compared in a group of the early clinical stage of" exact="migraine" post="patients without aura for 1 year. When they re-examined"/>
   <result pre="white matter changes were found. Thus, a possible connection between" exact="migraine" post="and alexithymia may be due to changes in specific"/>
   <result pre="controlled study of alexithymia in adolescent patients with persistent somatoform" exact="pain disorder" post=". Can. J. Psychiatry 51, 468– 471. 10.1177/070674370605100709 16838829"/>
   <result pre="quality of life in a group of Brazilian women with" exact="migraine" post="with aura . J. Headache Pain 14, 17– 27"/>
   <result pre="al. . ( 2013). Attachment styles in children affected by" exact="migraine" post="without aura. Neuropsychiatr. Dis. Treat. 9, 1513– 1519. 10.2147/NDT.S52716"/>
   <result pre="characteristics in pediatric patients with primary headache: a comparison between" exact="migraine" post="and tension-type headache . J. Headache Pain 16, 98."/>
   <result pre="strategies are associated with cognitive alexithymia in patients with severe" exact="somatoform disorder" post=". Int. J. Psychiatry Med. 49, 264– 278. 10.1177/0091217415589303"/>
   <result pre="Perez-Diaz F. Corcos M. ( 2012). Alexithymia in adolescents with" exact="borderline personality disorder." post="J. Psychosom. Res. 72, 147– 152. 10.1016/j.jpsychores.2011.11.006 22281457 Lulé"/>
   <result pre="F. Corcos M. ( 2012). Alexithymia in adolescents with borderline" exact="personality disorder." post="J. Psychosom. Res. 72, 147– 152. 10.1016/j.jpsychores.2011.11.006 22281457 Lulé"/>
   <result pre="determining the association between headache features and psychological symptoms in" exact="migraine" post="children and adolescents. an analytical observational case-control study ."/>
   <result pre="18, 62. 10.1186/s10194-017-0769-3 28560542 Wöber-Bingöl C. ( 2013). Epidemiology of" exact="migraine" post="and headache in children and adolescents. Curr. Pain Headache"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5820821/results/search/disease/results.xml">
   <result pre="JPGM-64-66 doi: 10.4103/jpgm.JPGM_306_17 : Letters Cinema-like sensory phenomena in a" exact="migraine" post="patient on topiramate Tandon R Verma SK [], rtlib161080@gmail.com"/>
   <result pre="under the identical terms. Topiramate is an antiepileptic used for" exact="migraine" post="prophylaxis. Several side effects may follow topiramate use such"/>
   <result pre="be a need for greater vigilance while prescribing topiramate for" exact="migraine" post="prophylaxis and monitoring patients, especially pediatric and adolescent patients,"/>
   <result pre="May A &quot;Alice in Wonderland syndrome&quot; associated with topiramate for" exact="migraine" post="prevention J Neurol Neurosurg Psychiatry 2011 82 228 9"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5836048/results/search/disease/results.xml">
   <result pre="review is to explore the literature reports of acute confusional" exact="migraine" post="(ACM) including patient characteristics, migraine symptomatology, and proposed diagnostic"/>
   <result pre="literature reports of acute confusional migraine (ACM) including patient characteristics," exact="migraine" post="symptomatology, and proposed diagnostic criteria. A literature review was"/>
   <result pre="with a slight male predominance. Personal or family history of" exact="migraine" post="was common. Most patients had a headache prior to"/>
   <result pre="treatment outcomes is lacking. Patients with most common forms of" exact="migraine" post="report attention and cognitive disturbances but awareness remains intact"/>
   <result pre="to further study this disorder and its association with other" exact="migraine" post="forms. acute confusional migraine aura disorientation agitation International Classification"/>
   <result pre="disorder and its association with other migraine forms. acute confusional" exact="migraine" post="aura disorientation agitation International Classification of Headache Disoders-3 beta"/>
   <result pre="aura disorientation agitation International Classification of Headache Disoders-3 beta version" exact="migraine" post="variant cognitive diagnosis 1. Introduction Migraine is best thought"/>
   <result pre="paroxysmal torticollis are episodic syndromes that may be associated with" exact="migraine" post="and are historically noted to occur in childhood, although"/>
   <result pre="frequently in adults. Moreover, a state of confusion during a" exact="migraine" post="attack was first described by Gascon and Barlow, in"/>
   <result pre="old [ 1]. In 1978, Ehyai and Fenichel named this" exact="migraine" post="variant as acute confusional migraine (ACM) [ 2]. Although"/>
   <result pre="Ehyai and Fenichel named this migraine variant as acute confusional" exact="migraine" post="(ACM) [ 2]. Although not a part of the"/>
   <result pre="diagnostic uncertainty, and may be the first presentation of a" exact="migraine" post="in children and/or adolescents. ACM is a migraine variant"/>
   <result pre="of a migraine in children and/or adolescents. ACM is a" exact="migraine" post="variant that manifests with acute confusion, agitation, disorientation, altered"/>
   <result pre="ACM as a distinct clinical entity versus a manifestation of" exact="migraine" post="biology based on migraine phases. 2. Materials and Methods"/>
   <result pre="clinical entity versus a manifestation of migraine biology based on" exact="migraine" post="phases. 2. Materials and Methods A literature review was"/>
   <result pre="in children and adult attributed to medical conditions other than" exact="migraine" post="were not included. All the relevant articles, case reports"/>
   <result pre="1). 3. Results Clinical Features Prevalence: The prevalence of these" exact="migraine" post="variants varies in literature. In a study that included"/>
   <result pre="had migraine, it was noted that 9.8% of those with" exact="migraine" post="had migraine equivalents. Among different types of migraine equivalents,"/>
   <result pre="it was noted that 9.8% of those with migraine had" exact="migraine" post="equivalents. Among different types of migraine equivalents, about 5%"/>
   <result pre="those with migraine had migraine equivalents. Among different types of" exact="migraine" post="equivalents, about 5% were identified as having ACM ["/>
   <result pre="In another study, of 2509 patients, aged 0–18 years old," exact="migraine" post="variants were seen in 24% of those with migraine"/>
   <result pre="old, migraine variants were seen in 24% of those with" exact="migraine" post="and 2.7% of these were reported as having ACM"/>
   <result pre="medical and family history: Relevant personal or family history of" exact="migraine" post="was present in the majority of cases. Among the"/>
   <result pre="to date, a personal and family history of either prior" exact="migraine" post="or headache was present in 54% and 62% patients,"/>
   <result pre="onset was unspecified because either the patients were confused or" exact="amnesia" post="was present during the episode. In addition to confusion,"/>
   <result pre="remaining cases. After resolution, patients usually had partial or global" exact="amnesia" post="of the episode. Diagnostic testing: Routine laboratory work performed"/>
   <result pre="[ 6]. EEG findings can help in differentiating ACM from" exact="transient global amnesia" post="(TGA), as EEG in the latter is usually normal."/>
   <result pre="EEG findings can help in differentiating ACM from transient global" exact="amnesia" post="(TGA), as EEG in the latter is usually normal."/>
   <result pre="Children, in whom confusional state was the initial presentation, developed" exact="migraine" post="with or without aura over a period of time."/>
   <result pre="and less commonly seen in adults. It is considered a" exact="migraine" post="variant, which is defined as an episodic syndrome that"/>
   <result pre="defined as an episodic syndrome that occurs in patients with" exact="migraine" post="with or without aura or in those who have"/>
   <result pre="therefore other potential etiologies such as infection, seizures, inflammatory, neoplastic," exact="transient global amnesia," post="vascular and metabolic abnormalities should be ruled out first."/>
   <result pre="and metabolic abnormalities should be ruled out first. In addition," exact="migraine" post="is comorbid with a wide range of other medical"/>
   <result pre="disorders. Similar to what has been referred to as late-life" exact="migraine" post="accompaniments, ACM can be a cause of unexplained transient"/>
   <result pre="cause of unexplained transient neurological events [ 31]. Moreover, both" exact="migraine" post="and epilepsy are characterized by paroxysmal brain dysfunction. The"/>
   <result pre="unexplained transient neurological events [ 31]. Moreover, both migraine and" exact="epilepsy" post="are characterized by paroxysmal brain dysfunction. The relationship between"/>
   <result pre="been debated since the time of Gowers, who referred to" exact="migraine" post="as a &quot;Borderland of Epilepsy&quot; in the 20th century"/>
   <result pre="episodic disorders. Epileptic seizures are also associated with cognitive dysfunction;" exact="epilepsy" post="and migraine share similarities in various aspects including epidemiology,"/>
   <result pre="Epileptic seizures are also associated with cognitive dysfunction; epilepsy and" exact="migraine" post="share similarities in various aspects including epidemiology, pathophysiology and"/>
   <result pre="ability/perception [ 34]. Some of the cognitive disturbances described by" exact="migraine" post="patients include concentration difficulties, memory complaints, difficulty reasoning and"/>
   <result pre="with cardinal findings of agitation and disorientation, speech difficulties and" exact="amnesia" post="of the event upon resolution of attack. Broadly speaking,"/>
   <result pre="feature described in ACM. Patients with most common forms of" exact="migraine" post="report attention and cognitive disturbances; however, awareness is generally"/>
   <result pre="acute confusional states resembling ACM have also been seen in" exact="migraine" post="with brainstem aura, familial hemiplegic migraine (FHM) and other"/>
   <result pre="ACM have also been seen in migraine with brainstem aura," exact="familial hemiplegic migraine" post="(FHM) and other neurological diseases such as episodic ataxia"/>
   <result pre="also been seen in migraine with brainstem aura, familial hemiplegic" exact="migraine" post="(FHM) and other neurological diseases such as episodic ataxia"/>
   <result pre="familial hemiplegic migraine (FHM) and other neurological diseases such as" exact="episodic ataxia" post="type 2 (EA2) and CADASIL [ 23, 36, 37,"/>
   <result pre="manifestation of cortical spreading depression (CSD), the pathophysiological correlate of" exact="migraine" post="aura, as it moves across the cortex to higher"/>
   <result pre="by bright colored lights prior to confusion [ 2], scintillating" exact="scotoma" post="and complete blindness [ 11]. Some of the speech"/>
   <result pre="speech, aphasia, dysarthria, and slurred speech. Transient expressive or receptive" exact="aphasia" post="may also be due to a migrainous phenomenon in"/>
   <result pre="literature reports of what was previously known as basilar artery" exact="migraine" post="has now been modified and replaced with brainstem aura"/>
   <result pre="such as tinnitus, vertigo, diplopia and ataxia typically seen in" exact="migraine" post="with brainstem aura are usually absent in ACM. Some"/>
   <result pre="ACM. Some of the EEG findings reported in basilar artery" exact="migraine" post="[ 41, 42, 43, 44, 45, 46, 47, 48,"/>
   <result pre="slowing in the delta-theta range has also been described in" exact="migraine" post="with aura [ 45]. The presence of frontal intermittent"/>
   <result pre="52]. Mild head trauma is a common trigger in hemiplegic" exact="migraine" post="and ACM. In our review of ACM patients, a"/>
   <result pre="disturbances, among other non-headache symptoms, have been reported during all" exact="migraine" post="phases. Karsan, et al. [ 54] studied and characterized"/>
   <result pre="in 100 randomly selected children with a final diagnosis of" exact="migraine" post="or New Daily Persistent Headache with migrainous features, ages"/>
   <result pre="study was not intended to study specifically cognitive symptoms in" exact="migraine" post="phases and thus description is limited. Another study evaluating"/>
   <result pre="thus description is limited. Another study evaluating non-headache symptoms in" exact="migraine" post="reported tiredness, stiff neck and difficulty concentrating as their"/>
   <result pre="during the confusion. Furthermore, cognitive symptoms are increasingly recognized during" exact="migraine" post="attacks. Gil-Gouveia et al. [ 36], in a cross"/>
   <result pre="[ 36], in a cross sectional survey of 165 episodic" exact="migraine" post="patients with or without typical aura, ages ranging from"/>
   <result pre="the frequency and characteristics of subjective cognitive symptoms during a" exact="migraine" post="attack. The most common cognitive complaints were those in"/>
   <result pre="to abbreviate conversations. In another prospective study that involved 121" exact="migraine" post="patients that collected non-headache symptoms of migraine, cognitive disturbances"/>
   <result pre="or writing and difficulty with speech, were reported during all" exact="migraine" post="phases, but seen more pronounced during the ictal phase"/>
   <result pre="of the reported cases is consistent with typical forms of" exact="migraine" post="and supports hypothalamic involvement as part of the possible"/>
   <result pre="and/or confusion. Other studies investigating premonitory and postdrome symptoms in" exact="migraine" post="patients report cognitive changes, tiredness and mood changes as"/>
   <result pre="Another recent study investigating cognitive dysfunctions and psychological symptoms in" exact="migraine" post="without aura excluded patients &quot;exhibiting symptoms compatible with acute"/>
   <result pre="without aura excluded patients &quot;exhibiting symptoms compatible with acute confusional" exact="migraine" post="during migraine attacks&quot; [ 58]. Since there are no"/>
   <result pre="excluded patients &quot;exhibiting symptoms compatible with acute confusional migraine during" exact="migraine" post="attacks&quot; [ 58]. Since there are no adult or"/>
   <result pre="evidence-based guidelines are unavailable. Based on the review, we found" exact="migraine" post="treatments were often used. Migraine specific treatments such as"/>
   <result pre="pathway [ 60, 61]. ACM, although rare, is an important" exact="migraine" post="variant seen in ambulatory neurology practice. Because of the"/>
   <result pre="of attacks as the patient wakes up symptom free with" exact="amnesia" post="for the whole episode. Mild head trauma can act"/>
   <result pre="trauma can act as a trigger in both trauma triggered" exact="migraine" post="and ACM, and the altered consciousness following the head"/>
   <result pre="criteria for ACM. A past medical and family history of" exact="migraine" post="should be taken into consideration while making a definitive"/>
   <result pre="is listed in Table 2. 5. Conclusions ACM is a" exact="migraine" post="variant that is not well understood. While it is"/>
   <result pre="of its symptoms and signs overlap with non-headache features of" exact="migraine" post="with and without aura. The lack of specific classification"/>
   <result pre="to further study this disorder and its association with other" exact="migraine" post="forms. Inclusion in the appendix of ICHD-3β criteria is"/>
   <result pre="Padilla declare no conflict of interest. Abbreviations ACM Acute confusional" exact="migraine" post="ICHD-3β International Headache Society’s International Classification of Headache Disoders-3"/>
   <result pre="International Classification of Headache Disoders-3 beta version FHM Familial hemiplegic" exact="migraine" post="EA2 Episodic ataxia type 2 CADASIL Cerebral Autosomal-Dominant Arteriopathy"/>
   <result pre="Ehyai A. Fenichel G.M. The natural history of acute confusional" exact="migraine" post="Arch. Neurol. 1978 35 368 369 10.1001/archneur.1978.00500300042007 655910 3."/>
   <result pre="655910 3. Emery E.S. Acute confusional state in children with" exact="migraine" post="Pediatrics 1977 60 111 114 876724 4. Parrino L."/>
   <result pre="Parrino L. Pietrini V. Spaggiari M.C. Terzano M.G. Acute confusional" exact="migraine" post="attacks resolved by sleep: Lack of significant abnormalities in"/>
   <result pre="R.D. Riggs J.E. Bodensteiner J.B. Acute confusional migraine: Variant of" exact="transient global amnesia" post="Pediatr. Neurol. 1995 12 129 131 10.1016/0887-8994(94)00154-T 7779209 11."/>
   <result pre="J.E. Bodensteiner J.B. Acute confusional migraine: Variant of transient global" exact="amnesia" post="Pediatr. Neurol. 1995 12 129 131 10.1016/0887-8994(94)00154-T 7779209 11."/>
   <result pre="131 10.1016/0887-8994(94)00154-T 7779209 11. Ferrera P.C. Reicho P.R. Acute confusional" exact="migraine" post="and trauma-triggered migraine Am. J. Emerg. Med. 1996 14"/>
   <result pre="11. Ferrera P.C. Reicho P.R. Acute confusional migraine and trauma-triggered" exact="migraine" post="Am. J. Emerg. Med. 1996 14 276 278 10.1016/S0735-6757(96)90176-X"/>
   <result pre="1996 14 276 278 10.1016/S0735-6757(96)90176-X 8639202 12. Shaabat A. Confusional" exact="migraine" post="in childhood Pediatr. Neurol. 1996 15 23 25 10.1016/0887-8994(96)00089-6"/>
   <result pre="Kimura S. Ohtsuki N. Tanaka M. Takebayashi S. Acute confusional" exact="migraine" post="and migrainous infarction in childhood Brain Dev. 1997 19"/>
   <result pre="148 151 10.1016/S0387-7604(96)00551-7 9105664 14. Neinstein L. Milgrom E. Trauma-triggered" exact="migraine" post="and acute confusional migraine J. Adolesc. Health 2000 27"/>
   <result pre="14. Neinstein L. Milgrom E. Trauma-triggered migraine and acute confusional" exact="migraine" post="J. Adolesc. Health 2000 27 119 224 10.1016/S1054-139X(99)00099-3 10899472"/>
   <result pre="S. Cavaliere B. Faggioli R. Scarpa P. Borgna-Pignatti C. Confusional" exact="migraine" post="precipitated by mild head trauma Arch. Pediatr. Adolesc. Med."/>
   <result pre="154 90 91 10632261 16. Al-Twaijri W.A. Shevell M.I. Pediatric" exact="migraine" post="equivalents: Occurrence and clinical features in practice Pediatr. Neurol."/>
   <result pre="Bechtel K. Acute mental status change due to acute confusional" exact="migraine" post="Pediatr. Emerg. Care 2004 20 238 241 10.1097/01.pec.0000121244.99242.67 15057179"/>
   <result pre="efficacy of sodium valproate and a MRA finding in confusional" exact="migraine" post="Brain Dev. 2007 29 178 181 10.1016/j.braindev.2006.08.001 16973324 20."/>
   <result pre="Sathe S. Deperalta E. Pastores G. Kolodny E.H. Acute confusional" exact="migraine" post="may be a presenting feature of Cadasil Headache 2009"/>
   <result pre="Khatri R. Hershey A.D. Wong B. Prochlorperazine-Treatment for acute confusional" exact="migraine" post="Headache 2009 49 477 480 10.1111/j.1526-4610.2008.01250.x 19280697 22. Avraham"/>
   <result pre="19280697 22. Avraham S.B. Har-Gil M. Watemberg N. Acute confusional" exact="migraine" post="in an adolescent: Response to intravenous valproate Pediatrics 2010"/>
   <result pre="J. Biethahn S. Gossrau G. Waldvogel D. Sándor P.S. Confusional" exact="migraine" post="is an adult as well as a childhood disease"/>
   <result pre="L. Sala B. Biasucci G. Guidetti D. &quot;Possessed&quot;: Acute confusional" exact="migraine" post="in an adolescent, prevented by topiramate Case Rep. Neurol."/>
   <result pre="intravenous propofol as a possible therapeutic option for acute confusional" exact="migraine" post="Am. J. Emerg. Med. 2017 35 195.e5 195.e6 10.1016/j.ajem.2016.06.104"/>
   <result pre="Cephalagia 2013 33 629 808 10.1177/0333102413485658 31. Fisher C.M. Late-life" exact="migraine" post="accompaniments as a cause of unexplained transient ischemic attacks"/>
   <result pre="R. Oliveira A.G. Martins I.P. Assessment of cognitive dysfunction during" exact="migraine" post="attacks: A systematic review J. Neurol. 2015 262 654"/>
   <result pre="36. Merwick A. Fernandez D. McNamara B. Harrington H. Acute" exact="encephalopathy" post="in familial hemiplegic migraine with ATP1A2 mutation BMJ Case"/>
   <result pre="A. Fernandez D. McNamara B. Harrington H. Acute encephalopathy in" exact="familial hemiplegic migraine" post="with ATP1A2 mutation BMJ Case Rep. 2013 2013 10.1136/bcr-2013-009750"/>
   <result pre="D. McNamara B. Harrington H. Acute encephalopathy in familial hemiplegic" exact="migraine" post="with ATP1A2 mutation BMJ Case Rep. 2013 2013 10.1136/bcr-2013-009750"/>
   <result pre="Spranger S. Schwab S. Benninger C. Dichgans M. Familial hemiplegic" exact="migraine" post="with cerebellar ataxia and paroxysmal psychosis Eur. Neurol. 1999"/>
   <result pre="Schwab S. Benninger C. Dichgans M. Familial hemiplegic migraine with" exact="cerebellar ataxia" post="and paroxysmal psychosis Eur. Neurol. 1999 41 150 152"/>
   <result pre="D. Callaghan N. Episodes of acute confusion or psychosis in" exact="familial hemiplegic migraine" post="Acta Neurol. Scand. 1982 65 369 375 10.1111/j.1600-0404.1982.tb03094.x 7102264"/>
   <result pre="N. Episodes of acute confusion or psychosis in familial hemiplegic" exact="migraine" post="Acta Neurol. Scand. 1982 65 369 375 10.1111/j.1600-0404.1982.tb03094.x 7102264"/>
   <result pre="10.1111/j.1600-0404.1982.tb03094.x 7102264 39. Tan R.Y.Y. Markus H.S. CADASIL: Migraine, encephalopathy," exact="stroke" post="and their inter-relationships PLoS ONE 2016 11 e0157613 10.1371/journal.pone.0157613"/>
   <result pre="S. Rothner A.D. Tepper S.J. Link between confusional migraine, hemiplegic" exact="migraine" post="and episodic ataxia type 2: Hypothesis, family genealogy, gene"/>
   <result pre="A.D. Tepper S.J. Link between confusional migraine, hemiplegic migraine and" exact="episodic ataxia" post="type 2: Hypothesis, family genealogy, gene typing and classification"/>
   <result pre="Golden G.S. Rowan A.J. The electroencephalogram in childhood basilar artery" exact="migraine" post="Neurology 1977 27 580 583 10.1212/WNL.27.6.580 559268 42. Ganji"/>
   <result pre="Morimoto Y. Nakajima S. Nishioka R. Nakamura H. Basilar artery" exact="migraine" post="with transient MRI and EEG abnormalities Rinsho Shinkeigaku 1993"/>
   <result pre="Muellbacher W. Mamoli B. Prolonged impaired consciousness in basilar artery" exact="migraine" post="Headache 1994 34 282 285 10.1111/j.1526-4610.1994.hed3405282.x 8026947 47. La"/>
   <result pre="Sturzenegger M. Donati F. Karbowski K. EEG findings during basilar" exact="migraine" post="attacks in children Electroencephalogr. Clin. Neurophysiol. 1998 107 374"/>
   <result pre="Fusco C. Ictal and interictal EEG findings in children with" exact="migraine" post="J. Headache Pain. 2004 5 23 29 10.1007/s10194-004-0064-y 50."/>
   <result pre="N. Prabhakar P. Goadsby P.J. Characterising the premonitory stage of" exact="migraine" post="in children: A clinic-based study of 100 patients in"/>
   <result pre="10.1111/j.1526-4610.2004.04168.x 15447695 57. Kelman L. The postdrome of the acute" exact="migraine" post="attack Cephalalgia 2006 26 214 220 10.1111/j.1468-2982.2005.01026.x 16426278 58."/>
   <result pre="Tessitore A. Tedeschi G. Cognitive dysfunctions and psychological symptoms in" exact="migraine" post="without aura: A cross-sectional study J. Headache Pain 2016"/>
   <result pre="Dalkara T. Moskowitz M.A. Suppression of cortical spreading depression in" exact="migraine" post="prophylaxis Ann. Neurol. 2006 59 652 661 10.1002/ana.20778 16450381"/>
   <result pre="for ACM Cases. Figure 2 Schematic distribution of acute confusional" exact="migraine" post="among different age groups. The figure shows two-thirds (75%)"/>
   <result pre="1 Brief description of previously reported cases of acute confusional" exact="migraine" post="including demographic information of the patients (age, gender), clinical"/>
   <result pre="(4) 2 15 min–24 h NA NA Three patients developed" exact="migraine" post="D’Cruz O. and Walsh D. J. [ 9] 3"/>
   <result pre="had headache 3 1–12 h NA NA Four patients developed" exact="migraine" post="with aura &amp;amp; one w/o aura Al-Twaijri W. and"/>
   <result pre="Diazepam and phenobarbital None Two patients had 1–2 episodes of" exact="migraine" post="without aura per month Verma R. et al. ["/>
   <result pre="within 24 h or after sleep with partial or complete" exact="amnesia" post="of event (E) Normal neurological or no persistent neurologic"/>
   <result pre="At least one of the following: Past medical history of" exact="migraine" post="Family history of migraine Headache, if present, may occur"/>
   <result pre="the following: Past medical history of migraine Family history of" exact="migraine" post="Headache, if present, may occur before, during and after"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5844943/results/search/disease/results.xml">
   <result pre="test, was administered to 35 children and adolescents affected by" exact="migraine" post="or tension-type headache and to 23 healthy subjects. We"/>
   <result pre="a possible common physiopathology ground, including noradrenergic and dopaminergic pathways." exact="migraine" post="tension-type headache non-verbal cognitive abilities non-verbal memory attention skills"/>
   <result pre="found deficits in selective and alternate attention in children with" exact="migraine" post="( 8). D’Andrea et al. described an impairment in"/>
   <result pre="memory and attention abilities, in children and adolescents affected by" exact="migraine" post="and TTH. In addition, we investigated the effects of"/>
   <result pre="clinical features on cognitive functioning in children and adolescents with" exact="migraine" post="and TTH. Materials and Methods We recruited 35 patients"/>
   <result pre="events/month). PedMIDAS is a questionnaire developed in order to assess" exact="migraine" post="disability in pediatric and adolescent patients. It has been"/>
   <result pre="Wechsler Intelligence Scale for Children-Revised to 82 children affected by" exact="migraine" post="without aura and TTH ( 11). They found significant"/>
   <result pre="Cancelation Test and the Brazilian computerized Visual Attention Test. The" exact="migraine" post="group showed worse results in selective and alternate attention"/>
   <result pre="the participants had a normal cognitive performance, but children with" exact="migraine" post="and TTH showed worse performance in attention, memory, and"/>
   <result pre="21). Both dopaminergic and noradrenergic pathways are also involved in" exact="migraine" post="pathogenesis ( 22– 25). In fact, noradrenaline modulates hyperexcitability"/>
   <result pre="such as tachycardia and high pressure levels, associated with the" exact="migraine" post="attack ( 23, 26). On the other hand, normal"/>
   <result pre="disorder. In conclusion, the results of this study revealed that" exact="migraine" post="and TTH may have an impact on both non-verbal"/>
   <result pre="1): A148 10.1186/1129-2377-16-S1-A148 28132240 2 Wöber-Bingöl C . Epidemiology of" exact="migraine" post="and headache in children and adolescents. Curr Pain Headache"/>
   <result pre="S Sivaraman B Graham C The prevalence of headache and" exact="migraine" post="in children and adolescents: a systematic review of population-based"/>
   <result pre=". Cognitive disturbances and regional cerebral blood flow abnormalities in" exact="migraine" post="patients: their relationship with the clinical manifestations of the"/>
   <result pre="ML Reggio E Morana R et al. Memory disturbances in" exact="migraine" post="with and without aura: a strategy problem? Cephalalgia ("/>
   <result pre="E Paruta N et al. Cognitive and behavioural effects of" exact="migraine" post="in childhood and adolescence. Cephalalgia ( 2006) 26: 596–"/>
   <result pre="Hönscheid A Müller-Sinik DP . Cognitive development in children with" exact="migraine" post="and their healthy unaffected siblings. Headache ( 2002) 42("/>
   <result pre="Alessandri M Del Rosso A . Dopamine involvement in the" exact="migraine" post="attack. Funct Neurol ( 2000) 15( Suppl 3): 171–"/>
   <result pre=". Neuropeptides and neurotransmitters that modulate thalamo-cortical pathways relevant to" exact="migraine" post="headache . Headache ( 2017) 57( Suppl 2): 97–"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5878019/results/search/disease/results.xml">
   <result pre="Background and aim Riboflavin may have an acceptable effect on" exact="migraine" post="among children. This study was carried out to determine"/>
   <result pre="carried out to determine the prophylactic effect of riboflavin on" exact="migraine" post="in children. Methods This randomized clinical trial study was"/>
   <result pre="Iran from December 2012 to February 2015. Ninety children with" exact="migraine" post="were allocated randomly into 3 groups (placebo, low-dose and"/>
   <result pre="for statistical analyses. Results There was a significant decrease of" exact="migraine" post="frequency (p=0.000) and mean duration (p=0.000) in the high-dose"/>
   <result pre="(p=0.49 and p=0.69 respectively). There was no significant reduction of" exact="migraine" post="intensity in the low-dose and high-dose groups compared to"/>
   <result pre="23% in adolescents ( 1). Occasionally, frequency and severity of" exact="migraine" post="become overwhelming which cause disturbance of life quality and"/>
   <result pre="3). The safety of many prophylactic drugs in adults with" exact="migraine" post="has not been tested completely on children, so symptomatic"/>
   <result pre="that has been documented as an effective prophylactic agent for" exact="migraine" post="( 2). Nevertheless, in spite of various drugs, no"/>
   <result pre="Drug Administration (FDA) approved medication is recommended for prophylaxis of" exact="migraine" post="in children ( 8). Riboflavin is involved in the"/>
   <result pre="that suggest the efficacy of high-dose riboflavin (400 mg/day) for" exact="migraine" post="prevention in adults ( 14– 16), and doses of"/>
   <result pre="randomized, placebo-controlled trial showed no effect of high-dose riboflavin on" exact="migraine" post="prophylaxis in children ( 13, 17). Another study on"/>
   <result pre="on 8 to 18-year-old children in Italy indicated decrease of" exact="migraine" post="frequency and intensity by riboflavin ( 1). The side-effects"/>
   <result pre="The side-effects of riboflavin have been shown as minimal, including" exact="diarrhea" post="and polyuria (1 out of 43 adults). The most"/>
   <result pre="substantial controversy about the effectiveness of riboflavin in children with" exact="migraine" post="and a few side effects of it, we decided"/>
   <result pre="and high dose riboflavin on intensity, duration and frequency of" exact="migraine" post="2. Material and Methods 2.1. Study design and participants"/>
   <result pre="were filled. The questions covered different areas including age, sex," exact="migraine" post="with and without aura, months passed since onset of"/>
   <result pre="aura, months passed since onset of migraine, family history of" exact="migraine" post="and mean intensity, frequency and duration of headache in"/>
   <result pre="our trial. Diagnoses were made based on diagnostic criteria for" exact="migraine" post="with or without aura and tension headaches present in"/>
   <result pre="per month. Exclusion criteria were: 1- severe neurologic disorders or" exact="epilepsy" post="2- liver, kidney, gastrointestinal, cardiovascular or metabolic disorders 3-"/>
   <result pre="hours daily. The parents and children received data concerning childhood" exact="migraine" post="( 3) and the patients consumed acetaminophen or ibuprofen"/>
   <result pre="2 shows the mean (SD) frequency, duration and intensity of" exact="migraine" post="attacks at baseline and the end of riboflavin prophylaxis"/>
   <result pre="of frequency attacks (p=0.49), but there was significant decrease of" exact="migraine" post="frequency in the high-dose group compared with the placebo"/>
   <result pre="and 24 (80%) patients had 50% or more decrease in" exact="migraine" post="frequency in the placebo, low dose and high dose"/>
   <result pre="dose groups respectively (p=0.000). There was no significant diminution of" exact="migraine" post="intensity in low-dose and high-dose groups in comparison to"/>
   <result pre="Meanwhile, there was a dramatic shortening of mean duration of" exact="migraine" post="attacks among the high-dose group individuals compared to those"/>
   <result pre="Also, there was a marked decline in mean duration of" exact="migraine" post="attacks in the high-dose group compared with the low-dose"/>
   <result pre="comparison with the low-dose group (p=0.000). No significant reduction of" exact="migraine" post="intensity was seen among the high-dose group compared to"/>
   <result pre="Discussion The present study showed that riboflavin prophylaxis significantly reduces" exact="migraine" post="duration and frequency, but not the intensity. These data"/>
   <result pre="mg/day riboflavin was not effective on frequency and severity of" exact="migraine" post="attacks ( 17) which is inconsistent with our study,"/>
   <result pre="to the fact that no upper limit ( 19) for" exact="migraine" post="frequency (15 or more attacks per month is indicative"/>
   <result pre="our study. Condo et al. showed that riboflavin prophylaxis reduced" exact="migraine" post="intensity and frequency, and this is compatible with our"/>
   <result pre="intensity ( 1). Notably, they found a significant reduction of" exact="migraine" post="frequency among children less than 12 years of age"/>
   <result pre="than 12 years of age and a substantial decrease of" exact="migraine" post="intensity in males ( 1). It seems that age"/>
   <result pre="between age and sex and effect of riboflavin treatment on" exact="migraine" post="intensity and frequency. Some adult studies have suggested that"/>
   <result pre="frequency. Some adult studies have suggested that riboflavin prophylaxis diminishes" exact="migraine" post="frequency but not migraine intensity, and this is congruent"/>
   <result pre="have suggested that riboflavin prophylaxis diminishes migraine frequency but not" exact="migraine" post="intensity, and this is congruent with our results ("/>
   <result pre="Nevertheless, no effect was reported on frequency and duration of" exact="migraine" post="( 13). Probably due to use of low- dose"/>
   <result pre="dose between 100 to 400 mg daily in children with" exact="migraine" post="seems to be safe for several months ( 12)."/>
   <result pre="its use could be recommended to parents of children with" exact="migraine" post="who have financial restrictions. Some limitations of our investigation"/>
   <result pre="be about 4 months ( 1). 2- Upper limit for" exact="migraine" post="frequency as an exclusion criterion was not ascertained. 3-"/>
   <result pre="indicates that high-dose riboflavin decreases the frequency and duration of" exact="migraine" post="attacks in children, with no side effects. The practical"/>
   <result pre="It is recommended that high dose riboflavin be used for" exact="migraine" post="prophylaxis among children. Further studies with larger sample sizes"/>
   <result pre="Arbizzani A Parmeggiani A Riboflavin prophylaxis in pediatric and adolescent" exact="migraine" post="J Headache Pain 2009 10 5 361 5 10.1007/s10194-009-0142-2"/>
   <result pre="al. Efficacy and safety of cinnarizine in the prophylaxis of" exact="migraine" post="in children: a double-blind placebo-controlled randomized trial Pediatr Neurol"/>
   <result pre="D Yonker M Silberstein S Practice parameter: pharmacological treatment of" exact="migraine" post="headache in children and adolescents: report of the American"/>
   <result pre="Wroolie TE Topiramate: Effects on cognition in patients with epilepsy," exact="migraine" post="headache and obesity Ther Adv Neurol Disord 2013 6"/>
   <result pre="Effects on cognition in patients with epilepsy, migraine headache and" exact="obesity" post="Ther Adv Neurol Disord 2013 6 4 211 27"/>
   <result pre="Bolzonella B Sartori S Battistella PA The pharmacological treatment of" exact="migraine" post="in children and adolescents: an overview Expert Rev Neurother"/>
   <result pre="11 Sherwood M Goldman RD Effectiveness of riboflavin in pediatric" exact="migraine" post="prevention Can Fam Physician 2014 60 3 244 6"/>
   <result pre="Einhaupl KM Arnold G High-dose riboflavin treatment is efficacious in" exact="migraine" post="prophylaxis: an open study in a tertiary care centre"/>
   <result pre="Burchette R A combination of riboflavin, magnesium, and feverfew for" exact="migraine" post="prophylaxis: a randomized trial Headache 2004 44 9 885"/>
   <result pre="J Jacquy J Lenaerts M Effectiveness of high-dose riboflavin in" exact="migraine" post="prophylaxis. A randomized controlled trial Neurology 1998 50 2"/>
   <result pre="KM Ratanayake PD Fagan E Antony J High-dose riboflavin for" exact="migraine" post="prophylaxis in children: a double-blind, randomized, placebo-controlled trial J"/>
   <result pre="A Luchetti A Paolino MC Villa MP Melatonin to prevent" exact="migraine" post="or tension-type headache in children Neurol Sci 2008 29"/>
   <result pre="(50) 19 (63.3) 19 (63.3) 0.38 Months since onset of" exact="migraine" post="(mean ± SD) 29.33±15.54 25.37±14.69 22.77±12.33 0.21 Frequency of"/>
   <result pre="migraine (mean ± SD) 29.33±15.54 25.37±14.69 22.77±12.33 0.21 Frequency of" exact="migraine" post="per month (mean ± SD) 8.20±3.25 7.83±3.83 9.27±3.03 0.24"/>
   <result pre="month (mean ± SD) 8.20±3.25 7.83±3.83 9.27±3.03 0.24 Duration of" exact="migraine" post="in hours (mean ± SD) 7.97±2.92 6.97±2.62 7.90±3.03 0.36"/>
   <result pre="hours (mean ± SD) 7.97±2.92 6.97±2.62 7.90±3.03 0.36 Intensity of" exact="migraine" post="in degree (Likert scale) (mean ± SD) 2.30±0.47 2.37±0.49"/>
   <result pre="0.72 Table 2 Mean (SD) frequency, duration and intensity of" exact="migraine" post="attacks at baseline and end of riboflavin prophylaxis and"/>
   <result pre="(baseline); Wk. 12, week 12 (end); Frequency, frequency (number) of" exact="migraine" post="attacks monthly; Duration, mean duration of migraine attacks in"/>
   <result pre="frequency (number) of migraine attacks monthly; Duration, mean duration of" exact="migraine" post="attacks in hours monthly; Intensity, mean intensity of migraine"/>
   <result pre="of migraine attacks in hours monthly; Intensity, mean intensity of" exact="migraine" post="attacks in degree monthly; Decrease, decrease of headache items"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5923275/results/search/disease/results.xml">
   <result pre="Limited, provided the work is properly attributed. Abstract Background Abdominal" exact="migraine" post="(AM) is a common cause of chronic and recurrent"/>
   <result pre="It is also well recognized as a type of pediatric" exact="migraine" post="variant. A careful history, thorough physical examination, and use"/>
   <result pre="patients. However, these patients have a strong propensity to develop" exact="migraine" post="later in life. Explanation and reassurance should be the"/>
   <result pre="room visits, hospitalizations, and expensive laboratory and imaging services. Abdominal" exact="migraine" post="(AM) is one of the most common causes of"/>
   <result pre="is also currently well recognized as a type of pediatric" exact="migraine" post="variant and has specific diagnostic criteria under the International"/>
   <result pre="clinical association of the condition with cephalic migraine, other pediatric" exact="migraine" post="equivalents, and FGIDs. Definition AM is characterized by paroxysmal"/>
   <result pre="medical condition. Most often, there is a family history of" exact="migraine" post="and it has a strong propensity to evolve into"/>
   <result pre="migraine and it has a strong propensity to evolve into" exact="migraine" post="headaches in adulthood. Historical considerations The term &quot;abdominal migraine&quot;"/>
   <result pre="strong association of the condition with migraine. Most patients had" exact="migraine" post="themselves or had a family history of migraine and"/>
   <result pre="patients had migraine themselves or had a family history of" exact="migraine" post="and also responded well to anti-migraine therapy. In 1933,"/>
   <result pre="abdominal pain. 12 The relationship between recurrent abdominal pain and" exact="migraine" post="headaches was demonstrated in multiple studies over the years."/>
   <result pre="17 The International Headache Society recognized AM as a pediatric" exact="migraine" post="equivalent in 2004 and included it under the ICHD"/>
   <result pre="of them have been definitively confirmed. Visceral hyperalgesia hypothesis Visceral" exact="hypersensitivity" post="is the most definitive and unifying theory explaining the"/>
   <result pre="specific guidelines were published for the diagnosis of AM. Diet-induced" exact="allergy" post="and altered mucosal immunity hypothesis Dietary factors may also"/>
   <result pre="27, 31 The role of diet in patients with cephalic" exact="migraine" post="has been extensively studied. 32– 34 The incidence of"/>
   <result pre="has been extensively studied. 32– 34 The incidence of cephalic" exact="migraine" post="is significantly higher in patients with atopy and other"/>
   <result pre="disrupted immune system is involved in the pathogenesis of cephalic" exact="migraine" post="as well. 36, 37 Further research specifically focused on"/>
   <result pre="serotonin, adenosine diphosphate, platelet activating factor, nitric oxide resulting in" exact="migraine" post="headache. A similar mechanism involving increased activity of excitatory"/>
   <result pre="an accumulation of inflammatory neuropeptides and neurotransmitters that activate the" exact="migraine" post="cascade. The enzyme is also inhibited by several dietary"/>
   <result pre="constituents including cheese, red wine etc which can all precipitate" exact="migraine" post="headache. In 1995, Bentley et al reviewed the platelet"/>
   <result pre="metabolism in the CNS and contribute to the pathophysiology of" exact="migraine" post="headaches. 43, 44 There is a strong genetic predisposition"/>
   <result pre="is further supported by the presence of family history of" exact="migraine" post="or chronic abdominal pain in most of the patients."/>
   <result pre="small intestinal bacterial overgrowth, acute infectious diseases with chronic changes," exact="lactose intolerance," post="and abnormal mitochondrial function are the other theories that"/>
   <result pre="for other possible organic causes. 2 Clinical associations Association with" exact="migraine" post="AM shares many clinical, epidemiologic, and pathophysiologic similarities with"/>
   <result pre="AM in the ICHD classification in 2002. A history of" exact="migraine" post="headache in a first-degree relative is described in 34%–90%"/>
   <result pre="is described in 34%–90% of patients. A personal history of" exact="migraine" post="headaches is seen in 24%–47% of patients. AM and"/>
   <result pre="headaches is seen in 24%–47% of patients. AM and cephalic" exact="migraine" post="also share common triggers and also similar relieving factors"/>
   <result pre="clearly shown to be a precursor to the development of" exact="migraine" post="with and without aura. Also, many of the treatment"/>
   <result pre="and without aura. Also, many of the treatment strategies for" exact="migraine" post="have been found to be effective in patients with"/>
   <result pre="Russell reviewed the prevalence and clinical features of children with" exact="migraine" post="and AM. 46 One hundred and fifty nine children"/>
   <result pre="and AM. 46 One hundred and fifty nine children with" exact="migraine" post="and 58 children with AM were included in the"/>
   <result pre="were included in the study. They concluded that patients with" exact="migraine" post="and AM shared many similarities to suggest a common"/>
   <result pre="many similarities to suggest a common pathogenesis. The prevalence of" exact="migraine" post="in children with AM was 24%, which was twice"/>
   <result pre="with AM was 24%, which was twice the prevalence of" exact="migraine" post="in the general population (10%). Conversely, among children with"/>
   <result pre="migraine in the general population (10%). Conversely, among children with" exact="migraine" post="the prevalence of AM was 9%, which was again"/>
   <result pre="in the general population (4.1%). Also, a family history of" exact="migraine" post="in a first-degree relative was twice as common in"/>
   <result pre="by Good showed that cyclic vomiting syndrome (CVS), AM, and" exact="migraine" post="with and without aura share many neurophysiologic similarities including"/>
   <result pre="This further supports the classification of AM as a true" exact="migraine" post="equivalent. Of note, migraine is associated with other GI"/>
   <result pre="classification of AM as a true migraine equivalent. Of note," exact="migraine" post="is associated with other GI disorders that can be"/>
   <result pre="GI disorders that can be misdiagnosed as AM. Prevalence of" exact="migraine" post="is significantly high in patients with celiac disease. 48"/>
   <result pre="significantly high in patients with celiac disease. 48 Children with" exact="migraine" post="can present with abdominal pain and irritable bowel syndrome"/>
   <result pre="48 Children with migraine can present with abdominal pain and" exact="irritable bowel syndrome" post="(IBS)-like symptoms. 48 Association with other pediatric migraine equivalents"/>
   <result pre="irritable bowel syndrome (IBS)-like symptoms. 48 Association with other pediatric" exact="migraine" post="equivalents Pediatric migraine variants are a group of paroxysmal,"/>
   <result pre="(IBS)-like symptoms. 48 Association with other pediatric migraine equivalents Pediatric" exact="migraine" post="variants are a group of paroxysmal, periodic syndromes occurring"/>
   <result pre="group of paroxysmal, periodic syndromes occurring in patients who have" exact="migraine" post="with or without aura, or have an increased propensity"/>
   <result pre="It was previously called childhood periodic syndromes, recurrent pain syndromes," exact="migraine" post="equivalents, or migraine precursors. 49– 52 AM, CVS, benign"/>
   <result pre="called childhood periodic syndromes, recurrent pain syndromes, migraine equivalents, or" exact="migraine" post="precursors. 49– 52 AM, CVS, benign paroxysmal vertigo, and"/>
   <result pre="benign paroxysmal torticollis are episodic syndromes that are associated with" exact="migraine" post="headaches. 51, 52 AM and CVS were initially thought"/>
   <result pre="and benign paroxysmal vertigo, some link has been noted between" exact="motion sickness" post="and AM. Farqahar et al reviewed the characteristics of"/>
   <result pre="of children with symptoms suggestive of AM. He observed that" exact="motion sickness" post="was a common complaint in these patients and their"/>
   <result pre="although it was not formally analyzed. 56 A link with" exact="motion sickness" post="was further noted in epidemiologic studies conducted in 1983"/>
   <result pre="shown a correlation between AM and atopy. Patients with cephalic" exact="migraine" post="have a higher incidence of atopy and other allergic"/>
   <result pre="27 Prognosis AM is considered as a precursor to cephalic" exact="migraine" post="although abdominal pain is proven to resolve completely in"/>
   <result pre="had resolved completely in 61% cases. In all, 70% developed" exact="migraine" post="with or without aura compared with 20% of the"/>
   <result pre="of children, anecdotal evidence, and close association of AM with" exact="migraine" post="headaches and FGIDs. 62 The present treatment options are"/>
   <result pre="illness, presence of possible triggers and relieving factors, association with" exact="migraine" post="and other FGIDs, and prognosis of the disease based"/>
   <result pre="will help cope with symptoms. Avoidance of triggers AM and" exact="migraine" post="share many common triggers as shown in previous studies."/>
   <result pre="to confirm its efficacy. Dietary management Dietary modifications recommended in" exact="migraine" post="may also be effective in patients with AM. Avoidance"/>
   <result pre="have been found to be effective in patients with cephalic" exact="migraine" post="and hence were tried in patients with AM due"/>
   <result pre="with daily activities. It is considered as a precursor of" exact="migraine" post="headaches and shares a similar pathophysiology and treatment responses."/>
   <result pre="1261 27147121 5 Napthali K Koloski N Talley NJ Abdominal" exact="migraine" post="Cephalalgia 2016 36 10 980 986 26582952 6 Winner"/>
   <result pre="2016 36 10 980 986 26582952 6 Winner P Abdominal" exact="migraine" post="Semin Pediatr Neuro 2016 23 1 111 113 7"/>
   <result pre="Neuro 2016 23 1 111 113 7 Wang SJ Abdominal" exact="migraine" post="Greenamyre JT MedLink Neurology Online October 8, 2016 San"/>
   <result pre="F Abu-Arafeh I Russell G The prognosis of childhood abdominal" exact="migraine" post="Arch Dis Child 2001 84 5 415 418 11316687"/>
   <result pre="MJ Kay J Jaron A Clinical epidemiology of childhood abdominal" exact="migraine" post="in an urban general practice Dev Med Child Neurol"/>
   <result pre="27 Bentley D Kehely A Al-Bayaty M Michie CA Abdominal" exact="migraine" post="as a cause of vomiting in children J Pediatr"/>
   <result pre="171 25666642 30 Devanarayana NM Rajindrajith S Benninga MA Abdominal" exact="migraine" post="in children: association between gastric motility parameters and clinical"/>
   <result pre="26 26924750 31 Bentley D Katachburian A Brostoff J Abdominal" exact="migraine" post="and food sensitivity in children Clin Allergy 1984 14"/>
   <result pre="S et al. Atopic disorders are more common in childhood" exact="migraine" post="and correlated headache phenotype Pediatr Int 2014 56 6"/>
   <result pre="J Wilson J Carter CM Turner MW Soothill JF Is" exact="migraine" post="food allergy? A double-blind controlled trial of oligoantigenic diet"/>
   <result pre="Wilson J Carter CM Turner MW Soothill JF Is migraine" exact="food allergy?" post="A double-blind controlled trial of oligoantigenic diet treatment Lancet"/>
   <result pre="14 3 143 159 28096541 36 Goadsby PJ Pathophysiology of" exact="migraine" post="Ann Indian Acad Neurol 2012 15 Suppl 1 S15"/>
   <result pre="Roads less traveled: sexual dimorphism and mast cell contributions to" exact="migraine" post="pathology Front Immunol 2016 7 140 27148260 38 D’Andrea"/>
   <result pre="40 Tan V Sahami AR Peebles R Shaw RJ Abdominal" exact="migraine" post="and treatment with intravenous valproic acid Psychosomatics 2006 47"/>
   <result pre="W Reduced platelet phenolsulphotransferase activity towards dopamine and 5-hydroxytryptamine in" exact="migraine" post="Eur J Clin Pharmacol 1995 49 1 109 114"/>
   <result pre="K Kowa H et al. Glutathione S-transferase polymorphisms: susceptibility to" exact="migraine" post="without aura Eur Neurol 2003 49 4 218 222"/>
   <result pre="J Jaron A Good PA Does a history of maternal" exact="migraine" post="or depression predispose children to headache and stomach ache?"/>
   <result pre="Abu-Arafeh I Russell G Prevalence and clinical features of abdominal" exact="migraine" post="compared with those of migraine headache Arch Dis Child"/>
   <result pre="and clinical features of abdominal migraine compared with those of" exact="migraine" post="headache Arch Dis Child 1995 72 5 413 417"/>
   <result pre="R Pirovano S Vaccari R Gibelli M Rossi A Abdominal" exact="migraine" post="simulating acute abdomen Pediatr Med Chir 1991 14 2"/>
   <result pre="Dimitrova AK Ungaro RC Lebwohl B et al. Prevalence of" exact="migraine" post="in patients with celiac disease and inflammatory bowel disease"/>
   <result pre="U Fazzi E Rosano FB The periodic syndrome in pediatric" exact="migraine" post="sufferers Cephalalgia 1983 3 1_Suppl 91 93 6616613 51"/>
   <result pre="6 420 424 21093733 52 Lagman-Bartolome AM Lay C Pediatric" exact="migraine" post="variants: a review of epidemiology, diagnosis, treatment, and outcome"/>
   <result pre="53 Symon DN Is cyclical vomiting an abdominal form of" exact="migraine" post="in children? Dig Dis Sci 1999 44 8 Suppl"/>
   <result pre="Suppl 23S 25S 10490035 54 Catto-Smith AG Ranuh R Abdominal" exact="migraine" post="and cyclical vomiting Semin Pediatr Surg 2003 12 254"/>
   <result pre="E Arisi D Cyclic vomiting and recurrent abdominal pains as" exact="migraine" post="or epileptic equivalents Cephalalgia 1983 2 115 118 56"/>
   <result pre="equivalents Cephalalgia 1983 2 115 118 56 Farquhar HG Abdominal" exact="migraine" post="in children Br Med J 1956 1 4975 1082"/>
   <result pre="Y Ota M Kurakami Y Matsubayashi M Kanno M Abdominal" exact="migraine" post="in a middle-aged woman Intern Med 2016 55 19"/>
   <result pre="61 Scicchitano B Humphreys G Mitton SG Jaiganesh T Abdominal" exact="migraine" post="in childhood: a review Pediatr Health Med Ther 2014"/>
   <result pre="Schlarb AA Stress reactivity in childhood functional abdominal pain or" exact="irritable bowel syndrome" post="Eur J Pain 2017 21 1 166 177 27470170"/>
   <result pre="Newly approved agents for the treatment and prevention of pediatric" exact="migraine" post="CNS Drugs 2016 30 9 837 844 27503180 68"/>
   <result pre="flunarizine in the prophylaxis of cyclical vomiting syndrome and abdominal" exact="migraine" post="Eur J Paediatr Neurol 2005 9 1 23 26"/>
   <result pre="controlled trial of pizotifen syrup in the treatment of abdominal" exact="migraine" post="Arch Dis Child 1995 72 1 48 50 7717738"/>
   <result pre="Figure 1 Diagnostic algorithm for abdominal migraine. Table 1 Abdominal" exact="migraine" post="– differential diagnosis Gastrointestinal disorders  Acid peptic disease (esophagitis,"/>
   <result pre="– differential diagnosis Gastrointestinal disorders  Acid peptic disease (esophagitis, gastritis," exact="peptic ulcer" post="disease)  Eosinophilic diseases (esophagitis, gastritis, enteropathy)  Celiac disease  Gall"/>
   <result pre="ulcer disease)  Eosinophilic diseases (esophagitis, gastritis, enteropathy)  Celiac disease  Gall" exact="bladder disease" post="(choledochal cyst, cholelithiasis, cholecystitis)  Gastroesophageal reflex  Small bowel obstruction"/>
   <result pre=" Gall bladder disease (choledochal cyst, cholelithiasis, cholecystitis)  Gastroesophageal reflex  Small" exact="bowel obstruction" post=" Inflammatory bowel disease  Pancreatitis  Other functional abdominal pain disorders"/>
   <result pre="bowel disease  Pancreatitis  Other functional abdominal pain disorders (functional dyspepsia," exact="irritable bowel syndrome," post="cyclic vomiting syndrome, functional abdominal pain – not otherwise"/>
   <result pre="functional abdominal pain – not otherwise specified)  Lactose intolerance  Chronic" exact="hepatitis" post=" Surgical causes (hernia, appendicitis, intussusception) Central nervous system disorders"/>
   <result pre="disorders  Posterior fossa disorders  Epilepsy  Intracranial hypertension Metabolic  Acute intermittent" exact="porphyria" post=" Lead poisoning  Diabetes mellitus Urogenital causes  Urinary tract infection"/>
   <result pre="disease  Tumors (intestinal polyps) Infectious   Parasitic   Helicobacter pylori" exact="gastritis" post=" Pneumonia Rheumatic  Collagen vascular disease Others  Foreign body  Munchausen"/>
   <result pre="Table 2 Alarm symptoms and signs in children with abdominal" exact="migraine" post="Alarm symptoms  Persistent right upper or right lower quadrant"/>
   <result pre="or bilious vomiting  Gastrointestinal blood loss  Hematuria  Chronic and unexplained" exact="diarrhea" post=" Involuntary weight loss  Recurrent or unexplained fever  Dysphagia  Hematochezia,"/>
   <result pre="joint swelling Alarm signs  Deceleration of linear growth  Signs of" exact="peritonitis" post="(rebound, guarding)  Leucocytosis  Hypoalbuminemia  Localized abdominal tenderness, away from"/>
   <result pre="brain Endoscopic procedures  Esophagogastroduodenoscopy  Colonoscopy Table 5 Treatment of abdominal" exact="migraine" post="Nonpharmacologic therapy  Explanation and reassurance  Avoidance of triggers  Modified"/>
   <result pre="HT, hydroxytryptamine. Table 6 Abortive and prophylactic therapy in abdominal" exact="migraine" post="Study Mechanism of action Type of study Participants Interventions"/>
   <result pre="agonist (5-HT ID) Case report (2010) 1 child with abdominal" exact="migraine" post="Intranasal sumatriptan for acute attack of abdominal pain Complete"/>
   <result pre="40 GABA agonist Case report (2006) 2 children with abdominal" exact="migraine" post="IV valproate Symptomatic relief Prophylactic therapy with cyproheptadine (Madani"/>
   <result pre="channel blocking properties Retrospective study (2016) 18 children with abdominal" exact="migraine" post="0.13–0.2 mg/kg/day 72% of patients with improvement in symptoms"/>
   <result pre="Calcium channel blocker Clinical trial (2005) 8 children with abdominal" exact="migraine" post="7.5 mg daily PO 61% reduction in frequency and"/>
   <result pre="channel blocking properties Retrospective study (1999) 36 children with abdominal" exact="migraine" post="(12 treated with cyproheptadine; 24 treated with propranolol) Cyproheptadine"/>
   <result pre="2D) Double-blind placebo controlled trial (1995) 14 children with abdominal" exact="migraine" post="5 mL BID to TID (0.25 mg/5 mL) Effective"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5954057/results/search/disease/results.xml">
   <result pre="an irregular number of daily bowel movements (i.e., varying from" exact="constipation" post="to the opposite and diarrhea), nausea or vomiting, lack"/>
   <result pre="pain disorders, functional gastro-intestinal disorders, recurrent abdominal pain, functional dyspepsia," exact="irritable bowel syndrome," post="and FAPD. Preference for the inclusion of studies was"/>
   <result pre="a subgroup of FGIDs that includes four defined diagnoses: functional" exact="dyspepsia" post="(FD), irritable bowel syndrome (IBS), abdominal migraine (AM), and"/>
   <result pre="of FGIDs that includes four defined diagnoses: functional dyspepsia (FD)," exact="irritable bowel syndrome" post="(IBS), abdominal migraine (AM), and functional abdominal pain—not otherwise"/>
   <result pre="defined diagnoses: functional dyspepsia (FD), irritable bowel syndrome (IBS), abdominal" exact="migraine" post="(AM), and functional abdominal pain—not otherwise specified (FAP-NOS) ["/>
   <result pre="syndrome  H1d. Aerophagia H2. Functional abdominal pain disorders  H2a. Functional" exact="dyspepsia" post=" H2b. Irritable bowel syndrome  H2c. Abdominal migraine  H2d. Functional"/>
   <result pre="disorders  H2a. Functional dyspepsia  H2b. Irritable bowel syndrome  H2c. Abdominal" exact="migraine" post=" H2d. Functional abdominal pain—not otherwise specified H3. Functional defecation"/>
   <result pre="abdominal pain—not otherwise specified H3. Functional defecation disorders  H3a. Functional" exact="constipation" post=" H3b. Non-retentive fecal incontinence Diagnosis The diagnosis and proper"/>
   <result pre="for different groups of abdominal pain-related functional gastrointestinal disorders Functional" exact="dyspepsia" post="Functional dyspepsia has been defined by the Rome IV"/>
   <result pre="groups of abdominal pain-related functional gastrointestinal disorders Functional dyspepsia Functional" exact="dyspepsia" post="has been defined by the Rome IV criteria and"/>
   <result pre="constipation, the pain does not resolve with resolution of the" exact="constipation" post="(children in whom the pain resolves have functional constipation,"/>
   <result pre="symptoms cannot be fully explained by another medical condition Abdominal" exact="migraine" post="The Rome IV criteria have specified certain characteristics for"/>
   <result pre="during physiologic events (e.g., eating, menses) 2. Insufficient criteria for" exact="irritable bowel syndrome," post="functional dyspepsia, or abdominal migraine 3. After appropriate evaluation,"/>
   <result pre="Insufficient criteria for irritable bowel syndrome, functional dyspepsia, or abdominal" exact="migraine" post="3. After appropriate evaluation, the abdominal pain cannot be"/>
   <result pre="explained by another medical condition FGIDs functional gastrointestinal disorders, IBS" exact="irritable bowel syndrome," post="RAP recurrent abdominal pain In diagnosing FAP, then, according"/>
   <result pre="breath test (HBT) [ 4]. Two prospective studies identified fructose" exact="malabsorption" post="as a frequent cause of FAPD in children with"/>
   <result pre="children, mechanisms involved in wheat-associated clinical effects could be the" exact="malabsorption" post="of wheat carbohydrates and wheat proteins, such as FODMAPs"/>
   <result pre="specifically are known to be avoided when gastro-oesophageal reflux and" exact="gastritis" post="are suspected. Chocolate, caffeine, spicy and fatty foods; nitrite-"/>
   <result pre="lumen towards an anti-inflammatory state [ 22]; (4) reducing visceral" exact="hypersensitivity" post="associated with both inflammation and psychological stress [ 23];"/>
   <result pre="or when symptoms have been triggered following an episode of" exact="gastroenteritis" post="or after an antibiotic course [ 27]. Bio-Psychosocial Modifying"/>
   <result pre="in the gut may be responsible for dysmotility and visceral" exact="hypersensitivity" post="[ 61]. Antireflux Agents A study by See et"/>
   <result pre="anti-H1 effects and is currently used in the prophylaxis of" exact="migraine" post="in both adults and children. It was evaluated as"/>
   <result pre="in the literature. This drug is usually used to treat" exact="migraine" post="and was tested in children with AM. The results"/>
   <result pre="relationship with both children and their families. In our experience," exact="constipation" post="or abnormal defecation patterns are frequently involved and should"/>
   <result pre="7. Faure C Giguere L Functional gastrointestinal disorders and visceral" exact="hypersensitivity" post="in children and adolescents suffering from Crohn’s disease Inflamm"/>
   <result pre="H Bengtsson U Björnsson ES Food-related gastrointestinal symptoms in the" exact="irritable bowel syndrome" post="Digestion 2001 63 108 115 10.1159/000051878 11244249 10. Garg"/>
   <result pre="Macarthur C. Psychosocial interventions for recurrent abdominal pain (RAP) and" exact="irritable bowel syndrome" post="(IBS) in childhood. Cochrane Database Syst Rev. 2008;1:CD003014. 12."/>
   <result pre="M Pilic D Schmidt-Choudhury A Zilbauer M Wirth S Fructose" exact="malabsorption" post="in children with recurrent abdominal pain: positive effects of"/>
   <result pre="21078735 23. Spiller R Review article: probiotics and prebiotics in" exact="irritable bowel syndrome" post="Aliment Pharmacol Ther 2008 28 385 396 10.1111/j.1365-2036.2008.03750.x 18532993"/>
   <result pre="O Quantitative profiling of gut microbiota of children with diarrhea-predominant" exact="irritable bowel syndrome" post="Am J Gastroenterol 2012 107 1740 1751 10.1038/ajg.2012.287 22986438"/>
   <result pre="26. Martens U Enck P Zieseniss E Probiotic treatment of" exact="irritable bowel syndrome" post="in children Ger Med Sci 2010 8 7 27."/>
   <result pre="vs. standard care in children with functional abdominal pain or" exact="irritable bowel syndrome" post="Am J Gastroenterol 2012 107 627 631 10.1038/ajg.2011.487 22310221"/>
   <result pre="Schlarb AA Brief hypnotherapeutic-behavioral intervention for functional abdominal pain and" exact="irritable bowel syndrome" post="in childhood: a randomized controlled trial Eur J Pediatr"/>
   <result pre="AM Benninga MA Gut-directed hypnotherapy for functional abdominal pain or" exact="irritable bowel syndrome" post="in children: a systematic review Arch Dis Child 2013"/>
   <result pre="vs individual hypnotherapy with a therapist for treatment of pediatric" exact="irritable bowel syndrome," post="functional abdominal pain, or functional abdominal pain syndrome: a"/>
   <result pre="Enteric-coated, pH dependent peppermint oil capsules for the treatment of" exact="irritable bowel syndrome" post="in children J Pediatr 2001 138 125 128 10.1067/mpd.2001.109606"/>
   <result pre="A Wittmann T Role of antispasmodics in the treatment of" exact="irritable bowel syndrome" post="World J Gastroenterol 2014 20 6031 6043 10.3748/wjg.v20.i20.6031 24876726"/>
   <result pre="Kutlu T, Coku ra FÇ, Erkan T. The incidence of" exact="irritable bowel syndrome" post="in children using the Rome III criteria and the"/>
   <result pre="Miele E Staiano A Do children just grow out of" exact="irritable bowel syndrome?" post="J Pediatr 2017 183 122–126 e1 54. Bahar RJ"/>
   <result pre="Double-blind placebo controlled trial of amitriptyline for the treatment of" exact="irritable bowel syndrome" post="in adolescents J Pediatr 2008 152 685 689 10.1016/j.jpeds.2007.10.012"/>
   <result pre="flunarizine in the prophylaxis of cyclical vomiting syndrome and abdominal" exact="migraine" post="Eur J Paediatr Neurol 2005 9 23 26 10.1016/j.ejpn.2004.11.002"/>
   <result pre="controlled trial of pizotifen syrup in the treatment of abdominal" exact="migraine" post="Arch Dis Child 1995 72 48 50 10.1136/adc.72.1.48 7717738"/>
   <result pre="of a laxative with and without tegaserod in adolescents with" exact="constipation" post="predominant irritable bowel syndrome Aliment Pharmacol Ther 2006 23"/>
   <result pre="laxative with and without tegaserod in adolescents with constipation predominant" exact="irritable bowel syndrome" post="Aliment Pharmacol Ther 2006 23 191 196 10.1111/j.1365-2036.2006.02705.x 16393297"/>
   <result pre="70. Spiller RC Problems and challenges in the design of" exact="irritable bowel syndrome" post="clinical trials: experience from published trials Am J Med"/>
   <result pre="in adults: a systematic review and metaanalysis in drug-resistant partial" exact="epilepsy" post="PLoS Med 2008 5 e166 10.1371/journal.pmed.0050166 18700812 78. Ford"/>
   <result pre="Moayyedi P Meta-analysis: factors affecting placebo response rate in the" exact="irritable bowel syndrome" post="Aliment Pharmacol Ther 2010 32 144 158 10.1111/j.1365-2036.2010.04328.x 20412064"/>
   <result pre="Kaptchuk TJ Conboy L et al. The placebo effect in" exact="irritable bowel syndrome" post="trials: a meta-analysis Neurogastroenterol Motil 2005 17 332 340"/>
   <result pre="the placebo response in complementary and alternative medicine trials of" exact="irritable bowel syndrome" post="Neurogastroenterol Motil 2007 19 630 637 10.1111/j.1365-2982.2007.00937.x 17640177 81."/>
   <result pre="Placebo response in randomized controlled trials of antidepressants for pediatric" exact="major depressive disorder" post="Am J Psychiatry 2009 166 42 49 10.1176/appi.ajp.2008.08020247 19047322"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5961492/results/search/disease/results.xml">
   <result pre="headache onset was 8.5 years. Among the types of headache," exact="migraine" post="showed the earliest onset (7.5 years) and tension headache"/>
   <result pre="There was no statistically significant increase in tension-type headache or" exact="migraine" post="during the study period, but other primary headaches revealed"/>
   <result pre="aged below 7, the most common types of headache were" exact="migraine" post="(239, 45%), TTH (186, 35%), and other primary headaches"/>
   <result pre="preschool children under 7 years old and the percentage of" exact="migraine" post="was higher in preschool children. Other primary headaches and"/>
   <result pre="migraine was higher in preschool children. Other primary headaches and" exact="migraine" post="were varied significantly in both groups ( P = 0.048, P = 0.041,"/>
   <result pre="was statistically significant ( P = 0.012). Aura symptoms were uncommon in" exact="migraine" post="(15%, Table 2). The most common features of migraine"/>
   <result pre="in migraine (15%, Table 2). The most common features of" exact="migraine" post="were aggravated by phonophobia and photophobia. In general, other"/>
   <result pre="most common type of recurrent headache in young children is" exact="migraine" post="[ 5]. The frequency of tension type headache increases"/>
   <result pre="the most common type of primary headache (20–25%), followed by" exact="migraine" post="(8%) [ 6]. Chronic TTH affects about 1% of"/>
   <result pre="headaches [ 11]. In a Finnish study, the prevalence of" exact="migraine" post="in seven-year-old children showed a three-fold increase over a"/>
   <result pre="9.8% in 1995 to 23% in 2003 [ 1]. And" exact="migraine" post="prevalence rates increased considerably from 11 to 17%. In"/>
   <result pre="fully understand. According to Tarantino et al. children with severe" exact="migraine" post="show propensity to retrain anger, whereas those with low"/>
   <result pre="migraine show propensity to retrain anger, whereas those with low" exact="migraine" post="vent anger while suffering from separation anxiety [ 15]."/>
   <result pre="distress and emotional problems in children including attention deficit, depression," exact="conduct disorder," post="eating disorders, and obsessive compulsive disorder. Data derived from"/>
   <result pre="Razak S Sivaraman B Graham C Prevalence of headache and" exact="migraine" post="in children and adolescents: a systematic review of population-based"/>
   <result pre="10779665 7. Abu-Arefeh I Russell G Prevalence of headache and" exact="migraine" post="in schoolchildren BMJ 1994 309 6957 765 769 10.1136/bmj.309.6957.765"/>
   <result pre="Springer Healthcare, Tarporley. 2010. pp15–26. 14. Wang S-J Epidemiology of" exact="migraine" post="and other types of headache in Asia Current neurology"/>
   <result pre="Clinical features, anger management and anxiety: a possible correlation in" exact="migraine" post="children J Headache Pain 2013 14 39 10.1186/1129-2377-14-39 23651123"/>
   <result pre="of chronic daily headache: focus on traumatic experiences in childhood," exact="post-traumatic stress disorder" post="and suicidality Curr Pain Headache Rep 2014 18 4"/>
   <result pre="E Martin VT Hutchinson S Aurora SK Childhood maltreatment and" exact="migraine" post="(part II). Emotional abuse as a risk factor for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC5996089/results/search/disease/results.xml">
   <result pre="not comply with these terms. Abstract Migraine is a common" exact="neurological disorder" post="characterized by episodic headaches with specific features, presenting familial"/>
   <result pre="specialist through a structured questionnaire. The age of onset of" exact="migraine" post="was 21.8 ± 9. The duration of headaches was"/>
   <result pre="of subjects. A familial aggregation was referred by 67.4%, while" exact="migraine" post="precursors were reported by 52.3% of subjects. Patients reporting"/>
   <result pre="our results in VM subjects with previously published papers in" exact="migraine" post="sufferers, our patients presented a lower duration of headaches"/>
   <result pre="and vomiting and clustering of attacks. Vestibular Migraine vertigo headache" exact="migraine" post="clinical diagnosis vestibular disorders fig-count: table-count: equation-count: ref-count: page-count:"/>
   <result pre="page-count: word-count: Introduction Migraine is one of the most prevalent" exact="neurological disorder" post="with an estimated number of more than 80 millions"/>
   <result pre="there is at least one of: Nausea and vomiting during" exact="migraine" post="attacks. Photophobia and phonophobia. Visual and other aura may"/>
   <result pre="3, 4). In clinical practice the association of vertigo and" exact="migraine" post="is of common observation. Particularly, the complaint of vertigo"/>
   <result pre="been used to describe episodic vestibular symptoms in patients with" exact="migraine" post="when an alternative diagnosis has been ruled out ("/>
   <result pre="the following diagnostic criteria for both definite and probable vestibular" exact="migraine" post="(VM), the nosological disorder in which migraine is associated"/>
   <result pre="and probable vestibular migraine (VM), the nosological disorder in which" exact="migraine" post="is associated with the occurrence of vestibular symptoms and"/>
   <result pre="5 min to 72 h. Current or previous history of" exact="migraine" post="with or without aura according to the International Classification"/>
   <result pre="the International Classification of Headache Disorders (ICHD). One or more" exact="migraine" post="features with at least 50% of the vestibular episodes:"/>
   <result pre="disorders ( 3). Familial aggregation has been widely observed in" exact="migraine" post="( 11) and episodic vertigo ( 12), and both"/>
   <result pre="between genetic predisposition and environmental factors. Finally, ICHD-III included four" exact="migraine" post="equivalents in infancy and childhood, defined as &quot;episodic syndromes"/>
   <result pre="occurring during movement, has also been studied as a possible" exact="migraine" post="precursor ( 13). The aim of our work was"/>
   <result pre="assess the features of headaches, accompanying symptoms, familial history and" exact="migraine" post="precursors in a large sample of subjects with a"/>
   <result pre="excluded after the follow up since they developed a low-frequencies" exact="sensorineural hearing loss" post="possible related to hydrops. The centers were tertiary referral"/>
   <result pre="with contrast was performed before inclusion. Patients with low frequency" exact="sensorineural hearing loss" post="were not included. A diagnosis of migraine was confirmed"/>
   <result pre="frequency sensorineural hearing loss were not included. A diagnosis of" exact="migraine" post="was confirmed by a senior neurologist. A structured questionnaire"/>
   <result pre="another relative in the first or second degree, suffered from" exact="migraine" post="in the family. Finally, the following migraine precursors were"/>
   <result pre="degree, suffered from migraine in the family. Finally, the following" exact="migraine" post="precursors were investigated in the questionnaire: motion sickness, cyclic"/>
   <result pre="Finally, the following migraine precursors were investigated in the questionnaire:" exact="motion sickness," post="cyclic vomiting, episodic abdominal pain, episodic vertigo, torticollis ("/>
   <result pre="episodic abdominal pain, episodic vertigo, torticollis ( 13). To diagnose" exact="migraine" post="precursors, criteria of ICHD III beta version were observed"/>
   <result pre="warning and resolving spontaneously, in otherwise healthy children. We included" exact="motion sickness" post="among them, although not commonly accepted, and probably better"/>
   <result pre="among them, although not commonly accepted, and probably better definable" exact="migraine" post="marker. Statistical analysis Absolute and relative frequencies of each"/>
   <result pre="regression model was calculated to assess the independent role of" exact="migraine" post="precursors on age of onset of vertigo. We used"/>
   <result pre="71 subjects with aura, 62 (87.3%) reported familial cases of" exact="migraine" post="( p = 0.001). One hundred forty-six subjects (52.3%)"/>
   <result pre="(52.3%) reported a positive history for at least one of" exact="migraine" post="precursors. The total number and frequency are reported in"/>
   <result pre="of migraine, resulting in recurrent vestibular symptoms in association with" exact="migraine" post="features. It is the most frequent central cause of"/>
   <result pre="diagnosis rely on very accurate anamnestic self-report data, focused on" exact="migraine" post="and vestibular symptoms: since the structured interview was performed"/>
   <result pre="VM female prevalence is higher in comparison with Caucasian female:male" exact="migraine" post="(with or without aura) prevalence at the same age"/>
   <result pre="at the same age (3.5:1) ( 17). The onset of" exact="migraine" post="preceded the onset of vertigo by around 15 years,"/>
   <result pre="15 years, while the age of the first episode of" exact="migraine" post="in VM patients does not demonstrate differences with that"/>
   <result pre="2). Interestingly, in VM patients reporting a synchronous onset of" exact="migraine" post="and vertigo, the age of onset of both is"/>
   <result pre="patients with or without aura. Considering the well-known aggregation of" exact="migraine" post="within families, it could be speculated a genetic contribution"/>
   <result pre="high rate of VM patients with a familial history of" exact="migraine" post="(67.4%) compared to previously published data on general population"/>
   <result pre="ranging from 34 to 57% ( 18). As far as" exact="migraine" post="symptoms are concerned, in our VM patients' sample duration"/>
   <result pre="symptoms are concerned, in our VM patients' sample duration of" exact="migraine" post="is variable, although a high rate of VM patients"/>
   <result pre="the pediatric precursors of migraine, with a particular preminence of" exact="motion sickness" post="(42.8%). As far as the rate of migraine precursors"/>
   <result pre="of motion sickness (42.8%). As far as the rate of" exact="migraine" post="precursors in pediatric age is concerned, these data are"/>
   <result pre="this is the first work describing a possible relationship between" exact="migraine" post="precursors and onset of headache on adulthood. Considering data"/>
   <result pre="precursors and onset of headache on adulthood. Considering data on" exact="migraine" post="precursor, we can speculate about some possible predisposing factor"/>
   <result pre="summary, in our group of Caucasian VM patients, preminent phenotypic" exact="migraine" post="features are: female patients with migraine attacks of moderate"/>
   <result pre="VM patients, preminent phenotypic migraine features are: female patients with" exact="migraine" post="attacks of moderate to severe intensity, duration less of"/>
   <result pre="Above all, evaluation of familial cases and clinical history of" exact="migraine" post="precursors may present some uncertainty, since these data were"/>
   <result pre="LS Baloh RW . Association of benign recurrent vertigo and" exact="migraine" post="in 208 patients. Cephalalgia ( 2009) 29: 550– 5."/>
   <result pre="53. 10.1007/s00415-015-7988-9 26477026 13. Lagman-Bartolome AM Lay C . Pediatric" exact="migraine" post="variants: a review of epidemiology, diagnosis, treatment, and outcome."/>
   <result pre="Caletrio A et al . Clinical features, familial history, and" exact="migraine" post="precursors in patients with definite vestibular migraine: the VM-Phenotypes"/>
   <result pre="28527080 17. Stewart WF Lipton RB . Population variation in" exact="migraine" post="prevalence: a meta-analysis. J Clin Epidemiol. ( 1995) 48:"/>
   <result pre="Lipton RB . Work related disability: results from the American" exact="migraine" post="study. Cepahalalgia ( 1996) 16: 231– 8. 10.1046/j.1468-2982.1996.1604231.x 8792034"/>
   <result pre="Gentile S et al . Migraine equivalents as part of" exact="migraine" post="syndrome in childhood. Pediatr Neurol. ( 2014) 51: 645–"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6024458/results/search/disease/results.xml">
   <result pre="highly accessed articles published in 2017 covered topics related to" exact="status epilepticus" post="[ 4] and migraine [ 5]. The Editors would"/>
   <result pre="2017 covered topics related to status epilepticus [ 4] and" exact="migraine" post="[ 5]. The Editors would like to take this"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6025595/results/search/disease/results.xml">
   <result pre="to incorporate all evidenced-based practices, whether complementary or conventional. headache" exact="migraine" post="integrative medicine complementary therapies pediatric mind-body clinic model multidisciplinary"/>
   <result pre="Q10 are dietary supplements that are more commonly used for" exact="migraine" post="headaches, based on the American Academy of Neurology and"/>
   <result pre="AHS and AAN as Level B evidence: Probably effective for" exact="migraine" post="prevention [ 7]. CoQ10 is considered Level C: Possibly"/>
   <result pre="[ 7]. CoQ10 is considered Level C: Possibly effective for" exact="migraine" post="prevention [ 7]. The American Academy of Neurology withdrew"/>
   <result pre="The American Academy of Neurology withdrew butterbur from their 2012" exact="migraine" post="prevention guidelines due to the associated risk of hepatotoxicity,"/>
   <result pre="review demonstrated that acupuncture may be more effective at reducing" exact="migraine" post="frequency compared to prophylactic drug treatment (Standard Mean Deviation"/>
   <result pre="five studies with 137 participants, found that biofeedback reduced pediatric" exact="migraine" post="frequency (Mean Difference (MD) −1.97 (95% CI, −2.72–−1.21); p"/>
   <result pre="in children, progressive muscle relaxation (PMR) was shown to decrease" exact="migraine" post="frequency in adults by up to 41% after a"/>
   <result pre="size of 0.55 (CI: 0.14–0.96), representing a moderate improvement in" exact="migraine" post="headaches [ 28]. The CMH headache providers utilize a"/>
   <result pre="Claire Claire is an 18 year-old female with diagnoses of" exact="migraine" post="without aura, vestibular dysfunction, and ulcerative colitis. At age"/>
   <result pre="female with diagnoses of migraine without aura, vestibular dysfunction, and" exact="ulcerative colitis." post="At age 14, she sought care with a neurologist"/>
   <result pre="partially improved. Claire’s nurse practitioner ordered the CMH comprehensive aggressive" exact="migraine" post="protocol (CAMP) after nine additional months of intractable headaches"/>
   <result pre="18 year-old female with diagnoses of chronic daily headache, asthma," exact="allergic rhinitis," post="and anxiety. She began treatment with a nurse practitioner"/>
   <result pre="Makayla Makayla is a 13 year-old female with diagnoses of" exact="migraine" post="headache, ankle pain, asthma, chronic urticaria, food allergies, and"/>
   <result pre="migraine headache, ankle pain, asthma, chronic urticaria, food allergies, and" exact="vasomotor rhinitis." post="She began treatment with a Headache Clinic nurse practitioner"/>
   <result pre="post-concussion syndrome, after sustaining several concussions. She reported that her" exact="migraine" post="headaches began at age seven, with worsening of headache"/>
   <result pre="nerve block with lidocaine and bupivacaine, she developed a delayed" exact="hypersensitivity" post="reaction to lidocaine with worsening headaches after the nerve"/>
   <result pre="D. Hershey A.D. Outcome of a multidisciplinary approach to pediatric" exact="migraine" post="at 1, 2, and 5 years Headache 2005 45"/>
   <result pre="Vickers A. White A.R. Acupuncture for the prevention of episodic" exact="migraine" post="Cochrane Database Syst. Rev. 2016 28 CD001218 10.1002/14651858.CD001218.pub3 27351677"/>
   <result pre="M. Foroughipour M. Lavender essential oil in the treatment of" exact="migraine" post="headache: A placebo-controlled clinical trial Eur. Neurol. 2012 67"/>
   <result pre="Overath C.H. Müller B. Kropp P. Progressive muscle relaxation reduces" exact="migraine" post="frequency and normalizes amplitudes of contingent negative variation (CNV)"/>
   <result pre="meta-analysis of cognitive behavioral therapy for the management of pediatric" exact="migraine" post="Headache 2017 57 349 362 10.1111/head.13016 28028812 15. Libera"/>
   <result pre="Evidence-based guideline update: NSAIDs and other complementary treatments for episodic" exact="migraine" post="prevention in adults: [RETIRED] Neurology 2012 78 1346 1353"/>
   <result pre="27. Silberstein S.D. Edlund W. Practice parameter: Evidence-based guidelines for" exact="migraine" post="headache (an evidence-based review): Report of the Quality Standards"/>
   <result pre="Choi H.A. Choi H. Chung C.S. Caffeine discontinuation improves acute" exact="migraine" post="treatment: A prospective clinic-based study J. Headache Pain 2016"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6029397/results/search/disease/results.xml">
   <result pre="attacks. Four patients had prior history of gastrointestinal diseases, including" exact="intussusception" post="( n = 2) and Henoch-Schonlein purpura ( n = 2). One patient"/>
   <result pre="history of gastrointestinal diseases, including intussusception ( n = 2) and Henoch-Schonlein" exact="purpura" post="( n = 2). One patient had nephroblastoma at 6 months"/>
   <result pre="suffered from other neurologic comorbidities, including paresthesia ( n = 1) and" exact="motion sickness" post="( n = 1). Twelve patients (28.6%) reported weight loss during"/>
   <result pre="Treatment During attacks, patients received fluid replacement ( n = 25), acid" exact="suppression" post="( n = 19) and ondansetron ( n = 1) in the local"/>
   <result pre="Frequency: reported in Gene Bank, HTN hypertension, LHON Leber hereditary" exact="optic neuropathy," post="MELAS mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes,"/>
   <result pre="hypertension, LHON Leber hereditary optic neuropathy, MELAS mitochondrial encephalomyopathy with" exact="lactic acidosis" post="and stroke-like episodes, MS multiple sclerosis, N/A not available,"/>
   <result pre="MELAS mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes, MS" exact="multiple sclerosis," post="N/A not available, NVM noncompaction of ventricular myocardium, N"/>
   <result pre="showed that only 11.9% of patients had family history of" exact="migraine" post="and 2.3% had personal history of migraine. The frequency"/>
   <result pre="of migraine. The frequency of personal and/or family history of" exact="migraine" post="in this study seemed lower than that reported in"/>
   <result pre="39–82% [ 22, 23]. Dong et al. reported that personal" exact="migraine" post="history was seen only in 7.3% of Chinese children"/>
   <result pre="7.3% of Chinese children with CVS [ 18]. Prevalence of" exact="migraine" post="in the general Chinese population was 9.3% in a"/>
   <result pre="States [ 25]. Study found that under-diagnosis and misdiagnosis of" exact="migraine" post="were common in China, which might be an explanation"/>
   <result pre="an explanation for the low frequency of personal/family history of" exact="migraine" post="among our cohort [ 26]. Moreover, parent-reported coffee-ground vomitus"/>
   <result pre="which was previously reported in a family with Leber hereditary" exact="optic neuropathy" post="(LHON) [ 35]. Other mtDNA mutations were also found"/>
   <result pre="was previously reported in a family with Leber hereditary optic" exact="neuropathy" post="(LHON) [ 35]. Other mtDNA mutations were also found"/>
   <result pre="CT Computed tomography CVS Cyclic vomiting syndrome LHON Leber hereditary" exact="optic neuropathy" post="MRI Magnetic resonance imaging mtDNA Mitochondrial DNA Acknowledgements We"/>
   <result pre="Computed tomography CVS Cyclic vomiting syndrome LHON Leber hereditary optic" exact="neuropathy" post="MRI Magnetic resonance imaging mtDNA Mitochondrial DNA Acknowledgements We"/>
   <result pre="al. Two common mitochondrial DNA polymorphisms are highly associated with" exact="migraine" post="headache and cyclic vomiting syndrome Cephalalgia 2009 29 7"/>
   <result pre="Steiner T Lifting the burden of headache in China: managing" exact="migraine" post="in a SMART way J Headache Pain 2017 18"/>
   <result pre="S Loder E et al. The prevalence and burden of" exact="migraine" post="and severe headache in the United States: updated statistics"/>
   <result pre="(CVS) biologically different conditions? Relationship of adult-onset CVS with the" exact="migraine" post="and pediatric CVS-associated common mtDNA polymorphisms 16519T and 3010A"/>
   <result pre="vomiting syndrome: a comparison with published data on youth with" exact="irritable bowel syndrome" post="and organic gastrointestinal disorders J Pediatr 2013 163 2"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6031985/results/search/disease/results.xml">
   <result pre="initial evaluation in 8 patients who had received encephalo-duro-arterio-synangiosis for" exact="moyamoya disease." post="We performed brain imaging, including diffusion weighted imaging and"/>
   <result pre="the transient cortical depression triggered by mechanical stimulation, analogous to" exact="migraine" post="aura associated with cortical spreading depression. transient neurologic dysfunction"/>
   <result pre="cortical spreading depression. transient neurologic dysfunction cortical spreading depression postoperative" exact="migraine" post="moyamoya disease encephalo-duro-arterio-synangiosis INTRODUCTION Sudden neurological deterioration without any"/>
   <result pre="spreading depression. transient neurologic dysfunction cortical spreading depression postoperative migraine" exact="moyamoya disease" post="encephalo-duro-arterio-synangiosis INTRODUCTION Sudden neurological deterioration without any correlating structural"/>
   <result pre="occurred during the postoperative period of indirect revascularization surgery for" exact="moyamoya disease" post="as an initial study, because we could perform comprehensive"/>
   <result pre="depression (CSD), which has been suggested as a pathophysiology of" exact="migraine" post="aura. 2 Recently, there has been increasing evidence that"/>
   <result pre="initial evaluation during the postoperative period of encephalo-duro-arterio-synangiosis (EDAS) for" exact="moyamoya disease." post="Detailed diagnostic and surgical procedures have been described in"/>
   <result pre="and neurologic status during index events, symptoms associated with underlying" exact="moyamoya disease," post="and the type of surgery were also collected. This"/>
   <result pre="Case 1 (patient 1) This was an 11-year-old boy with" exact="moyamoya disease" post="who had presented one month ago with sudden onset"/>
   <result pre="(patient 4) A 36-year-old female underwent right EDAS due to" exact="moyamoya disease." post="She initially presented with a transient ischemic attack (TIA)"/>
   <result pre="of headache due to intraventricular hemorrhage. Three of them had" exact="cerebral infarction." post="All were diagnosed with moyamoya disease based on the"/>
   <result pre="Three of them had cerebral infarction. All were diagnosed with" exact="moyamoya disease" post="based on the typical symptoms and angiographic findings. The"/>
   <result pre="by hyperactivity, electrical hypersynchrony, and hyperperfusion. Considering the nature of" exact="moyamoya disease" post="and its common postoperative complications, intracranial bleeding such as"/>
   <result pre="minutes. A close similarity exists between this phenomenon and hemiplegic" exact="migraine" post="with regard to semiology, EEG depression, and hyperperfusion. Migraine"/>
   <result pre="similarity between the typical pattern of symptom evolution of a" exact="migraine" post="aura and the propagation of CSD triggered in animal"/>
   <result pre="humans. 1 9 Later, genetic mutations in ion channels in" exact="familial hemiplegic migraine" post="supported the link between CSD and migraine. 10 EEGs"/>
   <result pre="9 Later, genetic mutations in ion channels in familial hemiplegic" exact="migraine" post="supported the link between CSD and migraine. 10 EEGs"/>
   <result pre="supported the link between CSD and migraine. 10 EEGs during" exact="migraine" post="attacks usually show attenuation or slow activity in the"/>
   <result pre="been documented. Most cases showed vasodilation or hyperperfusion during a" exact="migraine" post="aura on vascular or perfusion imaging. 11 In our"/>
   <result pre="of migraines, just as seizures may arise in patients with" exact="epilepsy" post="whereas an acute symptomatic seizure can be provoked by"/>
   <result pre="In some patients, the symptoms resembled an attack of hemiplegic" exact="migraine" post="experienced by the patients or their relatives. Classic migraine"/>
   <result pre="hemiplegic migraine experienced by the patients or their relatives. Classic" exact="migraine" post="with visual aura precipitated by head-on collision while playing"/>
   <result pre="after mild TBI, whereas previous reports of severe TBI and" exact="stroke" post="suggested that the presence of prolonged CSD was associated"/>
   <result pre="been no treatment methods proven to be effective for abolishing" exact="migraine" post="aura. However, certain medications such as calcium channel blockers,"/>
   <result pre="antiepileptic drugs have been reported to decrease the recurrence of" exact="migraine" post="attacks. Studies on the benefits of prophylactic medications in"/>
   <result pre="Ernestus RI et al. Spreading depolarizations occur in human ischemic" exact="stroke" post="with high incidence Ann Neurol 2008 63 720 728"/>
   <result pre="et al. Long-term outcomes after combined revascularization surgery in adult" exact="moyamoya disease" post="Stroke 2014 45 3025 3031 25184359 9 Pietrobon D"/>
   <result pre="3025 3031 25184359 9 Pietrobon D Striessnig J Neurobiology of" exact="migraine" post="Nat Rev Neurosci 2003 4 386 398 12728266 10"/>
   <result pre="Ryu SW Kim SS Lee SH et al. Familial hemiplegic" exact="migraine" post="with prolonged coma and cerebellar atrophy: CACNA1A T666M mutation"/>
   <result pre="superficial temporal artery-middle cerebral artery anastomosis in a child with" exact="moyamoya disease" post="Childs Nerv Syst 2007 23 1195 1198 17486352 13"/>
   <result pre="Symptomatic cerebral hyperperfusion on SPECT after indirect revascularization surgery for" exact="moyamoya disease" post="Clin Nucl Med 2013 38 44 46 23242046 15"/>
   <result pre="46 23242046 15 Rajapakse T Buchhalter J The borderland of" exact="migraine" post="and epilepsy in children Headache 2016 56 1071 1080"/>
   <result pre="15 Rajapakse T Buchhalter J The borderland of migraine and" exact="epilepsy" post="in children Headache 2016 56 1071 1080 27103497 16"/>
   <result pre="667 9310985 18 John Graham senior clinicians award lecture. posttraumatic" exact="migraine" post="Headache 1998 38 772 778 11279902 Supplementary Materials The"/>
   <result pre="initial evaluation during the postoperative period of indirect revascularization for" exact="moyamoya disease" post="Case Sex Age Preoperative symptom Type of surgery Post"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6045946/results/search/disease/results.xml">
   <result pre="with the mean age of 9.65±2.75 yr were diagnosed with" exact="migraine" post="without aura. Among the 54 male patients, 8 patients"/>
   <result pre="the 27 female patients, 12 patients (44.4%) were diagnosed with" exact="migraine" post="(RR: 1.5, 95%CI: 1.07-2.18, P=0.004). Ten migraine patients had"/>
   <result pre="were diagnosed with migraine (RR: 1.5, 95%CI: 1.07-2.18, P=0.004). Ten" exact="migraine" post="patients had abnormal MRI findings (50%), including 8 cases"/>
   <result pre="high signal white matter lesions was significantly greater in the" exact="migraine" post="patients (RR: 3.91, 95% CI: 2.10-7.25, P=0.001). Conclusion The"/>
   <result pre="white matter lesions in the brain MRI of children with" exact="migraine" post="was significantly higher compared with other headache types. Key"/>
   <result pre="autonomic symptoms. Migraine may be divided into 2 types: classic" exact="migraine" post="called migraine with aura and common migraine called migraine"/>
   <result pre="Migraine may be divided into 2 types: classic migraine called" exact="migraine" post="with aura and common migraine called migraine without aura"/>
   <result pre="2 types: classic migraine called migraine with aura and common" exact="migraine" post="called migraine without aura ( 2, 3). The primary"/>
   <result pre="classic migraine called migraine with aura and common migraine called" exact="migraine" post="without aura ( 2, 3). The primary medical concern"/>
   <result pre="difficult for physicians to distinguish between first, second, and third" exact="migraine" post="headaches attacks and headaches caused by brain tumors, subarachnoid"/>
   <result pre="attacks and headaches caused by brain tumors, subarachnoid hemorrhage, vasculopathy," exact="arteriovenous malformation," post="and other underlying diseases ( 5). These patients usually"/>
   <result pre="However, the physicians do not recommend radiological evaluation for a" exact="migraine" post="with typical patterns ( 6). The case of complicated"/>
   <result pre="migraine with typical patterns ( 6). The case of complicated" exact="migraine" post="with focal neurological signs whose manifestations cannot be distinguished"/>
   <result pre="imaging is recommended for ophthalmoplegic migraine, hemiplegic migraine, and basilar" exact="migraine" post="(involvement of brain nerve 3, 4, 6) ( 2)."/>
   <result pre="( 2). Brain imaging finding in children with headaches especially" exact="migraine" post="included sinusitis, Chiari malformation type I, unspecified white matter"/>
   <result pre="was determined by a neurologist, based on diagnostic criteria. Finally," exact="migraine" post="patients´ MRI results were studied and compared with other"/>
   <result pre="dysphonia, or phantosmia. The most prevalent diagnoses of headaches were" exact="migraine" post="and sinusitis affecting 20 patients (24.7%) and 19 patients"/>
   <result pre="phantosmia. The most prevalent diagnoses of headaches were migraine and" exact="sinusitis" post="affecting 20 patients (24.7%) and 19 patients (23.5%), respectively"/>
   <result pre="Enlarged cisterna magna 1 (1.2) Migraine patients´ characteristics: Diagnosis of" exact="migraine" post="without aura was made by the pediatric neurologist in"/>
   <result pre="society criteria for pediatric migraine. The mean age of the" exact="migraine" post="patients and other patients were 9.54±2.75 yr (median=9.5) and"/>
   <result pre="27 female cases were diagnosed with migraine. The prevalence of" exact="migraine" post="was significantly higher in the females (1.5) compared with"/>
   <result pre="The prevalence of these symptoms was significantly higher among the" exact="migraine" post="patients compared with the other patients ( P˂0.001). The"/>
   <result pre="with the other patients ( P˂0.001). The possibility of having" exact="migraine" post="in those having 3 or 4 out of the"/>
   <result pre="95% CI: 6.02-300.6, P˂0.0001), respectively. However, the possibility of having" exact="migraine" post="in the patients having 1 or 2 out of"/>
   <result pre="P=0.079). Relative risk is the ratio of the probability of" exact="migraine" post="attack in first group to the probability of a"/>
   <result pre="migraine attack in first group to the probability of a" exact="migraine" post="occurring in a comparison, second group. There were no"/>
   <result pre="duration of the attacks per hours (39.5±32.11 vs. 46.48±67.49) between" exact="migraine" post="and non-migraine patients ( P&amp;gt;0.05). Among the 19 patients"/>
   <result pre="history of migraine, the relative risk of being affected by" exact="migraine" post="was 17.6 compared with the other participants (RR: 17.6,"/>
   <result pre="high signal white matter lesions in the brain MRI of" exact="migraine" post="patients was 3.91 fold higher than other patients (RR:3.91,"/>
   <result pre="dysfunction of autonomic nervous system ( 11). The prevalence of" exact="migraine" post="in general population is 15% ( 12) and it"/>
   <result pre="USA and Europe, the direct and indirect medical costs from" exact="migraine" post="exceed $ 15 billion and € 27 billion per"/>
   <result pre="per yr, respectively ( 16, 17). A better investigation of" exact="migraine" post="mechanisms will result in more effective treatments and reduction"/>
   <result pre="mechanisms will result in more effective treatments and reduction of" exact="migraine" post="impact ( 18). Thereby, this study designed to investigate"/>
   <result pre="brain MRI findings in children with migraine. The prevalence of" exact="migraine" post="among the children presented with headache was 23.5%. The"/>
   <result pre="children presented with headache was 23.5%. The overall prevalence of" exact="migraine" post="was 16.72% among the children with headache ( 19)."/>
   <result pre="with headache ( 19). In general, the overall prevalence of" exact="migraine" post="among the children and adolescents with headache was 1.7%-21.4%"/>
   <result pre="same as another study, the prevalence and relative risk of" exact="migraine" post="was greater in females compared with males ( 20)."/>
   <result pre="headache worsened by activity), the possibility of being affected by" exact="migraine" post="was 21.33 . Fig. 1 High signal areas in"/>
   <result pre="out of these symptoms, the possibility of being affected by" exact="migraine" post="was 0.23. In a similar with our study, in"/>
   <result pre="the 5 aforementioned symptoms, the possibility of being affected by" exact="migraine" post="was 24 (RR: 24, 95% CI: 1.5-388), and in"/>
   <result pre="out of these symptoms, the possibility of being affected by" exact="migraine" post="reduced to 0.41 (RR: 0.41, 95% CI: 0.32-0.52) ("/>
   <result pre="deep white matter lesions, stroke, and increased iron accumulation in" exact="migraine" post="patients ( 2, 11, 18). In this study, the"/>
   <result pre="this study, the MRI findings of the 50% of the" exact="migraine" post="patients were abnormal. The most common abnormalities were the"/>
   <result pre="the occurrence of these lesions was significantly higher in the" exact="migraine" post="patients compared with other participants. On the contrary, the"/>
   <result pre="lesions were only seen in 17% of the children with" exact="migraine" post="( 22). Whereas same as our study, the MRI"/>
   <result pre="study, the MRI findings of 55% of the children with" exact="migraine" post="were abnormal, but the abnormalities were not in concordance"/>
   <result pre="of white matter lesions was 10% in pediatric patients with" exact="migraine" post="(without aura) and 4% in control group ( P=0.119)"/>
   <result pre="matter lesions were reported in 10.6% of the children with" exact="migraine" post="while the healthy children had no high signal white"/>
   <result pre="matter lesions were reported in 50% of the children with" exact="migraine" post="and in 17% of the control group ( 26)."/>
   <result pre="of high signal white matter lesions among the children with" exact="migraine" post="was significantly high ( 22- 26). In addition, the"/>
   <result pre="( 22- 26). In addition, the studies on adults with" exact="migraine" post="showed that the prevalence of the high signal white"/>
   <result pre="the high signal white matter lesions was between 12%-47% in" exact="migraine" post="cases compared with normal cases ( 27- 30). The"/>
   <result pre="risk of the high signal white matter lesions in the" exact="migraine" post="patients was 3.91 in our study and 2.1 on"/>
   <result pre="risk of the high signal white matter lesions in the" exact="migraine" post="patients was 3.9 (95% CI: 2.26-6.72) compared with the"/>
   <result pre="white matter lesions in the brain MRI of children with" exact="migraine" post="was significantly higher compared with other headaches. Moreover, there"/>
   <result pre="3 364 371 1536351 2 Shah UH Kalra V Pediatric" exact="migraine" post="Int J Pediatr 2009 2009 424192 20041017 3 Gutiérrez-Mata"/>
   <result pre="et al. Cranial magnetic resonance imaging findings in patients with" exact="migraine" post="Headache 2004 44 2 166 9 14756856 5 Iurlaro"/>
   <result pre="motor cortical activation and phases of headache attacks in childhood" exact="migraine" post="PLoS One 2013 8 12 e83669 24386250 10 Kliegman"/>
   <result pre="Stewart WF Wood C Reed ML et al. Cumulative lifetime" exact="migraine" post="incidence in women and men Cephalalgia 2008 28 11"/>
   <result pre="GM Ferrari MD Tijhuis M et al. The impact of" exact="migraine" post="on quality of life in the general population: the"/>
   <result pre="Hu XH Markson LE Lipton RB et al. Burden of" exact="migraine" post="in the United States: disability and economic costs Arch"/>
   <result pre="1 27 18 Schwedt TJ Dodick DW Advanced neuroimaging of" exact="migraine" post="Lancet Neurol 2009 8 6 560 8 19446275 19"/>
   <result pre="8 6 560 8 19446275 19 Wöber-Bingöl C Epidemiology of" exact="migraine" post="and headache in children and adolescents Curr Pain Headache"/>
   <result pre="Razak S Sivaraman B et al. Prevalence of headache and" exact="migraine" post="in children and adolescents: a systematic review of population-based"/>
   <result pre="al. Diagnostic screen for assessment of the IHS criteria for" exact="migraine" post="by general practitioners Cephalalgia 1993 13 Suppl 12 54"/>
   <result pre="et al. White matter lesions in children and adolescents with" exact="migraine" post="Pediatr Neurol 2013 49 6 393 6 24095578 23"/>
   <result pre="A et al. MRI and MRA data in children with" exact="migraine" post="with aura PrzeglLek 2007 64 11 934 6 24"/>
   <result pre="Isbell S et al. Prevalence of white matter lesions and" exact="stroke" post="in children with migraine Neurology 2013 81 16 1387"/>
   <result pre="Prevalence of white matter lesions and stroke in children with" exact="migraine" post="Neurology 2013 81 16 1387 91 24042095 25 Eidlitz-Markus"/>
   <result pre="Haimi-Cohen Y et al. MRI white matter lesions in pediatric" exact="migraine" post="Cephalalgia 2013 33 11 906 13 23575818 26 Hämäläinen"/>
   <result pre="R et al. The prevalence of cerebral damage varies with" exact="migraine" post="type: a MRI study Headache 1992 32 6 287"/>
   <result pre="al. Frequency of magnetic resonance imaging abnormalities in patients with" exact="migraine" post="Headache 1996 36 10 616 21 8990603 29 Rocca"/>
   <result pre="magnetization transfer imaging study of the brain in patients with" exact="migraine" post="Neurology 2000 54 507 9 10668727 30 De Benedettis"/>
   <result pre="Lorenzetti A Sina C et al. Magnetic resonance imaging in" exact="migraine" post="and tension-type headache Headache 1995 35 5 264 8"/>
   <result pre="Koppen H Terwindt GM et al. Structural brain changes in" exact="migraine" post="JAMA 2012 308 18 1889 97 23150008 32 Swartz"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6078717/results/search/disease/results.xml">
   <result pre="implicated in the pathophysiology of migraines, as well as functional" exact="dyspepsia" post="(FD) and irritable bowel syndrome (IBS). The primary aims"/>
   <result pre="pathophysiology of migraines, as well as functional dyspepsia (FD) and" exact="irritable bowel syndrome" post="(IBS). The primary aims of the current study were"/>
   <result pre="the result of mast cell activation. Keywords abdominal pain functional" exact="dyspepsia" post="headache irritable bowel syndrome mast cells 1 Introduction Pediatric"/>
   <result pre="of mast cell activation. Keywords abdominal pain functional dyspepsia headache" exact="irritable bowel syndrome" post="mast cells 1 Introduction Pediatric chronic pain is increasingly"/>
   <result pre="is estimated at over 50%, while systematic reviews report specific" exact="migraine" post="headache prevalence of approximately 8% to 9%. [ 2,"/>
   <result pre="8% to 9%. [ 2, 3] Prevalence rates for both" exact="migraine" post="and non-migraine headache types appear to be increasing significantly"/>
   <result pre="to abdominal pain with the 2 most common being functional" exact="dyspepsia" post="(FD) and irritable bowel syndrome (IBS). [ 7, 8]"/>
   <result pre="with the 2 most common being functional dyspepsia (FD) and" exact="irritable bowel syndrome" post="(IBS). [ 7, 8] The most current version of"/>
   <result pre="have demonstrated an increased incidence of upper abdominal symptoms, while" exact="migraine" post="headaches in youth have been associated with both FD"/>
   <result pre="in children and adolescents presenting to an emergency department with" exact="migraine" post="headaches, as compared to pediatric patients presenting with mild"/>
   <result pre="biopsy is a standard part of the diagnostic evaluation of" exact="dyspepsia" post="yielding an unselected clinical group for comparison. An additional"/>
   <result pre="nerves signaling pain or can sensitize afferent nerves resulting in" exact="hypersensitivity" post="and changes in electromechanical function. In children and adolescents,"/>
   <result pre="Histamine infusion induces headaches in patients with muscle contraction and" exact="migraine" post="headaches, but not in controls without headache; further, this"/>
   <result pre="pain in 50% of children with FD associated with mucosal" exact="eosinophilia" post="and in 79% of adults with FD associated with"/>
   <result pre="urinary leukotrienes (LT-E4) has been shown to increase significantly during" exact="migraine" post="headaches in children. [ 33] Although there are not"/>
   <result pre="a leukotriene inhibitor, montelukast, demonstrated a &amp;gt; 50% reduction in" exact="migraine" post="headache occurrence in over half of a group of"/>
   <result pre="occurrence in over half of a group of adults with" exact="migraine" post="headaches. [ 34] Montelukast also has demonstrated efficacy for"/>
   <result pre="with FD. [ 35] The use of montelukast to treat" exact="migraine" post="headaches or FD should be considered investigational. In the"/>
   <result pre="= functional dyspepsia, FGID = functional gastrointestinal disorder, IBS =" exact="irritable bowel syndrome." post="The authors declare no conflicts of interest. References References"/>
   <result pre="Razak S Sivaraman B et al. Prevalence of headache and" exact="migraine" post="in children and adolescents: a systematic review of population-based"/>
   <result pre="2010; 52: 1088– 97. 20875042 [3] Wöber-Bingöl C Epidemiology of" exact="migraine" post="and headache in children and adolescents. Curr Pain Headache"/>
   <result pre="Rinaldi VE et al. Association between functional gastrointestinal disorders and" exact="migraine" post="in children and adolescents: a case-control study . Lancet"/>
   <result pre="[17] Wang IC Tsai JD Lin CL et al. Allergic" exact="rhinitis" post="and associated risk of migraine among children: a nationwide"/>
   <result pre="Lin CL et al. Allergic rhinitis and associated risk of" exact="migraine" post="among children: a nationwide population-based cohort study . Int"/>
   <result pre="in proximity to colonic nerves correlate with abdominal pain in" exact="irritable bowel syndrome" post=". Gastroenterology 2004; 126: 693– 702. 14988823 [21] Hall"/>
   <result pre="Gastric mucosal mast cells are increased in Helicobacter pylori-negative functional" exact="dyspepsia" post=". Clin Gastroenterol Hepatol 2003; 1: 363– 9. 15017654"/>
   <result pre="headache and mucosal mast cells in pediatric Helicobacter pylori-negative functional" exact="dyspepsia" post=". Cephalalgia 2013; 33: 323– 9. 23291287 [23] Weston"/>
   <result pre="Bhatia PS et al. Terminal ileal mucosal mast cells in" exact="irritable bowel syndrome." post="Dig Dis Sci 1993; 38: 1590– 5. 8359068 [24]"/>
   <result pre="N Breslin NP et al. Increased mast cells in the" exact="irritable bowel syndrome." post="Neurogastroenterol Motil 2000; 12: 449– 57. 11012945 [25] Friesen"/>
   <result pre="Antral inflammatory cells, gastric emptying, and electrogastrography in pediatric functional" exact="dyspepsia" post=". Dig Dis Sci 2008; 53: 2634– 40. 18320315"/>
   <result pre="9516384 [29] Lassen LH Thomsen LL Olesen J Histamine induces" exact="migraine" post="via the H-1 receptor. Support fot the NO hypothesis"/>
   <result pre="via the H-1 receptor. Support fot the NO hypothesis of" exact="migraine" post=". Neuroreport 1995; 6: 1475– 9. 7579128 [30] Krabbe"/>
   <result pre="[31] Friesen CA Sandridge L Andre L et al. Mucosal" exact="eosinophilia" post="and response to H1/H2 anatagonists and cromolyn therapy in"/>
   <result pre="and response to H1/H2 anatagonists and cromolyn therapy in pediatric" exact="dyspepsia" post=". Clin Pediatr (Phila) 2006; 45: 143– 7. 16528434"/>
   <result pre="efficacy and pharmacokinetics of montelukast in dyspeptic children with duodenal" exact="eosinophilia" post=". J Pediatr Gastroenterol Nutr 2004; 38: 343– 51."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6109211/results/search/disease/results.xml">
   <result pre="tummy hurts – a case report of abdominal pain and" exact="macrocytic anemia" post="caused by hypothyroidism K Hamid and others Abdominal pain"/>
   <result pre="hurts – a case report of abdominal pain and macrocytic" exact="anemia" post="caused by hypothyroidism K Hamid and others Abdominal pain"/>
   <result pre="case report of abdominal pain and macrocytic anemia caused by" exact="hypothyroidism" post="K Hamid and others Abdominal pain caused by hypothyroidism"/>
   <result pre="by hypothyroidism K Hamid and others Abdominal pain caused by" exact="hypothyroidism" post="Hamid Kewan 1 Dayalani Neha 2 Jabbar Muhammad 2"/>
   <result pre="endured. When clinical picture was combined with laboratory finding of" exact="macrocytic anemia," post="a diagnosis of hypothyroidism was made. Although chronic abdominal"/>
   <result pre="combined with laboratory finding of macrocytic anemia, a diagnosis of" exact="hypothyroidism" post="was made. Although chronic abdominal pain in pediatric population"/>
   <result pre="pediatric population is usually due to functional causes such as" exact="irritable bowel syndrome," post="abdominal migraine and functional abdominal pain. Hypothyroidism can have"/>
   <result pre="due to functional causes such as irritable bowel syndrome, abdominal" exact="migraine" post="and functional abdominal pain. Hypothyroidism can have unusual presentation"/>
   <result pre="main presentation of thyroid disorder is limited. Pediatricians should exclude" exact="hypothyroidism" post="in a patient who presents with chronic abdominal pain."/>
   <result pre="chronic abdominal pain. Contrast to its treatment, clinical presentation of" exact="hypothyroidism" post="can be diverse and challenging, leading to a delay"/>
   <result pre="pediatric patients presenting with chronic abdominal pain as only symptom," exact="hypothyroidism" post="should be considered by the pediatricians and ruled out."/>
   <result pre="the pediatricians and ruled out. In pediatric population, treatment of" exact="hypothyroidism" post="varies depending on patients’ weight and age. Delay in"/>
   <result pre="depending on patients’ weight and age. Delay in diagnosis of" exact="hypothyroidism" post="can cause significant morbidity and distress in pediatrics population."/>
   <result pre="pediatric population is usually due to functional causes such as" exact="irritable bowel syndrome," post="abdominal migraine and functional abdominal pain ( 3). Absence"/>
   <result pre="due to functional causes such as irritable bowel syndrome, abdominal" exact="migraine" post="and functional abdominal pain ( 3). Absence of organic"/>
   <result pre="4). Hypothyroidism can have unusual presentation including abdominal pain. Also," exact="macrocytic anemia" post="can be present in up to 55% of cases"/>
   <result pre="Hypothyroidism can have unusual presentation including abdominal pain. Also, macrocytic" exact="anemia" post="can be present in up to 55% of cases"/>
   <result pre="main presentation of thyroid disorder is limited. Pediatricians should exclude" exact="hypothyroidism" post="in a patient who presents with chronic abdominal pain,"/>
   <result pre="presents with chronic abdominal pain, especially if other evidence of" exact="hypothyroidism" post="such as macrocytic anemia is present. Case presentation A"/>
   <result pre="abdominal pain, especially if other evidence of hypothyroidism such as" exact="macrocytic anemia" post="is present. Case presentation A 6-year-old female presented to"/>
   <result pre="pain, especially if other evidence of hypothyroidism such as macrocytic" exact="anemia" post="is present. Case presentation A 6-year-old female presented to"/>
   <result pre="were inconclusive except for increased fecal matter concerning for mild" exact="constipation" post="on plain abdominal film; however, no increased fecal material"/>
   <result pre="observed benefit. Family history was positive for maternal cutaneous Lupus," exact="leukemia" post="in a cousin and unclear thyroid diseases in maternal"/>
   <result pre="with trimethoprim-sulfamethoxasole. During this episode a complete blood count revealed" exact="macrocytic anemia" post="that was overlooked. Her immunization is documented as up"/>
   <result pre="trimethoprim-sulfamethoxasole. During this episode a complete blood count revealed macrocytic" exact="anemia" post="that was overlooked. Her immunization is documented as up"/>
   <result pre="for her age. Patient’s newborn screen which included screening for" exact="congenital hypothyroidism" post="was within normal limits. Rest of history and review"/>
   <result pre="her age. Patient’s newborn screen which included screening for congenital" exact="hypothyroidism" post="was within normal limits. Rest of history and review"/>
   <result pre="Pertinent laboratory investigations included CBC with differential which revealed mild" exact="pancytopenia" post="with macrocytosis ( Table 1), peripheral blood microscopy showed"/>
   <result pre="further assessing for possible underlying bone marrow disease such as" exact="myelodysplastic syndrome" post="or hypoplastic anemia secondary to combination of recent antibiotic"/>
   <result pre="underlying bone marrow disease such as myelodysplastic syndrome or hypoplastic" exact="anemia" post="secondary to combination of recent antibiotic use and viral"/>
   <result pre="investigations revealed elevated thyroid-stimulating hormone (TSH). A diagnosis of primary" exact="hypothyroidism" post="was made with further work up for a potential"/>
   <result pre="made with further work up for a potential etiology of" exact="thyroid disease" post="including thyroid antibodies ( Table 2) and ultrasound of"/>
   <result pre="– because thyroid antibody levels could normalize in longstanding overt" exact="hypothyroidism" post="– autoimmune thyroiditis continued to be the most likely"/>
   <result pre="thyroid antibody levels could normalize in longstanding overt hypothyroidism –" exact="autoimmune thyroiditis" post="continued to be the most likely underlining etiology ("/>
   <result pre="antibody levels could normalize in longstanding overt hypothyroidism – autoimmune" exact="thyroiditis" post="continued to be the most likely underlining etiology ("/>
   <result pre="6). Work up for possible adrenal insufficiency that could accompany" exact="hypothyroidism" post="with early morning serum cortisol was obtained and was"/>
   <result pre="is one of the most common endocrine disorders worldwide. Overt" exact="hypothyroidism" post="has a prevalence of between 0.3% and 3.7% in"/>
   <result pre="adverse events and is potentially fatal. The clinical presentation of" exact="hypothyroidism" post="is variable and lacks specificity, adding to physicians' frustration"/>
   <result pre="of normal thyroid function) ( 9).The most common cause of" exact="hypothyroidism" post="in developed countries is autoimmune thyroiditis (Hashimotos thyroiditis). It"/>
   <result pre="9).The most common cause of hypothyroidism in developed countries is" exact="autoimmune thyroiditis" post="(Hashimotos thyroiditis). It is also important to mention that"/>
   <result pre="most common cause of hypothyroidism in developed countries is autoimmune" exact="thyroiditis" post="(Hashimotos thyroiditis). It is also important to mention that"/>
   <result pre="thyroiditis (Hashimotos thyroiditis). It is also important to mention that" exact="hypothyroidism" post="secondary to iodine deficiency still affects specific subpopulations, particularly"/>
   <result pre="women in the United States ( 7). Clinical manifestation of" exact="hypothyroidism" post="in pediatric populations is broad, and it also presents"/>
   <result pre="or occasionally precocious puberty. One should keep in mind that" exact="hypothyroidism" post="is not associated with mental retardation beyond 3 years"/>
   <result pre="of our knowledge, this is the first reported case of" exact="hypothyroidism" post="presenting only as abdominal pain in a pediatric patient."/>
   <result pre="observed poor growth rate is better explained by the overt" exact="hypothyroidism" post="plus decreased tolerance to solid foods rather than poor"/>
   <result pre="factor aided in the diagnosis of this case was the" exact="macrocytic anemia" post="observed on her hematological investigation. Macrocytic anemia can be"/>
   <result pre="aided in the diagnosis of this case was the macrocytic" exact="anemia" post="observed on her hematological investigation. Macrocytic anemia can be"/>
   <result pre="was the macrocytic anemia observed on her hematological investigation. Macrocytic" exact="anemia" post="can be seen in up to 55% of patients"/>
   <result pre="can be seen in up to 55% of patients with" exact="hypothyroidism" post="without comorbid nutrition deficiency ( 5). Our patient had"/>
   <result pre="explained by her recent antibiotic treatment and her current viral" exact="influenza" post="A infection. However, presence of her macrocytosis few weeks"/>
   <result pre="reference range by the laboratory initially caused some delay. Once" exact="hypothyroidism" post="is diagnosed, treatment is straightforward with levothyroxine. The goal"/>
   <result pre="H Ko G Lawson G Perera J. Chiropractic management of" exact="fibromyalgia" post="syndrome: a systematic review of the literature. Journal of"/>
   <result pre="headache: an unusual combination of hypothyroidism, vitamin D deficiency, cervical" exact="radiculopathy" post="and cortical vein sinus thrombosis . BMJ Case Reports"/>
   <result pre="evaluation of thyroid function test evolution in children with hashimoto’s" exact="thyroiditis" post="presenting with either euthyroidism or subclinical hypothyroidism . Thyroid"/>
   <result pre="children with hashimoto’s thyroiditis presenting with either euthyroidism or subclinical" exact="hypothyroidism" post=". Thyroid 2016 26 1450– 1456. (doi: 10.1089/thy.2016.0080 )"/>
   <result pre="Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of" exact="congenital hypothyroidism" post=". Hormone Research in Paediatrics 2014 81 80– 103."/>
   <result pre="Endocrinology consensus guidelines on screening, diagnosis, and management of congenital" exact="hypothyroidism" post=". Hormone Research in Paediatrics 2014 81 80– 103."/>
   <result pre="S Venkateshwar V Kanitkar M Devgan A. Varied presentations of" exact="hypothyroidism" post="in children. Medical Journal Armed Forces India 2011 67"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6119171/results/search/disease/results.xml">
   <result pre="Milan pmcid: 6119171 910 doi: 10.1186/s10194-018-0910-y : Short Report Prolonged" exact="migraine" post="aura: new insights from a prospective diary-aided study http://orcid.org/0000-0003-4356-8109"/>
   <result pre="of PA. Findings Two hundred and twenty-four patients suffering from" exact="migraine" post="with aura were recruited from the Headache Centers of"/>
   <result pre="RC 2013-2015 to IRCCS Mondino Foundation Viana Michele Introduction Worldwide" exact="migraine" post="is the third most common disorder [ 1] and"/>
   <result pre="common disorder [ 1] and around 30% of sufferers experience" exact="migraine" post="auras [ 2]. Aura comprises completely reversible visual, sensory,"/>
   <result pre="these symptoms can last longer in a rare subtype of" exact="migraine" post="with aura, namely hemiplegic migraine, which is not discussed"/>
   <result pre="in this paper. The first version of the ICHD included" exact="migraine" post="with prolonged aura (PA) and defined it as migraine"/>
   <result pre="included migraine with prolonged aura (PA) and defined it as" exact="migraine" post="with one or more aura symptoms lasting more than"/>
   <result pre="from the classification [ 5, 6]. Currently a prolonged non-hemiplegic" exact="migraine" post="with aura (NHMA) is classified as ‘persistent aura without"/>
   <result pre="min and less than 7 days are classified as ‘probable" exact="migraine" post="with aura (prolonged aura)’. The term &quot;probable&quot; used in"/>
   <result pre="such classification indicates suspicion as to whether the symptom is" exact="migraine" post="aura and from our clinical experience we feel it"/>
   <result pre="is important for achieving a more evidence-based nosographic framing of" exact="migraine" post="with aura. So far there are no systematic studies"/>
   <result pre="to the evaluation of the temporal and qualitative aspects of" exact="migraine" post="with aura, whose results have been partly published in"/>
   <result pre="Pavia and Trondheim (198 and 26 respectively) who suffered from" exact="migraine" post="with aura. The recruitment period was between October 2012"/>
   <result pre="and REC-Central, Trondheim, Norway). Inclusion criteria were: patients suffering from" exact="migraine" post="with aura for at least 1 year which met"/>
   <result pre="met the ICHD-2 criteria for 1.2.1 [G43.10] typical aura with" exact="migraine" post="headache,1.2.2 [G43.10], typical aura with non-migraine headache, 1.2.3 [G43.104]"/>
   <result pre="history of myocardial infarction and/or transitory ischemic attack (TIA) and/or" exact="stroke" post="and/or others thrombophilic disturbances; vii) patients with episodes that"/>
   <result pre="from other disturbances (TIA, seizures). Each patient was diagnosed with" exact="migraine" post="with aura by a neurologist of the headache center,"/>
   <result pre="in their own words, highlight the main characteristics of their" exact="migraine" post="and record the duration of the aura symptoms and"/>
   <result pre="58 (80%) Age (years) 41 ± 14 (18–65) Age at onset of" exact="migraine" post="with aura (years) 22 ± 20 (6–60) Frequency of migraine with"/>
   <result pre="onset of migraine with aura (years) 22 ± 20 (6–60) Frequency of" exact="migraine" post="with aura (attacks/year) 21 ± 12 (2–130) Headache  on 3/3 attacks"/>
   <result pre="attacks 6 (8)  on 0 attacks 3 (4) Co-occurrence of" exact="migraine" post="without aura 54 (75) Age at onset of migraine"/>
   <result pre="of migraine without aura 54 (75) Age at onset of" exact="migraine" post="without aura (years) 16 ± 14 (7–45) Co-occurrence of tension type"/>
   <result pre="Co-occurrence of tension type headache 10 (14) Family history of" exact="migraine" post="with aura a 15 (21) Use of preventive drugs"/>
   <result pre="p = 0.043). Discussion This study prospectively analysed a significant number of" exact="migraine" post="auras recorded with the use of an ad hoc"/>
   <result pre="International Classification of Headache Disorders IQR Interquartile range NHMA Non-hemiplegic" exact="migraine" post="with aura PA Prolonged aura SS Sensory symptom VS"/>
   <result pre="26063472 2. Rasmussen BK Olesen J Migraine with aura and" exact="migraine" post="without aura: an epidemiological study Cephalalgia 1992 12 221"/>
   <result pre="N Guaschino E Allena M et al. Clinical features of" exact="migraine" post="aura: results from a prospective diary-aided study Cephalalgia 2017"/>
   <result pre="211 10.1177/0333102417738202 29368949 7. Pye S Ahmed M Duration of" exact="migraine" post="aura Cephalalgia 2014 34 236 10.1177/0333102413500729 23963356 8. Silva"/>
   <result pre="Ina ´cio N Simões N Costa C Parreira E Prolonged" exact="migraine" post="auras J Headache Pain 2010 11 Suppl 1 S79"/>
   <result pre="EJ Tatsui CE Lange MC Ribas LC Werneck LC Prolonged" exact="migraine" post="aura without headache arrested by sumatriptan. A case report"/>
   <result pre="G Linde M Nappi G Goadsby PJ Tassorelli C Prolonged" exact="migraine" post="aura: new insights from a prospective diary-aided study (EP-02-024)"/>
   <result pre="Queiroz LP Friedman DI Rapoport AM Purdy RA Characteristics of" exact="migraine" post="visual aura in Southern Brazil and Northern USA Cephalalgia"/>
   <result pre="Goadsby PJ ‘Visual snow’ - a disorder distinct from persistent" exact="migraine" post="aura Brain 2014 137 1419 1428 10.1093/brain/awu050 24645145"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6119173/results/search/disease/results.xml">
   <result pre="Effect of exogenous estrogens and progestogens on the course of" exact="migraine" post="during reproductive age: a consensus statement by the European"/>
   <result pre="effect of exogenous estrogens and progestogens on the course of" exact="migraine" post="during reproductive age. Thereafter a consensus procedure among international"/>
   <result pre="support clinical decision making, in terms of possible effects on" exact="migraine" post="course of exogenous estrogens and progestogens and on possible"/>
   <result pre="Introduction The role of female hormones in the pathogenesis of" exact="migraine" post="is well-recognized [ 1, 2]. Migraine is more prevalent"/>
   <result pre="menstrual phase of the female cycle represents a trigger for" exact="migraine" post="attacks in many women [ 1, 4]. Additionally, exogenous"/>
   <result pre="1, 4]. Additionally, exogenous hormones may change the course of" exact="migraine" post="by inducing de novo migraine, inducing de novo aura,"/>
   <result pre="inducing de novo migraine, inducing de novo aura, worsening previous" exact="migraine" post="but also improving migraine particularly those attacks related to"/>
   <result pre="inducing de novo aura, worsening previous migraine but also improving" exact="migraine" post="particularly those attacks related to menstruation [ 5, 6]."/>
   <result pre="related to menstruation [ 5, 6]. The criteria to diagnose" exact="migraine" post="related to menstruation (Table 1) and to diagnose headache"/>
   <result pre="Disorders (ICHD), 1988, did not report any formal criteria for" exact="migraine" post="related to menstruation [ 7]. The authors recognized that"/>
   <result pre="menstruation [ 7]. The authors recognized that in some women," exact="migraine" post="without aura (MO) may be almost exclusively linked with"/>
   <result pre="may be almost exclusively linked with menstruation, so called menstrual" exact="migraine" post="(MM), and indicated that it seemed reasonable to require"/>
   <result pre="menses and the last day of menses. Appendix criteria for" exact="migraine" post="related to menstruation were introduced in 2004, with the"/>
   <result pre="(Table 1) [ 8]. Two entities were recognised: pure menstrual" exact="migraine" post="(PMM) where attacks are exclusively related to menstruation; menstrually"/>
   <result pre="(PMM) where attacks are exclusively related to menstruation; menstrually related" exact="migraine" post="(MRM) where attacks occur additionally at other times of"/>
   <result pre="Both were forms of MO, along with non-menstrual MO or" exact="migraine" post="with aura (MA) in the case of MRM. PMM"/>
   <result pre="available since 2018 [ 10]. Table 1 Diagnostic criteria of" exact="migraine" post="related to menstruation according to the different editions of"/>
   <result pre="Headache Disorders (ICHD) ICHD, II edition, 2004  A.1.1.1 Pure menstrual" exact="migraine" post="without aura   A. Attacks, in a menstruating woman, fulfilling"/>
   <result pre="and at no other times of the cycle  A.1.1.2 Menstrually-related" exact="migraine" post="without aura   A. Attacks, in a menstruating woman, fulfilling"/>
   <result pre="cycle ICHD, III edition, beta version, 2013  A1.1.1 Pure menstrual" exact="migraine" post="without aura   A. Attacks, in a menstruating woman, fulfilling"/>
   <result pre="at no other times of the cycle  A1.1.2 Menstrually related" exact="migraine" post="without aura   A. Attacks, in a menstruating woman, fulfilling"/>
   <result pre="of the cycle ICHD, III edition, 2018  A1.1.1 Pure menstrual" exact="migraine" post="without aura   A. Attacks, in a menstruating woman, fulfilling"/>
   <result pre="at no other times of the cycle  A1.1.2 Menstrually related" exact="migraine" post="without aura   A. Attacks, in a menstruating woman, fulfilling"/>
   <result pre="additionally at other times of the cycle  A1.2.0.1 Pure menstrual" exact="migraine" post="with aura   A. Attacks, in a menstruating woman, fulfilling"/>
   <result pre="at no other times of the cycle  A1.2.0.2 Menstrually related" exact="migraine" post="with aura   A. Attacks, in a menstruating woman, fulfilling"/>
   <result pre="II edition, 2004  8.3.1 Exogenous hormone-induced headache   A. Headache or" exact="migraine" post="fulfilling criteria C and D   B. Regular use of"/>
   <result pre="D   B. Regular use of exogenous hormones   C. Headache or" exact="migraine" post="develops or markedly worsens within 3 months of commencing"/>
   <result pre="within 3 months of commencing exogenous hormones   D. Headache or" exact="migraine" post="resolves or reverts to its previous pattern within 3"/>
   <result pre="discontinuation of exogenous hormones  8.4.3 Estrogen-withdrawal headache   A. Headache or" exact="migraine" post="fulfilling criteria C and D   B. Daily use of"/>
   <result pre="estrogen for ≥3 weeks, which is interrupted   C. Headache or" exact="migraine" post="develops within 5 days after last use of estrogen"/>
   <result pre="5 days after last use of estrogen   D. Headache or" exact="migraine" post="resolves within 3 days ICHD, III edition, beta version,"/>
   <result pre="by another ICHD-3 diagnosis  8.3.3 Estrogen-withdrawal headache   A. Headache or" exact="migraine" post="fulfilling criterion C   B. Daily use of exogenous estrogen"/>
   <result pre="causation demonstrated by both of the following:     1. headache or" exact="migraine" post="has developed within five days after the last use"/>
   <result pre="days after the last use of estrogen     2. headache or" exact="migraine" post="has resolved within three days of its onset   D."/>
   <result pre="by another ICHD-3 diagnosis  8.3.3 Estrogen-withdrawal headache   A. Headache or" exact="migraine" post="fulfilling criterion C   B. Daily use of exogenous estrogen"/>
   <result pre="causation demonstrated by both of the following:     1. headache or" exact="migraine" post="has developed within five days after the last use"/>
   <result pre="days after the last use of estrogen     2. headache or" exact="migraine" post="has resolved within three days of its onset   D."/>
   <result pre="to manipulate the female hormonal cycle to try to improve" exact="migraine" post="[ 6, 11]. Studies have investigated both MO, MA"/>
   <result pre="[ 6, 11]. Studies have investigated both MO, MA and" exact="migraine" post="attacks related to menstruation [ 6, 11]. Additionally, as"/>
   <result pre="11]. Additionally, as in users of combined hormonal contraceptives (CHC)" exact="migraine" post="attacks mostly occur during the hormone free interval, studies"/>
   <result pre="different estrogen or progestogen regimens impact on the course of" exact="migraine" post="[ 12– 15]. CHC have been associated with an"/>
   <result pre="CHC have been associated with an increased risk of ischemic" exact="stroke" post="in women with migraine [ 16– 21]. A working"/>
   <result pre="with an increased risk of ischemic stroke in women with" exact="migraine" post="[ 16– 21]. A working group including headache experts,"/>
   <result pre="[ 16– 21]. A working group including headache experts, gynaecologists," exact="stroke" post="experts, and epidemiologists developed a first consensus document about"/>
   <result pre="consensus document is to provide recommendations on the management of" exact="migraine" post="with the use of estrogens and progestogens in women"/>
   <result pre="EHF representatives selected a panel of international multidisciplinary experts in" exact="migraine" post="and hormonal contraception (HC). The panel was chosen to"/>
   <result pre="guidance to clinicians about evidence-based options for the management of" exact="migraine" post="with exogenous estrogens and progestogens. Review of the literature"/>
   <result pre="study period, number of included patients, diagnostic criteria for migraine," exact="migraine" post="type, treatments type, duration of observations and treatments, study"/>
   <result pre="of estrogen or progestogen; 5) reporting any outcome referring to" exact="migraine" post="frequency, severity, duration, disability, or use of drugs to"/>
   <result pre="headache [ 15, 40]. Drugs which were evaluated to manage" exact="migraine" post="in women of reproductive age include the desogestrel progestogen-only"/>
   <result pre="headache intensity, days with headache score 3, analgesic use Reduced" exact="migraine" post="days, headache intensity, days with headache and use of"/>
   <result pre="neurological symptoms or associated symptoms, analgesic use Reduced number of" exact="migraine" post="attacks in previous COCs users and nonusers Desogestrel progestogen-only"/>
   <result pre="score 3, pain medication, triptan use, quality of life Reduced" exact="migraine" post="days, headache days pain intensity, number of days with"/>
   <result pre="treatment (pre-treatment observation period not-defined) Severity, number and duration of" exact="migraine" post="attacks, associated symptoms Decreased number and intensity of migraine"/>
   <result pre="of migraine attacks, associated symptoms Decreased number and intensity of" exact="migraine" post="attacks in POP users Extended regimen of combined oral"/>
   <result pre="phenomena, analgesic use Reduction in the number and duration of" exact="migraine" post="attacks, in hours of severe pain, and in use"/>
   <result pre="days of migraine; severity of migraine; number of days of" exact="migraine" post="with associated symptoms Trend towards reducing the frequency and"/>
   <result pre="associated symptoms Trend towards reducing the frequency and severity of" exact="migraine" post="with the patch Combined hormonal contraceptive patch  LaGuardia, 2005"/>
   <result pre="1986 [ 31] Randomized, placebo-controlled, double-blind, crossover MM (No ICHD;" exact="migraine" post="without aura occurring exclusively not earlier than 2 days"/>
   <result pre="of treatment, 27 cycles of placebo Occurrence, duration, severity of" exact="migraine" post="attacks, aspirin use Reduction in the occurrence and severity"/>
   <result pre="[ 32] Randomized, placebo-controlled, double-blind, crossover MM (No ICHD; regular" exact="migraine" post="in the paramenstruum); women specifically treated for headache 22;"/>
   <result pre="attacks, associated symptoms, occurrence of aura, analgesic use Reduction in" exact="migraine" post="days and attacks severity; increase in migraine occurrence in"/>
   <result pre="use Reduction in migraine days and attacks severity; increase in" exact="migraine" post="occurrence in the 5 days immediately after estradiol use"/>
   <result pre="3 cycles for active treatment Number, severity and intensity of" exact="migraine" post="attacks No differences between active treatment and placebo  Guidotti,"/>
   <result pre="treatment (6 days before expected menstruation) Number and severity of" exact="migraine" post="attacks Reduction in number of migraine attacks and severity"/>
   <result pre="Number and severity of migraine attacks Reduction in number of" exact="migraine" post="attacks and severity of attacks with frovatriptan than with"/>
   <result pre="for 3 cycles (estradiol-placebo-estradiol or placebo-estradiol-placebo) Presence, duration, severity of" exact="migraine" post="attacks, analgesic use No differences between active treatment and"/>
   <result pre="month 2.5 years (mean duration) of treatment Improvement of menstrual" exact="migraine" post="95.8% of patients with improvement in MM; 46% became"/>
   <result pre="became headache-free and 37.5% gained almost complete symptomatic relief MO" exact="migraine" post="without aura, MA migraine with aura, ICHD International Classification"/>
   <result pre="gained almost complete symptomatic relief MO migraine without aura, MA" exact="migraine" post="with aura, ICHD International Classification of Headache Disorders, EE"/>
   <result pre="PMM pure menstrual migraine, MRM menstrually related migraine, MM menstrual" exact="migraine" post="Table 4 Assessment for rating up the quality of"/>
   <result pre="Treatment with desogestrel was associated with a significant reduction in" exact="migraine" post="days (6.2 ± 4.2 vs 5.2 ± 5.3; P = 0.001"/>
   <result pre="The authors found a significant reduction in the number of" exact="migraine" post="attacks ( P &amp;lt; 0.001) and of aura symptoms ( P &amp;lt; 0.02)"/>
   <result pre="pain and on analgesic consumption. Benefits in the reduction of" exact="migraine" post="attacks were evident in both users (3.9 ± 1.0 vs 2.9 ± 0.8;"/>
   <result pre="that treatment with desogestrel was associated with a reduction in" exact="migraine" post="days per month (5.5 ± 2.6 vs 3.5 ± 1.2; P &amp;lt; 0.001), headache days"/>
   <result pre="vs 4.9 ± 1.7; P = 0.005), and duration (20.5 ± 7.9 vs 15.9 ± 4.4; P &amp;lt; 0.001) of" exact="migraine" post="attacks. Side effects associated with desogestrel use included higher"/>
   <result pre="treatment with oral desogestrel may be associated with improvement in" exact="migraine" post="in women with MO and MA. However, treatment has"/>
   <result pre="of estrogens and progestogens in women of reproductive age with" exact="migraine" post="considering their effect on migraine course Treatment Population Recommendation"/>
   <result pre="women of reproductive age with migraine considering their effect on" exact="migraine" post="course Treatment Population Recommendation Quality of Evidence Strength of"/>
   <result pre="combined contraceptive regimen with oral pill or patch* Women with" exact="migraine" post="who require hormonal contraception Not suggested None Weak Alternative"/>
   <result pre="usual headache with combined hormonal contraceptives; women with new onset" exact="migraine" post="with combined hormonal contraceptives Suggested None Weak Women with"/>
   <result pre="None Weak Women with migraine, related to menstruation, who require" exact="migraine" post="preventive treatments and who have contraindication or failure of"/>
   <result pre="Women with migraine, related to menstruation, who have not tried" exact="migraine" post="preventive drugs and who have no need of desogestrel-only"/>
   <result pre="of pill or patch) of combined contraceptives for women with" exact="migraine" post="Extended regimens of the contraceptive patch may be preferable"/>
   <result pre="None Weak Women with migraine, related to menstruation, who require" exact="migraine" post="preventive treatments and who have contraindication or failure of"/>
   <result pre="Women with migraine, related to menstruation, who have not tried" exact="migraine" post="preventive drugs and who have no need of desogestrel-only"/>
   <result pre="Transdermal estradiol supplementation with estradiol gel Women with pure menstrual" exact="migraine" post="Suggested Low Weak Patients should be informed that delayed"/>
   <result pre="migraine Suggested Low Weak Patients should be informed that delayed" exact="migraine" post="may occur and that treatment is potentially effective only"/>
   <result pre="effective only on attacks related to menstruation Women with menstrually-related" exact="migraine" post="Suggested Low Weak Women with estrogen-withdrawal headache Suggested None"/>
   <result pre="Weak Transdermal estradiol supplementation with patch Women with pure menstrual" exact="migraine" post="Not suggested Low Weak Women with menstrually-related migraine Not"/>
   <result pre="pure menstrual migraine Not suggested Low Weak Women with menstrually-related" exact="migraine" post="Not suggested Low Weak Women with estrogen-withdrawal headache Not"/>
   <result pre="with patch in women induced in pharmacological menopause Women with" exact="migraine" post="Not suggested Low Weak Subcutaneous estradiol; implant and cyclical"/>
   <result pre="Subcutaneous estradiol; implant and cyclical progestogen Women with pure menstrual" exact="migraine" post="Not suggested Low Weak Women with menstrually-related migraine Not"/>
   <result pre="pure menstrual migraine Not suggested Low Weak Women with menstrually-related" exact="migraine" post="Not suggested Low Weak *According to the Consensus Statement"/>
   <result pre="migraine, compounds containing estrogens are not suggested for women with" exact="migraine" post="with aura and for women with migraine without aura"/>
   <result pre="for women with migraine with aura and for women with" exact="migraine" post="without aura and additional vascular risk factors [ 22]"/>
   <result pre="contraceptive was associated with a reduction in the duration of" exact="migraine" post="attacks (22.7 ± 9.0 vs 18.9 ± 6.0; P = 0.007) but not in reduction"/>
   <result pre="the use of extended oral CHCs regimens in women with" exact="migraine" post="is limited as it comes from observational studies performed"/>
   <result pre="P = 0.044). There was no difference between the two group in" exact="migraine" post="days, headache days, headache intensity, days with headache score"/>
   <result pre="were associated with reduction in headache intensity and days of" exact="migraine" post="as compared to baseline observation. Treatment with the shortened"/>
   <result pre="least 3 months before enrollment. After treatment, the number of" exact="migraine" post="attack days was reduced from 2.7 ± 0.9 days at baseline"/>
   <result pre="of oral CHCs with shortened pill-free interval in women with" exact="migraine" post="is limited. Available studies included PMM or MRM. One"/>
   <result pre="but it is important to note that some women with" exact="migraine" post="may be particularly sensitive to hormonal administration and need"/>
   <result pre="related to treatment or rather to natural fluctuations in the" exact="migraine" post="course nor it is clear if improvements can be"/>
   <result pre="in women with MO associated with menstruation and women with" exact="migraine" post="associated with CHC withdrawal bleeding [ 44]. The study"/>
   <result pre="oral estrogen supplementation during the pill-free interval in women with" exact="migraine" post="is limited to a single unreliable study. Recommendations for"/>
   <result pre="benefits of transdermal estradiol supplementation with patch in women with" exact="migraine" post="during the pill-free interval of combined oral contraceptives ["/>
   <result pre="days of migraine, severity of migraine, number of days with" exact="migraine" post="with associated symptoms. Adverse events related to transdermal estradiol"/>
   <result pre="study show no benefit of estradiol supplementation with patches on" exact="migraine" post="occurrence during the pill-free interval, this cannot be considered"/>
   <result pre="conclusion, data referring to the effect of CHC patch on" exact="migraine" post="are very limited. One study only evaluated the effect"/>
   <result pre="not defined and authors did not provide any information about" exact="migraine" post="frequency, severity or disability before and after treatments. The"/>
   <result pre="on the use of CHC vaginal ring in women with" exact="migraine" post="is very limited. There are not enough data to"/>
   <result pre="concerns over a possible increase in the risk of ischemic" exact="stroke" post="[ 22]. No ischemic strokes were reported during the"/>
   <result pre="less use of aspirin. One out of 20 patients had" exact="migraine" post="three days after stopping estradiol treatment. Dennerstein et al."/>
   <result pre="significant difference in the occurrence of moderate to severe intensity" exact="migraine" post="during the months of treatment with percutaneous estradiol compared"/>
   <result pre="authors considered that treatment would not be expected to affect" exact="migraine" post="which occurred prior to or after the use of"/>
   <result pre="according to ICHD-2 criteria. The authors reported a reduction in" exact="migraine" post="days and attack severity. Estradiol was associated with a"/>
   <result pre="attack severity. Estradiol was associated with a 22% reduction in" exact="migraine" post="days per woman (relative risk [RR] 0.78; 95% CI"/>
   <result pre="significant. However, in this study authors found an increase in" exact="migraine" post="occurrence in the 5 days immediately following estradiol use"/>
   <result pre="had fewer migraines compared to using placebo), 15 experienced post-gel" exact="migraine" post="(they had more migraine days during the 5 days"/>
   <result pre="to using placebo), 15 experienced post-gel migraine (they had more" exact="migraine" post="days during the 5 days after the estradiol gel"/>
   <result pre="use of transdermal estradiol supplementation with gel in women with" exact="migraine" post="is limited. Transdermal estradiol supplementation with gel is easy"/>
   <result pre="life. Possible benefits may be offset by an increase in" exact="migraine" post="following gel use, associated with an iatrogenic delayed estrogen"/>
   <result pre="withdrawal. Possible reasons for the occurrence of post-gel estrogen withdrawal" exact="migraine" post="are that the dose of estradiol was inadequate; the"/>
   <result pre="or are not feasible. Women should be aware that delayed" exact="migraine" post="may occur and in those circumstances treatment should be"/>
   <result pre="not find any benefit in number, severity, and intensity of" exact="migraine" post="attacks. Guidotti et al. performed an observational, prospective, parallel"/>
   <result pre="single cycle. Authors reported that frovatriptan was associated with reduced" exact="migraine" post="incidence and severity while they did not report benefits"/>
   <result pre="not find any difference in presence, duration, and severity of" exact="migraine" post="attacks and in the use of analgesics between active"/>
   <result pre="the time of the anticipated start of the bleeding and" exact="migraine" post="attacks, dosing and timing of treatment are very important."/>
   <result pre="clinical benefits whereas higher doses may increase risk of ischemic" exact="stroke" post="[ 33]. Also, duration of estradiol supplementation may impact"/>
   <result pre="no data showing benefits of estradiol supplementation with patches on" exact="migraine" post="occurrence, this cannot be considered as a possible therapeutic"/>
   <result pre="wall. Patients were included in this study specifically to treat" exact="migraine" post="after failure of previous treatments. Mean duration of treatment"/>
   <result pre="not defined and authors did not provide any information about" exact="migraine" post="frequency, severity or disability before and after treatment. No"/>
   <result pre="all but one patient noted an improvement in their menstrual" exact="migraine" post="following treatment. Eleven (46%) became completely headache-free and nine"/>
   <result pre="progestogens in women of reproductive age and their effect on" exact="migraine" post="is limited. All the recommendations were based on low"/>
   <result pre="is the option which may offer more evident benefit on" exact="migraine" post="course. From a cardiovascular point of view in women"/>
   <result pre="course. From a cardiovascular point of view in women with" exact="migraine" post="it is also the safest form [ 22, 46]."/>
   <result pre="safest form [ 22, 46]. The desogestrel pill may improve" exact="migraine" post="frequency and severity in women with MA or MO"/>
   <result pre="this drug as a specific therapeutic option for women with" exact="migraine" post="is available. It is important to note that in"/>
   <result pre="note that in some patient the desogestrel pill may worsen" exact="migraine" post="or may be associated with new onset migraine. Unfavorable"/>
   <result pre="estrogen withdrawal headache, particularly those women already experiencing headache or" exact="migraine" post="during the pill-free interval. Less certain is the option"/>
   <result pre="this contraceptive method is associated with de novo occurrence of" exact="migraine" post="or migraine worsening in a substantial proportion of female"/>
   <result pre="method is associated with de novo occurrence of migraine or" exact="migraine" post="worsening in a substantial proportion of female migraineurs, although"/>
   <result pre="interval [ 47– 50]. It is important to note that" exact="migraine" post="may improve in some patients with the use of"/>
   <result pre="no tools or clinical features to predict the course of" exact="migraine" post="after oral CHC initiation. In women who have menstrual"/>
   <result pre="oral CHC initiation. In women who have menstrual attacks of" exact="migraine" post="during natural cycles, a therapeutic option may the administration"/>
   <result pre="evidence-based and expert-agreed guidance to clinicians for the management of" exact="migraine" post="with exogenous estrogens and progestogens. The available evidence is"/>
   <result pre="whether the treatments discussed may be specifically applied to treat" exact="migraine" post="in selected women. Abbreviations CHC Combined hormonal contraceptives CI"/>
   <result pre="Classification of Headache Disorders MA Migraine with aura MM Menstrual" exact="migraine" post="MO Migraine without aura MRM Menstrually related migraine PHC"/>
   <result pre="MM Menstrual migraine MO Migraine without aura MRM Menstrually related" exact="migraine" post="PHC Progestogen-only hormonal contraceptive PMM Pure menstrual migraine POP"/>
   <result pre="Menstrually related migraine PHC Progestogen-only hormonal contraceptive PMM Pure menstrual" exact="migraine" post="POP Progestogen-only pill RR Relative risk SE Standard error"/>
   <result pre="affiliations. References References 1. MacGregor EA Oestrogen and attacks of" exact="migraine" post="with and without aura Lancet Neurol 2014 3 354"/>
   <result pre="Sex differences in the epidemiology, clinical features, and pathophysiology of" exact="migraine" post="Lancet Neurol 2017 16 76 87 10.1016/S1474-4422(16)30293-9 27836433 3."/>
   <result pre="Garrick R Tomlinson SE Effectiveness of the progestin-only pill for" exact="migraine" post="treatment in women: a systematic review and meta-analysis Cephalalgia"/>
   <result pre="10.1177/0333102417738202 29368949 11. MacGregor EA Prevention and treatment of menstrual" exact="migraine" post="Drugs 2010 70 1799 1818 10.2165/11538090-000000000-00000 20836574 12. Martin"/>
   <result pre="with and without estrogen add-back therapy in the prevention of" exact="migraine" post="headache Headache 2003 43 309 321 10.1046/j.1526-4610.2003.03065.x 12656701 13."/>
   <result pre="oral contraceptive in the treatment of pain symptoms caused by" exact="endometriosis" post="in patients with migraine without aura Eur J Obstet"/>
   <result pre="treatment of pain symptoms caused by endometriosis in patients with" exact="migraine" post="without aura Eur J Obstet Gynecol Reprod Biol 2014"/>
   <result pre="contraception compared with extended combined oral contraceptive in women with" exact="migraine" post="without aura: a retrospective pilot study Eur J Obstet"/>
   <result pre="16. Carolei A Marini C De Matteis G History of" exact="migraine" post="and risk of cerebral ischaemia in young adults The"/>
   <result pre="young adults The Italian National Research Council study group on" exact="stroke" post="in the young Lancet 1996 347 1503 1506 17."/>
   <result pre="hormonal contraceptives among women with migraines and risk of ischemic" exact="stroke" post="Am J Obstet Gynecol 2017 216 489.e1 489.e7 10.1016/j.ajog.2016.12.019"/>
   <result pre="28034652 18. Chang CL Donaghy M Poulter N Migraine and" exact="stroke" post="in young women: case–control study. The World Health Organization"/>
   <result pre="women: case–control study. The World Health Organization collaborative study of" exact="cardiovascular disease" post="and steroid hormone contraception BMJ 1999 318 13 18"/>
   <result pre="J Wozniak M Stern B Mitchell BD Kittner SJ Probable" exact="migraine" post="with visual aura and risk of ischemic stroke: the"/>
   <result pre="migraine with visual aura and risk of ischemic stroke: the" exact="stroke" post="prevention in young women study Stroke 2007 38 2438"/>
   <result pre="21. Sacco S Kurth T Migraine and the risk of" exact="stroke" post="and cardiovascular disease Curr Cardiol Rep 2014 16 524"/>
   <result pre="S Kurth T Migraine and the risk of stroke and" exact="cardiovascular disease" post="Curr Cardiol Rep 2014 16 524 10.1007/s11886-014-0524-1 25059466 22."/>
   <result pre="Contraception and Reproductive Health (ESC) HCs and risk of ischemic" exact="stroke" post="in women with migraine: a consensus statement from the"/>
   <result pre="M Lindh-Åstrand L Landtblom AM Brynhildsen J Prevention of menstrual" exact="migraine" post="with perimenstrual transdermal 17-β-estradiol: a randomized, placebo-controlled, double-blind crossover"/>
   <result pre="P Mas JL Touboul PJ Bousser MG Prevention of menstrual" exact="migraine" post="by percutaneous estradiol Br Med J 1986 293 1540"/>
   <result pre="transdermal oestrogens or naproxen sodium for the prophylaxis of menstrual" exact="migraine" post="J Heachache Pain 2007 8 283 288 10.1007/s10194-007-0417-4 34."/>
   <result pre="283 288 10.1007/s10194-007-0417-4 34. MacGregor EA Hackshaw A Prevention of" exact="migraine" post="in the pill-free interval of combined oral contraceptives: a"/>
   <result pre="36. Magos A Zilkha KJ Studd JW Treatment of menstrual" exact="migraine" post="by oestradiol implants JNNP 1983 46 1044 1046 37."/>
   <result pre="Correlation between estradiol plasma level and therapeutic effect on menstrual" exact="migraine" post="New advances in headache research 1994 London Smith-Gordon 129"/>
   <result pre="the value of contingent negative variation and exteroceptive temporalis muscle" exact="suppression" post="test Headache 1993 34 103 106 10.1111/j.1526-4610.1994.hed3402103.x 39. De"/>
   <result pre="G Cianci A Combined oral contraceptives in women with menstrual" exact="migraine" post="without aura Fertil Steril 2011 96 917 920 10.1016/j.fertnstert.2011.07.1089"/>
   <result pre="Imthurn B Dubey R Sándor PS Gantenbein AR Improvement of" exact="migraine" post="with change from combined hormonal contraceptives to progestin-only contraception"/>
   <result pre="of an estrogen-free, desogestrel containing oral contraceptive in women with" exact="migraine" post="with aura: a prospective diary-based pilot study Contraception 2011"/>
   <result pre="containing estradiol valerate and dienogest (E2V/DNG) in women with menstrually-related" exact="migraine" post="(MRM) Contraception 2013 88 369 375 10.1016/j.contraception.2013.02.001 23453784 44."/>
   <result pre="23453784 44. Calhoun AH A novel specific prophylaxis for menstrual-associated" exact="migraine" post="South Med J 2004 97 819 822 10.1097/01.SMJ.0000129924.15619.D9 15455962"/>
   <result pre="Pruitt A The impact of extended-cycle vaginal ring contraception on" exact="migraine" post="aura: a retrospective case series Headache 2012 52 1246"/>
   <result pre="Martins L, Luminoso D (2010) Epidemiological and clinical aspects of" exact="migraine" post="in users of combined oral contraceptives. Contraception 81:202–208"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6119283/results/search/disease/results.xml">
   <result pre="type of migraine, though the statistical significance was greatest in" exact="migraine" post="with aura. The homocysteine serum levels were significantly higher"/>
   <result pre="with aura. The homocysteine serum levels were significantly higher in" exact="migraine" post="with aura compared to migraine without aura. In a"/>
   <result pre="levels were significantly higher in migraine with aura compared to" exact="migraine" post="without aura. In a pediatric population MTHFR T/T homozygosity"/>
   <result pre="population MTHFR T/T homozygosity influences susceptibility to migraine. Keywords Children" exact="migraine" post="MTHFR C677T Hyperhomocysteinemia Migraine with aura Migraine MTHFR Funding"/>
   <result pre="Università di Pisa 2017_38, DR n.83/2017 Background The prevalence of" exact="migraine" post="in the pediatric population ranges from 3.3 to 21.4%"/>
   <result pre="school performance [ 1]. At present, without validated biochemical investigations," exact="migraine" post="remains a clinical diagnosis supported by the diagnostic criteria"/>
   <result pre="IHS have comprehensively classified tension-type headache (TTH) and migraine, with" exact="migraine" post="divided in turn into two main subtypes; migraine without"/>
   <result pre="migraine, with migraine divided in turn into two main subtypes;" exact="migraine" post="without aura (MOA) and migraine with aura (MA) ["/>
   <result pre="turn into two main subtypes; migraine without aura (MOA) and" exact="migraine" post="with aura (MA) [ 2]. Migraine is a multifactorial"/>
   <result pre="genetic with strong familial aggregation. It is likely that both" exact="migraine" post="subtypes have some genetic determinants in common, although different"/>
   <result pre="MTHFR gene, have been linked to the pathogenesis of both" exact="migraine" post="subtypes [ 4– 8]. The human MTHFR gene mapped"/>
   <result pre="disorders. Previous research investigating the association between this polymorphism and" exact="migraine" post="has produced conflicting results [ 4– 8]. However, there"/>
   <result pre="in pediatric populations have not always included both subtypes of" exact="migraine" post="and have been limited by their small sample size"/>
   <result pre="potential relationship between MTHFR polymorphisms, high homocysteine serum levels and" exact="migraine" post="[ 4, 5, 8, 9, 12]. Table 1 Summary"/>
   <result pre="causes of headache were excluded with relevant investigations. Patients with" exact="migraine" post="were only included in the study if they had"/>
   <result pre="MTHFR C677T polymorphism, for positive familiar anamnesis of thrombosis, for" exact="arthritis" post="or syncope episodes without headache comorbidity. We considered as"/>
   <result pre="2 Previous studies that analyzed the relationship between MTHFR polymorphisms" exact="migraine" post="compared to ours C677T MTHFR Polymorphism TT genotype in"/>
   <result pre="to ours C677T MTHFR Polymorphism TT genotype in children with" exact="migraine" post="C677T MTHFR Polymorphism TT genotype in general pediatric population"/>
   <result pre="lesser extent with MOA. Across all patients diagnosed with a" exact="migraine" post="(MA + MOA) the frequency of the T/T genotype was 35%"/>
   <result pre="We also divided the population into 2 subgroups: patients with" exact="migraine" post="(220/427) and patients without migraine, and we reported a"/>
   <result pre="we reported a significant relation with the T/T genotype and" exact="migraine" post="group ( p &amp;lt; 0.0001). We then stratified the population in"/>
   <result pre="MA ( p = 0.0183), and the absence of correlation with the" exact="migraine" post="itself ( p = 0.61). Patients with the T/T genotype and"/>
   <result pre="12] (Table 2). One retrospective study of 41 patients with" exact="migraine" post="reported a similar association between the T/T genotype and"/>
   <result pre="migraine reported a similar association between the T/T genotype and" exact="migraine" post="to our results but included only 11 patients who"/>
   <result pre="polymorphism research for both diagnostic and therapeutic purposes in our" exact="migraine" post="patients, aiming to reduce both frequency and severity of"/>
   <result pre="migraine patients, aiming to reduce both frequency and severity of" exact="migraine" post="attacks by dietary supplementation with folic acid in patients"/>
   <result pre="constitute a modest, but significant, genetic risk factor for ischemic" exact="stroke" post="with conflicting results [ 8, 12]. The results of"/>
   <result pre="also found a negative correlation between age of onset of" exact="migraine" post="and T/T genotype. Our results suggest that the T/T"/>
   <result pre="that the T/T genotype is related to earlier onset of" exact="migraine" post="in a pediatric population (8.54 years compared with 8.89"/>
   <result pre="an adjunct to other treatment in the long-term management of" exact="migraine" post="and in particular in MA [ 4, 9]. Clearly,"/>
   <result pre="mutations in MTHFR alone are not the causal factor for" exact="migraine" post="given that it is a complex, multifaceted disorder. However,"/>
   <result pre="the high levels of circulating homocysteine, improve the course of" exact="migraine" post="and reduce longer-term risk of possible complications such as"/>
   <result pre="Our retrospective study performed in this large pediatric cohort of" exact="migraine" post="patients provides evidence to support that MTHFR T/T homozygosity"/>
   <result pre="evidence to support that MTHFR T/T homozygosity influences susceptibility to" exact="migraine" post="and in particular in MA. Abbreviations 5, 10-CH2-THF 5,"/>
   <result pre="Griffiths L The methylenetetrahydrofolatereductase gene variant C677T influences susceptibility to" exact="migraine" post="with aura BMC Med 2004 2 3 10.1186/1741-7015-2-3 15053827"/>
   <result pre="Amato S et al. Metabolic and genetic risk factors for" exact="migraine" post="in children Cephalalgia 2006 26 731 737 10.1111/j.1468-2982.2006.01107.x 16686913"/>
   <result pre="Yang M He M et al. MTHFR C677T polymorphism and" exact="migraine" post="risk: a meta-analysis J Neurol Sci 2014 336 68"/>
   <result pre="al. lack of association between the MTHFR C677T variant and" exact="migraine" post="with Aura in an older population: could selective survival"/>
   <result pre="G et al. Efficacy of folic acid in children with" exact="migraine" post="hyperhomocysteinemia and MTHFR polymorphisms Headache 2007 47 1342 1344"/>
   <result pre="Sutherland M, et al Effects of dietary folate intake on" exact="migraine" post="disability and frequencyHeadache 2015 55 301 309 12. Ferrara"/>
   <result pre="Ferrara D Russo R Thrombophilic gene mutations in children with" exact="migraine" post="Hematology 2012 17 115 117 10.1179/102453312X13221316478010 22664050 13. Kaur"/>
   <result pre="A Pandey AK Singh. Association of MTHFR gene polymorphisms with" exact="migraine" post="in north Indian population Neurol Sci 2018 39 691"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6131682/results/search/disease/results.xml">
   <result pre=": Correction Correction to: Hormonal contraceptives and risk of ischemic" exact="stroke" post="in women with migraine: a consensus statement from the"/>
   <result pre="noticed that they incorrectly reported the Absolute risk of ischemic" exact="stroke" post="in women aged 20 to 44 years in relation"/>
   <result pre="years in relation to the use of hormonal contraception and" exact="migraine" post="status due to a miscalculation. They apologize for this"/>
   <result pre="in this correction. Table 4 (Revised) Absolute risk of ischemic" exact="stroke" post="in women aged 20 to 44 years in relation"/>
   <result pre="years in relation to the use of hormonal contraception and" exact="migraine" post="status No migraine Migraine with aura Migraine without aura"/>
   <result pre="to the use of hormonal contraception and migraine status No" exact="migraine" post="Migraine with aura Migraine without aura Without hormonal contraception"/>
   <result pre="4.0/100,000 With hormonal contraception 6.3/100,000 14.5/100,000 10.0/100,000 Considering women with" exact="migraine" post="with aura, the risk of ischemic stroke in those"/>
   <result pre="Considering women with migraine with aura, the risk of ischemic" exact="stroke" post="in those young women who do not use HC"/>
   <result pre="use HC is 14.5 /100,000 per year Considering women with" exact="migraine" post="without aura, the risk of ischemic stroke in those"/>
   <result pre="Considering women with migraine without aura, the risk of ischemic" exact="stroke" post="in those young women who do not use HC"/>
   <result pre="Sacco S et al. Hormonal contraceptives and risk of ischemic" exact="stroke" post="in women with migraine: a consensus statement from the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6144833/results/search/disease/results.xml">
   <result pre="cause of disability worldwide. The first magnetic resonance imaging (MRI)" exact="migraine" post="study was reported in 1995,[ 1] with many subsequent"/>
   <result pre="study was reported in 1995,[ 1] with many subsequent MRI" exact="migraine" post="studies appearing after the development of structural brain and"/>
   <result pre="a key role in the diagnosis, evaluation, and understanding of" exact="migraine" post="neuromechanisms. Published MRI migraine studies have provided detailed information"/>
   <result pre="the diagnosis, evaluation, and understanding of migraine neuromechanisms. Published MRI" exact="migraine" post="studies have provided detailed information about migraines. The current"/>
   <result pre="is a literature analysis investigating the citation links of MRI" exact="migraine" post="research. The search strategy assessed brain changes studied using"/>
   <result pre="2 Rocca MA, et al. Brain gray matter changes in" exact="migraine" post="patients with T2-visible lesions – A 3-T MRI study."/>
   <result pre="reveals hyperexcitability of the temporal pole in interictal and Ictal" exact="migraine" post="states. Cereb Cortex 2011;21:435-48 29 LCS: Local citation score."/>
   <result pre="documents LCR 1 Bhaskar S, et al. Recent progress in" exact="migraine" post="pathophysiology: Role of cortical spreading depression and magnetic resonance"/>
   <result pre="Neural Plast 2015;2015:205985 23 5 Evans RW. Diagnostic testing for" exact="migraine" post="and other primary headaches. Neurol Clin 2009;27:393-415 18 6"/>
   <result pre="From neuroimaging to clinical setting: What have we learned from" exact="migraine" post="pain? Neurol Sci 2012;33:S95-7 13 10 Gelfand AA, et"/>
   <result pre="A graph analysis using the backward method demonstrated that MRI" exact="migraine" post="studies were classified into two subdivisions: (1) migraine as"/>
   <result pre="that MRI migraine studies were classified into two subdivisions: (1)" exact="migraine" post="as a risk factor for subclinical brain lesions from"/>
   <result pre="(2) gray matter structural changes over the whole brain in" exact="migraine" post="from an MRI perspective [ Figure 1a]. Based on"/>
   <result pre="perspective [ Figure 1a]. Based on the forward method, MRI" exact="migraine" post="studies were categorized into two branches: (1) migraines related"/>
   <result pre="The current research demonstrated that from 1995 to 2017, MRI" exact="migraine" post="studies evolved from conventional MRI visual observations to advanced"/>
   <result pre="neuroimaging. MRI and processing techniques improved the understanding of the" exact="migraine" post="brain. The current study referred to 840 MRI studies,"/>
   <result pre="3571 authors, proving that MRI plays a key role in" exact="migraine" post="research. All of the documents searched in this study"/>
   <result pre="For example, Kruit's study had the highest LCS, demonstrating that" exact="migraine" post="as a risk factor for subclinical brain lesions has"/>
   <result pre="role of cortical spreading depression to understand the pathophysiology of" exact="migraine" post="in future research. Based on Recs and the TLCS"/>
   <result pre="helpful in locating the key journals and institutions in MRI" exact="migraine" post="studies. The graph analysis provided valuable information for research"/>
   <result pre="The graph analysis provided valuable information for research on MRI" exact="migraine" post="studies. MRI studies from 1995 to 2017 were classified"/>
   <result pre="the whole brain using advanced MRI techniques (voxel-based morphometry) in" exact="migraine" post="patients with[ 2] or without[ 3] T2-visible white matter"/>
   <result pre="due to the lack of diagnostic evidence. In clinical practice," exact="migraine" post="patients commonly undergo computed tomography (CT) examinations, and normal"/>
   <result pre="resolution and subclinical brain lesions can be clearly observed. Therefore," exact="migraine" post="patients should undergo MRI examinations, which might answer the"/>
   <result pre="future research. In conclusion, the literature analysis herein assessed MRI" exact="migraine" post="studies. Future research should focus on multimodal MRI migraine"/>
   <result pre="MRI migraine studies. Future research should focus on multimodal MRI" exact="migraine" post="studies to elucidate if migraines increase the risk of"/>
   <result pre="Lorenzetti A Sina C Bernasconi V Magnetic resonance imaging in" exact="migraine" post="and tension-type headache Headache 1995 35 264 8 7775189"/>
   <result pre="P Bernasconi L et al. Brain gray matter changes in" exact="migraine" post="patients with T2-visible lesions: A 3-T MRI study Stroke"/>
   <result pre="activity and corresponding brain circuit changes during resting state in" exact="migraine" post="without aura NMR Biomed 2013 26 1051 8 doi:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6160635/results/search/disease/results.xml">
   <result pre="sleep quality and intensity of headache between school-age children with" exact="migraine" post="as well as tension headache and healthy children. Materials"/>
   <result pre="and linear regression tests. Results Approximately, 45.5% of children with" exact="migraine" post="and 37.9% of them with tension headache had experienced"/>
   <result pre="between mean scores of headache intensity and sleep quality in" exact="migraine" post="group ( P&amp;lt;0.05). There was a significant difference in"/>
   <result pre="quality among three groups ( P&amp;lt;0.001). Conclusion The children with" exact="migraine" post="experienced more unsuitable sleep in duration of severe headache."/>
   <result pre="between intensity of headache and sleep problem of children with" exact="migraine" post="and tension headache is important to improve treatment strategies"/>
   <result pre="reported in childhood and adolescence&quot; ( 1). Prevalence range of" exact="migraine" post="in the pediatric population is 3.3%-21.4% and it increases"/>
   <result pre="increases from childhood to adolescence ( 2). &quot;The prevalence of" exact="migraine" post="headache was 12.3% (95% CI: 10.2–14.4) and tension-type headache"/>
   <result pre="impact on quality of life and reduced efficiency in children," exact="migraine" post="and tension headaches are considered as two fundamental problems"/>
   <result pre="in social life of children ( 5). However, children with" exact="migraine" post="headache have worse consequences, especially in terms of quality"/>
   <result pre="quality of life and school attendance, compared to those without" exact="migraine" post="( 6). Migraine headache in most cases is accompanied"/>
   <result pre="on personal performance, social and educational situation ( 8). Besides," exact="migraine" post="and tension headaches have adverse effects on sleep quality"/>
   <result pre="prolonged sleep can favor the onset of headache, in particular," exact="migraine" post="attack in many cases, and especially in children ("/>
   <result pre="of sleep problems ( 9). Sleep difficulties in children with" exact="migraine" post="and tension headaches when they suffer from severe headache"/>
   <result pre="similar results. A significant relationship between insomnia and tension and" exact="migraine" post="headaches is reported ( 12, 13), and patients with"/>
   <result pre="migraine headaches is reported ( 12, 13), and patients with" exact="migraine" post="had high midnight insomnia, sleepwalking and sleep disorders overnight"/>
   <result pre="low pain threshold ( 14). Almost 50% of people with" exact="migraine" post="headache had insomnia, 38% slept less than six hours"/>
   <result pre="per night and 50% of patients had sleep disturbances during" exact="migraine" post="headache attacks. Moreover, children with tension headaches in the"/>
   <result pre="little energy ( 15). Total sleep time in children with" exact="migraine" post="and tension headaches are lower than those have no"/>
   <result pre="Insomnia is a common complaint in children with tension and" exact="migraine" post="headaches ( 16). Because of the differences in the"/>
   <result pre="differences in the duration, frequency, and intensity of pain in" exact="migraine" post="and tension headaches, effect of it on sleep quality"/>
   <result pre="the quality of sleep and headaches between school-age children with" exact="migraine" post="well as tension headaches and healthy children. Material &amp;amp;"/>
   <result pre="divided into three equal groups as follows: 66 patients with" exact="migraine" post="headache, 66 participants with tension headache and 66 healthy"/>
   <result pre="( k - 1 ) = 0.3 2 Children with" exact="migraine" post="and tension headaches based on inclusion criteria were selected"/>
   <result pre="the hospital at the time of the study; diagnosis of" exact="migraine" post="and tension headaches by a neurologist (history and physical"/>
   <result pre="neurologist (history and physical and neurological examination, diagnostic criteria for" exact="migraine" post="and criteria for tension and chronic daily headaches; a"/>
   <result pre="criteria for tension and chronic daily headaches; a history of" exact="migraine" post="and tension headaches at least four months; experienced at"/>
   <result pre="at least four months; experienced at least two attacks of" exact="migraine" post="or tension-type headaches during last months; lack of other"/>
   <result pre="type of drug use, duration of drug use, history of" exact="migraine" post="in the family, parent level of education, the job"/>
   <result pre="of the study subjects. Results The majority of subjects with" exact="migraine" post="(57.6%), tension headache (60.6%) and healthy groups (45.5%) were"/>
   <result pre="did not consume any medication (84.8%). In both groups with" exact="migraine" post="and tension headache, the incidence of headache attacks at"/>
   <result pre="more than at night. Moreover, in 66% of children with" exact="migraine" post="headache, there was a positive history of headache in"/>
   <result pre="mean hours of sleep at night were 6.75±1.31 h in" exact="migraine" post="group, 7.7± 1.27 h in the tension headache group"/>
   <result pre="on Post Hoc test, the sleep quality in children with" exact="migraine" post="was lower than in other two groups ( Table"/>
   <result pre="of sleep quality subscales belongs to daytime sleepiness subscale in" exact="migraine" post="group (14.33 ± 3.59) and then in tension headache"/>
   <result pre="P&amp;lt; 0.05). The findings in relation to the intensity of" exact="migraine" post="headache showed that 45.5% of children with migraine and"/>
   <result pre="intensity of migraine headache showed that 45.5% of children with" exact="migraine" post="and 37.9% of them with tension headache had experienced"/>
   <result pre="relationship between mean scores of intensity and sleep quality in" exact="migraine" post="group ( P&amp;lt;0.05). In other words, in children with"/>
   <result pre="migraine group ( P&amp;lt;0.05). In other words, in children with" exact="migraine" post="headache, the sleep quality was decreased due to severe"/>
   <result pre="severe headaches ( Table 3). Sleep quality of children in" exact="migraine" post="group was significant related with onset and duration of"/>
   <result pre="duration of headache, type and dosage of medication, history of" exact="migraine" post="headaches in the family, amount of sleep during day"/>
   <result pre="headache attack ( P&amp;lt;0.05) ( Table 4). Discussion Children with" exact="migraine" post="headache experienced more sleep disturbances than those with tension"/>
   <result pre="tension headache and healthy children. Sleep quality in children with" exact="migraine" post="headache was lower particularly when they experienced severe headaches."/>
   <result pre="migraines aged 5-15 yr old. Sleep quality in children with" exact="migraine" post="was lower than that of healthy children ( 26)."/>
   <result pre="clinical studies published to date reported sleep complaints among 1283" exact="migraine" post="patients presenting for headache treatment ( 27). In contrast,"/>
   <result pre="Tension 0.203 P= 0.041 Table 4 Liner Regression result in" exact="migraine" post="group Variable Beta In S. E. T P-value Constant"/>
   <result pre="T P-value Constant 61.085 0.579 105.381 .000 v Length of" exact="migraine" post="disease (month) 0.008 0.008 0.991 0.322 Duration of headache"/>
   <result pre="headache attack (year) -0.455 0.056 8.048 .000 * History of" exact="migraine" post="in the family 0.203 0.222 0.915 0.36 * Amount"/>
   <result pre="quality Significant in P&amp;lt; 0.001 Among adolescents and children with" exact="migraine" post="and tension-type headache, insomnia is the most common sleep"/>
   <result pre="of sleep problems happened more frequent among school-age children with" exact="migraine" post="compared with tension headache and healthy children. However, daytime"/>
   <result pre="sleepiness was the common sleep complaint among the children with" exact="migraine" post="and tension headache. Similar to the present study, the"/>
   <result pre="study, the sleep problems were more frequent among school-aged with" exact="migraine" post="compared with non-migraine and no headache groups ( 30)."/>
   <result pre="relationship between sleep quality and pain intensity in children with" exact="migraine" post="and tension headaches, inconsistent with another study ( 31)."/>
   <result pre="important factors of sleep disorders in children and adolescents with" exact="migraine" post="aged from 10 to 18 yr old ( 32)."/>
   <result pre="controlling for child demographics, we found that the months of" exact="migraine" post="disease and duration of headache, type and dosage of"/>
   <result pre="duration of headache, type and dosage of medication, history of" exact="migraine" post="headaches in the family, amount of sleep during day"/>
   <result pre="of first headache predicted the sleep quality of children in" exact="migraine" post="group. The duration of headache attacks was one of"/>
   <result pre="and anxiety symptom severity in a group of children with" exact="epilepsy" post="and related factors Turk Psikiyatri Derg 2006 17 3"/>
   <result pre="165 72 17004168 3 Fallahzadeh H Alihaydari M Prevalence of" exact="migraine" post="and tension-type headache among school children in Yazd, Iran"/>
   <result pre="Saip S et al. One-year prevalence and the impact of" exact="migraine" post="and tension-type headache in Turkey: A nationwide home-based study"/>
   <result pre="economic burden associated with chronic daily headache, focusing on chronic" exact="migraine" post="with or without medication overuse: a systematic review Cephalalgia"/>
   <result pre="Comorbidities of sleep disorders in childhood and adolescence: focus on" exact="migraine" post="Nat Sci Sleep 2013 5 77 85 23788845 11"/>
   <result pre="Comprehensive assessment of the relative frequency of sleep disorders in" exact="migraine" post="and non-migraine in 6-to-14 year-old children Iran J Child"/>
   <result pre="N A case-control study on excessive daytime sleepiness in chronic" exact="migraine" post="Sleep Med 2013 14 3 278 281 23317931 26"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6167431/results/search/disease/results.xml">
   <result pre="and topiramate (TPM), initially developed as antiepileptics, are approved for" exact="migraine" post="prophylaxis in adults but not children. The differences in"/>
   <result pre="in their antimigraine mechanism(s) by age remain unclear. Methods: A" exact="migraine" post="model induced by intra-cisternal ( i.c.) capsaicin instillation in"/>
   <result pre="by the irritant capsaicin triggered trigeminovascular system (TGVS) activation mimicking" exact="migraine" post="condition, which were assessed peripherally by the depletion of"/>
   <result pre="results suggest VPA exerted peripheral inhibition in adult, but central" exact="suppression" post="in pediatric migraine-rats. In contrast, TPM involves both central"/>
   <result pre="In contrast, TPM involves both central and peripheral inhibition of" exact="migraine" post="with an optimal therapeutic window in both ages. These"/>
   <result pre="anti-migraine drugs in the future. valproic acid topiramate age difference" exact="migraine" post="CGRP Funding National Taiwan University Hospital 10.13039/501100005762 NTUH 101-M1999"/>
   <result pre="table-count: equation-count: ref-count: page-count: word-count: Introduction As compared with adult" exact="migraine" post="(12–17%) ( Stewart et al., 1994; Wang, 2003), pediatric"/>
   <result pre="migraine (12–17%) ( Stewart et al., 1994; Wang, 2003), pediatric" exact="migraine" post="is characterized by more bilateral involvement, shorter duration, less"/>
   <result pre="processing and cerebrovascular regulation, also plays a pivotal role in" exact="migraine" post="pathophysiology ( Lance et al., 1983). Activation of trigeminal"/>
   <result pre="antimigraine drugs ( Durham and Russo, 1999). In a rat" exact="migraine" post="model induced by intra-cisternal ( i.c.) instillation of capsaicin,"/>
   <result pre="Valproic acid (VPA) and topiramate (TPM), both clinically effective in" exact="migraine" post="prophylaxis were used to validate this animal model. Both"/>
   <result pre="their neuronal stabilizing effects. The hypothesis of cortical hyperexcitability in" exact="migraine" post="pathogenesis has led to a great number of large,"/>
   <result pre="why only a few AEDs have a good efficacy in" exact="migraine" post="prophylaxis. To stabilize the hyperexcitability in the cortex may"/>
   <result pre="be the only mechanism for those effective epileptic drugs in" exact="migraine" post="prophylaxis. The stabilization of TGVS activity, in terms of"/>
   <result pre="are approved by the Food and Drug Administration (FDA) for" exact="migraine" post="prevention in adults and recently TPM was approved in"/>
   <result pre="migraine, but not VPA. However, their off-label use for pediatric" exact="migraine" post="is a common practice. VPA is a GABA transaminase"/>
   <result pre="sinus-evoked firing of TCC neurons in a cat model of" exact="migraine" post="( Storer and Goadsby, 2004), attenuated neurogenic dural vasodilation"/>
   <result pre="of these two drugs on the same animal model of" exact="migraine" post="induced by i.c. capsaicin instillation ( Fan et al.,"/>
   <result pre="access to food and water. Intra-Cisternal Instillation of Capsaicin The" exact="migraine" post="model induced by i.c. instillation of capsaicin is similar"/>
   <result pre="mainly peripheral inhibition of TGVS in adult rats, whereas central" exact="suppression" post="of TCC in pediatrics. VPA at high dose, 100"/>
   <result pre="30 mg/kg, in both central and peripheral responsiveness in this" exact="migraine" post="model. TPM Reduced c-Fos-ir TCC Neurons in Both Age"/>
   <result pre="drugs, are effective in suppressing central (TCC) or/and peripheral (TGVS)" exact="migraine" post="responses induced by capsaicin in both adult and pediatric"/>
   <result pre="inhibition of the TGVS in adults. For TPM, the central" exact="suppression" post="of c-Fos was significantly effective at higher dose (≥30"/>
   <result pre="dose. Interestingly, low-dose TPM is better than high-dose for peripheral" exact="suppression" post="in adult TG and pediatric dura while high-dose TPM"/>
   <result pre="and pediatric dura while high-dose TPM is better in central" exact="suppression" post="at the TCC of both age groups. There may"/>
   <result pre="Migraine Intravenous VPA is clinically effective for abortive therapy of" exact="migraine" post="headaches in adults and children ( Kinze et al.,"/>
   <result pre="et al., 2005). It has been studied and used for" exact="migraine" post="prevention with success ( Linde et al., 2013). VPA"/>
   <result pre="sodium/calcium neuronal channels that inhibit the excitatory process seen in" exact="migraine" post="headaches ( Cutrer et al., 1997). In the same"/>
   <result pre="headaches ( Cutrer et al., 1997). In the same capsaicin-induced" exact="migraine" post="model in adult guinea pigs, VPA suppressed the elevated"/>
   <result pre="includes TNC and upper cervical spinal cord, and the central" exact="suppression" post="by VPA in adult rats is not significant. Different"/>
   <result pre="cervical spinal cord) toward the VPA treatment in i.c. capsaicin-induced" exact="migraine" post="model. As for the age-dependent differences, a better central"/>
   <result pre="TNC neuronal activation via GABA A receptors, whether VPA treats" exact="migraine" post="is mediated by CGRP remains unclear. VPA treatments had"/>
   <result pre="ganglia (DRG) and improve the generalized hyperalgesia resulting from induced" exact="endometriosis" post="( Zhao et al., 2011). This study with capsaicin-induced"/>
   <result pre="endometriosis ( Zhao et al., 2011). This study with capsaicin-induced" exact="migraine" post="model first provides direct evidence that VPA inhibited CGRP"/>
   <result pre="crucial in regulating CGRP expression and release in relation to" exact="migraine" post="pathogenesis ( Thalakoti et al., 2007). Hayasaki et al."/>
   <result pre="It warrants further study to clarify the mechanism of central" exact="suppression" post="by TPM in migraine. In human, it was reported"/>
   <result pre="at low doses of TPM in both peripheral effects, the" exact="suppression" post="of TG CGRP and the rescue of dural CGRP"/>
   <result pre="These results suggest an optimal dose window of TPM for" exact="migraine" post="therapy, namely 30 mg/kg in this study, which is"/>
   <result pre="both VPA and TPM are effective in central or/and peripheral" exact="suppression" post="of capsaicin activation in both adult and pediatric rats."/>
   <result pre="These results validate that this capsaicin-induced animal model can mimic" exact="migraine" post="clinically. The antimigraine responsiveness to VPA and TPM are"/>
   <result pre="different in both pediatric and adult animals. VPA involved central" exact="suppression" post="of TCC in the pediatric rat, in contrast to"/>
   <result pre="their anti-migraine effect in pediatric and adult rat model of" exact="migraine" post="induced by i.c. instillation of capsaicin, via central and"/>
   <result pre="of sexual difference, with association with age-difference, in responsiveness toward" exact="migraine" post="therapy. Author Contributions PH and P-CF designed and conducted"/>
   <result pre="Abu-Arefeh I. Russell G. ( 1994). Prevalence of headache and" exact="migraine" post="in schoolchildren. BMJ 309 765– 769. 10.1136/bmj.309.6957.765 7950559 Akerman"/>
   <result pre="inhibits cortical spreading depression in rat and cat: impact in" exact="migraine" post="aura. Neuroreport 16 1383– 1387. 16056144 Akerman S. Goadsby"/>
   <result pre="Mahfelati F. ( 2005). Sodium valproate versus propranolol in paediatric" exact="migraine" post="prophylaxis. Eur. J. Paediatr. Neurol. 9 333– 338. 10.1016/j.ejpn.2005.05.004"/>
   <result pre="Damigos D. Mavreas V. ( 2009). Anticonvulsant drugs for pediatric" exact="migraine" post="prevention: an evidence-based review. Eur. J. Pain 13 893–"/>
   <result pre="D. W. Schmitt J. et al. ( 2004). Topiramate for" exact="migraine" post="prevention: a randomized controlled trial. JAMA 291 965– 973."/>
   <result pre="Moskowitz M. A. ( 1997). Possible mechanisms of valproate in" exact="migraine" post="prophylaxis. Cephalalgia 17 93– 100. 10.1046/j.1468-2982.1997.1702093.x 9137844 Cutrer F."/>
   <result pre="Different trigemino-vascular responsiveness between adolescent and adult rats in a" exact="migraine" post="model. Cephalalgia 32 979– 990. 10.1177/0333102412455710 22843221 Fan P."/>
   <result pre="M. et al. ( 2001). Valproic acid is effective in" exact="migraine" post="prophylaxis at low serum levels: a prospective open-label study."/>
   <result pre="A. I. Guo Y. ( 2017). Is topiramate effective for" exact="migraine" post="prevention in patients less than 18 years of age?"/>
   <result pre="a combination of the two) for the prophylaxis of episodic" exact="migraine" post="in adults. Cochrane Database Syst. Rev. 6: CD010611. 10.1002/14651858.CD010611"/>
   <result pre="N. et al. ( 2012). Canadian Headache Society guideline for" exact="migraine" post="prophylaxis. Can. J. Neurol. Sci. 39(2 Suppl. 2), S1–"/>
   <result pre="Jacobs D. collab: Migr-001 Study Group. ( 2004). Topiramate in" exact="migraine" post="prevention: results of a large controlled trial. Arch. Neurol."/>
   <result pre="al. ( 2007). Neuron-glia signaling in trigeminal ganglion: implications for" exact="migraine" post="pathology. Headache 47 1008– 1023;discussio n1024– 1005. 17635592 Tsai"/>
   <result pre="1381. 10.1177/0883073808318547 19073842 Wang S. J. ( 2003). Epidemiology of" exact="migraine" post="and other types of headache in Asia. Curr. Neurol."/>
   <result pre="K. D. Lu S. R. ( 2005). Rising prevalence of" exact="migraine" post="in Taiwanese adolescents aged 13-15 years. Cephalalgia 25 433–"/>
   <result pre="ectopic endometrial implants and alleviates generalized hyperalgesia in experimentally induced" exact="endometriosis" post="in rats. Reprod. Sci. 18 28– 45. 10.1177/1933719110381928 20884991"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6169122/results/search/disease/results.xml">
   <result pre="Migraine headache without aura is the most common type of" exact="migraine" post="especially among pediatric patients. It has always been a"/>
   <result pre="pediatric patients. It has always been a great challenge of" exact="migraine" post="diagnosis using quantitative electroencephalography measurements through feature classification. It"/>
   <result pre="beta) and for all wave bands combined. Results: The highest" exact="migraine" post="detection accuracy of 93% was obtained utilizing Welch’s method"/>
   <result pre="and Burg-AR method and classifiers like support vector machine, for" exact="migraine" post="detection is not a new subject [ 6, 7],"/>
   <result pre="the efficacy of different classification methods is a novelty for" exact="migraine" post="detection, which can absolutely aid migraine computer-aided diagnosis and"/>
   <result pre="is a novelty for migraine detection, which can absolutely aid" exact="migraine" post="computer-aided diagnosis and follow up. In this research, EEG"/>
   <result pre="all 4 combinations were compared to obtain best combination of" exact="migraine" post="detection accuracy. Materials and Methods Data acquisition EEG recording"/>
   <result pre="(12.7 ± 3.12 years, mean ± standard deviation) diagnosed with" exact="migraine" post="without aura, based on ICHD3 criteria of headache disorders,"/>
   <result pre="healthy subjects (7 males and 12 females) in terms of" exact="migraine" post="or any other headache disorder, also aged between 8"/>
   <result pre="feature extraction and classification method in computer aided diagnosis of" exact="migraine" post="without aura has very little amount of background of"/>
   <result pre="O2 are the most decisive ones in EEG-based diagnosis of" exact="migraine" post="having a maximum of 88.4% diagnostic accuracy which is"/>
   <result pre="effort which makes this research distinct from previous efforts in" exact="migraine" post="EEG classification. Besides, this work has some practical limitations."/>
   <result pre="the future. Besides, although this study focuses on pediatric EEG" exact="migraine" post="classification, further efforts in this field could include EEG"/>
   <result pre="could include EEG from adult migraineurs. In sum, analyzing pediatric" exact="migraine" post="EEG using two feature extraction tools and two classification"/>
   <result pre="[ PMC Free Article] 15145989 3 Hedges TR Jr Pediatric" exact="migraine" post="Am J Ophthalmol 1983 95 844 5 6859200 4"/>
   <result pre="Tuncel D Alkan A Classification of multi-channel EEG signals for" exact="migraine" post="detection Biomedical Research 2016 27 743 8 7 Bellotti"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6182488/results/search/disease/results.xml">
   <result pre="8.9 years [range, 1–18 years]; 165 females). Majority had functional" exact="constipation" post="(35.4%), followed by functional abdominal pain (30.6%), irritable bowel"/>
   <result pre="had functional constipation (35.4%), followed by functional abdominal pain (30.6%)," exact="irritable bowel syndrome" post="(17.0%), functional dyspepsia (12.6%), functional nausea (3.4%) and abdominal"/>
   <result pre="by functional abdominal pain (30.6%), irritable bowel syndrome (17.0%), functional" exact="dyspepsia" post="(12.6%), functional nausea (3.4%) and abdominal migraine (1.0%). Regression"/>
   <result pre="syndrome (17.0%), functional dyspepsia (12.6%), functional nausea (3.4%) and abdominal" exact="migraine" post="(1.0%). Regression model found that only significant factor associated"/>
   <result pre="vomiting) at diagnosis. Furthermore, in pain symptoms (functional abdominal pain," exact="irritable bowel syndrome," post="dyspepsia) no treatment positively correlated with pain improvement. Conclusion"/>
   <result pre="male and 165 (56.1%) were female. Most prevalent FGIDs were" exact="constipation" post="and functional abdominal pain (FAP), distribution is presented in"/>
   <result pre="complaint or the type of functional disorder. Thus, patients with" exact="constipation" post="received laxatives and fibers, while pain predominant disorders (FAP"/>
   <result pre="received laxatives and fibers, while pain predominant disorders (FAP and" exact="irritable bowel syndrome" post="[IBS]) received different type of therapy. In patients with"/>
   <result pre="syndrome [IBS]) received different type of therapy. In patients with" exact="dyspepsia" post="majority received ranitidine. Due to differences in the symptoms"/>
   <result pre="at diagnosis ( p=0.763). In pain disorders (FAP, IBS, functional" exact="dyspepsia" post="and abdominal migraine) no treatment positively correlated with pain"/>
   <result pre="migraine. Similarly, certain European studies estimated the prevalence of functional" exact="constipation" post="to be highest, ranging from 6% to even 52.7%,"/>
   <result pre="by FAP with frequency of 10.2–53.8%, IBS of 10.3–43%, functional" exact="dyspepsia" post="of 7–13.4%, and abdominal migraine of 4–23% [ 10"/>
   <result pre="10.2–53.8%, IBS of 10.3–43%, functional dyspepsia of 7–13.4%, and abdominal" exact="migraine" post="of 4–23% [ 10 11 12 13]. Comparison and"/>
   <result pre="(e.g,. presence of persistent vomiting in patients suffering from abdominal" exact="migraine" post="or functional nausea) or could be otherwise explained in"/>
   <result pre="due to feeling of discomfort in patients suffering from functional" exact="dyspepsia" post="and IBS). Although alarm symptoms still hold a great"/>
   <result pre="for pediatric patients exists solely for those suffering from functional" exact="constipation" post="[ 17]. To this day, incomplete pathophysiological understanding of"/>
   <result pre="and improvement of symptoms was the highest amongst children with" exact="constipation" post="(83.7%) and the lowest rates were found amongst children"/>
   <result pre="the lowest rates were found amongst children diagnosed with abdominal" exact="migraine" post="(33.3%). No significant difference in improvement of symptoms between"/>
   <result pre="drive diagnostic costs for children with functional abdominal pain and" exact="irritable bowel syndrome" post="in primary or tertiary care Pediatrics 2009 123 758"/>
   <result pre="MW Nurko S et al. Evaluation and treatment of functional" exact="constipation" post="in infants and children: evidence-based recommendations from ESPGHAN and"/>
   <result pre="the different functional gastrointestinal disorders. FAP: functional abdominal pain, IBS:" exact="irritable bowel syndrome." post="Table 1 Differences in Age and Anthropometrics between Diagnoses"/>
   <result pre="median (range) or numer (%). FAP: functional abdominal pain, IBS:" exact="irritable bowel syndrome." post="*Post-hoc analysis (Bonferroni) not significant for intergroup analysis. Table"/>
   <result pre="are presented as numer (%). FAP: functional abdominal pain, IBS:" exact="irritable bowel syndrome." post="Table 3 Prognostic Factors for Symptom Improvement Binary logistic"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6190553/results/search/disease/results.xml">
   <result pre="pmcid: 6190553 1149 doi: 10.1186/s12883-018-1149-6 : Research Article Comorbidity of" exact="migraine" post="with ADHD in adults Hansen Thomas Folkmann +45 22825659"/>
   <result pre="or otherwise healthy population. Assessing the comorbidity between ADHD and" exact="migraine" post="may clarify the etiopathology of both diseases. Thus, the"/>
   <result pre="of both diseases. Thus, the objective is to assess whether" exact="migraine" post="(with and without visual disturbances) and ADHD are comorbid"/>
   <result pre="Study ( N = 26,456, age 18–65, 46% female) were assessed for" exact="migraine" post="and ADHD using the ASRS ver 1.1 clinically validated"/>
   <result pre="using the ASRS ver 1.1 clinically validated questionnaire and self-reported" exact="migraine" post="in a cross-sectional study. Logistic regression was used to"/>
   <result pre="study. Logistic regression was used to examine the comorbidity between" exact="migraine" post="and ADHD, and their associated endophenotypes. Results Migraine was"/>
   <result pre="increasing with age and female sex. Post-hoc analysis showed that" exact="migraine" post="with visual disturbance was generally associated with a marginally"/>
   <result pre="the association with ADHD was most prominent for participants with" exact="migraine" post="with visual disturbances. Future studies will elucidate which genetic"/>
   <result pre="[ 1– 3]. According to the World Health Organization (WHO)," exact="migraine" post="is the sixth most disabling disease in the world"/>
   <result pre="medication [ 5]. There are two major endophenotypes in migraine:" exact="migraine" post="with or without aura. Aura is a sensory disturbance,"/>
   <result pre="seen as visual disturbances (99%) with a subsequent headache or" exact="migraine" post="[ 6, 7]. Attention deficit and hyperactivity disorder (ADHD)"/>
   <result pre="adverse reactions [ 10, 11]. It is well established that" exact="migraine" post="is comorbid with psychiatric traits, in particular depressive and"/>
   <result pre="migraine is comorbid with psychiatric traits, in particular depressive and" exact="bipolar disorder" post="[ 12, 13], and that the comorbidity is partly"/>
   <result pre="by shared genetics [ 14]. More recently, the comorbidity between" exact="migraine" post="and ADHD has also been assessed [ 15– 18]."/>
   <result pre="study of ADHD ( n = 572/675) found an increased prevalence of" exact="migraine" post="when compared to community controls [ 16], and subsequently"/>
   <result pre="al. reported a higher prevalence of ADHD among children with" exact="migraine" post="(5–12 years) than for non-headache individuals in a pediatric"/>
   <result pre="et al. adult study, there is a positive association between" exact="migraine" post="and ADHD with odds-ratio of 1.3 [ 16, 20]."/>
   <result pre="of adults (age 18–65 years), we test the hypothesis that" exact="migraine" post="is comorbid with ADHD in 26,456 participants using clinically"/>
   <result pre="DBDS and subsequently answers a digital tablet-based questionnaire including a" exact="migraine" post="(two questions) and an ADHD (18 questions) module. In"/>
   <result pre="years, IQR = 30–52 years) (Wilcoxon test, P-value = 3.7e-8). Importantly, the frequency of" exact="migraine" post="in individuals excluded because of missing information in the"/>
   <result pre="was similar to that of the study population 4.2%. The" exact="migraine" post="module The presence of migraine was evaluated by two"/>
   <result pre="the study population 4.2%. The migraine module The presence of" exact="migraine" post="was evaluated by two questions from the population screening"/>
   <result pre="evaluated by two questions from the population screening questionnaire for" exact="migraine" post="(SQM). The participants were asked two questions (&quot;Have you"/>
   <result pre="to either of the two questions were considered to have" exact="migraine" post="and are referred as migraine cases in this study."/>
   <result pre="questions were considered to have migraine and are referred as" exact="migraine" post="cases in this study. Individuals with missing information or"/>
   <result pre="has previously been shown to identify 93% of those with" exact="migraine" post="with aura and 75% of those with migraine without"/>
   <result pre="those with migraine with aura and 75% of those with" exact="migraine" post="without aura in a Danish setting [ 23]. Using"/>
   <result pre="continuous variables. Differences in distributions between participants with and without" exact="migraine" post="and ADHD symptoms were analyzed using Fisher’s exact test"/>
   <result pre="used). Logistic regression was used to analyze the association between" exact="migraine" post="and ADHD (dichotomous variables) in the study population, adjusting"/>
   <result pre="age, sex, and the interaction between sex and age, with" exact="migraine" post="as the dependent variable. We used a logistic regression"/>
   <result pre="logistic regression model with a binary outcome of either migraine," exact="migraine" post="with visual disturbance, or migraine without visual disturbances. We"/>
   <result pre="binary outcome of either migraine, migraine with visual disturbance, or" exact="migraine" post="without visual disturbances. We did not include sampling weights,"/>
   <result pre="years) from the DBDS, of whom 24.2% screened positive for" exact="migraine" post="(median age: 42 years, IQR = 31–51 years, female-to-male ratio: 1:0.6),"/>
   <result pre="IQR = 25–40 years, female-to-male ratio: 1:1.4), and 0.90% reported having both" exact="migraine" post="and ADHD (median age: 31 years, IQR = 24–41 years, male-to-female"/>
   <result pre="in the age and sex distributions for participants with either" exact="migraine" post="or ADHD (Wilcoxon test and chi-square exact, P &amp;lt; 1e-15 and"/>
   <result pre="Characteristics of the study population ( N = 26,456) with respect to" exact="migraine" post="and ADHD symptoms N Description Female (% e) Male"/>
   <result pre="and ADHD 137 (57.6) 101 238 (0.90) &amp;lt; 0.001 aSymptoms of" exact="migraine" post="was assessed by the SQM [ 19], b ADHD"/>
   <result pre="phenotype status on the right There was an association between" exact="migraine" post="and ADHD symptoms with OR = 1.81 (95CI%: 1.53–2.12, P = 1.4e-14) including"/>
   <result pre="questionnaire (data not shown). The highest risk was found for" exact="migraine" post="with visual disturbances and ADHD symptoms (OR = 2.05, 95CI%: 1.55–2.68,"/>
   <result pre="Age:Gender (Male) 0.99 0.98–1.00 &amp;lt; 0.001 Multivariable Logistic regression analysis of" exact="migraine" post="and migraine with and without visual disturbances, subsequent stratified"/>
   <result pre="0.99 0.98–1.00 &amp;lt; 0.001 Multivariable Logistic regression analysis of migraine and" exact="migraine" post="with and without visual disturbances, subsequent stratified on gender."/>
   <result pre="0,69 0,50-0,94 0.021 a Reference is age &amp;lt; 30 The association between" exact="migraine" post="and ADHD symptoms was statistically significant irrespective of the"/>
   <result pre="score. The same results were observed for ADHD symptoms and" exact="migraine" post="with visual disturbances (Fig. 2b), however; no association was"/>
   <result pre="visual disturbances (Fig. 2b), however; no association was detected for" exact="migraine" post="without visual disturbances with ASRS scores below 10 and"/>
   <result pre="was associated with both ADHD endophenotypes (inattention and hyperactivity-impulsivity), with" exact="migraine" post="with visual disturbances showing a marginally larger effect than"/>
   <result pre="migraine with visual disturbances showing a marginally larger effect than" exact="migraine" post="without visual disturbances, notably with overlapping confidence intervals (Fig."/>
   <result pre="odds ratio of 1. The three graphs display migraine, and" exact="migraine" post="with and without visual disturbances. The Y-axis displays the"/>
   <result pre="and two ADHD endophenotypes Discussion We address the comorbidity of" exact="migraine" post="and ADHD symptoms in a healthy population of 29,489"/>
   <result pre="The regression model clearly shows that being male protects against" exact="migraine" post="and increased age is further protective as seen in"/>
   <result pre="migraineurs experiencing visual disturbances; however, no differences in association with" exact="migraine" post="were seen for the two ADHD endophenotypes (inattention and"/>
   <result pre="study significantly supplements the sparse literature regarding the comorbidity between" exact="migraine" post="and ADHD in adults by using a large, healthy"/>
   <result pre="individuals who have not been exposed to chronic treatment for" exact="migraine" post="or for ADHD. It supports the meta-analysis by Salem"/>
   <result pre="the entire Norwegian population [ 17]. Thus, the comorbidity between" exact="migraine" post="and ADHD seems present both in and out of"/>
   <result pre="contradicting. It has previously been suggested that the co-occurrence of" exact="migraine" post="and ADHD originates from common pathophysiological mechanisms potentially related"/>
   <result pre="[ 16, 17, 31]. This arises because many of the" exact="migraine" post="symptoms, including prodromal symptoms, can be provoked with dopamine"/>
   <result pre="by Antilla et al., showing a significant genetic correlation between" exact="migraine" post="and ADHD [ 37]. Interestingly, major depressive disorder was"/>
   <result pre="significant genetic correlation between migraine and ADHD [ 37]. Interestingly," exact="major depressive disorder" post="was also found to significantly correlate with both migraine"/>
   <result pre="depressive disorder was also found to significantly correlate with both" exact="migraine" post="and ADHD suggesting that common pleiotropic factors exist. The"/>
   <result pre="suggesting that common pleiotropic factors exist. The observed prevalence of" exact="migraine" post="and ADHD (34.7%) was higher than reported by Fasmer"/>
   <result pre="Despite these methodological differences, we found the prevalence of self-reported" exact="migraine" post="and ADHD symptoms in males (24% vs. 23%) to"/>
   <result pre="et al. [ 16]. We found that the comorbidity between" exact="migraine" post="and ADHD was most prevalent among participants peaking at"/>
   <result pre="(Fig. 1). This could imply that the manifestations of comorbid" exact="migraine" post="and ADHD occur rather late in life when compared"/>
   <result pre="in general, or that ADHD symptoms mask the presence of" exact="migraine" post="in the younger participants. Similar results have been reported"/>
   <result pre="suggesting that ADHD among adolescents may have no comorbidity with" exact="migraine" post="and thus having a distinct etiopathology or, as previously"/>
   <result pre="etiopathology or, as previously mentioned, there is a masking of" exact="migraine" post="symptoms in young individuals with ADHD. The notion of"/>
   <result pre="not detect a specific association between any ADHD endophenotypes and" exact="migraine" post="which is congruent with previous reports for children, e.g.,"/>
   <result pre="are not permitted to donate blood [ 40]. Participants reporting" exact="migraine" post="preceded by visual disturbances (migraine with visual aura symptoms)"/>
   <result pre="spreading is suggested as the pathophysiology of aura symptoms in" exact="migraine" post="patients [ 41], however, there are no published studies"/>
   <result pre="is the large sample size and that chronic treatment of" exact="migraine" post="and ADHD do not influence the results, e.g., treatment-induced"/>
   <result pre="migraine and ADHD do not influence the results, e.g., treatment-induced" exact="migraine" post="attacks. Furthermore, we used validated questionnaires to assess migraine"/>
   <result pre="treatment-induced migraine attacks. Furthermore, we used validated questionnaires to assess" exact="migraine" post="and ADHD symptoms. In accordance with Danish clinical guides"/>
   <result pre="to assess causality. Conclusion We demonstrate a significant corbobidity between" exact="migraine" post="and ADHD in adults, and this is most prominent"/>
   <result pre="in adults, and this is most prominent for participants with" exact="migraine" post="with visual disturbances. These results contribute to the understanding"/>
   <result pre="to the understanding of genetic correlation seen between ADHD and" exact="migraine" post="and seeds future studies that will elucidate which genetic"/>
   <result pre="migraine-ADHD comorbidity. Article highlights This study examined the association between" exact="migraine" post="and ADHD in a large adult population There is"/>
   <result pre="a large adult population There is a strong association between" exact="migraine" post="and ADHD (odds ratio = 1.8, 95% CI = 1.5–2.1) The association between"/>
   <result pre="migraine and ADHD (odds ratio = 1.8, 95% CI = 1.5–2.1) The association between" exact="migraine" post="and ADHD seems strongest for individuals with visual disturbances"/>
   <result pre="IQR Interquartile range OR Odss Ratio SQM Screening questionnaire for" exact="migraine" post="WHO World Health Organization We acknowledge the Danish blood"/>
   <result pre="References References 1. Dahlof C Linde M One-year prevalence of" exact="migraine" post="in Sweden: a population-based study in adults Cephalalgia 2001"/>
   <result pre="Zwart JA Vatten L Stovner LJ Bovim G Prevalence of" exact="migraine" post="and non-migrainous headache--head-HUNT, a large population-based study Cephalalgia 2000"/>
   <result pre="P Olesen J Prevalence and sex-ratio of the subtypes of" exact="migraine" post="Int J Epidemiol 1995 24 612 618 10.1093/ije/24.3.612 7672904"/>
   <result pre="7. Russell MB Olesen J A nosographic analysis of the" exact="migraine" post="aura in a general population Brain 1996 119 355"/>
   <result pre="Patten S Williams J Becker W Wiebe S Comorbidity of" exact="migraine" post="and psychiatric disorders--a national population-based study Headache 2008 48"/>
   <result pre="Madden PA Martin NG Nyholt DR Shared genetic factors underlie" exact="migraine" post="and depression Twin Res Hum Genet 2016 19 341"/>
   <result pre="16. Fasmer OB Halmoy A Oedegaard KJ Haavik J Adult" exact="attention deficit hyperactivity disorder" post="is associated with migraine headaches Eur Arch Psychiatry Clin"/>
   <result pre="Haavik J Adult attention deficit hyperactivity disorder is associated with" exact="migraine" post="headaches Eur Arch Psychiatry Clin Neurosci 2011 261 595"/>
   <result pre="Lund A Dilsaver SC Hundal O Oedegaard KJ Comorbidity of" exact="migraine" post="with ADHD J Atten Disord 2012 16 339 345"/>
   <result pre="Arruda R, Guidetti V, Bigal ME. ADHD is comorbid to" exact="migraine" post="in childhood: a population-based study. J Atten Disord. 2017:1087054717710767."/>
   <result pre="Gervil M Ulrich V Olesen J Russell MB Screening for" exact="migraine" post="in the general population: validation of a simple questionnaire"/>
   <result pre="Jorgensen SL Dalsgaard S Bilenberg N Danish standardization of the" exact="attention deficit hyperactivity disorder" post="rating scale Ugeskr Laeger 2009 171 1500 1504 19419629"/>
   <result pre="133 156 10.1016/S0163-7258(99)00029-7 10596903 32. Fasmer OB The prevalence of" exact="migraine" post="in patients with bipolar and unipolar affective disorders Cephalalgia"/>
   <result pre="Clinical characteristics of patients with major affective disorders and comorbid" exact="migraine" post="World J Biol Psychiatry 2001 2 149 155 10.3109/15622970109026801"/>
   <result pre="Fort GG Cervantes P Prevalence, clinical correlates, and treatment of" exact="migraine" post="in bipolar disorder Headache 2003 43 940 949 10.1046/j.1526-4610.2003.03184.x"/>
   <result pre="Cervantes P Prevalence, clinical correlates, and treatment of migraine in" exact="bipolar disorder" post="Headache 2003 43 940 949 10.1046/j.1526-4610.2003.03184.x 14511270 35. Breslau"/>
   <result pre="14511270 35. Breslau N Merikangas K Bowden CL Comorbidity of" exact="migraine" post="and major affective disorders Neurology 1994 44 S17 S22"/>
   <result pre="Colvin A Comorbidity of psychiatric and behavioral disorders in pediatric" exact="migraine" post="Headache 2005 45 590 596 10.1111/j.1526-4610.2005.05113.x 15953278 40. Millstein"/>
   <result pre="2 159 166 10.1177/108705479700200302 41. Lauritzen M Pathophysiology of the" exact="migraine" post="aura. The spreading depression theory Brain 1994 117 Pt"/>
   <result pre="Visual function and ocular features in children and adolescents with" exact="attention deficit hyperactivity disorder," post="with and without treatment with stimulants Eye (Lond) 2007"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6190892/results/search/disease/results.xml">
   <result pre="precise description of them is often very difficult. pseudotumor cerebri" exact="idiopathic intracranial hypertension" post="papilloedema children adolescents ICHD-2 ICHD-3 fig-count: table-count: equation-count: ref-count:"/>
   <result pre="known as pseudotumor cerebri syndrome (PTC), is a rare pediatric" exact="neurological disorder" post="( 1). It is characterized by increased intracranial pressure"/>
   <result pre="to venous system, endocrinological or metabolic causes, chronic inflammation, and" exact="obesity" post="(in pre- and post-pubertal females) ( 8– 15). The"/>
   <result pre="performed lumbar puncture 2. Diagnosis of pseudotumor cerebri syndrome without" exact="papilledema" post="In the absence of papilledema, a diagnosis of pseudotumor"/>
   <result pre="unilateral or bilateral abducens nerve palsy In the absence of" exact="papilledema" post="or sixth nerve palsy, a diagnosis of pseudotumor cerebri"/>
   <result pre="common. Therefore, in most cases, headache characteristics are similar to" exact="migraine" post="and tension-type headache ( 17). If retrobulbar pain and"/>
   <result pre="International Headache Society (IHS) in the second international classification of" exact="migraine" post="disorders in 2004 and subsequently modified in 2018 in"/>
   <result pre="headache secondary to IIH can be really overlapping to chronic" exact="migraine" post="or chronic tension-type headache. Indeed, these disorders often coexist"/>
   <result pre="and in all patients still complaining of headaches after treatment," exact="migraine" post="should be considered in order to use appropriate treatment"/>
   <result pre="10.1212/WNL.0b013e3182a55f17 23966248 4. Kesler A Gadoth N . Epidemiology of" exact="idiopathic intracranial hypertension" post="in Israel. J Neuroophthalmol. ( 2001) 21: 12– 4."/>
   <result pre="Pepper IM Hickman SJ . The incidence and prevalence of" exact="idiopathic intracranial hypertension" post="in Sheffield, UK . Eur J Neurol. ( 2011)"/>
   <result pre="11425944 14. Bateman GA Smith RL Siddique SH . Idiopathic" exact="hydrocephalus" post="in children and idiopathic intracranial hypertension in adults: two"/>
   <result pre="Smith RL Siddique SH . Idiopathic hydrocephalus in children and" exact="idiopathic intracranial hypertension" post="in adults: two manifestations of the same pathophysiological process?"/>
   <result pre="S Sharrack B Woodroofe N . Cytokines and chemokines in" exact="idiopathic intracranial hypertension." post="Headache ( 2009) 49: 282– 5. 10.1111/j.1526-4610.2008.001329.x 19222599 16."/>
   <result pre="6. 3156890 17. Wall M . The headache profile of" exact="idiopathic intracranial hypertension." post="Cephalalgia ( 1990) 10: 331– 5. 10.1046/j.1468-2982.1990.1006331.x 2289234 18."/>
   <result pre="Calver D Lin JP . Visual failure without headache in" exact="idiopathic intracranial hypertension." post="Arch Dis Child. ( 2005) 90: 206– 10. 10.1136/adc.2003.039305"/>
   <result pre="Zavari A Nabovvati M . Migraine headache in patients with" exact="idiopathic intracranial hypertension." post="Neurol Int. ( 2017) 9: 7280. 10.4081/ni.2017.7280 29071043"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6213149/results/search/disease/results.xml">
   <result pre="of this systematic review was to explore the relationship between" exact="coeliac disease" post="(CD) and headache. The objectives were to establish the"/>
   <result pre="such patients may symptomatically benefit from a GFD. gluten sensitivity" exact="coeliac disease" post="gluten free diet migraine headache 1. Introduction Gluten-related disorders"/>
   <result pre="from a GFD. gluten sensitivity coeliac disease gluten free diet" exact="migraine" post="headache 1. Introduction Gluten-related disorders (GRDs) represent a diverse"/>
   <result pre="best-recognised GRD and it is characterized by a small bowel" exact="enteropathy" post="occurring in genetically susceptible individuals whilst exposed to the"/>
   <result pre="absence of GI symptoms. The most well-known neurological GRDs are" exact="cerebellar ataxia" post="[ 4] and peripheral neuropathy [ 5], however clear"/>
   <result pre="most well-known neurological GRDs are cerebellar ataxia [ 4] and" exact="peripheral neuropathy" post="[ 5], however clear links between GS/CD and epilepsy"/>
   <result pre="well-known neurological GRDs are cerebellar ataxia [ 4] and peripheral" exact="neuropathy" post="[ 5], however clear links between GS/CD and epilepsy"/>
   <result pre="peripheral neuropathy [ 5], however clear links between GS/CD and" exact="epilepsy" post="[ 3], various movement disorders [ 6], and headaches"/>
   <result pre="subjects were diagnosed with idiopathic headache and gluten sensitivity or" exact="coeliac disease." post="The study subjects were human. The study contained original"/>
   <result pre="investigated the prevalence of CD amongst 90 adults with idiopathic" exact="migraine" post="when compared to blood donor controls. Of them, 4.4%"/>
   <result pre="the prevalence of CD was not higher in patients with" exact="migraine" post="relative to the control group [ 38], the other"/>
   <result pre="described in the literature were adults, with no evidence of" exact="epilepsy" post="or epileptiform activity on EEG. By contrast, all three"/>
   <result pre="calcifications in the context of CD have been associated with" exact="epilepsy" post="[ 3], which is most commonly known as &quot;epilepsy"/>
   <result pre="signs of central nervous system dysfunction, most of which had" exact="cerebellar ataxia," post="ten patients (four with CD and six with GS)"/>
   <result pre="al. conducted a case-controlled study of four adult patients with" exact="migraine" post="and newly diagnosed CD and five control patients with"/>
   <result pre="free period. All four patients that were affected by both" exact="migraine" post="and CD showed evident abnormalities in regional cerebral blood"/>
   <result pre="interhemispheric asymmetries of cortical regional blood flow in the five" exact="migraine" post="patients without evidence of CD. 3.4.4. Positron Emission Tomography"/>
   <result pre="of boys (three and four years old) who presented with" exact="idiopathic intracranial hypertension" post="(IIH). Diagnostic work-up revealed low serum vitamin A titres"/>
   <result pre="and intracranial hypertension should be investigated further. 3.7. Gluten–Encephalopathy Gluten" exact="encephalopathy" post="is a term that is used to describe a"/>
   <result pre="the pooled mean prevalence of GS in children with idiopathic" exact="migraine" post="is 6.2% (95% CI 2.6–14.1%). Figure 7 demonstrates that"/>
   <result pre="CI 2.6–14.1%). Figure 7 demonstrates that the odds of having" exact="migraine" post="are higher (trend for statistical significance) in children with"/>
   <result pre="with a significant reduction of pain in patients with gluten" exact="neuropathy" post="and an improvement of their quality of life ["/>
   <result pre="D.R. Symptomatic suspected gluten exposure is common among patients with" exact="coeliac disease" post="on a gluten-free diet Aliment. Pharmacol. Ther. 2016 44"/>
   <result pre="I.D. Griffiths P.D. Hoggard N. Should we be &quot;nervous&quot; about" exact="coeliac disease?" post="Brain abnormalities in patients with coeliac disease referred for"/>
   <result pre="be &quot;nervous&quot; about coeliac disease? Brain abnormalities in patients with" exact="coeliac disease" post="referred for neurological opinion J. Neurol. Neurosurg. Psychiatry 2012"/>
   <result pre="Tennyson C.A. Green M.W. Babyatsky M.W. Green P.H. Prevalence of" exact="migraine" post="in patients with celiac disease and inflammatory bowel disease"/>
   <result pre="and psychosocial problems in a paediatric cohort of patients with" exact="coeliac disease" post="Acta Paediatr. 2013 102 e325 e328 10.1111/apa.12239 23521635 25."/>
   <result pre="P. de Roux C. Christides C. Weiller P.J. Migraine and" exact="coeliac disease" post="Headache 1998 38 627 628 10.1046/j.1526-4610.1998.3808627.x 11398309 32. Mingomataj"/>
   <result pre="E. Bakiri A. Xhixha F. Hyso E. Ibranji A. Gliadin" exact="allergy" post="manifested with chronic urticaria, headache and amenorrhea BMJ Case"/>
   <result pre="due to carnitine deficiency in an adult patient with gluten" exact="enteropathy" post="Clin. Neurol. Neurosurg. 2006 108 794 797 10.1016/j.clineuro.2005.10.012 16325996"/>
   <result pre="10.1111/j.1526-4610.2005.00253_2.x 16178961 36. Benjilali L. Zahlane M. Essaadouni L. A" exact="migraine" post="as initial presentation of celiac disease Rev. Neurol. 2012"/>
   <result pre="Candelli M. Gasbarrini A. Pola P. Gasbarrini A. Association between" exact="migraine" post="and Celiac disease: Results from a preliminary case-control and"/>
   <result pre="M.H. A comparative study of celiac disease in children with" exact="migraine" post="headache and a normal control group Turk. J. Gastroenterol."/>
   <result pre="M. Calacoci M. Soriani S. Celiac disease in children with" exact="migraine" post="Pediatrics 2004 114 1371 10.1542/peds.2004-1337 15520135 40. Nenna R."/>
   <result pre="F. Erol I. Canan O. Cemil T. Increased risk for" exact="coeliac disease" post="in paediatric patients with migraine Cephalalgia 2008 28 945"/>
   <result pre="T. Increased risk for coeliac disease in paediatric patients with" exact="migraine" post="Cephalalgia 2008 28 945 949 10.1111/j.1468-2982.2008.01630.x 18624809 42. Rani"/>
   <result pre="Selby W.S. Loblay R.H. Dietary analysis in symptomatic patients with" exact="coeliac disease" post="on a gluten-free diet: The role of trace amounts"/>
   <result pre="D. Grünewald R.A. Hadjivassiliou M. Transglutaminase 6 antibodies in gluten" exact="neuropathy" post="Dig. Liver Dis. 2017 49 1196 1200 10.1016/j.dld.2017.08.019 28886934"/>
   <result pre="Figure 2 Pooled mean prevalence of headache in adults with" exact="coeliac disease." post="Figure 3 Meta-analysis results as illustrated in the forest"/>
   <result pre="plot regarding the odds of having headache in adults with" exact="coeliac disease" post="compared to controls. Figure 4 Pooled mean prevalence of"/>
   <result pre="Figure 4 Pooled mean prevalence of headache in children with" exact="coeliac disease." post="Figure 5 Pooled mean prevalence of coeliac disease in"/>
   <result pre="children with coeliac disease. Figure 5 Pooled mean prevalence of" exact="coeliac disease" post="in children with idiopathic headache. Figure 6 Pooled mean"/>
   <result pre="illustrated in the forest plot regarding the odds of having" exact="migraine" post="in children with coeliac disease compared to controls. nutrients-10-01445-t001_Table"/>
   <result pre="plot regarding the odds of having migraine in children with" exact="coeliac disease" post="compared to controls. nutrients-10-01445-t001_Table 1 Table 1 Descriptive of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6258963/results/search/disease/results.xml">
   <result pre="magnetic resonance imaging, 20 showed positive findings. The diagnoses were" exact="migraine" post="(including probable migraine) in 34, tension-type headache in 5,"/>
   <result pre="ng/dL; and triiodothyronine, 1.03 ng/mL. She was diagnosed with subclinical" exact="hypothyroidism" post="by a pediatric endocrinologist. Otherwise, there were no unusual"/>
   <result pre="the results showed that 3 patients had congenital malformation, including" exact="moyamoya disease," post="Chiari 1 malformation, and cavernous malformation. Two patients (10.0%)"/>
   <result pre="variation rather than congenital malformation. Additionally, 15 patients (75.0%) had" exact="sinusitis" post="or otomastoiditis. Some patients had more than 1 positive"/>
   <result pre="3 of 53 children had unusual results including subdural hematoma," exact="cavernous hemangioma," post="or subarachnoid cyst. They also suggested that 17% of"/>
   <result pre="spike/sharp (7.5%), or paroxysmal slow wave (1.9%). In this study," exact="sinusitis" post="was considered as the cause of secondary headache, and"/>
   <result pre="4- to 6-year-old patients had migraine, and the prevalence of" exact="migraine" post="increased gradually with age as in other studies ["/>
   <result pre="this study similarly showed a tendency for the percentage of" exact="migraine" post="or probable migraine to be the highest, followed by"/>
   <result pre="showed a tendency for the percentage of migraine or probable" exact="migraine" post="to be the highest, followed by tension-type headache. In"/>
   <result pre="controversy and that early intervention might improve the prognosis of" exact="migraine" post="and tensiontype headache in children and adolescents. The present"/>
   <result pre="2006 26 162 71 16426271 5 Sillanpaa M Prevalence of" exact="migraine" post="and other headache in Finnish children starting school Headache"/>
   <result pre="303 17376106 9 Hernandez-Latorre MA Roig M Natural history of" exact="migraine" post="in childhood Cephalalgia 2000 20 573 9 11075841 10"/>
   <result pre="Mavromichalis I Anagnostopoulos D Metaxas N Papanastassiou E Prevalence of" exact="migraine" post="in schoolchildren and some clinical comparisons between migraine with"/>
   <result pre="Prevalence of migraine in schoolchildren and some clinical comparisons between" exact="migraine" post="with and without aura Headache 1999 39 728 36"/>
   <result pre="Eidlitz-Markus T Gorali O Haimi-Cohen Y Zeharia A Symptoms of" exact="migraine" post="in the paediatric population by age group Cephalalgia 2008"/>
   <result pre="Karwautz A et al. Clinical features, classification and prognosis of" exact="migraine" post="and tension-type headache in children and adolescents: a long-term"/>
   <result pre="(%) Diagnosis  Primary headache 39 (26.7)   Migraine 16 (11)   Probable" exact="migraine" post="18 (12.3)   Tension-type headache 5 (3.4)  Secondary headache 18"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6277635/results/search/disease/results.xml">
   <result pre="for these approaches. cognitive-behavioral therapy biofeedback mindfulness transcranial magnetic stimulation" exact="migraine" post="tension-type headache disability depression fig-count: table-count: equation-count: ref-count: page-count:"/>
   <result pre="( 4), and several drugs used in the prevention of" exact="migraine" post="in adults are commonly prescribed for children ( 5,"/>
   <result pre="abstracts, or key-words provided: headache OR &quot;tension type headache&quot; OR" exact="migraine" post="OR &quot;chronic tension type headache&quot; OR &quot;chronic migraine&quot; OR"/>
   <result pre="further had to focus on the primary headache disorders of" exact="migraine" post="or tension-type headache. Studies drawing from populations that included"/>
   <result pre="the other three trials evaluated CBT in patients with episodic" exact="migraine" post="( 13), chronic migraine ( 12) or &quot;chronic headache&quot;"/>
   <result pre="evaluated CBT in patients with episodic migraine ( 13), chronic" exact="migraine" post="( 12) or &quot;chronic headache&quot; ( 14) alone. In"/>
   <result pre="study, Sharma et al. ( 16) enrolled adolescents diagnosed as" exact="migraine" post="or tension type headache, with comorbid anxiety disorders, who"/>
   <result pre="the efficacy of single-pulse TMS in adolescents diagnosed with chronic" exact="migraine" post="( 21). During the 12-week treatment period participants were"/>
   <result pre="literature suggests that children and adolescents with headache disorders, and" exact="migraine" post="in particular, may have higher symptoms of anxiety and"/>
   <result pre="certain scale items overlap some symptoms of depression, anxiety, and" exact="migraine" post="(e.g., mood and energy level changes may incur in"/>
   <result pre="changes may incur in both premonitory and post-drome phases of" exact="migraine" post="and are core symptoms of anxiety and depression). Taken"/>
   <result pre="mantle that is purported to be a physiological substrate of" exact="migraine" post="with aura ( 38). It is not associated with"/>
   <result pre="4. Winner P Pearlman E Linder S . Topiramate for" exact="migraine" post="prevention in children: a randomized, double-blind, placebo-controlled trial ."/>
   <result pre=". Revised French guidelines for the diagnosis and management of" exact="migraine" post="in adults and children . J Headache Pain ("/>
   <result pre="B Magis D Coppola G . Noninvasive neurostimulation methods for" exact="migraine" post="therapy: the available evidence. Cephalalgia ( 2016) 36: 1170–"/>
   <result pre="M. et al. Cognitive behavioral therapy plus amitriptyline for chronic" exact="migraine" post="in children and adolescents: a randomized clinical trial ."/>
   <result pre="Hershey AD Allen JR. et al. Headstrong intervention for pediatric" exact="migraine" post="headache: a randomized clinical trial. J Headache Pain ("/>
   <result pre="I Goadsby PJ Gelfand AA . Transcranial magnetic stimulation for" exact="migraine" post="prevention in adolescents: a pilot open label study ."/>
   <result pre="AA . Psychological and behavioral issues in the management of" exact="migraine" post="in children and adolescents . Curr Pain Headache Rep."/>
   <result pre="517– 24. 10.1111/head.13002 28028801 38. Tfelt-Hansen PC . History of" exact="migraine" post="with aura and cortical spreading depression from 1941 and"/>
   <result pre="et al. Single-pulse transcranial magnetic stimulation for acute treatment of" exact="migraine" post="with aura: a randomised, double-blind, parallel-group, sham-controlled trial ."/>
   <result pre="J Bhoi SK . High-rate repetitive transcranial magnetic stimulation in" exact="migraine" post="prophylaxis: a randomized, placebo-controlled study . J Neurol. ("/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6287109/results/search/disease/results.xml">
   <result pre="classification. mild traumatic brain injury (mTBI) epidemiology cognitive fatigue vestibular" exact="migraine" post="sleep fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction Concussions"/>
   <result pre="easily upset by bright light,&quot; as being associated with the" exact="migraine" post="profile. The presence of a severe, at-least-moderate, or at-least-mild-symptom"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6288497/results/search/disease/results.xml">
   <result pre=": Observational Study Association between functional abdominal pain disorders and" exact="asthma" post="in adolescents: A cross-sectional study Kumari Manori Vijaya [],"/>
   <result pre="use is non-commercial. Abstract AIM To find the association between" exact="asthma" post="and different types of functional abdominal pain disorders (FAPDs)"/>
   <result pre="the 1101 children included in the analysis, 157 (14.3%) had" exact="asthma" post="and 101 (9.2%) had at least one FAPDs. Of"/>
   <result pre="functional abdominal pain (FAP) (8.9% vs 3.3% in non-asthmatics), functional" exact="dyspepsia" post="(FD) (2.5% vs 0.7%), and abdominal migraine (AM) (3.2%"/>
   <result pre="in non-asthmatics), functional dyspepsia (FD) (2.5% vs 0.7%), and abdominal" exact="migraine" post="(AM) (3.2% vs 0.4%) were higher in those with"/>
   <result pre="migraine (AM) (3.2% vs 0.4%) were higher in those with" exact="asthma" post="( P &amp;lt; 0.05, multiple logistic regression analysis), but"/>
   <result pre="0.05, multiple logistic regression analysis), but not in those with" exact="irritable bowel syndrome" post="(4.5% vs 3.1%, P = 0.2). Severe abdominal pain"/>
   <result pre="related quality of life (HRQoL) were lower in those with" exact="asthma" post="and FAPDs ( P &amp;lt; 0.05, unpaired t-test). CONCLUSION"/>
   <result pre="AM, and FAP. HRQoL is significantly impaired in teenagers with" exact="asthma" post="and FAPDs. Health related quality of life Functional gastrointestinal"/>
   <result pre="A cross-sectional study was conducted to assess the association between" exact="asthma" post="and functional abdominal pain disorders (FAPDs) in teenagers. We"/>
   <result pre="(FAPDs) in teenagers. We observed a strong, independent association between" exact="asthma" post="and three types of FAPDs, namely, functional abdominal pain,"/>
   <result pre="of common underlying pathophysiology. However, no association was observed with" exact="irritable bowel syndrome." post="Most upper gastrointestinal symptoms were more common among asthmatics"/>
   <result pre="Health related quality of life was significantly decreased in both" exact="asthma" post="and FAPDs, indicating the significant impact of both disorders."/>
   <result pre="are four recognized types of FAPDs in children, namely, functional" exact="dyspepsia" post="(FD), irritable bowel syndrome (IBS), abdominal migraine (AM), and"/>
   <result pre="recognized types of FAPDs in children, namely, functional dyspepsia (FD)," exact="irritable bowel syndrome" post="(IBS), abdominal migraine (AM), and functional abdominal pain (FAP)["/>
   <result pre="children, namely, functional dyspepsia (FD), irritable bowel syndrome (IBS), abdominal" exact="migraine" post="(AM), and functional abdominal pain (FAP)[ 1]. It is"/>
   <result pre="300 million people worldwide. In children, the global prevalence of" exact="asthma" post="ranges from 0.8% to 32.6%[ 4]. Patho-physiology of asthma"/>
   <result pre="of asthma ranges from 0.8% to 32.6%[ 4]. Patho-physiology of" exact="asthma" post="involves complex immunological reactions, environmental triggers, smooth muscle dysfunction,"/>
   <result pre="muscle dysfunction, and psychological factors[ 5, 6]. Both FAPDs and" exact="asthma" post="are known to have significant repercussion on child health"/>
   <result pre="significant proportion of health budgets[ 9, 10]. The association between" exact="asthma" post="and FAPDs has been previously assessed only in IBS["/>
   <result pre="paediatric age groups. Exact reason for association between FAPDs and" exact="asthma" post="is not clear. However, smooth muscle dysfunction[ 14, 15]"/>
   <result pre="objective of this study was to evaluate the association between" exact="asthma" post="and different types of FAPDs in the paediatric population"/>
   <result pre="while filling the questionnaire. Identification of children with FAPDs or" exact="asthma" post="Types of FAPDs (IBS, FD, AM, and FAP) were"/>
   <result pre="moderate, and severe). Students reporting to have both physician diagnosed" exact="asthma" post="and wheezing during the previous 12 mo[ 20] were"/>
   <result pre="required for determining the prevalence of FAPDs and prevalence of" exact="asthma" post="was 672. Data from all schools were pooled for"/>
   <result pre="regression model was used to evaluate an independent association between" exact="asthma" post="and FAPDs. The association between asthma and severity of"/>
   <result pre="an independent association between asthma and FAPDs. The association between" exact="asthma" post="and severity of abdominal pain was assessed using binary"/>
   <result pre="of 0.8 years). In this study, the prevalence of current" exact="asthma" post="was 14.3%. One hundred and one adolescents had at"/>
   <result pre="(1%) had FD, and 9 (0.8%) had AM. Association between" exact="asthma" post="and FAPDs Of children with asthma, 19.1% had at"/>
   <result pre="FAPD. Logistic regression analysis showed a strong, independent association between" exact="asthma" post="and FAP, FD, and AM after adjusting for age"/>
   <result pre="sex (Table 1). There was also a significant association between" exact="asthma" post="and severity of abdominal pain (Table 2). Table 1"/>
   <result pre="Table 1 Prevalence of functional abdominal pain disorders according to" exact="asthma" post="( n = 1101) n (%) Disease category Asthmatics"/>
   <result pre="pain disorders. Table 2 Severity of abdominal pain according to" exact="asthma" post="( n = 1101) n (%) Abdominal pain severity"/>
   <result pre="Upper gastrointestinal symptoms which showed a significant association with bronchial" exact="asthma" post="were abdominal pain, bloating, nausea, and loss of appetite."/>
   <result pre="of appetite. However, lower gastrointestinal symptoms were not associated with" exact="asthma" post="(Table 3). Table 3 Prevalence of gastrointestinal symptoms among"/>
   <result pre="compared to controls (Table 4). Children with both FAPDs and" exact="asthma" post="had significantly lower quality of life than those with"/>
   <result pre="asthma had significantly lower quality of life than those with" exact="asthma" post="alone. Furthermore, children having FAPDs only had a higher"/>
   <result pre="impairment of the quality of life, compared to those with" exact="asthma" post="alone, but there was no significant difference between children"/>
   <result pre="Quality of life domain Children with FAPDs only Children with" exact="asthma" post="only Children with both asthma and FAPDs Controls mean"/>
   <result pre="with FAPDs only Children with asthma only Children with both" exact="asthma" post="and FAPDs Controls mean (SD) n = 70 mean"/>
   <result pre="the paediatric literature, we found a strong, independent association between" exact="asthma" post="and three different types of FAPDs, namely, FAP, FD,"/>
   <result pre="most of the studies have specifically studied the association between" exact="asthma" post="and patients with IBS only[ 11, 12, 23]. One"/>
   <result pre="12 years in Sweden. They found that the presence of" exact="asthma" post="during the first 2 years was significantly associated with"/>
   <result pre="origin at 12 years. They looked at the association between" exact="asthma" post="and non-specific abdominal pain, but did not attempt to"/>
   <result pre="FAPDs. In our study, the gastrointestinal symptoms independently associated with" exact="asthma" post="were abdominal pain, bloating, nausea, and loss of appetite."/>
   <result pre="studies found higher prevalence of gastrointestinal symptoms in patients with" exact="allergic rhinitis" post="and wheeze[ 28, 29]. In our study, the prevalence"/>
   <result pre="found higher prevalence of gastrointestinal symptoms in patients with allergic" exact="rhinitis" post="and wheeze[ 28, 29]. In our study, the prevalence"/>
   <result pre="criteria would have contributed to these differences. The prevalence of" exact="asthma" post="in this study is more than that previously reported"/>
   <result pre="Lankan adolescents aged 12-14 years. However, the prevalence rate of" exact="asthma" post="reported in this study is within the range reported"/>
   <result pre="and case definition used. We observed that adolescents with only" exact="asthma" post="or FAPDs together with adolescents suffering from both disease"/>
   <result pre="this is the first study which reported the impact of" exact="asthma" post="on quality of life among Sri Lankan adolescents. An"/>
   <result pre="life among Sri Lankan adolescents. An Australian study found that" exact="asthma" post="caused mild to moderate quality of life impairment among"/>
   <result pre="among adolescents with severe asthma[ 30]. Another study reported that" exact="asthma" post="impairs quality of life not only among asthmatic children"/>
   <result pre="diseases (FAPDs and asthma) had lower HRQoL than children with" exact="asthma" post="alone. This can be explained by the dual disease"/>
   <result pre="FAPDs had a lower total HRQoL score than adolescents with" exact="asthma" post="alone. Although asthma is a chronic condition similar to"/>
   <result pre="lower total HRQoL score than adolescents with asthma alone. Although" exact="asthma" post="is a chronic condition similar to FAPDs, the impact"/>
   <result pre="to the lower HRQoL in adolescents with FAPDs only. Why" exact="asthma" post="and FAPDs, two different disorders involving two different systems,"/>
   <result pre="6, 40]. These studies indicate the possibility of FAPDs and" exact="asthma" post="sharing the same immunological mechanisms and perhaps similar underlying"/>
   <result pre="(Rome III questionnaire for children and ISAAC tool to diagnose" exact="asthma" post="in children) in data collection, which were translated and"/>
   <result pre="and investigations of these children to confirm the diagnosis of" exact="asthma" post="and FAPDs. We could not perform lung function testing"/>
   <result pre="testing and bronchodilator reversibility test to confirm the diagnosis of" exact="asthma" post="and basic investigation to exclude organic pathologies causing abdominal"/>
   <result pre="effect on our conclusions. Identifying the association between FAPDs and" exact="asthma" post="has several implications. Both these disorders are very common"/>
   <result pre="between these two disorders as well as the association between" exact="asthma" post="and upper gastrointestinal symptoms to provide holistic clinical care"/>
   <result pre="is the first report of a strong independent association between" exact="asthma" post="and three different types of FAPDs, namely, FAP, FD,"/>
   <result pre="Upper gastrointestinal symptoms are significantly more common among children with" exact="asthma" post="than in non-asthmatics. Our findings suggest the possibility of"/>
   <result pre="HIGHLIGHTS Research background Both functional abdominal pain disorders (FAPDs) and" exact="asthma" post="are highly prevalent diseases among children and have a"/>
   <result pre="motivation Studies among adults have shown a potential association between" exact="irritable bowel syndrome" post="and bronchial asthma and suggested the possibility of common"/>
   <result pre="shown a potential association between irritable bowel syndrome and bronchial" exact="asthma" post="and suggested the possibility of common patho-physiology for both"/>
   <result pre="our study is to explore the association between FAPDs and" exact="asthma" post="in children and their impact on HRQoL. Research methods"/>
   <result pre="to diagnose FAPDs. Students reporting to have both physician diagnosed" exact="asthma" post="and wheezing during the previous year were categorized as"/>
   <result pre="1101 questionnaires were included in the final analysis. We found" exact="asthma" post="in 14.3% of children and at least one type"/>
   <result pre="The logistic regression analysis model showed an independent association between" exact="asthma" post="and functional abdominal pain (FAP), functional dyspepsia (FD), and"/>
   <result pre="independent association between asthma and functional abdominal pain (FAP), functional" exact="dyspepsia" post="(FD), and abdominal migraine (AM). Upper gastrointestinal symptoms such"/>
   <result pre="and functional abdominal pain (FAP), functional dyspepsia (FD), and abdominal" exact="migraine" post="(AM). Upper gastrointestinal symptoms such as abdominal pain, bloating,"/>
   <result pre="with asthma. Quality of life scores in both children with" exact="asthma" post="and those with FAPDs were lower when compared to"/>
   <result pre="normal children. Research conclusions We found a clear association between" exact="asthma" post="and three FAPDs, namely, FAP, FD, and AM, suggesting"/>
   <result pre="FAPDs, namely, FAP, FD, and AM, suggesting the possibility of" exact="asthma" post="and FAPDs sharing same pathophysiological mechanisms. Generalized smooth muscle"/>
   <result pre="Study Group Global variation in the prevalence and severity of" exact="asthma" post="symptoms: phase three of the International Study of Asthma"/>
   <result pre="Berger P The pivotal role of airway smooth muscle in" exact="asthma" post="pathophysiology J Allergy (Cairo) 2011 2011 742710 22220184 6"/>
   <result pre="Brightling CE et al. The cost of treating severe refractory" exact="asthma" post="in the UK: an economic analysis from the British"/>
   <result pre="Hoseini-Asl MK Rahmani AR Golshan M Mohamad-Zadeh Z Correlation between" exact="asthma" post="and irritable bowel syndrome in a general population in"/>
   <result pre="Rahmani AR Golshan M Mohamad-Zadeh Z Correlation between asthma and" exact="irritable bowel syndrome" post="in a general population in Iran in 2003 Respir"/>
   <result pre="A Respiratory symptoms and pulmonary functional changes in patients with" exact="irritable bowel syndrome" post="Am J Gastroenterol 2001 96 1511 1516 11374691 13"/>
   <result pre="B Emami MH Drooshi B Golshan M Airway resistance in" exact="irritable bowel syndrome" post="as measured by impulse oscillometry Indian J Gastroenterol 2006"/>
   <result pre="5 and granulocyte/macrophage colony-stimulating factor of intestinal mucosa in bronchial" exact="asthma" post="J Exp Med 1995 182 1897 1904 7500035 17"/>
   <result pre="CA Sandridge L Andre L Roberts CC Abdel-Rahman SM Mucosal" exact="eosinophilia" post="and response to H1/H2 antagonist and cromolyn therapy in"/>
   <result pre="and response to H1/H2 antagonist and cromolyn therapy in pediatric" exact="dyspepsia" post="Clin Pediatr (Phila) 2006 45 143 147 16528434 18"/>
   <result pre="et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in" exact="irritable bowel syndrome" post="Gastroenterology 2007 132 26 37 17241857 19 Walker LS"/>
   <result pre="Rajapaksa LC Weerasinghe A Genetic, familial and environmental correlates of" exact="asthma" post="among early adolescents in Sri Lanka: a case control"/>
   <result pre="Uz E Bozalan R Türkay C Yildirim Z Relationship between" exact="asthma" post="and irritable bowel syndrome: role of food allergy J"/>
   <result pre="Z Relationship between asthma and irritable bowel syndrome: role of" exact="food allergy" post="J Asthma 2006 43 773 775 17169830 24 Jones"/>
   <result pre="Relationship between asthma and irritable bowel syndrome: role of food" exact="allergy" post="J Asthma 2006 43 773 775 17169830 24 Jones"/>
   <result pre="De Angelis G Atherton DJ Gastrointestinal symptoms in patients with" exact="asthma" post="Arch Dis Child 2000 82 131 135 10648366 27"/>
   <result pre="Mortella S Falasca C Ciofetta G Poggi B Association of" exact="asthma" post="with extra-respiratory symptoms in schoolchildren: two cross-sectional studies 6"/>
   <result pre="JD Toro AA Evaluation of quality of life according to" exact="asthma" post="control and asthma severity in children and adolescents J"/>
   <result pre="Evaluation of quality of life according to asthma control and" exact="asthma" post="severity in children and adolescents J Bras Pneumol 2015"/>
   <result pre="gastric emptying and antral motility according to the subtypes of" exact="irritable bowel syndrome" post="in children J Pediatr Gastroenterol Nutr 2013 56 443"/>
   <result pre="425, e207 22273006 35 Hamid Q Tulic M Immunobiology of" exact="asthma" post="Annu Rev Physiol 2009 71 489 507 19575684 36"/>
   <result pre="Storskrubb T Harmsen WS Zinsmeister AR Agreus L Duodenal mastocytosis," exact="eosinophilia" post="and intraepithelial lymphocytosis as possible disease markers in the"/>
   <result pre="eosinophilia and intraepithelial lymphocytosis as possible disease markers in the" exact="irritable bowel syndrome" post="and functional dyspepsia Aliment Pharmacol Ther 2009 29 765"/>
   <result pre="possible disease markers in the irritable bowel syndrome and functional" exact="dyspepsia" post="Aliment Pharmacol Ther 2009 29 765 773 19183150 37"/>
   <result pre="in proximity to colonic nerves correlate with abdominal pain in" exact="irritable bowel syndrome" post="Gastroenterology 2004 126 693 702 14988823 38 Cremon C"/>
   <result pre="The role of the mast cell in the pathophysiology of" exact="asthma" post="J Allergy Clin Immunol 2006 117 1277 1284 16750987"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6293067/results/search/disease/results.xml">
   <result pre="or adaptations are made. file:EPI4-3-210.pdf Abstract Summary The treatment of" exact="epilepsy" post="is not limited to the achievement of a seizure‐free"/>
   <result pre="and anxiety disorders are the most frequent psychiatric comorbidities, whereas" exact="stroke" post="and migraine are among the more common neurologic comorbidities,"/>
   <result pre="disorders are the most frequent psychiatric comorbidities, whereas stroke and" exact="migraine" post="are among the more common neurologic comorbidities, migraine among"/>
   <result pre="stroke and migraine are among the more common neurologic comorbidities," exact="migraine" post="among the younger patients and stroke among the older"/>
   <result pre="more common neurologic comorbidities, migraine among the younger patients and" exact="stroke" post="among the older patients. Not only do these psychiatric"/>
   <result pre="bidirectional relation with these 2 neurologic disorders. Furthermore, depression and" exact="migraine" post="have been each associated with a more severe epilepsy"/>
   <result pre="and migraine have been each associated with a more severe" exact="epilepsy" post="course, whereas depression has been associated with a more"/>
   <result pre="depression has been associated with a more severe course of" exact="stroke" post="and migraines. The purpose of this article is to"/>
   <result pre="to review the clinical implications of the complex relations among" exact="epilepsy" post="and these 3 comorbid disorders, and to identify any"/>
   <result pre="and course of epilepsy. Stroke Migraine Major depressive episodes Treatment‐resistant" exact="epilepsy" post="fig-count: table-count: page-count: word-count: 1 Key Points Depression, migraine,"/>
   <result pre="fig-count: table-count: page-count: word-count: 1 Key Points Depression, migraine, and" exact="stroke" post="are common comorbidities of epilepsy with a bidirectional relation"/>
   <result pre="Key Points Depression, migraine, and stroke are common comorbidities of" exact="epilepsy" post="with a bidirectional relation among each of the entities"/>
   <result pre="a bidirectional relation among each of the entities Depression and" exact="migraine" post="are associated with a worse course of the seizure"/>
   <result pre="should be an integral part of the effective management of" exact="epilepsy" post="2 Comorbidities in epilepsy are those conditions that have"/>
   <result pre="part of the effective management of epilepsy 2 Comorbidities in" exact="epilepsy" post="are those conditions that have a higher prevalence in"/>
   <result pre="those conditions that have a higher prevalence in people with" exact="epilepsy" post="(PWE) than in the general population, 1 either because"/>
   <result pre="quality of life and the course and prognosis of the" exact="epilepsy" post="and neurologic comorbidities (NCs). 2, 3, 4, 5 Population‐based"/>
   <result pre="and migraines are 2 relatively common NCs in PWE, with" exact="migraine" post="being the most frequent among younger patients 3 and"/>
   <result pre="migraine being the most frequent among younger patients 3 and" exact="stroke" post="among the elderly. 4, 5 Indeed, 8–15% of PWE"/>
   <result pre="Indeed, 8–15% of PWE are reported to have migraines, whereas" exact="stroke" post="accounts for 30–50% of epilepsy after the age of"/>
   <result pre="reported to have migraines, whereas stroke accounts for 30–50% of" exact="epilepsy" post="after the age of 60. 3, 5 Two large"/>
   <result pre="population‐based studies found a two‐ to sevenfold higher prevalence of" exact="stroke" post="and migraine in PWE than in the general population."/>
   <result pre="found a two‐ to sevenfold higher prevalence of stroke and" exact="migraine" post="in PWE than in the general population. 5, 6,"/>
   <result pre="mood and anxiety disorders, are high among patients with primary" exact="migraine" post="and stroke. 8 Typically, in PWE, clinicians consider PCs"/>
   <result pre="a complication of NCs (e.g., stroke). Yet, the relation between" exact="epilepsy" post="and these PCs and NCs and the relation among"/>
   <result pre="are complex. First, a bidirectional relation has been identified between" exact="epilepsy" post="and several PCs, including mood and anxiety disorders, ADHD,"/>
   <result pre="In addition, a bidirectional relation has also been identified between" exact="epilepsy" post="on the one hand and migraine and stroke on"/>
   <result pre="also been identified between epilepsy on the one hand and" exact="migraine" post="and stroke on the other. 10, 13, 14 Third,"/>
   <result pre="identified between epilepsy on the one hand and migraine and" exact="stroke" post="on the other. 10, 13, 14 Third, a bidirectional"/>
   <result pre="has been reported between depression on the one hand and" exact="migraine" post="and stroke on the other. 15, 16 Thus, not"/>
   <result pre="reported between depression on the one hand and migraine and" exact="stroke" post="on the other. 15, 16 Thus, not only are"/>
   <result pre="of developing these NCs and PCs, but the existence of" exact="migraine" post="and stroke and/or primary mood, anxiety, ADHD, and psychotic"/>
   <result pre="these NCs and PCs, but the existence of migraine and" exact="stroke" post="and/or primary mood, anxiety, ADHD, and psychotic disorders increases"/>
   <result pre="may also have an impact on the course of the" exact="epilepsy" post="and neurologic disorders. Indeed, patients with a history of"/>
   <result pre="patients with a history of depression preceding the onset of" exact="epilepsy" post="have an increased risk of developing treatment‐resistant focal epilepsy."/>
   <result pre="of depression has been associated with a worse course of" exact="migraine" post="20 and stroke. 21 Thus, if depression is associated"/>
   <result pre="Thus, if depression is associated with a worse course of" exact="epilepsy" post="and of these 2 NCs, does depression in patients"/>
   <result pre="2 NCs, does depression in patients with primary migraines and" exact="stroke" post="increase even more their risk of developing epilepsy and"/>
   <result pre="migraines and stroke increase even more their risk of developing" exact="epilepsy" post="and its severity. The purpose of this article is"/>
   <result pre="this question. 2.1 Complex relation between common psychiatric comorbidities and" exact="epilepsy" post="2.2 Bidirectional relation between mood disorders and epilepsy Several"/>
   <result pre="comorbidities and epilepsy 2.2 Bidirectional relation between mood disorders and" exact="epilepsy" post="Several population‐based studies have suggested that primary depression increases"/>
   <result pre="have suggested that primary depression increases the risk of developing" exact="epilepsy" post="by twofold and suicidality by three‐ to fourfold, 9,"/>
   <result pre="three‐ to fourfold, 9, 19 and as indicated above, a" exact="mood disorder" post="preceding the onset of epilepsy has been associated with"/>
   <result pre="as indicated above, a mood disorder preceding the onset of" exact="epilepsy" post="has been associated with an increased risk of developing"/>
   <result pre="exists. The existence of common pathogenic mechanisms operant in both" exact="epilepsy" post="and mood disorders, has been suggested as the explanation"/>
   <result pre="relation among epilepsy, mood disorders, and common neurologic comorbidities of" exact="epilepsy" post="Migraine and stroke are 2 common neurologic comorbidities that"/>
   <result pre="mood disorders, and common neurologic comorbidities of epilepsy Migraine and" exact="stroke" post="are 2 common neurologic comorbidities that have a bidirectional"/>
   <result pre="2 common neurologic comorbidities that have a bidirectional relation with" exact="epilepsy" post="on the one hand and with depression on the"/>
   <result pre="and with depression on the other. 2.4 Bidirectional relation between" exact="migraine" post="and epilepsy The onset of migraines can precede, follow,"/>
   <result pre="depression on the other. 2.4 Bidirectional relation between migraine and" exact="epilepsy" post="The onset of migraines can precede, follow, or appear"/>
   <result pre="headaches, or can occur independently of seizures. The prevalence of" exact="epilepsy" post="among patients with migraine (PWM) ranges from 1 to"/>
   <result pre="independently of seizures. The prevalence of epilepsy among patients with" exact="migraine" post="(PWM) ranges from 1 to 17% (vs 0.5–1% in"/>
   <result pre="(vs 0.5–1% in the general population), whereas the prevalence of" exact="migraine" post="in PWE ranges from 8 to 15%. 3, 24"/>
   <result pre="population‐based study estimated the adjusted hazard ratio (aHR) of developing" exact="epilepsy" post="among 10,016 adults 20‐years‐old or older diagnosed with migraine"/>
   <result pre="developing epilepsy among 10,016 adults 20‐years‐old or older diagnosed with" exact="migraine" post="between 2000 and 2009 when compared to a control"/>
   <result pre="when compared to a control cohort of 40,064. In the" exact="migraine" post="cohort, the aHR was 1.85 (95% confidence interval [CI]"/>
   <result pre="1.85 (95% confidence interval [CI] 1.22–2.81). The incidence of developing" exact="epilepsy" post="was increased in patients aged 20–44 years, yielding an"/>
   <result pre="aHR of 2.14 (95% CI 1.24–3.68); the aHR for developing" exact="epilepsy" post="in female migraineurs was 2.04 (95% CI 1.20–3.48) and"/>
   <result pre="migraineurs 1.53 (95% CI 0.78–3.00). 25 The bidirectional relation between" exact="migraine" post="and epilepsy was suggested in a population‐based study done"/>
   <result pre="(95% CI 0.78–3.00). 25 The bidirectional relation between migraine and" exact="epilepsy" post="was suggested in a population‐based study done in Iceland"/>
   <result pre="included all children age 5‐ through 15‐years‐old with newly diagnosed" exact="epilepsy" post="or first unprovoked seizure from December 1995 through February"/>
   <result pre="from December 1995 through February 1999. 14 A history of" exact="migraine" post="was associated with a fourfold increased risk for developing"/>
   <result pre="migraine was associated with a fourfold increased risk for developing" exact="epilepsy" post="and a threefold higher risk of developing a first"/>
   <result pre="For example, in a follow‐up study of 59 PWE with" exact="migraine" post="and 56 without migraine, those with migraine had a"/>
   <result pre="59 PWE with migraine and 56 without migraine, those with" exact="migraine" post="had a significantly lower cumulative probability of being seizure‐free"/>
   <result pre="of being seizure‐free over 10 years compared with patients without" exact="migraine" post="(5% vs. 25%). 26 Furthermore, those patients with migraine"/>
   <result pre="without migraine (5% vs. 25%). 26 Furthermore, those patients with" exact="migraine" post="also had a seizure disorder of longer duration, a"/>
   <result pre="ATP1A2), which have also been involved in different types of" exact="epilepsy" post="and febrile seizures; neurotransmitter disturbances affecting serotonergic, dopaminergic, and"/>
   <result pre="positive photoparoxysmal responses on electroencephalography (EEG) recordings of patients with" exact="migraine" post="(in the absence of any history of clinical seizures)."/>
   <result pre="hyperexcitable state associated with auras explain the increased risk of" exact="epilepsy" post="in migraines with auras? This is a very attractive"/>
   <result pre="attractive hypothesis, given the lack of an increased risk of" exact="epilepsy" post="associated with migraines without auras. The increased incidence of"/>
   <result pre="epilepsy associated with migraines without auras. The increased incidence of" exact="stroke" post="in women with migraine may be another potential pathogenic"/>
   <result pre="without auras. The increased incidence of stroke in women with" exact="migraine" post="may be another potential pathogenic mechanism associated with the"/>
   <result pre="another potential pathogenic mechanism associated with the increased risk of" exact="epilepsy" post="in these patients. 29 Given the close relationship and"/>
   <result pre="prophylactic treatment of migraines and epilepsy. 2.5 Bidirectional relation between" exact="migraine" post="and mood disorders Epidemiologic studies have found that migraine"/>
   <result pre="between migraine and mood disorders Epidemiologic studies have found that" exact="migraine" post="is associated with an increased prevalence of mood disorders."/>
   <result pre="population study of 36,984 subjects from Canada, the prevalence of" exact="major depressive disorder" post="Major depressive disorder (MDD), bipolar disorder, panic disorder, and"/>
   <result pre="the prevalence of major depressive disorder Major depressive disorder (MDD)," exact="bipolar disorder," post="panic disorder, and social phobia was more than 2"/>
   <result pre="of major depressive disorder Major depressive disorder (MDD), bipolar disorder," exact="panic disorder," post="and social phobia was more than 2 times higher"/>
   <result pre="disorder Major depressive disorder (MDD), bipolar disorder, panic disorder, and" exact="social phobia" post="was more than 2 times higher in patients with"/>
   <result pre="phobia was more than 2 times higher in patients with" exact="migraine" post="than in those without. 30 In a case‐control study"/>
   <result pre="associated significantly with a greater than fivefold higher prevalence of" exact="migraine" post="with aura, more than a threefold higher prevalence of"/>
   <result pre="migraine with aura, more than a threefold higher prevalence of" exact="migraine" post="without aura, and a twofold higher prevalence of other"/>
   <result pre="chronic headaches. 31 Furthermore, suicide attempts have been associated with" exact="migraine" post="with aura. In one study of 1007 young adults,"/>
   <result pre="aura. In one study of 1007 young adults, those with" exact="migraine" post="had higher rates of suicide attempts than persons without"/>
   <result pre="of suicide attempts than persons without migraine, with patients with" exact="migraine" post="with aura being at significantly higher risk of suicide"/>
   <result pre="risk of suicide (odds ratio [OR] for suicide attempts in" exact="migraine" post="with aura: 3.0, 95% confidence interval [CI] 1.4‐6.6, after"/>
   <result pre="study of 121 adolescents with chronic daily headache, in whom" exact="migraine" post="with aura (in contrast to patients with migraine without"/>
   <result pre="in whom migraine with aura (in contrast to patients with" exact="migraine" post="without aura) was a predictor for suicidal risk after"/>
   <result pre="gender, depression, and anxiety disorders. 33 A bidirectional relation between" exact="migraine" post="and mood disorders was suggested in a study by"/>
   <result pre="15 who found that compared to healthy controls, patients with" exact="migraine" post="had significantly higher rates of depression after the onset"/>
   <result pre="whereas patients with major depression had significantly higher rates of" exact="migraine" post="after the onset of depression at follow‐up. Of note,"/>
   <result pre="disturbances have been considered as potential mechanisms operant in both" exact="migraine" post="and depression. Among the neurotransmitters, serotonin is known to"/>
   <result pre="A potential common pathogenic role of dopamine in depression and" exact="migraine" post="has been suggested by the involvement of the dopamine"/>
   <result pre="by the involvement of the dopamine D2 receptor gene in" exact="migraine" post="with aura and MDD. 36 Shared genetic mechanisms between"/>
   <result pre="migraine with aura and MDD. 36 Shared genetic mechanisms between" exact="migraine" post="and depression have been proposed as a potential common"/>
   <result pre="with aura. The OR for depression increased among patients with" exact="migraine" post="but was highest among those with aura (OR 1.29,"/>
   <result pre="CI 1.28–2.24). Heritability estimates were significant for all patients with" exact="migraine" post="but highest for those with migraine with aura. 37"/>
   <result pre="for all patients with migraine but highest for those with" exact="migraine" post="with aura. 37 In a twin study, migraine and"/>
   <result pre="those with migraine with aura. 37 In a twin study," exact="migraine" post="and MDD were found to share genetic factors, as"/>
   <result pre="as an estimated 20% of the variability in depression and" exact="migraine" post="was due to shared genetic factors, whereas 4% was"/>
   <result pre="unique environmental factors. 38 2.6 Relation between migraine, depression, and" exact="epilepsy" post="The data cited above reveals a complex relation between"/>
   <result pre="with major clinical implications. First is the bidirectional relation between" exact="migraine" post="with aura and MDD; next is the association between"/>
   <result pre="migraine with aura and MDD; next is the association between" exact="migraine" post="with aura and increased suicidal risk; third, is the"/>
   <result pre="associated with migraine. The relative impact of depression, suicidality, and" exact="migraine" post="on the risk of developing epilepsy was investigated by"/>
   <result pre="of depression, suicidality, and migraine on the risk of developing" exact="epilepsy" post="was investigated by Hesdorffer et al., in a population‐based"/>
   <result pre="(OR 7.9), compared to suicide attempt alone (OR 4.7) or" exact="migraine" post="with aura alone (OR 2.4). Likewise, patients with major"/>
   <result pre="aura alone (OR 2.4). Likewise, patients with major depression +" exact="migraine" post="with aura had a higher risk of a first"/>
   <result pre="higher risk of a first seizure (OR 4.6) compared to" exact="migraine" post="with aura alone (OR 2.5) or major depression alone"/>
   <result pre="an additive effect on seizure risk in the presence of" exact="migraine" post="with aura and major depression and/or suicide attempt. Two"/>
   <result pre="pediatric population. 40 Not surprisingly, these 2 comorbid disorders of" exact="epilepsy" post="have been associated with a worse quality of life"/>
   <result pre="quality of life in PWE. 41 2.7 Bidirectional relation between" exact="stroke" post="and epilepsy There is unquestionable evidence that a history"/>
   <result pre="life in PWE. 41 2.7 Bidirectional relation between stroke and" exact="epilepsy" post="There is unquestionable evidence that a history of cerebrovascular"/>
   <result pre="risk of developing epilepsy. 4, 42 In fact, patients with" exact="stroke" post="have a 17‐fold higher risk of developing epilepsy compared"/>
   <result pre="patients with stroke have a 17‐fold higher risk of developing" exact="epilepsy" post="compared to the general population. 4 Based on these"/>
   <result pre="these observations, it is not surprising that the relation between" exact="epilepsy" post="and stroke is typically considered to be unidirectional. Yet,"/>
   <result pre="it is not surprising that the relation between epilepsy and" exact="stroke" post="is typically considered to be unidirectional. Yet, there is"/>
   <result pre="to be unidirectional. Yet, there is evidence that patients with" exact="epilepsy" post="may have an increased risk of stroke, and thus,"/>
   <result pre="may have an increased risk of stroke, and thus, that" exact="stroke" post="and epilepsy may have a bidirectional relation. For example,"/>
   <result pre="an increased risk of stroke, and thus, that stroke and" exact="epilepsy" post="may have a bidirectional relation. For example, a population‐based"/>
   <result pre="General Practice Research Database, compared the risk of developing a" exact="stroke" post="between 4709 subjects who had seizures beginning at or"/>
   <result pre="matched for age and gender. Subjects with a history of" exact="epilepsy" post="had a 2.89 (95% CI 2.45–3.41) relative higher hazard"/>
   <result pre="2.89 (95% CI 2.45–3.41) relative higher hazard of developing a" exact="stroke" post="compared with the control group. 13 Another population‐based study"/>
   <result pre="prospective population‐based study conducted in Finland, 245 subjects with childhood‐onset" exact="epilepsy" post="were followed at 45 years of age. 44 Of"/>
   <result pre="neurologic signs were significantly more common in subjects with uncomplicated" exact="epilepsy" post="than in controls including a higher rate of 3T"/>
   <result pre="disease (RR 2.5, CI 1.04–5.9). Yet, the higher risk of" exact="stroke" post="in PWE may be also related to iatrogenic effects"/>
   <result pre="the risk of developing a stroke. 2.8 Bidirectional relation between" exact="stroke" post="and depression Several cross‐sectional studies have identified prevalence rates"/>
   <result pre="around 31.8% (range 30–44%). 49 Conversely, the increased risk of" exact="stroke" post="associated with a prior history of depression was investigated"/>
   <result pre="prospective cohort studies that encompassed 317,540 subjects among whom 8478" exact="stroke" post="cases were identified during a follow‐up period ranging from"/>
   <result pre="of developing a stroke, as the pooled aHRs for total" exact="stroke" post="were 1.45 (95% CI 1.29–1.63), 1.55 for fatal stroke,"/>
   <result pre="for fatal stroke, (95% CI 1.25–1.93), and 1.25 for ischemic" exact="stroke" post="(95% CI 1.11–1.40). A worse course of the stroke"/>
   <result pre="ischemic stroke (95% CI 1.11–1.40). A worse course of the" exact="stroke" post="in the presence of PSD may be another consequence"/>
   <result pre="serum cortisol has been associated with an increased risk of" exact="atherosclerosis" post="and sympathoadrenal hyperactivity, which in‐turn can lead to vasoconstriction,"/>
   <result pre="risk of stroke. 61 2.9 Relation between depression, epilepsy, and" exact="stroke" post="Given the bidirectional relations between depression and epilepsy and"/>
   <result pre="epilepsy, and stroke Given the bidirectional relations between depression and" exact="epilepsy" post="and stroke and epilepsy, patients with stroke and depression"/>
   <result pre="stroke Given the bidirectional relations between depression and epilepsy and" exact="stroke" post="and epilepsy, patients with stroke and depression should be"/>
   <result pre="between depression and epilepsy and stroke and epilepsy, patients with" exact="stroke" post="and depression should be expected to be at increased"/>
   <result pre="should be expected to be at increased risk of developing" exact="epilepsy" post="compared to patients with only stroke or only depression."/>
   <result pre="increased risk of developing epilepsy compared to patients with only" exact="stroke" post="or only depression. Furthermore, the seizure disorder would be"/>
   <result pre="whether the use of SSRIs increased the risk of developing" exact="epilepsy" post="25 and in which a total of 4688 subjects"/>
   <result pre="exposed to an SSRI had 2.45‐fold higher risk of developing" exact="epilepsy" post="than those who did not receive antidepressant drugs, and"/>
   <result pre="risk of epilepsy. 62 In fact, the increased risk of" exact="epilepsy" post="identified in this study was comparable to a 2.5"/>
   <result pre="reported to increase the risk of seizures in patients without" exact="epilepsy" post="in a dose‐dependent manner. 64 There is a general"/>
   <result pre="patients with primary depression have of developing unprovoked seizures and" exact="epilepsy" post="alluded to above, but also raises the question of"/>
   <result pre="below, data from several experimental studies in animal models of" exact="epilepsy" post="may suggest an antiepileptic effect of SSRIs and TCAs,"/>
   <result pre="available clinical data to establish whether the comorbid occurrence of" exact="stroke" post="and depression can worsen the risk and/or the severity"/>
   <result pre="epilepsy. 2.10 Can animal models of depression, epilepsy, stroke, and" exact="migraine" post="demonstrate an agonistic effect of these 3 comorbidities on"/>
   <result pre="of epilepsy? 2.11 Can a bidirectional relation between depression and" exact="epilepsy" post="be identified in animal models of epilepsy? In previous"/>
   <result pre="the existence of common pathogenic mechanisms operant in PC and" exact="epilepsy" post="as an explanation of the bidirectional relation between epilepsy"/>
   <result pre="and epilepsy as an explanation of the bidirectional relation between" exact="epilepsy" post="and these psychiatric disorders. 13, 14 Psychiatric phenomena facilitate"/>
   <result pre="the increase of plasma corticosterone levels under conditions of pilocarpine" exact="status epilepticus." post="76 Conversely, depressive‐like impairments have been well established in"/>
   <result pre="depressive‐like impairments have been well established in animal models of" exact="temporal lobe epilepsy" post="(TLE). Thus, kindling of limbic seizures, 77, 78, 79"/>
   <result pre="have been well established in animal models of temporal lobe" exact="epilepsy" post="(TLE). Thus, kindling of limbic seizures, 77, 78, 79"/>
   <result pre="epilepsy (TLE). Thus, kindling of limbic seizures, 77, 78, 79" exact="status epilepticus" post="(SE) induced by pilocarpine 80 and kainic acid, 81"/>
   <result pre="from kindled sites (e.g., hippocampus, amygdala). Status epilepticus produces chronic" exact="epilepsy" post="more resembling human TLE than kindling, whereby the animals"/>
   <result pre="several studies examining the relation between the severity of post‐SE" exact="epilepsy" post="and depression, failed to find a correlation between the"/>
   <result pre="and kainic acid models. 2.12 Can a bidirectional relation between" exact="migraine" post="and epilepsy be identified in animal models of epilepsy?"/>
   <result pre="acid models. 2.12 Can a bidirectional relation between migraine and" exact="epilepsy" post="be identified in animal models of epilepsy? The development"/>
   <result pre="symptoms of depression and anxiety in a rat model of" exact="migraine" post="were demonstrated in one study, which used a chronic"/>
   <result pre="migraine were demonstrated in one study, which used a chronic" exact="migraine" post="model based on the method of repeated dura mater"/>
   <result pre="was reversed by low‐dose of amitriptyline. Of note, patients with" exact="migraine" post="and depression are known to have a persistent decrease"/>
   <result pre="low dopamine cortical concentrations demonstrated in this animal model of" exact="migraine" post="is supported by previous reports of low dopamine levels"/>
   <result pre="D2 receptor genotype has been related to the comorbidity of" exact="migraine" post="and depression. 36 2.13 Can a bidirectional relation between"/>
   <result pre="migraine and depression. 36 2.13 Can a bidirectional relation between" exact="migraine" post="and epilepsy be identified in animal models of epilepsy?"/>
   <result pre="depression. 36 2.13 Can a bidirectional relation between migraine and" exact="epilepsy" post="be identified in animal models of epilepsy? A review"/>
   <result pre="In this article we review the very complex relation among" exact="epilepsy" post="and 3 of its more common neurologic and psychiatric"/>
   <result pre="between their respective bidirectional relations with epilepsy. Although an increased" exact="epilepsy" post="risk is associated with each of the 3 comorbidities"/>
   <result pre="comorbid occurrence of depression and migraine, 10 but not for" exact="stroke" post="and depression. A history of depression and migraine has"/>
   <result pre="not for stroke and depression. A history of depression and" exact="migraine" post="has been associated with an increased risk of treatment‐resistant"/>
   <result pre="successful treatment of each comorbidity on the severity of the" exact="epilepsy" post="been investigated and vice versa. Clearly, these questions need"/>
   <result pre="in future prospective studies. Failure to recognize bidirectional relations among" exact="epilepsy" post="and these 3 common comorbidities may result in misinterpretation"/>
   <result pre="the impact of the bidirectional relation between mood disorders and" exact="epilepsy" post="on the interpretation of the role played by SSRIs"/>
   <result pre="of the epileptogenic process has taken front and center in" exact="epilepsy" post="research. Although clinical and experimental data appear to suggest"/>
   <result pre="at all, is yet to be established and the increased" exact="epilepsy" post="risk may result from the existence of common pathogenic"/>
   <result pre="observations can be made for the other 2 comorbidities of" exact="epilepsy" post="discussed in this article. Experimental studies are needed to"/>
   <result pre="of a depression and then subjected to the development of" exact="migraine" post="equivalent. The same paradigm can be followed in testing"/>
   <result pre="be followed in testing any additive effect of depression on" exact="stroke" post="on the epileptogenic process. This type of experimental model"/>
   <result pre="applied in other neurologic conditions associated with epilepsy, such as" exact="dementia" post="and traumatic brain injury. In summary, the treatment of"/>
   <result pre="dementia and traumatic brain injury. In summary, the treatment of" exact="epilepsy" post="cannot be limited to the achievement of a seizure‐free"/>
   <result pre="ILAE Commission on EpidemiologyStandards for epidemiologic studies and surveillance of" exact="epilepsy" post=". Epilepsia 2011; 52( suppl 7): 2– 26. 21899536"/>
   <result pre="Lipton RB . Chronic disorders with episodic manifestations: focus on" exact="epilepsy" post="and migraine. Lancet Neurol 2006; 5: 148– 157. 16426991"/>
   <result pre="WA , et al. Population‐based study of seizure disorders after" exact="cerebral infarction." post="Neurology 1996; 46: 350– 355. 8614493 5 Gaitatzis A"/>
   <result pre="A , et al. The epidemiology of the comorbidity of" exact="epilepsy" post="in the general population. Epilepsia 2004; 45: 1613– 1622."/>
   <result pre=", Matijevic S , Wiebe S . Somatic comorbidity of" exact="epilepsy" post="in the general population in Canada. Epilepsia 2005; 46:"/>
   <result pre="et al. Co‐occurrence of major depression or suicide attempt with" exact="migraine" post="with aura and risk for unprovoked seizure . Epilepsy"/>
   <result pre="PC , Tsai IJ , et al. Bidirectional relation between" exact="schizophrenia" post="and epilepsy: a population‐based retrospective cohort study . Epilepsia"/>
   <result pre="ADHD as a risk factor for incident unprovoked seizures and" exact="epilepsy" post="in children. Arch Gen Psychiatry 2004; 61: 731– 736."/>
   <result pre="Lipton RB , Stewart WF , et al. Comorbidity of" exact="migraine" post="and depression: investigating potential etiology and prognosis. Neurology 2003;"/>
   <result pre=", Okereke OI , et al. Depression and risk of" exact="stroke" post="morbidity and mortality: a meta‐analysis and systematic review ."/>
   <result pre=", et al. Association of depression and treated depression with" exact="epilepsy" post="and seizure outcomes: a Multicohort Analysis . JAMA Neurol"/>
   <result pre="24719199 24 Ottman R , Lipton RB . Comorbidity of" exact="migraine" post="and epilepsy. Neurology 1994; 44: 2105– 2110. 7969967 25"/>
   <result pre="YC , Kao CH . High risk of developing subsequent" exact="epilepsy" post="in young adults with migraine: a nationwide population‐based cohort"/>
   <result pre=", Boz C , Ozmenoglu M . The impact of" exact="migraine" post="on epilepsy: a prospective prognosis study. Cephalalgia 2005; 25:"/>
   <result pre="Zarcone D , Corbetta S . Shared mechanisms of epilepsy," exact="migraine" post="and affective disorders. Neurol Sci 2017; 38( Suppl 1):"/>
   <result pre="Patten S , Williams J , et al. Comorbidity of" exact="migraine" post="and psychiatric disorders–a national population‐based study. Headache 2008; 48("/>
   <result pre="H , Bertilsson L , et al. Suicide attempts and" exact="impulse control disorder" post="are related to low cerebrospinal fluid 5‐HIAA in mentally"/>
   <result pre=", Price SC , Wilhoit TL , et al. Comorbid" exact="migraine" post="with aura, anxiety, and depression is associated with dopamine"/>
   <result pre=", Janssens AC , et al. Shared genetic factors in" exact="migraine" post="and depression: evidence from a genetic isolate. Neurology 2010;"/>
   <result pre="al. Patterns of diagnosis and acute and preventive treatment for" exact="migraine" post="in the United States: results from the American Migraine"/>
   <result pre="SA , Hartman AL , Kossof EH . Comorbidity of" exact="migraine" post="in children presenting with epilepsy to a tertiary care"/>
   <result pre="Kossof EH . Comorbidity of migraine in children presenting with" exact="epilepsy" post="to a tertiary care center. Neurology 2012; 79: 468–"/>
   <result pre="between midlife risk factors and late‐onset epilepsy: results from the" exact="atherosclerosis" post="risk in communities study . JAMA Neurol 2018; [Epub"/>
   <result pre="Liao CH , Lin CC , et al. Patients with" exact="epilepsy" post="are at an increased risk of subsequent stroke: a"/>
   <result pre=", Anttinen A , Rinne JO , et al. Childhood‐onset" exact="epilepsy" post="five decades later. A prospective population‐based cohort study ."/>
   <result pre="risk factors and oxidative stress as independent predictors of asymptomatic" exact="atherosclerosis" post="in adult patients with epilepsy . Epilepsy Res 2007;"/>
   <result pre="as independent predictors of asymptomatic atherosclerosis in adult patients with" exact="epilepsy" post=". Epilepsy Res 2007; 74: 183– 192. 17448640 46"/>
   <result pre="circulatory markers for vascular risk in patients with newly diagnosed" exact="epilepsy" post=". Epilepsia 2013; 54: 146– 149. 49 Kanner AM"/>
   <result pre="et al. The association of elevated plasma cortisol and early" exact="atherosclerosis" post="as demonstrated by coronary angiography . Atherosclerosis 1977; 26:"/>
   <result pre="Stein PK , et al. Depression, heart rate variability, and" exact="acute myocardial infarction." post="Circulation 2001; 104: 2024– 2028. 11673340 52 Watkins LL"/>
   <result pre="VC , et al. Increased QT variability in patients with" exact="panic disorder" post="and depression. Psychiatry Res 2000; 93: 225– 235. 10760381"/>
   <result pre="between selective serotonin‐reuptake inhibitor antidepressants and increased risk of poststroke" exact="epilepsy" post=". Mayo Clin Proc 2017; 92( 2): 179– 181."/>
   <result pre="A , et al. Predicting and treating stress‐induced vulnerability to" exact="epilepsy" post="and depression. Ann Neurol 2015; 78: 128– 136. 25869354"/>
   <result pre="al. Elevated plasma corticosterone level and depressive behavior in experimental" exact="temporal lobe epilepsy" post=". Neurobiol Dis 2009; 34: 457– 461. 19285131 83"/>
   <result pre="plasma corticosterone level and depressive behavior in experimental temporal lobe" exact="epilepsy" post=". Neurobiol Dis 2009; 34: 457– 461. 19285131 83"/>
   <result pre="depressive‐ and impulsive‐like behaviors and on monoamine transmission in experimental" exact="temporal lobe epilepsy" post=". Epilepsia 2016; 57: 506– 515. 26813337 84 Pineda"/>
   <result pre="impulsive‐like behaviors and on monoamine transmission in experimental temporal lobe" exact="epilepsy" post=". Epilepsia 2016; 57: 506– 515. 26813337 84 Pineda"/>
   <result pre="RJ . Chapter 54. Kindling: a model and phenomenon of" exact="epilepsy" post="In Pitkanen A , Buckmaster PS , Galanopoulou AS"/>
   <result pre="Coulter DA . Chapter 42. The pilocarpine model of acquired" exact="epilepsy" post="In Pitkanen A , Buckmaster PS , Galanopoulou AS"/>
   <result pre="fluoxetine and TFMPP on spontaneous seizures in rats with pilocarpine‐induced" exact="epilepsy" post=". Epilepsia 2002; 43: 1337– 1345. 12423383 90 Jaako"/>
   <result pre="citalopram and reboxetine reduce seizure frequency in rats with chronic" exact="epilepsy" post=". Epilepsia 2012; 53: 870– 878. 22429158 94 Zhang"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6294621/results/search/disease/results.xml">
   <result pre="47 Quantitative assessment of the association between GRIA1 polymorphisms and" exact="migraine" post="risk http://orcid.org/0000-0003-1161-0771 Gao Xueren Wang Jianguo [], Correspondence: Xueren"/>
   <result pre="association between GRIA1 rs548294 G&amp;gt;A and rs2195450 C&amp;gt;T polymorphisms and" exact="migraine" post="risk has been reported in several case–control studies. However,"/>
   <result pre="more precisely estimate the association of the two polymorphisms with" exact="migraine" post="risk. Methods: Eligible studies were retrieved and screened from"/>
   <result pre="that GRIA1 rs548294 G&amp;gt;A polymorphism was not significantly associated with" exact="migraine" post="risk. GRIA1 rs2195450 C&amp;gt;T polymorphism was significantly associated with"/>
   <result pre="migraine risk. GRIA1 rs2195450 C&amp;gt;T polymorphism was significantly associated with" exact="migraine" post="risk under heterozygous model (CT vs. CC, OR ="/>
   <result pre="showed a significant association of GRIA1 rs2195450 C&amp;gt;T polymorphism with" exact="migraine" post="risk in Asian population, but not in Caucasian population."/>
   <result pre="indicates that GRIA1 rs2195450 C&amp;gt;T polymorphism is significantly associated with" exact="migraine" post="risk. However, the number of studies included in the"/>
   <result pre="sample size are still required to confirm these findings. GRIA1" exact="migraine" post="polymorphism risk page-count: Introduction Migraine is a common neurovascular"/>
   <result pre="accompanied by nausea, vomiting, photo- and phonophobia [ 2]. Clinically," exact="migraine" post="is divided into two main subtypes: migraine with aura"/>
   <result pre="[ 2]. Clinically, migraine is divided into two main subtypes:" exact="migraine" post="with aura (MA) and without aura (MO). MA is"/>
   <result pre="attacks lasting 4–72 h [ 3]. Although the pathogenesis of" exact="migraine" post="is still unclear, studies suggests that inheritance factor plays"/>
   <result pre="Synaptic hyperexcitability has been recognized as one major factor causing" exact="migraine" post="[ 7]. Glutamate is an excitatory neurotransmitter in the"/>
   <result pre="depression, which plays an important role in the pathophysiology of" exact="migraine" post="[ 8–10]. Therefore, GRIA1 gene was inferred as a"/>
   <result pre="in migraine-related genes have been reported to be associated with" exact="migraine" post="risk [ 4–6]. Thus GRIA1 polymorphisms may also be"/>
   <result pre="[ 4–6]. Thus GRIA1 polymorphisms may also be involved in" exact="migraine" post="risk. In order to confirm this hypothesis, some case–control"/>
   <result pre="the association of GRIA1 polymorphisms (rs548294 G&amp;gt;A, rs2195450 C&amp;gt;T) with" exact="migraine" post="risk. However, the results were inconsistent [ 7, 11–13]."/>
   <result pre="the association between GRIA1 polymorphisms (rs548294 G&amp;gt;A, rs2195450 C&amp;gt;T) and" exact="migraine" post="risk; (ii) available data of genotype and allele distributions"/>
   <result pre="corresponding 95% confidence intervals (CIs) were calculated to assess the" exact="migraine" post="risk associated with GRIA1 rs548294 G&amp;gt;A and rs2195450 C&amp;gt;T"/>
   <result pre="was no significant association between GRIA1 rs548294 G&amp;gt;A polymorphism and" exact="migraine" post="risk under all genetic models. Further stratified analysis based"/>
   <result pre="showed no statistical association between GRIA1 rs548294 G&amp;gt;A polymorphism and" exact="migraine" post="risk under all genetic models. Figure 2 Forest plots"/>
   <result pre="plots of the association of GRIA1 rs548294 G&amp;gt;A polymorphism and" exact="migraine" post="risk ( A: Homozygous model; B: Dominant model; C:"/>
   <result pre="Meta-analysis of the association between GRIA1 rs548294 G&amp;gt;A polymorphism and" exact="migraine" post="risk Comparison Subgroup P H Model P Z OR"/>
   <result pre="was a significant association between GRIA1 rs2195450 C&amp;gt;T polymorphism and" exact="migraine" post="risk under heterozygous model (CT vs. CC, OR ="/>
   <result pre="showed that GRIA1 rs2195450 C&amp;gt;T polymorphism was significantly associated with" exact="migraine" post="risk in Asian population ((TT+CT) vs. CC, OR ="/>
   <result pre="plots of the association of GRIA1 rs2195450 C&amp;gt;T polymorphism and" exact="migraine" post="risk ( A: Homozygous model; B: Dominant model; C:"/>
   <result pre="Meta-analysis of the association between GRIA1 rs2195450 C&amp;gt;T polymorphism and" exact="migraine" post="risk Comparison Subgroup P H Model P Z OR"/>
   <result pre="result on the association between GRIA1 rs548294 G&amp;gt;A polymorphism and" exact="migraine" post="risk. However, after removing Cargnin’s study, the significant association"/>
   <result pre="study, the significant association between GRIA1 rs2195450 C&amp;gt;T polymorphism and" exact="migraine" post="risk was observed under homozygous model (TT vs. CC,"/>
   <result pre="significant association was observed between GRIA1 rs2195450 C&amp;gt;T polymorphism and" exact="migraine" post="risk under heterozygous model. Funnel plots were used to"/>
   <result pre="studies have identified more than a dozen loci associated with" exact="migraine" post="risk, which suggests novel genes and pathways involved in"/>
   <result pre="migraine risk, which suggests novel genes and pathways involved in" exact="migraine" post="pathophysiology that point toward neuronal and vascular mechanisms of"/>
   <result pre="GRIA1 polymorphisms (rs548294 G&amp;gt;A, rs2195450 C&amp;gt;T) were significantly associated with" exact="migraine" post="risk in an Italian population. Subsequently, three independent case–control"/>
   <result pre="that GRIA1 rs548294 G&amp;gt;A polymorphism was not significantly associated with" exact="migraine" post="risk. For GRIA1 rs2195450 C&amp;gt;T polymorphism, the result of"/>
   <result pre="that the GRIA1 rs2195450 C&amp;gt;T polymorphism was significantly associated with" exact="migraine" post="risk [ 11]. These inconsistent results would not be"/>
   <result pre="our understanding of the association between the two polymorphisms and" exact="migraine" post="risk. Therefore, an effective method should be adopted to"/>
   <result pre="association between GRIA1 rs548294 G&amp;gt;A and rs2195450 C&amp;gt;T polymorphisms and" exact="migraine" post="risk, and found that GRIA1 rs548294 G&amp;gt;A polymorphism was"/>
   <result pre="that GRIA1 rs548294 G&amp;gt;A polymorphism was not significantly associated with" exact="migraine" post="risk, but GRIA1 rs2195450 C&amp;gt;T polymorphism was significantly associated"/>
   <result pre="risk, but GRIA1 rs2195450 C&amp;gt;T polymorphism was significantly associated with" exact="migraine" post="risk. Due to the fact that rs2195450 polymorphism was"/>
   <result pre="for rs2195450 would contribute to finding functional variant associated with" exact="migraine" post="risk. Subgroup analysis based on ethnicity showed a significant"/>
   <result pre="showed a significant association of GRIA1 rs2195450 C&amp;gt;T polymorphism with" exact="migraine" post="risk in Asian population, but not in Caucasian population,"/>
   <result pre="association of GRIA1 rs548294 G&amp;gt;A and rs2195450 C&amp;gt;T polymorphisms and" exact="migraine" post="risk. Although the present results could provide stronger evidence"/>
   <result pre="indicates that GRIA1 rs2195450 C&amp;gt;T polymorphism is significantly associated with" exact="migraine" post="risk. However, more high-quality case–control studies with large sample"/>
   <result pre="al. ( 2015) Common polygenic variation contributes to risk of" exact="migraine" post="in the Norfolk Island population. Hum. Genet. 134, 1079–"/>
   <result pre="regions of GRIA1 and GRIA3 receptor genes are associated with" exact="migraine" post="susceptibility . BMC Med. Genet. 11, 103 10.1186/1471-2350-11-103 20579352"/>
   <result pre="2014) Lack of association between GRIA1 polymorphisms and haplotypes with" exact="migraine" post="without aura or response to triptans . Neurol. Sci."/>
   <result pre="al. ( 2013) Association of a GRIA3 gene polymorphism with" exact="migraine" post="in an Australian case-control cohort . Headache 53, 1245–"/>
   <result pre="Kallela M. et al. ( 2010) Genome-wide association study of" exact="migraine" post="implicates a common susceptibility variant on 8q22.1 . Nat."/>
   <result pre="al. ( 2012) Genome-wide association analysis identifies susceptibility loci for" exact="migraine" post="without aura . Nat. Genet. 44, 777– 782 10.1038/ng.2307"/>
   <result pre="2011) Genome-wide association study reveals three susceptibility loci for common" exact="migraine" post="in the general population . Nat. Genet. 43, 695–"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6306866/results/search/disease/results.xml">
   <result pre="promise for the treatment of common pediatric conditions such as" exact="irritable bowel syndrome," post="acute and chronic pain, headache, and allergy, among others."/>
   <result pre="long-lasting wellbeing. Exercise and lifestyle changes can treat depression, coronary" exact="heart disease," post="and type II diabetes [ 13, 14, 15, 16,"/>
   <result pre="(21%) for disease management [ 63, 64]. In patients with" exact="irritable bowel syndrome" post="(IBS), there exists increasing evidence for the bidirectional connection"/>
   <result pre="in a Canadian children’s hospital diagnosed with epilepsy, headache, and" exact="cerebral palsy" post="illustrated high use of multivitamins, massage, and chiropractic therapies"/>
   <result pre="practices were reported as helpful [ 85]. Among children with" exact="autism" post="spectrum disorder (ASD), special diets are the most common"/>
   <result pre="88]. Furthermore, screening and treating comorbid sleep disorders such as" exact="sleep apnea," post="bruxism, insomnia, and restless leg syndrome can indirectly improve"/>
   <result pre="headache [ 89]. Neurofeedback has documented potential in treatment of" exact="epilepsy" post="and headache [ 90, 91]. Meditation, breath work, and"/>
   <result pre="low risk, with several trials showing decreased side effects of" exact="cancer" post="therapy, increased patient self-confidence, and improved coping skills ["/>
   <result pre="95]. Integrative modalities may also play a role in long-term" exact="cancer" post="risk reduction. Patient lifestyle factors such as stress, cigarette"/>
   <result pre="in later life [ 102]. 2.5. Asthma and Allergy Pediatric" exact="asthma" post="is another area where an integrative approach may provide"/>
   <result pre="vegetables, and legumes) have been shown to protect children from" exact="asthma" post="and allergies [ 103, 104, 105]. A systematic review"/>
   <result pre="al. in 2014 highlighted yoga as a supplementary intervention for" exact="asthma" post="patients to improve symptoms and quality of life ["/>
   <result pre="instance, that diet and exercise management can halt or reverse" exact="cardiovascular disease," post="diabetes, and obesity [ 10, 13, 23, 111, 112,"/>
   <result pre="exercise management can halt or reverse cardiovascular disease, diabetes, and" exact="obesity" post="[ 10, 13, 23, 111, 112, 113]. Integrative cardiology"/>
   <result pre="behavioral therapy has been used as an adjuvant in pediatric" exact="obesity" post="management [ 115]. Mindfulness-based cognitive therapy has shown preliminary"/>
   <result pre="Mindfulness-based cognitive therapy has shown preliminary efficacy in youths with" exact="anxiety disorder" post="and mindfulness based stress reduction programs in urban youth"/>
   <result pre="has proposed mechanistic pathways of action of acupuncture in alleviating" exact="cardiovascular disease" post="[ 117, 118, 119, 120]. As the evidence base"/>
   <result pre="study found immersive virtual reality safe and effective for treating" exact="complex regional pain syndrome" post="[ 80, 122]. This has prompted further research on"/>
   <result pre="these as needed medications particularly helpful in treating her abdominal" exact="migraine" post="episodes. Supplements included melatonin nightly and peppermint oil by"/>
   <result pre="A.M. Benninga M.A. Gut-directed hypnotherapy for functional abdominal pain or" exact="irritable bowel syndrome" post="in children: A systematic review Arch. Dis. Child. 2013"/>
   <result pre="G.J. Enteric-coated, pH-dependent peppermint oil capsules for the treatment of" exact="irritable bowel syndrome" post="in children J. Pediatr. 2001 138 125 128 10.1067/mpd.2001.109606"/>
   <result pre="Arbizzani A. Parmeggiani A. Riboflavin prophylaxis in pediatric and adolescent" exact="migraine" post="J. Headache Pain 2009 10 361 365 10.1007/s10194-009-0142-2 19649688"/>
   <result pre="Protective effect of fruits, vegetables and the Mediterranean diet on" exact="asthma" post="and allergies among children in Crete Thorax 2007 62"/>
   <result pre="diet during pregnancy and first years of life on wheezing," exact="rhinitis" post="and dermatitis in preschoolers Allergol. Immunopathol. (Madrid) 2016 44"/>
   <result pre="pregnancy and first years of life on wheezing, rhinitis and" exact="dermatitis" post="in preschoolers Allergol. Immunopathol. (Madrid) 2016 44 400 409"/>
   <result pre="S.C. Systematic review of the effectiveness of breathing retraining in" exact="asthma" post="management Expert Rev. Respir. Med. 2011 5 789 807"/>
   <result pre="334 340 10.1097/MOP.0000000000000217 25888149 127. Mark J.D. Integrative medicine and" exact="asthma" post="Pediatr. Clin. N. Am. 2007 54 1007 1023 10.1016/j.pcl.2007.09.005"/>
   <result pre="[ 127] Literature review Details integrative approach for children with" exact="asthma" post="N/A Nutrition in Pediatric Cystic Fibrosis [ 128] Book"/>
   <result pre="Book chapter Details evidence of nutritional therapies in children with" exact="cystic fibrosis" post="N/A Integrated Medicine and Asthma [ 129] Book chapter"/>
   <result pre="[ 129] Book chapter Details evidence of integrative approach to" exact="asthma" post="N/A Pediatric gastroenterology Yoga as adjunct therapy for adolescents"/>
   <result pre="review Describes integrative approach to children with reflux and functional" exact="dyspepsia" post="N/A Acupuncture and Integrative Medicine for Pediatric Gastroesophageal Reflux"/>
   <result pre="Describes effect of acupuncture on children with GERD and functional" exact="dyspepsia" post="Stanford Medical Scholars Program Pediatric neurology Integrative Medicine in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6320380/results/search/disease/results.xml">
   <result pre="relaxation of arterial smooth muscle and vasodilation and possibly during" exact="migraine" post="attacks. Therefore, in this study, the coding and noncoding"/>
   <result pre="of Prostaglandin I2 receptor gene were examined in patients with" exact="migraine" post="headache and healthy controls and the potential effects of"/>
   <result pre="( 1, 2). After dental problems and tension type headaches," exact="migraine" post="is the third most common disease. Migraine ia believed"/>
   <result pre="migraines are not identified ( 3- 5). The pathophysiology of" exact="migraine" post="is complex and considered as a neurovascular disease. Historically,"/>
   <result pre="migraine: vascular and neuronal. Vascular or blood vessel hypothesis of" exact="migraine" post="gives importance to cerebral and meningeal arteries and their"/>
   <result pre="to healthy controls, may have a critical role in triggering" exact="migraine" post="attacks ( 12). The PTGIR gene located on 19q13.3"/>
   <result pre="in the relaxation of arterial smooth muscle and vasodilation during" exact="migraine" post="attacks. Thus, in this study, the direct PCR amplification"/>
   <result pre="exon-intron boundaries of PTGIR gene was examined in patients with" exact="migraine" post="headache and healthy controls. Also, the potential effects of"/>
   <result pre="Materials and Methods The study sample included 50 patients with" exact="migraine" post="who referred to local hospitals in Isfahan province (Khorshid"/>
   <result pre="All patients were identified as having a common type of" exact="migraine" post="(without aura) using the classification of all headaches, including"/>
   <result pre="Clinical Variables This case–control study consisted of 50 patients with" exact="migraine" post="and 50 healthy controls. The patients had a mean"/>
   <result pre="hIP receptor, resulting in deficits of hIP receptor function with" exact="migraine" post="disease ( 18, 19). In addition, genetic variants of"/>
   <result pre="mutation we described, should be considered even in cases of" exact="migraine" post="headache. The presence of this mutation in patients with"/>
   <result pre="presence of this mutation in patients with family history of" exact="migraine" post="raises the importance of genetic counselling. Figure 1 Details"/>
   <result pre="ME Lipton RB Chronic disorders with episodic manifestations: focus on" exact="epilepsy" post="and migraine Lancet Neurol. 2006 5 148 157 16426991"/>
   <result pre="RB Chronic disorders with episodic manifestations: focus on epilepsy and" exact="migraine" post="Lancet Neurol. 2006 5 148 157 16426991 2 Society"/>
   <result pre="Parsons AA Strijbos PJ The neuronal versus vascular hypothesis of" exact="migraine" post="and cortical spreading depression Curr Opin Pharmacol 2003 3"/>
   <result pre="al. Expression of prostaglandin I2 (prostacyclin) receptor in blood of" exact="migraine" post="patients: A potential biomarker Adv Biomed Res 2015 4"/>
   <result pre="Douville K MacKenzie T Fetalvero KM et al. Acceleration of" exact="cardiovascular disease" post="by a dysfunctional prostacyclin receptor mutation: potential implications for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6327687/results/search/disease/results.xml">
   <result pre="numerous conditions such as hypertension, cardiac arrhythmias, myocardial infarction, migraine," exact="portal hypertension," post="anxiety, essential tremors, hyperthyroidism, and pheochromocytoma. Owing to its"/>
   <result pre="inception to the present day. Keywords: Anxiety beta-blocker myocardial infarction" exact="portal hypertension" post="propranolol I NTRODUCTION The invention of the beta-adrenergic receptor"/>
   <result pre="propranolol in several noncardiovascular conditions including migraine, essential tremors, anxiety," exact="portal hypertension," post="hyperthyroidism, and pheochromocytoma have been recognized.[ 9] Interestingly, many"/>
   <result pre="The widespread use of propranolol in cardiovascular diseases including ischemic" exact="heart disease," post="arrhythmias, and myocardial infarction has been known for more"/>
   <result pre="usage in the management of migraine, essential tremors, anxiety, and" exact="portal hypertension." post="Cardiovascular indications Even today, more than half a century"/>
   <result pre="(8.9% vs. 6.6%, P &amp;lt; 0.01), mortality due to arteriosclerotic" exact="heart disease" post="(8.5% vs. 6.2%, P &amp;lt; 0.01), and sudden death"/>
   <result pre="left ventricular volume and function after primary coronary stenting in" exact="acute myocardial infarction." post="Propranolol, being cost-effective, can be preferred over carvedilol for"/>
   <result pre="shown promising results in heart failure caused by pediatric hypertrophic" exact="cardiomyopathy" post="and is considered as treatment of choice in this"/>
   <result pre="22] Propranolol has been extensively used for the management of" exact="essential hypertension." post="Although the exact mechanism of its antihypertensive effect is"/>
   <result pre="Management mainly aims to reduce frequency, duration, and severity of" exact="migraine" post="attacks; increase responsiveness of acute attacks to abortive therapy;"/>
   <result pre="abortive therapy; and improve quality of life. First-line drugs for" exact="migraine" post="prophylaxis include divalproex sodium, sodium valproate, topiramate, metoprolol, propranolol,"/>
   <result pre="et al. accidentally found the therapeutic effect of propranolol for" exact="migraine" post="while they were studying its use in the management"/>
   <result pre="propranolol was found to be safe and effective in managing" exact="migraine" post="headaches.[ 28 29 30 31] Holroyd et al. conducted"/>
   <result pre="(N = 2403) that assessed the effect of propranolol on" exact="migraine" post="headaches. Reduction in migraine activity was 44% (when daily"/>
   <result pre="assessed the effect of propranolol on migraine headaches. Reduction in" exact="migraine" post="activity was 44% (when daily headache recordings were used"/>
   <result pre="He et al. conducted a network meta-analysis to compare various" exact="migraine" post="prophylactic medications. A network meta-analysis is a relatively new"/>
   <result pre="medications studied, propranolol, topiramate, and divalproex demonstrated significantly less average" exact="migraine" post="headache days compared to placebo (topiramate: −1.20, 95% CI:"/>
   <result pre="review of controlled trials to assess the agents used for" exact="migraine" post="treatment in children, of the several drugs studied, propranolol"/>
   <result pre="randomized double-blind trial which compared propranolol with sodium valproate for" exact="migraine" post="prophylaxis in pediatric patients, while both drugs were found"/>
   <result pre="Health Organization classifies anxiety into four categories as follows: phobic" exact="anxiety disorder" post="(agoraphobia with/without panic disorder, social phobias, and specific phobia);"/>
   <result pre="into four categories as follows: phobic anxiety disorder (agoraphobia with/without" exact="panic disorder," post="social phobias, and specific phobia); other anxiety disorder (panic"/>
   <result pre="(agoraphobia with/without panic disorder, social phobias, and specific phobia); other" exact="anxiety disorder" post="(panic disorder, generalized anxiety disorder [GAD], mixed anxiety, and"/>
   <result pre="social phobias, and specific phobia); other anxiety disorder (panic disorder," exact="generalized anxiety disorder" post="[GAD], mixed anxiety, and depressive disorder); obsessive-compulsive disorder; and"/>
   <result pre="phobias, and specific phobia); other anxiety disorder (panic disorder, generalized" exact="anxiety disorder" post="[GAD], mixed anxiety, and depressive disorder); obsessive-compulsive disorder; and"/>
   <result pre="disorder, generalized anxiety disorder [GAD], mixed anxiety, and depressive disorder);" exact="obsessive-compulsive disorder;" post="and reaction to severe stress and adjustment disorders (acute"/>
   <result pre="complications such as development of varices, decompensation of cirrhosis, and" exact="hepatocellular carcinoma" post="and is therefore considered clinically significant.[ 48] The gastrointestinal"/>
   <result pre="clinically significant.[ 48] The gastrointestinal varices that are caused by" exact="portal hypertension" post="may cause variceal hemorrhage, and the main aim of"/>
   <result pre="variceal ligation (EVL). The mechanism of action of propranolol in" exact="portal hypertension" post="is through both beta-1 and beta-2 receptors. Beta-1 blockade"/>
   <result pre="also believed to have a role in preventing spontaneous bacterial" exact="peritonitis" post="which seems to be responsible for variceal bleeding in"/>
   <result pre="candesartan and propranolol combination therapy with propranolol monotherapy in reducing" exact="portal hypertension" post="in patients with cirrhosis. The study reported no significant"/>
   <result pre="Therefore, addition of candesartan to propranolol in treating patients with" exact="portal hypertension" post="is not recommended.[ 56] It has been suggested in"/>
   <result pre="that retrospectively evaluated a large cohort of 2419 patients with" exact="cirrhosis" post="and portal hypertension found that all-cause mortality was lower"/>
   <result pre="evaluated a large cohort of 2419 patients with cirrhosis and" exact="portal hypertension" post="found that all-cause mortality was lower in patients taking"/>
   <result pre="The first report of the use of propranolol in infantile" exact="hemangioma" post="was published in 2008.[ 63] Further studies have reported"/>
   <result pre="Further, it is used for preparing patients for surgery in" exact="hyperthyroidism" post="and pheochromocytoma. Beta-adrenergic blockade by propranolol also helps in"/>
   <result pre="by propranolol also helps in reversing the hemodynamic abnormalities in" exact="portal hypertension" post="and is widely used for primary and secondary prophylaxis"/>
   <result pre="Propranolol therapy in patients with acute myocardial infarction: The beta-blocker" exact="heart attack" post="trial Circulation 1983 67 I53 7 6342840 9 Ogrodowczyk"/>
   <result pre="KL Effect of adrenergic receptor blockade of the tachycardia of" exact="thyrotoxicosis" post="and anxiety state Lancet 1965 2 1316 8 4165805"/>
   <result pre="5 14172035 15 Morganroth J Lichstein E Byington R Beta-blocker" exact="heart attack" post="trial: Impact of propranolol therapy on ventricular arrhythmias Prev"/>
   <result pre="on left-ventricular volume and function after primary coronary stenting in" exact="acute myocardial infarction" post="Angiology 2008 59 676 81 18388053 17 Barton AL"/>
   <result pre="E et al. Evidence-based guideline update: Pharmacologic treatment for episodic" exact="migraine" post="prevention in adults: Report of the quality standards subcommittee"/>
   <result pre="28 Borgesen SE Nielsen JL Moller CE Prophylactic treatment of" exact="migraine" post="with propranolol. A clinical trial Acta Neurol Scand 1974"/>
   <result pre="Shapiro DB Long-term study of propranolol in the treatment of" exact="migraine" post="Headache 1982 22 268 71 7174304 30 Rosen JA"/>
   <result pre="Observations on the efficacy of propranolol for the prophylaxis of" exact="migraine" post="Ann Neurol 1983 13 92 3 6338806 31 Wideroe"/>
   <result pre="31 Wideroe TE Vigander T Propranolol in the treatment of" exact="migraine" post="Br Med J 1974 2 699 701 4604977 32"/>
   <result pre="333 40 1830566 33 Linde K Rossnagel K Propranolol for" exact="migraine" post="prophylaxis Cochrane Database Syst Rev 2004 2 CD003225 34"/>
   <result pre="26 28220376 35 Victor S Ryan SW Drugs for preventing" exact="migraine" post="headaches in children Cochrane Database Syst Rev 2003 4"/>
   <result pre="trial of propranolol versus sodium valproate for the prophylaxis of" exact="migraine" post="in pediatric patients Paediatr Drugs 2010 12 269 75"/>
   <result pre="22135272 38 Hedera P Cibulčík F Davis TL Pharmacotherapy of" exact="essential tremor" post="J Cent Nerv Syst Dis 2013 5 43 55"/>
   <result pre="1752 5 22013182 40 Pal PK Guidelines for management of" exact="essential tremor" post="Ann Indian Acad Neurol 2011 14 S25 8 21847325"/>
   <result pre="Saumier D Tremblay J Propranolol's impact on cognitive performance in" exact="post-traumatic stress disorder" post="J Affect Disord 2016 192 98 103 26707354 48"/>
   <result pre="98 103 26707354 48 Bari K Garcia-Tsao G Treatment of" exact="portal hypertension" post="World J Gastroenterol 2012 18 1166 75 22468079 49"/>
   <result pre="75 22468079 49 Miñano C Garcia-Tsao G Clinical pharmacology of" exact="portal hypertension" post="Gastroenterol Clin North Am 2010 39 681 95 20951924"/>
   <result pre="ligation for the prevention of variceal rebleeding in patients with" exact="cirrhosis" post="Gastroenterology 2002 123 1013 9 12360462 52 Sarin SK"/>
   <result pre="and propranolol in preventing variceal bleeding in patients with noncirrhotic" exact="portal hypertension" post="Gastroenterology 2010 139 1238 45 20547163 53 Di Pascoli"/>
   <result pre="Cost-effectiveness analysis of beta-blockers vs. endoscopic surveillance in patients with" exact="cirrhosis" post="and small varices World J Gastroenterol 2014 20 10464"/>
   <result pre="U Patch D et al. Beta-blockers protect against spontaneous bacterial" exact="peritonitis" post="in cirrhotic patients: A meta-analysis Liver Int 2009 29"/>
   <result pre="H Vilstrup H Keiding S et al. Propranolol treatment of" exact="portal hypertension" post="in cirrhosis patients is better the higher the untreated"/>
   <result pre="Keiding S et al. Propranolol treatment of portal hypertension in" exact="cirrhosis" post="patients is better the higher the untreated pressure: A"/>
   <result pre="candesartan and propranolol combination therapy versus propranolol monotherapy in reducing" exact="portal hypertension" post="Clin Mol Hepatol 2014 20 376 83 25548744 57"/>
   <result pre="DC The beneficial effect of beta-blockers in patients with cirrhosis," exact="portal hypertension" post="and ascites Am J Med Sci 2016 351 169"/>
   <result pre="XP Canary JJ Propranolol and thyroidectomy in the treatment of" exact="thyrotoxicosis" post="Ann Surg 1982 195 766 73 7082068 60 Caswell"/>
   <result pre="Channick BJ Propranolol for the preoperative preparation of patients with" exact="thyrotoxicosis" post="Surg Gynecol Obstet 1978 146 908 10 653566 61"/>
   <result pre="al. A randomized, controlled trial of oral propranolol in infantile" exact="hemangioma" post="N Engl J Med 2015 372 735 46 25693013"/>
   <result pre="et al. Beta-blockers may reduce intrusive thoughts in newly diagnosed" exact="cancer" post="patients Psychooncology 2013 22 1889 94 23255459 69 Jang"/>
   <result pre="JW et al. Perioperative administration of propranolol to women undergoing" exact="ovarian cancer" post="surgery: A pilot study Obstet Gynecol Sci 2017 60"/>
   <result pre="et al. Perioperative administration of propranolol to women undergoing ovarian" exact="cancer" post="surgery: A pilot study Obstet Gynecol Sci 2017 60"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6331488/results/search/disease/results.xml">
   <result pre="of defined physical problems (epilepsy, migraine, asthma, cancer, diabetes, psoriasis," exact="lactose intolerance," post="celiac disease, diarrhea, constipation, daytime enuresis, encopresis) in a"/>
   <result pre="with either ASD or ADHD, such as the association between" exact="autism" post="and epilepsy, which has been documented in many studies"/>
   <result pre="Valicenti-McDermott et al. 2006), eating problems (Rastam et al. 2013)," exact="diarrhea" post="and constipation (Chaidez et al. 2014), headache (Parisi et"/>
   <result pre="al. 2006), eating problems (Rastam et al. 2013), diarrhea and" exact="constipation" post="(Chaidez et al. 2014), headache (Parisi et al. 2014)"/>
   <result pre="(Chaidez et al. 2014), headache (Parisi et al. 2014) and" exact="asthma" post="(Kotey et al. 2014) has been shown in children"/>
   <result pre="in ASD compared to controls; allergy, various autoimmune diseases and" exact="psoriasis" post="(Zerbo et al. 2015). With regards to a link"/>
   <result pre="al. 2015). With regards to a link between type 1" exact="diabetes mellitus" post="(T1DM) and ASD, the results are diverse. One study"/>
   <result pre="A 35% increased risk of children with ASD to have" exact="asthma" post="as compared to children in the general population was"/>
   <result pre="et al. 2014). Some studies have shown increased prevalence of" exact="epilepsy" post="(Cohen et al. 2013), migraine (Fasmer et al. 2011)"/>
   <result pre="have shown increased prevalence of epilepsy (Cohen et al. 2013)," exact="migraine" post="(Fasmer et al. 2011) and asthma (Fasmer et al."/>
   <result pre="(Cohen et al. 2013), migraine (Fasmer et al. 2011) and" exact="asthma" post="(Fasmer et al. 2011) in patients diagnosed with ADHD,"/>
   <result pre="of children with somatic problems. For example, in children with" exact="asthma" post="a significantly higher risk of developing ADHD during the"/>
   <result pre="the school years has been detected compared to children without" exact="asthma" post="(Chen et al. 2013). A recent Swedish study found"/>
   <result pre="review on somatic comorbidity among adults with ADHD found that" exact="asthma" post="is a well-documented comorbidity among adults with ADHD while"/>
   <result pre="for both patients and healthy controls (59.0% vs. 37.8%), and" exact="migraine" post="was found in 26.0% of ADHD cases and 9.9%"/>
   <result pre="prescription of anti-migraine and ADHD medications and higher prevalence of" exact="migraine" post="was found among adults with ADHD in Norway (Fasmer"/>
   <result pre="showed that the most common comorbid NDD among children with" exact="epilepsy" post="was LD with a prevalence of 13% (Chiang and"/>
   <result pre="published investigating coexisting medical conditions in children with diagnoses of" exact="autism" post="and/or ADHD (Schieve et al. 2012). This study found"/>
   <result pre="known to cause physical problems and NDDs alike. Children with" exact="tuberous sclerosis" post="have higher prevalence of ASD and learning disabilities (Mitchell"/>
   <result pre="et al. 2011), but still the field of NDD in" exact="cancer" post="patients is relatively unexplored. Even though comorbidity of NDDs"/>
   <result pre="variety of physical problems (epilepsy, migraine, asthma, cancer, diabetes, psoriasis," exact="lactose intolerance," post="celiac disease, diarrhea, constipation, daytime enuresis, encopresis) and (b)"/>
   <result pre="A-TAC autism-tics, ADHD and other comorbidities, NDD neurodevelopmental disorders, ASD" exact="autism" post="spectrum disorder, ADHD attention-deficit/ hyperactivity disorder; LD learning disorder"/>
   <result pre="Population In this population of 9 or 12 year-old children," exact="asthma" post="had the highest prevalence (14.2%), followed by daytime enuresis"/>
   <result pre="prevalence (14.2%), followed by daytime enuresis (7.4%), encopresis (4.0%), and" exact="migraine" post="(3.5%). Of the GI problems, the most prevalent was"/>
   <result pre="migraine (3.5%). Of the GI problems, the most prevalent was" exact="constipation" post="(8.4%) and lactose intolerance (5.9%) (Figs. 2a–f, 3a–f). All"/>
   <result pre="the GI problems, the most prevalent was constipation (8.4%) and" exact="lactose intolerance" post="(5.9%) (Figs. 2a–f, 3a–f). All physical problems were more"/>
   <result pre="negative peers. Fig. 2 The figures show the prevalence of" exact="epilepsy" post="( a), migraine ( b), asthma ( c), cancer"/>
   <result pre="2 The figures show the prevalence of epilepsy ( a)," exact="migraine" post="( b), asthma ( c), cancer ( d), diabetes"/>
   <result pre="show the prevalence of epilepsy ( a), migraine ( b)," exact="asthma" post="( c), cancer ( d), diabetes ( e) and"/>
   <result pre="of epilepsy ( a), migraine ( b), asthma ( c)," exact="cancer" post="( d), diabetes ( e) and psoriasis ( f)"/>
   <result pre="asthma ( c), cancer ( d), diabetes ( e) and" exact="psoriasis" post="( f) in our study groups and the statistical"/>
   <result pre="by ** and p &amp;lt; 0.001 by ***. NDDs neurodevelopmental disorders, ASD" exact="autism" post="spectrum disorder, ADHD attention-deficit/hyperactivity disorder and LD learning disorder"/>
   <result pre="learning disorder Fig. 3 The figures show the prevalence of" exact="lactose intolerance" post="( a), celiac disease ( b), diarrhea ( c),"/>
   <result pre="prevalence of lactose intolerance ( a), celiac disease ( b)," exact="diarrhea" post="( c), constipation ( d), daytime enuresis ( e)"/>
   <result pre="intolerance ( a), celiac disease ( b), diarrhea ( c)," exact="constipation" post="( d), daytime enuresis ( e) and encopresis ("/>
   <result pre="by ** and p &amp;lt; 0.001 by ***. NDDs neurodevelopmental disorders, ASD" exact="autism" post="spectrum disorder, ADHD attention-deficit/hyperactivity disorder and LD learning disorder"/>
   <result pre="and encopresis (p &amp;lt; 0.001). For children with ASD, the OR of" exact="epilepsy" post="and encopresis were the highest compared to comparison group,"/>
   <result pre="were the highest compared to comparison group, OR 9.9 for" exact="epilepsy" post="and 12.1 for encopresis although prevalence of enuresis was"/>
   <result pre="screened positive for LD only had significantly higher risk of" exact="epilepsy" post="(OR 15) and cancer (OR 3.9), even though asthma,"/>
   <result pre="only had significantly higher risk of epilepsy (OR 15) and" exact="cancer" post="(OR 3.9), even though asthma, celiac disease, diarrhea, constipation,"/>
   <result pre="common than among controls. ADHD was associated with epilepsy, asthma," exact="lactose intolerance," post="diarrhea, constipation, daytime enuresis and encopresis (p &amp;lt; 0.001) (supplementary material)."/>
   <result pre="had an over 36 times increase in the prevalence of" exact="epilepsy" post="(Fig. 2a, OR 36.2), six times increase in the"/>
   <result pre="2a, OR 36.2), six times increase in the prevalence of" exact="constipation" post="(Fig. 3d, OR 6.2), almost 14 times increased prevalence"/>
   <result pre="The coexistence of ASD and ADHD increased the odds for" exact="epilepsy" post="(Fig. 2.a, OR 5.2) migraine (Fig. 2b, OR 3.2),"/>
   <result pre="ADHD increased the odds for epilepsy (Fig. 2.a, OR 5.2)" exact="migraine" post="(Fig. 2b, OR 3.2), asthma (Fig. 2c, OR 2.6),"/>
   <result pre="epilepsy (Fig. 2.a, OR 5.2) migraine (Fig. 2b, OR 3.2)," exact="asthma" post="(Fig. 2c, OR 2.6), cancer (Fig. 2d, OR 5.2),"/>
   <result pre="migraine (Fig. 2b, OR 3.2), asthma (Fig. 2c, OR 2.6)," exact="cancer" post="(Fig. 2d, OR 5.2), diarrhea (Fig. 3c, OR 6.0),"/>
   <result pre="asthma (Fig. 2c, OR 2.6), cancer (Fig. 2d, OR 5.2)," exact="diarrhea" post="(Fig. 3c, OR 6.0), constipation (Fig. 3d, OR 3.4),"/>
   <result pre="cancer (Fig. 2d, OR 5.2), diarrhea (Fig. 3c, OR 6.0)," exact="constipation" post="(Fig. 3d, OR 3.4), daytime enuresis (Fig. 3e, OR"/>
   <result pre="problems and specific NDDs. Recently, the well-documented association between childhood" exact="epilepsy" post="and ASD has been confirmed using the same twin"/>
   <result pre="with both ASD and LD have the highest prevalence of" exact="epilepsy" post="(OR 53), and that as many as 1/5 of"/>
   <result pre="may be affected in childhood. The association between ASD and" exact="epilepsy" post="may be partially mediated by the presence of LD"/>
   <result pre="some symptomatic similarities, e.g. many children with ASD have sensory" exact="hypersensitivity" post="(Sullivan et al. 2014), many migraine patients report symptoms"/>
   <result pre="with ASD have sensory hypersensitivity (Sullivan et al. 2014), many" exact="migraine" post="patients report symptoms such as photophobia during headache attacks"/>
   <result pre="provides some preliminary evidence for a link between migraine, sensory" exact="hypersensitivity" post="and anxiety in ASD (Sullivan et al. 2014). In"/>
   <result pre="present study we found significant increase in the prevalence of" exact="migraine" post="in children with ASD, ADHD and their combination as"/>
   <result pre="through increasing serotonergic activity) can improve repetitive behavioral symptoms of" exact="autism" post="(Hollander et al. 2000). Considering the overlap of migraine"/>
   <result pre="of autism (Hollander et al. 2000). Considering the overlap of" exact="migraine" post="with ADHD, it has previously been suggested that migraine"/>
   <result pre="of migraine with ADHD, it has previously been suggested that" exact="migraine" post="is not comorbid with ADHD in children, but with"/>
   <result pre="et al. 2010). In adult ADHD patients, the risk of" exact="migraine" post="is increased by about 70% (Fasmer, Halmoy, Oedegaard, et"/>
   <result pre="of ADHD in adults seems to indicate a link between" exact="migraine" post="and ADHD (Fasmer et al. 2012). Asthma was found"/>
   <result pre="diagnosis of asthma, found, in line with our results, that" exact="asthma" post="was independently associated with ADHD and LD (Blackman and"/>
   <result pre="2007). Moreover, a study by Chen and co-workers indicated that" exact="asthma" post="in early life among Taiwanese children predispose for ADHD"/>
   <result pre="autonomic nervous system (Ward et al. 2015). The association between" exact="cancer" post="and central nervous system disorders has been explored in"/>
   <result pre="0.3% of children from the comparison group) had a parent-reported" exact="cancer" post="history. Our result should be interpreted with caution as"/>
   <result pre="be interpreted with caution as the number of individuals reporting" exact="cancer" post="was small and that only living children were included."/>
   <result pre="and that only living children were included. The link between" exact="cancer" post="and NDD might speculatively be mediated through the various"/>
   <result pre="cancer and NDD might speculatively be mediated through the various" exact="cancer" post="treatments such as cranial radiation (Edelstein et al. 2011),"/>
   <result pre="addition, it is also well known that many children with" exact="tuberous sclerosis" post="(a proliferative genetic condition) develop ASD and/or have LD"/>
   <result pre="2015). Similarly, in our study we found increased prevalence of" exact="cancer" post="among children with ASD (1.1%) or LD (1.4%). As"/>
   <result pre="al. 2009), while other studies indicate a possible link between" exact="autism" post="and T1DM where 0.9% of children with T1DM in"/>
   <result pre="with T1DM in a tertiary hospital were also diagnosed with" exact="autism" post="(Freeman et al. 2005). In our study, 0.4% of"/>
   <result pre="have also shown significantly higher occurrence of autoimmune diseases (mainly" exact="hypothyroidism" post="and rheumatic fever) in relatives of children with ASD,"/>
   <result pre="ASD, even higher than among family members to children with" exact="autoimmune disease" post="(Sweeten et al. 2003). In a Swedish nationwide register-based"/>
   <result pre="not easily report such problems. Many children with LD or" exact="autism" post="also have impaired communicative abilities, which may further contribute"/>
   <result pre="different subcategories of each problem type/diagnosis such as subtypes of" exact="epilepsy" post="or of migraine. Previous validation studies have shown that"/>
   <result pre="such confounding factors, e.g. pre-, peri- and postnatal factors in" exact="autism" post="(Hisle-Gorman et al. 2018) or shared heritability. Electronic supplementary"/>
   <result pre="2010/507-31/1. References References collab: AmericanPsychiatricAssociation Diagnostic and statistical manual of" exact="mental disorder" post="2013 5 Philadelphia American Psychiatric Association Amiet C Gourfinkel-An"/>
   <result pre="Tordjman S Baulac M Lechat P Cohen D Epilepsy in" exact="autism" post="is associated with intellectual disability and gender: Evidence from"/>
   <result pre="Parner ET Association of family history of autoimmune diseases and" exact="autism" post="spectrum disorders Pediatrics 2009 124 2 687 694 19581261"/>
   <result pre="12193358 Blackman JA Gurka MJ Developmental and behavioral comorbidities of" exact="asthma" post="in children Journal of Developmental and Behavioral Pediatrics 2007"/>
   <result pre="Fernell E Coexisting disorders and problems in preschool children with" exact="autism" post="spectrum disorders Scientific World Journal 2013 Chaidez V Hansen"/>
   <result pre="Chiang KL Cheng CY Prevalence and neuro-psychiatric comorbidities of pediatric" exact="epilepsy" post="in Taiwan: A national population-based study Epilepsy Research 2014"/>
   <result pre="Inbar D Chodick G Shalev V Raz R Prevalence of" exact="epilepsy" post="and attention-deficit hyperactivity (ADHD) disorder: A population-based study Journal"/>
   <result pre="123 22550087 Crawley JN Heyer WD LaSalle JM Autism and" exact="cancer" post="share risk genes, pathways, and drug targets Trends in"/>
   <result pre="26830258 Croen LA Grether JK Selvin S Descriptive epidemiology of" exact="autism" post="in a California population: Who is at risk? Journal"/>
   <result pre="BE Splansky GL Kurth T Wolf PA Inverse association between" exact="cancer" post="and Alzheimer’s disease: Results from the Framingham heart study"/>
   <result pre="BJ Long-term neurocognitive outcomes in young adult survivors of childhood" exact="acute lymphoblastic leukemia" post="Journal of Pediatric Hematology/Oncology 2011 33 6 450 458"/>
   <result pre="Long-term neurocognitive outcomes in young adult survivors of childhood acute" exact="lymphoblastic leukemia" post="Journal of Pediatric Hematology/Oncology 2011 33 6 450 458"/>
   <result pre="neurocognitive outcomes in young adult survivors of childhood acute lymphoblastic" exact="leukemia" post="Journal of Pediatric Hematology/Oncology 2011 33 6 450 458"/>
   <result pre="OB Halmoy A Eagan TM Oedegaard KJ Haavik J Adult" exact="attention deficit hyperactivity disorder" post="is associated with asthma BMC Psychiatry 2011 11 128"/>
   <result pre="Haavik J Adult attention deficit hyperactivity disorder is associated with" exact="asthma" post="BMC Psychiatry 2011 11 128 21819624 Fasmer OB Halmoy"/>
   <result pre="21819624 Fasmer OB Halmoy A Oedegaard KJ Haavik J Adult" exact="attention deficit hyperactivity disorder" post="is associated with migraine headaches European Archives of Psychiatry"/>
   <result pre="Haavik J Adult attention deficit hyperactivity disorder is associated with" exact="migraine" post="headaches European Archives of Psychiatry and Clinical Neuroscience 2011"/>
   <result pre="Lund A Dilsaver SC Hundal O Oedegaard KJ Comorbidity of" exact="migraine" post="with ADHD Journal of Attention Disorders 2012 16 4"/>
   <result pre="Sohl K Veenstra-VanderWeele J Psychophysiological associations with gastrointestinal symptomatology in" exact="autism" post="spectrum disorder Autism Research 2016 Freeman SJ Daneman D"/>
   <result pre="Gervil M Ulrich V Olesen J Russell MB Screening for" exact="migraine" post="in the general population: Validation of a simple questionnaire"/>
   <result pre="Nilsson G Neville B Febrile seizures and epilepsy: Association with" exact="autism" post="and other neurodevelopmental disorders in the child and adolescent"/>
   <result pre="voiding symptoms, and response to medical therapy in children with" exact="attention deficit hyperactivity disorder" post="and autism spectrum disorder Journal of Pediatric Urology 2012"/>
   <result pre="medical therapy in children with attention deficit hyperactivity disorder and" exact="autism" post="spectrum disorder Journal of Pediatric Urology 2012 8 3"/>
   <result pre="L Grether J Risch N On the twin risk in" exact="autism" post="American Journal of Human Genetics 2002 71 4 941"/>
   <result pre="PJ Charles AC Variability of clinical features in attacks of" exact="migraine" post="with aura Cephalalgia 2015 Hansson SL Rojvall AS Rastam"/>
   <result pre="Norrelgen F Kjellmer L Olsson MB Gillberg C Preschoolers with" exact="autism" post="spectrum disorder followed for 2 years: Those who gained"/>
   <result pre="C Nylund CM Prenatal, perinatal, and neonatal risk factors of" exact="autism" post="spectrum disorder Pediatric Research 2018 Hollander E Novotny S"/>
   <result pre="CM Sparen P Cnattingius S Perinatal risk factors for infantile" exact="autism" post="Epidemiology 2002 13 4 417 423 12094096 Instanes JT"/>
   <result pre="Ning Y Kendler KS Sundquist J Chen X Incidence of" exact="cancer" post="in patients with schizophrenia and their first-degree relatives: A"/>
   <result pre="Sundquist J Chen X Incidence of cancer in patients with" exact="schizophrenia" post="and their first-degree relatives: A population-based study in Sweden"/>
   <result pre="ZX Ruan B Maternal infection during pregnancy and risk of" exact="autism" post="spectrum disorders: A systematic review and meta-analysis Brain, Behavior,"/>
   <result pre="Brown AS Sillanpaa M Epilepsy among children and adolescents with" exact="autism" post="spectrum disorders: A population-based study Journal of Autism and"/>
   <result pre="LS Characterization and management of voiding dysfunction in children with" exact="attention deficit hyperactivity disorder" post="Urology 2010 76 1 220 224 20350758 Kohane IS"/>
   <result pre="S The co-morbidity burden of children and young adults with" exact="autism" post="spectrum disorders PLoS ONE 2012 7 4 e33224 22511918"/>
   <result pre="e33224 22511918 Kotey S Ertel K Whitcomb B Co-occurrence of" exact="autism" post="and asthma in a nationally-representative sample of children in"/>
   <result pre="Kotey S Ertel K Whitcomb B Co-occurrence of autism and" exact="asthma" post="in a nationally-representative sample of children in the United"/>
   <result pre="Markers of celiac disease and gluten sensitivity in children with" exact="autism" post="PLoS ONE 2013 8 6 e66155 23823064 Li Q"/>
   <result pre="Engstrom AC Nylander C Fernell E Adolescents with type 1" exact="diabetes mellitus" post="and attention-deficit/hyperactivity disorder require specific support from healthcare professionals"/>
   <result pre="and behavioral problems and gastrointestinal symptoms among children with high-functioning" exact="autism" post="Autism 2014 18 5 493 501 24104507 Mazurek MO"/>
   <result pre="LA Anxiety, sensory over-responsivity, and gastrointestinal problems in children with" exact="autism" post="spectrum disorders Journal of Abnormal Child Psychology 2013 41"/>
   <result pre="Herman GE Confirmation study of PTEN mutations among individuals with" exact="autism" post="or developmental delays/mental retardation and macrocephaly Autism Research 2010"/>
   <result pre="BO McCracken C Karpen S Sharp WG Gastrointestinal symptoms in" exact="autism" post="spectrum disorder: A meta-analysis Pediatrics 2014 McKeown C Hisle-Gorman"/>
   <result pre="Hisle-Gorman E Eide M Gorman GH Nylund CM Association of" exact="constipation" post="and fecal incontinence with attention-deficit/hyperactivity disorder Pediatrics 2013 132"/>
   <result pre="Harvey AS Williams K Risk factors for the development of" exact="autism" post="spectrum disorder in children with tuberous sclerosis complex: protocol"/>
   <result pre="for the development of autism spectrum disorder in children with" exact="tuberous sclerosis" post="complex: protocol for a systematic review Systematic Review 2017"/>
   <result pre="Pelham WE Jr. Fabiano GA Massetti GM Evidence-based assessment of" exact="attention deficit hyperactivity disorder" post="in children and adolescents Journal of Clinical Child and"/>
   <result pre="P Kerekes N Eating problems and overlap with ADHD and" exact="autism" post="spectrum disorders in a nationwide twin study of 9-"/>
   <result pre="S Loucas T Baird G Psychiatric disorders in children with" exact="autism" post="spectrum disorders: prevalence, comorbidity, and associated factors in a"/>
   <result pre="association with sensory hyperreactivity and anxiety symptomatology in children with" exact="autism" post="spectrum disorder Autism 2014 18 6 743 747 24072661"/>
   <result pre="M Takase M Sasaki H Sleep disorder in children with" exact="autism" post="Psychiatry and Clinical Neuroscience 1998 52 2 182 183"/>
   <result pre="with autistic spectrum disorders and association with family history of" exact="autoimmune disease" post="Journal of Developmental and Behavioral Pediatrics 2006 27 2"/>
   <result pre="Pirrung M Niemczyk J Equit M Incontinence in children with" exact="autism" post="spectrum disorder Journal of Pediatric and Urology 2015 11"/>
   <result pre="Bernal P Fireman B Croen LA Immune mediated conditions in" exact="autism" post="spectrum disorders Brain, Behavior, and Immunity 2015 46 232"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6332564/results/search/disease/results.xml">
   <result pre="idiopathic. Secondary trochleitis is rare, and trochleitis associated with paranasal" exact="sinusitis" post="in children has not yet been reported. Case presentation"/>
   <result pre="imaging showed focal enhancement on the left trochlea and paranasal" exact="sinusitis" post="on the left side. The patient’s symptoms and signs"/>
   <result pre="no need to inject a local steroid. Conclusion Although rare," exact="sinusitis" post="should be considered when diagnosing and treating trochleitis in"/>
   <result pre="idiopathic. Secondary trochleitis is rare and is associated with systemic" exact="autoimmune disease" post="or lymphoma [ 1, 2]. Herein, we report the"/>
   <result pre="is rare and is associated with systemic autoimmune disease or" exact="lymphoma" post="[ 1, 2]. Herein, we report the first case"/>
   <result pre="were normal, although there were 10 prism diopters of intermittent" exact="exotropia" post="as determined by prism and alternate cover testing. There"/>
   <result pre="on the left trochlea (Fig. 1). Left frontal, ethmoidal, and" exact="maxillary sinusitis" post="was also detected. The patient, however, had not been"/>
   <result pre="the left trochlea (Fig. 1). Left frontal, ethmoidal, and maxillary" exact="sinusitis" post="was also detected. The patient, however, had not been"/>
   <result pre="leukotriene receptor antagonist, and steroid nasal sprays to control the" exact="sinusitis" post="and rhinitis. The symptoms and signs were completely resolved"/>
   <result pre="demonstrating enhancement on the left trochlea (arrows). Frontal, ethmoidal, and" exact="maxillary sinusitis" post="is also observed. a axial image, b coronal image"/>
   <result pre="enhancement on the left trochlea (arrows). Frontal, ethmoidal, and maxillary" exact="sinusitis" post="is also observed. a axial image, b coronal image"/>
   <result pre="the trochlear region without evidence of inflammation [ 3]. Trochlear" exact="migraine" post="is diagnosed when exacerbation of the trochlear pain triggers"/>
   <result pre="is diagnosed when exacerbation of the trochlear pain triggers a" exact="migraine" post="attack [ 1]. Trochleitis is trochlear pain with evidence"/>
   <result pre="through a trochlea generates chronic microtrauma, which results in stenosing" exact="tenosynovitis" post="[ 1]. Secondary trochleitis associated with rheumatologic and immunologic"/>
   <result pre="with rheumatologic and immunologic disorders, including systemic lupus erythematous and" exact="rheumatoid arthritis," post="can develop [ 1, 7]. Because the majority of"/>
   <result pre="in children has never been reported. However, orbital infections including" exact="orbital cellulitis" post="and orbital abscesses are well known and common complications"/>
   <result pre="children has never been reported. However, orbital infections including orbital" exact="cellulitis" post="and orbital abscesses are well known and common complications"/>
   <result pre="and orbital abscesses are well known and common complications of" exact="sinusitis" post="in children [ 9, 10]. Incomplete paranasal sinus development"/>
   <result pre="reason [ 11]. In our case, the child with paranasal" exact="sinusitis" post="presented with focal isolated inflammation in the trochlea area."/>
   <result pre="area. His symptoms resolved after 2 weeks of empirical treatments for" exact="sinusitis" post="and rhinitis. There was no need for local steroid"/>
   <result pre="considered as the treatment for general trochleitis. Ruling out paranasal" exact="sinusitis" post="is recommended before initiating oral or local corticosteroid treatment"/>
   <result pre="is the first report of isolated trochleitis associated with paranasal" exact="sinusitis" post="in a pediatric patient. Although rare, sinusitis should be"/>
   <result pre="associated with paranasal sinusitis in a pediatric patient. Although rare," exact="sinusitis" post="should be considered when diagnosing and treating trochleitis in"/>
   <result pre="Tse DT Ossoinig K Anderson RL Trochleitis with superior oblique" exact="myositis" post="Ophthalmology 1984 91 1075 1079 10.1016/S0161-6420(84)34198-7 6387570 5. Jarrin"/>
   <result pre="Buitrago Gomez A Acquired Brown's syndrome in a patient with" exact="systemic lupus erythematosus" post="Ann Rheum Dis 1993 52 63 64 10.1136/ard.52.1.63 8427518"/>
   <result pre="Gomez A Acquired Brown's syndrome in a patient with systemic" exact="lupus erythematosus" post="Ann Rheum Dis 1993 52 63 64 10.1136/ard.52.1.63 8427518"/>
   <result pre="Miller NR Bilateral sequential trochleitis as the presenting feature of" exact="systemic lupus erythematosus" post="J Neuroophthalmol 2013 33 74 76 10.1097/WNO.0b013e318275a597 23114286 8."/>
   <result pre="NR Bilateral sequential trochleitis as the presenting feature of systemic" exact="lupus erythematosus" post="J Neuroophthalmol 2013 33 74 76 10.1097/WNO.0b013e318275a597 23114286 8."/>
   <result pre="10.1001/archotol.1984.00800280054016 6696682 9. Oxford LE McClay J Complications of acute" exact="sinusitis" post="in children Otolaryngol Head Neck Surg 2005 133 32"/>
   <result pre="10.1016/j.amjoto.2009.10.002 20031268 11. Arjmand EM Lusk RP Muntz HR Pediatric" exact="sinusitis" post="and subperiosteal orbital abscess formation: diagnosis and treatment Otolaryngol"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6343438/results/search/disease/results.xml">
   <result pre="no previous history of brain injury or developmental delay or" exact="sleep disorder" post="or psychiatric disorder. Those with concussion were invited to"/>
   <result pre="2007). A factor analysis has identified four symptom clusters including" exact="migraine" post="(physical), cognitive, sleep, and psychiatric (mood-affect) Kontos et al.,"/>
   <result pre="with total symptoms and symptom clusters including sleep symptoms and" exact="migraine" post="(physical symptom cluster) ( Murdaugh et al., 2018). Furthermore,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6353836/results/search/disease/results.xml">
   <result pre="calcitonin gene-related peptide (CGRP) plays a key role in the" exact="migraine" post="pathophysiology. This study aimed to investigate its role in"/>
   <result pre="Plasma CGRP concentrations were measured by ELISA. Results: In the" exact="migraine" post="group, more patients required acute therapy, as compared to"/>
   <result pre="the other preventives. Conclusion: The plasma CGRP level can differentiate" exact="migraine" post="from non-migraine headache. It may also serve as a"/>
   <result pre="the therapeutic strategy since it is higher in patients requiring" exact="migraine" post="prevention and responsive to short-term topiramate treatment. These results"/>
   <result pre="practice for the diagnosis and treatment of pediatric migraine. pediatric" exact="migraine" post="calcitonin gene-related peptide plasma biomarker anti-migraine drugs topiramate fig-count:"/>
   <result pre="of medication for a certain time period ( 5). The" exact="migraine" post="associations such as abdominal pain, limb pain, and motion"/>
   <result pre="The migraine associations such as abdominal pain, limb pain, and" exact="motion sickness" post="are common in children ( 6) but less in"/>
   <result pre="there are limited reports on the efficacy and safety of" exact="migraine" post="medications in the pediatric group. Only a few randomized"/>
   <result pre="CGRP has been shown to play a causative role in" exact="migraine" post="attacks since its level is shown to be elevated"/>
   <result pre="attacks since its level is shown to be elevated during" exact="migraine" post="attacks ( 10). Thus, CGRP is believed to be"/>
   <result pre="Thus, CGRP is believed to be a potential biomarker of" exact="migraine" post="( 11– 21). Pre-clinical studies have shown that trigeminal"/>
   <result pre="( 22– 24), resulting in pia vessel dilatation, leading to" exact="migraine" post="( 17). Moreover, CGRP antagonists can reduce cortical spreading"/>
   <result pre="which is believed to be an important pathogenic manifestation of" exact="migraine" post="with aura ( 18, 20, 21), in animal models"/>
   <result pre="considerably higher than those in healthy controls ( 15). During" exact="migraine" post="attacks, plasma CGRP levels are elevated in both adult"/>
   <result pre="CGRP receptor antagonist, olcegepant (BIBN4096BS), is effective in treating acute" exact="migraine" post="attacks ( 16) and anti-CGRP or anti-CGRP receptor monoclonal"/>
   <result pre="and anti-CGRP or anti-CGRP receptor monoclonal antibodies are approved for" exact="migraine" post="prevention ( 25, 26). Third, triptans, clinically effective anti-migraine"/>
   <result pre="of the plasma CGRP level in pediatric migraine, especially during" exact="migraine" post="attack ( 19). The present study further explored whether"/>
   <result pre="below 12 years and had never taken any medicine for" exact="migraine" post="prevention. There were 68 patients with migraine, 30 patents"/>
   <result pre="headache and 22 non-headache control subjects. The diagnosis of pediatric" exact="migraine" post="was based on the criteria of the International Classification"/>
   <result pre="compliance in children and the intent to seek for efficient" exact="migraine" post="preventives, we measured the short-term therapeutic response for at"/>
   <result pre="IL). Results Plasma samples were collected from 68 patients with" exact="migraine" post="(28 boys) aged 5–18 years (mean age, 11.7 ±"/>
   <result pre="response to each drug ( p &amp;gt; 0.05). In the" exact="migraine" post="group, 91% (62 out of 68 patients) required acute"/>
   <result pre="and Migraine Treatment Plasma CGRP levels were significantly different among" exact="migraine" post="(during or between attacks), non-migraine headache, and non-headache control"/>
   <result pre="that plasma CGRP is a potential diagnostic biomarker for pediatric" exact="migraine" post="( 19). Furthermore, a relatively higher plasma CGRP level"/>
   <result pre="CGRP level to serve as a biomarker guiding the pediatric" exact="migraine" post="treatment, which has never been mentioned before. According to"/>
   <result pre="in pain relief in a double-blind cross-over study of childhood" exact="migraine" post="( 28). The response rate of acetaminophen (42%) in"/>
   <result pre="that even as a second-line drug of choice for acute" exact="migraine" post="treatment, NSAIDs are better than acetaminophen (response rate: 56"/>
   <result pre="be not significantly superior to placebo in a trial on" exact="migraine" post="in Finland children ( 30). However, it was effective"/>
   <result pre="younger than 10 year old as a first-line choice for" exact="migraine" post="headache ( 31). Only one-third of patients here responded"/>
   <result pre="approved by the United States Food and Drug Administration for" exact="migraine" post="prevention for adults ( 33), is the highest (75%)."/>
   <result pre="drugs in this study. The effectiveness of beta-blockers for pediatric" exact="migraine" post="remains controversial ( 35– 37). This study shows that"/>
   <result pre="the findings of Bidabadi and Mashouf ( 38) in pediatric" exact="migraine" post="prophylaxis. The effectiveness of gabapentin in pediatric migraine has"/>
   <result pre="in pediatric migraine prophylaxis. The effectiveness of gabapentin in pediatric" exact="migraine" post="has rarely been studied ( 33, 39). The present"/>
   <result pre="use of gabapentin was found to be ineffective in adult" exact="migraine" post="treatment ( 40). The present study showed that plasma"/>
   <result pre="study showed that plasma CGRP can significantly differentiate children with" exact="migraine" post="from non-headache controls as well as from non-migraine headache."/>
   <result pre="that the recruited patients with relatively more severe or frequent" exact="migraine" post="headaches who need either acute or preventive therapy in"/>
   <result pre="acute therapy. It is interesting that disability, evaluated by pediatric" exact="migraine" post="assessment score (PedMIDAS), tended to be higher in patients"/>
   <result pre="could be a biomarker helping in the diagnosis of chronic" exact="migraine" post="in adults, whose pain pathways become sensitized after repeated"/>
   <result pre="with higher plasma CGRP levels may suffer from more frequent" exact="migraine" post="attacks, which may cause disability and require preventive therapy."/>
   <result pre="biomarker not only for determining the severity or chronicity of" exact="migraine" post="( 19, 42) but also for predicting the need"/>
   <result pre="0.81 and specificity 0.75 in predicting the diagnosis of pediatric" exact="migraine" post="in our previous study ( 19). Topiramate was developed"/>
   <result pre="anti-epileptic drug and was also found to be effective in" exact="migraine" post="prevention ( 45). Multi-center, randomized, double-blind, placebo-controlled trials established"/>
   <result pre="of topiramate in significantly reducing the frequency and severity of" exact="migraine" post="attacks in adults ( 46, 47). Topiramate also showed"/>
   <result pre="several open-label or randomized, double-blind, placebo-controlled studies in children with" exact="migraine" post="( 48, 49). However, its exact anti-migraine mechanism(s) remain"/>
   <result pre="inhibition of neurogenic dural vasodilatation ( 50). Pre-clinical studies in" exact="migraine" post="animal models have shown that topiramate inhibited neurogenic dural"/>
   <result pre="and dura ( 23, 24) of rats in a capsaicin-stimulated" exact="migraine" post="model ( 22). Topiramate has been also reported to"/>
   <result pre="were recently identified to be a novel drug target for" exact="migraine" post="treatment ( 23). It remains to be elucidated whether"/>
   <result pre="that the prophylactic effect of topiramate is mediated by a" exact="suppression" post="of CGRP release, which is a marker of trigeminal"/>
   <result pre="a potential biomarker for guiding the drug of choice for" exact="migraine" post="prevention. Some limitations of this study need to be"/>
   <result pre="cause body weight loss in some patients ( 55) and" exact="obesity" post="has been highlighted to be significantly associated with headache"/>
   <result pre="this study suggest that the plasma CGRP level can differentiate" exact="migraine" post="from non-migraine headache conditions in pediatric patients. It may"/>
   <result pre="of CGRP was significantly higher in pediatric migraineurs who required" exact="migraine" post="prophylaxis and were topiramate-responsive. Our results also suggest that"/>
   <result pre="into the clinical practice for the diagnosis and treatment of" exact="migraine" post="in children. Author Contributions P-CF designed and conducted experiments,"/>
   <result pre="References References 1. Goadsby PJ . Recent advances in understanding" exact="migraine" post="mechanisms, molecules and therapeutics. Trends Mol Med. ( 2007)"/>
   <result pre="1545– 602. 10.1016/S0140-6736(16)31678-6 27733282 4. Silberstein SD . Current management:" exact="migraine" post="headache. CNS Spectr. ( 2017) 22: 1– 13. 10.1017/S1092852917000864"/>
   <result pre="Gentile S et al. . Migraine equivalents as part of" exact="migraine" post="syndrome in childhood. Pediatr Neurol. ( 2014) 51: 645–"/>
   <result pre="25155656 7. Silberstein SD . Practice parameter: evidence-based guidelines for" exact="migraine" post="headache (an evidence-based review): report of the Quality Standards"/>
   <result pre="Papetti L Rubio-Beltran E et al. . Blocking CGRP in" exact="migraine" post="patients—a review of pros and cons. J Headache Pain"/>
   <result pre="al. . Vasoactive peptide levels in the plasma of young" exact="migraine" post="patients with and without aura assessed both interictally and"/>
   <result pre="Olajos S Jakab B Nemeth J et al. . NO-induced" exact="migraine" post="attack: strong increase in plasma calcitonin gene-related peptide (CGRP)"/>
   <result pre="receptor antagonist BIBN 4096 BS for the acute treatment of" exact="migraine" post=". N Engl J Med. ( 2004) 350: 1104–"/>
   <result pre="10.1111/j.1468-2982.2008.01816.x 19236383 20. Ayata C . Cortical spreading depression triggers" exact="migraine" post="attack: pro. Headache ( 2010) 50: 725– 30. 10.1111/j.1526-4610.2010.01647.x"/>
   <result pre="Different trigemino-vascular responsiveness between adolescent and adult rats in a" exact="migraine" post="model . Cephalalgia ( 2012) 32: 979– 90. 10.1177/0333102412455710"/>
   <result pre="monoclonal CGRP antibody in development for the preventive treatment of" exact="migraine" post=". Curr Pain Headache Rep. ( 2015) 19: 6."/>
   <result pre="K Krause DN . CGRP as the target of new" exact="migraine" post="therapies—successful translation from bench to clinic . Nat Rev"/>
   <result pre="P . Ibuprofen or acetaminophen for the acute treatment of" exact="migraine" post="in children: a double-blind, randomized, placebo-controlled, crossover study ."/>
   <result pre="30. Hamalainen ML Hoppu K Santavuori P . Sumatriptan for" exact="migraine" post="attacks in children: a randomized placebo-controlled study. Do children"/>
   <result pre="attacks in children: a randomized placebo-controlled study. Do children with" exact="migraine" post="respond to oral sumatriptan differently from adults? Neurology ("/>
   <result pre="31. Bille B Ludvigsson J Sanner G . Prophylaxis of" exact="migraine" post="in children. Headache ( 1977) 17: 61– 3. 10.1111/j.1526-4610.1977.hed1702061.x"/>
   <result pre="GR Mahfelati F . Sodium valproate versus propranolol in paediatric" exact="migraine" post="prophylaxis. Eur J Paediatr Neurol. ( 2005) 9: 333–"/>
   <result pre="trial of propranolol versus sodium valproate for the prophylaxis of" exact="migraine" post="in pediatric patients . Paediatr Drugs ( 2010) 12:"/>
   <result pre="Mccrory DC Gabapentin or pregabalin for the prophylaxis of episodic" exact="migraine" post="in adults. Cochr Database Syst Rev. ( 2013) CD010609."/>
   <result pre="CGRP levels in peripheral blood as a biomarker for chronic" exact="migraine" post=". Neurology ( 2013) 81: 1191– 6. 10.1212/WNL.0b013e3182a6cb72 23975872"/>
   <result pre="194: 451– 91. 10.1007/978-3-540-79090-7_13 45. Silberstein SD . Topiramate in" exact="migraine" post="prevention. Headache ( 2005) 45 ( Suppl. 1): S57–"/>
   <result pre="JR Lewis DW Schmitt J et al. . Topiramate for" exact="migraine" post="prevention: a randomized controlled trial. JAMA ( 2004) 291:"/>
   <result pre="SD Neto W Schmitt J Jacobs D . Topiramate in" exact="migraine" post="prevention: results of a large controlled trial. Arch Neurol."/>
   <result pre="SL Jordan DM Fisher AC Hulihan J . Topiramate for" exact="migraine" post="prevention in children: a randomized, double-blind, placebo-controlled trial ."/>
   <result pre="receptor alpha6 expression in the trigeminal ganglion alters inflammatory TMJ" exact="hypersensitivity" post=". Neuroscience ( 2012) 213: 179– 90. 10.1016/j.neuroscience.2012.03.059 22521829"/>
   <result pre="changes associated with antiepileptic mood stabilizers in the treatment of" exact="bipolar disorder" post=". Eur J Clin Pharmacol. ( 2018) 74: 1485–"/>
   <result pre="Pavone P Verrotti A Lubrano R et al. . Headache," exact="migraine" post="and obesity: an overview on plausible links. J Biol"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6360466/results/search/disease/results.xml">
   <result pre="cat scratch disease infection and suggests that cat scratch disease" exact="encephalitis" post="should be considered during evaluation of a pediatric patient"/>
   <result pre="pediatric patient with acute flaccid paralysis. EEG electroencephalogram pediatric adolescents" exact="encephalitis" post="Todd paralysis infectious disease cat scratch disease epidemiology In"/>
   <result pre="acute flaccid paralysis. EEG electroencephalogram pediatric adolescents encephalitis Todd paralysis" exact="infectious disease" post="cat scratch disease epidemiology In the United States, there"/>
   <result pre="and on average appear within 2 weeks after fever and" exact="lymphadenopathy" post="onset. 1, 2 The authors present a case of"/>
   <result pre="2 The authors present a case of cat scratch disease" exact="encephalitis" post="with acute flaccid paralysis of the left arm alongside"/>
   <result pre="a concern for infectious encephalitis. Despite the normal CSF, infectious" exact="encephalitis" post="was still in the differential diagnosis. The patient’s presentation"/>
   <result pre="differential diagnosis. The patient’s presentation raised clinical suspicion for an" exact="encephalitis" post="and some studies demonstrate normocellular CSF can occur in"/>
   <result pre="represented a postictal state after an unwitnessed seizure, particularly since" exact="herpes simplex" post="virus encephalitis was in the differential diagnosis. The morning"/>
   <result pre="state after an unwitnessed seizure, particularly since herpes simplex virus" exact="encephalitis" post="was in the differential diagnosis. The morning after admission,"/>
   <result pre="unlikely diagnosis, as the patient did not exhibit features of" exact="tic disorder" post="or obsessive compulsive disorder associated with the syndrome. 6"/>
   <result pre="suggestive of acute infection. 14 – 17 High titers alongside" exact="encephalopathy" post="support the diagnosis of Bartonella encephalitis. The infectious disease"/>
   <result pre="titers alongside encephalopathy support the diagnosis of Bartonella encephalitis. The" exact="infectious disease" post="team chose doxycycline monotherapy rather than adding rifampin due"/>
   <result pre="19 In one large study from Toronto, 60% of pediatric" exact="encephalitis" post="cases presented with focal seizures and 50% had other"/>
   <result pre="patients with cat scratch disease who have neurological manifestations, encephalopathy," exact="status epilepticus," post="convulsions, retinitis, cerebral vasculitis, and transverse myelitis are all"/>
   <result pre="disease who have neurological manifestations, encephalopathy, status epilepticus, convulsions, retinitis," exact="cerebral vasculitis," post="and transverse myelitis are all documented presentations. 20 –"/>
   <result pre="manifestations, encephalopathy, status epilepticus, convulsions, retinitis, cerebral vasculitis, and transverse" exact="myelitis" post="are all documented presentations. 20 – 24 Encephalopathy is"/>
   <result pre="child who had temporary right hemiparesis after cat scratch disease–associated" exact="status epilepticus," post="suggestive of Todd paralysis. 27 There have also been"/>
   <result pre="been at least two case reports of cat scratch disease–associated" exact="vasculitis" post="as etiology for stroke and resultant hemiparesis. 2 One"/>
   <result pre="case reports of cat scratch disease–associated vasculitis as etiology for" exact="stroke" post="and resultant hemiparesis. 2 One retrospective review found 20"/>
   <result pre="reports suggest that the flaccid paralysis from cat scratch disease" exact="encephalitis" post="could be due to a direct infection of the"/>
   <result pre="case describes a patient who died from cat scratch disease–associated" exact="encephalitis" post="and microglial nodules were found on his brain biopsy"/>
   <result pre="patient also had no personal or family history of classic" exact="migraine" post="or hemiplegic migraine, the latter of which is a"/>
   <result pre="AW Wacharapluesadee S Petcharat S et al. Normocellular CSF in" exact="herpes simplex" post="encephalitis. BMC Research Notes, 2016; 9 doi:10.1186/s13104-016-1922-9. 26728848 4"/>
   <result pre="Byington CL Shah SS et al. The management of community-acquired" exact="pneumonia" post="in infants and children older than 3 months of"/>
   <result pre="quintana and Afipia felis antigens in 64 patients with suspected" exact="cat-scratch disease" post=". Scand J Infect Dis. 1996; 28( 4): 361–"/>
   <result pre="Ford-Jones EL Richardson S et al. Etiology of acute childhood" exact="encephalitis" post="at the hospital for sick children, Toronto, 1994-1995 ."/>
   <result pre="MT Lattuada CP Jr Dolan MJ Schwab IR Bartonella henselae" exact="neuroretinitis" post="in cat scratch disease. Diagnosis, management, and sequelae ."/>
   <result pre="169. 7551113 22 Selby G Walker GL Cerebral arteritis in" exact="cat-scratch disease." post="Neurology. 1979; 29( 10): 1413– 1418. 573385 23 Baylor"/>
   <result pre="A Karpathios T Lutz J Mogelof J Moseley D Transverse" exact="myelitis" post="in 2 patients with Bartonella henselae infection (cat scratch"/>
   <result pre="Pellegrino LN Riella LV Martins LT Acute hemiplegia associated with" exact="cat-scratch disease." post="Braz J Infect Dis. 2004; 8( 3): 263– 266."/>
   <result pre="with cat-scratch disease: case report and literature review of vertebral" exact="osteomyelitis" post="caused by Bartonella henselae . Pediatr Infect Dis J."/>
   <result pre="case of fatal disseminated Bartonella henselae infection (cat-scratch disease) with" exact="encephalitis" post=". Arch Pathol Lab Med. 2007; 131( 10): 1591–"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6366439/results/search/disease/results.xml">
   <result pre="of patients with a wide spectrum of neurological conditions including" exact="stroke" post="[ 16, 21, 22], headache [ 23– 25], multiple"/>
   <result pre="including stroke [ 16, 21, 22], headache [ 23– 25]," exact="multiple sclerosis" post="[ 26], mental health disorders [ 27, 28], epilepsy"/>
   <result pre="multiple sclerosis [ 26], mental health disorders [ 27, 28]," exact="epilepsy" post="[ 29, 30] and neurodegenerative diseases [ 31– 34]."/>
   <result pre="Dix-Hallpike and supine roll testing for patients with suspected post-traumatic" exact="benign paroxysmal positional vertigo." post="In addition, a cervical spine examination is performed including"/>
   <result pre="vestibulo-ocular dysfunction, cervical spine dysfunction, exercise intolerance, post-traumatic headaches or" exact="migraine" post="headaches and post-injury mood or psychiatric disorders [ 39,"/>
   <result pre="concussion (6; 30%), depression (2; 10%), anxiety (1, 5%) and" exact="attention deficit hyperactivity disorder" post="(1; 5%). Mechanisms of injury included hockey (10; 50%),"/>
   <result pre="acute concussion, 1 (5%) was diagnosed with PPCS and post-traumatic" exact="migraine" post="headaches and 2 infants were diagnosed with head injuries."/>
   <result pre="This approach has been successfully applied to disorders, such as" exact="stroke" post="[ 52] and paediatric headache [ 23], and may"/>
   <result pre=", Lindsay MP , Foley N , et al Canadian" exact="stroke" post="best practice recommendations: telestroke best practice guidelines update 2017"/>
   <result pre="Wiebe S , Mann C , et al Telemedicine and" exact="epilepsy" post="care - a Canada wide survey. Can J Neurol"/>
   <result pre="Boyd EL , Barrett KM , et al Comparison of" exact="stroke" post="outcomes of hub and spoke hospital treated patients in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6368276/results/search/disease/results.xml">
   <result pre="with or without mouth opening limitation (Group 2-G2); and arthralgia," exact="osteoarthritis" post="and osteoarthrosis (Group 3-G3). The prevalence of TMD was"/>
   <result pre=", Woolf CJ . Central sensitization: a generator of pain" exact="hypersensitivity" post="by central neural plasticity. Journal of Pain. 2009; 10:"/>
   <result pre="MB , Javaras KN , Hess EV . Comorbidity of" exact="fibromyalgia" post="and psychiatric disorders. J Clin Psychiatric. 2006; 67: 1219–"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6369373/results/search/disease/results.xml">
   <result pre="due to a lesion, has been documented in strokes and" exact="multiple sclerosis," post="which is often manifested as unilateral movements that are"/>
   <result pre="history of focal dystonia or seizures. The mother reported occasional" exact="migraine" post="headaches. For our case patient, oxcarbazepine was initiated at"/>
   <result pre="that are often preceded by an aura and include dystonia," exact="chorea" post="or athetosis, and can be bilateral, unilateral or asymmetric."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6375438/results/search/disease/results.xml">
   <result pre="serious medical condition, such as high fever, severe pain, or" exact="migraine" post="headaches. They should always ask their doctor before taking"/>
   <result pre="more serious conditions, such as high fever, severe pain, or" exact="migraine" post="headaches. &quot;Pregnant women should always consult with a physician"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6380461/results/search/disease/results.xml">
   <result pre="of 33) of the late-stage pipeline of antibody therapeutics for" exact="cancer" post="are immune checkpoint modulators or antibody-drug conjugates. Of these,"/>
   <result pre="Keywords antibody therapeutics Food and Drug Administration European Medicines Agency" exact="cancer" post="immune-mediated disorders success rates fig-count: table-count: ref-count: page-count: Introduction"/>
   <result pre="for a wide variety of immune-mediated disorders (rheumatoid arthritis, juvenile" exact="rheumatoid arthritis," post="Crohn’s disease, psoriatic arthritis, psoriasis, axial spondyloarthritis, ulcerative colitis,"/>
   <result pre="of immune-mediated disorders (rheumatoid arthritis, juvenile rheumatoid arthritis, Crohn’s disease," exact="psoriatic arthritis," post="psoriasis, axial spondyloarthritis, ulcerative colitis, uveitis, hidradenitis suppurativa and"/>
   <result pre="juvenile rheumatoid arthritis, Crohn’s disease, psoriatic arthritis, psoriasis, axial spondyloarthritis," exact="ulcerative colitis," post="uveitis, hidradenitis suppurativa and Behçet syndrome). Compared to phage"/>
   <result pre="Crohn’s disease, psoriatic arthritis, psoriasis, axial spondyloarthritis, ulcerative colitis, uveitis," exact="hidradenitis suppurativa" post="and Behçet syndrome). Compared to phage display, the discovery"/>
   <result pre="James P. Allison and Tasuku Honjo for their discovery of" exact="cancer" post="therapy by inhibition of negative immune regulation. 6 Tasuku"/>
   <result pre="used to treat many types of cancers, including melanoma, non-small-cell" exact="lung cancer," post="renal cell cancer, urothelial carcinoma, hepatocellular cancer, gastric cancer,"/>
   <result pre="cancer, renal cell cancer, urothelial carcinoma, hepatocellular cancer, gastric cancer," exact="colorectal cancer," post="head and neck cancer, Merkel cell carcinoma and Hodgkin’s"/>
   <result pre="cell cancer, urothelial carcinoma, hepatocellular cancer, gastric cancer, colorectal cancer," exact="head and neck cancer," post="Merkel cell carcinoma and Hodgkin’s lymphoma. Remarkably, there are"/>
   <result pre="shows a remarkable trend toward development of antibody therapeutics for" exact="cancer" post="at the expense of the development of such therapeutics"/>
   <result pre="therapeutics for non-cancer indications only. Red bars, antibody therapeutics for" exact="cancer" post="only. Dotted lines, 2-year moving averages. Totals include only"/>
   <result pre="entering clinical studies during 2000–2009 indicated that mAbs developed for" exact="cancer" post="indications had lower phase transition rates and a lower"/>
   <result pre="therapeutics for non-cancer indications only. Red bars, antibody therapeutics for" exact="cancer" post="only. Cohorts included only antibody therapeutics sponsored by commercial"/>
   <result pre="2000–09: all, n = 357; non-cancer only, n = 181;" exact="cancer" post="only, n = 176. Final fates (approval or termination)"/>
   <result pre="therapeutics for non-cancer indications only. Red bars, antibody therapeutics for" exact="cancer" post="only. Cohorts included only antibody therapeutics sponsored by commercial"/>
   <result pre="2005–14: all, n = 569; non-cancer only, n = 295;" exact="cancer" post="only, n = 274. Final fates (approval or termination)"/>
   <result pre="that approval success rates were lower for mAbs developed for" exact="cancer" post="vs non-cancer indications, but the difference (21 vs 24%,"/>
   <result pre="are for cancer. The numbers of mAbs intended to treat" exact="cancer" post="vs non-cancer indications are similar for mAbs currently at"/>
   <result pre="of the products are for such diseases, including 3 for" exact="migraine" post="prevention and 1 for human immunodeficiency virus (HIV) infection."/>
   <result pre="Migraine prevention 11/14/2018 9/27/2018 Burosumab Crysvita FGF23; Human IgG1 X-linked" exact="hypophosphatemia" post="2/19/2018 4/17/2018 Lanadelumab Takhzyro Plasma kallikrein; Human IgG1 Hereditary"/>
   <result pre="hypophosphatemia 2/19/2018 4/17/2018 Lanadelumab Takhzyro Plasma kallikrein; Human IgG1 Hereditary" exact="angioedema" post="attacks 11/22/2018 8/23/2018 Caplacizumab Cablivi von Willebrand factor; Humanized"/>
   <result pre="11/22/2018 8/23/2018 Caplacizumab Cablivi von Willebrand factor; Humanized Nanobody Acquired" exact="thrombotic thrombocytopenic purpura" post="8/31/2018 In review Mogamulizumab Poteligeo CCR4; Humanized IgG1 Mycosis"/>
   <result pre="Caplacizumab Cablivi von Willebrand factor; Humanized Nanobody Acquired thrombotic thrombocytopenic" exact="purpura" post="8/31/2018 In review Mogamulizumab Poteligeo CCR4; Humanized IgG1 Mycosis"/>
   <result pre="Moxetumomab pasudodox Lumoxiti CD22; Murine IgG1 dsFv immunotoxin Hairy cell" exact="leukemia" post="NA 9/13/2018 Cemiplimab Libtayo PD-1; Human mAb Cutaneous squamous"/>
   <result pre="review 3/6/2018 Tildrakizumab Ilumetri, Ilumya IL-23 p19; Humanized IgG1 Plaque" exact="psoriasis" post="9/17/2018 3/20/2018 Emapalumab Gamifant IFNγ; Human IgG1 Primary hemophagocytic"/>
   <result pre="Plaque psoriasis 9/17/2018 3/20/2018 Emapalumab Gamifant IFNγ; Human IgG1 Primary" exact="hemophagocytic lymphohistiocytosis" post="In review 11/20/2018 Data available as of November 30,"/>
   <result pre="Administration (FDA) approved erenumab-aooe (Aimovig) for the preventive treatment of" exact="migraine" post="in adults. Erenumab is a human IgG2 mAb that"/>
   <result pre="thereby blocking the activity of CGRP, which is involved in" exact="migraine" post="attacks. The treatment is given by once-monthly subcutaneous (SC)"/>
   <result pre="administered erenumab-aooe experienced, on average, one to two fewer monthly" exact="migraine" post="days than those on placebo over a 6-month period."/>
   <result pre="episodic migraine, patients administered erenumab-aooe experienced, on average, one fewer" exact="migraine" post="day per month than those on placebo over a"/>
   <result pre="patients treated with erenumab-aooe experienced, on average, 2.5 fewer monthly" exact="migraine" post="days than those receiving placebo over a 3-month period."/>
   <result pre="issued a marketing authorization in the EU for prophylaxis of" exact="migraine" post="in adults who have at least 4 migraine days"/>
   <result pre="prophylaxis of migraine in adults who have at least 4" exact="migraine" post="days per month. Fremanezumab (Teva Pharmaceuticals) On September 14,"/>
   <result pre="FDA approved fremanezumab-vfrm (Ajovy TM) for the preventive treatment of" exact="migraine" post="in adults. The drug may be administered as either"/>
   <result pre="3 study (NCT02629861) of patients with migraines administered fremanezumab, mean" exact="migraine" post="days per month decreased from 8.9 days to 4.9"/>
   <result pre="the FDA approved galcanezumab-gnlm (Emgality®) for the preventive treatment of" exact="migraine" post="in adults, making Emgality the third antibody therapeutic approved"/>
   <result pre="in two Phase 3 clinical trials in patients with episodic" exact="migraine" post="(EVOLVE-1 (NCT02614183), EVOLVE-2 (NCT02614196)) and one Phase 3 clinical"/>
   <result pre="and one Phase 3 clinical trial in patients with chronic" exact="migraine" post="(REGAIN (NCT02614261)). In all three studies, patients were randomized"/>
   <result pre="(EC) granted marketing authorization for Emgality® for the prophylaxis of" exact="migraine" post="in adults who have at least four migraine days"/>
   <result pre="prophylaxis of migraine in adults who have at least four" exact="migraine" post="days per month. Burosumab (KRN23; Kyowa Hakko Kirin Co."/>
   <result pre="the EU for burosumab (Crysvita) as a treatment for X-linked" exact="hypophosphatemia" post="(XLH) in children 1 year of age and older,"/>
   <result pre="lanadelumab-flyo (Takhzyro TM) injection for prophylaxis to prevent attacks of" exact="hereditary angioedema" post="(HAE) in patients 12 years of age and older."/>
   <result pre="(Takhzyro TM) injection for prophylaxis to prevent attacks of hereditary" exact="angioedema" post="(HAE) in patients 12 years of age and older."/>
   <result pre="as a treatment of adults experiencing an episode of acquired" exact="thrombotic thrombocytopenic purpura" post="(aTTP). During episodes of this rare, life-threatening blood clotting"/>
   <result pre="treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic" exact="purpura" post="(aTTP). During episodes of this rare, life-threatening blood clotting"/>
   <result pre="for the treatment of adult patients with relapsed or refractory" exact="mycosis" post="fungoides (MF) or Sézary syndrome (SS) after at least"/>
   <result pre="prior systemic therapy. The diseases are subtypes of cutaneous T-cell" exact="lymphoma" post="(CTCL), which is a rare and difficult-to-treat type of"/>
   <result pre="mAb that binds to CC chemokine receptor type 4 on" exact="cancer" post="cells. 32 Mogamulizumab was produced using Kyowa Hakko Kirin’s"/>
   <result pre="for the treatment of adult patients with relapsed or refractory" exact="hairy cell leukemia" post="who have received at least two prior systemic therapies,"/>
   <result pre="treatment of adult patients with relapsed or refractory hairy cell" exact="leukemia" post="who have received at least two prior systemic therapies,"/>
   <result pre="approved tildrakizumab-asmn (Ilumya) for treatment of adults with moderate-to-severe plaque" exact="psoriasis" post="who are candidates for systemic therapy or phototherapy. Tildrakizumab,"/>
   <result pre="for the treatment of adults with moderate to severe plaque" exact="psoriasis" post="who are candidates for systemic therapy. Emapalumab (Novimmune/Swedish Orphan"/>
   <result pre="of pediatric (newborn and above) and adult patients with primary" exact="hemophagocytic lymphohistiocytosis" post="(HLH) who have refractory, recurrent or progressive disease or"/>
   <result pre="in US Sacituzumab govitecan (Pending) TROP-2; humanized IgG1 ADC Triple-negative" exact="breast cancer" post="NA In review Ravulizumab (ALXN1210) (Pending) C5; humanized IgG2/4"/>
   <result pre="US Sacituzumab govitecan (Pending) TROP-2; humanized IgG1 ADC Triple-negative breast" exact="cancer" post="NA In review Ravulizumab (ALXN1210) (Pending) C5; humanized IgG2/4"/>
   <result pre="In review Ravulizumab (ALXN1210) (Pending) C5; humanized IgG2/4 Paroxysmal nocturnal" exact="hemoglobinuria" post="In review In review Risankizumab (Pending) IL-23 p19; Humanized"/>
   <result pre="review In review Risankizumab (Pending) IL-23 p19; Humanized IgG1 Plaque" exact="psoriasis" post="In review In review Romosozumab EVENITY Sclerostin; Humanized IgG2"/>
   <result pre="approval of sacituzumab govitecan as third-line therapy for metastatic triple-negative" exact="breast cancer" post="was granted Priority Review by the FDA, and the"/>
   <result pre="of sacituzumab govitecan as third-line therapy for metastatic triple-negative breast" exact="cancer" post="was granted Priority Review by the FDA, and the"/>
   <result pre="study of sacituzumab govitecan as a treatment for metastatic urothelial" exact="cancer" post="after failure of platinum-based regimen or anti-PD-1/PD-L1 based immunotherapy"/>
   <result pre="2 study of the ADC in patients with metastatic castration-resistant" exact="prostate cancer" post="who have progressed on second generation androgen receptor-directed therapy"/>
   <result pre="study of the ADC in patients with metastatic castration-resistant prostate" exact="cancer" post="who have progressed on second generation androgen receptor-directed therapy"/>
   <result pre="BLA for approval of ravulizumab for treatment of patients with" exact="paroxysmal nocturnal hemoglobinuria" post="(PNH) is undergoing review at FDA. The BLA’s action"/>
   <result pre="approval of ravulizumab for treatment of patients with paroxysmal nocturnal" exact="hemoglobinuria" post="(PNH) is undergoing review at FDA. The BLA’s action"/>
   <result pre="which targets sclerostin, has been evaluated as a treatment for" exact="osteoporosis" post="in women and men. A BLA for romosozumab as"/>
   <result pre="and men. A BLA for romosozumab as a treatment of" exact="osteoporosis" post="in postmenopausal women at high risk for fracture was"/>
   <result pre="study, an alendronate-active comparator trial including 4,093 postmenopausal women with" exact="osteoporosis" post="who experienced a fracture, and the Phase 3 BRIDGE"/>
   <result pre="evaluated in Phase 3 studies of patients with non-small cell" exact="lung cancer," post="hepatocellular carcinoma and esophageal squamous cell carcinoma. Sintilimab (IBI308;"/>
   <result pre="Phase 3 studies of patients with non-small cell lung cancer," exact="hepatocellular carcinoma" post="and esophageal squamous cell carcinoma. Sintilimab (IBI308; Innovent Biologics)"/>
   <result pre="the NDA for sintilimab for relapsed and refractory classical Hodgkin’s" exact="lymphoma" post="was submitted in China and granted priority review status."/>
   <result pre="evaluated as first-line treatment for patients with non-squamous non-small cell" exact="lung cancer" post="(NCT03607539 Phase 3 ORIENT-11 study) and as first-line treatment"/>
   <result pre="as first-line treatment for patients with non-squamous non-small cell lung" exact="cancer" post="(NCT03607539 Phase 3 ORIENT-11 study) and as first-line treatment"/>
   <result pre="first-line treatment for patients with previously untreated squamous non-small cell" exact="lung cancer" post="(NCT03629925 Phase 3 ORIENT-12 study). Camrelizumab (SHR-1210; Jiangsu Hengrui"/>
   <result pre="treatment for patients with previously untreated squamous non-small cell lung" exact="cancer" post="(NCT03629925 Phase 3 ORIENT-12 study). Camrelizumab (SHR-1210; Jiangsu Hengrui"/>
   <result pre="a humanized IgG4 antibody targeting PD-1, for relapsed/refractory classic Hodgkin’s" exact="lymphoma" post="submitted by Hengrui to China’s NMPA was accepted in"/>
   <result pre="studies of camrelizumab in patients with advanced non-squamous non-small cell" exact="lung cancer," post="55 advanced hepatocellular carcinoma, gastric or esophagogastric junction cancer,"/>
   <result pre="patients with advanced non-squamous non-small cell lung cancer, 55 advanced" exact="hepatocellular carcinoma," post="gastric or esophagogastric junction cancer, 56 nasopharyngeal carcinoma, 57"/>
   <result pre="55 advanced hepatocellular carcinoma, gastric or esophagogastric junction cancer, 56" exact="nasopharyngeal carcinoma," post="57 advanced esophageal carcinoma, 58 and advanced solid tumors."/>
   <result pre="syndrome Novartis Ligelizumab Human IgG1 IgE Phase 3 Chronic spontaneous" exact="urticaria" post="Bioverativ Sutimlimab, BIVV009 Humanized mAb C1s Phase 3 Cold"/>
   <result pre="Regeneron Pharmaceuticals Evinacumab Human mAb Angiopoietin-like 3 Phase 3 Homozygous" exact="familial hypercholesterolemia" post="Novartis Crizanlizumab Humanized IgG2 CD62 (aka P-selectin) Phase 3"/>
   <result pre="UCB Bimekizumab Humanized IgG1 IL-17A, F Phase 3 Ankylosing spondylitis," exact="psoriasis" post="Biocad BCD-085 Humanized mAb IL-17 Phase 3 Ankylosing spondylitis,"/>
   <result pre="psoriasis Biocad BCD-085 Humanized mAb IL-17 Phase 3 Ankylosing spondylitis," exact="psoriasis" post="AstraZeneca/MedImmune LLC Tralokinumab Human IgG4 IL-13 Phase 3 Atopic"/>
   <result pre="psoriasis AstraZeneca/MedImmune LLC Tralokinumab Human IgG4 IL-13 Phase 3 Atopic" exact="dermatitis" post="Novartis Ianalumab (VAY736) Human IgG1 BLyS/BAFF/TACI/BCMA receptor Phase 2/3"/>
   <result pre="Novartis Ianalumab (VAY736) Human IgG1 BLyS/BAFF/TACI/BCMA receptor Phase 2/3 Autoimmune" exact="hepatitis" post="R-Pharm Olokizumab Humanized IgG4 IL-6 Phase 3 Rheumatoid arthritis"/>
   <result pre="Autoimmune hepatitis R-Pharm Olokizumab Humanized IgG4 IL-6 Phase 3 Rheumatoid" exact="arthritis" post="AstraZeneca/MedImmune LLC Anifrolumab Human IgG1 IFN α, β, ω"/>
   <result pre="IgG1 IFN α, β, ω receptor 1 Phase 3 Systemic" exact="lupus erythematosus" post="Genentech Etrolizumab Humanized IgG1 a4-b7/aE-b7 integrin receptor Phase 3"/>
   <result pre="disease Boehringer Ingelheim BI655130 Human IgG1 IL-36R Phase 2/3 Ulcerative" exact="colitis" post="Eli Lilly &amp;amp; Co. Mirikizumab Humanized IgG4 IL-23p19 Phase"/>
   <result pre="&amp;amp; Co. Mirikizumab Humanized IgG4 IL-23p19 Phase 3 Ulcerative colitis," exact="psoriasis" post="Shire SHP-647 Human IgG2 Mucosal addressin cell adhesion molecule"/>
   <result pre="Tezepelumab Human IgG2 Thymic stromal lymphopoietin Phase 3 Severe uncontrolled" exact="asthma" post="CytoDyn Leronlimab (PRO140) Humanized IgG4 CCR5 Phase 2/3 HIV"/>
   <result pre="Hoffmann-La Roche Faricimab Bispecific CrossMab VEGF-A, Ang2 Phase 3 Diabetic" exact="macular edema" post="Novartis Brolucizumab Humanized scFv VEGF-A Phase 3 Neovascular age-related"/>
   <result pre="edema Novartis Brolucizumab Humanized scFv VEGF-A Phase 3 Neovascular age-related" exact="macular degeneration" post="Viela Bio Inebilizumab Humanized IgG1 CD19 Phase 2/3 Neuromyelitis"/>
   <result pre="Bio Inebilizumab Humanized IgG1 CD19 Phase 2/3 Neuromyelitis optica and" exact="neuromyelitis optica" post="spectrum disorders Chugai Pharmaceuticals/Roche Satralizumab Humanized IgG2 IL-6R Phase"/>
   <result pre="Pharmaceuticals/Roche Satralizumab Humanized IgG2 IL-6R Phase 3 Neuromyelitis optica and" exact="neuromyelitis optica" post="spectrum disorders Horizon Pharma USA Teprotumumab Human IgG1 IGF-1R"/>
   <result pre="Horizon Pharma USA Teprotumumab Human IgG1 IGF-1R Phase 3 Thyroid" exact="eye disease" post="Alder Biopharmaceuticals Eptinezumab Humanized IgG1 CGRP Phase 3 Episodic"/>
   <result pre="Human IgG4 Nerve growth factor Phase 3 Pain due to" exact="osteoarthritis" post="of knee or hip, low back pain Pfizer; Eli"/>
   <result pre="Humanized IgG2 Nerve growth factor Phase 3 Pain due to" exact="osteoarthritis" post="of knee or hip, low back pain, cancer pain"/>
   <result pre="due to osteoarthritis of knee or hip, low back pain," exact="cancer" post="pain due to bone metastasis Data available as of"/>
   <result pre="potential as a drug target for other diseases, such as" exact="cancer" post="and immune-mediated disorders. 60 Leronlimab, a humanized IgG4 mAb"/>
   <result pre="developing leronlimab as a treatment for graft-vs.-host disease and triple-negative" exact="breast cancer." post="Brolucizumab (RTH258; Novartis) This ~26 kDa humanized scFv targets"/>
   <result pre="it is undergoing evaluation as a treatment for neovascular age-related" exact="macular degeneration" post="(nAMD). Novartis has indicated that regulatory submissions for brolucizumab"/>
   <result pre="Emgality and Ajovy, eptinezumab targets CGRP and it is for" exact="migraine" post="prevention. In November 2018, Alder announced that they are"/>
   <result pre="PROMISE 2 studies evaluated the effects of eptinezumab in episodic" exact="migraine" post="patients (n = 888) or chronic migraine patients (n"/>
   <result pre="eptinezumab in episodic migraine patients (n = 888) or chronic" exact="migraine" post="patients (n = 1,072), respectively. In PROMISE 1, the"/>
   <result pre="2018, which indicated that, following the first quarterly infusion, episodic" exact="migraine" post="patients treated with 300 mg eptinezumab experienced 4.3 fewer"/>
   <result pre="patients treated with 300 mg eptinezumab experienced 4.3 fewer monthly" exact="migraine" post="days (MMDs) from a baseline of 8 MMDs, compared"/>
   <result pre="MMDs for placebo-treated patients. 66 In addition, ~31% of episodic" exact="migraine" post="patients achieved, on average per month, 100% reduction of"/>
   <result pre="migraine patients achieved, on average per month, 100% reduction of" exact="migraine" post="days from baseline compared to ~ 21% for placebo."/>
   <result pre="These results indicated that, after the first quarterly infusion, chronic" exact="migraine" post="patients dosed with 300 mg of eptinezumab experienced 8.2"/>
   <result pre="for those with placebo. In addition, ~ 21% of chronic" exact="migraine" post="patients achieved, on average, 100% reduction of MMDs from"/>
   <result pre="growth factor-1 receptor. Teprotumumab is in development for moderate-to-severe thyroid" exact="eye disease," post="which is commonly associated with Grave’s disease (hyperthyroidism). Data"/>
   <result pre="(IL-6) receptor mAb is undergoing development as a treatment for" exact="neuromyelitis optica" post="spectrum disorder (NMOSD), which is a rare autoimmune disease"/>
   <result pre="for neuromyelitis optica spectrum disorder (NMOSD), which is a rare" exact="autoimmune disease" post="that affects the central nervous system. The constant and"/>
   <result pre="been studied extensively in late-stage clinical studies of patients with" exact="osteoarthritis" post="pain, cancer pain, and chronic low back pain. In"/>
   <result pre="extensively in late-stage clinical studies of patients with osteoarthritis pain," exact="cancer" post="pain, and chronic low back pain. In July 2018,"/>
   <result pre="SC administration of tanezumab compared to placebo in patients with" exact="osteoarthritis" post="of the knee or hip. 74 In this study,"/>
   <result pre="pain, physical function and the patients’ overall assessment of their" exact="osteoarthritis" post="compared to those receiving placebo. Tanezumab was granted FDA’s"/>
   <result pre="FDA’s Fast Track designation for tanezumab for the treatment of" exact="osteoarthritis" post="pain and chronic low back pain. Lilly has indicated"/>
   <result pre="pain. Lilly has indicated that a BLA for tanezumab for" exact="osteoarthritis" post="pain may potentially be submitted in 2019. 75 Antibodies"/>
   <result pre="be submitted in 2019. 75 Antibodies to watch in 2019:" exact="cancer" post="indications As of November 2018, 33 novel antibody therapeutics"/>
   <result pre="33 novel antibody therapeutics were in late-stage clinical studies for" exact="cancer" post="indications ( Table 4). Antibody therapeutics for solid tumors"/>
   <result pre="Table 4. Investigational monoclonal antibodies in late-stage clinical studies for" exact="cancer" post="indications. Primary sponsoring company INN or code name Molecular"/>
   <result pre="TG Therapeutics Ublituximab Chimeric IgG1 CD20 Phase 3 Chronic lymphocytic" exact="leukemia" post="ADC Therapeutics Sarl Loncastuximab tesirine Humanized IgG1 ADC CD19"/>
   <result pre="Humanized IgG1 ADC CD19 Pivotal Phase 2 Diffuse large B-cell" exact="lymphoma" post="Hoffmann-La Roche Polatuzumab vedotin Humanized IgG1 ADC CD79b Phase"/>
   <result pre="vedotin Humanized IgG1 ADC CD79b Phase 3 Diffuse large B-cell" exact="lymphoma" post="Pfizer Utomilumab Human IgG2 4-1BB (CD137) Phase 3 Diffuse"/>
   <result pre="Utomilumab Human IgG2 4-1BB (CD137) Phase 3 Diffuse large B-cell" exact="lymphoma" post="MorphoSys XMAB-5574, MOR208 Humanized IgG1 CD19 Phase 2/3 Diffuse"/>
   <result pre="XMAB-5574, MOR208 Humanized IgG1 CD19 Phase 2/3 Diffuse large B-cell" exact="lymphoma" post="Sanofi Isatuximab Humanized IgG1 CD38 Phase 3 Multiple myeloma"/>
   <result pre="IgG4 PD-1 Phase 3; regulatory review in China Hodgkin’s lymphoma," exact="hepatocellular carcinoma" post="Actinium Pharmaceuticals I-131-BC8, Iomab-B Murine IgG1, radio-labeled CD45 Phase"/>
   <result pre="Bio Oportuzumab monatox Humanized scFv immunotoxin EpCAM Phase 3 Bladder" exact="cancer" post="Bio-Thera Solutions BAT8001 Humanized IgG1 ADC HER2 Phase 3"/>
   <result pre="Bio-Thera Solutions BAT8001 Humanized IgG1 ADC HER2 Phase 3 Breast" exact="cancer" post="Synthon Biopharmaceuticals BV (vic-)trastuzumab duocarmazine Humanized IgG1 ADC HER2"/>
   <result pre="BV (vic-)trastuzumab duocarmazine Humanized IgG1 ADC HER2 Phase 3 Breast" exact="cancer" post="MacroGenics Margetuximab Chimeric IgG1 HER2 Phase 3 Breast cancer"/>
   <result pre="Breast cancer MacroGenics Margetuximab Chimeric IgG1 HER2 Phase 3 Breast" exact="cancer" post="Daiichi Sankyo Trastuzumab deruxtecan Humanized ADC HER2 Phase 3"/>
   <result pre="adenocarcinoma Gilead Sciences Andecaliximab Humanized IgG4 MMP9 Phase 3 Gastric" exact="cancer" post="or gastroesophageal junction adenocarcinoma AbbVie Depatuxizumab mafodotin IgG1 ADC"/>
   <result pre="Y-mabs Therapeutics Naxitamab Humanized mAb GD2 Phase 3 High risk" exact="neuroblastoma" post="and refractory osteomedullary disease Bristol-Myers Squibb Relatlimab (BMS-986016) Human"/>
   <result pre="mAb PD-1 Phase 3; regulatory review in China Non-small cell" exact="lung cancer," post="Hodgkin’s lymphoma Innovent Biologics (Suzhou) Co. Ltd. IBI308 Human"/>
   <result pre="3; regulatory review in China Non-small cell lung cancer, Hodgkin’s" exact="lymphoma" post="Innovent Biologics (Suzhou) Co. Ltd. IBI308 Human mAb PD-1"/>
   <result pre="Phase 3; regulatory review in China Squamous cell non-small cell" exact="lung cancer" post="CStone Pharmaceuticals CS1001 Human PD-L1 Phase 3 Non-small cell"/>
   <result pre="3; regulatory review in China Squamous cell non-small cell lung" exact="cancer" post="CStone Pharmaceuticals CS1001 Human PD-L1 Phase 3 Non-small cell"/>
   <result pre="cancer CStone Pharmaceuticals CS1001 Human PD-L1 Phase 3 Non-small cell" exact="lung cancer" post="AstraZeneca/MedImmune LLC Tremelimumab Human IgG2 CTLA4 Phase 3 Non-small"/>
   <result pre="CStone Pharmaceuticals CS1001 Human PD-L1 Phase 3 Non-small cell lung" exact="cancer" post="AstraZeneca/MedImmune LLC Tremelimumab Human IgG2 CTLA4 Phase 3 Non-small"/>
   <result pre="CTLA4 Phase 3 Non-small cell lung, head &amp;amp; neck, urothelial" exact="cancer" post="Tesaro, Inc. TSR-042 Humanized mAb PD-1 Phase 3 Ovarian"/>
   <result pre="cancer Tesaro, Inc. TSR-042 Humanized mAb PD-1 Phase 3 Ovarian" exact="cancer" post="ImmunoGen Mirvetuximab soravtansine IgG1 ADC Folate receptor 1 Phase"/>
   <result pre="Mirvetuximab soravtansine IgG1 ADC Folate receptor 1 Phase 3 Ovarian" exact="cancer" post="AbbVie Rovalpituzumab tesirine Humanized IgG1 ADC DLL3 Phase 3"/>
   <result pre="Rovalpituzumab tesirine Humanized IgG1 ADC DLL3 Phase 3 Small cell" exact="lung cancer" post="Seattle Genetics Enfortumab vedotin Human IgG1 ADC Nectin 4"/>
   <result pre="tesirine Humanized IgG1 ADC DLL3 Phase 3 Small cell lung" exact="cancer" post="Seattle Genetics Enfortumab vedotin Human IgG1 ADC Nectin 4"/>
   <result pre="Enfortumab vedotin Human IgG1 ADC Nectin 4 Phase 3 Urothelial" exact="cancer" post="Data available as of November 30, 2018. Abbreviations: ADC,"/>
   <result pre="US and EU Orphan Drug designations for diffuse large B-cell" exact="lymphoma" post="(DLBCL). Roche has indicated that, based on positive clinical"/>
   <result pre="rituximab (R) or obinutuzumab in patients with relapsed or refractory" exact="follicular lymphoma" post="(FL) or diffuse DLBCL. Study results indicating that, at"/>
   <result pre="(R) or obinutuzumab in patients with relapsed or refractory follicular" exact="lymphoma" post="(FL) or diffuse DLBCL. Study results indicating that, at"/>
   <result pre="mAb is being evaluated as a treatment for patients with" exact="multiple myeloma" post="(MM). Isatuximab in combination with chemotherapy is being evaluated"/>
   <result pre="studies as a treatment for other cancers, including neuroendocrine tumors," exact="nasopharyngeal carcinoma," post="non-small cell lung cancer, triple-negative breast cancer, hepatocellular carcinoma"/>
   <result pre="for other cancers, including neuroendocrine tumors, nasopharyngeal carcinoma, non-small cell" exact="lung cancer," post="triple-negative breast cancer, hepatocellular carcinoma and colorectal cancer. Spartalizumab"/>
   <result pre="including neuroendocrine tumors, nasopharyngeal carcinoma, non-small cell lung cancer, triple-negative" exact="breast cancer," post="hepatocellular carcinoma and colorectal cancer. Spartalizumab was granted US"/>
   <result pre="tumors, nasopharyngeal carcinoma, non-small cell lung cancer, triple-negative breast cancer," exact="hepatocellular carcinoma" post="and colorectal cancer. Spartalizumab was granted US Orphan Drug"/>
   <result pre="non-small cell lung cancer, triple-negative breast cancer, hepatocellular carcinoma and" exact="colorectal cancer." post="Spartalizumab was granted US Orphan Drug designation for the"/>
   <result pre="effector cells. MOR208 has been shown to induce lysis of" exact="leukemia" post="cells that is mediated by natural killer cells. 82"/>
   <result pre="EU and US Orphan Drug designations for the treatment of" exact="chronic lymphocytic leukemia" post="(CLL), as well as FDA’s Breakthrough Therapy and Fast"/>
   <result pre="US Orphan Drug designations for the treatment of chronic lymphocytic" exact="leukemia" post="(CLL), as well as FDA’s Breakthrough Therapy and Fast"/>
   <result pre="aeruginosa exotoxin A. 85 Once bound to EpCAM expressed by" exact="cancer" post="cells, oportuzumab monatox is internalized into the cytoplasm, where"/>
   <result pre="in 2005, and FDA’s Fast Track designation for non-muscle invasive" exact="bladder cancer" post="(NMIBC) that is unresponsive to treatment with bacillus Calmette-Guérin"/>
   <result pre="2005, and FDA’s Fast Track designation for non-muscle invasive bladder" exact="cancer" post="(NMIBC) that is unresponsive to treatment with bacillus Calmette-Guérin"/>
   <result pre="total of 133 patients with high-grade NMIBC that is either" exact="carcinoma in situ" post="(CIS) or papillary with or without CIS, who have"/>
   <result pre="6 weeks thereafter in four cohorts: microsatellite instability high (MSI-H)" exact="endometrial cancer," post="MSI-H non-endometrial cancer, microsatellite-stable endometrial cancer and non-small cell"/>
   <result pre="microsatellite instability high (MSI-H) endometrial cancer, MSI-H non-endometrial cancer, microsatellite-stable" exact="endometrial cancer" post="and non-small cell lung cancer. Among the 25 patients"/>
   <result pre="instability high (MSI-H) endometrial cancer, MSI-H non-endometrial cancer, microsatellite-stable endometrial" exact="cancer" post="and non-small cell lung cancer. Among the 25 patients"/>
   <result pre="cancer, MSI-H non-endometrial cancer, microsatellite-stable endometrial cancer and non-small cell" exact="lung cancer." post="Among the 25 patients with MSI-H endometrial cancer who"/>
   <result pre="non-small cell lung cancer. Among the 25 patients with MSI-H" exact="endometrial cancer" post="who had at least one post-baseline tumor assessment, one"/>
   <result pre="cell lung cancer. Among the 25 patients with MSI-H endometrial" exact="cancer" post="who had at least one post-baseline tumor assessment, one"/>
   <result pre="as first-line treatment of Stage III or IV non-mucinous epithelial" exact="ovarian cancer." post="Enfortumab vedotin (ASG22ME; Seattle Genetics, Inc./Astellas Pharma Inc.) This"/>
   <result pre="enfortumab vedotin in patients with locally advanced or metastatic urothelial" exact="cancer" post="who previously received a checkpoint inhibitor (PD-L1 or PD-1)"/>
   <result pre="investigation in a total of 5 late-stage clinical studies in" exact="cancer" post="(CLL, non-Hodgkin’s lymphoma) and non-cancer (multiple sclerosis) indications, with"/>
   <result pre="of ublituximab compared to teriflunomide in 440 patients with relapsing" exact="multiple sclerosis." post="For both studies, the primary outcome measure is annualized"/>
   <result pre="in the near future. This is especially the case for" exact="cancer" post="patients, who may soon have a substantially larger number"/>
   <result pre="regimens in patients with relapsed or refractory diffuse large B-cell" exact="lymphoma" post="may be available near the study’s primary completion date"/>
   <result pre="study (NCT02631876) of patients with folate receptor alpha-positive advanced epithelial" exact="ovarian cancer," post="primary peritoneal cancer or fallopian tube cancer. This study"/>
   <result pre="with folate receptor alpha-positive advanced epithelial ovarian cancer, primary peritoneal" exact="cancer" post="or fallopian tube cancer. This study has a primary"/>
   <result pre="receptor alpha-positive advanced epithelial ovarian cancer, primary peritoneal cancer or" exact="fallopian tube cancer." post="This study has a primary completion date in November"/>
   <result pre="growth factor receptor 2 (HER2)-positive unresectable locally advanced or metastatic" exact="breast cancer." post="This study has a primary completion date in May"/>
   <result pre="Fast Track designation for treating patients diagnosed with HER2-positive metastatic" exact="breast cancer" post="that has progressed during or after at least two"/>
   <result pre="Track designation for treating patients diagnosed with HER2-positive metastatic breast" exact="cancer" post="that has progressed during or after at least two"/>
   <result pre="undergoing evaluation in three Phase 3 studies of small cell" exact="lung cancer" post="(SCLC) patients, TAHOE (NCT03061812), MERU (NCT03033511) and M16-292 (NCT03334487),"/>
   <result pre="evaluation in three Phase 3 studies of small cell lung" exact="cancer" post="(SCLC) patients, TAHOE (NCT03061812), MERU (NCT03033511) and M16-292 (NCT03334487),"/>
   <result pre="events ARR annualized relapse rate ART antiretroviral therapy aTTP acquired" exact="thrombotic thrombocytopenic purpura" post="BCG bacillus Calmette-Guérin BLA biologics license application C5 complement"/>
   <result pre="annualized relapse rate ART antiretroviral therapy aTTP acquired thrombotic thrombocytopenic" exact="purpura" post="BCG bacillus Calmette-Guérin BLA biologics license application C5 complement"/>
   <result pre="peptide CHMP Committee for Medicinal Products for Human Use CIS" exact="carcinoma in situ" post="CLL chronic lymphocytic leukemia CR complete response CSCC cutaneous"/>
   <result pre="Medicinal Products for Human Use CIS carcinoma in situ CLL" exact="chronic lymphocytic leukemia" post="CR complete response CSCC cutaneous squamous cell carcinoma CTCL"/>
   <result pre="for Human Use CIS carcinoma in situ CLL chronic lymphocytic" exact="leukemia" post="CR complete response CSCC cutaneous squamous cell carcinoma CTCL"/>
   <result pre="complete response CSCC cutaneous squamous cell carcinoma CTCL cutaneous T-cell" exact="lymphoma" post="DLBCL diffuse large B-cell lymphoma EC European Commission EMA"/>
   <result pre="cell carcinoma CTCL cutaneous T-cell lymphoma DLBCL diffuse large B-cell" exact="lymphoma" post="EC European Commission EMA European Medicines Agency EpCAM epithelial"/>
   <result pre="EU European Union FDA US Food and Drug Administration FL" exact="follicular lymphoma" post="HAE hereditary angioedema HCL hairy cell leukemia HIV human"/>
   <result pre="European Union FDA US Food and Drug Administration FL follicular" exact="lymphoma" post="HAE hereditary angioedema HCL hairy cell leukemia HIV human"/>
   <result pre="FDA US Food and Drug Administration FL follicular lymphoma HAE" exact="hereditary angioedema" post="HCL hairy cell leukemia HIV human immunodeficiency virus HLH"/>
   <result pre="US Food and Drug Administration FL follicular lymphoma HAE hereditary" exact="angioedema" post="HCL hairy cell leukemia HIV human immunodeficiency virus HLH"/>
   <result pre="and Drug Administration FL follicular lymphoma HAE hereditary angioedema HCL" exact="hairy cell leukemia" post="HIV human immunodeficiency virus HLH hemophagocytic lymphohistiocytosis IV intravenous"/>
   <result pre="Administration FL follicular lymphoma HAE hereditary angioedema HCL hairy cell" exact="leukemia" post="HIV human immunodeficiency virus HLH hemophagocytic lymphohistiocytosis IV intravenous"/>
   <result pre="angioedema HCL hairy cell leukemia HIV human immunodeficiency virus HLH" exact="hemophagocytic lymphohistiocytosis" post="IV intravenous mAb monoclonal antibody MF mycosis fungoides MM"/>
   <result pre="virus HLH hemophagocytic lymphohistiocytosis IV intravenous mAb monoclonal antibody MF" exact="mycosis" post="fungoides MM multiple myeloma MMD monthly migraine days MSI"/>
   <result pre="lymphohistiocytosis IV intravenous mAb monoclonal antibody MF mycosis fungoides MM" exact="multiple myeloma" post="MMD monthly migraine days MSI microsatellite instability nAMD neovascular"/>
   <result pre="monoclonal antibody MF mycosis fungoides MM multiple myeloma MMD monthly" exact="migraine" post="days MSI microsatellite instability nAMD neovascular age-related macular degeneration"/>
   <result pre="MMD monthly migraine days MSI microsatellite instability nAMD neovascular age-related" exact="macular degeneration" post="NDA new drug application NGF nerve growth factor NMIBC"/>
   <result pre="new drug application NGF nerve growth factor NMIBC non-muscle invasive" exact="bladder cancer" post="NMOSD neuromyelitis optica spectrum disorder NMPA National Medical Products"/>
   <result pre="drug application NGF nerve growth factor NMIBC non-muscle invasive bladder" exact="cancer" post="NMOSD neuromyelitis optica spectrum disorder NMPA National Medical Products"/>
   <result pre="NGF nerve growth factor NMIBC non-muscle invasive bladder cancer NMOSD" exact="neuromyelitis optica" post="spectrum disorder NMPA National Medical Products Administration PD-1 programmed"/>
   <result pre="protein PD-L1 programmed death ligand 1 PFS progression-free survival PNH" exact="paroxysmal nocturnal hemoglobinuria" post="SC subcutaneous scFv single-chain variable fragment SCLC small cell"/>
   <result pre="programmed death ligand 1 PFS progression-free survival PNH paroxysmal nocturnal" exact="hemoglobinuria" post="SC subcutaneous scFv single-chain variable fragment SCLC small cell"/>
   <result pre="hemoglobinuria SC subcutaneous scFv single-chain variable fragment SCLC small cell" exact="lung cancer" post="SS Sézary syndrome US United States XLH X-linked hypophosphatemia"/>
   <result pre="SC subcutaneous scFv single-chain variable fragment SCLC small cell lung" exact="cancer" post="SS Sézary syndrome US United States XLH X-linked hypophosphatemia"/>
   <result pre="lung cancer SS Sézary syndrome US United States XLH X-linked" exact="hypophosphatemia" post="Disclosure Potential Conflicts of Interest No potential conflicts of"/>
   <result pre=", Aglietta M , Sangiolo D Next generation immune-checkpoints for" exact="cancer" post="therapy. J Thorac Dis. 2018; 10( Suppl 13): S1581–"/>
   <result pre="both quarterly and monthly dosing for the preventive treatment of" exact="migraine" post="in adults . 9 14, 2018 press release http://ir.tevapharm.com/phoenix.zhtml?c=73925&amp;amp;p=irol-newsArticle&amp;amp;ID=2367592."/>
   <result pre="(galcanezumab-gnlm) receives U.S. FDA approval for the preventive treatment of" exact="migraine" post="in adults . 9 27, 2018 press release https://investor.lilly.com/news-releases/news-release-details/lillys-emgalitytm-galcanezumab-gnlm-receives-us-fda-approval."/>
   <result pre="conditional marketing authorisation in Europe for the treatment of X–linked" exact="hypophosphatemia" post="in children . 2 23, 2018 press release www.kyowa-kirin.com/news_releases/2018/pdf/e20180223_01.pdf."/>
   <result pre="FDA approves first therapy for rare inherited form of rickets," exact="x-linked hypophosphatemia." post="4 17, 2018 press release https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm604810.htm 28. collab: Shire"/>
   <result pre="approval of TAKHZYRO™ (lanadelumab-flyo), a first-of-its-kind mAb preventive treatment for" exact="hereditary angioedema" post=". 8 23, 2018 press release https://www.shire.com/en/newsroom/2018/august/4fhgmy 29. collab:"/>
   <result pre="of TAKHZYRO™ (lanadelumab-flyo), a first-of-its-kind mAb preventive treatment for hereditary" exact="angioedema" post=". 8 23, 2018 press release https://www.shire.com/en/newsroom/2018/august/4fhgmy 29. collab:"/>
   <result pre="Sanofi Cablivi™ (caplacizumab) approved in Europe for adults with acquired" exact="thrombotic thrombocytopenic purpura" post="(aTTP) . 9 3, 2018 press release http://www.news.sanofi.us/2018-09-03-Cablivi-TM-caplacizumab-approved-in-Europe-for-adults-with-acquired-thrombotic-thrombocytopenic-purpura-aTTP 30."/>
   <result pre="(caplacizumab) approved in Europe for adults with acquired thrombotic thrombocytopenic" exact="purpura" post="(aTTP) . 9 3, 2018 press release http://www.news.sanofi.us/2018-09-03-Cablivi-TM-caplacizumab-approved-in-Europe-for-adults-with-acquired-thrombotic-thrombocytopenic-purpura-aTTP 30."/>
   <result pre="phase 3 Hercules study of caplacizumab in patients with acquired" exact="thrombotic thrombocytopenic purpura" post=". 59th Annual Meeting of the American Society of"/>
   <result pre="Hercules study of caplacizumab in patients with acquired thrombotic thrombocytopenic" exact="purpura" post=". 59th Annual Meeting of the American Society of"/>
   <result pre=", Gotic M , et al Moxetumomab pasudotox in relapsed/refractory" exact="hairy cell leukemia." post="Leukemia. 2018; 32( 8): 1768– 1777. doi: 10.1038/s41375-018-0210-1 ."/>
   <result pre="et al Tildrakizumab versus placebo or etanercept for chronic plaque" exact="psoriasis" post="(reSURFACE 1 and reSURFACE 2): results from two randomised"/>
   <result pre="FDA for investigational treatment risankizumab for moderate to severe plaque" exact="psoriasis" post=". 4 25, 2018 press release https://news.abbvie.com/news/abbvie-submits-biologics-license-application-to-us-fda-for-investigational-treatment-risankizumab-for-moderate-to-severe-plaque-psoriasis.htm. 46. Gordon"/>
   <result pre="et al Efficacy and safety of risankizumab in moderate-to-severe plaque" exact="psoriasis" post="(UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled"/>
   <result pre="of new drug application for anti-PD-1 antibody tislelizumab in Hodgkin’s" exact="lymphoma" post="in China . 8 31, 2018 press release http://ir.beigene.com/phoenix.zhtml?c=254246&amp;amp;p=irol-newsArticle&amp;amp;ID=2365642."/>
   <result pre="announces the study result of its anti-PD-1 antibody in Hodgkin" exact="lymphoma" post="5 17, 2018 press release http://innoventbio.com/en/#/news/102. 53. collab: LSK"/>
   <result pre="decitabine-primed anti-PD-1 (SHR-1210) treatment in patients with relapsed/refractory classical Hodgkin" exact="lymphoma" post=". 2018 American Society of Clinical Oncology meeting abstract"/>
   <result pre="plus apatinib for heavily previously treated advanced non-squamous non-small cell" exact="lung cancer" post="(NSCLC) patients . 2018 American Society of Clinical Oncology"/>
   <result pre="apatinib for heavily previously treated advanced non-squamous non-small cell lung" exact="cancer" post="(NSCLC) patients . 2018 American Society of Clinical Oncology"/>
   <result pre="et al Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced" exact="hepatocellular carcinoma," post="gastric or esophagogastric junction cancer: an open-label, dose escalation"/>
   <result pre="65. collab: Alder Biopharmaceuticals Transforming the prevention treatment paradigm for" exact="migraine" post="patients. 11 5, 2018 corporate presentation https://investor.alderbio.com/index.php/encrypt/files?file=nasdaq_kms/assets/2018/11/06/3-08-52/Corporate%20Deck%20November%205th%20FINAL%20FINAL.pdf&amp;amp;file_alias=18416. 66. collab:"/>
   <result pre="PROMISE 1 phase 3 trial demonstrating long-term efficacy in episodic" exact="migraine" post=". 6 29, 2018 press release https://investor.alderbio.com/news-releases/news-release-details/alder-biopharmaceuticalsr-presents-new-one-year-data-eptinezumab. 67. collab:"/>
   <result pre="in efficacy in PROMISE 2 phase 3 trial for chronic" exact="migraine" post=". 6 29, 2018 press release https://investor.alderbio.com/news-releases/news-release-details/alder-biopharmaceuticalsr-presents-new-six-month-data. 68. collab:"/>
   <result pre="CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of" exact="acute lymphoblastic leukemia" post="cells from pediatric and adult patients . Leukemia. 2013"/>
   <result pre="antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute" exact="lymphoblastic leukemia" post="cells from pediatric and adult patients . Leukemia. 2013"/>
   <result pre="MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic" exact="leukemia" post="cells from pediatric and adult patients . Leukemia. 2013"/>
   <result pre="data from L-MIND study of MOR208 plus lenalidomide in aggressive" exact="lymphoma" post="(r/r DLBCL) . 3 13, 2018 https://www.morphosys.com/media-investors/media-center/morphosys-reports-updated-data-from-l-mind-study-of-mor208-plus. 84. collab:"/>
   <result pre="Scheinfeld N VB4-845, a conjugated recombinant antibody and immunotoxin for" exact="head and neck cancer" post="and bladder cancer . Curr Opin Mol Ther. 2008;"/>
   <result pre="a conjugated recombinant antibody and immunotoxin for head and neck" exact="cancer" post="and bladder cancer . Curr Opin Mol Ther. 2008;"/>
   <result pre="recombinant antibody and immunotoxin for head and neck cancer and" exact="bladder cancer" post=". Curr Opin Mol Ther. 2008; 10( 2): 176–"/>
   <result pre="antibody and immunotoxin for head and neck cancer and bladder" exact="cancer" post=". Curr Opin Mol Ther. 2008; 10( 2): 176–"/>
   <result pre="fast track designation by FDA for treatment of non-muscle invasive" exact="bladder cancer" post=". 8 09, 2018 press release https://sesenbio.gcs-web.com/news-releases/news-release-details/sesen-bio-announces-vicinium-granted-fast-track-designation-fda. 87. collab:"/>
   <result pre="track designation by FDA for treatment of non-muscle invasive bladder" exact="cancer" post=". 8 09, 2018 press release https://sesenbio.gcs-web.com/news-releases/news-release-details/sesen-bio-announces-vicinium-granted-fast-track-designation-fda. 87. collab:"/>
   <result pre="collab: Sesen Bio Phase 3 registration trial for non-muscle invasive" exact="bladder cancer" post="achieves 42% complete response rate at three months in"/>
   <result pre="Sesen Bio Phase 3 registration trial for non-muscle invasive bladder" exact="cancer" post="achieves 42% complete response rate at three months in"/>
   <result pre="cancer achieves 42% complete response rate at three months in" exact="carcinoma in situ" post="patients . 5 21, 2018 press release https://sesenbio.gcs-web.com/news-releases/news-release-details/phase-3-registration-trial-non-muscle-invasive-bladder-cancer. 88."/>
   <result pre="announce updated enfortumab vedotin phase 1 data in metastatic urothelial" exact="cancer" post="at 2017 ASCO annual meeting . 6 5, 2017"/>
   <result pre="Seattle Genetics and Astellas announce progress in enfortumab vedotin urothelial" exact="cancer" post="clinical development program . 10 25, 2018 press release"/>
   <result pre="for third-line treatment of patients with DLL3-expressing relapsed/refractory small cell" exact="lung cancer" post=". 3 22, 2018 press release https://news.abbvie.com/news/abbvie-announces-results-from-phase-2-study-evaluating-rovalpituzumab-tesirine-rova-t-for-third-line-treatment-patients-with-dll3-expressing-relapsedrefractory-small-cell-lung-cancer.htm."/>
   <result pre="third-line treatment of patients with DLL3-expressing relapsed/refractory small cell lung" exact="cancer" post=". 3 22, 2018 press release https://news.abbvie.com/news/abbvie-announces-results-from-phase-2-study-evaluating-rovalpituzumab-tesirine-rova-t-for-third-line-treatment-patients-with-dll3-expressing-relapsedrefractory-small-cell-lung-cancer.htm."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6383087/results/search/disease/results.xml">
   <result pre="across time points (3, 12, and 24 months), although criteria for" exact="major depressive disorder" post="were met by a larger proportion of patients with"/>
   <result pre="children aged 5 to 14 with mTBI developed a new-onset" exact="anxiety disorder" post="within 1 year, with younger age and premorbid anxiety being"/>
   <result pre="preschool years were at greater risk of attention-deficit/hyperactivity, conduct, or" exact="oppositional defiant disorder" post="during adolescence. 39 Negative outcomes may be attributable to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6384232/results/search/disease/results.xml">
   <result pre="the study: To evaluate pain catastrophizing in episodic and chronic" exact="migraine" post="children and adolescents selected in a tertiary headache Center."/>
   <result pre="Pain Catastrophizing Scale (PCS-C), and to the disability scale for" exact="migraine" post="(PedMIDAS), general quality of life estimated by children (PedsQL)"/>
   <result pre="in Total Pain Catastrophizing score (PCS-C) between chronic and episodic" exact="migraine" post="groups (ANOVA F = 0.59, p = 0.70); the"/>
   <result pre="episodic and chronic migraine. The PCS-C was not correlated with" exact="migraine" post="related disability as expressed by Ped MIDAS, but it"/>
   <result pre="this evolution is consistent and worthy of further prospective evaluation." exact="migraine" post="children pain catastrophizing allodynia pericranial tenderness central sensitization Funding"/>
   <result pre="a decrease in the quality of life ( 1). Chronic" exact="migraine" post="affects 0.8–1.8% of adolescents and 0.6% of children and"/>
   <result pre="specific pain mechanisms, disease progression, and potential complications in childhood" exact="migraine" post="allows the development of more specific and more efficient"/>
   <result pre="therapy. Nowadays, the most important recognized factors associated to chronic" exact="migraine" post="are obesity, depression, presence of allodynia, and stressful life"/>
   <result pre="better understand some of the precipitating and aggravating factors of" exact="migraine" post="in pediatric patients, the present cross-sectional observational study aimed:"/>
   <result pre="study aimed: To evaluate pain catastrophizing in episodic and chronic" exact="migraine" post="children and adolescents selected in a tertiary headache Center."/>
   <result pre="Pediatric Migraine Disability Assessment Scale (PedMIDAS) is a measure for" exact="migraine" post="related disability in children and adolescents. The PedMIDAS is"/>
   <result pre="( 22). We asked mothers to interview their children during" exact="migraine" post="attack, in order to help them in filling the"/>
   <result pre="to help them in filling the allodynia questionnaire for each" exact="migraine" post="attack. The allodynia questionnaire is not presently adapted for"/>
   <result pre="continuous and categorical variables, age and sex, in the main" exact="migraine" post="subgroups, and used the ANOVA test and chi square"/>
   <result pre="taking into consideration the distribution of cases in the main" exact="migraine" post="subgroups, we divided children in episodic and chronic migraine"/>
   <result pre="main migraine subgroups, we divided children in episodic and chronic" exact="migraine" post="groups (EM and CM), merging the groups including migraine"/>
   <result pre="chronic migraine groups (EM and CM), merging the groups including" exact="migraine" post="with aura and without aura in a sole group."/>
   <result pre="Table 1. The most of patients were diagnosed as episodic" exact="migraine" post="without aura –MO. Patients with migraine with aura were"/>
   <result pre="were diagnosed as episodic migraine without aura –MO. Patients with" exact="migraine" post="with aura were older than were patients with migraine"/>
   <result pre="with migraine with aura were older than were patients with" exact="migraine" post="without aura. Females prevailed in all but the MA"/>
   <result pre="are reported ( Table 1S). Table 1 Demographic data of" exact="migraine" post="patients. Diagnosis age (years) sex F M MA Mean"/>
   <result pre="Total Pain catastrophizing score was similar between chronic and episodic" exact="migraine" post="groups ( Figure 1). Figure 1 Mean and 95%"/>
   <result pre="total pain catastrophizing test (PCS-C) and main sub-items in the" exact="migraine" post="chronic and episodic subgroups. Total PCS-S Student's t-test 1.24,"/>
   <result pre="(PCS-S) and main sub-items, and clinical features evaluated in 190" exact="migraine" post="patients. TTS ALLODYNIA PedMIDAS PEDS-QL PEDS-QL-PHY PEDS-QL-PSY PEDS-QL-P PEDS-QL-P-PHY"/>
   <result pre="( Table 3). These variables discriminated between episodic and chronic" exact="migraine" post="with 73, 2% accuracy. Table 3 Discriminant variables between"/>
   <result pre="sensitization symptoms. However, it does not distinguish chronic from episodic" exact="migraine" post="in children, similarly to anxiety, depression and general disability."/>
   <result pre="similarly to anxiety, depression and general disability. Children with frequent" exact="migraine" post="differ from episodic ones for those clinical aspects, which"/>
   <result pre="with higher levels of pain and higher frequency of both" exact="migraine" post="headaches and low back pain ( 26). More recent"/>
   <result pre="that pain catastrophizing is associated with more severe and frequent" exact="migraine" post="attacks, and that it could be a risk factor"/>
   <result pre="and that it could be a risk factor for chronic" exact="migraine" post="( 27– 30). The results of Orr et al"/>
   <result pre="30). The results of Orr et al study on pediatric" exact="migraine" post="( 31), confirmed what we observed, that pain catastrophizing"/>
   <result pre="what we observed, that pain catastrophizing was not associated to" exact="migraine" post="related disability, but was a negative factor for quality"/>
   <result pre="and anticipated pain experience may be an intrinsic feature of" exact="migraine" post="patients who could prospectively develop severe migraine. Correlation Between"/>
   <result pre="and anxiety and depression levels, which was well-described in adult" exact="migraine" post="( 27, 29, 30). This association is also present"/>
   <result pre="processing of pain experiences ( 36), being modified in adult" exact="migraine" post="patients ( 37). In fact, we observed that pain"/>
   <result pre="tended to attribute the reduction of quality of life to" exact="migraine" post="severity and perceived the poor quality of life of"/>
   <result pre="the other discriminating factor, because persistent muscle pain characterizes chronic" exact="migraine" post="in adult and childhood age ( 14, 39). In"/>
   <result pre="adjunctive notes and changes to the criteria provided for adult" exact="migraine" post="( 15). Another important limit relies in data referring"/>
   <result pre="tertiary headache center, and not to general population. The episodic" exact="migraine" post="children, who requests for headache specialist's visit, could in"/>
   <result pre="of present results to the wider population of children with" exact="migraine" post="needs to be confirmed. Conclusions Pain catastrophizing seems a"/>
   <result pre="of this easy evaluation in the clinical setting of children" exact="migraine" post="seems highly supported by present results. Author Contributions MdT:"/>
   <result pre="SH et al. . The prevalence of chronic and episodic" exact="migraine" post="in children and adolescents. Eur J Neurol. ( 2013)"/>
   <result pre="III Bathon J Haythornthwaite JA Catastrophizing and pain in arthritis," exact="fibromyalgia" post="and other rheumatic disease. Arthritis Rheum. ( 2006) 55:"/>
   <result pre="al. . Symptoms of central sensitization and comorbidity for juvenile" exact="fibromyalgia" post="in childhood migraine: an observational study in a tertiary"/>
   <result pre="Leone M Rigamonti A et al. . Use of the" exact="migraine" post="disability assessment questionnaire in children and adolescents with headache:"/>
   <result pre=". Laser-evoked potential habituation and central sensitization symptoms in childhood" exact="migraine" post=". Cephalalgia ( 2016) 36: 463– 73. 10.1177/0333102415597527 26232104"/>
   <result pre="S Reed ML et al. . Cutaneous allodynia in the" exact="migraine" post="population. Ann Neurol. ( 2008) 63: 148– 58. 10.1002/ana.21211"/>
   <result pre="Spitaleri C Consolo F Santangelo G et al. . Juvenile" exact="migraine" post="and allodynia: results of a retrospective study. Headache ("/>
   <result pre="J et al. . Clinical pain catastrophizing in women with" exact="migraine" post="and obesity. Headache ( 2015) 55: 923– 33. 10.1111/head.12597"/>
   <result pre="Grosberg BM et al. . psychological factors associated with chronic" exact="migraine" post="and severe migraine-related disability: an observational study in a"/>
   <result pre="SA Hubbard CS Goyal M et al. . High frequency" exact="migraine" post="is associated with lower acute pain sensitivity and abnormal"/>
   <result pre="lower acute pain sensitivity and abnormal insula activity related to" exact="migraine" post="pain intensity, attack frequency, and pain catastrophizing . Front"/>
   <result pre="and function correlate with disease severity and pain catastrophizing in" exact="migraine" post="patients . eNeuro ( 2014) 1:e20.14. 10.1523/ENEURO.0006-14.2014 25893216 34."/>
   <result pre="sensitization inventory with measures of sensitization in people with knee" exact="osteoarthritis" post=". Clin Rheumatol. ( 2018) 37: 3125– 32. 10.1007/s10067-018-4279-8"/>
   <result pre="headache disorders diagnostic criteria (ICHD I-1988) and (ICHD II-2004), for" exact="migraine" post="in children and adolescents . Cephalalgia ( 2005) 25:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6413701/results/search/disease/results.xml">
   <result pre="7.9%; p &amp;lt; 0.05), while the diagnosis of probable chronic" exact="migraine" post="was only possible by using the ICHD2 criteria (11.9%"/>
   <result pre="to conclude about the drug efficacy. chronic headache children chronic" exact="migraine" post="tension-type headache medication overuse headache prophylactic therapy fig-count: table-count:"/>
   <result pre="and adolescents who present to headache specialty clinics have chronic" exact="migraine" post="( 1). In adolescents and children suffering from this"/>
   <result pre="huge decrease of the quality of life ( 1). Chronic" exact="migraine" post="(CM), chronic tension-type headache (CTTH) and new daily persistent"/>
   <result pre="satisfy the ICHD 3 criteria for the diagnosis of episodic" exact="migraine" post="and TTH ( 6, 12). Taking into account the"/>
   <result pre="headache patients. Evidence of efficacy for prophylactic treatment of episodic" exact="migraine" post="in children and adolescents are available for flunarizine, topiramate,"/>
   <result pre="As for topiramate, its efficacy in the prophylaxis of episodic" exact="migraine" post="at high frequency has been reported ( 22, 23),"/>
   <result pre="related to drugs. An emerging literature demonstrates that patients with" exact="migraine" post="and other headaches hesitate to adhere to pharmacological regimens"/>
   <result pre="Turkel CC Winner P . Prevalence and burden of chronic" exact="migraine" post="in adolescents: results of the chronic daily headache in"/>
   <result pre="behavioral therapy plus amitriptyline for children and adolescents with chronic" exact="migraine" post="reduces headache days to ≤ 4 Per Month ."/>
   <result pre="Bigal ME . Recent advances in the management of chronic" exact="migraine" post="in children. Expert Rev Neurother. ( 2018) 18: 231–"/>
   <result pre="Battan B et al. . Features of aura in paediatric" exact="migraine" post="diagnosed using the ICHD 3 beta criteria. Cephalalgia ("/>
   <result pre="76. 10.1007/s10194-010-0205-4 20349201 24. Mack KJ . Episodic and chronic" exact="migraine" post="in children. Semin Neurol. ( 2006) 26: 223– 31."/>
   <result pre="Zeharia A . Factors influencing response to pharmacologic treatment of" exact="migraine" post="in a pediatric headache clinic . Headache ( 2016)"/>
   <result pre="et al. . Treatment adherence in child and adolescent chronic" exact="migraine" post="patients: results from the cognitive-behavioral therapy and amitriptyline trial"/>
   <result pre="CHAMP investigators. trial of amitriptyline, topiramate, and placebo for paediatric" exact="migraine" post=". N Engle J Med. ( 2017) 376: 115124"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6417521/results/search/disease/results.xml">
   <result pre="Research Article: Observational Study Cocoon devices for transcatheter closure of" exact="atrial septal defect" post="and patent ductus arteriosus in children Single center experience"/>
   <result pre="Cocoon devices for transcatheter closure of atrial septal defect and" exact="patent ductus arteriosus" post="in children Single center experience Mahmoud Hyam MD, PhD"/>
   <result pre="from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 medi-98-e14684.pdf Abstract Abstract Closure of the" exact="atrial septal defect" post="(ASD) and patent ductus arteriosus (PDA) are among the"/>
   <result pre="Abstract Abstract Closure of the atrial septal defect (ASD) and" exact="patent ductus arteriosus" post="(PDA) are among the most frequent cardiac interventional procedures."/>
   <result pre="with their use in our emerging center is encouraging. Keywords" exact="atrial septal defect" post="cocoon occluder congenital heart disease patent ductus arteriosus pediatric"/>
   <result pre="emerging center is encouraging. Keywords atrial septal defect cocoon occluder" exact="congenital heart disease" post="patent ductus arteriosus pediatric interventional cardiology 1 Introduction Atrial"/>
   <result pre="center is encouraging. Keywords atrial septal defect cocoon occluder congenital" exact="heart disease" post="patent ductus arteriosus pediatric interventional cardiology 1 Introduction Atrial"/>
   <result pre="encouraging. Keywords atrial septal defect cocoon occluder congenital heart disease" exact="patent ductus arteriosus" post="pediatric interventional cardiology 1 Introduction Atrial septal defects (ASD)"/>
   <result pre="pediatric interventional cardiology 1 Introduction Atrial septal defects (ASD) and" exact="patent ductus arteriosus" post="(PDA) are among the most frequent cardiac defects. Interventional"/>
   <result pre="cardiac defects which are inexorably surgical, or contraindications related to" exact="pulmonary hypertension" post="with increased pulmonary vascular resistance. [ 1, 3, 4]"/>
   <result pre="of ASD associated with other interventional approachable malformations such as" exact="ventricular septal defect" post="(VSD) or exclusion of other cardiac malformities are not"/>
   <result pre="to reduce morbidity and mortality in the pediatric population with" exact="congenital heart disease" post="was the main purpose to start a new project"/>
   <result pre="reduce morbidity and mortality in the pediatric population with congenital" exact="heart disease" post="was the main purpose to start a new project"/>
   <result pre="3 important advantages: better radiopacity, good bio-compatibility and prevents nickel" exact="allergy" post="by stopping nickel leaking into the blood (Fig. 1)."/>
   <result pre="pulmonary end (Fig. 2). Figure 2 Different anatomical types of" exact="patent ductus arteriosus" post="according to Kritchenco classification before and after Cocoon Duct"/>
   <result pre="the abnormal partial pulmonary venous return by TEE and suspected" exact="pulmonary hypertension" post="by right heart catheterization we continued with left superior"/>
   <result pre="of all PDA closures were performed in cases associated with" exact="pulmonary hypertension," post="with a mean pulmonary artery pressure (mPAP) of 35"/>
   <result pre="to 17 months. We did not encounter any case of" exact="pericardial effusion," post="nickel allergy, unexplained headache, stroke or cardiac erosion. Amplatzer"/>
   <result pre="encounter any case of pericardial effusion, nickel allergy, unexplained headache," exact="stroke" post="or cardiac erosion. Amplatzer Septal Occluder (ASO), with more"/>
   <result pre="oxide from nitinol during its preparation. The absence of nickel" exact="allergy" post="was shown to be another good quality of the"/>
   <result pre="to be another good quality of the Cocoon device. Nickel" exact="allergy" post="in population is estimated to 10%. [ 9, 15]"/>
   <result pre="estimated to 10%. [ 9, 15] No case of nickel" exact="allergy" post="related to the use of CSO for ASD closure"/>
   <result pre="Thanopoulos et al. reported that 6 patients known with nickel" exact="allergy" post="prior to implantation accepted CSO implantation for ASD, and"/>
   <result pre="since then, there have been no reported cases of nickel" exact="allergy" post="related to their use. This may be due to"/>
   <result pre="in Table 2. There was one device embolization, one massive" exact="pericardial effusion" post="for the Cocoon devices, and stroke at one month"/>
   <result pre="embolization, one massive pericardial effusion for the Cocoon devices, and" exact="stroke" post="at one month after implantation in a patient with"/>
   <result pre="at one month after implantation in a patient with previous" exact="atrial fibrillation." post="[ 4] Lairakdomrong et al have also performed a"/>
   <result pre="On intermediate term, the device was not associated with nickel" exact="allergy" post="or aortic erosions. Our study has some limitations. Firstly,"/>
   <result pre="– review &amp;amp; editing: Eliza Elena Cinteza. Abbreviations: ASD =" exact="atrial septal defect," post="ASO = Amplatzer Septal Occluder, CDO = Cocoon Duct"/>
   <result pre="superior pulmonary vein, mPAP = mean pulmonary artery pressure, PDA" exact="patent ductus arteriosus," post="PS = pulmonary stenosis, RAO = right anterior oblique,"/>
   <result pre="= right anterior oblique, TEE = transesophageal echocardiography, VSD =" exact="ventricular septal defect." post="The authors have no conflicts of interest to disclose."/>
   <result pre="Ramachandran P Kadavigere R et al. Transcatheter closure of an" exact="atrial septal defect" post="with single coronary artery and retro-aortic right coronary artery"/>
   <result pre="S Lertsapcharoen P et al. Clinical results of large secundum" exact="atrial septal defect" post="closure in adult using percutaneous transcatheter Cocoon atrial septal"/>
   <result pre="Whitehead KJ Michaels AD et al. Unusual presentation of nickel" exact="allergy" post="requiring explantation of an Amplatzer atrial septal occluder device"/>
   <result pre="P Khongphatthanayothin A La-Orkhon V et al. Transcatheter closure of" exact="patent ductus arteriosus" post="with a self-expanding platinum-coated nitinol device . J Invasive"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6419324/results/search/disease/results.xml">
   <result pre="now growing interest for natural supplements used to control recurrent" exact="migraine" post="headaches. Such approach may increase acceptance and adherence to"/>
   <result pre="(T4: 4.46 + 1.75; p &amp;lt; 0.001 vs T0). The frequency of" exact="migraine" post="attacks was also reduced in the MO group during"/>
   <result pre="the use of nutraceutical in pediatric headache/migraine. Keywords Nutraceuticals Pediatric" exact="migraine" post="Observational study Tanacetum parthenium Prophylaxis Background Migraine is one"/>
   <result pre="to 19 years [ 1]. Migraine is defined as an episodic" exact="pain disorder" post="that can vary from an occasional occurrence to a"/>
   <result pre="loss of school, work, and social activities. As for adults," exact="migraine" post="treatment traditionally includes acute therapy for aborting migraine attacks"/>
   <result pre="for adults, migraine treatment traditionally includes acute therapy for aborting" exact="migraine" post="attacks and prophylactic treatment for reducing the frequency, duration"/>
   <result pre="by patients; in particular, parents ask healthcare professionals to provide" exact="migraine" post="relief for their children. Moreover, even clinicians prefer to"/>
   <result pre="10]. There is now growing interest for natural supplements for" exact="migraine" post="and headache treatment. Due to the low side effects,"/>
   <result pre="natural treatments, in particular nutraceuticals, in the prophylactic treatment of" exact="migraine" post="in children and adolescents, even if the evidences are"/>
   <result pre="furthermore it has antioxidant proprieties. A role of Cq10 in" exact="migraine" post="pathogenesis has been postulated because migraineurs have difficulties in"/>
   <result pre="a multicenter, prospective, observational study in children and adolescents with" exact="migraine" post="(with or without aura) or tension-type headache. From January"/>
   <result pre="study. During the assessment patients reported their age, medical history," exact="migraine" post="family history, headache type and localization. Inclusion criteria were"/>
   <result pre="migraine family history, headache type and localization. Inclusion criteria were" exact="migraine" post="with aura (MA), without aura (MO) or tension-type headache"/>
   <result pre="+ 1.75; p &amp;lt; 0.001 respect to T0). A significant reduction of" exact="migraine" post="frequency was also found for MO group (F(2.740, 131.5);"/>
   <result pre="with Partena was associated with lower intensity of pain for" exact="migraine" post="episodes among pediatric patients suffering from MA and MO."/>
   <result pre="along with anti-nociceptive effects in an animal model of sensory" exact="hypersensitivity" post="associated with migraine) [ 15]. Guidelines of the Società"/>
   <result pre="trigeminovascular system [ 20]. Clinical evidences about the treatment of" exact="migraine" post="are still controversial although the contradictory results may be"/>
   <result pre="about the efficacy of parthenium in the prophylactic treatment of" exact="migraine" post="[ 17, 21]. Studies on Feverfew efficacy in children"/>
   <result pre="21]. Studies on Feverfew efficacy in children and adolescents with" exact="migraine" post="are lacking [ 11]. The other active principles of"/>
   <result pre="and clinical evidences supporting their usefulness in prophylactic treatment of" exact="migraine" post="[ 21]. Several studies revealed decreased levels of the"/>
   <result pre="B2), magnesium (Mg) and CQ10 in plasma and brain of" exact="migraine" post="patients [ 22]. On the other hand, numerous studies"/>
   <result pre="at mitochondrial level, multiple trials have assessed their efficacy in" exact="migraine" post="prevention [ 23– 25]. Riboflavin is a cofactor in"/>
   <result pre="The role of magnesium in the prophylactic treatment of pediatric" exact="migraine" post="is still unclear and high-quality adequately powered trials are"/>
   <result pre="in pediatric population is a continuous challenge for clinicians. Although" exact="migraine" post="in children is phenotypically similar to adult migraine, medications"/>
   <result pre="of the most utilized drugs for prophylactic therapy in pediatric" exact="migraine" post="and there are no significant differences between the high"/>
   <result pre="risk–benefit profile for the use of these therapies in pediatric" exact="migraine" post="prevention [ 9]. On the other hand, our result"/>
   <result pre="frequency and pain intensity in children and adolescences suffering from" exact="migraine" post="and TTH, therefore should be considered as a potential"/>
   <result pre="needed to further assess the effectiveness in nutraceuticals’ use for" exact="migraine" post="treatment in child and adolescent. Abbreviations AAN American Academy"/>
   <result pre="comparative effectiveness meta-analysis of drugs for the prophylaxis of pediatric" exact="migraine" post="headache JAMA Pediatr 2013 167 3 250 258 10.1001/jamapediatrics.2013.508"/>
   <result pre="al. Trial of amitriptyline, topiramate, and place- Bo for pediatric" exact="migraine" post="N Engl J Med 2017 376 2 115 124"/>
   <result pre="Evidence-based guideline update: NSAIDs and other complementary treatments for episodic" exact="migraine" post="prevention in adults: report of the quality standards Subcommittee"/>
   <result pre="paniculata shows anti-nociceptive effects in an animal model of sensory" exact="hypersensitivity" post="associated with migraine Functional Neurology 2016 31 1 53"/>
   <result pre="effects in an animal model of sensory hypersensitivity associated with" exact="migraine" post="Functional Neurology 2016 31 1 53 60 10.11138/FNeur/2016.31.1.053 27027895"/>
   <result pre="inhibits nitroglycerin-induced Fos activation: studies in an animal model of" exact="migraine" post="Cephalalgia: An International Journal of Headache 2005 25 612"/>
   <result pre="O Mauskop A Nutraceuticals in acute and prophylactic treatment of" exact="migraine" post="Curr Treat Options Neurol 2016 18 4 14 10.1007/s11940-016-0398-1"/>
   <result pre="L Agosti RM Schoenen J Efficacy of coenzyme Q10 in" exact="migraine" post="prophylaxis: a randomized controlled trial Neurology. 2005 64 4"/>
   <result pre="Tang PH Pesce AJ Coenzyme Q10 changes are associated with" exact="metabolic syndrome" post="Clin Chim Acta 2004 344 1–2 173 179 10.1016/j.cccn.2004.02.016"/>
   <result pre="A Role of magnesium in the pathogenesis and treatment of" exact="migraine" post="Expert Rev Neurother 2009 9 3 369 379 10.1586/14737175.9.3.369"/>
   <result pre="AD Powers SW Coffey CS et al. Childhood and adolescent" exact="migraine" post="prevention (CHAMP) study: a double-blinded, placebo-controlled, comparative effectiveness study"/>
   <result pre="Topiramate and placebo in the prevention of childhood and adolescent" exact="migraine" post="Headache. 2013 53 5 799 816 10.1111/head.12105 23594025"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6423905/results/search/disease/results.xml">
   <result pre="been conducted on the prodromal and postdromal phases of the" exact="migraine" post="attack in children and adolescents. Using a questionnaire, we"/>
   <result pre="we found that 67% of 103 children and adolescents with" exact="migraine" post="reported at least one prodromal symptom, with a mean"/>
   <result pre="aura classic and/or accompany the headache phase. Functional imaging in" exact="migraine" post="has showed that the activations in areas such as"/>
   <result pre="children, adolescents and adults might contribute to the understanding of" exact="migraine" post="neurobiology. migraine prodrome postdrome child adolescent adult pathophysiology fig-count:"/>
   <result pre="and adults might contribute to the understanding of migraine neurobiology." exact="migraine" post="prodrome postdrome child adolescent adult pathophysiology fig-count: table-count: equation-count:"/>
   <result pre="issue of school absenteeism ( 2, 3). Phenotypical expressions of" exact="migraine" post="vary greatly both in the adult and pediatric age"/>
   <result pre="both populations, and probably more so in the latter, that" exact="migraine" post="headaches are frequently associated with non-headache symptoms has been"/>
   <result pre="ultimately epitomized by episodic syndromes which may be associated with" exact="migraine" post="( 5). It is meaningful that the historical recognition"/>
   <result pre="is probably unfortunate as they may provide an insight on" exact="migraine" post="pathophysiology, particularly if one takes advantage of the developmental"/>
   <result pre="Generally speaking, PS refers to symptoms preceding the onset of" exact="migraine" post="headache whereas PD corresponds to symptoms which begin after"/>
   <result pre="the pre-ictal state and should not be confused with the" exact="migraine" post="aura, nor with triggers as food craving, for example,"/>
   <result pre="a day or two before the other symptoms of a" exact="migraine" post="attack with aura. They include various combinations of fatigue,"/>
   <result pre="to 48 h, occurring before the onset of pain in" exact="migraine" post="without aura or before the aura in migraine with"/>
   <result pre="pain in migraine without aura or before the aura in" exact="migraine" post="with aura. Among the common prodromal symptoms are fatigue,"/>
   <result pre="up to 48 h, following the resolution of pain in" exact="migraine" post="attacks with or without aura. Among the common postdromal"/>
   <result pre="in 103 children and adolescents (&amp;lt; 18 years) suffering from" exact="migraine" post="(with (MA) and/or without aura (MO), but not chronic"/>
   <result pre="randomly drawn from a clinic-based database. Each interview concerned the" exact="migraine" post="patient and one of his/her parents. The definition of"/>
   <result pre="(see above). The questionnaire comprised two parts; part 1 addressed" exact="migraine" post="characteristics, part 2 listed 15 possible prodromal symptoms selected"/>
   <result pre="had prodrome. There was no statistically significant link with gender," exact="migraine" post="subtype and mean monthly attack frequency. As for gender,"/>
   <result pre="&amp;gt;12 59 (57%) 42 (71%) 1.6 [0.7–3.6] 0.4 Number of" exact="migraine" post="attacks per month &amp;lt; 1 29 (28%) 23 (79%)"/>
   <result pre="Moreover, included patients (children and adolescents) not only suffered from" exact="migraine" post="but also from New Daily Persistent Headache &quot;with migrainous"/>
   <result pre="Daily Persistent Headache &quot;with migrainous features.&quot; Exclusion criteria included typical" exact="migraine" post="aura and cranial autonomic symptoms. In this study, prodromal"/>
   <result pre="because of their discrete pathophysiology&quot; ( 12). Of note, chronic" exact="migraine" post="and episodic migraine accounted for 58 and 29% of"/>
   <result pre="discrete pathophysiology&quot; ( 12). Of note, chronic migraine and episodic" exact="migraine" post="accounted for 58 and 29% of the diagnoses, respectively."/>
   <result pre="New Daily Persistent Headache with migrainous features (8%) and hemiplegic" exact="migraine" post="(5%). Thirty one percent of patients reported a history"/>
   <result pre="( 13). The sample study consisted of patients suffering from" exact="migraine" post="seen by neurologists at outpatient headache clinics in six"/>
   <result pre="adults), prodromal symptoms were more than twice more frequent in" exact="migraine" post="vs. non-migraine patients. Patients with MA had more prodromal"/>
   <result pre="number of prodromal symptoms: 0.8) whereas patients suffering from hemiplegic" exact="migraine" post="had the greater rate of prodromal symptoms (frequency: 93%,"/>
   <result pre="prodromal symptoms. Comparison to Adult Studies The proportion of pediatric" exact="migraine" post="patients reporting PS was available in two studies only"/>
   <result pre="398 children and adolescents suffering from primary headache (78.5% with" exact="migraine" post="or probable migraine), only 11.8% of patients reported PS"/>
   <result pre="11) Telephone Questionnaire/Checklist R 103 Clinical sample of Children/adolescent with" exact="migraine" post="Face changes (44%), fatigue (42%), irritability (24%) Frequency of"/>
   <result pre="al. ( 12) Clinical letter R 100 Clinical sample with" exact="migraine" post="(episodic/chronic, NDPH) Fatigue (62%), mood change (55%), neck stiffness"/>
   <result pre="16) Unstructured recall and checklist R 149 Population-based sample with" exact="migraine" post="PS–50% of patients with following PS the day before"/>
   <result pre="attack Kelman ( 21) Interview R 893 Clinical sample with" exact="migraine" post="Fatigue (25.6%); mood change (23.4%); head pain, aching, twitching"/>
   <result pre="et al. ( 25) Self-report R 100 Clinical sample with" exact="migraine" post="PS Thirty-three percent of patients affected by migraine without"/>
   <result pre="sample with migraine PS Thirty-three percent of patients affected by" exact="migraine" post="without aura reported PS in at least 50% of"/>
   <result pre="of PS the constancy of PS being associated with the" exact="migraine" post="attack, it concerned 64% of patients in our study,"/>
   <result pre="conducted in an outpatient clinic ( n = 460 adult" exact="migraine" post="patients), PS preceded migraine attacks in more than 2/3"/>
   <result pre="clinic ( n = 460 adult migraine patients), PS preceded" exact="migraine" post="attacks in more than 2/3 of events in 46%;"/>
   <result pre="Quintela et al. showed that PS was reproducible across different" exact="migraine" post="attacks ( 22), which allows self-prediction. Self-prediction is the"/>
   <result pre="22), which allows self-prediction. Self-prediction is the ability by the" exact="migraine" post="patient to assess the probability that he/she will have"/>
   <result pre="groups of symptoms occurring during the resolution phase of the" exact="migraine" post="headache: symptoms that had begun before and went on"/>
   <result pre="headache: symptoms that had begun before and went on after" exact="migraine" post="headache had subsidized, and symptoms that began strictly after"/>
   <result pre="18 years, to fulfill the ICHD-3 beta criteria for pediatric" exact="migraine" post="without typical aura (MO) and/or with aura (MA) at"/>
   <result pre="not chronic migraine, and not be on preventive drugs for" exact="migraine" post="or any other medication]. Patients and/or their parents were"/>
   <result pre="and TPD. The questionnaire comprised two parts; part 1 addressed" exact="migraine" post="characteristics, part 2 listed 31 resolution phase symptoms selected"/>
   <result pre="Figure 3). The median number of PTS differed according to" exact="migraine" post="subtype distribution: 2 [0–10], 3 [0–8], and 3 [0–5]"/>
   <result pre="3). The median number of TPD differed significantly according to" exact="migraine" post="subtype distribution: 2 [0–11], 3 [0–9], and 1 [0–3]"/>
   <result pre="= 0.03). Onset of TPD occurred &amp;lt; 30 min after" exact="migraine" post="headache cessation in 95% of patients. Table 3 presents"/>
   <result pre="our results we could conclude that children and adolescents with" exact="migraine" post="frequently experienced both PD symptoms subtypes. It is also"/>
   <result pre="in as many as 60% of children, which aborts the" exact="migraine" post="attack and thus avoids or masks the PD ("/>
   <result pre="22, 34). So What? Children, adolescents, and adults suffering from" exact="migraine" post="do have PS and PD frequently. Bearing in mind"/>
   <result pre="14). Several adult studies dedicated to the PD of a" exact="migraine" post="attack led to comparable conclusions ( 34, 35, 38)."/>
   <result pre="on the issue of why there being different subtypes of" exact="migraine" post="( 39– 41). The hypothesis of (a) possible migraine"/>
   <result pre="of migraine ( 39– 41). The hypothesis of (a) possible" exact="migraine" post="generator(s) has gained credit over the last years and"/>
   <result pre="neck stiffness). Some of the former prodromal symptoms reflect dopaminergic" exact="hypersensitivity" post="and are mediated by nitric oxide pathways ( 42)."/>
   <result pre="can modulate clinical susceptibility to migraine, at least in some" exact="migraine" post="patients, and dopamine can play a key role in"/>
   <result pre="biochemical cascade leading to the PS, and ultimately in the" exact="migraine" post="attack ( 43). Vasopressin and the orexins are alternative"/>
   <result pre="a critical physiological threshold be reached to induce the full-blown" exact="migraine" post="headache ( 19). Other prodromal symptoms (emotional change, fatigue,"/>
   <result pre="additionally proposed that it might reflect a slow decline in" exact="migraine" post="processes and that the diversity of PD symptoms could"/>
   <result pre="Bose et al. proposed that this hypoperfusion shown during the" exact="migraine" post="attack might be related to cortical spreading depression ("/>
   <result pre="pons and periaqueductal gray matter) in the mediation of the" exact="migraine" post="attack. The same team conducted a second positron emission"/>
   <result pre="photophobia to the visual cortex during the premonitory phase of" exact="migraine" post="in the absence of headache ( 48). With a"/>
   <result pre="months ( 12). One is tempted to link changes in" exact="migraine" post="symptomatology with developmental features associated to brain maturation. In"/>
   <result pre="so far. It is noteworthy that the well-known modification of" exact="migraine" post="pain location, evolving from bilateral in children and adolescents"/>
   <result pre="from the study of a periodic syndrome such as abdominal" exact="migraine" post="may be more in line with the issue under"/>
   <result pre="be more in line with the issue under examination. Abdominal" exact="migraine" post="is a childhood disorder which evolves to more usual"/>
   <result pre="migraine is a childhood disorder which evolves to more usual" exact="migraine" post="subtypes as the child gets older. Symptoms consist of"/>
   <result pre="such as locus coeruleus, in this process. In this way," exact="migraine" post="attacks would be initiated through dysautonomia. That the influence"/>
   <result pre="be another hint. Sleep alterations constitute an important trigger of" exact="migraine" post="attacks and many migraine attacks terminate with the child"/>
   <result pre="alterations constitute an important trigger of migraine attacks and many" exact="migraine" post="attacks terminate with the child falling asleep and awakening"/>
   <result pre="neural circuits change during before and with puberty. Remembering that" exact="migraine" post="often starts in adolescence, or attacks frequency is influenced"/>
   <result pre="older which matters ( 65). Whereas, brain maturation may affect" exact="migraine" post="symptoms phenomenology as time goes, conversely, migraine may influence"/>
   <result pre="maturation may affect migraine symptoms phenomenology as time goes, conversely," exact="migraine" post="may influence the development of the brain. Finally, it"/>
   <result pre="changes have been identified to be altered or associated with" exact="migraine" post="in children and adults ( 66), including increased levels"/>
   <result pre="(better accounted for as a brain tendency to over-respond) in" exact="migraine" post="is unclear, genetic factors are also at play. Several"/>
   <result pre="which support this statement are scarce but the efficacy in" exact="migraine" post="prevention of naratriptan and dopamine antagonists is suggested by"/>
   <result pre="this hypothesis. Similarly, domperidone, a dopamine antagonist, may block a" exact="migraine" post="attack, provided it is taken at least 6 h"/>
   <result pre="77, 78). The fact that children and adolescents experience shorter" exact="migraine" post="attacks as compared to adults makes this issue eminently"/>
   <result pre="in children and adolescents. It has been shown, in adult" exact="migraine" post="sufferers, that nitroglycerin and pituitary adenylate-cyclase activating protein could"/>
   <result pre="in order to better evaluate the whole burden of the" exact="migraine" post="attack, but also reliably predict the impending onset of"/>
   <result pre="This is unbelievably an interesting and exciting area for future" exact="migraine" post="research! Author Contributions The author confirms being the sole"/>
   <result pre="10.1111/j.1468-2982.2007.01288.x 17381554 2. Wöber-Bingöl C . ( 2013). Epidemiology of" exact="migraine" post="and headache in children and adolescents. Curr Pain Headache"/>
   <result pre="3. Abu-Arefeh I Russell G . Prevalence of headache and" exact="migraine" post="in schoolchildren. BMJ. ( 1994) 309: 765– 9. 10.1136/bmj.309.6957.765"/>
   <result pre="10.1016/j.pediatrneurol.2009.07.001 20004856 6. Dodick W . A phase-by-phase review of" exact="migraine" post="pathophysiology. Headache. ( 2018) 58: 4– 16. 10.1111/head.13300 29697154"/>
   <result pre="S Lipton RB . Trigger factors and premonitory features of" exact="migraine" post="attacks: summary of studies. Headache. ( 2014) 54: 1670–"/>
   <result pre="25399858 8. Bose P Karsan N Goadsby PJ . The" exact="migraine" post="postdrome. Continuum. ( 2018) 24: 1023– 31. 10.1212/CON.0000000000000626 30074547"/>
   <result pre="Prabhakar P Goadsby PJ . Characterising the premonitory stage of" exact="migraine" post="in children: a clinic-based study of 100 patients in"/>
   <result pre="10.1212/01.WNL.0000052998.58526.A9 12654956 20. Houtveen JH Sorbi MJ Prodromal functioning of" exact="migraine" post="patients relative to their interictal state - an ecological"/>
   <result pre="23. Rasmussen BK Olesen J . Migraine with aura and" exact="migraine" post="without aura: an epidemiological study. Cephalalgia. ( 1992) 12:"/>
   <result pre="BK Fenger K Olesen J . Migraine without aura and" exact="migraine" post="with aura are distinct clinical entities: a study of"/>
   <result pre="Bernasconi F Sessa F Venco A . Premonitory symptoms in" exact="migraine" post="without aura: a clinical investigation. Funct Neurol. ( 1990)"/>
   <result pre="P et al. . Prospective analysis of factors related to" exact="migraine" post="attacks: the PAMINA study. Cephalalgia. ( 2007) 27: 304–"/>
   <result pre="Kay J Jaron A . Epidemiology of headache and childhood" exact="migraine" post="in an urban general practice using ad hoc, Vahlquist"/>
   <result pre="P Ambrosini A Buzzi MG . Prodromes and predictors of" exact="migraine" post="attack. Funct Neurol. ( 2005) 20: 185– 91. 16483459"/>
   <result pre="580– 4. 10.1046/j.1468-2982.2000.00089.x 11075842 33. Blau JN . Resolution of" exact="migraine" post="attacks: sleep and the recovery phase. J Neurol Neurosurg."/>
   <result pre="7086442 34. Kelman L . The postdrome of the acute" exact="migraine" post="attack. Cephalalgia. ( 2006) 26: 214– 20. 10.1111/j.1468-2982.2005.01026.x 16426278"/>
   <result pre="Lipton RB Silberstein SD Olesen J Goadsby PJ . The" exact="migraine" post="postdrome: an electronic diary study. Neurology. ( 2016) 87:"/>
   <result pre="Nelsen LM Evans CJ et al. . Key concepts of" exact="migraine" post="postdrome: a qualitative study to develop a postmigraine questionnaire"/>
   <result pre="brain anticipates an attack: a study of neurophysiological periodicity in" exact="migraine" post=". Funct Neurol. ( 1999) 14: 69– 77. 10399619"/>
   <result pre="GL et al. . Association between dopamine receptor genes and" exact="migraine" post="without aura in a Sardinian sample . Neurology. ("/>
   <result pre="PJ . Brain activations in the premonitory phase of nitroglycerintriggered" exact="migraine" post="attacks. Brain. ( 2014) 137: 232– 41. 10.1093/brain/awt320 24277718"/>
   <result pre="10.1186/1129-2377-15-84 25471540 48. Maniyar S Shankin C Goadsby PJ Photic" exact="hypersensitivity" post="in the premonitory phase of migraine- a positron emission"/>
   <result pre="83. 10.1111/ene.12451 24780052 49. Schulte LH May A . The" exact="migraine" post="generator revisited: continuous scanning of the migraine cycle over"/>
   <result pre="A . The migraine generator revisited: continuous scanning of the" exact="migraine" post="cycle over 30 days and three spontaneous attacks ."/>
   <result pre="in cerebral blood flow during the postdrome phase of a" exact="migraine" post="attack captured with arterial spin labelled (ASL) MRI ."/>
   <result pre="RV et al. . Brain stem activation in spontaneous human" exact="migraine" post="attacks. Nat Med. ( 1995) 1: 658– 60. 10.1038/nm0795-658"/>
   <result pre="P Chollet F Géraud G . Hypothalamic activation in spontaneous" exact="migraine" post="attacks. Headache. ( 2007) 47: 1418– 26. 10.1111/j.1526-4610.2007.00776.x 18052951"/>
   <result pre="36: 413– 21. 10.1177/0333102415593089 26156076 54. Goadsby PJ Pathophysiology of" exact="migraine" post="and other headaches. In: Abu-Arefeh I, editors. Childhood Headache,"/>
   <result pre="al. . Longitudinal assessment of response preparation and evaluation in" exact="migraine" post="gives evidence for deviant maturation . Cephalalgia. ( 2008)"/>
   <result pre="U . Developmental changes of the contingent negative variation in" exact="migraine" post="and healthy children . J Head Pain. ( 2010)"/>
   <result pre="65. Schulte LH May A . Of generators, networks and" exact="migraine" post="attacks. Curr Opin Neurol. ( 2017) 30: 241– 5."/>
   <result pre="Q10 deficiency and response to supplementation in pediatric and adolescent" exact="migraine" post=". Headache. ( 2007) 47: 73– 80. 10.1111/j.1526-4610.2007.00652.x 17355497"/>
   <result pre="Kabbouche MA Lecates SL Segers A et al. . Menstrual" exact="migraine" post="in adolescents. Headache. ( 2009) 49: 341– 7. 10.1111/j.1526-4610.2009.01347.x"/>
   <result pre="10.1111/j.1526-4610.2009.01397.x 19562825 71. Martin VT Behbehani M Ovarian hormones and" exact="migraine" post="headache: understanding mechanisms and pathogenesis-part 1 . Headache. ("/>
   <result pre="16412147 72. Martin VT Behbehani M . Ovarian hormones and" exact="migraine" post="headache: understanding mechanisms and pathogenesis-part 2 . Headache. ("/>
   <result pre="et al. . Genome-wide association analysis identifies susceptibility loci for" exact="migraine" post="without aura . Nat Genet. ( 2012) 44: 777–"/>
   <result pre="L Hemphill M Diamond M Cady R . Prevention of" exact="migraine" post="during prodrome with naratriptan. Cephalalgia. ( 2000) 20: 122–"/>
   <result pre="nonheadache symptoms induced by CGRP and PACAP38 in patients with" exact="migraine" post=". Pain. ( 2016) 157: 2773– 81. 10.1097/j.pain.0000000000000702 27842045"/>
   <result pre="Pain. ( 2016) 157: 2773– 81. 10.1097/j.pain.0000000000000702 27842045 Abbreviations MA" exact="migraine" post="with aura MO migraine without aura PD postdrome PS"/>
   <result pre="2773– 81. 10.1097/j.pain.0000000000000702 27842045 Abbreviations MA migraine with aura MO" exact="migraine" post="without aura PD postdrome PS prodrome PTS persistent symptoms"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6426199/results/search/disease/results.xml">
   <result pre="The study’s purpose was to assess beta-blockers efficacy in preventing" exact="migraine" post="and tension-type headache. Methods Cochrane Register of Controlled Trials;"/>
   <result pre="least one comparison was a beta-blocker for the prevention of" exact="migraine" post="or tension-type headache in adults. The primary outcome, headache"/>
   <result pre="58 comparative effectiveness trials. Compared to placebo, propranolol reduced episodic" exact="migraine" post="headaches by 1.5 headaches/month at 8 weeks (95% CI:"/>
   <result pre="quality evidence that propranolol is better than placebo for episodic" exact="migraine" post="headache. Other comparisons were underpowered, rated as low-quality based"/>
   <result pre="impossible. There were few trials examining beta-blocker effectiveness for chronic" exact="migraine" post="or tension-type headache though there was limited evidence of"/>
   <result pre="problem, world-wide. The two most common types of headaches are" exact="migraine" post="and tension-type. Migraines have a prevalence of 6–8% ["/>
   <result pre="year [ 15; 16] in the US alone. While episodic" exact="migraine" post="is more common than chronic migraine, chronic migraine has"/>
   <result pre="While episodic migraine is more common than chronic migraine, chronic" exact="migraine" post="has greater disability as well as financial and occupational"/>
   <result pre="to assess the efficacy of beta-blockers in the prophylaxis of" exact="migraine" post="and tension-type headache. Two previous systematic reviews focused on"/>
   <result pre="previous systematic reviews focused on the use of beta-blockers in" exact="migraine" post="headaches, both are more than 15 years old ["/>
   <result pre="management that included beta-blockers. Shamliyan reviewed pharmacologic treatment for episodic" exact="migraine" post="and reported that beta-blockers were effective; their outcome was"/>
   <result pre="the other meta-analysis, we found that beta-blockers were beneficial for" exact="migraine" post="headaches, but did not differentiate between episodic and chronic"/>
   <result pre="migraine headaches, but did not differentiate between episodic and chronic" exact="migraine" post="headaches, did not include all possible outcomes and did"/>
   <result pre="to determine if the headache could be reasonably classified as" exact="migraine" post="or tension-type headache and as either frequent episodic or"/>
   <result pre="based on results from our previous review of treatment of" exact="migraine" post="headaches [ 17]. Studies with more than one arm"/>
   <result pre="effectiveness arms. Nearly all trials (n = 106) focused on" exact="migraine" post="headaches, most (n = 83) could be classified as"/>
   <result pre="secondary outcomes, the majority of trials studied subjects with episodic" exact="migraine" post="headaches ( Table 3). Propranolol was the most commonly"/>
   <result pre="— Low 10 weeks -0.70 (-4.0 to 2.6) — Chronic" exact="migraine" post="There were four trials that evaluated beta-blockers for chronic"/>
   <result pre="migraine There were four trials that evaluated beta-blockers for chronic" exact="migraine" post="headaches, none were placebo controlled. ( Table 6). Propranolol"/>
   <result pre="trials. Nearly all evaluated the efficacy of beta-blockers for episodic" exact="migraine" post="headaches. Compared to placebo, propranolol was effective in reducing"/>
   <result pre="headaches. Compared to placebo, propranolol was effective in reducing episodic" exact="migraine" post="frequency. The effect began as early as four weeks."/>
   <result pre="benefit. Acebutolol, alprenolol and nadolol appeared to be ineffective in" exact="migraine" post="prophylaxis. This is unlikely to be due to properties"/>
   <result pre="in the United States, is well-established as effective in treating" exact="migraine" post="headache. Universally, beta-blockers were associated with bradycardia and with"/>
   <result pre="have been studied almost exclusively in the management of episodic" exact="migraine" post="headaches. Their benefit for chronic episodic or tension-type headaches"/>
   <result pre="is effective in reducing the burden of patients with episodic" exact="migraine" post="headaches, reducing headaches from 5 to 3 headaches a"/>
   <result pre="from 5 to 3 headaches a month. This means that" exact="migraine" post="sufferers given propranolol will have substantial residual headache burden."/>
   <result pre="774– 777. 10.1177/033310240102100708 11595011 2 Wang SJ . Epidemiology of" exact="migraine" post="and other types of headache in Asia. Current Neurology"/>
   <result pre=", Neuhauser H . Prevalence and burden of headache and" exact="migraine" post="in Germany. Headache 2009; 49( 1): 79– 89. 10.1111/j.1526-4610.2008.01263.x"/>
   <result pre="D , Reed ML , Turkel CC et al. Chronic" exact="migraine" post="prevalence, disability, and sociodemographic factors: results from the American"/>
   <result pre="of life, disability and severity of disease in patients with" exact="migraine" post="attending to a specialty headache center . Headache 2010;"/>
   <result pre="cycle of migraine: patients' quality of life during and between" exact="migraine" post="attacks. Clin Ther 2007; 29( 5): 939– 949. 10.1016/j.clinthera.2007.05.008"/>
   <result pre="RB , Stewart WF , Berger ML . Burden of" exact="migraine" post="in the United States: disability and economic costs. Archives"/>
   <result pre="813– 818. 10219926 16 Goldberg LD . The cost of" exact="migraine" post="and its treatment. Am J Manag Care 2005; 11("/>
   <result pre="Jorgensen T , Jensen R . Has the prevalence of" exact="migraine" post="and tension-type headache changed over a 12-year period? European"/>
   <result pre="R , Gulliford M , Ridsdale L . Headache and" exact="migraine" post="in primary care: consultation, prescription, and referral rates in"/>
   <result pre="26 Chronicle E , Mulleners W . Anticonvulsant drugs for" exact="migraine" post="prophylaxis. Cochrane Library 2004;( 3). 27 Linde K ,"/>
   <result pre="3). 27 Linde K , Rossnagel K . Propranolol for" exact="migraine" post="prophylaxis. Cochrane Database Syst Rev 2004;( 2): CD003225 10.1002/14651858.CD003225.pub2"/>
   <result pre="Hayashino Y . Botulinum toxin A for prophylactic treatment of" exact="migraine" post="and tension headaches in adults: a meta-analysis . JAMA"/>
   <result pre="T , Davenport WJ , Becker WJ . Prophylaxis of" exact="migraine" post="headache. CMAJ 2010; 182( 7): E269– E276. 10.1503/cmaj.081657 20159899"/>
   <result pre="Canepari C . Selective serotonin re-uptake inhibitors (SSRIs) for preventing" exact="migraine" post="and tension-type headaches . Cochrane Database Syst Rev 2005;("/>
   <result pre="Ashman E . Evidence-based guideline update: pharmacologic treatment for episodic" exact="migraine" post="prevention in adults: report of the Quality Standards Subcommittee"/>
   <result pre=", Dodick D . Persistence and switching patterns of oral" exact="migraine" post="prophylactic medications among patients with chronic migraine: a retrospective"/>
   <result pre="1830566 40 Linde K , Rossnagel K . Propranolol for" exact="migraine" post="prophylaxis. Cochrane Database Syst Rev 2004;( 2): CD003225 10.1002/14651858.CD003225.pub2"/>
   <result pre=", Taylor FR et al. Preventive pharmacologic treatments for episodic" exact="migraine" post="in adults. J Gen Intern Med 2013; 28( 9):"/>
   <result pre="propranolol LA 80 mg and propranolol LA 160 mg in" exact="migraine" post="prophylaxis: a placebo controlled study . Cephalalgia 1993; 13("/>
   <result pre="Petersen EN . Propranolol and femoxetine, a HT-uptake inhibitor, in" exact="migraine" post="prophylaxis. A double-blind crossover study . Acta Neurol Scand"/>
   <result pre="Kristensen TN et al. Prophylactic treatment of classical and non-classical" exact="migraine" post="with metoprolol—a comparison with placebo . Cephalalgia 1983; 3("/>
   <result pre="A double-blind, randomized trial of low-dose topiramate vs propranolol in" exact="migraine" post="prophylaxis . 2008; 118( 5): 301– 305. 64 Baldrati"/>
   <result pre=", Baruzzi A et al. Propranolol and acetylsalicylic acid in" exact="migraine" post="prophylaxis. Double-blind crossover study . Acta Neurol Scand 1983;"/>
   <result pre="Amato D , Scellini T et al. Long-term outcome of" exact="migraine" post="therapy: predictive value of the frontotemporal nitroglycerin test ."/>
   <result pre="JG . Propranolol vs flunarizine vs flunarizine plus propranolol in" exact="migraine" post="without aura prophylaxis. A double-blind trial . Arq Neuropsiquiatr"/>
   <result pre=", Nielsen JL , Moller CE . Prophylactic treatment of" exact="migraine" post="with propranolol. A clinical trial. Acta Neurol Scand 1974;"/>
   <result pre="4611129 69 Briggs RS , Millac PA . Timolol in" exact="migraine" post="prophylaxis. Headache 1979; 19: 379– 381. 511540 70 Carroll"/>
   <result pre="HP , Nappi G et al. Efficacy and tolerability in" exact="migraine" post="prophylaxis of flunarizine in reduced doses: a comparison with"/>
   <result pre=", Sandrini G , Wang SJ et al. Topiramate in" exact="migraine" post="prophylaxis—results from a placebo-controlled trial with propranolol as an"/>
   <result pre="combination of propranolol and nortriptyline for the preventive treatment of" exact="migraine" post=". 2009; 67( 4): 973– 977. 77 Ekbom K"/>
   <result pre="of LB-46 (d, 1-4-(2-hydroxy-3-isopropylaminopropoxy)indol. An adrenergic beta-receptor blocking agent in" exact="migraine" post="prophylaxis . Headache 1972; 12( 1): 15– 17. 4402287"/>
   <result pre="1): 15– 17. 4402287 78 Ekbom K . Alprenolol for" exact="migraine" post="prophylaxis. Headache 1975; 15( 2): 129– 132. 1097368 79"/>
   <result pre="B , Henriksson KG , Johannsson V . Propranolol for" exact="migraine" post="prophylaxis. Headache 1976; 16: 238– 245. 977330 82 Forssman"/>
   <result pre="B , Lindblad CJ , Zbornikova V . Atenolol for" exact="migraine" post="prophylaxis. Headache 1983; 23( 4): 188– 190. 6350226 83"/>
   <result pre="and safety of flunarizine to propranolol in the prophylaxis of" exact="migraine" post=". Can J Neurol Sci 1992; 19( 3): 340–"/>
   <result pre="Responders and non-responders to metoprolol, propranolol and nifedipine treatment in" exact="migraine" post="prophylaxis: a dose-range study based on time-series analysis ."/>
   <result pre="Jivad N . The prophylactic activity of propranol and nimodipineon" exact="migraine" post="headache. 2013; 8( 2): 144– 146. 88 Grotemeyer KH"/>
   <result pre=", Schlake HP , Husstedt IW . [ Prevention of" exact="migraine" post="with metoprolol and flunarizine. A double-blind crossover study]. Nervenarzt"/>
   <result pre="HP , Husstedt IW . Acetylsalicylic acid vs. metoprolol in" exact="migraine" post="prophylaxis—a double-blind cross-over study . Headache 1990; 30( 10):"/>
   <result pre="beta 1-selective beta-blockers in their effect on platelet function in" exact="migraine" post="patients . Acta Neurol Scand 1986; 74( 6): 475–"/>
   <result pre="Mogelvang B , Simonsen H . Acupuncture versus metoprolol in" exact="migraine" post="prophylaxis: a randomized trial of trigger point inactivation ."/>
   <result pre="et al. Effect of preventive (Î 2 blocker) treatment, behavioural" exact="migraine" post="management, or their combination on outcomes of optimised acute"/>
   <result pre=", Hellman P , Akesson JA et al. Atenolol in" exact="migraine" post="prophylaxis a double-blind cross-over multicentre study. Headache 1987; 27("/>
   <result pre=". Comparison of mefenamic acid and propranolol with placebo in" exact="migraine" post="prophylaxis. Acta Neurol Scand 1986; 73( 5): 490– 492."/>
   <result pre="new 5-HT uptake inhibitor—and propranolol in the prophylactic treatment of" exact="migraine" post=". Acta neurologica Scandinavica 1983; 68: 262– 267. 6606930"/>
   <result pre="of divalproex with propranolol and placebo for the prophylaxis of" exact="migraine" post="without aura . Arch Neurol 1997; 54( 9): 1141–"/>
   <result pre="and systematic relaxation versus propranolol in long term prophylaxis of" exact="migraine" post=". Complement Ther Med 2005; 13( 3): 165– 174."/>
   <result pre="of divalproex sodium and propranolol HCl in the prevention of" exact="migraine" post="headaches . HEADACHE Q 1994; 5: 50– 53. 106"/>
   <result pre="107 Kuritzky A , Hering R . Prophylactic treatment of" exact="migraine" post="with long acting propranolol—a comparison with placebo . Cephalalgia"/>
   <result pre="Mayer K , Schroth G . Clomipramine and metoprolol in" exact="migraine" post="prophylaxis—a double-blind crossover study. Headache 1985; 25( 2): 107–"/>
   <result pre="effect of 5-hydroxytryptophan and propranolol in the interval treatment of" exact="migraine" post="]. Schweiz Med Wochenschr 1991; 121( 43): 1585– 1590."/>
   <result pre="4): 163– 167. 4566216 114 Mathew NT . Prophylaxis of" exact="migraine" post="and mixed headache. A randomized controlled study. Headache 1981;"/>
   <result pre=", Pedersen KK , Christiansen LV . Prophylactic treatment of" exact="migraine" post="with tolfenamic acid, propranolol and placebo. Acta Neurol Scand"/>
   <result pre=", Srinivasa R . Oral riboflavin versus oral propranolol in" exact="migraine" post="prophylaxis: An open label randomized controlled trial . 2011;"/>
   <result pre="Melville ID . A double blind trial of acebutolol for" exact="migraine" post="prophylaxis. Headache 1978; 18( 1): 20– 22. 348644 119"/>
   <result pre="Gustavsson CL , Furberg B . Nadolol and propranolol in" exact="migraine" post="management. Headache 1986; 26( 10): 490– 493. 3546194 120"/>
   <result pre="G , Johansson F et al. Metoprolol and propranolol in" exact="migraine" post="prophylaxis: a double-blind multicentre study. Acta Neurol Scand 1984;"/>
   <result pre="Feve J , Masson M et al. Long-acting propranolol in" exact="migraine" post="prophylaxis: results of a double-blind, placebo-controlled study . Cephalalgia"/>
   <result pre="propranolol hydrochloride and a placebo control for the prophylaxis of" exact="migraine" post="headache . Headache 1985; 25( 6): 320– 324. 3902723"/>
   <result pre="Randomized, placebo-controlled trial of propranolol added to topiramate in chronic" exact="migraine" post=". Neurology 2012; 78( 13): 976– 984. 10.1212/WNL.0b013e31824d5846 22377815"/>
   <result pre="H , Alslev T et al. Flunarizine versus metoprolol in" exact="migraine" post="prophylaxis: a double-blind, randomized parallel group study of efficacy"/>
   <result pre="timolol versus propranolol and placebo in common migraine: beta-blockers in" exact="migraine" post=". Cephalalgia 1982; 2( 3): 165– 170. 10.1046/j.1468-2982.1982.0203165.x 6758949"/>
   <result pre="of phopranolol in racemic form (Inderal), D-propranolol and placebo in" exact="migraine" post=". Acta Neurol Scand 1976; 53( 3): 229– 232."/>
   <result pre="et al. A comparative study of candesartan versus propranolol for" exact="migraine" post="prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study ."/>
   <result pre="al. Effectiveness and tolerability of acupuncture compared with metoprolol in" exact="migraine" post="prophylaxis . Headache 2006; 46( 10): 1492– 1502. 10.1111/j.1526-4610.2006.00598.x"/>
   <result pre="Olesen J . Timolol vs propranolol vs placebo in common" exact="migraine" post="prophylaxis: a double-blind multicenter trial. Acta Neurol Scand 1984;"/>
   <result pre=", Franke CL , Koehler PJ . Prophylactic treatment of" exact="migraine" post="with bisoprolol: a placebo-controlled study. Cephalalgia 1997; 17( 5):"/>
   <result pre="144 Weber RB , Reinmuth OM . The treatment of" exact="migraine" post="with propranolol. Neurology 1971; 21: 404– 405. 145 Wideroe"/>
   <result pre=", Grotemeyer KH , Scharafinski HW . [ Prevention of" exact="migraine" post="using bisoprolol. Results of a double-blind study versus metoprolol]."/>
   <result pre="148 Chen J . Clinical study of topiramate in preventing" exact="migraine" post="attacks. Sichuan Medical Journal 2009; 30( 1): 119. 149"/>
   <result pre=". Therapeutic effect of metoprolol tartrate combined with flunarizine on" exact="migraine" post="in the treatment of migraine . Journ of Integrative"/>
   <result pre="tartrate combined with flunarizine on migraine in the treatment of" exact="migraine" post=". Journ of Integrative Medicine, Cardiovascular and Cerebrovascular Diseases"/>
   <result pre="S . Therapeutic effect of sodium valproate on prevention of" exact="migraine" post="recurrence. Sichuan Medical Journal 2004; 25( 4): 416. 154"/>
   <result pre=". Therapeutic effect of metoprolol tartrate combined with flunarizine on" exact="migraine" post="in the treatment of migraine . Modern Practical Medicine"/>
   <result pre="tartrate combined with flunarizine on migraine in the treatment of" exact="migraine" post=". Modern Practical Medicine 2011; 23( 11): 1275– 1276."/>
   <result pre=". The effect of metoprolol combined with fluoxetine on preventing" exact="migraine" post="and its effect on serotonin . Chinese Journal of"/>
   <result pre="Preliminary randomized controlled trial of topiramate and propranolol to prevent" exact="migraine" post="attacks . Huaxi Pharmaceutical Journal 2005; 20( 2): 182–"/>
   <result pre="Clinical trial of a beta-receptor blocking agent (LB 46) in" exact="migraine" post="prophylaxis. Acta Neurol Scand 1972; 48( 1): 124– 128."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6438928/results/search/disease/results.xml">
   <result pre="Sonal Sekhar et al., 2012). Given that many patients have" exact="migraine" post="for many years, the notion of how the disease"/>
   <result pre="to dissect brain related changes within different age cohorts in" exact="migraine" post="would be to use longitudinal imaging studies. Yet that"/>
   <result pre="of baseline intrinsic brain activity generated by long-term episodes of" exact="migraine" post="attacks in adults. These studies showed that brain connectivity"/>
   <result pre="the current study was to expand our understanding of how" exact="migraine" post="may affect the development of the young brain by"/>
   <result pre="association between rs-FC patterns within each developmental group and individual" exact="migraine" post="characteristics (i.e., duration of migraine in years and attack"/>
   <result pre="each developmental group and individual migraine characteristics (i.e., duration of" exact="migraine" post="in years and attack frequency per month). We hypothesized"/>
   <result pre="accordance with previous adult and pediatric rs-FC studies performed in" exact="migraine" post="and other pain conditions, we expected to find differences"/>
   <result pre="associated with more rs-FC brain changes in young adults with" exact="migraine" post="than in adolescents. Some previous studies have highlighted a"/>
   <result pre="cohort including 7–27 years-old volunteers with a history of episodic" exact="migraine" post="(with or without aura) and age- and sex-matched HC."/>
   <result pre="al., 2017). Overall, 51 right-handed adolescents and young adults with" exact="migraine" post="and 51 HC were included in this particular study."/>
   <result pre="Greater Boston Area). All patients met the criteria for episodic" exact="migraine" post="as defined by the International Classification for Headache Disorders,"/>
   <result pre="if they had continuous background headache and/or were taking prophylactic" exact="migraine" post="treatment. All participants (migraine or HC) were excluded if"/>
   <result pre="if they had significant medical problem (e.g., systemic or CNS," exact="sickle cell anemia," post="severe psychiatric disorders, and other neurological disorders than migraine),"/>
   <result pre="or weight &amp;gt;235 lbs (magnet table limits). Patients experiencing a" exact="migraine" post="within 72 h before the study visit were rescheduled."/>
   <result pre="headache history questionnaire included for example questions regarding age of" exact="migraine" post="onset, attack frequency, attack duration, accompanying symptoms (i.e., nausea,"/>
   <result pre="was performed on all subjects to exclude the possibility of" exact="substance abuse." post="The Institutional Review Board at Boston Children’s Hospital approved"/>
   <result pre="To investigate group differences in rs-FC within each group of" exact="migraine" post="patients (adolescents and young adults) in comparison to HC"/>
   <result pre="the four dimensions being subject identification) and tested for the" exact="migraine" post="effect within each developmental group (adolescents and young adults"/>
   <result pre="that we ran one Group ICA on both control and" exact="migraine" post="data together. To evaluate these group differences, we used"/>
   <result pre="the following contrasts: (1) Migraine effect in adolescents (adolescents with" exact="migraine" post="vs. adolescents HC), (2) Migraine effect in young adults"/>
   <result pre="HC), (2) Migraine effect in young adults (young adults with" exact="migraine" post="vs. young adults HC), (3) Interaction of migraine by"/>
   <result pre="adults with migraine vs. young adults HC), (3) Interaction of" exact="migraine" post="by age [(adolescents with migraine &amp;gt; HC) &amp;gt; (young"/>
   <result pre="adults HC), (3) Interaction of migraine by age [(adolescents with" exact="migraine" post="&amp;gt; HC) &amp;gt; (young adults with migraine &amp;gt; HC);"/>
   <result pre="age [(adolescents with migraine &amp;gt; HC) &amp;gt; (young adults with" exact="migraine" post="&amp;gt; HC); (young adults with migraine &amp;gt; HC) &amp;gt;"/>
   <result pre="&amp;gt; (young adults with migraine &amp;gt; HC); (young adults with" exact="migraine" post="&amp;gt; HC) &amp;gt; (adolescents with migraine &amp;gt; HC)]. Although"/>
   <result pre="HC); (young adults with migraine &amp;gt; HC) &amp;gt; (adolescents with" exact="migraine" post="&amp;gt; HC)]. Although adolescence is typically defined as the"/>
   <result pre="Maldjian et al., 2003) and tabulated. Finally, within each developmental" exact="migraine" post="group, we evaluate the linear relation between rs-FC and"/>
   <result pre="GLM analysis was done with frequency or duration of the" exact="migraine" post="as covariate of interest. This analysis was performed using"/>
   <result pre="displacement and absolute displacement (calculated during MCFLIRT motion correction) between" exact="migraine" post="patients and HC using unpaired t-test. The association between"/>
   <result pre="and absolute displacement) was also tested with Pearson’s correlation in" exact="migraine" post="patients and HC. Results Participants All participants with migraine"/>
   <result pre="in migraine patients and HC. Results Participants All participants with" exact="migraine" post="were age- and sex-matched with HC. From the 102"/>
   <result pre="2 HC were excluded due to brain abnormalities and 4" exact="migraine" post="participants due to positive drug testing, headache just before"/>
   <result pre="scan, or problem of registration; (2) 2 HC and 3" exact="migraine" post="participants were excluded due to peaks of motion higher"/>
   <result pre="and 1 young adult) and one young adult male with" exact="migraine" post="were randomly excluded from the analyses. Among the migraine"/>
   <result pre="with migraine were randomly excluded from the analyses. Among the" exact="migraine" post="participants, 2 experienced a migraine 48h following the scanning"/>
   <result pre="from the analyses. Among the migraine participants, 2 experienced a" exact="migraine" post="48h following the scanning session (1 adolescent and 1"/>
   <result pre="h following the scanning session (1 adolescent male). Overall, 36" exact="migraine" post="participants from 12 to 27 years old (mean ±"/>
   <result pre="There is no difference of age between male and female" exact="migraine" post="patients in the adolescent group [mean age (mean ±"/>
   <result pre="= 0.71, p = 0.49]. Table 1 Demographic characteristics of" exact="migraine" post="and healthy controls participants. Adolescents Young adults Healthy controls"/>
   <result pre="1.78 23.57 ± 2.21 22.87 ± 1.99 A summary of" exact="migraine" post="patient characteristics by developmental age is presented in Table"/>
   <result pre="age is presented in Table 2. The mean age at" exact="migraine" post="onset and the mean frequency of migraine attacks per"/>
   <result pre="mean age at migraine onset and the mean frequency of" exact="migraine" post="attacks per month did not differ between adolescents and"/>
   <result pre="the two groups regarding the occurrence of accompanying symptoms of" exact="migraine" post="(nausea, vomit, photophobia, phonophobia). Table 2 Migraine patient characteristics"/>
   <result pre="relative displacement and absolute displacement did not differ between the" exact="migraine" post="patients and the HC [ Relative displacement (mean ±"/>
   <result pre="patients and the HC [ Relative displacement (mean ± SD):" exact="migraine" post="patients: 0.06 ± 0.03 mm, HC: 0.06 ± 0.02"/>
   <result pre="0.02 mm, t(70) = 0.05, p = 0.96; Absolute displacement:" exact="migraine" post="patients: 0.25 ± 0.12, HC: 0.28 ± 0.13, t(70)"/>
   <result pre="p = 0.26], nor between adolescents and young adults with" exact="migraine" post="[ Relative displacement: adolescents migraineurs: 0.07 ± 0.04 mm,"/>
   <result pre="absolute displacement were not correlated with age either in the" exact="migraine" post="group ( Relative displacement r = -0.04, p ="/>
   <result pre="Significant differences in brain network connectivity between the adolescents with" exact="migraine" post="and matched HC were found in the AN, CEN"/>
   <result pre="or decreased connectivity with the listed networks for adolescents with" exact="migraine" post="vs. healthy controls. Coordinates and max statistical value (z-stat)"/>
   <result pre="displayed cortical and sub-cortical increased/decreased connectivity in the adolescents with" exact="migraine" post="in comparison to matched HC. Increased connectivity was observed"/>
   <result pre="and the following cortical and subcortical regions in adolescents with" exact="migraine" post="in comparison to HC: inferior triangular, inferior operculum, SMA,"/>
   <result pre="vs. HC) Significant differences in brain network connectivity due to" exact="migraine" post="in young adults in comparison to controls were found"/>
   <result pre="decreased connectivity with the listed networks for young adults with" exact="migraine" post="vs. healthy controls. Coordinates and max statistical value (z-stat)"/>
   <result pre="B displayed an increased in connectivity in young adults with" exact="migraine" post="in comparison to HC in the supramarginal parietal area."/>
   <result pre="network was also the only one in young adults with" exact="migraine" post="in comparison to controls to display increased connectivity in"/>
   <result pre="rs-FC Between Adolescent and Young Adult Migraineurs Groups Adolescents with" exact="migraine" post="exhibited greater connectivity in comparison to young adults with"/>
   <result pre="migraine exhibited greater connectivity in comparison to young adults with" exact="migraine" post="and their HC (significant migraine-related age differences) in the"/>
   <result pre="significant increased connectivity with the listed networks for adolescents with" exact="migraine" post="vs. young adults with migraine and healthy controls. Coordinates"/>
   <result pre="listed networks for adolescents with migraine vs. young adults with" exact="migraine" post="and healthy controls. Coordinates and max statistical value (z-stat)"/>
   <result pre="figure summarizes the statistically significant greater rs-FC in adolescents with" exact="migraine" post="in comparison to young adults with migraine and their"/>
   <result pre="in adolescents with migraine in comparison to young adults with" exact="migraine" post="and their healthy controls. Greater connectivity was found in"/>
   <result pre="in adolescents migraineurs vs. young adults migraineurs. Young adults with" exact="migraine" post="exhibited greater connectivity in comparison to adolescents with migraine"/>
   <result pre="with migraine exhibited greater connectivity in comparison to adolescents with" exact="migraine" post="and their HC (significant migraine-related age differences) in the"/>
   <result pre="increased connectivity with the listed networks for young adults with" exact="migraine" post="vs. adolescents with migraine and healthy controls. Coordinates and"/>
   <result pre="listed networks for young adults with migraine vs. adolescents with" exact="migraine" post="and healthy controls. Coordinates and max statistical value (z-stat)"/>
   <result pre="summarizes the statistically significant greater rs-FC in young adults with" exact="migraine" post="in comparison to adolescents with migraine and their healthy"/>
   <result pre="in young adults with migraine in comparison to adolescents with" exact="migraine" post="and their healthy controls. Greater connectivity was found in"/>
   <result pre="FIGURE 6 Association between the rs-FC of the adolescents with" exact="migraine" post="and two clinical indicators of the disease: attack frequency"/>
   <result pre="7 Association between the rs-FC of the young adults with" exact="migraine" post="and two clinical indicators of the disease: attack frequency"/>
   <result pre="brain rs-FC within and between adolescents and young adults with" exact="migraine" post="and a group of age- and sex-matched healthy controls."/>
   <result pre="significant differences in neuropsychological features are present in that young" exact="migraine" post="brain ( Oelkers-Ax et al., 2004, 2005). rs-FC Within"/>
   <result pre="DMN A with most changes showing increased rs-FC for the" exact="migraine" post="group vs. HC (exception being the DMN A, the"/>
   <result pre="with sensory, motor and affective functions in pediatric females with" exact="migraine" post="compared with males with migraine and HC (adolescents from"/>
   <result pre="functions in pediatric females with migraine compared with males with" exact="migraine" post="and HC (adolescents from 10 to 16 years) and"/>
   <result pre="could be linked to alteration of functional sensory processing and" exact="hypersensitivity" post="to painful stimuli that have been suggested in adult"/>
   <result pre="hypersensitivity to painful stimuli that have been suggested in adult" exact="migraine" post="patients with potential persistence with less magnitude in the"/>
   <result pre="the present study, adolescents reported accompanied sensory symptoms during their" exact="migraine" post="attacks (photophobia, phonophobia, nausea, vomit). Moreover, increased rs-FC in"/>
   <result pre="and SMN networks were also found in the adolescents with" exact="migraine" post="vs. HC as well as increased rs-FC between the"/>
   <result pre="a disruption of nociceptive pathways as observed in adults with" exact="migraine" post="( Colombo et al., 2015; Schulte and May, 2016)."/>
   <result pre="AN, VN) with most changes showing increased rs-FC for the" exact="migraine" post="group vs. HC (exception being for some activations with"/>
   <result pre="the increased presence of sensory related rs-FC may relate to" exact="migraine" post="related processes involving conscious or non-conscious changes in pain,"/>
   <result pre="are in line with prior reports in adults showing that" exact="migraine" post="is a process that affects the brain in a"/>
   <result pre="repetition of the attacks or a condition that precedes the" exact="migraine" post="disease remains unclear. Parts of these alterations could be"/>
   <result pre="alterations in some networks would be the consequence of the" exact="migraine" post="attacks and in other networks precede the disease (see"/>
   <result pre="and between networks were globally observed in the adolescents with" exact="migraine" post="vs. HC than in the young adults with migraine"/>
   <result pre="with migraine vs. HC than in the young adults with" exact="migraine" post="vs. HC, as well as for the adolescents in"/>
   <result pre="right medial prefrontal cortex has been noted in adults with" exact="migraine" post="( Jin et al., 2013). Finally, as in the"/>
   <result pre="the DMN and regions such as the insula may encode" exact="migraine" post="headache ( Coppola et al., 2018); (3) spontaneous migraine"/>
   <result pre="encode migraine headache ( Coppola et al., 2018); (3) spontaneous" exact="migraine" post="attacks alter DMN connectivity ( Edes et al., 2017);"/>
   <result pre="(4) DMN may be a potential predictor of neuromodulation of" exact="migraine" post="( Kinfe, 2018); and (5) increased DMN connectivity ("/>
   <result pre="an indicator of the dynamic state of brain processing with" exact="migraine" post="&quot;maturation.&quot; In the present study, this theme applies to"/>
   <result pre="we have assessed the relationship between rs-FC patterns and individual" exact="migraine" post="characteristics (i.e., duration of migraine in years and attack"/>
   <result pre="between rs-FC patterns and individual migraine characteristics (i.e., duration of" exact="migraine" post="in years and attack frequency per month). In the"/>
   <result pre="of the disease was significantly higher in young adults with" exact="migraine" post="than in adolescents and may explain the presence of"/>
   <result pre="of the disease have been also reported in adults with" exact="migraine" post="( Yu et al., 2012; Jin et al., 2013;"/>
   <result pre="found here in young adults may be linked to the" exact="migraine" post="disease progression. Moreover, the fact that in adolescents only"/>
   <result pre="fact that in adolescents only minor associations were found with" exact="migraine" post="duration may suggest that part of the rs-FC network"/>
   <result pre="the rs-FC network changes may arise before the onset of" exact="migraine" post="in the adolescent group. In accordance with this hypothesis,"/>
   <result pre="The present study has a number of caveats including: (1)" exact="migraine" post="subgroups: patients with episodic migraine within 48 and 72"/>
   <result pre="number of caveats including: (1) migraine subgroups: patients with episodic" exact="migraine" post="within 48 and 72 h after the scan session"/>
   <result pre="and 72 h after the scan session were included; both" exact="migraine" post="with or without aura were included; (2) medication: medication,"/>
   <result pre="given prior reports of the potential interaction between onset of" exact="migraine" post="and puberty ( Borsook et al., 2014), binning based"/>
   <result pre="brain development is still ongoing and at a time when" exact="migraine" post="prevalence is near its peak ( Bigal and Lipton,"/>
   <result pre="or different in migraineurs vs. healthy controls and within the" exact="migraine" post="groups with development. Such changes provide a basis to"/>
   <result pre="( 2014). Intrinsic brain networks normalize with treatment in pediatric" exact="complex regional pain syndrome." post="Neuroimage Clin. 6 347– 369. 10.1016/j.nicl.2014.07.012 25379449 Beckman C."/>
   <result pre="Grant P. E. et al. ( 2014). Sex and the" exact="migraine" post="brain. Neurobiol. Dis. 68 200– 214. 10.1016/j.nbd.2014.03.008 24662368 Borsook"/>
   <result pre="D. Maleki N. Becerra L. McEwen B. ( 2012). Understanding" exact="migraine" post="through the lens of maladaptive stress responses: a model"/>
   <result pre="state connectivity between default mode network and insula encodes acute" exact="migraine" post="headache. Cephalalgia 38 846– 854. 10.1177/0333102417715230 28605972 Coppola G."/>
   <result pre="al. ( 2015). Evidence for brain morphometric changes during the" exact="migraine" post="cycle: a magnetic resonance-based morphometry study. Cephalalgia 35 783–"/>
   <result pre="T. Kokonyei G. Bagdy G. et al. ( 2017). Spontaneous" exact="migraine" post="attack causes alterations in default mode network connectivity: a"/>
   <result pre="A. Wolff R. Fair D. et al. ( 2015). The" exact="migraine" post="brain in transition: girls vs boys. Pain 156 2212–"/>
   <result pre="M. et al. ( 2013). Structural and functional abnormalities in" exact="migraine" post="patients without aura. NMR Biomed. 26 58– 64. 10.1002/nbm.2819."/>
   <result pre="Kelman L. ( 2006). Migraine changes with age: impact on" exact="migraine" post="classification. Headache 46 1161– 1171. 10.1111/j.1526-4610.2006.00444.x. 16866720 Kinfe T."/>
   <result pre="reveals hyperexcitability of the temporal pole in interictal and ictal" exact="migraine" post="states. Cereb. Cortex 21 435– 448. 10.1093/cercor/bhq109. 20562317 Muetzel"/>
   <result pre="et al. ( 2004). Pattern-reversal visual-evoked potentials in children with" exact="migraine" post="and other primary headache: evidence for maturation disorder? Pain"/>
   <result pre="D. ( 2015). Temporal lobe cortical thickness correlations differentiate the" exact="migraine" post="brain from the healthy brain. PLoS One 10: e0116687."/>
   <result pre="Episodic and chronic migraineurs are hypersensitive to thermal stimuli between" exact="migraine" post="attacks. Cephalalgia 31 6– 12. 10.1177/0333102410365108 20974609 Seeley W."/>
   <result pre="May A. ( 2011). Increased limbic and brainstem activity during" exact="migraine" post="attacks following olfactory stimulation. Neurology 77 476– 482. 10.1212/WNL.0b013e318227e4a8"/>
   <result pre="J. Stovner L. J. Vos T. ( 2016). GBD 2015:" exact="migraine" post="is the third cause of disability in under 50s."/>
   <result pre="( 2016). Increased interictal visual network connectivity in patients with" exact="migraine" post="with aura. Cephalalgia 36 139– 147. 10.1177/0333102415584360. 25926619 Tessitore"/>
   <result pre="et al. ( 2013). Disrupted default mode network connectivity in" exact="migraine" post="without aura. J. Headache Pain 14: 89. 10.1186/1129-2377-14-89 24207164"/>
   <result pre="activity and corresponding brain circuit changes during resting state in" exact="migraine" post="without aura. NMR Biomed 26 1051– 1058. 10.1002/nbm.2917. 23348909"/>
   <result pre="al. ( 2012). Regional homogeneity abnormalities in patients with interictal" exact="migraine" post="without aura: a resting-state study. NMR Biomed. 25 806–"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6444142/results/search/disease/results.xml">
   <result pre="n=1,801, 77.8%) comprised patients with febrile seizures ( n=605, 26.1%)," exact="meningitis" post="( n=550, 23.8%), epilepsy ( n=393, 17.0%), and other"/>
   <result pre="with febrile seizures ( n=605, 26.1%), meningitis ( n=550, 23.8%)," exact="epilepsy" post="( n=393, 17.0%), and other symptoms. Upper respiratory infections"/>
   <result pre="among N-PEDs ( p&amp;lt;0.001 for both), while febrile seizures and" exact="meningitis" post="were significantly more common among N-PEDs ( p&amp;lt;0.001 for"/>
   <result pre="the 5-year study period ( Table 6): epilepsy, neurometabolic diseases," exact="muscular dystrophy," post="spinal atrophy, meningitis, and migraine. Epilepsy was the mostcommon"/>
   <result pre="cause of symptoms was known for 12 patients in the" exact="epilepsy" post="group: complications of hypoxic ischemic encephalopathy ( n=6, 10.9%),"/>
   <result pre="12 patients in the epilepsy group: complications of hypoxic ischemic" exact="encephalopathy" post="( n=6, 10.9%), central nervous system infection ( n=3,"/>
   <result pre="other 14 patients. In the neurometabolic disease group, mitochondrial encephalomyopathy," exact="lactic acidosis," post="and stroke-like episodes ( n=7, 12.7%), Leigh syndrome ("/>
   <result pre="diseases that were not considered in this study, such as" exact="tuberous sclerosis" post="complex, Rett syndrome, Dravet syndrome, and autism/autistic spectrum disorder."/>
   <result pre="1 Camfield PR Camfield CS What happens to children with" exact="epilepsy" post="when they become adults? Some facts and opinions Pediatr"/>
   <result pre="transition from pediatric to adult care. Recommendations of the Ontario" exact="epilepsy" post="implementation task force Epilepsia 2017 58 1502 1517 28681381"/>
   <result pre="Louw AJ Transition to adult medical care for adolescents with" exact="epilepsy" post="Epilepsy Behav 2015 44 127 135 25679495 11 Bourgeois"/>
   <result pre="H Desquerre I Dulac O et al. Outcome of childhood-onset" exact="epilepsy" post="from adolescence to adulthood: transition issues Epilepsy Behav 2017"/>
   <result pre="C Cramer JA et al. Treatment issues for children with" exact="epilepsy" post="transitioning to adult care Epilepsy Behav 2017 69 153"/>
   <result pre="Camfield C Camfield P Preventable and unpreventable causes of childhood-onset" exact="epilepsy" post="plus mental retardation Pediatrics 2007 120 e52 e55 17606549"/>
   <result pre="Pharmacology aspects during transition and at transfer in patients with" exact="epilepsy" post="Epilepsia 2014 55 8 11 25209078 25 Affdal AO"/>
   <result pre="difficult transition from childhood to adult healthcare: the case of" exact="epilepsy" post="Arch Pediatr 2015 22 337 342 25727476 26 Young"/>
   <result pre="  Meningitis 550 (23.8)   Encephalitis 34 (1.5)   Migraine 66 (2.9)   Metabolic" exact="encephalopathy" post="127 (5.5)   Myopathy 15 (0.6)   Peripheral neuropathy 11 (0.5)"/>
   <result pre="66 (2.9)   Metabolic encephalopathy 127 (5.5)   Myopathy 15 (0.6)   Peripheral" exact="neuropathy" post="11 (0.5)  Systemic diagnosis group 514 (22.2)   Sepsis 50"/>
   <result pre="1 (0.1) &amp;lt;0.001   Migraine 7 (0.6) 59 (5.1) &amp;lt;0.001   Metabolic" exact="encephalopathy" post="105 (9.2) 22 (1.9) &amp;lt;0.001   Myopathy 10 (0.9) 5"/>
   <result pre="22 (1.9) &amp;lt;0.001   Myopathy 10 (0.9) 5 (0.4) 0.205   Peripheral" exact="neuropathy" post="6 (0.5) 5 (0.4) 0.772  Systemic diagnosis group 363"/>
   <result pre="34 (1.5) 0.439   Migraine 1 (1.8) 65 (2.9) 0.530   Metabolic" exact="encephalopathy" post="13 (23.6) 114 (5.0) &amp;lt;0.001   Myopathy 5 (9.1) 10"/>
   <result pre="114 (5.0) &amp;lt;0.001   Myopathy 5 (9.1) 10 (0.4) &amp;lt;0.001   Peripheral" exact="neuropathy" post="0 (0.0) 11 (0.5) 0.767  Systemic diagnosis group 7"/>
   <result pre="0 (0.0) -   Migraine 1 (2.1) 0 (0.0) 0.873   Metabolic" exact="encephalopathy" post="13 (27.1) 0 (0.0) 0.179   Myopathy 4 (8.3) 1"/>
   <result pre="0 (0.0) 0.179   Myopathy 4 (8.3) 1 (14.3) 0.508   Peripheral" exact="neuropathy" post="0 (0.0) 0 (0.0) -  Systemic diagnosis group 6"/>
   <result pre="1 (0.1) &amp;lt;0.001   Migraine 6 (0.5) 59 (5.1) &amp;lt;0.001   Metabolic" exact="encephalopathy" post="92 (8.4) 22 (1.9) &amp;lt;0.001   Myopathy 6 (0.5) 4"/>
   <result pre="22 (1.9) &amp;lt;0.001   Myopathy 6 (0.5) 4 (0.3) 0.538   Peripheral" exact="neuropathy" post="6 (0.5) 5 (0.4) 0.769  Systemic diagnosis group 357"/>
   <result pre="4 3 4 6 9 26 (47.3)  With hypoxic ischemic" exact="encephalopathy" post="0 0 1 2 3 6 (10.9)  With CNS"/>
   <result pre="n (%) values. CNS: central nervous system, MELAS: mitochondrial encephalomyopathy," exact="lactic acidosis," post="and stroke-like episodes, N-TAPs: transient and adult patients with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6451865/results/search/disease/results.xml">
   <result pre="Objectives In this study, the EEG findings in children with" exact="migraine" post="headache were assessed in Bahrami Hospital, Tehran, Iran from"/>
   <result pre="Methods In this observational cross-sectional study, 71 consecutive children with" exact="migraine" post="headache were enrolled. The EEG findings were determined and"/>
   <result pre="and 8(32%) patients, respectively Conclusion Nearly one-third of children with" exact="migraine" post="might have abnormal EEG. Key Words EEG Children Migraine"/>
   <result pre="definite diagnosis and treatment is crucial ( 3). More severe" exact="migraine" post="headache would result in more decrease in quality of"/>
   <result pre="6, 7). Diagnostic procedures are important for both diagnosis of" exact="migraine" post="and rule out of other differential diagnoses ( 5-"/>
   <result pre="occipital cortex may trigger epileptic seizure ( 8). Occipital lobe" exact="epilepsy" post="is an important differential diagnosis of migraine headache ("/>
   <result pre="8). Occipital lobe epilepsy is an important differential diagnosis of" exact="migraine" post="headache ( 9). For this matter, electroencephalography (EEG) is"/>
   <result pre="The rate of EEG abnormalities is reported from 5.4% of" exact="migraine" post="without aura to 43.5% in children suffering from migraine"/>
   <result pre="of migraine without aura to 43.5% in children suffering from" exact="migraine" post="with aura. There are little investigations on the electroencephalogram"/>
   <result pre="Hence in this study, the EEG findings in children with" exact="migraine" post="headache were assessed. Materials &amp;amp; Methods In this observational"/>
   <result pre="Methods In this observational cross-sectional study, 71 consecutive children with" exact="migraine" post="headache were assessed with census manner in Bahrami Children"/>
   <result pre="criteria included 1) age 5-15 yr, 2) the criteria's of" exact="migraine" post="based on the International Headache Society, 2nd Edition, First"/>
   <result pre="were 1) Disorders including any type of seizure, epilepsy, and" exact="encephalitis" post="which might lead to electroencephalogram abnormalities, 2) Using any"/>
   <result pre="were 5-9-yr-old, and 10 to 15-yr-old, respectively. The frequency of" exact="migraine" post="headache was 5 times, 5 to 10 times, and"/>
   <result pre="in 65.7%, 35.2%, and 49.3%, respectively. 45.1% of children had" exact="allergy" post="history including 11.3%, 5.6%, and 28.2% for food, drug,"/>
   <result pre="Discussion In this study, the electroencephalographic findings in children with" exact="migraine" post="headache were assessed and 35.2% had abnormal EEG as"/>
   <result pre="contributing to EEG abnormality. In Iran, 20% of children with" exact="migraine" post="had abnormal EEG and the type of migraine was"/>
   <result pre="children with migraine had abnormal EEG and the type of" exact="migraine" post="was related to EEG abnormality ( 10). However, there"/>
   <result pre="was no association in our study. Four children with basilar" exact="migraine" post="were assessed which all had abnormal EEG as delta"/>
   <result pre="and theta waves ( 11). However, in our study basilar" exact="migraine" post="was not seen but the slow waves constituted the"/>
   <result pre="abnormal EEG. EEG should be performed in children with basilar" exact="migraine" post="or those with prolonged aura or suspected seizure ("/>
   <result pre="to abnormality of EEG in our study. Twelve percent of" exact="migraine" post="children had abnormal EEG ( 13). The abnormality was"/>
   <result pre="This matter is not in congruence with our study. Hemiplegic" exact="migraine" post="children were assessed and reported that EEG had good"/>
   <result pre="good diagnostic value in these cases ( 16). Type of" exact="migraine" post="was not related to EEG findings in our study."/>
   <result pre="in our study. In conclusion, nearly one-third of children with" exact="migraine" post="might have abnormal EEG within headache attacks. However further"/>
   <result pre="A Nejad Biglari H Alizadeh M Ahmadabadi F Relationship between" exact="migraine" post="and abnormal EEG findings in children Iran J Child"/>
   <result pre="Sturzenegger M Donati F Karbowski K EEG findings during basilar" exact="migraine" post="attacks in children Electroencephalogr Clin Neurophysiol 1998 107 5"/>
   <result pre="migraine: a review with focus on quantitative electroencephalography and the" exact="migraine" post="vs epilepsy relationship Cephalalgia 2003 23 Suppl 1 5"/>
   <result pre="review with focus on quantitative electroencephalography and the migraine vs" exact="epilepsy" post="relationship Cephalalgia 2003 23 Suppl 1 5 11 12699455"/>
   <result pre="15 Gupta SN Gupta VS Fields DM Spectrum of complicated" exact="migraine" post="in children: A common profile in aid to clinical"/>
   <result pre="HE Palm D Meiser W The EEG during the hemiplegic" exact="migraine" post="attack of children EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6469474/results/search/disease/results.xml">
   <result pre="10.2147/TCRM.S159690 tcrm-15-557 : Review Once-monthly galcanezumab for the prevention of" exact="migraine" post="in adults: an evidence-based descriptive review and potential place"/>
   <result pre="is one of the antibodies developed and studied to prevent" exact="migraine" post="by targeting CGRP. The scope of this review is"/>
   <result pre="to available data, galcanezumab is safe and efficacious in preventing" exact="migraine" post="in episodic migraine patients, also reducing disability and functional"/>
   <result pre="galcanezumab is safe and efficacious in preventing migraine in episodic" exact="migraine" post="patients, also reducing disability and functional impairment due to"/>
   <result pre="galcanezumab was approved in the USA for the prevention of" exact="migraine" post="in adults. The placement of galcanezumab into the current"/>
   <result pre="into the current therapeutic scenario will be a revolution for" exact="migraine" post="patients, and probably in a less near future also"/>
   <result pre="of data from the Global Burden of Disease (GBD) established" exact="migraine" post="as the second leading cause of years lived with"/>
   <result pre="leading cause of years lived with disability (YLDs). 2 Accordingly," exact="migraine" post="has a strong social impact with an economic burden"/>
   <result pre="in the case of treatment failure, the natural course of" exact="migraine" post="is toward an increase of headache frequency with a"/>
   <result pre="and out of four distinct stages: no migraine, low-frequency episodic" exact="migraine" post="(EM) (&amp;lt;10 days/month), high-frequency EM (10–14 days/month), and chronic"/>
   <result pre="migraine (EM) (&amp;lt;10 days/month), high-frequency EM (10–14 days/month), and chronic" exact="migraine" post="(CM) (&amp;gt;15 days/month). 5 It has been estimated that"/>
   <result pre="sleep disorders, and substance use) risk factors are involved in" exact="migraine" post="progression from EM to CM. 6 In particular, the"/>
   <result pre="turn decreases responsiveness to acute or prophylactic drugs. 7 Nowadays," exact="migraine" post="is still a treatable rather than a curable disorder."/>
   <result pre="disease, while another treatment could be effective to treat both" exact="migraine" post="and the other condition, at the same time reducing"/>
   <result pre="the risk of drug–drug interactions. 16 Despite the progress in" exact="migraine" post="management, a significant portion of patients has unmet needs."/>
   <result pre="successful, when advising about prophylaxis, the point of view of" exact="migraine" post="patients should be borne in mind. Patients need to"/>
   <result pre="As already stated, the preventive therapies currently available are not" exact="migraine" post="specific and the development of drugs acting on the"/>
   <result pre="the development of drugs acting on the crucial steps of" exact="migraine" post="pathogenesis will radically change migraine prophylaxis. Migraine pathophysiology is"/>
   <result pre="on the crucial steps of migraine pathogenesis will radically change" exact="migraine" post="prophylaxis. Migraine pathophysiology is multifactorial, complex, and not yet"/>
   <result pre="enteric neurons. 34– 36 Accordingly, alpha-CGRP is primarily involved in" exact="migraine" post="pathogenesis. The CGRP acts by targeting a G protein-coupled"/>
   <result pre="receptor. 37 Several findings support the involvement of CGRP in" exact="migraine" post="pathophysiology: 1) CGRP levels are increased during a migraine"/>
   <result pre="in migraine pathophysiology: 1) CGRP levels are increased during a" exact="migraine" post="attack 38 and in CM patients also in the"/>
   <result pre="2) intravenous infusion of CGRP can induce migraine-like attacks in" exact="migraine" post="patients, 44, 45 as well as dilatation of the"/>
   <result pre="generation of light intolerance (photophobia), a typical feature of a" exact="migraine" post="attack. 47 Accordingly, in the last 15 years relevant"/>
   <result pre="is one of the antibodies developed and studied to prevent" exact="migraine" post="by targeting CGRP. Pharmacology of galcanezumab Pharmacodynamics Galcanezumab, initially"/>
   <result pre="galcanezumab is different from that of drugs traditionally used in" exact="migraine" post="prophylaxis. Like other MAbs, it has considerable dimensions (144.1"/>
   <result pre="This attribute is particularly suitable for a variable condition like" exact="migraine" post="that does not favor adherence to oral prophylactic therapies"/>
   <result pre="MAbs is still debated. 77, 78 Most prophylactic treatments for" exact="migraine" post="are supposed to have various effects on the central"/>
   <result pre="blood–brain barrier remains tight for 11C-dihydroergotamine during acute glyceryl trinitrate-induced" exact="migraine" post="attacks, both ictally and interictally. However, considering the ability"/>
   <result pre="supporting the clinical development of this drug for prophylaxis in" exact="migraine" post="patients. 72 The efficacy of galcanezumab as a preventive"/>
   <result pre="72 The efficacy of galcanezumab as a preventive treatment for" exact="migraine" post="has been primarily evaluated in subjects affected by EM."/>
   <result pre="adult subjects, with at least a 1-year history of migraine," exact="migraine" post="onset prior to age 50, and 4–14 migraine headache"/>
   <result pre="of migraine, migraine onset prior to age 50, and 4–14" exact="migraine" post="headache days (MHD), were randomly (1:1) assigned to receive"/>
   <result pre="significant reduction in headache days (−4.9 vs −3.7, P=0.012) and" exact="migraine" post="attacks (−3.1 vs −2.3, P=0.0051). In a post hoc"/>
   <result pre="outcomes (ie, number of MHD plus probable MHD, probable MHD," exact="migraine" post="attacks, proportion of patients reporting 50% and 100% reduction"/>
   <result pre="prophylactic treatment for EM. 64, 65 Galcanezumab also provided effective" exact="migraine" post="prevention in patients with CM. During the 3-month double-blind"/>
   <result pre="Further relevant efficacy data on galcanezumab in the prophylaxis of" exact="migraine" post="come from post hoc analysis of integrated EVOLVE-1 and"/>
   <result pre="offer any evidence of differential responses from patients affected by" exact="migraine" post="with aura vs patients affected by migraine without aura."/>
   <result pre="patients affected by migraine with aura vs patients affected by" exact="migraine" post="without aura. Additional clinical trials on galcanezumab for different"/>
   <result pre="focused on the use of galcanezumab for the prevention of" exact="migraine" post="in adults, it is noteworthy that galcanezumab has been"/>
   <result pre="common treatment-emergent adverse events (TEAEs) were headache, nasopharyngitis, hematuria, and" exact="contact dermatitis;" post="they were transient, with no apparent relationship with the"/>
   <result pre="72 The safety and the tolerability of monthly galcanezumab in" exact="migraine" post="patients have been further demonstrated in both randomized double-blind"/>
   <result pre="injection-site pruritus, urinary tract infections, upper respiratory tract infections, and" exact="nasopharyngitis" post="were frequently reported. In particular, in Phase III trials,"/>
   <result pre="was associated with statistically significant reduced functional impairment due to" exact="migraine" post="as measured in the MSQ role-function restrictive domain at"/>
   <result pre="to available data, galcanezumab is safe and efficacious in preventing" exact="migraine" post="in EM patients, also reducing disability and functional impairment"/>
   <result pre="in the current therapeutic scenario will be a revolution for" exact="migraine" post="patients, and probably in a less near future for"/>
   <result pre="first time after methysergide has been withdrawn from the market," exact="migraine" post="patients may have access to a mechanism-driven therapy. Importantly,"/>
   <result pre="a differential place in therapy may be considered for diverse" exact="migraine" post="endophenotypes, hopefully identifiable through a reliable biomarker – that,"/>
   <result pre="N Wu S Pucci E Costa A Recent advances in" exact="migraine" post="therapy Springerplus 2016 5 1 637 27330903 5 Lipton"/>
   <result pre="5 1 637 27330903 5 Lipton RB Tracing transformation: chronic" exact="migraine" post="classification, progression, and epidemiology Neurology 2009 72 5 Suppl"/>
   <result pre="Levetiracetam in compare to sodium valproate for prophylaxis in chronic" exact="migraine" post="headache: a randomized double-blind clinical trial Curr Clin Pharmacol"/>
   <result pre="al. Comparing zonisamide with sodium valproate in the management of" exact="migraine" post="headaches: double-blind randomized clinical trial of efficacy and safety"/>
   <result pre="Diener HC Gendolla A Feuersenger A et al. Telmisartan in" exact="migraine" post="prophylaxis: a randomized, placebo-controlled trial Cephalalgia 2009 29 9"/>
   <result pre="et al. A comparative study of candesartan versus propranolol for" exact="migraine" post="prophylaxis: a randomised, triple-blind, placebo-controlled, double cross-over study Cephalalgia"/>
   <result pre="with sodium valproate (divalproex) on frequency and intensity of frequent" exact="migraine" post="headaches: a double-blind randomized controlled study Clin Neuropharmacol 2018"/>
   <result pre="F Use of melatonin versus valproic acid in prophylaxis of" exact="migraine" post="patients: a double-blind randomized clinical trial Restor Neurol Neurosci"/>
   <result pre="Cho SJ Song TJ Chu MK Treatment update of chronic" exact="migraine" post="Curr Pain Headache Rep 2017 21 6 26 28424953"/>
   <result pre="M et al. Choosing the safest acute therapy during chronic" exact="migraine" post="prophylactic treatment: pharmacokinetic and pharmacodynamic considerations Expert Opin Drug"/>
   <result pre="EB Adherence to oral migraine-preventive medications among patients with chronic" exact="migraine" post="Cephalalgia 2015 35 6 478 488 25164920 19 Bigal"/>
   <result pre="19 Bigal ME Serrano D Reed M Lipton RB Chronic" exact="migraine" post="in the population: burden, diagnosis, and satisfaction with treatment"/>
   <result pre="use and reasons for discontinuation of prophylactic medications for episodic" exact="migraine" post="and chronic migraine: results from the second International burden"/>
   <result pre="and chronic migraine: results from the second International burden of" exact="migraine" post="study (IBMS-II) Headache 2013 53 4 644 655 23458496"/>
   <result pre="21 Hepp Z Bloudek LM Varon SF Systematic review of" exact="migraine" post="prophylaxis adherence and persistence J Manag Care Pharm 2014"/>
   <result pre="MFP Silberstein S Moreira F et al. Patients’ preference for" exact="migraine" post="preventive therapy Headache 2007 47 4 540 545 17445103"/>
   <result pre="Tepper SJ Rejection and acceptance of possible side effects of" exact="migraine" post="prophylactic drugs Headache 2009 49 7 1022 1027 19438733"/>
   <result pre="SJ Assendelft WJJ Blom JW Acceptance of preventive treatment in" exact="migraine" post="patients: results of a survey Eur J Gen Pract"/>
   <result pre="143 148 22954193 28 Goadsby PJ The vascular theory of" exact="migraine" post="– a great story wrecked by the facts Brain"/>
   <result pre="6 7 19098031 29 Pietrobon D Moskowitz MA Pathophysiology of" exact="migraine" post="Annu Rev Physiol 2013 75 1 365 391 23190076"/>
   <result pre="Warfvinge K Krause DN CGRP as the target of new" exact="migraine" post="therapies – successful translation from bench to clinic Nat"/>
   <result pre="et al. Vasoactive peptide levels in the plasma of young" exact="migraine" post="patients with and without aura assessed both interictally and"/>
   <result pre="CGRP levels in peripheral blood as a biomarker for chronic" exact="migraine" post="Neurology 2013 81 14 1191 1196 23975872 40 Goadsby"/>
   <result pre="Vasoactive peptide release in the extracerebral circulation of humans during" exact="migraine" post="headache Ann Neurol 1990 28 2 183 187 1699472"/>
   <result pre="trigeminal vasoactive peptides in internal jugular vein blood during spontaneous" exact="migraine" post="attacks Cephalalgia 2000 20 10 907 918 11304026 43"/>
   <result pre="parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and" exact="migraine" post="headache during nitroglycerin induced migraine attack Cephalalgia 2005 25"/>
   <result pre="gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced" exact="migraine" post="attack Cephalalgia 2005 25 3 179 183 15689192 44"/>
   <result pre="migraine: regional cerebral blood flow and blood flow velocity in" exact="migraine" post="patients J Headache Pain 2008 9 3 151 157"/>
   <result pre="M Calcitonin gene-related peptide triggers migraine-like attacks in patients with" exact="migraine" post="with aura Cephalalgia 2010 30 10 1179 1186 20855363"/>
   <result pre="Amin FM et al. Evidence for a vascular factor in" exact="migraine" post="Ann Neurol 2011 69 4 635 645 21416486 47"/>
   <result pre="Role of calcitonin gene-related peptide in light-aversive behavior: implications for" exact="migraine" post="J Neurosci 2009 29 27 8798 8804 19587287 48"/>
   <result pre="receptor antagonist BIBN 4096 BS for the acute treatment of" exact="migraine" post="N Engl J Med 2004 350 11 1104 1110"/>
   <result pre="Randomized, controlled trial of telcagepant for the acute treatment of" exact="migraine" post="Neurology 2009 73 12 970 977 19770473 51 Voss"/>
   <result pre="double-blind, placebo-controlled trial of ubrogepant for the acute treatment of" exact="migraine" post="Cephalalgia 2016 36 9 887 898 27269043 52 Hewitt"/>
   <result pre="the CGRP receptor antagonist MK-3207 in the acute treatment of" exact="migraine" post="Cephalalgia 2011 31 6 712 722 21383045 53 Marcus"/>
   <result pre="Y et al. A controlled trial of Erenumab for episodic" exact="migraine" post="N Engl J Med 2017 377 22 2123 2132"/>
   <result pre="ME et al. Fremanezumab for the preventive treatment of chronic" exact="migraine" post="N Engl J Med 2017 377 22 2113 2122"/>
   <result pre="Effect of different doses of Galcanezumab vs placebo for episodic" exact="migraine" post="prevention: a randomized clinical trial JAMA Neurol 2018 75"/>
   <result pre="30271122 77 Tfelt-Hansen P Site of effect of LY2951742 for" exact="migraine" post="prophylaxis Lancet Neurol 2015 14 1 31 32 25496894"/>
   <result pre="Sweeney SP Grayzel DS Site of effect of LY2951742 for" exact="migraine" post="prophylaxis – authors’ reply Lancet Neurol 2015 14 1"/>
   <result pre="integrity of the blood-brain barrier for 11C-dihydroergotamine during glyceryl trinitrate-induced" exact="migraine" post="Brain 2016 139 7 1994 2001 27234268 80 Preston"/>
   <result pre="M Cgrp AM CGRP, a target for preventive therapy in" exact="migraine" post="and cluster headache: systematic review of clinical data Cephalalgia"/>
   <result pre="Mitsikostas DD Reuter U Calcitonin gene-related peptide monoclonal antibodies for" exact="migraine" post="prevention: comparisons across randomized controlled studies Curr Opin Neurol"/>
   <result pre="3, long-term, open-label safety study of Galcanezumab in patients with" exact="migraine" post="BMC Neurol 2018 18 1 188 30413151 87 Ford"/>
   <result pre="galcanezumab: results from a 12-month open-label study in patients with" exact="migraine" post="2018 2018 2413 2424 88 Förderreuther S Zhang Q"/>
   <result pre="effects of galcanezumab in adult patients with episodic or chronic" exact="migraine" post="are persistent: data from the phase 3, randomized, double-blind,"/>
   <result pre="Lilly and Company AAN 2018: Lilly’s galcanezumab significantly reduced monthly" exact="migraine" post="headache days in patients with migraine who previously failed"/>
   <result pre="galcanezumab significantly reduced monthly migraine headache days in patients with" exact="migraine" post="who previously failed to respond to multiple preventive therapies"/>
   <result pre="Rains JA Nicholson RA Lipton RB Improving medication adherence in" exact="migraine" post="treatment Curr Pain Headache Rep 2015 19 6 24"/>
   <result pre="a P-value indicates nominal significance without multiplicity adjustment. Abbreviations: MHD," exact="migraine" post="headache days; S, significant after multiplicity adjustment. Table 2"/>
   <result pre="is considered not statistically significant regardless of P-value. Abbreviations: MHD," exact="migraine" post="headache days; NS, not significant after multiplicity adjustment; S,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6473052/results/search/disease/results.xml">
   <result pre="permitted which does not comply with these terms. Abstract Pediatric" exact="migraine" post="remains still a challenge for the headache specialists as"/>
   <result pre="of their migraines and the lack of reliable biomarker for" exact="migraine" post="contribute to complicate the diagnostic process. Therefore, there's need"/>
   <result pre="perspective for application of TMS and tDCS technique in children" exact="migraine" post="principally based on evidence coming by studies in adults."/>
   <result pre="magnetic stimulation transcranial direct current stimulation non-invasive brain stimulation pediatric" exact="migraine" post="therapeutics fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction Pediatric"/>
   <result pre="migraine therapeutics fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction Pediatric" exact="migraine" post="remains a challenge for headache specialists, as concerns both"/>
   <result pre="but has also found therapeutic application in symptomatic treatment of" exact="migraine" post="with aura attack ( 10). Double-pulse TMS has found"/>
   <result pre="a perspective about the potential of NBS techniques in children" exact="migraine" post="based on data about safety, coming from studies on"/>
   <result pre="are believed to be involved in the main mechanism of" exact="migraine" post="pain through multiple vasoactive peptides (calcitonin gene-related peptide, substance"/>
   <result pre="mechanisms are invoked as causes of signs and symptoms of" exact="migraine" post="attack and chronicization ( 18). On these bases, it"/>
   <result pre="suggest the existence of primary visual cortex hyperexcitability, especially in" exact="migraine" post="with aura ( 21). These studies are limited by"/>
   <result pre="migraineurs vs. controls, with changing excitability levels 1–2 days before" exact="migraine" post="attacks, reflecting the relation of fluctuating excitability to the"/>
   <result pre="migraine attacks, reflecting the relation of fluctuating excitability to the" exact="migraine" post="cycle ( 23). To date, to our knowledge, only"/>
   <result pre="only one pivotal study ( 24) in adolescents affected by" exact="migraine" post="has explored the therapeutic use of rTMS as a"/>
   <result pre="because NIBS showed promise in the treatment of pain and" exact="migraine" post="in adults. High-frequency magnetic stimulation of the motor cortex"/>
   <result pre="of the study were mainly the sample population exhibiting only" exact="migraine" post="with visual aura; moderate gain on sham effect (17%),"/>
   <result pre="of clear conclusions regarding the effectiveness of TMS against chronic" exact="migraine" post="( 28– 30). However, the generally reported lack of"/>
   <result pre="our knowledge, studies using tDCS in the treatment of pediatric" exact="migraine" post="and pain have not yet been published. However, observing"/>
   <result pre="Evidence regarding the effect of tDCS on adult patients with" exact="migraine" post="is still inconclusive; however, two studies applying cathodal currents"/>
   <result pre="use of TMS and tDCS in the treatment of pediatric" exact="migraine" post="and, in general, for pediatric pain treatment. However, adult"/>
   <result pre="in adults but also in the pediatric population, suggest that" exact="migraine" post="may represent an effective therapeutic target. Moreover, NBS of"/>
   <result pre="comorbid with disease, sharing also a stimulation target employed for" exact="migraine" post="treatment, like DLPFC. Among these disorders, in addition to"/>
   <result pre="role played by the psychiatric diseases, of particular importance is" exact="obesity" post="which also favors the chronification of migraine ( 35,"/>
   <result pre="particular importance is obesity which also favors the chronification of" exact="migraine" post="( 35, 36). Due to the large prevalence of"/>
   <result pre="concerns regarding pharmacological therapies, especially for continuing preventive treatment, pediatric" exact="migraine" post="appears to be an optimal candidate for future studies"/>
   <result pre="S Sivaraman B Graham C . Prevalence of headache and" exact="migraine" post="in children and adolescents: a systematic review of population-based"/>
   <result pre="Turkel CC Winner P . Prevalence and burden of chronic" exact="migraine" post="in adolescents: results of the chronic daily headache in"/>
   <result pre="Primary headache in children and adolescents: update on pharmacotherapy of" exact="migraine" post="and tension-type headache . Neuropediatrics. ( 2013) 44: 3–"/>
   <result pre="al. . Single-pulse transcranial magnetic stimulation for acute treatment of" exact="migraine" post="with aura: a randomised, double-blind, parallel-group, sham-controlled trial ."/>
   <result pre="RSJ Weiner R Goadsby PJ . Central neuromodulation in chronic" exact="migraine" post="patients with suboccipital stimulators: a PET study . Brain."/>
   <result pre="O Stude P Diener HC . Visual cortex excitability in" exact="migraine" post="evaluated by single and paired magnetic stimuli. Headache. ("/>
   <result pre=". Peri-ictal changes of cortical excitability in children suffering from" exact="migraine" post="without aura . Pain. ( 2009) 147: 132– 140."/>
   <result pre="I Goadsby PJ Gelfand AA . Transcranial magnetic stimulation for" exact="migraine" post="prevention in adolescents: a pilot open-label study . Headache."/>
   <result pre="Pringsheim T Becker WJ . Triptans for symptomatic treatment of" exact="migraine" post="headache. BMJ. ( 2014) 348: g2285. 10.1136/bmj.g2285 24711666 26."/>
   <result pre="prospective, single arm, open label, observational study of sTMS for" exact="migraine" post="prevention (ESPOUSE Study) . Cephalalgia. ( 2018) 38: 1038–"/>
   <result pre="on non-pharmacological neuromodulation for the acute and preventive treatment of" exact="migraine" post=". Headache. ( 2017) 57: 685– 91. 10.1111/head.13069 28295242"/>
   <result pre="stimulation of the visual cortex in the prophylactic treatment of" exact="migraine" post=". Cephalalgia. ( 2011) 31: 820– 8. 10.1177/0333102411399349 21398419"/>
   <result pre="Pavone P Verrotti A Lubrano R et al. . Headache," exact="migraine" post="and obesity: an overview on plausible links. J Biol"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6473667/results/search/disease/results.xml">
   <result pre="to &quot;severe&quot; (GCS 3–8, an extended period of unconsciousness or" exact="amnesia" post="after injury). Simply stated, concussion overlaps with mTBI, with"/>
   <result pre="longer recovery [ 32]. Other studies have shown that on-field" exact="amnesia" post="[ 33] and oculomotor dysfunction [ 34] are associated"/>
   <result pre="outcome. 4.4. Migraine Headaches A personal or family history of" exact="migraine" post="headaches has been associated with susceptibility to PCS. Zemek"/>
   <result pre="the emergency department for concussion (and had adequate follow-up), personal" exact="migraine" post="history was associated with recovery time of 28 days"/>
   <result pre="Zemek et al. study, no correlation between family history of" exact="migraine" post="and concussion recovery was seen. Morgan et al., however,"/>
   <result pre="with control patients without persistent symptoms, that family history of" exact="migraine" post="and PCS development were positively correlated ( p ="/>
   <result pre="[ 37]. These findings suggest that some underlying susceptibility to" exact="migraine" post="headaches may predispose athletes to a longer recovery, and"/>
   <result pre="is complicated by difficulty differentiating between a headache history vs." exact="migraine" post="history. The direct interaction between SRC, PCS, and migraine"/>
   <result pre="vs. migraine history. The direct interaction between SRC, PCS, and" exact="migraine" post="remains exploratory until further investigation. 4.5. Learning Disability or"/>
   <result pre="Attention Deficit Hyperactivity Disorder The literature evaluating the effect of" exact="learning disability" post="(LD) on SRC susceptibility and recovery is inconsistent in"/>
   <result pre="et al., [ 48] the authors concluded that those with" exact="attention deficit hyperactivity disorder" post="(ADHD) or with LD had a greater lifetime risk"/>
   <result pre="which were due to sports, assessed the importance depression, anxiety," exact="bipolar disorder," post="suicidal attempts, or post-traumatic stress disorder [ 53]. Guerriero"/>
   <result pre="assessed the importance depression, anxiety, bipolar disorder, suicidal attempts, or" exact="post-traumatic stress disorder" post="[ 53]. Guerriero et al. [ 53] found that"/>
   <result pre="spreading, depression-like state that clinically causes post-concussion impairment, which includes" exact="migraine" post="symptoms, vulnerability to repeat injury, and cognitive impairment ["/>
   <result pre="26330572 5. Gardner A. Iverson G.L. McCrory P. Chronic traumatic" exact="encephalopathy" post="in sport: A systematic review Br. J. Sports Med."/>
   <result pre="H.H. Lonser R.R. The science and questions surrounding chronic traumatic" exact="encephalopathy" post="Neurosurg. Focus 2016 40 E15 10.3171/2016.2.FOCUS15609 27032918 8. Manley"/>
   <result pre="immediate postictal diffusion-weighted MRI in localizing epileptogenic foci of mesial" exact="temporal lobe epilepsy" post="and non-lesional neocortical epilepsy Seizure 2004 13 509 516"/>
   <result pre="diffusion-weighted MRI in localizing epileptogenic foci of mesial temporal lobe" exact="epilepsy" post="and non-lesional neocortical epilepsy Seizure 2004 13 509 516"/>
   <result pre="epileptogenic foci of mesial temporal lobe epilepsy and non-lesional neocortical" exact="epilepsy" post="Seizure 2004 13 509 516 10.1016/j.seizure.2003.12.005 15324831 70. Song"/>
   <result pre="differentiates axon and myelin degeneration in mouse optic nerve after" exact="retinal ischemia" post="Neuroimage 2003 20 1714 1722 10.1016/j.neuroimage.2003.07.005 14642481 71. Song"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6480981/results/search/disease/results.xml">
   <result pre="cavernous sinus thrombus, inflammatory processes (sarcoidosis, IgG4 [immunoglobulin G4] disease)," exact="autoimmune disease" post="(lupus, granulomatosis with polyangiitis), neoplasm (schwannoma, lymphoma, and metastatic"/>
   <result pre="IgG4 [immunoglobulin G4] disease), autoimmune disease (lupus, granulomatosis with polyangiitis)," exact="neoplasm" post="(schwannoma, lymphoma, and metastatic disease), paraneoplastic syndrome, infectious (cryptococcal,"/>
   <result pre="lymphoma, and metastatic disease), paraneoplastic syndrome, infectious (cryptococcal, mycoplasma, and" exact="herpes simplex" post="virus), and idiopathic etiology. Figure 1. MRI of the"/>
   <result pre="angiogram and magnetic resonance venography were normal and ruled out" exact="cavernous sinus thrombosis." post="Anti-nuclear antibody, IgG subclasses, anti-neutrophil cytoplasmic antibody, anti-double stranded"/>
   <result pre="Cerebral spinal fluid (CSF) studies showed normal cell count, normal" exact="meningitis" post="polymerase chain reaction panel, no growth on culture, normal"/>
   <result pre="note, computed tomography of the chest is more sensitive for" exact="sarcoidosis" post="compared to chest X-ray. Although chest X-ray was completed,"/>
   <result pre="4% to 5% of the cases. 4 Diplopia results from" exact="mononeuropathy" post="or polyneuropathy. The third cranial nerve is most commonly"/>
   <result pre="If the orbital apex is involved, patients may develop an" exact="optic neuropathy." post="5 Diagnosis The clinical diagnostic criteria for THS per"/>
   <result pre="with magnetic resonance venography of the brain is to exclude" exact="cavernous sinus thrombosis" post="as well as intraorbital or intraparenchymal tumor. 2 Biopsy"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6505731/results/search/disease/results.xml">
   <result pre="syncope (50%), orthostatic hypotension (20%), dehydration (15%), atypical seizure (7.5%)," exact="anemia" post="(5%), migraine headache (5%), and minor head trauma (5%),"/>
   <result pre="orthostatic hypotension (20%), dehydration (15%), atypical seizure (7.5%), anemia (5%)," exact="migraine" post="headache (5%), and minor head trauma (5%), as well"/>
   <result pre="heart block that may result in sudden cardiac death and" exact="epilepsy" post="may be underlying etiologies of syncope as a presenting"/>
   <result pre="upon this, a differential diagnosis including brain tumor, AVM, and" exact="neurofibromatosis" post="was developed. At this point, the pediatrician ordered an"/>
   <result pre="for an MRI of the brain with gadolinium which revealed" exact="hydrocephalus" post="and a large AVM involving mainly the thalamus on"/>
   <result pre="demonstrating a 5 cm x 4 cm x 3 cm" exact="arteriovenous malformation" post="involving mainly the thalamus on the right side and"/>
   <result pre="Cerebral angiogram showing a large right basal ganglia and thalamic" exact="arteriovenous malformation" post="with mild involvement of the left basal ganglia. Three"/>
   <result pre="syncope (50%), orthostatic hypotension (20%), dehydration (15%), atypical seizure (7.5%)," exact="anemia" post="(5%), migraine headache (5%), and minor head trauma (5%)"/>
   <result pre="orthostatic hypotension (20%), dehydration (15%), atypical seizure (7.5%), anemia (5%)," exact="migraine" post="headache (5%), and minor head trauma (5%) [ 8]."/>
   <result pre="heart block that may result in sudden cardiac death and" exact="epilepsy" post="[ 10]. Interestingly, 82.1% of patients experienced recurrent syncope"/>
   <result pre="et al. 218 225 5 2016 27781052 2 De novo" exact="arteriovenous malformation" post="in a pediatric patient: case report and review of"/>
   <result pre="Y Lasjaunias P et al. 309 331 1992 6 Cerebral" exact="arteriovenous malformation" post="in children Can J Anaesth Millar C Bissonette B"/>
   <result pre="Demographic morphological, and clinical characteristics of 1289 patients with brain" exact="arteriovenous malformation" post="Stroke Hofmeister C Stapf C Hartmann A et al."/>
   <result pre="11 Recurrent episodes of syncope in a patient with cerebral" exact="arteriovenous malformation" post="Clin Ter De Biase L Di Lisi F Perna"/>
   <result pre="al. 147 150 158 2007 https://www.ncbi.nlm.nih.gov/pubmed/17566516 17566516 12 Extradural retro-orbital," exact="arteriovenous malformation" post="as the cause of a long-term history of syncope"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6506428/results/search/disease/results.xml">
   <result pre="III criteria conditions: functional abdominal pain, functional abdominal pain syndrome," exact="irritable bowel syndrome," post="functional dyspepsia, and abdominal migraine [ 1 2]. Clinical"/>
   <result pre="abdominal pain syndrome, irritable bowel syndrome, functional dyspepsia, and abdominal" exact="migraine" post="[ 1 2]. Clinical decision guidelines have been developed"/>
   <result pre="38%–89% in performing chest X-rays in hospitalized infants &amp;lt;1-year-old with" exact="bronchiolitis" post="was reported [ 7]. Also, the performance of diagnostic"/>
   <result pre="studies, inflammatory markers, and chest radiographs in children with community-acquired" exact="pneumonia" post="across emergency departments in the United States showed a"/>
   <result pre="Zerr DM Variation in inpatient diagnostic testing and management of" exact="bronchiolitis" post="Pediatrics 2005 115 878 884 15805359 8 Florin TA"/>
   <result pre="Variation in emergency department diagnostic testing and disposition outcomes in" exact="pneumonia" post="Pediatrics 2013 132 237 244 23878049 9 Urkin J"/>
   <result pre="JP Chang YC et al. Understanding physician adherence with a" exact="pneumonia" post="practice guideline: effects of patient, system, and physician factors"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6514150/results/search/disease/results.xml">
   <result pre="reproduction is permitted which does not comply with these terms." exact="multiple sclerosis" post="misdiagnosis McDonald criteria diagnostic error multiple sclerosis mimics fig-count:"/>
   <result pre="with these terms. multiple sclerosis misdiagnosis McDonald criteria diagnostic error" exact="multiple sclerosis" post="mimics fig-count: table-count: equation-count: ref-count: page-count: word-count: Despite significant"/>
   <result pre="fig-count: table-count: equation-count: ref-count: page-count: word-count: Despite significant refinement in" exact="multiple sclerosis" post="(MS) diagnosis in recent decades, no specific disease biomarker"/>
   <result pre="migraine, cerebral small vessel disease, fibromyalgia, functional neurological disorders, and" exact="neuromyelitis optica" post="spectrum disorders, along with uncommon inflammatory, infectious and metabolic"/>
   <result pre="in patients with a typical clinical isolated syndrome (CIS) (i.e.," exact="optic neuritis," post="transverse myelitis, brainstem syndrome) ( 4). In this sense,"/>
   <result pre="( 2, 3), worsening of underlying disease such as in" exact="neuromyelitis optica" post="spectrum disorders (NMOSDs; ( 11), or delay in treatment"/>
   <result pre="detection of a polyspecific intrathecal humoral immune response against measles," exact="rubella" post="and varicela zoster virus called MRZ reaction has been"/>
   <result pre="PM Howard DB et al. . The contemporary spectrum of" exact="multiple sclerosis" post="misdiagnosis: a multicenter study. Neurology. ( 2016) 87: 1393–"/>
   <result pre="43: 578– 83. 3718285 6. Poser CM . Misdiagnosis of" exact="multiple sclerosis" post="and beta-interferon. Lancet. ( 1997) 349: 1916. 10.1016/S0140-6736(05)63920-7 9217787"/>
   <result pre="sclerosis: guidelines from the International Panel on the diagnosis of" exact="multiple sclerosis" post=". Ann Neurol. ( 2001) 50: 121– 7. 10.1002/ana.1032"/>
   <result pre="Brousseau KM Arciniegas DB Corboy JR . Initial evaluations for" exact="multiple sclerosis" post="in a university multiple sclerosis center: outcomes and role"/>
   <result pre="JR . Initial evaluations for multiple sclerosis in a university" exact="multiple sclerosis" post="center: outcomes and role of magnetic resonance imaging in"/>
   <result pre="brain lesions following fingolimod (FTY720) treatment in a patient with" exact="neuromyelitis optica" post="spectrum disorder . Mult Scler. ( 2012) 18: 113–"/>
   <result pre="SJ Verkman AS Hinson SR . IgG marker of optic-spinal" exact="multiple sclerosis" post="binds to the aquaporin-4 water channel. J Exp Med."/>
   <result pre="T et al. . Epstein-Barr virus persistence and reactivation in" exact="neuromyelitis optica." post="J Neurol Neurosurg Psychiatry. ( 2015) 86: 1137– 42."/>
   <result pre="Davis A Giovannoni G . Cerebrospinal fluid oligoclonal bands in" exact="multiple sclerosis" post="and clinically isolated syndromes: a meta-analysis of prevalence, prognosis"/>
   <result pre=". A serum autoantibody marker of neuromyelitis optica: distinction from" exact="multiple sclerosis." post="Lancet. ( 2004) 364: 2106– 12. 10.1016/S0140-6736(04)17551-X 15589308 25."/>
   <result pre=". Intrathecal, polyspecific antiviral immune response in oligoclonal band negative" exact="multiple sclerosis" post=". PLoS ONE. ( 2012) 7: e40431. 10.1371/journal.pone.0040431 22792316"/>
   <result pre="UC Giovannoni G et al. . The risk of developing" exact="multiple sclerosis" post="in individuals seronegative for Epstein-Barr virus: a meta-analysis ."/>
   <result pre="et al. . Are there Epstein-Barr virus seronegative patients with" exact="multiple sclerosis?" post="Mult Scler. ( 2013) 19: 1242– 3. 10.1177/1352458512472751 23307904"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6516648/results/search/disease/results.xml">
   <result pre="headache underwent funduscopic evaluation and grouped as either headache with" exact="papilledema" post="or headache without papilledema. A control group of patients"/>
   <result pre="found to have significantly higher values (p&amp;lt;0.001) in patients with" exact="papilledema" post="(median 0.24, interquartile range (IQR) = 0.22–0.25) compared to"/>
   <result pre="0.24, interquartile range (IQR) = 0.22–0.25) compared to patients without" exact="papilledema" post="(median 0.18, IQR = 0.16–0.19) and the control group"/>
   <result pre="index showed excellent discrimination ability for patients with headache and" exact="papilledema" post="(AUC = 0.96, 95% CI, 0.94–0.99). The ONSD/ETD index"/>
   <result pre="can be used as an easy-to-use reference tool for diagnosing" exact="papilledema" post="and elevated intracranial pressure in pediatric patients. Funding The"/>
   <result pre="is a vast differential diagnosis spectrum, including respiratory tract infections," exact="viral meningitis," post="migraine, tension-type headache, trauma, increased intracranial pressure (ICP), and"/>
   <result pre="symptoms of increased ICP are often nonspecific [ 6], although" exact="papilledema" post="is believed to be a reliable clinical indicator of"/>
   <result pre="on the optic disc, causing disc swelling; this explains why" exact="papilledema" post="occurs in the presence of increased ICP and why"/>
   <result pre="occurs in the presence of increased ICP and why diagnosing" exact="papilledema" post="may be used as a surrogate for diagnosing increased"/>
   <result pre="patients with traumatic and non-traumatic brain injury, including intracerebral hemorrhage," exact="idiopathic intracranial hypertension" post="(IIH), meningitis, cardiac arrest, and various other pathological conditions"/>
   <result pre="brain injury, including intracerebral hemorrhage, idiopathic intracranial hypertension (IIH), meningitis," exact="cardiac arrest," post="and various other pathological conditions that may‏ lead to"/>
   <result pre="on presenting symptoms and funduscopic findings: patients without signs of" exact="papilledema" post="composed study group 1 and patients with signs of"/>
   <result pre="papilledema composed study group 1 and patients with signs of" exact="papilledema" post="composed study group 2. Subjects who underwent brain CT"/>
   <result pre="not related to elevated ICP and were unlikely to have" exact="papilledema" post="served as the control group. Patients who had no"/>
   <result pre="in study groups. A significant female predominance in patients with" exact="papilledema" post="(study group 2) comparing to the group without papilledema"/>
   <result pre="with papilledema (study group 2) comparing to the group without" exact="papilledema" post="(study group 1) and control group (76%, 40.5% and"/>
   <result pre="p-values. ONSD/ETD index is significantly higher (p&amp;lt;0.001) in patients with" exact="papilledema" post="(median 0.24, IQR = 0.22–0.25) compared to patients in"/>
   <result pre="= 0.22–0.25) compared to patients in with no signs of" exact="papilledema" post="(median 0.18, IQR = 0.16–0.19) and control group (median"/>
   <result pre="between the control group and patients with no signs of" exact="papilledema" post="(p = 0.052). The ONSD/ETD index showed an excellent"/>
   <result pre="index showed an excellent discrimination ability for patients with headache" exact="papilledema" post="(AUC = 0.96, 95%CI, 0.94–0.99). An ROC curve at"/>
   <result pre="index values and how they relate to the presence of" exact="papilledema" post="in pediatric patients presenting with headache due to papilledema"/>
   <result pre="of papilledema in pediatric patients presenting with headache due to" exact="papilledema" post="being a well-established indicator for increased ICP and the"/>
   <result pre="cause to ONSD enlargement [ 14, 16, 18]. Patients with" exact="papilledema" post="expressed increased ONSD/ETD index values compared to those without."/>
   <result pre="Calculating ONSD/ETD index value can therefore be used to diagnose" exact="papilledema" post="and, given papilledema’s acceptance as a surrogate marker of"/>
   <result pre="ICP in pediatric patients by comparing the mean ONSD in" exact="idiopathic intracranial hypertension" post="(IIH) (previously referred to as pseudotumor cerebri) cases with"/>
   <result pre="significant variability, thus questioning the precision of ONSD in diagnosing" exact="papilledema" post="and elevated ICP [ 16]. Meanwhile, Vaiman et al."/>
   <result pre="different pathologies [ 20– 22]. Furthermore, Vaiman et al. studied" exact="papilledema" post="in adults, whereas we looked to see if this"/>
   <result pre="whereas we looked to see if this method of identifying" exact="papilledema" post="applies to pediatric patients, as well [ 13, 16,"/>
   <result pre="appropriate treatment. However, it should be taken into consideration that" exact="papilledema" post="is known to be both sensitive and specific as"/>
   <result pre="study group 2, this was not possible. The data about" exact="papilledema" post="on ophthalmological study was collected retrospectively and the examination"/>
   <result pre="control group. At this same time, a female patient with" exact="papilledema" post="raises suspicion for pseudotumor cerebri, which can occur at"/>
   <result pre="shows that the ONSD/ETD ratio may be used for diagnosing" exact="papilledema" post="in pediatric patients. Using this as a diagnostic tool"/>
   <result pre=", Heidary G . Update on the evaluation of pediatric" exact="idiopathic intracranial hypertension." post="Curr Opin Ophthalmol [Internet]. 2016; 27( 6): 493– 7."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6520671/results/search/disease/results.xml">
   <result pre="positively influence other pathways commonly believed to be part of" exact="migraine" post="pathophysiology, namely: mitochondrial functioning, oxidative stress, cerebral excitability, inflammation"/>
   <result pre="the presence of KBs, D-BHB in particular, could influence those" exact="migraine" post="pathophysiological mechanisms. To this end, common abnormalities in migraines"/>
   <result pre="elaborate on the potential therapeutic mechanisms of elevated KBs in" exact="migraine" post="pathophysiology, with a particular focus on the actions of"/>
   <result pre="of KBs, or both, are of primary importance for the" exact="migraine" post="protective effects of the KD. migraine beta-hydroxybutyrate ketone bodies"/>
   <result pre="primary importance for the migraine protective effects of the KD." exact="migraine" post="beta-hydroxybutyrate ketone bodies ketosis migraine prevention ketogenic diet exogenous"/>
   <result pre="protective effects of the KD. migraine beta-hydroxybutyrate ketone bodies ketosis" exact="migraine" post="prevention ketogenic diet exogenous ketone bodies 1. Introduction Migraine"/>
   <result pre="bodies 1. Introduction Migraine is a complex, common and debilitating" exact="neurological disorder" post="[ 1]. Its episodic form is characterized by recurrent"/>
   <result pre="a peak incidence during the most productive years of life," exact="migraine" post="not only causes a huge amount of suffering, but"/>
   <result pre="billion per year in Europe alone [ 3, 4]. Current" exact="migraine" post="treatment options have limited efficacy and many—often intolerable—side-effects ["/>
   <result pre="least partially—an energy deficit syndrome of the brain, and the" exact="migraine" post="attack a response to increased oxidative stress and/or (cerebral)"/>
   <result pre="30, 31, 32]). Several case studies have demonstrated the potentially" exact="migraine" post="protective effects of ketosis [ 22, 33, 34, 35,"/>
   <result pre="36, 37]. A one-month observational study of KD in 96" exact="migraine" post="patients as part of a weight loss program found"/>
   <result pre="loss program found a reduction of up to 80% in" exact="migraine" post="frequency, severity and acute medication use [ 37]. The"/>
   <result pre="intervention in 18 episodic migraineurs induced a 62.5% reduction in" exact="migraine" post="days, which was accompanied by a normalization of the"/>
   <result pre="deficit of visual evoked responses [ 36]. The reduction in" exact="migraine" post="attack frequency, severity and the use of acute anti-migraine"/>
   <result pre="ketosis [ 33], as is often the case in pediatric" exact="epilepsy" post="patients, and could be the result of longer-lasting gene-expression"/>
   <result pre="the presence of ketone bodies, D-BHB in particular, could influence" exact="migraine" post="pathophysiology (see Figure 1). To this end, common abnormalities"/>
   <result pre="pathophysiology (see Figure 1). To this end, common abnormalities in" exact="migraine" post="(such as abnormalities in glucose metabolism and transport, mitochondrial"/>
   <result pre="elaborate on the potential therapeutic mechanisms of elevated KBs in" exact="migraine" post="pathophysiology with a particular focus on the actions of"/>
   <result pre="Mechanisms of Ketosis 2.1. Hypoglycemia/Hypometabolism Hypoglycaemia has been associated with" exact="migraine" post="for almost a century [ 39, 40, 41] and"/>
   <result pre="a meal is not only amongst the most commonly cited" exact="migraine" post="triggers [ 42, 43, 44], but it can also"/>
   <result pre="44], but it can also be used experimentally to elicit" exact="migraine" post="attacks in susceptible patients [ 39]. Due to very"/>
   <result pre="especially vulnerable to their potential short-comings. A simple comparison between" exact="migraine" post="associated symptoms, premonitory symptoms in particular, and symptoms of"/>
   <result pre="cognitive difficulties, tiredness, fatigue, visual dysfunction and slurred speech. Increased" exact="migraine" post="frequency has also been observed during Ramadan [ 46]"/>
   <result pre="frequency has also been observed during Ramadan [ 46] and" exact="migraine" post="prevalence in type 2 diabetics was shown to proportionally"/>
   <result pre="for the role of energy deficiency and/or glucose metabolism in" exact="migraine" post="comes from neuroimaging studies. Using 31P-MRS, an impairment of"/>
   <result pre="impairment of brain oxidative phosphorylation (OXPHOS) was detected first during" exact="migraine" post="attacks [ 48] and thereafter between attacks [ 49,"/>
   <result pre="52, 53, 54, 55, 56]. OXPHOS abnormalities in patients with" exact="migraine" post="were found both in the resting brain and in"/>
   <result pre="More recently, a 16% decrease of absolute ATP levels in" exact="migraine" post="without aura patients was demonstrated interictally using 31P-MRS ["/>
   <result pre="exceeded glucose uptake in visual areas in 90% of interictal" exact="migraine" post="without aura patients, but in only 15% of healthy"/>
   <result pre="brain activity and glucose metabolism may be a cornerstone of" exact="migraine" post="pathophysiology. KBs are known to be able to counteract"/>
   <result pre="be able to counteract some of the negative effects of" exact="hypoglycemia" post="and/or hypometabolism or prevent it all together. D-BHB has"/>
   <result pre="oral glucose tolerance tests after an overnight fast can elicit" exact="migraine" post="attacks in susceptible patients [ 68, 69]. Interestingly, the"/>
   <result pre="in migraine. GLUT1 deficiency syndrome has been linked to hemiplegic" exact="migraine" post="and migraine with aura [ 70]. GLUT4 (adipose tissue"/>
   <result pre="GLUT1 deficiency syndrome has been linked to hemiplegic migraine and" exact="migraine" post="with aura [ 70]. GLUT4 (adipose tissue and striated"/>
   <result pre="the cells. Interictal impaired glucose tolerance and insulin resistance in" exact="migraine" post="has been reported in various studies [ 72, 73,"/>
   <result pre="Some genetic support for a potential role of insulin in" exact="migraine" post="comes from associations between polymorphisms in insulin-related genes and"/>
   <result pre="migraine comes from associations between polymorphisms in insulin-related genes and" exact="migraine" post="[ 79, 80, 81, 82]. KBs are taken up"/>
   <result pre="a role of mitochondrial functioning in migraine. The prevalence of" exact="migraine" post="in mitochondrial disorders is more than doubled (29–35.5% of"/>
   <result pre="patients) [ 87, 88] and migraine-like attacks in Mitochondrial encephalomyopathy," exact="lactic acidosis," post="and stroke-like episodes (MELAS) are especially severe and prolonged"/>
   <result pre="are especially severe and prolonged [ 89]. Maternal transmission in" exact="migraine" post="is more common [ 90], which suggests that either"/>
   <result pre="mtDNA derives exclusively from maternal origin. Furthermore, enrichment of a" exact="migraine" post="genome-wide association study (GWAS) signal was found for mitochondria"/>
   <result pre="that identifies a genetic link between mitochondrial function and common" exact="migraine" post="[ 91]. Further support for a generalized metabolic dysfunction"/>
   <result pre="[ 91]. Further support for a generalized metabolic dysfunction in" exact="migraine" post="comes from the reduced activity of mitochondrial enzymes, such"/>
   <result pre="succinate-dehydrogenase, NADH-dehydrogenase, cyclooxygenase (COX) and citrate-synthetase in the platelets of" exact="migraine" post="patients with and without aura [ 92, 93]. Interestingly,"/>
   <result pre="in migraine. Most nutraceuticals that have been demonstrated to be" exact="migraine" post="preventative can directly be linked to energy metabolism and/or"/>
   <result pre="and magnesium [ 113]. Even pharmaceutical prophylactic agents used against" exact="migraine" post="are able to influence mitochondrial functioning and metabolism. For"/>
   <result pre="and Valproate preserves mitochondrial function in a rat model of" exact="migraine" post="[ 118] and increases mitochondrial biogenesis [ 119]. KBs"/>
   <result pre="it exceeds the anti-oxidant capacity of the organism. All common" exact="migraine" post="triggers (stress/relaxation thereafter, fasting/skipping a meal, sleep changes (too"/>
   <result pre="highly pro-oxidant and accumulates in the brain stem nuclei of" exact="migraine" post="patients proportionally to disease duration [ 129]. Other heavy"/>
   <result pre="heavy metals with pro-oxidant properties may also be increased in" exact="migraine" post="[ 130]. Increased oxidative/nitrosative stress and/or decreased anti-oxidant capacity"/>
   <result pre="and/or decreased anti-oxidant capacity have also directly been found in" exact="migraine" post="patients [ 117, 131, 132, 133, 134, 135, 136,"/>
   <result pre="superoxide dismutase (SOD) activity seems to be consistently reduced in" exact="migraine" post="patients, also interictally [ 144]. Reduced anti-oxidant capacity or"/>
   <result pre="[ 144]. Reduced anti-oxidant capacity or increased oxidative stress in" exact="migraine" post="could be related to a genetic predisposition. A polymorphism"/>
   <result pre="SOD2 gene was associated with unilateral cranial autonomic symptoms in" exact="migraine" post="with aura patients [ 145], and in paediatric migraine"/>
   <result pre="in migraine with aura patients [ 145], and in paediatric" exact="migraine" post="patients’ polymorphisms in the SOD2 and catalase gene were"/>
   <result pre="the SOD2 and catalase gene were significantly higher in both" exact="migraine" post="with and without aura patients compared to controls ["/>
   <result pre="146]. Further support for the role of oxidative stress in" exact="migraine" post="is that as aforementioned antioxidants, such as Coenzyme Q10"/>
   <result pre="acid) [ 107, 108, 109] have been shown to have" exact="migraine" post="protective effects. The elevation of KBs, D-BHB in particular,"/>
   <result pre="be hypothesized that the aforementioned increased KB levels during a" exact="migraine" post="attack [ 68, 69] could represent an analogous reaction"/>
   <result pre="KD is known to be effective as treatment for refractory" exact="epilepsy" post="[ 157]. There is comorbidity and shared genetic susceptibility"/>
   <result pre="[ 157]. There is comorbidity and shared genetic susceptibility between" exact="migraine" post="and epilepsy [ 158] and hence partially similar pathophysiologic"/>
   <result pre="There is comorbidity and shared genetic susceptibility between migraine and" exact="epilepsy" post="[ 158] and hence partially similar pathophysiologic mechanisms are"/>
   <result pre="be a pathogenic cornerstone in migraine, as it is in" exact="epilepsy" post="[ 160, 161, 162, 163, 164]. The genetic association"/>
   <result pre="[ 160, 161, 162, 163, 164]. The genetic association between" exact="migraine" post="and epilepsy is illustrated by their co-occurrence in the"/>
   <result pre="161, 162, 163, 164]. The genetic association between migraine and" exact="epilepsy" post="is illustrated by their co-occurrence in the hitherto known"/>
   <result pre="by their co-occurrence in the hitherto known three subtypes of" exact="familial hemiplegic migraine" post="(FHM), a rare autosomal dominant monogenic form of migraine."/>
   <result pre="co-occurrence in the hitherto known three subtypes of familial hemiplegic" exact="migraine" post="(FHM), a rare autosomal dominant monogenic form of migraine."/>
   <result pre="inhibitory interneurons (FHM3—SCN1A) [ 168]. In the common forms of" exact="migraine" post="with and without aura, GWAS have identified 38 susceptibility"/>
   <result pre="which may lead to a &quot;generalized&quot; neuronal hyperexcitability of the" exact="migraine" post="brain. The observation that increased KB metabolism produces seizure"/>
   <result pre="inhibition as well as a reduction in excitability could be" exact="migraine" post="protective. 2.6. Cortical Spreading Depression Cortical spreading depression (CSD)"/>
   <result pre="and has been implicated as the underlying pathophysiological mechanism in" exact="migraine" post="aura. CSD susceptibility is strongly modulated by metabolic factors."/>
   <result pre="or injury. Even though the involvement of neurogenic inflammation in" exact="migraine" post="remains controversial [ 186], and migraine has not classically"/>
   <result pre="of neurogenic inflammation in migraine remains controversial [ 186], and" exact="migraine" post="has not classically been considered an inflammatory disease, possibly"/>
   <result pre="involvement of pro-inflammatory peptides or a &quot;sterile neurogenic inflammation&quot; in" exact="migraine" post="pain (review [ 187, 188]). Most importantly, calcitonin gene"/>
   <result pre="some extent cytokines [ 199], are all molecules associated with" exact="migraine" post="both in animal and human studies review [ 187,"/>
   <result pre="Cytokine Polymorphism (TNF-α and IL-1β gene polymorphisms) in patients with" exact="migraine" post="without aura provide some more suggestive evidence for a"/>
   <result pre="more suggestive evidence for a possible contribution of inflammation in" exact="migraine" post="[ 201]. Meningeal mast cell activation has been discussed"/>
   <result pre="discussed to play a role in meningeal nociceptor activation in" exact="migraine" post="[ 202]. D-BHB was reported to reduce inflammation generated"/>
   <result pre="the KD [ 205, 206, 207], which could further be" exact="migraine" post="protective. 2.8. Gut Microbiome The potential role of the"/>
   <result pre="2.8. Gut Microbiome The potential role of the microbiome in" exact="migraine" post="pathophysiology is not yet fully established. Two recent reviews"/>
   <result pre="an increased frequency of gastrointestinal (GI) symptoms or disorders in" exact="migraine" post="patients compared to the general population, such as increased"/>
   <result pre="increased rates of nausea, cyclic vomiting syndrome, inflammatory bowel syndrome," exact="irritable bowel syndrome," post="celiac disease, gastroparesis, hepatobiliary disorders, helicobacter pylori infection, gastric"/>
   <result pre="patients using a multispecies probiotic showed a significant reduction in" exact="migraine" post="days, headache intensity and the use of painkillers ["/>
   <result pre="painkillers [ 212]. Additionally, an immunoglobulin-G based elimination diet among" exact="migraine" post="patients with irritable bowel syndrome was associated with significant"/>
   <result pre="Additionally, an immunoglobulin-G based elimination diet among migraine patients with" exact="irritable bowel syndrome" post="was associated with significant reductions in attack frequency, duration,"/>
   <result pre="severity and medication use [ 213]. Possible underlying mechanisms of" exact="migraine" post="and GI diseases could be inflammation, alterations in the"/>
   <result pre="well as increased gut permeability. The role of inflammation in" exact="migraine" post="as well as the anti-inflammatory effects of ketosis have"/>
   <result pre="recently been shown that a KD in children with severe" exact="epilepsy" post="alters the gut microbiome [ 214, 215]. Recent experiments"/>
   <result pre="[ 216]. In support of this, in infants with refractory" exact="epilepsy" post="a KD decreased seizure frequency in the majority of"/>
   <result pre="normalization of the microbiota in two other neurological disorders, namely" exact="autism" post="[ 218] and multiple sclerosis [ 219]. In the"/>
   <result pre="in two other neurological disorders, namely autism [ 218] and" exact="multiple sclerosis" post="[ 219]. In the BTBRT+tf/j mouse model of autism"/>
   <result pre="multiple sclerosis [ 219]. In the BTBRT+tf/j mouse model of" exact="autism" post="spectrum disorder, a KD significantly increased the Firmicutes/Bacteroidetes ratio"/>
   <result pre="significantly increased the Firmicutes/Bacteroidetes ratio which is typically low in" exact="autism" post="spectrum disorder and also normalized the overabundance of the"/>
   <result pre="the mucin-degrading bacterium Akkermansia muciniphila [ 218]. In patients with" exact="multiple sclerosis" post="who were characterized by a reduced mass and diversity"/>
   <result pre="studies. For example, a small study on children with severe" exact="epilepsy" post="found that the relative abundance of bifidobacteria as well"/>
   <result pre="protein and carbohydrates and other factors. The children with severe" exact="epilepsy" post="were mostly on a very strict classical KD with"/>
   <result pre="genetic polymorphisms and in turn pathophysiological mechanisms contributing to the" exact="migraine" post="phenotype. We have reviewed the potential contribution of eight"/>
   <result pre="inflammation and (8) the microbiome. Which mechanisms contribute to the" exact="migraine" post="phenotype in a given individual are likely to vary."/>
   <result pre="importance of these metabolic mechanisms within the broad range of" exact="migraine" post="pathophysiology remains to be determined. With migraine being such"/>
   <result pre="broad range of migraine pathophysiology remains to be determined. With" exact="migraine" post="being such a diverse and multigenic disease, finding the"/>
   <result pre="have been shown to potentially influence all of the aforementioned" exact="migraine" post="pathophysiological mechanisms, might offer a long-needed relatively side-effect free"/>
   <result pre="relatively side-effect free remedy for at least a proportion of" exact="migraine" post="sufferers. It remains to be determined whether the absence/restriction"/>
   <result pre="KBs, or both, are of primary importance for the potentially" exact="migraine" post="protective effects of the KD that has previously been"/>
   <result pre="potentially disease-modifying effects of ketosis are actually also occurring in" exact="migraine" post="patients. Patents E.C.G. and D.F. are the inventors of"/>
   <result pre="and University of Basel on the use of beta-hydroxybutyrate in" exact="migraine" post="prevention. D.P.D. is inventor on International Patent # PCT/US2014/031237,"/>
   <result pre="R.B. Global perspectives on the burden of episodic and chronic" exact="migraine" post="Cephalalgia Int. J. Headache 2013 33 885 890 10.1177/0333102413477736"/>
   <result pre="1311 10.1111/head.12154 23879870 8. Pietrobon D. Moskowitz M.A. Pathophysiology of" exact="migraine" post="Annu. Rev. Physiol. 2013 75 365 391 10.1146/annurev-physiol-030212-183717 23190076"/>
   <result pre="Fischer D. Sandor P.S. Schoenen J. The metabilic face of" exact="migraine" post="Nat. Neurosci. 2019 7 50708 50718 10. Edmond J."/>
   <result pre="Thiele E.A. The use of diet in the treatment of" exact="epilepsy" post="Epilepsy Behav. E&amp;amp;B 2005 6 4 8 12. Danial"/>
   <result pre="14. Barañano K.W. Hartman A.L. The ketogenic diet: Uses in" exact="epilepsy" post="and other neurologic illnesses Curr. Treat. Opt. Neurol. 2008"/>
   <result pre="J.I. Sperling M.R. Ketogenic diet in adolescents and adults with" exact="epilepsy" post="Seizure 2014 23 439 442 10.1016/j.seizure.2014.02.015 24675110 20. Reid"/>
   <result pre="E.H. Ketosis and the ketogenic diet, 2010: Advances in treating" exact="epilepsy" post="and other disorders Adv. Pediatrics 2010 57 315 329"/>
   <result pre="H.-S. Medium-chain triglyceride ketogenic diet, an effective treatment for drug-resistant" exact="epilepsy" post="and a comparison with other ketogenic diets Biomed. J."/>
   <result pre="Rabier D. Ottolenghi C. et al. Successful treatment of severe" exact="cardiomyopathy" post="in glycogen storage disease type III With D,L-3-hydroxybutyrate, ketogenic"/>
   <result pre="Ottolenghi C. et al. Successful treatment of severe cardiomyopathy in" exact="glycogen storage disease" post="type III With D,L-3-hydroxybutyrate, ketogenic and high-protein diet Pediatric"/>
   <result pre="2056 2065 10.1016/j.bbadis.2015.07.009 26170063 33. Strahlman R.S. Can ketosis help" exact="migraine" post="sufferers? A case report Headache 2006 46 182 10.1111/j.1526-4610.2006.00321_5.x"/>
   <result pre="Cardillo A. De Nardis L. Pierelli F. Diet transiently improves" exact="migraine" post="in two twin sisters: Possible role of ketogenesis? Funct."/>
   <result pre="35. Maggioni F. Margoni M. Zanchin G. Ketogenic diet in" exact="migraine" post="treatment: A brief but ancient history Cephalalgia Int. J."/>
   <result pre="G. The ketogenic diet: Metabolic influences on brain excitability and" exact="epilepsy" post="Trends Neurosci. 2013 36 32 40 10.1016/j.tins.2012.11.005 23228828 39."/>
   <result pre="Blau J.N. Cumings J.N. Method of precipitating and preventing some" exact="migraine" post="attacks Br. Med. J. 1966 2 1242 1243 10.1136/bmj.2.5524.1242"/>
   <result pre="S.J. What turns on a migraine? A systematic review of" exact="migraine" post="precipitating factors Curr. Pain Headache Rep. 2014 18 454"/>
   <result pre="L.R. Helpern J.A. Preliminary observations on brain energy metabolism in" exact="migraine" post="studied by in vivo phosphorus 31 NMR spectroscopy Neurology"/>
   <result pre="shown by 31P magnetic resonance spectroscopy in patients affected by" exact="migraine" post="with aura Neurology 1992 42 1209 1214 10.1212/WNL.42.6.1209 1603349"/>
   <result pre="with low free magnesium in the brains of patients with" exact="migraine" post="and cluster headache Brain Res. Bull. 2001 54 437"/>
   <result pre="Frassineti C. Zaniol P. Lugaresi E. 31P-magnetic resonance spectroscopy in" exact="migraine" post="without aura Neurology 1994 44 666 669 10.1212/WNL.44.4.666 8164822"/>
   <result pre="Quantitative analysis of skeletal muscle bioenergetics and proton efflux in" exact="migraine" post="and cluster headache J. Neurol. Sci. 1997 146 73"/>
   <result pre="P. Martinelli P. Sacquegna T. Zaniol P. Lugaresi E. Complicated" exact="migraine" post="studied by phosphorus magnetic resonance spectroscopy Cephalalgia 1990 10"/>
   <result pre="a reduction in high-energy phosphates in the occipital lobe of" exact="migraine" post="without aura patients Cephalalgia Int. J. Headache 2011 31"/>
   <result pre="neuronal activation-to-resting glucose uptake ratio in the visual cortex of" exact="migraine" post="patients: A study comparing 18FDG-PET and visual evoked potentials"/>
   <result pre="Williamson D.H. Whitty C.W.M. Blood-glucose levels and fatty-acid metabolism in" exact="migraine" post="related to fasting Lancet 1971 297 1153 1156 10.1016/S0140-6736(71)91662-X"/>
   <result pre="R.H. Keogh H.J. Metabolic changes during glucose tolerance tests in" exact="migraine" post="attacks J. Neurol. Sci. 1977 33 51 59 10.1016/0022-510X(77)90181-2"/>
   <result pre="R. Pinessi L. Insulin sensitivity is impaired in patients with" exact="migraine" post="Cephalalgia 2005 25 593 597 10.1111/j.1468-2982.2005.00928.x 16033384 75. Fava"/>
   <result pre="Ermio C. De Bartolo M. Opipari C. et al. Chronic" exact="migraine" post="in women is associated with insulin resistance: A cross-sectional"/>
   <result pre="detected in the INSR gene in a chromosome 19p13 linked" exact="migraine" post="pedigree Eur. J. Med. Genet. 2006 49 57 62"/>
   <result pre="H. Nissilä M. et al. Chromosome 19p13 loci in Finnish" exact="migraine" post="with aura families Am. J. Med. Genet. B Neuropsychiatr."/>
   <result pre="alleles in the insulin receptor gene are associated with typical" exact="migraine" post="Genomics 2001 78 135 149 10.1006/geno.2001.6647 11735220 82. Netzer"/>
   <result pre="Kubisch C. Replication study of the insulin receptor gene in" exact="migraine" post="with aura Genomics 2008 91 503 507 10.1016/j.ygeno.2008.03.006 18455362"/>
   <result pre="of ketogenesis in cultured astroglia and neurons under hypoxia and" exact="hypoglycemia" post="ASN Neuro 2014 6 1759091414550997 10.1177/1759091414550997 25290061 85. Veggiotti"/>
   <result pre="co-expression analysis identifies brain regions and cell types involved in" exact="migraine" post="pathophysiology: A GWAS-based study using the Allen Human Brain"/>
   <result pre="Montagna P. Abnormal platelet mitochondrial function in patients affected by" exact="migraine" post="with and without aura Cephalalgia Int. J. Headache 1994"/>
   <result pre="Einhäupl K.M. Arnold G. High-dose riboflavin treatment is efficacious in" exact="migraine" post="prophylaxis: An open study in a tertiary care centre"/>
   <result pre="Arbizzani A. Parmeggiani A. Riboflavin prophylaxis in pediatric and adolescent" exact="migraine" post="J. Headache Pain 2009 10 361 365 10.1007/s10194-009-0142-2 19649688"/>
   <result pre="H.-C. Danesch U. collab: Migravent ® Study Group Improvement of" exact="migraine" post="symptoms with a proprietary supplement containing riboflavin, magnesium and"/>
   <result pre="J. Jacquy J. Lenaerts M. Effectiveness of high-dose riboflavin in" exact="migraine" post="prophylaxis. A randomized controlled trial Neurology 1998 50 466"/>
   <result pre="Tarighat-Esfanjani A. Efficacy of coenzyme Q10 for the prevention of" exact="migraine" post="in women: A randomized, double-blind, placebo-controlled study Eur. J."/>
   <result pre="L. Agosti R.M. Schoenen J. Efficacy of coenzyme Q10 in" exact="migraine" post="prophylaxis: A randomized controlled trial Neurology 2005 64 713"/>
   <result pre="M. The effects of concurrent Coenzyme Q10, L-carnitine supplementation in" exact="migraine" post="prophylaxis: A randomized, placebo-controlled, double-blind trial Cephalalgia 2019 6"/>
   <result pre="Oryani M. Effectiveness of coenzyme Q10 in prophylactic treatment of" exact="migraine" post="headache: An open-label, add-on, controlled trial Acta Neurol. Belg."/>
   <result pre="Silberstein S. Open label trial of coenzyme Q10 as a" exact="migraine" post="preventive Cephalalgia 2002 22 137 141 10.1046/j.1468-2982.2002.00335.x 11972582 107."/>
   <result pre="J. A randomized double-blind placebo-controlled trial of thioctic acid in" exact="migraine" post="prophylaxis Headache 2007 47 52 57 10.1111/j.1526-4610.2006.00626.x 17355494 108."/>
   <result pre="T.G. Al-Adl N.M. Efficacy of combined topiramate/thioctic acid therapy in" exact="migraine" post="prophylaxis Saudi Pharm. J. 2010 18 239 243 10.1016/j.jsps.2010.07.006"/>
   <result pre="of vitamin supplementation and MTHFR (C677T) genotype on homocysteine-lowering and" exact="migraine" post="disability Pharmacogenet. Genom. 2009 19 422 428 10.1097/FPC.0b013e32832af5a3 111."/>
   <result pre="MTHFR C677T and MTRR A66G genes act independently to reduce" exact="migraine" post="disability in response to vitamin supplementation Pharmacogenet. Genom. 2012"/>
   <result pre="mechanism of neuroprotection by topiramate in an animal model of" exact="epilepsy" post="Epilepsia 2004 45 1478 1487 10.1111/j.0013-9580.2004.13504.x 15571505 115. Motaghinejad"/>
   <result pre="Kalita J. Misra U.K. A study of oxidative stress in" exact="migraine" post="with special reference to prophylactic therapy Int. J. Neurosci."/>
   <result pre="A ketogenic diet as a potential novel therapeutic intervention in" exact="amyotrophic lateral sclerosis" post="BMC Neurosci. 2006 7 29 16584562 127. Kelman L."/>
   <result pre="of trace elements and heavy metals in patients with acute" exact="migraine" post="headache J. Pak. Med. Assoc. 2015 65 694 697"/>
   <result pre="A. Koçyiğit A. Oxidative and antioxidative balance in patients of" exact="migraine" post="Eur. Rev. Med. Pharmacol. Sci. 2010 14 877 882"/>
   <result pre="İnan L.E. Durak İ. Yoldaş T.K. Decreased antioxidant status in" exact="migraine" post="patients with brain white matter hyperintensities Neurol. Sci. 2014"/>
   <result pre="S. Fazekas F. et al. Oxidative stress is associated with" exact="migraine" post="and migraine-related metabolic risk in females Eur. J. Neurol."/>
   <result pre="A. Topaktas S. Bakir S. Intraerythrocyte antioxidant enzyme activities in" exact="migraine" post="and tension-type headaches J. Chin. Med. Assoc. 2004 67"/>
   <result pre="Taysi S. Oxidative stress and DNA damage in patients with" exact="migraine" post="J. Headache Pain 2016 17 10 10.1186/s10194-016-0606-0 26883365 139."/>
   <result pre="Deniz O. Erel O. A novel oxidative stress marker in" exact="migraine" post="patients: Dynamic thiol-disulphide homeostasis Neurol. Sci. 2016 37 1311"/>
   <result pre="Yücel D. Increased nitrosative and oxidative stress in platelets of" exact="migraine" post="patients Tohoku J. Exp. Med. 2007 211 23 30"/>
   <result pre="biomarkers related to oxidative stress and nitric oxide pathway in" exact="migraine" post="Cephalalgia 2015 35 931 937 10.1177/0333102414564888 25573894 145. Palmirotta"/>
   <result pre="Della-Morte D. et al. Is SOD2 Ala16Val polymorphism associated with" exact="migraine" post="with aura phenotype? Antioxid. Redox Signal. 2015 22 275"/>
   <result pre="Bessone S.K. Kossoff E.H.W. The ketogenic diet in pharmacoresistant childhood" exact="epilepsy" post="Expert Rev. Neurother 2015 15 621 628 10.1586/14737175.2015.1044982 25994046"/>
   <result pre="M.R. Connors R. Evidence for a shared genetic susceptibility to" exact="migraine" post="and epilepsy Epilepsia 2013 54 288 295 10.1111/epi.12072 23294289"/>
   <result pre="R. Evidence for a shared genetic susceptibility to migraine and" exact="epilepsy" post="Epilepsia 2013 54 288 295 10.1111/epi.12072 23294289 159. Coppola"/>
   <result pre="23294289 159. Coppola G. Pierelli F. Schoenen J. Habituation and" exact="migraine" post="Neurobiol. Learn. Mem. 2009 92 249 259 10.1016/j.nlm.2008.07.006 18675928"/>
   <result pre="160. Aurora S.K. Wilkinson F. The brain is hyperexcitable in" exact="migraine" post="Cephalalgia Int. J. Headache 2007 27 1442 1453 10.1111/j.1468-2982.2007.01502.x"/>
   <result pre="Franceschetti S. Mantegazza M. Self-limited hyperexcitability: Functional effect of a" exact="familial hemiplegic migraine" post="mutation of the Nav1.1 (SCN1A) Na+ channel J. Neurosci."/>
   <result pre="Mantegazza M. Self-limited hyperexcitability: Functional effect of a familial hemiplegic" exact="migraine" post="mutation of the Nav1.1 (SCN1A) Na+ channel J. Neurosci."/>
   <result pre="reveals hyperexcitability of the temporal pole in interictal and ictal" exact="migraine" post="States Cerebral Cortex 2011 21 435 448 10.1093/cercor/bhq109 20562317"/>
   <result pre="Vicaut E. Bousser M.G. Tournier-Lasserve E. The clinical spectrum of" exact="familial hemiplegic migraine" post="associated with mutations in a neuronal calcium channel New"/>
   <result pre="Bousser M.G. Tournier-Lasserve E. The clinical spectrum of familial hemiplegic" exact="migraine" post="associated with mutations in a neuronal calcium channel New"/>
   <result pre="Mohrenweiser H.W. Bulman D.E. Ferrari M. et al. Familial hemiplegic" exact="migraine" post="and episodic ataxia type-2 are caused by mutations in"/>
   <result pre="Bulman D.E. Ferrari M. et al. Familial hemiplegic migraine and" exact="episodic ataxia" post="type-2 are caused by mutations in the Ca2+ channel"/>
   <result pre="of ATP1A2 encoding the Na+/K+ pump alpha2 subunit associated with" exact="familial hemiplegic migraine" post="type 2 Nat. Genet. 2003 33 192 196 10.1038/ng1081"/>
   <result pre="encoding the Na+/K+ pump alpha2 subunit associated with familial hemiplegic" exact="migraine" post="type 2 Nat. Genet. 2003 33 192 196 10.1038/ng1081"/>
   <result pre="al. Mutation in the neuronal voltage-gated sodium channel SCN1A in" exact="familial hemiplegic migraine" post="Lancet 2005 366 371 377 10.1016/S0140-6736(05)66786-4 16054936 169. Anttila"/>
   <result pre="in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic" exact="migraine" post="Lancet 2005 366 371 377 10.1016/S0140-6736(05)66786-4 16054936 169. Anttila"/>
   <result pre="Freilinger T. Müller-Myhsok B. et al. Genome-wide association study of" exact="migraine" post="implicates a common susceptibility variant on 8q22.1 Nat. Genet."/>
   <result pre="al. Genome-wide association study reveals three susceptibility loci for common" exact="migraine" post="in the general population Nat. Genet. 2011 43 695"/>
   <result pre="W.P.J. et al. Genome-wide association analysis identifies susceptibility loci for" exact="migraine" post="without aura Nat. Genet. 2012 44 777 782 10.1038/ng.2307"/>
   <result pre="treatment. Targeting LDH enzymes with a stiripentol analog to treat" exact="epilepsy" post="Science 2015 347 1362 1367 10.1126/science.aaa1299 25792327 179. Won"/>
   <result pre="28707585 188. Ramachandran R. Neurogenic inflammation and its role in" exact="migraine" post="Semin. Immunopathol. 2018 40 301 314 10.1007/s00281-018-0676-y 29568973 189."/>
   <result pre="CGRP as a new target in prevention and treatment of" exact="migraine" post="Lancet. Neurol. 2014 13 1065 1067 10.1016/S1474-4422(14)70228-5 25297015 190."/>
   <result pre="Vasoactive peptide release in the extracerebral circulation of humans during" exact="migraine" post="headache Ann. Neurol. 1990 28 183 187 10.1002/ana.410280213 1699472"/>
   <result pre="B. Olesen J. CGRP may play a causative role in" exact="migraine" post="Cephalalgia Int. J. Headache 2002 22 54 61 10.1046/j.1468-2982.2002.00310.x"/>
   <result pre="A. Ashina M. CGRP, a target for preventive therapy in" exact="migraine" post="and cluster headache: Systematic review of clinical data Cephalalgia"/>
   <result pre="18789357 198. Olesen J. Ashina M. Can nitric oxide induce" exact="migraine" post="in normal individuals? Cephalalgia 2015 35 1125 1129 10.1177/0333102414566201"/>
   <result pre="Sendrowski K. Anti-inflammatory plasma cytokines in children and adolescents with" exact="migraine" post="headaches Pharmacol. Rep. 2010 62 287 291 10.1016/S1734-1140(10)70268-1 20508283"/>
   <result pre="200. Longoni M. Ferrarese C. Inflammation and excitotoxicity: Role in" exact="migraine" post="pathogenesis Neurol. Sci. 2006 27 s107 s110 10.1007/s10072-006-0582-2 16688611"/>
   <result pre="M.G. Witteman B.J.M. The effects of a multispecies probiotic on" exact="migraine" post="and markers of intestinal permeability-results of a randomized placebo-controlled"/>
   <result pre="functional composition of the gut microbiota in children with severe" exact="epilepsy" post="NPJ Biofilms Microbiomes 2019 5 5 10.1038/s41522-018-0073-2 30701077 215."/>
   <result pre="Wang Y. Altered gut microbiome composition in children with refractory" exact="epilepsy" post="after ketogenic diet Epilepsy Res. 2018 145 163 168"/>
   <result pre="significant effect on imbalanced gut microbiota in infants with refractory" exact="epilepsy" post="World J. Gastroenterol 2017 23 6164 6171 10.3748/wjg.v23.i33.6164 28970732"/>
   <result pre="diet modifies the gut microbiota in a murine model of" exact="autism" post="spectrum disorder Mol. Autism 2016 7 37 10.1186/s13229-016-0099-3 27594980"/>
   <result pre="trial Trials 2019 20 61 10.1186/s13063-018-3120-7 30654835 Figure 1 Potentially" exact="migraine" post="relevant mechanisms of ketosis. ( a) Amongst key migraine"/>
   <result pre="Potentially migraine relevant mechanisms of ketosis. ( a) Amongst key" exact="migraine" post="pathophysiological mechanisms are hypometabolism, decreased glucose transport (including glucose"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6525804/results/search/disease/results.xml">
   <result pre="practice in the context of chronic widespread pain (CWP) and" exact="fibromyalgia" post="syndrome (FMS). Studies of risk markers are required considerations"/>
   <result pre="sleep, primary pain disorders, multiregional pain, physical trauma, infectious illness," exact="obesity" post="and inactivity, hypermobility of joints, iron deficiency, and small-fiber"/>
   <result pre="biomarkers, or pathological features for chronic widespread pain (CWP) and" exact="fibromyalgia" post="syndrome (FMS). Thus, in the absence of a single"/>
   <result pre="pain, and back pain [ 8], and children with one" exact="pain disorder" post="not infrequently experience multiple other pain disorders [ 9–"/>
   <result pre="[ 31] concluded that the 2010/2011 American College of Rheumatology" exact="fibromyalgia" post="criteria [ 25] had diagnostic applicability in adolescent females;"/>
   <result pre="FMS which have applied the 2016 revisions to the 2010/2011" exact="fibromyalgia" post="criteria [ 29]. The onset of juvenile FMS is"/>
   <result pre="depression in both parents, significant anxiety in her father, and" exact="migraine" post="in her maternal grandfather. Born six weeks premature. Childhood"/>
   <result pre="and headaches in early childhood, and a diagnosis of common" exact="migraine" post="several years later. Iron deficiency, though it was unknown"/>
   <result pre="as to why the expression of this young woman's chronic" exact="pain disorder" post="was relatively mild. It was apparent that she possessed"/>
   <result pre="to be secondary to CWP or FMS were excluded, including" exact="restless legs syndrome," post="low bone mineral density, and cardiovascular disease aggravation. Trauma"/>
   <result pre="excluded, including restless legs syndrome, low bone mineral density, and" exact="cardiovascular disease" post="aggravation. Trauma and infection were included because, like most"/>
   <result pre="Vehof et al. demonstrated that chronic pain syndromes, including CWP," exact="irritable bowel syndrome," post="chronic pelvic pain, and spinal pain, [ 40] shared"/>
   <result pre="coaggregated in families with reduced pressure pain thresholds and major" exact="mood disorder" post="[ 43]. 3.2. Female Sex CWP and FMS demonstrated"/>
   <result pre="The lifetime prevalence of psychiatric comorbidity, notably depression, anxiety, and" exact="bipolar disorder," post="with FMS may suggest a shared underlying pathophysiological link."/>
   <result pre="somatic syndromes were risk markers for CWP, specifically chronic fatigue," exact="irritable bowel syndrome," post="and chronic pelvic pain [ 82], and for FMS,"/>
   <result pre="and chronic pelvic pain [ 82], and for FMS, specifically" exact="migraine" post="[ 83, 84]. 3.8. Hypermobility of Joints In adolescents"/>
   <result pre="101]; however, studies in adolescents have only reported associations between" exact="obesity" post="and the prevalence and severity of knee pain and"/>
   <result pre="covariate in increasing the risk of both widespread pain and" exact="obesity" post="[ 85]. Other potential causal influences of obesity on"/>
   <result pre="pain and obesity [ 85]. Other potential causal influences of" exact="obesity" post="on CWP and FMS included physical inactivity, sleep disturbance,"/>
   <result pre="effects [ 103– 105]. 3.10. Rheumatic Conditions The 2016 revised" exact="fibromyalgia" post="criteria permitted a diagnosis of FMS in association with"/>
   <result pre="occurring in 10–30% of patients with primary rheumatic diseases, including" exact="rheumatoid arthritis" post="and systemic lupus erythematosus, to be termed secondary or"/>
   <result pre="in 10–30% of patients with primary rheumatic diseases, including rheumatoid" exact="arthritis" post="and systemic lupus erythematosus, to be termed secondary or"/>
   <result pre="of patients with primary rheumatic diseases, including rheumatoid arthritis and" exact="systemic lupus erythematosus," post="to be termed secondary or comorbid FMS. However, this"/>
   <result pre="patients with primary rheumatic diseases, including rheumatoid arthritis and systemic" exact="lupus erythematosus," post="to be termed secondary or comorbid FMS. However, this"/>
   <result pre="rest and persistent fatigue might be a causal influence. Postinfection" exact="chronic fatigue syndrome" post="is probably a more appropriate diagnostic term, especially in"/>
   <result pre="In patients with widespread pain beginning before age 21, small-fiber" exact="polyneuropathy" post="was &quot;definite&quot; in 59% and &quot;probable&quot; in 17% ["/>
   <result pre="biopsychosocial model of risk markers for chronic widespread pain and" exact="fibromyalgia" post="syndrome in young people ( Figure 1). For a"/>
   <result pre="C.-W. Pujol J. et al. Towards a neurophysiological signature for" exact="fibromyalgia" post="Pain 2017 158 1 34 47 10.1097/j.pain.0000000000000707 27583567 2"/>
   <result pre="american college of rheumatology 1990 criteria for the classification of" exact="fibromyalgia" post="Arthritis &amp;amp; Rheumatism 1990 33 2 160 172 10.1002/art.1780330203"/>
   <result pre="Smith A. J. et al. Musculoskeletal pain is associated with" exact="restless legs syndrome" post="in young adults BMC Musculoskeletal Disorder 2015 16 1"/>
   <result pre="J. Arnold L. M. McCarberg B. H. The science of" exact="fibromyalgia" post="Mayo Clinic Proceedings 2011 86 9 907 911 10.4065/mcp.2011.0206"/>
   <result pre="Gordh T. Evidence of both systemic inflammation and neuroinflammation in" exact="fibromyalgia" post="patients, as assessed by a multiplex protein panel applied"/>
   <result pre="J. Fitzcharles M.-A. et al. 2016 revisions to the 2010/2011" exact="fibromyalgia" post="diagnostic criteria Seminars in Arthritis and Rheumatism 2016 46"/>
   <result pre="al. The American college of rheumatology preliminary diagnostic criteria for" exact="fibromyalgia" post="and measurement of symptom severity Arthritis Care &amp;amp; Research"/>
   <result pre="F. How to use the new American College of Rheumatology" exact="fibromyalgia" post="diagnostic criteria Arthritis Care &amp;amp; Research 2011 63 7"/>
   <result pre="Henrickson M. Kashikar-Zuck S. 2010 American College of Rheumatology adult" exact="fibromyalgia" post="criteria for use in an adolescent female population with"/>
   <result pre="criteria for use in an adolescent female population with juvenile" exact="fibromyalgia" post="Journal of Pediatrics 2016 169 181.e1 187.e1 10.1016/j.jpeds.2015.10.011 26545727"/>
   <result pre="Sil S. et al. Long-term outcomes of adolescents with juvenile-onset" exact="fibromyalgia" post="in early adulthood Pediatrics 2014 133 3 e592 e600"/>
   <result pre="J. I. Hess E. V. et al. Family study of" exact="fibromyalgia" post="Arthritis &amp;amp; Rheumatism 2004 50 3 944 952 10.1002/art.20042"/>
   <result pre="Kang J.-H. Yim Y.-R. et al. Exploring genetic susceptibility to" exact="fibromyalgia" post="Chonnam Medical Journal 2015 51 2 58 65 10.4068/cmj.2015.51.2.58"/>
   <result pre="P. Solitar B. Dubois M. Childhood risk factors for developing" exact="fibromyalgia" post="Open Access Rheumatology: Research and Reviews 2012 109 10.2147/oarrr.s36086"/>
   <result pre="symptom intensity, depression, and somatoform dissociative symptoms in patients with" exact="fibromyalgia" post="syndrome: a single-center cohort study Journal of Trauma &amp;amp;"/>
   <result pre="Schweinhardt P. Early life adversity as a risk factor for" exact="fibromyalgia" post="in later life Pain Research and Treatment 2012 2012"/>
   <result pre="childhood maltreatment and traumatic events among Israeli patients suffering from" exact="fibromyalgia" post="and rheumatoid arthritis Pain Research and Management 2017 2017"/>
   <result pre="and traumatic events among Israeli patients suffering from fibromyalgia and" exact="rheumatoid arthritis" post="Pain Research and Management 2017 2017 8 10.1155/2017/3865249 51"/>
   <result pre="traumatic events among Israeli patients suffering from fibromyalgia and rheumatoid" exact="arthritis" post="Pain Research and Management 2017 2017 8 10.1155/2017/3865249 51"/>
   <result pre="B. Social functioning and peer relationships of adolescents with juvenile" exact="fibromyalgia" post="syndrome Arthritis &amp;amp; Rheumatism 2007 57 3 474 480"/>
   <result pre="Russell I. J. Hebert L. The prevalence and characteristics of" exact="fibromyalgia" post="in the general population Arthritis &amp;amp; Rheumatism 1995 38"/>
   <result pre="Anxiety, mood, and behavioral disorders among pediatric patients with juvenile" exact="fibromyalgia" post="syndrome Clinical Journal of Pain 2008 24 7 620"/>
   <result pre="et al. Psychiatric disorders in young adults diagnosed with juvenile" exact="fibromyalgia" post="in adolescence Journal of Rheumatology 2015 42 12 2427"/>
   <result pre="Y. Temperament and stress response in children with juvenile primary" exact="fibromyalgia" post="syndrome Arthritis &amp;amp; Rheumatism 2003 48 10 2923 2930"/>
   <result pre="al. Sleep and periodic limb movement in sleep in juvenile" exact="fibromyalgia" post="Pediatrics 2000 106 5 p. e70 10.1542/peds.106.5.e70 62 Ting"/>
   <result pre="64 Oaklander A. L. Klein M. M. Evidence of small-fiber" exact="polyneuropathy" post="in unexplained, juvenile-onset, widespread pain syndromes Pediatrics 2013 131"/>
   <result pre="Raphael K. G. Janal M. N. Nayak S. Comorbidity of" exact="fibromyalgia" post="and posttraumatic stress disorder symptoms in a community sample"/>
   <result pre="Galek A. Erbslöh-Möller B. et al. Posttraumatic stress disorder in" exact="fibromyalgia" post="syndrome: prevalence, temporal relationship between posttraumatic stress and fibromyalgia"/>
   <result pre="in fibromyalgia syndrome: prevalence, temporal relationship between posttraumatic stress and" exact="fibromyalgia" post="symptoms, and impact on clinical outcome Pain 2013 154"/>
   <result pre="E. H. S. The role of sleep in pain and" exact="fibromyalgia" post="Nature Reviews Rheumatology 2015 11 9 513 520 10.1038/nrrheum.2015.56"/>
   <result pre="Serpino C. et al. Clinical features of headache patients with" exact="fibromyalgia" post="comorbidity Journal of Headache and Pain 2011 12 6"/>
   <result pre="M. A. Affaitati G. Martelletti P. et al. Impact of" exact="migraine" post="on fibromyalgia symptoms Journal of Headache and Pain 2016"/>
   <result pre="Affaitati G. Martelletti P. et al. Impact of migraine on" exact="fibromyalgia" post="symptoms Journal of Headache and Pain 2016 17 1"/>
   <result pre="Basaran A. Ankarali H. Association between serum ferritin level and" exact="fibromyalgia" post="syndrome European Journal of Clinical Nutrition 2010 64 3"/>
   <result pre="M. Coughlan R. J. Lee J. M. High prevalence of" exact="fibromyalgia" post="in patients with HFE-related hereditary hemochromatosis Journal of Clinical"/>
   <result pre="Kao C.-H. Tsai C.-H. Tseng C.-H. Increased risk of new-onset" exact="fibromyalgia" post="among chronic osteomyelitis patients: evidence from a taiwan cohort"/>
   <result pre="C.-H. Tseng C.-H. Increased risk of new-onset fibromyalgia among chronic" exact="osteomyelitis" post="patients: evidence from a taiwan cohort study Journal of"/>
   <result pre="childhood trauma and loss of functionality in adult women with" exact="fibromyalgia" post="Trends in Psychiatry and Psychotherapy 2013 35 1 46"/>
   <result pre="Gota C. E. Kaouk S. Wilke W. S. Fibromyalgia and" exact="obesity" post="JCR: Journal of Clinical Rheumatology 2015 21 6 289"/>
   <result pre="activity to reduce systemic inflammation associated with chronic pain and" exact="obesity" post="Clinical Journal of Pain 2016 32 4 365 370"/>
   <result pre="Biopsychosocial model of risk markers for chronic widespread pain and" exact="fibromyalgia" post="syndrome in young people. Note. Risk markers for which"/>
   <result pre="high. Table 3 Risk markers for chronic widespread pain and" exact="fibromyalgia" post="in pediatric samples. Risk marker Modifiable Pain context Type"/>
   <result pre="Population 3214 Yes Norris et al. [ 63] ++++ Small-fiber" exact="polyneuropathy" post="No FMS Case series Clinic 41 No Oaklander and"/>
   <result pre="high. Table 4 Risk markers for chronic widespread pain and" exact="fibromyalgia" post="in adult samples. Risk marker Modifiable Pain context Type"/>
   <result pre="86 No Giamberardino et al. [ 84] + Overweight and" exact="obesity" post="Yes CWP Prospective population cohort Population 28,367 Yes Mundal"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6533686/results/search/disease/results.xml">
   <result pre="to a lower quality of life. There are several possible" exact="migraine" post="triggers in a patient’s environment, which should be avoided"/>
   <result pre="The objective of this Austrian monocentric study was to identify" exact="migraine" post="triggers and the areas, in which children and adolescents"/>
   <result pre="triggers and the areas, in which children and adolescents with" exact="migraine" post="have a lower quality of life than healthy, headache-free"/>
   <result pre="age was 13.00 (10.00–16.00) years. Average age of onset for" exact="migraine" post="was 9.22 ± 3.34 years. Non-migraineurs skipped trendwise fewer meals (p.adjust = 0.108) and"/>
   <result pre="functioning, the father’s nationality being Austrian might be related to" exact="migraine" post="(p.adjust = 0.108). Children with migraine had a significantly lower quality"/>
   <result pre="being Austrian might be related to migraine (p.adjust = 0.108). Children with" exact="migraine" post="had a significantly lower quality of life in school"/>
   <result pre="and had significantly less often &quot;good&quot; grades than children without" exact="migraine" post="(p.adjust = 0.048). Conclusion Children with migraine show a reduced quality"/>
   <result pre="&quot;good&quot; grades than children without migraine (p.adjust = 0.048). Conclusion Children with" exact="migraine" post="show a reduced quality of life in the areas"/>
   <result pre="of physical and emotional triggering factors, which can induce a" exact="migraine" post="attack. Physical factors that can trigger migraine are age"/>
   <result pre="can induce a migraine attack. Physical factors that can trigger" exact="migraine" post="are age [ 5– 7], comorbidities (i.e. atopic disorders"/>
   <result pre="7], comorbidities (i.e. atopic disorders [ 8], food intolerances and" exact="allergy" post="[ 9], obesity [ 10, 11], sleep disorders (sleep"/>
   <result pre="atopic disorders [ 8], food intolerances and allergy [ 9]," exact="obesity" post="[ 10, 11], sleep disorders (sleep walking, sleep talking,"/>
   <result pre="compared to their siblings [ 23], furthermore the risk of" exact="migraine" post="is increased by lack of empathy during headache attacks"/>
   <result pre="status [ 27]. School stress is the biggest predicator for" exact="migraine" post="[ 28]. In children with migraine absenteeism is increased,"/>
   <result pre="the biggest predicator for migraine [ 28]. In children with" exact="migraine" post="absenteeism is increased, whilst school performance is reduced ["/>
   <result pre="performance is reduced [ 28]. Severity, duration and frequency of" exact="migraine" post="attacks can cause poorer performance in school [ 29]."/>
   <result pre="29]. With regard to these data it becomes obvious that" exact="migraine" post="affects already pediatric patients in various areas of their"/>
   <result pre="their lives. We aimed, therefore, to analyse the impact of" exact="migraine" post="on quality of life in young children and adolescents"/>
   <result pre="that, in a single-center cohort, Austrian children and adolescents with" exact="migraine" post="have a lower quality of life than healthy controls"/>
   <result pre="specific areas of life. To collect data concerning features of" exact="migraine" post="attacks and treatment in this Austrian cohort To identify"/>
   <result pre="To identify lifestyle factors that might influence the prevalence of" exact="migraine" post="and to reveal how migraine affects the patient’s life,"/>
   <result pre="might influence the prevalence of migraine and to reveal how" exact="migraine" post="affects the patient’s life, in the areas of: (a)"/>
   <result pre="Age- and sex-matched pediatric patients, who do not suffer from" exact="migraine" post="were enrolled in this study as control group. These"/>
   <result pre="February 2016. The designed part is a survey of: (1)" exact="migraine" post="features, (2) migraine triggering factors, based on results of"/>
   <result pre="designed part is a survey of: (1) migraine features, (2)" exact="migraine" post="triggering factors, based on results of earlier studies, (3)"/>
   <result pre="based on results of earlier studies, (3) the influence of" exact="migraine" post="on the patient’s life. The part of &quot;school functioning&quot;"/>
   <result pre="or both? Headache parameters At what age did the first" exact="migraine" post="attack occur? What type of medication and how often"/>
   <result pre="all participants concerning diet in migraineurs, regarding physical exercise and" exact="migraine" post="triggering situations? What are the participants’ habits when it"/>
   <result pre="square meters? e. Is there any lack of understanding concerning" exact="migraine" post="attacks, coming from: 2. Family, including parents and siblings"/>
   <result pre="Additional self-designed questions of school functioning included: Are there more" exact="migraine" post="attacks before or after school tests? Does the patient"/>
   <result pre="daily? Does the patient smoke? Are there any problems with" exact="migraine" post="in leisure time? going-out: alcohol, drugs, clubbing, concerts, cinema"/>
   <result pre="sex, effect of sex on migraine), effect of contraceptives on" exact="migraine" post="Are there any problems with migraine associated with menstruation?"/>
   <result pre="effect of contraceptives on migraine Are there any problems with" exact="migraine" post="associated with menstruation? Ad 5. &quot;socio-economic functioning&quot;: Evaluating the"/>
   <result pre="as reference person. Ad 6. &quot;school functioning&quot;: [ 34] Does" exact="migraine" post="influence the choice of a specific education? Statistics The"/>
   <result pre="was performed to determine whether there is a relationship between" exact="migraine" post="(dependent variable) and several independent variables. These variables were:"/>
   <result pre="of 76 pediatric participants was included in the study. The" exact="migraine" post="group accounted for 37 (48.7%), the non-migraineur group 39"/>
   <result pre="of questionnaire was 13.00 years (10.00–16.00). Average age of onset in" exact="migraine" post="was 9.22 ± 3.34 years. Treatment, medical care and triggering factors of"/>
   <result pre="factors of migraineurs In the group of migraineurs ( n = 37)," exact="migraine" post="accompanying symptoms (Fig. 1) included nausea, photo- and phonophobia"/>
   <result pre="(89.2%) patients used medication, 32 (86.5%) only in case of" exact="migraine" post="attack while 2 (5.4% of) patients used preventative medication"/>
   <result pre="and 13 (35.1%) patients have visited the GP due to" exact="migraine" post="attacks since they were diagnosed. Triggering situations were indicated"/>
   <result pre="were diagnosed. Triggering situations were indicated in 30 (81.1%) of" exact="migraine" post="responses (Fig. 2). Triggering hobbies were noted in 6"/>
   <result pre="were stated by 1 (4.3%) of 23 migraineurs, sex influenced" exact="migraine" post="for the better in three (13.0%). A bad influence"/>
   <result pre="menstruation. Fig. 1 Migraine-accompanying symptoms. The percentages of symptoms accompanying" exact="migraine" post="in migraineurs are depicted Fig. 2 Migraine triggers. Certain"/>
   <result pre="are given Fig. 3 Migraine triggers in adolescents. Percentages of" exact="migraine" post="triggers when going-out are shown in 13 to 17-"/>
   <result pre="differ between the groups. Impairment in physical exercising due to" exact="migraine" post="was stated by eleven (29.7%) migraineurs. A significant relationship"/>
   <result pre="significant relationship was found between physical exercise per week and" exact="migraine" post="(χ 2 (3) = 8.091 , p = 0.045): Migraineurs exercised less often"/>
   <result pre="Socioeconomic functioning There was no relationship between maternal nationality and" exact="migraine" post="(χ 2 (1) = 0.781, p = 0.377), but their might been between"/>
   <result pre="(1) = 0.781, p = 0.377), but their might been between paternal nationality and" exact="migraine" post="(χ 2 (1) = 4.356, p = 0.037, p.adjust = 0.108): Migraineurs more often had"/>
   <result pre="17-year olds, one of 23 (4.3% of cases) stated that" exact="migraine" post="influenced the choice of education. This is underlined by"/>
   <result pre="in binomial logistic regression and therefore a causal relationship towards" exact="migraine" post="in our cohort. &quot;Paternal nationality&quot; had significant results (χ"/>
   <result pre="fathers from &quot;other country&quot; had 75.5% lower odds to have" exact="migraine" post="than children with fathers from Austria. None of the"/>
   <result pre="In literature, data on characteristics, triggering factors and impact of" exact="migraine" post="on quality of life are based on epidemiological population"/>
   <result pre="as we know this is the first report on pediatric" exact="migraine" post="patients in an Austrian cohort. To identify the impact"/>
   <result pre="conducted a monocentric, cross-sectional questionnaire study on children and adolescent" exact="migraine" post="patients and compared the results to age and sex-matched"/>
   <result pre="to reports in literature, such as a possible association of" exact="migraine" post="and gender or age [ 36, 37]. In our"/>
   <result pre="In our study, we observed the most incisive effects of" exact="migraine" post="on school performance and physical activity. School per se"/>
   <result pre="and physical activity. School per se is not only a" exact="migraine" post="triggering factor, but school performance is negatively correlated with"/>
   <result pre="school compared to non-migraineurs. Further, more than a third of" exact="migraine" post="patients thought that their grades would be better without"/>
   <result pre="(PedsQL™ 4.0) [ 38– 40]. It may be hypothesized that" exact="migraine" post="mostly affects the area of school functioning, as especially"/>
   <result pre="mostly affects the area of school functioning, as especially severe" exact="migraine" post="attacks may disable patients, sometimes for days, which renders"/>
   <result pre="accomplishing school tasks impossible. With regard to physical functioning, our" exact="migraine" post="patients exercised less often 3 or more times per"/>
   <result pre="accompanied by an impaired ability for physical exercising due to" exact="migraine" post="in one third of migraineurs and which might be"/>
   <result pre="be explained by the assumption that exercise might trigger a" exact="migraine" post="attack [ 18, 41]. Spending less time with sports"/>
   <result pre="Spending less time with sports seemed to be associated with" exact="migraine" post="in some studies [ 14, 42], even though others"/>
   <result pre="could not find any significant relation in physical inactivity and" exact="migraine" post="[ 43]. Interestingly, the spare time migraineurs had due"/>
   <result pre="or not this might be due to digital media as" exact="migraine" post="trigger remains questionable and implies the need of additional"/>
   <result pre="42]. Other groups also reported on fasting and hunger as" exact="migraine" post="triggers [ 18, 44]. This, however, was discussed controversially"/>
   <result pre="by other authors, who could not detect a correlation of" exact="migraine" post="with students skipping meals [ 14]. A link between"/>
   <result pre="physical (nausea in attack) or emotional reasons. Other factors promoting" exact="migraine" post="attacks in our patients included most commonly weather conditions,"/>
   <result pre="[ 18, 39, 42– 44]. It may be hypothesized that" exact="migraine" post="is triggered by intense changes of physical factors in"/>
   <result pre="from alcohol consumption when going out as alcoholic beverages trigger" exact="migraine" post="attacks [ 43, 45], even if the relation between"/>
   <result pre="migraine attacks [ 43, 45], even if the relation between" exact="migraine" post="and alcohol is controversially discussed in literature [ 14]."/>
   <result pre="and alcohol is controversially discussed in literature [ 14]. Finally," exact="migraine" post="influenced socio-economic areas in our patients. Interestingly, a relationship"/>
   <result pre="in our patients. Interestingly, a relationship between father’s nationality and" exact="migraine" post="was observed, as children with migraine had Austrian fathers"/>
   <result pre="between father’s nationality and migraine was observed, as children with" exact="migraine" post="had Austrian fathers significantly more often, which however was"/>
   <result pre="not found for maternal nationality. While Singh et al. described" exact="migraine" post="prevalence to be significantly higher in children with native-born,"/>
   <result pre="[ 37]. Therefore, assuming a relation between paternal nationality and" exact="migraine" post="is questionable and needs to be addressed in future"/>
   <result pre="also educational and socio-economic status of the family might influence" exact="migraine" post="in children. Parents with a low educational level have"/>
   <result pre="48]. Whether there is an association between social relationships and" exact="migraine" post="is hard to assess, due to conflicting outcomes from"/>
   <result pre="socio-economic and school functioning, compared to healthy children. Most prevalent" exact="migraine" post="triggers were weather, stress, noise, alcohol, cinema, clubbing and"/>
   <result pre="weather, stress, noise, alcohol, cinema, clubbing and concerts. In general," exact="migraine" post="triggers and implications of migraine on areas of life"/>
   <result pre="clubbing and concerts. In general, migraine triggers and implications of" exact="migraine" post="on areas of life are controversially reported on in"/>
   <result pre="approach of this study. However, our results implicate that pediatric" exact="migraine" post="patients do not only need special medical attendance but"/>
   <result pre="10.1111/head.12190 2. Gelfand A. Pathophysiology, clincal features, and diagnosis of" exact="migraine" post="in children [internet]. UpToDate, Wolters Kluwer. 2017. p. 1–13."/>
   <result pre="p. 1–13. Available from: https://www.uptodate.com/contents/pathophysiology-clinical-features-and-diagnosis-of-migraine-in-children 3. Wöber-Bingöl C Epidemiology of" exact="migraine" post="and headache in children and adolescents Curr Pain Headache"/>
   <result pre="Razak S Sivaraman B Graham C Prevalence of headache and" exact="migraine" post="in children and adolescents: a systematic review of population-based"/>
   <result pre="J et al. IHS criteria and gender: a study on" exact="migraine" post="and tension-type headache in children and adolescents Cephalalgia. 1996"/>
   <result pre="Kaleaǧasi SH et al. The prevalence of chronic and episodic" exact="migraine" post="in children and adolescents Eur J Neurol 2013 20"/>
   <result pre="JG Yee MM The diet factor in pediatric and adolescent" exact="migraine" post="Pediatr Neurol 2003 28 1 9 15 10.1016/S0887-8994(02)00466-6 12657413"/>
   <result pre="Y, Murphy R, Wall C, Mitchell EA. Risk factors for" exact="migraine" post="and tension-type headache in 11 year old children. 2014;15:60."/>
   <result pre="[Internet] 2009;106(31–32):509–16. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2735834&amp;amp;tool=pmcentrez&amp;amp;rendertype=abstract 22. Bicakci S Comorbidity of" exact="migraine" post="Noropsikiyatri Arsivi-Archives of Neuropsychiatry 2013 50 1 14 20"/>
   <result pre="A Dafer RM Stein MR et al. Childhood maltreatment and" exact="migraine" post="(part III). Association with comorbid pain conditions Headache. 2010"/>
   <result pre="C, Lang T. Psychosocial factors in children and adolescents with" exact="migraine" post="and tension-type headache: a controlled study and review of"/>
   <result pre="A Trojsi F Tessitore A Tedeschi G Lifestyle factors and" exact="migraine" post="in childhood Curr Pain Headache Rep 2016 20 2"/>
   <result pre="Diamond S Diamond ML Reed M Prevalence and burden of" exact="migraine" post="in the United States data from the American migraine"/>
   <result pre="of migraine in the United States data from the American" exact="migraine" post="study II Headache. 2001 41 646 657 10.1046/j.1526-4610.2001.041007646.x 11554952"/>
   <result pre="JG Quality of life and health-related disability in children with" exact="migraine" post="Headache. 2014 54 2 325 334 10.1111/head.12251 24512577 39."/>
   <result pre="shoulder pain in adolescents is associated with episodic and chronic" exact="migraine" post="Cephalalgia 2016 36 8 807 811 10.1177/0333102415610875 26460336 44."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6541167/results/search/disease/results.xml">
   <result pre="original author and source are credited. https://www.cureus.com/articles/18250-further-evidence-that-onabotulinum-toxin-is-a-viable-treatment-option-for-pediatric-chronic-migraine-patients Abstract Introduction Chronic" exact="migraine" post="is particularly devastating. It affects school work, extracurricular activities,"/>
   <result pre="the International Classification of Headache Disorders, 3rd edition (ICHD-3), chronic" exact="migraine" post="is defined as 15 or more headache days per"/>
   <result pre="least on eight days per month, there are features of" exact="migraine" post="headache. Although botulinum toxin type A (BoNTA) has been"/>
   <result pre="type A (BoNTA) has been proven effective for treating chronic" exact="migraine" post="in adults, little literature exists about its use in"/>
   <result pre="of 30 adolescent migraineurs who met ICHD-3 criteria for chronic" exact="migraine" post="were treated with BoNTA injection according to the standardized"/>
   <result pre="BoNTA injection was a safe and effective therapy for chronic" exact="migraine" post="in our cohort of children recalcitrant to medical therapy."/>
   <result pre="evaluate the long-term safety and efficacy in this population. chronic" exact="migraine" post="pain management pediatrics children headaches stress social health academic"/>
   <result pre="children headaches stress social health academic performance family relations pediatric" exact="migraine" post="The content published in Cureus is the result of"/>
   <result pre="all age groups. It appears that the typical onset of" exact="migraine" post="is during early to mid-adolescence. It can begin at"/>
   <result pre="any age and, unfortunately for many, this early onset of" exact="migraine" post="often continues into adulthood [ 1- 2]. Migraine headache"/>
   <result pre="shot up to 20% in older adolescents [ 9]. A" exact="migraine" post="headache in children is usually frontotemporal and an occipital"/>
   <result pre="the adult and pediatric populations, overall, the clinical presentation of" exact="migraine" post="is similar, regardless of age, and the pathophysiology is"/>
   <result pre="International Classification of Headache Disorders, 3rd edition (ICHD-3) defines chronic" exact="migraine" post="as 15 or more headache days per month for"/>
   <result pre="at least eight days per month, there are features of" exact="migraine" post="headache. The other days can also be migraine or"/>
   <result pre="features of migraine headache. The other days can also be" exact="migraine" post="or tension-type; however, at least eight days per month"/>
   <result pre="Current literature regarding pediatric headaches uses terminology such as chronic" exact="migraine" post="and chronic daily headache, including both terms in the"/>
   <result pre="5- 6, 11- 13]. For the purpose of clarity, chronic" exact="migraine" post="and chronic tension type headaches are the most frequent"/>
   <result pre="Type A (BoNTA) has been proven effective for treating chronic" exact="migraine" post="in adults, scant literature exists about its use in"/>
   <result pre="to the muscle relaxation effects mentioned above, in particular, with" exact="migraine" post="headaches. In 2014, Burstein et al. were able to"/>
   <result pre="meningeal nociceptors have an important role in the initiation of" exact="migraine" post="headaches [ 17]. Burstein et al. showed that BoNTA"/>
   <result pre="Duke pediatric neurology clinic) who met ICHD-3 criteria for chronic" exact="migraine" post="and were treated with Botox (BoNTA; Allergan, Dublin, Ireland)"/>
   <result pre="that Botox significantly decreased the severity and frequency of chronic" exact="migraine" post="headache [ 18- 19]. The head/neck region is divided"/>
   <result pre="severe range. Figure 1 Pre- and Post-Treatment Severity Discussion Chronic" exact="migraine" post="is a serious problem and can be particularly devastating,"/>
   <result pre="[ 20- 23]. There are no FDA-approved medications for chronic" exact="migraine" post="in the pediatric population. This, along with the fact"/>
   <result pre="trials, shows just how much of a challenge treating chronic" exact="migraine" post="in the pediatric population is. The American Academy of"/>
   <result pre="in producing various guidelines [ 24]. Although the pathomechanism of" exact="migraine" post="is not fully understood, there are treatments that have"/>
   <result pre="in the adult population that are not even specific for" exact="migraine" post="such as antidepressants, antiepileptics, antihistamines, calcium ion channel antagonists,"/>
   <result pre="have a basic understanding of how this toxin works in" exact="migraine" post="as opposed to some of the oral medications. Importantly,"/>
   <result pre="side effects of the use of onabotulinum in the adult" exact="migraine" post="population and among not only our retrospective study but"/>
   <result pre="be interesting to see if there is a certain chronic" exact="migraine" post="profile that would suggest that onabotulinum toxin would be"/>
   <result pre="and if this treatment would be efficacious in patients with" exact="migraine" post="variants. How the pediatric chronic migraine multimodal prevention model"/>
   <result pre="efficacious in patients with migraine variants. How the pediatric chronic" exact="migraine" post="multimodal prevention model will look in the near future"/>
   <result pre="what will the role of cGRP inhibitors be in pediatric" exact="migraine" post="prophylaxis, as it is widely utilized now in the"/>
   <result pre="prophylaxis, as it is widely utilized now in the adult" exact="migraine" post="population. Perhaps there may be an additive effect of"/>
   <result pre="frequently observed in the pediatric population. The shorter duration of" exact="migraine" post="attacks and other semeiological features of migraines in children"/>
   <result pre="BoNTA injection was a safe and effective therapy for chronic" exact="migraine" post="in our cohort of children recalcitrant to medical therapy."/>
   <result pre="studies already published, commenting on different aspects, such as chronic" exact="migraine" post="frequency, intensity, duration, and effect on quality of life,"/>
   <result pre="involve animal subjects or tissue. References References 1 Prevalence of" exact="migraine" post="headache in the United States. Relation to age, income,"/>
   <result pre="117 12 2012 22274570 6 Botulinum toxin injections for chronic" exact="migraine" post="in adolescents - an early therapeutic option in the"/>
   <result pre="82 2014 24446117 7 The epidemiology, burden, and comorbidities of" exact="migraine" post="Neurol Clin Bigal ME Lipton RB 321 334 27"/>
   <result pre="Lipton RB 321 334 27 2009 19289218 8 Epidemiology of" exact="migraine" post="and headache in children and adolescents Curr Pain Headache"/>
   <result pre="Headache Rep Wöber-Bingöl Ç 341 17 2013 23700075 9 Pediatric" exact="migraine" post="Neurol Clin Lewis D 481 501 27 2009 19289227"/>
   <result pre="481 501 27 2009 19289227 10 Similarities and differences between" exact="migraine" post="in children and adults: presentation, disability, and response to"/>
   <result pre="Powers SW 48 21 2017 29071512 11 Botox treatment for" exact="migraine" post="and chronic daily headache in adolescents J Neurosci Nurs"/>
   <result pre="meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for" exact="migraine" post="and other pains Cephalalgia Burstein R Zhang X Levy"/>
   <result pre="KR Weisman SJ 991 1002 36 2011 21 Impact of" exact="migraine" post="on the family: perspectives of people with migraine and"/>
   <result pre="Impact of migraine on the family: perspectives of people with" exact="migraine" post="and their spouse/domestic partner in the CaMEO study Mayo"/>
   <result pre="Adams AM Lipton RB 596 611 91 2016 22 Chronic" exact="migraine" post="prevalence, disability, and sociodemographic factors: results from the American"/>
   <result pre="Lipton RB 1456 1470 52 2012 22830411 23 Impact of" exact="migraine" post="on the family Headache Smith R 423 426 38"/>
   <result pre="205 11 2010 25 Preventive drugs in childhood and adolescent" exact="migraine" post="Curr Pain Headache Rep Kacperski J Hershey AD 422"/>
   <result pre="AD 422 18 2014 24760491 26 Prophylactic drug treatment of" exact="migraine" post="in children and adolescents: an update Curr Pain Headache"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6543047/results/search/disease/results.xml">
   <result pre="most common primary headaches in children and the prevalence of" exact="migraine" post="is about 8%. Accompanying sensory symptoms are common before,"/>
   <result pre="8%. Accompanying sensory symptoms are common before, during and after" exact="migraine" post="attacks. They may be a part of a wider"/>
   <result pre="study. Fifty-four children (22 boys and 32 girls) with episodic" exact="migraine" post="were prospectively recruited from pediatric neurological clinics during the"/>
   <result pre="and the Pediatric Quality of Life Inventory. Results: Children with" exact="migraine" post="showed significantly higher prevalence of sensory processing difficulties and"/>
   <result pre="difficulties predicted quality of life. Conclusion: The possible relationship between" exact="migraine" post="and sensory processing disorder or difficulties stresses the need"/>
   <result pre="need to screen for sensory processing difficulties among children with" exact="migraine" post="and when found—refer to their impacts on children's daily"/>
   <result pre="quality of life. sensory processing quality of life children headache" exact="migraine" post="fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction Headache is"/>
   <result pre="peak around 7 years old ( 7). The prevalence of" exact="migraine" post="increases from 3% in the preschool years to 4–11%"/>
   <result pre="the high school years. The mean age of onset for" exact="migraine" post="is 7 years for boys and 11 years for"/>
   <result pre="parents ( 13). Migraine in particularly is associated with increased" exact="hypersensitivity" post="to various sensory stimuli: visual, auditory, odor, and somatosensory"/>
   <result pre="more likely to have depression, anxiety disorders as well as" exact="social phobia" post="( 18) and avoidant personality disorder ( 19– 21)."/>
   <result pre="anxiety disorders as well as social phobia ( 18) and" exact="avoidant personality disorder" post="( 19– 21). Dunn's model for sensory processing may"/>
   <result pre="disorders as well as social phobia ( 18) and avoidant" exact="personality disorder" post="( 19– 21). Dunn's model for sensory processing may"/>
   <result pre="more frequent reactions to stimuli from the environment resulting in" exact="hypersensitivity" post="( 23). Nevertheless, the knowledge about the ability of"/>
   <result pre="23). Nevertheless, the knowledge about the ability of children with" exact="migraine" post="to process sensory input is limited. Since sensory processing"/>
   <result pre="25), by exploring the prevalence of SPD among children with" exact="migraine" post="and their impacts on children's quality of life, intervention"/>
   <result pre="study were: (1) Compare sensory processing abilities between children with" exact="migraine" post="and healthy controls (2) Compare the quality of life"/>
   <result pre="controls (2) Compare the quality of life between children with" exact="migraine" post="and healthy controls (3) Examine the correlations between sensory"/>
   <result pre="and healthy controls (3) Examine the correlations between sensory processing," exact="migraine" post="characteristics and severity and quality of life among children"/>
   <result pre="characteristics and severity and quality of life among children with" exact="migraine" post="(4) Examine the contribution of headache-related disability and sensory"/>
   <result pre="among children with migraine. It was hypothesized that children with" exact="migraine" post="will have more difficulties to process sensory information and"/>
   <result pre="to healthy controls; that sensory processing would correlate with enhanced" exact="migraine" post="pain and with lower quality of life and that"/>
   <result pre="12 years participated in this study. Sixty children with episodic" exact="migraine" post="were prospectively recruited from the following outpatient pediatric neurology"/>
   <result pre="1). Table 1 Participants' health and demographic information. Children with" exact="migraine" post="( n = 54) Healthy controls ( n ="/>
   <result pre="Median of headache frequency (per month) 2 Duration of episodic" exact="migraine" post="(%) 1 h 26 2 h and more 62"/>
   <result pre="evaluates by the PedMIDAS questionnaire. It was developed to assess" exact="migraine" post="disability in pediatric and adolescent patients and has been"/>
   <result pre="examination was performed during the visit. After the diagnosis of" exact="migraine" post="was made according to ICHD-3 beta ( 27), including"/>
   <result pre="migraine, Spearman correlation examined the correlations between sensory processing patterns," exact="migraine" post="characteristics/related disability and quality of life. Stepwise linear regression"/>
   <result pre="Abilities Between Children With Migraine and Healthy Controls Children with" exact="migraine" post="had lower scores (greater sensory processing difficulties) than healthy"/>
   <result pre="with Migraine and healthy controls using Mann–Whitney test. Children with" exact="migraine" post="( n = 54) Healthy controls ( n ="/>
   <result pre="on Chi square analysis, significantly higher percentage of children with" exact="migraine" post="was found in the definite difference performance range in"/>
   <result pre="HRQoL Between Children With Migraine and Healthy Controls Children with" exact="migraine" post="reported lower Health-Related Quality of Life than healthy controls."/>
   <result pre="with Migraine and healthy controls using Mann–Whitney test. Children with" exact="migraine" post="( n = 54) Healthy controls ( n ="/>
   <result pre="≤ 0.004), no significant correlations were between sensory processing and" exact="migraine" post="characteristics/related disability. However, lower physical HRQOL significantly correlated with"/>
   <result pre="found that sensory processing difficulties are prevalent among children with" exact="migraine" post="and that their quality of life is predicted by"/>
   <result pre="both headache-related disability and sensory processing difficulties. A connection between" exact="migraine" post="and sensory processing difficulties is not surprising. Patients with"/>
   <result pre="migraine and sensory processing difficulties is not surprising. Patients with" exact="migraine" post="tend to have enhanced perception of various sensory stimuli"/>
   <result pre="32, 33), and increased sensitivity to light during and between" exact="migraine" post="attacks ( 34). According to some reports, smells and"/>
   <result pre="to some reports, smells and flashing lights are triggers of" exact="migraine" post="attacks. These symptoms correlate with the findings that have"/>
   <result pre="37). Enhanced sensory sensitivity and habituation difficulties among patients with" exact="migraine" post="were also observed in studies that applied quantitative sensory"/>
   <result pre="quantitative sensory testing (QST) ( 38) noting that patients with" exact="migraine" post="may have greater reactivity to pain. The meta analysis"/>
   <result pre="by Nahman-Averbuch et al. ( 39) revealed that patients with" exact="migraine" post="present lower heat and pressure pain thresholds, higher pain"/>
   <result pre="Tyll and Noseda both ( 40, 41) suggested that sensory" exact="hypersensitivity" post="may result from activation of subcortical brain regions that"/>
   <result pre="olfactory. Mainero et al. ( 42) demonstrated that patients with" exact="migraine" post="have stronger connectivity between the ventrolateral periaqueductal gray (PAG)"/>
   <result pre="proposed ( 34, 43) that both the aura and the" exact="migraine" post="attack, may represent a form of hypersensitivity due to"/>
   <result pre="aura and the migraine attack, may represent a form of" exact="hypersensitivity" post="due to sensory processing difficulties. The present study used"/>
   <result pre="the present study, a relatively high percentage of children with" exact="migraine" post="were found to score in the &quot;definite difference&quot; range"/>
   <result pre="main outcome of the present study was that children with" exact="migraine" post="had lower quality of life in various domains as"/>
   <result pre="previous reports. For example, Powers ( 11, 12) found that" exact="migraine" post="may reduce children's QoL, and this impact may differ"/>
   <result pre="the reduction in social quality of life in children with" exact="migraine" post="and the PedMIDAS score. Nevertheless, this study not only"/>
   <result pre="score. Nevertheless, this study not only supports the relationship between" exact="migraine" post="influence and children's HRQoL, but it brings innovative information"/>
   <result pre="relevance of screening for sensory processing difficulties among children with" exact="migraine" post="and refer to their impacts on child's daily life"/>
   <result pre="and other forms of psychopathology in children, and adolescence with" exact="migraine" post="( 4, 46– 48) with respect to sensory processing"/>
   <result pre="function. By that, clinicians may reduce the negative consequences of" exact="migraine" post="and related difficulties in terms of social, academic and"/>
   <result pre="assess allodynia. Conclusions Sensory processing difficulties may characterize children with" exact="migraine" post="and reduce their quality of life. Hence, sensory processing"/>
   <result pre="The implication of these findings as regards the treatment of" exact="migraine" post="in children needs further study. Ethics Statement This study"/>
   <result pre="Holmen TL Stovner LJ Sand T . The prevalence of" exact="migraine" post="and tension-type headaches among adolescents in Norway. The Nord-Trøndelag"/>
   <result pre="S Sivarama B Graham C . Prevalence of headache and" exact="migraine" post="in children and adolescents: a systematic review of population-based"/>
   <result pre="23566020 5. Abu-Arefeh I Russell G Prevalence of headache and" exact="migraine" post="in school children. BMJ. ( 1994) 309: 765– 9."/>
   <result pre="Kay J Jaron A . Epidemiology of headache and childhood" exact="migraine" post="in an urban general practice using Ad Hoc, Vahlquist"/>
   <result pre="of anxiety and depression: is there a specific relationship with" exact="social phobia?" post="Br J Clin Psychol. ( 2002) 41: 361– 74."/>
   <result pre=". Negative childhood accounts, sensitivity, and pessimism: a study of" exact="avoidant personality disorder" post="features in college students . J Pers Disord. ("/>
   <result pre="Negative childhood accounts, sensitivity, and pessimism: a study of avoidant" exact="personality disorder" post="features in college students . J Pers Disord. ("/>
   <result pre="in leisure activities and sensory modulation deficiencies of children with" exact="atopic dermatitis" post=". Acta Paediatr. ( 2011) 100: e152– 7. 10.1111/j.1651-2227.2011.02328.x"/>
   <result pre="leisure activities and sensory modulation deficiencies of children with atopic" exact="dermatitis" post=". Acta Paediatr. ( 2011) 100: e152– 7. 10.1111/j.1651-2227.2011.02328.x"/>
   <result pre="L . The place of osmophobia and taste abnormalities in" exact="migraine" post="classification: a tertiary care study of 1237 patients ."/>
   <result pre="Somatosensory evoked high-frequency oscillations reflecting thalamo-cortical activity are decreased in" exact="migraine" post="patients between attacks . Brain. ( 2005) 128: 98–"/>
   <result pre="magnetic resonance imaging resting-state connectivity in periaqueductal gray networks in" exact="migraine" post=". Ann Neurol. ( 2011) 70: 838– 45. 10.1002/ana.22537"/>
   <result pre="of inflammatory bowel disease predict health-related quality of life in" exact="ulcerative colitis" post="and Crohn's disease . Am J Gastroenterol. ( 2002)"/>
   <result pre="inflammatory bowel disease predict health-related quality of life in ulcerative" exact="colitis" post="and Crohn's disease . Am J Gastroenterol. ( 2002)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6558181/results/search/disease/results.xml">
   <result pre="set of associated symptoms such as tinnitus, hearing loss or" exact="migraine" post="features during the attacks. Both conditions may show symptom"/>
   <result pre="recurrent vertigo associated with ipsilateral cochlear symptoms, such as fluctuating" exact="sensorineural hearing loss" post="(SNHL), tinnitus or aural pressure ( 1, 2). Vestibular"/>
   <result pre="have tinnitus during vertigo attacks, and also that 25% of" exact="migraine" post="patients suffer from hearing loss ( 7, 8). VM"/>
   <result pre="a favorable response to anti-migraine drugs, which supports an underlying" exact="migraine" post="mechanism. However, this evidence is insufficient as it is"/>
   <result pre="multiple drug effect ( 3). Moreover, a high prevalence of" exact="migraine" post="in patients with MD has been previously described, suggesting"/>
   <result pre="disease; Group 3 clustered familial MD; Group 4 associated with" exact="migraine" post="in all cases and Group 5 was found in"/>
   <result pre="cases and Group 5 was found in patients with an" exact="autoimmune disease" post="in addition to MD ( 10, 11). Additionally, Frejo"/>
   <result pre="VM patients. A significant difference was found in the prevalence" exact="autoimmune disease" post="between VM and MD, namely MDL had the highest"/>
   <result pre="VM and MD, namely MDL had the highest history of" exact="autoimmune disease" post="( p = 9.77 × 10 −3). On the"/>
   <result pre="( p = 4.43 × 10 −16), and more specifically" exact="migraine" post="episodes ( p = 1.89 × 10 −26) than"/>
   <result pre="42.9 58.3 Migraine without Aura 40 57.1 41.7 History of" exact="autoimmune disease" post="(%) 7.7 17.3 1.7 9.77 ×10 −3 Tumarkin crises"/>
   <result pre="and MD. We observed that VM patients suffer more from" exact="migraine" post="( p = 1.87 × 10 −26) and have"/>
   <result pre="4 patients, which are sporadic MD patients that suffer from" exact="migraine" post="have been described to have a significantly earlier onset"/>
   <result pre="MD patients ( 10, 11). These MD patients with comorbid" exact="migraine" post="show migraine attacks that most of times are not"/>
   <result pre="( 10, 11). These MD patients with comorbid migraine show" exact="migraine" post="attacks that most of times are not associated with"/>
   <result pre="the episodic vertigo, but the temporal relationship between vertigo and" exact="migraine" post="in MD needs to be investigated in a prospective"/>
   <result pre="Elevated levels of CCL3 have been reported in patients with" exact="migraine" post="( 21), which could support the hypothesis that VM"/>
   <result pre="( 21), which could support the hypothesis that VM shares" exact="migraine" post="mechanisms ( 3). CCL22 or MDC (Macrophage-derived chemokine) is"/>
   <result pre="disruption. Some studies have quantified cytokine levels in serum from" exact="migraine" post="patients during the attack and non-attack periods. Fidan et"/>
   <result pre="30) described an increase in TNFα, IL-4, and IL-5 in" exact="migraine" post="patients, but no differences in IL-10 and IFNγ. In"/>
   <result pre="levels were found. Therefore, a comparison between VM patients and" exact="migraine" post="patients, namely IL- 1β, CCL3, CCL22, and CXCL1 levels,"/>
   <result pre="to understand if there is a shared cytokine profile between" exact="migraine" post="and VM or if this cytokine signature is specific"/>
   <result pre="immunodeficiency disorders ( 31). Moreover, many of these diseases have" exact="sensorineural hearing loss" post="as a symptom ( 31, 32). Autoimmune inner ear"/>
   <result pre="sensorineural hearing loss as a symptom ( 31, 32). Autoimmune" exact="inner ear disease" post="(AIED) is characterized by recurrent episodes of bilateral SNHL"/>
   <result pre="hearing loss as a symptom ( 31, 32). Autoimmune inner" exact="ear disease" post="(AIED) is characterized by recurrent episodes of bilateral SNHL"/>
   <result pre="Liu YF Xu H . The intimate relationship between vestibular" exact="migraine" post="and meniere disease: a review of pathogenesis and presentation"/>
   <result pre="epidemiological study to investigate the relationship between Meniere's disease and" exact="migraine" post=". Clin Otolaryngol. ( 2016) 41: 707– 10. 10.1111/coa.12608"/>
   <result pre="Serum levels of adiponectin, CCL3 MIP-1 α, and CCL5/RANTES discriminate" exact="migraine" post="from tension-type headache patients . Arq Neuropsiquiatr. ( 2016)"/>
   <result pre="is overexpressed and aberrantly regulated in corticosteroid nonresponders with autoimmune" exact="inner ear disease" post=". J Immunol. ( 2011) 186: 1870– 9. 10.4049/jimmunol.1002275"/>
   <result pre="overexpressed and aberrantly regulated in corticosteroid nonresponders with autoimmune inner" exact="ear disease" post=". J Immunol. ( 2011) 186: 1870– 9. 10.4049/jimmunol.1002275"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6572967/results/search/disease/results.xml">
   <result pre="found in 56 (21.4%) children, while 206 (78.6%) had no" exact="refractive error." post="Out of children with ametropia, 20 (35.7%) had myopia,"/>
   <result pre="children with ametropia, 20 (35.7%) had myopia, 24 (42.8%) had" exact="astigmatism" post="and 12 (21.5%) had hypermetropia. There was no difference"/>
   <result pre="child with un-explained headache must undergo ophthalmic evaluation to diagnose" exact="refractive error," post="if any. Ametropia Headache Refractive error INTRODUCTION Patients are"/>
   <result pre="to ophthalmology department from pediatric care units for evaluation of" exact="refractive error" post="in case of headache. While there are numerous causes"/>
   <result pre="4 The international headache society has delineated headache due to" exact="refractive error" post="in a methodical manner. It shows that headache is"/>
   <result pre="methodical manner. It shows that headache is caused by uncorrected" exact="hyperopia" post="or astigmatism. The headache is usually mild, more common"/>
   <result pre="were included in the study. Children with history of squint," exact="refractive error," post="head injury, trauma, intracranial space occupying lesions, sinusitis, migraine,"/>
   <result pre="found in 56 (21.4%) children, while 206 (78.6%) had no" exact="refractive error." post="Out of children with ametropia, 20 (35.7%) had myopia,"/>
   <result pre="children with ametropia, 20 (35.7%) had myopia, 24 (42.8%) had" exact="astigmatism" post="and 12 (21.5%) had hypermetropia. The comparison of groups"/>
   <result pre="Cameron ME revealed that very few cases with headache had" exact="refractive error." post="They also found that in presbyopia and hypermetropia, headaches"/>
   <result pre="with headache had refractive error. They also found that in" exact="presbyopia" post="and hypermetropia, headaches are infrequent. They postulated that headaches"/>
   <result pre="subject including 2465 subjects revealed that majority of children with" exact="asthenopia" post="had no refractive error and estimated a pooled prevalence"/>
   <result pre="subjects revealed that majority of children with asthenopia had no" exact="refractive error" post="and estimated a pooled prevalence of ametropia of 19.7%"/>
   <result pre="non-ocular causes. 9 While majority of these are related to" exact="asthenopia" post="or refractive errors, other conditions like corneal ulcers, migraine,"/>
   <result pre="other conditions like corneal ulcers, migraine, glaucoma, giant cell arteritis," exact="idiopathic intracranial hypertension," post="sinusitis, hypertension and scleritis are also known to cause"/>
   <result pre="glaucoma, giant cell arteritis, idiopathic intracranial hypertension, sinusitis, hypertension and" exact="scleritis" post="are also known to cause headache. 10 This shows"/>
   <result pre="We included children with all sorts of headache, frontal, temporal," exact="migraine" post="like and cluster type. In a study by Gunes"/>
   <result pre="study by Gunes A and associates, it was found that" exact="migraine" post="was a common type of headache in children with"/>
   <result pre="had a normal eye examination, while refractive errors, amblyopia, and" exact="strabismus" post="were found in 15.0%, 3.6%, and 7.3%, respectively. 13"/>
   <result pre="reported in 23.1% of schoolchildren and it was concluded that" exact="asthenopia" post="was significantly associated with uncorrected visual acuity and myopia"/>
   <result pre="gem polishing industries revealed that excessive near work lead to" exact="asthenopia" post="or eye strain in as many as 32.2% children."/>
   <result pre="do not appear to be caused by ophthalmic disease, including" exact="refractive error." post="16 However, other studies have clearly described that compound"/>
   <result pre="compound and mixed types of astigmatism, anisometropia, and miscorrection of" exact="refractive error" post="were found more often in patients with headache than"/>
   <result pre="children with ametropia, 20 (35.7%) had myopia, 24 (42.8%) had" exact="astigmatism" post="and 12 (21.5%) had hypermetropia. This is in accordance"/>
   <result pre="with prevalence found by studies showing that low degrees of" exact="astigmatism" post="and anisometropia are relevant in migraine and headache. 20"/>
   <result pre="found by studies showing that low degrees of astigmatism and" exact="anisometropia" post="are relevant in migraine and headache. 20 In another"/>
   <result pre="that low degrees of astigmatism and anisometropia are relevant in" exact="migraine" post="and headache. 20 In another study conducted in Israel,"/>
   <result pre="In another study conducted in Israel, it was found that" exact="anisometropia" post="and myopia were the most common refractive errors encountered,"/>
   <result pre="myopia were the most common refractive errors encountered, followed by" exact="hyperopia" post="and astigmatism in children with headache. 21 We also"/>
   <result pre="the most common refractive errors encountered, followed by hyperopia and" exact="astigmatism" post="in children with headache. 21 We also found out"/>
   <result pre="children with un-explained headache have refractive errors. Proper evaluation of" exact="refractive error" post="and full optical correction can help in improvement in"/>
   <result pre="Bhanderi DJ Choudhary S Doshi VG A community-based study of" exact="asthenopia" post="in computer operators Indian J Ophthalmol 2008 56 51"/>
   <result pre="Vilela MA Pellanda LC Fassa AG Castagno VD Prevalence of" exact="asthenopia" post="in children:a systematic review with meta-analysis J Pediatr (Rio"/>
   <result pre="31 492 494 doi:10.3109/08820538.2014.962177 25412330 12 Orbell G Headaches and" exact="migraine" post="associated with eyestrain. Preliminary report of a trial of"/>
   <result pre="S Lennerstrand G Pansell T Rydberg A Orthoptic findings and" exact="asthenopia" post="in a population of Swedish schoolchildren aged 6 to"/>
   <result pre="262 12010381 20 Harle DE Evans BJ The correlation between" exact="migraine" post="headache and refractive errors Optom Vis Sci 2006 83"/>
   <result pre="Zghal I Ayed S et al. Full optical correction after" exact="cycloplegia" post="in headache J Fr Ophtalmol 2002 25 270 273"/>
   <result pre="EP Rolan P Why do we still not know whether" exact="refractive error" post="causes headaches?Towards a framework for evidence based practice Ophthalmic"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6582055/results/search/disease/results.xml">
   <result pre="under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Abstract Recurrent painful ophthalmoplegic" exact="neuropathy" post="is a form of cranial neuralgia and rare source"/>
   <result pre="the observed symptoms. Keywords Oculomotor nerve enhancement Recurrent painful opthalmoplegic" exact="neuropathy" post="Introduction Ophthalmoplegic neuropathy is a rare condition that is"/>
   <result pre="Keywords Oculomotor nerve enhancement Recurrent painful opthalmoplegic neuropathy Introduction Ophthalmoplegic" exact="neuropathy" post="is a rare condition that is characterized by recurrent"/>
   <result pre="exact etiology is unknown [1], [2], [3], [4]. Mydriasis and" exact="ptosis" post="are common symptoms, as the oculomotor nerve is the"/>
   <result pre="of patients have permanent neurologic deficits [5], [6], [7]. Ophthalmoplegic" exact="migraine" post="is commonly confused with migraine with visual aura, in"/>
   <result pre="deficits [5], [6], [7]. Ophthalmoplegic migraine is commonly confused with" exact="migraine" post="with visual aura, in which a patient has a"/>
   <result pre="migraine with visual aura, in which a patient has a" exact="migraine" post="headache with associated transient visual phenomena [8]. Ophthalmoplegic migraine"/>
   <result pre="a migraine headache with associated transient visual phenomena [8]. Ophthalmoplegic" exact="migraine" post="has been reclassified under cranial neuralgia in the International"/>
   <result pre="[10]]. Presented here are 2 pediatric cases of pediatric ophthalmoplegic" exact="migraine" post="with distinctive MRI findings. Case report 1 The patient"/>
   <result pre="eye redness, burning, and diplopia as well as right eye" exact="ptosis" post="for 2 days. The patient also complained of continuous"/>
   <result pre="home from school 2 days later due to new onset" exact="ptosis" post="of the right eye. He was then referred to"/>
   <result pre="normal ocular pressure. The ophthalmologist diagnosed the patient with right" exact="orbital cellulitis" post="and referred him to the emergency department for urgent"/>
   <result pre="ocular pressure. The ophthalmologist diagnosed the patient with right orbital" exact="cellulitis" post="and referred him to the emergency department for urgent"/>
   <result pre="weeks of worsening nausea, vomiting, left temporal headache, and left" exact="ptosis" post="as well as decreased appetite and 1 episode of"/>
   <result pre="therapy, and the headache had resolved on discharge. Discussion Ophthalmoplegic" exact="migraine" post="in the pediatric population is a cranial neuralgia that"/>
   <result pre="It should be noted that this entity is distinct from" exact="migraine" post="with aura, another disorder involving cephalgia with visual disturbances."/>
   <result pre="with aura, another disorder involving cephalgia with visual disturbances. In" exact="migraine" post="with visual aura, there are transient visual disturbances including"/>
   <result pre="Enhancement of the oculomotor nerve has not been reported in" exact="migraine" post="with visual aura. Improvement in enhancement of the affected"/>
   <result pre="nerve can occur with concurrent resolution of the symptoms. Ophthalmoplegic" exact="migraine" post="is likely underdiagnosed in the pediatric population without appropriate"/>
   <result pre="M.A. Anderson R.T. Brown D. Magnetic resonance imaging in ophthalmoplegic" exact="migraine" post="of children J AAPOS 5 2001 307 310 11641641"/>
   <result pre="O'Hara M.A., Anderson R.T., Brown D.Magnetic resonance imaging in ophthalmoplegic" exact="migraine" post="of children. J AAPOS2001;5: 307–310. 3 Bharucha D.X. Campbell"/>
   <result pre="H.J. Keene D.L. Jacob P. Humphreys P. Ophthalmoplegic migraine: inflammatory" exact="neuropathy" post="with secondary migraine? Can J Neurol Sci 34 3"/>
   <result pre="McMillan H.J., Keene D.L., Jacob P., Humphreys P.Ophthalmoplegic migraine: inflammatory" exact="neuropathy" post="with secondary migraine?Can J Neurol Sci. 2007;34(3):349–355. 6 Ramelli"/>
   <result pre="child with transient oculomotor paresis: a possible ause of ophthalmoplegic" exact="migraine" post="Neuropediatrics 31 2000 145 147 10963102 Ramelli G.P., Vella"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6587744/results/search/disease/results.xml">
   <result pre="equated as comparable to, or greater than, the impact of" exact="psoriasis" post="or eczema. 8 In children, the condition negatively affects"/>
   <result pre="one patient with bilateral mydriasis, dry mouth, urinary retention, and" exact="anhidrosis" post="[discontinued]; older subgroup: dry mouth [completed]; dry mouth [discontinued];"/>
   <result pre="older subgroup: dry mouth [completed]; dry mouth [discontinued]; application site" exact="rash" post="[completed]). A slightly greater proportion of GT‐treated pediatric patients"/>
   <result pre="treatment (completed). b Bilateral mydriasis, dry mouth, urinary retention, and" exact="anhidrosis" post="(discontinued) considered related to treatment. c Dry mouth (completed);"/>
   <result pre="treatment. c Dry mouth (completed); dry mouth (discontinued); application site" exact="rash" post="(completed); all events were considered related to treatment. d"/>
   <result pre="is a rare but reported occurrence in the setting of" exact="migraine" post="headaches; the patient had a history of migraines and"/>
   <result pre="patient had a history of migraines and reported a moderate" exact="migraine" post="at the time of mydriasis, which resolved at the"/>
   <result pre="and dominant vehicle (placebo) effect in the topical treatment of" exact="acne vulgaris" post=". Int J Clin Pharmacol Ther. 2012; 50( 6):"/>
   <result pre="meta‐analysis of randomized controlled trials for determining biologic efficacy in" exact="psoriasis" post="treatment . Arch Dermatol Res. 2012; 304( 9): 707‐"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6589204/results/search/disease/results.xml">
   <result pre="medium, provided the original work is properly cited. Abstract Juvenile" exact="fibromyalgia" post="(JFM) is a chronic pain syndrome with onset in"/>
   <result pre="loss, difficulty concentration, and mood disorders [ 1]. In 1992," exact="fibromyalgia" post="was recognized by the World Health Organization as a"/>
   <result pre="FM in developmental age. Few studies report rates of juvenile" exact="fibromyalgia" post="(JFM) prevalence ranging from 2% to 6% of school-aged"/>
   <result pre="with a JFM sample and one observational with a chronic" exact="migraine" post="sample. In Table 1 are reported the obtained results"/>
   <result pre="headache and JFM features, and assessment tools. 4. Discussion Juvenile" exact="fibromyalgia" post="(JFM) is commonly described as a noninflammatory chronic pain"/>
   <result pre="15– 17], there are few studies about the comorbidity between" exact="fibromyalgia" post="and migraine in the pediatric population. Some studies report"/>
   <result pre="there are few studies about the comorbidity between fibromyalgia and" exact="migraine" post="in the pediatric population. Some studies report that FM"/>
   <result pre="studied 151 patients affected by PH (47 chronic headache; 92" exact="migraine" post="without aura; 12 migraine with aura). Only 5 out"/>
   <result pre="by PH (47 chronic headache; 92 migraine without aura; 12" exact="migraine" post="with aura). Only 5 out 151 patients (0.03%) fulfilled"/>
   <result pre="central sensitivity syndromes and chronic pain disorders such us whiplash," exact="irritable bowel syndrome," post="temporomandibular syndrome, low back pain, restless legs syndrome, myofacial"/>
   <result pre="us whiplash, irritable bowel syndrome, temporomandibular syndrome, low back pain," exact="restless legs syndrome," post="myofacial pain syndrome, chronic fatigue syndrome, and osteoarthritis ["/>
   <result pre="syndrome, low back pain, restless legs syndrome, myofacial pain syndrome," exact="chronic fatigue syndrome," post="and osteoarthritis [ 14, 18– 22]. Central pain sensitization"/>
   <result pre="restless legs syndrome, myofacial pain syndrome, chronic fatigue syndrome, and" exact="osteoarthritis" post="[ 14, 18– 22]. Central pain sensitization is a"/>
   <result pre="Central pain sensitization is a process characterized by a generalized" exact="hypersensitivity" post="of the somatosensory system, and it reflects not only"/>
   <result pre="A. et al. Assessment of nonarticular tenderness and prevalence of" exact="fibromyalgia" post="in children Journal of Rheumatology 1993 20 2 368"/>
   <result pre="R. Medina-Palma C. Lavielle P. Marina F. F. Prevalence of" exact="fibromyalgia" post="in children: a clinical study of Mexican children Journal"/>
   <result pre="Fantini F. Assessment of nonarticular tenderness and prevalence of primary" exact="fibromyalgia" post="syndrome in healthy Italian schoolchildren Arthritis &amp;amp; Rheumatism 1998"/>
   <result pre="Schanberg L. E. Assessment and management of pain syndromes and" exact="arthritis" post="pain in children and adolescents Rheumatic Disease Clinics of"/>
   <result pre="Henrickson M. Kashikar-Zuck S. 2010 American College of Rheumatology adult" exact="fibromyalgia" post="criteria for use in an adolescent female population with"/>
   <result pre="criteria for use in an adolescent female population with juvenile" exact="fibromyalgia" post="Journal of Pediatrics 2016 169 181 187.e1 10.1016/j.jpeds.2015.10.011 26545727"/>
   <result pre="A. Press J. Klein M. Buskila D. Joint hypermobility and" exact="fibromyalgia" post="in schoolchildren Annals of the Rheumatic Diseases 1993 52"/>
   <result pre="et al. Psychiatric disorders in young adults diagnosed with juvenile" exact="fibromyalgia" post="in adolescence Journal of Rheumatology 2015 42 12 2427"/>
   <result pre="Anxiety, mood, and behavioral disorders among pediatric patients with juvenile" exact="fibromyalgia" post="syndrome The Clinical Journal of Pain 2008 24 7"/>
   <result pre="et al. Symptoms of central sensitization and comorbidity for juvenile" exact="fibromyalgia" post="in childhood migraine: an observational study in a tertiary"/>
   <result pre="R. B. Bendtsen L. et al. Increased pain sensitivity in" exact="migraine" post="and tension-type headache coexistent with low back pain: a"/>
   <result pre="Delussi M. Todarello O. Personality profiles and coping styles in" exact="migraine" post="patients with fibromyalgia comorbidity Comprehensive Psychiatry 2014 55 1"/>
   <result pre="O. Personality profiles and coping styles in migraine patients with" exact="fibromyalgia" post="comorbidity Comprehensive Psychiatry 2014 55 1 80 86 10.1016/j.comppsych.2013.08.006"/>
   <result pre="J. Mohabbat A. B. Stillman M. Vincent A. Frequency of" exact="migraine" post="headaches in patients with fibromyalgia Headache: The Journal of"/>
   <result pre="M. Vincent A. Frequency of migraine headaches in patients with" exact="fibromyalgia" post="Headache: The Journal of Head and Face Pain 2015"/>
   <result pre="M. A. Affaitati G. Martelletti P. et al. Impact of" exact="migraine" post="on fibromyalgia symptoms Journal of Headache and Pain 2016"/>
   <result pre="Affaitati G. Martelletti P. et al. Impact of migraine on" exact="fibromyalgia" post="symptoms Journal of Headache and Pain 2016 17 1"/>
   <result pre="B. Risko R. Cappelleri J. Sadosky A. Characterizing classes of" exact="fibromyalgia" post="within the continuum of central sensitization syndrome Journal of"/>
   <result pre="Temporomandibular disorder and cervicalgia: pathophysiology underlying the comorbidity with chronic" exact="migraine" post="Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 2019 119"/>
   <result pre="Staud R. Rodriguez M. E. Mechanisms of disease: pain in" exact="fibromyalgia" post="syndrome Nature Clinical Practice Rheumatology 2006 2 2 90"/>
   <result pre="Nardi K. Calabresi P. Sensitization, glutamate, and the link between" exact="migraine" post="and fibromyalgia Current Pain and Headache Reports 2007 11"/>
   <result pre="Calabresi P. Sensitization, glutamate, and the link between migraine and" exact="fibromyalgia" post="Current Pain and Headache Reports 2007 11 5 343"/>
   <result pre="Serpino C. et al. Clinical features of headache patients with" exact="fibromyalgia" post="comorbidity Journal of Headache and Pain 2011 12 6"/>
   <result pre="Frequency of headache (days/migraine/month) Type of primary headache: chronic migraine," exact="migraine" post="without aura, migraine with aura Allodynia Pericranial tenderness Pain"/>
   <result pre="(days/migraine/month) Type of primary headache: chronic migraine, migraine without aura," exact="migraine" post="with aura Allodynia Pericranial tenderness Pain catastrophizing Allodynia: symptoms"/>
   <result pre="JFM symptoms: widespread index, symptom severity index; quality of life:" exact="migraine" post="disability (Ped MIDAS); PedsQL; parent proxy report Sleep assessment:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6593911/results/search/disease/results.xml">
   <result pre="from 8% to 23% in the adolescence. The prevalence of" exact="migraine" post="in adolescent girls is higher. For the migraine diagnosis,"/>
   <result pre="prevalence of migraine in adolescent girls is higher. For the" exact="migraine" post="diagnosis, the imaging studies are unnecessary, and a detailed"/>
   <result pre="a 17-year-old girl with mirror movements accompanied by migraine. Child" exact="migraine" post="mirror movements The mirror movement disorder is a condition"/>
   <result pre="movements accompanied by migraine. Child migraine mirror movements The mirror" exact="movement disorder" post="is a condition in which voluntary movements on one"/>
   <result pre="with many different clinical conditions has been reported, ranging from" exact="cerebral palsy" post="to schizophrenia [ 2, 3]. This study contributes to"/>
   <result pre="clinical conditions has been reported, ranging from cerebral palsy to" exact="schizophrenia" post="[ 2, 3]. This study contributes to the relevant"/>
   <result pre="Headache Classification-3 beta (ICHD-3 beta), the patient was diagnosed with" exact="migraine" post="[ 4]. In the laboratory investigation, the hemogram, routine"/>
   <result pre="Based on the findings, the patient was diagnosed with mirror" exact="movement disorder" post="and migraine and began flunarizine treatment. During the patient’s"/>
   <result pre="findings, the patient was diagnosed with mirror movement disorder and" exact="migraine" post="and began flunarizine treatment. During the patient’s reevaluation at"/>
   <result pre="basilar invagination, chondrodystrophy, Usher syndrome, epilepsy, dystonia, stroke, Friedreich ataxia," exact="diabetes insipidus," post="phenylketonuria, and intracranial tumor [ 3, 5]. Although it"/>
   <result pre="during adolescence, and most often in girls during adolescence. The" exact="migraine" post="diagnosis is based on patient’s history and examination, which"/>
   <result pre="7]. The complaints defined by the patient were compatible with" exact="migraine" post="when evaluated according to the ICHD-3 beta. The patient’s"/>
   <result pre="Heinen F von Kries R High diagnostic stability of confirmed" exact="migraine" post="and confirmed tension-type headache according to the ICHD-3 beta"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6604354/results/search/disease/results.xml">
   <result pre="have investigated the incidence of infant colic in patients with" exact="migraine" post="and TTH. The meta-analysis was to assess the relationship"/>
   <result pre="meta-analysis was to assess the relationship between infant colic and" exact="migraine" post="as well as TTH. Methods PubMed, Web of Science,"/>
   <result pre="were calculated to determine the association between infant colic and" exact="migraine" post="as well as TTH, respectively. Results A total of"/>
   <result pre="A higher incidence of colic during infancy was revealed in" exact="migraine" post="patients than controls ( P=0.05, OR: 2.51, 95% CI:"/>
   <result pre="OR: 1.17, 95% CI: 0.73–1.89). Conclusion This meta-analysis indicated that" exact="migraine" post="was associated with increased incidence of infantile colic history,"/>
   <result pre="of frequent mild to moderate headache, but not associated with" exact="migraine" post="symptoms of nausea, vomiting, photophobia, and phonophobia. A child"/>
   <result pre="Several studies have investigated the association between infantile colic and" exact="migraine" post="as well as TTH [ 10, 11]. Patients with"/>
   <result pre="migraine as well as TTH [ 10, 11]. Patients with" exact="migraine" post="are likely to have a medical history of infant"/>
   <result pre="and an infant with colic tends to have parents with" exact="migraine" post="[ 12, 13]. And infant colic is considered to"/>
   <result pre="And infant colic is considered to be early expression of" exact="migraine" post="[ 14]. TTH and migraine exhibit similar pathogenic mechanisms,"/>
   <result pre="to be early expression of migraine [ 14]. TTH and" exact="migraine" post="exhibit similar pathogenic mechanisms, resulting from the dysfunction of"/>
   <result pre="detect the studies assessing the relationship between infantile colic and" exact="migraine" post="as well as TTH. The search terms used to"/>
   <result pre="(3) full record of the incidence of infant colic in" exact="migraine" post="or detailed information could be retrieved through contacting the"/>
   <result pre="could be retrieved through contacting the authors. The diagnosis of" exact="migraine" post="and TTH were defined according to the criteria of"/>
   <result pre="21]. All the studies compared the occurrence of colic in" exact="migraine" post="and control groups, and 2 trials of them also"/>
   <result pre="total of 3174 subjects were enrolled, of which 606 were" exact="migraine" post="sufferers, 239 were TTH patients, and 2329 were controls."/>
   <result pre="A higher incidence of colic during infancy was found in" exact="migraine" post="patients than controls ( P=0.005, OR: 2.51, 95% CI:"/>
   <result pre="Figure 3). We also analyzed the infantile colic incidence between" exact="migraine" post="and TTH subjects, and a higher incidence was also"/>
   <result pre="study with medical history from patients indicated comparable results between" exact="migraine" post="and control groups ( P=0.55). 3.3. Publication Bias Analysis"/>
   <result pre="Discussion This meta-analysis evaluated the association between infantile colic and" exact="migraine" post="as well as TTH. It indicated that migraine was"/>
   <result pre="colic and migraine as well as TTH. It indicated that" exact="migraine" post="was associated with increased incidence of infantile colic history."/>
   <result pre="little direct localization evidence. An association between infant colic and" exact="migraine" post="has been established in several studies [ 27– 29]."/>
   <result pre="29]. Our study assessed the associations between infant colic and" exact="migraine" post="as well as TTH. And we did not find"/>
   <result pre="Seven studies indicated a higher incidence of infant colic in" exact="migraine" post="patients, which is consistent with the previous trials. Bruni"/>
   <result pre="Although similarities do exist in the symptoms and treatment for" exact="migraine" post="between adults and children, some differences still can be"/>
   <result pre="adults, indicating the high proportion of psychological factors in children" exact="migraine" post="[ 30]. Also the different ways to define the"/>
   <result pre="also have a bad sleep status [ 31]. Children with" exact="migraine" post="are more likely to have colic during infancy, and"/>
   <result pre="more likely to have colic during infancy, and parents with" exact="migraine" post="are more likely to have a baby with colic"/>
   <result pre="colic [ 12, 20]. It is believed that infants with" exact="migraine" post="genetics may be more sensitive to environments than healthy"/>
   <result pre="pooling results. Also, no potential mechanisms of infant colic in" exact="migraine" post="were assessed in these studies. Further investigation on this"/>
   <result pre="on this field should be done. 5. Conclusion In conclusion," exact="migraine" post="was associated with increased incidence of infantile colic history."/>
   <result pre="10.1159/000455219 6 Abu-Arefeh I. Russell G. Prevalence of headache and" exact="migraine" post="in schoolchildren BMJ 1994 309 6957 765 769 10.1136/bmj.309.6957.765"/>
   <result pre="S. Spiri D. Marcuzzi E. et al. Association between childhood" exact="migraine" post="and history of infantile colic JAMA 2013 309 15"/>
   <result pre="the headache: infant colic as an early life expression of" exact="migraine" post="Neurology 2012 79 13 1392 1396 10.1212/wnl.0b013e31826c1b7b 22972642 13"/>
   <result pre="A. Goadsby I. E. Allen I. E. The relationship between" exact="migraine" post="and infant colic: a systematic review and meta-analysis Cephalalgia"/>
   <result pre="14 Gelfand A. A. Episodic syndromes of childhood associated with" exact="migraine" post="Current Opinion in Neurology 2018 31 3 281 285"/>
   <result pre="Cigaran-Mendez M. Navarro-Pardo E. Sleep disturbances in tension-type headache and" exact="migraine" post="Therapeutic Advances in Neurological Disorders 2018 11 10.1177/1756285617745444 16"/>
   <result pre="Torres-Hinojal M. C. Redondo P. Fernández-Salazar L. Natural history of" exact="irritable bowel syndrome" post="Pediatrics International 2013 55 2 204 207 10.1111/ped.12028 23253156"/>
   <result pre="2017 11 3 37 41 24 Gelfand A. A. Childhood" exact="migraine" post="is associated with a history of infantile colic Journal"/>
   <result pre="A. Buse D. C. Grimes B. Goadsby P. J. Mothers’" exact="migraine" post="associated with infant colic, but not fathers’ Headache 2017"/>
   <result pre="Holroyd K. Drew J. Behavioral approaches to the treatment of" exact="migraine" post="Seminars in Neurology 2006 26 2 199 207 10.1055/s-2006-939920"/>
   <result pre="Lee J. T et al. Associations between sleep quality and" exact="migraine" post="frequency: a cross-sectional case-control study Medicine (Baltimore) 2016 95"/>
   <result pre="10.1097/md.0000000000003554 32 Spiri D. Rinaldi V. E. Titomanlio L. Pediatric" exact="migraine" post="and episodic syndromes that may be associated with migraine"/>
   <result pre="Pediatric migraine and episodic syndromes that may be associated with" exact="migraine" post="Italian Journal of Pediatrics 2014 40 1 p. 92"/>
   <result pre="2 df I 2 (%) P- Q test Colic in" exact="migraine" post="7 0.005 2.51 [1.32, 4.77] 44.14 6 86 &amp;lt;0.00001"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6613423/results/search/disease/results.xml">
   <result pre="the identical terms. Abstract Objectives: More than just a headache," exact="migraine" post="attack is a severe, prolonged head pain preceded and/or"/>
   <result pre="a proper diagnosis will be the most challenging step of" exact="migraine" post="care. When cranial autonomic symptoms (CASs), and/or neck pain"/>
   <result pre="study was to investigate the frequency of these symptoms in" exact="migraine" post="and to compare the clinical characteristics of patients with"/>
   <result pre="patients who were referred to our tertiary teaching hospital with" exact="migraine" post="were enrolled. Results: A total of 170 children, 61"/>
   <result pre="common nature of CASs and neck pain/stiffness in children with" exact="migraine" post="to prevent unnecessary procedures. High frequency of migrain attacks"/>
   <result pre="frequency of CAS and neck pain. Keywords: Cranial autonomic symptoms" exact="migraine" post="neck pain pediatrics I NTRODUCTION Migraine headaches are common"/>
   <result pre="characteristic of trigeminal autonomic headaches, although studies in patients with" exact="migraine" post="have shown that cranial autonomic manifestations may be accompanied"/>
   <result pre="allergic symptom. Failure to be aware of CASs associated with" exact="migraine" post="may cause physicians to misdiagnose. Newly, in the reports"/>
   <result pre="the International Classification of Headache Disorders (ICHD-3), a comment that" exact="migraine" post="attacks can be associated with CASs was added.[ 1]"/>
   <result pre="1] In addition to the headache phase of the migraine," exact="migraine" post="attack may also consist of prodromal, aura, and postdromal"/>
   <result pre="features, accompanying CAS and neck pain in pediatric patients with" exact="migraine" post="who were referred to our tertiary teaching hospital. It"/>
   <result pre="failure to recognize these symptoms as a part of on-going" exact="migraine" post="clinics which may lead to unnecessary investigations. M ATERIALS"/>
   <result pre="2016 to March 2017 and meeting the diagnostic criteria for" exact="migraine" post="according to the ICHD-3 were enrolled. A semi-structured questionnaire"/>
   <result pre="appropriate. R ESULTS One hundred and seventy patients diagnosed with" exact="migraine" post="according to the ICHD III criteria[ 1] were enrolled."/>
   <result pre="age of the patients was 13.1 ± 3.4 years. Episodic" exact="migraine" post="was diagnosed in 97 patients (57%) and chronic migraine"/>
   <result pre="Episodic migraine was diagnosed in 97 patients (57%) and chronic" exact="migraine" post="was diagnosed in 73 patients (43%). Aura was reported"/>
   <result pre="(30%) and bilateral in 119 patients (70%). Family history of" exact="migraine" post="was present in 109 patients (64.3%). Vertigo was reported"/>
   <result pre="neck pain. Table 1 Type of cranial autonomic symptoms in" exact="migraine" post="CAS (one symptom), n=31 n (%) CAS (more than"/>
   <result pre="brain dysfunction with systemic manifestations. Headache is the tip of" exact="migraine" post="iceberg. Migraine patients often see multiple physicians for multiple"/>
   <result pre="our study, we found that 40% of the patients with" exact="migraine" post="had CAS, of which 35% were exposed to skin"/>
   <result pre="allergic disorders. Recognition of CAS as a common component of" exact="migraine" post="is important. Conjunctival injection, lacrimation (or both), nasal congestion,"/>
   <result pre="edema, forehead and facial sweating, forehead/facial flushing, and/or miosis and" exact="ptosis" post="were included in the ICHD-II.[ 9] In ICHD-III, aural"/>
   <result pre="added as a CAS.[ 1] The incidence of CAS in" exact="migraine" post="reported in different studies ranges from 27% to 73%.["/>
   <result pre="migraine.[ 2] Previously, in an Italian study involving patients with" exact="migraine" post="from a tertiary referral headache center, unilateral autonomic features"/>
   <result pre="at least one autonomic symptom. In this study, CAS in" exact="migraine" post="was reported more likely to be bilateral and less"/>
   <result pre="lacrimation were the most frequent symptoms in our patients with" exact="migraine" post="and CAS. In our study, these symptoms were generally"/>
   <result pre="misdiagnosed as a component of allergic diseases, and testing for" exact="allergy" post="was performed in 35% of the patients with CAS."/>
   <result pre="performed in 35% of the patients with CAS. Misdiagnosis of" exact="migraine" post="as a sinus headache is common.[ 15 16 17]"/>
   <result pre="Study II, showed that many people who were diagnosed with" exact="migraine" post="thought they had &quot;sinus&quot; headache. In this study, only"/>
   <result pre="In this study, only about 50% who were diagnosed with" exact="migraine" post="knew they had migraine before the study. CAS during"/>
   <result pre="about 50% who were diagnosed with migraine knew they had" exact="migraine" post="before the study. CAS during headaches was present in"/>
   <result pre="headache was also the most common diagnosis by allergists (38%)," exact="allergy" post="was diagnosed in nearly 25% of the patients by"/>
   <result pre="of 113 patients found that neck pain occurred with the" exact="migraine" post="attacks more often than nausea, even though nausea is"/>
   <result pre="In a large population study from Spain, individuals with self-reported" exact="migraine" post="were approximately 2 and 3 times more likely to"/>
   <result pre="the United States, 38% of individuals with severe headache or" exact="migraine" post="assessed by self-report had neck pain in the past"/>
   <result pre="without neck pain/stiffness, indicating a possible shared pathophysiological mechanism with" exact="migraine" post="and CAS. Kelman et al. also reported that CAS"/>
   <result pre="pain; also pragmatic therapies and exercise were advised instead of" exact="migraine" post="therapy. The strength of the present study is that"/>
   <result pre="The first step can be rising the awareness of the" exact="migraine" post="symptoms by both health-care providers and the caregivers of"/>
   <result pre="group, CAS and neck pain/stiffness can be observed during the" exact="migraine" post="clinic. We found that pediatric patients with frequent migraine"/>
   <result pre="the migraine clinic. We found that pediatric patients with frequent" exact="migraine" post="attacks can also have high frequency of CAS and"/>
   <result pre="and by ignoring these symptoms as a clinical part of" exact="migraine" post="and making unnecessary investigations produces an economic burden. Financial"/>
   <result pre="AE Çomoǧlu SS Unilateral cranial autonomic symptoms in patients with" exact="migraine" post="Acta Neurol Belg 2013 113 237 42 23160810 5"/>
   <result pre="Monteith T Schankin CJ Goadsby PJ The premonitory phase of" exact="migraine" post="– What can we learn from it? Headache 2015"/>
   <result pre="M Vanacore N Cerbo R Unilateral cranial autonomic symptoms in" exact="migraine" post="Cephalalgia 2002 22 256 9 12100086 11 Lai TH"/>
   <result pre="12 Goadsby PJ Lacrimation, conjunctival injection, nasal symptoms. Cluster headache," exact="migraine" post="and cranial autonomic symptoms in primary headache disorders –"/>
   <result pre="AA Reider AC Goadsby PJ Cranial autonomic symptoms in pediatric" exact="migraine" post="are the rule, not the exception Neurology 2013 81"/>
   <result pre="18219442 16 Eross E Dodick D Eross M The sinus," exact="allergy" post="and migraine study (SAMS) Headache 2007 47 213 24"/>
   <result pre="Eross E Dodick D Eross M The sinus, allergy and" exact="migraine" post="study (SAMS) Headache 2007 47 213 24 17300361 17"/>
   <result pre="Nie Y et al. The prevalence of neck pain in" exact="migraine" post="Headache 2010 50 1273 7 20100298 19 Fernández-de-Las-Peñas C"/>
   <result pre="C Palacios-Ceña D Jiménez-Sánchez S et al. Population-based study of" exact="migraine" post="in spanish adults: Relation to socio-demographic factors, lifestyle and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6620449/results/search/disease/results.xml">
   <result pre="comprised 36 with epilepsy, 6 with headache, and 2 with" exact="cerebral infarction." post="Thirty-one of the 36 epileptic patients showed definite partial"/>
   <result pre="findings were normal in all patients except for five with" exact="periventricular leukomalacia" post="unrelated to seizure symptoms. There was agreement between mIP"/>
   <result pre="excellent lateralizing indicator in pediatric patients with partial epilepsy. focal" exact="epilepsy" post="minimum intensity projection susceptibility-weighted imaging INTRODUCTION Susceptibility-weighted imaging (SWI)"/>
   <result pre="and hypoparathyroidism. 7 Identifying the epileptogenic zone when managing focal" exact="epilepsy" post="is very important in the diagnosis of epilepsy and"/>
   <result pre="managing focal epilepsy is very important in the diagnosis of" exact="epilepsy" post="and the planning of future treatment. Efforts have been"/>
   <result pre="had epilepsy, 6 (13.6%) had headache, and 2 (4.5%) had" exact="cerebral infarction." post="The 36 patients diagnosed with epilepsy comprised 28 (77.8%)"/>
   <result pre="2 (4.5%) had cerebral infarction. The 36 patients diagnosed with" exact="epilepsy" post="comprised 28 (77.8%) with complex partial seizures, 6 (16.7%)"/>
   <result pre="comprised 28 (77.8%) with complex partial seizures, 6 (16.7%) with" exact="status epilepticus," post="and 2 (5.6%) with febrile convulsion. Thirty-one of the"/>
   <result pre="6 headache patients had MRI abnormalities, with a diagnosis of" exact="moyamoya disease." post="The headache patients complained of headache in the right"/>
   <result pre="periorbital, left temporal, and left frontolateral areas. Two patients with" exact="cerebral infarction" post="were found to have right-sided weakness and left-sided head-turning"/>
   <result pre="with seizures confirmed by EEG. The 31 patients with focal" exact="epilepsy" post="who showed concordance between semiology and mIP abnormality included"/>
   <result pre="same-side EEG abnormalities. Among 6 headache patients comprising 5 with" exact="migraine" post="and 1 with moyamoya disease, 5 (80%) showed concordance"/>
   <result pre="6 headache patients comprising 5 with migraine and 1 with" exact="moyamoya disease," post="5 (80%) showed concordance between mIP abnormalities and clinical"/>
   <result pre="and EEG abnormalities were concordant in the 2 cases of" exact="cerebral infarction." post="DISCUSSION The occurrences of epilepsy and their locations are"/>
   <result pre="the 2 cases of cerebral infarction. DISCUSSION The occurrences of" exact="epilepsy" post="and their locations are very important factors to consider"/>
   <result pre="the sensitivities of SPECT in localizing the epileptogenic focus in" exact="temporal lobe epilepsy" post="were 44%, 75%, and 97% for interictal, postictal, and"/>
   <result pre="of SPECT in localizing the epileptogenic focus in temporal lobe" exact="epilepsy" post="were 44%, 75%, and 97% for interictal, postictal, and"/>
   <result pre="epilepsy were 44%, 75%, and 97% for interictal, postictal, and" exact="temporal lobe epilepsy." post="15 The increased cerebral blood flow that is inevitable"/>
   <result pre="idiopathic. These symptomatic causes such as ischemic stroke, mitochondrial encephalopathy," exact="lactic acidosis," post="and stroke-like episodes, or infarction can induce cerebral vascular"/>
   <result pre="patients like ours could not obstruct the blood flow. Most" exact="epilepsy" post="events are unpredictable, and so epileptic patients are often"/>
   <result pre="in mIP images of bilateral hemispheres in patients with generalized" exact="epilepsy" post="(data not shown). We expect that these findings would"/>
   <result pre="activities in semiology, of which 29 (93.5%) patients with focal" exact="epilepsy" post="had increased venous vascularity at the site, consistent with"/>
   <result pre="epileptic patients. Eleven (35.5%) of the 31 patients with focal" exact="epilepsy" post="who showed concordance between seizure semiology and mIP abnormality"/>
   <result pre="them. Brain MRI mIP images could be useful for assessing" exact="epilepsy" post="localization as an alternative to EEG and conventional brain"/>
   <result pre="Sehgal V Hu J et al. Characterizing iron deposition in" exact="multiple sclerosis" post="lesions using susceptibility weighted imaging J Magn Reson Imaging"/>
   <result pre="Springer E Schindler K et al. Focal hemodynamic patterns of" exact="status epilepticus" post="detected by susceptibility weighted imaging (SWI) Eur Radiol 2014"/>
   <result pre="176 24262343 Fig. 1 Brain images of patients with Focal" exact="epilepsy" post="on brain MRI and ImageJ. There were no specific"/>
   <result pre="Changes in mIP image over time after seizure in focal" exact="epilepsy" post="patients. The initial MRI mIP image obtained 3 hours"/>
   <result pre="onset of seizures in a patient with right occipital lobe" exact="epilepsy" post="showed an increase in venous vascularity (arrow) in the"/>
   <result pre="infarction 2 (4.5) *The six headache patients comprised five with" exact="migraine" post="and one with moyamoya disease. Table 2 Concordance between"/>
   <result pre="six headache patients comprised five with migraine and one with" exact="moyamoya disease." post="Table 2 Concordance between seizure semiology (focal signs) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6629194/results/search/disease/results.xml">
   <result pre="Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License. Abstract SUMMARY Hereditary" exact="angioedema" post="(HAE) is a rare autosomal dominant disease with deficiency"/>
   <result pre="HAE is still underdiagnosed in pediatric population. Key words: Hereditary" exact="angioedema" post="types I and II – diagnosis Complement C1 inhibitor"/>
   <result pre="– diagnosis Complement C1 inhibitor protein Child Croatia Introduction Hereditary" exact="angioedema" post="(HAE) due to C1 inhibitor deficiency (C1-INH-HAE) is a"/>
   <result pre="). In some patients with a normal level of C1-INH," exact="angioedema" post="is related to mutation in coagulation factor XII gene"/>
   <result pre="(HAE-FXII), plasminogen (HAE-PLG) and angiopoetin-1 (HAE-ANGPT1), or the cause of" exact="angioedema" post="remains unknown (U-HAE) ( 2 , 4 ). All"/>
   <result pre="also affect genitalia, urinary bladder, muscles, joints, or can cause" exact="migraine" post="or visual disturbances and headache ( 8 ). The"/>
   <result pre="be early established and also considered in patients experiencing recurrent" exact="angioedema" post="with poor response to epinephrine, glucocorticoids and antihistamines, since"/>
   <result pre="Some children may develop prodromal nonpruritic rash, erythema marginatum, but" exact="urticaria" post="with itching at any age practically excludes HAE diagnosis"/>
   <result pre="to asphyxiation, such as hoarseness, lump in the throat or" exact="shortness" post="of breath, is crucial. Endoscopy procedures or operations in"/>
   <result pre="assistance. References References 1 Zuraw BL Christiansen SC Pathophysiology of" exact="hereditary angioedema." post="Am J Rhinol Allergy. 2011; 25( 6): 373– 8."/>
   <result pre="K et al. Defective glycosylation of coagulation factor XII underlies" exact="hereditary angioedema" post="type III. J Clin Invest. 2015; 125( 8): 3132–"/>
   <result pre="et al. Defective glycosylation of coagulation factor XII underlies hereditary" exact="angioedema" post="type III. J Clin Invest. 2015; 125( 8): 3132–"/>
   <result pre="10.1160/TH12-08-0549 23306453 7 Kaplan AP Bradykinin and the pathogenesis of" exact="hereditary angioedema." post="World Allergy Organ J. 2011; 4( 4): 73– 5."/>
   <result pre="119( 3): 267– 74. 10.1016/j.amjmed.2005.09.064 16490473 9 Farkas H Pediatric" exact="hereditary angioedema" post="due to C1-inhibitor deficiency. Allergy Asthma Clin Immunol. 2010;"/>
   <result pre="3): 267– 74. 10.1016/j.amjmed.2005.09.064 16490473 9 Farkas H Pediatric hereditary" exact="angioedema" post="due to C1-inhibitor deficiency. Allergy Asthma Clin Immunol. 2010;"/>
   <result pre="P Silar M Zidarn M Miljkovic J Kosnik M Hereditary" exact="angioedema" post="nationwide study in Slovenia reveals four novel mutations in"/>
   <result pre="of laryngeal edema with C1 inhibitor concentrate in patients with" exact="hereditary angioedema." post="Arch Intern Med. 2001; 161( 5): 714– 8. 10.1001/archinte.161.5.714"/>
   <result pre="death from asphyxiation after tooth extraction in four patients with" exact="hereditary angioedema." post="J Am Dent Assoc. 2003; 134( 8): 1088– 94."/>
   <result pre="consensus on the diagnosis and management of pediatric patients with" exact="hereditary angioedema" post="with C1 inhibitor deficiency. Allergy. 2016; 72( 2): 300–"/>
   <result pre="on the diagnosis and management of pediatric patients with hereditary" exact="angioedema" post="with C1 inhibitor deficiency. Allergy. 2016; 72( 2): 300–"/>
   <result pre="S et al. Guidelines for the diagnosis and treatment of" exact="hereditary angioedema." post="Lijec Vjesn. 2014; 136( 5-6): 117– 29. [Smjernice za"/>
   <result pre="clinical guidelines in the United States for the diagnosis of" exact="hereditary angioedema" post="and the screening of family members of affected patients?"/>
   <result pre="guidelines in the United States for the diagnosis of hereditary" exact="angioedema" post="and the screening of family members of affected patients?"/>
   <result pre="Sofia S Casali A Bolondi L Sonographic findings in abdominal" exact="hereditary angioedema." post="J Clin Ultrasound. 1999; 27( 9): 537– 40. 10.1002/(SICI)1097-0096(199911/12)27:9&amp;lt;537::AID-JCU9&amp;gt;3.0.CO;2-L"/>
   <result pre="International consensus algorithm for the diagnosis, therapy and management of" exact="hereditary angioedema." post="Allergy Asthma Clin Immunol. 2010; 6( 1): 24. 10.1186/1710-1492-6-24"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6631099/results/search/disease/results.xml">
   <result pre="the second-most disabling disease worldwide, and the second most common" exact="neurological disorder." post="Attacks can last many hours or days, and consist"/>
   <result pre="days, and consist of multiple symptoms including headache, nausea, vomiting," exact="hypersensitivity" post="to stimuli such as light and sound, and in"/>
   <result pre="in some cases, an aura is present. Mechanisms contributing to" exact="migraine" post="are still poorly understood. However, transient receptor potential (TRP)"/>
   <result pre="to calcitonin gene-related peptide (CGRP), a neuropeptide strongly implicated in" exact="migraine" post="pathophysiology. Discussion will then focus on recent developments in"/>
   <result pre="in preclinical and clinical studies that implicate TRP channels in" exact="migraine" post="pathophysiology or in the efficacy of therapeutics. Given the"/>
   <result pre="prevalence in reproductive age for both genders [ 2]. Importantly," exact="migraine" post="is the most common severe primary headache, characterized by"/>
   <result pre="sound [ 1]. In current clinical practice, diagnosis of a" exact="migraine" post="is made in accordance to the criteria of the"/>
   <result pre="[ 3], which also allow the homogenous identification of the" exact="migraine" post="phenotype worldwide for research purposes. According to the current"/>
   <result pre="the International Classification of Headache Disorders (ICHD-3) [ 3], the" exact="migraine" post="can be with or without an aura (i.e., transient"/>
   <result pre="Disease (GBD) study, promoted by the World Health Organization, reported" exact="migraine" post="as the most disabling neurological disorder, and the second"/>
   <result pre="the World Health Organization, reported migraine as the most disabling" exact="neurological disorder," post="and the second leading cause of years lived with"/>
   <result pre="causes a significant socio-economic burden. In the European Union, where" exact="migraine" post="is estimated to affect 75 million patients, each year"/>
   <result pre="Migraine: Therapeutics and Pathophysiology Therapeutic options for the treatment of" exact="migraine" post="include drugs for both the attacks, aimed to abort"/>
   <result pre="nortriptyline), but there are also some drugs used only with" exact="migraine" post="prevention objectives, such as flunarizine and pizotifene [ 1]."/>
   <result pre="of onabotulinum toxin A (BoNTA) among the recommended drugs for" exact="migraine" post="prevention, but only for chronic patients [ 6, 7]."/>
   <result pre="only for chronic patients [ 6, 7]. Mechanisms contributing to" exact="migraine" post="are multifactorial, complex, and not yet completely clarified ["/>
   <result pre="that has counter posed the neuronal and the vascular theory," exact="migraine" post="is now considered a neurovascular disorder, with a primary"/>
   <result pre="According to the expression pattern, alpha-CGRP is primarily involved in" exact="migraine" post="pathogenesis. CGRP acts via a G protein-coupled receptor constituted"/>
   <result pre="clinical evidence has accumulated supporting a role of CGRP in" exact="migraine" post="mechanisms. First, CGRP levels are increased during a migraine"/>
   <result pre="in migraine mechanisms. First, CGRP levels are increased during a" exact="migraine" post="attack [ 19] and in chronic migraine patients also"/>
   <result pre="increased during a migraine attack [ 19] and in chronic" exact="migraine" post="patients also in the pain-free interval [ 20], returning"/>
   <result pre="Second, intravenous infusion of CGRP can induce migraine-like attacks in" exact="migraine" post="patients [ 25, 26]. Third, animal data suggest that"/>
   <result pre="a parallel of human photophobia, a phenomenon typically reported during" exact="migraine" post="attack [ 27]. According to the abovementioned evidence, CGRP"/>
   <result pre="Pain While the mechanisms leading to the pain phase of" exact="migraine" post="are unclear, the most likely explanation is that activation"/>
   <result pre="46]. Dilation of meningeal vessels on the headache side during" exact="migraine" post="attacks triggered by cilostazol has recently been found, a"/>
   <result pre="the extracellular events within the tissues themselves that occur during" exact="migraine" post="attacks and the receptors expressed on nociceptors that respond"/>
   <result pre="Reasons for the interest in a TRP channel contribution to" exact="migraine" post="are largely due to their expression on meningeal nociceptors"/>
   <result pre="endogenous and exogenous stimuli that may be of relevance to" exact="migraine" post="attacks ( Figure 1). Further, activation of TRP channels"/>
   <result pre="[ 15, 51, 52]. Given the role of CGRP in" exact="migraine" post="described above, and the as yet unclear mechanism by"/>
   <result pre="number of reviews on the topic of TRP channels and" exact="migraine" post="have been published in recent years documenting the evidence"/>
   <result pre="here, while the focus will be on newer TRP channel" exact="migraine" post="studies. 4.1. TRPV1 Based primarily on preclinical animal studies,"/>
   <result pre="among other factors many of which may be relevant for" exact="migraine" post="[ 48]. TRPV1 was hypothesized to be present on"/>
   <result pre="fibers in the arterial wall of scalp vessels from chronic" exact="migraine" post="patients, where channel expression was higher compared to healthy"/>
   <result pre="[ 61]. Mechanisms leading to increased TRPV1 expression in chronic" exact="migraine" post="patients are unclear, but preclinical studies using repeated 30-day"/>
   <result pre="found increased TRPV1 (and TRPA1) in the trigeminal ganglia, so" exact="migraine" post="itself may upregulate the channel and/or migraine therapeutics may"/>
   <result pre="trigeminal ganglia, so migraine itself may upregulate the channel and/or" exact="migraine" post="therapeutics may also have this potential [ 62]. There"/>
   <result pre="capsaicin-induced meningeal blood flow changes in the presence of diet-induced" exact="obesity" post="[ 63] in mice and suggest a role for"/>
   <result pre="a role for TRPV1 signaling in the increased prevalence of" exact="migraine" post="with obesity (consistent with the increase in capsaicin-induced nociception"/>
   <result pre="for TRPV1 signaling in the increased prevalence of migraine with" exact="obesity" post="(consistent with the increase in capsaicin-induced nociception and photophobia"/>
   <result pre="(consistent with the increase in capsaicin-induced nociception and photophobia with" exact="obesity" post="[ 64]; a similar finding was also seen with"/>
   <result pre="dermal blood flow was seen in female (but not male)" exact="migraine" post="patients compared to controls, suggesting that changes occur in"/>
   <result pre="suggesting that changes occur in TRPV1 fiber neurovascular responses in" exact="migraine" post="[ 67]; similar changes in migraine patients in capsaicin-induced"/>
   <result pre="fiber neurovascular responses in migraine [ 67]; similar changes in" exact="migraine" post="patients in capsaicin-induced dermal blood flow were also recently"/>
   <result pre="by which TRPV1 may be activated in the meninges during" exact="migraine" post="attacks, they only show that the function of the"/>
   <result pre="(CSD), which is thought to be the underlying basis of" exact="migraine" post="aura and has been shown to activate meningeal nociceptors"/>
   <result pre="implicate [ 73] changes in meningeal immune cell function during" exact="migraine" post="as one mechanism of activation of dural nociceptors. Ultimately,"/>
   <result pre="in headache, the TRPV1 antagonist SB-705498 failed in a clinical" exact="migraine" post="study [ 74]. This does not exclude a possibility"/>
   <result pre="74]. This does not exclude a possibility for TRPV1 in" exact="migraine" post="pathology, but it casts serious doubt on selective TRPV1"/>
   <result pre="mechanosensory complex. It is thus interesting in the context of" exact="migraine" post="as headache is known to be influenced by changes"/>
   <result pre="has also been the subject of much interest in the" exact="migraine" post="community, initially based on the repeated identification of single-nucleotide"/>
   <result pre="TRPM8 in migraine. The context of channel activation during native" exact="migraine" post="attacks is not yet clear, so it remains unknown"/>
   <result pre="on a novel TRPM8 antagonist proposed to be tested for" exact="migraine" post="[ 95]. One of the more intriguing studies related"/>
   <result pre="One of the more intriguing studies related to TRPM8 and" exact="migraine" post="in recent years was the finding that the TRPM8"/>
   <result pre="T at chr2:234835093), which has been identified in GWAS of" exact="migraine" post="populations [ 53], is differentially expressed across the Earth"/>
   <result pre="who carry the T;T allele have a higher risk of" exact="migraine" post="than those carrying the rarer versions C;C or C;T"/>
   <result pre="to be predicted by a latitudinal cline, suggesting that human" exact="migraine" post="to the colder climates of Northern Europe introduced positive-selection"/>
   <result pre="climates, lower in warmer climates) matches with the epidemiology of" exact="migraine" post="which shows higher prevalence in Europe, lower prevalence in"/>
   <result pre="(see [ 99, 100, 101]), investigation of this channel in" exact="migraine" post="expanded following a couple of key studies. One was"/>
   <result pre="other key study leading to increased interest in TRPA1 and" exact="migraine" post="was the finding that this channel mediates the vasodilatory"/>
   <result pre="and TRPV1 activation [ 110] and leads to migraine-like cutaneous" exact="hypersensitivity" post="and increased responses of the trigeminal afferent system to"/>
   <result pre="to be complex. NO donors have long been recognized as" exact="migraine" post="triggers, provoking attacks in approximately 75% of patients within"/>
   <result pre="and medulla [ 128]. These studies further implicates TRPA1 in" exact="migraine" post="by directly demonstrating that it plays a role in"/>
   <result pre="by CFA and this is likely to happen by the" exact="suppression" post="of CGRP signalling [ 129]. Notably, it has been"/>
   <result pre="CGRP signalling [ 129]. Notably, it has been shown in" exact="migraine" post="patients that CGRP levels after BoNTA treatment are significantly"/>
   <result pre="the TRPA1 agonist acrolein in a rodent model of chronic" exact="migraine" post="[ 111]. Together, these studies support the concept that"/>
   <result pre="There is currently a great deal of excitement in the" exact="migraine" post="field due to the approval of several, new CGRP-based"/>
   <result pre="regarding the viability of TRP channels as drug targets for" exact="migraine" post="and these questions require additional work among the research"/>
   <result pre="with an agonist. Little work currently exists surrounding TRPV4 and" exact="migraine" post="and this is the area that needs to most"/>
   <result pre="exposure to endogenous substances, reactive oxygen species, environmental irritants, and" exact="migraine" post="triggers such as NO donors as well as its"/>
   <result pre="Taken together, the data currently available surrounding TRP channels and" exact="migraine" post="continue to make a compelling case for further development"/>
   <result pre="Sex differences in the epidemiology, clinical features, and pathophysiology of" exact="migraine" post="Lancet Neurol. 2019 16 76 87 3. collab: Headache"/>
   <result pre="Doan L.P. et al. Global, regional, and national burden of" exact="migraine" post="and tension-type headache, 1990-2016: A systematic analysis for the"/>
   <result pre="W.P. et al. Genome-wide association analysis identifies susceptibility loci for" exact="migraine" post="without aura Nat. Genet. 2012 44 777 782 10.1038/ng.2307"/>
   <result pre="9. Borsook D. Maleki N. Becerra L. McEwen B. Understanding" exact="migraine" post="through the lens of maladaptive stress responses: A model"/>
   <result pre="al. Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for" exact="migraine" post="Nat. Genet. 2016 48 856 866 10.1038/ng.3598 27322543 12."/>
   <result pre="Warfvinge K. Krause D.N. CGRP as the target of new" exact="migraine" post="therapies—Successful translation from bench to clinic Nat. Rev. Neurol."/>
   <result pre="Palumbo R. Vasoactive peptide levels in the plasma of young" exact="migraine" post="patients with and without aura assessed both interictally and"/>
   <result pre="CGRP levels in peripheral blood as a biomarker for chronic" exact="migraine" post="Neurology 2013 81 1191 1196 10.1212/WNL.0b013e3182a6cb72 23975872 21. Goadsby"/>
   <result pre="Vasoactive peptide release in the extracerebral circulation of humans during" exact="migraine" post="headache Ann. Neurol. 1990 28 183 187 10.1002/ana.410280213 1699472"/>
   <result pre="trigeminal vasoactive peptides in internal jugular vein blood during spontaneous" exact="migraine" post="attacks Cephalalgia 2000 20 907 918 10.1046/j.1468-2982.2000.00146.x 11304026 24."/>
   <result pre="parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and" exact="migraine" post="headache during nitroglycerin induced migraine attack Cephalalgia 2005 25"/>
   <result pre="gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced" exact="migraine" post="attack Cephalalgia 2005 25 179 183 10.1111/j.1468-2982.2005.00836.x 15689192 25."/>
   <result pre="migraine: Regional cerebral blood flow and blood flow velocity in" exact="migraine" post="patients J. Headache Pain 2008 9 151 157 10.1007/s10194-008-0036-8"/>
   <result pre="M. Calcitonin gene-related peptide triggers migraine-like attacks in patients with" exact="migraine" post="with aura Cephalalgia 2010 30 1179 1186 10.1177/0333102410368444 20855363"/>
   <result pre="Role of calcitonin gene-related peptide in light-aversive behavior: Implications for" exact="migraine" post="J. Neurosci. 2009 29 8798 8804 10.1523/JNEUROSCI.1727-09.2009 19587287 28."/>
   <result pre="receptor antagonist BIBN 4096 BS for the acute treatment of" exact="migraine" post="N. Engl. J. Med. 2004 350 1104 1110 10.1056/NEJMoa030505"/>
   <result pre="Randomized, controlled trial of telcagepant for the acute treatment of" exact="migraine" post="Neurology 2009 73 970 977 10.1212/WNL.0b013e3181b87942 19770473 31. Voss"/>
   <result pre="double-blind, placebo-controlled trial of ubrogepant for the acute treatment of" exact="migraine" post="Cephalalgia 2016 36 887 898 10.1177/0333102416653233 27269043 32. Hewitt"/>
   <result pre="the CGRP receptor antagonist MK-3207 in the acute treatment of" exact="migraine" post="Cephalalgia 2011 31 712 722 10.1177/0333102411398399 21383045 33. Marcus"/>
   <result pre="R. Sensitization of the trigeminovascular pathway: Perspective and implications to" exact="migraine" post="pathophysiology J. Cl.in Neurol. 2012 8 89 99 10.3988/jcn.2012.8.2.89"/>
   <result pre="de Koning P.J.H. Larsson H.B.W. Ashina M. Meningeal contribution to" exact="migraine" post="pain: A magnetic resonance angiography study Brain 2019 142"/>
   <result pre="M.H. Dodick D.W. Porreca F. Targeting TRP channels for novel" exact="migraine" post="therapeutics ACS Chem. Neurosci. 2014 5 1085 1096 10.1021/cn500083e"/>
   <result pre="S. De Cesaris F. CGRP receptors and TRP channels in" exact="migraine" post="J. Headache Pain 2015 16 A21 10.1186/1129-2377-16-S1-A21 28132367 55."/>
   <result pre="Lupi C. Geppetti P. TRPA1 and other TRP channels in" exact="migraine" post="J. Headache Pain 2013 14 71 10.1186/1129-2377-14-71 23941062 56."/>
   <result pre="Fusi C. Trevisan G. Geppetti P. The TRPA1 channel in" exact="migraine" post="mechanism and treatment Br. J. Pharmacol. 2014 171 2552"/>
   <result pre="and SP in scalp arteries of patients suffering from chronic" exact="migraine" post="J. Neurol. Neurosurg. Psychiatry 2015 86 393 397 10.1136/jnnp-2014-308813"/>
   <result pre="A. Nemeth J. Szilvassy Z. Jancso G. Dux M. Diet-induced" exact="obesity" post="alters dural CGRP release and potentiates TRPA1-mediated trigeminovascular responses"/>
   <result pre="Lesaffre E. MaassenVanDenBrink A. de Hoon J. The influence of" exact="migraine" post="and female hormones on capsaicin-induced dermal blood flow Cephalalgia"/>
   <result pre="Mamontov O.V. Giniatullin R. Novel capsaicin-induced parameters of microcirculation in" exact="migraine" post="patients revealed by imaging photoplethysmography J. Headache Pain 2018"/>
   <result pre="Activation of meningeal nociceptors by cortical spreading depression: Implications for" exact="migraine" post="with aura J. Neurosci. 2010 30 8807 8814 10.1523/JNEUROSCI.0511-10.2010"/>
   <result pre="investigate the efficacy of the TRPV1 antagonist SB-705498 in acute" exact="migraine" post="Proceedings of the yje Pain in Europe VI Lisbon,"/>
   <result pre="M.F. Yarnitsky D. The development of cutaneous allodynia during a" exact="migraine" post="attack clinical evidence for the sequential recruitment of spinal"/>
   <result pre="the sequential recruitment of spinal and supraspinal nociceptive neurons in" exact="migraine" post="Brain J. Neurol. 2000 123 Pt 8 1703 1709"/>
   <result pre="Transient receptor potential vanilloid-4 has a major role in visceral" exact="hypersensitivity" post="symptoms Gastroenterology 2008 135 937 946 10.1053/j.gastro.2008.05.024 18565335 82."/>
   <result pre="et al. Genome-wide association study identifies novel susceptibility loci for" exact="migraine" post="in Han Chinese resided in Taiwan Cephalalgia 2018 38"/>
   <result pre="transient receptor potential V1 in the trigeminal system: Relevance to" exact="migraine" post="pathophysiology Cephalalgia 2018 38 833 845 10.1177/0333102417712719 28554243 93."/>
   <result pre="al. Genome-wide association study reveals three susceptibility loci for common" exact="migraine" post="in the general population Nat. Genet. 2011 43 695"/>
   <result pre="P. The TRPA1 channel in inflammatory and neuropathic pain and" exact="migraine" post="Rev. Physiol. Biochem. Pharmacol. 2014 167 1 43 24668446"/>
   <result pre="L. Johnson P.L. Oxford G.S. Hurley J.H. Induction of chronic" exact="migraine" post="phenotypes in a rat model after environmental irritant exposure"/>
   <result pre="of the transient receptor potential ankyrin type-1 (TRPA1) channel in" exact="migraine" post="pain: Evaluation in an animal model J. Headache Pain"/>
   <result pre="toxin type A in cranial dura: Implications for treatment of" exact="migraine" post="and other headaches Br. J. Pharmacol. 2016 173 279"/>
   <result pre="OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic" exact="migraine" post="Pain 2015 156 820 824 10.1097/j.pain.0000000000000119 25735000 131. Cady"/>
   <result pre="to acute interventions and preventative treatment with onabotulinumtoxinA in chronic" exact="migraine" post="Headache 2014 54 269 277 10.1111/head.12250 24147647 132. Shimizu"/>
   <result pre="J.E. Saper J.R. Intranasal civamide for the acute treatment of" exact="migraine" post="headache Cephalalgia 2000 20 597 602 10.1046/j.1468-2982.2000.00088.x 11075845 Figure"/>
   <result pre="TRP channels on trigeminal afferents and their potential role in" exact="migraine" post="pathology. Multiple TRP channels are expressed on trigeminal sensory"/>
   <result pre="which may also contribute to signaling within this circuit. Multiple" exact="migraine" post="therapeutics may act in this circuit, including: BoNTA, which"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6631815/results/search/disease/results.xml">
   <result pre="with LWD. Their prime clinical complaints were severe bouts of" exact="migraine" post="and antalgic gait. Results: Interestingly, via a 3D reconstruction"/>
   <result pre="CT scan we encountered several major anomalies. Notable features of" exact="craniosynostosis" post="through premature fusion of the squamosal sutures and partial"/>
   <result pre="as a novel features associated with LWD. Leri-Weil dyschondrosteosis tomography" exact="craniosynostosis" post="deficient ribs number ischial dysplasia coxa valga SHOX gene"/>
   <result pre="further understand the etiology behind the frequent severe bouts of" exact="migraine" post="and the antalgic gait. 2. Materials and Methods 2.1."/>
   <result pre="In her early childhood, the complaint of severe bouts of" exact="migraine" post="was a constant reason to seek medical advice. She"/>
   <result pre="feature associated with problems in mastication. In order to exclude" exact="papilledema" post="as a possible reason behind her migraine, a funduscopic"/>
   <result pre="disability; therefore, many remain undiagnosed. It is characterized by moderate" exact="shortness" post="of stature due to short tibia and fibula, and"/>
   <result pre="entities, and can occur as a sporadic occurrence, but nevertheless," exact="craniosynostosis" post="was not previously reported as an associated abnormality in"/>
   <result pre="tarsal synostosis, and talipes equinovarus; however, no ischial hypoplasia and" exact="craniosynostosis" post="were reported. Langer et al. [ 7] reported two"/>
   <result pre="with the autosomal recessive transmission. Similarly, neither ischial hypoplasia nor" exact="craniosynostosis" post="were reported. Mesomelic dysplasia is also a feature of"/>
   <result pre="In almost all the reported patients with Leri-Wiel dyschondrosteosis, neither" exact="craniosynostosis" post="nor ischial hypoplasia have been described. Following the clinical"/>
   <result pre="behind the abnormal craniofacial contour and the associated bouts of" exact="migraine" post="and borderline schooling achievement. The frequent bouts of migraine"/>
   <result pre="of migraine and borderline schooling achievement. The frequent bouts of" exact="migraine" post="and the antalgic gait associated with progressive waddling gait"/>
   <result pre="stature homeobox containing gene (SHOX) in dyschondrosteosis but not in" exact="hypochondroplasia" post="Hum. Genet. 2000 107 145 149 10.1007/s004390000352 11030412 28."/>
   <result pre="Wall S.A. Periodical shifts in the surgical correction of sagittal" exact="craniosynostosis" post="J. Neurosurg. Pediatr. 2015 15 348 349 25996012 31."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6635047/results/search/disease/results.xml">
   <result pre="NEUROIMAGING: Edited by Stefan Klöppel Recent developments in imaging of" exact="epilepsy" post="Wiest Roland a Beisteiner Roland b [a], [b], Correspondence"/>
   <result pre="recent attempts toward minimal invasive therapy in the treatment of" exact="epilepsy" post="and its comorbidities based on a combination of imaging"/>
   <result pre="with ultrasound. Recent findings Peri-ictal perfusion changes can differentiate ictal" exact="stroke" post="mimics from acute ischemic stroke if focal areas of"/>
   <result pre="perfusion changes can differentiate ictal stroke mimics from acute ischemic" exact="stroke" post="if focal areas of increased perfusion are depicted by"/>
   <result pre="and do not reach enough diagnostic sensitivity to differentiate between" exact="stroke" post="and its mimics. Noninvasive magnetic resonance-techniques as arterial spin"/>
   <result pre="(FUS) bears the potential to ablate epileptogenic tissue and allows" exact="suppression" post="of epileptic activity. Imaging guided blood–brain-barrier opening with FUS"/>
   <result pre="Issue 2 (RB) will introduce new imaging-based ultrasound therapies for" exact="epilepsy" post="and its comorbidities. The new therapies allow low-invasive ablation"/>
   <result pre="data relate to the emergency diagnostic workup of acute ischemic" exact="stroke" post="[ 2 ▪▪, 3– 7, 8 ▪▪]. Peri-ictal clinical"/>
   <result pre="most of the adult patients suspected of presenting with a" exact="stroke" post="mimic have a seizure due to a remote symptomatic"/>
   <result pre="a seizure due to a remote symptomatic cause or nonconvulsive" exact="status epilepticus" post="(NCSE) [ 9]. In a pediatric population, seizures that"/>
   <result pre="[ 9]. In a pediatric population, seizures that presented as" exact="stroke" post="mimics were mainly associated with an acute neurological illness"/>
   <result pre="can be found in 2–30% of patients admitted to a" exact="stroke" post="unit [ 11], whereas peri-ictal presentations account for 20%"/>
   <result pre="[ 11], whereas peri-ictal presentations account for 20% of all" exact="stroke" post="mimics. Transient peri-ictal abnormalities (TPA) can be depicted by"/>
   <result pre="than 1 h and a final diagnosis of a seizure or" exact="status epilepticus" post="that received PCT for suspected transient ischemic attack (TIA)"/>
   <result pre="PCT for suspected transient ischemic attack (TIA) or acute ischemic" exact="stroke" post="within 24 h. They detected focal hyperperfusion in 30% and"/>
   <result pre="deficit or impaired consciousness. TPA can be distinguished from ischemic" exact="stroke" post="patterns, if CT angiography is included in the protocol"/>
   <result pre="other causes of symptomatic perfusion deficits (e.g. due to a" exact="migraine" post="attack, reversible encephalopathy syndrome, metabolic or inflammatory disorders) can"/>
   <result pre="symptomatic perfusion deficits (e.g. due to a migraine attack, reversible" exact="encephalopathy" post="syndrome, metabolic or inflammatory disorders) can be excluded (Exemplary"/>
   <result pre="are displayed in Fig. 1a and b, peri-ictal perfusion patterns;" exact="stroke" post="hypoperfusion and ictal hyperperfusion patterns). FIGURE 1 (a) Exemplary"/>
   <result pre="imaging patterns in a patient who presented with an ischemic" exact="stroke" post="and witnessed seizure with postictal aphasia (left) and a"/>
   <result pre="presented with an ischemic stroke and witnessed seizure with postictal" exact="aphasia" post="(left) and a patient who presented with aphasia and"/>
   <result pre="with postictal aphasia (left) and a patient who presented with" exact="aphasia" post="and motor hemiparesis suspected for an ischemic stroke (right)."/>
   <result pre="presented with aphasia and motor hemiparesis suspected for an ischemic" exact="stroke" post="(right). The perfusion patterns reflect hypoperfusion within a segmental"/>
   <result pre="segmental artery (cerebral blood flow, left) characteristic for an ischemic" exact="stroke" post="vs. multisegmental hyperperfusion (TTP, right) characteristic for peri-ictal abnormalities."/>
   <result pre="a single seizure or seizure cluster and 29.4% after a" exact="status epilepticus." post="MRI findings encompassed restricted diffusion, reduced apparent diffusion coefficient"/>
   <result pre="Perfusion asymmetries have been reported in 22% of patients with" exact="migraine" post="associated with aura, lasting up to 24 h after symptom"/>
   <result pre="17]. In contrast to TPMA, DWI restrictions in patients with" exact="migraine" post="are exceptional and cortical oligemia is predominantly observed in"/>
   <result pre="in patients with perfusion abnormalities [ 17]. Mitochondrial myopathy, encephalopathy," exact="lactic acidosis," post="and a stroke-like episode may present with atypical combinations"/>
   <result pre="65 min, 45–116). This has been shown in patients with drug-resistant" exact="epilepsy" post="when compared to interictal epochs and seizure freedom ["/>
   <result pre="to detect structural epileptogenic lesions that predispose patients to develop" exact="epilepsy" post="after a first seizure. Factors like temporal or frontal"/>
   <result pre="investigated 69 patients who presented with a first seizure or" exact="status epilepticus" post="within 24 h after seizure onset ∗[ 20]. Abnormal hyperintensities"/>
   <result pre="the predilection areas detected in previous studies in patients with" exact="status epilepticus" post="or after single seizures [ 29– 33]. ASL perfusion"/>
   <result pre="to investigate large-scale network differences between patients with new onset" exact="epilepsy" post="and healthy controls. Reduced functional connectivity between regions within"/>
   <result pre="brain has recently been demonstrated in patients with newly diagnosed" exact="epilepsy" post="and normal brain MRI [ 36 ▪ ]. These"/>
   <result pre="are not necessarily a consequence of secondary effects of chronic" exact="epilepsy" post="rather than being present at the onset of epilepsy."/>
   <result pre="the effects of the spin-lock experiment were absent after successful" exact="epilepsy" post="surgery (Engel Class I), but remained detectable in cases"/>
   <result pre="target tissue). Clinical FDA approval has been granted for refractory" exact="essential tremor" post="[ 42], but current investigations include a wide variety"/>
   <result pre="41, 43]. Clinical trials are investigating FUS ablation for lesional" exact="epilepsy" post="(including dysplasia) and for removing cortical seizure foci. A"/>
   <result pre="further trial concerns prevention of secondary generalization with partial-onset refractory" exact="epilepsy" post="by targeting the anterior thalamic nucleus [ 39 ▪▪]."/>
   <result pre="noninvasive deep brain area stimulation is possible. For epilepsy, efficient" exact="suppression" post="of epileptic activity has been shown in an animal"/>
   <result pre="clinical trials on brain tumors, Alzheimer's disease, Parkinson's disease (PD)," exact="dementia" post="and amyotrophic lateral sclerosis. The importance of imaging tools"/>
   <result pre="on brain tumors, Alzheimer's disease, Parkinson's disease (PD), dementia and" exact="amyotrophic lateral sclerosis." post="The importance of imaging tools relates to the definition"/>
   <result pre="via functional MRI [ 57]. Although no specific studies on" exact="epilepsy" post="have yet been published, therapeutically applicable mechanisms may include"/>
   <result pre="32: 54– 59. 30239360 Overview article/introduction on conditions that resemble" exact="stroke" post="clinically and by imaging. 3 Garcia-Esperon C Bivard A"/>
   <result pre="C et al. Use of computed tomography perfusion for acute" exact="stroke" post="in routine clinical practice: complex scenarios, mimics, and artifacts"/>
   <result pre="Meyne J et al. Advanced CT for diagnosis of seizure-related" exact="stroke" post="mimics. Eur Radiol 2018; 28: 1791– 1800. 29218615 5"/>
   <result pre="S Goehl C et al. Novel algorithm to help identify" exact="stroke" post="mimics. J Stroke Cerebrovasc Dis 2018; 27: 703– 708."/>
   <result pre="M Nadareishvili Z et al. Effects of increasing IV tPA-treated" exact="stroke" post="mimic rates at CT-based centers on clinical outcomes ."/>
   <result pre="S Nikoubashman O et al. Can perfusion CT unmask postictal" exact="stroke" post="mimics? A case–control study of 133 patients. Neurology 2018;"/>
   <result pre="9 Sato K Arai N Hida A Takeuchi S Old" exact="stroke" post="as an independent risk etiology for Todd's paralysis. J"/>
   <result pre="JG Luby M Benson RT et al. Predictors of acute" exact="stroke" post="mimics in 8187 patients referred to a stroke service."/>
   <result pre="of acute stroke mimics in 8187 patients referred to a" exact="stroke" post="service. J Stroke Cerebrovasc Dis 2013; 22: e397– e403."/>
   <result pre="L Diffusion-weighted magnetic resonance imaging demonstrates parenchymal pathophysiological changes in" exact="epilepsy" post=". Brain Res Rev 2008; 59: 34– 41. 18514917"/>
   <result pre="J Nirkko A et al. Cortical regional hyperperfusion in nonconvulsive" exact="status epilepticus" post="measured by dynamic brain perfusion CT . AJNR Am"/>
   <result pre="F El-Koussy M Jung S et al. Cerebellar hypoperfusion in" exact="migraine" post="attack: incidence and significance. AJNR Am J Neuroradiol 2018;"/>
   <result pre="Abela E Buerki SE et al. Focal hemodynamic patterns of" exact="status epilepticus" post="detected by susceptibility weighted imaging (SWI) . Eur Radiol"/>
   <result pre="and generalized patterns of cerebral cortical veins due to non-convulsive" exact="status epilepticus" post="or prolonged seizure episode after convulsive status epilepticus –"/>
   <result pre="to non-convulsive status epilepticus or prolonged seizure episode after convulsive" exact="status epilepticus" post="– a MRI study using susceptibility weighted imaging ."/>
   <result pre="Bromfield E Frequency and patterns of MRI abnormalities due to" exact="status epilepticus." post="Seizure 2009; 18: 104– 108. 18723376 31 Szabo K"/>
   <result pre="Diffusion-weighted and perfusion MRI demonstrates parenchymal changes in complex partial" exact="status epilepticus" post=". Brain 2005; 128 (Pt. 6): 1369– 1376. 15743871"/>
   <result pre="A et al. Features of acute DWI abnormalities related to" exact="status epilepticus." post="Epilepsy Res 2011; 97: 45– 51. 21802259 34 Mabray"/>
   <result pre="et al. A randomized trial of focused ultrasound thalamotomy for" exact="essential tremor." post="N Engl J Med 2016; 375: 730– 739. 27557301"/>
   <result pre="al. The impact of large structural brain changes in chronic" exact="stroke" post="patients on the electric field caused by transcranial brain"/>
   <result pre="Min BK Bystritsky A Jung KI et al. Focused ultrasound-mediated" exact="suppression" post="of chemically-induced acute epileptic EEG activity . BMC Neurosci"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6636037/results/search/disease/results.xml">
   <result pre="6636037 2108 doi: 10.1186/s13256-019-2108-6 : Case Report Extradural cervical spinal" exact="schwannoma" post="in a child: a case report and review of"/>
   <result pre="available in this article, unless otherwise stated. Abstract Introduction Extradural" exact="schwannoma" post="arising from high cervical spinal root is a rare"/>
   <result pre="entity in children. We report a case of extradural cervical" exact="schwannoma" post="in a 14-year-old boy. Case presentation Our patient is"/>
   <result pre="of his neck. The radiological features suggested solitary extradural cervical" exact="schwannoma" post="which was confirmed later by histopathological findings. There were"/>
   <result pre="no postoperative neurological complications in our patient. Conclusion Extradural spinal" exact="schwannoma" post="is a benign tumor. Gross total resection with good"/>
   <result pre="clinical outcome can be achieved with minimal risks. Keywords Spinal" exact="schwannoma" post="Extradural schwannoma Magnetic resonance imaging Introduction The incidence rate"/>
   <result pre="can be achieved with minimal risks. Keywords Spinal schwannoma Extradural" exact="schwannoma" post="Magnetic resonance imaging Introduction The incidence rate of spinal"/>
   <result pre="dermoid, epidermoid, and teratomas are common in this population. Spinal" exact="schwannoma" post="is relatively rare in the pediatric population [ 2–"/>
   <result pre="scientific knowledge especially of rare diseases. A solitary extradural cervical" exact="schwannoma" post="is a very rare entity. There are no case"/>
   <result pre="follow-up, and ultimate neurological outcome of high cervical extradural spinal" exact="schwannoma" post="in a 14-year-old patient. Case presentation A 14-year-old Madhesi"/>
   <result pre="to neural foramina No other clinical or radiological features of" exact="neurofibromatosis" post="such as light brown spots on the skin, freckles"/>
   <result pre="a young age, balance problems, flesh-colored skin flaps, muscle wasting," exact="vestibular schwannoma," post="meningioma, glioma, neurofibroma, or posterior subcapsular lenticular opacities were"/>
   <result pre="findings were consistent with schwannoma. An excision of our patient’s" exact="schwannoma" post="was planned. A supraclavicular incision was made and subplatysmal"/>
   <result pre="1 year of follow-up (Fig. 5). Fig. 3 Dissection of" exact="schwannoma" post="through supraclavicular incision Fig. 4 Surgical specimen Fig. 5"/>
   <result pre="hypocellular and hypercellular areas respectively Discussion Solitary extradural cervical spinal" exact="schwannoma" post="is a rare disease. This case report describes the"/>
   <result pre="are within the spinal cord parenchyma [ 10]. Dumbbell-shaped cervical" exact="schwannoma" post="involves both the spinal canal and the posterior triangle"/>
   <result pre="located in the thoracic spine. Although the extraspinal component of" exact="schwannoma" post="is usually larger than the intraspinal tumor part, the"/>
   <result pre="life and more common in females. Extradural cervical spinal cord" exact="schwannoma" post="in the pediatric population has never been reported in"/>
   <result pre="the tumor can present with unusual symptoms like syncopal attacks," exact="migraine" post="headaches, and unrelated motor and sensory symptoms. This can"/>
   <result pre="seen even after 1 year of follow-up. Conclusion Extradural cervical spinal" exact="schwannoma" post="in the pediatric population is a rare encounter. These"/>
   <result pre="10.1080/10790268.2007.11753963 17874681 11. Kumar SA Kumar M Malgonde M Dumbbell-shaped" exact="neurofibroma" post="of the upper thoracic spine: A case report South"/>
   <result pre="8701778 13. Celli P Trillò G Ferrante L Spinal extradural" exact="schwannoma" post="J Neurosurg Spine. 2005 2 4 447 456 10.3171/spi.2005.2.4.0447"/>
   <result pre="Surgery of spinal nerve sheath tumors with special reference to" exact="neurofibromatosis" post="Neurosurgery. 1998 42 2 279 289 10.1097/00006123-199802000-00042 9482178 17."/>
   <result pre="279 289 10.1097/00006123-199802000-00042 9482178 17. Goldhammer L Second cervical root" exact="neurofibroma" post="and ipsilateral migraine headache Cephalalgia. 1993 13 2 132"/>
   <result pre="9482178 17. Goldhammer L Second cervical root neurofibroma and ipsilateral" exact="migraine" post="headache Cephalalgia. 1993 13 2 132 134 10.1046/j.1468-2982.1993.1302132.x 8495456"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6636407/results/search/disease/results.xml">
   <result pre="included a control group (n=9) and a rat model of" exact="migraine" post="(n=54) induced by intraperitoneal injection of nitroglycerin (1 mg/0.1"/>
   <result pre="still has unknown mechanisms [ 1]. Currently, treatments for acute" exact="migraine" post="attacks and chronic forms of migraine remain unsatisfactory due"/>
   <result pre="Currently, treatments for acute migraine attacks and chronic forms of" exact="migraine" post="remain unsatisfactory due to lack of understanding of pathophysiological"/>
   <result pre="an important mechanism in the pathogenesis of pain associated with" exact="migraine" post="[ 2, 3]. The migraine threshold depends on the"/>
   <result pre="pathogenesis of pain associated with migraine [ 2, 3]. The" exact="migraine" post="threshold depends on the stimulation of central nervous system"/>
   <result pre="Increased NO production has a vasodilator effect that contributes to" exact="migraine" post="pathophysiology. In experimental migraine, treatment with nitroglycerin induces an"/>
   <result pre="way one of the most crucial pathophysiological mechanism associated with" exact="migraine" post="[ 4]. Nitroglycerin as a NO donor represents a"/>
   <result pre="4]. Nitroglycerin as a NO donor represents a trigger for" exact="migraine" post="attack by inducing cortical spreading depression, a phenomenon which"/>
   <result pre="cortical spreading depression, a phenomenon which is electrophysiologically correlated with" exact="migraine" post="with aura [ 5]. Cortical spreading depression is also"/>
   <result pre="factor-alpha (TNF-alpha) is released, which mediates the inflammatory response in" exact="migraine" post="[ 9, 10]. The release of the calcitonin-gene-related peptide"/>
   <result pre="result in vasoconstriction and are widely used as medications for" exact="migraine" post="attacks [ 11]. Nonsteroidal anti-inflammatory drugs (NSAIDs) including naproxen,"/>
   <result pre="cyclooxygenase (COX) [ 12], are used as alternative treatments for" exact="migraine" post="attacks that aim to reduce inflammation associated with nociception."/>
   <result pre="to reduce inflammation associated with nociception. The treatment strategies for" exact="migraine" post="attacks that mainly modulate pain mechanisms have several limitations."/>
   <result pre="long-term use [ 15], NSAIDs remain an alternative treatment for" exact="migraine" post="attacks [ 16]. Also, current studies have supported a"/>
   <result pre="patients who also suffer from other types of pain, including" exact="osteoarthritis" post="or rheumatoid disorders [ 18, 19]. In migraine, NSAIDs"/>
   <result pre="COX-1 [ 20]. Naproxen has been successfully used for menstrual" exact="migraine" post="[ 22], pediatric migraine [ 23], and migraine associated"/>
   <result pre="has been successfully used for menstrual migraine [ 22], pediatric" exact="migraine" post="[ 23], and migraine associated with breastfeeding [ 24],"/>
   <result pre="for menstrual migraine [ 22], pediatric migraine [ 23], and" exact="migraine" post="associated with breastfeeding [ 24], supporting both its analgesic"/>
   <result pre="with analgesia by reducing inflammation and oxidative stress associated with" exact="migraine" post="attacks [ 25]. However, curcumin has poor bioavailability, poor"/>
   <result pre="in the hippocampus, which is involved in pain during a" exact="migraine" post="attack [ 29, 30]. The antioxidant effects and analgesic"/>
   <result pre="included a control group (n=9) and a rat model of" exact="migraine" post="(n=54) induced by intraperitoneal injection of nitroglycerin (1 mg/0.1"/>
   <result pre="is detailed in Table 1. In the experimental rat model," exact="migraine" post="was induced by intraperitoneal administration of nitroglycerin at a"/>
   <result pre="nitroglycerin at a dose of 1 mg/0.1 kg. In the" exact="migraine" post="model treated with naproxen (M+NP), naproxen (2.8 mg/kg) was"/>
   <result pre="animals were lost during the experiment. The rats in the" exact="migraine" post="model had significantly increased values of all metrics that"/>
   <result pre="parameters (P&amp;lt;0.001) ( Table 2, Figure 1). The induction of" exact="migraine" post="was associated with a significant decrease in both the"/>
   <result pre="increased number of flinches and shakes was observed in the" exact="migraine" post="rat model group when compared with the normal control"/>
   <result pre="when compared with the normal control rat group without a" exact="migraine" post="for both phases of the formalin test (Mann-Whitney test,"/>
   <result pre="Pretreatment with liposomal curcumin in the experimental rat model of" exact="migraine" post="rats showed its effectiveness on both oxidative stress, by"/>
   <result pre="NO synthesis can influence the level of MDA. While chronic" exact="migraine" post="is associated with the risk of stroke [ 48],"/>
   <result pre="MDA. While chronic migraine is associated with the risk of" exact="stroke" post="[ 48], increased NO synthesis and inflammatory mechanisms can"/>
   <result pre="cortical atrophy and cognitive decline [ 49– 51]. However, a" exact="migraine" post="attack, with or without aura, may cause an increase"/>
   <result pre="Evidence of serotonin release by activated platelets due to nitroglycerin-induced" exact="migraine" post="attacks have been previously reported [ 53]. The antioxidant"/>
   <result pre="like ischemic stroke, can produce neuronal dysfunction, increased cellular vulnerability," exact="neurodegeneration" post="and cell death due to a common pathophysiological mechanism"/>
   <result pre="matter microstructural differences have been observed in patients suffering from" exact="migraine" post="with aura, when compared with the controls, which is"/>
   <result pre="neuroprotective mechanisms against the oxidative stress that is associated with" exact="migraine" post="attacks. Several studies have shown that the outcome of"/>
   <result pre="of curcumin had a significant effect on the rat experimental" exact="migraine" post="model, when associated with naproxen treatment ( Table 4,"/>
   <result pre="[ 77], capsaicin-induced thermal hyperalgesia [ 78], and nitroglycerin-induced experimental" exact="migraine" post="[ 31]. The mechanisms underlying the analgesic action of"/>
   <result pre="and reduced glutathione [ 83]. In a rat model of" exact="rheumatoid arthritis," post="characterized by chronic inflammation, curcumin-loaded nanoparticles also demonstrated an"/>
   <result pre="a curcumin nanoformulation was achieved in a rat model of" exact="ulcerative colitis" post="[ 61]. Also, the anti-inflammatory and antioxidant properties of"/>
   <result pre="curcumin nanoformulation was achieved in a rat model of ulcerative" exact="colitis" post="[ 61]. Also, the anti-inflammatory and antioxidant properties of"/>
   <result pre="Nimeri R Ahmed F Current understanding on pain mechanism in" exact="migraine" post="and cluster headache Anesth Pain Med 2016 6 e35190"/>
   <result pre="Obermann M Holle D Recent advances in the management of" exact="migraine" post="F1000Res 2016 5 2726 29098075 16 Xu H Han"/>
   <result pre="H Han W Wang J Li M Network meta-analysis of" exact="migraine" post="disorder treatment by NSAIDs and triptans J Headache Pain"/>
   <result pre="83 17651900 22 Maasumi K Tepper SJ Kriegler JS Menstrual" exact="migraine" post="and treatment options Headache 2017 57 194 208 27910087"/>
   <result pre="23 Merison K Jacobs H Diagnosis and treatment of childhood" exact="migraine" post="Curr Treat Options Neurol 2016 18 48 27704257 24"/>
   <result pre="Davanzo R Bua J Paloni G Facchina G Breastfeeding and" exact="migraine" post="drugs Eur J Clin Pharmacol 2014 70 1313 24"/>
   <result pre="MA et al. Efficacy of biodegradable curcumin nanoparticles in delaying" exact="cataract" post="in diabetic rat model PLoS One 2013 8 e78217"/>
   <result pre="J et al. Common hippocampal structural and functional changes in" exact="migraine" post="Brain Struct Funct 2013 218 903 12 22760159 31"/>
   <result pre="al. Preemptive analgesic and antioxidant effect of curcumin for experimental" exact="migraine" post="Biomed Res Int 2017 2017 4754701 32 Bulboacă AE"/>
   <result pre="liposomal curcumin in addition to sumatriptan treatment in an experimental" exact="migraine" post="model in rats Int J Nanomedicine 2018 13 3093"/>
   <result pre="et al. Clinically relevant behavioral endpoints in a recurrent nitroglycerin" exact="migraine" post="model in rats J Headache Pain 2016 17 40"/>
   <result pre="45 Burstein R Jakubowski M Rauch SD The science of" exact="migraine" post="Vestib Res 2011 21 305 14 46 Mittal M"/>
   <result pre="Mawet J Hervé D et al. Prevalence and characteristics of" exact="migraine" post="in CADASIL Cephalalgia 2016 36 1038 47 26646784 49"/>
   <result pre="53 Juhasz G Zsombok T Modos EA et al. NO-induced" exact="migraine" post="attack: Strong increase in plasma calcitonin gene-related peptide (CGRP)"/>
   <result pre="P pH-sensitive nanoparticles of curcumin-celecoxib combination: Evaluating drug synergy in" exact="ulcerative colitis" post="model J Pharm Sci 2014 103 687 96 24375287"/>
   <result pre="pH-sensitive nanoparticles of curcumin-celecoxib combination: Evaluating drug synergy in ulcerative" exact="colitis" post="model J Pharm Sci 2014 103 687 96 24375287"/>
   <result pre="al. Intrinsic brain activity triggers trigeminal meningeal afferents in a" exact="migraine" post="model Nat Med 2002 8 136 42 11821897 68"/>
   <result pre="P Király A et al. Evidence for plastic processes in" exact="migraine" post="with aura: A diffusion weighted MRI study Front Neuroanat"/>
   <result pre="IP Chopra K Curcumin loaded solid lipid nanoparticles ameliorate adjuvant-induced" exact="arthritis" post="in rats Eur J Pain 2015 19 940 52"/>
   <result pre="the circles represent the individual values. The rat model of" exact="migraine" post="(M) (n=54), was induced by intraperitoneal injection of nitroglycerin"/>
   <result pre="the circles represent the individual values. The rat model of" exact="migraine" post="(M) (n=54), was induced by intraperitoneal injection of nitroglycerin"/>
   <result pre="rat control group (no medication) (n=9). The rat model of" exact="migraine" post="(M) (n=54), was induced by intraperitoneal injection of nitroglycerin"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6646427/results/search/disease/results.xml">
   <result pre="to adulthood, there is no drug with exclusive indication for" exact="migraine" post="treatment in pediatric age. This raises several limitations in"/>
   <result pre="investigate the real evidence concerning the prophylactic therapy of pediatric" exact="migraine" post="by reviewing the clinical studies published between 2010 and"/>
   <result pre="by reviewing the clinical studies published between 2010 and 2019." exact="migraine" post="pediatric migraine prophylactic drugs therapy treatment guidelines preventive fig-count:"/>
   <result pre="the clinical studies published between 2010 and 2019. migraine pediatric" exact="migraine" post="prophylactic drugs therapy treatment guidelines preventive fig-count: table-count: equation-count:"/>
   <result pre="even in childhood and adolescence. The average prevalence of pediatric" exact="migraine" post="varies according to age, going from 3% in younger"/>
   <result pre="( 2). A noticeable social problem is represented by chronic" exact="migraine" post="(more than 15 days with headache a month) that"/>
   <result pre="although the last version (ICHD 3) considers some peculiarities of" exact="migraine" post="in pediatric age, such as the shorted duration of"/>
   <result pre="in terms of reduction of both frequency and intensity of" exact="migraine" post="attacks ( 6). Though representing a precious resource, the"/>
   <result pre="with placebo. Migraine prophylaxis aims at reducing the impact of" exact="migraine" post="by improving the frequency and intensity of attacks. In"/>
   <result pre="to investigate the actual evidence concerning prophylactic therapy of pediatric" exact="migraine" post="by reviewing clinical studies published between 2010 and 2019."/>
   <result pre="the above described strategy, 64 articles concerning preventive treatment of" exact="migraine" post="in children were included in our study. Among them,"/>
   <result pre="impotence, hallucinations, weight gain History of hypertension No history of" exact="asthma" post="or allergy No history of bradyarrhythmia TRICYCLIC ANTIDEPRESSANT Amitriptyline"/>
   <result pre="weight gain History of hypertension No history of asthma or" exact="allergy" post="No history of bradyarrhythmia TRICYCLIC ANTIDEPRESSANT Amitriptyline B 1"/>
   <result pre="gain Not obese patients history of depression or insomnia chronic" exact="migraine" post="ANTIEPILEPTIC DRUGS Sodium Valproate B 30 mg/kg/day Somnolence, nausea/vomiting,"/>
   <result pre="Male patients Topiramate A 2–3 mg/Kg/day Paresthesia, somnolence, dizziness, anorexia," exact="metabolic acidosis," post="cognitive/memory dysfunction Overweight No history of cognitive impairment SEROTONIN"/>
   <result pre="Increased appetite, weight gain, drowsiness, sleepiness, dizziness, dry mouth, tiredness," exact="constipation" post="No obese patients history of depression or insomnia Cyproheptadine"/>
   <result pre="Drowsiness, fatigue, increased appetite, weight gain, dizziness No history of" exact="asthma" post="NUTRACEUTICS Hydroxytryptophan C 100 mg Kg/day Nausea, bloating Flatulence,"/>
   <result pre="C 100 mg Kg/day Nausea, bloating Flatulence, loose stools or" exact="diarrhea" post="Mild intensity of the attack Low frequency Refusal of"/>
   <result pre="Coenzyme Q10 C 150–300 mg/day Nausea and/or vomiting upset stomach," exact="diarrhea" post="heartburn, loss of appetite, abdominal pain or discomfort Tenacetum"/>
   <result pre="properties on the cerebrovascular circulation. How flunarizine acts in preventing" exact="migraine" post="is not yet established but it probably has both"/>
   <result pre="the response rate was particularly high in patients with hemiplegic" exact="migraine" post="(85%). The study also showed that flunarizine was well-tolerated"/>
   <result pre="pediatric age are needed to confirm its effectiveness in pediatric" exact="migraine" post="( 13). Beta-Blockers Propranolol is a non-selective beta (b)"/>
   <result pre="receptors. Propranolol started to be used in the prophylaxis of" exact="migraine" post="for more than 50 years ( 14). Propranolol showed"/>
   <result pre="high profile of tolerability in several clinical trials on adult" exact="migraine" post="( 4). On the contrary, there are only a"/>
   <result pre="a dosage of 3 mg/kg/day) and valproate (30 mg/Kg/day) for" exact="migraine" post="prophylaxis in childhood. In this study, 60 patients were"/>
   <result pre="with non-pharmacologic treatments, showed efficacy in reducing the frequency of" exact="migraine" post="attacks in children (reduction of attack frequency &amp;gt;50% per"/>
   <result pre="of the most used drugs for preventive treatment of pediatric" exact="migraine" post="( 22). It is also recommended in cases of"/>
   <result pre="if combined with non-pharmacological measures, were both effective in reducing" exact="migraine" post="attacks frequency ( 19). Between July 2012 and November"/>
   <result pre="topiramate (50–100 mg/day) were evaluated for prophylactic therapy of pediatric" exact="migraine" post="in some controlled studies ( 7). In the last"/>
   <result pre="efficacy of valproate and propranolol for the preventive treatment of" exact="migraine" post="in the pediatric age. Sixty children (aged 5–15 years)"/>
   <result pre="in the pediatric age. Sixty children (aged 5–15 years) with" exact="migraine" post="without aura were included. Patients received propranolol (3 mg/kg/day)"/>
   <result pre="18). Topiramate is a first-line strategy for the treatment of" exact="migraine" post="in adults. In 2014, the U.S. Food and Drug"/>
   <result pre="the U.S. Food and Drug Administration (FDA) approved topiramate for" exact="migraine" post="treatment in the pediatric patients aged 12 to 17"/>
   <result pre="In adults, topiramate proved efficacious in the preventive treatment of" exact="migraine" post="with and without aura in episodic and chronic form,"/>
   <result pre="± 1.55 to 0.94 ± 0.35 h, respectively. The pediatric" exact="migraine" post="disability assessment score was reduced from 32.4 ± 9.3"/>
   <result pre="topiramate could be considered a safe and effective drug for" exact="migraine" post="therapy in pediatric patients ( 32). As reported above,"/>
   <result pre="migraine. Measures of secondary efficacy were the intensity of monthly" exact="migraine" post="and a response rate higher than 50%. During the"/>
   <result pre="p = 0.004; topiramate: 50%, p = 0.001). Also monthly" exact="migraine" post="intensity reduced in both groups ( p &amp;lt; 0.001)"/>
   <result pre="After 12 weeks of treatment, a significant reduction of monthly" exact="migraine" post="frequency was observed for both cinnarizine and topiramate ("/>
   <result pre="dose of 1–1.5 mg, administered for 6 months in 47" exact="migraine" post="subjects (7–14 years), was not more effective than placebo."/>
   <result pre="is drowsiness, weight gain and tenderness. Contraindications consist of asthma," exact="glaucoma" post="and peptic ulcer. Despite the lack of definitive data,"/>
   <result pre="weight gain and tenderness. Contraindications consist of asthma, glaucoma and" exact="peptic ulcer." post="Despite the lack of definitive data, Pizotifen is the"/>
   <result pre="rationale of the use of nutraceutics in the treatment of" exact="migraine" post="is based on the involvement of these substances in"/>
   <result pre="of coenzyme Q10 (100 mg/day) in the prophylaxis of pediatric" exact="migraine" post="( 44). A significant reduction in migraine frequency ("/>
   <result pre="prophylaxis of pediatric migraine ( 44). A significant reduction in" exact="migraine" post="frequency ( p &amp;lt; 0.001), severity ( p &amp;lt;"/>
   <result pre="present side effects of oral drugs or in drug resistant" exact="migraine" post="( 46). In a retrospective case series study, Ahmed"/>
   <result pre="dose of 75 units and maximum of 200) for chronic" exact="migraine" post="in a pediatric headache center from 2004 to 2010."/>
   <result pre="of pain ( 48). Complementary Therapies Non-pharmacological treatment for pediatric" exact="migraine" post="includes cognitive behavioral therapy, acupuncture, and biofeedback. As stated"/>
   <result pre="on 135 patients (mean age 14.4 ± 2) with chronic" exact="migraine" post="evaluated the efficacy at 20 weeks of the combined"/>
   <result pre="of acupuncture in reducing the frequency of the attacks of" exact="migraine" post="was shown in earlier studies ( 50, 51), no"/>
   <result pre="or pilot studies ( 53– 55). Overall, non-pharmacological treatment for" exact="migraine" post="can be a valid alternative for selected patients. The"/>
   <result pre="novelty of the last decade in the prophylaxis of pediatric" exact="migraine" post="comes from the results of the CHAMP study. This"/>
   <result pre="Placebo response rate is known to be high in pediatric" exact="migraine" post="studies ( 25). The high therapeutic efficacy of placebo"/>
   <result pre="not consider some dynamics that may influence the course of" exact="migraine" post="independently of drug therapy, such as psychological factors mostly"/>
   <result pre="no drug available in pediatric age with exclusive indication for" exact="migraine" post="treatment ( 59). From this point of view, there"/>
   <result pre="antagonists could be considered in postpubertal adolescent patients with frequent" exact="migraine" post="attacks (≥8 headache days/month), who have moderate to severe"/>
   <result pre="headache days/month), who have moderate to severe disability associated with" exact="migraine" post="(PedMIDAS score ≥30) and have failed ≥2 preventive therapies."/>
   <result pre="Bigal ME . Recent advances in the management of chronic" exact="migraine" post="in children. Expert Rev Neurother. ( 2018) 18: 231–"/>
   <result pre="Battan B et al. . Features of aura in paediatric" exact="migraine" post="diagnosed using the ICHD 3 beta criteria. Cephalalgia. ("/>
   <result pre="20349201 8. Abu-Arafeh I . Flunarizine for the prevention of" exact="migraine" post="- a new look at an old drug. Dev"/>
   <result pre="11 years' experience, with emphasis on its effect in hemiplegic" exact="migraine" post=". Dev Med Child Neurol. ( 2012) 54: 274–"/>
   <result pre="S Bayram E Sozmen K Yis U . The Paediatric" exact="migraine" post="disability assessment score is a useful tool for evaluating"/>
   <result pre="disability assessment score is a useful tool for evaluating prophylactic" exact="migraine" post="treatment . Acta Paediatr. ( 2014) 103: e484– 9."/>
   <result pre="4958813 15. Ludvigsson J . Propranolol used in prophylaxis of" exact="migraine" post="in children. Acta Neurol Scand. ( 1974) 50: 109–"/>
   <result pre="trial of propanolol versus sodium valproate for the prophylaxis of" exact="migraine" post="in pediatric patients . Paediatr Drugs. ( 2010) 12:"/>
   <result pre="Y Haimi-Cohen Y Goldberg-Stern H Zeharia A Nonpharmacologic treatment of" exact="migraine" post="with low-dose propranolol or amitriptyline. Pediatr Neurol. ( 2012)"/>
   <result pre=". The efficacy and safety of topiramate for prophylaxis of" exact="migraine" post="in children. Iran J Child Neurol. ( 2013) 7:"/>
   <result pre="topiramate, and placebo in the prevention of childhood and adolescent" exact="migraine" post=". Headache. ( 2013) 53: 799– 816. 10.1111/head.12105 23594025"/>
   <result pre="clinical trial comparing the efficacy of melatonin and amitriptyline in" exact="migraine" post="prophylaxis of children . Iran J Child Neurol. ("/>
   <result pre="K et al. Treatment adherence to biobehavioral recommendations in pediatric" exact="migraine" post="as measured by electronic monitoring: the Adherence in Migraine"/>
   <result pre="et al. . Cognitive behavioral therapy plus amitriptyline for chronic" exact="migraine" post="in children and adolescents: a randomized clinical trial ."/>
   <result pre="behavioral therapy plus amitriptyline for children and adolescents with chronic" exact="migraine" post="reduces headache days to &amp;lt; 4 per month ."/>
   <result pre="637– 44. 10.1016/j.jpain.2017.01.002 28108386 29. collab: FDA approves Topamax for" exact="migraine" post="prevention in adolescents J Pain Palliat Care Pharmacother. ("/>
   <result pre=". The efficacy and safety of topiramate for prophylaxis of" exact="migraine" post="in children. Iran J Child Neurol. ( 2013) 7:"/>
   <result pre="35. Lawrence ER Hossain M Littlestone W . Sanomigran for" exact="migraine" post="prophylaxis; controlled multicenter trial in general practice. Headache. ("/>
   <result pre="3510125 37. Billie B Ludvigsson J Sanner G Prophylaxis of" exact="migraine" post="in children. Headache. ( 1977) 17: 61– 3. 10.1111/j.1526-4610.1977.hed1702061.x"/>
   <result pre="B Sartori S Battistella PA . The pharmacological treatment of" exact="migraine" post="in children and adolescents: an overview. Expert Rev Neurother."/>
   <result pre="M Pascotto A Carotenuto M . Nutraceutical preparations in childhood" exact="migraine" post="prophylaxis. Neurol Sci. ( 2012) 33: 1365– 8. 10.1007/s10072-012-1019-8"/>
   <result pre="of CoEnzyme Q10 in the prevention of pediatric and adolescent" exact="migraine" post=". Cephalalgia. ( 2011) 31: 897– 905. 10.1177/0333102411406755 21586650"/>
   <result pre="M . Ginkgolide B complex efficacy for brief prophylaxis of" exact="migraine" post="in schoolaged children: an open-label study . Neurol Sci."/>
   <result pre="Canetta E et al. . Circadian and seasonal variation of" exact="migraine" post="attacks in children. Headache. ( 2006) 46: 1571– 4."/>
   <result pre="al. . Efficacy and safety of erenumab (AMG334) in episodic" exact="migraine" post="patients with prior preventive treatment failure: a subgroup analysis"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6646581/results/search/disease/results.xml">
   <result pre="(rPMS) has been successfully applied recently in migraineurs to alleviate" exact="migraine" post="symptoms. Symptom relief has been achieved by stimulating myofascial"/>
   <result pre="this background, this study presents the setup of rPMS in" exact="migraine" post="and evaluates effects on skeletal musculature. Materials and Methods:"/>
   <result pre="(mean age: 25.0 ± 4.1 years, 36 females) suffering from" exact="migraine" post="and presenting mTrPs according to physical examination underwent rPMS"/>
   <result pre="supporting the role of the TCC in migraineurs. deltoid muscle" exact="migraine" post="active myofascial trigger points repetitive peripheral magnetic stimulation trapezius"/>
   <result pre="word-count: Introduction More than 1 billion people worldwide suffer from" exact="migraine" post="according to a systematic analysis of the Global Burden"/>
   <result pre="Global Burden of Disease Study of 2016 ( 1). Moreover," exact="migraine" post="has become the first cause of disability in subjects"/>
   <result pre="in fields of epidemiology, etiology, acute and preventive treatment of" exact="migraine" post="in the last decades, the distinct pathophysiology of migraine"/>
   <result pre="of migraine in the last decades, the distinct pathophysiology of" exact="migraine" post="remains complex and multifactorial and is far from being"/>
   <result pre="functional link between musculoskeletal dysfunction of the cranio-cervical region and" exact="migraine" post="( 5– 10). Especially alterations in the trapezius muscles,"/>
   <result pre="have demonstrated a high occurrence of mTrPs in subjects with" exact="migraine" post="and their associations with neck mobility ( 18– 22)."/>
   <result pre="TCC by different invasive and non-invasive approaches in subjects with" exact="migraine" post="to achieve symptom improvements. Neurosurgical, invasive occipital nerve stimulation"/>
   <result pre="is applicable on the trapezius muscles and may successfully alleviate" exact="migraine" post="symptoms ( 36). Furthermore, potential local effects of rPMS"/>
   <result pre="the stimulated muscle in addition to its global effects on" exact="migraine" post="frequency ( 36). Previous studies were able to demonstrate"/>
   <result pre="to be decreased in the cranio-cervical region among subjects with" exact="migraine" post="( 7, 37– 40). This supports the importance of"/>
   <result pre="of different muscles of the cranio-cervical region in patients with" exact="migraine" post="(e.g., trapezius, sternocleidomastoid, splenius, levator scapulae, or scalene muscles),"/>
   <result pre="TCC, might further support the role of the TCC in" exact="migraine" post="and the role of techniques like rPMS as valuable"/>
   <result pre="criteria were (1) age between 18 and 35 years, (2)" exact="migraine" post="(according to the German version of the headache questionnaire"/>
   <result pre="diseases except for migraine, (2) intake of any medication for" exact="migraine" post="prophylaxis, (3) any changes in hormonal contraception during or"/>
   <result pre="used in a previous pilot study ( 36). To verify" exact="migraine" post="diagnosis, the subjects had to initially fill in the"/>
   <result pre="its beta version). Only those who fulfilled the criteria of" exact="migraine" post="(migraine ± aura and/or ± tension-type headache [TTH]) were"/>
   <result pre="(trapezius group and deltoid group) concerning their baseline characteristics regarding" exact="migraine" post="before intervention. Directly after each of the six individual"/>
   <result pre="Female sex b 100.0 (19) 94.4 (17) 0.978 Type of" exact="migraine" post="c Migraine without aura 47.4 (9) 27.8 (5) 0.229"/>
   <result pre="test. c Fisher test. All participants presented with high-frequency episodic" exact="migraine" post="and had one latent mTrP in each of the"/>
   <result pre="similar, but slightly more prominent than her well-known sensations during" exact="migraine" post="attacks. The participant decided to continue with the remaining"/>
   <result pre="4). Various non-invasive techniques have been applied in subjects with" exact="migraine" post="with the intention to alleviate symptoms via neuromodulation ("/>
   <result pre="common options. A new non-invasive technique in the field of" exact="migraine" post="is represented by rPMS, which is an especially attractive"/>
   <result pre="muscles are known for being linked to the incidence of" exact="migraine" post="and the occurrence of its attacks ( 6, 8,"/>
   <result pre="the TCC, which aims to explain the complex pathogenesis of" exact="migraine" post="associated with neck pain ( 13). Of note, investigations"/>
   <result pre="it could be applied in different types or stages of" exact="migraine" post="( 24, 62). To date, rPMS has been applied"/>
   <result pre="to active mTrPs of the trapezius muscles in subjects with" exact="migraine" post="in one pilot study ( 36). This small study"/>
   <result pre="acceptance and feasibility, performed algometry, and assessed potential impact on" exact="migraine" post="( 36). In both the present study as well"/>
   <result pre="higher than in the previous pilot trial on rPMS in" exact="migraine" post="where rPMS was rated as pleasant regarding 55.8% of"/>
   <result pre="in the cranio-cervical region is generally elevated in subjects with" exact="migraine" post="when compared to healthy controls ( 37, 38, 40)."/>
   <result pre="to healthy controls ( 37, 38, 40). Consequently, subjects with" exact="migraine" post="suffer more often from neck pain and cranio-cervical hyperalgesia,"/>
   <result pre="are regularly lower in the cranio-cervical region of patients with" exact="migraine" post="than in healthy controls ( 7, 37, 39, 41,"/>
   <result pre="and central convergence of nociceptive afferents of C1-C3 could explain" exact="migraine" post="pathogenesis in relation to neck pain ( 13). We"/>
   <result pre="trapezius muscle that is considered part of the TCC in" exact="migraine" post="might be more prone to improvements in hyperalgesia following"/>
   <result pre="as well as the focus on subjects with high-frequency episodic" exact="migraine" post="might represent shortcomings as results obtained in this study"/>
   <result pre="characteristics of migraine. Third, the inclusion of individuals suffering from" exact="migraine" post="and TTH as well as individuals suffering only from"/>
   <result pre="migraine and TTH as well as individuals suffering only from" exact="migraine" post="can be considered as a limitation as there is"/>
   <result pre="characteristics of migraine. Potential alleviating effects on the number of" exact="migraine" post="attacks and migraine intensity, amongst other factors, have been"/>
   <result pre="Potential alleviating effects on the number of migraine attacks and" exact="migraine" post="intensity, amongst other factors, have been suggested by a"/>
   <result pre="however, further evidence for the positive impact of rPMS on" exact="migraine" post="characteristics is needed. With regards to the study's setup"/>
   <result pre="GBD 2016 Headache Collaborators Global, regional, and national burden of" exact="migraine" post="and tension-type headache, 1990–2016: a systematic analysis for the"/>
   <result pre="K et al. . Self-reported muscle pain in adolescents with" exact="migraine" post="and tension-type headache. Cephalalgia. ( 2012) 32: 241– 9."/>
   <result pre="Straube A et al. Self-reported neck pain is associated with" exact="migraine" post="but not with tension-type headache in adolescents . Cephalalgia."/>
   <result pre=". Generalized neck-shoulder hyperalgesia in chronic tension-type headache and unilateral" exact="migraine" post="assessed by pressure pain sensitivity topographical maps of the"/>
   <result pre="shoulder pain in adolescents is associated with episodic and chronic" exact="migraine" post=". Cephalalgia. ( 2016) 36: 807– 11. 10.1177/0333102415610875 26460336"/>
   <result pre="Luedtke K Starke W May A . Musculoskeletal dysfunction in" exact="migraine" post="patients. Cephalalgia. ( 2018) 38: 865– 75. 10.1177/0333102417716934 28641450"/>
   <result pre="the upper cervical spine in women with episodic or chronic" exact="migraine" post=". Eur J Phys Rehabil Med. ( 2017) 53:"/>
   <result pre="muscles - assessment of myofascial trigger points in patients with" exact="migraine" post=". J Headache Pain. ( 2019) 20: 8. 10.1186/s10194-019-0960-9"/>
   <result pre="21422773 15. Olesen J . Clinical and pathophysiological observations in" exact="migraine" post="and tension-type headache explained by integration of vascular, supraspinal"/>
   <result pre="J Garcia-Leiva JM Rico-Villademoros F . Trigger point evaluation in" exact="migraine" post="patients: an indication of peripheral sensitization linked to migraine"/>
   <result pre="in migraine patients: an indication of peripheral sensitization linked to" exact="migraine" post="predisposition? Eur J Neurol. ( 2006) 13: 244– 9."/>
   <result pre="between active trigger points and head/neck posture in patients with" exact="migraine" post=". Am J Phys Med Rehabil. ( 2016) 95:"/>
   <result pre="points and migraine-related disability in women with episodic and chronic" exact="migraine" post=". Clin J Pain. ( 2017) 33: 109– 15."/>
   <result pre="on non-pharmacological neuromodulation for the acute and preventive treatment of" exact="migraine" post=". Headache. ( 2017) 57: 685– 91. 10.1111/head.13069 28295242"/>
   <result pre="LT Hvedstrup J Schytz HW . Myofascial trigger points in" exact="migraine" post="and tension-type headache. J Headache Pain. ( 2018) 19:"/>
   <result pre="al. . Single-pulse transcranial magnetic stimulation for acute treatment of" exact="migraine" post="with aura: a randomised, double-blind, parallel-group, sham-controlled trial ."/>
   <result pre=". Transcranial direct current stimulation in the prophylactic treatment of" exact="migraine" post="based on interictal visual cortex excitability abnormalities: a pilot"/>
   <result pre="stimulation of the visual cortex in the prophylactic treatment of" exact="migraine" post=". Cephalalgia. ( 2011) 31: 820– 8. 10.1177/0333102411399349 21398419"/>
   <result pre="Grosberg BM Cady RK Dorlas S et al. . Chronic" exact="migraine" post="headache prevention with noninvasive vagus nerve stimulation: the EVENT"/>
   <result pre="Magnetic stimulation of the upper trapezius muscles in patients with" exact="migraine" post="- A pilot study . Eur J Paediatr Neurol."/>
   <result pre="pressure pain sensitivity maps of the scalp between patients with" exact="migraine" post="and healthy controls . Headache. ( 2017) 57: 226–"/>
   <result pre="Dach F Fernandez-de-Las-Penas C et al. . Generalized pressure pain" exact="hypersensitivity" post="in the cervical muscles in women with migraine. Pain"/>
   <result pre="Ordas-Bandera C et al. . Women with chronic and episodic" exact="migraine" post="exhibit similar widespread pressure pain sensitivity . Pain Med."/>
   <result pre="J Edmeads JG . Clinical utility of an instrument assessing" exact="migraine" post="disability: the Migraine Disability Assessment (MIDAS) questionnaire . Headache."/>
   <result pre="M . Therapeutic effects of peripheral repetitive magnetic stimulation on" exact="myofascial pain syndrome" post=". Clin Neurophysiol. ( 2003) 114: 350– 8. 10.1016/S1388-2457(02)00367-X"/>
   <result pre="M . Repetitive magnetic stimulation: a novel therapeutic approach for" exact="myofascial pain syndrome" post=". J Neurol. ( 2005) 252: 307– 14. 10.1007/s00415-005-0642-1"/>
   <result pre="G Benlier N Neck pain: is it part of a" exact="migraine" post="attack or a trigger before a migraine attack? Acta"/>
   <result pre="part of a migraine attack or a trigger before a" exact="migraine" post="attack? Acta Neurol Belg. ( 2018). 10.1007/s13760-018-1030-9. [Epub ahead"/>
   <result pre="V Jensen RH . Neurostimulation for the treatment of chronic" exact="migraine" post="and cluster headache. Acta Neurol Scand. ( 2019) 139:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6650527/results/search/disease/results.xml">
   <result pre="Some studies have demonstrated the high impact of headache and" exact="migraine" post="in several areas of children and adolescents' life. In"/>
   <result pre="been an increase in scientific interest in the relationship between" exact="migraine" post="and emotional regulation, investigating the possible consequences of emotional"/>
   <result pre="carried out on the relationship between alexithymia and headache or" exact="migraine" post="(especially in adults), no data exist on relationship between"/>
   <result pre="children and adolescents with migraine. Methods: Children with diagnosis of" exact="migraine" post="without aura (MWoA) (36 males and 34 females) were"/>
   <result pre="in the literature. Future research will have to focus on" exact="migraine" post="with aura and tension-type headache to evaluate any differences"/>
   <result pre="children with MWoA. alexithymia metacognition theory of mind children pre-adolescents" exact="migraine" post="without aura MWoA fig-count: table-count: equation-count: ref-count: page-count: word-count:"/>
   <result pre="are focusing their interest on the relationship between headache or" exact="migraine" post="and emotional regulation and, in particular, they are trying"/>
   <result pre="only few studies have addressed the association between headache or" exact="migraine" post="and impairment on metacognitive or TOM abilities in children"/>
   <result pre="deficit in TOM and metacognition abilities in pediatric patients with" exact="migraine" post="without aura (MWoA) and in healthy control subjects. Our"/>
   <result pre="the EG. Initially, several clinical variables were collected in the" exact="migraine" post="patients, with the idea of looking for a possible"/>
   <result pre="of this study is the association found among children with" exact="migraine" post="and the higher presence of some alexithymic traits. In"/>
   <result pre="and expression. Probably the frequency and the intensity of the" exact="migraine" post="attacks might have a greater impact ( 32). There"/>
   <result pre="with the slight cognitive dysfunction found in recent studies in" exact="migraine" post="patients ( 33, 34). From the present research, no"/>
   <result pre="case, there were no significant differences between the group of" exact="migraine" post="patients and the control group. It is possible that"/>
   <result pre="from all the variables we studied and, moreover, that the" exact="migraine" post="condition does not influence the development of this ability."/>
   <result pre="a comparison between children and adolescents with chronic and episodic" exact="migraine" post="and to detect any differences in mentalization and theory"/>
   <result pre="work such as: the intensity and the frequency of the" exact="migraine" post="attacks, the familiarity, and the type of therapy. A"/>
   <result pre="taken into account. Our plan is to compare children with" exact="migraine" post="with aura, without aura and those with TTH to"/>
   <result pre="has showed higher alexithymia traits compared to control group. Moreover," exact="migraine" post="characteristics do not seem to affect the psychological construct"/>
   <result pre="to confirm the existence of a statistically significant association between" exact="migraine" post="and alexithymic traits in children and pre-adolescents. In addition,"/>
   <result pre="psychopathology and quality of life in children and adolescents with" exact="migraine" post=". J Child Neurol. ( 2016) 31: 837– 42."/>
   <result pre="Demirci H Virit O Neyal A . Alexithymic features in" exact="migraine" post="patients. Eur Arch Psychiatry Clin Neurosci. ( 2004) 254:"/>
   <result pre="self-reflectivity in emotional awareness and subjective indices of recovery in" exact="schizophrenia" post=". J Nerv Ment Dis. ( 2016) 204: 903–"/>
   <result pre="characteristics in pediatric patients with primary headache: a comparison between" exact="migraine" post="and tension-type headache . J Headache Pain. ( 2015)"/>
   <result pre="M et al. . Cognitive dysfunctions and psychological symptoms in" exact="migraine" post="without aura: a cross-selectional study . J Headache Pain."/>
   <result pre="Y Cho SJ . Subjective cognitive decline in patients with" exact="migraine" post="and its relationship with depression, anxiety, and sleep quality"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6657237/results/search/disease/results.xml">
   <result pre="doi: 10.5114/aoms.2019.86061 : State Of the art paper Mitochondria in" exact="migraine" post="pathophysiology – does epigenetics play a role? Fila Michał"/>
   <result pre="its license. Abstract The approximately three times higher rate of" exact="migraine" post="prevalence in women than men may result from the"/>
   <result pre="in mitochondrial metabolism in specific regions of the brain in" exact="migraine" post="patients. Migraine shares some clinical features with several mitochondrial"/>
   <result pre="features with several mitochondrial diseases and many other disorders include" exact="migraine" post="headaches. Epigenetic regulation of mitochondrial DNA (mtDNA) is a"/>
   <result pre="Further studies on the role of mitochondrial epigenetic modifications in" exact="migraine" post="are needed, but they require new methods and approaches."/>
   <result pre="than in men ( Figure 1). Hover, the peak of" exact="migraine" post="incidence is observed in adolescence. It is a complex"/>
   <result pre="release of some neuromodulators, such as dopamine [ 2]. Current" exact="migraine" post="therapies are effective only in a proportion of patients"/>
   <result pre="studies on new therapeutic targets are needed. Figure 1 Worldwide" exact="migraine" post="prevalence in 2016 according to WHO (both sexes, all"/>
   <result pre="( https://vizhub.healthdata.org/gbd-compare/) Recurrent episodes of headache are the hallmark of" exact="migraine" post="and they are usually associated with an array of"/>
   <result pre="to the International Headache Society, two main clinical subtypes of" exact="migraine" post="can be considered: migraine with aura (MA) and without"/>
   <result pre="Society, two main clinical subtypes of migraine can be considered:" exact="migraine" post="with aura (MA) and without aura (MO). Other rarer"/>
   <result pre="aura (MA) and without aura (MO). Other rarer type of" exact="migraine" post="are basilar-type migraine (BTM) and familial hemiplegic migraine (FHM)."/>
   <result pre="without aura (MO). Other rarer type of migraine are basilar-type" exact="migraine" post="(BTM) and familial hemiplegic migraine (FHM). Aura occurs in"/>
   <result pre="Other rarer type of migraine are basilar-type migraine (BTM) and" exact="familial hemiplegic migraine" post="(FHM). Aura occurs in about one third of all"/>
   <result pre="type of migraine are basilar-type migraine (BTM) and familial hemiplegic" exact="migraine" post="(FHM). Aura occurs in about one third of all"/>
   <result pre="migraine (FHM). Aura occurs in about one third of all" exact="migraine" post="patients and includes mainly visual symptoms, but also aphasia,"/>
   <result pre="syndrome and proper name anomia [ 3]. The pathophysiology of" exact="migraine" post="is not fully known and there were two opposite"/>
   <result pre="were two opposite theories on the cause and nature of" exact="migraine" post="attacks – the vascular and the neuronal theory, which"/>
   <result pre="interaction between genetic, environmental and life-style factors. The pathogenesis of" exact="migraine" post="is determined by phenomena occurring in the sensory cortex"/>
   <result pre="5]. It is commonly accepted, although not firmly evidenced, that" exact="migraine" post="is a threshold disease, released by a brain-related trigger"/>
   <result pre="disease, released by a brain-related trigger [ 6– 9]. Such" exact="migraine" post="trigger and the wave of depolarization induce the activation"/>
   <result pre="the dilation of blood vessels and inflammation, which directly cause" exact="migraine" post="headache ( Figure 2). Cortical spreading depression (CSD), a"/>
   <result pre="spreading depression (CSD), a wave of neuronal hyperexcitability followed by" exact="suppression" post="of neural activity, may be responsible for disturbances occurring"/>
   <result pre="for disturbances occurring in MA [ 10]. Figure 2 A" exact="migraine" post="trigger (yellow thunder) acts on the nucleus (light blue"/>
   <result pre="dilation of brain blood vessels (red), which in turn evokes" exact="migraine" post="headache. This figure does not correspond to actual anatomical"/>
   <result pre="low level of high energy phosphates in the brain of" exact="migraine" post="patients, suggesting defects in brain energy metabolism in migraine"/>
   <result pre="of migraine patients, suggesting defects in brain energy metabolism in" exact="migraine" post="[ 11]. These studies had several limitations. First of"/>
   <result pre="associated with observed effects. Currently, more detailed imaging studies on" exact="migraine" post="mechanisms are conducted with positron emission tomography (PET) and"/>
   <result pre="12] for review). Studies with these techniques showed that repeated" exact="migraine" post="attacks modified metabolism in specific regions of the brain"/>
   <result pre="depletion due to a deficient mitochondrial metabolism in brains of" exact="migraine" post="patients [ 13]. These studies suggest a significant role"/>
   <result pre="of mitochondria in the pathophysiology of migraine. Figure 3 Repeated" exact="migraine" post="attacks are associated with a metabolic modification of specific"/>
   <result pre="to depleted ATP production Mitochondria – an important player in" exact="migraine" post="pathogenesis Approximately three times higher frequency of migraine prevalence"/>
   <result pre="player in migraine pathogenesis Approximately three times higher frequency of" exact="migraine" post="prevalence in females than males suggests either X-linked form"/>
   <result pre="associated with increased neuronal excitability resulting in increased susceptibility to" exact="migraine" post="[ 14]. Any mitochondrial impairment in the brain likely"/>
   <result pre="deficit in mitochondrial energy, which in turn can be a" exact="migraine" post="trigger. Some positive results on the influence of a"/>
   <result pre="the influence of a high-fat and low-carbohydrate (ketogenic) diet on" exact="migraine" post="and epilepsy course seem to support this assumption because"/>
   <result pre="of a high-fat and low-carbohydrate (ketogenic) diet on migraine and" exact="epilepsy" post="course seem to support this assumption because such a"/>
   <result pre="of the mitochondrial electron transport system (ETS, respiratory chain) against" exact="migraine" post="[ 17– 19]. A cross-sectional questionnaire-based study on 85"/>
   <result pre="of tension-type headache (TTH) was observed, but the prevalence of" exact="migraine" post="and probable migraine was only slightly lower. This study"/>
   <result pre="(TTH) was observed, but the prevalence of migraine and probable" exact="migraine" post="was only slightly lower. This study was supported by"/>
   <result pre="study was supported by research showing a higher prevalence of" exact="migraine" post="in individuals with MDs than in the general population"/>
   <result pre="MDs than in the general population [ 21]. Stratification of" exact="migraine" post="cases into MD types suggested that migraine might not"/>
   <result pre="21]. Stratification of migraine cases into MD types suggested that" exact="migraine" post="might not be a phenotypic feature of a particular"/>
   <result pre="Riboflavin as well as MELAS and other mitochondrial diseases link" exact="migraine" post="with mitochondria Riboflavin (vitamin B 2) belongs to the"/>
   <result pre="myopathies [ 23– 29]. As brain metabolism is disturbed in" exact="migraine" post="and riboflavin ameliorates the functioning of ETS, its evaluation"/>
   <result pre="agent is justified [ 30]. Riboflavin prophylaxis was effective in" exact="migraine" post="in adults, which may follow from the general neuroprotective"/>
   <result pre="compound [ 30– 33]. Di Lorenzo et al. reported that" exact="migraine" post="patients with non-H mtDNA haplogroup responded more frequently to"/>
   <result pre="in combination with other agents both in adult and adolescent" exact="migraine" post="patients brought positive results – more details are presented"/>
   <result pre="protect against oxidative stress [ 22]. This compound protected against" exact="hyperglycemia" post="and DNA damage in diabetic mice [ 37]. As"/>
   <result pre="and the American Headache Society ( http://www.aan.com/guidelines). Mitochondrial myopathy, encephalopathy," exact="lactic acidosis," post="and stroke-like episodes (MELAS) is a complex, progressive neurodegenerative"/>
   <result pre="with nausea and vomiting [ 21]. Another mitochondrial disease, myoclonic" exact="epilepsy" post="with ragged-red fibers (MERRF), is also associated with episodes"/>
   <result pre="with episodes of hemicranial headaches. This provokes the question whether" exact="migraine" post="can be a monosymptomatic form of MELAS or MERRF."/>
   <result pre="MERRF. However, no association of mutations typical for MELAS with" exact="migraine" post="was reported. Klopstock et al. did not observe any"/>
   <result pre="another study no association between nine point mutations (substitutions) and" exact="migraine" post="with prolonged aura was observed [ 42]. Therefore, variability"/>
   <result pre="and so these results do not support the thesis on" exact="migraine" post="as a monosymptomatic form of MELAS. However, these studies,"/>
   <result pre="relatively small populations. Table I presents some diseases associated with" exact="migraine" post="[ 43]. Table I Some clinical conditions associated with"/>
   <result pre="migraine [ 43]. Table I Some clinical conditions associated with" exact="migraine" post="[ 43] Condition Disease Genetic syndromes Mitochondrial myopathy, encephalopathy,"/>
   <result pre="migraine [ 43] Condition Disease Genetic syndromes Mitochondrial myopathy, encephalopathy," exact="lactic acidosis," post="and stroke-like episodes (MELAS) Cerebral autosomal dominant arteriopathy with"/>
   <result pre="infarcts and leukoencephalopathy (CARASIL) Hereditary endotheliopathy with retinopathy, nephropathy, and" exact="stroke" post="(HERNS) Fabry disease Vascular acquired diseases Strokes: ischemic and"/>
   <result pre="(TIA) episodes Mitochondrial diseases Chronic progressive external ophthalmoplegia (CPEO) Myoclonic" exact="epilepsy" post="with ragged red fibers (MERRF) Mitochondrial encephalomyopathy, lactic acidosis"/>
   <result pre="(CPEO) Myoclonic epilepsy with ragged red fibers (MERRF) Mitochondrial encephalomyopathy," exact="lactic acidosis" post="and stroke-like episodes (MELAS) Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) Myoclonic"/>
   <result pre="acidosis and stroke-like episodes (MELAS) Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) Myoclonic" exact="epilepsy" post="with ragged-red fibers (MERRF) Kearns-Sayre syndrome Leber hereditary optic"/>
   <result pre="Myoclonic epilepsy with ragged-red fibers (MERRF) Kearns-Sayre syndrome Leber hereditary" exact="optic neuropathy" post="Other diseases Pediatric cyclic vomiting syndrome Epilepsy Energy deficiency"/>
   <result pre="epilepsy with ragged-red fibers (MERRF) Kearns-Sayre syndrome Leber hereditary optic" exact="neuropathy" post="Other diseases Pediatric cyclic vomiting syndrome Epilepsy Energy deficiency"/>
   <result pre="impairment and seizures [ 45]. Therefore, some mitochondrial encephalomyopathies and" exact="migraine" post="can share similar pathways of pathogenesis and so it"/>
   <result pre="it is reasonable to look for a genetic background of" exact="migraine" post="in mtDNA [ 46]. Moreover, this association allows one"/>
   <result pre="this association allows one to speculate on the connection between" exact="migraine" post="and epigenetic changes, which are reported for migraine comorbid"/>
   <result pre="connection between migraine and epigenetic changes, which are reported for" exact="migraine" post="comorbid disorders [ 47, 48]. The human mitochondrial genome"/>
   <result pre="48]. The human mitochondrial genome and its changes related to" exact="migraine" post="The human mitochondrial genome is a closed, double-stranded DNA"/>
   <result pre="the disease [ 53]. As mentioned, a strong connection between" exact="migraine" post="and mitochondria was evidenced by the observation that migraine-affected"/>
   <result pre="in OXPHOS. Oxidative stress is considered as a factor in" exact="migraine" post="pathogenesis and is associated with an excess of ROS,"/>
   <result pre="total oxidant status (TAS) and oxidative stress index (OSI) between" exact="migraine" post="patients and controls [ 58]. An increased level of"/>
   <result pre="58]. An increased level of 8-hydroxy-2’-deoxyguanosine (8-oxoG) in plasma of" exact="migraine" post="patients was observed in that study and this increase"/>
   <result pre="the small number of patients enrolled – less than 100" exact="migraine" post="cases in either study. Moreover, the studies were performed"/>
   <result pre="in those papers are a weak rationale to causatively correlate" exact="migraine" post="with oxidative stress and allocate the source of this"/>
   <result pre="were observed in trigeminal neurons in a rat model of" exact="migraine" post="[ 67]. Variability of mitochondrial DNA in migraine The"/>
   <result pre="model of migraine [ 67]. Variability of mitochondrial DNA in" exact="migraine" post="The mitochondrial genome has limited autonomy as thousands of"/>
   <result pre="nuclear genes involved in mitochondrial functioning may be important in" exact="migraine" post="pathogenesis. The problem of genetic variability in migraine is"/>
   <result pre="important in migraine pathogenesis. The problem of genetic variability in" exact="migraine" post="is connected with migraine hereditability. An identical twin study"/>
   <result pre="The problem of genetic variability in migraine is connected with" exact="migraine" post="hereditability. An identical twin study resulted in the conclusion"/>
   <result pre="identical twin study resulted in the conclusion of approximately 50%" exact="migraine" post="hereditability [ 68]. A positive association between the m.4336A&amp;gt;G"/>
   <result pre="m.4336A&amp;gt;G mutation, located on the tRNA Gln , gene and" exact="sensorineural hearing loss" post="and/or migraine was observed [ 69]. Wang et al."/>
   <result pre="the tRNA Gln , gene and sensorineural hearing loss and/or" exact="migraine" post="was observed [ 69]. Wang et al. found an"/>
   <result pre="mtDNA replication were associated with both cyclic vomiting syndrome and" exact="migraine" post="without aura. In another study, Zaki et al. found"/>
   <result pre="an association between two mtDNA polymorphisms, m.16519C&amp;gt;T and m.3010G&amp;gt;A, and" exact="migraine" post="headache and cyclic vomiting syndrome [ 71]. A higher,"/>
   <result pre="syndrome [ 71]. A higher, about three times, prevalence of" exact="migraine" post="in individuals with the m.3243A&amp;gt;G mutation was reported ["/>
   <result pre="and women separately. No association between the m.11084A&amp;gt;G polymorphism and" exact="migraine" post="occurrence, whether MA or MO, in a Japanese population"/>
   <result pre="Danish population [ 74]. This mutation was detected neither in" exact="migraine" post="patients, MA or MO, nor controls. It has functional"/>
   <result pre="was absent in tension-type headache patients and individuals with no" exact="migraine" post="[ 75]. Mitochondrial haplogroup U, represented by the 12308A&amp;gt;G"/>
   <result pre="represented by the 12308A&amp;gt;G polymorphism, can play a role in" exact="migraine" post="pathophysiology as this polymorphism was reported to associate with"/>
   <result pre="was reported to associate with an increased risk of occipital" exact="stroke" post="[ 76, 77]. Also other haplogroups in mtDNA can"/>
   <result pre="efficacy of energy production by ETS [ 78]. As mentioned," exact="migraine" post="is associated with energy deficit, so that haplogroup and"/>
   <result pre="and its polymorphisms of mtDNA may influence the susceptibility to" exact="migraine" post="as well as to other diseases associated with energy"/>
   <result pre="are few studies on the association between mtDNA variants and" exact="migraine" post="occurrence and these studies are usually performed on relatively"/>
   <result pre="Therefore, further studies on the role of mtDNA disturbances in" exact="migraine" post="are justified and needed. Epigenetics of mtDNA and its"/>
   <result pre="justified and needed. Epigenetics of mtDNA and its potential in" exact="migraine" post="Epigenetics deals with mechanisms of the regulation of gene"/>
   <result pre="modifications and RNA regulation. Two aspects of epigenetic regulation in" exact="migraine" post="pathophysiology can be considered. One is related to transient"/>
   <result pre="clinical trials [ 79]. Such therapy is also considered in" exact="migraine" post="[ 80]. Valproate, a histone deacetylate inhibitor, has been"/>
   <result pre="has been successfully tested in prophylaxis of several classes of" exact="migraine" post="[ 81– 85]. However, its action cannot be unequivocally"/>
   <result pre="study suggests a potentially important role of epigenetic modifications in" exact="migraine" post="pathogenesis, which was supported by subsequent studies [ 89–"/>
   <result pre="62 independent regions in DNA isolated from peripheral blood of" exact="migraine" post="patients, which were specifically methylated [ 89]. Many migraine"/>
   <result pre="of migraine patients, which were specifically methylated [ 89]. Many" exact="migraine" post="comorbid mitochondrial diseases are associated with changes in the"/>
   <result pre="to explore the role of epigenetic modifications to mtDNA in" exact="migraine" post="pathogenesis. However, the issue of epigenetics in mitochondria is"/>
   <result pre="to be associated with an abnormal mtDNA methylation pattern in" exact="amyotrophic lateral sclerosis," post="a progressive neurological disease [ 98]. However, it should"/>
   <result pre="knowledge the role of lncRNA, either nuclear or mitochondrial, in" exact="migraine" post="pathophysiology has not been explored so far. An association"/>
   <result pre="extension dependent on stress [ 117]. Several loci associated with" exact="migraine" post="in the human genome have been identified in genome-wide"/>
   <result pre="and premature organismal aging. So far, no mtDNA damage in" exact="migraine" post="has been reported, but the extent of mtDNA damage"/>
   <result pre="expression of PGC-1α in neurons of a rat model of" exact="migraine" post="provokes a question about the potential role of this"/>
   <result pre="a key element in the regulation of mitochondrial number, in" exact="migraine" post="pathogenesis [ 123]. Migraine can be diagnosed as an"/>
   <result pre="There is no general agreement whether these two categories of" exact="migraine" post="are different or not. Some reports suggest that there"/>
   <result pre="that there are essential differences between these two forms of" exact="migraine" post="not resulting from individual susceptibility to this disease. These"/>
   <result pre="of all with a prolonged aura and stroke-like episodes in" exact="migraine" post="associated with other diseases. However, Vollono et al. recently"/>
   <result pre="associated with other diseases. However, Vollono et al. recently observed" exact="migraine" post="without aura in about 80% of mitochondrial disease cases"/>
   <result pre="[ 43]. Therefore, it may be difficult to distinguish autonomous" exact="migraine" post="from migraine associated with other diseases. Several mitochondrial encephalomyopathies"/>
   <result pre="Therefore, it may be difficult to distinguish autonomous migraine from" exact="migraine" post="associated with other diseases. Several mitochondrial encephalomyopathies share neurological"/>
   <result pre="in its supply can result in an increased sensitivity to" exact="migraine" post="attack. Complex mitochondrial diseases cannot be related exclusively to"/>
   <result pre="pedigree studies to find a correlation between mtDNA mutation and" exact="migraine" post="to eventually identify true causal variants. Moreover, these studies"/>
   <result pre="to mitochondria ( http://mitoproteome.org/). Riboflavin proved to be effective in" exact="migraine" post="prophylaxis in several clinical trials. However, some issues concerning"/>
   <result pre="completely known. In clinical practice, it is important to distinguish" exact="migraine" post="from monosymptomatic forms of other diseases manifested by headaches,"/>
   <result pre="manifested by headaches, first of all MELAS, especially considering that" exact="migraine" post="can share morbidity with some mitochondrial disorders. Mitochondria add"/>
   <result pre="share morbidity with some mitochondrial disorders. Mitochondria add complexity to" exact="migraine" post="pathogenesis. Therefore, new integrated approaches are needed to better"/>
   <result pre="pathogenesis. Therefore, new integrated approaches are needed to better understand" exact="migraine" post="pathophysiology and translate molecular research into clinical practice to"/>
   <result pre="accumulating body of evidence suggests the involvement of mitochondria in" exact="migraine" post="pathogenesis, the exact mechanism of this involvement is unknown."/>
   <result pre="unknown. The potential role of mitochondrially enriched miRNAs (mitomiRNAs) in" exact="migraine" post="pathogenesis should be investigated. GWAS provided information on many"/>
   <result pre="However, the evaluation of the significance of mitochondrial genome/epigenome in" exact="migraine" post="pathophysiology requires new methods and approaches. Conflict of interest"/>
   <result pre="Goadsby PJ CGRP and its receptors provide new insights into" exact="migraine" post="pathophysiology Nature Rev Neurol 2010 6 573 82 20820195"/>
   <result pre="KM Al-Sayed F The threshold for phosphenes is lower in" exact="migraine" post="Cephalalgia 2003 23 258 63 12716342 7 Mulleners WM"/>
   <result pre="Palmer JE Koehler PJ Vredeveld JW Visual cortex excitability in" exact="migraine" post="with and without aura Headache 2001 41 565 72"/>
   <result pre="a reduction in high-energy phosphates in the occipital lobe of" exact="migraine" post="without aura patients Cephalalgia 2011 31 1243 53 21289000"/>
   <result pre="C Correlation of increase in phosphene threshold with reduction of" exact="migraine" post="frequency: observation of levetiracetam-treated subjects Headache 2008 48 1490"/>
   <result pre="20 44 27215627 11 Montagna P Magnetic resonance spectroscopy in" exact="migraine" post="Cephalalgia 1995 15 323 7 7585931 12 Russo A"/>
   <result pre="Tarducci R Presciutti O et al. Functional 1H-MRS findings in" exact="migraine" post="patients with and without aura assessed interictally Neuroimage 2005"/>
   <result pre="and medium-chain triglyceride ketogenic diets in the treatment of childhood" exact="epilepsy" post="Epilepsia 2009 50 1109 17 19054400 17 D’Onofrio F"/>
   <result pre="Spitaleri D Casucci G Bussone G Usefulness of nutraceuticals in" exact="migraine" post="prophylaxis Neurol Sci 2017 38 S117 120 18 Gaul"/>
   <result pre="120 18 Gaul C Diener HC Danesch U Improvement of" exact="migraine" post="symptoms with a proprietary supplement containing riboflavin, magnesium and"/>
   <result pre="of CoEnzyme Q10 in the prevention of pediatric and adolescent" exact="migraine" post="Cephalalgia 2011 31 897 905 21586650 20 Kraya T"/>
   <result pre="C Kroksmark AK Moslemi AR Kollberg G Oldfors A Benign" exact="mitochondrial myopathy" post="with exercise intolerance in a large multigeneration family due"/>
   <result pre="Kroksmark AK Moslemi AR Kollberg G Oldfors A Benign mitochondrial" exact="myopathy" post="with exercise intolerance in a large multigeneration family due"/>
   <result pre="3650 60 27029320 30 Thompson DF Saluja HS Prophylaxis of" exact="migraine" post="headaches with riboflavIn: a systematic review J Clin Pharm"/>
   <result pre="O Mauskop A Nutraceuticals in acute and prophylactic treatment of" exact="migraine" post="Curr Treat Options Neurol 2016 18 14 26923604 32"/>
   <result pre="SA Riboflavin has neuroprotective potential: focus on parkinson’s disease and" exact="migraine" post="Front Neurol 2017 8 333 28775706 33 Namazi N"/>
   <result pre="Heshmati J Tarighat-Esfanjani A Supplementation with riboflavin (Vitamin B2) for" exact="migraine" post="prophylaxis in adults and children: a review Int J"/>
   <result pre="J Jacquy J Lenaerts M Effectiveness of high-dose riboflavin in" exact="migraine" post="prophylaxis A randomized controlled trial. Neurology 1998 50 466"/>
   <result pre="Arefnia E Effectiveness of vitamin B2 versus sodium valproate in" exact="migraine" post="prophylaxis: a randomized clinical trial Electron Physician 2015 7"/>
   <result pre="P Papagiannuli E Diener HC Reichmann H Mitochondrial DNA in" exact="migraine" post="with aura Neurology 1996 46 1735 8 8649580 40"/>
   <result pre="mtDNA A3243G MELAS mutation is not associated with multigenerational female" exact="migraine" post="Neurology 2000 54 1005 7 10691007 41 Di Gennaro"/>
   <result pre="al. Assessing the relative incidence of mitochondrial DNA A3243G in" exact="migraine" post="without aura with maternal inheritance Headache 2000 40 568"/>
   <result pre="et al. Study of mitochondrial DNA mutations in patients with" exact="migraine" post="with prolonged aura Headache 2004 44 674 7 15209689"/>
   <result pre="A Enriquez JA Micol V Fernandez-Silva P Attardi G The" exact="mitochondrial myopathy," post="encephalopathy, lactic acidosis, and stroke-like episode syndrome-associated human mitochondrial"/>
   <result pre="Micol V Fernandez-Silva P Attardi G The mitochondrial myopathy, encephalopathy," exact="lactic acidosis," post="and stroke-like episode syndrome-associated human mitochondrial tRNALeu(UUR) mutation causes"/>
   <result pre="Abnormal brain and muscle energy metabolism shown by 31P-MRS in" exact="familial hemiplegic migraine" post="J Neurol Sci 1995 129 214 22 7608738 55"/>
   <result pre="and muscle energy metabolism shown by 31P-MRS in familial hemiplegic" exact="migraine" post="J Neurol Sci 1995 129 214 22 7608738 55"/>
   <result pre="Taysi S Oxidative stress and DNA damage in patients with" exact="migraine" post="J Headache Pain 2016 17 10 26883365 59 Alp"/>
   <result pre="A Kocyigit A Oxidative and antioxidative balance in patients of" exact="migraine" post="Eur Rev Med Pharmacol Sci 2010 14 877 82"/>
   <result pre="biogenesis in trigeminal ganglion neurons in a rat model of" exact="migraine" post="Neurosci Lett 2017 636 127 33 27984195 68 Gasparini"/>
   <result pre="Griffiths LR Studies on the pathophysiology and genetic basis of" exact="migraine" post="Curr Genomics 2013 14 300 15 24403849 69 Finnila"/>
   <result pre="S Autere J Lehtovirta M et al. Increased risk of" exact="sensorineural hearing loss" post="and migraine in patients with a rare mitochondrial DNA"/>
   <result pre="M et al. Increased risk of sensorineural hearing loss and" exact="migraine" post="in patients with a rare mitochondrial DNA variant 4336A&amp;gt;G"/>
   <result pre="K et al. Mitochondrial DNA control region sequence variation in" exact="migraine" post="headache and cyclic vomiting syndrome Am J Med Genet"/>
   <result pre="al. Two common mitochondrial DNA polymorphisms are highly associated with" exact="migraine" post="headache and cyclic vomiting syndrome Cephalalgia 2009 29 719"/>
   <result pre="Guo S Esserlind AL Andersson Z et al. Prevalence of" exact="migraine" post="in persons with the 3243A&amp;gt;G mutation in mitochondrial DNA"/>
   <result pre="74 Russell MB Diamant M Norby S Genetic heterogeneity of" exact="migraine" post="with and without aura in Danes cannot be explained"/>
   <result pre="Takahashi K Mutation in platelet mitochondrial gene in patients with" exact="migraine" post="Cephalalgia 1995 15 10 8749240 76 Sparaco M Feleppa"/>
   <result pre="sodium valproate (Depakine) versus dexamethasone for the treatment of acute" exact="migraine" post="headache: a double-blind randomized clinical trial Clin Exp Emerg"/>
   <result pre="venlafaxine, flunarizine, and valproic acid in the prophylaxis of vestibular" exact="migraine" post="Front Neurol 2017 8 524 29075232 83 Yi L"/>
   <result pre="Chen N et al. Valproate plays a protective role against" exact="migraine" post="by inhibiting protein kinase C signalling in nitroglycerin-treated mice"/>
   <result pre="methylation profiling in whole blood reveals epigenetic signatures associated with" exact="migraine" post="BMC Genomics 2018 19 69 29357833 90 van der"/>
   <result pre="versatile master regulators of gene expression and crucial players in" exact="cancer" post="Am J Transl Res 2012 4 127 50 22611467"/>
   <result pre="as predictors for CNS relapse of systemic diffuse large B-cell" exact="lymphoma" post="Oncotarget 2017 8 86020 30 29156774 106 Leggio L"/>
   <result pre="W Up-regulation of the long non-coding RNA RMRP contributes to" exact="glioma" post="progression and promotes glioma cell proliferation and invasion Arch"/>
   <result pre="long non-coding RNA RMRP contributes to glioma progression and promotes" exact="glioma" post="cell proliferation and invasion Arch Med Sci 2017 13"/>
   <result pre="profiles of lncRNAs and mRNAs in ER-negative and HER-2 positive" exact="breast cancer" post="Arch Med Sci Civil Dis 2017 2 e148 60"/>
   <result pre="of lncRNAs and mRNAs in ER-negative and HER-2 positive breast" exact="cancer" post="Arch Med Sci Civil Dis 2017 2 e148 60"/>
   <result pre="association with strong perturbation of long noncoding RNAs expression in" exact="down syndrome" post="Int J Biochem Cell Biol 2017 92 115 20"/>
   <result pre="et al. Genome-wide association study identifies novel susceptibility loci for" exact="migraine" post="in Han Chinese resided in Taiwan Cephalalgia 2018 38"/>
   <result pre="Bettella F Witoelar A et al. Shared genetic risk between" exact="migraine" post="and coronary artery disease: a genome-wide analysis of common"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6659392/results/search/disease/results.xml">
   <result pre="nervous system (CNS) involvement as the underlying mechanism of pain" exact="hypersensitivity" post="in SOR. Based on the mutual central processing of"/>
   <result pre="which may be associated with abnormal sensory processing such as" exact="hypersensitivity" post="to different sensory stimuli (Zhang and Sun, 2011). The"/>
   <result pre="system including the pain, auditory, tactile, and visual systems. The" exact="hypersensitivity" post="and lingering in response to experimental pain observed in"/>
   <result pre="recently found SMD to be a contributing factor for having" exact="complex regional pain syndrome" post="(CRPS). CRPS is a chronic pain syndrome of unknown"/>
   <result pre="2009; Noseda and Burstein, 2013; Schwedt, 2013). Thus, this multi-sensory" exact="hypersensitivity" post="may point to an abnormal central multisensory integration in"/>
   <result pre="hypersensitivity may point to an abnormal central multisensory integration in" exact="migraine" post="(Schwedt, 2013). Similar to the suggested SMD pathophysiology, the"/>
   <result pre="pathophysiology, the underlying neurophysiological mechanisms of increased sensitivity in inter-ictal" exact="migraine" post="suggest alterations in the cortical circuits and neurotransmitters which"/>
   <result pre="results of our recent study have revealed that 45% of" exact="migraine" post="patients are diagnosed with SMD (Granovsky et al., 2018),"/>
   <result pre="2009; Bar-Shalita et al., 2015). The association of SOR with" exact="migraine" post="pain symptoms such as having sensory aura, a higher"/>
   <result pre="cortical hyperexcitability and the lack of habituation to light in" exact="migraine" post="patients (Boulloche et al., 2010). This phenomenon can be"/>
   <result pre="state characterized by a global disturbance in sensory responsiveness is" exact="fibromyalgia" post="(FM). Many studies have reported on greater sensitivity to"/>
   <result pre="Responses as a Shared Mechanism for SMD and Pain In" exact="migraine" post="and FM, along with enhanced pain psychophysical responses, cortical"/>
   <result pre="a standardized low resolution brain electromagnetic tomography (sLORETA) study in" exact="migraine" post="that these neurophysiological markers may be linked with enhanced"/>
   <result pre="refer to the abnormal alpha, theta or beta activity in" exact="migraine" post="and FM. More specifically in migraine, increased alpha power"/>
   <result pre="and Yarnitsky, 2013; Yarnitsky et al., 2014; Yarnitsky, 2015), including" exact="migraine" post="and FM. Despite the still open chicken-and-egg question on"/>
   <result pre="2016). Extent of recovery in the first 12 months of" exact="complex regional pain syndrome" post="type-1: a prospective study . Eur. J. Pain 20,"/>
   <result pre="C.-C. Wang S.-J. ( 2018). Exploring resting-state EEG complexity before" exact="migraine" post="attacks. Cephalalgia 38, 1296– 1306. 10.1177/0333102417733953 28958151 Cao Z."/>
   <result pre=". ( 2016). Resting-state EEG power and coherence vary between" exact="migraine" post="phases. J. Headache Pain 17: 102. 10.1186/s10194-016-0697-7 27807767 Chien"/>
   <result pre="al. . ( 2014). Update on laser-evoked potential findings in" exact="fibromyalgia" post="patients in light of clinical and skin biopsy features"/>
   <result pre="EEG α and β bands during intermittent flash stimulation in" exact="migraine" post="with and without aura . Cephalalgia 33, 938– 947."/>
   <result pre="Mauguière F. ( 2016). Central nervous system underpinnings of sensory" exact="hypersensitivity" post="in migraine: insights from neuroimaging and electrophysiological studies ."/>
   <result pre="Del Paso G. A. ( 2017). Diminished interoceptive awareness in" exact="fibromyalgia" post="syndrome. Behav. Med. 43, 100– 107. 10.1080/08964289.2015.1094442 26431269 Dyck"/>
   <result pre="A. ( 2018). Altered theta oscillations in resting EEG of" exact="fibromyalgia" post="syndrome patients. Eur. J. Pain 22, 49– 57. 10.1002/ejp.1076"/>
   <result pre="psychophysical study of auditory and pressure sensitivity in patients with" exact="fibromyalgia" post="and healthy controls . J. Pain 9, 417– 422."/>
   <result pre="potentials following painful CO 2 laser stimulation in subjects with" exact="fibromyalgia" post="syndrome . Pain 58, 185– 193. 10.1016/0304-3959(94)90198-8 7816486 Gottrup"/>
   <result pre="2010). Validation of proposed diagnostic criteria (the &quot;Budapest Criteria&quot;) for" exact="complex regional pain syndrome" post=". Pain 150, 268– 274. 10.1016/j.pain.2010.04.030 20493633 Harper D."/>
   <result pre="V. et al. . ( 2009). Elevated insular glutamate in" exact="fibromyalgia" post="is associated with experimental pain. Arthritis Rheum. 60, 3146–"/>
   <result pre="Y. Yarnitsky D. ( 2010). Orbitofrontal disinhibition of pain in" exact="migraine" post="with aura: an interictal EEG-mapping study . Cephalalgia 30,"/>
   <result pre="E. M. ( 2013). A review of psychosocial factors in" exact="complex regional pain syndrome." post="J. Clin. Psychol. Med. Settings 20, 247– 254. 10.1007/s10880-012-9322-3"/>
   <result pre="somatosensory evoked potentials after painful laser stimulation in patients with" exact="fibromyalgia" post="syndrome . Electroencephalogr. Clin. Neurophysiol. 100, 165– 168. 10.1016/0013-4694(95)00259-6"/>
   <result pre="A. Kaitz M. ( 1997). Somatosensory functioning in children with" exact="attention deficit hyperactivity disorder." post="Dev. Med. Child Neurol. 39, 464– 468. 10.1111/j.1469-8749.1997.tb07466.x 9285437"/>
   <result pre="2012). Altered excitation-inhibition balance in the brain of patients with" exact="diabetic neuropathy." post="Acad. Radiol. 19, 607– 612. 10.1016/j.acra.2012.02.004 22463961 Peyron R."/>
   <result pre="T. ( 2015). Potential risk factors for the onset of" exact="complex regional pain syndrome" post="type 1: a systematic literature review . Anesthesiol. Res."/>
   <result pre=". ( 2009). Excitatory neurotransmitters in brain regions in interictal" exact="migraine" post="patients. Mol. Pain 5: 34. 10.1186/1744-8069-5-34 19566960 Price D."/>
   <result pre="20160007. 10.1098/rstb.2016.0007 28080966 Staud R. ( 2011). Brain imaging in" exact="fibromyalgia" post="syndrome. Clin. Exp. Rheumatol. 29, S109– S117. 22243558 Staud"/>
   <result pre="α rhythm power and the effect of photic stimulation in" exact="migraine" post="with brain mapping. Clin. Electroencephalogr. 23, 1– 6. 10.1177/155005949202300103"/>
   <result pre="M. I. ( 2017). Exteroceptive and interoceptive body-self awareness in" exact="fibromyalgia" post="patients. Front. Hum. Neurosci. 11: 117. 10.3389/fnhum.2017.00117 28348526 Valeriani"/>
   <result pre="al. . ( 2003). Reduced habituation to experimental pain in" exact="migraine" post="patients: a CO2 laser evoked potential study . Pain"/>
   <result pre="( 2014). Health-related quality of life in 975 patients with" exact="complex regional pain syndrome" post="type 1 . Pain 155, 629– 634. 10.1016/j.pain.2013.12.017 24342465"/>
   <result pre="Altered resting-state ascending/descending pathways associated with the posterior thalamus in" exact="migraine" post="without aura . Neuroreport 27, 257– 263. 10.1097/wnr.0000000000000529 26825347"/>
   <result pre="Weiner S. S. Brunner F. ( 2013). Prognostic factors in" exact="complex regional pain syndrome" post="1: a systematic review. J. Rehabil. Med. 45, 225–"/>
   <result pre="acid receptor activation; implications for the treatment of post-injury pain" exact="hypersensitivity" post="states . Pain 44, 293– 299. 10.1016/0304-3959(91)90100-c 1828878 Yarnitsky"/>
   <result pre="Pratt H. Engel-Yeger B. ( 2018). Neurophysiological manifestations of auditory" exact="hypersensitivity" post="correlate with daily life experiences . Neurosci. Med. 9,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6664028/results/search/disease/results.xml">
   <result pre="comply with these terms. Abstract The relationship between headache and" exact="epilepsy" post="is complex and despite the nature of this association"/>
   <result pre="the issues related to the neurophysiopathological link between headache and" exact="epilepsy" post="as well as to the classification of these epileptic"/>
   <result pre="epileptic events as &quot;autonomic seizure.&quot; ictal epileptic headache hemicrania epileptica" exact="epilepsy" post="migraine tension-type headache EEG autonomic seizures panayiotopoulos syndrome fig-count:"/>
   <result pre="events as &quot;autonomic seizure.&quot; ictal epileptic headache hemicrania epileptica epilepsy" exact="migraine" post="tension-type headache EEG autonomic seizures panayiotopoulos syndrome fig-count: table-count:"/>
   <result pre="page-count: word-count: Headache, Epilepsy, and &quot;Ictal Epileptic Headache&quot; Headache and" exact="epilepsy" post="are characterized by transient attacks of altered brain function."/>
   <result pre="attacks of altered brain function. The links between headache and" exact="epilepsy" post="are complex and in the last century there have"/>
   <result pre="to state that chronic headache itself may occasionally represent an" exact="epilepsy" post="condition and that often headache can represent the only"/>
   <result pre="to anti-migraine therapy ( 35– 39), particularly in children with" exact="epilepsy" post="that also express other types of seizures ( 34)."/>
   <result pre="increased neocortical excitability is the leading mechanism underlying headache and" exact="epilepsy" post="( 53). Taking into account that in migraine, during"/>
   <result pre="to be the most likely pathophysiological link between headache and" exact="epilepsy" post="( 5, 6, 36, 39, 40, 58, 59), is"/>
   <result pre="presents a peri-ictal headache than a cephalalgic patient who presents" exact="epilepsy" post="( 36, 40, 43, 50, 53, 57, 60). The"/>
   <result pre="of epileptic seizures ( 5, 50, 55, 56, 62). Both" exact="migraine" post="and epilepsy have an important genetic component, with strong"/>
   <result pre="seizures ( 5, 50, 55, 56, 62). Both migraine and" exact="epilepsy" post="have an important genetic component, with strong evidence pointing"/>
   <result pre="evidence pointing to a shared genetic basis between headache and" exact="epilepsy" post="emerging from clinical/EEG and genetic studies on Familial Hemiplegic"/>
   <result pre="69– 73). Other genetic findings pointing to a link between" exact="migraine" post="and epilepsy have been published ( 74, 75). In"/>
   <result pre="Other genetic findings pointing to a link between migraine and" exact="epilepsy" post="have been published ( 74, 75). In addition, glutamate"/>
   <result pre="(sodium, potassium, and chloride) function might be impaired in both" exact="epilepsy" post="and migraine ( 69, 79). In Most Cases IEH"/>
   <result pre="and chloride) function might be impaired in both epilepsy and" exact="migraine" post="( 69, 79). In Most Cases IEH is Probably"/>
   <result pre="long-lasting IEH attacks may even fulfill the criteria for autonomic" exact="status epilepticus" post="( 81). Although it is difficult to explain the"/>
   <result pre="molecules, blood or infection), causing a painful perception similar to" exact="migraine" post="and its most commonly associated symptoms/signs (nausea, throbbing pain,"/>
   <result pre="of the Vagus Nerve Stimulation (VNS) in the treatment of" exact="migraine" post="and cluster headaches are not yet clear; probably, it"/>
   <result pre="autonomic regulation, enteroception, and somatosensation. There are complex behaviors in" exact="migraine" post="(conscious awareness and error detection), which are less investigated"/>
   <result pre="be to decode the signals of altered internal milieu in" exact="migraine" post="(along with other chronic pain conditions), taking into account"/>
   <result pre="References 1. Rajapakse T Buchhalter J . The borderland of" exact="migraine" post="and epilepsy in children. Headache. ( 2016) 56: 1071–"/>
   <result pre="Rajapakse T Buchhalter J . The borderland of migraine and" exact="epilepsy" post="in children. Headache. ( 2016) 56: 1071– 80. 10.1111/head.12827"/>
   <result pre="C et al. . A case with atypical childhood occipital" exact="epilepsy" post="&quot;Gastaut type&quot;: an ictal migraine manifestation with a good"/>
   <result pre="case with atypical childhood occipital epilepsy &quot;Gastaut type&quot;: an ictal" exact="migraine" post="manifestation with a good response to intravenous diazepam ."/>
   <result pre="M et al. . Ictal epileptic headache revealing non convulsive" exact="status epilepticus" post="in a case of eyelid myoclonia with absences ."/>
   <result pre="of suspected ictal epileptic headache, a rare form of paediatric" exact="epilepsy" post=". Acta Paediatr. ( 2017) 106: 786– 90. 10.1111/apa.13713"/>
   <result pre="Tonekaboni H . Headache as a sole manifestation in nonconvulsive" exact="status epilepticus." post="J Child Neurol. ( 2006) 21: 981– 3. 10.1177/08830738060210111801"/>
   <result pre="F . Migraine triggered by epileptic discharges in a Rasmussen's" exact="encephalitis" post="patient after surgery . Brain Dev. ( 2011) 33:"/>
   <result pre="Wieser HG Egli M Hemicrania epileptica: synchronous ipsilateral ictal headachewith" exact="migraine" post="features. In: Andermann F Lugaresi E editors. Migraine and"/>
   <result pre="10: 327– 329. 10.1007/s10194-009-0149-8 19705058 36. Parisi P Why is" exact="migraine" post="rarely, and not usually, the sole ictal epileptic manifestation?"/>
   <result pre="Buttinelli C Kasteleijn-NolstTrenéte DGA . Hypothesis on neurophysiopathological mechanisms linking" exact="epilepsy" post="and headache. Med Hypotheses. ( 2008) 70: 1150– 4."/>
   <result pre="Cantonetti L Parisi P Chapter 97: Visual stimuli, photosensitivity and" exact="photosensitive epilepsy." post="In: Shorvon SD Andermann F Guerrini F editors. The"/>
   <result pre="al. entitled &quot;Migraine triggered by epileptic discharges in a Rasmussen's" exact="encephalitis" post="patient after surgery&quot;. Brain Dev. ( 2011) 33: 704–"/>
   <result pre="48. Belcastro V Striano P Parisi P . Migraine and" exact="epilepsy" post="terminology and classification: opening Pandora's box. Epileptic Disord. ("/>
   <result pre="7. 10.1007/s10072-012-1012-2 22426786 50. Parisi P The complex relationship between" exact="epilepsy" post="and headache and the concept of ictal epileptic headache"/>
   <result pre="as the basis for facilitated spreading depression in Ca(v)2.1 knockin" exact="migraine" post="mice . Neuron. ( 2009) 61: 762– 73. 10.1016/j.neuron.2009.01.027"/>
   <result pre="MA . Intrinsic brain activity triggers trigeminal meningeal afferents in" exact="migraine" post="model. Nat Med. ( 2002) 8: 136– 42. 10.1038/nm0202-136"/>
   <result pre="encoding the Na +/K + pump a2 subunit associated with" exact="familial hemiplegic migraine" post="type 2 . Nat Genet. ( 2003) 33: 192–"/>
   <result pre="Na +/K + pump a2 subunit associated with familial hemiplegic" exact="migraine" post="type 2 . Nat Genet. ( 2003) 33: 192–"/>
   <result pre="E Haan J Raininko R et al. . Childhood epilepsy," exact="familial hemiplegic migraine," post="cerebellar ataxia, and a new CACNA1A mutation . Neurology."/>
   <result pre="Raininko R et al. . Childhood epilepsy, familial hemiplegic migraine," exact="cerebellar ataxia," post="and a new CACNA1A mutation . Neurology. ( 2004)"/>
   <result pre="in ATP1A2 and CACNA1A are frequent in early-onset sporadic hemiplegic" exact="migraine" post=". Neurology. ( 2010) 75: 967– 72. 10.1212/WNL.0b013e3181f25e8f 20837964"/>
   <result pre="MN Ca(V)2.1 voltage activated calcium channels and synaptic transmission in" exact="familial hemiplegic migraine" post="pathogenesis . J Physiol. ( 2012) 106: 12– 22."/>
   <result pre="voltage activated calcium channels and synaptic transmission in familial hemiplegic" exact="migraine" post="pathogenesis . J Physiol. ( 2012) 106: 12– 22."/>
   <result pre="in the Na +/K +-ATPase pump gene ATP1A2 associated with" exact="familial hemiplegic migraine" post="and benign familial infantile convulsions . Ann Neurol. ("/>
   <result pre="Na +/K +-ATPase pump gene ATP1A2 associated with familial hemiplegic" exact="migraine" post="and benign familial infantile convulsions . Ann Neurol. ("/>
   <result pre="J Palos TP Mutations in the glutamate transporter EAAT1 causes" exact="episodic ataxia," post="hemiplegia, and seizures . Neurology. ( 2005) 65: 529–"/>
   <result pre="A genetic analysis of serotonergic biosynthetic and metabolic enzymes in" exact="migraine" post="using a DNA pooling approach . J Hum Genet."/>
   <result pre="Panayiotopoulos syndrome: an important electroclinical example of benign childhood system" exact="epilepsy" post=". Epilepsia. ( 2007) 48: 1044– 53. 10.1111/j.1528-1167.2007.01096.x 17441996"/>
   <result pre="Demirbilek V Dervent A Fejerman N et al. . Autonomic" exact="status epilepticus" post="in Panayiotopoulos syndrome and other childhood and adult epilepsies:"/>
   <result pre="72. 10.1111/j.1528-1167.2007.01087.x 17442005 82. Nobili L . Nocturnal frontal lobe" exact="epilepsy" post="and non-rapid eye movement sleep parasomnias: differences and similarities"/>
   <result pre="angiography of intracranial and extracranial arteries in patients with spontaneous" exact="migraine" post="without aura: a cross-sectional study . Lancet Neurol. ("/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6679182/results/search/disease/results.xml">
   <result pre="( http://creativecommons.org/licenses/by/4.0/). Abstract MicroRNAs (miRs) have emerged as biomarkers of" exact="migraine" post="disease in both adults and children. In this study"/>
   <result pre="saliva of young subjects (age 11 ± 3.467 years) with" exact="migraine" post="without aura (MWA), while some underwent pharmacological treatment, and"/>
   <result pre="[ 1]. NSAIDs represent the first line treatment for acute" exact="migraine" post="attack [ 2, 3, 4], but their use can"/>
   <result pre="choice of treatment, to monitor the improvement or worsening of" exact="migraine" post="symptoms during the treatment and to determine the appropriate"/>
   <result pre="(CGRP) [ 9], since its serum level increases during acute" exact="migraine" post="attack [ 10] and decreases upon treatment with onabotulinumtoxin"/>
   <result pre="migraine-headache, that plasma CGRP level could be able to differentiate" exact="migraine" post="from non-migraine headache. However, other authors reported that it"/>
   <result pre="modification in chronic neuropathic pain [ 19, 20] and in" exact="migraine" post="[ 21, 22] and represent a functional interplay between"/>
   <result pre="25] described an increased expression of has-miR-34a-5p in patients with" exact="migraine" post="attacks, while Chen et al. [ 26] reported that"/>
   <result pre="in serum and saliva of treated and untreated children with" exact="migraine" post="without aura. 2. Materials and Methods 2.1. Study Subjects"/>
   <result pre="from their parents. 2.2. Inclusion and Exclusion Criteria Subjects with" exact="migraine" post="without aura, of both sexes and aged from 4–17"/>
   <result pre="excluded if they: Were aged &amp;lt;4 years or &amp;gt;18 years;" exact="obesity" post="(body mass index &amp;gt;95 percentiles), or had a history"/>
   <result pre="(body mass index &amp;gt;95 percentiles), or had a history of" exact="cardiovascular disease," post="hypertension, diabetes, hyperlipidemia, or stroke; a heavy smoker (&amp;gt;10"/>
   <result pre="bipolar disorders according to DSM-5; or had a history of" exact="substance abuse," post="mental retardation (intelligence quotient &amp;lt;70), genetic syndromes (e.g., Down"/>
   <result pre="liver or renal diseases, gastrointestinal disorders such as peptic or" exact="duodenal ulcer," post="dyspepsia, or heartburn and hypersensitivity to NSAIDs. Patients enrolled"/>
   <result pre="such as peptic or duodenal ulcer, dyspepsia, or heartburn and" exact="hypersensitivity" post="to NSAIDs. Patients enrolled were in migraine ictal phase."/>
   <result pre="or heartburn and hypersensitivity to NSAIDs. Patients enrolled were in" exact="migraine" post="ictal phase. 2.3. Experimental Protocol In a balanced recruitment"/>
   <result pre="2.3. Experimental Protocol In a balanced recruitment study, subjects with" exact="migraine" post="were enrolled in two groups: Treated-group: subjects with migraine"/>
   <result pre="with migraine were enrolled in two groups: Treated-group: subjects with" exact="migraine" post="without aura that were on pharmacological treatment at the"/>
   <result pre="observation (with magnesium or NSAIDs; i.e., acetaminophen). Untreated-group: subjects with" exact="migraine" post="without aura that presented to the observation for the"/>
   <result pre="mL) were collected in sterile tubes from both groups of" exact="migraine" post="subjects. In order to evaluate the expression of miRs"/>
   <result pre="3.1. Population During the study, we enrolled 78 subjects with" exact="migraine" post="(41 females and 38 males), age 13 ± 2.9"/>
   <result pre="± 2.9 years. After clinical evaluation and laboratory investigations, 35" exact="migraine" post="subjects (19 females and 16 males) fulfilled the inclusion"/>
   <result pre="blood samples). All enrolled subjects ( n = 24) presented" exact="migraine" post="without aura and were enclosed in the two groups:"/>
   <result pre="were enclosed in the two groups: Treated-group: n = 12" exact="migraine" post="subjects, 6 males and 6 females, between 7 and"/>
   <result pre="the acute attack ( Table 1). Untreated-group: n = 12" exact="migraine" post="subjects, 6 males and 6 females, between 4 and"/>
   <result pre="4 and 16 years (mean 11 ± 4.5 years), without" exact="migraine" post="pain, were enrolled as control-group ( Table 1). 3.2."/>
   <result pre="and serum frozen fractions obtained from all enrolled subjects with" exact="migraine" post="(treated and untreated) constitutively expressed both hsa-miR-34a-5p and hsa-miR-375,"/>
   <result pre="qRT-PCR revealed expression of hsa-miR-34a-5p and hsa-miR-375 in saliva of" exact="migraine" post="subjects enrolled in untreated subjects respect to both biological"/>
   <result pre="hsa-miR-375 in both serum and saliva of untreated patients with" exact="migraine" post="respect to both healthy people and treated migraine patients."/>
   <result pre="patients with migraine respect to both healthy people and treated" exact="migraine" post="patients. Even if some authors reported that CGRP could"/>
   <result pre="if some authors reported that CGRP could represent biomarkers of" exact="migraine" post="attack [ 9, 10, 12], its short half-life could"/>
   <result pre="More recently, miRNAs’ deregulation has been documented in patients with" exact="migraine" post="both during attacks and pain-free periods [ 32], highlighting"/>
   <result pre="highlighting the significance of these biomolecules in the pathophysiology of" exact="migraine" post="and their potential use as potential biomarkers. However, these"/>
   <result pre="miR-34a-5p and hsa-miR-375 in serum of children and adolescents with" exact="migraine" post="without aura suggesting their involvement in the pathogenetic mechanisms"/>
   <result pre="33]. Notably a recent study [ 25] showed that acute" exact="migraine" post="attacks in adults are associated with up-regulation of serum"/>
   <result pre="hsa-miR-34a-5p and hsa-miR-375 in saliva from children and adolescents with" exact="migraine" post="without aura respect to healthy subjects, suggesting that miRs"/>
   <result pre="readout of pathological processes arising into central nervous system since" exact="migraine" post="is known to be associated with activation and sensitization"/>
   <result pre="HCN3, NV3, and GPR158were found in DIANA-TOOLS database associated in" exact="trigeminal neuralgia" post="and targets of hsa-miR-34a-5p. In particular, HCN3 belong to"/>
   <result pre="by dosing biomarkers on saliva samples from young subjects with" exact="migraine" post="without aura could represent a clinical tool as mentioned"/>
   <result pre="of disease and of drug efficacy in young subjects with" exact="migraine" post="without aura and that saliva could be used to"/>
   <result pre="S.Z. subject’s enrolment and clinical evaluation, S.S. clinical test for" exact="migraine" post="history; A.V. laboratory test for microRNAs analysis; A.M., L.S.,"/>
   <result pre="Guidetti V. Effects of acetaminophen and ibuprofen in children with" exact="migraine" post="receiving preventive treatment with magnesium Headache 2014 54 313"/>
   <result pre="in periaqueductal gray matter as a potential biomarker for chronic" exact="migraine" post="Neurology 2019 92 e1076 e1085 10.1212/WNL.0000000000007047 30709968 8. Ferroni"/>
   <result pre="Calcitonin gene-related peptide in peripheral blood as a biomarker for" exact="migraine" post="Curr. Opin. Neurol. 2017 30 281 286 10.1097/WCO.0000000000000440 28234796"/>
   <result pre="CGRP levels in peripheral blood as a biomarker for chronic" exact="migraine" post="Neurology 2013 81 1191 1196 10.1212/WNL.0b013e3182a6cb72 23975872 11. Cernuda-Morollon"/>
   <result pre="as predictors of efficacy of Onabotulinumtoxin type A in chronic" exact="migraine" post="Headache 2014 54 987 995 10.1111/head.12372 24673487 12. Fan"/>
   <result pre="Vasoactive peptide release in the extracerebral circulation of humans during" exact="migraine" post="headache Ann. Neurol. 1990 28 183 187 10.1002/ana.410280213 1699472"/>
   <result pre="OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic" exact="migraine" post="Pain 2015 156 820 824 10.1097/j.pain.0000000000000119 25735000 16. Kee"/>
   <result pre="M. Mezzetti A. Giamberardino M.A. Cipollone F. MicroRNA profiling in" exact="migraine" post="without aura: Pilot study Ann. Med. 2015 47 468"/>
   <result pre="in peripheral blood mononuclear cells from patients with type 2" exact="diabetes mellitus" post="Exp. Ther. Med. 2017 14 5589 5596 10.3892/etm.2017.5254 29285097"/>
   <result pre="17 2011 10.3390/ijms17122011 39. Pietrobon D. Moskowitz M.A. Pathophysiology of" exact="migraine" post="Ann. Rev. Physiol. 2013 75 365 391 10.1146/annurev-physiol-030212-183717 23190076"/>
   <result pre="P.J. Holland P.R. Divergent influences of the locus coeruleus on" exact="migraine" post="pathophysiology Pain 2019 160 385 394 10.1097/j.pain.0000000000001421 30371556 41."/>
   <result pre="Clinical characteristics of treated and untreated groups of subjects with" exact="migraine" post="without aura (MWA) and healthy group without MWA, herein"/>
   <result pre="miRNA Validated Target Genes Associated Disease hsa-miR-34a-5p HCN3, NAV3, GPR158" exact="trigeminal neuralgia" post="hsa-miR-375 MTPN -"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6680509/results/search/disease/results.xml">
   <result pre="the occipital cortex, followed by temporary neuronal silencing. During a" exact="migraine" post="attack, increased expression of inflammatory mediators, along with a"/>
   <result pre="receptor antagonist (IL-1RN), following CSD in a mouse model of" exact="familial hemiplegic migraine" post="type 1 (FHM-1). We show here that the expression"/>
   <result pre="(IL-1RN), following CSD in a mouse model of familial hemiplegic" exact="migraine" post="type 1 (FHM-1). We show here that the expression"/>
   <result pre="researchers to better understand the development of the disease and" exact="aids" post="in the search for new therapeutic strategies in migraine."/>
   <result pre="aids in the search for new therapeutic strategies in migraine." exact="migraine" post="IL-1RN cortical spreading depression mouse model 1. Introduction Migraine"/>
   <result pre="events may also play a role in the pathogenesis of" exact="migraine" post="[ 7, 8]. In particular, much attention has been"/>
   <result pre="role of immune-system hormones, named cytokines, to the pathogenesis of" exact="migraine" post="[ 9]. Based on preclinical and clinical studies, the"/>
   <result pre="contribute to the initiation of cell-mediated autoimmune diseases such as" exact="rheumatoid arthritis," post="type 1 diabetes, multiple sclerosis, and Guillain-Barré syndrome ["/>
   <result pre="cell-mediated autoimmune diseases such as rheumatoid arthritis, type 1 diabetes," exact="multiple sclerosis," post="and Guillain-Barré syndrome [ 10, 11, 13]. Anti-inflammatory cytokines"/>
   <result pre="15, 16, 17]. Sometimes, such as in the case of" exact="systemic lupus erythematosus," post="it seems that the combined action of Th1/Th2 cytokines"/>
   <result pre="16, 17]. Sometimes, such as in the case of systemic" exact="lupus erythematosus," post="it seems that the combined action of Th1/Th2 cytokines"/>
   <result pre="that blood levels of IL-1ra are augmented during attacks of" exact="multiple sclerosis" post="and are further augmented from the treatment of the"/>
   <result pre="have been found [ 23, 24, 25]. The association between" exact="migraine" post="and the interleukin-1 receptor antagonist variable number tandem repeat"/>
   <result pre="inflammation in the trigeminal nerve territory is often observed during" exact="migraine" post="attacks [ 32], so the acute administration of corticosteroids"/>
   <result pre="has been tested to block pain [ 33]. Familial hemiplegic" exact="migraine" post="type 1 (FHM-1) is a monogenic type of migraine"/>
   <result pre="hemiplegic migraine type 1 (FHM-1) is a monogenic type of" exact="migraine" post="with aura caused by mutations in the CACNA1A gene"/>
   <result pre="3B). 4. Discussion Many studies have shown a relationship between" exact="migraine" post="and inflammation [ 51, 52]. Neurogenic inflammation is characterized"/>
   <result pre="degranulation [ 51]. In particular, it has been proposed that" exact="migraine" post="may be associated with an inflammation of the meninges,"/>
   <result pre="inflammation of the meninges, especially the dura mater. During a" exact="migraine" post="attack, an idiopathic activation of the trigeminal sensory afferents"/>
   <result pre="been tested as potential therapeutic strategies in the treatment of" exact="migraine" post="[ 51]. The main current therapy for migraine is"/>
   <result pre="treatment of migraine [ 51]. The main current therapy for" exact="migraine" post="is based on triptans [ 53], which have been"/>
   <result pre="have been found to be either unaltered or reduced in" exact="migraine" post="patients as compared to healthy controls. Moreover, during a"/>
   <result pre="migraine patients as compared to healthy controls. Moreover, during a" exact="migraine" post="attack, the serum concentrations of IL-1β, IL-6, IL-8, and"/>
   <result pre="type 2 cytokines IL-4 and IL-5 decrease [ 54]. Interestingly," exact="migraine" post="seems to be associated with immune-inflammatory and atopic diseases"/>
   <result pre="Th1- or Th2-dominant responses, such as Inflammatory Bowel Disease and" exact="asthma" post="[ 54]. Many studies have already observed that CSD"/>
   <result pre="variety of diseases (e.g., autoimmunity [ 59, 60, 61, 62]," exact="cancer" post="[ 63, 64, 65, 66], hepatic [ 67, 68],"/>
   <result pre="studies [ 21, 22, 70, 71]. However, its role in" exact="migraine" post="is still largely unexplored. In a previous study, significantly"/>
   <result pre="of IL-1RN, TGF-β1, and MCP-1 in the cerebrospinal fluid of" exact="migraine" post="patients as compared to controls were found [ 72]."/>
   <result pre="[ 74]. Indeed, a role for the IFN pathway in" exact="migraine" post="has been described [ 44]. We may speculate that"/>
   <result pre="may speculate that compensatory mechanisms may be working constantly in" exact="migraine" post="patients via the reciprocal regulation of pro- and anti-inflammatory"/>
   <result pre="contribute to the vasodilatation and to the swelling mechanism underlying" exact="migraine" post="and nasal congestion, which represents one of the most"/>
   <result pre="most common symptoms [ 75]. The role of inflammation in" exact="migraine" post="is further supported by the therapeutic effects of non-steroidal"/>
   <result pre="drugs (NSAIDs), currently recommended as the first-line medications for acute" exact="migraine" post="attacks, as they improve both pain and breathing ["/>
   <result pre="symptoms, quality of life, and disability, and to reduce monthly" exact="migraine" post="days [ 78, 79, 80, 81]. This study may"/>
   <result pre="gene expression of pro- and anti-inflammatory cytokines in a mouse" exact="migraine" post="model. In particular, we focus on the expression of"/>
   <result pre="Sex differences in the epidemiology, clinical features, and pathophysiology of" exact="migraine" post="Lancet Neurol. 2017 16 76 87 10.1016/S1474-4422(16)30293-9 27836433 3."/>
   <result pre="P. Olesen J. Prevalence and sex-ratio of the subtypes of" exact="migraine" post="Int. J. Epidemiol. 1995 10.1093/ije/24.3.612 7672904 4. collab: Headache"/>
   <result pre="version) Cephalalgia 2013 10.1177/0333102413485658 5. Lauritzen M. Pathophysiology of the" exact="migraine" post="aura: The spreading depression theory Brain 1994 117 Pt"/>
   <result pre="Y. Role of cortical spreading depression in the pathophysiology of" exact="migraine" post="Neurosci. Bull. 2014 30 812 822 10.1007/s12264-014-1471-y 25260797 7."/>
   <result pre="7. Longoni M. Ferrarese C. Inflammation and excitotoxicity: Role in" exact="migraine" post="pathogenesis Neurol. Sci. 2006 10.1007/s10072-006-0582-2 8. Edvinsson L. Haanes"/>
   <result pre="Raj V. Liam C.K. Relationship between various cytokines implicated in" exact="asthma" post="Hum. Immunol. 2019 10.1016/j.humimm.2019.04.018 15. Nicoletti F. Mancuso G."/>
   <result pre="(TGF-beta1) are elevated in both relapsing remitting and chronic progressive" exact="multiple sclerosis" post="(MS) patients and are further augmented by treatment with"/>
   <result pre="Circulating serum levels of IL-1ra in patients with relapsing remitting" exact="multiple sclerosis" post="are normal during remission phases but significantly increased either"/>
   <result pre="M. Müller N. Förderreuther S. Straube A. Decreased sTNF-RI in" exact="migraine" post="patients? Cephalalgia 2003 10.1046/j.1468-2982.2003.00453.x 25. Covelli V. Munno I."/>
   <result pre="Exaggerated spontaneous release of tumor necrosis factor-alpha/cachectin in patients with" exact="migraine" post="without aura Acta Neurol. (Napoli) 1990 12 257 263"/>
   <result pre="Cytokine polymorphism in patients with migraine: Some suggestive clues of" exact="migraine" post="and inflammation Pain Med. 2010 10.1111/j.1526-4637.2009.00791.x 20113413 27. Skaper"/>
   <result pre="Moskowitz M.A. Neurogenic inflammation in the pathophysiology and treatment of" exact="migraine" post="Neurology 1993 43 Suppl. S3 S16 S20 8389008 29."/>
   <result pre="10.1523/JNEUROSCI.6440-10.2011 32. Friedman M.H. Local inflammation as a mediator of" exact="migraine" post="and tension-type headache Headache 2004 10.1111/j.1526-4610.2004.04143.x 33. Rowe B.H."/>
   <result pre="controlled trial of intravenous dexamethasone to prevent relapse in acute" exact="migraine" post="headache Headache 2008 10.1111/j.1526-4610.2007.00959.x 34. Van Den Maagdenberg A.M.J.M."/>
   <result pre="Mohrenweiser H.W. Bulman D.E. Ferrari M. et al. Familial hemiplegic" exact="migraine" post="and episodic ataxia type-2 are caused by mutations in"/>
   <result pre="Bulman D.E. Ferrari M. et al. Familial hemiplegic migraine and" exact="episodic ataxia" post="type-2 are caused by mutations in the Ca2+ channel"/>
   <result pre="Der Kaa J. Plomp J.J. et al. A Cacna1a knockin" exact="migraine" post="mouse model with increased susceptibility to cortical spreading depression"/>
   <result pre="20824453 38. Tfelt-Hansen P.C. Koehler P.J. One hundred years of" exact="migraine" post="research: Major clinical and scientific observations from 1910 to"/>
   <result pre="10.4103/0972-2327.182302 52. Ramachandran R. Neurogenic inflammation and its role in" exact="migraine" post="Semin. Immunopathol. 2018 40 301 314 10.1007/s00281-018-0676-y 29568973 53."/>
   <result pre="53. Johnston M.M. Rapoport A.M. Triptans for the management of" exact="migraine" post="Drugs 2010 70 1505 1518 10.2165/11537990-000000000-00000 20687618 54. Oliveira"/>
   <result pre="M.F.P. Unbalanced plasma TNF-α and IL-12/IL-10 profile in women with" exact="migraine" post="is associated with psychological and physiological outcomes J. Neuroimmunol."/>
   <result pre="Berman N.E.J. Cortical spreading depression and gene regulation: Relevance to" exact="migraine" post="Ann. Neurol. 2002 10.1002/ana.10158 58. Urbach A. Bruehl C."/>
   <result pre="cell biomarkers for predicting the response of patients with relapsing-remitting" exact="multiple sclerosis" post="to natalizumab treatment Mol. Med. Rep. 2019 20 678"/>
   <result pre="Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal models of" exact="multiple sclerosis" post="Oncotarget 2018 9 8263 8277 10.18632/oncotarget.23862 29492193 62. Fagone"/>
   <result pre="Toll-like receptor 4 activation and in a murine model of" exact="systemic lupus erythematosus" post="Immunology 2014 142 10.1111/imm.12267 63. Presti M. Mazzon E."/>
   <result pre="receptor 4 activation and in a murine model of systemic" exact="lupus erythematosus" post="Immunology 2014 142 10.1111/imm.12267 63. Presti M. Mazzon E."/>
   <result pre="M. et al. Identification of novel chemotherapeutic strategies for metastatic" exact="uveal melanoma" post="Sci. Rep. 2017 7 44564 10.1038/srep44564 28303962 65. Basile"/>
   <result pre="al. Differential modulation and prognostic values of immune-escape genes in" exact="uveal melanoma" post="PLoS ONE 2019 14 e0210276 10.1371/journal.pone.0210276 30653520 66. Mangano"/>
   <result pre="with the CO-releasing molecule CORM-A1, in a murine model of" exact="autoimmune hepatitis" post="J. Cell. Physiol. 2018 233 4156 4165 10.1002/jcp.26223 29034470"/>
   <result pre="the CO-releasing molecule CORM-A1, in a murine model of autoimmune" exact="hepatitis" post="J. Cell. Physiol. 2018 233 4156 4165 10.1002/jcp.26223 29034470"/>
   <result pre="Evaluation of the changes in the nasal cavity during the" exact="migraine" post="attack J. Craniofac. Surg. 2014 10.1097/SCS.0b013e31827c80b1 76. Aukerman G."/>
   <result pre="Aukerman G. Knutson D. Miser W.F. Management of the acute" exact="migraine" post="headache Am. Fam. Physician 2002 66 2123 2130 12484694"/>
   <result pre="Y.Y. Chen W.H. et al. Medical treatment guidelines for acute" exact="migraine" post="attacks Acta Neurol. Taiwan. 2017 26 78 96 29250761"/>
   <result pre="H. Neeb L. Reuter U. Erenumab and galcanezumab in chronic" exact="migraine" post="prevention: Effects after treatment termination J. Headache Pain 2019"/>
   <result pre="Subgroup analyses of efficacy by high versus low frequency of" exact="migraine" post="headaches in phase 3 studies (EVOLVE-1 &amp;amp; EVOLVE-2) J."/>
   <result pre="Cohen J.M. Yeung P.P. Fremanezumab for the preventive treatment of" exact="migraine" post="Expert Opin. Biol. 2019 1 9 10.1080/14712598.2019.1627323 82. Neven"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6681503/results/search/disease/results.xml">
   <result pre="The aim of this study was to investigate whether pediatric" exact="migraine" post="is associated with vitamin D deficiency and the effect"/>
   <result pre="of vitamin D therapy on the frequency, duration, severity of" exact="migraine" post="attacks, and Pediatric Migraine Disability Assessment (PedMIDAS). Materials and"/>
   <result pre="hormone, alkaline phosphatase, and 25-OH vitamin D of 92 pediatric" exact="migraine" post="patients. The patients were divided into two groups: Group"/>
   <result pre="therapy. Migraine severity measured by the visual analog scale (VAS)," exact="migraine" post="frequency, and duration as well as scores on the"/>
   <result pre="D levels. In addition, pre- and posttreatment pedMIDAS scores, VAS," exact="migraine" post="frequency, and duration were compared with baseline values. Results:"/>
   <result pre="D deficiency (vitamin D levels &amp;lt; 10 ng/mL). Migraine frequency," exact="migraine" post="duration, and PedMIDAS scores were significantly higher in the"/>
   <result pre="0.001). After vitamin D therapy at sixth months of supplementation," exact="migraine" post="duration was reported statistically significant shorter ( p &amp;lt;"/>
   <result pre="reported statistically significant shorter ( p &amp;lt; 0.001) and the" exact="migraine" post="frequency, VAS scores, and pedMIDAS scores were statistically significant"/>
   <result pre="&amp;lt; 0.001). Conclusion: We found a marked correlation between pediatric" exact="migraine" post="and vitamin D levels. Vitamin D therapy was beneficial"/>
   <result pre="and vitamin D levels. Vitamin D therapy was beneficial in" exact="migraine" post="pediatric patients. childhood migraine vitamin D pedMIDAS 1. Introduction"/>
   <result pre="Vitamin D therapy was beneficial in migraine pediatric patients. childhood" exact="migraine" post="vitamin D pedMIDAS 1. Introduction Migraine is a neurologic"/>
   <result pre="pedMIDAS 1. Introduction Migraine is a neurologic condition characterized by" exact="hypersensitivity" post="to auditory, olfactory, visual, and cutaneous stimuli; vomiting and"/>
   <result pre="stimuli; vomiting and nausea; and severe headache. The pathophysiology of" exact="migraine" post="is not completely understood; however, the commonly reported hypotheses"/>
   <result pre="indicates that various brain disorders, such as epilepsy, Alzheimer’s disease," exact="multiple sclerosis," post="depression, autism, and schizophrenia, and some immune-mediated disorders, such"/>
   <result pre="and schizophrenia, and some immune-mediated disorders, such as type I" exact="diabetes mellitus," post="rheumatoid arthritis, inflammatory bowel diseases, and systemic lupus erythematosus,"/>
   <result pre="and some immune-mediated disorders, such as type I diabetes mellitus," exact="rheumatoid arthritis," post="inflammatory bowel diseases, and systemic lupus erythematosus, may arise"/>
   <result pre="type I diabetes mellitus, rheumatoid arthritis, inflammatory bowel diseases, and" exact="systemic lupus erythematosus," post="may arise due to vitamin D imbalance [ 8]."/>
   <result pre="I diabetes mellitus, rheumatoid arthritis, inflammatory bowel diseases, and systemic" exact="lupus erythematosus," post="may arise due to vitamin D imbalance [ 8]."/>
   <result pre="9]. Few recent studies have demonstrated that tension-type headache and" exact="migraine" post="may be related to low vitamin D serum levels"/>
   <result pre="17, 18]. In this study, we aimed to clarify whether" exact="migraine" post="and vitamin D deficiency are related in pediatric patients"/>
   <result pre="Materials and Methods This retrospective study included patients with episodic" exact="migraine" post="who were admitted to the pediatric neurology outpatient clinic"/>
   <result pre="of chronic diseases (e.g., liver, skin, metabolic, renal, gastrointestinal, or" exact="bone disease;" post="psychiatric disorder; cerebral palsy; and cognitive/intellectual disability), those with"/>
   <result pre="liver, skin, metabolic, renal, gastrointestinal, or bone disease; psychiatric disorder;" exact="cerebral palsy;" post="and cognitive/intellectual disability), those with diseases causing immobilization and"/>
   <result pre="and age. The patients were evaluated with regard to their" exact="migraine" post="duration and frequency. The duration of the migraine headache"/>
   <result pre="to their migraine duration and frequency. The duration of the" exact="migraine" post="headache was determined as hours in the day. The"/>
   <result pre="migraine headache was determined as hours in the day. The" exact="migraine" post="frequency was determined as the number of migraine attacks"/>
   <result pre="day. The migraine frequency was determined as the number of" exact="migraine" post="attacks within one month. Serum levels of 25-OH vitamin"/>
   <result pre="&amp;gt;20 ng/mL were group 2. The PedMIDAS and VAS scores;" exact="migraine" post="frequency; migraine duration; and 25-OH vitamin D, Ca, P,"/>
   <result pre="were group 2. The PedMIDAS and VAS scores; migraine frequency;" exact="migraine" post="duration; and 25-OH vitamin D, Ca, P, ALP, PTH"/>
   <result pre="significant. 4. Results A total of 92 pediatric patients with" exact="migraine" post="(67 girls (72.8%) and 25 (27.2%) boys) were included"/>
   <result pre="The median patient age was 12.6 (range, 6–18) years. The" exact="migraine" post="frequency, migraine duration, and pedMIDAS scores were found to"/>
   <result pre="patient age was 12.6 (range, 6–18) years. The migraine frequency," exact="migraine" post="duration, and pedMIDAS scores were found to be significantly"/>
   <result pre="there was no difference between the groups in terms of" exact="migraine" post="severity. Table 1 presents the patients’ characteristics. Vitamin D"/>
   <result pre="of the patients are given in Table 2. The median" exact="migraine" post="severity score was 6.9. There was no difference in"/>
   <result pre="severity score was 6.9. There was no difference in the" exact="migraine" post="severity between girls and boys. There were also no"/>
   <result pre="and boys. There were also no significant differences in the" exact="migraine" post="severity, frequency, and migraine duration as well as in"/>
   <result pre="also no significant differences in the migraine severity, frequency, and" exact="migraine" post="duration as well as in the PedMIDAS scores between"/>
   <result pre="of migraine. We found statistically significant negative correlations between the" exact="migraine" post="frequency, migraine duration, PedMIDAS score, and the vitamin D"/>
   <result pre="We found statistically significant negative correlations between the migraine frequency," exact="migraine" post="duration, PedMIDAS score, and the vitamin D levels ("/>
   <result pre="( p &amp;lt; 0.001). However, we observed no association between" exact="migraine" post="severity and 25-OH vitamin D levels Table 3. Migraine"/>
   <result pre="&amp;lt; 0.001). However, we found no considerable association between the" exact="migraine" post="severity and vitamin D level, between duration of migraine"/>
   <result pre="the migraine severity and vitamin D level, between duration of" exact="migraine" post="and vitamin D level, or between the patients with"/>
   <result pre="patients in group 1 reported statistically significant shorter durations of" exact="migraine" post="after vitamin D therapy ( p &amp;lt; 0.001). After"/>
   <result pre="therapy ( p &amp;lt; 0.001). After 6-month of therapy, the" exact="migraine" post="frequency and duration as well as the VAS scores"/>
   <result pre="cause chronic pain and headache disorders, specifically tension-type headache and" exact="migraine" post="[ 14, 25, 26]. Through our survey, we observed"/>
   <result pre="notable decreases in the PedMIDAS score as well as the" exact="migraine" post="duration, frequency, and severity in the patients who received"/>
   <result pre="levels of vitamin D, such as hypoparathyroidism, bone fractures, and" exact="multiple sclerosis," post="are more frequent at levels &amp;lt;20 ng/mL [ 3,"/>
   <result pre="and apoptosis [ 14, 33]. Moreover, in chronic pain and" exact="migraine" post="attacks, the levels of substance P, the calcitonin gene-related"/>
   <result pre="factors as well oxidative stress. Vitamin D deficiency can cause" exact="secondary hyperparathyroidism." post="Some studies have reported that the levels of PTH,"/>
   <result pre="serotonin synthesis, which is usually observed in tension-type headache and" exact="migraine" post="[ 12]. Vitamin D inhibits matrix metalloproteinase 9 (MMP-9)"/>
   <result pre="but could not propose a correlation between vitamin D and" exact="migraine" post="[ 41]. Thys-Jacobs et al. stated that supplemental calcium"/>
   <result pre="and vitamin D administration produced a sudden reduction in the" exact="migraine" post="duration and frequency [ 13]. The results could be"/>
   <result pre="which in turn may have led to a decrease in" exact="migraine" post="headaches [ 13, 15]. O’Brien et al. also documented"/>
   <result pre="PTH in patients with migraines, which could be due to" exact="secondary hyperparathyroidism" post="that was treated by optimal levels of vitamin D"/>
   <result pre="in patients with migraines, which could be due to secondary" exact="hyperparathyroidism" post="that was treated by optimal levels of vitamin D"/>
   <result pre="that vitamin D therapy with amitriptyline reduces the recurrence of" exact="migraine" post="attacks in pediatric patients with migraine [ 17]. To"/>
   <result pre="reduces the recurrence of migraine attacks in pediatric patients with" exact="migraine" post="[ 17]. To the best of our knowledge, this"/>
   <result pre="suffering from migraine. We detected significant negative relationships between the" exact="migraine" post="frequency and serum vitamin D levels, as well as"/>
   <result pre="frequency and serum vitamin D levels, as well as between" exact="migraine" post="duration and PedMIDAS scores (r = −0.591, p &amp;lt;"/>
   <result pre="no association was observed ( p = 0.128) between the" exact="migraine" post="severity and vitamin D levels. After treatment with vitamin"/>
   <result pre="severity and vitamin D levels. After treatment with vitamin D," exact="migraine" post="severity (VAS scores), migraine duration, migraine frequency, and PedMIDAS"/>
   <result pre="levels. After treatment with vitamin D, migraine severity (VAS scores)," exact="migraine" post="duration, migraine frequency, and PedMIDAS scores were significantly decreased"/>
   <result pre="treatment with vitamin D, migraine severity (VAS scores), migraine duration," exact="migraine" post="frequency, and PedMIDAS scores were significantly decreased in the"/>
   <result pre="vitamin D levels were not compared between patients diagnosed with" exact="migraine" post="and a healthy control group. 6. Conclusions We found"/>
   <result pre="group. 6. Conclusions We found a significant relationship between pediatric" exact="migraine" post="and vitamin D levels. We also demonstrated that vitamin"/>
   <result pre="publication of this article. References References 1. Schwedt T.J. Chronic" exact="migraine" post="BMJ 2014 348 1416 10.1136/bmj.g1416 24662044 2. Antonucci R."/>
   <result pre="of the International Classification of Headache Disorders for diagnosis of" exact="migraine" post="and tension-type headache in children Dev. Med. Child Neurol."/>
   <result pre="19619241 15. Thys-Jacobs S. Vitamin D and calcium in menstrual" exact="migraine" post="Headache 1994 34 544 546 10.1111/j.1526-4610.1994.hed3409544.x 8002332 16. O’Brien"/>
   <result pre="Effect of vitamin D therapy in addition to amitriptyline on" exact="migraine" post="attacks in pediatric patients Braz. J. Med. Biol. Res."/>
   <result pre="ratings of headache pain in a randomizedcontrolled clinical trial with" exact="migraine" post="patients Pain 2001 93 185 190 10.1016/S0304-3959(01)00315-3 11427330 22."/>
   <result pre="practice recommendations for native vitamin D therapy in children with" exact="chronic kidney disease" post="Stages 2–5 and on dialysis Nephrol. Dial. Transplant 2017"/>
   <result pre="chronic tension-type headache, musculoskeletal pain, and vitamin D deficiency: Is" exact="osteomalacia" post="responsible for both headache and musculoskeletal pain? Ann. Indian."/>
   <result pre="Ebrahimi H. Haghdoost F. Saadatnia M. Vitamin D status in" exact="migraine" post="patients: A case-control study Biomed. Res. Int. 2014 514782"/>
   <result pre="between the vitamin D level of the patients and the" exact="migraine" post="severity, migraine duration, migraine frequency, and PedMIDAS score. 25-OH"/>
   <result pre="vitamin D level of the patients and the migraine severity," exact="migraine" post="duration, migraine frequency, and PedMIDAS score. 25-OH vitamin D"/>
   <result pre="level of the patients and the migraine severity, migraine duration," exact="migraine" post="frequency, and PedMIDAS score. 25-OH vitamin D r *"/>
   <result pre="medicina-55-00321-t004_Table 4 Table 4 Relationship between Vitamin D levels and" exact="migraine" post="severity, duration, frequency, and PedMIDAS score. 25-OH vitamin D,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6682174/results/search/disease/results.xml">
   <result pre="influenced by commonly seen clinical problems including feeding difficulties, hypogonadotropic" exact="hypogonadism" post="and growth hormone deficiency. Furthermore, we provide recommendations for"/>
   <result pre="multidisciplinary approach. Keywords CHARGE syndrome growth short stature multidisciplinary hypogonadotropic" exact="hypogonadism" post="fig-count: table-count: ref-count: page-count: Introduction CHARGE syndrome (OMIM 214800)"/>
   <result pre="gene as a major criterion. 13 Growth retardation and hypogonadotropic" exact="hypogonadism" post="(HH) are important aspects of CHARGE syndrome in both"/>
   <result pre="syndrome CHARGE, morphometry and growth, development and aging. Abbreviations: CHARGE," exact="coloboma" post="of the eye, heart defects, atresia of the choanae,"/>
   <result pre="IUGR, intra uterine growth retardation; m, male; f, female; CHARGE," exact="coloboma" post="of the eye, heart defects, atresia of the choanae,"/>
   <result pre="26, 28, 30 In these years, the risk of developing" exact="scoliosis" post="should warrant attention (see section Factors contributing to growth"/>
   <result pre="addition, endocrinological problems such as growth hormone deficiency, HH and" exact="hypothyroidism" post="can negatively influence growth. Below we review the most"/>
   <result pre="of the facio-oral region, such as atresia of choanae and" exact="cleft lip" post="and/or palate. A vascular ring can also impede food"/>
   <result pre="down through the esophagus. In addition, sensory problems such as" exact="hypersensitivity" post="and anosmia can make eating or drinking uncomfortable or"/>
   <result pre="reflux is a common problem in CHARGE syndrome, and abdominal" exact="migraine" post="and constipation can cause abdominal pain and reduced appetite."/>
   <result pre="a common problem in CHARGE syndrome, and abdominal migraine and" exact="constipation" post="can cause abdominal pain and reduced appetite. 35 Critical"/>
   <result pre="older patients with CHARGE syndrome, 19 were reported to have" exact="scoliosis" post="with variable severity, and the mean age at which"/>
   <result pre="scoliosis with variable severity, and the mean age at which" exact="scoliosis" post="was diagnosed was 6.25 years. 14 The prevalence of"/>
   <result pre="scoliosis was diagnosed was 6.25 years. 14 The prevalence of" exact="scoliosis" post="was also high in another cohort of older individuals"/>
   <result pre="be conducted with special attention paid to the presence of" exact="scoliosis" post="because of the risk of deterioration with increased growth"/>
   <result pre="risk of deterioration with increased growth rate. Growth hormone deficiency," exact="hypothyroidism" post="and hypoparathyroidism Because most individuals with CHARGE syndrome have"/>
   <result pre="deterioration with increased growth rate. Growth hormone deficiency, hypothyroidism and" exact="hypoparathyroidism" post="Because most individuals with CHARGE syndrome have short stature"/>
   <result pre="dysfunction is uncommon in CHARGE syndrome. Some authors have reported" exact="hypothyroidism" post="among patients with CHARGE syndrome with a prevalence of"/>
   <result pre="16, 21, 23 However, Pinto et al did not report" exact="hypothyroidism" post="among 26 patients tested for abnormal levels of TSH"/>
   <result pre="levels of TSH and free T4. 18 Incidental cases of" exact="hypoparathyroidism" post="have been found in patients with typical and atypical"/>
   <result pre="their low prevalence, the risk of poor growth due to" exact="hypothyroidism" post="or hypoparathyroidism in CHARGE syndrome is probably small. Growth"/>
   <result pre="prevalence, the risk of poor growth due to hypothyroidism or" exact="hypoparathyroidism" post="in CHARGE syndrome is probably small. Growth hormone deficiency"/>
   <result pre="be conducted with special attention to the possible presence of" exact="scoliosis" post="due to its increased prevalence in CHARGE syndrome and"/>
   <result pre="of deterioration with increased growth velocity. From 12–18 years Hypogonadotropic" exact="hypogonadism" post="Delayed or absent puberty due to HH is common"/>
   <result pre="88%, with HH being more common in boys. In boys," exact="cryptorchidism" post="and micropenis may be signs of HH, while girls"/>
   <result pre="important complication of delayed puberty is osteoporosis. The risk for" exact="osteoporosis" post="is probably further increased in patients with CHARGE syndrome"/>
   <result pre="characteristics, hormone replacement therapy may be important to both prevent" exact="osteoporosis" post="and improve growth. Recommendations for multidisciplinary care The need"/>
   <result pre="the presence of confounders. 61, 62 Research among children with" exact="congenital heart disease" post="showed that low weight for age was associated with"/>
   <result pre="presence of confounders. 61, 62 Research among children with congenital" exact="heart disease" post="showed that low weight for age was associated with"/>
   <result pre="spine. Radiologic evaluation. Orthopedic surgeon Rehabilitation specialist Endocrinological problems Hypogonadotropic" exact="hypogonadism" post="Before 6 months of age: LH and FSH testing."/>
   <result pre="hormone replacement therapy. Continue hormone replacement therapy. (Pediatric) endocrinologist Hypothyroidism," exact="hypoparathyroidism" post="Test when symptoms Test when symptoms Test when symptoms"/>
   <result pre="Diagnostic tests for GH deficiency. Check for scoliosis. Abbreviations: CHARGE," exact="coloboma" post="of the eye, heart defects, atresia of the choanae,"/>
   <result pre="At birth, children with CHARGE syndrome should be checked for" exact="choanal atresia" post="by an ENT-specialist. Orofacial anomalies that require surgery, such"/>
   <result pre="by an ENT-specialist. Orofacial anomalies that require surgery, such as" exact="choanal atresia" post="and cleft lip and/or palate, can be treated by"/>
   <result pre="Orofacial anomalies that require surgery, such as choanal atresia and" exact="cleft lip" post="and/or palate, can be treated by an ENT specialist"/>
   <result pre="age or when growth hormone deficiency is suspected. Evaluation for" exact="hypothyroidism" post="and hypoparathyroidism is only necessary if there are clinical"/>
   <result pre="when growth hormone deficiency is suspected. Evaluation for hypothyroidism and" exact="hypoparathyroidism" post="is only necessary if there are clinical signs or"/>
   <result pre="JM Jr , Zonana J , Yong SL . Coloboma," exact="congenital heart disease," post="and choanal atresia with multiple anomalies: CHARGE association ."/>
   <result pre="Jr , Zonana J , Yong SL . Coloboma, congenital" exact="heart disease," post="and choanal atresia with multiple anomalies: CHARGE association ."/>
   <result pre="J , Yong SL . Coloboma, congenital heart disease, and" exact="choanal atresia" post="with multiple anomalies: CHARGE association . J Pediatr ."/>
   <result pre="Meiners LC , van Ravenswaaij-Arts CMA . Anosmia predicts hypogonadotropic" exact="hypogonadism" post="in CHARGE syndrome. J Pediatr . 2011; 158( 3):"/>
   <result pre=", Mesnage R , et al. CHARGE Syndrome includes hypogonadotropic" exact="hypogonadism" post="and abnormal olfactory bulb development . J Clin Endocrinol"/>
   <result pre="KW , et al. Prioritizing genetic testing in patients with" exact="kallmann syndrome" post="using clinical phenotypes. J Clin Endocrinol Metab . 2013;"/>
   <result pre="AM , et al. Evaluating CHARGE syndrome in congenital hypogonadotropic" exact="hypogonadism" post="patients harboring CHD7 variants . Genet Med . 2018;"/>
   <result pre="patients with rare genetic disorders with and without developmental disability:" exact="neurofibromatosis" post="1 and Williams-Beuren syndrome . Am J Med Genet"/>
   <result pre="Vignoli A . Healthcare transition from childhood to adulthood in" exact="tuberous sclerosis" post="complex. Am J Med Genet C Semin Med Genet"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6682654/results/search/disease/results.xml">
   <result pre="may reduce the headache burden. primary headache children adolescent prevalence" exact="migraine" post="tension type headache fig-count: table-count: equation-count: ref-count: page-count: word-count:"/>
   <result pre="at 11–13 years old in both sexes ( 2). Both" exact="migraine" post="and tension type headache (TTH) are the most predominant"/>
   <result pre="It was reported that 6.1 to 13.6% of children have" exact="migraine" post="and 9.8 to 24.7% have TTH ( 4). Migraine"/>
   <result pre="( 6). The male to female ratio is 1:3 for" exact="migraine" post="and 4:5 for TTH after 12 years of age"/>
   <result pre="community, face-to face interviews in random subsamples of participants with" exact="migraine" post="or TTH according to questionnaire diagnoses was performed. Fifty"/>
   <result pre="CIs, confidence intervals; * significant P-value. Table 2 shows that" exact="migraine" post="was the most prevalent headache, followed by TTH and"/>
   <result pre="prevalent headache, followed by TTH and chronic headache. Prevalence of" exact="migraine" post="and TTH increased significantly at age group 12–17 when"/>
   <result pre="&amp;lt; 0.001) and ( P &amp;lt; 0.05), respectively. Prevalence of" exact="migraine" post="was significantly higher among girls compared to boys ("/>
   <result pre="years ( 14). Our earlier study demonstrated the prevalence of" exact="migraine" post="among medical students 27.9% ( 15). These previous results"/>
   <result pre="accounted for differences in the results. Our results reported that" exact="migraine" post="was the most prevalent (10.9%), followed by TTH (6.2%)"/>
   <result pre="and which included 60% females and 40% males, showed that" exact="migraine" post="was the most prevalent headache followed by TTH, and"/>
   <result pre="also in line with the Indian study that showed that" exact="migraine" post="was most prevalent in their cohort followed by TTH"/>
   <result pre="other studies found a higher prevalence of TTH compared to" exact="migraine" post="( 23). Our results were in line with a"/>
   <result pre="than any other headache subtypes. The 1 year prevalence of" exact="migraine" post="in our result is 10.9%, which is comparable to"/>
   <result pre="in 32 countries and reported an overall mean prevalence of" exact="migraine" post="of 9% ( 13) which is similar to our"/>
   <result pre="our 10.9% results. Previous studies of headaches in children showed" exact="migraine" post="to be the most common cause of primary headache"/>
   <result pre="change that take place around this age. Hormonal effect triggers" exact="migraine" post="in female adolescents ( 34). Headaches are more common"/>
   <result pre="different epidemiological studies. Laurell reported a higher rate TTH and" exact="migraine" post="in females ( 7). However, Lyngberg, in a large"/>
   <result pre="1:3 in episodic tension-type headache ( 37). We reported that" exact="migraine" post="was more prevalent in girls compared to boys by"/>
   <result pre="headache occurrence in the present study, but higher prevalence of" exact="migraine" post="headache and onset of menarche is clear. Headache is"/>
   <result pre="Holmen TL Stovner LJ Sand T . The prevalence of" exact="migraine" post="and tension-type headaches among adolescents in Norway. The Nord-Trondelag"/>
   <result pre="S Sivaraman B Graham C . Prevalence of headache and" exact="migraine" post="in children and adolescents: a systematic review of population-based"/>
   <result pre="Telli E et al. . Epidemiology and clinical characteristics of" exact="migraine" post="among school children in the Menderes region . Cephalalgia."/>
   <result pre="Suppl. 1): 1– 160. 13. Wöber-Bingöl Ç . Epidemiology of" exact="migraine" post="and headache in children and adolescents. Curr Pain. ("/>
   <result pre="23098390 17. Hussein FA Hussein AB Prevalence of headache and" exact="migraine" post="among school children in Jordan. Sudanese J. Public Health."/>
   <result pre="32. Ayatollahi SM Moradi F Ayatollahi SA . Prevalences of" exact="migraine" post="and tension-type headache in adolescent girls of Shiraz (southern"/>
   <result pre="D Ivanković M Demarin V . Prevalence of migraine, probable" exact="migraine" post="and tension-type head- ache in the Croatian population ."/>
   <result pre="JM Chung CS Lee KS . Prevalence and impact of" exact="migraine" post="and tension-type headache in Korea. J Clin Neurol. ("/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6688625/results/search/disease/results.xml">
   <result pre="and remote communities. To address similar challenges facing patients with" exact="stroke" post="and other neurological disorders, physicians have begun to leverage"/>
   <result pre="utility, and cost-effectiveness of telemedicine in the management of acute" exact="stroke" post="( 14– 20), use of this technology is now"/>
   <result pre="specialized neurological care and thrombolytic therapy for patients with acute" exact="stroke" post="presenting to rural and remote hospitals that were not"/>
   <result pre="to rural and remote hospitals that were not staffed by" exact="stroke" post="neurologists. Following this seminal commentary, subsequent work has established"/>
   <result pre="supporting the feasibility, safety, efficacy and cost-effectiveness of telemedicine-based acute" exact="stroke" post="management ( 19, 20, 33). Research has now demonstrated"/>
   <result pre="are comparable between remote hospitals serviced by telestroke and comprehensive" exact="stroke" post="centers and that telemedicine is also helpful for identifying"/>
   <result pre="interventions or emergency neurosurgery ( 16). Moving beyond initial acute" exact="stroke" post="management, telemedicine is now used to facilitate multi-disciplinary care"/>
   <result pre="used to facilitate multi-disciplinary care including intensive care monitoring, secondary" exact="stroke" post="prevention and rehabilitation ( 14, 17). Today, telestroke is"/>
   <result pre="Today, telestroke is a well-established component of care for comprehensive" exact="stroke" post="centers that can now provide expanded clinical coverage to"/>
   <result pre="of patients with other neurological disorders such as dementia, headache," exact="multiple sclerosis," post="spinal cord injury, cerebral palsy, epilepsy and movement disorders"/>
   <result pre="disorders such as dementia, headache, multiple sclerosis, spinal cord injury," exact="cerebral palsy," post="epilepsy and movement disorders ( 21, 23, 26, 27)."/>
   <result pre="as dementia, headache, multiple sclerosis, spinal cord injury, cerebral palsy," exact="epilepsy" post="and movement disorders ( 21, 23, 26, 27). Preliminary"/>
   <result pre="establish telemedicine-based networks that provide specialized care for youth with" exact="epilepsy" post="and headaches ( 38, 39). In addition, there is"/>
   <result pre="management should be collected including a history of previous concussion/TBI," exact="migraine" post="headaches, epilepsy, learning and mood disorders ( 63). The"/>
   <result pre="should undergo Dix-Hallpike or Supine Roll testing to screen for" exact="benign paroxysmal positional vertigo" post="(BPPV). Lastly, assessment of the cervical spine including range"/>
   <result pre="their pre-injury neurological status in those with pre-existing conditions such" exact="migraine" post="or mental health disorders), are tolerating full-time school, work,"/>
   <result pre="concussions, one patient was diagnosed persistent post-concussion symptoms and post-traumatic" exact="migraine" post="headaches and two infants were diagnosed with head injuries."/>
   <result pre="indicate a more serious brain or spine injury or other" exact="neurological disorder" post="- Patients who may require diagnostic tests (e.g., imaging)"/>
   <result pre="symptoms (&amp;gt;1 month post-injury) - Patients with pre-existing conditions (e.g.," exact="migraine" post="headaches, mood disorders) that can make it difficult to"/>
   <result pre="- Patients who experience an exacerbation of pre-existing conditions (e.g.," exact="migraine" post="headaches, mood disorders) and may require multi-disciplinary care -"/>
   <result pre="of a more serious brain or spine injury or other" exact="neurological disorder" post="(e.g., focal neurological deficits, neck pain). Physicians must maintain"/>
   <result pre="the &quot;hub-and-spoke&quot; model. In this system of care, a comprehensive" exact="stroke" post="center that meets strict credentialing guidelines serves as the"/>
   <result pre="not all of the personnel and resources of a comprehensive" exact="stroke" post="center act as intermediate sites or &quot;sub-hubs.&quot; The authors"/>
   <result pre=". Recommendations for the implementation of telehealth in cardiovascular and" exact="stroke" post="care: a policy statement from the American Heart Association"/>
   <result pre="of hub-and-spoke telestroke networks for the management of acute ischemic" exact="stroke" post="from the hospitals' perspectives . Circ Cardiovasc Qual Outcomes."/>
   <result pre="review of the evidence for the use of telemedicine within" exact="stroke" post="systems of care: a scientific statement from the American"/>
   <result pre="RG Zorowitz RD et al. Recommendations for the establishment of" exact="stroke" post="systems of care: a 2019 update: a policy statement"/>
   <result pre="Taralson C Alcock S Balg C et al. . Canadian" exact="stroke" post="best practice recommendations: telestroke best practice guidelines update 2017"/>
   <result pre="et al. . Recommendations for the implementation of telemedicine within" exact="stroke" post="systems of care: a policy statement from the American"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6704740/results/search/disease/results.xml">
   <result pre="(29.5) &amp;lt;.001 Developmental disorders 47 (12.4) 594 (15.7) Headaches and" exact="migraine" post="25 (6.6) 615 (16.2) Disorders of muscle and nerve"/>
   <result pre="to be greater for children with chronic conditions such as" exact="epilepsy" post="and seizure disorders, which often confer developmental and mental"/>
   <result pre="with emergency department and/or unplanned hospital utilization for children with" exact="epilepsy" post=". Epilepsy Behav. 2014; 31: 172- 175. doi: 10.1016/j.yebeh.2013.12.008"/>
   <result pre=", Cohen DM Reduced emergency department utilization by patients with" exact="epilepsy" post="using QI methodology. Pediatrics. 2017; 139( 2): e20152358. doi:"/>
   <result pre="department visits using an urgent clinic for children with established" exact="epilepsy" post=". Neurol Clin Pract. 2016; 6( 6): 480- 486."/>
   <result pre="10.1212/CPJ.0000000000000649 15 Rasmusson KA , Hartshorn JC A comparison of" exact="epilepsy" post="patients in a traditional ambulatory clinic and a telemedicine"/>
   <result pre="RS , et al. Effect of the school-based telemedicine enhanced" exact="asthma" post="management (SB-TEAM) program on asthma morbidity: a randomized clinical"/>
   <result pre="of the school-based telemedicine enhanced asthma management (SB-TEAM) program on" exact="asthma" post="morbidity: a randomized clinical trial . JAMA Pediatr. 2018;"/>
   <result pre="Larson K , Halfon N A national profile of childhood" exact="epilepsy" post="and seizure disorder. Pediatrics. 2012; 129( 2): 256- 264."/>
   <result pre="a primary care medical home for children and youth with" exact="spina bifida." post="Pediatrics. 2011; 128( 6): e1645- e1657. doi: 10.1542/peds.2011-2219 22123894"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6706934/results/search/disease/results.xml">
   <result pre="frequency of asthma, hay fever, anemia, stomach and intestinal illness," exact="obesity" post="and ear infections. Furthermore, they have a higher prevalence"/>
   <result pre="and ear infections. Furthermore, they have a higher prevalence of" exact="learning disability" post="and attention deficit disorders when compared to children without"/>
   <result pre="symptoms as other types of chronic tension type headache or" exact="migraine" post="but they typically have a history of recurrences, and"/>
   <result pre="Karwautz A et al. Clinical features, classification and prognosis of" exact="migraine" post="and tension-type headache in children and adolescents: a long-term"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6709659/results/search/disease/results.xml">
   <result pre="over 1 year. Recently, the patient noted right upper eyelid" exact="ptosis" post="and a smaller right pupil ( Figure 1C). Figure"/>
   <result pre="anisocoria with a smaller right pupil and right upper lid" exact="ptosis" post="was noted. Ophthalmologic and neurologic examinations were normal except"/>
   <result pre="distortion were diagnosed as tadpole pupil. The anisocoria and lid" exact="ptosis" post="were pharmacologically confirmed as a right Horner syndrome, which,"/>
   <result pre="reactive to light. Dilute pilocarpine testing (not shown) revealed cholinergic" exact="hypersensitivity" post="of the left pupil indicating a left Adie pupil."/>
   <result pre="miosis ( Figure 3B). The palpebral fissures were symmetric. No" exact="anhidrosis" post="was noted. The left pupil demonstrated a poor constriction"/>
   <result pre="in both eyes caused left pupillary constriction consistent with cholinergic" exact="hypersensitivity" post="of the left but not right pupil. Topical 1%"/>
   <result pre="an anisocoria with left pupillary miosis and left upper lid" exact="ptosis" post="(1 mm). The onset of anisocoria could not be"/>
   <result pre="left Horner syndrome was suspected on clinical grounds, sympathetic denervation" exact="hypersensitivity" post="was not demonstrated. Discussion To search the literature about"/>
   <result pre="Once Every 6 months Blurred vision /left orbital pain Possible" exact="migraine" post="Thompson F/37 R Right HS At time of tadpole"/>
   <result pre="several hours with up to 50 episodes Blurred vision Possible" exact="migraine" post="Thompson M/29 L or R or bilat sec–min Daily"/>
   <result pre="Charcot-Marie-tooth / papillary druse Weir M/2 L 45 min During" exact="strabismus" post="surgery No No Kawasaki F/young L A few minutes"/>
   <result pre="spontaneously, then only with exercise Physical exercise No Juvenile idiopathic" exact="arthritis" post="Ladaique F/39 L Left HS/asymmetric facial flushing 2 months"/>
   <result pre="3–4 episodes in 2 months Blurred vision Left miosis and" exact="ptosis" post="but no demonstrated HS/retinal break F, female; M, male;"/>
   <result pre="four cases of non-spontaneous pupillary distortion were temporally related to" exact="strabismus" post="surgery, morning awakening, physical exercise, and hyponatremia with seizures:"/>
   <result pre="a single episode of tadpole pupil occurring during a non-complicated" exact="strabismus" post="surgery and lasting 45 min ( 7); Aggarwal et"/>
   <result pre="pupil. Given the frequent association with Horner syndrome, sympathetic denervation" exact="hypersensitivity" post="has been considered to be one mechanism of tadpole"/>
   <result pre="focal segment of iris dilator spasm, presumably due to denervation" exact="hypersensitivity" post="to circulating catecholamines during exercise ( 3). Hansen et"/>
   <result pre="pupil appeared following physical exercise and they suggested a focal" exact="hypersensitivity" post="to circulating catecholamines. However, pharmacologic evidence of sympathetic denervation"/>
   <result pre="their patient ( 11). The hypothesis of segmental denervation with" exact="hypersensitivity" post="may explain tadpole pupil following exercise or waking up,"/>
   <result pre="to reproduce the tadpole shape as evidence of a focal" exact="hypersensitivity" post="reaction. Though an attractive hypothesis for these specific aforementioned"/>
   <result pre="an attractive hypothesis for these specific aforementioned cases, focal denervation" exact="hypersensitivity" post="to circulating adrenergic substances would not explain the tadpole"/>
   <result pre="33%). These have included hypoplastic internal carotid artery ( 3)," exact="strabismus" post="surgery ( 7), and hyponatremia ( 10). Further investigations"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6709817/results/search/disease/results.xml">
   <result pre="Abstract Calcitonin gene-related peptide (CGRP) is a major player in" exact="migraine" post="pathophysiology, and CGRP monoclonal antibodies including fremanezumab may be"/>
   <result pre="a safe effective preventive therapy. Phase IIb studies in episodic" exact="migraine" post="(EM) and chronic migraine (CM) demonstrated efficacy at both"/>
   <result pre="therapy. Phase IIb studies in episodic migraine (EM) and chronic" exact="migraine" post="(CM) demonstrated efficacy at both the monthly 225 mg"/>
   <result pre="both showed a reduction in the primary endpoint of monthly" exact="migraine" post="days (MMD). In the EM trial, the baseline MMD"/>
   <result pre="for EM and CM fremanezumab is a new option for" exact="migraine" post="preventive treatment. Keywords fremanezumab migraine headache calcitonin gene-related peptide,"/>
   <result pre="is a new option for migraine preventive treatment. Keywords fremanezumab" exact="migraine" post="headache calcitonin gene-related peptide, CGRP treatment monoclonal antibody table-count:"/>
   <result pre="peptide (CGRP) is believed to play a major role in" exact="migraine" post="pathophysiology. Evidence to date suggests that inhibition of CGRP"/>
   <result pre="threshold trigeminovascular neurons being activated and/or sensitized hence preventing the" exact="migraine" post="pain phase. 4 The half-life has been reported in"/>
   <result pre="studies, as well as the inclusion of patients with chronic" exact="migraine" post="(CM) and medication overuse (MO), also raise the question"/>
   <result pre="September 14, 2018 with the indication of preventive treatment for" exact="migraine" post="in adults. Fremanezumab in clinical trials A Phase IIb"/>
   <result pre="in clinical trials A Phase IIb study of high-frequency episodic" exact="migraine" post="(HFEM) in 297 patients looked at both 225 and"/>
   <result pre="placebo for primary and secondary endpoints of change in monthly" exact="migraine" post="days (MMD) and in headache days from baseline at"/>
   <result pre="wk 675 mg q12 wk Placebo 12 weeks Mean monthly" exact="migraine" post="days 225 mg: −3.7 675 mg: −3.4 Placebo: −2.2"/>
   <result pre="wk Placebo Every 4 weeks for 12 weeks Mean monthly" exact="migraine" post="days 675/225: −4.6 675: −4.3 Placebo: −2.5 Notes: aInjection"/>
   <result pre="compared to placebo of −2.2 days. A reduction in acute" exact="migraine" post="medication (all types) was also assessed with a 3-day"/>
   <result pre="and 18% for placebo (both p&amp;lt;0.001). The use of acute" exact="migraine" post="treatment was reduced by 4.2 days in monthly fremanezumab,"/>
   <result pre="a patient with previously unreported Ehlers-Danlos syndrome and another was" exact="glaucoma" post="with increased intra-ocular pressure 84 days after treatment. 21"/>
   <result pre="was injection site reaction. There were three patients with drug" exact="hypersensitivity" post="of which two were on placebo. Respiratory events were"/>
   <result pre="drug exposure, and cause of death was determined to be" exact="chronic obstructive pulmonary disease." post="18 The most common adverse events reports were injection"/>
   <result pre="There were reports of upper respiratory tract infections (4%) and" exact="nasopharyngitis" post="(4%). Unlike erenumab, constipation has not been reported as"/>
   <result pre="upper respiratory tract infections (4%) and nasopharyngitis (4%). Unlike erenumab," exact="constipation" post="has not been reported as a common adverse effect"/>
   <result pre="ischemic attack, three deep vein thromboses, and one new onset" exact="atrial fibrillation." post="Safety with fremanezumab in cardiac patients has not been"/>
   <result pre="data demonstrated &amp;lt;1% ophthalmologic disorders. Specific cases described included bilateral" exact="retinal detachment" post="after fremanezumab 675 mg and vitreous detachment after 2"/>
   <result pre="described included bilateral retinal detachment after fremanezumab 675 mg and" exact="vitreous detachment" post="after 2 doses of fremanezumab 675 mg (taken monthly)."/>
   <result pre="were also reported as well as individual cases of unilateral" exact="retinal detachment," post="vitreous detachment, vitreous prolapse, and unilateral vision loss. The"/>
   <result pre="reported as well as individual cases of unilateral retinal detachment," exact="vitreous detachment," post="vitreous prolapse, and unilateral vision loss. The direct correlation"/>
   <result pre="also raises the question of safety in the setting of" exact="stroke" post="– could a transient ischemic attack or minor stroke"/>
   <result pre="of stroke – could a transient ischemic attack or minor" exact="stroke" post="be converted to a larger more debilitating stroke with"/>
   <result pre="or minor stroke be converted to a larger more debilitating" exact="stroke" post="with these agents? The same question is raised for"/>
   <result pre="these agents? The same question is raised for those with" exact="unstable angina" post="and the risk of myocardial infarction. The long-term effects"/>
   <result pre="this neuropeptide that has been shown to be integral to" exact="migraine" post="pathophysiology. At this time, the prophylactic effects in EM"/>
   <result pre="at least 18 years of age with a diagnosis of" exact="migraine" post="with or without aura. In those with a low"/>
   <result pre="has benefit for not only complex patients but the entire" exact="migraine" post="population with indication for prophylaxis. Further post-market studies are"/>
   <result pre="monoclonal CGRP antibody in development for the preventive treatment of" exact="migraine" post=". Curr Pain Headache Rep . 2015; 19( 3):"/>
   <result pre="al. Fremanezumab as add-on treatment for patients treated with other" exact="migraine" post="preventive medicines . Headache . 2017; 57( 9): 1375–"/>
   <result pre=", McDonald M , Dodick DW . Sustained reductions in" exact="migraine" post="days, moderate-to-severe headache days and days with acute medication"/>
   <result pre=", et al. Efficacy of fremanezumab in patients with chronic" exact="migraine" post="who had prior use of topiramate or onabotulinumtoxinA (P4.104)"/>
   <result pre="as a function of triptan use among individuals with chronic" exact="migraine" post="(P2.205) . Neurology . 2016; 86( 16 Supplement): P2.205."/>
   <result pre=". The American Headache Society position statement on integrating new" exact="migraine" post="treatments into clinical practice . Headache . 2019; 59("/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6716213/results/search/disease/results.xml">
   <result pre="tumors, central nervous system infections, dysfunction of ventriculo-peritoneal shunts, hydrocephalus," exact="idiopathic intracranial hypertension," post="and intracranial hemorrhage. In the emergency setting, the main"/>
   <result pre="age of the child &amp;lt;6 years; no family history for" exact="migraine" post="or primary headache; occipital headache; change of headache; new"/>
   <result pre="significantly more effective than placebo in determining headache relief. headache" exact="migraine" post="emergency child life threatening condition secondary headache diagnosis neuroimaging"/>
   <result pre="has been a substantial increase in the incidence of childhood" exact="migraine" post="and headache over the last 30 years. This increase"/>
   <result pre="( 2). Burton et al. ( 13) reported viral infections," exact="sinusitis" post="and pharyngitis in over 60% of pediatric patients presenting"/>
   <result pre="Burton et al. ( 13) reported viral infections, sinusitis and" exact="pharyngitis" post="in over 60% of pediatric patients presenting to the"/>
   <result pre="brain tumors, central nervous system infections, ventriculo-peritoneal shunt malfunction, hydrocephalus," exact="idiopathic intracranial hypertension" post="and intracranial hemorrhage ( Table 2) ( 3, 13,"/>
   <result pre="Primary headache accounts for 21.8–66.3% of headaches in children and" exact="migraine" post="is the most frequent type. Migraine is a recurrent"/>
   <result pre="and phonophobia ( 28). Table 4 ICHD-3 diagnostic criteria for" exact="migraine" post="without aura ( 28). A. At least five attacks"/>
   <result pre="by another ICHD-3 diagnosis. Table 5 ICHD-3 diagnostic criteria for" exact="migraine" post="with aura ( 28). A. At least two attacks"/>
   <result pre="episodes are specific for duration and characteristics, the diagnosis of" exact="migraine" post="can be made before five episodes. In the new"/>
   <result pre="headache pattern and associated symptoms make it possible to differentiate" exact="migraine" post="without aura from other forms of primary and secondary"/>
   <result pre="33). Migraine with brainstem aura is a particular kind of" exact="migraine" post="in which symptoms of aura originate unequivocally from the"/>
   <result pre="28). The symptoms of aura of this particular form of" exact="migraine" post="are immediately traceable to the brain stem in the"/>
   <result pre="to be excluded by MRI ( 34). The difference between" exact="migraine" post="with brainstem aura and migraine with typical aura is"/>
   <result pre="( 34). The difference between migraine with brainstem aura and" exact="migraine" post="with typical aura is the origin of the symptoms."/>
   <result pre="case the brainstem or bilateral occipital hemispheres are involved, while" exact="migraine" post="with typical aura is mainly restricted to a unilateral"/>
   <result pre="typical aura is mainly restricted to a unilateral hemisphere. Hemiplegic" exact="migraine" post="(HM) is a type of migraine with aura and"/>
   <result pre="a unilateral hemisphere. Hemiplegic migraine (HM) is a type of" exact="migraine" post="with aura and motor weakness. For diagnosis, fully reversible"/>
   <result pre="setting to exclude those secondary headache disorders than can mimic" exact="migraine" post="and are potentially life threatening ( 35, 36), by"/>
   <result pre="essential to know the characteristics of the primary forms of" exact="migraine" post="in order to avoid unnecessary, expensive, and potentially dangerous"/>
   <result pre="is clear that whenever there is suspicion for secondary headache," exact="migraine" post="should be a diagnosis of exclusion. Migraine is also"/>
   <result pre="significantly raise the suspicion of a secondary form due to" exact="stroke" post="or other vasculopathies: rapid onset of headache, presence of"/>
   <result pre="stroke, reversible cerebral vasoconstriction syndrome, venous sinus thrombosis, or even" exact="pituitary apoplexy" post="( 38). The more gradual onset of neurological symptoms"/>
   <result pre="cortex ( 39). Furthermore, hemiparesis is an infrequent form of" exact="migraine" post="aura, with a frequency of &amp;lt;10% and seldomly presents"/>
   <result pre="40). Another useful element is that children with arterial ischemic" exact="stroke" post="(AIS) are older than those with migraine, and considered"/>
   <result pre="up to 8 years of age ( 40). In fact," exact="migraine" post="with aura is uncommon in children &amp;lt;8 years of"/>
   <result pre="aura may occur without headache and must be differentiated from" exact="stroke" post="in which negative signs with visual defects are present."/>
   <result pre="are: complete well-being between episodes, stereotypy of episodes, familiarity for" exact="migraine" post="or headache ( 2). Patients with this group of"/>
   <result pre="2). Patients with this group of disorders can present with" exact="migraine" post="(with or without aura) or are likely to develop"/>
   <result pre="are likely to develop them. These patients may also have" exact="motion sickness" post="or periodic sleep disorders ( 28). Episodic syndromes can"/>
   <result pre="or at foreseeable intervals. These conditions can be associated with" exact="migraine" post="( 28). An acute presentation could be confused with"/>
   <result pre="vomiting syndrome because it is often misdiagnosed or unrecognized. Abdominal" exact="migraine" post="is an idiopathic condition, which is found mainly in"/>
   <result pre="history regarding headache must be taken and a diagnosis of" exact="migraine" post="without aura should be considered if headache is present"/>
   <result pre="abdominal pain resolves in 61% of patients, but 70% develop" exact="migraine" post="with or without aura ( 47). Migraine therapies have"/>
   <result pre="47). Migraine therapies have been reported effective in treating abdominal" exact="migraine" post="( 48). Benign paroxysmal infantile vertigo (BPV) is a"/>
   <result pre="audiometric examination, and vestibular tests are normal. Posterior fossa tumors," exact="epilepsy" post="and vestibular disorders must be excluded ( 28). BPV"/>
   <result pre="Often the symptoms of TTH can overlap with those of" exact="migraine" post="and a migraine may transform over time to a"/>
   <result pre="of TTH can overlap with those of migraine and a" exact="migraine" post="may transform over time to a tension type of"/>
   <result pre="in about 10% of pediatric cases compared to 25% for" exact="migraine" post="( 3). The clinical characteristics of pediatric onset CH,"/>
   <result pre="side as headache, watery eyes, nasal congestion, rhinorrhea, sweating, miosis," exact="ptosis" post="and/or palpebral oedema, and agitation ( 28). Tearing of"/>
   <result pre="portion of the affected cranial nerve, suggesting a recurrent demyelinating" exact="neuropathy" post="( 3), which may sometimes determine permanent cranial nerve"/>
   <result pre="in ICHD-3 Revised Infantile colic, alternating hemiplegic migraine, and vestibular" exact="migraine" post="represent three additional forms that may be listed among"/>
   <result pre="that may be listed among &quot;Episodic Syndromes&quot; possibly associated with" exact="migraine" post="(section 1.6 point in ICHD-3 revised) ( 28). Nevertheless,"/>
   <result pre="week. Given the recent evidence of a possible association between" exact="migraine" post="and infantile colic, the latter is now part of"/>
   <result pre="during the episodes. Migraine-related syndromes [such as BPV and vestibular" exact="migraine" post="(VM)] are the most common cause of episodic vertigo"/>
   <result pre="novel Alice in Wonderland. It seems that Carroll suffered from" exact="migraine" post="and described in his famous story the symptoms that"/>
   <result pre="children, unlike in adults where it occurs in conjunction with" exact="migraine" post="episodes ( 54). It can also present in different"/>
   <result pre="states ( 44). Increasing scientific evidence of the relationship between" exact="migraine" post="and AWS, means that in many patients it was"/>
   <result pre="or equivalent migraine, particularly in children ( 54). Acute confusional" exact="migraine" post="(ACM) is a rare condition and the data reported"/>
   <result pre="few hours. Resolution within 24 h and often associated with" exact="retrograde amnesia." post="Encephalitis, convulsions, strokes, vasculitis of the central nervous system,"/>
   <result pre="h and often associated with retrograde amnesia. Encephalitis, convulsions, strokes," exact="vasculitis" post="of the central nervous system, metabolic encephalopathy, toxic ingestion,"/>
   <result pre="to serious LT intracranial disorders such as brain tumors, hydrocephalus," exact="idiopathic intracranial hypertension," post="brain abscess/meningitis, aneurysm and vascular malformation, intoxication, and ventriculo-peritoneal"/>
   <result pre="cervical arterial dissection; venous sinus thrombosis; reversible cerebral vasoconstriction syndrome;" exact="pituitary apoplexy;" post="posterior reversible encephalopathy; hypertensive crisis; spontaneous intracranial hypotension. Very"/>
   <result pre="together with symptomatic measures. Spontaneous intracranial hemorrhage (ICH) and ischemic" exact="stroke" post="are rare causes of headache in children. Although an"/>
   <result pre="symptom of ICH, most children who have ICH or ischemic" exact="stroke" post="have additional signs or symptoms by the time they"/>
   <result pre="be considered especially if there is a recent history of" exact="otitis media," post="mastoiditis, endocarditis or immunosuppression ( 57). In encephalitis (viral,"/>
   <result pre="if there is a recent history of otitis media, mastoiditis," exact="endocarditis" post="or immunosuppression ( 57). In encephalitis (viral, bacterial, and/or"/>
   <result pre="of otitis media, mastoiditis, endocarditis or immunosuppression ( 57). In" exact="encephalitis" post="(viral, bacterial, and/or autoimmune) the distinctive sign is headache"/>
   <result pre="in the ED. Symptoms or signs reported were headache (66.7%)," exact="hydrocephalus" post="(58.6%), nausea/vomiting (49.4%), gait disturbance (42.5%), vision problems (20.7%),"/>
   <result pre="nerve deficits (16.1%), altered mental status (16.1%), back/neck pain (16.1%)," exact="papilledema" post="(12.6%), facial asymmetry (10.3%), sensory deficits (8%), focal motor"/>
   <result pre="deficits (8%), focal motor weakness (6.9%), cranial nerve deficit (6.9%)," exact="ptosis" post="(5.7%), macrocephaly (4.6%), asymptomatic (3.4%), and anisocoria (1.1%) ("/>
   <result pre="of causing it. In these patients ophthalmic assessment shows bilateral" exact="papilledema" post="while neuroimaging is found to be within normal limits."/>
   <result pre="evaluated very carefully. Fever during upper respiratory tract infection and" exact="sinusitis" post="are the most frequent causes of sudden onset of"/>
   <result pre="the spectrum of chronic daily headache with or without superimposed" exact="migraine" post="or analgesic abuse ( 55). Headache on awakening or"/>
   <result pre="was most likely to be caused by primary headaches, particularly" exact="migraine" post="or tension type headaches, and this needs to be"/>
   <result pre="headache Upper respiratory tract infection, with or without fever Acute" exact="sinusitis" post="Pharyngitis Meningitis (viral or bacterial) Migraine (first attack) Post-ictal"/>
   <result pre="birth control pills, tetracycline, vitamin A) Intoxication (lead poisoning) Chronic" exact="migraine" post="Chronic tension-type headaches(analgesic overuse) Post-concussive syndrome Temporomandibular joint syndrome"/>
   <result pre="searched for possible signs of a neurocutaneous syndrome, in particular" exact="neurofibromatosis" post="and tuberous sclerosis, which could be indicative of intracranial"/>
   <result pre="possible signs of a neurocutaneous syndrome, in particular neurofibromatosis and" exact="tuberous sclerosis," post="which could be indicative of intracranial neoplasms ( 70)."/>
   <result pre="neurological signs, symptoms of disease (other than typical aura), and" exact="papilledema" post="( 35, 36). Occipital headache is considered a risk"/>
   <result pre="frequently requested by the emergency room physician to rule out" exact="papilledema" post="(optic disc swelling) in patients with headache ( 72)."/>
   <result pre="400 pediatric patients with brain tumors reported the presence of" exact="papilledema" post="in only 13% of patients ( 73). Segev-Becker et"/>
   <result pre="ED to investigate for papilledema. Only six children (3.5%) had" exact="papilledema" post="(four IIH, one meningococcal meningitis, and one patient was"/>
   <result pre="70). A headache that appears during or after treatment of" exact="otitis media" post="or sinusitis may indicate the possible intracranial spread of"/>
   <result pre="that appears during or after treatment of otitis media or" exact="sinusitis" post="may indicate the possible intracranial spread of the infection."/>
   <result pre="intracranial complications are reported in about 3% of patients with" exact="sinusitis" post="being represented by epidural and subdural empyema, followed by"/>
   <result pre="( 77, 78). Sinus thrombosis is a possible complication of" exact="otitis media" post="and mastoiditis ( 77). In infants and toddler, signs"/>
   <result pre="Sinus thrombosis is a possible complication of otitis media and" exact="mastoiditis" post="( 77). In infants and toddler, signs of intracranial"/>
   <result pre="can fall asleep, sleep may be useful in terminating a" exact="migraine" post="attack. A variety of physical, complementary, and lifestyle interventions"/>
   <result pre="these substances though the role of exclusion diets in infantile" exact="migraine" post="is still not demonstrated. Acute Treatment Treatments for migraine"/>
   <result pre="infantile migraine is still not demonstrated. Acute Treatment Treatments for" exact="migraine" post="include symptom relief of acute attacks ( Table 9)."/>
   <result pre="Vomiting can sometimes be a very important part of a" exact="migraine" post="attack in young children. In these cases, it is"/>
   <result pre="labeled by the US Food and Drug Administration for acute" exact="migraine" post="in adolescents 12–17 years of age: almotriptan (oral), zolmitriptan"/>
   <result pre="in a study in adolescents ( 86). Children with long-lasting" exact="migraine" post="or status migrainosus may need ED treatment, if home"/>
   <result pre="using prochlorperazine or metoclopramide instead of promethazine for pediatric ED" exact="migraine" post="treatment ( 91). Dihydroergotamine (DHE) has shown efficacy and"/>
   <result pre="( 93– 95). The usefulness of IV DHE in pediatric" exact="migraine" post="has been suggested by two small retrospective studies of"/>
   <result pre="of 62 children and adolescents admitted to hospital for refractory" exact="migraine" post="or status migrainosus ( 93, 94). Pain-free status upon"/>
   <result pre="headache relief at 30 min in children or adolescents with" exact="migraine" post="in the ED. However, a clinically meaningful response was"/>
   <result pre="explicitly discouraged for primary headache disorders because they may potentiate" exact="migraine" post="pathophysiology at the molecular level by blunting the response"/>
   <result pre="pain has been concurrent with the rising rate of prescription" exact="opioid abuse" post="and related morbidity and mortality, especially in adolescents ("/>
   <result pre="headache (MOH). These patients, who previously had episodic tension-type headache," exact="migraine" post="without aura or migraine with aura, develop a chronic"/>
   <result pre="who previously had episodic tension-type headache, migraine without aura or" exact="migraine" post="with aura, develop a chronic headache(≥15 days a month"/>
   <result pre="a month. MOH typically presents when a bad patch of" exact="migraine" post="with or without aura has transformed into a chronic"/>
   <result pre="aura has transformed into a chronic daily headache, including chronic" exact="migraine" post="( 85). The suspect medication must be withdrawn abruptly"/>
   <result pre="physical examination. LP should be performed in case of suspected" exact="meningitis" post="and it is diagnostic in the case of IIH."/>
   <result pre="the acute episode immediately according to evidence based medicine. When" exact="migraine" post="is suspected, the administration of NSAIDs and triptans should"/>
   <result pre="5. Abu-Arefeh I Russell G . Prevalence of headache and" exact="migraine" post="in schoolchildren. BMJ. ( 1994) 309: 765– 9. 7950559"/>
   <result pre="Hämäläinen ML Hoppu K Santavuori PR Pain and disability in" exact="migraine" post="or other recurrent headache as reported by children. Eur"/>
   <result pre="6826344 8. Sillanpää M . Changes in the prevalence of" exact="migraine" post="and other headaches during the first seven school years"/>
   <result pre="42. 1773439 10. Deubner DC . An epidemiologic study of" exact="migraine" post="and headache in 10–20 year olds. Headache. ( 1997)"/>
   <result pre="DJD Sullivan SM et al. . The childhood and adolescent" exact="migraine" post="prevention (CHAMP) study: a report on baseline characteristics of"/>
   <result pre="Zelnik N Schertz M Srugo I . Frequency of pediatric" exact="migraine" post="with aura in a clinic-based sample. Headache. ( 2016)"/>
   <result pre="Donnan GA Monagle P et al. . Differentiating arterial ischaemic" exact="stroke" post="from migraine in the paediatric emergency department . Dev"/>
   <result pre="Monagle P et al. . Differentiating arterial ischaemic stroke from" exact="migraine" post="in the paediatric emergency department . Dev Med Child"/>
   <result pre="T Gorali O Haimi-Cohen Y Zeharia A . Symptoms of" exact="migraine" post="in the paediatric population by age group. Cephalalgia. ("/>
   <result pre="et al. . Is benign paroxysmal vertigo of childhood a" exact="migraine" post="precursor? Eur J Paediatr Neurol. ( 2013) 17: 397–"/>
   <result pre="Lehrer N Borggraefe I Heinen F Jahn K . Vestibular" exact="migraine" post="in children and adolescents: clinical findings and laboratory tests"/>
   <result pre="C Patella R Zedde M Gandolfo C . Association between" exact="migraine" post="and cervical artery dissection: the italian project on stroke"/>
   <result pre="between migraine and cervical artery dissection: the italian project on" exact="stroke" post="in young adults . JAMA Neurol. ( 2017) 74:"/>
   <result pre="S Vigevano F et al. . Clinical features of pediatric" exact="idiopathic intracranial hypertension" post="and applicability of new ICHD-3 criteria . Front Neurol."/>
   <result pre="JR Moodley M . Identifying and managing intracranial complications of" exact="sinusitis" post="in children: a retrospective series . Pediatr Infect Dis"/>
   <result pre="F et al. . Pattern-reversal visual-evoked potentials in children with" exact="migraine" post="and other primary headache: evidence for maturation disorder? Pain."/>
   <result pre="ET et al. . Drugs for the acute treatment of" exact="migraine" post="in children and adolescents. Cochrane Database Syst Rev. ("/>
   <result pre="P . Ibuprofen or acetaminophen for the acute treatment of" exact="migraine" post="in children: a double-blind, randomized, placebo controlled, crossover study"/>
   <result pre="Duffy SJ Anderson AC Linakis JG . Treatment of pediatric" exact="migraine" post="headaches: a randomized, double-blind trial of prochlorperazine versus ketorolac"/>
   <result pre="et al. . Relative effectiveness of dopamine antagonists for pediatric" exact="migraine" post="in the emergency department . Pediatr Emerg Care. ("/>
   <result pre="P Biederman S et al. . Inpatient treatment of status" exact="migraine" post="with dihydroergotamine in children and adolescents. Headache. ( 2009)"/>
   <result pre="ML Hoppu K Santavuori PR . Oral dihydroergotamine for therapy-resistant" exact="migraine" post="attacks in children. Pediatr Neurol. ( 1997) 16: 114–"/>
   <result pre="controlled trial of treatment expectation and intravenous fluid in pediatric" exact="migraine" post=". Headache. ( 2014) 54: 1496– 505. 10.1111/head.12443 25168404"/>
   <result pre="10.1016/j.jemermed.2015.02.024 25986331 100. Casucci G Cevoli S . Controversies in" exact="migraine" post="treatment: opioids should be avoided. Neurol Sci. ( 2013)"/>
   <result pre="A Agarwal R Thomas R Sivaswamy L Management of pediatric" exact="migraine" post="in a tertiary care versus community based emergencydepartment: an"/>
   <result pre="10.1016/j.jpeds.2018.08.078 30274923 108. Sheridan DC Meckler GD . Inpatient pediatric" exact="migraine" post="treatment: does choice of abortive therapy affect length of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6732618/results/search/disease/results.xml">
   <result pre="original work is properly cited. Abstract Several studies suggested that" exact="migraine" post="attack onset shows a circadian variation; however, there has"/>
   <result pre="investigating this topic. Results of these studies mostly show that" exact="migraine" post="attacks follow a monophasic 24-hour cyclic pattern with an"/>
   <result pre="contradictory results. Several theories emerged explaining the diurnal distribution of" exact="migraine" post="attacks suggesting roles for different phenomena including a morning"/>
   <result pre="cortisol levels, a possible hypothalamic dysfunction, a circadian variation of" exact="migraine" post="triggers, sleep stages, and a potentially different setting of"/>
   <result pre="studies show an early morning or late night peak of" exact="migraine" post="attack onset, but a significant amount of studies reveals"/>
   <result pre="understanding of the complex mechanism behind the circadian variation of" exact="migraine" post="attacks that can shed light on new targets for"/>
   <result pre="migraine attacks that can shed light on new targets for" exact="migraine" post="therapy. Funding Hungarian Brain Research Program KTIA_13_NAPA-II/14 2017-1.2.1-NKP-2017-00002 National"/>
   <result pre="ratio of 3:1 [ 2]. The most prevalent form is" exact="migraine" post="without aura, which is characterized by usually unilateral, moderate,"/>
   <result pre="of migraineurs also show transient neurological deficits associated with their" exact="migraine" post="attacks, collectively termed migraine aura (for example, sensory, retinal,"/>
   <result pre="transient neurological deficits associated with their migraine attacks, collectively termed" exact="migraine" post="aura (for example, sensory, retinal, or motor symptoms) ["/>
   <result pre="While this high prevalence and the high burden associated with" exact="migraine" post="motivate research for underlying pathomechanisms, there is still no"/>
   <result pre="is still no clear explanation of when and why a" exact="migraine" post="attack will occur. Both clinicians and patients have noted"/>
   <result pre="Both clinicians and patients have noted the diurnal variation of" exact="migraine" post="attack onset and several terms have been used to"/>
   <result pre="several terms have been used to describe the periodicity of" exact="migraine" post="attacks including cyclical migraine, weekend, or nocturnal migraine, suggesting"/>
   <result pre="attacks including cyclical migraine, weekend, or nocturnal migraine, suggesting that" exact="migraine" post="attacks do not occur randomly but show distinct temporal"/>
   <result pre="[ 3]. A better understanding of the circadian variation of" exact="migraine" post="attack onset could provide relevant information for migraine prevention"/>
   <result pre="variation of migraine attack onset could provide relevant information for" exact="migraine" post="prevention and intervention. For example, a pulsatile press coated"/>
   <result pre="administration was created to ensure early morning release to prevent" exact="migraine" post="attacks after sleep [ 4]. However, less than a"/>
   <result pre="than a dozen studies examined directly the circadian variation of" exact="migraine" post="attack onset, and the synthesis of these findings has"/>
   <result pre="synthesize the results of studies regarding the 24-hour variation in" exact="migraine" post="attack onset. We also assemble the suggested theories explaining"/>
   <result pre="Title/Abstract field to identify studies on the daily distribution of" exact="migraine" post="attacks. The search was limited to publications in English"/>
   <result pre="we selected relevant papers reporting on the 24-hour distribution of" exact="migraine" post="attacks and collated research data from those directly investigating"/>
   <result pre="research data from those directly investigating the circadian variation of" exact="migraine" post="attack onset. 3. Results 3.1. Literature Search Results Our"/>
   <result pre="30 papers with possibly relevant information on diurnal variation of" exact="migraine" post="attack onset. At this stage, we also kept reviews"/>
   <result pre="studies were identified that directly investigated the circadian variation of" exact="migraine" post="attack onset providing new data (for details see Figure"/>
   <result pre="Five studies clearly showed a monophasic 24-hour cyclic pattern of" exact="migraine" post="attacks with an early morning or late night peak"/>
   <result pre="11], and (3) just after noon in cases of insomnia-related" exact="migraine" post="attacks [ 12]. The latter study interestingly also showed"/>
   <result pre="participants did not report a constant daily distribution of their" exact="migraine" post="attacks [ 13]. 3.3. Details of the Studies on"/>
   <result pre="studies: van Oosterhout et al. [ 10] showed that earlier" exact="migraine" post="attack onset (12PM-6AM) was related to higher age, and"/>
   <result pre="the morning onset group (6AM-12AM). Participants were in most cases" exact="migraine" post="patients both with and without aura, but a number"/>
   <result pre="10, 13]. One study included data on nonmigraine headache besides" exact="migraine" post="[ 8]. Three studies did not provide any information"/>
   <result pre="4. Discussion The majority of studies on circadian variation of" exact="migraine" post="attack onset showed an early morning or late night"/>
   <result pre="a higher risk of myocardial infarction has been associated with" exact="migraine" post="in a recent meta-analysis [ 14]. Solomon [ 9]"/>
   <result pre="in serotonin release potentially contributing to vasospasm which may trigger" exact="migraine" post="attacks. Serotonergic neurons can influence the trigeminal system, which"/>
   <result pre="influence the trigeminal system, which has a well-known role in" exact="migraine" post="pathophysiology [ 15], shows increased activity during sleep, and"/>
   <result pre="in the morning hours. One study [ 17] reported that" exact="migraine" post="patients (compared to headache-free controls) showed higher variation of"/>
   <result pre="peak in the early morning hours, might contribute to some" exact="migraine" post="attacks in the morning, but only among some migraineurs."/>
   <result pre="the studies working with different subgroups of migraineurs and measuring" exact="migraine" post="attacks occurring at different times reported that morning cortisol"/>
   <result pre="evening saliva cortisol) over four days prior to a spontaneous" exact="migraine" post="attack onset could not identify a temporal relationship between"/>
   <result pre="cortisol changes (or changes in any other stress-related measures) and" exact="migraine" post="attack onset [ 19]. Many other hormones related to"/>
   <result pre="migraine attack onset [ 19]. Many other hormones related to" exact="migraine" post="also might have a role in circadian variation of"/>
   <result pre="migraine also might have a role in circadian variation of" exact="migraine" post="attack onset. For example, a study found elevated levels"/>
   <result pre="hormone, cortisol, and prolactin [ 20]. Another study with chronic" exact="migraine" post="(CM) patients (compared to healthy controls) showed an abnormal"/>
   <result pre="may be particularly important in understanding the diurnal variation of" exact="migraine" post="attack onset. The related studies mostly show lower melatonin"/>
   <result pre="are needed to understand the exact role of melatonin in" exact="migraine" post="pathophysiology and its potential effect on attack onset. Authors"/>
   <result pre="recent study [ 8] collected results suggesting that early morning" exact="migraine" post="attacks are associated with more severe symptoms (compared to"/>
   <result pre="They emphasized the role of a possible hypothalamic dysfunction in" exact="migraine" post="which may contribute to the circadian variation of migraine"/>
   <result pre="in migraine which may contribute to the circadian variation of" exact="migraine" post="attack onset through the hypothalamic involvement in nociception and"/>
   <result pre="attacks; (2) in acute pain state; and possibly (3) in" exact="migraine" post="chronification. Another theory was proposed by Park et al."/>
   <result pre="al. [ 8] who suggested that different trigger factors of" exact="migraine" post="occur at different circadian periods, and among them exposure"/>
   <result pre="et al. [ 8] notably concluded that circadian variation of" exact="migraine" post="attack onset may be a result of interactions between"/>
   <result pre="migraine attack onset may be a result of interactions between" exact="migraine" post="triggers and the innate circadian periodicity. A social nature"/>
   <result pre="triggers and the innate circadian periodicity. A social nature of" exact="migraine" post="attack onset has been also suggested by Alstadhaug et"/>
   <result pre="might be connected to work-related stress in comparison to morning" exact="migraine" post="which might be induced by lack of restorative sleep."/>
   <result pre="the afternoon among children [ 11]. A temporal relationship between" exact="migraine" post="and sleep stages has also been suggested [ 7]."/>
   <result pre="serotonin levels found in both REM sleep [ 25] and" exact="migraine" post="attack [ 26]. A recent review [ 27] reported"/>
   <result pre="wave sleep and a possible involvement of REM sleep in" exact="migraine" post="suggesting a probable brainstem dysfunction in networks involved in"/>
   <result pre="also show the following sleep characteristics of the night before" exact="migraine" post="attacks occur early in the morning or late at"/>
   <result pre="the varying results of studies on the diurnal distribution of" exact="migraine" post="attacks. As a favourable tendency, most studies used a"/>
   <result pre="a shorter follow-up time which might bias the results, because" exact="migraine" post="attacks may also show seasonal variation. In arctic populations"/>
   <result pre="also show seasonal variation. In arctic populations higher frequency of" exact="migraine" post="attacks were found during the bright arctic summer (mostly"/>
   <result pre="probably connected to the prolonged light exposure that might trigger" exact="migraine" post="[ 29– 31]. A study in Italy identified a"/>
   <result pre="lowest attack incidence in August [ 32]. Hospital admissions for" exact="migraine" post="have also been detected to show seasonal variation. A"/>
   <result pre="the importance of considering the possibility of seasonal variation in" exact="migraine" post="attacks in case of a research period spanning less"/>
   <result pre="contrasting results. Another important aspect is the exact diagnosis of" exact="migraine" post="patients. Most of the reviewed studies included samples of"/>
   <result pre="migraine patients. Most of the reviewed studies included samples of" exact="migraine" post="patients with and without aura, but their actual numbers"/>
   <result pre="are large differences in the number of patients in these" exact="migraine" post="categories [ 8, 13]. Therefore results of these studies"/>
   <result pre="help identify specific mechanisms that occur only in a certain" exact="migraine" post="subsample or attack type. Although, this approach also weakens"/>
   <result pre="weakens the comparability of results between studies employing differently defined" exact="migraine" post="subcategories. Use of allowed medications is a crucial factor"/>
   <result pre="reviewed studies. For example beta-blockers might affect the rhythm of" exact="migraine" post="attack onset [ 9]. The blockage of β 1-receptors"/>
   <result pre="way [ 37]; meanwhile Z-drug eszopiclone has no influence on" exact="migraine" post="[ 38]. Contraceptives can also contribute to a different"/>
   <result pre="resulted in changes in stress hormone level. In insulin induced" exact="hypoglycemia" post="stress test, indomethacin intake resulted in increased ACTH and"/>
   <result pre="control for medication use in studies of circadian variation of" exact="migraine" post="attack onset. Migraine has several comorbidities including ones connected"/>
   <result pre="connected to circadian dysregulation, such as asthma, insomnia [ 23]," exact="major depressive disorder," post="and bipolar disorder [ 43]. Comorbid illnesses can influence"/>
   <result pre="such as asthma, insomnia [ 23], major depressive disorder, and" exact="bipolar disorder" post="[ 43]. Comorbid illnesses can influence migraine symptoms. For"/>
   <result pre="disorder, and bipolar disorder [ 43]. Comorbid illnesses can influence" exact="migraine" post="symptoms. For example, migraineurs with comorbid psychiatric diseases have"/>
   <result pre="to control for comorbidities in studies on circadian variation of" exact="migraine" post="attack onset. However, only a small amount of the"/>
   <result pre="control for environmental factors in studies of circadian variation of" exact="migraine" post="attacks. Night or shift work can result in a"/>
   <result pre="carcinogenic effect [ 48]. Sleep disturbances are known triggers of" exact="migraine" post="[ 49], and a study from Denmark showed a"/>
   <result pre="a study from Denmark showed a higher prevalence of treatment-seeking" exact="migraine" post="patients among evening workers [ 50]. These data suggest"/>
   <result pre="comparison with) nonshift workers in studies of circadian variation of" exact="migraine" post="attack onset. 5. Limitations Only published articles (until August"/>
   <result pre="a full 24-hour long time range regarding the distribution of" exact="migraine" post="attacks; therefore such articles were left out from the"/>
   <result pre="current review. 6. Conclusion Most studies on circadian variation of" exact="migraine" post="attack onset show an early morning or late night"/>
   <result pre="result from methodological differences between studies. Heterogeneity among migraineurs and" exact="migraine" post="attacks is another option possibly contributing to discrepancy, as"/>
   <result pre="attacks is another option possibly contributing to discrepancy, as different" exact="migraine" post="subtypes may develop via different pathways in their pathomechanism,"/>
   <result pre="subtypes may develop via different pathways in their pathomechanism, and" exact="migraine" post="attacks can be provoked by several factors. Future studies"/>
   <result pre="data with the use of large enough samples (even among" exact="migraine" post="subtypes) and controlling for all the relevant determinants, including"/>
   <result pre="studies as the exact mechanism explaining the circadian variation of" exact="migraine" post="attack onset is not fully understood yet. A better"/>
   <result pre="of this complex mechanism could contribute to the development of" exact="migraine" post="therapy. Acknowledgments The study was supported by the Hungarian"/>
   <result pre="Acetylsalicylic acid CKIδ: Casein kinase I δ gene CM: Chronic" exact="migraine" post="MA: Migraine with aura MO: Migraine without aura NSAID:"/>
   <result pre="final manuscript. References 1 Global, regional, and national burden of" exact="migraine" post="and tension-type headache, 1990-2016: a systematic analysis for the"/>
   <result pre="3 Alstadhaug K. Salvesen R. Bekkelund S. 24-hour distribution of" exact="migraine" post="attacks Headache: The Journal of Head and Face Pain"/>
   <result pre="xanthan gum coated floating pulsatile delivery of sumatriptan succinate in" exact="migraine" post="treatment BioMed Research International 2014 2014 10 10.1155/2014/547212 5"/>
   <result pre="L. Sleep quality, chronotypes and preferential timing of attacks in" exact="migraine" post="without aura The Journal of Headache and Pain 2005"/>
   <result pre="554 10.1080/07420528.2017.1420076 29283309 9 Solomon G. D. Circadian rhythms and" exact="migraine" post="Cleveland Clinic Journal of Medicine 1992 59 3 326"/>
   <result pre="E. Schoonman G. et al. Chronotypes and circadian timing in" exact="migraine" post="Cephalalgia 2017 38 4 617 625 10.1177/0333102417698953 28944680 11"/>
   <result pre="E. Manfredini R. et al. Circadian and seasonal variation of" exact="migraine" post="attacks in children Headache: The Journal of Head and"/>
   <result pre="Bekkelund S. Insomnia and circadian variation of attacks in episodic" exact="migraine" post="Headache: The Journal of Head and Face Pain 2007"/>
   <result pre="10.1111/j.1526-4610.2007.00858.x 13 de Tommaso M. Delussi M. Circadian rhythms of" exact="migraine" post="attacks in episodic and chronic patients: a cross sectional"/>
   <result pre="e020498 10.1136/bmjopen-2017-020498 15 Pietrobon D. Moskowitz M. A. Pathophysiology of" exact="migraine" post="Annual Review of Physiology 2013 75 365 391 10.1146/annurev-physiol-030212-183717"/>
   <result pre="M. Seabra M. L. et al. Hypothalamic involvement in chronic" exact="migraine" post="Journal of Neurology, Neurosurgery &amp;amp; Psychiatry 2001 71 6"/>
   <result pre="Bigal M. E. Role of melatonin in the pathophysiology of" exact="migraine" post="CNS Drugs 2006 20 5 343 350 10.2165/00023210-200620050-00001 16696576"/>
   <result pre="Allers A. May A. Hypothalamus as a mediator of chronic" exact="migraine" post="Neurology 2017 88 21 2011 2016 10.1212/WNL.0000000000003963 28446645 25"/>
   <result pre="25 Dexter J. D. Riley T. L. Studies in nocturnal" exact="migraine" post="Headache: The Journal of Head and Face Pain 1975"/>
   <result pre="Juhasz G. Zsombok T. Modos E. A. et al. NO-induced" exact="migraine" post="attack: strong increase in plasma calcitonin gene-related peptide (CGRP)"/>
   <result pre="R. E. et al. Casein kinase I mutations in familial" exact="migraine" post="and advanced sleep phase Science Translational Medicine 2013 5"/>
   <result pre="30 Alstadhaug K. Salvesen R. Bekkelund S. Seasonal variation in" exact="migraine" post="Cephalalgia 2005 25 10 811 816 10.1111/j.1468-2982.2005.01018.x 16162258 31"/>
   <result pre="Cugini P. Romit A. Di Palma L. Giacovazzo M. Common" exact="migraine" post="as a weekly and seasonal headache Chronobiology International 1990"/>
   <result pre="George M. S. A study of the seasonal variation of" exact="migraine" post="Headache: The Journal of Head and Face Pain 1990"/>
   <result pre="C. Tseng C. Association between use of short-acting benzodiazepines and" exact="migraine" post="occurrence: a nationwide population-based case–control study Current Medical Research"/>
   <result pre="M. et al. Association study of clock gene (CLOCK) and" exact="schizophrenia" post="and mood disorders in the Japanese population European Archives"/>
   <result pre="S. Lipton R. B. Psychiatric comorbidities of episodic and chronic" exact="migraine" post="Journal of Neurology 2013 260 8 1960 1969 10.1007/s00415-012-6725-x"/>
   <result pre="45 Borsook D. Maleki N. Becerra L. McEwen B. Understanding" exact="migraine" post="through the lens of maladaptive stress responses: a model"/>
   <result pre="C. B. et al. Reduction in perceived stress as a" exact="migraine" post="trigger: Testing the &quot;let-down headache&quot; hypothesis Neurology 2014 82"/>
   <result pre="H. Nabe-Nielsen K. The association between shift work and treatment-seeking" exact="migraine" post="in Denmark Ergonomics 2017 60 9 1207 1217 10.1080/00140139.2016.1278463"/>
   <result pre="PubMed search for studies directly investigating the circadian variation of" exact="migraine" post="attack onset. Table 1 Details and results of the"/>
   <result pre="Details and results of the studies on circadian variation of" exact="migraine" post="attack onset. Study Design Time-span Sample Age (years) ["/>
   <result pre="onset (peak) Studies showing a monophasic 24-hour cyclic manner of" exact="migraine" post="attacks Solomon (1992) [ 9] prospective 20 weeks 15"/>
   <result pre="AM-12 AM Studies showing a biphasic 24-hour cyclic manner of" exact="migraine" post="attacks Soriani, et al. (2006) [ 11] prospective 12"/>
   <result pre="∗] MO, MA use of sleep medication (no data on" exact="migraine" post="medication) depression and anxiety symptoms, lifetime depression; sleep quality"/>
   <result pre="important details of the selected studies on circadian variation of" exact="migraine" post="attack onset. Abbreviations. CM: chronic migraine; MA: migraine with"/>
   <result pre="variation of migraine attack onset. Abbreviations. CM: chronic migraine; MA:" exact="migraine" post="with aura; MO: migraine without aura; NSAID: nonsteroidal anti-inflammatory"/>
   <result pre="onset. Abbreviations. CM: chronic migraine; MA: migraine with aura; MO:" exact="migraine" post="without aura; NSAID: nonsteroidal anti-inflammatory drug; ∗: adjustment for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6734209/results/search/disease/results.xml">
   <result pre="doi: 10.1186/s10194-019-1046-4 : Review Article Differences in treatment response between" exact="migraine" post="with aura and migraine without aura: lessons from clinical"/>
   <result pre="Article Differences in treatment response between migraine with aura and" exact="migraine" post="without aura: lessons from clinical practice and RCTs http://orcid.org/0000-0002-9417-2481"/>
   <result pre="disability worldwide, yet our understanding of the basis mechanisms of" exact="migraine" post="remains incomplete. About a third of migraine patients have"/>
   <result pre="basis mechanisms of migraine remains incomplete. About a third of" exact="migraine" post="patients have attacks with aura, consisting of transient neurological"/>
   <result pre="mechanisms of migraine. Several observations point toward important differences between" exact="migraine" post="with and without aura. Compared with migraine without aura,"/>
   <result pre="important differences between migraine with and without aura. Compared with" exact="migraine" post="without aura, migraine with aura has different heritability, greater"/>
   <result pre="migraine with and without aura. Compared with migraine without aura," exact="migraine" post="with aura has different heritability, greater association with different"/>
   <result pre="by imaging studies. A number of studies also indicate that" exact="migraine" post="with aura may respond differently to acute and preventive"/>
   <result pre="respond differently to acute and preventive therapies as compared to" exact="migraine" post="without aura. The purpose of this review is to"/>
   <result pre="and to discuss the possibility of different therapeutic strategies for" exact="migraine" post="with vs. without aura. Keywords Migraine Migraine aura Migraine"/>
   <result pre="dawn of medicine with the first accounts of attacks of" exact="migraine" post="with aura dating back more than two millennia ["/>
   <result pre="dating back more than two millennia [ 5]. Still today," exact="migraine" post="aura is both an alarming symptom to patients and"/>
   <result pre="clinicians and scientists. Several observations point toward important differences between" exact="migraine" post="with and without aura. Migraine with and without aura"/>
   <result pre="of ischemic stroke, whereas no increased risk is associated with" exact="migraine" post="without aura [ 7, 8]. A number of other"/>
   <result pre="8]. A number of other disorders are also associated with" exact="migraine" post="with aura, but not with migraine without aura ["/>
   <result pre="are also associated with migraine with aura, but not with" exact="migraine" post="without aura [ 9]. Imaging studies suggest that structural"/>
   <result pre="that structural brain changes are more prevalent in those with" exact="migraine" post="than in controls, and some of these changes are"/>
   <result pre="controls, and some of these changes are most pronounced in" exact="migraine" post="with aura [ 10]. During attacks, cerebral blood flow"/>
   <result pre="10]. During attacks, cerebral blood flow changes may differ between" exact="migraine" post="with and without aura [ 11, 12]. Whether migraine"/>
   <result pre="between migraine with and without aura [ 11, 12]. Whether" exact="migraine" post="with aura represents a distinct disorder or is simply"/>
   <result pre="disorder or is simply a part of the spectrum of" exact="migraine" post="remains an open question. Regardless of the answer to"/>
   <result pre="therapies, and also in the efficacy of preventive approaches for" exact="migraine" post="with vs. without aura. What is migraine aura? Up"/>
   <result pre="preventive approaches for migraine with vs. without aura. What is" exact="migraine" post="aura? Up to 1/3 of migraine patients experiences aura"/>
   <result pre="without aura. What is migraine aura? Up to 1/3 of" exact="migraine" post="patients experiences aura [ 13]; reversible transient focal neurological"/>
   <result pre="the cortex or brainstem [ 14]. The diagnostic criteria for" exact="migraine" post="with aura are listed in Table 1. Table 1"/>
   <result pre="are listed in Table 1. Table 1 ICHD-3 criteria for" exact="migraine" post="with aura [ 14] A. At least two attacks"/>
   <result pre="symptom; dysarthria may or may not be Among patients with" exact="migraine" post="with aura, 99% of patients report visual symptoms in"/>
   <result pre="Clinical observations suggest a high degree of clinical variability in" exact="migraine" post="aura both between patients [ 16] and from one"/>
   <result pre="one attack to the next [ 17]. Most patients with" exact="migraine" post="with aura also have migraine attacks without aura. In"/>
   <result pre="[ 17]. Most patients with migraine with aura also have" exact="migraine" post="attacks without aura. In patients with attacks with and"/>
   <result pre="brain tissue. Fig. 1 Typical propagation pattern of a visual" exact="migraine" post="aura. The figure depicts the right visual hemifield and"/>
   <result pre="figure depicts the right visual hemifield and the travelling visual" exact="migraine" post="aura, with the numbers indicating the time passed (in"/>
   <result pre="The temporal and spatial characteristics of the spread of the" exact="migraine" post="visual aura are similar to those that would be"/>
   <result pre="clinical symptoms and therefore considered a likely mechanisms of the" exact="migraine" post="visual aura [ 25]. Potential differences in disease mechanisms"/>
   <result pre="visual aura [ 25]. Potential differences in disease mechanisms in" exact="migraine" post="with and without aura Cortical spreading depression The migraine"/>
   <result pre="in migraine with and without aura Cortical spreading depression The" exact="migraine" post="aura served to differ between migraines two major clinical"/>
   <result pre="blood-brain barrier remained intact during the headache phase of spontaneous" exact="migraine" post="with aura [ 29] and attacks without aura ["/>
   <result pre="attacks without aura [ 30] as well as during GTN-induced" exact="migraine" post="[ 31]. Most migraine patients do not have auras,"/>
   <result pre="30] as well as during GTN-induced migraine [ 31]. Most" exact="migraine" post="patients do not have auras, and auras may also"/>
   <result pre="tonabasat [ 32] that auras may be reduced without reducing" exact="migraine" post="headache without aura speak against subclinical CSD happening silently"/>
   <result pre="aura. Imaging Two metaanalyses have looked at the relationship between" exact="migraine" post="and white matter abnormalities on MRI. Based on seven"/>
   <result pre="Based on seven studies, it was found that patients with" exact="migraine" post="has an four times increased risk for WMA, OR"/>
   <result pre="in controls. Compared to controls, the risk was higher in" exact="migraine" post="with aura, OR 1.68 (95% CI 1.07–2.65), but not"/>
   <result pre="with aura, OR 1.68 (95% CI 1.07–2.65), but not in" exact="migraine" post="without aura OR 1.34; 95% CI 0.96–1.87), without any"/>
   <result pre="aura. The risk for infarct-like lesions did not differ between" exact="migraine" post="with aura and controls, or between migraine without aura"/>
   <result pre="not differ between migraine with aura and controls, or between" exact="migraine" post="without aura and controls. The risk in migraine with"/>
   <result pre="or between migraine without aura and controls. The risk in" exact="migraine" post="with aura was, however, greater than in migraine without"/>
   <result pre="risk in migraine with aura was, however, greater than in" exact="migraine" post="without aura OR 1.44 (95% CI 1.02–2.03), based on"/>
   <result pre="imaging biomarkers that may potentially be used in decisions regarding" exact="migraine" post="diagnoses, treatment and prognostication. In patients with migraine with"/>
   <result pre="decisions regarding migraine diagnoses, treatment and prognostication. In patients with" exact="migraine" post="with aura different pattern of cortical thickness was observed"/>
   <result pre="also exist outside the brain, as it was reported that" exact="migraine" post="with, but not without, aura was associated with foveal"/>
   <result pre="and cerebrovascular disease The available data of the association between" exact="migraine" post="and ischemic stroke have been examined in four pooled"/>
   <result pre="The available data of the association between migraine and ischemic" exact="stroke" post="have been examined in four pooled meta-analyses [ 9,"/>
   <result pre="stroke. Endothelial dysfunction Endothelial dysfunction might play a role connecting" exact="migraine" post="and stroke. Endothelial dysfunction in the broadest sense would"/>
   <result pre="coagulation, inflammation and oxidative stress [ 42]. In total 125" exact="migraine" post="patients were included, evenly divided between migraine with and"/>
   <result pre="In total 125 migraine patients were included, evenly divided between" exact="migraine" post="with and without aura. The authors reported a robust"/>
   <result pre="number of biomarkers of endothelial activation and migraine, especially for" exact="migraine" post="with aura. Vasoconstriction and the use of anti-migraine-drugs Some"/>
   <result pre="increased risk of vascular events [ 43]. Ergot alkaloids in" exact="migraine" post="patients has not been statistically verified as a stroke"/>
   <result pre="in migraine patients has not been statistically verified as a" exact="stroke" post="risk factor but high ergotamine consumption is possibly associated"/>
   <result pre="it must be fairly limited [ 45]. Patent foramen ovale," exact="migraine" post="and aura Patent foramen ovale (PFO) is a common"/>
   <result pre="congenital cardiac defect that may serve as right-to-left shunt for" exact="paradoxical embolism" post="and cause ischemic stroke, especially in the young ["/>
   <result pre="especially in the young [ 46]. In patients with cryptogenic" exact="stroke" post="with concomitant migraine, there is a high prevalence of"/>
   <result pre="high prevalence of PFO (79%), and in the group with" exact="migraine" post="with frequent auras an astounding 93% had PFO ["/>
   <result pre="review [ 48] demonstrates that compared to the general population," exact="migraine" post="is associated with a higher prevalence of patent foramen"/>
   <result pre="general population, migraine is associated with a higher prevalence of" exact="patent foramen ovale," post="especially for migraine with aura. As for tonbasat, PFO"/>
   <result pre="with a higher prevalence of patent foramen ovale, especially for" exact="migraine" post="with aura. As for tonbasat, PFO closure does not"/>
   <result pre="As for tonbasat, PFO closure does not seem to benefit" exact="migraine" post="patients in general [ 49, 50], but the patients"/>
   <result pre="[ 51] supporting a causative role for right-to-left shunt in" exact="migraine" post="aura. Interestingly, one study retrospectively examined the effect intensified"/>
   <result pre="and aspirin resulted in fewer patients (12.2%) reported aura or" exact="migraine" post="with aura or aura compared to aspirin alone (42.3%)"/>
   <result pre="with aspirin alone, resulted in a lower monthly frequency of" exact="migraine" post="attacks over 3 months, but no difference between the two"/>
   <result pre="no difference between the two groups regarding the type of" exact="migraine" post="(aura vs no aura) [ 53]. Psychiatric and cognitive"/>
   <result pre="no aura) [ 53]. Psychiatric and cognitive symptoms associated with" exact="migraine" post="with aura In a large population-based study, depression and"/>
   <result pre="In a large population-based study, depression and depression with comorbid" exact="anxiety disorder" post="were more likely in women with MA than in"/>
   <result pre="needs validation. Some, reversible, cognitive impairment may be reported during" exact="migraine" post="attacks [ 55]. A study evaluated cognitive functions and"/>
   <result pre="functions and psychological symptoms in MO and MA, and although" exact="migraine" post="patients in some aspects differed from controls (lower scores"/>
   <result pre="differences emerged between MA and MO [ 56]. Treatment of" exact="migraine" post="with aura Current guidelines recommend that the same treatment"/>
   <result pre="Current guidelines recommend that the same treatment be used in" exact="migraine" post="with and without aura. This is not surprising because"/>
   <result pre="surprising because almost all studies of both acute and preventative" exact="migraine" post="treatments are based on mixed populations of patients that"/>
   <result pre="based on mixed populations of patients that include those with" exact="migraine" post="with aura and/or without aura, and the treatment effect"/>
   <result pre="this diagnosis or attack subtype is rarely reported. Targeting the" exact="migraine" post="aura The aura is transient in nature, and acute"/>
   <result pre="midazolam as an active control. In the 18 subjects with" exact="migraine" post="with prolonged aura completing the study, ketamine reduced the"/>
   <result pre="[ 59]. The usefulness of ketamine for aura-treatment in classical" exact="migraine" post="aura remains to be established. Based on clinical experience"/>
   <result pre="be established. Based on clinical experience and the assumption that" exact="migraine" post="is associated with defective platelets [ 60], aspirin have"/>
   <result pre="with defective platelets [ 60], aspirin have been tested for" exact="migraine" post="aura prophylaxis. In an observational case series of 49"/>
   <result pre="prophylaxis. In an observational case series of 49 patients with" exact="migraine" post="given aspirin 80 mg daily, the aura frequency was reduced"/>
   <result pre="(48%) [ 61]. Another, retrospective study of 203 patients with" exact="migraine" post="with aura, out of whom 95 (46.8%) used acetylsalicylic"/>
   <result pre="well-tolerated, the use of daily aspirin prophylaxis in patients with" exact="migraine" post="aura should be studied further, preferably in a larger"/>
   <result pre="A small open-label trial of levetiracetam included 16 patients with" exact="migraine" post="with aura, and led to reduction in monthly attacks,"/>
   <result pre="tree leaves has been tested for the prophylactic treatment of" exact="migraine" post="with aura (MA). In open-label study in 50 women"/>
   <result pre="aura (MA). In open-label study in 50 women suffering from" exact="migraine" post="with typical aura, or migraine aura without headache the"/>
   <result pre="in 50 women suffering from migraine with typical aura, or" exact="migraine" post="aura without headache the compound lead to a reduced"/>
   <result pre="in a subsequent open-label study [ 66]. Acute treatment of" exact="migraine" post="headache in migraine with aura Triptans Previous studies indicated"/>
   <result pre="open-label study [ 66]. Acute treatment of migraine headache in" exact="migraine" post="with aura Triptans Previous studies indicated that triptans, specifically"/>
   <result pre="and zolmitriptan [ 67– 69], were not effective in relieving" exact="migraine" post="when taken during the aura phase of an attack."/>
   <result pre="relief at one hour. Patients who had aura with their" exact="migraine" post="and those without aura responded similarly to sumatriptan with"/>
   <result pre="three attacks, as soon as they were aware of a" exact="migraine" post="with aura. Sumatriptan reduced the severity of the first"/>
   <result pre="migraine with aura. Sumatriptan reduced the severity of the first" exact="migraine" post="attack (sumatriptan 63% vs. 33% placebo), but the severity"/>
   <result pre="post-hoc comparison of the efficacy of acute treatment in individual" exact="migraine" post="attacks with aura vs. without aura, and for sumatriptan"/>
   <result pre="indicates that sumatriptan is less effective as acute therapy for" exact="migraine" post="attacks with aura compared to attacks without aura. Different"/>
   <result pre="with aura compared to attacks without aura. Different responses of" exact="migraine" post="with vs. without aura to acute therapies may provide"/>
   <result pre="without aura to acute therapies may provide insight into underlying" exact="migraine" post="mechanisms and influence the choice of acute therapies for"/>
   <result pre="influence the choice of acute therapies for different types of" exact="migraine" post="attacks. Transcranial magnetic simulation and other treatments Transcranial magnetic"/>
   <result pre="is a non-invasive procedure designed for the acute treatment of" exact="migraine" post="with aura, based on the principle that a single"/>
   <result pre="transcranial magnetic stimulation interrupt the wave of CSD during a" exact="migraine" post="aura. In a randomized, sham-controlled trial including 164 patients,"/>
   <result pre="n = 14) reported no difference between sTMS and sham for" exact="migraine" post="attacks or migraine days during 8 week trial, but did"/>
   <result pre="no difference between sTMS and sham for migraine attacks or" exact="migraine" post="days during 8 week trial, but did not evaluate aura"/>
   <result pre="on 5 studies concluded that sTMS may be effective for" exact="migraine" post="with aura, but found no effect of sTMS in"/>
   <result pre="with aura, but found no effect of sTMS in chronic" exact="migraine" post="[ 83]. Blinding is an issue in all these"/>
   <result pre="but randomized, placebo-controlled, double blind study of dipyrone (Metamizol) in" exact="migraine" post="with and without aura, the authors reported more pronounced"/>
   <result pre="pain and associated symptoms after placebo administration in patients with" exact="migraine" post="with aura and migraine without aura. After placebo administration,"/>
   <result pre="after placebo administration in patients with migraine with aura and" exact="migraine" post="without aura. After placebo administration, reduction of symptom intensity"/>
   <result pre="symptom intensity (pain, nausea, photophobia, and phonophobia) in patients with" exact="migraine" post="without aura was significantly greater than that observed in"/>
   <result pre="aura was significantly greater than that observed in patients with" exact="migraine" post="with aura, and the authors suggest that future studies"/>
   <result pre="of aura [ 85]. If the placebo rate differs between" exact="migraine" post="with and without aura, studies reporting therapeutic gains and"/>
   <result pre="86]. The effect of magnesium was tested in patients with" exact="migraine" post="without aura and migraine with aura in a randomized,"/>
   <result pre="magnesium was tested in patients with migraine without aura and" exact="migraine" post="with aura in a randomized, double-blind, placebo-controlled study. In"/>
   <result pre="await replication in larger studies. Preventive therapy Preventive treatment for" exact="migraine" post="with aura has historically been for the most part"/>
   <result pre="historically been for the most part similar to treatment for" exact="migraine" post="without aura, and most studies examining preventive migraine treatment"/>
   <result pre="treatment for migraine without aura, and most studies examining preventive" exact="migraine" post="treatment have been done in mixed populations of MA"/>
   <result pre="and MO. A systematic review with meta-analysis of preventive pharmacologic" exact="migraine" post="treatments found that no trials directly compared drug effects"/>
   <result pre="animal studies chronic treatment with a number of widely prescribed" exact="migraine" post="prophylactic drugs (topiramate, valproate, propranolol, amitriptyline, and methysergide) suppressed"/>
   <result pre="suggesting that CSD in rodents is a translational model for" exact="migraine" post="prophylaxis [ 90]. In rats lamotrigine and valproate also"/>
   <result pre="role in headache, it might be expected that patients with" exact="migraine" post="with aura are more likely to respond to prophylaxis"/>
   <result pre="treatment of chronic migraine. In patients using OnabotulinumtoxinA for preventive" exact="migraine" post="treatment, some authors found that aura predict a more"/>
   <result pre="92], whereas others did not [ 93]. Glutamatergic targets for" exact="migraine" post="with aura The link between glutamate and migraine includes"/>
   <result pre="targets for migraine with aura The link between glutamate and" exact="migraine" post="includes increased levels of glutamate in migraine patients, genetics"/>
   <result pre="between glutamate and migraine includes increased levels of glutamate in" exact="migraine" post="patients, genetics suggesting aberrant glutamate signaling in migraine, and"/>
   <result pre="and in a randomized, double-blind, placebo-controlled trial in patients with" exact="migraine" post="without aura, memantine led to an significant reduction in"/>
   <result pre="the proposed mode of action, memantine should also work in" exact="migraine" post="with aura. In a prospective, open-label trial of 127"/>
   <result pre="patients, 81 patients 74.3% had at least one episode of" exact="migraine" post="with aura during baseline, Memantine was effective, but detailed"/>
   <result pre="95]. Another retrospective study also found mementine effective in both" exact="migraine" post="with and without aura. Out of 20 patients with"/>
   <result pre="migraine with and without aura. Out of 20 patients with" exact="migraine" post="with aura, 16 reported that it reduced the frequency"/>
   <result pre="a larger open-label study of lamotrigine examined the prevention of" exact="migraine" post="aura and reported that more than 75% of patients"/>
   <result pre="of aura symptoms experienced a significant reduction of frequency of" exact="migraine" post="attacks. The authors suggested a potential role of aura-like"/>
   <result pre="trigger for trigeminal vascular activation, and subsequently the development of" exact="migraine" post="headaches [ 98]. Another open-label study examined whether lamotrigine"/>
   <result pre="lamotrigine could cause a &amp;gt; 50% reduction in the mean frequency of" exact="migraine" post="auras. Response was considered as excellent (&amp;gt; 75% reduction) in"/>
   <result pre="significant effect [ 100]. In a separate RCT, focused on" exact="migraine" post="with aura, tonabasat was found to prevent attacks of"/>
   <result pre="migraine with aura, tonabasat was found to prevent attacks of" exact="migraine" post="with aura but not those without aura [ 32],"/>
   <result pre="32], suggesting that tonabasat could be a selective drug for" exact="migraine" post="with aura. Topiramate has been shown to inhibit cortical"/>
   <result pre="tended to be somewhat more pronounced than the reduction in" exact="migraine" post="headaches [ 103]. Another study randomized 213 subjects from"/>
   <result pre="[ 104]. Seventy-five (35.5%) subjects in the ITT population had" exact="migraine" post="with aura. The change in mean monthly migraine frequency"/>
   <result pre="population had migraine with aura. The change in mean monthly" exact="migraine" post="frequency was not different between topiramate and placebo. In"/>
   <result pre="is a non-invasive procedure designed for the acute treatment of" exact="migraine" post="with aura, based on the principle that a single"/>
   <result pre="transcranial magnetic stimulation interrupt the wave of CSD during a" exact="migraine" post="aura. In a randomized, sham-controlled trial including 164 patients,"/>
   <result pre="n = 14) reported no difference between sTMS and sham for" exact="migraine" post="attacks or migraine days during 8 week trial, but did"/>
   <result pre="no difference between sTMS and sham for migraine attacks or" exact="migraine" post="days during 8 week trial, but did not evaluate aura"/>
   <result pre="on 5 studies concluded that sTMS may be effective for" exact="migraine" post="with aura, but found no effect of sTMS in"/>
   <result pre="with aura, but found no effect of sTMS in chronic" exact="migraine" post="[ 83]. Blinding is an issue in all these"/>
   <result pre="has not been described. Implications for future trials Patients with" exact="migraine" post="with aura, may have attacks with and without aura"/>
   <result pre="without aura and most had more than one subtype of" exact="migraine" post="with aura [ 106]. Even though few patients report"/>
   <result pre="subcommittee [ 107]. The trials of tonerbasat showed efficacy in" exact="migraine" post="with aura, but not in migraine without aura, suggesting"/>
   <result pre="tonerbasat showed efficacy in migraine with aura, but not in" exact="migraine" post="without aura, suggesting that migraine with and without aura"/>
   <result pre="with aura, but not in migraine without aura, suggesting that" exact="migraine" post="with and without aura should be studied separately ["/>
   <result pre="without aura should be studied separately [ 108]. Trials of" exact="migraine" post="prophylactic drugs generally focus on reduction in the number"/>
   <result pre="prophylactic drugs generally focus on reduction in the number of" exact="migraine" post="days as the key efficacy parameter, and little attention"/>
   <result pre="that some treatments may have different efficacy in attacks of" exact="migraine" post="with aura vs. without aura. It is an important"/>
   <result pre="It is an important confounder that many patients diagnosed with" exact="migraine" post="with aura occasionally have attacks of migraine without aura"/>
   <result pre="patients diagnosed with migraine with aura occasionally have attacks of" exact="migraine" post="without aura – and vice versa. It is unresolved"/>
   <result pre="employ different treatment strategies based on a previous history of" exact="migraine" post="with versus without aura, or based on the presence"/>
   <result pre="may be an important step to personalized medicine in acute" exact="migraine" post="treatment. Publisher’s Note Springer Nature remains neutral with regard"/>
   <result pre="Press 6. Russell MB et al. Migraine without aura and" exact="migraine" post="with aura are distinct clinical entities: a study of"/>
   <result pre="Stang PE et al. Headache, cerebrovascular symptoms, and stroke: the" exact="atherosclerosis" post="risk in communities study Neurology 2005 64 9 1573"/>
   <result pre="Kurth T et al. Migraine, headache, and the risk of" exact="stroke" post="in women: a prospective study Neurology 2005 64 6"/>
   <result pre="1268 10.1212/WNL.0b013e3182a6cb32 23986301 11. Olesen J et al. The common" exact="migraine" post="attack may not be initiated by cerebral ischaemia Lancet"/>
   <result pre="and topography of cerebral blood flow, aura, and headache during" exact="migraine" post="attacks Ann Neurol 1990 28 6 791 798 10.1002/ana.410280610"/>
   <result pre="MB et al. Prevalence and sex-ratio of the subtypes of" exact="migraine" post="Int J Epidemiol 1995 24 3 612 618 10.1093/ije/24.3.612"/>
   <result pre="PJ Charles AC Variability of clinical features in attacks of" exact="migraine" post="with aura Cephalalgia : an international journal of headache"/>
   <result pre="Viana M et al. Variability of the characteristics of a" exact="migraine" post="attack within patients Cephalalgia : an international journal of"/>
   <result pre="18. Hauge AW Kirchmann M Olesen J Trigger factors in" exact="migraine" post="with aura Cephalalgia : an international journal of headache"/>
   <result pre="2049 10.1212/WNL.0b013e3182749eed 23115208 20. Queiroz LP et al. Characteristics of" exact="migraine" post="visual aura in southern Brazil and northern USA Cephalalgia"/>
   <result pre="21. Russell MB Olesen J A nosographic analysis of the" exact="migraine" post="aura in a general population Brain 1996 119 Pt"/>
   <result pre="K Patterns of cerebral integration indicated by the scotomas of" exact="migraine" post="Arch Neurol Psychiatr 1941 46 2 331 339 10.1001/archneurpsyc.1941.02280200137007"/>
   <result pre="6 359 390 10.1152/jn.1944.7.6.359 25. Lauritzen M Pathophysiology of the" exact="migraine" post="aura. The spreading depression theory Brain 1994 117 Pt"/>
   <result pre="al. Intrinsic brain activity triggers trigeminal meningeal afferents in a" exact="migraine" post="model Nat Med 2002 8 2 136 142 10.1038/nm0202-136"/>
   <result pre="brainstem perfusion, but no blood-brain barrier disruption, during attacks of" exact="migraine" post="with aura Brain 2017 140 6 1633 1642 10.1093/brain/awx089"/>
   <result pre="FM et al. Intact blood-brain barrier during spontaneous attacks of" exact="migraine" post="without aura: a 3T DCE-MRI study Eur J Neurol"/>
   <result pre="integrity of the blood-brain barrier for 11C-dihydroergotamine during glyceryl trinitrate-induced" exact="migraine" post="Brain : a journal of neurology 2016 139 Pt"/>
   <result pre="27234268 32. Hauge AW et al. Effects of tonabersat on" exact="migraine" post="with aura: a randomised, double-blind, placebo-controlled crossover study The"/>
   <result pre="Chang MY et al. Foveal and Peripapillary vascular decrement in" exact="migraine" post="with Aura demonstrated by optical coherence tomography angiography Invest"/>
   <result pre="10.1007/s10072-016-2746-z 39. Spector JT et al. Migraine headache and ischemic" exact="stroke" post="risk: an updated meta-analysis Am J Med 2010 123"/>
   <result pre="10.1016/j.amjmed.2009.12.021 20493462 40. Etminan M et al. Risk of ischaemic" exact="stroke" post="in people with migraine: systematic review and meta-analysis of"/>
   <result pre="GC et al. Triptans in migraine: the risks of stroke," exact="cardiovascular disease," post="and death in practice Neurology 2004 62 4 563"/>
   <result pre="131 10.1177/0333102414550416 25246519 46. Lechat P et al. Prevalence of" exact="patent foramen ovale" post="in patients with stroke N Engl J Med 1988"/>
   <result pre="et al. Prevalence of patent foramen ovale in patients with" exact="stroke" post="N Engl J Med 1988 318 18 1148 1152"/>
   <result pre="BH et al (2018) Frequency of patent foramen Ovale and" exact="migraine" post="in patients with cryptogenic stroke. Stroke 48. Lip PZ"/>
   <result pre="Stroke 48. Lip PZ Lip GY Patent foramen ovale and" exact="migraine" post="attacks: a systematic review Am J Med 2014 127"/>
   <result pre="10.1016/j.jacc.2017.09.1105 29191325 50. Mattle HP et al. Percutaneous closure of" exact="patent foramen ovale" post="in migraine with aura, a randomized controlled trial Eur"/>
   <result pre="HP et al. Percutaneous closure of patent foramen ovale in" exact="migraine" post="with aura, a randomized controlled trial Eur Heart J"/>
   <result pre="51. Nozari A et al. Microemboli may link spreading depression," exact="migraine" post="aura, and patent foramen ovale Ann Neurol 2010 67"/>
   <result pre="et al. Microemboli may link spreading depression, migraine aura, and" exact="patent foramen ovale" post="Ann Neurol 2010 67 2 221 229 10.1002/ana.21871 20225282"/>
   <result pre="229 10.1002/ana.21871 20225282 52. Wilmshurst PT et al. Clopidogrel reduces" exact="migraine" post="with aura after transcatheter closure of persistent foramen ovale"/>
   <result pre="al. Effect of Clopidogrel and aspirin vs aspirin alone on" exact="migraine" post="headaches after Transcatheter atrial septal defect closure: the CANOA"/>
   <result pre="and aspirin vs aspirin alone on migraine headaches after Transcatheter" exact="atrial septal defect" post="closure: the CANOA randomized clinical trial JAMA : the"/>
   <result pre="al. Migraine with and without aura: association with depression and" exact="anxiety disorder" post="in a population-based study. The HUNT study Cephalalgia :"/>
   <result pre="R Oliveira AG Martins IP Assessment of cognitive dysfunction during" exact="migraine" post="attacks: a systematic review J Neurol 2015 262 3"/>
   <result pre="Charles A Glutamate and its receptors as therapeutic targets for" exact="migraine" post="Neurotherapeutics : the journal of the American Society for"/>
   <result pre="58. Kaube H et al. Aura in some patients with" exact="familial hemiplegic migraine" post="can be stopped by intranasal ketamine Neurology 2000 55"/>
   <result pre="H et al. Aura in some patients with familial hemiplegic" exact="migraine" post="can be stopped by intranasal ketamine Neurology 2000 55"/>
   <result pre="et al. A randomized controlled trial of intranasal ketamine in" exact="migraine" post="with prolonged aura Neurology 2013 80 7 642 647"/>
   <result pre="10.1016/S0140-6736(82)92373-X 6123003 61. Turk WE et al. Aspirin prophylaxis for" exact="migraine" post="with Aura: an observational case series Eur Neurol 2017"/>
   <result pre="62. Anoaica MB Anoaica PG Popescu F Acetylsalicylic acid in" exact="migraine" post="with aura prevention - a retrospective study Curr Health"/>
   <result pre="63. Brighina F et al. Levetiracetam in the prophylaxis of" exact="migraine" post="with aura: a 6-month open-label study Clin Neuropharmacol 2006"/>
   <result pre="al. Acid-sensing ion channel 1: a novel therapeutic target for" exact="migraine" post="with aura Ann Neurol 2012 72 4 559 563"/>
   <result pre="et al. Efficacy of Ginkgolide B in the prophylaxis of" exact="migraine" post="with aura Neurological sciences : official journal of the"/>
   <result pre="The efficacy of ginkgolide B in the acute treatment of" exact="migraine" post="aura: an open preliminary trial Neurological sciences : official"/>
   <result pre="10.1007/s10072-013-1413-x 67. Bates, D., et al., Subcutaneous sumatriptan during the" exact="migraine" post="aura . Sumatriptan Aura Study Group Neurology, 1994. 44(9):"/>
   <result pre="Dowson A Can oral 311C90, a novel 5-HT1D agonist, prevent" exact="migraine" post="headache when taken during an aura? Eur Neurol 1996"/>
   <result pre="No effect of eletriptan administration during the aura phase of" exact="migraine" post="European journal of neurology : the official journal of"/>
   <result pre="the efficacy of sumatriptan therapy during the aura phase of" exact="migraine" post="Headache 2009 49 7 1001 1004 10.1111/j.1526-4610.2009.01429.x 19438735 71."/>
   <result pre="Mathew N Nett R Triptans in the treatment of basilar" exact="migraine" post="and migraine with prolonged aura Headache 2001 41 10"/>
   <result pre="Nett R Triptans in the treatment of basilar migraine and" exact="migraine" post="with prolonged aura Headache 2001 41 10 981 984"/>
   <result pre="10.1046/j.1526-4610.2001.01192.x 11903526 72. Artto V et al. Treatment of hemiplegic" exact="migraine" post="with triptans Eur J Neurol 2007 14 9 1053"/>
   <result pre="14 9 1053 1056 10.1111/j.1468-1331.2007.01900.x 17718700 73. Subcutaneous_Sumatriptan_International_Study_Group, Treatment of" exact="migraine" post="attacks with sumatriptan. The subcutaneous Sumatriptan international study group"/>
   <result pre="Banerjee M Findley LJ Sumatriptan in the treatment of acute" exact="migraine" post="with aura Cephalalgia : an international journal of headache"/>
   <result pre="S Moore RA Sumatriptan (subcutaneous route of administration) for acute" exact="migraine" post="attacks in adults Cochrane Database Syst Rev 2012 2"/>
   <result pre="S Moore RA Sumatriptan (oral route of administration) for acute" exact="migraine" post="attacks in adults Cochrane Database Syst Rev 2012 2"/>
   <result pre="S Moore RA Sumatriptan (intranasal route of administration) for acute" exact="migraine" post="attacks in adults Cochrane Database Syst Rev 2012 2"/>
   <result pre="JM Goadsby PJ Charles A Reduced efficacy of sumatriptan in" exact="migraine" post="with aura vs without aura Neurology 2015 84 18"/>
   <result pre="et al. Single-pulse transcranial magnetic stimulation for acute treatment of" exact="migraine" post="with aura: a randomised, double-blind, parallel-group, sham-controlled trial Lancet"/>
   <result pre="Low-frequency rTMS of the vertex in the prophylactic treatment of" exact="migraine" post="Cephalalgia : an international journal of headache 2010 30"/>
   <result pre="ME et al. Intravenous dipyrone in the acute treatment of" exact="migraine" post="without aura and migraine with aura: a randomized, double"/>
   <result pre="dipyrone in the acute treatment of migraine without aura and" exact="migraine" post="with aura: a randomized, double blind, placebo controlled study"/>
   <result pre="12390611 85. Bigal ME et al. Migraine with aura versus" exact="migraine" post="without aura: pain intensity and associated symptom intensities after"/>
   <result pre="et al. Intravenous magnesium sulphate in the acute treatment of" exact="migraine" post="without aura and migraine with aura. A randomized, double-blind,"/>
   <result pre="sulphate in the acute treatment of migraine without aura and" exact="migraine" post="with aura. A randomized, double-blind, placebo-controlled study Cephalalgia :"/>
   <result pre="89. Shamliyan TA et al. Preventive pharmacologic treatments for episodic" exact="migraine" post="in adults 2013 90. Ayata C et al. Suppression"/>
   <result pre="Ayata C et al. Suppression of cortical spreading depression in" exact="migraine" post="prophylaxis Ann Neurol 2006 59 4 652 661 10.1002/ana.20778"/>
   <result pre="PM Alvarez MV Jones L Headache direction and aura predict" exact="migraine" post="responsiveness to rimabotulinumtoxin B Headache 2013 53 1 126"/>
   <result pre="93. Jakubowski M et al. Exploding vs. imploding headache in" exact="migraine" post="prophylaxis with botulinum toxin a Pain 2006 125 3"/>
   <result pre="94. Noruzzadeh R et al. Memantine for prophylactic treatment of" exact="migraine" post="without Aura: a randomized double-blind placebo-controlled study Headache 2016"/>
   <result pre="efficacy of Memantine as add on therapy in patients with" exact="migraine" post="Iranian journal of pharmaceutical research : IJPR 2017 16"/>
   <result pre="Lampl C et al. Lamotrigine in the prophylactic treatment of" exact="migraine" post="aura--a pilot study Cephalalgia : an international journal of"/>
   <result pre="63 10.1111/j.1468-2982.1999.1901058.x 10099861 98. Lampl C et al. Lamotrigine reduces" exact="migraine" post="aura and migraine attacks in patients with migraine with"/>
   <result pre="98. Lampl C et al. Lamotrigine reduces migraine aura and" exact="migraine" post="attacks in patients with migraine with aura J Neurol"/>
   <result pre="Lamotrigine reduces migraine aura and migraine attacks in patients with" exact="migraine" post="with aura J Neurol Neurosurg Psychiatry 2005 76 12"/>
   <result pre="1732 10.1136/jnnp.2005.063750 16291905 99. Pascual J et al. Preventing disturbing" exact="migraine" post="aura with lamotrigine: an open study Headache 2004 44"/>
   <result pre="and safety in two randomized, placebo-controlled, dose-ranging studies of acute" exact="migraine" post="Cephalalgia : an international journal of headache 2009 29"/>
   <result pre="102. Diener HC et al. Cessation versus continuation of 6-month" exact="migraine" post="preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled"/>
   <result pre="and tolerability of topiramate 200 mg/d in the prevention of" exact="migraine" post="with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week"/>
   <result pre="IH et al. Factors associated with favorable outcome of Topiramate" exact="migraine" post="prophylaxis in pediatric patients Journal of clinical neurology 2017"/>
   <result pre="MK et al. Clinical characteristics of 362 patients with familial" exact="migraine" post="with aura Cephalalgia 2004 24 7 564 575 10.1111/j.1468-2982.2003.00718.x"/>
   <result pre="A Olesen J On the methodology of drug trials in" exact="migraine" post="with aura Cephalalgia : an international journal of headache"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6734211/results/search/disease/results.xml">
   <result pre="gioacchino.tedeschi@unicampania.it 15 Russo Antonio dottor.russo@gmail.com 15 collab: The Italian chronic" exact="migraine" post="group [1], [2], 0000000417581884 grid.18887.3e Headache and Pain Unit,"/>
   <result pre="license, and indicate if changes were made. Abstract Background Chronic" exact="migraine" post="is a disabling condition that is currently underdiagnosed and"/>
   <result pre="In this narrative review, we discuss the future of chronic" exact="migraine" post="management in relation to recent progress in evidence-based pharmacological"/>
   <result pre="recent progress in evidence-based pharmacological treatment. Findings Patients with chronic" exact="migraine" post="require prophylactic therapy to reduce the frequency of migraine"/>
   <result pre="chronic migraine require prophylactic therapy to reduce the frequency of" exact="migraine" post="attacks, but the only currently available evidence-based prophylactic treatment"/>
   <result pre="the only currently available evidence-based prophylactic treatment options for chronic" exact="migraine" post="are topiramate and onabotulinumtoxinA. Improved prophylactic therapy is needed"/>
   <result pre="therapy is needed to reduce the high burden of chronic" exact="migraine" post="in Italy. Monoclonal antibodies that target the calcitonin gene-related"/>
   <result pre="antibodies that target the calcitonin gene-related peptide (CGRP) pathway of" exact="migraine" post="pathogenesis have been specifically developed for the prophylactic treatment"/>
   <result pre="not benefitting from their current treatment. Conclusions Treatment of chronic" exact="migraine" post="is a dynamic and rapidly advancing area of research."/>
   <result pre="personal, social and economic burden of chronic migraine. Keywords Chronic" exact="migraine" post="Fremanezumab onabotulinumtoxinA Prophylaxis Topiramate Anti-CGRP monoclonal antibodies Background Chronic"/>
   <result pre="migraine Fremanezumab onabotulinumtoxinA Prophylaxis Topiramate Anti-CGRP monoclonal antibodies Background Chronic" exact="migraine" post="(CM), defined by the current International Headache Society classification"/>
   <result pre="as headache occurring on ≥15 days/month for &amp;gt; 3 months with features of" exact="migraine" post="on ≥8 days/month [ 1], is a disabling condition that"/>
   <result pre="frequency, especially if they have psychiatric comorbidities. Compared with episodic" exact="migraine" post="(EM), CM is less common but is associated with"/>
   <result pre="progression include the frequency of headache attacks, overuse of acute" exact="migraine" post="medication, ineffective acute treatment, stressful life events and obesity"/>
   <result pre="acute migraine medication, ineffective acute treatment, stressful life events and" exact="obesity" post="[ 8, 12, 16, 17]. Medication-overuse headache (MOH) is"/>
   <result pre="is now considered a sequela rather than a cause of" exact="migraine" post="and can co-exist with CM [ 1, 18, 19]."/>
   <result pre="authors’ knowledge of the area. Understanding the pathophysiology of chronic" exact="migraine" post="The pathophysiology of CM is not fully understood, but"/>
   <result pre="modulatory activity [ 21– 23]. It is postulated that recurring" exact="migraine" post="episodes and comorbid conditions, such as medication overuse or"/>
   <result pre="activation of the trigeminovascular pathway, both of which occur in" exact="migraine" post="[ 25, 26], implicate hyperexcitability of certain central nervous"/>
   <result pre="CGRP in headache pain notwithstanding, the first step of the" exact="migraine" post="attack is likely to involve central mechanisms, as suggested"/>
   <result pre="attack stages [ 28], as well as the concept that" exact="migraine" post="may occur without pain in the paediatric population (migraine-associated"/>
   <result pre="paediatric population (migraine-associated periodic syndromes) and in patients who experience" exact="migraine" post="with aura. CGRP, which is involved in pain modulation,"/>
   <result pre="seems to have a major role in the pathogenesis of" exact="migraine" post="{Goldberg, 2015 #47;Ho, 2010 #21;Edvinsson, 2019 #139}. Activation of"/>
   <result pre="cortical spreading depression, which is a key pathophysiological component of" exact="migraine" post="with aura [ 32, 33]. Release of CGRP from"/>
   <result pre="trigeminal nervous system in CM [ 35]. Treatment of chronic" exact="migraine" post="Some patients with low frequency EM can be managed"/>
   <result pre="acute therapy (i.e. drugs taken during the prodrome or the" exact="migraine" post="attack to abort it) without prophylactic treatment, but patients"/>
   <result pre="Whereas the goal of acute therapy is to abort a" exact="migraine" post="attack once it has started, the goals of prophylactic"/>
   <result pre="developing MOH [ 8, 20, 31]. Effective acute treatment of" exact="migraine" post="attacks with triptans may help to prevent progression from"/>
   <result pre="CM, but rather than relying on taking drugs to stop" exact="migraine" post="attacks after they have started, the aim of treatment"/>
   <result pre="aim of treatment for CM should be the prevention of" exact="migraine" post="attacks [ 35]. Fig. 1 Mechanisms of action of"/>
   <result pre="1 Mechanisms of action of antimigraine treatments used in chronic" exact="migraine" post="and emerging treatments in relation to calcitonin gene-related peptide"/>
   <result pre="not responded adequately or are intolerant of commonly prescribed oral" exact="migraine" post="treatments [ 47]. Treatment should be repeated every 3 months."/>
   <result pre="to prevent the development of cortical spreading depression associated with" exact="migraine" post="by modulating ion channels (e.g. blockade of voltage-gated sodium"/>
   <result pre="of principle that targeting the CGRP pathway may effectively prevent" exact="migraine" post="[ 27, 60]. Telcagepant has been investigated for the"/>
   <result pre="CGRP receptor antagonists are currently in phase III development for" exact="migraine" post="(atogepant, rimegepant, and ubrogepant), with atogepant and rimegepant being"/>
   <result pre="excessive CGRP released in the trigeminal sensory nerve fibres during" exact="migraine" post="attacks (Fig. 1) [ 27, 60, 63]. Three anti-CGRP/R"/>
   <result pre="resulted in significant reductions in the primary endpoints of monthly" exact="migraine" post="days and headache hours, respectively, versus placebo [ 63,"/>
   <result pre="significantly reducing both the average number of headache days/month and" exact="migraine" post="days/month compared with placebo in the 12-week period after"/>
   <result pre="Medicines Agency for the prophylactic treatment of chronic and episodic" exact="migraine" post="[ 75, 76] . This review will be based"/>
   <result pre="phase III studies in these indications [ 73, 77]. Chronic" exact="migraine" post="management in Italy On the basis of the results"/>
   <result pre="of therapy would require careful assessment of clinical characteristics of" exact="migraine" post="in each CM patient, as well as their overall"/>
   <result pre="on variables such as lifestyle, behavioral and socio-demographic factors, comorbidities," exact="migraine" post="features before and after chronification (e.g. disease duration; location,"/>
   <result pre="to focus attention on preventive rather than acute treatment of" exact="migraine" post="attacks in patients with CM. To this end, neurologists,"/>
   <result pre="by a combined treatment approach of acute treatment to reduce" exact="migraine" post="severity and prophylactic treatments to reduce migraine frequency ["/>
   <result pre="treatment to reduce migraine severity and prophylactic treatments to reduce" exact="migraine" post="frequency [ 11]. A pooled analysis of clinical trial"/>
   <result pre="with topiramate in patients with EM may help to prevent" exact="migraine" post="chronification [ 88]. Anti-CGRP monoclonal antibodies may also prove"/>
   <result pre="a phase II clinical trial in which fremanezumab significantly reduced" exact="migraine" post="days versus placebo in patients with high-frequency migraine ["/>
   <result pre="significantly reduced migraine days versus placebo in patients with high-frequency" exact="migraine" post="[ 72]. Although in this review we focus on"/>
   <result pre="mechanism of action of these treatments is so specific to" exact="migraine" post="that inappropriate use will almost invariably result in treatment"/>
   <result pre="this devastating disease. Abbreviations CGRP Calcitonin gene-related peptide CM Chronic" exact="migraine" post="EM Episodic migraine ICHD-3 International Headache Society classification of"/>
   <result pre="Abbreviations CGRP Calcitonin gene-related peptide CM Chronic migraine EM Episodic" exact="migraine" post="ICHD-3 International Headache Society classification of Headache Disorders MOH"/>
   <result pre="contributions The Authors were the members of The Italian chronic" exact="migraine" post="group. They contributed equally to this work drafting the"/>
   <result pre="2. Bigal ME Serrano D Reed M Lipton RB Chronic" exact="migraine" post="in the population burden, diagnosis, and satisfaction with treatment"/>
   <result pre="Rapoport AM Lipton RB Tepper SJ Sheftell FD Assessment of" exact="migraine" post="disability using the migraine disability assessment (MIDAS) questionnaire: a"/>
   <result pre="Tepper SJ Sheftell FD Assessment of migraine disability using the" exact="migraine" post="disability assessment (MIDAS) questionnaire: a comparison of chronic migraine"/>
   <result pre="the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic" exact="migraine" post="with episodic migraine Headache. 2003 43 4 336 342"/>
   <result pre="assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic" exact="migraine" post="Headache. 2003 43 4 336 342 10.1046/j.1526-4610.2003.03068.x 12656704 6."/>
   <result pre="Turkel C Lipton R Sociodemographic and comorbidity profiles of chronic" exact="migraine" post="and episodic migraine sufferers J Neurol Neurosurg Psychiatry 2010"/>
   <result pre="R Sociodemographic and comorbidity profiles of chronic migraine and episodic" exact="migraine" post="sufferers J Neurol Neurosurg Psychiatry 2010 81 4 428"/>
   <result pre="Young WB Quality-of-life differences between patients with episodic and transformed" exact="migraine" post="Headache. 2001 41 6 573 578 10.1046/j.1526-4610.2001.041006573.x 11437893 8."/>
   <result pre="10.1046/j.1526-4610.2001.041006573.x 11437893 8. Lipton RB Silberstein SD Episodic and chronic" exact="migraine" post="headache: breaking down barriers to optimal treatment and prevention"/>
   <result pre="E De Simone R et al. Underdiagnosis and undertreatment of" exact="migraine" post="in Italy: a survey of patients attending for the"/>
   <result pre="Herberhold J Steiner TJ Poor medical care for people with" exact="migraine" post="in Europe - evidence from the Eurolight study J"/>
   <result pre="D Buse D Scher A Stewart WF Lipton RB Acute" exact="migraine" post="medications and evolution from episodic to chronic migraine: a"/>
   <result pre="WBF Adams AM et al. Fluctuations in episodic and chronic" exact="migraine" post="status over the course of 1 year: implications for"/>
   <result pre="Sungur MA Selekler M Siva A Phenotypic features of chronic" exact="migraine" post="J Headache Pain. 2016 17 26 10.1186/s10194-016-0616-y 26975363 16."/>
   <result pre="26975363 16. Bigal ME Lipton RB Modifiable risk factors for" exact="migraine" post="progression Headache. 2006 46 9 1334 1343 10.1111/j.1526-4610.2006.00577.x 17040331"/>
   <result pre="DC Manack AN Lipton RB Defining the differences between episodic" exact="migraine" post="and chronic migraine Curr Pain Headache Rep 2012 16"/>
   <result pre="Lipton RB Defining the differences between episodic migraine and chronic" exact="migraine" post="Curr Pain Headache Rep 2012 16 1 86 92"/>
   <result pre="C Rapoport AM Update on the pharmacological treatment of chronic" exact="migraine" post="Curr Pain Headache Rep 2016 20 1 6 10.1007/s11916-015-0533-9"/>
   <result pre="1 6 10.1007/s11916-015-0533-9 26728188 21. Mathew NT Pathophysiology of chronic" exact="migraine" post="and mode of action of preventive medications Headache. 2011"/>
   <result pre="D Goor-Aryeh I Ransil BJ Bajwa ZH An association between" exact="migraine" post="and cutaneous allodynia Ann Neurol 2000 47 5 614"/>
   <result pre="Goldberg SW Silberstein SD Targeting CGRP: a new era for" exact="migraine" post="treatment CNS Drugs 2015 29 6 443 452 10.1007/s40263-015-0253-z"/>
   <result pre="443 452 10.1007/s40263-015-0253-z 26138383 28. Schulte LH May A The" exact="migraine" post="generator revisited: continuous scanning of the migraine cycle over"/>
   <result pre="May A The migraine generator revisited: continuous scanning of the" exact="migraine" post="cycle over 30 days and three spontaneous attacks Brain"/>
   <result pre="Lupi C Geppetti P TRPA1 and other TRP channels in" exact="migraine" post="J Headache Pain. 2013 14 1 71 10.1186/1129-2377-14-71 23941062"/>
   <result pre="Fusi C Trevisan G Geppetti P The TRPA1 channel in" exact="migraine" post="mechanism and treatment Br J Pharmacol 2014 171 10"/>
   <result pre="MH Dodick DW Porreca F Targeting TRP channels for novel" exact="migraine" post="therapeutics ACS Chem Neurosci 2014 5 11 1085 1096"/>
   <result pre="CGRP levels in peripheral blood as a biomarker for chronic" exact="migraine" post="Neurology. 2013 81 14 1191 1196 10.1212/WNL.0b013e3182a6cb72 23975872 35."/>
   <result pre="27389092 36. Weatherall MW The diagnosis and treatment of chronic" exact="migraine" post="Ther Adv Chronic Dis 2015 6 3 115 123"/>
   <result pre="Goadsby PJ CGRP and its receptors provide new insights into" exact="migraine" post="pathophysiology Nat Rev Neurol 2010 6 10 573 582"/>
   <result pre="(nVNS) for preventive and acute treatment of episodic and chronic" exact="migraine" post="and migraine-associated sleep disturbance: a prospective observational cohort study"/>
   <result pre="J Eren O Blum B Ruscheweyh R Treatment of chronic" exact="migraine" post="with transcutaneous stimulation of the auricular branch of the"/>
   <result pre="Cho SJ Song TJ Chu MK Treatment update of chronic" exact="migraine" post="Curr Pain Headache Rep 2017 21 6 26 10.1007/s11916-017-0628-6"/>
   <result pre="44. Hepp Z Bloudek LM Varon SF Systematic review of" exact="migraine" post="prophylaxis adherence and persistence J Manag Care Pharm 2014"/>
   <result pre="EB Adherence to oral migraine-preventive medications among patients with chronic" exact="migraine" post="Cephalalgia. 2015 35 6 478 488 10.1177/0333102414547138 25164920 46."/>
   <result pre="Silberstein S OnabotulinumtoxinA: a review in the prevention of chronic" exact="migraine" post="Drugs. 2018 78 5 589 600 10.1007/s40265-018-0894-6 29532439 47."/>
   <result pre="Geppetti P et al. Optimizing the long-term management of chronic" exact="migraine" post="with onabotulinumtoxinA in real life Expert Rev Neurother 2018"/>
   <result pre="and divalproex sodium for prophylactic treatment of episodic or chronic" exact="migraine" post="Headache. 2008 48 2 210 220 10.1111/j.1526-4610.2007.00949.x 18047502 51."/>
   <result pre="type a versus amitriptyline for the treatment of chronic daily" exact="migraine" post="Clin Neurol Neurosurg 2010 112 6 463 466 10.1016/j.clineuro.2010.02.004"/>
   <result pre="LA et al. Onabotulinumtoxin a for the management of chronic" exact="migraine" post="in current clinical practice: results of a survey of"/>
   <result pre="T Papetti L Rubio-Beltran E et al. Blocking CGRP in" exact="migraine" post="patients - a review of pros and cons J"/>
   <result pre="Reuter U CGRP monoclonal antibodies for the preventative treatment of" exact="migraine" post="Curr Pain Headache Rep 2018 22 5 38 10.1007/s11916-018-0686-4"/>
   <result pre="Salvatore CA Kane SA CGRP receptor antagonists: toward a novel" exact="migraine" post="therapy Curr Pharm Biotechnol 2011 12 10 1671 1680"/>
   <result pre="AR Goadsby PJ Anti-CGRP monoclonal antibodies: the next era of" exact="migraine" post="prevention? Curr Treat Options Neurol 2017 19 8 27"/>
   <result pre="Randomized controlled trial of the CGRP receptor antagonist telcagepant for" exact="migraine" post="prevention Neurology. 2014 83 11 958 966 10.1212/WNL.0000000000000771 25107879"/>
   <result pre="al. Rimegepant, an oral calcitonin gene–related peptide receptor antagonist, for" exact="migraine" post="N Engl J Med 2019 381 142 149 10.1056/NEJMoa1811090"/>
   <result pre="receptor antagonists and antibodies against CGRP and its receptor in" exact="migraine" post="treatment Br J Clin Pharmacol 2015 80 2 193"/>
   <result pre="T et al. Fremanezumab for the preventive treatment of chronic" exact="migraine" post="N Engl J Med 2017 377 22 2113 2122"/>
   <result pre="license application for fremanezumab with priority review for prevention of" exact="migraine" post="and grants fast track designation for cluster headache development"/>
   <result pre="Goadsby PJ et al. Cost of healthcare for patients with" exact="migraine" post="in five European countries: results from the international burden"/>
   <result pre="in five European countries: results from the international burden of" exact="migraine" post="study (IBMS) J Headache Pain. 2012 13 5 361"/>
   <result pre="C Egeo G et al. Establishment of an Italian chronic" exact="migraine" post="database: a multicenter pilot study Neurol Sci 2018 39"/>
   <result pre="as predictors of efficacy of onabotulinumtoxin type a in chronic" exact="migraine" post="Headache. 2014 54 6 987 995 10.1111/head.12372 24673487 87."/>
   <result pre="87. Martelletti P The application of CGRP(r) monoclonal antibodies in" exact="migraine" post="spectrum: needs and priorities BioDrugs. 2017 31 6 483"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6734233/results/search/disease/results.xml">
   <result pre="investigate the whole-brain resting-state functional connectivity in patients with chronic" exact="migraine" post="(CM) using a data-driven method. Methods We prospectively recruited"/>
   <result pre="data-driven method. Methods We prospectively recruited patients with either episodic" exact="migraine" post="(EM) or CM aged 18–60 years who visited the headache"/>
   <result pre="Patients were considered interictal if they did not have a" exact="migraine" post="headache at the day and ± 1 days of functional MRI acquisition."/>
   <result pre="p = 0.046). This association remained significant after adjustment for age, sex," exact="migraine" post="with aura (MWA), allodynia, depression, and anxiety ( p = 0.038)."/>
   <result pre="alteration of the pain network might play a role in" exact="migraine" post="chronification. Keywords Migraine Chronic migraine Functional MRI Neuroimaging Pain"/>
   <result pre="might play a role in migraine chronification. Keywords Migraine Chronic" exact="migraine" post="Functional MRI Neuroimaging Pain matrix Funding http://dx.doi.org/10.13039/501100003725 National Research"/>
   <result pre="2017R1A2B4007254 Lee Mi Ji Chung Chin-Sang Introduction Migraine is a" exact="neurological disorder" post="characterized by episodic headaches associated with nausea, vomiting, and"/>
   <result pre="with nausea, vomiting, and increased sensitivity to external stimuli. Chronic" exact="migraine" post="(CM) is a devastating subtype of migraine, which is"/>
   <result pre="as headache days of 15 or more per month and" exact="migraine" post="days of eight or more per month for &amp;gt; 3 months"/>
   <result pre="and results in a much higher disease burden than episodic" exact="migraine" post="(EM) [ 3]. About 3% of EMs progress to"/>
   <result pre="progress to CMs annually [ 4]. However, the pathophysiology of" exact="migraine" post="chronification is still unknown. Although epidemiological studies revealed risk"/>
   <result pre="promote the conversion of EM to CM, biological mechanism of" exact="migraine" post="chronification has not been fully elucidated yet, particularly in"/>
   <result pre="4, 5]. Therefore, it is likely that a predisposition to" exact="migraine" post="chronification exists. To elucidate this, researchers have investigated functional"/>
   <result pre="comparisons were performed. Methods Study subjects We prospectively recruited new" exact="migraine" post="patients who visited the headache clinic of the Samsung"/>
   <result pre="diagnosed with EM or CM, and 3) currently not on" exact="migraine" post="preventive medications were included in the study. Patients were"/>
   <result pre="acquisition. Patients were considered interictal if they did not have" exact="migraine" post="headache, defined as any headache of moderate to severe"/>
   <result pre="phonophobia, or headaches that led to the taking of acute" exact="migraine" post="medications, at the day and ± 1 days of fMRI acquisition. Data"/>
   <result pre="differences, we tested whether the identified network was relevant to" exact="migraine" post="pathophysiology. We defined three regions of interest (ROIs): the"/>
   <result pre="1. Table 1 Demographics and characteristics of study participants Episodic" exact="migraine" post="( n = 44) Chronic migraine ( n = 18) P Age (range)"/>
   <result pre="and characteristics of study participants Episodic migraine ( n = 44) Chronic" exact="migraine" post="( n = 18) P Age (range) 40 ± 10.2 (22–57) 41.4 ± 10.9 (19–55)"/>
   <result pre="remained significant after adjustment for covariates such as age, sex," exact="migraine" post="with aura (MWA), allodynia, depression, anxiety, disease duration, headache"/>
   <result pre="connectivity Figure 5 shows connectivity between key regions involved in" exact="migraine" post="pathophysiology and the pain matrix. The strength of the"/>
   <result pre="connectivity of the pain matrix may play a role in" exact="migraine" post="chronification. Data-driven vs. ROI-based method To date, the neural"/>
   <result pre="Data-driven vs. ROI-based method To date, the neural mechanism underlying" exact="migraine" post="chronification is still unknown. To unveil functional characteristics of"/>
   <result pre="the CM brain, which might play a major role in" exact="migraine" post="chronification. Different functional features between CM and EM Whether"/>
   <result pre="are not a consequence of them but a predisposition to" exact="migraine" post="chronification. We are currently conducting a prospective fMRI study"/>
   <result pre="functional characteristics in association with disease courses in patients with" exact="migraine" post="(ClinicalTrials.gov Identifier: NCT03487978). Comparison with functional neuroimaging of chronic"/>
   <result pre="the default mode network and insular cortices in patients with" exact="fibromyalgia" post="[ 45]; in the salience network, central executive network,"/>
   <result pre="executive network, and default mode network in pediatric patients with" exact="complex regional pain syndrome" post="(CRPS) [ 46]; and between the right insular cortices"/>
   <result pre="the right insular cortices and cingulate gyri in patients with" exact="fibromyalgia" post="[ 47]; while reduced connectivity among the medial prefrontal"/>
   <result pre="differs from other chronic pain disorders because the &quot;chronicity&quot; in" exact="migraine" post="does not imply persistent pain but increased days of"/>
   <result pre="connectivity within the pain matrix may play a role in" exact="migraine" post="chronification. However, the role of the migraine generator should"/>
   <result pre="a role in migraine chronification. However, the role of the" exact="migraine" post="generator should not be overlooked because small structures such"/>
   <result pre="our study. Thus, we further tested three structures involved in" exact="migraine" post="pathophysiology: the hypothalamus, a migraine generator; PAG, a pain"/>
   <result pre="tested three structures involved in migraine pathophysiology: the hypothalamus, a" exact="migraine" post="generator; PAG, a pain modulatory center; and DRN, the"/>
   <result pre="modulatory center; and DRN, the main serotonergic center activated during" exact="migraine" post="attack [ 49– 51]. As a result, patients with"/>
   <result pre="some important structures (e.g. dorsal pons) and nuclei involved in" exact="migraine" post="pathophysiology (e.g., the nucleus raphe magnus and superior salivatory"/>
   <result pre="alteration of the pain network might play a role in" exact="migraine" post="chronification. We thank Ms. Miran Jung and Ms. Jinju"/>
   <result pre="and institutional affiliations. Abbreviations AAL Automated anatomical labeling CM Chronic" exact="migraine" post="CRPS Complex regional pain syndrome DC Degree centrality DLPFC"/>
   <result pre="DLPFC Dorsolateral prefrontal cortex DRN Dorsal raphe nucleus EM Episodic" exact="migraine" post="FD Frame-wise displacement FDR False discovery rate FOV Field"/>
   <result pre="economic burden associated with chronic daily headache, focusing on chronic" exact="migraine" post="with or without medication overuse: a systematic review Cephalalgia"/>
   <result pre="leads to activation of the nociceptive trigeminal nucleus in chronic" exact="migraine" post="Neurology 2018 90 e1973 e1978 10.1212/WNL.0000000000005622 29703770 8. Schwedt"/>
   <result pre="Atypical resting-state functional connectivity of affective pain regions in chronic" exact="migraine" post="Headache 2013 53 737 751 10.1111/head.12081 23551164 9. collab:"/>
   <result pre="Silberstein S Reed ML et al. Cutaneous allodynia in the" exact="migraine" post="population Ann Neurol 2008 63 148 158 10.1002/ana.21211 18059010"/>
   <result pre="the patient health Questionnaire-9 (PHQ-9) and PHQ-2 in patients with" exact="migraine" post="J Headache Pain 2015 16 65 10.1186/s10194-015-0552-2 26174509 12."/>
   <result pre="Payoux P Chollet F Geraud G Hypothalamic activation in spontaneous" exact="migraine" post="attacks Headache 2007 47 1418 1426 18052951 27. Linnman"/>
   <result pre="activity of pain-processing regions in a case-control study of episodic" exact="migraine" post="Cephalalgia 2014 34 947 958 10.1177/0333102414526069 24627432 41. Wager"/>
   <result pre="S Altered functional connectivity of amygdala underlying the neuromechanism of" exact="migraine" post="pathogenesis J Headache Pain 2017 18 7 10.1186/s10194-017-0722-5 28116559"/>
   <result pre="As-Sanie S Clauw DJ Harris RE Intrinsic brain connectivity in" exact="fibromyalgia" post="is associated with chronic pain intensity Arthritis Rheum 2010"/>
   <result pre="et al. Intrinsic brain networks normalize with treatment in pediatric" exact="complex regional pain syndrome" post="Neuroimage Clin 2014 6 347 369 10.1016/j.nicl.2014.07.012 25379449 47."/>
   <result pre="resting state connectivity of the insular cortex in individuals with" exact="fibromyalgia" post="J Pain 2014 15 815 826 e1 10.1016/j.jpain.2014.04.007 24815079"/>
   <result pre="Schayck RV et al. Brain stem activation in spontaneous human" exact="migraine" post="attacks Nat Med 1995 1 658 660 10.1038/nm0795-658 7585147"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6734273/results/search/disease/results.xml">
   <result pre="made. Abstract Background The burden of headache disorders, and of" exact="migraine" post="in particular, is multifaceted and fragmented. The aim of"/>
   <result pre="main topics underlying the concepts of burden and impact of" exact="migraine" post="disorders. Main results MedLine has been searched for publications"/>
   <result pre="the qualitative analysis. Six main themes were identified: prevalence of" exact="migraine" post="disorders, overall impact of migraine disorders, impact on work"/>
   <result pre="themes were identified: prevalence of migraine disorders, overall impact of" exact="migraine" post="disorders, impact on work or school activities, family impact,"/>
   <result pre="disease costs. Majority of included studies concluded that patients with" exact="migraine" post="reported an higher burden or impact in one or"/>
   <result pre="research should focus on understanding and facing the impact of" exact="migraine" post="on work-related activities and on everyday life activities, as"/>
   <result pre="(i.e. interictal burden and reduced quality of life) facets of" exact="migraine" post="burden. Disease-specific measures have been implemented and should be"/>
   <result pre="implemented and should be exploited to enhance our understanding of" exact="migraine" post="burden. This approach would allow to better understand the"/>
   <result pre="set of disease categories in which stroke, brain cancers, tetanus," exact="encephalitis" post="and meningitis were added to the usual set of"/>
   <result pre="disease categories in which stroke, brain cancers, tetanus, encephalitis and" exact="meningitis" post="were added to the usual set of neurological disorders"/>
   <result pre="GBD 2015 in fact show that tension-type headache (TTH) and" exact="migraine" post="are the most common conditions and they account for"/>
   <result pre="44.5 million YLDs in 2015). The considerable burden associated to" exact="migraine" post="and TTH is connected to the huge prevalence of"/>
   <result pre="suggest that reducing the burden of headache disorders, and of" exact="migraine" post="in particular, should be a primary objective for health"/>
   <result pre="debate. In fact, dealing with the &quot;natural&quot; within-person variation in" exact="migraine" post="headache frequency, which is the fundamental driver of the"/>
   <result pre="of the instability in diagnostic classification for episodic and chronic" exact="migraine" post="(EM and CM) [ 5– 8] is inevitable. As"/>
   <result pre="8] is inevitable. As a consequence, addressing the impact of" exact="migraine" post="disorders is made difficult by the intrinsic nature of"/>
   <result pre="migraine disorders is made difficult by the intrinsic nature of" exact="migraine" post="headaches, and by issues connected to the daily tasks"/>
   <result pre="out and that can be to different extents impaired by" exact="migraine" post="headaches: patients may in fact be limited in their"/>
   <result pre="interictal ones (although the presence of an interictal burden in" exact="migraine" post="has been shown [ 9, 10]). The debate on"/>
   <result pre="on which domains or daily life are mostly affected by" exact="migraine" post="headaches is therefore not easy to address and needs"/>
   <result pre="with others [ 12– 14]. These difficulties clearly depend on" exact="migraine" post="features, in terms of frequency as well as of"/>
   <result pre="be forgotten that the burden of headache disorders, and of" exact="migraine" post="in particular, is also an economic burden, where work-related"/>
   <result pre="19]. It can be therefore concluded that the burden of" exact="migraine" post="is multifaceted and the lack of clear information on"/>
   <result pre="the lack of clear information on the different aspects of" exact="migraine" post="burden may produce fragmented research results: this, in turn,"/>
   <result pre="included in MIDAS: therefore our notion on the impact of" exact="migraine" post="from the patients’ perspective is limited to few domains."/>
   <result pre="limited to few domains. Parallel to this, studies strictly addressing" exact="migraine" post="burden rely on YLDs and DALYs, and eventually on"/>
   <result pre="research and policy targets, we need to understand what for" exact="migraine" post="is behind the &quot;D&quot; of YLDs and DALYs. The"/>
   <result pre="existing literature jointly dealing with the impact and burden of" exact="migraine" post="disorders. To pursue this objective, we performed a revision"/>
   <result pre="publications dealing with impact and burden in episodic and chronic" exact="migraine" post="by searching on MedLine. We selected 1990 as start"/>
   <result pre="with mixed populations (e.g. studies addressing the burden due to" exact="migraine" post="comorbidity in patients with other conditions, or studies addressing"/>
   <result pre="over 25 years (1994–2018). Six main themes were identified: prevalence of" exact="migraine" post="disorders; overall impact of migraine disorders; impact on work"/>
   <result pre="themes were identified: prevalence of migraine disorders; overall impact of" exact="migraine" post="disorders; impact on work or school activities; impact on"/>
   <result pre="a consistent growth gradient for the themes &quot;overall impact of" exact="migraine" post="disorders&quot; and &quot;impact on work or school activities&quot; since"/>
   <result pre="39] Italy 373 √ √ A new questionnaire to address" exact="migraine" post="impact on work-related activities is presented. Al-Hashel 2017 ["/>
   <result pre="[ 63] US 13,064 √ A new questionnaire to address" exact="migraine" post="impact on partners and adolescent children is presented. D’Amico"/>
   <result pre="higher levels of PSD were predicted by younger age, higher" exact="migraine" post="frequency, higher comorbidities index, and smoking status Manandhar 2015"/>
   <result pre="2250€/year. Pavlović 2015 [ 45] US 1697 √ Patients with" exact="migraine" post="related to menses reported higher disability and disease impact"/>
   <result pre="EM in Brazil is 15.8%,of pMOH is 6.1%; patients with" exact="migraine" post="and pMOH showed higher disability compared to TTH. Raggi"/>
   <result pre="Silva Junior 2012 [ 27] Brazil 47 √ Prevalence of" exact="migraine" post="(EM and CM) is 18.2% Buse 2012 [ 51]"/>
   <result pre="Radtke 2009 [ 30] Germany 769 √ √ Prevalence of" exact="migraine" post="in Germany is 10.6%; compared to other headache sufferers,"/>
   <result pre="Netherlands 24 √ During inter-ictal periods, compared with healthy controls" exact="migraine" post="patients spent relatively less time being active and, when"/>
   <result pre="vigour Ware 2003 [ 55] US/UK 221 √ Patients with" exact="migraine" post="reported higher HIT-6 scores compared to patients with other"/>
   <result pre="Lipton 2001 [ 35] Global 10,654 √ √ Prevalence of" exact="migraine" post="in the general population across studies was 8.3%, higher"/>
   <result pre="Lipton 2001 [ 36] US 6915 √ √ Prevalence of" exact="migraine" post="in US population is around 12%; more than half"/>
   <result pre="half of patients reported severe disability/bed rest as impact of" exact="migraine" post="Michel 1997 [ 58] France 989 √ √ A"/>
   <result pre="58] France 989 √ √ A total of 49.1% of" exact="migraine" post="patients reported health impairment, which was higher than healthy"/>
   <result pre="1997 [ 37] Global 6794 √ √ √ Prevalence of" exact="migraine" post="is 10.7%; migraineurs reported worse QoL scores; patients with"/>
   <result pre="migraine is 10.7%; migraineurs reported worse QoL scores; patients with" exact="migraine" post="lost between 2 and 7 workdays per year Abu-Arefeh"/>
   <result pre="√ Migraine prevalence among school-aged children was 10.6%; children with" exact="migraine" post="lost 4.1 schooldays because of migraine Notes. EM Episodic"/>
   <result pre="was 10.6%; children with migraine lost 4.1 schooldays because of" exact="migraine" post="Notes. EM Episodic Migraine, CM Chronic Migraine, TTH Tension-Type"/>
   <result pre="2 Trend over time for main selected themes Prevalence of" exact="migraine" post="disorders Information on EM and CM prevalence was reported"/>
   <result pre="a selected sample of young-age women [ 32]; prevalence of" exact="migraine" post="disorders with monthly frequency higher than 15 days (irrespectively of"/>
   <result pre="9.2% [ 29] and 10.6% [ 38]. Overall impact of" exact="migraine" post="disorders Overall impact of EM and CM was the"/>
   <result pre="44, 46, 52– 54]. All studies in which patients with" exact="migraine" post="were compared to those with TTH, or to non-headache"/>
   <result pre="TTH, or to non-headache patients, showed that people suffering of" exact="migraine" post="had worse disability or QoL, and that higher headache"/>
   <result pre="the first showed that 10.6% of school-aged children suffer from" exact="migraine" post="and that they missed on average 4.1 school-days per"/>
   <result pre="second paper reported that almost half of students suffering from" exact="migraine" post="reduced or missed some school-days, and that their parents"/>
   <result pre="The majority of studies (20 out of 22) were on" exact="migraine" post="impact on work productivity. In 15 studies, sufficient information"/>
   <result pre="worked with reduced productivity, was available: on average patients with" exact="migraine" post="lost between 3.2 and 89.2 work-equivalent days per year,"/>
   <result pre="unrelated to work, thus addressing the issue of pervasiveness of" exact="migraine" post="on different life domains [ 47]. Finally, a recent"/>
   <result pre="status (vs. EM). Impact on family life The impact of" exact="migraine" post="disorders on family life was reported in five studies"/>
   <result pre="burden was in fact shown to increase consistently with increased" exact="migraine" post="headaches frequency [ 17], and most of the limitations"/>
   <result pre="the second, it was shown that caregiving for children with" exact="migraine" post="was associate to parents’ reduced workforce participation [ 48]."/>
   <result pre="which showed good metric properties and addresses the impact of" exact="migraine" post="on family activities in general, on relationships with partners"/>
   <result pre="burden was in fact shown to increase consistently with increased" exact="migraine" post="headaches frequency [ 17] and, in fact, it was"/>
   <result pre="interictal burden, the third paper showed that, during interictal phases," exact="migraine" post="patients spent relatively less time being active compared with"/>
   <result pre="cost of CM was 8243$/year: in this study, 60–64% of" exact="migraine" post="costs was due to direct medical ones [ 40]."/>
   <result pre="indirect [ 59]. Discussion The fact that headache disorders, and" exact="migraine" post="in particular, are burdensome conditions has been repeated so"/>
   <result pre="burden and disease costs. The issue of high prevalence of" exact="migraine" post="is of great epidemiological relevance and it is a"/>
   <result pre="of such themes in available research on the impact of" exact="migraine" post="is more than doubled, and condition-specific assessment instruments for"/>
   <result pre="is more than doubled, and condition-specific assessment instruments for detecting" exact="migraine" post="impact on work and family life (i.e. the HEADWORK"/>
   <result pre="features of EM, i.e. its episodicity: in fact, by definition" exact="migraine" post="headache attacks last 4–72 h, which might have led researchers"/>
   <result pre="phases. In recent years, the importance of interictal phases in" exact="migraine" post="has been increasingly recognized, mostly in basic-science covering vascular,"/>
   <result pre="in basic-science covering vascular, neurophysiological, neuropsychological or neuroimaging aspects of" exact="migraine" post="[ 70– 74]. However, the fact that migraine may"/>
   <result pre="aspects of migraine [ 70– 74]. However, the fact that" exact="migraine" post="may impact on patients’ lives also during interictal phases"/>
   <result pre="shown [ 9, 10], and the importance of being a" exact="migraine" post="sufferer also during interictal phases is witnessed by some"/>
   <result pre="business, shopping, or caring for others, when you had a" exact="migraine" post="?). Despite this, the burden and impact of migraine"/>
   <result pre="a migraine ?). Despite this, the burden and impact of" exact="migraine" post="during interictal phases is still neglected and deserves more"/>
   <result pre="as it requires a broad knowledge of the impact of" exact="migraine" post="not only on direct healthcare costs but also on"/>
   <result pre="(absenteeism) and to days worked with reduced productivity due to" exact="migraine" post="(presenteeism). Our analysis shows that the economic impact of"/>
   <result pre="40, 59, 61, 65]. However, defining the total costs of" exact="migraine" post="on the basis of the literature herein collated is"/>
   <result pre="[ 44, 49]. Finally, our specific search was not on" exact="migraine" post="costs, so some relevant studies might have been excluded."/>
   <result pre="be summed up in few words. In general, patients with" exact="migraine" post="reported an higher burden or impact, defined with one"/>
   <result pre="research for the following reasons. First, prevalence data show that" exact="migraine" post="mostly affects people of working age, and women in"/>
   <result pre="the core of professional and personal life of most of" exact="migraine" post="patients, with women in particular being at risk of"/>
   <result pre="Second, there is a direct connection between the impact of" exact="migraine" post="on work-related tasks and reduced productivity, but the degree"/>
   <result pre="still to be verified. Disease-specific questionnaires for the evaluation of" exact="migraine" post="impact on work-related tasks, like HEADWORK, might be used"/>
   <result pre="burden and costs of migraine. The issue of impact of" exact="migraine" post="on employment (and vice-versa) is an open one due"/>
   <result pre="is still needed to understand how to support people with" exact="migraine" post="in the workplace. This is of importance in consideration"/>
   <result pre="the papers included in our narrative review, living with a" exact="migraine" post="sufferer – either an adult or a child –"/>
   <result pre="burden due to caregiving activities [ 48, 54]. Caregiving for" exact="migraine" post="patients is still a neglected issue but it can"/>
   <result pre="to take care of these activities. Such an aspect of" exact="migraine" post="burden is considered as &quot;intangible&quot;, but it is actual"/>
   <result pre="looking for the way in which burden is conceptualized in" exact="migraine" post="research. Future reviews, in which a systematic approach is"/>
   <result pre="are, the possibility that patients incorrectly self-identify themselves as having" exact="migraine" post="instead of other headache is concrete. Conclusions In conclusion,"/>
   <result pre="papers covering 25 years. Six main themes were identified: prevalence of" exact="migraine" post="disorders, overall impact of migraine disorders, impact on work"/>
   <result pre="themes were identified: prevalence of migraine disorders, overall impact of" exact="migraine" post="disorders, impact on work or school activities, family impact,"/>
   <result pre="be implemented in research to enhance our understanding of the" exact="migraine" post="burden. A better understanding of the issues behind migraine"/>
   <result pre="the migraine burden. A better understanding of the issues behind" exact="migraine" post="burden could translate into a change in the primary"/>
   <result pre="GBD 2016 Headache Collaborators Global, regional, and national burden of" exact="migraine" post="and tension-type headache, 1990–2016: a systematic analysis for the"/>
   <result pre="Diamond S Diamond ML Reed M Prevalence and burden of" exact="migraine" post="in the United States: data from the American migraine"/>
   <result pre="of migraine in the United States: data from the American" exact="migraine" post="study II Headache 2001 41 646 657 10.1046/j.1526-4610.2001.041007646.x 11554952"/>
   <result pre="KM Serrano D Reed ML Turkel CC Lipton RB Chronic" exact="migraine" post="prevalence, disability, and sociodemographic factors: results from the American"/>
   <result pre="chronic and episodic migraineurs: results from the international burden of" exact="migraine" post="study (IBMS) Cephalalgia 2011 31 301 315 10.1177/0333102410381145 20813784"/>
   <result pre="WBF Adams AM Buse DC Fluctuations in episodic and chronic" exact="migraine" post="status over the course of 1 year: implications for"/>
   <result pre="Eurolight project. J Headache Pain 17(9) 10. Brandes JL The" exact="migraine" post="cycle: patient burden of migraine during and between migraine"/>
   <result pre="17(9) 10. Brandes JL The migraine cycle: patient burden of" exact="migraine" post="during and between migraine attacks Headache 2008 48 430"/>
   <result pre="The migraine cycle: patient burden of migraine during and between" exact="migraine" post="attacks Headache 2008 48 430 441 10.1111/j.1526-4610.2007.01004.x 18179565 11."/>
   <result pre="Sawyer J An international study to assess reliability of the" exact="migraine" post="disability assessment (MIDAS) score Neurology 1999 53 988 994"/>
   <result pre="Ajovalasit D Bussone G D’Amico D Functioning and disability in" exact="migraine" post="Disabil Rehabil 2010 32 S23 S32 10.3109/09638288.2010.511687 20825342 13."/>
   <result pre="systematic review of the psychosocial difficulties relevant to patients with" exact="migraine" post="J Headache Pain 2012 13 595 606 10.1007/s10194-012-0482-1 23001069"/>
   <result pre="Lancaster 21. Al-Hashel JY Ahmed SF Alroughani R Burden of" exact="migraine" post="in a Kuwaiti population: a door-to-door survey J Headache"/>
   <result pre="WJ Migraine prevalence, treatment and impact: the Canadian women and" exact="migraine" post="study Can J Neurol Sci 2010 37 580 587"/>
   <result pre="Radtke A Neuhauser H Prevalence and burden of headache and" exact="migraine" post="in Germany Headache 2009 49 79 89 10.1111/j.1526-4610.2008.01263.x 19125877"/>
   <result pre="32. Dueland AN Leira R Cabelli ST The impact of" exact="migraine" post="on psychological well-being of young women and their communication"/>
   <result pre="M Lucas C Chazot G Gaudin AF Economic impact of" exact="migraine" post="and other episodic headaches in France: data from the"/>
   <result pre="RB Stewart WF Scher AI Epidemiology and economic impact of" exact="migraine" post="Curr Med Res Opin 2001 17 S4 S12 10.1185/0300799039117005"/>
   <result pre="10168038 38. Abu-Arefeh I Russell G Prevalence of headache and" exact="migraine" post="in schoolchildren BMJ 1994 309 765 769 10.1136/bmj.309.6957.765 7950559"/>
   <result pre="M Schiavolin S Raggi A Multimorbidity in patients with chronic" exact="migraine" post="and medication overuse headache Acta Neurol Scand 2018 138"/>
   <result pre="Lipton RB Direct and indirect costs of chronic and episodic" exact="migraine" post="in the United States: a web-based survey Headache 2016"/>
   <result pre="Gorman JA Sun H Buse DC Lipton RB Burden of" exact="migraine" post="related to menses: results from the AMPP study J"/>
   <result pre="Di Fiore P Grazzi L Usai S D'Amico D Chronic" exact="migraine" post="with medication overuse: association between disability and quality of"/>
   <result pre="pervasive effect over disability in patients with episodic and chronic" exact="migraine" post="Neurol Sci 2015 36 S9 S11 10.1007/s10072-015-2130-4 48. Wöber-Bingöl"/>
   <result pre="Cortelli P Martelletti P Cost of healthcare for patients with" exact="migraine" post="in five European countries: results from the international burden"/>
   <result pre="in five European countries: results from the international burden of" exact="migraine" post="study (IBMS) J Headache Pain 2012 13 361 378"/>
   <result pre="of life, disability and severity of disease in patients with" exact="migraine" post="attending to a specialty headache center Headache 2010 50"/>
   <result pre="MacGregor EA Brandes J Eikermann A Giammarco R Impact of" exact="migraine" post="on patients and their families: the migraine and Zolmitriptan"/>
   <result pre="R Impact of migraine on patients and their families: the" exact="migraine" post="and Zolmitriptan evaluation (MAZE) survey--phase III Curr Med Res"/>
   <result pre="Dasbach EJ Visser WH Santanello NC The multinational impact of" exact="migraine" post="symptoms on healthcare utilisation and work loss Pharmacoeconomics 2001"/>
   <result pre="Henry P Loss of productivity and quality of life in" exact="migraine" post="sufferers among French workers: results from the GAZEL cohort"/>
   <result pre="T Burke TA Laínez MJ The impact of a worksite" exact="migraine" post="intervention program on work productivity, productivity costs, and non-workplace"/>
   <result pre="ML Family impact of migraine: development of the impact of" exact="migraine" post="on partners and adolescent children (IMPAC) scale Headache 2017"/>
   <result pre="Bussmann JB Mulder LJ Passchier J Interictal daily functioning in" exact="migraine" post="Cephalalgia 2004 24 271 279 10.1111/j.1468-2982.2004.00661.x 15030535 65. Linde"/>
   <result pre="(2019) Selective attention network impairment during the interictal period of" exact="migraine" post="without aura. J Clin Neurosci 60:73-78 71. Sable JJ"/>
   <result pre="Andrasik F Auditory event-related potentials in the interictal phase of" exact="migraine" post="indicate alterations in automatic attention Appl Psychophysiol Biofeedback 2017"/>
   <result pre="Vécsei L, Kincses ZT (2017) Interictal brain activity differs in" exact="migraine" post="with and without aura: resting state fMRI study. J"/>
   <result pre="during interictal period in patients with long disease duration in" exact="migraine" post="Neurosci Lett 2016 612 62 65 10.1016/j.neulet.2015.11.045 26644335 74."/>
   <result pre="of regional cerebral blood flow in the interictal phase of" exact="migraine" post="PLoS One 2015 10 e0137971 10.1371/journal.pone.0137971 26372461"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6734284/results/search/disease/results.xml">
   <result pre="is constant and lacks special characteristics but in some has" exact="migraine" post="features. The exact pathogenic mechanism of NDPH is unknown,"/>
   <result pre="diagnosis required characteristics like chronic tension-type headache and presence of" exact="migraine" post="features was against the diagnosis of NDPH [ 3]."/>
   <result pre="Further observations demonstrated, however, that NDPH may sometimes have predominantly" exact="migraine" post="features. Therefore, the diagnostic criteria in the ICHD-3β and"/>
   <result pre="and B of the ICHD-2 regardless of the presence of" exact="migraine" post="features.) GP General population, CDH Chronic daily headache In"/>
   <result pre="lacks special characteristic features but in some has characteristics of" exact="migraine" post="(including unilateral pain, pulsating quality, worsening by physical activity,"/>
   <result pre="difference was reported between patients who had a history of" exact="migraine" post="vs no migraine and aside from stressful life event,"/>
   <result pre="between patients who had a history of migraine vs no" exact="migraine" post="and aside from stressful life event, existence of prior"/>
   <result pre="migraine and aside from stressful life event, existence of prior" exact="migraine" post="headache did not increase the frequency of precipitated vs"/>
   <result pre="to exclude several brain disorders particularly spontaneous CSF leak and" exact="cerebral venous sinus thrombosis" post="that can mimic NDPH (Table 4). A gadolinium-enhanced brain"/>
   <result pre="headache (subarachnoid hemorrhage, subdural hematoma, …) • Meningitis • Sphenoid" exact="sinusitis" post="• Contact-point headache (caused by contact of intranasal structures)"/>
   <result pre="duration of headache was longer in persisting NDPH patients with" exact="migraine" post="features (31 month) than those who had characteristics like tension-type"/>
   <result pre="10.1016/S0140-6736(87)90119-X 2880216 21. Santoni JR Santoni-Williams CJ Headache and painful" exact="lymphadenopathy" post="in extracranial or systemic infection: etiology of new daily"/>
   <result pre="levels in new daily persistent headache and treatment refractory chronic" exact="migraine" post="Headache 2007 47 7 1050 1055 10.1111/j.1526-4610.2006.00722.x 17635596 23."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6734342/results/search/disease/results.xml">
   <result pre="1017 doi: 10.1186/s10194-019-1017-9 : Review Article Advances in genetics of" exact="migraine" post="Sutherland Heidi G. heidi.sutherland@qut.edu.au Albury Cassie L. calbury15@hotmail.com http://orcid.org/0000-0002-6774-5475"/>
   <result pre="and understanding of the genes and genetic variations implicated in" exact="migraine" post="etiology. Findings Migraine is characterised into two main types,"/>
   <result pre="migraine etiology. Findings Migraine is characterised into two main types," exact="migraine" post="without aura (MO) and migraine with aura (MA). Hemiplegic"/>
   <result pre="characterised into two main types, migraine without aura (MO) and" exact="migraine" post="with aura (MA). Hemiplegic migraine is a rare monogenic"/>
   <result pre="migraine without aura (MO) and migraine with aura (MA). Hemiplegic" exact="migraine" post="is a rare monogenic MA subtype caused by mutations"/>
   <result pre="or in vascular function, can also cause monogenic migraine, hemiplegic" exact="migraine" post="and related disorders with overlapping symptoms. Next-generation sequencing will"/>
   <result pre="understanding the mechanisms of disease-causing variants. With respect to common" exact="migraine" post="forms, large genome-wide association studies (GWAS) have greatly expanded"/>
   <result pre="both neuronal and vascular pathways. Dissecting the genetic architecture of" exact="migraine" post="leads to greater understanding of what underpins relationships between"/>
   <result pre="expression and epigenetic factors will help bridge the genetics with" exact="migraine" post="pathophysiology. Conclusions The complexity of migraine disorders is mirrored"/>
   <result pre="bridge the genetics with migraine pathophysiology. Conclusions The complexity of" exact="migraine" post="disorders is mirrored by their genetic complexity. A comprehensive"/>
   <result pre="genetic complexity. A comprehensive knowledge of the genetic factors underpinning" exact="migraine" post="will lead to improved understanding of molecular mechanisms and"/>
   <result pre="mechanisms and pathogenesis, to enable better diagnosis and treatments for" exact="migraine" post="sufferers. Keywords Migraine Genetics Migraine without aura Migraine with"/>
   <result pre="Keywords Migraine Genetics Migraine without aura Migraine with aura Hemiplegic" exact="migraine" post="Mutation Variant Single nucleotide polymorphism Genome-wide association study Background"/>
   <result pre="photophobia and phonophobia. It is classified into two major types:" exact="migraine" post="without aura (MO) and migraine with aura (MA), with"/>
   <result pre="classified into two major types: migraine without aura (MO) and" exact="migraine" post="with aura (MA), with visual, sensory or other central"/>
   <result pre="central nervous system (CNS) symptoms preceding the headache and associated" exact="migraine" post="symptoms, in the latter [ 1]. Other subtypes or"/>
   <result pre="1]. Other subtypes or forms have been classified, including chronic" exact="migraine" post="and episodic syndromes associated with migraine. Hemiplegic migraine (HM)"/>
   <result pre="including chronic migraine and episodic syndromes associated with migraine. Hemiplegic" exact="migraine" post="(HM) is a rare, severe subtype of MA, in"/>
   <result pre="(HM) is a rare, severe subtype of MA, in which" exact="migraine" post="symptoms are accompanied by motor symptoms such as temporary"/>
   <result pre="weakness, affecting one side of the body (hemiparesis). Familial hemiplegic" exact="migraine" post="(FHM) is a familial form of HM where it"/>
   <result pre="MO and MA, has greatly helped in our understanding of" exact="migraine" post="pathophysiology through the discovery of the genes that contribute"/>
   <result pre="thought to produce the characteristic sensation of throbbing pain in" exact="migraine" post="[ 6, 7]. Migraine progression and mechanisms During migraine,"/>
   <result pre="of the brain are activated, each contributing to aspects of" exact="migraine" post="pathophysiology, whether this is triggering the attack, generating the"/>
   <result pre="fluxes, which spreads across the brain cortex, followed by a" exact="suppression" post="of activity [ 9]. It coincides with the initiation"/>
   <result pre="dysfunction, may also be important [ 14]. Brain alterations in" exact="migraine" post="A variety of imaging techniques have revealed both structural"/>
   <result pre="both structural and functional brain alterations in individuals that suffer" exact="migraine" post="[ 14]. Furthermore, clinical and neurophysiological studies have found"/>
   <result pre="[ 14]. Furthermore, clinical and neurophysiological studies have found chronic" exact="hypersensitivity" post="to sensory stimuli and or abnormal processing of sensory"/>
   <result pre="repetitive exposure to pain or stress, the brain biology of" exact="migraine" post="sufferers appears to differ from healthy controls [ 2]."/>
   <result pre="stress, and skipping meals. However, these triggers only lead to" exact="migraine" post="in migraineurs. Some aspects of the altered brain biology"/>
   <result pre="are likely to be genetically predetermined. A genetic basis for" exact="migraine" post="Family and twin studies have demonstrated that there are"/>
   <result pre="individual to migraine. This is clear for individuals with monogenic" exact="migraine" post="disorders, such as FHM, in which a pathogenic variant"/>
   <result pre="complete penetrance. Family and twin studies also suggest that common" exact="migraine" post="is also a heritable trait, with heritability estimated between"/>
   <result pre="heritability estimated between 30 and 60% [ 19– 21]. Common" exact="migraine" post="forms, including MO and MA, are most likely due"/>
   <result pre="regards to polygenic forms, genome-wide association studies (GWAS) in large" exact="migraine" post="case-control cohorts has greatly helped our understanding of the"/>
   <result pre="understanding of the causal mechanisms. Main text Genetics of monogenic" exact="migraine" post="disorders Valuable insights into how some of the underlying"/>
   <result pre="of the underlying genetic factors contribute to the pathophysiology of" exact="migraine" post="have been provided by a number of rare inherited"/>
   <result pre="migraine have been provided by a number of rare inherited" exact="migraine" post="disorders, which can be caused by mutations in a"/>
   <result pre="mutations in a single gene (Table 1). These include hemiplegic" exact="migraine" post="(HM) and familial migraine (where migraine is inherited in"/>
   <result pre="gene (Table 1). These include hemiplegic migraine (HM) and familial" exact="migraine" post="(where migraine is inherited in a Mendelian manner), as"/>
   <result pre="1). These include hemiplegic migraine (HM) and familial migraine (where" exact="migraine" post="is inherited in a Mendelian manner), as well as"/>
   <result pre="some types of episodic ataxias, paroxysmal movement disorders, and the" exact="stroke" post="syndrome cerebral autosomal dominant arteriopathy with subcortical infarcts and"/>
   <result pre="Mendelian Inheritance in Man catalogue, MIM #125310), and commonly feature" exact="migraine" post="and/or episodic attacks of associated symptoms such as motor"/>
   <result pre="Migraine • Nystagmus • Muscle weakness • Paraesthesia • Progressive" exact="cerebellar ataxia" post="(e.g. imbalance and incoordination) • Vertigo CACNA1A Loss-of-function mutations"/>
   <result pre="Migraine • Cerebellar atrophy • Dysarthria • Nystagmus • Progressive" exact="cerebellar ataxia" post="• Sensory neuropathy (e.g. pins and needles, tingling and"/>
   <result pre="• Dysarthria • Nystagmus • Progressive cerebellar ataxia • Sensory" exact="neuropathy" post="(e.g. pins and needles, tingling and burning) CACNA1A Expansion"/>
   <result pre="and regulates GJA1/Connexin43, an astrocytic gap junction protein and a" exact="migraine" post="GWAS loci.  ROSAH syndrome • Ocular (e.g. retinal dystrophy,"/>
   <result pre="May affect ciliary formation, regulation of apical transport. Etiology of" exact="migraine" post="unclear, but kinase function may affect CGRP activity.  Paroxysmal"/>
   <result pre="exercise [PED] • Can present with, or have, accompanying hemiplegic" exact="migraine" post="PRRT2 Missense or most frequently loss of function truncating"/>
   <result pre="Autosomal Dominant Arteriopathy Subcortical Infarcts with Leukoencephalopathy (CADASIL) • Premature" exact="stroke" post="• Cognitive disturbances (e.g. dementia, • psychiatric issues varying"/>
   <result pre=" COL4A1/A2 disorders • Stroke and small vessel disease (e.g. porencephaly," exact="leukodystrophy" post="• Eye defects (e.g.retinal arterial tortuosity, Axenfeld-Rieger anomaly, cataract)"/>
   <result pre="effects (e.g. kidney, muscle cramps, Raynaud phenomenon, cardiac arrhythmia, and" exact="hemolytic anemia" post="• Migraine with and without Aura COL4A1 COL4A2 Usually"/>
   <result pre="(e.g. kidney, muscle cramps, Raynaud phenomenon, cardiac arrhythmia, and hemolytic" exact="anemia" post="• Migraine with and without Aura COL4A1 COL4A2 Usually"/>
   <result pre="leukodystophy (RVCL) • Vascular retinopathy, visual loss • Mini-strokes, cerebral" exact="leukodystrophy" post="• Cognitive disturbances (e.g. depression, seizures, mental impairment) •"/>
   <result pre="(OST), release of free glycans and potentially glycosylation defects. Hemiplegic" exact="migraine" post="Hemiplegic Migraine (HM) is a rare subtype of MA"/>
   <result pre="a rare subtype of MA characterised by episodes of severe" exact="migraine" post="and aura symptoms involving motor weakness or numbness, usually"/>
   <result pre="fatal after a minor head trauma [ 24]. Familial hemiplegic" exact="migraine" post="(FHM) The prevalence of HM has been found to"/>
   <result pre="[ 42], while another with the severe S218 L mutation exhibits" exact="cerebellar ataxia" post="and spontaneous seizures in accordance with severity of the"/>
   <result pre="penetrance of FHM pathogenic variants and the female preponderance of" exact="migraine" post="disorders (49). Episodic Ataxia 2 and spinocerebellar Ataxia type"/>
   <result pre="heterozygous mutations within CACNA1A can cause two other neurological disorders," exact="episodic ataxia" post="type 2 (EA2; MIM #108500) and spinocerebellar ataxia type"/>
   <result pre="neurological disorders, episodic ataxia type 2 (EA2; MIM #108500) and" exact="spinocerebellar ataxia" post="type 6 (SCA6; #MIM 183086) [ 32, 55]. EA2"/>
   <result pre="and nausea, while SCA6 is typified by adult-onset, slowly progressive" exact="cerebellar ataxia," post="dysarthria, and nystagmus. There can be overlapping clinical features"/>
   <result pre="allelic disorders [ 56], e.g. ~ 50% EA2 patients also suffer" exact="migraine" post="[ 57], and episodic headaches and nausea are also"/>
   <result pre="spectrum [ 62, 64], which includes neurological disorders such as" exact="alternating hemiplegia of childhood" post="[ 65], epilepsy [ 66], seizures [ 67], and"/>
   <result pre="neurological disorders such as alternating hemiplegia of childhood [ 65]," exact="epilepsy" post="[ 66], seizures [ 67], and permanent mental retardation"/>
   <result pre="balance of excitation and inhibition in the brain seen in" exact="migraine" post="[ 89]. FHM3 due to mutations in SCN1A SCN1A"/>
   <result pre="of the CNS [ 91]. SCN1A is commonly mutated in" exact="epilepsy" post="syndromes with hundreds of heterozygous truncating and missense mutations"/>
   <result pre="generalised tonic-clonic epilepsy, elicited repetitive transient daily blindness and childhood" exact="epilepsy" post="[ 96– 98]. Epileptic mutations mainly cause loss-of-function, resulting"/>
   <result pre="help further understanding of their mechanisms of pathogenesis. Sporadic hemiplegic" exact="migraine" post="(SHM) Sporadic Hemiplegic Migraine (SHM) is diagnosed when there"/>
   <result pre="SHM cases may also represent a phenotypic extreme of common" exact="migraine" post="due to a combination of lower-risk genetic variants. For"/>
   <result pre="than those with mutations in those genes [ 41]. Hemiplegic" exact="migraine" post="and disorders with overlapping symptoms caused by mutations in"/>
   <result pre="the gene for the glial glutamate transporter EAAT1, can cause" exact="episodic ataxia," post="type 6, (EA6; MIM #612656), but have also been"/>
   <result pre="the sodium bicarbonate cotransporter NBCe1, which is usually involved in" exact="renal tubular acidosis" post="syndromes (MIM #604278) are also found in some HM"/>
   <result pre="of patients without mutations in the main HM genes. Familial" exact="migraine" post="with Aura and associated disorders The majority of studies"/>
   <result pre="with Aura and associated disorders The majority of studies of" exact="migraine" post="in family pedigrees with Mendelian inheritance have focussed on"/>
   <result pre="which have revealed other genes and molecular mechanisms involved in" exact="migraine" post="biology. Familial migraine with Aura caused by mutations in"/>
   <result pre="other genes and molecular mechanisms involved in migraine biology. Familial" exact="migraine" post="with Aura caused by mutations in KCNK18 encoding the"/>
   <result pre="spinal cord potassium channel (TRESK, encoded by KCNK18), segregating with" exact="migraine" post="[ 135]. TRESK is a member of the two"/>
   <result pre="dominant negative TRESK mutation, C110R, which is not associated with" exact="migraine" post="[ 141], does not trigger sensory neuron hyperexcitability, even"/>
   <result pre="downregulates TREK1 and TREK2 function, which appears to contribute to" exact="migraine" post="induction. Furthermore, Royal et al. (2019) identified another TRESK"/>
   <result pre="a human exome sequence database, and which is associated with" exact="migraine" post="in ClinVar, that appears to work via the same"/>
   <result pre="be involved in migraine. Familial advanced sleep-phase syndrome (FASPS) and" exact="migraine" post="caused mutations in CSNK1D Casein kinase 1 delta (CKIδ)"/>
   <result pre="the human CKIδ-T44A mutation displayed sensitization to pain after triggering" exact="migraine" post="with nitroglycerin, and a reduced threshold for CSD; cultured"/>
   <result pre="signalling [ 144, 145]. Further details of its role in" exact="migraine" post="are to be elucidated, but CKIδ is a ubiquitous"/>
   <result pre="in the majority of monogenic migraine, and the connection between" exact="migraine" post="and FASPs is consistent with a likely role of"/>
   <result pre="likely role of the hypothalamus in regulating physiological stresses and" exact="migraine" post="susceptibility [ 147– 149]. ROSAH syndrome – retinal dystrophy,"/>
   <result pre="149]. ROSAH syndrome – retinal dystrophy, optic nerve edema, splenomegaly," exact="anhidrosis" post="and migraine headache – caused by mutations in ALPK1"/>
   <result pre="syndrome – retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis and" exact="migraine" post="headache – caused by mutations in ALPK1 ROSAH is"/>
   <result pre="recently described distinct autosomal dominant ocular systemic disorder, which features" exact="migraine" post="headache as one of the key clinical features. Exome"/>
   <result pre="protein would contribute to migraine. Monogenic vascular disorders which feature" exact="migraine" post="Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy"/>
   <result pre="vascular disorders caused by mutations in single genes, in which" exact="migraine" post="is a common symptom. Cerebral autosomal dominant arteriopathy with"/>
   <result pre="[ 54]. It is the most common heritable cause of" exact="stroke" post="and vascular dementia in adults, caused by toxic gain-mutations"/>
   <result pre="It is the most common heritable cause of stroke and" exact="vascular dementia" post="in adults, caused by toxic gain-mutations in NOTCH3, which"/>
   <result pre="is the most common heritable cause of stroke and vascular" exact="dementia" post="in adults, caused by toxic gain-mutations in NOTCH3, which"/>
   <result pre="of 300 symptomatic CADASIL patients found that three quarters had" exact="migraine" post="(90% of which was MA), and in two-thirds of"/>
   <result pre="was the presenting symptom [ 153]. Retinal vasculopathy with cerebral" exact="leukodystrophy" post="(RVCL) and COL4A1-related SVDs Other SVDs that commonly feature"/>
   <result pre="leukodystrophy (RVCL) and COL4A1-related SVDs Other SVDs that commonly feature" exact="migraine" post="include syndromes such as retinal vasculopathy with cerebral leukodystrophy"/>
   <result pre="feature migraine include syndromes such as retinal vasculopathy with cerebral" exact="leukodystrophy" post="(RVCL; MIM #192315) caused by mutations in TREX1 ["/>
   <result pre="through which vascular disorders lead to an increased prevalence of" exact="migraine" post="is unknown [ 154], but they indicate that some"/>
   <result pre="in migraine, something which has also become apparent in polygenic" exact="migraine" post="from both epidemiological studies and GWAS [ 161, 162]."/>
   <result pre="162]. Methods and applications for identifying disease-causing variants in monogenic" exact="migraine" post="and related disorders Next-generation sequencing for molecular testing of"/>
   <result pre="and related disorders Next-generation sequencing for molecular testing of hemiplegic" exact="migraine" post="Until relatively recently HM genetic testing involved Sanger sequencing"/>
   <result pre="has revealed that likely pathogenic variants in other known familial" exact="migraine" post="and migraine-related genes are also rare [ 41], [our"/>
   <result pre="variant profiles of unaffected individuals to those with sporadic idiopathic" exact="epilepsy" post="from targeted exome sequencing; rare missense variants were prevalent"/>
   <result pre="of the causative genetic mutation [ 22]. Genetics of common" exact="migraine" post="Monogenic migraine disorders have a large impact on the"/>
   <result pre="causative genetic mutation [ 22]. Genetics of common migraine Monogenic" exact="migraine" post="disorders have a large impact on the individuals and"/>
   <result pre="and families involved, but they are rare. The majority of" exact="migraine" post="is polygenic, i.e. it is a complex disorder in"/>
   <result pre="lifestyle factors. Discovering loci and genes that contribute to common" exact="migraine" post="requires different approaches to the Mendelian disorders, mainly based"/>
   <result pre="frequencies of genetic variants linked to genes, between cohorts of" exact="migraine" post="cases and non-migraine controls, composed of unrelated individuals. Common"/>
   <result pre="studies are demanding as, although each variant may contribute to" exact="migraine" post="susceptibility, it is neither necessary, nor sufficient, to cause"/>
   <result pre="gene affected, is often challenging. Association studies of polymorphisms in" exact="migraine" post="candidate genes For many years, association studies of SNPs"/>
   <result pre="to 200 polymorphisms in ~ 100 genes have been published for" exact="migraine" post="[ 187], although subsequent and replication studies often reported"/>
   <result pre="associated with migraine, showed no clear evidence for involvement in" exact="migraine" post="using International Headache Genetics Consortium (IGHC) GWAS data for"/>
   <result pre="to divergent findings. One MTHFR C667T meta-analysis reported association with" exact="migraine" post="and MA of the T-allele, particularly in populations belonging"/>
   <result pre="to Asian ancestry [ 192]. Genome-wide association studies (GWAS) for" exact="migraine" post="Hypothesis-free GWAS present a more unbiased method to identify"/>
   <result pre="method to identify SNPs, and potentially genes, robustly involved in" exact="migraine" post="to gain insights into its pathways and pathophysiology. SNP"/>
   <result pre="for association with the trait in question. A number of" exact="migraine" post="GWAS have been performed, including five major studies ["/>
   <result pre="to 38 independent genomic loci [ 53]. Earlier GWAS identified" exact="migraine" post="susceptibility SNPs nearby genes with mainly putative or known"/>
   <result pre="( TGFBR2, PHACTR1) were also likely to be important in" exact="migraine" post="susceptibility [ 199]. For example, TGFBR2 encodes part of"/>
   <result pre="in vascular and smooth muscle tissues, underlining their contribution to" exact="migraine" post="pathophysiology [ 53, 161]. The most recent meta-analysis by"/>
   <result pre="studies from the International Headache Genetics Consortium (IGHC), comprised 59,674" exact="migraine" post="cases from clinic- and population-based collections, as well as"/>
   <result pre="This study brought the number of SNPs significantly associated with" exact="migraine" post="to 44 independent SNPs at 38 distinct genomic loci,"/>
   <result pre="cellular ion homeostasis. More unexpectedly, many genes that contribute to" exact="migraine" post="susceptibility are involved in metal ion homeostasis according to"/>
   <result pre="RNF213, JAG1, SLC24A3) suggesting the importance of these pathways in" exact="migraine" post="pathophysiology [ 162]. Metal ions (including Fe 2+, Cu"/>
   <result pre="regulated [ 210]. How these processes might be contribute to" exact="migraine" post="remains to be fully elucidated, however, it is known"/>
   <result pre="213]. Furthermore, there is some overlap in pathways between monogenic" exact="migraine" post="genes and GWAS loci. In common with the monogenic"/>
   <result pre="of multiple Notch receptors. Fine mapping and functional analysis of" exact="migraine" post="associated SNPs Analyses of the genes in the vicinity"/>
   <result pre="causal susceptibility SNP in a range of vascular disorders including" exact="migraine" post="[ 216]. From epigenomic data from human tissues, Gupta"/>
   <result pre="assays in cellular and animal models in further characterisation of" exact="migraine" post="GWAS signals. In another effort to refine GWAS loci,"/>
   <result pre="genes for &amp;gt; 40 complex traits with well-powered GWAS data, including" exact="migraine" post="[ 217]. Using this approach they showed that, with"/>
   <result pre="have a mQTL profile highly comparable to that of the" exact="migraine" post="GWAS, which implicated HEY2 in migraine. These results are"/>
   <result pre="and cell types [ 218– 220]. Migraine susceptibility loci in" exact="migraine" post="sub-types There has been some discussion about whether MO"/>
   <result pre="particular genes may contribute to phenotypic consequences. Most of the" exact="migraine" post="loci identified by Gormley et al., (2016) were implicated"/>
   <result pre="pain character, duration, frequency, nausea, photophobia and triggers) of the" exact="migraine" post="attack [ 224, 225]. Menstrual migraine affects a subset"/>
   <result pre="and triggers) of the migraine attack [ 224, 225]. Menstrual" exact="migraine" post="affects a subset of female MO sufferers; replication of"/>
   <result pre="migraine affects a subset of female MO sufferers; replication of" exact="migraine" post="GWAS loci in a menstrual migraine case-control cohort suggested"/>
   <result pre="MO sufferers; replication of migraine GWAS loci in a menstrual" exact="migraine" post="case-control cohort suggested a particular role for NRP1 in"/>
   <result pre="relatively little common genetic risk, suggesting largely independent etiological pathways," exact="migraine" post="appears to share some genetic architecture with psychiatric disorders,"/>
   <result pre="appears to share some genetic architecture with psychiatric disorders, including" exact="attention deficit hyperactivity disorder" post="(ADHD), Tourette’s syndrome, and major depressive disorder [ 228]."/>
   <result pre="disorders, including attention deficit hyperactivity disorder (ADHD), Tourette’s syndrome, and" exact="major depressive disorder" post="[ 228]. This, together with genetic correlations with other"/>
   <result pre="disease), is consistent with comorbidities that have been documented for" exact="migraine" post="and suggests they are underpinned by shared genetic factors"/>
   <result pre="by shared genetic factors [ 228– 233]. Similarly, the monogenic" exact="migraine" post="disorders show comorbidity with epilepsy, depression, vascular and sleep"/>
   <result pre="with overlapping etiologies [ 235, 236]. Migraine susceptibility loci in" exact="migraine" post="in specific populations As the large migraine GWAS have"/>
   <result pre="susceptibility loci in migraine in specific populations As the large" exact="migraine" post="GWAS have been performed in predominantly Caucasian populations of"/>
   <result pre="while rs2651899 and LRP1 rs11172113 showed a protective effect on" exact="migraine" post="susceptibility in a North Indian population [ 241]. Polymorphisms"/>
   <result pre="specific ethnic populations will determine whether the genetic contributions to" exact="migraine" post="vary, and identify migraine susceptibility loci which may be"/>
   <result pre="determine whether the genetic contributions to migraine vary, and identify" exact="migraine" post="susceptibility loci which may be particular to different groups."/>
   <result pre="a unique admixed Polynesian-Caucasian population with a high prevalence of" exact="migraine" post="(25%). A GWAS for migraine revealed a number of"/>
   <result pre="with a high prevalence of migraine (25%). A GWAS for" exact="migraine" post="revealed a number of loci of suggestive significance near"/>
   <result pre="245]. A GWAS in Taiwanese Han Chinese identified two novel" exact="migraine" post="susceptibility SNPs: rs655484 in DLG2, a gene involved in"/>
   <result pre="243]. The GWAS in American African children found association of" exact="migraine" post="with SNPs, including rs72793414, which were strongly correlated with"/>
   <result pre="neuromedin-U [ 244]. Genetic risk scores (GRS) and applications for" exact="migraine" post="Due to low effect sizes that the majority of"/>
   <result pre="data sets for migraine, GRS may be applied to: investigating" exact="migraine" post="subtypes and endophenotypes, understanding migraine pleiotropy and co-morbidites, disease"/>
   <result pre="may be applied to: investigating migraine subtypes and endophenotypes, understanding" exact="migraine" post="pleiotropy and co-morbidites, disease and phenotype prediction, and for"/>
   <result pre="personalised medicine [ 247]. Higher GRS have been correlated with" exact="migraine" post="diagnosis in specific cohorts [ 226, 248], as well"/>
   <result pre="diagnosis in specific cohorts [ 226, 248], as well as" exact="migraine" post="severity, and in cases where migraine is aggregated in"/>
   <result pre="248], as well as migraine severity, and in cases where" exact="migraine" post="is aggregated in families suggesting this results from a"/>
   <result pre="migraine-related loci will be discovered as sample numbers increase in" exact="migraine" post="GWAS using SNP-chips (including from various ethnicities), and the"/>
   <result pre="will deepen understanding of the important tissues and pathways in" exact="migraine" post="[ 218, 259]. Conclusions Migraine is a multifactorial disorder"/>
   <result pre="traits and conditions. Investigation of the genetic factors involved in" exact="migraine" post="have used family studies for the rare, Mendelian forms"/>
   <result pre="to be found, some of which may contribute to specific" exact="migraine" post="subtypes or symptoms. Moving from finding a risk SNP,"/>
   <result pre="research. Fig. 1 Approaches to identifying the genes involved in" exact="migraine" post="and their functions and putative pathways Genetics has further"/>
   <result pre="and putative pathways Genetics has further emphasized the complexity of" exact="migraine" post="disorders, but it is an exciting time to be"/>
   <result pre="an exciting time to be working in the field of" exact="migraine" post="biology, with the end game – to better diagnose,"/>
   <result pre="the end game – to better diagnose, manage and treat" exact="migraine" post="sufferers. Abbreviations BFIE Benign familial infantile epilepsy CADASIL Cerebral"/>
   <result pre="manage and treat migraine sufferers. Abbreviations BFIE Benign familial infantile" exact="epilepsy" post="CADASIL Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and"/>
   <result pre="Genome FASPS Familial advanced sleep phase syndrome FHM Familial hemiplegic" exact="migraine" post="GABA Gamma-Aminobutyric acid GDNF Glial cell line-derived neurotrophic factor"/>
   <result pre="GTex Gene-tissue expression project GWAS Genome-wide association study HM Hemiplegic" exact="migraine" post="ICCA Infantile convulsions and choreoarthetosis IHGC International Headache Genetics"/>
   <result pre="Polygenic risk score ROSAH Retinal dystrophy, optic nerve edema, splenomegaly," exact="anhidrosis" post="and migraine headache RTA Renal tubular acidosis SHM Sporadic"/>
   <result pre="score ROSAH Retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis and" exact="migraine" post="headache RTA Renal tubular acidosis SHM Sporadic hemiplegic migraine"/>
   <result pre="and migraine headache RTA Renal tubular acidosis SHM Sporadic hemiplegic" exact="migraine" post="SMR Summary-data-based Mendelian randomization SNARE SNAP Receptor WES Whole"/>
   <result pre="authors. Funding Our research group has previously received funding for" exact="migraine" post="genetics research from the Brain Foundation, the Migraine Research"/>
   <result pre="effects in the trigeminal system: pathophysiology and clinical relevance in" exact="migraine" post="Keio J Med 2011 60 3 82 89 10.2302/kjm.60.82"/>
   <result pre="7. Burstein R Jakubowski M Rauch SD The science of" exact="migraine" post="J Vestib Res 2011 21 6 305 314 22348935"/>
   <result pre="305 314 22348935 8. Dodick DW A phase-by-phase review of" exact="migraine" post="pathophysiology Headache 2018 58 Suppl 1 4 16 10.1111/head.13300"/>
   <result pre="MA Intrinsic brain activity triggers trigeminal meningeal afferents in a" exact="migraine" post="model Nat Med 2002 8 2 136 142 10.1038/nm0202-136"/>
   <result pre="Eippert F May A Trigeminal nociceptive transmission in migraineurs predicts" exact="migraine" post="attacks J Neurosci 2011 31 6 1937 1943 10.1523/JNEUROSCI.4496-10.2011"/>
   <result pre="Barrodale PM Tipton RL Khodavirdi A Brainstem dysfunction in chronic" exact="migraine" post="as evidenced by neurophysiological and positron emission tomography studies"/>
   <result pre="of the CACNA1A calcium channel subunit gene and relationship with" exact="familial hemiplegic migraine" post="Ann Neurol 2001 49 6 753 760 10.1002/ana.1031 11409427"/>
   <result pre="CACNA1A calcium channel subunit gene and relationship with familial hemiplegic" exact="migraine" post="Ann Neurol 2001 49 6 753 760 10.1002/ana.1031 11409427"/>
   <result pre="E Keiding N et al. An epidemiological survey of hemiplegic" exact="migraine" post="Cephalalgia 2002 22 5 361 375 10.1046/j.1468-2982.2002.00371.x 12110112 26."/>
   <result pre="A Damasio J Alonso I et al. The prevalence of" exact="familial hemiplegic migraine" post="with cerebellar ataxia and spinocerebellar ataxia type 6 in"/>
   <result pre="J Alonso I et al. The prevalence of familial hemiplegic" exact="migraine" post="with cerebellar ataxia and spinocerebellar ataxia type 6 in"/>
   <result pre="I et al. The prevalence of familial hemiplegic migraine with" exact="cerebellar ataxia" post="and spinocerebellar ataxia type 6 in Portugal Headache 2014"/>
   <result pre="The prevalence of familial hemiplegic migraine with cerebellar ataxia and" exact="spinocerebellar ataxia" post="type 6 in Portugal Headache 2014 54 5 911"/>
   <result pre="expression of mutations in the P/Q-type calcium channel gene in" exact="familial hemiplegic migraine." post="Dutch Migraine Genetics Research Group Neurology 1998 50 4"/>
   <result pre="CACNA1A gene T666M mutation: a description of 5 families with" exact="familial hemiplegic migraine" post="Arch Neurol 2003 60 5 684 688 10.1001/archneur.60.5.684 12756131"/>
   <result pre="T666M mutation: a description of 5 families with familial hemiplegic" exact="migraine" post="Arch Neurol 2003 60 5 684 688 10.1001/archneur.60.5.684 12756131"/>
   <result pre="in hemiplegic migraine: a clinical and genetic study in Finnish" exact="migraine" post="families Cephalalgia 2018 38 12 1849 1863 10.1177/0333102418761041 29486580"/>
   <result pre="Eijk R Oefner PJ Hoffman SM et al. Familial hemiplegic" exact="migraine" post="and episodic ataxia type-2 are caused by mutations in"/>
   <result pre="Oefner PJ Hoffman SM et al. Familial hemiplegic migraine and" exact="episodic ataxia" post="type-2 are caused by mutations in the Ca2+ channel"/>
   <result pre="MG et al. Large scale calcium channel gene rearrangements in" exact="episodic ataxia" post="and hemiplegic migraine: implications for diagnostic testing J Med"/>
   <result pre="Gualandi F et al. New CACNA1A deletions are associated to" exact="migraine" post="phenotypes J Headache Pain 2018 19 1 75 10.1186/s10194-018-0891-x"/>
   <result pre="Lescoat C Vahedi K et al. The clinical spectrum of" exact="familial hemiplegic migraine" post="associated with mutations in a neuronal calcium channel N"/>
   <result pre="Vahedi K et al. The clinical spectrum of familial hemiplegic" exact="migraine" post="associated with mutations in a neuronal calcium channel N"/>
   <result pre="Luvisetto S Striessnig J Fletcher C et al. Familial hemiplegic" exact="migraine" post="mutations increase ca (2+) influx through single human CaV2.1"/>
   <result pre="13289 10.1073/pnas.192242399 12235360 39. Tournier-Lasserve E CACNA1A mutations: hemiplegic migraine," exact="episodic ataxia" post="type 2, and the others Neurology 1999 53 1"/>
   <result pre="RR Ferrari MD van den Maagdenberg AM Molecular genetics of" exact="migraine" post="Hum Genet 2009 126 1 115 132 10.1007/s00439-009-0684-z 19455354"/>
   <result pre="Koelewijn SC Smagge A et al. Clinical spectrum of hemiplegic" exact="migraine" post="and chances of finding a pathogenic mutation Neurology 2018"/>
   <result pre="S Broos LA Cesetti T et al. A Cacna1a knockin" exact="migraine" post="mouse model with increased susceptibility to cortical spreading depression"/>
   <result pre="modulate spreading depression and transient hemiparesis in mouse models of" exact="familial hemiplegic migraine" post="type 1 J Clin Invest 2009 119 1 99"/>
   <result pre="depression and transient hemiparesis in mouse models of familial hemiplegic" exact="migraine" post="type 1 J Clin Invest 2009 119 1 99"/>
   <result pre="mouse trigeminal sensory neurons in a transgenic mouse model of" exact="familial hemiplegic migraine" post="type-1 Neuroscience 2017 351 47 64 10.1016/j.neuroscience.2017.03.033 28363781 45."/>
   <result pre="sensory neurons in a transgenic mouse model of familial hemiplegic" exact="migraine" post="type-1 Neuroscience 2017 351 47 64 10.1016/j.neuroscience.2017.03.033 28363781 45."/>
   <result pre="as the basis for facilitated spreading depression in ca(v)2.1 knockin" exact="migraine" post="mice Neuron 2009 61 5 762 773 10.1016/j.neuron.2009.01.027 19285472"/>
   <result pre="trigeminal sensory neurons expressing the R192Q Cacna1a missense mutation of" exact="familial hemiplegic migraine" post="type-1 Neuroscience 2014 266 244 254 10.1016/j.neuroscience.2014.02.020 24583041 47."/>
   <result pre="neurons expressing the R192Q Cacna1a missense mutation of familial hemiplegic" exact="migraine" post="type-1 Neuroscience 2014 266 244 254 10.1016/j.neuroscience.2014.02.020 24583041 47."/>
   <result pre="firing of trigeminal ganglion neurons in a mouse model of" exact="familial hemiplegic migraine" post="type-1 Neuroscience 2016 331 197 205 10.1016/j.neuroscience.2016.06.034 27346147 48."/>
   <result pre="trigeminal ganglion neurons in a mouse model of familial hemiplegic" exact="migraine" post="type-1 Neuroscience 2016 331 197 205 10.1016/j.neuroscience.2016.06.034 27346147 48."/>
   <result pre="calcium, oxygen, and vascular responses in a mouse model of" exact="familial hemiplegic migraine" post="type 1 Ann Neurol 2016 80 2 219 232"/>
   <result pre="and vascular responses in a mouse model of familial hemiplegic" exact="migraine" post="type 1 Ann Neurol 2016 80 2 219 232"/>
   <result pre="Chen SP Tolner EA Eikermann-Haerter K Animal models of monogenic" exact="migraine" post="Cephalalgia 2016 36 7 704 721 10.1177/0333102416645933 27154999 51."/>
   <result pre="CJ Helms TH Frank CA Drosophila CaV2 channels harboring human" exact="migraine" post="mutations cause synapse hyperexcitability that can be suppressed by"/>
   <result pre="al. Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for" exact="migraine" post="Nat Genet 2016 48 8 856 866 10.1038/ng.3598 27322543"/>
   <result pre="Ashizawa T Stockton DW Amos C et al. Autosomal dominant" exact="cerebellar ataxia" post="(SCA6) associated with small polyglutamine expansions in the alpha"/>
   <result pre="57. Jen J Kim GW Baloh RW Clinical spectrum of" exact="episodic ataxia" post="type 2 Neurology 2004 62 1 17 22 10.1212/01.WNL.0000101675.61074.50"/>
   <result pre="van Hilten BJ et al. Clinical and molecular correlations in" exact="spinocerebellar ataxia" post="type 6: a study of 24 Dutch families Arch"/>
   <result pre="novel and recurrent CACNA1A gene mutations in fifteen patients with" exact="episodic ataxia" post="type 2 J Neurol Sci 2010 291 1–2 30"/>
   <result pre="of ATP1A2 encoding the Na+/K+ pump alpha2 subunit associated with" exact="familial hemiplegic migraine" post="type 2 Nat Genet 2003 33 2 192 196"/>
   <result pre="encoding the Na+/K+ pump alpha2 subunit associated with familial hemiplegic" exact="migraine" post="type 2 Nat Genet 2003 33 2 192 196"/>
   <result pre="Herzog J Gobel H Petzold GC et al. Variability of" exact="familial hemiplegic migraine" post="with novel A1A2 Na+/K+-ATPase variants Neurology 2004 62 10"/>
   <result pre="Gobel H Petzold GC et al. Variability of familial hemiplegic" exact="migraine" post="with novel A1A2 Na+/K+-ATPase variants Neurology 2004 62 10"/>
   <result pre="et al. A novel mutation in the ATP1A2 gene causes" exact="alternating hemiplegia of childhood" post="J Med Genet 2004 41 8 621 628 10.1136/jmg.2003.017863"/>
   <result pre="Wilken B et al. Clinical spectrum in three families with" exact="familial hemiplegic migraine" post="type 2 including a novel mutation in the ATP1A2"/>
   <result pre="et al. Clinical spectrum in three families with familial hemiplegic" exact="migraine" post="type 2 including a novel mutation in the ATP1A2"/>
   <result pre="van Vliet JA et al. Recurrent coma and fever in" exact="familial hemiplegic migraine" post="type 2. A prospective 15-year follow-up of a large"/>
   <result pre="JA et al. Recurrent coma and fever in familial hemiplegic" exact="migraine" post="type 2. A prospective 15-year follow-up of a large"/>
   <result pre="Marchelli F et al. ATP1A2 mutations in 11 families with" exact="familial hemiplegic migraine" post="Hum Mutat 2005 26 3 281 10.1002/humu.9361 16088919 74."/>
   <result pre="et al. ATP1A2 mutations in 11 families with familial hemiplegic" exact="migraine" post="Hum Mutat 2005 26 3 281 10.1002/humu.9361 16088919 74."/>
   <result pre="in ATP1A2 and CACNA1A are frequent in early-onset sporadic hemiplegic" exact="migraine" post="Neurology 2010 75 11 967 972 10.1212/WNL.0b013e3181f25e8f 20837964 75."/>
   <result pre="R Alterations in the alpha2 isoform of Na,K-ATPase associated with" exact="familial hemiplegic migraine" post="type 2 Proc Natl Acad Sci U S A"/>
   <result pre="in the alpha2 isoform of Na,K-ATPase associated with familial hemiplegic" exact="migraine" post="type 2 Proc Natl Acad Sci U S A"/>
   <result pre="Diverse functional consequences of mutations in the Na+/K+-ATPase alpha2-subunit causing" exact="familial hemiplegic migraine" post="type 2 J Biol Chem 2008 283 45 31097"/>
   <result pre="consequences of mutations in the Na+/K+-ATPase alpha2-subunit causing familial hemiplegic" exact="migraine" post="type 2 J Biol Chem 2008 283 45 31097"/>
   <result pre="Horisberger JD Functional effects of Na+,K+-ATPase gene mutations linked to" exact="familial hemiplegic migraine" post="NeuroMolecular Med 2004 6 2–3 105 116 10.1385/NMM:6:2-3:105 15970628"/>
   <result pre="Functional effects of Na+,K+-ATPase gene mutations linked to familial hemiplegic" exact="migraine" post="NeuroMolecular Med 2004 6 2–3 105 116 10.1385/NMM:6:2-3:105 15970628"/>
   <result pre="De Pont JJ Bamberg E et al. Na,K-ATPase mutations in" exact="familial hemiplegic migraine" post="lead to functional inactivation Biochim Biophys Acta 2005 1669"/>
   <result pre="JJ Bamberg E et al. Na,K-ATPase mutations in familial hemiplegic" exact="migraine" post="lead to functional inactivation Biochim Biophys Acta 2005 1669"/>
   <result pre="protein stability by certain ATP1A2 mutations identified in sporadic or" exact="familial hemiplegic migraine" post="Channels (Austin) 2009 3 2 82 87 10.4161/chan.3.2.8085 19372756"/>
   <result pre="by certain ATP1A2 mutations identified in sporadic or familial hemiplegic" exact="migraine" post="Channels (Austin) 2009 3 2 82 87 10.4161/chan.3.2.8085 19372756"/>
   <result pre="types of Na(+),K(+)-ATPase alpha2 subunit-deficient mice as a model of" exact="familial hemiplegic migraine" post="2 Cephalalgia 2018 38 9 1515 1524 10.1177/0333102417738249 29041816"/>
   <result pre="Na(+),K(+)-ATPase alpha2 subunit-deficient mice as a model of familial hemiplegic" exact="migraine" post="2 Cephalalgia 2018 38 9 1515 1524 10.1177/0333102417738249 29041816"/>
   <result pre="susceptibility to cortical spreading depression in the mouse model of" exact="familial hemiplegic migraine" post="type 2 PLoS Genet 2011 7 6 e1002129 10.1371/journal.pgen.1002129"/>
   <result pre="cortical spreading depression in the mouse model of familial hemiplegic" exact="migraine" post="type 2 PLoS Genet 2011 7 6 e1002129 10.1371/journal.pgen.1002129"/>
   <result pre="al. Defective glutamate and K+ clearance by cortical astrocytes in" exact="familial hemiplegic migraine" post="type 2 EMBO Mol Med 2016 8 8 967"/>
   <result pre="glutamate and K+ clearance by cortical astrocytes in familial hemiplegic" exact="migraine" post="type 2 EMBO Mol Med 2016 8 8 967"/>
   <result pre="A et al. Glutamate-system defects behind psychiatric manifestations in a" exact="familial hemiplegic migraine" post="type 2 disease-mutation mouse model Sci Rep 2016 6"/>
   <result pre="al. Glutamate-system defects behind psychiatric manifestations in a familial hemiplegic" exact="migraine" post="type 2 disease-mutation mouse model Sci Rep 2016 6"/>
   <result pre="87. Gritz SM Radcliffe RA Genetic effects of ATP1A2 in" exact="familial hemiplegic migraine" post="type II and animal models Hum Genomics 2013 7"/>
   <result pre="SM Radcliffe RA Genetic effects of ATP1A2 in familial hemiplegic" exact="migraine" post="type II and animal models Hum Genomics 2013 7"/>
   <result pre="161 10.3389/fphys.2016.00161 27199775 89. Pietrobon D Moskowitz MA Pathophysiology of" exact="migraine" post="Annu Rev Physiol 2013 75 365 391 10.1146/annurev-physiol-030212-183717 23190076"/>
   <result pre="al. Mutation in the neuronal voltage-gated sodium channel SCN1A in" exact="familial hemiplegic migraine" post="Lancet 2005 366 9483 371 377 10.1016/S0140-6736(05)66786-4 16054936 91."/>
   <result pre="in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic" exact="migraine" post="Lancet 2005 366 9483 371 377 10.1016/S0140-6736(05)66786-4 16054936 91."/>
   <result pre="LR Genetics of migraine: insights into the molecular basis of" exact="migraine" post="disorders Headache 2017 57 4 537 569 10.1111/head.13053 28271496"/>
   <result pre="10.1177/0333102416677049 27919014 95. Mantegazza M Cestele S Pathophysiological mechanisms of" exact="migraine" post="and epilepsy: similarities and differences Neurosci Lett 2018 667"/>
   <result pre="Elicited repetitive daily blindness: a new familial disorder related to" exact="migraine" post="and epilepsy Neurology 2004 63 2 348 350 10.1212/01.WNL.0000130251.59422.B4"/>
   <result pre="daily blindness: a new familial disorder related to migraine and" exact="epilepsy" post="Neurology 2004 63 2 348 350 10.1212/01.WNL.0000130251.59422.B4 15277634 97."/>
   <result pre="mutation in the voltage-gated Nav1.1 subunit gene SCN1A with co-occurring" exact="familial hemiplegic migraine" post="and epilepsy Cephalalgia 2009 29 3 308 313 10.1111/j.1468-2982.2008.01721.x"/>
   <result pre="the voltage-gated Nav1.1 subunit gene SCN1A with co-occurring familial hemiplegic" exact="migraine" post="and epilepsy Cephalalgia 2009 29 3 308 313 10.1111/j.1468-2982.2008.01721.x"/>
   <result pre="Nav1.1 subunit gene SCN1A with co-occurring familial hemiplegic migraine and" exact="epilepsy" post="Cephalalgia 2009 29 3 308 313 10.1111/j.1468-2982.2008.01721.x 19220312 98."/>
   <result pre="GM et al. The novel p.L1649Q mutation in the SCN1A" exact="epilepsy" post="gene is associated with familial hemiplegic migraine: genetic and"/>
   <result pre="in GABAergic interneurons in a mouse model of severe myoclonic" exact="epilepsy" post="in infancy Nat Neurosci 2006 9 9 1142 1149"/>
   <result pre="Franceschetti S Mantegazza M Self-limited hyperexcitability: functional effect of a" exact="familial hemiplegic migraine" post="mutation of the Nav1.1 (SCN1A) Na+ channel J Neurosci"/>
   <result pre="Mantegazza M Self-limited hyperexcitability: functional effect of a familial hemiplegic" exact="migraine" post="mutation of the Nav1.1 (SCN1A) Na+ channel J Neurosci"/>
   <result pre="of the T1174S SCN1A mutation associated with seizures and hemiplegic" exact="migraine" post="Epilepsia 2013 54 5 927 935 10.1111/epi.12123 23398611 106."/>
   <result pre="Tobias Lerche Holger Borck Guntram Kubisch Christian Jurkat-Rott Karin Early-onset" exact="familial hemiplegic migraine" post="due to a novel SCN1A mutation Cephalalgia 2016 36"/>
   <result pre="Holger Borck Guntram Kubisch Christian Jurkat-Rott Karin Early-onset familial hemiplegic" exact="migraine" post="due to a novel SCN1A mutation Cephalalgia 2016 36"/>
   <result pre="GS Valvo G Cereda C et al. The revolution in" exact="migraine" post="genetics: from aching channels disorders to a next-generation medicine"/>
   <result pre="JM Ferrari MD et al. Divergent sodium channel defects in" exact="familial hemiplegic migraine" post="Proc Natl Acad Sci U S A 2008 105"/>
   <result pre="MD et al. Divergent sodium channel defects in familial hemiplegic" exact="migraine" post="Proc Natl Acad Sci U S A 2008 105"/>
   <result pre="Schiavon E Rusconi R Franceschetti S Mantegazza M Nonfunctional NaV1.1" exact="familial hemiplegic migraine" post="mutant transformed into gain of function by partial rescue"/>
   <result pre="Rusconi R Franceschetti S Mantegazza M Nonfunctional NaV1.1 familial hemiplegic" exact="migraine" post="mutant transformed into gain of function by partial rescue"/>
   <result pre="S Gain of function for the SCN1A/hNav1.1-L1670W mutation responsible for" exact="familial hemiplegic migraine" post="Front Mol Neurosci 2018 11 232 10.3389/fnmol.2018.00232 30038559 112."/>
   <result pre="of function for the SCN1A/hNav1.1-L1670W mutation responsible for familial hemiplegic" exact="migraine" post="Front Mol Neurosci 2018 11 232 10.3389/fnmol.2018.00232 30038559 112."/>
   <result pre="of three FHM genes in 39 sporadic patients with hemiplegic" exact="migraine" post="Neurology 2007 69 23 2170 2176 10.1212/01.wnl.0000295670.01629.5a 18056581 113."/>
   <result pre="Hughes JN et al. PRRT2 mutations cause benign familial infantile" exact="epilepsy" post="and infantile convulsions with choreoathetosis syndrome Am J Hum"/>
   <result pre="Guyant-Marechal L Lucas C et al. PRRT2 mutations cause hemiplegic" exact="migraine" post="Neurology 2012 79 21 2122 2124 10.1212/WNL.0b013e3182752cb8 23077016 122."/>
   <result pre="PRRT2 mutations in familial infantile seizures, paroxysmal dyskinesia, and hemiplegic" exact="migraine" post="Neurology 2012 79 21 2109 2114 10.1212/WNL.0b013e3182752ca2 23077026 123."/>
   <result pre="mutation with heterogeneous paroxysmal disorders including paroxysmal torticollis and hemiplegic" exact="migraine" post="Dev Med Child Neurol 2012 54 10 958 960"/>
   <result pre="Geilenkirchen MA et al. A novel SLC2A1 mutation linking hemiplegic" exact="migraine" post="with alternating hemiplegia of childhood Cephalalgia 2015 35 1"/>
   <result pre="et al. A novel SLC2A1 mutation linking hemiplegic migraine with" exact="alternating hemiplegia of childhood" post="Cephalalgia 2015 35 1 10 15 10.1177/0333102414532379 24824604 131."/>
   <result pre="BD Baloh RW Mutation in the glutamate transporter EAAT1 causes" exact="episodic ataxia," post="hemiplegia, and seizures Neurology 2005 65 4 529 534"/>
   <result pre="al. Impaired K(+) binding to glial glutamate transporter EAAT1 in" exact="migraine" post="Sci Rep 2017 7 1 13913 10.1038/s41598-017-14176-4 29066757 134."/>
   <result pre="of the Na(+)-HCO (3)(−) cotransporter NBCe1 is associated with familial" exact="migraine" post="Proc Natl Acad Sci U S A 2010 107"/>
   <result pre="mutation in the TRESK potassium channel is linked to familial" exact="migraine" post="with aura Nat Med 2010 16 10 1157 1160"/>
   <result pre="Huang Y et al. Casein kinase idelta mutations in familial" exact="migraine" post="and advanced sleep phase Sci Transl Med 2013 5"/>
   <result pre="Goadsby PJ Brain activations in the premonitory phase of nitroglycerin-triggered" exact="migraine" post="attacks Brain 2014 137 Pt 1 232 241 10.1093/brain/awt320"/>
   <result pre="Godin O Jouvent E et al. Prevalence and characteristics of" exact="migraine" post="in CADASIL Cephalalgia 2016 36 11 1038 1047 10.1177/0333102415620909"/>
   <result pre="10.1177/0333102415620909 26646784 153. Tan RY Markus HS CADASIL: migraine, encephalopathy," exact="stroke" post="and their inter-relationships PLoS One 2016 11 6 e0157613"/>
   <result pre="1284 1289 10.1177/0333102410370870 21038489 155. Rossi G Shambhu S Hemiplegic" exact="migraine" post="as the initial presentation of biopsy positive cerebral autosomal"/>
   <result pre="three families confirm a major role of COL4A1 in hereditary" exact="porencephaly" post="J Med Genet 2006 43 6 490 495 10.1136/jmg.2005.035584"/>
   <result pre="Hansen CK Christensen H Hereditary cerebral small vessel disease and" exact="stroke" post="Clin Neurol Neurosurg 2017 155 45 57 10.1016/j.clineuro.2017.02.015 28254515"/>
   <result pre="J Family studies to find rare high risk variants in" exact="migraine" post="J Headache Pain 2017 18 1 32 10.1186/s10194-017-0729-y 28255817"/>
   <result pre="nonsense mutation p.Tyr1957Ter of CACNA1A in a Chinese family with" exact="episodic ataxia" post="2 PLoS One 2013 8 2 e56362 10.1371/journal.pone.0056362 23441182"/>
   <result pre="ATP1A2 gene is associated with a novel phenotype of progressive" exact="sensorineural hearing loss" post="associated with migraine Eur J Hum Genet 2015 23"/>
   <result pre="a novel phenotype of progressive sensorineural hearing loss associated with" exact="migraine" post="Eur J Hum Genet 2015 23 5 639 645"/>
   <result pre="Griffiths LR Next-generation sequencing identifies novel CACNA1A gene mutations in" exact="episodic ataxia" post="type 2 Mol Genet Genomic Med 2016 4 2"/>
   <result pre="channel genes reveals complex profiles confounding personal risk assessment in" exact="epilepsy" post="Cell 2011 145 7 1036 1048 10.1016/j.cell.2011.05.025 21703448 169."/>
   <result pre="ME et al. Cerebral organoids model human brain development and" exact="microcephaly" post="Nature 2013 501 7467 373 379 10.1038/nature12517 23995685 182."/>
   <result pre="Houlden H Benefit of carbamazepine in a patient with hemiplegic" exact="migraine" post="associated with PRRT2 mutation Dev Med Child Neurol 2014"/>
   <result pre="BH Griffiths LR Identification of molecular genetic factors that influence" exact="migraine" post="Mol Gen Genomics 2011 285 6 433 446 10.1007/s00438-011-0622-3"/>
   <result pre="Yang M He M et al. MTHFR C677T polymorphism and" exact="migraine" post="risk: a meta-analysis J Neurol Sci 2014 336 1–2"/>
   <result pre="in 1798 Finnish individuals fails to confirm the association with" exact="migraine" post="with aura Cephalalgia 2006 26 12 1462 1472 10.1111/j.1468-2982.2006.01228.x"/>
   <result pre="Heinze A Heinze-Kuhn K et al. MTHFR C677T polymorphism and" exact="migraine" post="with aura Ann Neurol 2006 60 5 621 622"/>
   <result pre="Systematic re-evaluation of genes from candidate gene association studies in" exact="migraine" post="using a large genome-wide association data set Cephalalgia 2016"/>
   <result pre="Terwindt GM Calafato MS et al. Genome-wide association study of" exact="migraine" post="implicates a common susceptibility variant on 8q22 Nat Genet"/>
   <result pre="al. Genome-wide association study reveals three susceptibility loci for common" exact="migraine" post="in the general population Nat Genet 2011 43 7"/>
   <result pre="GM et al. Genome-wide association analysis identifies susceptibility loci for" exact="migraine" post="without aura Nat Genet 2012 44 7 777 782"/>
   <result pre="G et al. Genome-wide meta-analysis identifies new susceptibility loci for" exact="migraine" post="Nat Genet 2013 45 8 912 917 10.1038/ng.2676 23793025"/>
   <result pre="21923 10.1074/jbc.M112.444364 23760271 204. Dussor G Cao YQ TRPM8 and" exact="migraine" post="Headache 2016 56 9 1406 1417 10.1111/head.12948 27634619 205."/>
   <result pre="co-expression analysis identifies brain regions and cell types involved in" exact="migraine" post="pathophysiology: a GWAS-based study using the Allen human brain"/>
   <result pre="4 425 439 10.1007/s00439-016-1638-x 26899160 219. Renthal W Localization of" exact="migraine" post="susceptibility genes in human brain by single-cell RNA sequencing"/>
   <result pre="Ulrich V Gervil M Olesen J Migraine without aura and" exact="migraine" post="with aura are distinct disorders. A population-based twin survey"/>
   <result pre="Martin NG Latent class and genetic analysis does not support" exact="migraine" post="with aura and migraine without aura as separate entities"/>
   <result pre="and genetic analysis does not support migraine with aura and" exact="migraine" post="without aura as separate entities Genet Epidemiol 2004 26"/>
   <result pre="headache genetics C, Anttila V, et al. gene-based pleiotropy across" exact="migraine" post="with aura and migraine without aura patient groups Cephalalgia"/>
   <result pre="V, et al. gene-based pleiotropy across migraine with aura and" exact="migraine" post="without aura patient groups Cephalalgia 2016 36 7 648"/>
   <result pre="Kurth T et al. Selectivity in genetic association with sub-classified" exact="migraine" post="in women PLoS Genet 2014 10 5 e1004366 10.1371/journal.pgen.1004366"/>
   <result pre="Pedersen O Hansen T et al. The association between candidate" exact="migraine" post="susceptibility loci and severe migraine phenotype in a clinical"/>
   <result pre="al. The association between candidate migraine susceptibility loci and severe" exact="migraine" post="phenotype in a clinical sample Cephalalgia 2016 36 7"/>
   <result pre="Lea RA Haupt LM Frith A et al. The NRP1" exact="migraine" post="risk variant shows evidence of association with menstrual migraine"/>
   <result pre="NRP1 migraine risk variant shows evidence of association with menstrual" exact="migraine" post="J Headache Pain 2018 19 1 31 10.1186/s10194-018-0857-z 29671086"/>
   <result pre="Belin AC Smith GD et al. Molecular genetic overlap between" exact="migraine" post="and major depressive disorder Eur J Hum Genet 2018"/>
   <result pre="Smith GD et al. Molecular genetic overlap between migraine and" exact="major depressive disorder" post="Eur J Hum Genet 2018 26 8 1202 1216"/>
   <result pre="Bauer PR Ferrari MD Sander JW The comorbid relationship between" exact="migraine" post="and epilepsy: a systematic review and meta-analysis Eur J"/>
   <result pre="Heiden J Traylor M et al. Shared genetic basis for" exact="migraine" post="and ischemic stroke: a genome-wide analysis of common variants"/>
   <result pre="et al. Genetic analysis for a shared biological basis between" exact="migraine" post="and coronary artery disease Neurol Genet 2015 1 1"/>
   <result pre="et al. Prevalence of lifetime depression in a large hemiplegic" exact="migraine" post="cohort Neurology 2016 87 22 2370 2374 10.1212/WNL.0000000000003376 27807184"/>
   <result pre="a combination of the two) for the prophylaxis of episodic" exact="migraine" post="in adults. Cochrane Database Syst Rev 24(6):CD010611 237. Ran"/>
   <result pre="L Belin AC A replication study of GWAS findings in" exact="migraine" post="identifies association in a Swedish case-control sample BMC Med"/>
   <result pre="Arenas C Pozo-Rosich P et al. Replication study of previous" exact="migraine" post="genome-wide association study findings in a Spanish sample of"/>
   <result pre="migraine genome-wide association study findings in a Spanish sample of" exact="migraine" post="with aura Cephalalgia 2015 35 9 776 782 10.1177/0333102414557841"/>
   <result pre="PRDM16 rs2651899 variant is a risk factor for Chinese common" exact="migraine" post="patients Headache 2013 53 10 1595 1601 10.1111/head.12212 24021092"/>
   <result pre="Chen L Gui B Tan G et al. Replication of" exact="migraine" post="GWAS susceptibility loci in Chinese Han population Headache 2014"/>
   <result pre="241. Ghosh J Pradhan S Mittal B Genome-wide-associated variants in" exact="migraine" post="susceptibility: a replication study from North India Headache 2013"/>
   <result pre="LY Xin YT et al. Association of genetic loci for" exact="migraine" post="susceptibility in the she people of China J Headache"/>
   <result pre="et al. Genome-wide association study identifies novel susceptibility loci for" exact="migraine" post="in Han Chinese resided in Taiwan Cephalalgia 2018 38"/>
   <result pre="Mentch F et al. Common variants at 5q33.1 predispose to" exact="migraine" post="in African-American children J Med Genet 2018 55 12"/>
   <result pre="genome-wide analysis of 'Bounty' descendants implicates several novel variants in" exact="migraine" post="susceptibility Neurogenetics 2012 13 3 261 266 10.1007/s10048-012-0325-x 22678113"/>
   <result pre="AL Olesen J Hansen TF Polygenic risk score: use in" exact="migraine" post="research J Headache Pain 2018 19 1 29 10.1186/s10194-018-0856-0"/>
   <result pre="JE et al. Common polygenic variation contributes to risk of" exact="migraine" post="in the Norfolk Island population Hum Genet 2015 134"/>
   <result pre="al. Common variant burden contributes to the familial aggregation of" exact="migraine" post="in 1,589 families Neuron 2018 98 4 743 53"/>
   <result pre="Stefansson K Olesen J The influence of genetic constitution on" exact="migraine" post="drug responses Cephalalgia 2016 36 7 624 639 10.1177/0333102415610874"/>
   <result pre="risk score approach to predict headache response to Triptans in" exact="migraine" post="without Aura J Clin Pharmacol 2019 59 2 288"/>
   <result pre="Frequencies of genetic polymorphisms related to triptans metabolism in chronic" exact="migraine" post="J Headache Pain 2010 11 2 151 156 10.1007/s10194-010-0202-7"/>
   <result pre="Genetic studies of body mass index yield new insights for" exact="obesity" post="biology Nature 2015 518 7538 197 206 10.1038/nature14177 25673413"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6734460/results/search/disease/results.xml">
   <result pre="these symptoms changes during lifespan. Indeed, the clinical presentation of" exact="migraine" post="shows an age-dependent change with a significantly shorter duration"/>
   <result pre="short as 30–60 min. Otherwise, in the elderly patient with a" exact="migraine" post="in the history, the headache attacks become more like"/>
   <result pre="headache prevalence in the very young did not differentiate between" exact="migraine" post="and other primary headache due to the difficulties in"/>
   <result pre="abilities in children under 6 to 7 years age. The 12-month" exact="migraine" post="prevalence was 12.5% for 7–14-year-old children compared to 20.5%"/>
   <result pre="was diagnosed in 19.5% of the children. No differentiation between" exact="migraine" post="and tension-type headache was made, but there was a"/>
   <result pre="significant increase of headache prevalence with age [ 10]. The" exact="migraine" post="prevalence for younger children (below 7 years) does not differ"/>
   <result pre="girls and boys [ 11, 12]. Studies focusing more on" exact="migraine" post="also found an increase in prevalence with age (overview"/>
   <result pre="prevalence with age (overview in: [ 10]). The prevalence of" exact="migraine" post="varies, depending on the study and the age range"/>
   <result pre="[ 12]. There are several studies about the prevalence of" exact="migraine" post="in patients older than 18 years. In a telephone interview-based"/>
   <result pre="interview-based survey in the USA 145000 participants were screened. The" exact="migraine" post="prevalence (fulfilling complete criteria) was highest for the age"/>
   <result pre="6-month prevalence in the German study with about 11% for" exact="migraine" post="and probable migraine [ 15]. In the same study,"/>
   <result pre="the German study with about 11% for migraine and probable" exact="migraine" post="[ 15]. In the same study, the 6-month prevalence"/>
   <result pre="6-month prevalence in the 65–75-year-old group was about 3.5% for" exact="migraine" post="and about 12.5% for tension-type headache, with females affected"/>
   <result pre="and in a study from northern Italy the prevalence of" exact="migraine" post="after the 75th year was 2.7% for males and"/>
   <result pre="of migraine, it is not so rare that the first" exact="migraine" post="attack occurs after the 50th year of life ["/>
   <result pre="13, 14] and the average age of patients with chronic" exact="migraine" post="is higher than that of patients with episodic migraine"/>
   <result pre="chronic migraine is higher than that of patients with episodic" exact="migraine" post="[ 19]. Migraine prevalence during lifespan is also gender-dependent"/>
   <result pre="prevalence during lifespan is also gender-dependent [ 20]. Before puberty," exact="migraine" post="is slightly more common in boys, with the highest"/>
   <result pre="percentages differ [ 24]. Estrogen withdrawal as seen in menstrual" exact="migraine" post="is a reliable trigger of menstrual attacks in women"/>
   <result pre="women and this may account for the increased prevalence of" exact="migraine" post="in women compared to men in the reproductive years"/>
   <result pre="changes in the perimenopause phase mark a period of increased" exact="migraine" post="prevalence in women, during which maintenance of a stable"/>
   <result pre="hormonal replacement therapy can have a positive effect on estrogen-withdrawal" exact="migraine" post="[ 26]. Migraine in women usually declines after menopause"/>
   <result pre="27, 28], further indicating the influence of hormonal changes on" exact="migraine" post="occurrence. Clinical symptoms in children There is agreement that"/>
   <result pre="in children There is agreement that the clinical manifestation of" exact="migraine" post="in childhood is different from that in adulthood. It"/>
   <result pre="clear if classical headache syndromes can occur in infancy, but" exact="migraine" post="is diagnosed at the latest after the development of"/>
   <result pre="is much shorter than the minimum of 4 h for adult" exact="migraine" post="and the 2 h for children [ 11, 29]. Other"/>
   <result pre="[ 33]. Cranial autonomic signs are often seen in pediatric" exact="migraine" post="[ 34]. Red ear syndrome, a uni- or bilateral"/>
   <result pre="hour, was seen in up to 23% of children with" exact="migraine" post="and was highly specific for migraine [ 35]. Another"/>
   <result pre="23% of children with migraine and was highly specific for" exact="migraine" post="[ 35]. Another feature of childhood migraine is that"/>
   <result pre="highly specific for migraine [ 35]. Another feature of childhood" exact="migraine" post="is that there are a number of so-called migraine-related"/>
   <result pre="that a high proportion of these patients develop a clear" exact="migraine" post="in later life [ 36]; any episodic syndrome in"/>
   <result pre="syndrome in childhood increases the risk of later development of" exact="migraine" post="by more than 50% compared to children without such"/>
   <result pre="of an episodic syndrome. The classical episodic syndromes related to" exact="migraine" post="are benign paroxysmal torticollis, cyclic vomiting syndrome, abdominal migraine,"/>
   <result pre="paroxysmal torticollis, cyclic vomiting syndrome, abdominal migraine, and acute confusional" exact="migraine" post="(Table 1). Brainstem and/or hypothalamic disturbances have been suggested"/>
   <result pre="39]. Interestingly, benign paroxysmal vertigo, which is commonly considered a" exact="migraine" post="precursor, constitutes an age-specific manifestation of defective neuronal calcium"/>
   <result pre="CACNA1A gene [ 40– 42], which is also involved in" exact="familial hemiplegic migraine" post="[ 43]. There is also accumulating evidence that non"/>
   <result pre="[ 40– 42], which is also involved in familial hemiplegic" exact="migraine" post="[ 43]. There is also accumulating evidence that non"/>
   <result pre="terrors, which involve hypothalamic centers [ 44], are related to" exact="migraine" post="[ 36, 45]. The common factor is that otherwise"/>
   <result pre="syndromes is low; some authors stated that 10% of childhood" exact="migraine" post="cases also show such syndromes [ 46]. In a"/>
   <result pre="35, 45]) Syndrome Main symptom Clinical signs Duration Prevalence Abdominal" exact="migraine" post="Repeated attacks with midline abdominal pain Accompanied by anorexia,"/>
   <result pre="Nausea/vomiting several times per hour 1 h to days 0.99% Confusional" exact="migraine" post="Attacks with acute confusion Restlessness, agitation, altered sensorium, disorientation,"/>
   <result pre="sensorium, disorientation, bizarre behavior Less than 6 h 10% of childhood" exact="migraine" post="Somnambulism Unclear if related, rising up from sleep and"/>
   <result pre="syndrome may be associated Less than 1 h 0.07% In summary," exact="migraine" post="attacks in children are significantly shorter and less specific"/>
   <result pre="otherwise there are several paroxysmal syndromes, which are related to" exact="migraine" post="which all show an activation/disinhibition of the brainstem and"/>
   <result pre="in adults Premonitory symptoms, which occur prior to the actual" exact="migraine" post="headache, are regularly reported by about 70% of migraine"/>
   <result pre="actual migraine headache, are regularly reported by about 70% of" exact="migraine" post="patients [ 46]. The most frequently reported symptoms are"/>
   <result pre="nuclei and which pharmacological alterations such symptoms, and potentially a" exact="migraine" post="attack, are triggered remains however unknown. The occipital cortex,"/>
   <result pre="USA with more than 145,000 participants, about 80% of adult" exact="migraine" post="sufferers report throbbing pain and more than 60% unilateral"/>
   <result pre="vertigo and dizziness are also a major part of the" exact="migraine" post="attack. Vestibular migraine mainly manifests in the age range"/>
   <result pre="are also a major part of the migraine attack. Vestibular" exact="migraine" post="mainly manifests in the age range from 8 to"/>
   <result pre="authors found that the proportion of patients with a high-frequency" exact="migraine" post="increased slightly with age from 12.5% for the 18–29-year-old"/>
   <result pre="13]. But it is important to bear in mind that" exact="migraine" post="prevalence also decreases with age, thus the absolute number"/>
   <result pre="with age, thus the absolute number of patients with high-frequency" exact="migraine" post="is still higher in younger adults. A Swedish study"/>
   <result pre="focusing on female patients did not find any association of" exact="migraine" post="frequency or duration with age [ 14]. Rarer clinical"/>
   <result pre="which appears to be more prevalent in patients with vestibular" exact="migraine" post="[ 53]. A number of studies investigated neural mechanisms"/>
   <result pre="the different headache symptoms. During the actual headache of a" exact="migraine" post="attack, brain imaging studies found increased blood flow changes"/>
   <result pre="be part of the ascending trigemino-thalamic activation, its role in" exact="migraine" post="deserves greater attention. Studies by Noseda and colleagues identified"/>
   <result pre="in the development of allodynia during the headache phase of" exact="migraine" post="[ 60, 61], a symptom that occurs in about"/>
   <result pre="It most likely occurs primarily in the visual cortex in" exact="migraine" post="with aura patients [ 63, 64]. A number of"/>
   <result pre="patients [ 63, 64]. A number of studies in in" exact="migraine" post="with aura patients in the interictal phase, have also"/>
   <result pre="67]. A thicker cortical cortex has been also reported in" exact="migraine" post="with aura patients [ 71]. Although cortical hyperexcitability has"/>
   <result pre="patients [ 71]. Although cortical hyperexcitability has been proposed in" exact="migraine" post="without aura patients, meta-analysis studies suggest there is not"/>
   <result pre="were not present, even when the subjects had had typical" exact="migraine" post="in their youth. Acute medications, including triptans, seems to"/>
   <result pre="the intensity decreases [ 79]. In females about 20% of" exact="migraine" post="patients lose their attacks per 10 years of life after"/>
   <result pre="was also seen in middle-aged patients, the proportion of all" exact="migraine" post="patients with frequent attacks is relatively higher in the"/>
   <result pre="[ 13]. As a physiological reason for this change in" exact="migraine" post="representation in the elderly some authors propose a change"/>
   <result pre="[ 82]. Whether trigemino-thalamic pathways and other areas involved in" exact="migraine" post="pathophysiology undergo degenerative or connectivity changes during ageing has"/>
   <result pre="the autonomic nervous system, which is also part of the" exact="migraine" post="pathophysiology, shows a significant decline with increasing age ["/>
   <result pre="an increased volume of white matter hyper intensities in elder" exact="migraine" post="patients, while migraine with aura was found to be"/>
   <result pre="of white matter hyper intensities in elder migraine patients, while" exact="migraine" post="with aura was found to be associated with brain"/>
   <result pre="by Wen and colleagues even suggests that middle-aged and elderly" exact="migraine" post="patients display better cognitive performance [ 89]. Tension-type headache"/>
   <result pre="91, 92]. This decline is less than that seen in" exact="migraine" post="with increasing age [ 16]. For the group of"/>
   <result pre="aggravation due to physical activity best differentiate tension-type headache from" exact="migraine" post="in children [ 95]. In general, the symptoms of"/>
   <result pre="cortical excitability in TTH patients compared to control subjects and" exact="migraine" post="patients [ 104]. Gray matter changes as seen in"/>
   <result pre="there has been discussion as to whether tension-type headache and" exact="migraine" post="are distinct entities or two poles of one disorder."/>
   <result pre="of one disorder. Recently, a study concerning the comorbidity of" exact="migraine" post="and tension-type headaches in twins concludes that there both"/>
   <result pre="shorter attack duration in children. Otherwise, the clinical symptoms of" exact="migraine" post="show a much larger variation with age. In children,"/>
   <result pre="infancy and childhood. On the other hand, with increasing age" exact="migraine" post="patients report nausea and vomiting less often and the"/>
   <result pre="for the observed clinical symptoms. One general feature, especially in" exact="migraine" post="and less also in cluster headache, seems to be"/>
   <result pre="of publications, which report on aberrations in autonomic functions in" exact="migraine" post="patients. Unfortunately, no clear hypothesis can be drawn from"/>
   <result pre="the increased life-time prevalence of syncope and orthostatic intolerance in" exact="migraine" post="patients [ 130]. Another study based on analysis of"/>
   <result pre="findings may be that there is a differential effect of" exact="migraine" post="on the autonomic control of cranial autonomic reflexes and"/>
   <result pre="system. No studies in which autonomic function was assessed in" exact="migraine" post="patients in a longitudinal study or in different age"/>
   <result pre="prevalence of the autonomic symptoms during ageing and also why" exact="migraine" post="symptoms in very young children are not as typical"/>
   <result pre="the sympathetic skin response in studies with older children with" exact="migraine" post="(9 to 17 years) [ 135]. There is some evidence"/>
   <result pre="of autonomic functions is somewhat related to the time of" exact="migraine" post="onset as well as clinical symptoms in children. On"/>
   <result pre="in episodic cluster headache [ 144] as well as in" exact="migraine" post="attacks [ 145]. That stimulation of the cranial parasympathetic"/>
   <result pre="nasal concha, a strong parasympathetic stimulus, is able to abort" exact="migraine" post="attacks [ 146], and electrical stimulation of the sensory"/>
   <result pre="the ear conch is effective in the prophylaxis of chronic" exact="migraine" post="[ 147]. Interestingly, internal vagal stimulation, as occurs during"/>
   <result pre="as occurs during vomiting, is also able to abort a" exact="migraine" post="attack in some patients [ 148], which may indicate"/>
   <result pre="148], which may indicate that parasympathetic activation can abort the" exact="migraine" post="attack. A typical clinical feature of migraine attacks in"/>
   <result pre="can abort the migraine attack. A typical clinical feature of" exact="migraine" post="attacks in children is the significantly shorter duration and"/>
   <result pre="inhibitory pathways are responsible for the shorter duration of the" exact="migraine" post="attacks in childhood. On the other hand, autonomic symptoms"/>
   <result pre="On the other hand, autonomic symptoms are quite common in" exact="migraine" post="attacks in children and there might even be a"/>
   <result pre="authors argue that the parasympathetic activation facilitates trigemino-vascular activation in" exact="migraine" post="[ 149]. Concerning the above-cited results that external or"/>
   <result pre="external or internal vagal activation can also help to terminate" exact="migraine" post="attacks, one can also discuss if the strong parasympathetic"/>
   <result pre="can also discuss if the strong parasympathetic activation in childhood" exact="migraine" post="also helps to terminate the attack early. With regard"/>
   <result pre="150]. In summary, the episodic syndromes in infancy related to" exact="migraine" post="are characterized by temporary deficits in descending control of"/>
   <result pre="results, there has been discussion that the primary driver for" exact="migraine" post="attacks is in the hypothalamic-brainstem connectivity [ 152], as"/>
   <result pre="daily fMRI scan with trigeminal activation in patients with spontaneous" exact="migraine" post="attacks was done over a period of 1 month"/>
   <result pre="1 month [ 152]. The involvement of the hypothalamus in" exact="migraine" post="is also supported by the resting state activity and"/>
   <result pre="connectivity of the hypothalamus which was achieved in 12 interictal" exact="migraine" post="patients [ 153]. Interestingly, the hypothalamus showed multiple connections"/>
   <result pre="154]. These connections could explain episodic syndromes such as abdominal" exact="migraine" post="and cyclic vomiting by alteration of the central pathways"/>
   <result pre="in the cerebellum of rats and which was related to" exact="episodic ataxia" post="type 1 (EA1), a syndrome caused by a mutation"/>
   <result pre="disorder responds to acetazolamide which may be also beneficial in" exact="migraine" post="with hemiparetic aura [ 157]. Up to now there"/>
   <result pre="did show a possible involvement of cerebellar neuronal circuits in" exact="migraine" post="pathophysiology [ 158]. Migraineurs with an allodynia in the"/>
   <result pre="and temporal regions [ 159]. Thus, cerebellar activity could influence" exact="migraine" post="as well as vestibular and motor function. Interestingly, the"/>
   <result pre="these neuronal pathways in the development of vestibular symptoms during" exact="migraine" post="attacks and paroxysmal episodic vertigo in childhood has not"/>
   <result pre="so far. Concerning the change of clinical presentation with age," exact="migraine" post="is clearly distinguished from tension-type headache, which may be"/>
   <result pre="in migraine, although parasympathetic activation can also be seen in" exact="migraine" post="[ 166]. Otherwise, there seems to be no relation"/>
   <result pre="summary, there are typical changes in the clinical representation of" exact="migraine" post="during lifespan. In general, in children we see episodic"/>
   <result pre="cerebellar areas to different autonomic control centres during ageing in" exact="migraine" post="more than in cluster headache (Fig. 1 and Table"/>
   <result pre="of hypothalmic and cerebellar pathways involved in the modulation of" exact="migraine" post="and probably also of periodic syndromes [ 136, 155,"/>
   <result pre="the attacks are significantly shorter and episodic syndromes such as" exact="migraine" post="equivalents can be observed. Autonomic symptoms are often prominent."/>
   <result pre="T Benedek G Túri S Age-related prevalence and features of" exact="migraine" post="headache in Hungarian schoolchildren and adolescents Eur J Paediatr"/>
   <result pre="Libermann JN Lipton RB Age-dependent prevalence and clinical features of" exact="migraine" post="Neurology 2006 67 246 251 16864816 14. Mattsson P"/>
   <result pre="P Svärdsudd K Lundberg PO Westerberg CE The prevalence of" exact="migraine" post="in women aged 40-74 years: a population-based study Cephalalgia"/>
   <result pre="Hoffmann W Berger K Regional variations in the prevalence of" exact="migraine" post="and tension-type headache applying the new IHS criteria: the"/>
   <result pre="18823362 17. Rasmussen BK Olesen J Migraine with aura and" exact="migraine" post="without aura: an epidemiological study Cephalalgia 1992 12 4"/>
   <result pre="ME Speciali JG Migraine in the elderly: a comparison with" exact="migraine" post="in young adults Headache 2006 46 2 312 316"/>
   <result pre="P Olesen J Prevalence and sex-ratio of the subtypes of" exact="migraine" post="Int J Epidemiol 1995 24 3 612 618 7672904"/>
   <result pre="SD Stiles MA Young WB Epidemiology of migraine. Atlas of" exact="migraine" post="and other headaches 2005 London and New York Taylor"/>
   <result pre="49 24. Woldeamanuel YW Andreou AP Cowan RP Prevalence of" exact="migraine" post="headache and its weight on neurological burden in Africa:"/>
   <result pre="30. Maytal J Young M Shechter A Lipton RB Pediatric" exact="migraine" post="and the international headache society (IHS) criteria Neurology 1997"/>
   <result pre="3 602 607 9065533 31. Abu-Arafeh I Callaghan M Short" exact="migraine" post="attacks of less than 2 h duration in children"/>
   <result pre="Karsan N, Prabhakar P, Goadsby PJ (2017) Premonitory symptoms of" exact="migraine" post="in childhood and adolescence. Curr Pain Headache Rep 21(7):34"/>
   <result pre="Eidlitz-Markus T Gorali O Haimi-Cohen Y Zeharia A Symptoms of" exact="migraine" post="in the paediatric population by age group Cephalalgia 2008"/>
   <result pre="AA Reider AC Goadsby PJ Cranial autonomic symptoms in pediatric" exact="migraine" post="are the rule, not the exception Neurology 2013 81"/>
   <result pre="F Obermeier V Landgraf MN Do preschool episodic syndromes predict" exact="migraine" post="in primary school children? A retrospective cohort study on"/>
   <result pre="Wolff award 1997. Involvement of a Ca2+ channel gene in" exact="familial hemiplegic migraine" post="and migraine with and without aura. Dutch migraine genetics"/>
   <result pre="1997. Involvement of a Ca2+ channel gene in familial hemiplegic" exact="migraine" post="and migraine with and without aura. Dutch migraine genetics"/>
   <result pre="of a Ca2+ channel gene in familial hemiplegic migraine and" exact="migraine" post="with and without aura. Dutch migraine genetics research group"/>
   <result pre="familial hemiplegic migraine and migraine with and without aura. Dutch" exact="migraine" post="genetics research group Headache 1997 37 8 479 485"/>
   <result pre="Masruha MR Sleep terrors antecedent is common in adolescents with" exact="migraine" post="Arq Neuropsiquiatr 2013 71 2 83 86 23306208 46."/>
   <result pre="Migraine variants or episodic syndromes that May be associated with" exact="migraine" post="and other unusual pediatric headache syndromes Headache 2016 56"/>
   <result pre="Goadsby PJ Brain activations in the premonitory phase of nitroglycerin-triggered" exact="migraine" post="attacks Brain 2014 137 232 241 24277718 49. Denuelle"/>
   <result pre="P, Chollet F, Geraud G (2007) Hypothalamic activation in spontaneous" exact="migraine" post="attacks. Headache 47(10): 1418–1426 50. Schulte LH Allers A"/>
   <result pre="2016 28446645 51. Bolay H The first phase of a" exact="migraine" post="attack resides in the cortex J Neural Transm (Vienna)"/>
   <result pre="of Alice in wonderland syndrome in a cohort with vestibular" exact="migraine" post="Neurol Clin Pract 2018 8 5 389 396 30564492"/>
   <result pre="of cerebral cortex, thalamus and basal ganglia during spontaneously occurring" exact="migraine" post="headaches Headache 1989 29 5 282 289 2745066 55."/>
   <result pre="Buchel C Frackowiak RS Goadsby PJ Brainstem activation specific to" exact="migraine" post="headache Lancet 2001 357 9261 1016 1017 11293599 56."/>
   <result pre="A PET study exploring the laterality of brainstem activation in" exact="migraine" post="using glyceryl trinitrate Brain 2005 128 Pt 4 932"/>
   <result pre="J Gong Q Altered effective connectivity of posterior thalamus in" exact="migraine" post="with cutaneous allodynia: a resting-state fMRI study with granger"/>
   <result pre="and topography of cerebral blood flow, aura, and headache during" exact="migraine" post="attacks Ann Neurol 1990 28 6 791 798 2285266"/>
   <result pre="Rosen RB Tootell RB Sorensen AG Moskowitz MA Mechanisms of" exact="migraine" post="aura revealed by functional MRI in human visual cortex"/>
   <result pre="G Ictal and interictal hypoactivation of the occipital cortex in" exact="migraine" post="with aura. A neuroimaging and electrophysiological study Funct Neurol"/>
   <result pre="MS Ko YC Wang SJ Sustained visual cortex hyperexcitability in" exact="migraine" post="with persistent visual aura Brain 2011 134 2387 2395"/>
   <result pre="Cader MZ Altered neurochemical coupling in the occipital cortex in" exact="migraine" post="with visual aura Cephalalgia 2015 35 11 1025 1030"/>
   <result pre="FM Larsson HBW Olesen J Hoffmann MB Ashina M Heterogenous" exact="migraine" post="aura symptoms correlate with visual cortex functional magnetic resonance"/>
   <result pre="G Fierro B Abnormal facilitatory mechanisms in motor cortex of" exact="migraine" post="with aura Eur J Pain 2011 15 9 928"/>
   <result pre="Pierelli F Excitability of the motor cortex in patients with" exact="migraine" post="changes with the time elapsed from the last attack"/>
   <result pre="F Manganotti P Transcranial magnetic stimulation of visual cortex in" exact="migraine" post="patients: a systematic review with meta-analysis J Headache Pain"/>
   <result pre="network and spreading depression dynamics as neuromodulation targets in episodic" exact="migraine" post="Chaos 2013 23 4 046101 10.1063/1.4813815 24387580 75. Wöber-Bingöl"/>
   <result pre="Wessely P Wober-Bingol C Prospective analysis of factors related to" exact="migraine" post="attacks: the PAMINA study Cephalagia 2007 27 304 314"/>
   <result pre="314 78. Kelman L Migraine changes with age: impact on" exact="migraine" post="classification Headache 2006 46 1161 1171 16866720 79. Berk"/>
   <result pre="Wills PM Age-related cerebrovascular disease alters the symptomatic course of" exact="migraine" post="Cephalalgia 1998 18 4 202 208 9642495 81. Edvinsson"/>
   <result pre="Boutet F Roche F et al. Elderly patients with ongoing" exact="migraine" post="show reduced gray matter volume in second somatosensory cortex"/>
   <result pre="Hadjikhani H Thickening in the somatosensory cortex of patients with" exact="migraine" post="Neurology 2007 69 21 1990 1995 18025393 86. Kim"/>
   <result pre="Oh K Koh SB Thickening of the somatosensory cortex in" exact="migraine" post="without aura Cephalalgia 2014 34 14 1125 1133 24728304"/>
   <result pre="Jelicic M van Boxtel MP Houx PJ Jolles J Does" exact="migraine" post="headache affect cognitive function in the elderly? Report from"/>
   <result pre="IS Stefanov RS Diagnostic value of combinations of symptoms of" exact="migraine" post="and tension-type headache included in the diagnostic criteria for"/>
   <result pre="Lin YY Wang SJ Comparison of somatosensory cortex excitability between" exact="migraine" post="and &quot;strict-criteria&quot; tension-type headache: a magnetoencephalographic study Pain 2018"/>
   <result pre="Lin CP Wang SJ Comparison of gray matter volume between" exact="migraine" post="and &quot;strict-criteria&quot; tension-type headache J Headache Pain 2018 19"/>
   <result pre="Huijgen A Willemsen G de Geus EJC Boomsma DI Are" exact="migraine" post="and tension-type headache genetically related? An investigation of twin"/>
   <result pre="128. Komatsu K Fukutake T Hattori T Fingertip photoplethysmography and" exact="migraine" post="J Neurol Sci 2003 216 1 17 21 14607298"/>
   <result pre="B Matei R Popescu CD Autonomic impairment in patients with" exact="migraine" post="Eur Rev Med Pharmacol Sci 2015 19 20 3922"/>
   <result pre="Schöberl F Straube A The cold pressor test in interictal" exact="migraine" post="patients - different parasympathetic pupillary response indicates dysbalance of"/>
   <result pre="autonomic nervous system during paced breathing and mental stress in" exact="migraine" post="patients J Headache Pain 2015 16 82 10.1186/s10194-015-0567-8 26377932"/>
   <result pre="E Guler S Kolukisa M Tatli B Characteristic features of" exact="migraine" post="in schoolchildren and adolescents and its relationship with autonomic"/>
   <result pre="D Scherder E Autonomic responses to pain in aging and" exact="dementia" post="Rev Neurosci 2011 22 5 583 589 21967519 143."/>
   <result pre="Eren O, Blum B, Ruscheweyh R (2015) Treatment of chronic" exact="migraine" post="with transcutaneous stimulation of the auricular branch of the"/>
   <result pre="NC Shapiro RE Rapoport AM Why does vomiting stop a" exact="migraine" post="attack? Curr Pain Headache Rep 2013 17 9 362"/>
   <result pre="8803 1202 1207 1349944 152. Schulte LH May A The" exact="migraine" post="generator revisited: continuous scanning of the migraine cycle over"/>
   <result pre="May A The migraine generator revisited: continuous scanning of the" exact="migraine" post="cycle over 30 days and three spontaneous attacks Brain."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6734472/results/search/disease/results.xml">
   <result pre="muscles – assessment of myofascial trigger points in patients with" exact="migraine" post="http://orcid.org/0000-0002-8120-2223 Sollmann Nico +49 89 4140 4651 Nico.Sollmann@tum.de 1"/>
   <result pre="and indicate if changes were made. Abstract Background Research in" exact="migraine" post="points towards central-peripheral complexity with a widespread pattern of"/>
   <result pre="Methods Ten subjects (nine females, 25.6 ± 5.2 years) with a diagnosis of" exact="migraine" post="according to ICHD-3 underwent bilateral manual palpation of the"/>
   <result pre="C. Funding German Joint Federal Committee Momo – Modules on" exact="migraine" post="onset Heinen Florian Background Migraine belongs to the primary"/>
   <result pre="from mTrPs in neck and shoulder muscles potentially contributing to" exact="migraine" post="symptoms [ 8, 10]. Studies have repeatedly demonstrated a"/>
   <result pre="repeatedly demonstrated a high occurrence of mTrPs in subjects with" exact="migraine" post="and provided evidence of associations between such points and"/>
   <result pre="15]. The link of mTrPs of the neck area to" exact="migraine" post="is further suggested by investigations that were successful to"/>
   <result pre="is further suggested by investigations that were successful to provoke" exact="migraine" post="attacks by manual palpation delivered specifically to these points"/>
   <result pre="all participants. Participants and design Ten subjects with clinically confirmed" exact="migraine" post="were enrolled. These subjects represent a subsample derived from"/>
   <result pre="written informed consent, 2) age above 18 years, 3) diagnosis of" exact="migraine" post="(according to ICHD-3), and 4) reported mTrPs within the"/>
   <result pre="imaging with reduction factor R = 2 × 1.35 (RL × FH), no partial Fourier, fat" exact="suppression" post="using spectral inversion recovery, scan time = 7 min 17 s. During the"/>
   <result pre="male volunteer, mean age: 25.6 ± 5.2 years, range: 19.4–34.9 years), all diagnosed with" exact="migraine" post="according to ICHD-3, who reported on migraine since 13.0 ± 9.1 years"/>
   <result pre="all diagnosed with migraine according to ICHD-3, who reported on" exact="migraine" post="since 13.0 ± 9.1 years on average (range: 1.5–29.2 years). The age of"/>
   <result pre="average (range: 1.5–29.2 years). The age of the first manifestation of" exact="migraine" post="was 12.6 ± 6.5 years (range: 5.0–24.0 years), and subjects suffered from migraine"/>
   <result pre="of migraine was 12.6 ± 6.5 years (range: 5.0–24.0 years), and subjects suffered from" exact="migraine" post="on 5.5 ± 2.4 days per month (range: 3.0–10.0 days per months) with"/>
   <result pre="(range: 3.0–10.0 days per months) with an average pain rating for" exact="migraine" post="attacks of 7.2 ± 0.7 points (range: 6.0–8.0 points) according to"/>
   <result pre="for migraine). Registered comorbidities of the study cohort were pollen" exact="allergy" post="(one subject), asthma (one subject), and hypothyroidism (one subject)."/>
   <result pre="comorbidities of the study cohort were pollen allergy (one subject)," exact="asthma" post="(one subject), and hypothyroidism (one subject). Nine of the"/>
   <result pre="cohort were pollen allergy (one subject), asthma (one subject), and" exact="hypothyroidism" post="(one subject). Nine of the included subjects regularly performed"/>
   <result pre="period in all subjects, with an interval between the last" exact="migraine" post="attack and the study appointment of 0.7 ± 1.5 months (range: 0.1–5.1 months)."/>
   <result pre="has shown a high occurrence of mTrPs in subjects with" exact="migraine" post="and has linked mTrPs to neck mobility [ 11–"/>
   <result pre="of mTrPs of the neck area in the context of" exact="migraine" post="is further provided by the finding that migraine attacks"/>
   <result pre="context of migraine is further provided by the finding that" exact="migraine" post="attacks can be triggered by manually applied pressure to"/>
   <result pre="muscles and its sensory afferences. In line with this hypothesis," exact="migraine" post="has partially been attributed to nociceptive myofascial inputs that"/>
   <result pre="pressure pain thresholds of upper trapezius muscles in subjects with" exact="migraine" post="when compared to controls without migraine [ 38, 39]."/>
   <result pre="muscles in subjects with migraine when compared to controls without" exact="migraine" post="[ 38, 39]. This suggests that hyperalgesia perceived in"/>
   <result pre="muscles might indeed contribute to the development and/or maintenance of" exact="migraine" post="via cervical-to-trigeminal linking and vice versa, with mTrPs potentially"/>
   <result pre="muscles may help to guide interventions for the treatment of" exact="migraine" post="by targeting these points specifically in the context of"/>
   <result pre="intervention approaches were applied to target mTrPs in subjects with" exact="migraine" post="[ 18, 42]; yet, guidance is mostly led by"/>
   <result pre="(rPMS), which has shown to relieve pain in subjects with" exact="migraine" post="when applied to the upper trapezius muscles [ 43]."/>
   <result pre="clinical routine in all centers dealing with subjects suffering from" exact="migraine" post="at the current stage. Future studies including larger cohorts,"/>
   <result pre="German Joint Federal Committee (Innovation Committee; Momo – Modules on" exact="migraine" post="onset [NM, FH]). DK and DW would like to"/>
   <result pre="10.1007/s10194-010-0217-0 20473702 3. Edvinsson L Aspects on the pathophysiology of" exact="migraine" post="and cluster headache Pharmacol Toxicol 2001 89 2 65"/>
   <result pre="10.1007/s11916-015-0503-2 26049772 7. Olesen J Clinical and pathophysiological observations in" exact="migraine" post="and tension-type headache explained by integration of vascular, supraspinal"/>
   <result pre="F von Kries R Self-reported neck pain is associated with" exact="migraine" post="but not with tension-type headache in adolescents Cephalalgia 2014"/>
   <result pre="Kries R Heinen F Self-reported muscle pain in adolescents with" exact="migraine" post="and tension-type headache Cephalalgia 2012 32 3 241 249"/>
   <result pre="trigger points, neck mobility and forward head posture in unilateral" exact="migraine" post="Cephalalgia 2006 26 9 1061 1070 10.1111/j.1468-2982.2006.01162.x 16919056 12."/>
   <result pre="Hidalgo J Garcia-Leiva JM Rico-Villademoros F Trigger point evaluation in" exact="migraine" post="patients: an indication of peripheral sensitization linked to migraine"/>
   <result pre="in migraine patients: an indication of peripheral sensitization linked to" exact="migraine" post="predisposition? Eur J Neurol 2006 13 3 244 249"/>
   <result pre="between active trigger points and head/neck posture in patients with" exact="migraine" post="Am J Phys Med Rehabil / Association of Academic"/>
   <result pre="points and migraine-related disability in women with episodic and chronic" exact="migraine" post="Clin J Pain 2017 33 2 109 115 10.1097/AJP.0000000000000387"/>
   <result pre="Kolding LT Hvedstrup J Schytz HW Myofascial trigger points in" exact="migraine" post="and tension-type headache J Headache Pain 2018 19 1"/>
   <result pre="D McCain GA Russell IJ Sanders HO et al. The" exact="fibromyalgia" post="and myofascial pain syndromes: a preliminary study of tender"/>
   <result pre="of tender points and trigger points in persons with fibromyalgia," exact="myofascial pain syndrome" post="and no disease J Rheumatol 1992 19 6 944"/>
   <result pre="tissue characterization of the upper trapezius muscle in patients with" exact="myofascial pain syndrome" post="Conf Proc IEEE Eng Med Biol Soc 2012 2012"/>
   <result pre="JA Generalized neck-shoulder hyperalgesia in chronic tension-type headache and unilateral" exact="migraine" post="assessed by pressure pain sensitivity topographical maps of the"/>
   <result pre="Lapenna D Mezzetti A Contribution of myofascial trigger points to" exact="migraine" post="symptoms J Pain 2007 8 11 869 878 10.1016/j.jpain.2007.06.002"/>
   <result pre="D New therapeutic approaches for the prevention and treatment of" exact="migraine" post="Lancet Neurol 2015 14 10 1010 1022 10.1016/S1474-4422(15)00198-2 26376968"/>
   <result pre="Magnetic stimulation of the upper trapezius muscles in patients with" exact="migraine" post="- a pilot study Eur J Paediatr Neurol 2016"/>
   <result pre="of treatment of myofascial trigger points on the pain of" exact="fibromyalgia" post="Curr Pain Headache Rep 2011 15 5 393 399"/>
   <result pre="active trigger points in women with myofascial temporomandibular pain and" exact="fibromyalgia" post="syndrome J Headache Pain 2012 13 8 625 637"/>
   <result pre="points reproduce the overall spontaneous pain pattern in women with" exact="fibromyalgia" post="and are related to widespread mechanical hypersensitivity Clin J"/>
   <result pre="in women with fibromyalgia and are related to widespread mechanical" exact="hypersensitivity" post="Clin J Pain 2011 27 5 405 413 10.1097/AJP.0b013e318210110a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6736572/results/search/disease/results.xml">
   <result pre="which does not comply with these terms. Abstract Children with" exact="migraine" post="headaches appear to have a range of sleep disturbances."/>
   <result pre="sleep instability in a population of school-aged individuals affected by" exact="migraine" post="without aura (MoA). Thirty-three children with MoA (20 males,"/>
   <result pre="lower NREM lower sleep instability associated with MoA in children." exact="migraine" post="without aura (MoA) NREM sleep instability cyclic alternating pattern"/>
   <result pre="childhood, the most frequent primary headaches could be considered the" exact="migraine" post="without aura (MoA) and tension-type headache with a prevalence"/>
   <result pre="of 2–17 and 0.9–24%, respectively ( 8, 9). Children with" exact="migraine" post="headaches appear to have more frequent sleep troubles consisting"/>
   <result pre="conclusive association about any peculiar characteristics of sleep architecture, although" exact="migraine" post="attacks seem to be linked to REM stages and"/>
   <result pre="( 11). Moreover, Goder et al. ( 12) reported that" exact="migraine" post="attacks were preceded by a significant decrease in arousals"/>
   <result pre="high rate of awakenings) in children with mild or severe" exact="migraine" post="with an increasing related to the severity of symptoms"/>
   <result pre="overall CAP rate and CAP cycling in adult patients with" exact="migraine" post="as compared to controls ( 16). In this perspective,"/>
   <result pre="C. Materials and Methods Study Population Thirty-three children affected by" exact="migraine" post="without aura (MoA) (20 males, 13 females, mean age"/>
   <result pre="della Campania &quot;Luigi Vanvitelli&quot;, Campania Region, Italy. The diagnosis of" exact="migraine" post="was made according to international criteria ( 17). None"/>
   <result pre="at least the 2 weeks prior to neither recruitment nor" exact="migraine" post="attacks for 48 h at least before the study"/>
   <result pre="of sleep-related breathing disorders (i.e., habitual snoring, nocturnal apneas), for" exact="periodic limb movement disorder" post="(i.e., nocturnal hyperkinesias) and recurrent parasomnias (&amp;gt;3 episodes per"/>
   <result pre="breathing disorders (i.e., habitual snoring, nocturnal apneas), for periodic limb" exact="movement disorder" post="(i.e., nocturnal hyperkinesias) and recurrent parasomnias (&amp;gt;3 episodes per"/>
   <result pre="z-score Body Mass Index (z- BMI) ( Table 1). The" exact="migraine" post="characteristics such as frequency, intensity and duration of attacks"/>
   <result pre="were showed in Table 1. None of the children with" exact="migraine" post="in our series were affected by a migraine attack"/>
   <result pre="children with migraine in our series were affected by a" exact="migraine" post="attack during the sleep study. Table 1 The comparison"/>
   <result pre="attack during the sleep study. Table 1 The comparison between" exact="migraine" post="without aura (MoA) and typically developing children (Control) groups"/>
   <result pre="frequency, duration, and intensity (assessed with Visuo-analogic Scale, VAS) of" exact="migraine" post="attacks were described for MoA group. The t-Test and"/>
   <result pre="Differences evaluated with the Mann-Whitney-U test, among children affected by" exact="migraine" post="without aura (MoA) and control group in the following"/>
   <result pre="evaluated with the Mann-Whitney- U test, among children affected by" exact="migraine" post="without aura (MoA) and control group in the following"/>
   <result pre="related to the rapid eye movement sleep (REM) or to" exact="obstructive sleep apnea" post="syndrome (OSAS) ( 4). The details of the relationship"/>
   <result pre="to the rapid eye movement sleep (REM) or to obstructive" exact="sleep apnea" post="syndrome (OSAS) ( 4). The details of the relationship"/>
   <result pre="suggestive association between headaches and sleep disturbances, including primary snoring," exact="obstructive sleep apnea," post="and NREM parasomnias although these data are mainly derived"/>
   <result pre="association between headaches and sleep disturbances, including primary snoring, obstructive" exact="sleep apnea," post="and NREM parasomnias although these data are mainly derived"/>
   <result pre="the thalamus may be considered as the key structure for" exact="migraine" post="pathophysiology. EEG studies have shown that interictal migraine have"/>
   <result pre="structure for migraine pathophysiology. EEG studies have shown that interictal" exact="migraine" post="have low thalamo/thalamocortical transmission associated with low brainstem activation"/>
   <result pre="controls. Moreover, some reports have showed that children affected by" exact="migraine" post="may exhibit disrupted sleep architecture, such as abnormalities in"/>
   <result pre="showed an important alteration/disruption in sleep in children affected by" exact="migraine" post="and chronic migraine linked to the presence of sleep-disordered"/>
   <result pre="alteration/disruption in sleep in children affected by migraine and chronic" exact="migraine" post="linked to the presence of sleep-disordered breathing, shortened TST,"/>
   <result pre="Authors suggested that because some children may find relief from" exact="migraine" post="attacks with daytime naps (or the sleep could be"/>
   <result pre="and REM sleep percentages, as confirmed in adult subjects with" exact="migraine" post="( 33). Moreover, in adults, the reduction in REM"/>
   <result pre="arousals during REM was reported during the night preceding the" exact="migraine" post="( 34), and in this perspective a shorter sleep"/>
   <result pre="perspective a shorter sleep latency during the night before a" exact="migraine" post="attack was observed also in children, suggesting a sort"/>
   <result pre="our results seem to confirm the observation that children with" exact="migraine" post="tend to show a higher rate of awakenings per"/>
   <result pre="areas could be considered actually as the generators of the" exact="migraine" post="attacks ( 40, 41). In our sample the CAP"/>
   <result pre="evaluate NREM instability and CAP parameters in children affected by" exact="migraine" post="without aura compared with a control group. In conclusion,"/>
   <result pre="better comprehension of the pathophysiological mechanisms underlying the link between" exact="migraine" post="and NREM sleep and to investigate possible consequent clinical"/>
   <result pre="performed for children and adolescents in our Unit referred for" exact="migraine" post="without aura. Author Contributions MR, RM, FO, DS, FP,"/>
   <result pre="Giobbe L et al. . Evidence for an association between" exact="migraine" post="and the hypocretin receptor 1 gene. J Headache Pain."/>
   <result pre="H et al. . Polysomnographic findings in nights preceding a" exact="migraine" post="attack. Cephalalgia. ( 2001) 21: 31– 7. 10.1046/j.1468-2982.2001.00141.x 11298661"/>
   <result pre="et al. . Study of sleep microstructure in patients of" exact="migraine" post="without aura. Sleep Breath. ( 2016) 20: 263– 9."/>
   <result pre="scoring of sleep and associated events . Deliberations of the" exact="sleep apnea" post="definitions task force of the american academy of sleep"/>
   <result pre=". Impaired brainstem and thalamic high-frequency oscillatory EEG activity in" exact="migraine" post="between attacks . Cephalalgia. ( 2017) 37: 915– 26."/>
   <result pre="P Tonali PA . Dysfunction of arousal systems in sleep-related" exact="migraine" post="without aura. Cephalalgia. ( 2006) 26: 857– 64. 10.1111/j.1468-2982.2005.01037.x"/>
   <result pre="Di Lorenzo G et al. . Thalamo-cortical network activity between" exact="migraine" post="attacks: Insights from MRI-based microstructural and functional resting-state network"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6742947/results/search/disease/results.xml">
   <result pre="with sensory sensitivity/need was Autism Spectrum Disorder (48%), followed by" exact="cerebral palsy" post="(22.8%) and Attention-Deficit/Hyperactivity Disorder (16%). 1337 patients (51.8%) had"/>
   <result pre="can be seen in children with comorbid conditions such as" exact="autism" post="spectrum disorder (ASD) ( 3), cognitive disorder ( 4),"/>
   <result pre="comorbid conditions such as autism spectrum disorder (ASD) ( 3)," exact="cognitive disorder" post="( 4), prematurity ( 5), fetal alcohol syndrome ("/>
   <result pre="(ASD) ( 3), cognitive disorder ( 4), prematurity ( 5)," exact="fetal alcohol syndrome" post="( 6), cerebral palsy ( 7), certain genetic conditions"/>
   <result pre="( 4), prematurity ( 5), fetal alcohol syndrome ( 6)," exact="cerebral palsy" post="( 7), certain genetic conditions (for instance Trisomy 21"/>
   <result pre="and Fragile X Syndrome) ( 8) and in patients with" exact="attention deficit hyperactivity disorder" post="(ADHD) ( 9). Sensory processing or integration disorder can"/>
   <result pre="Pathway. Footnote- Gastrointestinal complaints include malnutrition, enteritis, esophagitis, acid reflux," exact="gastric ulcer," post="gastritis, gastroparesis, inflammatory bowel disease, appendicitis, constipation, gastrointestinal hemorrhage,"/>
   <result pre="colostomy or gastrostomy; Neurologic complaints include seizures, postconcussion syndrome, extrapyramidal" exact="movement disorder," post="myoclonus, migraine, cerebral ischemia, insomnia, hemiplegia, quadriplegia, hydrocephalus, pain,"/>
   <result pre="altered mental status, amnesia, headache and syncope; Respiratory complaints include" exact="cystic fibrosis," post="obstructive sleep apnea, tracheitis, croup, upper respiratory infection, pneumonia,"/>
   <result pre="status, amnesia, headache and syncope; Respiratory complaints include cystic fibrosis," exact="obstructive sleep apnea," post="tracheitis, croup, upper respiratory infection, pneumonia, cough, dyspnea, stridor,"/>
   <result pre="amnesia, headache and syncope; Respiratory complaints include cystic fibrosis, obstructive" exact="sleep apnea," post="tracheitis, croup, upper respiratory infection, pneumonia, cough, dyspnea, stridor,"/>
   <result pre="apnea, tracheitis, croup, upper respiratory infection, pneumonia, cough, dyspnea, stridor," exact="respiratory failure," post="wheezing, cyanosis and chest pain; Behavioral complaints include hallucinations,"/>
   <result pre="and physical violence; Trauma/burn/surgical complaints include burns, motor vehicle accident," exact="bowel obstruction," post="injuries and fractures, hernia, abrasions, contusions and laceration; Infectious"/>
   <result pre="tract infections, sepsis, viral and fungal infections; ENT complaints include" exact="otitis media," post="pharyngitis and foreign body, Renal/Fluids and electrolytes complaints include"/>
   <result pre="sepsis, viral and fungal infections; ENT complaints include otitis media," exact="pharyngitis" post="and foreign body, Renal/Fluids and electrolytes complaints include dehydration,"/>
   <result pre="and foreign body, Renal/Fluids and electrolytes complaints include dehydration, acidosis," exact="glomerulonephritis" post="and electrolyte disturbance; Dermatologic complaints included skin infections and"/>
   <result pre="pathological fractures; Hematology/Oncology complaints include anemia, pancytopenia, purpura, neutropenia, leukemia," exact="lymphoma" post="and solid tumors; Other complaints include genital problems, ingestions"/>
   <result pre="comorbidity associated with sensory sensitivity was ASD (48%), followed by" exact="cerebral palsy" post="(22.8%) and ADHD (16%) ( Figure 2). Only 34"/>
   <result pre="triggered the Sensory Pathway had multiple comorbidities including ASD, ADHD," exact="cerebral palsy," post="prematurity and chromosomal disorders. The most common diagnosis was"/>
   <result pre="chromosomal disorders. The most common diagnosis was ASD, followed by" exact="cerebral palsy" post="and ADHD ( Figure 2). 90% of the patients"/>
   <result pre="SL Rocha N . Sensory processing disorders in children with" exact="cerebral palsy." post="Infant Behav Dev. ( 2017) 46: 1– 6. 10.1016/j.infbeh.2016.10.007"/>
   <result pre="B Ely B . Caring for the child with an" exact="autism" post="spectrum disorder in the acute care setting. J Spec"/>
   <result pre="successful admission to hospital for young people with learning difficulties," exact="autism" post="and challenging behaviour: a continuous quality improvement and change"/>
   <result pre="Young GS Rogers SJ . Sensory symptoms in children with" exact="autism" post="spectrum disorder, other developmental disorders and typical development: a"/>
   <result pre="McCracken C Karpen S Sharp WG . Gastrointestinal symptoms in" exact="autism" post="spectrum disorder: a meta-analysis. Pediatrics. ( 2014) 133: 872–"/>
   <result pre="Autism comes to the hospital: the experiences of patients with" exact="autism" post="spectrum disorder, their parents and health-care providers at two"/>
   <result pre="D Levy SE . Caring for children and adolescents with" exact="autism" post="who require challenging procedures. Pediatr Nurs. ( 2002) 28:"/>
   <result pre="Sensory stimuli as obstacles to emergency care for children with" exact="autism" post="spectrum disorder. Adv Emerg Nurs J. ( 2014) 36:"/>
   <result pre="A Kern L . Social Story interventions for students with" exact="autism" post="spectrum disorders: a meta-analysis. J Autism Dev Disord. ("/>
   <result pre="30. Vaz I . Improving the management of children with" exact="learning disability" post="and autism spectrum disorder when they attend hospital ."/>
   <result pre=". Improving the management of children with learning disability and" exact="autism" post="spectrum disorder when they attend hospital . Child Care"/>
   <result pre="50. 10.1111/hex.12254 25156078 32. Owley TB Treatment of individuals with" exact="autism" post="spectrum disorders in the emergency department: special considerations ."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6743250/results/search/disease/results.xml">
   <result pre="is bi-directional, meaning that the risk for any given additional" exact="mental disorder" post="is increased by the presence of the first. Seemingly"/>
   <result pre="more disorders. A genome-wide association study (GWAS) of individuals with" exact="autism" post="spectrum disorder (ASD) found a significant overlap with schizophrenia"/>
   <result pre="with autism spectrum disorder (ASD) found a significant overlap with" exact="schizophrenia" post="(SCZ) at 8p11.23, 3p25.3 ( ATP2B2), and 3p13 ("/>
   <result pre="(CNV) duplications of 16p11.2 associated with SCZ as well as" exact="bipolar disorder" post="(BPD) and depression 9 . At the same time,"/>
   <result pre="cAMP responsive element-binding (CREB)-1 gene to study associations with BPD," exact="major depressive disorder" post="(MDD), and SCZ. A meta-analysis found both SNPs were"/>
   <result pre=". As an example of these methods, one GWAS on" exact="alcohol dependence" post="found genetic correlations based on LDSR with depressive symptoms,"/>
   <result pre="based on LDSR with depressive symptoms, a diagnosis of MDD," exact="attention deficit hyperactivity disorder" post="(ADHD), SCZ, neuroticism, and subjective well-being at the p"/>
   <result pre="been reported for ADHD and eating disorders 30 and between" exact="substance abuse" post="and psychotic disorders 31, 32 . In children, a"/>
   <result pre="the shared contribution among ADHD, several pediatric psychiatric disorders, depression," exact="panic disorder," post="and generalized anxiety disorder (GAD) 33 . In sum,"/>
   <result pre="among ADHD, several pediatric psychiatric disorders, depression, panic disorder, and" exact="generalized anxiety disorder" post="(GAD) 33 . In sum, Brikell and colleagues identified"/>
   <result pre="ADHD, several pediatric psychiatric disorders, depression, panic disorder, and generalized" exact="anxiety disorder" post="(GAD) 33 . In sum, Brikell and colleagues identified"/>
   <result pre="disorders and, in contrast, demonstrating differences with neurological disorders, except" exact="migraine" post="25 . This study determined the common variant heritability"/>
   <result pre="disparate domains such as affective disorders, anxiety disorders, SCZ, ADHD," exact="post-traumatic stress disorder" post="(PTSD), and ASD. Findings demonstrated SCZ was genetically correlated"/>
   <result pre="with PTSD, and co-existence of mood disorders and SCZ in" exact="schizoaffective disorder." post="The aforementioned findings with migraine included an association between"/>
   <result pre="disorders and SCZ in schizoaffective disorder. The aforementioned findings with" exact="migraine" post="included an association between migraine and ADHD ( r"/>
   <result pre="disorder. The aforementioned findings with migraine included an association between" exact="migraine" post="and ADHD ( r g = 0.26, p ="/>
   <result pre="r g = 0.26, p = 8.81 × 10 -8)," exact="migraine" post="and Tourette Syndrome ( r g = 0.19, p"/>
   <result pre="g = 0.19, p = 1.80 × 10 -5), and" exact="migraine" post="and MDD ( r g = 0.32, p ="/>
   <result pre="at least one GWAS determining genetic overlap between MDD and" exact="migraine" post="36 . LDSR was also used to demonstrate a"/>
   <result pre="used to demonstrate a 14.3% genetic correlation between SCZ and" exact="amyotrophic lateral sclerosis" post="(ALS), with PRS for SCZ explaining 0.12% of the"/>
   <result pre="of personality disorders; there is known overlap, for example, between" exact="borderline personality disorder" post="and MDD, anxiety disorders, and PTSD, although large-scale investigation"/>
   <result pre="personality disorders; there is known overlap, for example, between borderline" exact="personality disorder" post="and MDD, anxiety disorders, and PTSD, although large-scale investigation"/>
   <result pre="et al. : Genetic basis of psychopathological dimensions shared between" exact="schizophrenia" post="and bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2019; 89:"/>
   <result pre=": Genetic basis of psychopathological dimensions shared between schizophrenia and" exact="bipolar disorder." post="Prog Neuropsychopharmacol Biol Psychiatry. 2019; 89: 23– 29. 10.1016/j.pnpbp.2018.08.023"/>
   <result pre="Genomics Consortium: Meta-analysis of GWAS of over 16,000 individuals with" exact="autism" post="spectrum disorder highlights a novel locus at 10q24.32 and"/>
   <result pre="possible risk gene pathway partially explain the comorbidity of schizophrenia," exact="major depressive disorder," post="type 2 diabetes, and metabolic syndrome. Am J Med"/>
   <result pre="comorbidity of schizophrenia, major depressive disorder, type 2 diabetes, and" exact="metabolic syndrome." post="Am J Med Genet B Neuropsychiatr Genet. 2019; 180("/>
   <result pre="al. : Genome-wide analysis reveals extensive genetic overlap between schizophrenia," exact="bipolar disorder," post="and intelligence. Mol Psychiatry. 2019. 10.1038/s41380-018-0332-x 30610197 F1000 Recommendation"/>
   <result pre="et al. : Examination of the shared genetic basis of" exact="anorexia nervosa" post="and obsessive-compulsive disorder. Mol Psychiatry. 2018. 10.1038/s41380-018-0115-4 30087453 21"/>
   <result pre="Examination of the shared genetic basis of anorexia nervosa and" exact="obsessive-compulsive disorder." post="Mol Psychiatry. 2018. 10.1038/s41380-018-0115-4 30087453 21 Knowles EEM Curran"/>
   <result pre="O et al. : Identification of shared genetic variants between" exact="schizophrenia" post="and lung cancer. Sci Rep. 2018; 8( 1): 674."/>
   <result pre="al. : Identification of shared genetic variants between schizophrenia and" exact="lung cancer." post="Sci Rep. 2018; 8( 1): 674. 10.1038/s41598-017-16481-4 29330379 23"/>
   <result pre="Li M Sham PC et al. : Genetic overlap between" exact="epilepsy" post="and schizophrenia: Evidence from cross phenotype analysis in Hong"/>
   <result pre="Olesen J et al. : Polygenic risk score: use in" exact="migraine" post="research. J Headache Pain. 2018; 19( 1): 29. 10.1186/s10194-018-0856-0"/>
   <result pre="Polimanti R Johnson EC et al. : Transancestral GWAS of" exact="alcohol dependence" post="reveals common genetic underpinnings with psychiatric disorders. Nat Neurosci."/>
   <result pre="F Treutlein J et al. : Shared genetic etiology between" exact="alcohol dependence" post="and major depressive disorder. Psychiatr Genet. 2018; 28( 4):"/>
   <result pre="et al. : Shared genetic etiology between alcohol dependence and" exact="major depressive disorder." post="Psychiatr Genet. 2018; 28( 4): 66– 70. 10.1097/YPG.0000000000000201 29901528"/>
   <result pre="B Robinson EB Anttila V et al. : ASD and" exact="schizophrenia" post="show distinct developmental profiles in common genetic overlap with"/>
   <result pre="H Boomsma DI et al. : Molecular genetic overlap between" exact="migraine" post="and major depressive disorder. Eur J Hum Genet. 2018;"/>
   <result pre="DI et al. : Molecular genetic overlap between migraine and" exact="major depressive disorder." post="Eur J Hum Genet. 2018; 26( 8): 1202– 16."/>
   <result pre="D van Rheenen W et al. : Genetic correlation between" exact="amyotrophic lateral sclerosis" post="and schizophrenia. Nat Commun. 2017; 8: 14774. 10.1038/ncomms14774 28322246"/>
   <result pre="sets in cortical brains of individuals with autism, schizophrenia, and" exact="bipolar disorder." post="Transl Psychiatry. 2019; 9( 1): 152. 10.1038/s41398-019-0488-4 31127088 F1000"/>
   <result pre="al. : A gene co-expression network in whole blood of" exact="schizophrenia" post="patients is independent of antipsychotic-use and enriched for brain-expressed"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6753025/results/search/disease/results.xml">
   <result pre="compare procedural, early and long-term outcome of device closure of" exact="atrial septal defect" post="(ASD) between large ASD patients and very large ASD"/>
   <result pre="complication (0.4%) of stroke. Most common long-term minor event was" exact="migraine" post="headache (3.9%) followed by arrhythmias (1.9%) without statistical difference"/>
   <result pre="risk factors of coronary artery disease, or had history of" exact="stroke" post="or transient ischemic attack underwent coronary angiography. In case"/>
   <result pre="and TTE on the next day. Procedure- or device-related death," exact="cardiac tamponade," post="erosion, thromboembolism, stroke, complete atrioventricular (AV) block, ventricular arrhythmias"/>
   <result pre="was prescribed for 6 months, and routine prophylaxis for infectious" exact="endocarditis" post="for 6 months in cases without complication. Early complications"/>
   <result pre="presented as mean±standard deviation (range) or number (%). ASD =" exact="atrial septal defect;" post="BOD = balloon occlusive diameter; BSA = body surface"/>
   <result pre="pulmonary arterial pressure; MR = mitral regurgitation; Pul. HTN =" exact="pulmonary hypertension;" post="Qp/Qs = the ratio of pulmonary blood flow to"/>
   <result pre="to completion of hemostasis; ‡4 cases of radiofrequency ablations for" exact="atrial fibrillation" post="(n=2) and wolff-parkinson-white syndrome (n=2), 3 cases of direct"/>
   <result pre="‡4 cases of radiofrequency ablations for atrial fibrillation (n=2) and" exact="wolff-parkinson-white syndrome" post="(n=2), 3 cases of direct current cardioversions, 1 case"/>
   <result pre="*One case of device migration and 1 case of complete" exact="atrioventricular block;" post="†Two cases of device retrieval (1 of device migration"/>
   <result pre="4 cases of device closure with fenestration due to severe" exact="pulmonary hypertension" post="were excluded. All of the flow of the fenestrated"/>
   <result pre="hypertension were excluded. All of the flow of the fenestrated" exact="atrial septal defect" post="closure remained patent; §Late events were defined as adverse"/>
   <result pre="except 4 cases of closure with fenestrated devices due to" exact="pulmonary hypertension." post="The residual shunt rates of multiple defects after 6"/>
   <result pre="minor complications In our 269 patients, there was no death," exact="stroke" post="and cardiac tamponade. The overall major complication rate was"/>
   <result pre="In our 269 patients, there was no death, stroke and" exact="cardiac tamponade." post="The overall major complication rate was 1.5%, and there"/>
   <result pre="procedure, but as major complication. Table 4 Major complications of" exact="atrial septal defect" post="device closure Major complications Group 1 (n=216) Group 2"/>
   <result pre="(n=53) p value Death 0 (0.0) 0 (0.0) NS Ischemic/hemorrhagic" exact="stroke" post="0 (0.0) 0 (0.0) NS Cardiac tamponade 0 (0.0)"/>
   <result pre="1 (0.5) 0 (0.0) 0.620 Ventricular tachycardia 0 0 Complete" exact="atrioventricular block" post="1 0 NS = not significant. One patient underwent"/>
   <result pre="atrial flutter underwent successful radiofrequency ablation (RFA). Nine cases of" exact="atrial fibrillation" post="(AF) were treated as below: 4 cases were spontaneously"/>
   <result pre="or transient ischemic attack was not occurred. Two cases of" exact="migraine" post="were occurred in group 1, and one case of"/>
   <result pre="no procedure- or disease-related death, device erosion, device fracture, or" exact="cardiac tamponade" post="( Table 6). During follow-up, there was one non-cardiac"/>
   <result pre="follow-up, there was one non-cardiac death, 58-year-old female died of" exact="cholangiocarcinoma" post="3 years after the device closure. There was one"/>
   <result pre="was one (0.4%) major adverse event in our study. Middle" exact="cerebral infarction" post="was occurred 8 years after device closure in one"/>
   <result pre="Table 6 Late adverse events at least 6 months after" exact="atrial septal defect" post="device closure (n=256) Adverse event Group 1 (n=207) Group"/>
   <result pre="Follow-up duration (months) 46±32.1 (6.0–135.5) 52.5±33.1 (7.4–119.0) 0.215 AF =" exact="atrial fibrillation;" post="AT = atrial tachycardia; NS = not significant. *One"/>
   <result pre="atrial tachycardia; NS = not significant. *One patient died of" exact="cholangiocarcinoma" post="3 years after device closure; †One patient had a"/>
   <result pre="3 years after device closure; †One patient had a persistent" exact="atrial fibrillation" post="before atrial septal defect device closure, and had taken"/>
   <result pre="device closure; †One patient had a persistent atrial fibrillation before" exact="atrial septal defect" post="device closure, and had taken a warfarin. There was"/>
   <result pre="difference of minor late events in both groups. Newly developed" exact="migraine" post="headache (3.9%) was most common problem, followed by AFs"/>
   <result pre="long-term major complication was occurred, except one case (0.4%) of" exact="stroke" post="in above-mentioned patient with permanent AF. Long-term follow-up data"/>
   <result pre="reported. 20) However, a recent study focused on AF and" exact="stroke" post="showed a higher incidence rate of 11.8% after ASD"/>
   <result pre="rate of 11.8% after ASD closure and higher risk of" exact="stroke" post="even after ASD closure which was related with AF,"/>
   <result pre="article, we did not analysis of pre-existed atrial tachycardia. For" exact="migraine" post="headache, we reported 4.4% of incidence (0.7% in early"/>
   <result pre="percutaneous closure, which is compatible to a study focused on" exact="migraine" post="headache after transcathter closure of ASD and patent foramen"/>
   <result pre="focused on migraine headache after transcathter closure of ASD and" exact="patent foramen ovale." post="30) While other previous studies, which conducted all complication"/>
   <result pre="which conducted all complication in together, reported lower incidence of" exact="migraine" post="headache. Other reports supported new onset of migraine headache"/>
   <result pre="incidence of migraine headache. Other reports supported new onset of" exact="migraine" post="headache after percutaneous closure of ASD, 31) 32) whereas"/>
   <result pre="whereas percutaneous closure of ASD resulted in significant reduction of" exact="migraine" post="headache. There was gap of incidence of atrial tachycardia,"/>
   <result pre="migraine headache. There was gap of incidence of atrial tachycardia," exact="migraine" post="headache between studies focused on the complications and studies"/>
   <result pre="the comprehensive evaluation of quality of life or survey for" exact="migraine" post="headache was not obtained. Cardiopulmonary function tests were performed"/>
   <result pre="1 King TD Thompson SL Steiner C Mills NL Secundum" exact="atrial septal defect." post="Nonoperative closure during cardiac catheterization JAMA 1976 235 2506"/>
   <result pre="Amplatzer Investigators Comparison between transcatheter and surgical closure of secundum" exact="atrial septal defect" post="in children and adults: results of a multicenter nonrandomized"/>
   <result pre="J Sibinga E et al. Community use of the Amplatzer" exact="atrial septal defect" post="occluder: results of the multicenter MAGIC atrial septal defect"/>
   <result pre="Amplatzer atrial septal defect occluder: results of the multicenter MAGIC" exact="atrial septal defect" post="study Pediatr Cardiol 2009 30 240 247 19015911 8"/>
   <result pre="J Gavora P Podnar T Long-term outcome of transcatheter secundum-type" exact="atrial septal defect" post="closure using Amplatzer septal occluders J Am Coll Cardiol"/>
   <result pre="GG Kleinman CS Transesophageal echocardiographic guidance of transcatheter closure of" exact="atrial septal defect" post="Am J Cardiol 1990 66 207 213 2371953 12"/>
   <result pre="and alternative techniques for device closure of the large secundum" exact="atrial septal defect" post="Catheter Cardiovasc Interv 2004 61 131 139 14696173 15"/>
   <result pre="to provide appropriate deployment in the closure of large secundum" exact="atrial septal defect" post="using Amplatzer septal occluder in children J Invasive Cardiol"/>
   <result pre="B Short and long term complications of device closure of" exact="atrial septal defect" post="and patent foramen ovale: meta-analysis of 28,142 patients from"/>
   <result pre="M Amirghofran AA Complete heart block following transcatheter closure of" exact="atrial septal defect" post="due to growth of inflammatory tissue Pediatr Cardiol 2014"/>
   <result pre="25096905 27 Rohit MK Puri K Vadivelu R Reversible complete" exact="atrioventricular block" post="after percutaneous ASD device closure in a child &amp;lt;15"/>
   <result pre="C Olsen MS Nielsen-Kudsk JE Hjortdal VE Atrial fibrillation and" exact="stroke" post="in adult patients with atrial septal defect and the"/>
   <result pre="Hjortdal VE Atrial fibrillation and stroke in adult patients with" exact="atrial septal defect" post="and the long-term effect of closure Heart 2015 101"/>
   <result pre="of atrial tachyarrhythmia before and after percutaneous closure of secundum" exact="atrial septal defect" post="in patients over 40 years of age Zhonghua Xin"/>
   <result pre="A et al. Incidence, timing, and predictive factors of new-onset" exact="migraine" post="headache attack after transcatheter closure of atrial septal defect"/>
   <result pre="factors of new-onset migraine headache attack after transcatheter closure of" exact="atrial septal defect" post="or patent foramen ovale Am J Cardiol 2008 101"/>
   <result pre="headache attack after transcatheter closure of atrial septal defect or" exact="patent foramen ovale" post="Am J Cardiol 2008 101 688 692 18308022 31"/>
   <result pre="Migraine with aura related to the percutaneous closure of an" exact="atrial septal defect" post="Catheter Cardiovasc Interv 2003 60 540 542 14624438 32"/>
   <result pre="Thijs V Herroelen L Budts W The influence of percutaneous" exact="atrial septal defect" post="closure on the occurrence of migraine Eur Heart J"/>
   <result pre="of percutaneous atrial septal defect closure on the occurrence of" exact="migraine" post="Eur Heart J 2005 26 1533 1537 15746154 33"/>
   <result pre="normalization of right ventricular volume overload after transcatheter closure of" exact="atrial septal defect" post="in children and adults Am J Cardiol 2001 88"/>
   <result pre="S et al. Right ventricular form and function after percutaneous" exact="atrial septal defect" post="device closure J Am Coll Cardiol 2001 37 2108"/>
   <result pre="Samman A Haberer K et al. Outcomes in patients with" exact="pulmonary hypertension" post="undergoing percutaneous atrial septal defect closure Heart 2008 94"/>
   <result pre="et al. Outcomes in patients with pulmonary hypertension undergoing percutaneous" exact="atrial septal defect" post="closure Heart 2008 94 1189 1193 17932093 36 Steele"/>
   <result pre="PM Fuster V Cohen M Ritter DG McGoon DC Isolated" exact="atrial septal defect" post="with pulmonary vascular obstructive disease--long-term follow-up and prediction of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6753515/results/search/disease/results.xml">
   <result pre="chronic disease as well as an identifiable physical injury (e.g." exact="migraine" post="and tension headaches, and recurrent abdominal pain syndrome). Among"/>
   <result pre="et al. 40 (a) To compare children and adolescents with" exact="migraine" post="without aura and healthy control group on perceived attachment"/>
   <result pre="of attachment to mother and father mediated the association between" exact="migraine" post="and anxiety. N = 100 (M = 10.64 years, SD = 2.85), 52 F vs"/>
   <result pre="psychological symptoms in children/adolescent migraineurs and association between attachment style," exact="migraine" post="severity, and psychological symptoms. N = 90 (aged 8–18 years, M = 12.2,"/>
   <result pre="was found between maternal alexithymia levels, attachment style, and children’s" exact="migraine" post="features (severity and frequency). Maternal alexithymia shows a relationship"/>
   <result pre="assess the prevalent attachment style in school-aged children affected by" exact="migraine" post="without aura and (b) to test its putative relationship"/>
   <result pre="its putative relationship and correlation with the main characteristics of" exact="migraine" post="attacks. N = 219 (aged 6–11 years, M = 8.96, SD = 2.14), 116 F"/>
   <result pre="to threat in a sample of children experiencing different somatoform" exact="pain disorder." post="N = 28 (aged 3.75–17.66 years, M = 10.6 years), 17 F. Observational."/>
   <result pre="(a) To compare attachment type between children and adolescents with" exact="migraine" post="without aura (MoA) and healthy controls and (b) to"/>
   <result pre="level of perceived attachment security in children and adolescent with" exact="migraine" post="compared to the control group. 40 In particular, a"/>
   <result pre="responses and regulatory pattern. The study of chronic pain and" exact="post-traumatic stress disorder" post="(PTSD) comorbidity in pediatric population is often undervalued and"/>
   <result pre="bone marrow aspirations and lumbar punctures for the treatment of" exact="cancer" post="or other serious immune deficiencies, the memory of a"/>
   <result pre="determining the association between headache features and psychological symptoms in" exact="migraine" post="children and adolescents: an analytical observational case–control study ."/>
   <result pre="B , et al. Attachment styles in children affected by" exact="migraine" post="without aura . Neuropsychiatr Dis Treat 2013; 9: 1513–"/>
   <result pre="Child Dev 1968; 40: 969– 1025. 63 Liossi C Procedure-related" exact="cancer" post="pain in children. Oxford: Radcliffe Medical Press , 2002."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6755590/results/search/disease/results.xml">
   <result pre="therapies. Based on the existence of common patho-physiological features linking" exact="epilepsy" post="to migraine [ 8], it has been recently postulated"/>
   <result pre="on the existence of common patho-physiological features linking epilepsy to" exact="migraine" post="[ 8], it has been recently postulated that the"/>
   <result pre="glutamate receptors may play a role in the treatment of" exact="migraine" post="[ 9]. In fact, glutamate receptors have been localized"/>
   <result pre="fact, glutamate receptors have been localized in areas related to" exact="migraine" post="patho-physiology, including the trigeminal ganglion, trigeminal nucleus caudalis and"/>
   <result pre="and glutamate receptor antagonists proved effective in animal models of" exact="migraine" post="(reviewed in [ 9]), which encouraged a number of"/>
   <result pre="studies with mGluR5, AMPA and/or kainate receptor antagonists in acute" exact="migraine" post="[ 13– 15]. Within the framework of AEDs and"/>
   <result pre="calcitonin gene-related peptide (CGRP, a peptide neurotransmitter most important in" exact="migraine" post="pathophysiology [ 16]), from acute rat brainstem explants. To"/>
   <result pre="well with the oral administration at the onset of a" exact="migraine" post="attack. The therapeutic area of migraine treatment has recently"/>
   <result pre="the onset of a migraine attack. The therapeutic area of" exact="migraine" post="treatment has recently undergone a fast growth, because of"/>
   <result pre="highly effective and well tolerated, they all are approved for" exact="migraine" post="prevention, meaning that the frequency of migraine attacks in"/>
   <result pre="are approved for migraine prevention, meaning that the frequency of" exact="migraine" post="attacks in patients treated with anti-CGRP antibodies is significantly"/>
   <result pre="but not abolished [ 26]. Thus, the effective treatment of" exact="migraine" post="attacks remains a partially unmet need, which warrants studies"/>
   <result pre="AMPA-receptor antagonist that reduces seizure activity in rodent models of" exact="epilepsy" post="Epilepsia 2011 52 1331 1340 10.1111/j.1528-1167.2011.03109.x 21635236 3. French"/>
   <result pre="K VanDenBrink A Glutamate receptor antagonists in the management of" exact="migraine" post="Drugs 2014 74 1165 1176 10.1007/s40265-014-0262-0 25030431 10. Kai-Kai"/>
   <result pre="a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute" exact="migraine" post="Cephalalgia 2004 24 596 602 10.1111/j.1468-2982.2004.00723.x 15196302 14. Gomez-Mancilla"/>
   <result pre="novel AMPA receptor antagonist BGG492 for the treatment of acute" exact="migraine" post="attacks Cephalalgia 2014 34 103 113 10.1177/0333102413499648 23963355 15."/>
   <result pre="migraine: a proof of concept study of ADX10059 in acute" exact="migraine" post="treatment Cephalalgia 2009 29 Suppl 1 7 16. Villalón"/>
   <result pre="Olesen J The role of CGRP in the pathophysiology of" exact="migraine" post="and efficacy of CGRP receptor antagonists as acute antimigraine"/>
   <result pre="AR Goadsby PJ Anti-CGRP monoclonal antibodies: the next era of" exact="migraine" post="prevention? Curr Treat Options Neurol 2017 19 27 10.1007/s11940-017-0463-4"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6755612/results/search/disease/results.xml">
   <result pre="population ( n = 637), the most commonly associated primary headaches were" exact="migraine" post="( n = 456; 71.6%) and tension-type headache ( n = 137; 21.5%)."/>
   <result pre="tension-type headache 29 4.5 Other primary headaches 15 2.3 Chronic" exact="migraine" post="14 2.2 Total 637 100 The neurological examination was"/>
   <result pre="15 100 Upper respiratory tract disorders A personal history for" exact="allergy" post="was reported by 3 patients (20%), and for sinus"/>
   <result pre="Interestingly, we have found a relevant association between AH and" exact="migraine" post="with aura. Baldacci et al. [ 10] reported a"/>
   <result pre="[ 10] reported a patient with AH also affected by" exact="migraine" post="with aura: this primary headache is more rare compared"/>
   <result pre="with aura: this primary headache is more rare compared to" exact="migraine" post="without aura and episodic tension-type headache in the pediatric"/>
   <result pre="in the pediatric population. Therefore, the association between AH and" exact="migraine" post="with aura does not seems to be incidental and"/>
   <result pre="[ 24], nasal mucosal inflammation, adenoidal and tonsillar hypertrophy and" exact="sinusitis" post="were the pathophysiological mechanisms found to be responsible for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6755928/results/search/disease/results.xml">
   <result pre="2013 and July 2018. We excluded 2 children, respectively, with" exact="renal agenesis" post="and chromosomopathy. Results: Of the 401 patients, 101 girls"/>
   <result pre="of cases. We found urogenital abnormalities in 15.7% of cases," exact="constipation" post="in 14.5% of cases, innocence heart murmur in 21.4%"/>
   <result pre="cases, especially snoring (13.7%), restless sleep (5.7%), somniloquy (23.7%) and" exact="bruxism" post="(14.7%). Conclusions: Our experience demonstrates that there are a"/>
   <result pre="as urinary tract infections, obstructive sleep hypoventilation, diabetes mellitus/insipidus, and" exact="neurogenic bladder." post="NE is a multifactorial disorder caused by three related"/>
   <result pre="caused by three related mechanisms: nocturnal polyuria, bladder overactivity, and" exact="sleep disorder," post="which could be of urological, neurological, genetic, or psychological"/>
   <result pre="the Rome III criteria. We excluded 2 children respectively with" exact="renal agenesis" post="and chromosomopathy and we included 401 patients, 101 girls"/>
   <result pre="(13.7%) snored, 23/401 (5.7%) had restless sleep, 12/401 (3%) had" exact="sleep apnea," post="95/401 (23.7%) had somniloquy, and 59/401 (14.7%) had bruxism"/>
   <result pre="sleep apnea, 95/401 (23.7%) had somniloquy, and 59/401 (14.7%) had" exact="bruxism" post="[ Table 1]. Table 1 Comorbidities in nocturnal enuresis:"/>
   <result pre="0.0% 0 0.0% 0 0.0% 1 0.2% Migraine  Episodes of" exact="migraine" post="in the patient 12 5.0% 3 3.5% 15 4.6%"/>
   <result pre="3.4% 0 0.0% 2 2.7% 17 4.2%  Paternal history of" exact="migraine" post="17 7.0% 9 10.6% 26 8.0% 2 3.4% 0"/>
   <result pre="3.4% 0 0.0% 2 2.7% 28 7.0%  Maternal history of" exact="migraine" post="27 11.2% 11 12.9% 38 11.6% 5 8.6% 0"/>
   <result pre="0.0% 5 6.8% 43 10.7%  Paternal and maternal history of" exact="migraine" post="4 1.7% 1 1.2% 5 1.5% 0 0.0% 0"/>
   <result pre="0.0% 0 0.0% 0 0.0% 5 1.2%  Family history of" exact="migraine" post="14 5.8% 3 3.5% 17 5.2% 2 3.4% 0"/>
   <result pre="2 3.4% 0 0.0% 2 2.7% 19 4.7% Headache and" exact="migraine" post=" Episodes of headache/migraine in the patient 14 5.8% 5"/>
   <result pre="0.9% 2 3.4% 1 6.3% 3 4.1% 6 1.5% Preputial" exact="phimosis" post="2 0.8% 0 0.0% 2 0.6% 3 5.2% 0"/>
   <result pre="tract infections Table 4 Comorbidities in nocturnal enuresis: neurobehavioral alterations," exact="spina bifida" post="occulta, gastrointestinal system, cardiovascular system, and others MNE N-MNE"/>
   <result pre="4 suffered from tension-type headache (TTH) and 17 had benign" exact="migraine" post="associated with familiarity. Considering family history, 112 (27.3%) had"/>
   <result pre="3.3% (10/300) of boys and 2% (2/101) of girls have" exact="sleep apnea." post="It is more frequent in the N-MNE group, in"/>
   <result pre="2.1% (5/242) of males and none of the females have" exact="sleep apnea." post="About 2.1% (7/327) of children with NME and 4.1%"/>
   <result pre="adenoid enlargement. SDB may present as simple snoring or as" exact="obstructive sleep apnea" post="syndrome (OSAS). In a study, OSAS occurs in 47.8%"/>
   <result pre="enlargement. SDB may present as simple snoring or as obstructive" exact="sleep apnea" post="syndrome (OSAS). In a study, OSAS occurs in 47.8%"/>
   <result pre="our study, MNE patients are more affected by headaches or" exact="migraine" post="(5.8% – 19/327) than N-MNE patients (2.7% – 2/74)."/>
   <result pre="patients (2.7% – 2/74). In the MNE group, headaches or" exact="migraine" post="in the male and female groups are alike (5.8%"/>
   <result pre="other hand, the MNE group maternal heredity for headache or" exact="migraine" post="is more common (15% – 49/327) than paternal heredity"/>
   <result pre="and 17.6% (15/85) girl with MNE have maternal inheritance for" exact="migraine" post="or headaches, in contrast with paternal inheritance (10.3% and"/>
   <result pre="have maternal inheritance for migraine, higher than paternal inheritance for" exact="migraine" post="(8% – 26/327), paternal inheritance for headache (2.4% –"/>
   <result pre="21/401 (5.2%): 4 suffered from TTH and 17 had benign" exact="migraine" post="associated with familiarity. Our 17 children with benign migraine"/>
   <result pre="benign migraine associated with familiarity. Our 17 children with benign" exact="migraine" post="associated with familiarity had a recurrent tender or pulsating,"/>
   <result pre="other side, our four children with TTH had episodes of" exact="migraine" post="without particular features and symptoms. There is contrasting theory"/>
   <result pre="and symptoms. There is contrasting theory about the onset of" exact="migraine" post="or enuretic attacks during the night; in particular, micturition"/>
   <result pre="particular, micturition tends to occur during nonrapid eye-movement sleep, while" exact="migraine" post="attacks seem to be linked to rapid eye-movement sleep"/>
   <result pre="neurometabolic studies have reported altered levels of melatonin both in" exact="migraine" post="sufferers and enuretics. Children with NE may show signs"/>
   <result pre="micturition continence. In contrast with our study, in this study," exact="migraine" post="is more common in females. Innocent heart murmur is"/>
   <result pre="boys with N-MNE. It was observed the same for preputial" exact="phimosis" post="(5.2% vs. 0.8%), hypospadias (3.4% vs. 0.8%), and hydrocele"/>
   <result pre="was observed the same for preputial phimosis (5.2% vs. 0.8%)," exact="hypospadias" post="(3.4% vs. 0.8%), and hydrocele (3.4% vs. 0%). Boys"/>
   <result pre="preputial phimosis (5.2% vs. 0.8%), hypospadias (3.4% vs. 0.8%), and" exact="hydrocele" post="(3.4% vs. 0%). Boys are more affected by neurobehavioral"/>
   <result pre="spinal dysraphisms have distinct symptomatology, whereas closed spinal dysraphisms or" exact="spina bifida" post="occulta (SBO) may cause insignificant symptoms and might be"/>
   <result pre="symptomatic as they grow up due to tethered cord syndrome," exact="cauda equina syndrome," post="or split cord syndrome with the traction and deoxygenation"/>
   <result pre="(88.8%) than non-enuretic children (8.9%). Children with encopresis and functional" exact="constipation" post="have a significant incidence of such urinary disorders as"/>
   <result pre="a significant incidence of such urinary disorders as NE, infection," exact="vesicoureteral reflux," post="and hydronephrosis.[ 1 18 19] Constipation was defined as"/>
   <result pre="desmopressin or adenotonsillectomy in the hope that the treatment of" exact="obstructive sleep apnea" post="might resolve the NE. NE is a common disorder"/>
   <result pre="or adenotonsillectomy in the hope that the treatment of obstructive" exact="sleep apnea" post="might resolve the NE. NE is a common disorder"/>
   <result pre="Ghadami MR Risk factors of nocturnal enuresis in children with" exact="attention deficit hyperactivity disorder" post="Shanghai Arch Psychiatry 2018 30 20 6 29719355 8"/>
   <result pre="of nocturnal enuresis and Modified Pediatric Epworth Scale in pediatric" exact="obstructive sleep apnea" post="patients Int J Pediatr Otorhinolaryngol 2018 105 36 9"/>
   <result pre="nocturnal enuresis and Modified Pediatric Epworth Scale in pediatric obstructive" exact="sleep apnea" post="patients Int J Pediatr Otorhinolaryngol 2018 105 36 9"/>
   <result pre="16 Kurt O Yazici CM Paketci C Nocturnal enuresis with" exact="spina bifida" post="occulta: Does it interfere behavioral management success? Int Urol"/>
   <result pre="Kilinc M Sariogullari U The relationship between nocturnal enuresis and" exact="spina bifida" post="occulta: A prospective controlled trial Urology 2018 120 216"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6761714/results/search/disease/results.xml">
   <result pre="improving pain and disability in adults with tension-type, cervicogenic, or" exact="migraine" post="headaches: protocol for a systematic review http://orcid.org/0000-0001-5202-5478 Pourahmadi Mohammadreza"/>
   <result pre="not present simultaneously during the same episode [ 9]. This" exact="neurological disorder" post="is more common among female patients (female-to-man ratio of"/>
   <result pre="most cervicogenic headaches can be differentiated from tension-type headache and" exact="migraine" post="with some overlap. In addition, according to Linde et"/>
   <result pre="and 72 h and has unilateral location [ 31]. Despite many" exact="migraine" post="publications, the mechanism of migraine is not yet well"/>
   <result pre="location [ 31]. Despite many migraine publications, the mechanism of" exact="migraine" post="is not yet well understood [ 32]. The mechanism"/>
   <result pre="is not yet well understood [ 32]. The mechanism of" exact="migraine" post="is believed to involve the trigeminal cervicogenic complex, which"/>
   <result pre="by Florencio et al. [ 34] indicated that patients with" exact="migraine" post="exhibited active TrPs in their neck extensor muscles. According"/>
   <result pre="TrPs in their neck extensor muscles. According to the IHS," exact="migraine" post="is diagnosed if a person has at least 5"/>
   <result pre="evidence that acupuncture provides additional benefit to treatment of acute" exact="migraine" post="attacks only or to routine care. However, Linde et"/>
   <result pre="acupuncture should be considered a treatment option for patients with" exact="migraine" post="willing to undergo this treatment. Despite the widespread use"/>
   <result pre="headache, cervicogenic headache, or migraine. Tension-type headache, cervicogenic headache, and" exact="migraine" post="diagnoses must be based on the International Classification of"/>
   <result pre="discriminable and important characteristics of tension-type headache, cervicogenic headache, and" exact="migraine" post="disorders, as confirmed by patients’ doctors. Important characteristics of"/>
   <result pre="headache without neck pain [ 35]. Finally, important characteristics of" exact="migraine" post="attack include recurrent headache, unilateral pain, pulsating quality, moderate"/>
   <result pre="studies will not be included. Studies including tension-type headache and" exact="migraine" post="patients with medication-overuse history according to the ICHD-3 beta"/>
   <result pre="will be conducted separately on tension-type headache, cervicogenic headache, and" exact="migraine" post="within each study design. In the presence of a"/>
   <result pre="Jafari S Sprott J Hatef B A chaotic model of" exact="migraine" post="headache considering the dynamical transitions of this cyclic disease"/>
   <result pre="activation of superficial neck and extensor muscles in women with" exact="migraine" post="Clin J Pain 2017 33 238 245 27258994 35."/>
   <result pre="Brinkhaus B, Manheimer E, Vickers A, White AR. Acupuncture for" exact="migraine" post="prophylaxis: Cochrane Database of Systematic Reviews; 2009;1:CD001218. 52. Moher"/>
   <result pre="A comparison between personality characteristic of the people suffering from" exact="migraine" post="headache and personality characteristic of healthy people Procedia Soc"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6771736/results/search/disease/results.xml">
   <result pre="CCBs Calcium channel blockers cGMP Cyclic guanosine monophosphate CHD Congenital" exact="heart disease" post="EMA European Medicines Agency ERAs Endothelin receptor antagonists FDA"/>
   <result pre="pulmonary arterial hypertension (PAH) (Group 1), PH due to left" exact="heart disease" post="(Group 2), PH due to lung diseases and/or hypoxia"/>
   <result pre="due to lung diseases and/or hypoxia (Group 3), chronic thromboembolic" exact="pulmonary hypertension" post="(Group 4), and PH with unclear and/or multifactorial mechanisms"/>
   <result pre="(PVR) ≥3 Wood units × m 2 (≈240 dyn s cm –5), in the absence of" exact="lung disease" post="and Group 4 or 5 PH. 1, 2, 3"/>
   <result pre="a new definition for Group 4 to include chronic thromboembolic" exact="pulmonary hypertension" post="(CTEPH) and other pulmonary artery obstructions. 1, 3 1.1"/>
   <result pre="accounts for the majority of cases, and PH associated with" exact="lung disease" post="(Group 3), of which the most common form is"/>
   <result pre="PAH in children are idiopathic (iPAH), heritable gene defects, and" exact="congenital heart disease" post="(CHD); however, connective tissue disease, human immunodeficiency virus, drugs,"/>
   <result pre="in children are idiopathic (iPAH), heritable gene defects, and congenital" exact="heart disease" post="(CHD); however, connective tissue disease, human immunodeficiency virus, drugs,"/>
   <result pre="study in 50 children (age, 2 mo‐2 y) with high‐altitude" exact="heart disease" post="and severe PAH Sildenafil 1 mg/kg/day • Sildenafil reduced mPAP"/>
   <result pre="Retrospective chart review of 25 children (age, &amp;lt;2 y) with chronic" exact="lung disease" post="and PH 1.5–8.0 mg/kg/day • Hemodynamic improvement in 88% of"/>
   <result pre="(62‐46 mm Hg; P = .041) Abbreviations: 6MWD, 6‐minute walking distance; CHD," exact="congenital heart disease;" post="CI, confidence interval; FC, functional class; hPAH, heritable pulmonary"/>
   <result pre="mm Hg; P = .041) Abbreviations: 6MWD, 6‐minute walking distance; CHD, congenital" exact="heart disease;" post="CI, confidence interval; FC, functional class; hPAH, heritable pulmonary"/>
   <result pre="NYHA, New York Heart Association; PAH, pulmonary arterial hypertension; PH," exact="pulmonary hypertension;" post="pO 2, partial pressure of oxygen; PVO 2, peak"/>
   <result pre=", et al. Haemodynamic definitions and updated clinical classification of" exact="pulmonary hypertension." post="Eur Respir J. 2019; 53: 1801913. 30545968 4 Berger"/>
   <result pre=", Roofthooft MT , Hillege HL , et al. Pediatric" exact="pulmonary hypertension" post="in The Netherlands: Epidemiology and characterization during the period"/>
   <result pre="JD , Romer LH . Trends in hospitalization for pediatric" exact="pulmonary hypertension." post="Pediatrics. 2015; 136: 241‐ 250. 26148956 12 Vorhies EE"/>
   <result pre="12 Vorhies EE , Ivy DD . Drug treatment of" exact="pulmonary hypertension" post="in children. Paediatr Drugs. 2014; 16: 43‐ 65. 24114695"/>
   <result pre="Badesch D , Gibbs JSR , et al. Diagnosis of" exact="pulmonary hypertension." post="Eur Respir J. 2019; 53: 1801904. 30545972 14 Beghetti"/>
   <result pre=", Schulze‐Neick I , et al. Diagnostic evaluation of paediatric" exact="pulmonary hypertension" post="in current clinical practice. Eur Respir J. 2013; 42:"/>
   <result pre="Expert consensus statement on the diagnosis and treatment of paediatric" exact="pulmonary hypertension." post="The European Paediatric Pulmonary Vascular Disease Network, endorsed by"/>
   <result pre="IR . Right heart catheterisation: Best practice and pitfalls in" exact="pulmonary hypertension." post="Eur Respir Rev. 2015; 24: 642‐ 652. 26621978 17"/>
   <result pre="Hemodynamic and genetic analysis in children with idiopathic, heritable, and" exact="congenital heart disease" post="associated pulmonary arterial hypertension . Respir Res. 2013; 14:"/>
   <result pre="and genetic analysis in children with idiopathic, heritable, and congenital" exact="heart disease" post="associated pulmonary arterial hypertension . Respir Res. 2013; 14:"/>
   <result pre="Apitz C , Michel‐Behnke I. Pulmonary hypertension in children with" exact="congenital heart disease" post="(PAH‐CHD, PPHVD‐CHD). Expert consensus statement on the diagnosis and"/>
   <result pre="C , Michel‐Behnke I. Pulmonary hypertension in children with congenital" exact="heart disease" post="(PAH‐CHD, PPHVD‐CHD). Expert consensus statement on the diagnosis and"/>
   <result pre="Expert consensus statement on the diagnosis and treatment of paediatric" exact="pulmonary hypertension." post="The European Paediatric Pulmonary Vascular Disease Network, endorsed by"/>
   <result pre=", et al. Genetic testing and blood biomarkers in paediatric" exact="pulmonary hypertension." post="Expert consensus statement on the diagnosis and treatment of"/>
   <result pre="Expert consensus statement on the diagnosis and treatment of paediatric" exact="pulmonary hypertension." post="The European Paediatric Pulmonary Vascular Disease Network, endorsed by"/>
   <result pre="and survival in children with pulmonary arterial hypertension: the UK" exact="pulmonary hypertension" post="service for children 2001‐2006 . Heart. 2009; 95: 312‐"/>
   <result pre="al. Clinical classification in pediatric pulmonary arterial hypertension associated with" exact="congenital heart disease" post=". Pulm Circ. 2016; 6: 302‐ 312. 27683607 27"/>
   <result pre="Clinical classification in pediatric pulmonary arterial hypertension associated with congenital" exact="heart disease" post=". Pulm Circ. 2016; 6: 302‐ 312. 27683607 27"/>
   <result pre=", Abman SH , Barst RJ , et al. Pediatric" exact="pulmonary hypertension." post="J Am Coll Cardiol. 2013; 62: D117‐ D126. 24355636"/>
   <result pre="SP , Howard LS , et al. Treatment goals of" exact="pulmonary hypertension." post="J Am Coll Cardiol. 2013; 62: D73‐ D81. 24355644"/>
   <result pre=", Rubin LJ , Simonneau G. Improving patient outcomes in" exact="pulmonary hypertension." post="Eur Respir Rev. 2015; 24: 550‐ 551. 26621969 39"/>
   <result pre="imbalance between the excretion of thromboxane and prostacyclin metabolites in" exact="pulmonary hypertension" post=". N Engl J Med. 1992; 327: 70‐ 75."/>
   <result pre="synthase expression is decreased in lungs from patients with severe" exact="pulmonary hypertension" post=". Am J Respir Crit Care Med. 1999; 159:"/>
   <result pre=", Maislin G , Fishman AP . Vasodilator therapy for" exact="primary pulmonary hypertension" post="in children. Circulation. 1999; 99: 1197‐ 1208. 10069788 45"/>
   <result pre="Maislin G , Fishman AP . Vasodilator therapy for primary" exact="pulmonary hypertension" post="in children. Circulation. 1999; 99: 1197‐ 1208. 10069788 45"/>
   <result pre="of subcutaneous treprostinil infusions in the treatment of severe pediatric" exact="pulmonary hypertension" post=". Int J Cardiol. 2018; 264: 153‐ 157. 29650343"/>
   <result pre=", Beghetti M. Inhaled iloprost for the control of acute" exact="pulmonary hypertension" post="in children: a systematic review . Pediatr Crit Care"/>
   <result pre=", Haworth SG . Response to bosentan in children with" exact="pulmonary hypertension." post="Heart. 2006; 92: 664‐ 670. 16216850 53 Beghetti M"/>
   <result pre=", Osterloh IH , Grimminger F. Sildenafil: from angina to" exact="erectile dysfunction" post="to pulmonary hypertension and beyond. Nat Rev Drug Discov."/>
   <result pre=", Grimminger F. Sildenafil: from angina to erectile dysfunction to" exact="pulmonary hypertension" post="and beyond. Nat Rev Drug Discov. 2006; 5: 689‐"/>
   <result pre="responses to oral sildenafil during invasive testing in children with" exact="pulmonary hypertension" post=". J Am Coll Cardiol. 2010; 55: 1456‐ 1462."/>
   <result pre="The role of preoperative sildenafil therapy in controlling of postoperative" exact="pulmonary hypertension" post="in children with ventricular septal defects . J Cardiovasc"/>
   <result pre="the tolerability of intermittent intravenous sildenafil in pediatric patients with" exact="pulmonary hypertension" post=". J Pediatr Pharmacol Ther. 2016; 21: 419‐ 425."/>
   <result pre="R , Russolillo V , et al. Sildenafil therapy for" exact="pulmonary hypertension" post="before and after pediatric congenital heart surgery . Tex"/>
   <result pre="with pulmonary arterial hypertension associated with the different types of" exact="congenital heart disease" post=". Clin Cardiol. 2011; 34: 513‐ 518. 21678455 75"/>
   <result pre="pulmonary arterial hypertension associated with the different types of congenital" exact="heart disease" post=". Clin Cardiol. 2011; 34: 513‐ 518. 21678455 75"/>
   <result pre="safety of oral sildenafil in children with Down syndrome and" exact="pulmonary hypertension" post=". BMC Cardiovasc Disord. 2017; 17: 177. 28676038 78"/>
   <result pre="and safety of sildenafil in the treatment of high altitude" exact="heart disease" post="associated with severe pulmonary arterial hypertension in children: A"/>
   <result pre=". Safety and efficacy of sildenafil therapy in children with" exact="pulmonary hypertension." post="Int J Cardiol. 2005; 100: 267‐ 273. 15823634 81"/>
   <result pre=", Abman SH . Effects of long‐term sildenafil treatment for" exact="pulmonary hypertension" post="in infants with chronic lung disease . J Pediatr."/>
   <result pre="long‐term sildenafil treatment for pulmonary hypertension in infants with chronic" exact="lung disease" post=". J Pediatr. 2009; 154: 379‐ 384. 384 e371‐372."/>
   <result pre="JP , Evgenov OV . Soluble guanylate cyclase stimulators in" exact="pulmonary hypertension." post="Handb Exp Pharmacol. 2013; 218: 279‐ 313. 24092345 97"/>
   <result pre="acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in" exact="pulmonary hypertension" post=". Eur Respir J. 2009; 33: 785‐ 792. 19129292"/>
   <result pre="al. Clinical trials in neonates and children: Report of the" exact="pulmonary hypertension" post="academic research consortium pediatric advisory committee . Pulm Circ."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6773914/results/search/disease/results.xml">
   <result pre="be useful in decreasing symptoms such as muscular spasm, dystonia," exact="migraine" post="headaches and TMD. Therefore, the aim of the present"/>
   <result pre="the use of this toxin to relieve muscular spasm, dystonia," exact="migraine" post="headaches, blepharospasm, strabismus, spasmodic torticollis, removal of cleft lip"/>
   <result pre="toxin to relieve muscular spasm, dystonia, migraine headaches, blepharospasm, strabismus," exact="spasmodic torticollis," post="removal of cleft lip scars and the capability to"/>
   <result pre="spasm, dystonia, migraine headaches, blepharospasm, strabismus, spasmodic torticollis, removal of" exact="cleft lip" post="scars and the capability to permanently accept botulinum toxin."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6778936/results/search/disease/results.xml">
   <result pre="original work is properly cited. Abstract Background Recurrent painful ophthalmoplegic" exact="neuropathy" post="(RPON), previously known as ophthalmoplegic migraine (OM), is an"/>
   <result pre="Background Recurrent painful ophthalmoplegic neuropathy (RPON), previously known as ophthalmoplegic" exact="migraine" post="(OM), is an uncommon disorder with repeated episodes of"/>
   <result pre="an uncommon disorder with repeated episodes of ocular cranial nerve" exact="neuropathy" post="associated with ipsilateral headache. The age of presentation is"/>
   <result pre="paresis with ipsilateral headache, showed a nodular lesion described as" exact="schwannoma" post="of III cranial nerve. Then, we reviewed the literature"/>
   <result pre="nerves and other facial pains&quot; includes the recurrent painful ophthalmoplegic" exact="neuropathy" post="(RPON), a condition characterized by repeated attacks of paresis"/>
   <result pre="(1987) of the ICHD had considered this condition as a" exact="migraine" post="variant [ 6], but in the ICHD-II (2004), the"/>
   <result pre="10]. Moreover, few MRI studies show the presence of a" exact="schwannoma" post="in some patients with RPON disease. Isolated schwannomas are"/>
   <result pre="branch of the VIII nerve; otherwise oculomotor nerve schwannomas without" exact="neurofibromatosis" post="are very rare, and only few cases with pediatric"/>
   <result pre="paresis with ipsilateral headache showed a nodular lesion described as" exact="schwannoma" post="of III cranial nerve. Then, we reviewed the literature"/>
   <result pre="of Science. The following combinations of keywords were searched: &quot;opthalmoplegic" exact="migraine" post="AND magnetic resonance imaging&quot; and &quot;recurrent painful ophthalmoplegic neuropathy"/>
   <result pre="&quot;opthalmoplegic migraine AND magnetic resonance imaging&quot; and &quot;recurrent painful ophthalmoplegic" exact="neuropathy" post="AND magnetic resonance imaging.&quot; The initial search returned 227"/>
   <result pre="the age of 4. He had his first episode of" exact="migraine" post="associated with ocular pain and ptosis in the right"/>
   <result pre="his first episode of migraine associated with ocular pain and" exact="ptosis" post="in the right eyelid, lasting 24 hours, in Jun"/>
   <result pre="(Jan 2011), he had a heavier and persistent episode of" exact="migraine" post="associated with right ocular pain (partial responsiveness to administration"/>
   <result pre="Organs, University of Bari &quot;Aldo Moro,&quot; Italy. Family history of" exact="migraine" post="in both parents, multiple sclerosis in the father's family,"/>
   <result pre="&quot;Aldo Moro,&quot; Italy. Family history of migraine in both parents," exact="multiple sclerosis" post="in the father's family, and gastric neoplastic disease in"/>
   <result pre="Jul 2013 and Jun 2016, of OM, with ocular pain" exact="ptosis" post="in the right eyelid and diplopia. In both episodes"/>
   <result pre="near to perimesencephalic and interpeduncular cisterns, suggesting an oculomotor nerve" exact="schwannoma" post="without any vascular malformation (Figures 1 and 2). The"/>
   <result pre="the age of 4 years agreeing to diagnostic criteria of" exact="migraine" post="without aura. Since he was 7 years old, the"/>
   <result pre="he was 7 years old, the patient started to have" exact="migraine" post="episodes with the same clinical features but lasting more"/>
   <result pre="after contrast, which could be described as III cranial nerve" exact="schwannoma" post="(Figures 1 and 2). This case highlights the important"/>
   <result pre="a syndrome that may be &quot;primary&quot; as a variant of" exact="migraine" post="with aura for cases with normal imaging and spontaneous"/>
   <result pre="normal imaging and spontaneous resolution and &quot;secondary&quot; as a cranial" exact="neuropathy" post="with focal nerve enhancement on neuroimaging [ 31]. The"/>
   <result pre="ICHD classifications over time) showed only three cases with isolated" exact="schwannoma" post="of the oculomotor nerve associated with migraine and oculomotor"/>
   <result pre="cases with isolated schwannoma of the oculomotor nerve associated with" exact="migraine" post="and oculomotor nerve palsy after a long time history"/>
   <result pre="after a long time history of III nerve paresis and/or" exact="migraine" post="( Table 1). In 2005, Murakami et al. published"/>
   <result pre="Murakami et al. published the first histologically proved case of" exact="schwannoma" post="in an 11-year-old girl with a previous history of"/>
   <result pre="continuously. Histopathological finding after surgical treatment confirmed the diagnosis of" exact="schwannoma" post="[ 35]. Riahi et al. in 2014 published the"/>
   <result pre="of tissue in the cavernous sinus suggesting a third nerve" exact="schwannoma" post="[ 42]. Jibia et al. in 2015 published the"/>
   <result pre="of a 13-year-old girl with a previous medical history of" exact="migraine" post="since she was 6 years old. In coincidence of"/>
   <result pre="disabling ophthalmic migraine, the brain MRI revealed a right nodular" exact="schwannoma" post="located within the cisternal segment of the oculomotor nerve"/>
   <result pre="speculative explanations of the eventual pathophysiological relationship between RPON and" exact="schwannoma" post="have been proposed. The first one is related to"/>
   <result pre="a migrainous headache. According to this hypothesis, the oculomotor nerve" exact="schwannoma" post="mimics RPON, so the painful ophthalmoplegia may be considered"/>
   <result pre="[ 35, 44]. A review of pediatric isolated oculomotor nerve" exact="schwannoma" post="showed OM as one among the clinical signs of"/>
   <result pre="and remyelination may be associated with a potential transformation into" exact="schwannoma" post="from Schwann cells proliferation. According to this interpretation, isolated"/>
   <result pre="from Schwann cells proliferation. According to this interpretation, isolated oculomotor" exact="schwannoma" post="may be considered as a long-term complication of RPON."/>
   <result pre="to clarify whether in some patients an ocular motor nerve" exact="schwannoma" post="may closely mimic RPON or, alternatively, if the RPON"/>
   <result pre="F. Petruzzelli M. G. Procoli U. Dicuonzo F. Ophthalmoplegic migraine:" exact="migraine" post="or oculomotor neuropathy? Cephalalgia 2012 32 16 1208 1215"/>
   <result pre="I. Casselman J. Magnetic resonance imaging in a case of" exact="migraine" post="with ophthalmoplegia European Journal of Neurology 1997 4 1"/>
   <result pre="of MRI abnormalities of the oculomotor nerve in childhood ophthalmoplegic" exact="migraine" post="Cephalalgia 1999 19 7 655 659 10.1046/j.1468-2982.1999.019007655.x 10524659 19"/>
   <result pre="Yeh J.-H. Chiu H.-C. Chen W.-H. A case of ophthalmoplegic" exact="migraine" post="mimicking ocular myasthenia gravis European Neurology 2005 53 4"/>
   <result pre="H.-C. Chen W.-H. A case of ophthalmoplegic migraine mimicking ocular" exact="myasthenia gravis" post="European Neurology 2005 53 4 215 217 10.1159/000086734 16015006"/>
   <result pre="Keene D. L. Jacob P. Humphreys P. Ophthalmoplegic migraine: inflammatory" exact="neuropathy" post="with secondary migraine? Canadian Journal of Neurological Sciences/Journal Canadien"/>
   <result pre="Anderson R. T. Brown D. Magnetic resonance imaging in ophthalmoplegic" exact="migraine" post="of children Journal of American Association for Pediatric Ophthalmology"/>
   <result pre="P. Goadsby P. J. Ophthalmoplegic &quot;migraine&quot; or recurrent ophthalmoplegic cranial" exact="neuropathy" post="Journal of Child Neurology 2012 27 6 759 766"/>
   <result pre="10.1177/0883073811426502 22241707 24 Verma A. Kumar A. Singh V. Ophthalmoplegic" exact="migraine" post="in a child, an accelerated clinical and radiologic response"/>
   <result pre="357 359 25 Shin D.-J. Kim J.-H. Kang S.-S. Ophthalmoplegic" exact="migraine" post="with reversible thalamic ischemia. Shown by brain SPECT Headache:"/>
   <result pre="135 10.1046/j.1526-4610.2002.02029.x 26 Weiss A. H. Phillips J. O. Ophthalmoplegic" exact="migraine" post="Pediatric Neurology 2004 30 1 64 66 10.1016/s0887-8994(03)00424-7 14738955"/>
   <result pre="de l’enfant: place du syndrome de Tolosa-Hunt et de la" exact="migraine" post="ophtalmoplégique Archives de Pédiatrie 2007 14 8 996 999"/>
   <result pre="Prasad V. Rajam L. Magnetic resonance imaging findings in ophthalmoplegic" exact="migraine" post="Journal of Postgraduate Medicine 2009 55 2 137 138"/>
   <result pre="Murakami T. Funatsuka M. Komine M. et al. Oculomotor nerve" exact="schwannoma" post="mimicking ophthalmoplegic migraine Neuropediatrics 2005 36 6 395 398"/>
   <result pre="M. Komine M. et al. Oculomotor nerve schwannoma mimicking ophthalmoplegic" exact="migraine" post="Neuropediatrics 2005 36 6 395 398 10.1055/s-2005-873056 16429381 36"/>
   <result pre="Park M. H. Kim B. J. Lee D. H. Ophthalmoplegic" exact="migraine" post="with alternating unilateral and bilateral internal ophthalmoplegia Headache: The"/>
   <result pre="Castro J. Gomes L. B. Jacinto S. Dias A. Ophthalmoplegic" exact="migraine" post="and infundibular dilatation of a cerebral artery Headache: The"/>
   <result pre="48 9 1372 1374 10.1111/j.1526-4610.2008.01179.x 38 Arasho B. D. Ophthalmoplegic" exact="migraine" post="in a 15-year-old Ethiopian: case report and literature review"/>
   <result pre="P. Computed tomography and magnetic resonance imaging findings in ophthalmoplegic" exact="migraine" post="Pediatric Neurology 2010 42 6 434 436 10.1016/j.pediatrneurol.2010.02.005 20472197"/>
   <result pre="Peterson B. W. Lara A. K. McGrath T. M. Ophthalmoplegic" exact="migraine" post="Headache: The Journal of Head and Face Pain 2011"/>
   <result pre="P. Monteiro M. L. Magnetic resonance appearance of recurrent ophthalmoplegic" exact="migraine" post="Arquivos de Neuro-Psiquiatria 2012 70 1 p. 77 10.1590/s0004-282x2012000100018"/>
   <result pre="Ben Youssef-Turki I. Walha K. et al. Ophtalmoplégie douloureuse récidivante:" exact="migraine" post="ophtalmoplégique ou schwannome du nerf oculomoteur ? Pratique Neurologique-FMC"/>
   <result pre="Jibia A. Chenin L. Lefranc M. Peltier J. Oculomotor nerve" exact="schwannoma" post="in a child: case report and literature review Neurochirurgie"/>
   <result pre="(Jan 2011); (b) 5-6 mm nodular mass suggesting an oculomotor nerve" exact="schwannoma" post="(Oct 2018). Figure 2 Axial T1-weighted (a) and axial"/>
   <result pre="43 patients under the age of 18 years with ophthalmoplegic" exact="migraine" post="or recurrent painful ophthalmoplegic neuropathy. Author Reference Case M/F"/>
   <result pre="Severe right unilateral headache with photophobia and vomiting Diplopia and" exact="ptosis" post="of the right upper eyelid MRI: marked thickening and"/>
   <result pre="6 6 Headache in the left orbital region Moderate left" exact="ptosis" post="of the eyelid, mild mydriasis, and displacement of the"/>
   <result pre="nausea, vomiting, and sensitivity to light, sound, and smell Left" exact="ptosis" post="with paresis of upward deviation in the left eye"/>
   <result pre="Farage et al. [ 34] 19 M 16 16 Pulsatile" exact="migraine" post="associated with nausea Ptosis, mydriasis, and divergent strabismus MRI"/>
   <result pre="16 Pulsatile migraine associated with nausea Ptosis, mydriasis, and divergent" exact="strabismus" post="MRI weighted in T1 with contrast: enhanced signal at"/>
   <result pre="Right eye pain Abrupt onset right pupil dilatation, diplopia, and" exact="ptosis" post="Acute MRI: an area of prominent thickening and contrast"/>
   <result pre="20] 25 M 1 1 Not described Abrupt onset left" exact="ptosis" post="and eye deviation MRI: a small area of increased"/>
   <result pre="months later: headache, moderate intensity; episodes &amp;lt;24 hours Right eye" exact="ptosis" post="with mydriasis, complete III nerve palsy MRI: enlargement and"/>
   <result pre="F 3 10 Ipsilateral, throbbing headache Acute onset of right" exact="ptosis" post="with lateral/inferior eye deviation MRI: isolated enhancement of the"/>
   <result pre="2010 2011 12 Left side headache with vomiting Left eye" exact="ptosis" post="and diplopia Two cerebral MRI (2008–2010) normal 3 years"/>
   <result pre="42 F 7 13 Migraine with shimmering scotomas Incomplete right" exact="ptosis" post="with semi-midriasis, diplopia MRI: a right nodular schwannoma located"/>
   <result pre="Incomplete right ptosis with semi-midriasis, diplopia MRI: a right nodular" exact="schwannoma" post="located within the cisternal segment of the oculomotor nerve"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6780403/results/search/disease/results.xml">
   <result pre="landscape of randomized placebo controlled trials utilizing probiotic interventions as" exact="migraine" post="prophylaxis. Searches were conducted of scientific databases including PubMed,"/>
   <result pre="a dichotomy of results—one trial reported no significant change in" exact="migraine" post="frequency and intensity, while the second trial reported highly"/>
   <result pre="a series of recommendations for future probiotic–migraine research are included." exact="migraine" post="probiotics prophylaxis gut–brain axis systematic review 1. Introduction Migraine"/>
   <result pre="absence of aura symptoms (~70%) and (2) monthly burden: episodic" exact="migraine" post="(&amp;lt;15 headache days per month; &amp;gt;90%) and chronic migraine"/>
   <result pre="episodic migraine (&amp;lt;15 headache days per month; &amp;gt;90%) and chronic" exact="migraine" post="(15 or more headache days per month; &amp;lt;10%) ["/>
   <result pre="female sex hormones during the reproductive years. The pathophysiology of" exact="migraine" post="is complex and involves genetic, metabolic, and hormonal elements"/>
   <result pre="the brain, and indeed have a recently suggested role in" exact="migraine" post="headaches [ 6]. The microbiome–gut–brain axis consists of at"/>
   <result pre="that there are low levels of 5-HT before and between" exact="migraine" post="attacks, with high levels being seen during attacks, the"/>
   <result pre="Stress has been identified as the most common trigger for" exact="migraine" post="attacks [ 17], and evidence suggests there may be"/>
   <result pre="a well-documented pro-inflammatory effect. The relevance of lipopolysaccharides (LPS) to" exact="migraine" post="headache is highlighted by evidence that it sensitizes pain"/>
   <result pre="sensitizes pain receptors in trigeminal sensory neurons (those involved in" exact="migraine" post="headaches) [ 19]. Research has identified that probiotics are"/>
   <result pre="may explain an additional mechanism by which they can influence" exact="migraine" post="headaches. The primary goals of migraine treatments include relieving"/>
   <result pre="which they can influence migraine headaches. The primary goals of" exact="migraine" post="treatments include relieving pain, restoring function, and reducing headache"/>
   <result pre="restoring function, and reducing headache frequency with current treatments for" exact="migraine" post="centering on decreasing the frequency, severity, and duration of"/>
   <result pre="migraine centering on decreasing the frequency, severity, and duration of" exact="migraine" post="attacks [ 22, 23, 24]. Recently, probiotics have become"/>
   <result pre="aims to discuss the effectiveness of probiotic interventions in treating" exact="migraine" post="symptoms based on published randomized controlled trials. 2. Materials"/>
   <result pre="controlled trials of adult male and female participants diagnosed with" exact="migraine" post="based on defined clinical criteria, who were administered any"/>
   <result pre="control group or placebo with results reported for frequency of" exact="migraine" post="attacks and/or severity of migraine attacks at least at"/>
   <result pre="results reported for frequency of migraine attacks and/or severity of" exact="migraine" post="attacks at least at baseline and at the end"/>
   <result pre="the following symptoms were extracted from the included articles: demographics," exact="migraine" post="diagnostic criteria, migraine symptoms (severity, frequency, duration), quality of"/>
   <result pre="were extracted from the included articles: demographics, migraine diagnostic criteria," exact="migraine" post="symptoms (severity, frequency, duration), quality of life or disability"/>
   <result pre="or breastfeeding. In addition, de Roos excluded patients with chronic" exact="migraine" post="or with inflammatory bowel disease, while Martami excluded patients"/>
   <result pre="in CRP seen in the probiotic arm of the chronic" exact="migraine" post="(CM) group in the Martami study. Both studies used"/>
   <result pre="study. Both studies used daily diaries to obtain information about" exact="migraine" post="frequency and intensity; neither of which were validated. Migraine"/>
   <result pre="entirely comparable and suggest that Martami’s cohort had more severe" exact="migraine" post="attacks, as the total average at baseline was higher"/>
   <result pre="and 6.4 in placebo). De Roos demonstrated no change in" exact="migraine" post="symptoms after the intervention, while the other study reported"/>
   <result pre="intervention, while the other study reported significant improvement in the" exact="migraine" post="symptoms in both chronic and episodic migraine sufferers. Frequency"/>
   <result pre="improvement in the migraine symptoms in both chronic and episodic" exact="migraine" post="sufferers. Frequency of migraine attacks (migraine days) at baseline"/>
   <result pre="symptoms in both chronic and episodic migraine sufferers. Frequency of" exact="migraine" post="attacks (migraine days) at baseline were reported based on"/>
   <result pre="that the de Roos cohort had a similar frequency of" exact="migraine" post="attacks when compared to the episodic group in Martami’s"/>
   <result pre="paper. However, reporting of the effect of the intervention on" exact="migraine" post="days was different between the studies. De Roos’ reporting"/>
   <result pre="18 days in the probiotic arm and 0 to 15" exact="migraine" post="days in the placebo group. This was consistent with"/>
   <result pre="group. This was consistent with the results reported for the" exact="migraine" post="disability assessment test (MIDAS) questionnaire by the same author"/>
   <result pre="disability assessment test (MIDAS) questionnaire by the same author (total" exact="migraine" post="days over a 3 month period) suggesting 15 migraine"/>
   <result pre="(total migraine days over a 3 month period) suggesting 15" exact="migraine" post="days over 3 months both at baseline and at"/>
   <result pre="trial. Martami reported the effect of the intervention on the" exact="migraine" post="days at the end of the trial. Intervention in"/>
   <result pre="Roos trial did not translate into a significant reduction in" exact="migraine" post="days at any point of the trial, while Martami"/>
   <result pre="of the trial, while Martami demonstrated a reduction of 9.6" exact="migraine" post="days in the CM group and 2.6 days reduction"/>
   <result pre="the CM group and 2.6 days reduction in the episodic" exact="migraine" post="(EM) group, which was significantly different to results seen"/>
   <result pre="de Roos showed no difference in the median number of" exact="migraine" post="days between probiotic and placebo arms. The change in"/>
   <result pre="between probiotic and placebo arms. The change in severity of" exact="migraine" post="attacks was also different between the studies. Martami found"/>
   <result pre="the studies. Martami found a reduction in the severity of" exact="migraine" post="episodes in EM (mean change −2.1 points) and in"/>
   <result pre="in de Roos’ study. De Roos did not report on" exact="migraine" post="duration (despite the fact that it was a question"/>
   <result pre="question included in the daily diary), whereas Martami reported that" exact="migraine" post="duration remained unchanged in the EM cohort, while CM"/>
   <result pre="while CM patients had a significant decrease in duration of" exact="migraine" post="attacks compared to placebo (−0.59 hours). De Roos included"/>
   <result pre="arm had a reduction of 2 or more days in" exact="migraine" post="frequency from baseline to the end of the trial;"/>
   <result pre="recent years, the role played by the gut microbiota in" exact="migraine" post="pathophysiology remains to be convincingly established. This situation is"/>
   <result pre="number of human clinical studies investigating the gut microbiota in" exact="migraine" post="patients and how its manipulation might impact on its"/>
   <result pre="reproducible? The exact nature the gut microbiome of the typical" exact="migraine" post="patient is yet to be fully understood. Analysis of"/>
   <result pre="publication, Georgescu et al. demonstrated greater levels of dysbiosis in" exact="irritable bowel syndrome" post="(IBS) patients with migraine when compared to IBS controls"/>
   <result pre="levels of dysbiosis in irritable bowel syndrome (IBS) patients with" exact="migraine" post="when compared to IBS controls without a history of"/>
   <result pre="migraine when compared to IBS controls without a history of" exact="migraine" post="[ 32]. While these two papers illustrate the need"/>
   <result pre="that differences exist in the microbiome of patients that experience" exact="migraine" post="when compared to migraine-free controls. Neither of the randomized"/>
   <result pre="[ 27], failed to demonstrate a statistically significant change in" exact="migraine" post="frequency between the probiotic intervention group and placebo. In"/>
   <result pre="et al. [ 28], demonstrated an approximately 40% reduction in" exact="migraine" post="frequency in the probiotic groups. In their study of"/>
   <result pre="patients, Martami et al. [ 28] saw a reduction in" exact="migraine" post="frequency of 2.6 days per month compared to placebo."/>
   <result pre="a recent Cochrane review and meta-analysis of topiramate as a" exact="migraine" post="prophylaxis for EM patients, Linde et al. [ 33]"/>
   <result pre="Martami study demonstrates a statistically and clinically significant reduction in" exact="migraine" post="frequency in both EM and CM patients given the"/>
   <result pre="the Martami study. This particular population saw large reductions in" exact="migraine" post="frequency, but counter-intuitively saw a statistically significant increase in"/>
   <result pre="the microorganisms included here might be more—or less—effective at improving" exact="migraine" post="symptoms. Microbiome and probiotic research is conducted at strain"/>
   <result pre="lines of evidence hint at the role of bacteria in" exact="migraine" post="pathogenesis, however, which elements are more, or less, important"/>
   <result pre="example, multiple lines of evidence point towards an overlap between" exact="migraine" post="and certain GI diagnoses, suggesting that an impaired gut"/>
   <result pre="an impaired gut barrier function may play a role in" exact="migraine" post="pathogenesis [ 39]. Impaired gut barrier function can lead"/>
   <result pre="Equally important is consideration of the role of serotonin in" exact="migraine" post="pathophysiology—and the role of the gut microbiota in producing"/>
   <result pre="serotonin; both within the gut and within the CNS. Intra-ictally," exact="migraine" post="is known to be a low serotonin state and"/>
   <result pre="suggests that depletion of tryptophan (the precursor to serotonin) exacerbates" exact="migraine" post="symptoms [ 40]. Multiple probiotic strains produce serotonin or"/>
   <result pre="both with other microbiome interventions and also with conventional pharmacological" exact="migraine" post="studies. Based on the studies conducted to date, the"/>
   <result pre="as shown in Table 3, could be adopted for future" exact="migraine" post="studies. 5. Conclusions With nearly 70 trials of probiotics"/>
   <result pre="between studies and between probiotic and conventional pharmacological interventions for" exact="migraine" post="prophylaxis. Supplementary Materials The following are available online at"/>
   <result pre="criteria ICHD-II ICHD-III beta ICHD-III beta Migraine subtypes included Episodic" exact="migraine" post="Chronic migraine Episodic migraine Probiotic Ecologic Barrier, Winclove Bifidobacterium"/>
   <result pre="ICHD-III beta ICHD-III beta Migraine subtypes included Episodic migraine Chronic" exact="migraine" post="Episodic migraine Probiotic Ecologic Barrier, Winclove Bifidobacterium bifidum W23"/>
   <result pre="ICHD-III beta Migraine subtypes included Episodic migraine Chronic migraine Episodic" exact="migraine" post="Probiotic Ecologic Barrier, Winclove Bifidobacterium bifidum W23 Bifidobacterium lactis"/>
   <result pre="jcm-08-01441-t003_Table 3 Table 3 Recommendations for future probiotic trials in" exact="migraine" post="sufferers. Recommendations for future probiotic trials in migraine sufferers"/>
   <result pre="trials in migraine sufferers. Recommendations for future probiotic trials in" exact="migraine" post="sufferers Exclusion criteria Standardized exclusion criteria: use of medications"/>
   <result pre="Inclusion criteria Studies should explicitly focus on chronic or episodic" exact="migraine" post="sufferers and clearly indicate which group was studied. Studies"/>
   <result pre="clearly indicate which group was studied. Studies should focus on" exact="migraine" post="with aura and without aura and clearly indicate which"/>
   <result pre="cessation effects starts to diminish. General Use of validated standardized" exact="migraine" post="symptom questionnaires/diaries for recording of migraine frequency (frequency of"/>
   <result pre="Use of validated standardized migraine symptom questionnaires/diaries for recording of" exact="migraine" post="frequency (frequency of migraine onsets), duration (hours), and severity"/>
   <result pre="migraine symptom questionnaires/diaries for recording of migraine frequency (frequency of" exact="migraine" post="onsets), duration (hours), and severity (validated scale or a"/>
   <result pre="the effect of intervention in groups with different severities of" exact="migraine" post="symptoms. Inclusion of standard reporting metrics, such as 50%"/>
   <result pre="and non-responders, with explicit definition of responders (e.g., reduction of" exact="migraine" post="duration by over 2 days per month). Preferably, microbiome"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6780832/results/search/disease/results.xml">
   <result pre="associated with comorbid psychiatric concerns including depression, anxiety disorders, and" exact="post-traumatic stress disorder" post="(PTSD) [ 112] and the co-occurrence is likely bidirectional"/>
   <result pre="with chronic right arm pain secondary to a diagnosis of" exact="complex regional pain syndrome" post="(CRPS), type 1. Similar to results found within acute"/>
   <result pre="controlled study of minimal-contact thermal biofeedback treatment in children with" exact="migraine" post="J. Pediatr. Psychol. 2002 27 109 119 10.1093/jpepsy/27.2.109 11821495"/>
   <result pre="and after an integrative training program for adolescents with juvenile" exact="fibromyalgia" post="Pediatr. Rheumatol. Online J. 2016 14 43 10.1186/s12969-016-0103-7 27448801"/>
   <result pre="Miller J.C. Depression, coping, and functional disability in juvenile primary" exact="fibromyalgia" post="syndrome J. Pain 2002 3 412 419 10.1054/jpai.2002.126786 14622745"/>
   <result pre="S.L. Carlson L.E. Mindfulness-based stress reduction for the treatment of" exact="irritable bowel syndrome" post="symptoms: A randomized wait-list controlled trial Int. J. Behav."/>
   <result pre="Kidder M. Sapp L. Short-and long-term outcomes of children with" exact="complex regional pain syndrome" post="type I treated with exercise therapy Clin. J. Pain"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6785461/results/search/disease/results.xml">
   <result pre="original work is properly cited. Abstract Background and Purpose Benign" exact="epilepsy" post="with centrotemporal spikes (BECTS) is one of the most"/>
   <result pre="white-matter tracts. diffusion-tensor imaging language test dual-loop model INTRODUCTION Benign" exact="epilepsy" post="with centrotemporal spikes (BECTS) is one of the most"/>
   <result pre="has been used to evaluate pediatric psychiatric diseases such as" exact="autism" post="and attention deficit hyperactivity disorder (ADHD). 7 8 The"/>
   <result pre="used to evaluate pediatric psychiatric diseases such as autism and" exact="attention deficit hyperactivity disorder" post="(ADHD). 7 8 The white-matter fibers associated with language"/>
   <result pre="of the frontal lobes. 2 Furthermore, recent DTI studies of" exact="epilepsy" post="have detected white-matter deficits. 10 DTI showed a decrease"/>
   <result pre="They were not diagnosed with any headache-associated diseases such as" exact="migraine" post="or tension-type headache. The inclusion criteria were no history"/>
   <result pre="al. The neuropsychological and language profile of children with benign" exact="rolandic epilepsy" post="Epilepsia 2005 46 924 930 15946332 2 Völkl-Kernstock S"/>
   <result pre="The neuropsychological and language profile of children with benign rolandic" exact="epilepsy" post="Epilepsia 2005 46 924 930 15946332 2 Völkl-Kernstock S"/>
   <result pre="M Speech and school performance in children with benign partial" exact="epilepsy" post="with centro-temporal spikes (BCECTS) Seizure 2009 18 320 326"/>
   <result pre="A Gobbi G Benso F Neuropsychological profile in new-onset benign" exact="epilepsy" post="with centrotemporal spikes (BECTS): focusing on executive functions Epilepsy"/>
   <result pre="al. A diffusion tensor imaging study in children with ADHD," exact="autism" post="spectrum disorder, OCD, and matched controls: distinct and non-distinct"/>
   <result pre="et al. White matter development in children with benign childhood" exact="epilepsy" post="with centro-temporal spikes Brain 2014 137 1095 1106 24598359"/>
   <result pre="statistical analysis and voxel based morphometry of diffusion indices in" exact="temporal lobe epilepsy" post="Comput Biol Med 2011 41 1082 1091 21616484 14"/>
   <result pre="and voxel based morphometry of diffusion indices in temporal lobe" exact="epilepsy" post="Comput Biol Med 2011 41 1082 1091 21616484 14"/>
   <result pre="microstructural white matter abnormalities in children with active benign childhood" exact="epilepsy" post="with centrotemporal spikes (BECTS): a preliminary DTI study J"/>
   <result pre="Gong J Jiang S et al. Abnormal asymmetry in benign" exact="epilepsy" post="with unilateral and bilateral centrotemporal spikes: a combined fMRI"/>
   <result pre="Fig. 2 Flow chart of the study participants. BECTS: benign" exact="epilepsy" post="with centrotemporal spikes, NRS: numeric rating scale. Fig. 3"/>
   <result pre="p&amp;lt;0.05/18=0.003). AD: axial diffusivity, ATR: anterior thalamic radiation, BECTS: benign" exact="epilepsy" post="with centrotemporal spikes, CAB: cingulum-angular bundle, CCG: cingulum-cingulate gyrus"/>
   <result pre="1 Demographic characteristics in the two study groups BECTS: benign" exact="epilepsy" post="with centrotemporal spikes, EHI: Edinburgh Handedness Inventory, F: female,"/>
   <result pre="male. Table 2 EEG findings and medications in the benign" exact="epilepsy" post="with centrotemporal spikes group Table 3 Comparison of diffusion-tensor"/>
   <result pre="size, AD: axial diffusivity, ATR: anterior thalamic radiation, BECTS: benign" exact="epilepsy" post="with centrotemporal spikes, CAB: cingulum-angular bundle, CCG: cingulum-cingulate gyrus"/>
   <result pre="the BECTS and control groups *Significant at p&amp;lt;0.05. BECTS: benign" exact="epilepsy" post="with centrotemporal spikes, Expressive A: chronological age-expressive age, MLU-w:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6788925/results/search/disease/results.xml">
   <result pre="also experience aura symptoms, most often of visual type. Although" exact="migraine" post="is considered a benign condition, the association between migraine"/>
   <result pre="Although migraine is considered a benign condition, the association between" exact="migraine" post="with aura and ischemic stroke is well established. 2"/>
   <result pre="benign condition, the association between migraine with aura and ischemic" exact="stroke" post="is well established. 2 According to the International Classification"/>
   <result pre="migrainous infarction can be made in the presence of a" exact="migraine" post="attack, which occurs in patients fulfilling the criteria for"/>
   <result pre="migraine attack, which occurs in patients fulfilling the criteria for" exact="migraine" post="with aura, is typical of previous attacks except that"/>
   <result pre="2 ; the evidence about a possible link between migraine," exact="patent foramen ovale," post="and stroke is still not conclusive. 3 Cortical Laminar"/>
   <result pre="about a possible link between migraine, patent foramen ovale, and" exact="stroke" post="is still not conclusive. 3 Cortical Laminar Necrosis: From"/>
   <result pre="pediatric and adult age. The most common causes are hypoxic-ischemic" exact="encephalopathy" post="and watershed infarction; other etiologies include hypoglycemia, status epilepticus,"/>
   <result pre="are hypoxic-ischemic encephalopathy and watershed infarction; other etiologies include hypoglycemia," exact="status epilepticus," post="immunosuppressive and antineoplastic treatments, infections and autoimmune diseases of"/>
   <result pre="treatments, infections and autoimmune diseases of the central nervous system," exact="moyamoya disease," post="migrainous infarction, metabolic disorders such as citrullinemia, and hyponatremia"/>
   <result pre="it is worth to notice that increasing evidence suggests that" exact="stroke" post="recovery is multifactorial and depends on a huge number"/>
   <result pre="may offer additional resources and is a candidate to change" exact="stroke" post="medicine in the near future. Signally, as machine learning-based"/>
   <result pre="centers represents the conditio sine qua non to build &quot;big&quot;" exact="stroke" post="databases and develop integrated models of care in the"/>
   <result pre="Kalita A Cortical laminar necrosis as a presenting manifestation of" exact="migraine" post="in an apparently normal patient: a rare case report"/>
   <result pre="562 2 Zhang Y Parikh A Qian S Migraine and" exact="stroke" post="Stroke Vasc Neurol 2017 02 03 160 167 3"/>
   <result pre="Napoli M Di Silvestrini M Patent foramen ovale and cryptogenic" exact="stroke" post="or transient ischemic attack: To close or not to"/>
   <result pre="Silvestrini M Glycosylated hemoglobin and functional outcome after acute ischemic" exact="stroke" post="J Stroke Cerebrovasc Dis 2016 25 07 1786 1791"/>
   <result pre="is a sensitive prognostic marker for functional outcome in ischemic" exact="stroke" post="J Neuroinflammation 2016 13 16 26792363 8 Lattanzi S"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6790872/results/search/disease/results.xml">
   <result pre="Endocrinology pmcid: 6790872 doi: 10.6065/apem.2019.24.3.195 apem-2019-24-3-195 : Case Report Primary" exact="hyperparathyroidism" post="versus familial hypocalciuric hypercalcemia: a challenging diagnostic evaluation in"/>
   <result pre="medium, provided the original work is properly cited. Abstract Primary" exact="hyperparathyroidism" post="(PHPT) and familial hypocalciuric hypercalcemia (FHH) have significantly different"/>
   <result pre="computed tomography scan of the neck revealed a right superior" exact="parathyroid adenoma" post="which was excised with a focused parathyroidectomy. Although the"/>
   <result pre="tomography scan of the neck revealed a right superior parathyroid" exact="adenoma" post="which was excised with a focused parathyroidectomy. Although the"/>
   <result pre="the limitations of a first-line imaging tool in identifying a" exact="parathyroid adenoma." post="Hypercalcemia Primary hyperparathyroidism Familial hypocalciuric hypocalcemia Parathyroid adenoma Parathyroid"/>
   <result pre="first-line imaging tool in identifying a parathyroid adenoma. Hypercalcemia Primary" exact="hyperparathyroidism" post="Familial hypocalciuric hypocalcemia Parathyroid adenoma Parathyroid hormone Introduction Primary"/>
   <result pre="a parathyroid adenoma. Hypercalcemia Primary hyperparathyroidism Familial hypocalciuric hypocalcemia Parathyroid" exact="adenoma" post="Parathyroid hormone Introduction Primary hyperparathyroidism (PHPT) is a rare"/>
   <result pre="hyperparathyroidism Familial hypocalciuric hypocalcemia Parathyroid adenoma Parathyroid hormone Introduction Primary" exact="hyperparathyroidism" post="(PHPT) is a rare disease in children with an"/>
   <result pre="of the neck and 99mTc-Sestamibi scan did not show a" exact="parathyroid adenoma." post="Multiple endocrine neoplasia 1 sequencing (Baylor Genetic Laboratories, Houston,"/>
   <result pre="tomography (CT) scan of the neck revealed a right superior" exact="parathyroid adenoma" post="( Fig. 1). Although the patient's symptoms and PTH"/>
   <result pre="(CT) scan of the neck revealed a right superior parathyroid" exact="adenoma" post="( Fig. 1). Although the patient's symptoms and PTH"/>
   <result pre="the diagnosis was not confirmed until the identification of the" exact="parathyroid adenoma" post="on the 4D CT scan of the neck. The"/>
   <result pre="diagnosis was not confirmed until the identification of the parathyroid" exact="adenoma" post="on the 4D CT scan of the neck. The"/>
   <result pre="removed by focused parathyroidectomy, and a pathology examination revealed a" exact="parathyroid adenoma" post="(0.9 g in weight, 2.5 cm in greatest dimension)."/>
   <result pre="by focused parathyroidectomy, and a pathology examination revealed a parathyroid" exact="adenoma" post="(0.9 g in weight, 2.5 cm in greatest dimension)."/>
   <result pre="and a combination of amitriptyline, topiramate, and sumatriptan for newly-diagnosed" exact="migraine" post="headache. Discussion We report a challenging diagnostic evaluation of"/>
   <result pre="definitive diagnosis of PHPT could only be made after a" exact="parathyroid adenoma" post="was identified on a 4D CT scan of the"/>
   <result pre="diagnosis of PHPT could only be made after a parathyroid" exact="adenoma" post="was identified on a 4D CT scan of the"/>
   <result pre="Although a sestamibi scan failed to identify the solitary right" exact="parathyroid adenoma" post="in our patient, a 4D scan exposed the lesion."/>
   <result pre="a sestamibi scan failed to identify the solitary right parathyroid" exact="adenoma" post="in our patient, a 4D scan exposed the lesion."/>
   <result pre="for hypertension was discontinued shortly after the removal of the" exact="parathyroid adenoma," post="it was restarted a few months later due to"/>
   <result pre="of her persistent hypertension was unknown, but it was likely" exact="essential hypertension." post="She continued to require several medications to manage her"/>
   <result pre="editorial assistance. References References 1 Roizen J Levine MA Primary" exact="hyperparathyroidism" post="in children and adolescents J Chin Med Assoc 2012"/>
   <result pre="Patel KN Swischuk LE Lee PD Incidental hypercalcemia caused by" exact="primary hyperparathyroidism" post="with rapid progression to renal complications in a child"/>
   <result pre="KN Swischuk LE Lee PD Incidental hypercalcemia caused by primary" exact="hyperparathyroidism" post="with rapid progression to renal complications in a child"/>
   <result pre="Jr Dahir KM Broome JT Differentiating familial hypocalciuric hypercalcemia from" exact="primary hyperparathyroidism" post="Endocr Pract 2013 19 697 702 23425644 4 Bilezikian"/>
   <result pre="Dahir KM Broome JT Differentiating familial hypocalciuric hypercalcemia from primary" exact="hyperparathyroidism" post="Endocr Pract 2013 19 697 702 23425644 4 Bilezikian"/>
   <result pre="of renal calcium excretion for the distinction between familial hypocalciuric" exact="hypercalcaemia" post="and primary hyperparathyroidism: a follow-up study on methods Clin"/>
   <result pre="F Christiansen P Mosekilde L Vitamin D status, seasonal variations," exact="parathyroid adenoma" post="weight and bone mineral density in primary hyperparathyroidism Clin"/>
   <result pre="Christiansen P Mosekilde L Vitamin D status, seasonal variations, parathyroid" exact="adenoma" post="weight and bone mineral density in primary hyperparathyroidism Clin"/>
   <result pre="seasonal variations, parathyroid adenoma weight and bone mineral density in" exact="primary hyperparathyroidism" post="Clin Endocrinol (Oxf) 2005 63 506 13 16268801 7"/>
   <result pre="variations, parathyroid adenoma weight and bone mineral density in primary" exact="hyperparathyroidism" post="Clin Endocrinol (Oxf) 2005 63 506 13 16268801 7"/>
   <result pre="Jr A systematic review of the diagnosis and treatment of" exact="primary hyperparathyroidism" post="from 1995 to 2003 Otolaryngol Head Neck Surg 2005"/>
   <result pre="A systematic review of the diagnosis and treatment of primary" exact="hyperparathyroidism" post="from 1995 to 2003 Otolaryngol Head Neck Surg 2005"/>
   <result pre="computed tomography scan of the neck revealed a right superior" exact="parathyroid adenoma" post="(black arrow) and salivary glands (white arrow) in coronal"/>
   <result pre="tomography scan of the neck revealed a right superior parathyroid" exact="adenoma" post="(black arrow) and salivary glands (white arrow) in coronal"/>
   <result pre="and postoperative calcium and intact parathyroid hormone (iPTH) trends in" exact="parathyroid adenoma." post=""/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6791607/results/search/disease/results.xml">
   <result pre="signs and symptoms of CD in children. 1 Cerebellar ataxia," exact="peripheral neuropathy," post="epilepsy, myoclonic ataxia, progressive leukoencephalopathy, cerebral vasculitis, dementia, headache,"/>
   <result pre="1 Cerebellar ataxia, peripheral neuropathy, epilepsy, myoclonic ataxia, progressive leukoencephalopathy," exact="cerebral vasculitis," post="dementia, headache, chorea, myelopathy, attention-deficit hyperactivity disorder, cognitive impairment,"/>
   <result pre="dementia, headache, chorea, myelopathy, attention-deficit hyperactivity disorder, cognitive impairment, seizures," exact="mononeuropathy" post="multiplex, motor neuropathy, and Guillain-Barre–like syndrome have been described"/>
   <result pre="per day on average. There was a family history of" exact="hyperthyroidism" post="in maternal grandmother and Crohn's disease in paternal grandfather."/>
   <result pre="extraintestinal manifestations have been described in patients including dental hypoplasia," exact="dermatitis" post="herpetiformis, iron deficiency anemia, elevated liver enzymes, osteopenia, short"/>
   <result pre="have been described in patients including dental hypoplasia, dermatitis herpetiformis," exact="iron deficiency anemia," post="elevated liver enzymes, osteopenia, short stature, arthralgias, and behavioral"/>
   <result pre="were headache/migraine, attention-deficit hyperactivity disorder, and seizures. Other symptoms included" exact="cerebellar ataxia," post="mental retardation, and behavioral disorders. 9 A similar study"/>
   <result pre="by Sedat et al and additionally included breath-holding spells and" exact="cerebral palsy." post="10 Motor tics has also been reported as a"/>
   <result pre="et al found antiganglioside antibodies in patients with CD with" exact="peripheral neuropathy;" post="6 patients were positive for IgG antibody to GM1,"/>
   <result pre="CD. 16 Ciacci et al found a higher prevalence of" exact="panic disorder" post="and major depressive disorder in patients with CD who"/>
   <result pre="et al found a higher prevalence of panic disorder and" exact="major depressive disorder" post="in patients with CD who had positive antithyroperoxidase antibodies."/>
   <result pre="PH Sander HW et al. Ganglioside reactive antibodies in the" exact="neuropathy" post="associated with celiac disease. J Neuroimmunol. 2002; 127: 145–"/>
   <result pre="C Aström J Walan A Reversal of psychopathology in adult" exact="coeliac disease" post="with the aid of pyridoxine (vitamin B6) . Scand"/>
   <result pre="A Mazzacca G De Rosa A Depressive symptoms in adult" exact="coeliac disease." post="Scand J Gastroenterol. 1998; 33: 247– 50. 9548616 18."/>
   <result pre="Pengiran Tengah DSNA Wills AJ Holmes GKT Neurological complications of" exact="coeliac disease." post="Postgrad Med J. 2002; 78: 393– 8. 12151653"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6802300/results/search/disease/results.xml">
   <result pre="headache OR post-traumatic headache OR posttraumatic headache OR post traumatic" exact="migraine" post="OR post-traumatic migraine OR posttraumatic migraine OR post concussion"/>
   <result pre="headache OR posttraumatic headache OR post traumatic migraine OR post-traumatic" exact="migraine" post="OR posttraumatic migraine OR post concussion headache OR post-concussion"/>
   <result pre="headache OR post traumatic migraine OR post-traumatic migraine OR posttraumatic" exact="migraine" post="OR post concussion headache OR post-concussion headache OR post"/>
   <result pre="OR post concussion headache OR post-concussion headache OR post concussion" exact="migraine" post="OR post-concussion migraine) AND (treatment OR therapy) . The"/>
   <result pre="(ED) based study investigated the treatment response of intravenous acute" exact="migraine" post="therapies in an adolescent (aged 8–21 years) group consisting of"/>
   <result pre="suffered a non-blast mTBI. In addition, 52% screened positive for" exact="post-traumatic stress disorder," post="while 38% screened positive for depression. More than 90%"/>
   <result pre="across clinical trials with both acute and preventive medications for" exact="migraine" post="[ 16– 18]. A similar placebo effect could be"/>
   <result pre="responses to pharmacological treatment have previously been reported in pediatric" exact="migraine" post="patients [ 19]. Furthermore, the studies were also considerably"/>
   <result pre="guidelines for controlled trials of acute and preventive treatment of" exact="migraine" post="[ 20, 21]. These guidelines could serve as inspiration,"/>
   <result pre="would enable us to compare efficacy of acute and preventive" exact="migraine" post="drugs between PTH and migraine patients. Lastly, PTH patients"/>
   <result pre="efficacy of acute and preventive migraine drugs between PTH and" exact="migraine" post="patients. Lastly, PTH patients often present with a plethora"/>
   <result pre="12. Chan Steven Kurowski Brad Byczkowski Terri Timm Nathan Intravenous" exact="migraine" post="therapy in children with posttraumatic headache in the ED"/>
   <result pre="Baños JE A meta-analysis of the placebo response in acute" exact="migraine" post="and how this response may be influenced by some"/>
   <result pre="G Davies B et al. Cessation versus continuation of 6-month" exact="migraine" post="preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled"/>
   <result pre="et al. Trial of amitriptyline, Topiramate, and placebo for pediatric" exact="migraine" post="N Engl J Med 2016 376 2 115 124"/>
   <result pre="headache society for controlled trials of preventive treatment of chronic" exact="migraine" post="in adults Cephalalgia. 2018 38 5 815 832 10.1177/0333102418758283"/>
   <result pre="international headache society for controlled trials of acute treatment of" exact="migraine" post="attacks in adults: fourth edition Cephalalgia. 2019 39 6"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6803542/results/search/disease/results.xml">
   <result pre="of disease of sporadic (SHM) and familial (FHM) pediatric hemiplegic" exact="migraine" post="and to review the pertinent literature. Results: Retrospective study"/>
   <result pre="onset and severe attacks, had a favorable clinical evolution. hemiplegic" exact="migraine" post="FHM SHM children adolescents fig-count: table-count: equation-count: ref-count: page-count:"/>
   <result pre="children adolescents fig-count: table-count: equation-count: ref-count: page-count: word-count: Background Hemiplegic" exact="migraine" post="(HM) is a rare form of migraine with aura"/>
   <result pre="word-count: Background Hemiplegic migraine (HM) is a rare form of" exact="migraine" post="with aura characterized by transient motor weakness or hemiparesis"/>
   <result pre="by headache, nausea, vomiting, photophobia, or phonophobia, as occurs in" exact="migraine" post="( 1). The presence of motor deficits represents the"/>
   <result pre="represents the peculiarity of HM compared to other forms of" exact="migraine" post="with aura and its diagnostic criteria have been recently"/>
   <result pre="standard deviation; y, year; –, p &amp;gt; 0.99 ; °" exact="migraine" post="with non-motor aura or without aura; * significance level"/>
   <result pre="1). Concerning the personal history for other types of migraine," exact="migraine" post="with non-motor aura prevailed in SHM than in FMH"/>
   <result pre="FMH cases (SHM 5/32, 16% vs. FHM 0/14, 0%) while" exact="migraine" post="without aura was less frequent in SHM than in"/>
   <result pre="history of benign myoclonic epilepsy. One SHM patient had a" exact="neurological disorder" post="prior to the onset of HM attacks (congenital cerebellar"/>
   <result pre="neurological disorder prior to the onset of HM attacks (congenital" exact="cerebellar ataxia" post="with bilateral atrophy); this patient, previously described ( 7),"/>
   <result pre="proportion of SHM patients had a positive family history for" exact="migraine" post="(SHM 50% vs. FHM 33%; p = 0.33), while"/>
   <result pre="33%; p = 0.33), while a positive family history for" exact="epilepsy" post="was more common in FHM cases (SHM 6% vs."/>
   <result pre="h) and they were all SHM. Two patients had prolonged" exact="aphasia" post="(longer than 6 h) and they all were FHM"/>
   <result pre="(2/3 clumsiness, 1/3 hemiparesis), and in 2 FHM patients (1/2" exact="cerebellar ataxia," post="1/2 clumsiness). Cognitive and neuropsychological evaluation was available for"/>
   <result pre="23 SHM patients tested, three had mild intellectual disability, one" exact="expressive language disorder," post="one praxis difficulties, and one dyslexia. Among the 12"/>
   <result pre="SHM patients tested, three had mild intellectual disability, one expressive" exact="language disorder," post="one praxis difficulties, and one dyslexia. Among the 12"/>
   <result pre="sixth of patients (15%), early transient neurological symptoms (i.e., prolonged" exact="aphasia" post="during fever, isolated seizures, transient hemiparesis, prolonged clumsiness after"/>
   <result pre="hormones is preponderant, as occurs in the common forms of" exact="migraine" post="( 13), while in the monogenic forms of HM"/>
   <result pre="of the study population ( 3– 9). In fact, progressive" exact="cerebellar ataxia" post="and epilepsy were more frequent in patients with a"/>
   <result pre="population ( 3– 9). In fact, progressive cerebellar ataxia and" exact="epilepsy" post="were more frequent in patients with a disease-associated mutation"/>
   <result pre="SC Smagge A et al. . Clinical spectrum of hemiplegic" exact="migraine" post="and chances of finding a pathogenic mutation. Neurology. ("/>
   <result pre="I Olesen J Russell MB . A population-based study of" exact="familial hemiplegic migraine" post="suggests revised diagnostic criteria . Brain. ( 2002) 125:"/>
   <result pre="J Russell MB . A population-based study of familial hemiplegic" exact="migraine" post="suggests revised diagnostic criteria . Brain. ( 2002) 125:"/>
   <result pre="J Russell MB . Evidence for a separate type of" exact="migraine" post="with aura: sporadic hemiplegic migraine. Neurology. ( 2003) 60:"/>
   <result pre="C Vahedi K et al. . The clinical spectrum of" exact="familial hemiplegic migraine" post="associated with mutations in a neuronal calcium channel ."/>
   <result pre="K et al. . The clinical spectrum of familial hemiplegic" exact="migraine" post="associated with mutations in a neuronal calcium channel ."/>
   <result pre="in hemiplegic migraine: a clinical and genetic study in Finnish" exact="migraine" post="families . Cephalalgia. ( 2018) 38: 1849– 63. 10.1177/0333102418761041"/>
   <result pre="in ATP1A2 and CACNA1A are frequent in early-onset sporadic hemiplegic" exact="migraine" post=". Neurology. ( 2010) 75: 967– 72. 10.1212/WNL.0b013e3181f25e8f 20837964"/>
   <result pre="al. . The genetic spectrum of a population-based sample of" exact="familial hemiplegic migraine." post="Brain. ( 2007) 130: 346– 56. 10.1093/brain/awl334 17142831 11."/>
   <result pre=". Screen for CACNA1A and ATP1A2 mutations in sporadic hemiplegic" exact="migraine" post="patients . Cephalalgia. ( 2008) 28: 914– 21. 10.1111/j.1468-2982.2008.01599.x"/>
   <result pre="calcium voltage-gated channel subunit alpha1 A CT computed tomography FHM" exact="familial hemiplegic migraine" post="HM Hemiplegic migraine ICHD-III International Classification of Headache Disorders"/>
   <result pre="channel subunit alpha1 A CT computed tomography FHM familial hemiplegic" exact="migraine" post="HM Hemiplegic migraine ICHD-III International Classification of Headache Disorders"/>
   <result pre="A CT computed tomography FHM familial hemiplegic migraine HM Hemiplegic" exact="migraine" post="ICHD-III International Classification of Headache Disorders third edition MRI"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6815497/results/search/disease/results.xml">
   <result pre="Various symptoms can be associated with vomiting such as nausea," exact="migraine" post="or abdominal pain. Common triggers of CVS include infection,"/>
   <result pre="neurological and gastrointestinal. CVS shares many common features with catamenial" exact="migraine" post="including treatment. We herein report a case of CVS"/>
   <result pre="follow-up of 6 years. Cyclic vomiting syndrome menstrual period catamenial" exact="migraine" post="oestrogen Introduction Cyclic vomiting syndrome (CVS) is a relatively"/>
   <result pre="(e.g. chronic sinusitis, upper respiratory infections), emotional and psychological stress," exact="motion sickness," post="lack of sleep, physical exhaustion and certain food products"/>
   <result pre="children and frequently misdiagnosed as acute gastroenteritis, gastroesophageal reflux disease," exact="pancreatitis" post="or as an eating disorder [ 6, 7]. Patients"/>
   <result pre="as acute gastroenteritis, gastroesophageal reflux disease, pancreatitis or as an" exact="eating disorder" post="[ 6, 7]. Patients with CVS typically display recurrent"/>
   <result pre="These include infection, psychological stress, physical stress, inadequate sleep, diet," exact="motion sickness" post="and onset of menses [ 5]. The catamenial migraine"/>
   <result pre="motion sickness and onset of menses [ 5]. The catamenial" exact="migraine" post="is linked to the fall of oestrogen during a"/>
   <result pre="[ 12]. Supportive criteria include history or family history of" exact="migraine" post="headaches [ 8]. The recurrent vomiting attacks interspaced with"/>
   <result pre="being the triggering factor, the permenstrual oestrogen therapy in catamenial" exact="migraine" post="is a logical therapeutic approach, yet its level of"/>
   <result pre="of 7 days. Benoteau [ 10] has successfully treated catamenial" exact="migraine" post="with percutaneous oestrogen E2 (transdermal or patch) started 48"/>
   <result pre="therapy as a prophylactic method given its efficacy in catamenial" exact="migraine" post="and a relatively short period of cures. Our patient"/>
   <result pre="Yen-Hsuan N Wen-Chin W Wang-Tso L Cyclic vomiting syndrome and" exact="migraine" post="in children J Formos Med Assoc 2011 110 6"/>
   <result pre="Robbins JL Hayes JR Is cyclic vomiting syndrome related to" exact="migraine" post="J Pediatr 1999 134 5 567 572 10228291 15"/>
   <result pre="4 340 345 10203304 18 West CP Hiller H Ovarian" exact="suppression" post="with the gonadotrophin-releasing hormone agonist goserelin (Zoladex) in the"/>
   <result pre="gonadotrophin-releasing hormone agonist goserelin (Zoladex) in the management of the" exact="premenstrual tension" post="syndrome Human reproduction 1994 9 6 1058 1063 7962376"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6817617/results/search/disease/results.xml">
   <result pre="interest in the repurposing of other psychiatric drugs to combat" exact="brain cancer." post="In this review, we synthesize recent progress in understanding"/>
   <result pre="overcome to enhance our ability to successfully prevent and treat" exact="brain cancer," post="especially in the most vulnerable groups of patients, such"/>
   <result pre="future research and provide long-awaited new hope to patients with" exact="brain cancer" post="and their families. psychiatric drug brain cancer glioblastoma multiforme"/>
   <result pre="research and provide long-awaited new hope to patients with brain" exact="cancer" post="and their families. psychiatric drug brain cancer glioblastoma multiforme"/>
   <result pre="to patients with brain cancer and their families. psychiatric drug" exact="brain cancer" post="glioblastoma multiforme psychiatric disorder schizophrenia bipolar disorder depression Funding"/>
   <result pre="patients with brain cancer and their families. psychiatric drug brain" exact="cancer" post="glioblastoma multiforme psychiatric disorder schizophrenia bipolar disorder depression Funding"/>
   <result pre="with brain cancer and their families. psychiatric drug brain cancer" exact="glioblastoma multiforme" post="psychiatric disorder schizophrenia bipolar disorder depression Funding National Natural"/>
   <result pre="their families. psychiatric drug brain cancer glioblastoma multiforme psychiatric disorder" exact="schizophrenia" post="bipolar disorder depression Funding National Natural Science Foundation of"/>
   <result pre="families. psychiatric drug brain cancer glioblastoma multiforme psychiatric disorder schizophrenia" exact="bipolar disorder" post="depression Funding National Natural Science Foundation of China-Yunnan Joint"/>
   <result pre="Fund 10.13039/501100011002 fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction Brain" exact="cancer" post="is among the most lethal of all cancers. A"/>
   <result pre="of all cancers. A large fraction of adult patients with" exact="glioblastoma multiforme" post="(GBM), also known as glioblastoma, the most common and"/>
   <result pre="et al., 2014; Gilbert et al., 2014). The treatment of" exact="brain cancer" post="remains very challenging and is usually less clinically effective"/>
   <result pre="al., 2014; Gilbert et al., 2014). The treatment of brain" exact="cancer" post="remains very challenging and is usually less clinically effective"/>
   <result pre="effects of other such drugs relevant to the treatment of" exact="brain cancer." post="Rapid progress has also been made recently in the"/>
   <result pre="overcome to enhance our ability to successfully prevent and treat" exact="brain cancer," post="especially in the most vulnerable groups of patients, such"/>
   <result pre="overcome to enhance our ability to successfully prevent and treat" exact="brain cancer" post="and propose perspectives for future research. Psychiatric Drug-Use Influences"/>
   <result pre="to enhance our ability to successfully prevent and treat brain" exact="cancer" post="and propose perspectives for future research. Psychiatric Drug-Use Influences"/>
   <result pre="Risk Several epidemiological studies have shown that the incidence of" exact="cancer" post="is significantly lower in patients with schizophrenia than in"/>
   <result pre="the incidence of cancer is significantly lower in patients with" exact="schizophrenia" post="than in the general population ( Grinshpoon et al.,"/>
   <result pre="revealed decreased risks of the development of certain forms of" exact="cancer" post="in patients with schizophrenia compared with control individuals ("/>
   <result pre="the development of certain forms of cancer in patients with" exact="schizophrenia" post="compared with control individuals ( Cohen et al., 2002;"/>
   <result pre="Based on these findings, researchers have hypothesized that patients with" exact="schizophrenia" post="may be protected against some cancer types ( Cohen"/>
   <result pre="hypothesized that patients with schizophrenia may be protected against some" exact="cancer" post="types ( Cohen et al., 2002; Barak et al.,"/>
   <result pre="(SSRIs), tricyclic antidepressants, and monoamine oxidase inhibitors, rather than to" exact="schizophrenia" post="itself ( Huang et al., 2018; Fond et al.,"/>
   <result pre="Fond et al., 2012). The incidences of some forms of" exact="cancer" post="(e.g., prostate and colorectal cancers) were found to be"/>
   <result pre="cancers) were found to be significantly lower in patients with" exact="schizophrenia" post="treated with specific antipsychotic drugs than in control individuals"/>
   <result pre="to be involved in the development of both gliomas and" exact="schizophrenia" post="( Berezowska and Schlegel, 2011; Sotoyama et al., 2011;"/>
   <result pre="an atypical antipsychotic drug used widely for the treatment of" exact="schizophrenia" post="and schizoaffective disorder, has been proven to inhibit migration"/>
   <result pre="antipsychotic drug used widely for the treatment of schizophrenia and" exact="schizoaffective disorder," post="has been proven to inhibit migration and induce apoptosis"/>
   <result pre="has been proven to inhibit migration and induce apoptosis of" exact="glioma" post="cells directly through the inhibition of Src kinase, a"/>
   <result pre="certain psychiatric medications, which may help to explain the reduced" exact="cancer" post="incidence in patients taking these drugs and guide their"/>
   <result pre="their repurposing for use against GBM and other forms of" exact="brain cancer." post="The characteristics of the representative psychiatric drugs with anticancer"/>
   <result pre="Clozapine Fluphenazine Olanzapine Quetiapine Thioridazine Adults and children Schizophrenia, or" exact="bipolar disorder" post="Adults but not older adults with dementia Schizophrenia Adults"/>
   <result pre="Schizophrenia, or bipolar disorder Adults but not older adults with" exact="dementia" post="Schizophrenia Adults and children over 16 Schizophrenia Adults and"/>
   <result pre="Schizophrenia Adults and children aged 13 and older Schizophrenia, or" exact="bipolar disorder" post="Adults Schizophrenia, or bipolar disorder Adults with schizophrenia, or"/>
   <result pre="13 and older Schizophrenia, or bipolar disorder Adults Schizophrenia, or" exact="bipolar disorder" post="Adults with schizophrenia, or psychosis Glioma Glioblastoma Glioma Glioblastoma"/>
   <result pre="Glioblastoma Inhibition of the migration and induction of apoptosis of" exact="glioma" post="cells via Src oncogenic tyrosine kinase signaling Inhibition of"/>
   <result pre="stabilizers Valproic acid Adults and children Bipolar disorder, epilepsy, or" exact="migraine" post="headaches Glioblastoma Inhibition of cell proliferation by promoting cell"/>
   <result pre="a hallmark of many types of psychiatric disorder, such as" exact="attention deficit hyperactivity disorder" post="and schizophrenia, and DA antagonists have been developed as"/>
   <result pre="of HDACs induces the differentiation and suppresses the proliferation of" exact="cancer" post="cells through the modulation of early growth response 1;"/>
   <result pre="HDAC inhibitors have been proposed as effective epigenetic therapy for" exact="cancer" post="( Gottlicher et al., 2001; Sharma et al., 2010)."/>
   <result pre="anticancer drug that significantly inhibited abnormal chromatin remodeling in various" exact="cancer" post="cells and was developed by targeting histone acetylation through"/>
   <result pre="to reduce the proliferation and to induce the apoptosis of" exact="brain cancer" post="cells. Apoptosis is well understood to be involved in"/>
   <result pre="reduce the proliferation and to induce the apoptosis of brain" exact="cancer" post="cells. Apoptosis is well understood to be involved in"/>
   <result pre="a member of the chloride channel/transporter family, in glioblastoma and" exact="neuroblastoma" post="cells ( Jeon et al., 2015). Following treatment with"/>
   <result pre="clozapine, CLC-4 expression was increased in a dose-dependent manner in" exact="neuroblastoma" post="(SH-SY5Y) and glioma (U87) cells ( Jeon et al.,"/>
   <result pre="was increased in a dose-dependent manner in neuroblastoma (SH-SY5Y) and" exact="glioma" post="(U87) cells ( Jeon et al., 2015). Moreover, the"/>
   <result pre="clozapine may suppress tumor growth and promote apoptotic events in" exact="glioma" post="cells, partially through CLC-4 induction. Src Oncogenic Tyrosine Kinase"/>
   <result pre="antagonists has been used in the development of drugs for" exact="cancer" post="treatment ( Wheeler et al., 2009). ARP is an"/>
   <result pre="ARP is an atypical antipsychotic drug used widely to treat" exact="schizophrenia" post="and psychotic episodes in patients with bipolar disorders, depression,"/>
   <result pre="found that ARP significantly restricted the migratory capacity of U251" exact="glioma" post="cells, and the effect was associated with the regulation"/>
   <result pre="transducer and activator of transcription 3, and Akt) involved in" exact="glioma" post="cell proliferation and migration ( Kim et al., 2018a)."/>
   <result pre="the overexpression of β-catenin reduces the proliferation and migration of" exact="glioma" post="cells and the expression of stem cell markers, and"/>
   <result pre="miR-24 was due, at least in part, to effects on" exact="glioma" post="cell autophagy and viability ( Chen et al., 2019)."/>
   <result pre="et al., 2018b). Fluphenazine activated autophagic cell death in U87" exact="glioma" post="cells by inhibiting the phospahtidylinositol-3 kinase/Akt/mammalian target of rapamycin"/>
   <result pre="the potential application of psychiatric drugs in the treatment of" exact="brain cancer," post="several key challenges have been identified. These obstacles must"/>
   <result pre="be overcome to achieve more effective prevention and treatment of" exact="brain cancer." post="First, little research has examined the repurposing of psychiatric"/>
   <result pre="little research has examined the repurposing of psychiatric medications for" exact="brain cancer" post="treatment in children and pregnant women. Brain cancer is"/>
   <result pre="research has examined the repurposing of psychiatric medications for brain" exact="cancer" post="treatment in children and pregnant women. Brain cancer is"/>
   <result pre="for brain cancer treatment in children and pregnant women. Brain" exact="cancer" post="is the most common form of solid tumor in"/>
   <result pre="agents are available for pediatric than for adult patients with" exact="brain cancer," post="due in part to the difficulty of acquiring single-center"/>
   <result pre="medications with anticancer activities offer new hope for patients with" exact="brain cancer." post="However, greater understanding of the mechanisms of action of"/>
   <result pre="psychiatric drug repurposing for the treatment of primary and metastatic" exact="brain cancer" post="in vulnerable groups, such as children, adolescents, and pregnant"/>
   <result pre="drug repurposing for the treatment of primary and metastatic brain" exact="cancer" post="in vulnerable groups, such as children, adolescents, and pregnant"/>
   <result pre="L. ( 2007). Valproate use in children and adolescents with" exact="bipolar disorder." post="CNS Drugs 21, 1019– 1033. 10.2165/00023210-200721120-00005 18020481 Barak Y."/>
   <result pre="A. Mandel M. Mirecki I. Aizenberg D. ( 2005). Reduced" exact="cancer" post="incidence among patients with schizophrenia. Cancer 104, 2817– 2821."/>
   <result pre="F. M. et al. ( 2015). Radiation-induced PGE2 sustains human" exact="glioma" post="cells growth and survival through EGF signaling . Oncotarget"/>
   <result pre="regulates effects of miR-24 on the viability and autophagy of" exact="glioma" post="cells. Exp. Therapeut. Med. 18, 1285– 1290. 10.3892/etm.2019.7680 Chen"/>
   <result pre="2012). Valproic acid affected the survival and invasiveness of human" exact="glioma" post="cells through diverse mechanisms . J. Neuro-oncol. 109, 23–"/>
   <result pre="( 2011). The incidence and relative risk factors for developing" exact="cancer" post="among patients with schizophrenia: a nine-year follow-up study ."/>
   <result pre="M. Dembling B. Schorling J. ( 2002). The association between" exact="schizophrenia" post="and cancer: a population-based mortality study. Schizophrenia Res. 57,"/>
   <result pre="26775730 Fizazi K. ( 2007). The role of Src in" exact="prostate cancer." post="Ann. Oncol. 18, 1765– 1773. 10.1093/annonc/mdm086 17426060 Fond G."/>
   <result pre="A. Huang S. ( 2012). FoxM1 and Wnt/beta-catenin signaling in" exact="glioma" post="stem cells. Cancer Res. 72, 5658– 5662. 10.1158/0008-5472.CAN-12-0953 23139209"/>
   <result pre="cross talk in the central nervous system: pathological implications in" exact="schizophrenia" post="and Parkinson’s disease . Front. Cell. Neurosci. 7, 4."/>
   <result pre="safety of aripiprazole and haloperidol versus placebo in patients with" exact="schizophrenia" post="and schizoaffective disorder . J. Clin. Psychiatry 63, 763–"/>
   <result pre="aripiprazole and haloperidol versus placebo in patients with schizophrenia and" exact="schizoaffective disorder" post=". J. Clin. Psychiatry 63, 763– 771. 10.4088/JCP.v63n0903 12363115"/>
   <result pre="W. et al. ( 2008). Glycogen synthase kinase-3 inhibition induces" exact="glioma" post="cell death through c-MYC, nuclear factor-kappaB, and glucose regulation"/>
   <result pre="F. Wise L. H. ( 2003). Genome scan meta-analysis of" exact="schizophrenia" post="and bipolar disorder, part II: Schizophrenia. Am. J. Hum."/>
   <result pre="L. H. ( 2003). Genome scan meta-analysis of schizophrenia and" exact="bipolar disorder," post="part II: Schizophrenia. Am. J. Hum. Genet. 73, 34–"/>
   <result pre="Pukkala E. Tanskanen A. Lonnqvist J. ( 2001). Incidence of" exact="cancer" post="among persons with schizophrenia and their relatives. Arch. Gen."/>
   <result pre="Lonnqvist J. ( 2001). Incidence of cancer among persons with" exact="schizophrenia" post="and their relatives. Arch. Gen. Psychiatry 58, 573– 578."/>
   <result pre="10.1001/archpsyc.58.6.573 11386986 Mortensen P. B. ( 1989). The incidence of" exact="cancer" post="in schizophrenic patients. J. Epidemiol. Commun. Health 43, 43–"/>
   <result pre="P. B. ( 1992). Neuroleptic medication and reduced risk of" exact="prostate cancer" post="in schizophrenic patients. Acta Psychiatrica Scand. 85, 390– 393."/>
   <result pre="B. ( 1992). Neuroleptic medication and reduced risk of prostate" exact="cancer" post="in schizophrenic patients. Acta Psychiatrica Scand. 85, 390– 393."/>
   <result pre="S. Kim K. W. ( 2007). Autop- hagy signaling in" exact="cancer" post="and its potential as novel target to improve anticancer"/>
   <result pre="Saeki Y. et al. ( 2008). Lithium inhibits invasion of" exact="glioma" post="cells; possible involvement of glycogen synthase kinase-3 . Neuro-oncology"/>
   <result pre="A. ( 2012). Valproic acid inhibits angiogenesis in vitro and" exact="glioma" post="angiogenesis in vivo in the brain . Neurol. Med.-chirurgica"/>
   <result pre="( 2018). Valproic acid inhibits proliferation and reduces invasiveness in" exact="glioma" post="stem cells through wnt/beta catenin signalling activation . Genes"/>
   <result pre="induced autophagic cell death and its mechanisms in human U87" exact="glioma" post="cell . Oncol. Prog. (Chinese) 14, 744– 747. Shin"/>
   <result pre="Pallidal hyperdopaminergic innervation underlying D2 receptor-dependent behavioral deficits in the" exact="schizophrenia" post="animal model established by EGF . PloS One 6,"/>
   <result pre="A. ( 2000). The role of oncogenic kinases in human" exact="cancer" post="(Review). Int. J. Mol. Med. 5, 583– 590. 10.3892/ijmm.5.6.583"/>
   <result pre="Yu S. et al. ( 2017). Promoting oligodendroglial-oriented differentiation of" exact="glioma" post="stem cell: a repurposing of quetiapine for the treatment"/>
   <result pre="cell: a repurposing of quetiapine for the treatment of malignant" exact="glioma" post=". Oncotarget 8, 37511– 37524. 10.18632/oncotarget.16400 28415586 Wheeler D."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6819737/results/search/disease/results.xml">
   <result pre="S2214-4269(19)30166-1 doi: 10.1016/j.ymgmr.2019.100522 100522 : Letter to the Editor Mitochondrial" exact="myopathy" post="plus due to the variant m.586G &amp;gt; A in MT-TF Barcia"/>
   <result pre="same mitochondrial MTTF mutation (m.586G &amp;gt; A), namely a childhood-onset form of" exact="mitochondrial myopathy" post="[ 2] and a late-onset form of progressive neurodegenerative"/>
   <result pre="mitochondrial MTTF mutation (m.586G &amp;gt; A), namely a childhood-onset form of mitochondrial" exact="myopathy" post="[ 2] and a late-onset form of progressive neurodegenerative"/>
   <result pre="late-onset form of progressive neurodegenerative disorder with akinesia-rigidity, abnormal movements," exact="dementia" post="and psychiatric disorder in a 57 yrs-old woman [ 3]."/>
   <result pre="our best to postpone. References References 1 Finsterer J. Mitochondrial" exact="myopathy" post="plus due to the variant m.586G&amp;gt;a in MTTF Mol."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6826633/results/search/disease/results.xml">
   <result pre="Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/). Abstract Neurostimulation for" exact="epilepsy" post="refers to the application of electricity to affect the"/>
   <result pre="order to establish optimal stimulation paradigms. pediatric neurostimulation neuromodulation drug-resistant" exact="epilepsy" post="vagus nerve stimulation responsive neurostimulation deep brain stimulation chronic"/>
   <result pre="unlikely to be seizure-free by using medications alone, and the" exact="epilepsy" post="is termed pharma-co-resistant [ 1, 2, 3]. Other treatment"/>
   <result pre="for neurostimulation, and the evidence to support their use for" exact="epilepsy" post="in pediatric patients. We consider possible mechanisms of action,"/>
   <result pre="only a single randomized controlled trial for neurostimulation in pediatric" exact="epilepsy" post="[ 13]. The remainder of the evidence is limited"/>
   <result pre="nerve stimulation (VNS) gained US FDA approval for intractable focal" exact="epilepsy" post="in 1997, and is now approved for patients aged"/>
   <result pre="VNS devices have been implanted worldwide for the treatment of" exact="epilepsy" post="[ 16]. 2.2. Mechanism VNS is theorized to modulate"/>
   <result pre="in heart rate, based upon the observation that 82% of" exact="epilepsy" post="patients experience ictal tachycardia [ 30]. One study suggested"/>
   <result pre="35]. Evidence supports a relationship between VNS and central and" exact="obstructive sleep apnea" post="[ 36, 37, 38], and caution should be exercised"/>
   <result pre="Evidence supports a relationship between VNS and central and obstructive" exact="sleep apnea" post="[ 36, 37, 38], and caution should be exercised"/>
   <result pre="best-studied and most widely used of the neuromodulatory modalities for" exact="epilepsy" post="in pediatric populations. It is safe, effective and FDA-approved."/>
   <result pre="and FDA-approved. Data support its use across a variety of" exact="epilepsy" post="types. 3. Responsive Neurostimulation 3.1. Introduction A responsive neurostimulation"/>
   <result pre="was FDA-approved in 2013 for the treatment of focal drug-resistant" exact="epilepsy" post="in adults [ 40]. Bergey, et al. reported a"/>
   <result pre="rates are similar to those of other intracranial devices or" exact="epilepsy" post="surgery [ 50, 51]. The RNS system is not"/>
   <result pre="seizure focus in patients who were presumed to have multifocal" exact="epilepsy" post="[ 55, 56]. There is limited data to support"/>
   <result pre="RNS use in pediatrics is limited to off-label implantations at" exact="epilepsy" post="centers familiar with its use in adult patients, and"/>
   <result pre="Deep brain stimulation (DBS) was FDA-approved for use in intractable" exact="epilepsy" post="in patients 18 years of age or older in"/>
   <result pre="The CMT has been targeted for the treatment of generalized" exact="epilepsy" post="[ 8, 60, 61, 62, 63, 64, 65]. A"/>
   <result pre="9) randomized-controlled trials of stimulation of the hippocampus for mesial" exact="temporal lobe epilepsy," post="with all three showing a reduction in seizure frequency"/>
   <result pre="Valentin et al. [ 76] described two children with generalized" exact="epilepsy" post="who underwent stimulation of the bilateral CMT, and one"/>
   <result pre="stimulation of the bilateral CMT, and one with right frontotemporal" exact="epilepsy" post="who underwent stimulation of the ANT for a period"/>
   <result pre="FDA-approved for dystonia in children [ 82]. Stimulation parameters in" exact="epilepsy" post="and movement can be similar [ 83]. Safety data"/>
   <result pre="Safety data are favorable, and may reasonably be extrapolated to" exact="epilepsy" post="[ 84]. Among the 40 patients included in a"/>
   <result pre="summarize, DBS is safe, effective and FDA-approved to treat intractable" exact="epilepsy" post="in adults, but data is lacking in pediatrics. Patient"/>
   <result pre="seizure frequency. Velasco, et al. described 10 patients with intractable" exact="temporal lobe epilepsy" post="who subsequently went on to have temporal lobectomies, and"/>
   <result pre="Velasco, et al. described 10 patients with intractable temporal lobe" exact="epilepsy" post="who subsequently went on to have temporal lobectomies, and"/>
   <result pre="indications, and is FDA-approved for the treatment of major depression," exact="migraine" post="and pre-surgical mapping of motor and language function ["/>
   <result pre="in 21 patients with malformations of cortical development and refractory" exact="epilepsy" post="[ 98]. Patient ages were not individually reported (mean"/>
   <result pre="106]. This tDCS has been studied in pediatric patients for" exact="attention deficit hyperactivity disorder" post="(ADHD), depression, cerebral palsy and autism spectrum disorder (ASD,"/>
   <result pre="in pediatric patients for attention deficit hyperactivity disorder (ADHD), depression," exact="cerebral palsy" post="and autism spectrum disorder (ASD, among which is Asperger’s"/>
   <result pre="for attention deficit hyperactivity disorder (ADHD), depression, cerebral palsy and" exact="autism" post="spectrum disorder (ASD, among which is Asperger’s Syndrome) ["/>
   <result pre="level of evidence to support the use of tDCS in" exact="epilepsy" post="is limited. Initial studies have shown promising results in"/>
   <result pre="only stimulation modality that is FDA-approved for the treatment of" exact="epilepsy" post="in pediatric patients. It is therefore the first option"/>
   <result pre="Data supporting the use of RNS or CSCS for generalized" exact="epilepsy" post="is limited or non-existent. Each modality has been effective"/>
   <result pre="parameters. 10. Conclusions Neurostimulation for the treatment of pharmacoresistant pediatric" exact="epilepsy" post="is safe and effective. Multiple options exist and can"/>
   <result pre="Berg A.T. Levy S.R. Testa F.M. D’Souza R. Remission of" exact="epilepsy" post="after two drug failures in children: A prospective study"/>
   <result pre="Pharmacoresistance and the role of surgery in difficult to treat" exact="epilepsy" post="Nat. Rev. Neurol. 2012 8 669 677 10.1038/nrneurol.2012.181 22964510"/>
   <result pre="10.1097/WCO.0000000000000534 29493559 8. Schulze-Bonhage A. Brain stimulation as a neuromodulatory" exact="epilepsy" post="therapy Seizure 2017 44 169 175 10.1016/j.seizure.2016.10.026 27876408 9."/>
   <result pre="Two-year seizure reduction in adults with medically intractable partial onset" exact="epilepsy" post="treated with responsive neurostimulation: Final results of the RNS"/>
   <result pre="AspireSR ® (including cardiac-based seizure detection) at a large complex" exact="epilepsy" post="and surgery centre Seizure 2018 58 120 126 10.1016/j.seizure.2018.03.022"/>
   <result pre="C. Dijk D.-J. Eriksson S.H. Dijk P.D.-J. Circadian rhythm and" exact="epilepsy" post="Lancet Neurol. 2018 17 1098 1108 10.1016/S1474-4422(18)30335-1 30366868 12."/>
   <result pre="Chang E.F. Rao V.R. Multi-day rhythms modulate seizure risk in" exact="epilepsy" post="Nat. Commun. 2018 9 88 10.1038/s41467-017-02577-y 29311566 13. Klinkenberg"/>
   <result pre="et al. Vagus nerve stimulation for pediatric patients with intractable" exact="epilepsy" post="between 3 and 6 years of age: Study protocol"/>
   <result pre="29284319 32. Ben-Menachem E. Vagus-nerve stimulation for the treatment of" exact="epilepsy" post="Lancet Neurol. 2002 1 477 482 10.1016/S1474-4422(02)00220-X 12849332 33."/>
   <result pre="G. Canevini M.P. Laryngeal motility alteration: A missing link between" exact="sleep apnea" post="and vagus nerve stimulation for epilepsy Epilepsia 2016 57"/>
   <result pre="missing link between sleep apnea and vagus nerve stimulation for" exact="epilepsy" post="Epilepsia 2016 57 24 27 10.1111/epi.13252 26696504 37. Forde"/>
   <result pre="Responsive neurostimulation: Review of clinical trials and insights into focal" exact="epilepsy" post="Epilepsy Behav. 2018 88 11 20 10.1016/j.yebeh.2018.06.042 41. Bergey"/>
   <result pre="Jobst B.C. Critical review of the responsive neurostimulator system for" exact="epilepsy" post="Med Devices: Évid. Res. 2015 8 405 411 45."/>
   <result pre="F.T. Responsive neurostimulation suppresses synchronized cortical rhythms in patients with" exact="epilepsy" post="Neurosurg. Clin. N. Am. 2011 22 481 488 10.1016/j.nec.2011.07.007"/>
   <result pre="K.I. Rao V.R. Responsive neurostimulation for treatment of pediatric drug-resistant" exact="epilepsy" post="Epilepsy Behav. Case Rep. 2018 10 21 24 10.1016/j.ebcr.2018.02.002"/>
   <result pre="Responsive cortical stimulation for the treatment of medically intractable partial" exact="epilepsy" post="Neurology 2011 77 1295 1304 10.1212/WNL.0b013e3182302056 21917777 50. Skarpaas"/>
   <result pre="50. Skarpaas T.L. Jarosiewicz B. Morrell M.J. Brain-responsive neurostimulation for" exact="epilepsy" post="(RNS((R)) System) Epilepsy Res. 2019 153 68 70 10.1016/j.eplepsyres.2019.02.003"/>
   <result pre="M.J. Differential neuropsychological outcomes following targeted responsive neurostimulation for partial-onset" exact="epilepsy" post="Epilepsia 2015 56 1836 1844 10.1111/epi.13191 26385758 54. Meador"/>
   <result pre="Quality of life and mood in patients with medically intractable" exact="epilepsy" post="treated with targeted responsive neurostimulation Epilepsy Behav. 2015 45"/>
   <result pre="C.N. Goldman A. Jobst B. et al. Lateralization of mesial" exact="temporal lobe epilepsy" post="with chronic ambulatory electrocorticography Epilepsia 2015 56 959 967"/>
   <result pre="A. Jobst B. et al. Lateralization of mesial temporal lobe" exact="epilepsy" post="with chronic ambulatory electrocorticography Epilepsia 2015 56 959 967"/>
   <result pre="of the anterior nucleus of thalamus for treatment of refractory" exact="epilepsy" post="Epilepsia 2010 51 899 908 10.1111/j.1528-1167.2010.02536.x 20331461 58. Salanova"/>
   <result pre="Long-term efficacy and safety of thalamic stimulation for drug-resistant partial" exact="epilepsy" post="Neurology 2015 84 1017 1025 10.1212/WNL.0000000000001334 25663221 59. Li"/>
   <result pre="59. Li M.C.H. Cook M.J. Deep brain stimulation for drug-resistant" exact="epilepsy" post="Epilepsia 2018 59 273 290 10.1111/epi.13964 29218702 60. Yan"/>
   <result pre="review of deep brain stimulation for the treatment of drug-resistant" exact="epilepsy" post="in childhood J. Neurosurg. Pediatr. 2018 23 274 284"/>
   <result pre="Mittal S. Deep brain stimulation for seizure control in drug-resistant" exact="epilepsy" post="Neurosurg. Focus 2018 45 E4 10.3171/2018.4.FOCUS1872 62. Laxpati N.G."/>
   <result pre="A. Koziara H. Nauman P. Deep brain stimulation for refractory" exact="epilepsy" post="Arch. Med. Sci. 2012 8 805 816 10.5114/aoms.2012.31135 23185188"/>
   <result pre="A. Kubu C.S. Wiebe S. Hippocampal electrical stimulation in mesial" exact="temporal lobe epilepsy" post="Neurology 2006 66 1490 1494 10.1212/01.wnl.0000209300.49308.8f 16554495 67. Velasco"/>
   <result pre="C.S. Wiebe S. Hippocampal electrical stimulation in mesial temporal lobe" exact="epilepsy" post="Neurology 2006 66 1490 1494 10.1212/01.wnl.0000209300.49308.8f 16554495 67. Velasco"/>
   <result pre="T. Jiménez-Jiménez D. et al. Intracranial stimulation for children with" exact="epilepsy" post="Eur. J. Paediatr. Neurol. 2017 21 223 231 10.1016/j.ejpn.2016.10.011"/>
   <result pre="Marson A.G. Boon P. Deep brain and cortical stimulation for" exact="epilepsy" post="Cochrane Database Syst. Rev. 2017 2017 CD008497 10.1002/14651858.CD008497.pub3 78."/>
   <result pre="and mood outcomes after anterior thalamic stimulation for refractory partial" exact="epilepsy" post="Seizure 2017 45 133 141 10.1016/j.seizure.2016.12.014 28061418 79. Oh"/>
   <result pre="long-term electrical stimulation of bilateral anterior thalamic nucleus in refractory" exact="epilepsy" post="patients Seizure 2012 21 183 187 10.1016/j.seizure.2011.12.003 22209542 80."/>
   <result pre="cortical stimulation: A therapeutic and potentially restorative therapy for focal" exact="epilepsy" post="Expert Rev. Neurother. 2017 17 661 666 10.1080/14737175.2017.1331129 28532252"/>
   <result pre="Schuh L. Smith B. Long-term electrical stimulation–induced inhibition of partial" exact="epilepsy" post="J. Neurosurg. 2006 105 894 897 10.3171/jns.2006.105.6.894 17405261 91."/>
   <result pre="Chronic subthreshold cortical stimulation and stimulation-related EEG biomarkers for focal" exact="epilepsy" post="Brain Comm. 2019 1 fcz010 10.1093/braincomms/fcz010 92. Child N.D."/>
   <result pre="Chronic subthreshold subdural cortical stimulation for the treatment of focal" exact="epilepsy" post="originating from eloquent cortex Epilepsia 2014 55 18 21"/>
   <result pre="side effects from chronic electrical stimulation for treatment of focal" exact="epilepsy" post="Brain Stimul. 2019 12 1077 1079 10.1016/j.brs.2019.03.077 30981622 96."/>
   <result pre="J. Nolan S.J. Transcranial magnetic stimulation for the treatment of" exact="epilepsy" post="Cochrane Database Syst. Rev. 2016 8 10.1002/14651858.CD011025.pub2 98. Fregni"/>
   <result pre="trial of repetitive transcranial magnetic stimulation in patients with refractory" exact="epilepsy" post="Ann. Neurol. 2006 60 447 455 10.1002/ana.20950 17068786 99."/>
   <result pre="Gschwind M. Seeck M. Transcranial direct-current stimulation as treatment in" exact="epilepsy" post="Expert Rev. Neurother. 2016 16 1427 1441 10.1080/14737175.2016.1209410 27384886"/>
   <result pre="simultaneous EEG recording: Preliminary assessment in healthy subjects and human" exact="epilepsy" post="Epilepsy Behav. 2012 25 417 425 10.1016/j.yebeh.2012.06.027 23123281 111."/>
   <result pre="al. Randomized controlled trial of trigeminal nerve stimulation for drug-resistant" exact="epilepsy" post="Neurology 2013 80 786 791 10.1212/WNL.0b013e318285c11a 23365066 120. Soss"/>
   <result pre="prospective long-term study of external trigeminal nerve stimulation for drug-resistant" exact="epilepsy" post="Epilepsy Behav. 2015 42 44 47 10.1016/j.yebeh.2014.10.029 25499162 121."/>
   <result pre="between the responses to ANT-DBS and prior VNS in refractory" exact="epilepsy" post="Brain Behav. 2018 8 e00983 10.1002/brb3.983 29740975 Figure 1"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6827519/results/search/disease/results.xml">
   <result pre="a well-organized review of POTS and its &quot;overlapping pathophysiological mechanisms&quot;:" exact="chronic fatigue syndrome," post="Ehler-Danlos Syndrome and other hypermobile joint syndromes, vasovagal syncope,"/>
   <result pre="education or motivational-interviewing-based coaching compared to usual care to improve" exact="cancer" post="pain management . Oncol Nurs Forum . 2012; 39("/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6828958/results/search/disease/results.xml">
   <result pre="yield, further confirming the usefulness of gene panel analysis. dystonia" exact="chorea" post="neurodegeneration with brain iron accumulation disorders genetics next-generation sequencing"/>
   <result pre="further confirming the usefulness of gene panel analysis. dystonia chorea" exact="neurodegeneration" post="with brain iron accumulation disorders genetics next-generation sequencing children"/>
   <result pre="diagnostic work-up. Patients with tic disorders or Tourette’s syndrome, pure" exact="cerebellar ataxia," post="or hereditary spastic paraplegia were excluded, as were patients"/>
   <result pre="with tic disorders or Tourette’s syndrome, pure cerebellar ataxia, or" exact="hereditary spastic paraplegia" post="were excluded, as were patients with incomplete medical records."/>
   <result pre="disorders or Tourette’s syndrome, pure cerebellar ataxia, or hereditary spastic" exact="paraplegia" post="were excluded, as were patients with incomplete medical records."/>
   <result pre="the same gene panel analysis for a clinical suspicion of" exact="familial hemiplegic migraine" post="(fHM) or childhood periodic syndromes (e.g., paroxysmal torticollis) were"/>
   <result pre="gene panel analysis for a clinical suspicion of familial hemiplegic" exact="migraine" post="(fHM) or childhood periodic syndromes (e.g., paroxysmal torticollis) were"/>
   <result pre="isolated dystonia (21%), 34 patients for (PMDs) (23%), 20 for" exact="chorea" post="(13%), and 4 for tremor (3%) ( Figure 1"/>
   <result pre="the 34 patients referred for PMD, 10 were investigated for" exact="episodic ataxia" post="(EA), 18 for paroxysmal kinesigenic dyskinesia (PKD), 2 for"/>
   <result pre="the attacks, the paroxysmal MD group is further classified into" exact="episodic ataxia" post="(EA), paroxysmal kinesigenic dyskinesia (PKD), and exercise-induced paroxysmal dyskinesia"/>
   <result pre="paroxysmal dyskinesia (EPD), hemiplegic attacks, and paroxysmal myoclonus groups. MD," exact="movement disorder." post="Figure 2 Associated neurological features of the cohort and"/>
   <result pre="of genes sequenced in the panel). DD, developmental delay; EA," exact="episodic ataxia;" post="EPD, exercise-induced paroxysmal dyskinesia; ID, intellectual disability; MD, movement"/>
   <result pre="episodic ataxia; EPD, exercise-induced paroxysmal dyskinesia; ID, intellectual disability; MD," exact="movement disorder;" post="PKD, paroxysmal kinesigenic dyskinesia. Diagnostic Yield Pathogenic variants were"/>
   <result pre="the isolated dystonia group (16%), 5 of 20 in the" exact="chorea" post="group (25%), and 12 of 34 in the pMD"/>
   <result pre="the two most frequently reported and severe phenotypes, namely, early" exact="infantile epileptic encephalopathy" post="(EIEE17, OMIM 615473) and early-onset hyperkinetic phenotype (OMIM 617493)"/>
   <result pre="most frequently reported and severe phenotypes, namely, early infantile epileptic" exact="encephalopathy" post="(EIEE17, OMIM 615473) and early-onset hyperkinetic phenotype (OMIM 617493)"/>
   <result pre="boy with a severe neurodevelopmental disorder characterized by infantile-onset, drug-resistant" exact="epilepsy" post="(with generalized myoclonic and focal motor seizures), an intellectual"/>
   <result pre="5-hydroxyindoleacetic acids. First described as causative of a severe early" exact="infantile epileptic encephalopathy" post="(EIEE4, OMIM 612164) ( Saitsu et al., 2008), the"/>
   <result pre="First described as causative of a severe early infantile epileptic" exact="encephalopathy" post="(EIEE4, OMIM 612164) ( Saitsu et al., 2008), the"/>
   <result pre="next generation sequencing; DYT, dystonia; PMD, paroxysmal movement disorders; NBIA," exact="neurodegeneration" post="with brain iron accumulation; NT, inherited disorders of neurotransmitter"/>
   <result pre="dominant; AR, autosomal recessive; CSF: cerebrospinal fluid; DYT, dystonia; EA," exact="episodic ataxia;" post="EPD, exercise-induced paroxysmal dyskinesia; fHM, familial hemiplegic migraine; HSP,"/>
   <result pre="DYT, dystonia; EA, episodic ataxia; EPD, exercise-induced paroxysmal dyskinesia; fHM," exact="familial hemiplegic migraine;" post="HSP, hereditary spastic paraplegias; MAF, minor allele frequency; MD,"/>
   <result pre="allele frequency; MD, movement disorders; MRI, magnetic resonance imaging; NBIA," exact="neurodegeneration" post="with brain iron accumulation; NGS, next generation sequencing; NT,"/>
   <result pre="A novel KCTD17 mutation is associated with childhood early-onset hyperkinetic" exact="movement disorder" post=". Parkinsonism. Relat. Disord. 61, 4– 6. 10.1016/j.parkreldis.2018.12.001 30579817"/>
   <result pre="et al. ( 2012). De novo mutations in ATP1A3 cause" exact="alternating hemiplegia of childhood." post="Nat. Genet. 44, 1030– 1034. 10.1038/ng.2358 22842232 Kanemasa H."/>
   <result pre="novo p.Arg756Cys mutation of ATP1A3 causes an atypical form of" exact="alternating hemiplegia of childhood" post="with prolonged paralysis and choreoathetosis . BMC. Neurol. 16,"/>
   <result pre="novo mutations in the gene encoding STXBP1 (MUNC18-1) cause early" exact="infantile epileptic encephalopathy" post=". Nat. Genet. 40, 782– 788. 10.1038/ng.150 18469812 Sanger"/>
   <result pre="in the gene encoding STXBP1 (MUNC18-1) cause early infantile epileptic" exact="encephalopathy" post=". Nat. Genet. 40, 782– 788. 10.1038/ng.150 18469812 Sanger"/>
   <result pre="L. et al. ( 2018a). Phenomenology and clinical course of" exact="movement disorder" post="in GNAO1 variants: results from an analytical review ."/>
   <result pre="Nicita F. Elia M. et al. ( 2018b). ATP1A3-related epileptic" exact="encephalopathy" post="responding to ketogenic diet. Brain. Dev. 40, 433– 438."/>
   <result pre="gene in dyschromatosis symmetrica hereditaria and genetic differentiation from both" exact="dyschromatosis universalis hereditaria" post="and acropigmentatio reticularis . J. Invest. Dermatol. 124, 1186–"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6839327/results/search/disease/results.xml">
   <result pre="are rare disorders. In Western populations, the reported prevalence of" exact="narcolepsy" post="is 0.02%–0.05%. In Indian subcontinent, there are few reports"/>
   <result pre="is 0.02%–0.05%. In Indian subcontinent, there are few reports on" exact="narcolepsy" post="and none on IHS so far. Here, we compared"/>
   <result pre="2010 to December 2015 were included. Patients were diagnosed with" exact="narcolepsy" post="type 1 (NT1), narcolepsy type 2 (NT2), and IHS"/>
   <result pre="were included. Patients were diagnosed with narcolepsy type 1 (NT1)," exact="narcolepsy" post="type 2 (NT2), and IHS based on the International"/>
   <result pre="symptom onset to diagnosis was 71 months. Classical tetrad of" exact="narcolepsy" post="was rarely found in pediatric cohort, but they had"/>
   <result pre="rapid eye movement latency was 7.2 min. Conclusion: The pediatric" exact="narcolepsy" post="patients tend to have less classical symptoms and more"/>
   <result pre="this rare treatable disorder. Idiopathic hypersomnolence multiple sleep latency test" exact="narcolepsy" post="pediatric polysomnography I NTRODUCTION The idiopathic central disorders of"/>
   <result pre="polysomnography I NTRODUCTION The idiopathic central disorders of hypersomnolence including" exact="narcolepsy" post="and idiopathic hypersomnolence (IHS) are characterized by excessive daytime"/>
   <result pre="disorders of hypersomnolence along with other secondary disorders such as" exact="hypersomnia" post="due to a medical disorder, medication or substance use"/>
   <result pre="reported prevalence of &amp;lt;0.05% in Europe and North America, the" exact="narcolepsy" post="is often misdiagnosed for years. Many authors have found"/>
   <result pre="(CSF) hypocretin assay, more patients are receiving the diagnosis of" exact="narcolepsy" post="or IHS; however, many centers still depend on polysomnography"/>
   <result pre="reports from Asia and India on this rare condition, especially" exact="narcolepsy" post="with some showing a link with viral infections H1N1"/>
   <result pre="polysomnographic profile of a cohort of patients with central hypersomnolence" exact="narcolepsy" post="and IHS from a single center. In addition, we"/>
   <result pre="of excessive daytime sleepiness (EDS), where secondary causes such as" exact="obstructive sleep apnea" post="(OSA), periodic limb movement disorders, and medication-related conditions have"/>
   <result pre="excessive daytime sleepiness (EDS), where secondary causes such as obstructive" exact="sleep apnea" post="(OSA), periodic limb movement disorders, and medication-related conditions have"/>
   <result pre="of our patients were given a clinical diagnosis of probable" exact="narcolepsy" post="from outside and were on medications also. We asked"/>
   <result pre="We compared the clinical and polysomnographic profile of patients with" exact="narcolepsy" post="and IHS across the two age groups &amp;lt;18 versus"/>
   <result pre="statistically significant difference in the age of presentation between the" exact="narcolepsy" post="and IHS group ( P = 0.0003), with narcolepsy"/>
   <result pre="the narcolepsy and IHS group ( P = 0.0003), with" exact="narcolepsy" post="types 1 and 2 presenting at a younger age"/>
   <result pre="patients and 8 years for the older patients. Among the" exact="narcolepsy" post="patients, 14 were 18 years old and above (58.3%),"/>
   <result pre="by disturbed night sleep (3) and headache/migraine (2). Among the" exact="narcolepsy" post="subgroup, highest referral was from neurologists (11), followed by"/>
   <result pre="56 patients had EDS (100%). Comparison of other symptoms between" exact="narcolepsy" post="and IHS is given in Table 1. Nineteen patients"/>
   <result pre="and IHS is given in Table 1. Nineteen patients of" exact="narcolepsy" post="had cataplexy (33.9%) that was used for classification. Symptoms"/>
   <result pre="in Table 2 and comparison between the pediatric and adult" exact="narcolepsy" post="is given in Table 3. We assessed behavioral/psychiatric symptoms"/>
   <result pre="a mean ESS score of 15.8. Table 2 Comparison between" exact="narcolepsy" post="type 1 and narcolepsy type 2 NT-1 NT-2 n"/>
   <result pre="of 15.8. Table 2 Comparison between narcolepsy type 1 and" exact="narcolepsy" post="type 2 NT-1 NT-2 n 19 5 Male:female 13:6"/>
   <result pre="NT-2=Narcolepsy type 2 Table 3 Comparison between pediatric and adult" exact="narcolepsy" post="&amp;lt;18 years ( n=10), n (%) &amp;gt;18 years ("/>
   <result pre="112.18 min. There was no significant difference noted among the" exact="narcolepsy" post="and IHS group on comparing these parameters. The MSLT"/>
   <result pre="sleep-onset latency of 187.1 s. The mean sleep-onset latency for" exact="narcolepsy" post="patients was 1.8 ± 1.7 min and that for"/>
   <result pre="the MSLT was 7.20 min with much shorter latency in" exact="narcolepsy" post="subgroup as compared to IHS (5.3 ± 5.5 min"/>
   <result pre="subgroup as compared to IHS (5.3 ± 5.5 min for" exact="narcolepsy" post="patients and 12.7 ± 4.4 min for IHS patients;"/>
   <result pre="Table 4 Polysomnography and multiple sleep latency test findings in" exact="narcolepsy" post="and idiopathic hypersomnolence Narcolepsy 1 and 2 IHS P"/>
   <result pre="test, IHS=Idiopathic hypersomnolence D ISCUSSION Disorders of central hypersomnolence, including" exact="narcolepsy" post="and IHS, being rare often go undiagnosed and underreported,"/>
   <result pre="sleep disorders from South India reported the symptoms suggestive of" exact="narcolepsy" post="in a little over 1% of respondents, indicating that"/>
   <result pre="IHS in the existing literature from India. Male preponderance in" exact="narcolepsy" post="and IHS has been universally reported in almost all"/>
   <result pre="as well. However, ours was a female-predominant cohort, in both" exact="narcolepsy" post="and IHS with the pattern observed in younger and"/>
   <result pre="in small, single institutional series[ 16 17 18] in both" exact="narcolepsy" post="and IHS. Whether this observed difference is due to"/>
   <result pre="on the same to compare with. Delay in diagnosis of" exact="narcolepsy" post="is reported as early as 1976 with 5 years"/>
   <result pre="or neurologists with a suspicion of narcolepsy. Analyzing symptoms in" exact="narcolepsy" post="and IHS, we found that other than daytime sleepiness,"/>
   <result pre="that hypnagogic hallucinations and sleep paralysis are often seen in" exact="narcolepsy" post="type 1 (NT1) and have a lower but comparable"/>
   <result pre="found more weight gain and personality/behavioral disorders in our pediatric" exact="narcolepsy" post="patients, similar to reports from Asia and Europe.[ 27"/>
   <result pre="supporting the fact that the sensitivity of current criteria for" exact="narcolepsy" post="decreases with age as the number of SOREMPs decrease."/>
   <result pre="many were referred to us with a clinical suspicion of" exact="narcolepsy" post="itself. Ours was a female-predominant cohort, unlike the previous"/>
   <result pre="female-predominant cohort, unlike the previous reports of male preponderance of" exact="narcolepsy" post="in literature. IHS showed more behavioral or personality problems"/>
   <result pre="have not been reported in the literature. Pediatric and adult" exact="narcolepsy" post="did not significantly differ in their core symptoms, except"/>
   <result pre="the pediatric cohort. Epidemiological studies on rare diseases such as" exact="narcolepsy" post="are difficult to perform in resource-poor countries. Hence, we"/>
   <result pre="in resource-poor countries. Hence, we are planning to establish a" exact="narcolepsy" post="database linking other neurology centers in our state, whereby"/>
   <result pre="Panda S Status cataplecticus as initial presentation of late onset" exact="narcolepsy" post="J Clin Sleep Med 2014 10 207 9 24533005"/>
   <result pre="Sureshbabu S Muniem A Bhatia M Diagnosis and management of" exact="narcolepsy" post="in the Indian scenario Ann Indian Acad Neurol 2016"/>
   <result pre="MH Krahn LE Olson EJ Pankratz VS The epidemiology of" exact="narcolepsy" post="in Olmsted county, Minnesota: A population-based study Sleep 2002"/>
   <result pre="K et al. CSF hypocretin-1 levels and clinical profiles in" exact="narcolepsy" post="and idiopathic CNS hypersomnia in Norway Sleep 2007 30"/>
   <result pre="hypocretin-1 levels and clinical profiles in narcolepsy and idiopathic CNS" exact="hypersomnia" post="in Norway Sleep 2007 30 969 73 17702265 17"/>
   <result pre="V et al. The impact of gender on timeliness of" exact="narcolepsy" post="diagnosis J Clin Sleep Med 2014 10 89 95"/>
   <result pre="Sonka K Skibova J Does age at the onset of" exact="narcolepsy" post="influence the course and severity of the disease? Sleep"/>
   <result pre="Central disorders of hypersomnolence: Focus on the narcolepsies and idiopathic" exact="hypersomnia" post="Chest 2015 148 262 73 26149554 22 Thorpy MJ"/>
   <result pre="Montplaisir J Dauris JP et al. Delay in diagnosis of" exact="narcolepsy" post="in a European and North American population J Sleep"/>
   <result pre="JM Factors associated with a delay in the diagnosis of" exact="narcolepsy" post="Sleep Med 2004 5 37 41 14725825 27 Peraita-Adrados"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6854770/results/search/disease/results.xml">
   <result pre="indicate if changes were made. Abstract The global prevalence of" exact="migraine" post="as a primary headache has been estimated as 14.4%"/>
   <result pre="pro-inflammatory and oxidative state may play a putative role in" exact="migraine" post="pain generation. Knowledge about pathophysiological mechanisms of migraine should"/>
   <result pre="role in migraine pain generation. Knowledge about pathophysiological mechanisms of" exact="migraine" post="should be integrated into a multimodal treatment approach to"/>
   <result pre="promising in headache/migraine control through attenuating the inflammatory state. Moreover," exact="obesity" post="and headaches including migraine could be attributed to each"/>
   <result pre="through attenuating the inflammatory state. Moreover, obesity and headaches including" exact="migraine" post="could be attributed to each other through mechanisms like"/>
   <result pre="Regarding elimination diets, it appears that targeted these diets in" exact="migraine" post="patients with food sensitivities could be effective in headache/migraine"/>
   <result pre="burden of headache, 2016 [ 1], The global prevalence of" exact="migraine" post="as a primary headache has been estimated as 14.4%"/>
   <result pre="Furthermore, it has been evident that women are affected by" exact="migraine" post="2 or 3 times more than men and also"/>
   <result pre="Based on the number of headache days in a month," exact="migraine" post="is classified into episodic migraine ((EM): having &amp;lt; 15 headache"/>
   <result pre="headache days in a month, migraine is classified into episodic" exact="migraine" post="((EM): having &amp;lt; 15 headache days /month) or chronic migraine"/>
   <result pre="episodic migraine ((EM): having &amp;lt; 15 headache days /month) or chronic" exact="migraine" post="((CM): having ≥15 headache days /month with experiencing migraine"/>
   <result pre="chronic migraine ((CM): having ≥15 headache days /month with experiencing" exact="migraine" post="features in at least 8 days/month) [ 4]. Suffering from"/>
   <result pre="and psychiatric disorders, chronic pain, cardiovascular diseases, gastrointestinal (GI) complaints," exact="allergy" post="or /asthma, and obesity would also make the treatment"/>
   <result pre="pain, cardiovascular diseases, gastrointestinal (GI) complaints, allergy or /asthma, and" exact="obesity" post="would also make the treatment more complicated. These comorbidities"/>
   <result pre="and lifestyle modification are indispensable to the successful management of" exact="migraine" post="[ 7]. Therefore, knowledge about pathophysiological mechanisms of migraine"/>
   <result pre="of migraine [ 7]. Therefore, knowledge about pathophysiological mechanisms of" exact="migraine" post="should be integrated into a multimodal treatment approach to"/>
   <result pre="diet in protecting against primary headache with a focus on" exact="migraine" post="pathogenies will be explored at the end of each"/>
   <result pre="different types of diets have been studied in relation to" exact="migraine" post="and headache [ 14– 18]. It is speculated that"/>
   <result pre="18]. It is speculated that dietary interventions could affect headache/" exact="migraine" post="characteristics through a variety of mechanisms. These mechanisms may"/>
   <result pre="dysfunction, neuronal excitability, levels of factors with a role in" exact="migraine" post="pathogenesis (such as Calctonin-Gene-Related-Peptide (CGRP), nitric oxide (NO), adiponectin,"/>
   <result pre="the ketotic effects of fasting. Using KD for treating refractory" exact="epilepsy" post="dates back to the time of Hippocrates [ 35]."/>
   <result pre="In the mentioned case series study, 51 adults with chronic" exact="migraine" post="followed a low-calorie diet (1200–1500 kcal/d) for several months. Significant"/>
   <result pre="Twenty eight percent of the sample reached complete remission from" exact="migraine" post="headache. Also, continuous improvement was noted for 3 months"/>
   <result pre="been widely prescribed in the treatment of patients with intractable" exact="epilepsy" post="[ 15]. Carbohydrate content in KD is highly restricted"/>
   <result pre="on the conditions such as neurodegenerative disorders, brain tumors, autism," exact="amyotrophic lateral sclerosis," post="and migraine have also been of interest as a"/>
   <result pre="as neurodegenerative disorders, brain tumors, autism, amyotrophic lateral sclerosis, and" exact="migraine" post="have also been of interest as a therapeutic strategy"/>
   <result pre="In a recent study [ 40], 18 adults suffering from" exact="migraine" post="without aura were investigated during interictal state. They were"/>
   <result pre="Significant improvements were reported in frequency and duration of their" exact="migraine" post="attacks. This could be explained by the fact that"/>
   <result pre="14]. Di Lorenzo et al. [ 41] have additionally reported" exact="migraine" post="remission following ketosis in an open-label study on 96"/>
   <result pre="migraine remission following ketosis in an open-label study on 96" exact="migraine" post="suffers. During the ketogenic phase (the first month of"/>
   <result pre="be speculated that prescription of LGD may be promising in" exact="migraine" post="control, However, more RCTs are required in order to"/>
   <result pre="in order to fully elucidate the effects of LGD on" exact="migraine" post="characteristics. Suggested mechanisms for the effects of ketosis on"/>
   <result pre="the effects of ketosis on headache with a focus on" exact="migraine" post="pathogenesis Despite several animal studies have been conducted on"/>
   <result pre="it is thought that ketosis may attenuate the severity of" exact="migraine" post="headache through compensating serotoninergic dysfunction, inhibition of neuronal excitability,"/>
   <result pre="54] which is believed to play an important role in" exact="migraine" post="pathogenesis [ 28]. Also, animal studies revealed that ketosis"/>
   <result pre="55]. Weight loss strategies The relationship between primary headaches and" exact="obesity" post="was first suggested by Scher and colleagues in 2003"/>
   <result pre="reduction is among the suggested interventions for headaches due to" exact="idiopathic intracranial hypertension" post="[ 33]. Although data about the effects of weight"/>
   <result pre="loss on primary headache control is limited, the association between" exact="migraine" post="and obesity has been a growing field of interest"/>
   <result pre="primary headache control is limited, the association between migraine and" exact="obesity" post="has been a growing field of interest in the"/>
   <result pre="the recent years. According to an observational study, subjects with" exact="obesity" post="would experience more frequent and severe headaches compared to"/>
   <result pre="to normal-weight individuals [ 34]. Besides, both abdominal and general" exact="obesity" post="have been reported to be independent risk factors for"/>
   <result pre="[ 32]. Studies concerning the effects of weight reduction on" exact="migraine" post="applied two approaches including non-surgical modalities, especially dietary intervention,"/>
   <result pre="2 observational studies [ 57, 59] proposed a decrease in" exact="migraine" post="intensity, frequency and disability in obese women suffered from"/>
   <result pre="migraine intensity, frequency and disability in obese women suffered from" exact="migraine" post="after bariatric surgery [ 57, 59]. Indeed, these studies"/>
   <result pre="single blind trial examined the effect of low-calorie diet on" exact="migraine" post="and found no significant effect [ 14]. To conclude,"/>
   <result pre="proposed mechanisms of the association between excess body weight and" exact="migraine" post="will be discussed. Notwithstanding, when it comes to shared"/>
   <result pre="to shared pathophysiological pathways, inflammation received most attention. Migraine and" exact="metabolic syndrome" post="In addition to obesity, hypertension, dyslipidemia, insulin resistance, and"/>
   <result pre="augmented inflammation, that all are believed to be components of" exact="metabolic syndrome," post="tend to be highly prevalent diseases in migraineurs ["/>
   <result pre="also noted that IR might correlate with attacks duration in" exact="migraine" post="suffers [ 62]. Migraine and metabolic syndrome are usually"/>
   <result pre="with attacks duration in migraine suffers [ 62]. Migraine and" exact="metabolic syndrome" post="are usually comorbid, though no causal relationship has yet"/>
   <result pre="has yet been established [ 60]. Moreover, the association between" exact="metabolic syndrome" post="components and migraine characteristics including frequency of headache attacks,"/>
   <result pre="[ 60]. Moreover, the association between metabolic syndrome components and" exact="migraine" post="characteristics including frequency of headache attacks, severity and duration"/>
   <result pre="needs further studies [ 60]. Although no specific treatment for" exact="migraine" post="and concurrent metabolic syndrome has been proposed to date,"/>
   <result pre="[ 60]. Although no specific treatment for migraine and concurrent" exact="metabolic syndrome" post="has been proposed to date, general recommendations are given"/>
   <result pre="stress levels [ 60]. Suggested mechanisms for the association between" exact="obesity" post="and headache with a focus on migraine pathogenesis Three"/>
   <result pre="the association between obesity and headache with a focus on" exact="migraine" post="pathogenesis Three dimensional effect of inflammation, headache, and obesity"/>
   <result pre="on migraine pathogenesis Three dimensional effect of inflammation, headache, and" exact="obesity" post="The hypothetical relationship between obesity and migraine has been"/>
   <result pre="effect of inflammation, headache, and obesity The hypothetical relationship between" exact="obesity" post="and migraine has been linked to an elevated release"/>
   <result pre="inflammation, headache, and obesity The hypothetical relationship between obesity and" exact="migraine" post="has been linked to an elevated release of pro-inflammatory"/>
   <result pre="pro-inflammatory markers and neuroinflammation that might be principally involved in" exact="migraine" post="pain genesis [ 28]. Among the studied proinflammatory agents,"/>
   <result pre="seems there could be an epidemiological association between CRP and" exact="migraine" post="headache onset [ 63, 64]. Furthermore, a rise in"/>
   <result pre="In addition, due to the important role of CGRP in" exact="migraine" post="pathogenesis, the neuropeptide and its receptors are predominantly important"/>
   <result pre="the neuropeptide and its receptors are predominantly important targets for" exact="migraine" post="treatment [ 29]. On the other hand, evidence proposed"/>
   <result pre="adults with obesity, which is also observed in patients with" exact="migraine" post="[ 29, 30, 70, 71]. Moreover, it has been"/>
   <result pre="murine model, an elevation of CGRP level was reported before" exact="obesity" post="onset [ 70– 73]. Substance P (SP) in another"/>
   <result pre="another factor which is likely to play a role in" exact="migraine" post="attack pathogenesis that was also detected in adipose tissue"/>
   <result pre="accumulation and the start of the inflammatory cascade related to" exact="obesity" post="[ 70]. Adipokines and migraine Further, in recent years,"/>
   <result pre="the inflammatory cascade related to obesity [ 70]. Adipokines and" exact="migraine" post="Further, in recent years, the relationship between adipocytes released"/>
   <result pre="released factors, known as adipokines (e.g. adiponectin and leptin) and" exact="migraine" post="headache has given more insight into the contribution of"/>
   <result pre="into the contribution of adipose tissue in the pathophysiology of" exact="migraine" post="[ 23, 24]. Although more studies are required to"/>
   <result pre="increased between attack phases whereas it may be decreased during" exact="migraine" post="attacks [ 23, 24]. It has also been mentioned"/>
   <result pre="of this factor might be mediated following prophylactic treatment of" exact="migraine" post="with topiramate [ 23]. Thus, it could be hypothesized"/>
   <result pre="that chronic rise in adiponectin level might be beneficial in" exact="migraine" post="improvement [ 23]. This issue might be related to"/>
   <result pre="appears be involved in increasing the risk of developing obesity," exact="atherosclerosis" post="and diabetes [ 22, 75]. Additionally, increased leptin level"/>
   <result pre="induce secretion of proinflammatory factors that play a role in" exact="migraine" post="(IL-6 and TNF- α) and NO, through NFκβ signaling"/>
   <result pre="of the researches concerning the association between leptin levels and" exact="migraine" post="have not been conclusive yet [ 23]. Nonetheless, it"/>
   <result pre="hand, the increment in serotonin concentrations in ictal periods in" exact="migraine" post="can possibly be attributed to the secretion of serotonin"/>
   <result pre="homeostatic pathways which are involved in risk of attack generation," exact="migraine" post="nociception and characteristics, as well as its premonitory stage"/>
   <result pre="the medications that can affect the orexinergic system may ameliorate" exact="migraine" post="associated gastrointestinal features [ 77]. However, more studies are"/>
   <result pre="in order to address the association between orexin A and" exact="migraine" post="headache in obese and non-obese individuals and explore the"/>
   <result pre="treatment [ 77]. For instance, NPY concentrations in plasma of" exact="migraine" post="suffers may be elevated following treatment with flunarizine or"/>
   <result pre="trial conducted to assess the role of fat-reduced diet for" exact="migraine" post="control in 54 adults. Patients were instructed to restrict"/>
   <result pre="a diet change in comparison with a placebo supplement on" exact="migraine" post="patients. For the first 16-week duration, 42 individuals were"/>
   <result pre="association between dietary fat and headache with a focus on" exact="migraine" post="pathogenesis Fat intake, inflammation, hypercoagulability and hyperaggregability Amount and"/>
   <result pre="87]. On the flip side, it has been suggested that" exact="migraine" post="attack could be initiated following and condition that causes"/>
   <result pre="these factors simultaneously may contribute to head pain initiation in" exact="migraine" post="[ 88]. In particular, it is proposed that vulnerability"/>
   <result pre="[ 88]. In particular, it is proposed that vulnerability to" exact="migraine" post="is likely to be related to constant low concentration"/>
   <result pre="this regard, suppressing platelet aggregation might have therapeutic value in" exact="migraine" post="prevention [ 88]. Therefore, any modalities in dietary fat"/>
   <result pre="platelet aggregation, seems to decrease the frequency and duration of" exact="migraine" post="headache [ 78, 88]. Elimination diet Each headache patients"/>
   <result pre="red wine are among the proposed foods that may trigger" exact="migraine" post="attacks [ 13, 89, 90]. However, there is not"/>
   <result pre="speculation about the way that food triggers may act in" exact="migraine" post="attack initiation and some probable mechanisms are proposed: the"/>
   <result pre="(RCT), applied the personalized method for eliminating trigger food in" exact="migraine" post="suffers, using IgG antibodies to food antigens [ 92,"/>
   <result pre="92, 93]. Although, the 12-week parallel-group trial on patients with" exact="migraine" post="like headaches that examined the impact of the elimination"/>
   <result pre="[ 93], the other study demonstrated beneficial effects in reducing" exact="migraine" post="headaches [ 92]. In this research, the effect of"/>
   <result pre="of the eliminating diet in migraineurs, who also suffered from" exact="irritable bowel syndrome" post="was explored. It was reported that a diet excluding"/>
   <result pre="small cross-over RCT showed that individualized elimination diet could reduce" exact="migraine" post="frequency and abortive medication need, compared to a standard"/>
   <result pre="headache patients with food sensitivities could be effective in preventing" exact="migraine" post="attacks, though more studies are needed [ 94]. Some"/>
   <result pre="diet [ 95]. With respect to the probable link between" exact="migraine" post="and allergy [ 96, 97], and due to the"/>
   <result pre="95]. With respect to the probable link between migraine and" exact="allergy" post="[ 96, 97], and due to the beneficial effects"/>
   <result pre="hypothesized that this type of diet might be promising in" exact="migraine" post="control particularly among allergic patients. Suggested mechanisms for the"/>
   <result pre="effects of elimination diet on headache with a focus on" exact="migraine" post="pathogenesis The mechanisms of IgG-mediated food allergy have not"/>
   <result pre="with a focus on migraine pathogenesis The mechanisms of IgG-mediated" exact="food allergy" post="have not been entirely clarified, but it has been"/>
   <result pre="a focus on migraine pathogenesis The mechanisms of IgG-mediated food" exact="allergy" post="have not been entirely clarified, but it has been"/>
   <result pre="increase in production of pro-inflammatory mediators and IgG antibodies through" exact="food allergy" post="reaction can induce an inflammatory state that may play"/>
   <result pre="in production of pro-inflammatory mediators and IgG antibodies through food" exact="allergy" post="reaction can induce an inflammatory state that may play"/>
   <result pre="inflammatory state that may play a crucial role in the" exact="migraine" post="pathophysiology [ 92]. In both migraine and food sensitivities,"/>
   <result pre="crucial role in the migraine pathophysiology [ 92]. In both" exact="migraine" post="and food sensitivities, inflammation induced by food could make"/>
   <result pre="habits in order to prevent chronic inflammation and occurrence of" exact="migraine" post="in sensitized patients [ 18]. Low sodium diet According"/>
   <result pre="103]. Otherwise, in a descriptive study on 266 women with" exact="migraine" post="headache, severe headache (measured by visual analogue scale (VAS):"/>
   <result pre="able to make certain advice for optimal sodium intake in" exact="migraine" post="patients. Suggested mechanisms for the effects of low sodium"/>
   <result pre="the present review, different nutritional interventions might be effective in" exact="migraine" post="and their associated symptoms. There are different types of"/>
   <result pre="are different types of diets that are thought to attenuate" exact="migraine" post="headache. For example, KD and MAD might play a"/>
   <result pre="promising in headache/migraine control through attenuating the inflammatory state. Moreover," exact="obesity" post="and headaches especially migraine could be attributed to each"/>
   <result pre="through attenuating the inflammatory state. Moreover, obesity and headaches especially" exact="migraine" post="could be attributed to each other through mechanisms like"/>
   <result pre="tone. Regarding elimination diet, it could mostly be effective in" exact="migraine" post="patients with food sensitivities to prevent the headaches. Because"/>
   <result pre="some sections it was not possible to differentiate headache and" exact="migraine" post="in included articles, and given there is a dearth"/>
   <result pre="mass index CDH Chronic daily headache CGRP Calctonin-Gene-Related-Peptide CM Chronic" exact="migraine" post="CRP C-reactive protein CSD Cortical spreading depression DASH Dietary"/>
   <result pre="spreading depression DASH Dietary approach to stop hypertension EM Episodic" exact="migraine" post="GI Glycemic index IL Interleukin KD Ketogenic diets LGD"/>
   <result pre="Al-Raddadi RM et al. Global, regional, and national burden of" exact="migraine" post="and tension-type headache, 1990–2016: a systematic analysis for the"/>
   <result pre="Sex differences in the epidemiology, clinical features, and pathophysiology of" exact="migraine" post="Lancet Neurol 2017 16 1 76 87 10.1016/S1474-4422(16)30293-9 27836433"/>
   <result pre="63 70 10.1007/s10072-017-3141-0 29022143 7. Martin PR Behavioral management of" exact="migraine" post="headache triggers: learning to cope with triggers Curr Pain"/>
   <result pre="Spitaleri D Casucci G Bussone G Usefulness of nutraceuticals in" exact="migraine" post="prophylaxis Neurol Sci 2017 38 Suppl 1 117 120"/>
   <result pre="MM Gan SH Vitamin supplementation as possible prophylactic treatment against" exact="migraine" post="with aura and menstrual migraine Biomed Res Int 2015"/>
   <result pre="as possible prophylactic treatment against migraine with aura and menstrual" exact="migraine" post="Biomed Res Int 2015 2015 469529 25815319 10. Ferroni"/>
   <result pre="C Sivori G Food as trigger and aggravating factor of" exact="migraine" post="Neurol Sci 2012 33 Suppl 1 S77 S80 10.1007/s10072-012-1046-5"/>
   <result pre="Coppola G Sirianni G Pierelli F Short term improvement of" exact="migraine" post="headaches during ketogenic diet: a prospective observational study in"/>
   <result pre="15. Barañano KW Hartman AL The ketogenic diet: uses in" exact="epilepsy" post="and other neurologic illnesses Curr Treat Options Neurol 2008"/>
   <result pre="BL The role of the Adipocytokines Adiponectin and Leptin in" exact="migraine" post="J Am Osteopathic Assoc 2009 109 6 314 317"/>
   <result pre="Hansen HD Knudsen GM Ashina M Serotonergic mechanisms in the" exact="migraine" post="brain–a systematic review Cephalalgia. 2017 37 3 251 264"/>
   <result pre="LR Genetic and biochemical changes of the serotonergic system in" exact="migraine" post="pathobiology J Headache Pain 2017 18 1 20 10.1186/s10194-016-0711-0"/>
   <result pre="28194570 28. Ramachandran R Neurogenic inflammation and its role in" exact="migraine" post="Semin Immunopathol 2018 40 3 301 314 10.1007/s00281-018-0676-y 29568973"/>
   <result pre="Warfvinge K Krause DN CGRP as the target of new" exact="migraine" post="therapies—successful translation from bench to clinic Nat Rev Neurol"/>
   <result pre="T Ashrafian H Bariatric surgery or non-surgical weight loss for" exact="idiopathic intracranial hypertension?" post="A systematic review and comparison of meta-analyses Obes Surg"/>
   <result pre="The effect body fat mass and fat free mass on" exact="migraine" post="headache Iran J Neurol 2013 12 1 23 27"/>
   <result pre="2012 3 59 22509165 38. Strahlman RS Can ketosis help" exact="migraine" post="sufferers? A case report Headache 2006 46 1 182"/>
   <result pre="G Bracaglia M Cardillo A et al. Diet transiently improves" exact="migraine" post="in two twin sisters: possible role of ketogenesis? Funct"/>
   <result pre="J Redecillas S et al. Paroxysmal exercise-induced dyskinesia, writer's cramp," exact="migraine" post="with aura and absence epilepsy in twin brothers with"/>
   <result pre="Paroxysmal exercise-induced dyskinesia, writer's cramp, migraine with aura and absence" exact="epilepsy" post="in twin brothers with a novel SLC2A1 missense mutation"/>
   <result pre="long period follow-up results of low glycemic index diet for" exact="migraine" post="prophylaxis Agrı 2018 30 1 8 11 29450870 50."/>
   <result pre="Kim HD Low glycemic index treatment in patients with drug-resistant" exact="epilepsy" post="Brain Dev 2017 39 8 687 692 10.1016/j.braindev.2017.03.027 28431772"/>
   <result pre="Vithiananthan S Nash J Thomas J Wing R Improvement of" exact="migraine" post="headaches in severely obese patients after bariatric surgery Neurology"/>
   <result pre="Alizadeh Z Talebpour M et al. Bariatric surgery promising in" exact="migraine" post="control: a controlled trial on weight loss and its"/>
   <result pre="a controlled trial on weight loss and its effect on" exact="migraine" post="headache Obes Surg 2018 28 1 87 96 10.1007/s11695-017-2793-4"/>
   <result pre="al. Changes in headache frequency in premenopausal obese women with" exact="migraine" post="after bariatric surgery: a case series Cephalalgia 2011 31"/>
   <result pre="10.1177/0333102411413162 21700645 60. Sachdev A Marmura MJ Metabolic syndrome and" exact="migraine" post="Front Neurol 2012 3 161 10.3389/fneur.2012.00161 23181051 61. Cavestro"/>
   <result pre="Kalita J Misra UK Metabolic syndrome and insulin resistance in" exact="migraine" post="J Headache Pain 2012 13 4 321 326 10.1007/s10194-012-0416-y"/>
   <result pre="P Pavone P Verrotti A Lubrano R et al. Headache," exact="migraine" post="and obesity: an overview on plausible links J Biol"/>
   <result pre="338 27358118 64. Tietjen GE Khubchandani J Vascular biomarkers in" exact="migraine" post="Cephalalgia. 2015 35 2 95 117 10.1177/0333102414544976 25281220 65."/>
   <result pre="and lymphocyte integrin expression in the internal jugular blood of" exact="migraine" post="patients without aura assessed ictally Headache 2006 46 2"/>
   <result pre="importance of cytokines, chemokines and nitric oxide in pathophysiology of" exact="migraine" post="J Neuroimmunol 2006 171 1–2 184 188 10.1016/j.jneuroim.2005.10.005 16325275"/>
   <result pre="Cikriklar H Serum levels of endocan, claudin-5 and cytokines in" exact="migraine" post="Eur Rev Med Pharmacol Sci 2016 20 5 930"/>
   <result pre="HP Lips CJ Hackeng WH Calcitonin gene-related peptide in human" exact="obesity" post="Peptides 1991 12 4 861 863 10.1016/0196-9781(91)90147-H 1788147 72."/>
   <result pre="lacking the neuropeptide alpha-calcitonin gene-related peptide are protected against diet-induced" exact="obesity" post="Endocrinology. 2010 151 9 4257 4269 10.1210/en.2010-0284 20610563 73."/>
   <result pre="Lipton RB Holland PR Goadsby PJ Obesity, migraine, and chronic" exact="migraine" post="possible mechanisms of interaction Neurology. 2007 68 21 1851"/>
   <result pre="Srikiatkhachorn A Supronsinchai W Targeted Orexin and hypothalamic neuropeptides for" exact="migraine" post="Neurotherapeutics 2018 15 2 377 390 10.1007/s13311-017-0602-3 29442286 78."/>
   <result pre="influence of a low-fat diet on incidence and severity of" exact="migraine" post="headaches J Women’s Health Gender-Based Med 1999 8 5"/>
   <result pre="et al. Low-lipid diet reduces frequency and severity of acute" exact="migraine" post="attacks Nutr Metab Cardiovasc Dis 2015 25 4 370"/>
   <result pre="tumor necrosis factor (TNF)-α gene expression and serum level in" exact="migraine" post="patients Immunogenetics. 2017 69 6 371 378 10.1007/s00251-017-0992-8 28478481"/>
   <result pre="6 371 378 10.1007/s00251-017-0992-8 28478481 83. Horrobin D Prostaglandins and" exact="migraine" post="Headache 1977 17 3 113 117 10.1111/j.1526-4610.1977.hed1703113.x 330466 84."/>
   <result pre="acids on platelet function in healthy subjects and subjects with" exact="cardiovascular disease" post="Semin Thromb Hemost 2013 39 1 25 32 10.1055/s-0032-1333309"/>
   <result pre="control serotonin synthesis and action, part 2: relevance for ADHD," exact="bipolar disorder," post="schizophrenia, and impulsive behavior FASEB J 2015 29 6"/>
   <result pre="NM Matos FC Santos JP et al. Trigger factors in" exact="migraine" post="patients Arq Neuropsiquiatr 2008 66 3a 494 499 10.1590/S0004-282X2008000400011"/>
   <result pre="Littlewood JT Sandler M Clifford RF The prevalence of diet-induced" exact="migraine" post="Cephalalgia 1984 4 3 179 183 10.1046/j.1468-2982.1984.0403179.x 6498931 91."/>
   <result pre="Aksu M Gunsoy HG et al. IgG-based elimination diet in" exact="migraine" post="plus irritable bowel syndrome Headache 2013 53 3 514"/>
   <result pre="Gunsoy HG et al. IgG-based elimination diet in migraine plus" exact="irritable bowel syndrome" post="Headache 2013 53 3 514 525 10.1111/j.1526-4610.2012.02296.x 23216231 93."/>
   <result pre="elimination diet based on IgG antibodies for the prevention of" exact="migraine" post="like headaches Nutr J 2011 10 1 85 10.1186/1475-2891-10-85"/>
   <result pre="GV et al. Allergy and immunotherapy: are they related to" exact="migraine" post="headache? Headache 2011 51 1 8 20 10.1111/j.1526-4610.2010.01792.x 21054364"/>
   <result pre="adherence to dietary approaches to stop hypertension (DASH) diet and" exact="migraine" post="headache severity and duration among women. Nutr Neurosci:1–8 [Epub"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6854910/results/search/disease/results.xml">
   <result pre="gluten-dependent clinical manifestations, CD-specific antibodies, HLA-DQ2 or HLA-DQ8 haplotypes, and" exact="enteropathy" post="[ 1]. Potential CD (PCD) is the condition related"/>
   <result pre="first 12 months of GFD. However, the authors speculated about" exact="irritable bowel syndrome" post="as a significant confounding factor in these patients ["/>
   <result pre="Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of" exact="coeliac disease" post="Journal of Pediatric Gastroenterology and Nutrition 2012 54 1"/>
   <result pre="A. Bai J. C. et al. The Oslo definitions for" exact="coeliac disease" post="and related terms Gut 2013 62 1 43 52"/>
   <result pre="coeliac iceberg in Italy. A multicentre antigliadin antibodies screening for" exact="coeliac disease" post="in school-age subjects Acta Paediatrica. Supplement 1996 412 29"/>
   <result pre="amount of dietary gluten on gastrointestinal morphology and function in" exact="dermatitis" post="herpetiformis Human Nutrition. Clinical Nutrition 1984 38 4 279"/>
   <result pre="P. et al. Small-bowel mucosal transglutaminase 2-specific IgA deposits in" exact="coeliac disease" post="without villous atrophy: a prospective and randomized clinical study"/>
   <result pre="anti-transglutaminase 2 immunoglobulin A deposits in children at risk for" exact="coeliac disease" post="(CD): data from the prevent CD study Clinical and"/>
   <result pre="against transglutaminase 2 in the small intestinal mucosa predict forthcoming" exact="coeliac disease" post="Alimentary Pharmacology &amp;amp; Therapeutics 2006 24 3 541 552"/>
   <result pre="et al. Villous tip intraepithelial lymphocytes as markers of early-stage" exact="coeliac disease" post="Scandinavian Journal of Gastroenterology 2004 39 5 428 433"/>
   <result pre="S. Intraepithelial gamma delta T-cell-receptor lymphocytes and genetic susceptibility to" exact="coeliac disease" post="Lancet 1992 339 8808 1500 1503 10.1016/0140-6736(92)91262-7 1351185 30"/>
   <result pre="Kurppa K. Collin P. Viljamaa M. et al. Diagnosing mild" exact="enteropathy" post="celiac disease: a randomized, controlled clinical study Gastroenterology 2009"/>
   <result pre="in the morphologically normal jejunum were predictive of forthcoming overt" exact="coeliac disease" post="with villous atrophy. Jarvinen et al. [ 27] 2004"/>
   <result pre="lymphocyte count was statistically significantly higher in patients with early-stage" exact="coeliac disease" post="than in nonceliac controls (sensitivity, 0.84; specificity, 0.88). Paparo"/>
   <result pre="and specificity of 93% and 93%, respectively, in detecting subsequent" exact="coeliac disease." post="Koskinen et al. [ 21] 2010 Mucosal transglutaminase 2-specific"/>
   <result pre="[ 41] Against GFD 47 children Association between CD and" exact="irritable bowel syndrome" post="may be a significant confounding factor Irritable bowel syndrome"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6858833/results/search/disease/results.xml">
   <result pre="and 5 of our Terms ( https://www.dovepress.com/terms.php). Abstract Abstract Pediatric-onset" exact="multiple sclerosis" post="(POMS) is an immune-mediated, demyelinating, neurodegenerative disease that accounts"/>
   <result pre="immune-mediated, demyelinating, neurodegenerative disease that accounts for 3–5% of all" exact="multiple sclerosis" post="(MS) cases. Although evidence suggests that it has similar"/>
   <result pre="disease-modifying therapy demyelinating disease S1P receptor modulator neuroimmunology pediatric onset" exact="multiple sclerosis" post="table-count: ref-count: page-count: Introduction Multiple sclerosis (MS) is an"/>
   <result pre="MS cases occurring in childhood or adolescence. 1– 3 Pediatric-onset" exact="multiple sclerosis" post="(POMS) is defined as onset of disease prior to"/>
   <result pre="were transient cases of lymphopenia and cough, as well as" exact="urinary tract infection" post="and leg paresthesia. Compared to a historical cohort from"/>
   <result pre="events were observed with first dose and no lymphopenia or" exact="macular edema" post="were reported during periods of treatment. There were single"/>
   <result pre="genital herpes and upper respiratory infection, and 2 cases of" exact="urinary tract infection." post="Most recently Egyptian registry data of 186 POMS patients"/>
   <result pre="serious adverse events. There were also single cases of agranulocytosis," exact="second-degree atrioventricular block," post="elevated alanine aminotransferase and γ-glutamyltransferase levels, autoimmune uveitis, gastrointestinal"/>
   <result pre="adverse events. There were also single cases of agranulocytosis, second-degree" exact="atrioventricular block," post="elevated alanine aminotransferase and γ-glutamyltransferase levels, autoimmune uveitis, gastrointestinal"/>
   <result pre="alanine aminotransferase and γ-glutamyltransferase levels, autoimmune uveitis, gastrointestinal necrosis, and" exact="macular edema" post="reported, among others. Serious infections occurred in 4 fingolimod"/>
   <result pre="Fingolimod is an oral DMT for the treatment of relapsing-remitting" exact="multiple sclerosis." post="It was approved in September 2010 by FDA to"/>
   <result pre="observational studies, there were a few cases of seizures and" exact="leukopenia" post="among others in the PARADIGMS trial. In terms of"/>
   <result pre="infectious complications were most commonly reported. It is believed that" exact="leukopenia" post="and lymphopenia, as a result of fingolimod’s mechanism of"/>
   <result pre="less than 6% in PARADIGMS. Despite only 1 case of" exact="macular edema" post="reported in the PARADIGMS trial, similar screening measures for"/>
   <result pre="edema reported in the PARADIGMS trial, similar screening measures for" exact="macular edema," post="as well as for bradyarrythmia and herpes virus infection"/>
   <result pre="gastrointestinal necrosis (intussusception or necrotic bowel), head injury, humerus fracture," exact="hypersensitivity" post="vasculitis, migraine, migraine without aura, multiple sclerosis plaque, muscular"/>
   <result pre="or necrotic bowel), head injury, humerus fracture, hypersensitivity vasculitis, migraine," exact="migraine" post="without aura, multiple sclerosis plaque, muscular weakness, rectal tenesmus,"/>
   <result pre="head injury, humerus fracture, hypersensitivity vasculitis, migraine, migraine without aura," exact="multiple sclerosis" post="plaque, muscular weakness, rectal tenesmus, 2° atrioventricular block, and"/>
   <result pre="without aura, multiple sclerosis plaque, muscular weakness, rectal tenesmus, 2°" exact="atrioventricular block," post="and small-intestinal obstruction (0.9%) Huppke et al 19 Observational,"/>
   <result pre="al 21 Observational, 8 patients 50% None Abbreviations: POMS, pediatric-onset" exact="multiple sclerosis;" post="AE, adverse events; RCT, randomized controlled trial; ALT, alanine"/>
   <result pre=", Jaffin S , Healy B . Demographics of pediatric-onset" exact="multiple sclerosis" post="in an MS center population from the Northeastern United"/>
   <result pre="10.1212/WNL.0000000000003028 27572865 5. Chitnis T . Disease-modifying therapy of pediatric" exact="multiple sclerosis." post="Neurotherapeutics . 2013; 10: 89– 96. doi: 10.1007/s13311-012-0158-1 23224690"/>
   <result pre="I , von Kries R , Hanefeld F . Paediatric" exact="multiple sclerosis" post="and acute disseminated encephalomyelitis in Germany: results of a"/>
   <result pre="Kries R , Hanefeld F . Paediatric multiple sclerosis and" exact="acute disseminated encephalomyelitis" post="in Germany: results of a nationwide survey . Eur"/>
   <result pre=", Hanefeld F . Paediatric multiple sclerosis and acute disseminated" exact="encephalomyelitis" post="in Germany: results of a nationwide survey . Eur"/>
   <result pre="DL , et al. Clinical, environmental, and genetic determinants of" exact="multiple sclerosis" post="in children with acute demyelination: a prospective national cohort"/>
   <result pre=". Interactions between genetic, lifestyle and environmental risk factors for" exact="multiple sclerosis" post=". Nat Rev Neurol . 2017; 13( 1): 25–"/>
   <result pre="J , Weinstock-Guttman B , et al. Distinct effects of" exact="obesity" post="and puberty on risk and age at onset of"/>
   <result pre="B cell autoimmunity to a myelin surface antigen in pediatric" exact="multiple sclerosis" post=". J Immunol . 2009; 183( 6): 4067– 4076."/>
   <result pre="and sex hormones in determining the onset and outcome of" exact="multiple sclerosis" post=". Mult Scler . 2014; 20( 5): 520– 526."/>
   <result pre="et al. Trial of fingolimod versus interferon beta-1a in pediatric" exact="multiple sclerosis." post="N Engl J Med . 2018; 379( 11): 1017–"/>
   <result pre="Ellenberger D , et al. Therapy of highly active pediatric" exact="multiple sclerosis." post="Mult Scler . 2019; 25( 1): 72– 80. doi:"/>
   <result pre="AA , et al. Fingolimod prescribed for the treatment of" exact="multiple sclerosis" post="in patients younger than age 18 years . Pediatr"/>
   <result pre=", Abdel-Naseer M , Shalaby NM , et al. Pediatric-onset" exact="multiple sclerosis" post="in Egypt: a multi-center registry of 186 patients. Neuropsychiatr"/>
   <result pre=", et al. Disease reactivation after fingolimod discontinuation in two" exact="multiple sclerosis" post="patients. J Neurol . 2013; 260( 1): 327– 329."/>
   <result pre="Amato MP . Rebound after Fingolimod suspension in a pediatric-onset" exact="multiple sclerosis" post="patient. J Neurol . 2013; 260( 6): 1675– 1677."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6867755/results/search/disease/results.xml">
   <result pre="17864 : 6200: Research Article Clinical Case Report Acute ischemic" exact="stroke" post="in a 7-month-old infant, risk factors, and diagnosis peculiarities"/>
   <result pre="work is properly cited. http://creativecommons.org/licenses/by/4.0 medi-98-e17864.pdf Abstract Abstract Introduction: Ischemic" exact="stroke" post="is an extremely rare disorder in children. The timely"/>
   <result pre="and anti-beta2 glycoproteins I antibodies, whereas the genetic profile for" exact="thrombophilia" post="revealed heterozygote mutation in MTHFR C677T and A1298C genes."/>
   <result pre="altered lipid profiles contributed to the development of acute ischemic" exact="stroke" post="in our patient. Keywords infant ischemic stroke vascular malformation"/>
   <result pre="of acute ischemic stroke in our patient. Keywords infant ischemic" exact="stroke" post="vascular malformation 1 Introduction Stroke is defined by the"/>
   <result pre="acute radiological abnormality with evidence of ischemia. [ 1] Childhood" exact="stroke" post="must occur between the age of 28 days and"/>
   <result pre="for at least 24 hours. [ 2] The incidence of" exact="stroke" post="in pediatric ages is extremely low accounting for up"/>
   <result pre="[ 4] Moreover, up to 90% of the children with" exact="stroke" post="present neurologic deficits and seizures, 20% of cases present"/>
   <result pre="leading cause of death. [ 5, 6] The reports of" exact="stroke" post="in children are few in the literature and most"/>
   <result pre="between pediatric and adult stroke. Thus, in children 50% of" exact="stroke" post="cases are ischemic as compared to 85% of adult"/>
   <result pre="on these striking differences, the approach of a child with" exact="stroke" post="is different from adults. Brain imaging is mandatory for"/>
   <result pre="imaging is mandatory for both the confirmation of an ischemic" exact="stroke" post="and to exclude a hemorrhagic one. [ 10] Each"/>
   <result pre="sensitivity for acute hemorrhage, but low sensitivity for acute ischemic" exact="stroke" post="within the first 6 hours, being readily available and fast."/>
   <result pre="appropriate evaluation. [ 10] The evaluation of a child with" exact="stroke" post="should also involve the identification of potential risk factors"/>
   <result pre="The acute management in case of infants and children with" exact="stroke" post="involves appropriate oxygenation, assurance of airway integrity and adequate"/>
   <result pre="appropriateness pediatrician-child-parents relationship, and specific medical centers for children with" exact="stroke" post="should exist also in our country in order to"/>
   <result pre="the particularities related to the diagnosis and management of ischemic" exact="stroke" post="in a 7-month-old infant. The written informed consent was"/>
   <result pre="right limbs. The family history revealed that maternal grandfather had" exact="acute myocardial infarction" post="and maternal great grandmother had both acute myocardial infarction"/>
   <result pre="had acute myocardial infarction and maternal great grandmother had both" exact="acute myocardial infarction" post="and stroke. His recent personal history showed an episode"/>
   <result pre="glycoproteins I antibodies were positive, whereas the genetic profile for" exact="thrombophilia" post="revealed heterozygote mutation in MTHFR C677T and A1298C genes."/>
   <result pre="lipoprotein cholesterol (137 mg/dl). The echocardiography showed a minor ostium secundum" exact="atrial septal defect" post="and aneurism of interatrial septum, while the electrocardiogram was"/>
   <result pre="we recommended continuing the anticoagulant therapy lifelong. 3 Discussions Ischemic" exact="stroke" post="is extremely rare in children beyond the neonatal period."/>
   <result pre="is well-documented that during the neonatal period, the incidence of" exact="stroke" post="may vary between 1 in 4400 and 1 in"/>
   <result pre="[ 10, 12] Moreover, in the USA the prevalence of" exact="cerebral palsy" post="account for 3.1 cases in 1000 children with the"/>
   <result pre="a normal socio-economic level. The most common risk factors for" exact="stroke" post="in children are arteriopathy, cardiac diseases, other chronic disorders"/>
   <result pre="in children are arteriopathy, cardiac diseases, other chronic disorders (e.g." exact="iron deficiency anemia," post="sickle cell anemia, different genetic syndromes, aneurysms, autoimmune disorders,"/>
   <result pre="arteriopathy, cardiac diseases, other chronic disorders (e.g. iron deficiency anemia," exact="sickle cell anemia," post="different genetic syndromes, aneurysms, autoimmune disorders, prothrombotic state, etc.),"/>
   <result pre="also a complex cerebral vascular malformation. Despite the fact that" exact="dyslipidemia" post="and obesity are known as risk factors in adults,"/>
   <result pre="complex cerebral vascular malformation. Despite the fact that dyslipidemia and" exact="obesity" post="are known as risk factors in adults, our infant"/>
   <result pre="in diagnosis are due to both the rarity of ischemic" exact="stroke" post="and atypical symptoms in pediatric patients. Thus, stroke mimics"/>
   <result pre="of ischemic stroke and atypical symptoms in pediatric patients. Thus," exact="stroke" post="mimics in children might consist in seizures, migraine, syncope,"/>
   <result pre="also be taken into account for the differential diagnosis of" exact="stroke" post="in these age groups. [ 25] Our patient presented"/>
   <result pre="the first step in the assessment of a child with" exact="stroke" post="is CT since it is readily available, and it"/>
   <result pre="cases. Nevertheless, a study performed on 26 patients with acute" exact="stroke" post="suggested that magnetic resonance angiography might overestimate the stenosis"/>
   <result pre="stenosis, or occlusion as the most common etiology for ischemic" exact="stroke" post="in pediatric patients. [ 27] In our case, the"/>
   <result pre="of left anterior cerebral artery. The outcome of children with" exact="stroke" post="depends mostly on the timely diagnosis, but the mortality"/>
   <result pre="high. Thus, a prospective study performed on 95 children with" exact="stroke" post="from Switzerland with a follow-up period of approximately 7"/>
   <result pre="6 months from the incident of stroke. 4 Conclusions Ischemic" exact="stroke" post="in children is an uncommon pathology that is often"/>
   <result pre="altered lipid profiles contributed to the development of acute ischemic" exact="stroke" post="in our patient. The outcome of children with stroke"/>
   <result pre="ischemic stroke in our patient. The outcome of children with" exact="stroke" post="depends mostly on the timely diagnosis. Author contributions Conceptualization:"/>
   <result pre="Meliţ LE, Mărginean CO, Simu I, Bucur G. Acute ischemic" exact="stroke" post="in a 7-month-old infant, risk factors and diagnosis peculiarities."/>
   <result pre="and diagnosis peculiarities. Medicine. 2019;98:46(e17864). Table of Contents Summary: Ischemic" exact="stroke" post="is an extremely rare disorder in children. The timely"/>
   <result pre="profiles are important risk factors for both ischemic and hemorrhagic" exact="stroke" post="independently of the age. Verbal and written informed consent"/>
   <result pre="Masri A Al-Ammouri I Clinical presentation, etiology, and outcome of" exact="stroke" post="in children: A hospital-based study . Brain Dev 2016;"/>
   <result pre="of Neurological Disorders and Stroke workshop on perinatal and childhood" exact="stroke" post=". Pediatrics 2002; 109: 116– 23. 11773550 [3] Kissela"/>
   <result pre="Alwell K et al. Age at stroke: temporal trends in" exact="stroke" post="incidence in a large, biracial population. Neurology 2012; 79:"/>
   <result pre="Roach ES Golomb MR Adams R et al. Management of" exact="stroke" post="in infants and children: a scientific statement from a"/>
   <result pre="Varela-Bulgarelli F Barboza C et al. Presentation of acute childhood" exact="stroke" post="in a tertiary pediatric emergency department. Pediatr Emerg Care"/>
   <result pre="371– 8. 10668698 [10] Lo WD Kumar R Arterial ischemic" exact="stroke" post="in children and young adults. Continuum (Minneap Minn) 2017;"/>
   <result pre="Van Naarden Braun K Doernberg NS et al. Prevalence of" exact="cerebral palsy," post="co-occurring autism spectrum disorders, and motor functioning - Autism"/>
   <result pre="K Doernberg NS et al. Prevalence of cerebral palsy, co-occurring" exact="autism" post="spectrum disorders, and motor functioning - Autism and Developmental"/>
   <result pre="MH Krishnamurthi R et al. Global and regional burden of" exact="stroke" post="during 1990-2010: findings from the Global Burden of Disease"/>
   <result pre="C&amp;gt;G polymorphisms, fat mass, and anthropometric characteristics in predicting childhood" exact="obesity" post="at birth: a cross-sectional study according the parental characteristics"/>
   <result pre="study according the parental characteristics and newborn's risk for child" exact="obesity" post="(the newborns obesity's risk) NOR study . Medicine (Baltimore)"/>
   <result pre="Ghiga D et al. Early inflammatory status related to pediatric" exact="obesity" post="(STROBE compliant article). Front Pediatr 2019; 7. 30778379 [21]"/>
   <result pre="Mocanu S et al. A rare case of iron-pill induced" exact="gastritis" post="in a female teenager: a case report and a"/>
   <result pre="A Arnold M et al. Long-term outcome after arterial ischemic" exact="stroke" post="in children and young adults. Neurology 2015; 84: 1941–"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6868651/results/search/disease/results.xml">
   <result pre="medical history was notable for attention deficit disorder with hyperactivity," exact="bipolar disorder," post="exercise-induced asthma, hypermobile Ehlers–Danlos syndrome, and obsessive-compulsive disorder. At"/>
   <result pre="with hyperactivity, bipolar disorder, exercise-induced asthma, hypermobile Ehlers–Danlos syndrome, and" exact="obsessive-compulsive disorder." post="At diagnosis, his medications included albuterol, quetiapine, atomoxetine, and"/>
   <result pre="therapy with fludrocortisone and desmopressin. Increased pyridostigmine dosing for persistent" exact="constipation" post="led to muscle twitching, so the dose was reduced."/>
   <result pre="of venous pooling. Past medical history was notable for migraine," exact="anxiety disorder," post="obsessive-compulsive disorder, depression, Hashimoto's thyroiditis, bicuspid aortic valve with"/>
   <result pre="pooling. Past medical history was notable for migraine, anxiety disorder," exact="obsessive-compulsive disorder," post="depression, Hashimoto's thyroiditis, bicuspid aortic valve with trivial aortic"/>
   <result pre="obsessive-compulsive disorder, depression, Hashimoto's thyroiditis, bicuspid aortic valve with trivial" exact="aortic valve insufficiency" post="and no stenosis, and juvenile idiopathic arthritis. Medications at"/>
   <result pre="valve with trivial aortic valve insufficiency and no stenosis, and" exact="juvenile idiopathic arthritis." post="Medications at diagnosis included albuterol, azelastine, diclofenac, fludrocortisone, fluoxetine,"/>
   <result pre=", Grahame R , Jacob G Dysautonomia in the joint" exact="hypermobility syndrome." post="Am J Med. 2003; 115: 33– 40 12867232 12."/>
   <result pre="profile of postural orthostatic tachycardia patients with and without joint" exact="hypermobility syndrome" post=". Indian Pacing Electrophysiol J. 2010; 10: 173– 178"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6868768/results/search/disease/results.xml">
   <result pre="functional connectivity (FC) MRI has widely been used to understand" exact="migraine" post="pathophysiology and to identify an imaging marker of the"/>
   <result pre="articles reporting data obtained from conventional resting-state FC recording in" exact="migraine" post="patients compared with healthy controls or during and outside"/>
   <result pre="patients compared with healthy controls or during and outside of" exact="migraine" post="attacks in the same patients. Results We found 219"/>
   <result pre="after screening for inclusion and exclusion criteria. Twenty-five studies compared" exact="migraine" post="patients with healthy controls, whereas three studies investigated migraine"/>
   <result pre="compared migraine patients with healthy controls, whereas three studies investigated" exact="migraine" post="patients during and outside of attacks. In the studies"/>
   <result pre="during and outside of attacks. In the studies of interictal" exact="migraine" post="more alterations of more than 20 FC networks (including"/>
   <result pre="reported. We found a poor level of reproducibility and no" exact="migraine" post="specific pattern across these studies. Conclusion Based on the"/>
   <result pre="present review, it seems very difficult to extract knowledge of" exact="migraine" post="pathophysiology or to identify a biomarker of migraine. There"/>
   <result pre="Resting-state fMRI Functional connectivity Neuroimaging Migraine Headache Introduction Pathophysiology of" exact="migraine" post="is complex and, so far, no biomarker for any"/>
   <result pre="last decade, advanced neuroimaging modalities are increasingly used to understand" exact="migraine" post="pathophysiology and disease mechanisms in the search for imaging"/>
   <result pre="imaging (fMRI), which has been applied in increasing number of" exact="migraine" post="studies, since the first paper was published in 2011"/>
   <result pre="1]. Ideally, resting-state FC studies may be used to unveil" exact="migraine" post="mechanisms. The migraine resting-state literature is often analyzed and"/>
   <result pre="FC studies may be used to unveil migraine mechanisms. The" exact="migraine" post="resting-state literature is often analyzed and presented in several"/>
   <result pre="understand and are rarely reproduced. Thus, definitive imaging biomarkers for" exact="migraine" post="have still not been identified limiting the usefulness and"/>
   <result pre="to identify all original articles with resting-state FC data in" exact="migraine" post="patients. The literature search was finalized on Pubmed.com September"/>
   <result pre="control group was not available were also excluded (expect if" exact="migraine" post="attacks were compared to an interictal phase). Finally, studies"/>
   <result pre="1) and three during the ictal phase (Table 2) of" exact="migraine" post="(Fig. 1). The studies were published between 2011 and"/>
   <result pre="Table 1 Functional connectivity MRI during the interictal phase of" exact="migraine" post="compared with non-migraine controls Study Population and method Findings"/>
   <result pre="Findings Mainero, 2011 Ann Neurol [ 1] Origin: USA. 17" exact="migraine" post="(8 MA and 9 MO) patients were compared to"/>
   <result pre="Schwedt TJ, 2013 Headache [ 9] Origin: USA. 20 chronic" exact="migraine" post="patients were compared with 20 controls. Chronic migraine versus"/>
   <result pre="20 chronic migraine patients were compared with 20 controls. Chronic" exact="migraine" post="versus controls Anterior insula: atypical FC with pulvinar, middle"/>
   <result pre="and amygdala. Hadjikhani, 2013 Cephalalgia [ 10] Origin: USA. 22" exact="migraine" post="(11 MA and 11 MO) patients were compared to"/>
   <result pre="Headache Pain [ 18] Origin: China. 18 episodic migraine,16 chronic" exact="migraine" post="and 44 medication overuse headache (MOH) + chronic migraine patients were"/>
   <result pre="episodic migraine,16 chronic migraine and 44 medication overuse headache (MOH) + chronic" exact="migraine" post="patients were compared to 32 normal controls. Episodic migraine"/>
   <result pre="(MOH) + chronic migraine patients were compared to 32 normal controls. Episodic" exact="migraine" post="versus controls Right MdNS: increased FC with right ACC"/>
   <result pre="bilaterally placed in the marginal division of neostriatum (MdNS). Chronic" exact="migraine" post="versus controls Right MdNS: increased FC with right middle"/>
   <result pre="FC with bilateral middle frontal gyrus and left hippocampus. MOH + chronic" exact="migraine" post="versus controls Right MdNS: increased FC with right interior"/>
   <result pre="gyrus. Hodkinson DJ, 2016 eNeuro [ 19] Origin: USA 40" exact="migraine" post="patients were compared to 40 matched healthy controls. Migraine"/>
   <result pre="Androulakis M, 2017 Neurology [ 20] Origin: USA. 29 chronic" exact="migraine" post="patients were compared to 29 age- and sex-matched controls."/>
   <result pre="connectivity was decreased in all three networks in the chronic" exact="migraine" post="group compared to controls. Seed-based approach using MATLAB. Seeds"/>
   <result pre="2017 J Headache Pain [ 23] Origin: China. 18 episodic" exact="migraine" post="patients (15 MO, 3 MA) were compared with 18"/>
   <result pre="MO, 3 MA) were compared with 18 healthy controls. Episodic" exact="migraine" post="versus controls Right ventrolateral PAG: decreased FC with left"/>
   <result pre="2017 J Headache Pain [ 24] Origin: China. 18 episodic" exact="migraine" post="and 16 chronic migraine patients were compared to 18"/>
   <result pre="[ 24] Origin: China. 18 episodic migraine and 16 chronic" exact="migraine" post="patients were compared to 18 normal controls. Episodic migraine"/>
   <result pre="chronic migraine patients were compared to 18 normal controls. Episodic" exact="migraine" post="versus controls Left amygdala: increased FC with left middle"/>
   <result pre="approach using MATLAB. Seed were bilaterally placed in amygdala. Chronic" exact="migraine" post="versus controls Left amygdala: no change. Right amygdala: decreased"/>
   <result pre="occipital lobe and right middle occipital lobe. Chronic versus episodic" exact="migraine" post="Left amygdala: inferior temporal gyrus, right orbital part of"/>
   <result pre="connectivity MRI during and outside of the ictal phase of" exact="migraine" post="Study Population and method Findings Amin FM, 2016 Neurology"/>
   <result pre="before and after a vasodilator drug which did not provoke" exact="migraine" post="attacks. During versus before attack SN: increased FC of"/>
   <result pre="of the literature search on functional connectivity (FC) studies in" exact="migraine" post="Interictal migraine versus non-headache controls Twenty-five published studies reported"/>
   <result pre="literature search on functional connectivity (FC) studies in migraine Interictal" exact="migraine" post="versus non-headache controls Twenty-five published studies reported data comparing"/>
   <result pre="versus non-headache controls Twenty-five published studies reported data comparing interictal" exact="migraine" post="with non-migraine non-headache controls. In 12 studies a migraine"/>
   <result pre="interictal migraine with non-migraine non-headache controls. In 12 studies a" exact="migraine" post="without aura (MO) population was examined, while pure migraine"/>
   <result pre="a migraine without aura (MO) population was examined, while pure" exact="migraine" post="with aura (MA) was only investigated in a single"/>
   <result pre="results were reported in the remaining eight studies. When comparing" exact="migraine" post="patient to controls, the functional connectivity was changed within"/>
   <result pre="networks reported in a total of 25 studies of interictal" exact="migraine" post="patients compared with healthy controls Ictal migraine versus non-headache"/>
   <result pre="studies of interictal migraine patients compared with healthy controls Ictal" exact="migraine" post="versus non-headache controls Three conventional resting-state FC studies (one"/>
   <result pre="two MO) have been published during compared to outside of" exact="migraine" post="attacks. Following networks or areas showed altered connectivity during"/>
   <result pre="brainstem and cerebellum showed altered connectivity in interictal and ictal" exact="migraine" post="studies. The findings are very diverse, with change in"/>
   <result pre="change in FC in many area thought to relevant for" exact="migraine" post="as well as several other areas. The fact that"/>
   <result pre="introduced to investigate if FC changes can be linked to" exact="migraine" post="phenotypes in the examined populations, but even here findings"/>
   <result pre="none of the reported FC changes may be specific for" exact="migraine" post="as other studies reported similar or exact same network"/>
   <result pre="or exact same network changes in several other conditions, including" exact="fibromyalgia" post="[ 33], Parkinsonian syndromes [ 34, 35] altered consciousness"/>
   <result pre="consciousness states [ 36], systemic lupus [ 37] and chronic" exact="hepatitis" post="C virus infection [ 38]. Thus, it can be"/>
   <result pre="may be useful for the study of specific sub-types of" exact="migraine" post="if these are clearly selected beforehand, preferable based on"/>
   <result pre="underlying disease mechanisms, but so far no reproducible biomarkers of" exact="migraine" post="have been identified. Future FC studies should either pool"/>
   <result pre="either pool existing data to extract information about sub-phenotypes of" exact="migraine" post="patients or follow guidelines similar to RCT guidelines in"/>
   <result pre="connectivity to the examined networks throughout 25 studies of interictal" exact="migraine" post="compared with healthy volunteers Abbreviations ACC Anterior cingulate cortex"/>
   <result pre="magnetic resonance imaging resting-state connectivity in periaqueductal gray networks in" exact="migraine" post="Ann Neurol 2011 70 838 845 10.1002/ana.22537 22162064 2."/>
   <result pre="TJ Chiang CC Chong CD Dodick DW Functional MRI of" exact="migraine" post="Lancet Neurol 2015 14 81 91 10.1016/S1474-4422(14)70193-0 25496899 3."/>
   <result pre="of corpus callosum modulates inter-hemispheric resting state functional connectivity in" exact="migraine" post="patients without aura PLoS One 2012 7 e45476 10.1371/journal.pone.0045476"/>
   <result pre="R Esposito F Tedeschi G Executive resting-state network connectivity in" exact="migraine" post="without aura Cephalalgia 2012 32 1041 1048 10.1177/0333102412457089 22908362"/>
   <result pre="W Sun W Tian J Structural and functional abnormalities in" exact="migraine" post="patients without aura NMR Biomed 2013 26 58 64"/>
   <result pre="activity and corresponding brain circuit changes during resting state in" exact="migraine" post="without aura NMR Biomed 2013 26 1051 1058 10.1002/nbm.2917"/>
   <result pre="Esposito F Tedeschi G Disrupted default mode network connectivity in" exact="migraine" post="without aura J Headache Pain 2013 14 89 10.1186/1129-2377-14-89"/>
   <result pre="Atypical resting-state functional connectivity of affective pain regions in chronic" exact="migraine" post="Headache 2013 53 737 751 10.1111/head.12081 23551164 10. Hadjikhani"/>
   <result pre="link: enhanced functional connectivity between amygdala and visceroceptive cortex in" exact="migraine" post="Cephalalgia 2013 33 1264 1268 10.1177/0333102413490344 23720503 11. Yuan"/>
   <result pre="structure and resting-state functional connectivity of the basal ganglia in" exact="migraine" post="patients without aura J Pain 2013 14 836 844"/>
   <result pre="functional connectivity with autonomic circuits and the locus coeruleus in" exact="migraine" post="PLoS One 2014 9 e95508 10.1371/journal.pone.0095508 24743801 13. Tessitore"/>
   <result pre="F Tedeschi G Abnormal connectivity within executive resting-state network in" exact="migraine" post="with aura Headache 2015 55 794 805 10.1111/head.12587 26084236"/>
   <result pre="Colonnese C Schoenen J Pierelli F Thalamo-cortical network activity between" exact="migraine" post="attacks: insights from MRI-based microstructural and functional resting-state network"/>
   <result pre="SJ Reduced functional connectivity between salience and visual networks in" exact="migraine" post="with aura Cephalalgia 2016 36 53 66 10.1177/0333102415583144 25888585"/>
   <result pre="Tessitore A Increased interictal visual network connectivity in patients with" exact="migraine" post="with aura Cephalalgia 2016 36 139 147 10.1177/0333102415584360 25926619"/>
   <result pre="Modulation of intrinsic resting-state fMRI networks in women with chronic" exact="migraine" post="Neurology 2017 8 9 163 169 10.1212/WNL.0000000000004089 21. Lo"/>
   <result pre="Bramanti P Marino S Functional connectivity and cognitive impairment in" exact="migraine" post="with and without aura J Headache Pain 2017 18"/>
   <result pre="abnormalities of intrinsic brain connectivity in the interictal phase of" exact="migraine" post="with aura Eur J Neurol 2015 22 702 e46"/>
   <result pre="S Disrupted functional connectivity of periaqueductal gray subregions in episodic" exact="migraine" post="J Headache Pain 2017 18 36 10.1186/s10194-017-0747-9 28321594 24."/>
   <result pre="S Altered functional connectivity of amygdala underlying the neuromechanism of" exact="migraine" post="pathogenesis J Headache Pain 2017 18 7 10.1186/s10194-017-0722-5 28116559"/>
   <result pre="Lu X Abnormal functional integration across core brain networks in" exact="migraine" post="without aura Mol Pain 2017 13 1744806917737461 10.1177/1744806917737461 28969471"/>
   <result pre="T Ashina M Change in brain network connectivity during PACAP38-induced" exact="migraine" post="attacks: a resting-state functional MRI study Neurology 2016 86"/>
   <result pre="brain connectivity between pons and somatosensory cortex during attacks of" exact="migraine" post="with aura Hum Brain Mapp 2017 3 8 2635"/>
   <result pre="E Ashina M Altered thalamic connectivity during spontaneous attacks of" exact="migraine" post="without aura: a resting-state fMRI study Cephalalgia 2018 38"/>
   <result pre="Altered resting-state ascending/descending pathways associated with the posterior thalamus in" exact="migraine" post="without aura Neuroreport 2016 27 257 263 10.1097/WNR.0000000000000529 26825347"/>
   <result pre="The altered Granger causality connection among pain-related brain networks in" exact="migraine" post="Medicine (Baltimore) 2018 97 e0102 10.1097/MD.0000000000010102 29517685 32. Wang"/>
   <result pre="J Gong Q Altered effective connectivity of posterior thalamus in" exact="migraine" post="with cutaneous allodynia: a resting-state fMRI study with granger"/>
   <result pre="Harris RE What has functional connectivity and chemical neuroimaging in" exact="fibromyalgia" post="taught us about the mechanisms and management of ‘centralized’"/>
   <result pre="DS Villringer A Functional connectivity alterations in patients with chronic" exact="hepatitis" post="C virus infection: a multimodal MRI study J Viral"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6878943/results/search/disease/results.xml">
   <result pre="( figure 1). Her brain MRI was normal. Because the" exact="movement disorder" post="did not affect the patient's orolingual function, no treatment"/>
   <result pre="remission of the movements. There was no family history of" exact="epilepsy" post="or infantile convulsions. The patient's mother had severe recurrent"/>
   <result pre="epilepsy or infantile convulsions. The patient's mother had severe recurrent" exact="migraine" post="headaches. Her maternal cousin had been diagnosed with PKD."/>
   <result pre="mutation in the PRRT2 gene. Galloping tongue is an uncommon" exact="movement disorder." post="1 – 5 The characteristics of these lingual movements"/>
   <result pre="that the PRRT2 mutation could be linked to the patient's" exact="movement disorder" post="because it is action related and known causes of"/>
   <result pre="phenotype of PRRT2 mutations is not limited to dystonia and" exact="chorea" post="typical of PKD, but episodic ataxia and paroxysmal torticollis"/>
   <result pre="not limited to dystonia and chorea typical of PKD, but" exact="episodic ataxia" post="and paroxysmal torticollis have also been described. 7 Seizures"/>
   <result pre="and paroxysmal torticollis have also been described. 7 Seizures and" exact="migraine" post="seem to be also part of the clinical spectrum."/>
   <result pre="the lingual movements in our patient remains uncertain. A functional" exact="movement disorder" post="seemed unlikely because the movement disorder could not be"/>
   <result pre="remains uncertain. A functional movement disorder seemed unlikely because the" exact="movement disorder" post="could not be disrupted, suppressed, or entrained with examiner"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6881562/results/search/disease/results.xml">
   <result pre="present with a variety of clinical features including dyspnea, orthopnea," exact="pulmonary edema," post="and pulmonary or systemic emboli. Constitutional symptoms such as"/>
   <result pre="and vertigo, who was found to have a posterolateral medullary" exact="stroke" post="secondary to a large left atrial cardiac myxoma. 1."/>
   <result pre="known cause of ischemic stroke. Differential diagnoses most often include" exact="atrial fibrillation" post="and patent foramen ovale. Atrial myxoma is a rare"/>
   <result pre="ischemic stroke. Differential diagnoses most often include atrial fibrillation and" exact="patent foramen ovale." post="Atrial myxoma is a rare and potentially dangerous cause"/>
   <result pre="myxoma is a rare and potentially dangerous cause of ischemic" exact="stroke" post="and should be considered on a differential for cardiac"/>
   <result pre="of the tumor, with septal tumor location strongly associated with" exact="congestive heart failure" post="and extraseptal tumors associated with neurological events ( 6)."/>
   <result pre="and vertigo who was found to have a posterolateral medullary" exact="stroke" post="which was secondary to a large left atrial cardiac"/>
   <result pre="for one hour (thought to be consistent with her usual" exact="migraine" post="presentation) with accompanied numbness of the left face and"/>
   <result pre="and muscle strength was 5/5 in all extremities. Initial NIH" exact="stroke" post="scale was 1. On cardiac examination, the patient had"/>
   <result pre="diplopia, left-sided dysmetria, more pronounced vertigo, and difficulty swallowing. A" exact="stroke" post="alert was called and magnetic resonance imaging (MRI) of"/>
   <result pre="patient was transported to the step-down unit with an NIH" exact="stroke" post="scale score of 2 for neurological checks every two"/>
   <result pre="hours and then transferred to a monitored step-down unit. Her" exact="stroke" post="symptoms continued to persist through the postoperative stay, with"/>
   <result pre="a long-term acute care facility for extensive rehabilitation of her" exact="stroke" post="symptoms. A repeat transthoracic echocardiogram obtained one month after"/>
   <result pre="brain, spinal cord, or retinal cell death ( 8). Ischemic" exact="stroke" post="in particular is defined as &quot;an episode of neurologic"/>
   <result pre="Cardioembolic origin accounts for approximately 14-30% of ischemic strokes, with" exact="atrial fibrillation" post="being the most common (45%) underlying condition ( 9)."/>
   <result pre="common (45%) underlying condition ( 9). Other common etiologies include" exact="infective endocarditis," post="valvular heart disease, and much more rarely, cardiac myxoma."/>
   <result pre="underlying condition ( 9). Other common etiologies include infective endocarditis," exact="valvular heart disease," post="and much more rarely, cardiac myxoma. Previous research has"/>
   <result pre="condition ( 9). Other common etiologies include infective endocarditis, valvular" exact="heart disease," post="and much more rarely, cardiac myxoma. Previous research has"/>
   <result pre="syndrome is defined as a neurological condition due to a" exact="stroke" post="in the vertebral or posterior inferior cerebellar artery of"/>
   <result pre="is important to consider myxoma on the differential diagnosis of" exact="stroke" post="origin. The American Heart Association guidelines propose that initial"/>
   <result pre="E. Broderick J. P. et al. An updated definition of" exact="stroke" post="for the 21st century: a statement for healthcare professionals"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6885267/results/search/disease/results.xml">
   <result pre="and contribute to identify new therapeutic approaches. 1. Introduction Idiopathic" exact="restless legs syndrome" post="(RLS) is a large prevalent chronic sensory-motor disorder ["/>
   <result pre="may be present in various pathologic conditions, such as migraine," exact="rheumatoid arthritis," post="toothache, cancer, and intractable pain [ 19]. Also, in"/>
   <result pre="arthritis, toothache, cancer, and intractable pain [ 19]. Also, in" exact="fibromyalgia" post="there is a clear diurnal rhythmicity in pain perception"/>
   <result pre="with circadian modification of symptoms in other conditions, such as" exact="migraine" post="and cluster headache [ 37], could have a role."/>
   <result pre="rhythm of motor restlessness and sensory symptoms in the idiopathic" exact="restless legs syndrome" post="Sleep 1999 22 7 901 912 10.1093/sleep/22.7.901 10566908 3"/>
   <result pre="C. J. Griffin J. W. McArthur J. C. Subclinical sensory" exact="neuropathy" post="in late-onset restless legs syndrome Neurology 2000 55 8"/>
   <result pre="J. W. McArthur J. C. Subclinical sensory neuropathy in late-onset" exact="restless legs syndrome" post="Neurology 2000 55 8 1115 1121 10.1212/wnl.55.8.1115 11071488 8"/>
   <result pre="R. D. Magerl W. Hyperalgesia and functional sensory loss in" exact="restless legs syndrome" post="Pain 2013 154 8 1457 1463 10.1016/j.pain.2013.05.007 23707286 10"/>
   <result pre="Derambure P. Monaca C. A-delta and C-fibres function in primary" exact="restless legs syndrome" post="Neurophysiologie Clinique/Clinical Neurophysiology 2009 39 6 267 274 10.1016/j.neucli.2009.06.003"/>
   <result pre="LeBrocq C. Dhar A. et al. Validation of the international" exact="restless legs syndrome" post="study group rating scale for restless legs syndrome Sleep"/>
   <result pre="the international restless legs syndrome study group rating scale for" exact="restless legs syndrome" post="Sleep Medicine 2003 4 2 121 132 10.1016/s1389-9457(02)00258-7 14592342"/>
   <result pre="6 293 301 10.1016/j.neucli.2003.10.004 14678843 17 Winkelman J. W. Is" exact="restless legs syndrome" post="a sleep disorder? Neurology 2013 80 22 2006 2007"/>
   <result pre="14678843 17 Winkelman J. W. Is restless legs syndrome a" exact="sleep disorder?" post="Neurology 2013 80 22 2006 2007 10.1212/wnl.0b013e318294b4bb 23624567 18"/>
   <result pre="18 Gemignani F. Hyperalgesia without allodynia in primary and secondary" exact="restless legs syndrome" post="Pain 2014 155 1 198 200 19 Bruguerolle B."/>
   <result pre="diurnal rhythmicity in pain, stiffness, and fatigue in patients with" exact="fibromyalgia" post="The Journal of Rheumatology 2004 31 2 379 389"/>
   <result pre="Karadeniz D. Uysal Ö. Circadian changes in cortical excitability in" exact="restless legs syndrome" post="Journal of the Neurological Sciences 2012 316 1-2 122"/>
   <result pre="22305328 40 Baier P. C. Trenkwalder C. Circadian variation in" exact="restless legs syndrome" post="Sleep Medicine 2007 8 6 645 650 10.1016/j.sleep.2006.10.011 17383937"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6888880/results/search/disease/results.xml">
   <result pre="Severinsen J, Jansen-Olesen I, Ashina M. The KATP channel in" exact="migraine" post="pathophysiology: a novel therapeutic target for migraine. J Headache"/>
   <result pre="edition. Cephalalgia 38:1–211 S3 Hormonal contraceptives: how they impact on" exact="migraine" post="course Simona Sacco (simona.sacco@univaq.it) Department of Applied Clinical Sciences"/>
   <result pre="Italy The role of female hormones in the pathogenesis of" exact="migraine" post="is well-recognized [1,2]. Migraine is more prevalent in women"/>
   <result pre="menstrual phase of the female cycle represents a trigger for" exact="migraine" post="attacks in many women [1,4]. Additionally, exogenous hormones may"/>
   <result pre="women [1,4]. Additionally, exogenous hormones may change the course of" exact="migraine" post="by inducing de novo migraine, inducing de novo aura,"/>
   <result pre="inducing de novo migraine, inducing de novo aura, worsening previous" exact="migraine" post="but also improving migraine particularly those attacks related to"/>
   <result pre="inducing de novo aura, worsening previous migraine but also improving" exact="migraine" post="particularly those attacks related to menstruation [5,6]. Several attempts"/>
   <result pre="to improve migraine. A working group including headache experts, gynaecologists," exact="stroke" post="experts, and epidemiologists developed a first consensus document about"/>
   <result pre="consensus document is to provide recommendations on the management of" exact="migraine" post="with the use of estrogens and progestogens in women"/>
   <result pre="effect of exogenous estrogens and progestogens on the course of" exact="migraine" post="during reproductive age. Thereafter a consensus procedure among international"/>
   <result pre="support clinical decision making, in terms of possible effects on" exact="migraine" post="course of exogenous estrogens and progestogens and on possible"/>
   <result pre="withdrawal. References 1. MacGregor EA (2014) Oestrogen and attacks of" exact="migraine" post="with and without aura. Lancet Neurol 3:354-361. 2. Vetvik"/>
   <result pre="R, Tomlinson SE (2018) Effectiveness of the progestin-only pill for" exact="migraine" post="treatment in women: a systematic review and meta-analysis. Cephalalgia"/>
   <result pre="and Reproductive Health (ESC) (2017) HCs and risk of ischemic" exact="stroke" post="in women with migraine: a consensus statement from the"/>
   <result pre="S4 EHF Guidelines on the use of CGRP(r) MAbs in" exact="migraine" post="Simona Sacco (simona.sacco@univaq.it) Department of Applied Clinical Sciences and"/>
   <result pre="Great enthusiasm is preceding the marketing of new treatments for" exact="migraine" post="prevention which act on the calcitonin gene-related peptide (CGRP)"/>
   <result pre="This offsets the lack of significant novelties in treatment of" exact="migraine" post="for many years since in the 80s triptans were"/>
   <result pre="increasing enthusiasm are that those new treatments are, as triptans," exact="migraine" post="specific whereas all the other available preventive drugs were"/>
   <result pre="other available preventive drugs were developed for indications other than" exact="migraine" post="and have an unclear mechanism of action considering migraine"/>
   <result pre="than migraine and have an unclear mechanism of action considering" exact="migraine" post="pathophysiology. Poor tolerability and side effects which may particularly"/>
   <result pre="guideline to clinicians for the management of episodic and chronic" exact="migraine" post="with mAb acting on the CGRP or on its"/>
   <result pre="use and reasons for discontinuation of prophylactic medications for episodic" exact="migraine" post="and chronic migraine: results from the second international burden"/>
   <result pre="and chronic migraine: results from the second international burden of" exact="migraine" post="study (IBMS-II). Headache 53:644-655. 2. Berger A, Bloudek LM,"/>
   <result pre="A, Bloudek LM, Varon SF, Oster G (2012) Adherence with" exact="migraine" post="prophylaxis in clinical practice. Pain Pract 12:541-549. 3. Diamond"/>
   <result pre="(2007) Patterns of diagnosis and acute and preventive treatment for" exact="migraine" post="in the United States: results from the American Migraine"/>
   <result pre="Rizzoli P (2011) Tolerance and loss of beneficial effect during" exact="migraine" post="prophylaxis: clinical considerations. Headache 51:1336-1345. S5 Novel Insight into"/>
   <result pre="in its development. S6 Imaging inflammation in animal models of" exact="migraine" post="Aaron Schain, Agustin Melo-Carrillo, Andrew Strassman, Rami Burstein Department"/>
   <result pre="as nitric oxide, CGRP, and cytokines are able to recreate" exact="migraine" post="pain. Our lab has shown that cortical spreading depression"/>
   <result pre="shown that cortical spreading depression (CSD), the neural correlate of" exact="migraine" post="aura, can activate rodent dural nociceptors. Because CSD is"/>
   <result pre="and circuit mechanisms of the primary brain dysfunctions that cause" exact="familial hemiplegic migraine?" post="Daniela Pietrobon 1,2 (daniela.pietrobon@unipd.it) 1Department of Biomedical Sciences and"/>
   <result pre="headache is preceded by transient sensory disturbances, the so called" exact="migraine" post="aura, whose neurophysiological correlate is cortical spreading depression (CSD)."/>
   <result pre="and network mechanisms of the primary brain dysfunctions that underlie" exact="migraine" post="onset, susceptibility to CSD and altered interictal sensory processing"/>
   <result pre="these questions we studied the functional consequences of mutations causing" exact="familial hemiplegic migraine" post="(FHM), a rare monogenic subtype of migraine with aura,"/>
   <result pre="we studied the functional consequences of mutations causing familial hemiplegic" exact="migraine" post="(FHM), a rare monogenic subtype of migraine with aura,"/>
   <result pre="causing familial hemiplegic migraine (FHM), a rare monogenic subtype of" exact="migraine" post="with aura, in knock-in mouse models carrying either a"/>
   <result pre="main mechanisms underlying facilitation of experimental CSD in the genetic" exact="migraine" post="models; ii) the dynamic regulation of the excitatory-inhibitory balance"/>
   <result pre="is dysfunctional in FHM1 mice. The data from our genetic" exact="migraine" post="models are consistent with the hypothesis that a reduced"/>
   <result pre="brain networks may underlie the dysfunctional sensory information processing in" exact="migraine" post="and, in certain conditions, may favor CSD ignition and"/>
   <result pre="conditions, may favor CSD ignition and the onset of a" exact="migraine" post="attack. S8 What is the evidence for role of"/>
   <result pre="Copenhagen, Denmark In 1968, the first study linking prostaglandins and" exact="migraine" post="pathogenesis was conducted and reported that an intravenous injection"/>
   <result pre="other NSAIDs are widely used drugs for acute treatment of" exact="migraine" post="and comparative randomized clinical trials demonstrated efficacy similar to"/>
   <result pre="comparative randomized clinical trials demonstrated efficacy similar to triptans. Preclinical" exact="migraine" post="models have suggested that migraine pain is associated with"/>
   <result pre="efficacy similar to triptans. Preclinical migraine models have suggested that" exact="migraine" post="pain is associated with local inflammation in the meninges"/>
   <result pre="definitive evidence for inflammation in dura or perivascular space in" exact="migraine" post="patients is still lacking. S9 Emerging targets for treatment"/>
   <result pre="and is found in several key structures of interest in" exact="migraine" post="pathophysiology such as the trigeminovascular system. PACAP38 provokes migraine"/>
   <result pre="in migraine pathophysiology such as the trigeminovascular system. PACAP38 provokes" exact="migraine" post="attacks in migraine patients without aura. Interestingly, the structurally"/>
   <result pre="such as the trigeminovascular system. PACAP38 provokes migraine attacks in" exact="migraine" post="patients without aura. Interestingly, the structurally related vasoactive intestinal"/>
   <result pre="than VIP. Studies suggested three potential targets of interest in" exact="migraine" post="treatment; the PAC1 receptors, PACAP38 itself, or a de"/>
   <result pre="reveal whether targeting the PAC1 receptor shows clinical efficacy in" exact="migraine" post="treatment. S10 Counting cost: disability and lost productivity T."/>
   <result pre="of disability worldwide, after low back pain. Among specific diseases," exact="migraine" post="is top cause in people under 50. Disability, especially"/>
   <result pre="to their expected impact on indirect financial costs. S11 The" exact="migraine" post="brain is inheritably hyper-responsive Magis Delphine (dmagis@chuliege.be) Headache Research"/>
   <result pre="Liège, Belgium Increased responsivity to environmental stimuli is associated with" exact="migraine" post="attacks but is also reported interictally. The way the"/>
   <result pre="migraine attacks but is also reported interictally. The way the" exact="migraine" post="brain responds to sensory stimuli has been intriguing researchers"/>
   <result pre="sensory processing analysis. Neurophysiological studies demonstrated three functional features of" exact="migraine" post="patients compared to healthy controls: habituation modifications, cortical dysexcitability"/>
   <result pre="the arguments in favour of an inherited hyperresponsivity of the" exact="migraine" post="brain. S12 Seizure activates the trigeminovascular system differently than"/>
   <result pre="differently than CSD: Implications to differences between post-ictal headache and" exact="migraine" post="Agustin Melo Carrillo (amelo1@bidmc.harvard.edu) Department of Anesthesia, Critical Care"/>
   <result pre="which there are ample of evidence in human subjects suffering" exact="epilepsy" post="(and PIH), and thus, it bypass the bitter debate"/>
   <result pre="debate over the validity of studying the headache phase of" exact="migraine" post="using the controversial cortical spreading depression model – to"/>
   <result pre="Grant: RO1-NS094198. S13 Cortical Spreading Depression as a trigger for" exact="migraine" post="headache Rami Burstein Department of Anesthesia and Critical Care,"/>
   <result pre="Center Cortical spreading depression (CSD) has long been implicated in" exact="migraine" post="attacks that begin with visual aura. Over the years,"/>
   <result pre="the possible role activation of peripheral trigeminovascular neurons play in" exact="migraine" post="chronification. The process by which CSD, a cortical event"/>
   <result pre="this talk, I will review the population genetic studies suggesting" exact="migraine" post="as a genetic condition, including family and twin studies."/>
   <result pre="techniques and their stages in leading to the understanding of" exact="migraine" post="as a genetic disease will be discussed. S15 Providing"/>
   <result pre="of its much lower disability weight compared with those for" exact="migraine" post="and MOH. In practice, structured headache services will not"/>
   <result pre="headache attributed to spontaneous intracranial hypotension and headache attributed to" exact="idiopathic intracranial hypertension." post="Perspectives on how to approach the patient in tertiary"/>
   <result pre="Anne MacGregor (anne@annemacgregor.com) Barts Health NHS Trust, London UK Since" exact="migraine" post="is most prevalent during women of reproductive age, many"/>
   <result pre="most prevalent during women of reproductive age, many women with" exact="migraine" post="will be using contraception. Further, since some migraine medication"/>
   <result pre="women with migraine will be using contraception. Further, since some" exact="migraine" post="medication is contraindicated in pregnancy, for women with migraine"/>
   <result pre="some migraine medication is contraindicated in pregnancy, for women with" exact="migraine" post="using such medication, it is important that contraception is"/>
   <result pre="also benefit migraine, particularly for women who experience exacerbation of" exact="migraine" post="perimenstrually. Menstruation is associated with two independent migraine triggers"/>
   <result pre="exacerbation of migraine perimenstrually. Menstruation is associated with two independent" exact="migraine" post="triggers – estrogen ‘withdrawal’ which typically occurs premenstrually, and"/>
   <result pre="and a progestogen. The addition of ethinylestradiol provides greater ovarian" exact="suppression" post="and better cycle control than progestogen-only methods, although the"/>
   <result pre="be discussed. S19 Cortical spreading depression as mechanism of the" exact="migraine" post="aura: new mechanisms Martin Lauritzen (martin.johannes.lauritzen@regionh.dk) Department of Clinical"/>
   <result pre="for our perception of CSD as a pathophysiological mechanism of" exact="migraine" post="and for a group of acute neurological disorders. Specifically,"/>
   <result pre="findings are likely to have implications for how we understand" exact="migraine" post="with aura and for new strategies for migraine treatment."/>
   <result pre="we understand migraine with aura and for new strategies for" exact="migraine" post="treatment. S20 Pain regulation by non-neuronal cells and inflammation"/>
   <result pre="Rodrigo Noseda (rnoseda@bidmc.harvard.edu) The neural substrate of occipital headache in" exact="migraine" post="and other headaches is little understood. In theory, this"/>
   <result pre="showing altered activation and connectivity of the cerebellum in the" exact="migraine" post="brain. Yet, little is known about the role it"/>
   <result pre="may play in the initiation of headache. Anecdotally, patients whose" exact="migraine" post="headaches involve mainly or exclusively the occipital region appear"/>
   <result pre="attributed mainly to the cerebellum – more than patients whose" exact="migraine" post="are restricted to the periorbital and frontal regions of"/>
   <result pre="be discussed in the context of occipital migraine. S22 The" exact="migraine" post="brain is not hyper-responsive Trond Sand 1,2 (trond.sand@ntnu.no) 1Department"/>
   <result pre="common symptoms like phonophobia, photophobia and allodynia clearly suggest neural" exact="hypersensitivity" post="during a migraine attack. Reliable premonitory symptoms like photophobia"/>
   <result pre="phonophobia, photophobia and allodynia clearly suggest neural hypersensitivity during a" exact="migraine" post="attack. Reliable premonitory symptoms like photophobia are also reported"/>
   <result pre="preictal phase 24 hours before headache. However, the variety of" exact="migraine" post="triggers is huge, and the most reliable triggers are"/>
   <result pre="is transcranial magnetic stimulation (TMS). Again, results from TMS-studies in" exact="migraine" post="are widely divergent, although this variability is often neglected"/>
   <result pre="(MRI) techniques have been applied extensively to the study of" exact="migraine" post="patients, both in the course of an acute attack"/>
   <result pre="and during the interictal phase. It is now accepted that" exact="migraine" post="should be viewed as a complex brain network disorder"/>
   <result pre="vascular disorder. Numerous studies have consistently demonstrated that patients with" exact="migraine" post="experience not only abnormalities of function but also important"/>
   <result pre="migraineurs might be dynamic, since they differ according to the" exact="migraine" post="phase, attack frequency and disease duration. Recent longitudinal studies"/>
   <result pre="frequency and disease duration. Recent longitudinal studies revealed that the" exact="migraine" post="brain changes over time and different pathophysiological mechanisms are"/>
   <result pre="investigations have shown morphometric alterations that are not influenced by" exact="migraine" post="patients’ clinical characteristics and revealed that GM volume abnormalities"/>
   <result pre="the early stages of the disease, thus representing a potential" exact="migraine" post="biomarker. Numerous conventional MRI studies have also described an"/>
   <result pre="this is critical not only to improve the understanding of" exact="migraine" post="pathophysiology, but also to develop imaging biomarkers to be"/>
   <result pre="Correspondence: Paolo Martelletti (paolo.martelletti@uniroma1.it) The evidence of multiple comorbidities in" exact="migraine" post="population, especially at cardio-cerebrovascular, psychiatric, metabolic and musculoskeletal levels,"/>
   <result pre="pharmacological therapies. The use of different drugs in the same" exact="migraine" post="patient significantly increases the risk of potentially serious adverse"/>
   <result pre="have also to consider that in a real-world scenario each" exact="migraine" post="patient might also suffer from other (episodic or chronic)"/>
   <result pre="using a simple DDIs checker. S25 The EMA-EHF Documento for" exact="migraine" post="Efstratia Vatzaki 1*, Sabine Strauss 2, Jean-Michel Dogne 3,"/>
   <result pre="years. Valproate has been widely used for the prophylaxis of" exact="migraine" post="attacks and is also included in the main European"/>
   <result pre="and a more effective education campaign in migrainous women. Keywords:" exact="migraine" post="prophylaxis, valproate, pregnancy, teratogenic risk, foetotoxic effect, neurodevelopmental retard,"/>
   <result pre="workflow of the Italian National Health System. S27 Correlation of" exact="migraine" post="attacks with neck pain and tension E Anne MacGregor"/>
   <result pre="Correspondence: E Anne MacGregor (anne@annemacgregor.com) Background: Neck pain associated with" exact="migraine" post="attacks is common and usually first noticed close to"/>
   <result pre="occur prior to headache, it can be perceived as a" exact="migraine" post="trigger. We used a digital platform (Curelator Headache®) to"/>
   <result pre="determine 1) how many individuals suspect neck pain/tension as a" exact="migraine" post="trigger and 2) for how many individuals an association"/>
   <result pre="for how many individuals an association between neck pain/tension and" exact="migraine" post="attacks can be identified statistically. Methods: Individuals with migraine"/>
   <result pre="and migraine attacks can be identified statistically. Methods: Individuals with" exact="migraine" post="registered to use Curelator Headache® (now called N1-Headache®) and"/>
   <result pre="and for each individual the association between neck pain/tension and" exact="migraine" post="attacks was determined via a univariate Cox proportional hazard"/>
   <result pre="neck pain/tension. Conclusion: Neck pain/tension was widely suspected as a" exact="migraine" post="trigger. In one-third of individuals with adequate data there"/>
   <result pre="was a statistical association between same day neck pain/tension and" exact="migraine" post="headache. However, neck pain/tension the day before headache started"/>
   <result pre="supports the view that neck pain/tension is more likely a" exact="migraine" post="symptom rather than a trigger. References 1. Calhoun AH"/>
   <result pre="Centre, Neurology department, Montpellier University Hospital, France According to ICHD-3," exact="migraine" post="with brainstem aura is defined as a migraine with"/>
   <result pre="to ICHD-3, migraine with brainstem aura is defined as a" exact="migraine" post="with aura including at least two of the following"/>
   <result pre="diplopia, ataxia and/or decreased level of consciousness. Whereas the typical" exact="migraine" post="aura symptoms are thought to be the clinical consequence"/>
   <result pre="clinical consequence of cortical spreading depression (CSD), the mechanisms of" exact="migraine" post="with brainstem aura remain debated. One hypothesis could be"/>
   <result pre="with the theory of CSD as the underlying mechanism of" exact="migraine" post="aura. In conclusion, patients with brainstem aura are real,"/>
   <result pre="aura. In conclusion, patients with brainstem aura are real, but" exact="migraine" post="with brainstem aura is not real and could be"/>
   <result pre="with brainstem aura is not real and could be called" exact="migraine" post="with brainstem-like aura. S29 Migraine with brainstem aura does"/>
   <result pre="therefore renamed basilar migraine. In ICHD-2 it was called basilar-type" exact="migraine" post="in order to get further away from the basilar"/>
   <result pre="the basilar artery and finally, in ICHD-3, it was renamed" exact="migraine" post="with brainstem aura. Formally applying the diagnostic criteria of"/>
   <result pre="of the ICHD-II to a large material of systematically phenotyped" exact="migraine" post="with aura patients resulted in a surprisingly high number"/>
   <result pre="high number patients who fulfilled the criteria [1]. While formally" exact="migraine" post="with brain stem aura thus exists and formally is"/>
   <result pre="Center who undoubtedly have brainstem symptoms as an aura of" exact="migraine" post="and we shall present some cases. References [1] Li,"/>
   <result pre="August). Field-testing of the ICHD-3 beta/proposed ICD-11 diagnostic criteria for" exact="migraine" post="with aura. Cephalalgia, pp. 748-756. S30 Manual Approach to"/>
   <result pre="can have a high influence on the different expression of" exact="migraine" post="attacks. Specifically, it seems that female hormones, through epigenetic"/>
   <result pre="It has been demonstrated a high prevalence of headache and" exact="migraine" post="and substantial changes on neural circuits in adults who"/>
   <result pre="factors. Moreover, experiences like childhood maltreatment can lead to severe" exact="migraine" post="manifestations which can be also more refractory to treatment."/>
   <result pre="life experiences and female hormones are shared factors by both" exact="migraine" post="and depression. Studies on animal models demonstrated how aberrant"/>
   <result pre="pathways of headache and migraine. So, causal pathways shared between" exact="migraine" post="and its comorbid disorders may be moderated by epigenetic"/>
   <result pre="epigenetic mechanisms [3]. Because of prophylactic medication used to prevent" exact="migraine" post="is only effective in half of the patients, more"/>
   <result pre="effective in half of the patients, more studies on epigenetic" exact="migraine" post="mechanism may provide a new conception of migraine pharmacotherapy,"/>
   <result pre="on epigenetic migraine mechanism may provide a new conception of" exact="migraine" post="pharmacotherapy, specifically acting to modulate chromatin structure at migraine"/>
   <result pre="of migraine pharmacotherapy, specifically acting to modulate chromatin structure at" exact="migraine" post="features. References 1) Hershey AD, Faedda N. Guidetti V."/>
   <result pre="overuse, occipital neuralgia, and cervicogenic. Minor head injury can trigger" exact="migraine" post="with aura (footballer's migraine). The usual acute and preventive"/>
   <result pre="they show conflicting results. Since HAIH does not differ from" exact="migraine" post="and tension-type headache (TTH) based on clinical characteristics, some"/>
   <result pre="proper trials proving that a beta-blocker (propranolol) was affective as" exact="migraine" post="preventative. In the same tradition, professor Harald Schrader made"/>
   <result pre="leading to the development of lisinioril and later candesartan as" exact="migraine" post="prophylactics. The large epidemiological survey in Nord-Trøndelag county (the"/>
   <result pre="for treating chronic cluster headache and migraine. S36 Correlation of" exact="migraine" post="attacks with neck pain and tension E. Anne MacGregor"/>
   <result pre="E. Anne MacGregor Background: Repetitive yawning is a common premonitory" exact="migraine" post="symptom [1,2]. In contrast to other common premonitory symptoms"/>
   <result pre="more specific and has a high predictive value for a" exact="migraine" post="attack [3]. We used a digital platform (Curelator Headache®"/>
   <result pre="for how many individuals an association between excessive yawning and" exact="migraine" post="attacks can be identified statistically. Methods: Individuals with migraine"/>
   <result pre="and migraine attacks can be identified statistically. Methods: Individuals with" exact="migraine" post="registered to use Curelator Headache®. They then used this"/>
   <result pre="must include 90 tracked days or more, at least five" exact="migraine" post="attacks, more than 50 answers to the yawning question,"/>
   <result pre="and for each individual the association between excessive yawning and" exact="migraine" post="occurrence was determined via a univariate Cox proportional hazard"/>
   <result pre="for analysis. Excessive yawning was associated with increased risk of" exact="migraine" post="attack in 72 (25.3%), with decreased risk in 4"/>
   <result pre="that, for them, when yawning is present the occurrence of" exact="migraine" post="is about three times the rate per unit time"/>
   <result pre="that is a sensitive predictor of migraine. Early identification of" exact="migraine" post="provides an opportunity for early intervention. Future studies can"/>
   <result pre="of internal and external factors. The relationship between sleep and" exact="migraine" post="has always been known, but current knowledge on the"/>
   <result pre="current knowledge on the exact nature of the link between" exact="migraine" post="and sleep remains incomplete and unclear. In other primary"/>
   <result pre="between sleep and migraine. Results Fragmentation of sleep, insomnia and" exact="hypersomnia" post="all showed relationships with migraine. Primary sleep disorders such"/>
   <result pre="all associated with primary headaches, may cause headache, can worsen" exact="migraine" post="and are risk factors for migraine chronification. Medical, psychiatric"/>
   <result pre="cause headache, can worsen migraine and are risk factors for" exact="migraine" post="chronification. Medical, psychiatric and rheumatic diseases are associated with"/>
   <result pre="the sleep cycles) [2], changes in arousals mechanisms [3]. Sleep-related" exact="migraine" post="is characterized by a marked reduction in the CAP"/>
   <result pre="sleep (cortical hypoarousability) that could predispose to the appearance of" exact="migraine" post="episodes during sleep [4]. In migraineurs the autonomic balance"/>
   <result pre="sleep disorders. Moreover, widespread pathophysiological links have been shown between" exact="migraine" post="and sleep, expression of reduced effectiveness of the mechanisms"/>
   <result pre="the influence of biological rhythms, sleep and trigger factors on" exact="migraine" post="can allow the clinicians to control the frequency and"/>
   <result pre="Mariotti P, Tonali PA. Dysfunction of arousal systems in sleep-related" exact="migraine" post="without aura. Cephalalgia. 2006 Jul;26(7):857-64 [5] Vollono C, Gnoni"/>
   <result pre="Farina B, Della Marca G. Heart rate variability in sleep-related" exact="migraine" post="without aura. J Clin Sleep Med. 2013 Jul 15;9(7):707-14."/>
   <result pre="Interview Study reported that 49,5% of the patients suffering from" exact="migraine" post="use nutraceutical products and do not discuss this with"/>
   <result pre="these products with sometimes conflicting information. Although the understanding of" exact="migraine" post="pathophysiology has increased dramatically in recent years, the exact"/>
   <result pre="migraine. In these people, there is a lowered threshold for" exact="migraine" post="attacks and vulnerability to environmental triggers. In susceptible individuals,"/>
   <result pre="to the brainstem nuclei, thalamic nuclei, and the cortex, where" exact="migraine" post="pain is ultimately perceived. Although the mechanisms of action"/>
   <result pre="perceived. Although the mechanisms of action of these molecules in" exact="migraine" post="prevention are poorly known, their effects on vessel wall,"/>
   <result pre="wall, neurons, as well as on specific neurotransmitters involved in" exact="migraine" post="pathophysiology have been hypothesized based on numerous pre-clinical observations."/>
   <result pre="numerous pre-clinical observations. Many different nutraceuticals are currently used in" exact="migraine" post="prophylaxis other than in patients who do not want"/>
   <result pre="Dodick D, Sadovsky R et al. A self-administered screener for" exact="migraine" post="in primary care. The ID MigraineTM validation study. Neurology"/>
   <result pre="on behalf of ANIRCEF (Associazione Neurologica Italiana Ricerca Cefalee): Chronic" exact="migraine" post="classification: current knowledge and future perspectives. J Headache Pain"/>
   <result pre="trigeminal and the cervical systems as a trait symptom in" exact="migraine" post="[6,7,8]. The ICHD-III also does recommend the use of"/>
   <result pre="RB, Hajiyeva N, Jensen R. Prevalence of neck pain in" exact="migraine" post="and tension-type headache: a population study. Cephalalgia. 2015;35(3):211-9. doi:10.1177/0333102414535110."/>
   <result pre="6. Luedtke K, Starke W, May A. Musculoskeletal dysfunction in" exact="migraine" post="patients. Cephalalgia. 2017; Jan 1:333102417716934. doi:10.1177/0333102417716934.Headache Classification Committee of"/>
   <result pre="2013 Jul;33(9):629-808. doi: 10.1177/0333102413485658. 7. Luedtke and May A. Stratifying" exact="migraine" post="patients based on dynamic pain provocation over the upper"/>
   <result pre="2010, 17: 715–19. S43 The standard of care for chronic" exact="migraine" post="in lombardia SISC centres: results of a collaborative study"/>
   <result pre="Pontino, Department of Medico-Surgical Sciences and Biotechnologies, Latina, Italy Presently," exact="migraine" post="is considered a brain disorder. Many independent research groups"/>
   <result pre="Many independent research groups have observed that the brain of" exact="migraine" post="patients abnormally processes information of any sensory modality. These"/>
   <result pre="modality. These functional abnormalities are under continuous fluctuations following the" exact="migraine" post="cycle and the frequency of the attacks and are"/>
   <result pre="abnormalities. However, whatever the origin of these cerebral morpho-functional abnormalities," exact="migraine" post="clinical manifestation requires ignition of the central and peripheral"/>
   <result pre="and peripheral trigeminal system. The heterogeneous clinical presentation of visual" exact="migraine" post="aura symptoms runs in parallel with heterogeneous BOLD fMRI"/>
   <result pre="Parthenium and Andrographis, in combination with CoQ10 and Riboflavin, for" exact="migraine" post="prophylaxis: a randomized double blind versus placebo clinical trial"/>
   <result pre="consultation is characterized by a middle to high frequency of" exact="migraine" post="attacks. These patients need prophylactic treatments to reduce the"/>
   <result pre="treatments, the use of herbal medicine is very common among" exact="migraine" post="population. In the last years, phytoextracts of feverfew (tanacetum"/>
   <result pre="results show that the examined combination is effective in the" exact="migraine" post="prophylaxis if compared to placebo and safe if compared"/>
   <result pre="(cherub@inwind.it) IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy Background. Although" exact="migraine" post="is a neurological disorder in which a peripheral trigemino-vascular"/>
   <result pre="Don Carlo Gnocchi, Milan, Italy Background. Although migraine is a" exact="neurological disorder" post="in which a peripheral trigemino-vascular activation is elicited in"/>
   <result pre="attention on metabolic features among migraineurs, and their influence on" exact="migraine" post="clinical characteristics. Results. By a literature review, it is"/>
   <result pre="more expected outcome of MetS. It is well known that" exact="obesity" post="and hypertension are risk factors for migraine development and"/>
   <result pre="well known that obesity and hypertension are risk factors for" exact="migraine" post="development and its chronification, while their improvement leads to"/>
   <result pre="development and its chronification, while their improvement leads to a" exact="migraine" post="improvement. Besides, the most of attention was recently payed"/>
   <result pre="migraineurs a very late hypoglycemic response that may trigger the" exact="migraine" post="attack. The role of hypoglycemia, one of the early"/>
   <result pre="a state of stable hyperglycemia) seems to be protective against" exact="migraine" post="attacks. The insulin-resistance is characterized by an alteration of"/>
   <result pre="inflammatory cytokines (among these, the CGRP) that lead to the" exact="migraine" post="attack. Conclusions. One of the theories to explain the"/>
   <result pre="MetS development. If common genetic and biological backgrounds underpin both" exact="migraine" post="and MetS, according to this theory is possible to"/>
   <result pre="this theory is possible to explain the high prevalence of" exact="migraine" post="among general population. S47 Migraine and Ketogenic Diet Francesco"/>
   <result pre="Since 1921 this diet was proposed to treat drug resistant" exact="epilepsy" post="in children. Even if in 1928 and in 1930"/>
   <result pre="level (10.3), between Dyalisis headache (10.2) and Headache attributed to" exact="hypothyroidism" post="(10.4). Headache attributed to fasting (10.5) substituted the older"/>
   <result pre="modifications regarded the merger of Headache attributed to pre-eclampsia and" exact="eclampsia" post="in an unique digit (10.3.4), the disappearance of Headache"/>
   <result pre="ones. The most prevalent subtypes of chronic headaches are chronic" exact="migraine" post="and chronic tension-type headaches. Migraine and tension-type headaches are"/>
   <result pre="or in the early morning has been extensively ascertained in" exact="migraine" post="without aura. The preferential emergence of migraine attacks during"/>
   <result pre="extensively ascertained in migraine without aura. The preferential emergence of" exact="migraine" post="attacks during sleep and/or upon awakening progressively increases in"/>
   <result pre="the age of patients. The percentage of subjects with sleep-related" exact="migraine" post="was found to be 16% in patients aged 20-30"/>
   <result pre="present and episodic-relapsing remitting trend over time. A history of" exact="migraine" post="is common in HH patients, possibly due to a"/>
   <result pre="HH appears to be as an evolution from a pre-existing" exact="migraine" post="condition over time. References 1. Freedom T, Evans RW."/>
   <result pre="C, Morelli N, Maestri M, Bonanni E, Murri L. Sleep-related" exact="migraine" post="occurrence increases with aging. Acta Neurol Belg 2012;112: 183-187."/>
   <result pre="this headache. On the contrary, the evidence of physiotherapy in" exact="migraine" post="is less robust than for TTH, which seems to"/>
   <result pre="robust than for TTH, which seems to be expected since" exact="migraine" post="pathogenesis involves activation of sub-cortical structures and the trigemino-vascular"/>
   <result pre="all therapeutic interventions are appropriate for all patients with TTH," exact="migraine" post="or CeH, or maybe not all individuals with a"/>
   <result pre="are more effective than isolated therapeutic approaches for with TTH," exact="migraine" post="and CeH. All these topics will be further discussed"/>
   <result pre="Bari, Italy Most of the studies concerning psychiatric comorbidity in" exact="migraine" post="have focused on anxiety and depression disorders. According to"/>
   <result pre="to suffer from depression than non-migraineurs. When considering anxiety disorders," exact="panic disorder" post="and generalised anxiety disorder have been found more frequently"/>
   <result pre="than non-migraineurs. When considering anxiety disorders, panic disorder and generalised" exact="anxiety disorder" post="have been found more frequently in migraine than in"/>
   <result pre="and generalised anxiety disorder have been found more frequently in" exact="migraine" post="than in non-migraine individuals. Rates of psychiatric comorbidity are"/>
   <result pre="other psychiatric disorders have gained attention. A meta-analysis found a" exact="migraine" post="prevalence of 34,8% in subjects with bipolar disorder. Post-Traumatic"/>
   <result pre="meta-analysis found a migraine prevalence of 34,8% in subjects with" exact="bipolar disorder." post="Post-Traumatic Stress Disorder was found to be more prevalent"/>
   <result pre="Post-Traumatic Stress Disorder was found to be more prevalent in" exact="migraine" post="patients than in the general population. Psychiatric comorbidity is"/>
   <result pre="the general population. Psychiatric comorbidity is associated with more severe" exact="migraine" post="symptoms and disability. Longitudinal studies demonstrated that the comorbidity"/>
   <result pre="comorbidity with anxiety and depression may be a risk for" exact="migraine" post="chronification. Available data supports a bidirectional relationship between migraine"/>
   <result pre="for migraine chronification. Available data supports a bidirectional relationship between" exact="migraine" post="and depression. Several other theories have been proposed to"/>
   <result pre="imaging findings might express a brain state predisposing to both" exact="migraine" post="and psychiatric comorbidity, if they might be the result"/>
   <result pre="psychiatric comorbidity, if they might be the result of recurrent" exact="migraine" post="attacks enhancing emotional responses and leading to psychiatric comorbidity"/>
   <result pre="psychiatric comorbidity, drugs that are known to be effective for" exact="migraine" post="prevention but also to worsen the comorbid psychiatric disorder"/>
   <result pre="the comorbid psychiatric disorder should be avoided (i.e. topiramate in" exact="migraine" post="and depression). Drugs able to control both disorders, possibly"/>
   <result pre="disorders, possibly in monotherapy, should be preferred (i.e. propranolol in" exact="migraine" post="and mild anxiety). The migraine treatment plan might need"/>
   <result pre="be preferred (i.e. propranolol in migraine and mild anxiety). The" exact="migraine" post="treatment plan might need to be discussed and coordinated"/>
   <result pre="J Neurol. 2013; 260(8):1960-9. 2. Seng EK, Seng CD. Understanding" exact="migraine" post="and psychiatric comorbidity. Curr Opin Neurol. 2016;29(3):309-13 3. Minen"/>
   <result pre="the neuropeptide calcitonin gene-related peptide (CGRP) for the treatment of" exact="migraine" post="and other headache disorders. Small molecule antagonists and antibodies"/>
   <result pre="migraine, with or without aura, were included. Patients with 4-14" exact="migraine" post="days in the 28-day baseline period were randomized 2:1:2:1:2:1"/>
   <result pre="Primary efficacy endpoint was change from baseline in mean monthly" exact="migraine" post="days across the 12-week treatment period. Safety and tolerability"/>
   <result pre="(76.1%), female (86.5%), and had not taken preventive treatment for" exact="migraine" post="in the past (n=593, 71.9%). At baseline, patients reported"/>
   <result pre="(n=593, 71.9%). At baseline, patients reported an average 7.67 (SD=2.49)" exact="migraine" post="days. Mean change in migraine days across the 12-week"/>
   <result pre="reported an average 7.67 (SD=2.49) migraine days. Mean change in" exact="migraine" post="days across the 12-week treatment period (adjusted p-values for"/>
   <result pre="AEs were nausea, fatigue, constipation, upper respiratory tract infection, nasopharyngitis," exact="urinary tract infection," post="and blood creatine phosphokinase increase (reported in &amp;gt;5% of"/>
   <result pre="significant differences from placebo in reductions from baseline in mean" exact="migraine" post="days across the 12-week treatment period. Reductions in mean"/>
   <result pre="migraine days across the 12-week treatment period. Reductions in mean" exact="migraine" post="days and treatment differences versus placebo were clinically relevant."/>
   <result pre="addition, we compared our baseline findings with historical data on" exact="migraine" post="patients and healthy controls. The study was approved by"/>
   <result pre="studies of galcanezumab in the prevention of episodic and chronic" exact="migraine" post="Sheena K. Aurora, Paula A Morrow, Dustin D Ruff,"/>
   <result pre="superior to placebo in the prevention of episodic and chronic" exact="migraine" post="in three phase 3 studies. Medication overuse is common"/>
   <result pre="in three phase 3 studies. Medication overuse is common among" exact="migraine" post="patients. This study investigated medication overuse in a post-hoc"/>
   <result pre="phase 3, double-blind, randomised, placebo-controlled studies in patients with episodic" exact="migraine" post="(4 to 14 monthly migraine headache days [MHDs]; EVOLVE-1"/>
   <result pre="studies in patients with episodic migraine (4 to 14 monthly" exact="migraine" post="headache days [MHDs]; EVOLVE-1 and -2) and chronic migraine"/>
   <result pre="monthly migraine headache days [MHDs]; EVOLVE-1 and -2) and chronic" exact="migraine" post="(≥15 monthly MHDs per month for &amp;gt;3 months; REGAIN)."/>
   <result pre="phenomena. Indeed, while the first version of the ICHD included" exact="migraine" post="with PA, the subsequent two versions of the ICHD"/>
   <result pre="minutes and less than 7 days are classified as &quot;probable" exact="migraine" post="with aura (PA)&quot;. The term &quot;probable&quot; used in such"/>
   <result pre="such classification indicates suspicion as to whether the symptom is" exact="migraine" post="aura and we feel it does not help to"/>
   <result pre="of PA. Results: Two hundred and twenty-four patients suffering from" exact="migraine" post="with aura were recruited from the Headache Centers of"/>
   <result pre="first completing symptom as A O7 Ten factors associated to" exact="migraine" post="chronification: a cross-sectional study on 318 long-term migraine sufferers"/>
   <result pre="associated to migraine chronification: a cross-sectional study on 318 long-term" exact="migraine" post="sufferers Michele Viana 1, Sara Bottiroli 1, Grazia Sances"/>
   <result pre="Viana (michele.viana@ymail.com) Introduction: Factors implicated in the evolution of episodic" exact="migraine" post="(EM) into chronic migraine (CM) are mostly elusive. Medication"/>
   <result pre="implicated in the evolution of episodic migraine (EM) into chronic" exact="migraine" post="(CM) are mostly elusive. Medication overuse (MO) is considered"/>
   <result pre="to identify some of these factors. Method: We enrolled consecutive" exact="migraine" post="patients in two groups: long history of episodic migraine"/>
   <result pre="consecutive migraine patients in two groups: long history of episodic" exact="migraine" post="(EM) and CM with medication overuse (CM-MO) and compared"/>
   <result pre="mean age was 42.1±10.3, 80.8% were female. The duration of" exact="migraine" post="(before CM-MO onset in the CM-MO group) was 24.6"/>
   <result pre="the factors associated to CM-MO were: age of onset of" exact="migraine" post="(earlier), use of at least one migraine preventive medication,"/>
   <result pre="of onset of migraine (earlier), use of at least one" exact="migraine" post="preventive medication, marital status (married or separated/divorced/widowed marital status"/>
   <result pre="use of hypnotics (versus absence of insomnia), previous use of" exact="migraine" post="preventive medications, traumatic head injuries, snoring, use of combined"/>
   <result pre="of onset 0.016 0.94 (0.89-0.98)  Use of at least one" exact="migraine" post="preventive medication (whenever for EM, before chronification + MO"/>
   <result pre="effects of the non-paralytic botulinum toxin A molecule BiTox in" exact="migraine" post="animal models Ramla AbuukarAbdullahi 1,2, Joseph O. Lloyd 1,"/>
   <result pre="BiTox in the trigeminal ganglia and trigeminocervical system (TCC) in" exact="migraine" post="animal models. Methods In male rats, Bitox (200 ng)"/>
   <result pre="promising and significant advancement in the preventive therapeutic options for" exact="migraine" post="patients. Ethics Approval All experiments were conducted under UK"/>
   <result pre="(sashina@bidmc.harvard.edu) OBJECTIVES: Migraine can be associated with increased risk for" exact="stroke" post="and white matter (WM) abnormalities, though the linking mechanisms"/>
   <result pre="studies have revealed conflicting whether WM integrity is altered in" exact="migraine" post="patients. We investigated the normal-appearing WM in migraineurs using"/>
   <result pre="2 along 84 diffusion directions, TR/TE = 3500/95ms) of 49" exact="migraine" post="patients (age range 21-65, mean 40.65 +/- 12.77 years;"/>
   <result pre="ICHD-3 criteria. Patients were also divided in 2 groups: episodic" exact="migraine" post="(EM) and chronic migraine (CM). Diffusion data was processed"/>
   <result pre="also divided in 2 groups: episodic migraine (EM) and chronic" exact="migraine" post="(CM). Diffusion data was processed to generate parameter maps"/>
   <result pre="while co-varying for age and gender. RESULTS: Of the 49" exact="migraine" post="patients, 20 reported chronic migraine (CM) (age range 21-58,"/>
   <result pre="gender. RESULTS: Of the 49 migraine patients, 20 reported chronic" exact="migraine" post="(CM) (age range 21-58, mean 40.05 +/- 11.84 years;"/>
   <result pre="22 to 65 (mean 36.87 +/- 13.32; 3 men), reported" exact="migraine" post="with aura. TBSS analysis revealed significantly ( p &amp;lt;"/>
   <result pre="(increase), though to a smaller extent, as seen in acute" exact="stroke" post="infarcts compared to normal appearing white matter, and potentially"/>
   <result pre="longitudinal study to explore the role of DKI in predicting" exact="migraine" post="course, disease progression and development of comorbidities is warranted."/>
   <result pre="and development of comorbidities is warranted. O10 Meningeal contribution to" exact="migraine" post="pain: a 3T magnetic resonance angiography study Sabrina Khan"/>
   <result pre="of Copenhagen, Denmark Correspondence: Sabrina Khan (sksabrinakhan@gmail.com) The origin of" exact="migraine" post="pain is unknown but possibly implicates the dura mater,"/>
   <result pre="could reflect activation of dural perivascular nociceptors that leads to" exact="migraine" post="headache. To test this hypothesis, we measured circumference changes"/>
   <result pre="circumference changes of cranial arteries in patients with cilostazol-induced unilateral" exact="migraine" post="without aura using 3T high-resolution magnetic resonance angiography (MRA)."/>
   <result pre="as intracranial arterial segments. MRA scans were performed at baseline," exact="migraine" post="onset, after sumatriptan, and ≥27 hours after migraine onset.A"/>
   <result pre="at baseline, migraine onset, after sumatriptan, and ≥27 hours after" exact="migraine" post="onset.A total of 30 patients underwent MRA scans, of"/>
   <result pre="MRA scans, of which 26 patients developed unilateral attacks of" exact="migraine" post="without aura and were included in the final analysis."/>
   <result pre="were included in the final analysis. Eleven patients treated their" exact="migraine" post="with sumatriptan while the remaining 15 patients did not"/>
   <result pre="did not treat their attacks with analgesics or triptans. At" exact="migraine" post="onset, only MMA exhibited greater circumference increase on the"/>
   <result pre="found sustained bilateral dilation of MMA. In conclusion, onset of" exact="migraine" post="is associated with increase in MMA circumference specific to"/>
   <result pre="activation of dural perivascular nociceptors, indicating a meningeal site of" exact="migraine" post="headache. O11 Migraine induction with calcitonin gene-related peptide in"/>
   <result pre="could have a major impact on clinical practice. CGRP provokes" exact="migraine" post="attacks and the question is whether hypersensitivity to CGRP"/>
   <result pre="practice. CGRP provokes migraine attacks and the question is whether" exact="hypersensitivity" post="to CGRP infusion might be a predictor of erenumab"/>
   <result pre="correlation between individual efficacy of anti-CGRP treatment and susceptibility to" exact="migraine" post="induction by CGRP. Methods: Thirteen migraine patients, previously enrolled"/>
   <result pre="treatment and susceptibility to migraine induction by CGRP. Methods: Thirteen" exact="migraine" post="patients, previously enrolled in erenumab anti-CGRP receptor monoclonal antibody"/>
   <result pre="a double-blind, placebo-controlled, randomized design to investigate their susceptibility to" exact="migraine" post="induction. A standardized questionnaire was used to assess efficacy"/>
   <result pre="large-scale prospective CGRP provocation study in patients should confirm whether" exact="hypersensitivity" post="to CGRP could be a biomarker for predicting antibody"/>
   <result pre="clinical characteristics and long-term course of headache in patients with" exact="stroke" post="(DMKG multicenter study) Thomas Dresler 1,2, Sarah Dietrich 3,"/>
   <result pre="Ludwig-Maximilians-University Munich, Munich-Grosshadern, Germany Correspondence: Thomas Dresler (thomas.dresler@med.uni-tuebingen.de) Background: Post" exact="stroke" post="headache (symptomatic headache, ICHD 6.1-6.2.) has not been investigated"/>
   <result pre="American studies it is a common accompanying symptom. Nevertheless, other" exact="stroke" post="symptoms (e.g., palsy, aphasia) are dominating, clinical assessments and"/>
   <result pre="which risk factors modulate symptoms and occurrence of headache in" exact="stroke" post="[1,2]. Therefore, we planned a prospective multicenter register study"/>
   <result pre="characteristic of headache symptoms and long-term prognosis, as well as" exact="stroke" post="characteristics. Methods: Patients were included within 24 hours after"/>
   <result pre="Methods: Patients were included within 24 hours after onset of" exact="stroke" post="symptoms and interviewed for headache from day 1 to"/>
   <result pre="committees and all patients gave their informed consent. Results: 707" exact="stroke" post="patients were included. Diagnoses were: ischemic stroke (67%), TIA"/>
   <result pre="consent. Results: 707 stroke patients were included. Diagnoses were: ischemic" exact="stroke" post="(67%), TIA (transient ischemic attack, 22%), hemorrhagic stroke (5%),"/>
   <result pre="were: ischemic stroke (67%), TIA (transient ischemic attack, 22%), hemorrhagic" exact="stroke" post="(5%), SAH (subarachnoid hemorrhage, 0.8%), cerebral venous thrombosis (0.5%)"/>
   <result pre="(subarachnoid hemorrhage, 0.8%), cerebral venous thrombosis (0.5%) other diagnoses than" exact="stroke" post="(4.7%). 40% complained about headache on at least one"/>
   <result pre="in males, p&amp;lt;0.02). Headache affected 38% of patients with ischemic" exact="stroke" post="and 47% with TIA. The most common stroke affected"/>
   <result pre="with ischemic stroke and 47% with TIA. The most common" exact="stroke" post="affected vessel was the middle cerebral artery (62%). Headache"/>
   <result pre="could be that the patients were consequently asked on the" exact="stroke" post="unit. Headache prevalence was still that high, when excluding"/>
   <result pre="that headache is a frequent, yet often unrecognized symptom in" exact="stroke" post="which needs specific attention. References: 1. Bederson JB, Connolly"/>
   <result pre="(n=120, mean age 56.1, females 55%) had focal brain or" exact="retinal ischemia" post="with resolution of symptoms within 24 hours without presence"/>
   <result pre="&quot;lumbar spine osteochondrosis&quot; or &quot;gastrointestinal ulcer&quot;. Results: One-year prevalence of" exact="migraine" post="without aura was significantly higher in TIA patients than"/>
   <result pre="than anterior circulation TIA. Conclusions: The one year prevalence of" exact="migraine" post="was significantly higher in TIA patients than in controls"/>
   <result pre="susceptibility, which is a clinically-relevant animal model to screen for" exact="migraine" post="therapies. We aimed to optimize VNS efficacy on CSD"/>
   <result pre="O15 DNA methylation pattern of CALCA gene in patients with" exact="migraine" post="Elisa Rubino 1, Silvia Boschi 1,2, Alessandro Vacca 1,"/>
   <result pre="Italy Correpondence: Elisa Rubino (elisa.rubino@unito.it) Background. Migraine is a common" exact="neurological disorder" post="characterized by intense, recurrent or chronic pain, representing a"/>
   <result pre="(CGRP), encoded by CALCA gene, has a key role in" exact="migraine" post="pathogenesis, and successful new drugs for treatment of migraine"/>
   <result pre="in migraine pathogenesis, and successful new drugs for treatment of" exact="migraine" post="target CGRP. The aim of the study was to"/>
   <result pre="CALCA gene in patients with migraine. Methods. Twenty-two patients with" exact="migraine" post="(F/M 15/7; mean age± SD: 39.7± 13.4 years) and"/>
   <result pre="the Department of Neuroscience, University of Torino. The diagnosis of" exact="migraine" post="was made according to the ICHD-III beta version criteria."/>
   <result pre="found in the global methylation of CALCA in patients with" exact="migraine" post="and controls. Interestingly, stratification analysis showed that in migraineurs"/>
   <result pre="migraine: subgroup analyses of efficacy by low- versus high-frequency of" exact="migraine" post="headaches Stephen Silberstein 1, Virginia L Stauffer 2, Katie"/>
   <result pre="(stauffer_virginia@lilly.com) Objective: To investigate the efficacy of galcanezumab in episodic" exact="migraine" post="(EM) by subgroups of low- versus high-frequency of migraine"/>
   <result pre="episodic migraine (EM) by subgroups of low- versus high-frequency of" exact="migraine" post="headaches. Methods: Data were pooled from two phase 3"/>
   <result pre="system, and randomization was stratified by low-frequency (LFEM; 4-7 monthly" exact="migraine" post="headache days [MHDs]) or high-frequency (HFEM; 8-14 monthly MHDs)."/>
   <result pre="18-65 years old and experienced 4-14 MHDs, with ≥2 monthly" exact="migraine" post="attacks, determined during the prospective 1-month baseline period. Patients"/>
   <result pre="during the prospective 1-month baseline period. Patients had history of" exact="migraine" post="for ≥1 year prior onset, and onset was before"/>
   <result pre="role function-restrictive domain score compared to placebo (p&amp;lt;.001) and the" exact="migraine" post="disability assessment (MIDAS) total score compared with placebo (Table"/>
   <result pre="the Declaration of Helsinki guidelines Table 1 (abstract O17). Monthly" exact="migraine" post="headache days, average of months 1-6 LFEM HFEM Treatment"/>
   <result pre="Treatment-by-subgroup interaction p-value vs. placebo Table 2 (abstract O17). Monthly" exact="migraine" post="headache days with acute medication use, average of months"/>
   <result pre="from two parallel studies (EVOLVE-1=NCT02614183, EVOLVE-2=NCT02614196) of patients with episodic" exact="migraine" post="(between 4 and 14 migraine headache days [MHD] and"/>
   <result pre="EVOLVE-2=NCT02614196) of patients with episodic migraine (between 4 and 14" exact="migraine" post="headache days [MHD] and at least 2 migraine attacks"/>
   <result pre="and 14 migraine headache days [MHD] and at least 2" exact="migraine" post="attacks per month during baseline) and one study (REGAIN="/>
   <result pre="baseline) and one study (REGAIN= NCT02614261) of patients with chronic" exact="migraine" post="(headache ≥15 days/month for &amp;gt;3 months, with features of"/>
   <result pre="migraine (headache ≥15 days/month for &amp;gt;3 months, with features of" exact="migraine" post="headache ≥8 days/month at baseline) were analyzed. In all"/>
   <result pre="site. Results: A total of 1773 adult patients with episodic" exact="migraine" post="(n=444 for galcanezumab 120 mg; n=435 for galcanezumab 240"/>
   <result pre="for two episodic studies pooled) and 1113 patients with chronic" exact="migraine" post="(n=278 for galcanezumab 120 mg; n=277 for galcanezumab 240"/>
   <result pre="and clinically meaningful persistence of effect in patients with episodic" exact="migraine" post="(at least 3 and 6 consecutive months) and in"/>
   <result pre="3 and 6 consecutive months) and in patients with chronic" exact="migraine" post="(for 3 months). O19 Efficacy of galcanezumab in patients"/>
   <result pre="conducted for change from baseline in the number of monthly" exact="migraine" post="headache days (MHD) and ≥50% response (reduction in the"/>
   <result pre="neurophysiological effects of botulinum toxin type A treatment in chronic" exact="migraine" post="Gianluca Coppola 1*, Francesca Cortese 1, Davide Di Lenola"/>
   <result pre="A (BTX-A) has been approved for the treatment of chronic" exact="migraine" post="(CM). Although different studies have shown that this treatment"/>
   <result pre="cardiac death 5 years after RCVS1. One patient had a" exact="stroke" post="(0.6%) during her recurrent RCVS. Conclusions: RCVS patients have"/>
   <result pre="N. Carlsen (louise.ninett.carlsen@regionh.dk) Background: Complete stop of acute medication and/or" exact="migraine" post="medication for treatment of medication-overuse headache (MOH) has previously"/>
   <result pre="previously been reported more effective in reducing headache days and" exact="migraine" post="days per month compared with restricted intake of acute"/>
   <result pre="follow-up. Results: We included 72 MOH patients with a primary" exact="migraine" post="and/or tension-type headache diagnosis. Fifty-nine patients completed detoxification. At"/>
   <result pre="O24 The economic and humanistic burden of episodic and chronic" exact="migraine" post="in Europe Hicham Benhaddi 1; Timothy Fitzgerald 2; Sophie"/>
   <result pre="UK Correspondence: Hicham Benhaddi (mhowell@hcg-int.com) BACKGROUND: Migraine is a debilitating" exact="neurological disorder" post="characterized by attacks that may last 4–72 hours, with"/>
   <result pre="clinical, humanistic, and economic burden associated with chronic and episodic" exact="migraine" post="(CM and EM, respectively) in Europe. METHODS: Literature searches"/>
   <result pre="days per month) or CM (≥15 headache days with ≥8" exact="migraine" post="days per month) were included. Searches focused on resource"/>
   <result pre="Data from the World Health Organization indicated that in Europe," exact="migraine" post="burden weighed higher than that of epilepsy, multiple sclerosis,"/>
   <result pre="in Europe, migraine burden weighed higher than that of epilepsy," exact="multiple sclerosis," post="and Parkinson’s disease. Up to 57% of individuals with"/>
   <result pre="sclerosis, and Parkinson’s disease. Up to 57% of individuals with" exact="migraine" post="report severe disability, and many find treatments ineffective. Nausea"/>
   <result pre="occur up to three times more often in individuals with" exact="migraine" post="than in the general population. People with migraine have"/>
   <result pre="individuals with migraine than in the general population. People with" exact="migraine" post="have reported poorer health-related quality of life than those"/>
   <result pre="of life than those without migraine, which worsens with increasing" exact="migraine" post="attack frequency. Europeans with migraine perceive that it has"/>
   <result pre="migraine, which worsens with increasing migraine attack frequency. Europeans with" exact="migraine" post="perceive that it has a negative impact on work"/>
   <result pre="position, love, financial situation, career, and friendships. The prevalence of" exact="migraine" post="is highest for men and women during their peak"/>
   <result pre="higher than those for EM. CONCLUSIONS: This research demonstrates that" exact="migraine" post="has a substantial humanistic and economic burden on Europeans"/>
   <result pre="of life. O25 Headache outcome measures in medically refractory chronic" exact="migraine" post="patients treated with OnabotulinumtoxinA Lagrata Susie 1, Ahmed Maha"/>
   <result pre="(m.matharu@uclmail.net) Introduction OnabotulinumtoxinA is standard care of management for chronic" exact="migraine" post="(CM). Few studies on the use of OnabotulinumtoxinA on"/>
   <result pre="(SPO) to OnabotulinumtoxinA in reported by patients with medically-refractory chronic" exact="migraine" post="(rCM). Aim To identify components of headache characteristics (frequency,"/>
   <result pre="like a light touch. It occurs frequently in patients with" exact="migraine" post="and it seems to be associated with the duration"/>
   <result pre="was to investigate the presence of structural brain changes in" exact="migraine" post="patients with hallodynia as compared to migraine patients without"/>
   <result pre="brain changes in migraine patients with hallodynia as compared to" exact="migraine" post="patients without hallodynia. Materials and methods Consecutive eligible patients"/>
   <result pre="Center within a six-month period and with a diagnosis of" exact="migraine" post="were screened for the inclusion in the study. Hallodynia"/>
   <result pre="(19.3±13.9 vs 20.8±9.6, respectively; p&amp;gt;0.05) and number of days with" exact="migraine" post="per month (mean±SD 7.0±4.8 vs 8.0±5.8, respectively; p&amp;gt;0.05). Migraine"/>
   <result pre="right hemisphere (p&amp;lt; 0.005). No correlation was found between the" exact="migraine" post="duration and the extent of volumetric decrease in patients"/>
   <result pre="Eidlitz-Markus T. Cephalic cutaneous allodynia in children and adolescents with" exact="migraine" post="of short duration: A retrospective cohort study. Cephalalgia. 2018"/>
   <result pre="Reed ML, Serrano D, Stewart WF. Cutaneous allodynia in the" exact="migraine" post="population. Ann Neurol 2008;63:148-158. Barthas F, Sellmeijer J, Hugel"/>
   <result pre="Barbanti (piero.barbanti@sanraffaele.it) Background: Dopamine (DA) plays a major role in" exact="migraine" post="pathogenesis as suggested by clinical, genetic, biochemical and pharmacological"/>
   <result pre="Methods: We studied all patients affected by episodic and chronic" exact="migraine" post="consecutively seen at our Headache and Pain Unit from"/>
   <result pre="socio-demographic factors; 2) comorbidities and concomitant medications; and 3) clinical" exact="migraine" post="features encompassing family history, disease duration, site, quality and"/>
   <result pre="nausea, vomiting, mood changes or diuresis?&quot;. Results: We studied 1148" exact="migraine" post="patients (F/M: 902/246; without aura, MwA: 679; with aura,"/>
   <result pre="not differ for life-style, behavioral and socio-demographic factors and other" exact="migraine" post="variables. Stepwise logistic regression analysis revealed that DAs+ patients"/>
   <result pre="(p&amp;lt;0.0001), allodynia (p=0.0077), and unilateral autonomic symptoms (p=0.0426) than general" exact="migraine" post="population. Conclusions: More than 1/3 or migraineurs show DAs,"/>
   <result pre="associated with allodynia, osmophobia and unilateral autonomic symptoms than general" exact="migraine" post="population. DAs+ patients could represent a migraine endophenotype. O28"/>
   <result pre="symptoms than general migraine population. DAs+ patients could represent a" exact="migraine" post="endophenotype. O28 Non-invasive vagus nerve stimulation (nVNS) for the"/>
   <result pre="Med 2017;377:317-28. O30 Response to lasmiditan for acute treatment of" exact="migraine" post="based on prior response to triptan therapy Kerry Knievel"/>
   <result pre="Migraine Prevalence and Prevention Study, &amp;gt;40% of patients with episodic" exact="migraine" post="had unmet acute treatment needs with current therapies, including"/>
   <result pre="has demonstrated superiority to placebo in the acute treatment of" exact="migraine" post="in adults. In two Phase 3 studies, SAMURAI (NCT02439320)"/>
   <result pre="(NCT02439320) and SPARTAN (NCT02605174), the percentage of patients who were" exact="migraine" post="pain-free 2 hours post-first dose was significantly greater with"/>
   <result pre="p&amp;lt;0.001 vs placebo) taken within 4 hours of a single" exact="migraine" post="attack. This post-hoc analysis determined whether response to lasmiditan"/>
   <result pre="SAMURAI and SPARTAN. Methods: Both studies included patients with moderate/severe" exact="migraine" post="disability (MIDAS score ≥11). Current analyses considered combined data"/>
   <result pre="studies. Conclusion: Therapeutic benefit of lasmiditan in patients with moderate/severe" exact="migraine" post="disability was generally unaffected by prior triptan therapy response."/>
   <result pre="by prior triptan therapy response. Lasmiditan offers a possible alternative" exact="migraine" post="therapy option for patients regardless of prior response to"/>
   <result pre="2013;53:1300-11. O31 Effect of galcanezumab on severity and symptoms of" exact="migraine" post="in phase 3 trials in patients with episodic or"/>
   <result pre="in phase 3 trials in patients with episodic or chronic" exact="migraine" post="Kathleen A. Day 1, Michael Ament 2, Virginia L."/>
   <result pre="has demonstrated in multiple studies, a significant reduction in monthly" exact="migraine" post="headache days compared to placebo. Here, we present data"/>
   <result pre="present data from 3 randomized clinical trials in patients with" exact="migraine" post="showing that galcanezumab alleviates severity and symptoms of migraine."/>
   <result pre="male and female patients 18–65 years of age with episodic" exact="migraine" post="(i.e., 4–14 monthly migraine headache days [MHDs]). REGAIN was"/>
   <result pre="18–65 years of age with episodic migraine (i.e., 4–14 monthly" exact="migraine" post="headache days [MHDs]). REGAIN was a global study with"/>
   <result pre="study with a 3-month double-blind phase in patients with chronic" exact="migraine" post="(≥15 headache days [HDs] per month, where ≥8 met"/>
   <result pre="phonophobia, aura, and prodromal symptoms other than aura. Rating for" exact="migraine" post="severity was 1=mild, 2=moderate, and 3=severe. Analyses were conducted"/>
   <result pre="galcanezumab were statistically significantly superior to placebo (p&amp;lt;.05) in reducing" exact="migraine" post="symptoms and severity (Table 1). Conclusions: Galcanezumab was superior"/>
   <result pre="superior to placebo in reducing the mean severity of remaining" exact="migraine" post="headaches and in reducing the numbers of monthly moderate"/>
   <result pre="mean; BL baseline, CI confidence interval, HDs headache days, MHDs" exact="migraine" post="headache days, N number of intent-to-treat patients who have"/>
   <result pre="and REGAIN, respectively O32 Factors associated with significant reduction in" exact="migraine" post="headache days: a post hoc analysis of phase 3"/>
   <result pre="phase 3 placebo-controlled trials of patients with episodic and chronic" exact="migraine" post="treated with galcanezumab Sheena K. Aurora, Dustin D. Ruff,"/>
   <result pre="response predictors are revalidated in phase III episodic and chronic" exact="migraine" post="studies. Methods: This post hoc analysis of 3 randomized,"/>
   <result pre="galcanezumab in patients aged 18-65 years. Results of two episodic" exact="migraine" post="(EM) studies (NCT02614183, NCT02614196) that enrolled patients with a"/>
   <result pre="(NCT02614183, NCT02614196) that enrolled patients with a baseline of 4-14" exact="migraine" post="headache days (MHD) per month were pooled. One chronic"/>
   <result pre="migraine headache days (MHD) per month were pooled. One chronic" exact="migraine" post="(CM) study (NCT02614261) enrolled patients with ≥15 headache days"/>
   <result pre="Three possible predictors of clinical response – prior triptan use," exact="migraine" post="history ≥20 years, and history of failure to preventive"/>
   <result pre="being more prevalent in females of reproductive age. Attacks of" exact="migraine" post="in more than 50% of women correlate with menstrual"/>
   <result pre="more severe and difficult to manage with conventional therapies. Menstrual" exact="migraine" post="attacks are defined as attacks occurring during the 5-day"/>
   <result pre="and episodic migraine, on the incidence and severity of menstrual" exact="migraine" post="attacks. Methods: Post-hoc analyses were performed using data from"/>
   <result pre="aged 18-65 years with episodic (EVOLVE-1 &amp;amp; EVOLVE-2) or chronic" exact="migraine" post="(REGAIN). A total of 2,886 patients (858 EVOLVE-1, 915"/>
   <result pre="as well as headache characteristics, duration, and severity. A menstrual-related" exact="migraine" post="headache day (MRMHD) is defined as a headache with"/>
   <result pre="migraine headache day (MRMHD) is defined as a headache with" exact="migraine" post="characteristics (definition adapted from the standard IHS ICHD-3 beta"/>
   <result pre="(Table 1). Conclusion: Galcanezumab, given monthly, was effective in reducing" exact="migraine" post="headache days during the perimenstrual period. The studies were"/>
   <result pre="PACNS, p&amp;lt;0.0001) and more often had a past history of" exact="migraine" post="(32% versus 7%, p&amp;lt;0.0001). While headaches, especially thunderclap headaches,"/>
   <result pre="but only in 53 (31%) RCVS patients (p&amp;lt;0.0001). Acute ischemic" exact="stroke" post="was more frequent in PACNS than in RCVS (76%"/>
   <result pre="of Pavia, Pavia, Italy Correspondence: Simona Sacco (simona.sacco@univaq.it) Background Chronic" exact="migraine" post="(CM) is an underdiagnosed and undertreated condition. Tools to"/>
   <result pre="Pain 2017;18(Suppl 1):P43. O36 Migraine progression in natural subgroups of" exact="migraine" post="based on comorbidities and concomitant conditions: results of the"/>
   <result pre="(Richard.Lipton@einstein.yu.edu) Background: Prior research has identified 8 natural subgroups of" exact="migraine" post="based on profiles of comorbidities from the CaMEO Study."/>
   <result pre="subgroups differ in prognosis as measured by progression to chronic" exact="migraine" post="(CM). Methods: Participants from the prospective, web-based baseline CaMEO"/>
   <result pre="CaMEO Study (ClinicalTrials.gov, NCT01648530) were identified using quota sampling. Episodic" exact="migraine" post="(EM) and CM were distinguished. Based on respondents’ self-report,"/>
   <result pre="after (95% CI: 2.17, 4.20). Conclusions: Identified comorbid classes of" exact="migraine" post="are associated with risk of progression from EM to"/>
   <result pre="Understanding the biological differences among these subgroups may help minimize" exact="migraine" post="disease progression and optimize management. Table 1 (abstract O36)."/>
   <result pre="Forward stepwise model* for the discrete time hazard to chronic" exact="migraine" post="onset in comorbid classes of migraine in individuals with"/>
   <result pre="time hazard to chronic migraine onset in comorbid classes of" exact="migraine" post="in individuals with episodic migraine at baseline Hazard Ratio"/>
   <result pre="onset in comorbid classes of migraine in individuals with episodic" exact="migraine" post="at baseline Hazard Ratio (95% CI)* LCA Class Step"/>
   <result pre="N. Carlsen (louise.ninett.carlsen@regionh.dk) Background: Complete stop of acute medication and/or" exact="migraine" post="medication for treatment of medication-overuse headache (MOH) has previously"/>
   <result pre="previously been reported more effective in reducing headache days and" exact="migraine" post="days per month compared with restricted intake of acute"/>
   <result pre="Scale (HADS). Results: We included 72 MOH patients with primary" exact="migraine" post="and/or tension-type headache. Forty-nine completed detoxification and the SDS-questionnaire"/>
   <result pre="rates, acute medication use, and disability in patients with episodic" exact="migraine" post="who have failed at least one prior migraine preventive"/>
   <result pre="with episodic migraine who have failed at least one prior" exact="migraine" post="preventive medication Paul K. Winner 1; Rashmi B. Halker"/>
   <result pre="K. Winner (khokenson@hcg-int.com) BACKGROUND: Preventive medication is recommended for episodic" exact="migraine" post="(EM) patients with ≥4 headache days per month. Fremanezumab,"/>
   <result pre="in EM patients who failed at least one prior preventive" exact="migraine" post="medication. METHODS: In this Phase 3, multicenter, randomized, double-blind,"/>
   <result pre="performed in patients who failed at least one prior preventive" exact="migraine" post="medication (due to lack of efficacy or intolerability) using"/>
   <result pre="patients with ≥50% reduction in the monthly average number of" exact="migraine" post="days, mean change from baseline in the monthly average"/>
   <result pre="period. RESULTS: The subgroup who failed at least one prior" exact="migraine" post="preventive therapy included 58 fremanezumab quarterly, 65 fremanezumab monthly,"/>
   <result pre="had a ≥50% reduction in the monthly average number of" exact="migraine" post="days during the treatment period (quarterly: 38%, P=0.0100; monthly:"/>
   <result pre="Among EM patients who failed at least one prior preventive" exact="migraine" post="medication, fremanezumab treatment was efficacious, reduced acute headache medication"/>
   <result pre="or local regulations. O39 Impact of fremanezumab on response rates," exact="migraine" post="days, and acute medication use in patients with chronic"/>
   <result pre="migraine days, and acute medication use in patients with chronic" exact="migraine" post="who have failed at least one prior migraine preventive"/>
   <result pre="with chronic migraine who have failed at least one prior" exact="migraine" post="preventive medication Stephen D. Silberstein 1, Jessica Ailani 2,"/>
   <result pre="targets calcitonin gene-related peptide (CGRP), is efficacious in preventing chronic" exact="migraine" post="(CM), but its effectiveness in patients who have failed"/>
   <result pre="OBJECTIVE: To assess the effects of fremanezumab on response rates," exact="migraine" post="days and acute headache medication use in patients with"/>
   <result pre="use in patients with CM who failed one prior preventive" exact="migraine" post="medication. METHODS: In this Phase 3, multicenter, randomized, double-blind,"/>
   <result pre="performed in patients who failed at least one prior preventive" exact="migraine" post="medication (due to lack of efficacy or intolerability) using"/>
   <result pre="mean change from baseline in the monthly average number of" exact="migraine" post="days and mean change from baseline in the number"/>
   <result pre="subgroup of patients who failed at least one prior preventive" exact="migraine" post="therapy included 130 fremanezumab quarterly, 141 fremanezumab monthly, and"/>
   <result pre="placebo (8%). Fremanezumab treatment reduced the monthly average number of" exact="migraine" post="days during the 12-week treatment period ([least-squares mean change"/>
   <result pre="with CM who have failed at least one prior preventive" exact="migraine" post="medication, fremanezumab was efficacious, with effect sizes in excess"/>
   <result pre="to national or local regulations. O40 Efficacy of fremanezumab in" exact="migraine" post="patients who have failed at least one prior migraine"/>
   <result pre="in migraine patients who have failed at least one prior" exact="migraine" post="preventive medication Peter McAllister 1, David W. Dodick 2,"/>
   <result pre="been shown to be effective in the prevention of chronic" exact="migraine" post="(CM) and episodic migraine (EM). OBJECTIVE: To assess the"/>
   <result pre="effective in the prevention of chronic migraine (CM) and episodic" exact="migraine" post="(EM). OBJECTIVE: To assess the efficacy of fremanezumab in"/>
   <result pre="migraine (EM). OBJECTIVE: To assess the efficacy of fremanezumab in" exact="migraine" post="patients who failed at least one prior preventive migraine"/>
   <result pre="in migraine patients who failed at least one prior preventive" exact="migraine" post="medication. METHODS: Fremanezumab was studied in two Phase 3,"/>
   <result pre="at least moderate severity or the monthly average number of" exact="migraine" post="days during the 12-week treatment period were assessed in"/>
   <result pre="were assessed in patients who failed at least one prior" exact="migraine" post="preventive medication due to lack of efficacy or intolerability."/>
   <result pre="There were similar reductions in the monthly average number of" exact="migraine" post="days (quarterly: –4.2±0.55, P=0.005; monthly: –4.8±0.53, P&amp;lt;0.0001) compared with"/>
   <result pre="There were similar reductions in the monthly average number of" exact="migraine" post="days (quarterly: –3.3±0.61, P=0.0015; monthly: –3.8±0.59, P&amp;lt;0.0001) compared with"/>
   <result pre="stated are compared with placebo. CONCLUSIONS: Fremanezumab was efficacious in" exact="migraine" post="patients who failed at least one prior migraine preventive"/>
   <result pre="efficacious in migraine patients who failed at least one prior" exact="migraine" post="preventive medication, a potentially difficult-to-treat population. Effect sizes in"/>
   <result pre="or local regulations. O41 Cluster headache is not associated with" exact="sleep apnea" post="or specific sleep stages Nunu Lund 1; Mads Barloese"/>
   <result pre="fewer PLMs (0.67 vs. 1.30 hour -1, p&amp;lt;0.05). Finally, the" exact="sleep apnea" post="index was similar in both groups (9.63 vs. 7.76"/>
   <result pre="manifestation of a persisting, underlying pathology. Finally, the prevalence of" exact="sleep apnea" post="was comparable in all groups and attacks were not"/>
   <result pre="data was collected: socio-demographic data,; preventive treatment and choices different" exact="migraine" post="sub-types, and their personal perception of efficacy and tolerability"/>
   <result pre="headache . In regards to preventive treatment choice; in chronic" exact="migraine" post="topiramate (57%) amytriptiline (17.9%) and beta-blockers (14.6%), whereas in"/>
   <result pre="topiramate (57%) amytriptiline (17.9%) and beta-blockers (14.6%), whereas in episodic" exact="migraine" post="the preferred drugs were beta-blockers (47.7%), topiramate (21.5%) and"/>
   <result pre="perceived efficacy, topiramate was considered the best option in chronic" exact="migraine" post="(42.7%) followed by onabotulinumtoxinA (25.5%) and amitryptiline (22.4%). In"/>
   <result pre="of preventive therapy when improvement was achieved, when treating episodic" exact="migraine" post="43.5% of the surveyed neurologists recommended 3 months and"/>
   <result pre="first choices in most of the guidelines. Management of episodic" exact="migraine" post="differed from chronic migraine, both in the order or"/>
   <result pre="O43 Effect of the H 1-antihistamine clemastine on PACAP38 induced" exact="migraine" post="Luise Haulund Vollesen 1, Song Guo 1, Malene Rohr"/>
   <result pre="investigate the effect of the H 1-antihistamine clemastine on the" exact="migraine" post="inducing abilities of pituitary adenylate cyclase activating peptide-38 (PACAP38)."/>
   <result pre="conducted a double-blind, randomized, placebo controlled two-way cross-over study. Twenty" exact="migraine" post="without aura patients were randomly allocated to receive bolus"/>
   <result pre="and placebo pretreatment days. Conclusion H1-antihistamine, clemastine, failed to prevent" exact="migraine" post="or headache after PACAP38 infusion thus making a role"/>
   <result pre="for histamine release or mast cell degranulation in PACAP38 induced" exact="migraine" post="less likely. O44 CSF pressure fluctuations as a marker"/>
   <result pre="refractory chronic headaches suspected of having cerebrospinal fluid-pressure elevation without" exact="papilledema" post="or sixth nerve palsy and non-headache controls underwent 1-hour"/>
   <result pre="on the four main mechanisms involved in the pathophysiology of" exact="migraine" post="with aura: cortical Spreading Depression, sensitization of trigeminal vascular"/>
   <result pre="is well known to interact with the aura phenomena and" exact="migraine" post="itself.With this study we want to compare the efficacy"/>
   <result pre="32 years ), 31 women and 29 men, suffering from" exact="migraine" post="with aura, not assuming migraine preventive therapy. They have"/>
   <result pre="and 29 men, suffering from migraine with aura, not assuming" exact="migraine" post="preventive therapy. They have to refer of an aura"/>
   <result pre="magnesium alone. O48 Hemicrania continua-like headache revealed a subacute internal" exact="carotid artery dissection" post="in patient with unrecognized connective tissue disorder Silvia Ricci,"/>
   <result pre="case of a patient who developed typical HC-like headache after" exact="carotid artery dissection." post="Case-presentation On February 2018, a 43 year-old man presented"/>
   <result pre="(apart from the time criterion) unresponsive to habitual medication for" exact="migraine" post="associated with right tongue deviation. The routine laboratory test,"/>
   <result pre="Sharma DK, et al. Hemicrania continua-like headache associated with internal" exact="carotid artery dissection" post="may respond to indomethacin. Headache 2007; 47: 127–130. 2-"/>
   <result pre="Occipital Nerve (GON) Block in Chronic Migraine: relevance for chronic" exact="migraine" post="pathophysiology Alessandro Viganò 1,2, Maria Claudia Torrieri 3, Massimiliano"/>
   <result pre="month (-34.9%; p=0.003). Eight out 17CM patients reversed to episodic" exact="migraine" post="and medication overuse resolved in 11 out of 12"/>
   <result pre="Correspondence: B. Petolicchio (barbara.petolicchio@uniroma1.it) Background The preventive treatment for chronic" exact="migraine" post="(CM) is difficult and often complicated by analgesics overuse"/>
   <result pre="(p&amp;lt;0.01) O51 Resting-state between-networks functional connectivity is abnormal in chronic" exact="migraine" post="patients Gianluca Coppola 1*, Barbara Petolicchio 2, Antonio Di"/>
   <result pre="using resting state functional magnetic resonance imaging (RS-fMRI) in episodic" exact="migraine" post="depending on migraine phase (ictal/interictal) and the frequency of"/>
   <result pre="functional magnetic resonance imaging (RS-fMRI) in episodic migraine depending on" exact="migraine" post="phase (ictal/interictal) and the frequency of the attacks. Here,"/>
   <result pre="between networks connectivity using independent component analysis (ICA) in chronic" exact="migraine" post="(CM) patients. Materials and methods Twenty patients with untreated"/>
   <result pre="patients. Materials and methods Twenty patients with untreated de-novo chronic" exact="migraine" post="(CM) underwent 3T MRI scans and were compared to"/>
   <result pre="functional networks. Our data further suggest that the severity of" exact="migraine" post="pain is associated with proportional inverse pattern of frontal"/>
   <result pre="M 30 18 12 X Left, T Conjunctival injection and" exact="ptosis" post="Pressing and tightening 5 15 F 40 40 0.17"/>
   <result pre="Numerical Rating Scale EHF Poster Presentation P1 The cost of" exact="migraine" post="in Greece: a half billion euros disease Panagiotis Stafylas"/>
   <result pre="of this analysis is to approximate the economic burden of" exact="migraine" post="in Greece. Methods: A cost-of-Illness analysis was conducted to"/>
   <result pre="to estimate direct and indirect costs for the management of" exact="migraine" post="in Greece. Data on epidemiology and resource use were"/>
   <result pre="the analysis is societal. Results: Assuming that the prevalence of" exact="migraine" post="in Greek adults is 13.3%, it is estimated that"/>
   <result pre="13.3%, it is estimated that about 1,208,210 adults suffer from" exact="migraine" post="in Greece. Based on these data, the total direct"/>
   <result pre="these data, the total direct cost for the management of" exact="migraine" post="in Greece is €301,969,046. The total indirect costs due"/>
   <result pre="about 83% represent out-of-pocket expenses. Consequently, the economic burden of" exact="migraine" post="in Greece for the year 2017 (including both direct"/>
   <result pre="costs) was about €447,054,179. Conclusion: The total economic burden of" exact="migraine" post="in Greece has been estimated at about half billion"/>
   <result pre="currently the only NHS service commissioned to offer sTMS to" exact="migraine" post="patients. Here we present our interim results. Methods: This"/>
   <result pre="of sTMS as a non-pharmacological modality for the treatment of" exact="migraine" post="with and without aura in a real world setting."/>
   <result pre="migraine. Audit inclusion criteria were a documented diagnosis of chronic" exact="migraine" post="documented in a headache diary and patients willingness in"/>
   <result pre="were used to collect clinical outcomes. Change in headache days," exact="migraine" post="days and HIT-6 at 3 months of treatment compared"/>
   <result pre="Adverse events and treatment compliance were also collected. Results: Forty-two" exact="migraine" post="patients (11 with aura, 31 without aura) treated with"/>
   <result pre="patients displayed an average of 14.7 headache days (HD)/month, 11.1" exact="migraine" post="days (MD)/month and HIT-6 score of 63.3. Following 3-month"/>
   <result pre="and well tolerated preventive treatment option for difficult-to-treat high frequency/chronic" exact="migraine" post="patients in a real world setting. Since sTMS is"/>
   <result pre="one of the three preventive treatment to offer to chronic" exact="migraine" post="patients prior to Botox ®. P3 The impact of"/>
   <result pre="®. P3 The impact of fremanezumab on symptoms associated with" exact="migraine" post="in patients with episodic migraine Jan L. Brandes 1;"/>
   <result pre="fremanezumab on symptoms associated with migraine in patients with episodic" exact="migraine" post="Jan L. Brandes 1; Paul P. Yeung 2; Ernesto"/>
   <result pre="selectively targets calcitonin gene-related peptide (CGRP), reduced the number of" exact="migraine" post="days in EM patients. We assessed the effect of"/>
   <result pre="regulations. P4 The impact of fremanezumab on symptoms associated with" exact="migraine" post="in patients with chronic migraine Peter McAllister 1, Paul"/>
   <result pre="fremanezumab on symptoms associated with migraine in patients with chronic" exact="migraine" post="Peter McAllister 1, Paul P. Yeung 2, Ernesto Aycardi"/>
   <result pre="Headache Disorders, third edition (beta version) (ICHD-3 beta) criteria for" exact="migraine" post="include nausea, vomiting, photophobia, and phonophobia symptoms. Fremanezumab, a"/>
   <result pre="the frequency and severity of headaches in patients with chronic" exact="migraine" post="(CM). We assessed the effect of fremanezumab versus placebo"/>
   <result pre="calcitonin gene-related peptide (CGRP), has demonstrated efficacy in preventing episodic" exact="migraine" post="(EM) in 3-month studies; this analysis evaluates its long-term"/>
   <result pre="of patients achieving ≥50% reduction in monthly average number of" exact="migraine" post="days, the mean change from baseline in the monthly"/>
   <result pre="780 EM patients. The mean change in monthly number of" exact="migraine" post="days from baseline to Month 1 was –4.6 days"/>
   <result pre="of patients achieving ≥50% reduction in monthly average number of" exact="migraine" post="days at Month 6 was 61% with monthly dosing,"/>
   <result pre="been shown to be effective in the prevention of episodic" exact="migraine" post="(EM) or chronic migraine (CM). OBJECTIVE: To summarize the"/>
   <result pre="effective in the prevention of episodic migraine (EM) or chronic" exact="migraine" post="(CM). OBJECTIVE: To summarize the safety profile of fremanezumab"/>
   <result pre="No signal for hepatoxicity was observed. No anaphylaxis or severe" exact="hypersensitivity" post="occurred, and only three patients (two on placebo, and"/>
   <result pre="on placebo, and one on fremanezumab) had AEs of drug" exact="hypersensitivity" post="of mild or moderate severity. None of these events"/>
   <result pre="national or local regulations. P7 Reversion of patients with chronic" exact="migraine" post="to an episodic migraine classification with fremanezumab treatment Joshua"/>
   <result pre="P7 Reversion of patients with chronic migraine to an episodic" exact="migraine" post="classification with fremanezumab treatment Joshua M. Cohen 1; Kristen"/>
   <result pre="To evaluate the effect of fremanezumab on reversion from chronic" exact="migraine" post="(CM) to episodic migraine (EM). BACKGROUND: CM and EM"/>
   <result pre="of fremanezumab on reversion from chronic migraine (CM) to episodic" exact="migraine" post="(EM). BACKGROUND: CM and EM are clinically, functionally, and"/>
   <result pre="selectively targets calcitonin gene-related peptide (CGRP), has demonstrated efficacy in" exact="migraine" post="prevention. DESIGN/METHODS: In this Phase 3, multicenter, randomized, double-blind,"/>
   <result pre="adults with prospectively confirmed CM (≥15 headache days and ≥8" exact="migraine" post="days per month) were randomized 1:1:1 to subcutaneous injections"/>
   <result pre="in headache days. CONCLUSIONS: Along with its efficacy as a" exact="migraine" post="preventive treatment, fremanezumab demonstrated the potential benefit for reversion"/>
   <result pre="(clinical trials). P8 Efficacy of fremanezumab in patients with chronic" exact="migraine" post="with or without concomitant use of preventive medication Peter"/>
   <result pre="(srieger@hcg-int.com) OBJECTIVE: To investigate the efficacy of fremanezumab in chronic" exact="migraine" post="(CM) patients with or without concomitant use of preventive"/>
   <result pre="selectively targets calcitonin gene-related peptide (CGRP), has demonstrated efficacy in" exact="migraine" post="prevention. DESIGN/METHODS: In this Phase 3, randomized, double-blind, placebo-controlled,"/>
   <result pre="patients with prospectively confirmed CM (≥15 headache days and ≥8" exact="migraine" post="days per month) were randomized 1:1:1 to receive subcutaneous"/>
   <result pre="of headache days of at least moderate severity, and in" exact="migraine" post="days in patients with or without concomitant preventive medication."/>
   <result pre="receiving concomitant preventive medication ( P&amp;lt;0.0001). There were also fewer" exact="migraine" post="days with both fremanezumab regimens. CONCLUSIONS: Fremanezumab demonstrated efficacy"/>
   <result pre="Medicine, Istanbul, Turkey, 34096 Correspondence: Özlem Mercan (ozlemmercan3@gmail.com) Background: Chronic" exact="migraine" post="(CM) is still an underdiagnosed and undertreated headache disorder"/>
   <result pre="efficacy scores. P10 Efficacy of fremanezumab in patients with chronic" exact="migraine" post="and comorbid moderate to moderately severe depression Joshua M."/>
   <result pre="Cohen (mmathew@hcg-int.com) OBJECTIVE: To evaluate the efficacy of fremanezumab on" exact="migraine" post="symptoms and depression in patients with chronic migraine (CM)"/>
   <result pre="fremanezumab on migraine symptoms and depression in patients with chronic" exact="migraine" post="(CM) and comorbid moderate to moderately severe depression. BACKGROUND:"/>
   <result pre="selectively targets calcitonin gene-related peptide (CGRP), has demonstrated efficacy in" exact="migraine" post="prevention. DESIGN/METHODS: In this Phase 3, multicenter, randomized, double-blind,"/>
   <result pre="18–70, with prospectively confirmed CM (≥15 headache days and ≥8" exact="migraine" post="days per month) were randomized 1:1:1 to receive subcutaneous"/>
   <result pre="treatment period. Post hoc analyses evaluated changes in headache and" exact="migraine" post="frequency and depression in patients with moderate to moderately"/>
   <result pre="differences were observed for change in the mean number of" exact="migraine" post="days ( P&amp;lt;0.001). Fremanezumab also reduced the mean PHQ-9"/>
   <result pre="in patients with comorbid moderate to moderately severe depression, reducing" exact="migraine" post="and headache frequency and improving depression. TRIAL REGISTRATION: ClinicalTrials.gov,"/>
   <result pre="time with fremanezumab in the treatment of chronic and episodic" exact="migraine" post="Stephen D. Silberstein 1, Richard B. Lipton 2, Merle"/>
   <result pre="data from Phase 3 trials in episodic (EM) and chronic" exact="migraine" post="(CM) of fremanezumab, a fully humanized monoclonal antibody (IgG2a)"/>
   <result pre="treatment period. The percentage of patients with a reduction in" exact="migraine" post="days (response rates) &amp;gt;40% at Months 6 and 9"/>
   <result pre="the 12-week studies. RESULTS: CM patients with &amp;lt;20% reduction in" exact="migraine" post="days at Month 1 had &amp;gt;40% response rates of"/>
   <result pre="(41/101) at Month 9. EM patients with &amp;lt;20% reduction in" exact="migraine" post="days at Month 1 had &amp;gt;40% response rates of"/>
   <result pre="impact of fremanezumab on medication overuse in patients with chronic" exact="migraine" post="Stephen D. Silberstein 1, Sait Ashina 2, Zaza Katsarava"/>
   <result pre="can cause medication overuse headache (MOH), which often accompanies chronic" exact="migraine" post="(CM). Fremanezumab, a fully humanized monoclonal antibody (IgG2a) that"/>
   <result pre="burden globally [1]. However, limited evidence exists for those with" exact="migraine" post="who have used preventive medication. As part of the"/>
   <result pre="Voice survey, this study aimed to describe the impact of" exact="migraine" post="on work and activity impairment amongst migraine individuals who"/>
   <result pre="the impact of migraine on work and activity impairment amongst" exact="migraine" post="individuals who suffer from at least 4 monthly migraine"/>
   <result pre="amongst migraine individuals who suffer from at least 4 monthly" exact="migraine" post="days (MMDs) and reported use of preventive medication. Methods"/>
   <result pre="cross-sectional study was conducted using an online worldwide survey of" exact="migraine" post="patients from 31 countries across Africa, America, Asia, and"/>
   <result pre="with pre-specified 90% of them having reported having used preventive" exact="migraine" post="treatments. The impact of migraine on work productivity and"/>
   <result pre="having reported having used preventive migraine treatments. The impact of" exact="migraine" post="on work productivity and activities during the past seven"/>
   <result pre="and ≥2 TF patient subgroups. Results A total of 11,266" exact="migraine" post="patients with at least 4MMDs responded to the survey"/>
   <result pre="prior treatment showed that all WPAI outcomes are impacted by" exact="migraine" post="especially in those who have failed 2 or more"/>
   <result pre="prior prophylactic treatments. Conclusion This large worldwide study shows that" exact="migraine" post="is associated with work productivity and activity impairment especially"/>
   <result pre="human anti-CGRP receptor antibody approved as a preventive treatment for" exact="migraine" post="by the US FDA. We previously reported that erenumab"/>
   <result pre="groups, were representative of a high-risk patient population: 100% had" exact="cardiovascular disease," post="~40% had history of myocardial infarction, and 24% had"/>
   <result pre="SBP systolic blood pressure P16 Burden and patient-reported outcomes of" exact="migraine" post="patients with prior prophylactic treatment failure: Study design of"/>
   <result pre="available on the disease burden and quality of life in" exact="migraine" post="patients with prior treatment failure from European countries. Objectives"/>
   <result pre="of the BECOME study is to describe the proportion of" exact="migraine" post="patients with at least one prior prophylactic treatment failure."/>
   <result pre="prophylactic treatment failure. Other objectives include assessment of impact of" exact="migraine" post="on quality of life in this population and estimate"/>
   <result pre="headache clinics across 17 European countries and Israel in adult" exact="migraine" post="patients (aged 18–65 years) who have failed more than"/>
   <result pre="Helsiniki. In Part 1 of the study, the proportion of" exact="migraine" post="patients is determined by weekly collection of site-specific data"/>
   <result pre="Conclusions The outcome of the study will provide proportion of" exact="migraine" post="patients with at least one prior treatment failure visiting"/>
   <result pre="2 P17 My Migraine Voice: a worldwide survey of 11,266" exact="migraine" post="patients Elena Ruiz de la Torre 1, Rebeca Quintana"/>
   <result pre="Introduction The My Migraine Voice survey was conducted to assess" exact="migraine" post="characteristics and describe the current real-world burden and impact"/>
   <result pre="describe the current real-world burden and impact of living with" exact="migraine" post="from clinical, personal, and economic perspectives amongst those with"/>
   <result pre="and economic perspectives amongst those with at least 4 monthly" exact="migraine" post="days (MMDs). This analysis reports on survey respondents’ demographics,"/>
   <result pre="migraine days (MMDs). This analysis reports on survey respondents’ demographics," exact="migraine" post="characteristics, use of migraine therapies, and association with other"/>
   <result pre="analysis reports on survey respondents’ demographics, migraine characteristics, use of" exact="migraine" post="therapies, and association with other chronic conditions. Methods A"/>
   <result pre="was conducted using a 30-minute online survey of adults with" exact="migraine" post="recruited from 31 countries across Africa, America, Asia and"/>
   <result pre="were prioritized by ensuring 90% of patients had reported preventive" exact="migraine" post="treatment use (pre-specified). Results A total of 11,266 individuals"/>
   <result pre="treatment use (pre-specified). Results A total of 11,266 individuals with" exact="migraine" post="participated (75% female, mean age=39 years). Of all respondents,"/>
   <result pre="employed full-time, 56% married, 63% had children and 54% had" exact="migraine" post="family history. Patients had had migraine for 11.6 years"/>
   <result pre="children and 54% had migraine family history. Patients had had" exact="migraine" post="for 11.6 years on average (27% for &amp;gt;20 years),"/>
   <result pre="particularly among individuals who suffer from at least 4 monthly" exact="migraine" post="days (MMDs). Methods A cross-sectional study was conducted using"/>
   <result pre="A cross-sectional study was conducted using an online survey of" exact="migraine" post="patients in 31 countries across Africa, America, Asia and"/>
   <result pre="with pre-specified 90% among those having reported having used preventive" exact="migraine" post="treatment. Results A total of 11,266 migraine patients responded"/>
   <result pre="having used preventive migraine treatment. Results A total of 11,266" exact="migraine" post="patients responded to the survey (75% women, mean age:"/>
   <result pre="India, Brazil, Indonesia, Poland, USA, Portugal, Russia, and also for" exact="migraine" post="patients who have failed &amp;gt;=2 prophylactic treatments (Table 1)."/>
   <result pre="burden is higher among those who have failed a prophylactic" exact="migraine" post="treatment and this trend increased with the number of"/>
   <result pre="1 (abstract P18). Resource utilization in previous 12 months in" exact="migraine" post="individuals Overall (N=11266) No prior prophylactic treatment No prophylactic"/>
   <result pre="aged 18-65 years with 4 to 14 baseline number of" exact="migraine" post="headache days were enrolled into two double-blind, placebo-controlled, migraine"/>
   <result pre="of migraine headache days were enrolled into two double-blind, placebo-controlled," exact="migraine" post="prevention studies. The studies randomized 858 patients (EVOLVE-1) and"/>
   <result pre="events (AEs) were collected. Change from baseline in number of" exact="migraine" post="headache days (MHDs) over the 10 months of study"/>
   <result pre="(abstract P19). Change from baseline in the number of monthly" exact="migraine" post="headache days during 6 months treatment and 4 month"/>
   <result pre="(abstract P19). Change from baseline in the number of monthly" exact="migraine" post="headache days during 6 months treatment and 4 month"/>
   <result pre="from the extension phase of the STRIVE study in episodic" exact="migraine" post="Peter J. Goadsby 1, Uwe Reuter 2, Yngve Hallström"/>
   <result pre="erenumab 70mg or 140mg (during the 28-week dose-blinded ATP). Monthly" exact="migraine" post="days (MMDs), monthly acute migraine-specific medication treatment days (MSMDs),"/>
   <result pre="52 weeks, erenumab provides sustained efficacy in prevention of episodic" exact="migraine" post="and a safety profile comparable to placebo as observed"/>
   <result pre="mean (SE) unless specified ATP active treatment phase, MMD monthly" exact="migraine" post="days, MSMD monthly acute migraine-specific medication treatment days, SE"/>
   <result pre="P21 Efficacy outcomes in responder and nonresponder patients with episodic" exact="migraine" post="treated preventively with erenumab in the STRIVE study Gregor"/>
   <result pre="erenumab (70 mg and 140 mg) in patients with episodic" exact="migraine" post="(EM) [1]. In clinical practice, patients achieving/not achieving sufficient"/>
   <result pre="at the ≥50% threshold.To evaluate change from baseline in monthly" exact="migraine" post="days (MMD), migraine-specific medication treatment days (MSMD), and Migraine"/>
   <result pre="Methods Patients (N=955; aged 18–65 years) with ≥4 and &amp;lt;15" exact="migraine" post="days per month were randomised (1:1:1) to receive subcutaneous"/>
   <result pre="Data are mean ±standard deviation, except as indicated. MMD monthly" exact="migraine" post="days, MSMD migraine-specific medication treatment days, MPFID-EA Migraine Physical"/>
   <result pre="mg dose. P22 Efficacy of erenumab in patients with chronic" exact="migraine" post="achieving ≥50% response: Subgroup analysis of a double-blind, randomised"/>
   <result pre="human anti-CGRP receptor antibody approved as a preventive treatment for" exact="migraine" post="by the US FDA. A 12-week, randomised, double-blind, placebo-controlled"/>
   <result pre="erenumab (70 mg and 140 mg) in patients with chronic" exact="migraine" post="(CM). At Week 12, a greater proportion of patients"/>
   <result pre="aged 18-65 years, inclusive) with CM (≥15 headache days/month; ≥8" exact="migraine" post="days/month) were randomised (2:2:3) to receive subcutaneous, once-monthly erenumab"/>
   <result pre="Migraine Disability Assessment (higher score indicates worse outcomes), MMD monthly" exact="migraine" post="days, MSQ Migraine-Specific Quality-of-Life Questionnaire (higher scores indicate better"/>
   <result pre="year results from an ongoing open-label extension study in episodic" exact="migraine" post="Messoud Ashina 1*, Peter J. Goadsby 2, Uwe Reuter"/>
   <result pre="tolerability of erenumab (human anti-CGRP receptor antibody) in patients with" exact="migraine" post="after ≥3 years of treatment. Previously published 3-month placebo-controlled"/>
   <result pre="efficacy of erenumab during open-label treatment of subjects with chronic" exact="migraine" post="Stewart Tepper 1, Messoud Ashina 2, Uwe Reuter 3,"/>
   <result pre="Erenumab, fully human antibody, has demonstrated efficacy and safety in" exact="migraine" post="prevention studies (NCT02066415, NCT02456740). Chronic migraine (CM), the most"/>
   <result pre="efficacy and safety in migraine prevention studies (NCT02066415, NCT02456740). Chronic" exact="migraine" post="(CM), the most prevalent type of headache in tertiary"/>
   <result pre="endpoints were change from baseline to Week 52 in monthly" exact="migraine" post="days (MMD), monthly acute migraine-specific medication days (MSMD), monthly"/>
   <result pre="respiratory tract infection, upper respiratory tract infection, sinusitis, arthralgia, and" exact="migraine" post="(Table 1). Exposure-adjusted treatment-related AE and SAE rates were"/>
   <result pre="(n=165) CI confidence interval, OLE open label extension, MMD monthly" exact="migraine" post="days, MSMD migraine-specific medication treatment days, N number of"/>
   <result pre="Phase 3 galcanezumab trials in patients with episodic or chronic" exact="migraine" post="James M. Martinez, Sandra Garce, Greg Anglin, Michael Hodsdon,"/>
   <result pre="patients with episodic or chronic migraine. Methods: The Phase 3" exact="migraine" post="program for galcanezumab consisted of 4 studies: the 6-month"/>
   <result pre="in episodic migraine, the 3-month DB/PC REGAIN study in chronic" exact="migraine" post="(with optional 9-month open-label [OL] extension), and the 12-month"/>
   <result pre="status and efficacy was explored using average change in monthly" exact="migraine" post="headache day (MHD) in galcanezumab-treated patients. Safety analyses assessed"/>
   <result pre="Safety analyses assessed the potential relationship between TE ADA and" exact="hypersensitivity" post="events or adverse events (AEs) related to injection sites."/>
   <result pre="by TE ADA. Conclusion: These analyses from the Phase 3" exact="migraine" post="program characterize the immunogenicity profile of galcanezumab treatment in"/>
   <result pre="TE ADA did not appear to mediate the occurrence of" exact="hypersensitivity" post="events and AEs related to injection sites. Ethics approval"/>
   <result pre="CGAJ). P26 Lack of visual paired associative short-term plasticity in" exact="migraine" post="patients between attacks Gianluca Coppola 1, Chiara Abagnale 1,"/>
   <result pre="dysfunctioning associative plasticity might characterize the visual system of episodic" exact="migraine" post="without aura (MO) patients, where abnormalities in both inhibitory"/>
   <result pre="enhancing short-term associative plasticity mechanisms within the visual system in" exact="migraine" post="between attacks. References 1. Pierelli F, Iacovelli E, Bracaglia"/>
   <result pre="Bracaglia M, Serrao M, Coppola G. Abnormal sensorimotor plasticity in" exact="migraine" post="without aura patients. Pain. 2013 Sep;154(9):1738-42. P27 Effect of"/>
   <result pre="Background: Overuse of acute pain medication by people with chronic" exact="migraine" post="(CM) can increase the frequency and intensity of headache."/>
   <result pre="with disability, severity, duration and frequency of headaches in female" exact="migraine" post="patients Mansouerh Togha, Faraidoon Haghdoost, Faezeh Khorsha, Soodeh Razeghi"/>
   <result pre="(faraidoon haghdoost) Objectives: Migraine is a highly prevalent and debilitating" exact="neurological disorder." post="It is most common between the ages 20 and"/>
   <result pre="Index (BMI) is associated with increased frequency and severity of" exact="migraine" post="headaches. The aims of the current study were to"/>
   <result pre="with disability, severity, frequency and duration of headaches in female" exact="migraine" post="patients. Methods: This cross-sectional study evaluated the characteristics of"/>
   <result pre="migraine patients. Methods: This cross-sectional study evaluated the characteristics of" exact="migraine" post="attacks and also MIDAS (Migraine Disability Assessment) score in"/>
   <result pre="(Migraine Disability Assessment) score in female migrainures. The diagnosis of" exact="migraine" post="was based on ICHD-3 beta criteria. The data on"/>
   <result pre="migraine was based on ICHD-3 beta criteria. The data on" exact="migraine" post="attack characteristics; duration of each attack, frequency, and severity;"/>
   <result pre="from this patient. Results: In the current study, 170 female" exact="migraine" post="patients with the Mean (±SD) age of 34.03±8.03 were"/>
   <result pre="significant correlation was found between BMI and duration of each" exact="migraine" post="attacks (r=0.093, P=0.229). Conclusion: This study revealed an association"/>
   <result pre="index and disability, severity and frequency of headaches in female" exact="migraine" post="patients. On the other hand, no association was found"/>
   <result pre="β-adrenoceptor antagonist that is used for the prophylactic treatment of" exact="migraine" post="since many years. However, the mechanism of action of"/>
   <result pre="years. However, the mechanism of action of propranolol in preventing" exact="migraine" post="attacks has not yet been elucidated. Both a central"/>
   <result pre="technique shown to be a successful acute preventative treatment for" exact="migraine" post="patients. sTMS uses a single magnetic pulse of 170"/>
   <result pre="regions believed to be involved in the triggering of a" exact="migraine" post="attack. Such alterations in the hypothalamic region be sTMS"/>
   <result pre="Pharmacology Journal 2016; 9: 735-738. P33 A case of autoimmune" exact="encephalitis" post="preceded by posterior reversible encephalopathy syndrome and reversible cerebral"/>
   <result pre="P33 A case of autoimmune encephalitis preceded by posterior reversible" exact="encephalopathy" post="syndrome and reversible cerebral vasoconstriction syndrome Jaeho Kim, Mi"/>
   <result pre="Correspondence: Mi Ji Lee (mirony.lee@gmail.com) Background &amp;amp; Significance: Posterior reversible" exact="encephalopathy" post="syndrome (PRES) is typically characterized by headache, altered mental"/>
   <result pre="posterior distribution. We report a case of patient of Autoimmune" exact="encephalitis" post="preceded by PRES and reversible cerebral vasoconstriction syndrome (RCVS)."/>
   <result pre="have been improved, and she returned to work. Conclusions: Autoimmune" exact="encephalitis" post="can present with PRES and RCVS. Persistent encephalopathic symptoms,"/>
   <result pre="3.0 – 8.2) treatment and of suffering from associated chronic" exact="migraine" post="(OR 5.59; 95% CI, 3.0 - 10.4). Conclusion: This"/>
   <result pre="features, higher risk of intractability to treatment and associated chronic" exact="migraine" post="in patients with family history of CH. This highlights"/>
   <result pre="interval, OR Odds-ratio P35 The relevance of associated symptoms of" exact="migraine" post="according to migraine subtypes: A Clinical study Aynur Özge"/>
   <result pre="P35 The relevance of associated symptoms of migraine according to" exact="migraine" post="subtypes: A Clinical study Aynur Özge 1, Osman Özgür"/>
   <result pre="osmophobia and allodynia can be present with different frequency in" exact="migraine" post="subtypes. Clinical symptoms such as allodynia and osmophobia are"/>
   <result pre="clinical symptoms and headace intensity and frequency in patients with" exact="migraine" post="subtypes. Methods: The study was based on the Turkish"/>
   <result pre="3 beta. Patients were classified according to ICHD as; episodic" exact="migraine" post="and chronic migrane with or without aura. Patients were"/>
   <result pre="asked if they experienced photophobia, phonophobia, osmophobia and allodynia during" exact="migraine" post="attack. The results were compared within each subgroups. Results:"/>
   <result pre="within each subgroups. Results: Totally 1935 patients were enrolled. Chronic" exact="migraine" post="was diagnosed in 24.8%, episodic migraine in 75.2%, migraine"/>
   <result pre="patients were enrolled. Chronic migraine was diagnosed in 24.8%, episodic" exact="migraine" post="in 75.2%, migraine without aura in %60.7 and migraine"/>
   <result pre="Chronic migraine was diagnosed in 24.8%, episodic migraine in 75.2%," exact="migraine" post="without aura in %60.7 and migraine with aura in"/>
   <result pre="episodic migraine in 75.2%, migraine without aura in %60.7 and" exact="migraine" post="with aura in 39.3% of the patients. Osmophobia and"/>
   <result pre="patients. Osmophobia and allodynia were significantly more frequent among chronic" exact="migraine" post="patients (p=0.001). The presence of photophobia and phonophobia were"/>
   <result pre="in subgroups except photophobia was more frequent in patients with" exact="migraine" post="with aura (p&amp;lt;0.001). We analyzed effects of associated symptoms"/>
   <result pre="aura (p&amp;lt;0.001). We analyzed effects of associated symptoms within chronic" exact="migraine" post="patients. Photophobia and phonophobia were positively correlated with the"/>
   <result pre="chronicity. Awareness of those symptoms and understanding of revolution of" exact="migraine" post="in the term of time will provide new insight"/>
   <result pre="should further elucidate these relationships and focus on prevention of" exact="migraine" post="patients from chronification. P36 Descriptive analysis of a population"/>
   <result pre="from chronification. P36 Descriptive analysis of a population with chronic" exact="migraine" post="in a tertiary Headache Center Ana-Inês Martins, Joana Ramos-Lopes,"/>
   <result pre="Hospital Centre, Coimbra, Portugal Correspondence: Ana-Inês Martins (ana.inesm@hotmail.com) Background: Chronic" exact="migraine" post="(CM) is the 5th most prevalent disease and has"/>
   <result pre="is scarce. We aim to describe a population of chronic" exact="migraine" post="patients followed in a tertiary Headache Center. Patients diagnosed"/>
   <result pre="to 8.82 (±5.10). Phonophotophobia was the most common symptom accompanying" exact="migraine" post="(90.2%). Moreover, in our sample there was a loss"/>
   <result pre="epidemiological and clinical data about CM in Portugal. Prevention of" exact="migraine" post="chronification is essential and requires adequate treatment of individual"/>
   <result pre="migraine chronification is essential and requires adequate treatment of individual" exact="migraine" post="attacks, early initiation of preventive medication and avoiding analgesic"/>
   <result pre="(claravivero@hotmail.com) Background: White matter lessions (WML) have been described in" exact="migraine" post="patients, but their origin and role in migraine pathophysiology"/>
   <result pre="described in migraine patients, but their origin and role in" exact="migraine" post="pathophysiology is still under discussion. In this study we"/>
   <result pre="dysfunction, blood brain barrier disruption and brain damage in chronic" exact="migraine" post="(CM). Methods: Prospective study including 62 patients with CM"/>
   <result pre="Background: Response to treatment with Onabotulinumtoxin A (OnabotA) in chronic" exact="migraine" post="(CM) has been related with several clinical features and"/>
   <result pre="Fondo Europeo de Desarrollo Regional (FEDER). P39 Economic impact of" exact="migraine" post="in the EU5: a matched analysis of the NHWS"/>
   <result pre="Objectives This study aimed to describe the incremental burden of" exact="migraine" post="on work productivity and healthcare resource utilization (HRU) in"/>
   <result pre="self-reported a doctor diagnosis of migraine, experienced at least one" exact="migraine" post="during the prior month and overall ≥4 HDs during"/>
   <result pre="each subgroup and country using sociodemographic characteristics to respondents without" exact="migraine" post="(controls). Work and activity impairment was assessed via Work"/>
   <result pre="Analyses of the propensity score-matched sample of 1569 respondents with" exact="migraine" post="(4-7, 8-14 and ≥15HDs/month) showed that a significantly higher"/>
   <result pre="(Table 1). WPAI outcomes were also significantly impacted across all" exact="migraine" post="subgroups compared with controls. Conclusions Migraine patients across all"/>
   <result pre="migraine subgroups compared with controls. Conclusions Migraine patients across all" exact="migraine" post="frequency subgroups reported significantly higher HRU and work impairment"/>
   <result pre="matched non-migraine controls. This study highlights the economic implications of" exact="migraine" post="to the healthcare system and society. Ethics Approval The"/>
   <result pre="HDs (N=281) and &amp;gt;=15 HDs (N=176) P40 Humanistic burden of" exact="migraine" post="in the EU5: a matched analysis of the NHWS"/>
   <result pre="of this study was to describe the incremental burden of" exact="migraine" post="on health- related quality of life (HRQoL) in those"/>
   <result pre="health- related quality of life (HRQoL) in those suffering from" exact="migraine" post="of ≥4 monthly headache days (HDs) compared with matched"/>
   <result pre="self-reported a doctor diagnosis of migraine, experiencing at least one" exact="migraine" post="in the prior month, and overall ≥4 HDs during"/>
   <result pre="HDs) and matched by propensity scores to 1569 respondents without" exact="migraine" post="(controls) within each HD subgroup and country using sociodemographic"/>
   <result pre="significantly lower compared with outcomes of 1569 control respondents without" exact="migraine" post="(Table 1). Conclusions Individuals with migraine across migraine frequency"/>
   <result pre="1569 control respondents without migraine (Table 1). Conclusions Individuals with" exact="migraine" post="across migraine frequency subgroups report significantly worse HRQoL compared"/>
   <result pre="respondents without migraine (Table 1). Conclusions Individuals with migraine across" exact="migraine" post="frequency subgroups report significantly worse HRQoL compared with those"/>
   <result pre="Results highlight the burden that exists across the spectrum of" exact="migraine" post="patients who may be eligible for preventive treatment. Ethics"/>
   <result pre="Table 1 (abstract P40). HRQoL outcomes in NHWS respondents with" exact="migraine" post="versus matched controls* Non-migraine controls (N=1,569) 4-7 HDs (N=783)"/>
   <result pre="SPARTAN) of lasmiditan compared to placebo for acute treatment of" exact="migraine" post="Linda A. Wietecha 1, Bernice Kuca 2, Josephine Asafu-Adjei"/>
   <result pre="pivotal Phase 3 studies of lasmiditan for acute treatment of" exact="migraine" post="are reported here. Methods: SAMURAI (NCT02439320) and SPARTAN (NCT02605174)"/>
   <result pre="included Migraine Disability Assessment Score ≥11 (moderate disability) and 3–8" exact="migraine" post="attacks per month. Patients were randomized to a first"/>
   <result pre="mg or placebo) which was taken within 4 hours of" exact="migraine" post="onset (moderate severity or worse and not improving). For"/>
   <result pre="two Phase 3 studies. P42 Conversion from chronic to episodic" exact="migraine" post="with erenumab, a specific inhibitor of the calcitonin gene-related"/>
   <result pre="CA, USA Correspondence: Richard B. Lipton (richard.lipton@einstein.yu.edu) Background Patients with" exact="migraine" post="are classified into episodic migraine (EM: &amp;lt;15 headache days/month)"/>
   <result pre="Lipton (richard.lipton@einstein.yu.edu) Background Patients with migraine are classified into episodic" exact="migraine" post="(EM: &amp;lt;15 headache days/month) and chronic migraine (CM: ≥15"/>
   <result pre="classified into episodic migraine (EM: &amp;lt;15 headache days/month) and chronic" exact="migraine" post="(CM: ≥15 headache days/month). Over time, migraine patients may"/>
   <result pre="days/month) and chronic migraine (CM: ≥15 headache days/month). Over time," exact="migraine" post="patients may move from EM to CM and from"/>
   <result pre="calcitonin gene-related peptide receptor and was developed as a preventive" exact="migraine" post="therapy. Erenumab has been shown to significantly reduce the"/>
   <result pre="has been shown to significantly reduce the number of monthly" exact="migraine" post="days versus placebo in patients with CM and EM."/>
   <result pre="the long term. Fig. 1 (abstract P42). Conversion to episodic" exact="migraine" post="during the 12-week double-blind phase . Odds ratio (OR)"/>
   <result pre="confidence interval. P43 Erenumab impact on patient-reported outcomes in chronic" exact="migraine" post="in the presence of acute medication overuse Stewart J"/>
   <result pre="anti-CGRP receptor monoclonal antibody approved as a preventive treatment for" exact="migraine" post="by the US Food and Drug Administration. Erenumab has"/>
   <result pre="Drug Administration. Erenumab has demonstrated clinically relevant efficacy in chronic" exact="migraine" post="(CM), including in the presence of acute medication overuse"/>
   <result pre="with CM (≥15 headache days/month over 3 months with ≥8" exact="migraine" post="days/month). Patients were randomised to receive erenumab (70 or"/>
   <result pre="quality of life is likely due to reduction of monthly" exact="migraine" post="days and reduction of acute medication overuse. These data"/>
   <result pre="P43). Patient-reported outcomes at Month 3 in patients with chronic" exact="migraine" post="by baseline medication overuse status Medication overuse Without medication"/>
   <result pre="deviation P44 Long-term efficacy of erenumab in patients with chronic" exact="migraine" post="who failed prior prophylactic treatment Messoud Ashina 1, Stewart"/>
   <result pre="anti-CGRP receptor monoclonal antibody approved as a preventive treatment for" exact="migraine" post="by the US Food and Drug Administration. In a"/>
   <result pre="Administration. In a pivotal placebo-controlled study of adults with chronic" exact="migraine" post="(CM; NCT02066415), erenumab reduced the number of monthly migraine"/>
   <result pre="chronic migraine (CM; NCT02066415), erenumab reduced the number of monthly" exact="migraine" post="days (MMD) with a safety profile similar to placebo."/>
   <result pre="erenumab treatment after 12-week double-blind treatment in patients with chronic" exact="migraine" post="Treatment failure subgroup 52-week OLE completers by last dose"/>
   <result pre="parent study baseline BL, baseline; CI, confidence interval; MMD, monthly" exact="migraine" post="days; MSMD, monthly acute migraine-specific medication treatment days; N,"/>
   <result pre="phase 3 double-blind placebo-controlled clinical trials evaluating galcanezumab for episodic" exact="migraine" post="prevention (EVOLVE-1 and EVOLVE-2) Janet H. Ford; David W."/>
   <result pre="clinical studies (ClinicalTrials.gov NCT02614183 and NCT02614196). METHODS: Patients with episodic" exact="migraine" post="(4-14 monthly migraine headache days) were treated (monthly subcutaneous"/>
   <result pre="NCT02614183 and NCT02614196). METHODS: Patients with episodic migraine (4-14 monthly" exact="migraine" post="headache days) were treated (monthly subcutaneous injections) with galcanezumab"/>
   <result pre="indicate better functioning) was used to measure the impact of" exact="migraine" post="on daily functioning in three domains (Role Function-Restrictive [RFR],"/>
   <result pre="Eric Pearlman (eric.pearlman@lilly.com) Objective: To characterize adult patients with episodic" exact="migraine" post="headache who achieved 100% response to galcanezumab treatment. Methods:"/>
   <result pre="from 2 double-blind, 6‑month galcanezumab studies in patients with episodic" exact="migraine" post="(4 to 14 MHD and ≥2 migraine attacks per"/>
   <result pre="patients with episodic migraine (4 to 14 MHD and ≥2" exact="migraine" post="attacks per month at baseline). Patients were randomized (1:1:2)"/>
   <result pre="3 months of treatment. Considering the average number days between" exact="migraine" post="attacks across the 6-month period (not just during the"/>
   <result pre="just during the times of 100% response), the duration of" exact="migraine" post="headache free periods in the galcanezumab groups was 29"/>
   <result pre="baseline. Conclusion: More than a third of patients with episodic" exact="migraine" post="headache treated with galcanezumab 120 mg or 240 mg"/>
   <result pre="Kolos Hospital, Esztergom, Hungary Correspondence: C. Ertsey (konfreg1@bcdtravel.hu) Introduction: Validated" exact="migraine" post="screening tools are widely used for both research and"/>
   <result pre="at least 2 different headache diagnoses. The clinical diagnosis of" exact="migraine" post="was made in 324 patients (200 had only migraine,"/>
   <result pre="the 23 CH patients 21 (91%) were false positive for" exact="migraine" post="according to their ID-M scores and 20 (87%) according"/>
   <result pre="be overlooked. In the case of non-representative sampling studies using" exact="migraine" post="diagnostic screeners as the sole source of diagnosis may"/>
   <result pre="71, 41124, Modena, Italy. Correspondence: Baraldi Carlo (infocarlo.baraldi@gmail.com) Background Chronic" exact="migraine" post="usually leads to the excessive consumption of acute medications,"/>
   <result pre="patient-physician reliability of the questionnaire. Results: A total of 114" exact="migraine" post="patients (60.5 % female, mean age:35,8±9.2;77 episodic, 37 chronic)"/>
   <result pre="assessing the impact of headache in both episodic and chronic" exact="migraine" post="patients. Ethics approval The study received approval by the"/>
   <result pre="received &amp;gt; 1 block. The most commonly treated pathologies were:" exact="migraine" post="with 75/224 blocks (33.5%, 51/224 episodic and 24/224 chronic"/>
   <result pre="blocks performed: 29/41 (70%) in cervicogenic headache, 44/75 (58%) in" exact="migraine" post="and 16/ 28 (57%) in cluster headache. Conclusion: AB"/>
   <result pre="if the serum vitamin D levels correlate with severity of" exact="migraine" post="remains uncertain [1]. Materials and methods In this prospective"/>
   <result pre="into 3 groups: Group 1 included 113 patients with chronic" exact="migraine" post="(17 M, 96 F; age 41,5±13,4; BMI 25,5±4,2); Group"/>
   <result pre="41,5±13,4; BMI 25,5±4,2); Group 2 included 44 patients with episodic" exact="migraine" post="(8 M, 36 F; age 39,9±12,8; BMI 22,7±2,9); control"/>
   <result pre="a role in peripheral and central sensitization which lead to" exact="migraine" post="chronification and are responsible for other migraine related phenomena"/>
   <result pre="which lead to migraine chronification and are responsible for other" exact="migraine" post="related phenomena such as allodynia. Conclusion Our data indicate"/>
   <result pre="D deficiency is associated with higher frequency of headache in" exact="migraine" post="patients, suggesting that serum vitamin D levels correlate with"/>
   <result pre="in 312 (52.3%)pts: Subarachnoidal hemorrhage 35 (5.9%)pts, Other types of" exact="stroke" post="78pts (13.1%), Infections 65(3.8%)pts, Primary brain tumors 15(2.5%)pts, Secondary"/>
   <result pre="patient. With the results of GBTM analysis we developed pediatric" exact="migraine" post="specific comorbidity index. Results: The study conducted with 481"/>
   <result pre="specific comorbidity index. Results: The study conducted with 481 pediatric" exact="migraine" post="patients. Sub-group analysis performed to reveal effects of age,"/>
   <result pre="higher (p=0.018) Conclusion: In this study we developed a pediatric" exact="migraine" post="comorbidity index (p-MCI) to evaluate effect of covariates on"/>
   <result pre="migraine comorbidity index (p-MCI) to evaluate effect of covariates on" exact="migraine" post="course. There are need to studies to predict course"/>
   <result pre="course. There are need to studies to predict course of" exact="migraine" post="to classifify high risk patient groups. Keywords: Migraine, group-based"/>
   <result pre="Cerebral Venous Sinus Thrombosis (CVST) is a rare cause of" exact="stroke" post="in young age with a highly variable clinical presentation."/>
   <result pre="obtained from the patient follow up files and 35 national" exact="stroke" post="centers participated to this study. This study provides largest"/>
   <result pre="Department, Düzce, Turkey Correspondence: Osman Özgür Yalın (osmanozguryalin@yahoo.com) Background: Chronic" exact="migraine" post="is a disabling neurological disorder, affecting 0.5-2% of population."/>
   <result pre="Osman Özgür Yalın (osmanozguryalin@yahoo.com) Background: Chronic migraine is a disabling" exact="neurological disorder," post="affecting 0.5-2% of population. Exact understanding of pathophysiological mechanisms"/>
   <result pre="pathophysiological mechanisms are lack and treatment options are limited. Chronic" exact="migraine" post="is a disorder that affect individual quality of life,"/>
   <result pre="disorders patients (p=0.049). We compared features of chronic and episodic" exact="migraine" post="patients. Chronic migraine patients were older (p=0.026). Disease duration"/>
   <result pre="We compared features of chronic and episodic migraine patients. Chronic" exact="migraine" post="patients were older (p=0.026). Disease duration was longer and"/>
   <result pre="duration was longer and allodynia was more common at chronic" exact="migraine" post="group(p&amp;lt;0.001). Expectantly headache frequency per month was higher in"/>
   <result pre="in chronic migraine, aura was less commonly observed at chronic" exact="migraine" post="patients (p&amp;lt;0.001). Conclusion: This study is conducted with a"/>
   <result pre="the world and reflect high incidence of the disease. Chronic" exact="migraine" post="is related with prominent occupational disability and medication overuse."/>
   <result pre="present with headache, vertigo, visual and other sensory symptoms. Vestibular" exact="migraine" post="is a common cause of acute spontaneous vertigo lasting"/>
   <result pre="thought to represent peripheral vestibulopathy. Methods The diagnosis of vestibular" exact="migraine" post="was made according to International Headache Society and the"/>
   <result pre="with headache, in particular tension type headache (20%) compared to" exact="migraine" post="with aura (7.69%), but their prevalence was not significantly"/>
   <result pre="in particular among children with tension type headache compared to" exact="migraine" post="with aura, supporting &quot;the continuum model&quot; about tension type"/>
   <result pre="aura, supporting &quot;the continuum model&quot; about tension type headache and" exact="migraine" post="without aura (mixed headaches) as part of a continuum"/>
   <result pre="aura (mixed headaches) as part of a continuum opposed to" exact="migraine" post="with aura. Specific learning disabilities frequently show before school"/>
   <result pre="Astrocytes contribute to the trigeminal central sensitization and cephalic cutaneous" exact="hypersensitivity" post="in rat model of chronic migraine M. Megemont, A."/>
   <result pre="sensitization and cephalic cutaneous hypersensitivity in rat model of chronic" exact="migraine" post="M. Megemont, A. Descheemaeker, R. Dallel, L. Monconduit and"/>
   <result pre="Inserm, Neuro-Dol, F-63000 Clermont-Ferrand, France Correspondence: M. Megemont (philippe.luccarini@uca.fr) Repeated" exact="migraine" post="attacks are associated with maladaptive neural plasticity and lead"/>
   <result pre="of astrocytes activity in trigeminal central sensitization and cephalic cutaneous" exact="hypersensitivity" post="in a new model of chronic migraine (Dallel et"/>
   <result pre="and cephalic cutaneous hypersensitivity in a new model of chronic" exact="migraine" post="(Dallel et al, 2018). We investigated the effect of"/>
   <result pre="astrocytes contribute to the trigeminal central sensitization and cephalic cutaneous" exact="hypersensitivity" post="that characterize the migraine progression. P63 Withdrawn P64 Сortical"/>
   <result pre="trigeminal central sensitization and cephalic cutaneous hypersensitivity that characterize the" exact="migraine" post="progression. P63 Withdrawn P64 Сortical excitability in chronic migraine"/>
   <result pre="the migraine progression. P63 Withdrawn P64 Сortical excitability in chronic" exact="migraine" post="patients after OnabotulinumtoxinA preventive treatment Vladlena Shevchenko 1, Ada"/>
   <result pre="Moscow, 119991, Russian Federation Correspondence: Vladlena Shevchenkoˡ (vladashevchenko@list.ru) Background: Chronic" exact="migraine" post="(CM) is a common and disabling disease from the"/>
   <result pre="disabling disease from the primary headache group, one of the" exact="migraine" post="(M) form, characterized by 15 headache days a month"/>
   <result pre="per month, number of days with taking medications for acute" exact="migraine" post="treatment. We determined neurophysiological parameters using diagnostic TMS («MagPro"/>
   <result pre="days (p&amp;lt;0,05), number of days with taking medications for acute" exact="migraine" post="treatment on 13 days (p&amp;lt;0,05). No significant differences were"/>
   <result pre="2010 Jun; 50(6):921-36. P65 Beyond the headache phase of a" exact="migraine" post="attack: closer look at the burden of migraine phases"/>
   <result pre="of a migraine attack: closer look at the burden of" exact="migraine" post="phases - results from the worldwide My Migraine Voice"/>
   <result pre="quantitative burden associated with premonitory and postdromal phases of the" exact="migraine" post="attack. This study aimed to evaluate the burden of"/>
   <result pre="migraine attack. This study aimed to evaluate the burden of" exact="migraine" post="as described by patients in these specific migraine phases:"/>
   <result pre="burden of migraine as described by patients in these specific" exact="migraine" post="phases: premonitory, headache, and postdromal. Methods My Migraine Voice"/>
   <result pre="a cross-sectional study conducted using an online survey of 11,266" exact="migraine" post="patients (31 countries across Africa, America, Asia and Europe)"/>
   <result pre="recruited via online panels and patient organizations. Participants were adult" exact="migraine" post="patients per ICHD-3 criteria, who reported having had &amp;gt;=4"/>
   <result pre="migraine patients per ICHD-3 criteria, who reported having had &amp;gt;=4" exact="migraine" post="days/month in the 3 months preceding survey administration, with"/>
   <result pre="survey administration, with pre-specified 90% having reported having used preventive" exact="migraine" post="treatment. Results A total of 11,266 migraine patients responded"/>
   <result pre="having used preventive migraine treatment. Results A total of 11,266" exact="migraine" post="patients responded to the survey and reported that, over"/>
   <result pre="over the last 3 months, they had on average 9.8" exact="migraine" post="days/month; 37% reported being affected by migraine for &amp;gt;15"/>
   <result pre="on average 9.8 migraine days/month; 37% reported being affected by" exact="migraine" post="for &amp;gt;15 years. 44% of respondents’ migraine attack lasted"/>
   <result pre="being affected by migraine for &amp;gt;15 years. 44% of respondents’" exact="migraine" post="attack lasted one day or more (19% reported longer"/>
   <result pre="Half of patients (49%) reported feeling limited throughout the 3" exact="migraine" post="phases. Almost 1/3 of patients (29%) reported feeling very"/>
   <result pre="degree of impairment, the findings demonstrate that the burden of" exact="migraine" post="extends beyond the headache phase and is higher for"/>
   <result pre="AG, Basel Switzerland Table 1 (abstract P65). Description of the" exact="migraine" post="phases Proportion of respondents (%) Premonitory phase Headache phase"/>
   <result pre="6% 1% 3% Duration of the phase &amp;gt;24 hours in" exact="migraine" post="patients with:  - no failure to migraine preventive treatment"/>
   <result pre="&amp;gt;24 hours in migraine patients with:  - no failure to" exact="migraine" post="preventive treatment 11% 27% 20%  - 1 failure to"/>
   <result pre="migraine preventive treatment 11% 27% 20%  - 1 failure to" exact="migraine" post="preventive treatment 11% 29% 23%  - ≥2 failures to"/>
   <result pre="migraine preventive treatment 11% 29% 23%  - ≥2 failures to" exact="migraine" post="preventive treatment 17% 38% 30% Feeling very to extremely"/>
   <result pre="P66 Withdrawn P67 Carbon monoxide inhalation induces headache but no" exact="migraine" post="in patients with migraine without aura Hashmat Ghanizada 1,"/>
   <result pre="monoxide inhalation induces headache but no migraine in patients with" exact="migraine" post="without aura Hashmat Ghanizada 1, Nanna Arngrim 1, Henrik"/>
   <result pre="J, Ashina M. Carbon monoxide inhalation induces headache but no" exact="migraine" post="in patients with migraine without aura. Cephalagia. 2018: 333102418765771."/>
   <result pre="monoxide inhalation induces headache but no migraine in patients with" exact="migraine" post="without aura. Cephalagia. 2018: 333102418765771. doi: 10.1177/0333102418765771 P68 Demographic"/>
   <result pre="doi: 10.1177/0333102418765771 P68 Demographic and clinical characteristics of patients with" exact="trigeminal neuralgia" post="assisted by neurologists in an Emergency Department Javier Camiña"/>
   <result pre="and therapeutical characteristics of 100 patients with acute exacerbations of" exact="trigeminal neuralgia" post="treated in an Emergency Department. To analyze possible risk"/>
   <result pre="We have retrospectively searched for patients with a diagnosis of" exact="trigeminal neuralgia" post="by the clinical system of the Emergency Department (Firstnet®"/>
   <result pre="system. Results: One hundred (100) patients with acute exacerbation of" exact="trigeminal neuralgia" post="were treated in Emergency Department in 153 episodes between"/>
   <result pre="craniofacial pain assisted by Neurology in our Emergency Department have" exact="trigeminal neuralgia." post="One of the clinical objectives in trigeminal neuralgia patients"/>
   <result pre="Department have trigeminal neuralgia. One of the clinical objectives in" exact="trigeminal neuralgia" post="patients should be to reduce the probability of admission"/>
   <result pre="comparing galcanezumab and placebo in patients with episodic and chronic" exact="migraine" post="Virginia L. Stauffer, Shufang Wang, Mark E. Bangs, Tina"/>
   <result pre="play a protective role in cardiovascular (CV) health. People with" exact="migraine" post="often have CV risk; therefore, patients with comorbid CV"/>
   <result pre="injection site reaction, injection site erythema, injection site pruritus, and" exact="constipation" post="(Table 1). The proportion of DCAEs among galcanezumab-treated patients"/>
   <result pre="the clinical characteristics of a long-term follow-up of patients with" exact="migraine" post="in treatment with onabotulinumtoxinA. Methods: A three-year prospective observational"/>
   <result pre="three-year prospective observational study. We included patients diagnosed with chronic" exact="migraine" post="(CM) and high-frequency episodic migraine (HFEM) according to ICHD-3"/>
   <result pre="included patients diagnosed with chronic migraine (CM) and high-frequency episodic" exact="migraine" post="(HFEM) according to ICHD-3 beta. We collected clinical data."/>
   <result pre="The role of foods with a high glycemic index in" exact="migraine" post="patients: a real life preliminary study Gianluca Cecchi, Maria"/>
   <result pre="aimed at evaluating retrospectively the relationship between dietary habit, and" exact="migraine" post="frequency and disability. Methods We enrolled 149 consecutive patients"/>
   <result pre="domain optical coherence tomography findings in RVCL-S, a monogenic vascular" exact="migraine" post="model Irene de Boer 1, Sylvie R. Steenmeijer 2,"/>
   <result pre="homogenous, pathophysiological models we aim to increase our knowledge of" exact="migraine" post="pathophysiology. One of such models for studying migraine is"/>
   <result pre="knowledge of migraine pathophysiology. One of such models for studying" exact="migraine" post="is RVCL-S. Because the retina is a peripheral extension"/>
   <result pre="investigate retinal layer pathology as a possible biomarker for the" exact="migraine" post="model RVCL-S. Methods Seventeen TREX1 mutation carriers and nine"/>
   <result pre="study of vision and retinal nerve fiber layer thickness in" exact="multiple sclerosis." post="Ann Neurol. 2010;67(6):749-60. 6. Iseri PK, Altinas O, Tokay"/>
   <result pre="Güllü R. Retinal nerve fiber layer thickness is unaffected in" exact="migraine" post="patients. Acta Neurol Scand. 2005 Jul;112(1):19-23. 10. Reggio E,"/>
   <result pre="as predictors of detoxification-therapy outcome at 6 months in chronic" exact="migraine" post="with medication overuse Bottiroli Sara 1, Sances Grazia 1,"/>
   <result pre="of Antwerp, Belgium), approval number 2017-16. P78 Meningeal contribution to" exact="migraine" post="pain: a 3T magnetic resonance angiography study Sabrina Khan"/>
   <result pre="of Copenhagen, Denmark Correspondence: Sabrina Khan (sksabrinakhan@gmail.com) The origin of" exact="migraine" post="pain is unknown but possibly implicates the dura mater,"/>
   <result pre="could reflect activation of dural perivascular nociceptors that leads to" exact="migraine" post="headache. To test this hypothesis, we measured circumference changes"/>
   <result pre="circumference changes of cranial arteries in patients with cilostazol-induced unilateral" exact="migraine" post="without aura using 3T high-resolution magnetic resonance angiography (MRA)."/>
   <result pre="as intracranial arterial segments. MRA scans were performed at baseline," exact="migraine" post="onset, after sumatriptan, and ≥27 hours after migraine onset.A"/>
   <result pre="at baseline, migraine onset, after sumatriptan, and ≥27 hours after" exact="migraine" post="onset.A total of 30 patients underwent MRA scans, of"/>
   <result pre="MRA scans, of which 26 patients developed unilateral attacks of" exact="migraine" post="without aura and were included in the final analysis."/>
   <result pre="were included in the final analysis. Eleven patients treated their" exact="migraine" post="with sumatriptan while the remaining 15 patients did not"/>
   <result pre="did not treat their attacks with analgesics or triptans. At" exact="migraine" post="onset, only MMA exhibited greater circumference increase on the"/>
   <result pre="found sustained bilateral dilation of MMA. In conclusion, onset of" exact="migraine" post="is associated with increase in MMA circumference specific to"/>
   <result pre="activation of dural perivascular nociceptors, indicating a meningeal site of" exact="migraine" post="headache. P79 Sex differences in vascular responses to CGRP"/>
   <result pre="PA, 19107, USA Correspondence: Andrew M. Blumenfeld (blumenfeld@neurocenter.com) Background: Chronic" exact="migraine" post="(CM) is comorbid with anxiety and depression. This analysis"/>
   <result pre="evaluated and compared the effects of episodic (EM) and chronic" exact="migraine" post="(CM) across a range of domains. Methods: The CaMEO"/>
   <result pre="is a prospective, longitudinal, web-based survey study designed to characterize" exact="migraine" post="impact, among other objectives, in a systematic US sample"/>
   <result pre="were invited to complete the Family Burden Module. Answers by" exact="migraine" post="respondents (probands) relating to the impact of migraine on"/>
   <result pre="Answers by migraine respondents (probands) relating to the impact of" exact="migraine" post="on family life, career and finances, and overall health—including"/>
   <result pre="life would be better/a lot better without headache. Physicians managing" exact="migraine" post="should consider the overall burden of disease. P82 A"/>
   <result pre="Background: Patient-reported outcomes (PROs) can be important indicators of a" exact="migraine" post="therapy’s real world effectiveness. Safety, tolerability, and PROs of"/>
   <result pre="them had headache. Majority of patients with headache (19) had" exact="major depressive disorder" post=", recurrent in 15 patients. One patient had bipolar"/>
   <result pre="was present in 19 patients (migraine without aura – 6," exact="migraine" post="with aura – 2, chronic migraine – 2, episodic"/>
   <result pre="without aura – 6, migraine with aura – 2, chronic" exact="migraine" post="– 2, episodic tension type headache – 3, chronic"/>
   <result pre="established in three patients. One patient had headache attributed to" exact="somatization disorder," post="and one patient had headache attributed to psychotic disorder."/>
   <result pre="the current headache classification in which the headache attributed to" exact="somatization disorder" post="and headache attributed to psychotic disorder had been recognized."/>
   <result pre="VA: American Psychiatric Publishing. P84 Healthcare expenditure: does society give" exact="migraine" post="the focus and recognition patients deserve? Leonhard Schaetz 1,"/>
   <result pre="as high disability burden in all four countries, included osteoarthritis," exact="diabetes mellitus," post="skin and subcutaneous diseases, anxiety disorders, and migraine. Of"/>
   <result pre="Of these, and despite high disability burden, health expenditure on" exact="migraine" post="was consistently the lowest across all countries and constituted"/>
   <result pre="total direct annual healthcare expenditure. Comparatively, annual healthcare expenditure on" exact="osteoarthritis" post="was 7-times as that of migraine in the USA,"/>
   <result pre="annual healthcare expenditure on osteoarthritis was 7-times as that of" exact="migraine" post="in the USA, 4-times in Canada, 19-times in Germany,"/>
   <result pre="though the disability associated with it was much lower than" exact="migraine" post="(Fig. 1). Discussion and conclusion The study highlights the"/>
   <result pre="Discussion and conclusion The study highlights the significant underinvestment in" exact="migraine" post="despite its high burden and relative to other high"/>
   <result pre="diseases. Such underinvestment may be correlated with major gaps in" exact="migraine" post="management including low diagnosis rates, delays and barriers in"/>
   <result pre="that better-quality care leads to improved outcomes for patients with" exact="migraine" post="[8-10]. Further research is needed to expand this analysis"/>
   <result pre="8. Katsarava et al. Poor medical care for people with" exact="migraine" post="in Europe – evidence from the Eurolight study. The"/>
   <result pre="headache clinic in Singapore: diagnosis, treatment strategies, outcomes, knowledge of" exact="migraine" post="treatments and satisfaction. Cephalalgia. 2005; 25: 1122–32 10. Hu"/>
   <result pre="effect of gender on clinical response outcomes to triptans in" exact="migraine" post="patients and to relate these gender differences to pharmacokinetic"/>
   <result pre="their higher drug exposure, may be assigned to more persistent" exact="migraine" post="attacks that are triggered by sex hormonal changes, such"/>
   <result pre="that are triggered by sex hormonal changes, such as menstrually-related" exact="migraine" post="attacks and possibly attacks during perimenopause. Fig. 1 (abstract"/>
   <result pre="after the intake of a triptan in male and female" exact="migraine" post="patients. Fig. 3 (abstract P85). Forest plots of AUC0-∞"/>
   <result pre="intake of frovatriptan, rizatriptan or zolmitriptan in male and female" exact="migraine" post="patients. P86 Migraine induction with calcitonin gene-related peptide in"/>
   <result pre="could have a major impact on clinical practice. CGRP provokes" exact="migraine" post="attacks and the question is whether hypersensitivity to CGRP"/>
   <result pre="practice. CGRP provokes migraine attacks and the question is whether" exact="hypersensitivity" post="to CGRP infusion might be a predictor of erenumab"/>
   <result pre="correlation between individual efficacy of anti-CGRP treatment and susceptibility to" exact="migraine" post="induction by CGRP. Methods: Thirteen migraine patients, previously enrolled"/>
   <result pre="treatment and susceptibility to migraine induction by CGRP. Methods: Thirteen" exact="migraine" post="patients, previously enrolled in erenumab anti-CGRP receptor monoclonal antibody"/>
   <result pre="a double-blind, placebo-controlled, randomized design to investigate their susceptibility to" exact="migraine" post="induction. A standardized questionnaire was used to assess efficacy"/>
   <result pre="large-scale prospective CGRP provocation study in patients should confirm whether" exact="hypersensitivity" post="to CGRP could be a biomarker for predicting antibody"/>
   <result pre="Helsinki of 1964, with later revisions. P87 Mitochondrial DNA and" exact="migraine" post="Sigrid Børte 1,2, Bendik S. Winswold 2,3, Lars G."/>
   <result pre="and mitochondrial dysfunction have been suggested to be involved in" exact="migraine" post="pathogenesis, partly because migraine seems to be disproportion- ally"/>
   <result pre="been suggested to be involved in migraine pathogenesis, partly because" exact="migraine" post="seems to be disproportion- ally transmitted through the maternal"/>
   <result pre="is not the only cause of cognitive impairment in chronic" exact="migraine" post="Nina Latysheva 1,2*, Diana Osipova 1, Elena Filatova 1,2"/>
   <result pre="and chronic pain. Cognitive deficits have been demonstrated in episodic" exact="migraine" post="(EM) – both during attacks and interictally. Their severity"/>
   <result pre="evaluate subjective and objective cognitive impairment in patients with chronic" exact="migraine" post="(CM). Methods We recruited 53 subjects with ICHD-3beta-defined CM"/>
   <result pre="and attention impairment is prevalent in the CM population. As" exact="migraine" post="becomes chronic, central sensitization and cognitive impairment become persistent"/>
   <result pre="headache also had medication overuse. Chronic tension-type headache and chronic" exact="migraine" post="had one-year prevalence 1.3% (n=26) and 2.2% (n=45), respectively."/>
   <result pre="we investigated the prevalence of addiction disorder among the chronic" exact="migraine" post="patients Patients and methods. 75 patients with chronic migraine"/>
   <result pre="chronic migraine patients Patients and methods. 75 patients with chronic" exact="migraine" post="(CM) and MOH (ICHD-3) mean age 41,1±12,8y.o. (21-65), 9"/>
   <result pre="women. We assessed the mean amount of doses of acute" exact="migraine" post="drugs (triptans, combined analgetics) during 3 months and addiction"/>
   <result pre="Leeds Dependence Questionnaire (LDQ). Results. The mean amount of acute" exact="migraine" post="drugs per month was 31,6±23,2 (mean±SD) doses per month"/>
   <result pre="the patients into two groups: with daily consumption of acute" exact="migraine" post="drugs (group 1) – 25 patients, and the group"/>
   <result pre="the group 1 had 30,0±0 headache days per month, 18,9±3,9" exact="migraine" post="days per month and consumed 59,2±21,0 doses of acute"/>
   <result pre="the group 2 had 24,6±5,9 headache days per month, 16,6±4,5" exact="migraine" post="days per month and consumed 17,8±4.2 doses of acute"/>
   <result pre="addicted to acute medication, some not. Daily consumption of acute" exact="migraine" post="drugs may be a sign dependence. References: Headache Classification"/>
   <result pre="Effectiveness and safety of OnabotulinumtoxinA in the treatment of chronic" exact="migraine" post="in patients older than 65 M. Castañón, E. Ameijide,"/>
   <result pre="METHODS We retrospectively reviewed medical records of patients with chronic" exact="migraine" post="treated with Onabotulinumtoxin A. Patients older than 65 years"/>
   <result pre="The majority of participants mentioned headache as the most frequent" exact="neurological disorder" post="in their clinics. The concept of primary and secondary"/>
   <result pre="secondary headaches was not clear: only 26,2% of participants considered" exact="migraine" post="as a primary headache and only 12,2% tension type"/>
   <result pre="and only 12,2% tension type headache. 31,3% mentioned it specifically" exact="migraine" post="as a secondary headache. Only 57% believed clinical history"/>
   <result pre="while 50% thought fever could be a normal sign in" exact="migraine" post="patients. Symptoms such as aggravation with movement, photophobia or"/>
   <result pre="trauma (38,1%) and psychiatric disorders (31%). For the treatment of" exact="migraine" post="the preferred option was paracetamol (47,6%) followed by NSAID"/>
   <result pre="A real-world analysis of global patient‑reported outcomes in patients with" exact="migraine" post="Janet H. Ford 1, Sarah Cotton 2, James Jackson"/>
   <result pre="patients with migraine. Preventive treatment is recommended for patients with" exact="migraine" post="who experience ≥4 migraine headache days (MHDs)/month; however, many"/>
   <result pre="treatment is recommended for patients with migraine who experience ≥4" exact="migraine" post="headache days (MHDs)/month; however, many are untreated. It is"/>
   <result pre="Migraine Disease Specific Program, 2017) and their consulting patients with" exact="migraine" post="in the United States (US) and in five European"/>
   <result pre="MHDs/month (reported here), and 2) patients with ≥3 lines of" exact="migraine" post="preventives versus 0 to 2 lines. The PRO measures"/>
   <result pre="with ≥4 MHDs/month were on long-term sick leave/unemployed/retired due to" exact="migraine" post="in 5-EU (pooled result: 5.1% vs. 1.7%; p&amp;lt;0.01); US"/>
   <result pre="countries of 5-EU. Conclusions: These results suggest that patients with" exact="migraine" post="who experience &amp;lt;4 MHDs/month experience better outcomes on PRO"/>
   <result pre="≥4 MHDs/month. This suggests that goals of treatment regimens for" exact="migraine" post="should be targeted towards reducing the frequency to &amp;lt;4"/>
   <result pre="1 (abstract P96). Patient‑reported outcome (PRO) measures in patients with" exact="migraine" post="who experience ≥4 migraine headache days/month and &amp;lt;4 migraine"/>
   <result pre="outcome (PRO) measures in patients with migraine who experience ≥4" exact="migraine" post="headache days/month and &amp;lt;4 migraine headache days/month in the"/>
   <result pre="with migraine who experience ≥4 migraine headache days/month and &amp;lt;4" exact="migraine" post="headache days/month in the US and in five European"/>
   <result pre="populations from Germany, France, UK, Italy and Spain. Abbreviation: MHD" exact="migraine" post="headache days. P97 ONAMIG: Does onabotulinumtoxinA modulate cortical excitability"/>
   <result pre="Hospital, Barcelona, Spain Correspondence: P.Pozo- Rosich (ppozorosich@yahoo.com) Background: Symptoms in" exact="migraine" post="could be caused by changes in cortical excitability. Objective:"/>
   <result pre="excitability. Objective: To analyze changes in cortical excitability in chronic" exact="migraine" post="patients after onabotulinumtoxinA treatment. Methods: We included patients diagnosed"/>
   <result pre="for treatment with onabotulinumtoxinA, as well as patients with episodic" exact="migraine" post="(EM) as controls. We collected sociodemographic, clinical data, acute"/>
   <result pre="and grade A of recommendation in the treatment of chronic" exact="migraine" post="(CM). However, many patients receive other oral drugs before"/>
   <result pre="OnabotulinumtoxinA responders seems independent of the time of the chronic" exact="migraine" post="in which treatment is started. However, the time it"/>
   <result pre="presented with chronic migraine, with 9% fulfilling a diagnosis of" exact="migraine" post="with aura. As for the clinical features of migraine,"/>
   <result pre="Hanna Sophie Lapp (Hanna-Sophie.Lapp@uniklinikum-dresden.de) Background: Migraine is characterized by sensory" exact="hypersensitivity" post="and habituation deficits. Slow brushing over the skin activates"/>
   <result pre="P104 Frequency, referral and demographic characteristics of patients with vestibular" exact="migraine" post="from a tertiary centre Isabel Luzeiro 1, Isabel Pavão"/>
   <result pre="Hospital, Lisbon Correspondence: Isabel Luzeiro (isabeluzeiro@gmail.com) Background and goals. Vestibular" exact="migraine" post="is a recently-described entity, still classified in the Appendix"/>
   <result pre="miscellaneous. Patients referred because of a clinical hypothesis of vestibular" exact="migraine" post="were sent by otorhinolaryngologists, with a percentage of 30%."/>
   <result pre="because of migraine. Discussion. The percentage of patients with vestibular" exact="migraine" post="diagnosed at our tertiary center was 6.8%, slightly higher"/>
   <result pre="P105 Migraine comorbidity and cognitive performance in patients with focal" exact="epilepsy" post="Olivia AJ Begasse de Dhaem 1, Chris Morrison 2,"/>
   <result pre="Correspondence: Olivia AJ Begasse de Dhaem (oab2109@cumc.columbia.edu) Background: Migraine and" exact="epilepsy" post="are comorbid diseases that are both associated with cognitive"/>
   <result pre="with cognitive impairments. [1,2,3,4,5] The presence of cognitive impairment in" exact="migraine" post="patients is thought to be independent of migraine severity,"/>
   <result pre="impairment in migraine patients is thought to be independent of" exact="migraine" post="severity, duration, or medications. [1] Using prospective data from"/>
   <result pre="focal epilepsy, we will assess whether the comorbid presence of" exact="migraine" post="affects cognitive testing scores in epilepsy patients. Methods: The"/>
   <result pre="the comorbid presence of migraine affects cognitive testing scores in" exact="epilepsy" post="patients. Methods: The primary outcomes are the total and"/>
   <result pre="the total and subtest differences in initial cognitive performance between" exact="epilepsy" post="patients with migraine and epilepsy patients without migraine. Cognitive"/>
   <result pre="subtest differences in initial cognitive performance between epilepsy patients with" exact="migraine" post="and epilepsy patients without migraine. Cognitive function is assessed"/>
   <result pre="in initial cognitive performance between epilepsy patients with migraine and" exact="epilepsy" post="patients without migraine. Cognitive function is assessed with the"/>
   <result pre="potential confounders such as depression, anxiety, age, cardiovascular protective medications," exact="cardiovascular disease," post="and history of head trauma. Impact: We hypothesize that"/>
   <result pre="hypothesize that there will be significant differences in cognition between" exact="epilepsy" post="patients with migraine compared to epilepsy patients without migraine."/>
   <result pre="will be significant differences in cognition between epilepsy patients with" exact="migraine" post="compared to epilepsy patients without migraine. If this is"/>
   <result pre="differences in cognition between epilepsy patients with migraine compared to" exact="epilepsy" post="patients without migraine. If this is the case, future"/>
   <result pre="work could evaluate whether there is an association between new" exact="migraine" post="diagnosis at the end of the study and change"/>
   <result pre="organization dedicated to accelerating the development of new therapies in" exact="epilepsy" post="to improve patient care. The funding provided to ESCI"/>
   <result pre="F, Roccella M. Visual-spatial training efficacy in children affected by" exact="migraine" post="without aura: a multicenter study. Neuropsychiatr Dis Treat. 2017"/>
   <result pre="ME, Lipton RB. Chronic disorders with episodic manifestations: focus on" exact="epilepsy" post="and migraine. Lancet Neurol. 2006 Feb;5(2):148-157. [5] Smith DB,"/>
   <result pre="BR, Collins J, Mattson RH, Cramer JA. Behavioral characteristics of" exact="epilepsy" post="patients compared with normal controls. Epilepsia. 1986 Nov-Dec;27(6):760-8. P106"/>
   <result pre="Introduction Omophobia has been suggested as an additional symptom of" exact="migraine" post="without aura (MO) and high prevalence of osmophobia up"/>
   <result pre="were carefully phenotyped and fulfilled the ICHD-2 diagnostic criteria for" exact="migraine" post="or TTH. Statistical analyses were performed using statistical software"/>
   <result pre="patients. Results Osmophobia was present in 33.5% of patients with" exact="migraine" post="with aura, in 36.0% of patients with MO, and"/>
   <result pre="All migraineurs with osmophobia also fulfilled the current criteria for" exact="migraine" post="by having nausea or photophobia and phonophobia. The appendix"/>
   <result pre="study, online bulletin boards provided insights into the impact of" exact="migraine" post="on the lives of those affected and the coping"/>
   <result pre="recruited via online panels and patient organizations. Participants were adult" exact="migraine" post="patients who reported ≥4 MMD in the 3 months"/>
   <result pre="with pre-specified 90% among those having reported having used preventive" exact="migraine" post="treatment. Results A total of 11,266 migraine individuals participated"/>
   <result pre="having used preventive migraine treatment. Results A total of 11,266" exact="migraine" post="individuals participated (75% female, mean age 39 years); most"/>
   <result pre="migraines. 85% of participants reported negative aspects of living with" exact="migraine" post="(feeling helpless, depressed, not understood), sleeping difficulties (83%); 55%"/>
   <result pre="person (11%). Conclusion This study describes the daily reality of" exact="migraine" post="individuals, especially those with frequent attacks and who have"/>
   <result pre="individuals, especially those with frequent attacks and who have received" exact="migraine" post="preventive treatments. While it highlights the significant challenges and"/>
   <result pre="P108 A model concept for assessing the cost-effectiveness of prophylactic" exact="migraine" post="treatments Ronan Mahon 1*, Pamela Vo 2, Philip Cooney"/>
   <result pre="in order to assess the cost-effectiveness of erenumab as a" exact="migraine" post="prophylactic treatment compared to relevant alternatives. Methods Relevant clinical"/>
   <result pre="order to understand clinical practice and previous modelling approaches in" exact="migraine" post="prevention. Cost- effectiveness model concepts were devised and evaluated."/>
   <result pre="and quality-adjusted life-years (QALYs) can be estimated based on monthly" exact="migraine" post="day (MMD) frequency. Thus, each health state in the"/>
   <result pre="of erenumab in the prophylactic treatment of migraine, estimating both," exact="migraine" post="patients’ MMD frequencies and their response to treatment. Funding"/>
   <result pre="AS, Friedman D, Shevell M. Pediatr Neurol. 2015 Mar;52(3):270-80 Intravenous" exact="migraine" post="therapy in children with posttraumatic headache in the ED."/>
   <result pre="P110 Movement disorders as positive motor aura symptoms during hemiplegic" exact="migraine" post="attacks Elisa de la Cruz 1, Geneviève Demarquay 2,"/>
   <result pre="movement disorders) have not been described so far during hemiplegic" exact="migraine" post="(HM) attacks. Methods: Patients were included if they had"/>
   <result pre="according to local guidelines. We prospectively collected demographic data and" exact="migraine" post="characteristics from all the patients. We also recorded information"/>
   <result pre="the patients. We also recorded information about tolerability, headache days," exact="migraine" post="days, and the number of days on which patients"/>
   <result pre="± 12.3 years (16 - 69) at inclusion. Latency between" exact="migraine" post="and CM onset and OnabotA therapy was respectively 22.7"/>
   <result pre="and associated work productivity and activity impairment among patients with" exact="migraine" post="in Germany J. Scott Andrews 1*, Janet Ford 1,"/>
   <result pre="Grazia Dell’Agnello (andrews_jeffrey_scott@lilly.com) Background Limited research exists on patients with" exact="migraine" post="in Germany that addresses both acute and preventive treatment"/>
   <result pre="associated with various levels of headache frequency among patients with" exact="migraine" post="in Germany. Methods Data were taken from the 2017"/>
   <result pre="survey of physicians and their patients with a diagnosis of" exact="migraine" post="in Germany. Physicians (Primary care = 51, Neurologist ="/>
   <result pre="per month (0-3, 4-7, 8-14, 15+). Results Most patients with" exact="migraine" post="experienced 0-3 (40%) or 4-7 (42%) HD/month. Mean duration"/>
   <result pre="0-3 (40%) or 4-7 (42%) HD/month. Mean duration from first" exact="migraine" post="experienced to first diagnosis was 3.4 months. Mean duration"/>
   <result pre="of headache frequency, at least 1 in 4 patients with" exact="migraine" post="experienced impairment in work productivity and activity. The top"/>
   <result pre="Evaluation of concomitant use of preventive medications with OnabotulinumtoxinA in" exact="migraine" post="Marta Torres-Ferrus 1,2; Sonia Santos Lasaosa 3; Angel Guerrero"/>
   <result pre="is an effective, tolerable and safe preventive treatment for chronic" exact="migraine" post="(CM). Other than a reduction in headache frequency or"/>
   <result pre="This is a multicentre study. We consecutively included patients with" exact="migraine" post="(ICHD-3) that were on preventive treatment with OnabotulinumtoxinA. We"/>
   <result pre="mean age 47.6 ± 11.7 years. A 89.3% had chronic" exact="migraine" post="and 10.8% had high frequency episodic migraine. The mean"/>
   <result pre="of treatment. P115 Onset of effect of onabotulinumtoxinA for chronic" exact="migraine" post="treatment: analysis of PREEMPT data David W. Dodick 1*"/>
   <result pre="(onabotA) for the prevention of headache in adults with chronic" exact="migraine" post="(CM). This analysis assessed the time to onset of"/>
   <result pre="to placebo (PBO) on reduction of headache days and migraine/probable" exact="migraine" post="days per week from baseline. Methods: Each PREEMPT trial"/>
   <result pre="24). Additional analyses included change in headache days and migraine/probable" exact="migraine" post="days per wk vs baseline. Pooled analyses from the"/>
   <result pre="[1.6] days; PBO: 4.8 [1.6] days, P=0.70) and for migraine/probable" exact="migraine" post="days per wk (onabotA: 4.6 [1.7]; PBO: 4.6 [1.7]"/>
   <result pre="by –0.9 (2.2) vs PBO (–0.7 [2.1]; P=0.046) and migraine/probable" exact="migraine" post="days by –1.0 (2.4) vs PBO (0.7 [2.2]; P=0.031);"/>
   <result pre="in continued reduction in headache days (Fig. 1A) and migraine/probable" exact="migraine" post="days (Fig. 1B) over 5 treatment cycles. Conclusions: As"/>
   <result pre="first treatment, onabotA treatment significantly reduced headache days/wk and migraine/probable" exact="migraine" post="days/wk. This improvement persisted from wk 3 of the"/>
   <result pre="Change from baseline in A) headache days/week and B) migraine/probable" exact="migraine" post="days/week after treatment with onabotulinumtoxinA or placebo/onabotulinumtoxinA P116 New"/>
   <result pre="daily persistent headache is heterogeneous in presentation and may resemble" exact="migraine" post="or tension-type headache or both. Prevalence rate of NDPH"/>
   <result pre="and B of the ICHD-2 regardless of the presence of" exact="migraine" post="features.), GP general population, CDH chronic daily headache Table"/>
   <result pre="- - 18.3% 20% 29% 29.1% Past history of episodic" exact="migraine" post="headache none 2% - - - 7% 12% 25%"/>
   <result pre="Mack 2004, USA 40 (pediatric NDPH) 5(12%) 17(43%) 13(33%) 5(12%)" exact="idiopathic intracranial hypertension," post="high altitude climbing Takase 2004, Japan 30 24(80%) -"/>
   <result pre="• Cerebral venous thrombosis • Cranial artery dissection • Cranial" exact="arthritis" post="• Posttraumatic headache (subarachnoid hemorrhage, subdural hematoma,…) • Meningitis"/>
   <result pre="Posttraumatic headache (subarachnoid hemorrhage, subdural hematoma,…) • Meningitis • Sphenoid" exact="sinusitis" post="• Contact-point headache(caused by contact of intranasal structures) P117"/>
   <result pre="Introduction Typical aura without headache (TAWH) is a sort of" exact="migraine" post="with aura in which aura is not followed by"/>
   <result pre="by headache within 60 minutes. Approximately, 3-6% of patients with" exact="migraine" post="suffer TAWH without developing any kind of pain. We"/>
   <result pre="were visited. 135 of them fulfilled TAWH criteria (1.8% of" exact="migraine" post="visits), average onset age: 18 years old. They presented"/>
   <result pre="in MABs, which includes: age &amp;lt;50 years old (2-0 points)," exact="migraine" post="history (1-0), vascular risk factors (0-1), non-negative phenomena (2-0),"/>
   <result pre="to corresponding improvements in various associated psychological symptoms accompanying chronic" exact="migraine" post="such as anxiety and depression. Also reveal high levels"/>
   <result pre="± 9.4 years and a mean age of onset of" exact="migraine" post="of 17.3 ± 9.8years, diagnosed as Chronic Migraine with"/>
   <result pre="all females, (mean age 44.3 ± 8.1 years, onset of" exact="migraine" post="14.2 ± 6.3 years) have completed the third session"/>
   <result pre="are encouraging and await further replication P119 Mindfulness meditation for" exact="migraine" post="in pediatric population: a pilot study Licia Grazzi 1Emanuela"/>
   <result pre="work/school functioning. CM prevalence is around 2% among adolescents. Also" exact="migraine" post="at high frequency can be a problematic condition often"/>
   <result pre="school-age children to 20 % in adolescents [1,2]. Traditionally, pediatric" exact="migraine" post="treatment includes both prophylactic therapy, aimed at reducing the"/>
   <result pre="lack of controlled studies on the pharmacological treatment of pediatric" exact="migraine" post="still remains. Consequently, there is an urgent need for"/>
   <result pre="and other supplements, may be an alternative option in treating" exact="migraine" post="and may be offered to parents who are reluctant"/>
   <result pre="to evaluate the role of PEA in the management of" exact="migraine" post="without aura in pediatric patients. OBJECTIVE: The aim of"/>
   <result pre="administration in terms of reducing the frequency and severity of" exact="migraine" post="attacks in pediatric patients. METHODS: The study sample includes"/>
   <result pre="of age (mean 9.4 years). They had a diagnosis of" exact="migraine" post="according to the ICHD-3 criteria and received umPEA (600"/>
   <result pre="and White Matter Hyperintensities in patients Migraine with aura, young" exact="stroke" post="patients and controls C Altamura 1, CA Mallio 2,"/>
   <result pre="Aura (MA) were consistently reported to present an increase in" exact="stroke" post="risk, while if they display a higher White Matter"/>
   <result pre="Our study aimed at evaluating the relationship among cerebral hemodynamics," exact="patent foramen ovale" post="and white matter hyperintensities in patients affected by MA,"/>
   <result pre="hyperintensities in patients affected by MA, young patients with cryptogenetic" exact="stroke" post="or motor transient ischemic attack and controls. METHODS We"/>
   <result pre="age (Kruskal-Wallis test p=.004), higher prevalence in PFO (95%) and" exact="dyslipidemia" post="(Chi-squared p&amp;lt;.001), and higher WMH load in the MCA"/>
   <result pre="diffusion, white-matter hyperintensities, and cognitive function in Alzheimer’s disease and" exact="vascular dementia." post="J Clin Neurol 12: . doi: 10.3988/jcn.2016.12.2.201 P122 Prediction"/>
   <result pre="scan and MRIs. P123 Anxiety, depression and alexithymia in young" exact="migraine" post="patients: which relationship with body weight? Samuela Tarantino 1,"/>
   <result pre="Background A growing body of literature explored the relationship between" exact="migraine" post="and body weight. While several studies analyzed common pathophysiological"/>
   <result pre="weight. While several studies analyzed common pathophysiological mechanisms implicated in" exact="migraine" post="and feeding regulation, data on the role of psychological"/>
   <result pre="in migraineurs children/adolescents; 2) the possible relationship between frequency of" exact="migraine" post="and overweight; 3) the role of psychological symptoms (anxiety/depression)"/>
   <result pre="emotional processing /regulating (alexithymia) on Body mass Index (BMI) in" exact="migraine" post="patients. Methods Patients were identified though a systematic review"/>
   <result pre="overweight. The weight (normal or overweight) did not correlate with" exact="migraine" post="frequency in none of the groups (respectively: Group-1: χ(2)"/>
   <result pre="arise. P124 Health care resource use, sick-leaves and comorbidities among" exact="migraine" post="patients in occupational healthcare Minna A. Korolainen 1, Samu"/>
   <result pre="of this study was to assess how the burden of" exact="migraine" post="impacts a Finnish occupational health care patient cohort. Methods:"/>
   <result pre="comorbidities, healthcare resource use, medication use, and sick-leaves related to" exact="migraine" post="among 369’383 consented patients. The migraine cohorts were defined"/>
   <result pre="and sick-leaves related to migraine among 369’383 consented patients. The" exact="migraine" post="cohorts were defined using diagnosis code G43, prescription with"/>
   <result pre="and ended 31 st December 2017. Results: Of 17’623 identified" exact="migraine" post="patients, 8899 had no prescribed treatment, 6525 had acute"/>
   <result pre="migraine patients, 8899 had no prescribed treatment, 6525 had acute" exact="migraine" post="treatment and 2199 fulfilled the defined criteria for the"/>
   <result pre="increasing prophylactic treatment lines, and were 30% higher than in" exact="migraine" post="sufferers without prophylactic treatment. Patients with migraine receiving prophylaxis"/>
   <result pre="higher than in migraine sufferers without prophylactic treatment. Patients with" exact="migraine" post="receiving prophylaxis had 30-40% more concomitant diagnoses of depression"/>
   <result pre="retrospective study using data from routine clinical practice showed that" exact="migraine" post="was associated with substantial morbidity seen as an increase"/>
   <result pre="normal in all patients with significant pain relief. P128 Chronic" exact="migraine" post="is much more related to cardiovascular risk factors: a"/>
   <result pre="Gulnur Tekgol Uzuner (uzunergulnur@gmail.com) Background and purpose: The relation between" exact="migraine" post="and vascular risk factors is one of the curious"/>
   <result pre="still unknown. Perhaps, age-related risk factors and factors leading to" exact="migraine" post="progression will also change. Under these questions, our aim"/>
   <result pre="risk factors between several age groups and different subtypes of" exact="migraine" post="and also in their family. Methods: A dataset (the"/>
   <result pre="to vascular risk factors than MwA and CM. Conclusion: Chronic" exact="migraine" post="was associated with vascular risk factors at all ages"/>
   <result pre="Migraine&quot; has been described as the concurrence of strictly unilateral" exact="migraine" post="and ipsilateral trochleodynia with migraine relief after successful treatment"/>
   <result pre="the concurrence of strictly unilateral migraine and ipsilateral trochleodynia with" exact="migraine" post="relief after successful treatment of trochleodynia [1]. This disorder"/>
   <result pre="the attacks the glycemic levels was normal. Positive familiarity for" exact="migraine" post=". All exams resulted negative. 2° case: A 11-year"/>
   <result pre="zone , without irradiation or swollen trochlea. Positive familiarity for" exact="migraine" post="(mother). Neurological examination and instrumental exams were negative. In"/>
   <result pre="term seems to indicate more correctly the association of the" exact="migraine" post="syndrome to a topographical localization, similar to the &quot;nasal"/>
   <result pre="Pareja JA, Lopez N, Sanchez Del Rio M. Trochleitis and" exact="migraine" post="headache. Neurology 2002; 58:802–805 2) Alvarez M, Montojo T,"/>
   <result pre="Casa B, Vela L., Pareja J.A. Unilateral nasal pain with" exact="migraine" post="features. Cephalalgia , 2013, 33:1055-58 3) Chanlalit W, Teeyapant"/>
   <result pre="Pain Headache Rep. 2016, 20:19 Table 1 (abstract P129). Trochlear" exact="migraine" post="– two case report Clinical features Sex M M"/>
   <result pre="10 10 Migraine subtype Ep MwA Ep MwA Location of" exact="migraine" post="pain Troch. Troch/fronto-temp Age at onset trochlear pain 10"/>
   <result pre="trochlear pain + - Diplopia - - Trigger trochlear for" exact="migraine" post="attacks Not applicable Not applicable Response to local steroid"/>
   <result pre="Not applicable Not applicable P130 Efficient therapy for treatment of" exact="migraine" post="without aura: ergotamine based drugs or sumatriptan Sinisa Miljkovic"/>
   <result pre="are the most effective medications in the treatment of acute" exact="migraine" post="without aura. The aim of this study was to"/>
   <result pre="effectiveness was assessed on the basis of complete disappearance of" exact="migraine" post="pain two hours after administration of the study medication."/>
   <result pre="after administration of the study medication. Results: Complete reduction of" exact="migraine" post="pain after two hours was reported in 51.12% attacks"/>
   <result pre="(p=0.0015). Nomigren® has shown equally sustainable high efficiency through repeated" exact="migraine" post="attacks. The therapy’s effectiveness in repeated attacks in Nomigren®"/>
   <result pre="Conclusion: Nomigren® displayed better effectiveness in the complete cessation of" exact="migraine" post="pain and accompanying symptoms compared to sumatriptan in the"/>
   <result pre="and accompanying symptoms compared to sumatriptan in the treatment of" exact="migraine" post="without aura. P131 Analysis of Initial Non Responders to"/>
   <result pre="To assess response rates in adults with episodic or chronic" exact="migraine" post="without initial response to galcanezumab and the likelihood of"/>
   <result pre="patients with episodic [n=879; two 6-month studies (pooled)] or chronic" exact="migraine" post="(n=555; one 3-month study) treated with galcanezumab (pooled 120"/>
   <result pre="mg/month) were conducted. Patients without initial treatment response (≥50% fewer" exact="migraine" post="headache days [MHD] for episodic and ≥30% for chronic)"/>
   <result pre="had no response. Conclusions: Galcanezumab-treated patients with episodic or chronic" exact="migraine" post="who had not responded after 1 or 2 months"/>
   <result pre="which binds to calcitonin gene-related peptide, has been evaluated for" exact="migraine" post="prevention. The aim of these post-hoc analyses is to"/>
   <result pre="the onset of effect of galcanezumab for prevention of episodic" exact="migraine" post="based on data from the Phase 3 clinical program."/>
   <result pre="included patients aged 18-65 years with a diagnosis of episodic" exact="migraine" post="and a history of migraine headaches for ≥1 year."/>
   <result pre="with a diagnosis of episodic migraine and a history of" exact="migraine" post="headaches for ≥1 year. A total of 1,773 (858"/>
   <result pre="41.9 years EVOLVE-2). On average, patients had been diagnosed with" exact="migraine" post="approximately 20 years prior to study entry (20.1 years"/>
   <result pre="EVOLVE-1, 33.0 EVOLVE-2); the approximate mean number of baseline monthly" exact="migraine" post="headache days (MHDs) was 9 (9.1 days EVOLVE-1 9.1"/>
   <result pre="(christian.lampl@ordensklinikum.at) &amp;amp; Contributed equally to the study Although clinically distinguishable," exact="migraine" post="and cluster headache share prominent features such as unilateral"/>
   <result pre="also suggest efficacy of anti CGRP monoclonal antibodies in both" exact="migraine" post="and cluster headache. While exact mechanisms behind both disorders"/>
   <result pre="in phenotype, heritability, pathophysiology, imaging findings and treatment options of" exact="migraine" post="and cluster headache. A continued focus on their shared"/>
   <result pre="important in paving future treatment avenues that could benefit both" exact="migraine" post="and cluster headache patients. P134 Providing care: Cost-effective and"/>
   <result pre="of its much lower disability weight compared with those for" exact="migraine" post="and MOH. In practice, structured headache services will not"/>
   <result pre="assess functioning based on activity impairment in episodic and chronic" exact="migraine" post="patients ML Cala 1, CA Graham 1, RB Lipton"/>
   <result pre="a patient-reported outcome (PRO) measure to assess relevant impacts of" exact="migraine" post="in episodic migraine (EM) and chronic migraine (CM) patients"/>
   <result pre="(PRO) measure to assess relevant impacts of migraine in episodic" exact="migraine" post="(EM) and chronic migraine (CM) patients for use in"/>
   <result pre="relevant impacts of migraine in episodic migraine (EM) and chronic" exact="migraine" post="(CM) patients for use in clinical trials of migraine"/>
   <result pre="chronic migraine (CM) patients for use in clinical trials of" exact="migraine" post="preventive treatments. Methods: The AIM-D was developed using an"/>
   <result pre="conceptual saturation, helped to identify impacts that were relevant to" exact="migraine" post="patients and to develop the draft AIM-D. The AIM-D"/>
   <result pre="headache and non-headache administration options to better elicit responses from" exact="migraine" post="patients using a 24-hour recall period. Four additional items"/>
   <result pre="or other intellectual property. P136 Epidemiology of chronic and episodic" exact="migraine" post="in Europe Hicham Benhaddi 1, Timothy Fitzgerald 2, Sophie"/>
   <result pre="UK Correspondence: Hicham Benhaddi (kgora@hcg-int.com) BACKGROUND: Migraine is a debilitating" exact="neurological disorder" post="characterized by headaches of varying duration and intensity. Treatment"/>
   <result pre="therapy guidelines, and unmet needs of chronic (CM) and episodic" exact="migraine" post="(EM) in Europeans. METHODS: Literature searches and evidence screening"/>
   <result pre="headache days per month), CM (≥15 headache days with ≥8" exact="migraine" post="days per month), or medication overuse headache (MOH) were"/>
   <result pre="included 64 publications. The World Health Organization estimated 77 million" exact="migraine" post="sufferers in Europe, with an incidence of up to"/>
   <result pre="monthly and quarterly dosing options for a new class of" exact="migraine" post="preventive therapy on likelihood of acceptance and adherence in"/>
   <result pre="therapy on likelihood of acceptance and adherence in adults with" exact="migraine" post="Robert Cowan 1, Joshua Cohen 2, Erik Rosenman 3,"/>
   <result pre="million people in the US 1. A new class of" exact="migraine" post="preventive therapy launching in 2018-2019 will provide physicians and"/>
   <result pre="on acceptance of, and adherence to, the new class of" exact="migraine" post="preventive therapy among adults with migraine. Methods In this"/>
   <result pre="Methods In this double-blind, observational study, 420 US adults with" exact="migraine" post="completed a 20-minute, self-administered online survey. Respondents included 228"/>
   <result pre="high-frequency episodic (10-14 headache days / month), and 86 chronic" exact="migraine" post="patients (≥15 headache days / month). Adults with migraine"/>
   <result pre="chronic migraine patients (≥15 headache days / month). Adults with" exact="migraine" post="were exposed to three scenarios: 1) only monthly dosing"/>
   <result pre="scenarios: 1) only monthly dosing of the new class of" exact="migraine" post="preventive therapy is available, 2) only quarterly dosing is"/>
   <result pre="assuming roughly equivalent efficacy regardless of dosing schedule, adults with" exact="migraine" post="were asked their likelihood to fill the prescription (if"/>
   <result pre="set at p&amp;lt;0.05. Results A similar proportion of adults with" exact="migraine" post="preferred monthly (35.7%) and quarterly (39.5%) dosing regimens (24.8%"/>
   <result pre="p&amp;lt;0.008 and 62% vs. 54% p&amp;lt;0.023 respectively). Conclusions Adults with" exact="migraine" post="are more likely to fill the new class of"/>
   <result pre="http://migraineresearchfoundation.org/about-migraine/migraine-facts/ Last accessed June 22 nd, 2018 P138 Prognosis of" exact="trigeminal neuralgia" post="is very favourable when managed by specialists - a"/>
   <result pre="Copenhagen, Denmark Correspondence: Tone Bruvik Heinskou (tone.bruvik.heinskou@regionh.dk) Background: Prognosis of" exact="trigeminal neuralgia" post="is generally assumed to be poor with slowly deterioration"/>
   <result pre="deterioration over time. Prospective real-life studies of medical management of" exact="trigeminal neuralgia" post="are almost non-existent. The aim of this prospective real-life"/>
   <result pre="study was to investigate the two-year prognosis for patients with" exact="trigeminal neuralgia" post="treated by specialists. Methods: Consecutive patients were enrolled in"/>
   <result pre="patients and care providers and suggest that specialist management of" exact="trigeminal neuralgia" post="is highly rewarding. P139 Serum changes of apolipoproteins in"/>
   <result pre="(white) and healthy volunteers (grey). P140 Robust association between Obstructive" exact="sleep apnea" post="(OSA) and Idiopathic intracranial hypertension (IIH) in Chronic daily"/>
   <result pre="Correspondence: G. Demonte (g.dem.1990@gmail.com) Introduction It’s widely recognized that Obstructive" exact="sleep apnea" post="(OSA) is a risk factor for chronic daily headache"/>
   <result pre="(CDH) [1]. However, the association between OSA and CDH with" exact="idiopathic intracranial hypertension" post="(IIH) remains today uncertain. The aim of this study"/>
   <result pre="2014;83:792 P141 Loss of periventricular white matter microstructure integrity in" exact="idiopathic intracranial hypertension" post="Laura Rapisarda 1, Giulio Demonte 1, Federico Tosto 1,"/>
   <result pre="impairment of white matter (WM) microstructural integrity in patients with" exact="idiopathic intracranial hypertension" post="(IIH). Materials and methods We recruited 62 patients with"/>
   <result pre="IIH, Group 2 included 27 non-IIH patients with refractory chronic" exact="migraine" post="(CM) or chronic tension-type headache (CTTH). Patients underwent neurological"/>
   <result pre="a major cause of headache-related disability. MOH has similarities with" exact="substance dependence" post="disorders and withdrawal of acute headache analgesics has been"/>
   <result pre="MIDAS score: 42.1, 95% CI 31.7; 52.6). 55% 59/108) had" exact="migraine" post="co-occurrence and 13% (14/108) had chronic migraine. The mean"/>
   <result pre="follow-up (p&amp;lt;0.001) for those with successful self-detoxification. Co- occurrence of" exact="migraine" post="(p=0.044) and lower headache frequency at baseline (p=0.001) increased"/>
   <result pre="by multiple mechanisms including inhibition of the trigeminovascular pathway or" exact="suppression" post="of extracellular glutamate in the central nervous system [2,3]."/>
   <result pre="Cinzia Cavestro (cicaves@alice.it); Simona Sacco (simona.sacco@univaq.it) Background. The association between" exact="migraine" post="and increased risk of ischemic vascular events has been"/>
   <result pre="broadly investigated and supported [1]. Besides, available data indicate that" exact="migraine" post="is comorbid with antiphospholipid antibodies (aPLs) positivity [2], whereas"/>
   <result pre="(aPLs) positivity [2], whereas data referring to the comorbidity between" exact="migraine" post="and other thrombophilic alterations are not conclusive. Accordingly, we"/>
   <result pre="alterations are not conclusive. Accordingly, we investigated the association between" exact="migraine" post="and thrombophilic alterations and examined if the presence of"/>
   <result pre="presence of those alterations was associated with vascular events in" exact="migraine" post="patients. Methods. We designed a cross-sectional, case-control study. We"/>
   <result pre="a cross-sectional, case-control study. We included consecutive outpatients diagnosed with" exact="migraine" post="referring to a tertiary Headache Center. Migraine patients were"/>
   <result pre="anticoagulant, homocysteine, and antiphospholipid antibodies (aPLs). Past history of ischemic" exact="stroke" post="(IS) or transient ischemic attack (TIA), coronary heart disease,"/>
   <result pre="of ischemic stroke (IS) or transient ischemic attack (TIA), coronary" exact="heart disease," post="and peripheral venous thrombosis was ascertained. Results. We included"/>
   <result pre="and peripheral venous thrombosis was ascertained. Results. We included 329" exact="migraine" post="patients and 329 control subjects (mean age 41 years,"/>
   <result pre="As reported in Table 1, we identified an association of" exact="migraine" post="with aPLs positivity (OR=2.6, 95% CI 1.5-4.7, p=0.001) and"/>
   <result pre="(OR=4.7, 95% CI 1.6-14.0, p=0.002). We also found that in" exact="migraine" post="patients, aPLs positivity was independently associated with both IS"/>
   <result pre="IS or TIA (OR=5.6, 95% CI 1.5-20.4, p=0.009) and coronary" exact="heart disease" post="(OR=27.6, 95% CI 1.4-531.1, p=0.028) whereas free protein S"/>
   <result pre="some innovative results. To our best knowledge, the association between" exact="migraine" post="and protein S deficiency was previously investigated by a"/>
   <result pre="S deficiency was previously investigated by a single pilot studyinvolving" exact="migraine" post="with aura participants only [3] that demonstrated a non-significant"/>
   <result pre="low number of participants. We also found an association between" exact="migraine" post="and aPLs positivity, in line with most of the"/>
   <result pre="was not adequately powered to assess the association between selected" exact="migraine" post="subtypes (with and without aura, episodic and chronic) and"/>
   <result pre="and chronic) and thrombophilic alterations. Conclusion. Our study indicates that" exact="migraine" post="is comorbid with free protein S deficiency and aPLs"/>
   <result pre="factors are associated with the occurrence of vascular events in" exact="migraine" post="patients, suggesting that in migraine-prone subjects, comorbid thrombophilic defects"/>
   <result pre="suggesting that in migraine-prone subjects, comorbid thrombophilic defects may favor" exact="migraine" post="attacks occurrence and concur to ischemic events. Ethics Approval"/>
   <result pre="protein C system: shared risk factors in young adults with" exact="migraine" post="with aura and with ischemic stroke? Cephalalgia1998;18:618-621.Cephalalgia1998;18:618-621. Table 1"/>
   <result pre="ischemic stroke? Cephalalgia1998;18:618-621.Cephalalgia1998;18:618-621. Table 1 (abstract P145). Risk of ischemic" exact="stroke" post="or transient ischemic attack, heart disease, and peripheral venous"/>
   <result pre="(abstract P145). Risk of ischemic stroke or transient ischemic attack," exact="heart disease," post="and peripheral venous thrombosis in migraine patients (multivariate analysis)"/>
   <result pre="transient ischemic attack, heart disease, and peripheral venous thrombosis in" exact="migraine" post="patients (multivariate analysis) IS or TIA Coronary heart disease"/>
   <result pre="thrombosis in migraine patients (multivariate analysis) IS or TIA Coronary" exact="heart disease" post="Peripheral venous thrombosis OR 95% CI p OR 95%"/>
   <result pre="Marlow, Buckinghamshire, UK; 4Allergan plc, Irvine, CA, USA Objective: Chronic" exact="migraine" post="(CM) has been associated with substantial disability, healthcare resource"/>
   <result pre="or stock options. P147 Proposed new diagnostic criteria for chronic" exact="migraine" post="Mona Ameri Chalmer 1, Thomas Folkmann Hansen 1, Elena"/>
   <result pre="number of weaknesses with the current diagnostic criteria for chronic" exact="migraine" post="(CM): The criteria are complex, they include a mixture"/>
   <result pre="(CM): The criteria are complex, they include a mixture of" exact="migraine" post="and tension-type-like headaches, and they do not account for"/>
   <result pre="not account for patients who have a high frequency of" exact="migraine" post="but no other headaches. We suggest classifying CM as"/>
   <result pre="other headaches. We suggest classifying CM as simply ≥ 8" exact="migraine" post="days per month disregarding the request for ≥ 15"/>
   <result pre="ICHD-3 criteria[1] with patients who had ≥ 8 or more" exact="migraine" post="days per month but not 15 days with headache"/>
   <result pre="registries were used to compare the socioeconomic impact of chronic" exact="migraine" post="in these two groups. Results The number of migraine"/>
   <result pre="chronic migraine in these two groups. Results The number of" exact="migraine" post="patients with proposed CM-CM was almost two fold higher"/>
   <result pre="1987-2007 (Table 2). Conclusions Patients who suffer from ≥ 8" exact="migraine" post="days per month but not 15 days with headache"/>
   <result pre="than CM patients and are equally as disabled by their" exact="migraine" post="attacks measured on socioeconomic parameters such as early pension"/>
   <result pre="benefit. We propose to classify CM as simply ≥ 8" exact="migraine" post="days per month and to disregard the request for"/>
   <result pre="Cephalalgia 38:1–211. doi: 10.1177/0333102417738202 Table 1 (abstract P147). Number of" exact="migraine" post="patients Danish Headache Center The Mayo Clinic Russian students"/>
   <result pre="113 (83.7%) 113 (80.1%) pCM proposed chronic migraine, CM chronic" exact="migraine" post="Fig. 1 (abstract P147). Distribution of triptan purchases. pCM:"/>
   <result pre="Distribution of triptan purchases. pCM: proposed chronic migraine, CM: chronic" exact="migraine" post="P148 Safety and efficacy of cervical 10 kHz cervical"/>
   <result pre="in a recent prospective study conducted in subjects with chronic" exact="migraine" post="and medication overuse [2]. Aim of the investigation The"/>
   <result pre="of 10 kHz cervical spinal cord stimulation (SCS) in chronic" exact="migraine" post="subjects refractory to conventional medical therapies. The study design"/>
   <result pre="prospective, feasibility study. Methods Twenty adults diagnosed with refractory chronic" exact="migraine" post="were enrolled. Medication overuse headache and severe depression were"/>
   <result pre="study. Safety and effectiveness outcomes, including change in headache days," exact="migraine" post="days, responder rate, change in abortive treatments intake and"/>
   <result pre="± 5.2 days of which 21.6 ± 6.6 days were" exact="migraine" post="days. The average migraine-specific quality of life (MSQ) score"/>
   <result pre="to 4.9 days at week 24. The average reduction in" exact="migraine" post="days at 12 weeks was 6.2 days/month, which increased"/>
   <result pre="week 24 reported a reduction of more than 30% in" exact="migraine" post="days compared to baseline. In 50% of the subjects,"/>
   <result pre="compared to baseline. In 50% of the subjects, the chronic" exact="migraine" post="reverted to being episodic in pattern (&amp;lt;15 headache days/month)"/>
   <result pre="pituitary lesion. No statistical difference was found between patients with" exact="pituitary adenoma" post="and with normal pituitary MRI in terms of demographic,"/>
   <result pre="lesion. No statistical difference was found between patients with pituitary" exact="adenoma" post="and with normal pituitary MRI in terms of demographic,"/>
   <result pre="monthly and quarterly dosing options for a new class of" exact="migraine" post="preventive therapy Robert Cowan 1, Erik Rosenman 3, Tim"/>
   <result pre="million people in the US 1. A new class of" exact="migraine" post="preventive therapy launching in 2018-2019 will provide physicians and"/>
   <result pre="provide physicians and patients with an alternate approach to preventive" exact="migraine" post="treatment. This study sought to understand the impact, if"/>
   <result pre="available on physician intent to prescribe this new class of" exact="migraine" post="preventive therapy. Methods In this double-blind, observational study, 406"/>
   <result pre="this double-blind, observational study, 406 US physicians currently treating adult" exact="migraine" post="patients completed a 20-minute online survey. Respondents were selected"/>
   <result pre="and 60 headache specialists. Physicians allocated the proportion of their" exact="migraine" post="patients who would receive preventive therapies, including the new"/>
   <result pre="who would receive preventive therapies, including the new class of" exact="migraine" post="preventive therapy, in each of three scenarios: 1) only"/>
   <result pre="would likely receive each type of preventive therapy across three" exact="migraine" post="patient types: moderate-frequency episodic (5-9 headache days / month),"/>
   <result pre="proportion of patients expected to receive the new class of" exact="migraine" post="preventive therapy: moderate-frequency episodic patients were more likely to"/>
   <result pre="proportion of patients likely to receive this new class of" exact="migraine" post="preventive therapy. References 1. http://migraineresearchfoundation.org/about-migraine/migraine-facts/ Last accessed June 22"/>
   <result pre="Leiden, The Netherlands Correspondence: Hans-Christoph Diener (h.diener@uni-essen.de) Background: Novel preventive" exact="migraine" post="therapies such as non-invasive vagus nerve stimulation (nVNS; gammaCore®)"/>
   <result pre="stimulations bilaterally to the neck 3 times daily (TID). Abortive" exact="migraine" post="medication was permitted if needed, but adjunctive preventive migraine"/>
   <result pre="Abortive migraine medication was permitted if needed, but adjunctive preventive" exact="migraine" post="medication was not allowed until week 24. The intent-to-treat"/>
   <result pre="in all enrolled patients. Results: Mean reductions in number of" exact="migraine" post="days from the run-in period to the last 4"/>
   <result pre="Percentages of patients with a ≥50% reduction in number of" exact="migraine" post="days were 31.9% (nVNS) and 25.0% (sham) ( p=0.186)."/>
   <result pre="vs sham (n=140) were seen for reductions in number of" exact="migraine" post="days (–2.27 vs –1.53 days; p=0.043), headache days (–2.85"/>
   <result pre="obtaining a proper management of headache. Results: Patients with chronic" exact="migraine" post="or MOH were only 8% at the telephonic interview"/>
   <result pre="Mean age was 43,8 and mean age of onset of" exact="migraine" post="was 19,1. They suffered chronic migraine since a mean"/>
   <result pre="age of onset of migraine was 19,1. They suffered chronic" exact="migraine" post="since a mean of 38,73 months at the moment"/>
   <result pre="OnabotA administration. We did not find differences in number of" exact="migraine" post="days, analgesic or triptan uptake in the basal evaluation."/>
   <result pre="evaluation. Patients that showed habituation had a higher reduction in" exact="migraine" post="days (12,9 vs 7,1, p=0,08) and analgesic consumption (11,6"/>
   <result pre="Ibuprofen and not paracetamol as first line analgesic for acute" exact="migraine" post="due to its interaction with TRPA1 in the cinnamaldehyde"/>
   <result pre="Correspondence: Dorien Bamps (dorien.bamps@kuleuven.be) Background: In case of an acute" exact="migraine" post="headache, many patients rely on over-the-counter analgesics. Both ibuprofen"/>
   <result pre="on TRPA1, an ion channel implicated in the pathophysiology of" exact="migraine" post="with migraine triggers such as acrolein and umbellulone as"/>
   <result pre="an ion channel implicated in the pathophysiology of migraine with" exact="migraine" post="triggers such as acrolein and umbellulone as known TRPA1"/>
   <result pre="TRPA1 as a potential target for the development of new" exact="migraine" post="treatments. Ethics Approval Approval was obtained from the Ethics"/>
   <result pre="Cefaly® device has proven efficacy for the prevention of episodic" exact="migraine" post="[1]. In the PREMICE trial [1] patients with more"/>
   <result pre="In the PREMICE trial [1] patients with more than 6" exact="migraine" post="attacks per month benefited most from eTNS. Imaging studies"/>
   <result pre="NCT02342743): Seventy-three patients (18-65 years) fulfilling ICHD3 criteria for chronic" exact="migraine" post="were included in a single centre, prospective, open trial"/>
   <result pre="medication intake. The secondary outcome measures were mean change in" exact="migraine" post="days and moderate/severe headache days, in monthly cumulative headache"/>
   <result pre="headache days, average headache intensity, and 50% responder rate for" exact="migraine" post="days. Results : Fifty-eight patients (24 with permanent headache)"/>
   <result pre="P157). See text for description. P158 Abortive home treatment of" exact="migraine" post="with external trigeminal neurostimulation using the Cefaly® device: a"/>
   <result pre="with the Cefaly® Acute device for the acute treatment of" exact="migraine" post="have been demonstrated in previous in-hospital clinical trials that"/>
   <result pre="for patients using the device at home to treat a" exact="migraine" post="attack. The main objective of this study was to"/>
   <result pre="obtain efficacy data for e-TNS in the abortive treatment of" exact="migraine" post="using a protocol design similar to the one used"/>
   <result pre="one used in trials of triptans and other new abortive" exact="migraine" post="medications. Study protocol (ClinicalTrials.gov identifier NCT03217968): This was a"/>
   <result pre="to 65 years) suffering from 2-8 attacks per month of" exact="migraine" post="with or without aura (ICHD-3, codes 1.1 &amp;amp; 1.2.1)"/>
   <result pre="recruited to treat with a 2-hour eTNS session a single" exact="migraine" post="attack of moderate or severe intensity (grades 2 or"/>
   <result pre="a modified ITT analysis (mITT) if they treated a qualifying" exact="migraine" post="attack and filled in a headache diary at baseline"/>
   <result pre="effective, well tolerated and safe for the abortive treatment of" exact="migraine" post="attacks. Efficacy data are similar to those usually reported"/>
   <result pre="G, Winegarner D, Rowe V, Kuruvilla D. Acute treatment of" exact="migraine" post="with e-TNS: a multi-center, double-blind, randomized, sham-controlled trial. Cephalalgia."/>
   <result pre="the Cefaly® for the treatment of an attack in 45" exact="migraine" post="patients. Results are shown in % (numbers) Primary outcomes"/>
   <result pre="pain. Some pain states without headache have been associated with" exact="migraine" post="like abdominal migraine and recurrent limb pain. Migrainous corpalgia"/>
   <result pre="states without headache have been associated with migraine like abdominal" exact="migraine" post="and recurrent limb pain. Migrainous corpalgia is a migraine-related"/>
   <result pre="point is the response of the patient to the given" exact="migraine" post="prophylaxis agent; flunarizine. As a result, paroxysmal body pain"/>
   <result pre="As a result, paroxysmal body pain which is treated by" exact="migraine" post="prophylactic agent will open new horizons in pain physiopathology."/>
   <result pre="Patients with Migraine Aura (MA) display an increased risk for" exact="stroke" post="at least in part explained by paradoxical embolism via"/>
   <result pre="increased risk for stroke at least in part explained by" exact="paradoxical embolism" post="via Patent Foramen Ovale (PFO). Other pathogenetic mechanisms have"/>
   <result pre="(PFO). Other pathogenetic mechanisms have been also involved to explain" exact="stroke" post="occurrence in MA patients: increased prevalence of thrombophilia, cerebral"/>
   <result pre="predisposition to cervical artery dissection. We aimed at exploring if" exact="stroke" post="patients with MA presented peculiar clinical profiles. METHODS We"/>
   <result pre="territory were also defined. RESULTS All patients (mean age at" exact="stroke" post="onset was 46.6 ys (SD 8.2), 63.5% were male)"/>
   <result pre="ys (SD 8.2), 63.5% were male) had suffered for minor" exact="stroke" post="(NIHSS&amp;lt;2). In 54% of cases, stroke etiology corresponded &quot;other"/>
   <result pre="had suffered for minor stroke (NIHSS&amp;lt;2). In 54% of cases," exact="stroke" post="etiology corresponded &quot;other causes&quot;. In 59.5 % of cases,"/>
   <result pre="stroke etiology corresponded &quot;other causes&quot;. In 59.5 % of cases," exact="stroke" post="involved Middle Cerebral Artery territory. Prevalence of MA comorbidity"/>
   <result pre="and severe right-left shunts (Chi-square p=0.016) compared with the other" exact="stroke" post="patients. No difference in stroke vascular territory and etiology,"/>
   <result pre="p=0.016) compared with the other stroke patients. No difference in" exact="stroke" post="vascular territory and etiology, the prevalence of vascular risk"/>
   <result pre="PFO represents a relevant pathogenetic mechanism subtending the increase in" exact="stroke" post="risk observed especially in female MA patients. In our"/>
   <result pre="(pirimia@unav.es) BACKGROUND Cutaneous allodynia is a common feature that accompanies" exact="migraine" post="attacks and is considered a clinical marker of central"/>
   <result pre="central sensitization. Allodynia is one of the factors associated to" exact="migraine" post="chronification, and is also associated with the presence of"/>
   <result pre="anthropometric characteristics that are associated with allodynia in patients with" exact="migraine" post="and determine if the increase in body fat correlates"/>
   <result pre="cutaneous allodynia. METHODS Prospective descriptive study of patients with chronic" exact="migraine" post="(CM) and episodic migraine (EM) diagnosed in outpatient clinic."/>
   <result pre="descriptive study of patients with chronic migraine (CM) and episodic" exact="migraine" post="(EM) diagnosed in outpatient clinic. Cutaneous allodynia was studied"/>
   <result pre="the relation of allodynia with the frequency and severity of" exact="migraine" post="attacks, the presence of migrainous features (such as photophobia,"/>
   <result pre="been obtained from patients. RESULTS We included 80 patients with" exact="migraine" post="with chronic and EM according to International Classification of"/>
   <result pre="41 vs 36 (p=0,03), sedentary lifestyle 76,2% vs 23,8% (p=0,027)," exact="migraine" post="frequency 8,71 vs 4,78 days (p=0,03) and migraine severity"/>
   <result pre="23,8% (p=0,027), migraine frequency 8,71 vs 4,78 days (p=0,03) and" exact="migraine" post="severity 7,14 vs 5,93 (p=0,05), but not with the"/>
   <result pre="subcutaneous abdominal and body fat. Age, frequency and severity of" exact="migraine" post="attacks are also associated with allodynia. P162 CLINICAL PROFILE"/>
   <result pre="Roma Correspondence: Claudia Altamura (c.altamura@unicampus.it) BACKGROUND The physio-pathological relationship between" exact="patent foramen ovale" post="(PFO) and Migraine with Aura (MA) is the matter"/>
   <result pre="long-standing debate. Nevertheless, MA patients display an increased risk for" exact="stroke" post="at least in part explained by paradoxical embolism. The"/>
   <result pre="increased risk for stroke at least in part explained by" exact="paradoxical embolism." post="The aim of our study was to explore if"/>
   <result pre="detection of inter-atrial septal aneurysm (ISA), and the results for" exact="thrombophilia" post="screening. PFO test results were stratified for severity. The"/>
   <result pre="type. Age onset was not influenced by the presence of" exact="thrombophilia" post="or other vascular factor at onset, not even in"/>
   <result pre="predisposed subjects. This effect seems not to be mediated by" exact="thrombophilia" post="as in patients with PFO the presence of thrombophilia"/>
   <result pre="by thrombophilia as in patients with PFO the presence of" exact="thrombophilia" post="was not associated to a younger MA onset. On"/>
   <result pre="low carbohydrate diet (LCD) is widely used for seizure and" exact="epilepsy" post="treatment. Due to the suggested underlying relationship between migraine"/>
   <result pre="and epilepsy treatment. Due to the suggested underlying relationship between" exact="migraine" post="and epilepsy, LCD might have some effects on migraine"/>
   <result pre="between migraine and epilepsy, LCD might have some effects on" exact="migraine" post="headache too. But to date, there are a few"/>
   <result pre="energy intake revealed a marginally significant 35% reduced odds of" exact="migraine" post="for the subjects in the second quintile relative to"/>
   <result pre="lowest quintile of total LCD score whereas the odds of" exact="migraine" post="for those in the 4 th and 5 th"/>
   <result pre="models resulted in roughly 2-7 fold higher odds of developing" exact="migraine" post="for subjects in the fourth and fifth quintile of"/>
   <result pre="higher scores of plant based LCD had lower risk for" exact="migraine" post="[(OR=0.44,95%CI=0.30-0.65 for the 2 ndquintile);(OR=0.59,95%CI=0.40-0.86 for the 3 rdquintile);"/>
   <result pre="diet based on plant sources of fat and protein on" exact="migraine" post="headache. Conversely, it was shown that consuming a low"/>
   <result pre="fat and animal protein could highly increase the risk of" exact="migraine" post="in susceptible subjects. P164 The expanding burden of Idiopathic"/>
   <result pre="with secondary causes of raised intracranial pressure such as tumours," exact="hydrocephalus" post="and cerebral venous sinus thrombosis were excluded. Results 23,182"/>
   <result pre="causes of raised intracranial pressure such as tumours, hydrocephalus and" exact="cerebral venous sinus thrombosis" post="were excluded. Results 23,182 new IIH cases were diagnosed."/>
   <result pre="the study), highest in areas of social deprivation and mirroring" exact="obesity" post="trends. Re-admissions rates are high and growing yearly. The"/>
   <result pre="at least 1 medical claim with an ICD-9/10 code for" exact="migraine" post="in the 12-month pre-screening period. The 12-item ID-CM screener"/>
   <result pre="not administered the SSDI were excluded from this analysis. Additionally," exact="migraine" post="patients that had a medical claim with an ICD-9/10"/>
   <result pre="of the 6-item ID-CM screener included 109 patients with a" exact="migraine" post="diagnosis who completed the ID-CM screener and the SSDI."/>
   <result pre="Sanità, Roma Correspondence: Piero Barbanti (piero.barbanti@sanraffaele.it) Background A national chronic" exact="migraine" post="(CM) registry may improve disease knowledge and management, favor"/>
   <result pre="150 items detailing 1) life-style, behavioral and socio-demographic factors; 2)" exact="migraine" post="features before chronicization; 3) chronic migraine characteristics and comorbidities;"/>
   <result pre="and socio-demographic factors; 2) migraine features before chronicization; 3) chronic" exact="migraine" post="characteristics and comorbidities; 4) healthcare resource use and socio-economic"/>
   <result pre="patients and only 45.4% used a headache diary. Previous episodic" exact="migraine" post="characteristics: without aura 88.5%, with aura 6.15%, with and"/>
   <result pre="Only 11.5% of CM patients had used prophylaxis when their" exact="migraine" post="was episodic. Healthcare and resource use: age at first"/>
   <result pre="cost per patient and the impact on work t of" exact="migraine" post="in Spain. Material and Method: This is a prospective,"/>
   <result pre="relation to their migraine. A distinction was made between chronic" exact="migraine" post="(CM) and episodic migraine (EM), considering the monthly headache"/>
   <result pre="A distinction was made between chronic migraine (CM) and episodic" exact="migraine" post="(EM), considering the monthly headache days declared by patients."/>
   <result pre="monthly headache days declared by patients. The economic burden of" exact="migraine" post="was evaluated: direct health costs (including visits to specialists,"/>
   <result pre="and those assumed by the migraineur. The labor consequences of" exact="migraine" post="over the last year were analyzed. Chi-square and Mann-"/>
   <result pre="review board approved the study design. Results: 1,281 people with" exact="migraine" post="participated in the survey, 34.2% with CM, 88.2% women,"/>
   <result pre="impact is significantly greater in CM. P171 Chromig10: evolution of" exact="migraine" post="after 10 years E. Caronna 1, E. Fonseca Hernández"/>
   <result pre="To analyse the evolution of a cohort of patients with" exact="migraine" post="after 10 years, focusing on prognostic factors of improvement"/>
   <result pre="improvement and worsening. Methods Cross-sectional analysis of the cohort of" exact="migraine" post="patients from the Chromig study after 10 years. Using"/>
   <result pre="survey we collected demographic data, comorbidities, characteristics, treatment, impact of" exact="migraine" post="(HIT-6, MIDAS, BDI, SF-36) and subjective impression of evolution."/>
   <result pre="age 49.2 ± 10.5 years; 73.9% initial diagnosis of episodic" exact="migraine" post="(EM). After 10 years: patients have more arterial hypertension"/>
   <result pre="lower proportion of high- frequency EM (22.1% vs. 7.7%), chronic" exact="migraine" post="(15.9% vs. 2.6%) and chronic daily headache (6.6% 0"/>
   <result pre="follow-up for their migraine. Conclusion After 10 years, patients with" exact="migraine" post="improve, especially those who 10 years ago had a"/>
   <result pre="effect of the education on the Healthy eating Plate on" exact="migraine" post="frequency and disability. Methods We enrolled 148 consecutive Migraine"/>
   <result pre="that a healthy diet may be a real help for" exact="migraine" post="prevention. In particular, the shift from refined to whole"/>
   <result pre="mechanism explaining the beneficial effect of whole grain cereal on" exact="migraine" post="is possibly based on a more steady glycemic control."/>
   <result pre="tryptophan intake in regulating serotonin hemostasis and subsequent effects on" exact="migraine" post="attacks, we designed the current study to assess the"/>
   <result pre="study to assess the relationship between dietary tryptophan intake and" exact="migraine" post="headache risk. Methods The migraine group (n=550, diagnosed according"/>
   <result pre="between dietary tryptophan intake and migraine headache risk. Methods The" exact="migraine" post="group (n=550, diagnosed according to the ICHDIII criteria) were"/>
   <result pre="models were applied in order to explore the relationship between" exact="migraine" post="and dietary tryptophan intake. Results The mean(SD) of the"/>
   <result pre="mean(SD) of the age of participants in the controls and" exact="migraine" post="group was 43.83(14.50) and 36.21(9.85) years, respectively. Also, the"/>
   <result pre="the models showed significant inverse association between tryptophan intake and" exact="migraine" post="risk [(OR in the 3 rd quartile=0.31;95%CI= 0.13- 0.72)"/>
   <result pre="is the first relatively large population based investigation of the" exact="migraine" post="headache risk according to dietary tryptophan intake. Our results"/>
   <result pre="of tryptophan per day had a reduced odds of developing" exact="migraine" post="by approximately 69-81%, relative to those consumed ≤0.57 g/d."/>
   <result pre="a healthy diet could lead to attenuating the odds of" exact="migraine" post="among susceptible subjects. P174 Serum Vitamin B12 and Methyl-malonic"/>
   <result pre="two factors which are proposed to be probably implicated in" exact="migraine" post="pathogenesis. Thus, in the current study we aimed at"/>
   <result pre="specific biomarker, methyl-malonic acid (MMA) status in a group of" exact="migraine" post="patients compared to healthy controls. Methods Seventy migraine patients"/>
   <result pre="group of migraine patients compared to healthy controls. Methods Seventy" exact="migraine" post="patients (34 chronic and 36 episodic migraineurs) and 70"/>
   <result pre="levels of B12 were found to be significantly lower in" exact="migraine" post="patients than in control subjects(584.08± 300.20 vs. 750± 350.91pg/ml;P=0.007);"/>
   <result pre="(1995), 577-586. 3. SILBERSTEIN S.D., Practice parameter: Evidence-based guidelines for" exact="migraine" post="headache (an evidence-based review): Report of the Quality Standards"/>
   <result pre="P175). ESA SISC Poster Presentation P176 Efficacy in high frequency" exact="migraine" post="with aura prevention of a combination of Tanacethum Parthenium,"/>
   <result pre="target among the main mechanisms involved in the pathophysiology of" exact="migraine" post="and of the aura itself : sensitization of trigeminal"/>
   <result pre="test the effectiveness of Aurastop © in the prophylaxis of" exact="migraine" post="with aura with high frequency Materials and methods: 18"/>
   <result pre="age: 28 ) presenting with an ICHD-3 beta diagnosis of" exact="migraine" post="with aura (MWA ) with a frequency of more"/>
   <result pre=") with a frequency of more than 5 attacks of" exact="migraine" post="with aura per month since at least 6 months,"/>
   <result pre="Martelletti P. Altered kynurenine pathway metabolites in serum of chronic" exact="migraine" post="patients. J Headache Pain. 2015; 17: 47. 2. Geppetti"/>
   <result pre="safety of 6,25 mg t.i.d feverfew CO2-extract ( MIG-99) in" exact="migraine" post="prevention – a randomized , double blind, multicenter, placebo"/>
   <result pre="for assessment of salvageable tissue and infarct core in acute" exact="stroke" post="imaging [1,2]. Perfusion patterns found during migraine with aura"/>
   <result pre="core in acute stroke imaging [1,2]. Perfusion patterns found during" exact="migraine" post="with aura are controversial, in fact normal, hypo- and"/>
   <result pre="Methods: Patients who presented a focal neurological deficit compatible with" exact="migraine" post="with aura were enrolled. All the patients performed PTC"/>
   <result pre="All patients were migraineurs, two of them already suffered with" exact="migraine" post="with aura. Characteristics of migrainous aura are shown in"/>
   <result pre="J, Scott TF. Reversible CT perfusion abnormalities in patient with" exact="migraine" post="variant: a two phase process. Clin Neurol Neurosurg. 2013;115(6):830-832"/>
   <result pre="six patients with migrainous aura Patients Age Gender History of" exact="migraine" post="Symptoms Headache at the onset of symptoms NIHSS Time"/>
   <result pre="100) P178 Cerebello-thalamo-cortical inhibitory activity impairment in patients with chronic" exact="migraine" post="Gianluca Coppola 1, Clarissa Elizabeth Centurioni 1, Chiara Abagnale"/>
   <result pre="4IRCCS-Neuromed, Pozzilli (IS), Italy Correspondence: Gianluca Coppola (gianluca.coppola@gmail.com) Background Chronic" exact="migraine" post="(CM) patients with or without medication overuse often present"/>
   <result pre="of neurophysiological parameters with CM clinical features. Results In HVs," exact="suppression" post="occurs at an ISI of 5 ms (-19.4%) and"/>
   <result pre="ms (+3.0%, p=0.022). In CM patients, the percentage of MEP" exact="suppression" post="at 5 ms ISI negatively correlated with number of"/>
   <result pre="as add-on therapy in the detoxification of patients with chronic" exact="migraine" post="and medication overuse headache: clinical and EEG findings Roberto"/>
   <result pre="in the management of different painful conditions such as fibromyalgia," exact="trigeminal neuralgia," post="and migraine. Chronic migraine with medication overuse (CM+MO) represents"/>
   <result pre="painful conditions such as fibromyalgia, trigeminal neuralgia, and migraine. Chronic" exact="migraine" post="with medication overuse (CM+MO) represents a challenging condition where"/>
   <result pre="biomicroscopy detects secondary hemicrania continua attributed to hidden narrow angle" exact="glaucoma" post="A. Granato, A. Dinoto, C. Bertolotti, D. Stokelj, L."/>
   <result pre="HC, no case of secondary HC attributed to narrow angle" exact="glaucoma" post="has been described yet. Case report A 39-years old"/>
   <result pre="A 39-years old Caucasian woman with history of low frequency" exact="migraine" post="without aura accessed to the Emergency Department (ED) for"/>
   <result pre="headache, with 6-7 daily exacerbations, which were associated with omolateral" exact="ptosis" post="and lacrimation. Head CT scan was normal. Neurological examination"/>
   <result pre="Head CT scan was normal. Neurological examination evidenced right eyelid" exact="ptosis" post="and conjunctival injection during pain exacerbations (Fig. 1). Because"/>
   <result pre="a fourth-month follow-up visit she complained only her usual episodic" exact="migraine" post="she already suffered. Conclusions Ultrasound biomicroscopy may be a"/>
   <result pre="a useful and safe tool to detect hidden narrow angle" exact="glaucoma" post="as a possible cause of secondary hemicrania continua, when"/>
   <result pre="images for research purposes. Fig. 1 (abstract P180). Right eyelid" exact="ptosis" post="and conjunctival injection during pain exacerbations (a); normal eyes"/>
   <result pre="calcitonin gene-related peptide (CGRP) receptor and is under investigation for" exact="migraine" post="prevention. Design/Methods Data were obtained from four randomized, placebo-controlled"/>
   <result pre="and injection site reaction, injection site induration, and injection site" exact="urticaria" post="(n=1 each, &amp;lt;0.1%). There were no ISR-AEs of Grade"/>
   <result pre="image analysis to identify the possible hyperechogenicity of PAG in" exact="migraine" post="patients, as marker of metals deposition (2). PAG is"/>
   <result pre="that an alteration of PAG iron homeostasis is present in" exact="migraine" post="patient and this evidence correlates with the duration of"/>
   <result pre="examined a 64-year-old female patient with a long history of" exact="migraine" post="without aura and MOH from 15 years. She first"/>
   <result pre="Tapper et Al., Iron deposition in pain-regulatory nuclei in episodic" exact="migraine" post="and chronic daily headache by MRI. Headache. 2012 Feb;52(2):236-43"/>
   <result pre="3. Guaschino E. Hyperechogenicity of the periaqueductal gray in chronic" exact="migraine" post="and episodic migraine as a potential marker of progressive"/>
   <result pre="Hyperechogenicity of the periaqueductal gray in chronic migraine and episodic" exact="migraine" post="as a potential marker of progressive dysfunction: preliminary results"/>
   <result pre="Farma Italy Objective Report erenumab efficacy in patients with chronic" exact="migraine" post="(CM) with and without aura. Material Subgroups with CM"/>
   <result pre="(70mg or 140mg QM) for 12 weeks, and with ≥1" exact="migraine" post="with or without aura during baseline (duration: 4 weeks)"/>
   <result pre="(duration: 4 weeks) were used to assess changes in monthly" exact="migraine" post="days (MMD), acute migraine–specific medication days (MSMD), and ≥50%"/>
   <result pre="Authorities. Results Of 667 patients randomized, 49% (n=328) had ≥1" exact="migraine" post="with aura. Mean (SD) respective baseline MMD in patients"/>
   <result pre="data indicate that erenumab has similar efficacy in patients with" exact="migraine" post="with and without aura in terms of MMD, MSMD,"/>
   <result pre="April, 2018). P185 Efficacy and safety of erenumab in episodic" exact="migraine" post="patients with 2–4 prior preventive treatment failures: Results from"/>
   <result pre="the efficacy and safety of erenumab in patients with episodic" exact="migraine" post="who have failed 2–4 prior preventive migraine treatments (PMTs)."/>
   <result pre="patients with episodic migraine who have failed 2–4 prior preventive" exact="migraine" post="treatments (PMTs). Material and Methods: LIBERTY (NCT03096834) was a"/>
   <result pre="the proportion of patients achieving ≥50% reduction in mean monthly" exact="migraine" post="days (MMDs) during Weeks 9-12 (Month 3). Secondary endpoints"/>
   <result pre="patients who have failed multiple therapies. LIBERTY is the first" exact="migraine" post="prevention trial of its kind conducted specifically in patients"/>
   <result pre="patients on erenumab achieving at least a 50% reduction of" exact="migraine" post="days versus placebo, and all secondary endpoints. Conclusion: These"/>
   <result pre="of a difficult to treat population with 2–4 prior preventive" exact="migraine" post="treatment failures. Acknowledgements This study was supported by Novartis"/>
   <result pre="activity. In his past medical history, he reported Chronic lymphocytic" exact="leukemia" post="in hematological follow-up. A recent brain MRI scan was"/>
   <result pre="and CBD 8%, 10 drops orally bid, with reduction in" exact="migraine" post="frequency: 0-1 days/month in the last 4 months, as"/>
   <result pre="posology and prescription 3, since low doses of cannabinoids lower" exact="migraine" post="pain, while higher doses exacerbate it. Moreover, an important"/>
   <result pre="research to establish effectiveness and safety of these compounds in" exact="migraine" post="treatment, to uncover potential therapeutic effects still unknown. Consent"/>
   <result pre="2013; 154(Suppl 1):87–93. P187 Abnormal intracortical facilitation pattern in episodic" exact="migraine" post="without aura: results of a paired-pulse TMS study S."/>
   <result pre="intensities of the test stimulus (TS) in patients suffering from" exact="migraine" post="without aura (MwoA). Methods: We enrolled 24 patients suffering"/>
   <result pre="Palermo A, Puma A, Brighina F. Impaired glutamatergic neurotransmission in" exact="migraine" post="with aura? Evidence by an input-output curves transcranial magnetic"/>
   <result pre="about acute neurological symptoms. Distinguishing it from an acute ischemic" exact="stroke" post="is not always possible in the setting of the"/>
   <result pre="role. A recent revision of scientific literature about the so-called" exact="stroke" post="mimics reaffirmed the safety of rt-PA administration in patients"/>
   <result pre="infarcts and leukoencephalopathy (CADASIL) [2]. Discussion MA may mimic a" exact="stroke" post="causing an improper thrombolytic treatment. Scientific literature advocates the"/>
   <result pre="1. Terrin A, Toldo G, Ermani M et al. When" exact="migraine" post="mimics stroke: A systematic review. Cephalalgia. 2018 Jan 1:333102418767999."/>
   <result pre="visible, as well. P189 Central and peripheral FAAH inhibition and" exact="migraine" post="pain: potential mechanisms and targets in an animal model"/>
   <result pre="and the locus coeruleus in a well-known animal model of" exact="migraine" post="based on nitroglycerin (NTG) administration. Methods - Here, we"/>
   <result pre="test. We also evaluated mRNA levels of candidate mediators of" exact="migraine" post="pain in areas involved in trigeminal nociception and c-Fos"/>
   <result pre="nociception and c-Fos protein expression in brain nuclei involved in" exact="migraine" post="pain. Finally, we also tested the effects of ARN14633"/>
   <result pre="target for modulating the pathways that are likely involved in" exact="migraine" post="pain. Ethics approval The study was approved by the"/>
   <result pre="200 mg/day/orally=13mg THC+15mg CBD. Volunteers: Migraine sufferers (n=311) showing 15/18" exact="migraine" post="days/monthly. Exclusion criteria: Systemic, organic, psychiatric diseases, addiction to"/>
   <result pre="and Adverse Events: THC/CBD vs. Amitriptyline (Group 1) Decrease of" exact="migraine" post="day versus run-in: THC-CBD -47.05±6.8SD migraine hours/month vs. Amitriptyline="/>
   <result pre="(Group 1) Decrease of migraine day versus run-in: THC-CBD -47.05±6.8SD" exact="migraine" post="hours/month vs. Amitriptyline= -17.6± 10.9SD p&amp;gt;00001 Table of Side"/>
   <result pre="compared to amitriptyline. Cannabinoids might be of interest in chronic" exact="migraine" post="therapy References 1.Nicolodi M, Sandoval V. Therapeutic use of"/>
   <result pre="of cannabinoids -Dose finding, pilot data of effects in chronic" exact="migraine" post="and cluster headache. Proceedings EAN Congress, Amsterdam 24-27 June"/>
   <result pre="Granato (antonio_granato@hotmail.com) Introduction Efficacy of physical therapy (PT) in chronic" exact="migraine" post="(CM) is controversial, on the contrary Onabotulinumtoxin A (BoNT-A)"/>
   <result pre="Visual cortical hyperactivity to sound induced flash illusions in pediatric" exact="migraine" post="Salvatore Di Marco 1, Alice Pavone 1,Giuseppe Cosentino 1,"/>
   <result pre="[3]. Aim: To test the V1 excitability in children with" exact="migraine" post="through SIFI. Participants: Twenty-six migraineours children (examinated interictally) and"/>
   <result pre="(examinated interictally) and fifteen healthy children with no familiarity for" exact="migraine" post="were evaluated. Methods: Different combinations of visual (flash) and"/>
   <result pre="indicate the number of the flashes seen. Results: Children with" exact="migraine" post="do not differ from age matched control in the"/>
   <result pre="children have an increased ability to perceive flashes, even outside" exact="migraine" post="attack, that reveal a hyper-functional visual cortex in migraine"/>
   <result pre="outside migraine attack, that reveal a hyper-functional visual cortex in" exact="migraine" post="also in pediatric age. SIFI can be used in"/>
   <result pre="also in pediatric age. SIFI can be used in pediatric" exact="migraine" post="for testing the responsivity of V1. References 1. Bolognini"/>
   <result pre="Paladino P, Baschi R, Fierro B. Visual cortex hyperexcitability in" exact="migraine" post="in response to sound-induced flash illusions.Neurology 2015 84: 2057-2051."/>
   <result pre="presented with chronic migraine, with 9% fulfilling a diagnosis of" exact="migraine" post="with aura. As for the clinical features of migraine,"/>
   <result pre="C677T has been associated with an increased genetic risk in" exact="migraine" post="susceptibility, particularly for migraine with aura. Individuals with the"/>
   <result pre="with an increased genetic risk in migraine susceptibility, particularly for" exact="migraine" post="with aura. Individuals with the homozygous state for this"/>
   <result pre="MTHFR homozygous mutation were selected and underwent clinical evaluation of" exact="migraine" post="characteristics (frequency, severity of pain and use of acute"/>
   <result pre="reduction in Hcy levels (p=0.0001) and a significant improvement of" exact="migraine" post="disability in terms of frequency (p&amp;lt;0.0001), severity of pain"/>
   <result pre="efficacy of vitamin supplement in lowering Hcy plasma levels and" exact="migraine" post="disability in this condition not infrequent. References 1. Menon"/>
   <result pre="1 mg folic acid supplementation on clinical outcomes in female" exact="migraine" post="with aura patients. 2016; J Headache Pain.17(1):60. P195 The"/>
   <result pre="concerns the evaluation of the following parameters: headache diagnosis (ICHD-III,2013)," exact="migraine" post="index: \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek}"/>
   <result pre="Headache Rep.4;22(5):37 P196 Changes on cervical range of motion in" exact="migraine" post="patients after a strain counterstrain treatment Valerio Giustino 1,2,"/>
   <result pre="Italy Correspondence: Valerio Giustino (valeriogiustino@msn.com) Background Migraine is a chronic" exact="neurological disorder" post="that negatively influence the quality of life. This disabling"/>
   <result pre="provides passive positioning to relieve tender points palpation pain, in" exact="migraine" post="patients. Materials and Method A repeated measures within-subjects design"/>
   <result pre="the study on a number of 25 participants affected by" exact="migraine" post="(age: 43,24±15,61 yrs; height: 165,28±8,92 cm; weight: 70,2±18,99 kg)"/>
   <result pre="the other parameters ( p&amp;gt;0.05). Conclusions It is known that" exact="migraine" post="is associated with muscle pain in the neck region"/>
   <result pre="for the significant improvement on cervical rotation in patients with" exact="migraine" post="may be explained because the SCS treatment technique decreased"/>
   <result pre="Kries R, Heinen F. Self-reported muscle pain in adolescents with" exact="migraine" post="and tension-type headache. Cephalalgia. 2012;32(3):241-9. 2. Fernández-de-Las-Peñas C, Cuadrado"/>
   <result pre="and 28 [M/F= 9/19; mean age= 45.11±12.18 years] for episodic" exact="migraine" post="(EM)according to ICHD-3 [2]. Twenty-nine healthy controls (HC) [M/F="/>
   <result pre="making and predisposes these subjects to a relapse of chronic" exact="substance abuse." post="Further studies would be helpful to shed light on"/>
   <result pre="direct measure of aortic stiffness and an independent predictor of" exact="stroke" post="and CV disease, in young and middle-aged migraineurs(3) Here"/>
   <result pre="children. Materials and Methods: : We studied 10 children with" exact="migraine" post="without aura (age 12,9±1,9 years, 7 male and 3"/>
   <result pre="were measured using an oscillometric technique . Results: Children with" exact="migraine" post="without aura had a higher a PWV (5.65 ±"/>
   <result pre="The present study showed higher aPWV in children affected by" exact="migraine" post="without aura with respect to healthy controls. This result"/>
   <result pre="alteration, it’s likely to be associated with basic mechanisms of" exact="migraine" post="and could represent a new way to shed light"/>
   <result pre="Sep 14;75(11):960-6. P199 Efficacy of KUZIK® in the prophylaxis of" exact="migraine" post="without aura: a case report E. Pucci 1,2, R."/>
   <result pre="3Gam Farma Srl. Milan Correspondence: E. Pucci (ennio.pucci@mondino.it) Background A" exact="migraine" post="without aura is the most common type of migraine"/>
   <result pre="A migraine without aura is the most common type of" exact="migraine" post="headache ( about 60% to 80% of all migraines)."/>
   <result pre="after the menarche. Diagnosis according to the criteria ICHD-III beta-version:" exact="migraine" post="without aura.Frequency: 4 crisis / month. VAS (Visual Analogue"/>
   <result pre="safety, and good tolerability of Kuzik in the prophylaxis of" exact="migraine" post="without aura and the use of this medication should"/>
   <result pre="2009; 49: 98-105. P200 Anxiety, depression and alexithymia in young" exact="migraine" post="patients: which relationship with body weight? Samuela Tarantino 1,"/>
   <result pre="Background A growing body of literature explored the relationship between" exact="migraine" post="and body weight. While several studies analyzed common pathophysiological"/>
   <result pre="weight. While several studies analyzed common pathophysiological mechanisms implicated in" exact="migraine" post="and feeding regulation, data on the role of psychological"/>
   <result pre="in migraineurs children/adolescents; 2) the possible relationship between frequency of" exact="migraine" post="and overweight; 3) the role of psychological symptoms (anxiety/depression)"/>
   <result pre="emotional processing /regulating (alexithymia) on Body mass Index (BMI) in" exact="migraine" post="patients. Methods Patients were identified though a systematic review"/>
   <result pre="overweight. The weight (normal or overweight) did not correlate with" exact="migraine" post="frequency in none of the groups (respectively: Group-1: χ(2)"/>
   <result pre="case series the Authors did not find any association between" exact="migraine" post="and vitamin D status neither between severity of headaches"/>
   <result pre="patients were women, 6 were male; fourteen were diagnosed with" exact="migraine" post="without aura, 3 had tension-type headache, 1 had cluster"/>
   <result pre="headache, 1 had cluster headache, 3 fulfilled criteria both for" exact="migraine" post="without aura and tension-type headache; mean age was 38.6±17.5"/>
   <result pre="10 ng/ml. All these last three patients were diagnosed with" exact="migraine" post="without aura. Conclusion: Vitamin D insufficiency is a frequent"/>
   <result pre="Ebrahimi H, Haghdoost F, Saadatnia M. Vitamin D status in" exact="migraine" post="patients: a case-control study. Biomed Res Int. 2014;2014:514782. 4."/>
   <result pre="Müller-Hartmannsgruber V, Kokinogenis G, Egloff N. Vitamin D and central" exact="hypersensitivity" post="in patients with chronic pain. Pain Med. 2014 Sep;15(9):1609-18."/>
   <result pre="in emergency department, except for some specific signs, such as" exact="papilledema" post="or motor paralysis [1]. There are not studies specifically"/>
   <result pre="local (e.g.infectious, neoplastic or traumatic rhinopaty) and central, such us" exact="trigeminal neuralgia," post="nasociliary neuralgia, nasal migraine and idiopathic rhinalgia. In literature"/>
   <result pre="rhinopaty) and central, such us trigeminal neuralgia, nasociliary neuralgia, nasal" exact="migraine" post="and idiopathic rhinalgia. In literature have been described few"/>
   <result pre="is a 34 year-old woman with a history of episodic" exact="migraine" post="without aura who was injured striking her face against"/>
   <result pre="school-age children to 20 % in adolescents [1,2]. Traditionally, pediatric" exact="migraine" post="treatment includes both prophylactic therapy, aimed at reducing the"/>
   <result pre="lack of controlled studies on the pharmacological treatment of pediatric" exact="migraine" post="still remains. Consequently, there is an urgent need for"/>
   <result pre="and other supplements, may be an alternative option in treating" exact="migraine" post="and may be offered to parents who are reluctant"/>
   <result pre="to evaluate the role of PEA in the management of" exact="migraine" post="without aura in pediatric patients. OBJECTIVE: The aim of"/>
   <result pre="administration in terms of reducing the frequency and severity of" exact="migraine" post="attacks in pediatric patients. METHODS: The study sample includes"/>
   <result pre="of age (mean 9.4 years). They had a diagnosis of" exact="migraine" post="according to the ICHD-3 criteria and received umPEA (600"/>
   <result pre="(NCT) neurons. Among the various causes, particularly important is sleep" exact="bruxism" post="which, by activating theTrigeminal mesencephalic nucleus, activates ARAS nuclei"/>
   <result pre="which causes the classic pulsating pain of TTHs. In the" exact="migraine" post="with aura (MA), because of the aforementioned CH, at"/>
   <result pre="the pain. . Migraine without Aura (MO) are essentially menstrual" exact="migraine" post="and even in this case they do not differ"/>
   <result pre="(67 F) consecutive outpatients affected by episodic (EM) or chronic" exact="migraine" post="(CM) [2], admitted for the first visit at the"/>
   <result pre="conclusions The study provides important informations about the relationship between" exact="migraine" post="and more specific depression factors, like hopelessness, particularly in"/>
   <result pre="quality of life in a group of Brazilian women with" exact="migraine" post="without aura , J Headache Pain, 14:18. 2. Headache"/>
   <result pre="33(9):629–808. P211 Selected cannabinoids and cutaneous allodynia in chronic refractory" exact="migraine" post="Maria Nicolodi 1, Maria Stella Pinnarò 1 2, Vanessa"/>
   <result pre="400 mg /day/oral 6%THC-7.5%CBD has been administered to 68 chronic" exact="migraine" post="sufferers (33 males, 35 female, mean age 38.2±11.9SD), refractory"/>
   <result pre="Control Group: 55 age-sex matched volunteers showing overlapping number of" exact="migraine" post="hours/monthly, defined refractory to conventional therapies in other centres."/>
   <result pre="mg/day/orally in a 15 days treatment. No patient used acute" exact="migraine" post="treatments during the 3 days before allodynia evaluation and"/>
   <result pre="cannabinoids - Dose finding, pilot data of effects in chronic" exact="migraine" post="and cluster headache. Proceedings EAN Congress, 24-27 June 2017."/>
   <result pre="Reed ML, Serrano D, Stewart WF. Cutaneous allodynia in the" exact="migraine" post="population. Ann Neurol. 2008 Feb;63(2):148-58. P212 Follow-up study of"/>
   <result pre="very rare, both in relation to the temporal course of" exact="migraine" post="in school-age children and adolescents and to its clinical"/>
   <result pre="study confirms more prevalence of allodynia in follow-up of prescholar" exact="migraine" post="headaches [4] suggesting that the presence of allodynia during"/>
   <result pre="F, Santangelo G, Buffa ,D, Vanadia F, D'Amelio M. Juvenile" exact="migraine" post="and allodynia: results of a retrospective study. Headache. 2015"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6890234/results/search/disease/results.xml">
   <result pre="with image-forming vision and their implications in the development of" exact="migraine" post="symptoms. Methods We psychophysically assessed the functionality of the"/>
   <result pre="different hierarchical loci across three clinical groups: individuals who experience" exact="migraine" post="with aura (MA; n=13), experience migraine without aura (MWO;"/>
   <result pre="groups: individuals who experience migraine with aura (MA; n=13), experience" exact="migraine" post="without aura (MWO; n=14), and Controls (n=15). Participants completed"/>
   <result pre="to be factored in when considering the dysregulating influences of" exact="migraine" post="along the visual pathway. Keywords migraine S-cones koniocellular parvocellular"/>
   <result pre="the dysregulating influences of migraine along the visual pathway. Keywords" exact="migraine" post="S-cones koniocellular parvocellular magnocellular spatiochromatic Funding This work was"/>
   <result pre="to be factored in when considering the dysregulating influences of" exact="migraine" post="along the visual pathway. Introduction Although there is a"/>
   <result pre="visual pathway. Introduction Although there is a strong consensus that" exact="migraine" post="begins with cortical hyperexcitability followed by spreading waves of"/>
   <result pre="pathway operations in an attempt to identify the pathogenesis of" exact="migraine" post="through its characteristic visual symptoms such as triggers, visual"/>
   <result pre="L- and M-cones. 36– 39 Temporally modulated perimetry has revealed" exact="migraine" post="deficiencies aligned with MC operations 21, 27, 40, 41"/>
   <result pre="and controls using SWAP, and found that 50% of their" exact="migraine" post="patients had interictal sensitivity loss. Interestingly, these deficits were"/>
   <result pre="these higher level operations, particularly within the same individual. Selective" exact="migraine" post="deficits have not only been noted in S-cone functionality"/>
   <result pre="may be task-specific and thus not easily generalizable to all" exact="migraine" post="visual deficits. To our knowledge, only Shepherd 15 made"/>
   <result pre="our knowledge, only Shepherd 15 made specific attempts to assess" exact="migraine" post="performance deficits by running a series of experiments that"/>
   <result pre="KC stream. The logic goes that if the pathophysiology of" exact="migraine" post="is similar to that of glaucoma, then the vulnerable"/>
   <result pre="due to cortical redundancies and gain compensations. Alternatively, if indeed" exact="migraine" post="is strongly tied to an impairment of GABAergic inhibitory"/>
   <result pre="Ethics Board. Fifteen participants (10 female) with no history of" exact="migraine" post="or frequent headaches served as Controls. Remaining participants were"/>
   <result pre="t-tests revealed no significant differences in average lifetime duration of" exact="migraine" post="headaches (MA: 10.5 ± 7.58 years; MWO: 9.6 ±"/>
   <result pre="were taking any anti-migraine medication nor did they experience a" exact="migraine" post="attack within a 48 hr period prior to testing."/>
   <result pre="( C) Illustrates the grand mean and SEM for the" exact="migraine" post="with aura group. ( D) Illustrates the grand mean"/>
   <result pre="( D) Illustrates the grand mean and SEM for the" exact="migraine" post="without aura group. Experiment 2: Periodic Chromatic Contrast To"/>
   <result pre="34, 42, 73 Cortical blood flow is certainly diminished during" exact="migraine" post="attacks, 74 and vascular dysregulation has been shown to"/>
   <result pre="to extend to peripheral locations such as the fingers of" exact="migraine" post="patients. 75 Therefore, it is possible that ischemic, hypoxic,"/>
   <result pre="dysregulation. Second, the majority of studies that have identified MC" exact="migraine" post="effects used temporally modulated perimetry that measures visual field"/>
   <result pre="postreceptoral spatial or temporal contrast processing. Third, our sample of" exact="migraine" post="sufferers had a lower mean age than those of"/>
   <result pre="to be factored in when considering the dysregulating influences of" exact="migraine" post="on the visual pathway and its resultant perceptions–illusory or"/>
   <result pre="that have identified a pre-striatal retinal locus of dysfunction in" exact="migraine" post="S-cone functionality. 29, 40, 42 However, whereas other studies"/>
   <result pre="mind. The participants were young adults with lifetime duration of" exact="migraine" post="headaches of about 10 years. Whether the same results"/>
   <result pre="obtained with an older sample with a longer history of" exact="migraine" post="remains to be seen. Also, although we found no"/>
   <result pre="physiological or brain imaging techniques to further our understanding of" exact="migraine" post="and its associated spatiotemporal neural events. Finally, there is"/>
   <result pre="and psychometric analysis across pre(post)-ictal, ictal and interictal periods of" exact="migraine" post="to further assess the progression of cortical spreading depression"/>
   <result pre="help identify whether deficits exist prior to the onset of" exact="migraine" post="headaches, or whether they are the result of migraines"/>
   <result pre="K , Borhani P , et al. Recent progress in" exact="migraine" post="pathophysiology: role of cortical spreading depression and magnetic resonance"/>
   <result pre="3. Egilius LH , Spierings MD . Pathogenesis of the" exact="migraine" post="attack. Clin J Pain . 2003; 19( 4): 255–"/>
   <result pre="Pearson AJ, Mulleners WM. Objective assessment of cortical excitability in" exact="migraine" post="with and without aura. Cephalalgia . 2006; 26: 801–"/>
   <result pre="S , Accornero N . Impairment in color perception in" exact="migraine" post="with and without aura. Headache . 2007; 47( 6):"/>
   <result pre=", Handy TC . Top-down control of visual cortex in" exact="migraine" post="populations. Neuropsychologia . 2011; 49( 5): 1006– 1015. doi:"/>
   <result pre=", Kastrup O , et al. Visual cortex excitability in" exact="migraine" post="evaluated by single and paired magnetic stimuli. Headache ."/>
   <result pre="M , Cao Y . Visual cortical inhibitory function in" exact="migraine" post="is not generally impaired: evidence from a combined psychophysical"/>
   <result pre=", Sampson GP . Low spatial frequency contrast sensitivity in" exact="migraine" post="are not visual pathway selective. Cephalalgia . 2009; 29:"/>
   <result pre="is cortical under-inhibition: evidence from a novel functional test of" exact="migraine" post="patients . Cephalalgia . 2000; 20: 525– 532. doi:"/>
   <result pre=", Otuka K , et al. Abnormal visual processing in" exact="migraine" post="with aura: a study of steady-state visual evoked potentials"/>
   <result pre="DR , et al. Visual field losses in subjects with" exact="migraine" post="headaches. Invest Ophthalmol Vis Sci . 2000; 41( 5):"/>
   <result pre=", Lang E , et al. Visual evoked potentials in" exact="migraine" post="patients: alterations depend on pattern spatial frequency . Brain"/>
   <result pre="Hoffmann KP , et al. Persistent ocular motor disturbances in" exact="migraine" post="without aura. Neurol Sci . 2004; 25( 1): 8–"/>
   <result pre="P , Smith W . Is there an association between" exact="migraine" post="headache and open-angle glaucoma? Findings from the blue mountains"/>
   <result pre="associated with visual field deficits measured with flickering stimuli in-between" exact="migraine" post=". Cephalalgia . 2004b; 24: 389– 397. doi: 10.1111/j.1468-2982.2004.00682.x"/>
   <result pre="of spatial-contrast function and short-wavelength sensitivity deficits in patients with" exact="migraine" post=". Eye . 2007; 21: 218– 223. doi: 10.1038/sj.eye.6702251"/>
   <result pre="and retinal nerve fiber layer evaluation in suspected cases of" exact="glaucoma" post=". Arch Ophthalmol . 1998; 116( 10): 1295– 1298."/>
   <result pre="Bitrian E . Prognosis value of the topography of the" exact="glaucoma" post="perimetry defect. Invest Ophthalmol Vis Sci . 2008; 49("/>
   <result pre="MJ , Badcock DR . Contrast sensitivity changes due to" exact="glaucoma" post="and normal aging: low spatial frequency losses in both"/>
   <result pre="and topography of cerebral blood flow, aura, and headache during" exact="migraine" post="attacks. Ann Neurol . 1990; 28( 6): 791– 798."/>
   <result pre=", Dubler B , et al. Cold-induced acral vasospasm in" exact="migraine" post="as assessed by nailfold video-microscopy: prevalence and response to"/>
   <result pre="migraine as assessed by nailfold video-microscopy: prevalence and response to" exact="migraine" post="prophylaxis . Angiology . 1997; 48: 445– 449. doi:"/>
   <result pre=", Evans BJ . Visual stimuli are common triggers of" exact="migraine" post="and are associated with pattern glare. Headache . 2006;"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6899706/results/search/disease/results.xml">
   <result pre="be an integral part of this endeavor. Cannabinoids cyclic vomiting" exact="migraine" post="headaches multicenter registry psychosocial dysfunction fig-count: table-count: page-count: word-count:"/>
   <result pre="a rate that approaches that of gastroparesis, chronic constipation, and" exact="irritable bowel syndrome" post="in tertiary outpatient cohorts. 3, 4, 5, 6 However,"/>
   <result pre="phonophobia, and several autonomic symptoms similar to those observed in" exact="migraine" post="headache. As with most disorders defined by characteristic symptom"/>
   <result pre="the similarity of CVS to other periodic disorders such as" exact="migraine" post="and epilepsy offers clues about potential phenotypes that may"/>
   <result pre="of CVS to other periodic disorders such as migraine and" exact="epilepsy" post="offers clues about potential phenotypes that may lead to"/>
   <result pre="is followed by quiescent, largely asymptomatic intervals. Both CVS and" exact="migraine" post="attacks can be triggered by acute psychological or physiological"/>
   <result pre="menses. 9, 14, 15 A personal or family history of" exact="migraine" post="disorder is the most prominent CNS comorbidity in CVS,"/>
   <result pre="association. 16, 17 It is important to recognize that many" exact="migraine" post="sufferers report prominent nausea and vomiting with their headaches."/>
   <result pre="with their headaches. CVS also shares some clinical features with" exact="epilepsy" post="and even panic disorder. 14, 18 The compelling clinical"/>
   <result pre="CVS also shares some clinical features with epilepsy and even" exact="panic disorder." post="14, 18 The compelling clinical connection between migraine, panic,"/>
   <result pre="2.2 Genetic factors in CVS Cyclic vomiting syndrome, migraines, and" exact="epilepsy" post="all share links to some form of mitochondrial dysfunction."/>
   <result pre="CVS. Further, delayed gastric emptying should not be interpreted as" exact="gastroparesis" post="particularly in the setting of typical episodic vomiting and"/>
   <result pre="For example, a previously described cohort of patients with cyclic" exact="gastroparesis" post="may have simply had undiagnosed CVS. It is particularly"/>
   <result pre="identification of episode triggers, factors that have been implemented in" exact="migraine" post="prevention, may provide additional insight into CVS episode prevention."/>
   <result pre="independently associated with many physical conditions such as hypertension, arthritis," exact="thyroid disease," post="migraine, fibromyalgia, respiratory, cardiovascular, and gastrointestinal disorders, and this"/>
   <result pre="Newer therapies that target CGRP receptors have shown efficacy in" exact="migraine" post="prophylaxis in Phase IIb and III trials, and erenumab"/>
   <result pre="CVS, but may be effective in those with or without" exact="migraine" post="headaches given the strong link between CVS and migraine."/>
   <result pre="symptoms to greater degrees than placebo in 126 patients with" exact="gastroparesis" post="symptoms. 56 Furthermore, given the association of migraines with"/>
   <result pre="a decade. Prior to construction of this Consortium, research in" exact="gastroparesis" post="exhibited many features similar to those which plague current"/>
   <result pre="research in gastroparesis exhibited many features similar to those which" exact="plague" post="current CVS investigations. Since the consortium began recruitment, more"/>
   <result pre="CVS investigations. Since the consortium began recruitment, more than 1000" exact="gastroparesis" post="patients have been enrolled in longitudinal databases and three"/>
   <result pre="was released to describe FDA recommendations regarding trial design in" exact="gastroparesis" post="including definition of primary and secondary outcome measures, trial"/>
   <result pre="et al. The incidence, prevalence, and outcomes of patients with" exact="gastroparesis" post="in Olmsted County, Minnesota, from 1996 to 2006 ."/>
   <result pre=", West J , Card T . The epidemiology of" exact="irritable bowel syndrome." post="Clin Epidemiol. 2014; 6: 71‐ 80. 24523597 7 Aziz"/>
   <result pre="functional brain connectivity of the insular cortex: a cross‐comparison with" exact="migraine" post="and healthy adults . Neurogastroenterol Motil. 2017; 29: e13004."/>
   <result pre="(CVS) biologically different conditions? Relationship of adult‐onset CVS with the" exact="migraine" post="and pediatric CVS‐associated common mtDNA polymorphisms 16519T and 3010A"/>
   <result pre="al. Two common mitochondrial DNA polymorphisms are highly associated with" exact="migraine" post="headache and cyclic vomiting syndrome . Cephalalgia. 2009; 29:"/>
   <result pre="Slater S , Powers SW . Similarities and differences between" exact="migraine" post="in children and adults: presentation, disability, and response to"/>
   <result pre="disease etiology or degree of gastric retention in patients with" exact="gastroparesis" post=". Am J Gastroenterol. 2010; 105: 2357‐ 2367. 20588262"/>
   <result pre="effects on nausea and reduces other symptoms in patients with" exact="gastroparesis" post="and related disorders . Gastroenterology. 2018; 154: 65‐ 76"/>
   <result pre="and C‐peptide levels in patients with diabetes and symptoms of" exact="gastroparesis" post=". Front Endocrinol (Lausanne). 2018; 9: 32. 29487566 60"/>
   <result pre="the Homo sapiens heme oxygenase‐1 gene in diabetic and idiopathic" exact="gastroparesis" post=". PLoS ONE. 2017; 12: e0187772. 29161307 61 Harris"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6899751/results/search/disease/results.xml">
   <result pre="screening and treatment for comorbid conditions such as anxiety, depression," exact="migraine" post="headache, autonomic dysfunction, sleep disorders, and substance use with"/>
   <result pre="practice. While other disorders of nausea and vomiting such as" exact="gastroparesis" post="may be confused with CVS, these disorders lack the"/>
   <result pre="CVS. Several studies show that topiramate is effective in preventing" exact="migraine" post="headaches, but there is limited evidence on its utility"/>
   <result pre="monitoring serum electrolytes and renal function twice a year as" exact="metabolic acidosis" post="may occur. 37, 38 Oral bicarbonate supplementation may be"/>
   <result pre="if possible. 42 Caution is recommended in patients with severe" exact="liver disease." post="There is a single open‐label trial of aprepitant used"/>
   <result pre="fatigue (13%), increased appetite (13%), mild headache (6%), and severe" exact="migraine" post="in one patient (6%). Additional side effects in adults"/>
   <result pre="in one patient (6%). Additional side effects in adults include" exact="constipation" post="(up to 39%), in trials in CINV. In a"/>
   <result pre="a 4‐week, multicenter, randomized double‐masked trial of 126 adults with" exact="gastroparesis" post="(and related syndromes), although oral aprepitant (125 mg) failed"/>
   <result pre="probable contributory factor in the pathogenesis of both CVS and" exact="migraine" post="headache. 51, 52 Migraine sufferers exhibit decreased respiratory complex"/>
   <result pre="maternal inheritance. 3, 54, 55 Childhood CVS frequently progresses to" exact="migraine" post="headache. There is a high prevalence of migraine among"/>
   <result pre="progresses to migraine headache. There is a high prevalence of" exact="migraine" post="among close relatives with CVS and both often respond"/>
   <result pre="of the mitochondrial respiratory chain. Co‐Q10 has shown efficacy in" exact="migraine" post="prophylaxis. One retrospective Internet survey compared the efficacy, tolerability,"/>
   <result pre="oxidative reactions in mitochondria respiratory chain complexes. Prophylactic treatment in" exact="migraine" post="shows a significant reduction in headache frequency, good treatment"/>
   <result pre="in five clinical trials in adults with migraine. 59 Most" exact="migraine" post="studies report doses of riboflavin of 200 mg twice"/>
   <result pre="of distended dural blood vessels. The efficacy of sumatriptan in" exact="migraine" post="is due to multiple sites of action (vascular, neural,"/>
   <result pre="is also in the subgroup of periodic syndromes that include" exact="migraine" post="and its equivalents. While the mechanisms causing CVS are"/>
   <result pre="a clear‐cut clinical, familial, therapeutic, and likely pathogenic parallel with" exact="migraine" post="headaches. 63 In one non–placebo‐controlled study of 11 children"/>
   <result pre="treatment was high in those with a family history of" exact="migraine" post="compared to cases without a family history of migraine."/>
   <result pre="of migraine. 64 However, those without a family history of" exact="migraine" post="still responded to sumatriptan in 50% of their attacks."/>
   <result pre="with underlying coronary artery disease, peripheral vascular disease, hypertension, or" exact="stroke" post="due its vasoconstrictor properties. 4.2 Recommendation 7. We conditionally"/>
   <result pre="screening and treatment for comorbid conditions such as anxiety, depression," exact="migraine" post="headache, autonomic dysfunction, sleep disorders, and substance use. We"/>
   <result pre="is closely linked with CVS. 4, 5 The prevalence of" exact="migraine" post="headaches in adults with CVS varies between 13% and"/>
   <result pre="to have a first and/or second‐degree relative with migraines or" exact="migraine" post="variants. 75 It is unclear whether treating migraines independently"/>
   <result pre="and avoidance of fasting and dehydration may help reduce both" exact="migraine" post="headache and the frequency of CVS episodes. The emphasis"/>
   <result pre="screening and treatment for comorbid conditions such as anxiety, depression," exact="migraine" post="headache, sleep disorders, autonomic dysfunction, and substance use. We"/>
   <result pre="with symptom‐free intervals. However, patients may experience inter‐episodic nausea or" exact="dyspepsia" post="and may not be completely asymptomatic in between typical"/>
   <result pre="present between cycles Supportive remarks: Personal or family history of" exact="migraine" post="headaches Criteria must be fulfilled for the last 6"/>
   <result pre="behavior may also be observed. 75 Other symptoms include a" exact="migraine" post="headache, photosensitivity, and phonosensitivity. Patients are often unable to"/>
   <result pre="of emeses/hour Presence of other symptoms, particularly abdominal pain and" exact="migraine" post="headache Presence of inter‐episodic quiescent/asymptomatic intervals and any changes"/>
   <result pre="MRI) and would justify referral to a neurologist. Investigations for" exact="hypothyroidism" post="(thyroid‐stimulating hormone and/or T4/T3 serum levels), acute pancreatitis (serum"/>
   <result pre="neurologist. Investigations for hypothyroidism (thyroid‐stimulating hormone and/or T4/T3 serum levels)," exact="acute pancreatitis" post="(serum lipase), Addison disease (serum cortisol and/or an adrenocorticotropin"/>
   <result pre="Investigations for hypothyroidism (thyroid‐stimulating hormone and/or T4/T3 serum levels), acute" exact="pancreatitis" post="(serum lipase), Addison disease (serum cortisol and/or an adrenocorticotropin"/>
   <result pre="(serum lactate, pyruvate), or less common metabolic disorders such as" exact="acute intermittent porphyria" post="(urine porphyrins) may be considered, especially with supporting symptoms."/>
   <result pre="pyruvate), or less common metabolic disorders such as acute intermittent" exact="porphyria" post="(urine porphyrins) may be considered, especially with supporting symptoms."/>
   <result pre="be considered along with cognitive behavioral treatment of any underlying" exact="anxiety disorder." post="While opiates may occasionally be required for control of"/>
   <result pre="and or dyspepsia) In some patients, CVS episodes resemble a" exact="migraine" post="attack Patients may be restless, anxious, and distressed Patients"/>
   <result pre=", et al. Amitriptyline and carbamazepine utilize voltage‐gated ion channel" exact="suppression" post="to impair excitability of sensory dorsal horn neurons in"/>
   <result pre="and safety of topiramate as monotherapy in the treatment of" exact="epilepsy" post="in clinical practice . Epilepsy Behav 2009; 15: 506‐"/>
   <result pre=". Time course of adverse events in patients with localization‐related" exact="epilepsy" post="receiving topiramate added to carbamazepine . Epilepsia. 2005; 46:"/>
   <result pre="Holmes GL , Thiele E , et al. Topiramate and" exact="metabolic acidosis" post="in pediatric epilepsy. Epilepsia. 2001; 42: 387‐ 392. 11442157"/>
   <result pre="effects on nausea and reduces other symptoms in patients with" exact="gastroparesis" post="and related disorders . Gastroenterology. 2018; 154: 65‐ 76"/>
   <result pre="Delorenzo RJ . Mechanisms of levetiracetam in the control of" exact="status epilepticus" post="and epilepsy. Front Neurol. 2014; 5: 11. 24550884 50"/>
   <result pre="Li BU . Maternal inheritance in cyclic vomiting syndrome with" exact="neuromuscular disease." post="Am J Med Genet A. 2003; 120A: 474‐ 482."/>
   <result pre=", Arnold G . High‐dose riboflavin treatment is efficacious in" exact="migraine" post="prophylaxis: an open study in a tertiary care centre"/>
   <result pre="15257686 59 Thompson DF , Saluja HS . Prophylaxis of" exact="migraine" post="headaches with riboflavin: a systematic review. J Clin Pharm"/>
   <result pre="41: 693‐ 697. 11554957 61 Moran JA . Adult abdominal" exact="migraine" post="and sumatriptan: a case report. Ir Med J. 1998;"/>
   <result pre="Headache Society systematic review and recommendations on the treatment of" exact="migraine" post="pain in emergency settings . Cephalalgia. 2015; 35: 271‐"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6899798/results/search/disease/results.xml">
   <result pre="CVS diagnosis based on Rome III criteria: Personal history of" exact="migraine" post="was reported in 25% of the children and a"/>
   <result pre="in 25% of the children and a family history of" exact="migraine" post="in 72% Not specified 7 Treepongkaruna et al. (2014)"/>
   <result pre="(47%) Depression (49%) Dysautonomia (64%) 30/70 (43%) personal history of" exact="migraine" post="41/64 (64%) had a family history of migraine Mean"/>
   <result pre="history of migraine 41/64 (64%) had a family history of" exact="migraine" post="Mean duration of follow‐up was 11.2 ± 6.2 months."/>
   <result pre="with CVS by International Classification of Headache Disorders. Family history" exact="migraine" post="in a first‐degree relative in 33% (4 of 12)"/>
   <result pre="met the Rome III criteria for CVS 12 pts had" exact="migraine" post="headaches. 3 pts had a family history of migraine"/>
   <result pre="had migraine headaches. 3 pts had a family history of" exact="migraine" post="22/46 (53%) current/past marijuana use. In addition to TCAs,"/>
   <result pre="20%, symptoms were typical of migraine. 39/164 (24%): family history" exact="migraine" post="6 months to 12 years 16 Namin et al."/>
   <result pre="CVS The Hamilton Rating Scale for Anxiety: 84% had an" exact="anxiety disorder" post="Zung Depression Inventory: 78% suffered from mild‐to‐severe depression. 4/31"/>
   <result pre="structural or metabolic explanation for the symptoms. 4 patients with" exact="migraine" post="headache. 23 ± 7 months 21 Li et al."/>
   <result pre="(12.5%) Increased appetite 2/16 (12.5%) Mild headache 1/16 (6%) Severe" exact="migraine" post="1/16 (6%) Only child with migraine stopped medication. 9"/>
   <result pre="headache 1/16 (6%) Severe migraine 1/16 (6%) Only child with" exact="migraine" post="stopped medication. 9 Kumar et al. (2012) Complete response"/>
   <result pre="(46%) Non‐effective response: 2/11 (18%) Patients with a family history" exact="migraine" post="more likely to respond (defined as complete and effective"/>
   <result pre="said no relationship between MJ and symptoms). Amitriptyline: 1/27 discontinued:" exact="hypersomnia" post="and palpitations. 17 Clouse et al. (2007) Reduction of"/>
   <result pre="once switched to the other antiepileptic (including 1 patient with" exact="angioedema" post="on levetiracetam). 1/20 reported antiepileptic drugs intolerable despite switching"/>
   <result pre="0/15 Abortive IV Dextrose: 0/21 Ondansetron: 2/42 with palpitations and" exact="allergy" post="Lorazepam: 2/30 with &quot;untoward&quot; reaction* Promethazine: 0/23 Sumatriptan succinate:"/>
   <result pre="serious Serious [Link] Not serious None Only one child with" exact="migraine" post="stopped the medication (1/16) ⨁◯◯◯ VERY LOW IMPORTANT This"/>
   <result pre="increased appetite (2/16, 12.5%), mild headache (1/16, 6%), and severe" exact="migraine" post="(1/16, 6%). (C) John Wiley &amp;amp; Sons, Ltd, Potential"/>
   <result pre="the prophylaxis group, one patient discontinued therapy due to severe" exact="migraine" post="(1/16, 6%). Other side effects noted included hiccups (3/16,"/>
   <result pre="EVIDENCE‐Relief of (or improvement in) nausea within 2 hours in" exact="migraine" post="headache patients [Link] 8 Randomized trials (overview of srs)"/>
   <result pre="and vomiting. These 8 studies were conducted in individuals with" exact="migraine" post="headaches, and nausea relief was a secondary outcome. This"/>
   <result pre="Derry et al. Sumatriptan (all routes of administration) for acute" exact="migraine" post="attacks in adults‐overview of Cochrane reviews. Cochrane Database of"/>
   <result pre="study. 21 We additionally looked for indirect evidence in the" exact="migraine" post="literature to help inform outcomes, such as nausea and"/>
   <result pre="2/11 had a non‐effective response. Patients with a family history" exact="migraine" post="were more likely to respond (&quot;complete&quot; and &quot;effective&quot;). Among"/>
   <result pre="on symptom reduction (nausea and vomiting) were derived from the" exact="migraine" post="headache literature. 22 In a systematic review of patients"/>
   <result pre="headache literature. 22 In a systematic review of patients with" exact="migraine" post="headaches, but not necessarily CVS, of 8 randomized control"/>
   <result pre="8 randomized control trials, 45% to 76% of individuals with" exact="migraine" post="headaches experienced a reduction in nausea symptoms within 2"/>
   <result pre="downgraded for indirectness as the population studied was patients with" exact="migraine" post="headaches (CVS is in the subgroup of periodic syndromes"/>
   <result pre="(CVS is in the subgroup of periodic syndromes that include" exact="migraine" post="and its equivalents). With regard to the outcome of"/>
   <result pre="screen for and treat co‐morbid conditions, such as anxiety, depression," exact="migraine" post="headache, autonomic dysfunction, sleep disorders, and substance use in"/>
   <result pre="Moore RA . Sumatriptan (all routes of administration) for acute" exact="migraine" post="attacks in adults ‐ overview of Cochrane reviews ."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6902310/results/search/disease/results.xml">
   <result pre="settings 0 – Feel unstable on feet 0 – Have" exact="motion sickness" post="0 – Looking up makes feel dizzy or makes"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6904992/results/search/disease/results.xml">
   <result pre="headache attributed to mTBI, and have ≥2 headaches/wk with a" exact="migraine" post="or probable migraine phenotype. After a 2-wk run-in period,"/>
   <result pre="mTBI, and have ≥2 headaches/wk with a migraine or probable" exact="migraine" post="phenotype. After a 2-wk run-in period, subjects will be"/>
   <result pre="refractory chronic migraine. Methods: We recruited patients with refractory chronic" exact="migraine" post="and age-sex-matched headache-free controls. Using a 3T MR scanner,"/>
   <result pre="difference. Results: A total of 10 patients with refractory chronic" exact="migraine" post="and 10 age-sex-matched headache-free controls were recruited. Total susceptibility"/>
   <result pre="increased in patients with refractory chronic migraine. Pathophysiology of chronic" exact="migraine" post="may not be associated with iron metabolism or irreversible"/>
   <result pre="iron metabolism or irreversible damage to specific nuclei. A03 Typical" exact="migraine" post="aura without headache in Korean headache clinic Byung-Kun Kim"/>
   <result pre="kbk1403@eulji.ac.kr) Background: Typical aura without headache is a type of" exact="migraine" post="with typical aura, which has been rarely reported. The"/>
   <result pre="Clinic of Eulji Hospital from 2010 to 2018. We diagnosed" exact="migraine" post="with typical aura according to the diagnostic criteria of"/>
   <result pre="of 1:1.7 and a median age of 35 years) of" exact="migraine" post="with typical aura. Among them, 25% (8/32) have typical"/>
   <result pre="suggest that pure typical aura without headache is a rare" exact="migraine" post="subtype in headache clinics in Korea. A04 Factors reducing"/>
   <result pre="clinics in Korea. A04 Factors reducing depressive symptoms in depressed" exact="migraine" post="patients Sung-Pa Park Department of Neurology, School of Medicine,"/>
   <result pre="Correspondence: Sung-Pa Park( sppark@mail.knu.ac.kr) Background About 40 to 50% of" exact="migraine" post="patients have a comorbid depression. However, there is no"/>
   <result pre="is no evidence-based medicine for treating depressive symptoms in depressed" exact="migraine" post="patients. We identified factors reducing depressive symptoms in these"/>
   <result pre="Methods We reviewed electronic data which collected new patients with" exact="migraine" post="in our headache clinic. A total of 604 patients"/>
   <result pre="= 0.008). Discussion The improvement of depressive symptoms in depressed" exact="migraine" post="patients may rely on the headache management instead of"/>
   <result pre="psychiatric drugs. A05 AHS Abstract: The association between occurrence of" exact="migraine" post="headache and objectively-assessed sleep among adults with episodic migraine:"/>
   <result pre="Health, Boston, MA Correspondence: Angeliki Vgontzas( avgontzas@bwh.harvard.edu) Background: Patients with" exact="migraine" post="frequently report sleep disturbance, including difficulty falling sleep and"/>
   <result pre="disturbance in patients with migraine, we examined the association between" exact="migraine" post="headache and subsequent sleep duration and fragmentation. Methods: We"/>
   <result pre="onset until wake time, WASO). We examined whether days with" exact="migraine" post="headache were associated with sleep that night, using adjusted"/>
   <result pre="7.3 minutes (95% CI:1.5, 13.0) longer on nights following a" exact="migraine" post="headache day compared to nights following a headache-free day."/>
   <result pre="efficiency and WASO were not significantly different on nights following" exact="migraine" post="headache days compared to nights following headache-free days (sleep"/>
   <result pre="A06 Sleep characteristics and pain sensitivity in episodic and chronic" exact="migraine" post="and tension-type headache (TTH) - a population study Angeliki"/>
   <result pre="was to assess whether self-reported sleep characteristics in those with" exact="migraine" post="and TTH in a population-based sample were associated with"/>
   <result pre="pressure pain sensitivity in some musculoskeletal pain conditions, e.g., knee" exact="osteoarthritis" post="or whiplash associated neck pain. However, this association has"/>
   <result pre="role in the pathogenesis of cluster headache. Widespread pressure pain" exact="hypersensitivity" post="is a clinical manifestation of sensitization of central pain"/>
   <result pre="which has been observed in other primary headaches such as" exact="migraine" post="or tension type headache. The aim of this study"/>
   <result pre="meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for" exact="migraine" post="and other pains. Cephalalgia 2014;34(11): 853-69. A10 A particular"/>
   <result pre="A10 A particular case of facial paraesthesias due to a" exact="meningioma" post="Angelo Torrente 1, Concetta Rubino 2 1Department of Biomedicine,"/>
   <result pre="but persistence of paraesthesias. Discussion: cerebellopontine angle tumours may cause" exact="trigeminal neuralgia," post="but such painful condition is usually brief, intense and"/>
   <result pre="usually brief, intense and electric shock-like. In our case, the" exact="meningioma" post="is probably the cause of such particular clinical presentation"/>
   <result pre="was obtained from the patient. A11 Digital therapeutics neuromodulation for" exact="migraine" post="Oved Daniel 1 Eran chenker 2,3 1Headache &amp;amp; Facial"/>
   <result pre="The latest clinical performance and safety of self-administered treatment for" exact="migraine" post="using combined occipital and trigeminal neuromodulation utilized the Relivion"/>
   <result pre="the reviewed clinical trials demonstrate that self-administered abortive treatment of" exact="migraine" post="by the Relivion® was safe and highly effective. A12"/>
   <result pre="Konstantinos Kampouris( konstantinos_kab@hotmail.com) ABSTRACT Aim: To assess cognitive functions in" exact="migraine" post="patients (with and without aura) in comparison to a"/>
   <result pre="in two groups: the research group, which consists of 31" exact="migraine" post="patients (10 of them having migraine aura) that fulfill"/>
   <result pre="which consists of 31 migraine patients (10 of them having" exact="migraine" post="aura) that fulfill the diagnostic criteria of the ICHD-3"/>
   <result pre="effect of MoCA on the results no main effect of" exact="migraine" post="aura is found. Conclusions: In interictal stages migraineurs and"/>
   <result pre="micro-cauterisation (on cervical,occipital and temporal areas) for patients with chronic" exact="migraine" post="&amp;amp; headache due to medicaltion overuse (MOH). Report of"/>
   <result pre="evaluate the efficacy of micro-cautery stimulation on patients with chronic" exact="migraine" post="-with and without aura-and MOH Materials and methods: A"/>
   <result pre="MOH Materials and methods: A total of 21 patients with" exact="migraine" post="were selected. All of them were chronic migraneurs with"/>
   <result pre="to as the most painful points during the attack of" exact="migraine" post="and also during the inter-ictal period, once a week"/>
   <result pre="in headache PowerPoint 48 Migraine aura videos 37 Innovation in" exact="migraine" post="36 Continuum neurology 36 Dysphagia and neuromuscular disease PowerPoint"/>
   <result pre="37 Innovation in migraine 36 Continuum neurology 36 Dysphagia and" exact="neuromuscular disease" post="PowerPoint 31 Secondary headaches PowerPoint 29 Group IV headaches"/>
   <result pre="calcitonin gene-related peptide (CGRP) pathway for episodic (EM) and chronic" exact="migraine" post="(CM) and compare them to those of topiramate and"/>
   <result pre="patients who had at least 50% reduction from baseline in" exact="migraine" post="days per month. Meta- analysis of the incidence of"/>
   <result pre="for CM. A16 Functional connectivity and photo-, phono-, osmophobia in" exact="migraine" post="Noboru Imai 1, Asami Moriya 1, Eiji Kitamura 2"/>
   <result pre="phono-, or osmophobia. To explore the aforementioned 3 conditions in" exact="migraine" post="development, we investigated differences in whole brain resting-state functional"/>
   <result pre="patients with and without these conditions. Methods: Sixty-two women with" exact="migraine" post="underwent resting-state functional magnetic resonance imaging during the interictal"/>
   <result pre="between photo-, phono-, and/or osmophobia and neural FC, particularly in" exact="migraine" post="development. A17 ANTI-CALCITONIN GENE-RELATED PEPTIDE MONOCLONAL ANTIBODIES: ADVERSE EFFECTS."/>
   <result pre="programme, showing similar efficacy to the currently used drugs for" exact="migraine" post="prevention but a lot of skepticism exists regarding their"/>
   <result pre="overall safety profile of anti-CGRP mAb for the prevention of" exact="migraine" post="has been reported to be more than satisfactory. Safety"/>
   <result pre="anti-CGRP mAb. A18 A real-world analysis of the burden of" exact="migraine" post="in patients with prior treatment failures: evidence from the"/>
   <result pre="the burden of disease and quality of life (QoL) in" exact="migraine" post="patients with prior prophylactic treatment failures (PPTF). The aim"/>
   <result pre="aim of this analysis was to characterise the burden of" exact="migraine" post="in patients with≥1 PPTF and ≥4 monthly migraine days"/>
   <result pre="burden of migraine in patients with≥1 PPTF and ≥4 monthly" exact="migraine" post="days (MMD). METHODS BECOME was a prospective, multicentre, non-interventional"/>
   <result pre="Europe and Israel. Part 1 assessed the characteristics of all" exact="migraine" post="patients visiting headache specialist centres over a 3-month prospective"/>
   <result pre="disease using patient-reported outcome questionnaires ( Table 1) in visiting" exact="migraine" post="patients with ≥1 PPTF and ≥4 MMD, identified by"/>
   <result pre="43.0±11.56 years; the majority were female (86.9%) and diagnosed with" exact="migraine" post="without aura (53.4%). Overall, Part 2 patients reported a"/>
   <result pre="2). DISCUSSION BECOME confirms the significant burden of disease among" exact="migraine" post="patients who have failed prior prophylactic treatments and provides"/>
   <result pre="without aura 1291 (53.4)  Migraine with aura 290 (12.0)  Chronic" exact="migraine" post="731 (30.2)  Complications of migraine 9 (0.4)  Probable migraine"/>
   <result pre="with aura 290 (12.0)  Chronic migraine 731 (30.2)  Complications of" exact="migraine" post="9 (0.4)  Probable migraine 2 (0.1)  Episodic syndromes that"/>
   <result pre=" Chronic migraine 731 (30.2)  Complications of migraine 9 (0.4)  Probable" exact="migraine" post="2 (0.1)  Episodic syndromes that may be associated with"/>
   <result pre="migraine 2 (0.1)  Episodic syndromes that may be associated with" exact="migraine" post="# 6 (0.2) Diagnosis of medication overuse headache, n"/>
   <result pre="code; #previously known as ‘childhood periodic syndromes’, this type of" exact="migraine" post="may also occur in adults, who also have migraine"/>
   <result pre="of migraine may also occur in adults, who also have" exact="migraine" post="with or without aura, or who have an increased"/>
   <result pre="Headache Impact Test; ICHD, International Classification of Headache Disorders; MIDAS," exact="migraine" post="disability assessment; N, total number of patients; n, number"/>
   <result pre="MMD(n=806) 8–14 MMD(n=605) ≥15 headache days/month, of which ≥8 are" exact="migraine" post="days (n=1007) EQ-5D-5L utility index score 0.82 (0.19) 0.81"/>
   <result pre="EuroQol 5 dimensions 5 levels; HIT, Headache Impact Test; MIDAS," exact="migraine" post="disability assessment; MMD, monthly migraine days; N, total number"/>
   <result pre="HIT, Headache Impact Test; MIDAS, migraine disability assessment; MMD, monthly" exact="migraine" post="days; N, total number of patients; n, number of"/>
   <result pre="PRO, patient-reported outcomes; VAS, visual analogue scale A19 Characteristics of" exact="migraine" post="patients visiting the European headache specialist centres: real-world evidence"/>
   <result pre="AND AIMS Real-world evidence on the characteristics of patients with" exact="migraine" post="from Europe is limited. The current study provides real-world"/>
   <result pre="prospective, multicentre, non-interventional study in adult patients (18–65 years) with" exact="migraine" post="consisting of two parts, conducted across Europe and Israel."/>
   <result pre="screened for frequency of prior prophylactic treatment failures (PPTF), monthly" exact="migraine" post="days (MMD), and other characteristics ( Table 1). Patients"/>
   <result pre="Part 1. As shown in Table 1, 20,837 patients with" exact="migraine" post="visited the headache centres during screening period, of which"/>
   <result pre="with ≥8 MMD. Approximately a quarter (27.0%) of patients with" exact="migraine" post="visited the centres for the first time. DISCUSSION The"/>
   <result pre="time. DISCUSSION The BECOME study represents real-world characteristics of the" exact="migraine" post="patient population visiting headache specialist centres in Europe and"/>
   <result pre="of disease, and a high unmet need with current prophylactic" exact="migraine" post="therapy. Abstract topic: Epidemiology/Clinical Features Conflicts of Interest: This"/>
   <result pre="(14.7)   3 PPTF 2244 (10.8)   ≥4 PPTF 3513 (16.9) Monthly" exact="migraine" post="days  &amp;lt;4 MMD 5358 (25.7)  ≥4 MMD 15,479 (74.3)"/>
   <result pre="(2.3) All values are n (%) of patients MMD, monthly" exact="migraine" post="days; N, total number of patients; n, number of"/>
   <result pre="clinical predictors of response to OnabotulinumtoxinA in patients with chronic" exact="migraine" post="(CM) at 6 and 12 months of follow-up. Methods:"/>
   <result pre="221 patients (86.1% women, mean age 45.9±11.3 years and mean" exact="migraine" post="evolution time 27.6±14.3 years). A 54.2% had medication overuse"/>
   <result pre="associated with daily frequency patients with MO (p&amp;lt;0.01) and higher" exact="migraine" post="days/month rate (p&amp;lt;0.05). At month 12, clinical predictors of"/>
   <result pre="predictors of excellent response were patients with less years of" exact="migraine" post="evolution (p&amp;lt;0.01) and the presence of anxiety and aura"/>
   <result pre="There are restricted evidence based data about the chronification of" exact="migraine" post="in the natural course of the disease. The main"/>
   <result pre="determine the factors affecting the chronicity of patients with episodic" exact="migraine" post="in patients undergoing headache outpatient process. Patients and Methods:"/>
   <result pre="conducted as a part of Turkish Headache Database Project. 3629" exact="migraine" post="patients registered in database, between 2000-2017. Among these, 2042"/>
   <result pre="Among these, 2042 of these patients were diagnosed as episodic" exact="migraine" post="and 1227 had chronic migraine at first visit. 68"/>
   <result pre="patients were diagnosed as episodic migraine and 1227 had chronic" exact="migraine" post="at first visit. 68 patients undergoing follow-up at least"/>
   <result pre="68 patients undergoing follow-up at least two visits, transformed chronic" exact="migraine" post="and compared to others. Demographic, clinic, phenotypic, epigenetic factors"/>
   <result pre="between chronicity and vertigo (p=0.007), cranial autonomic symptoms (p=0.037) and" exact="allergy" post="(p=0.026). Co morbidity of allergy in migraine patients with"/>
   <result pre="cranial autonomic symptoms (p=0.037) and allergy (p=0.026). Co morbidity of" exact="allergy" post="in migraine patients with chronic is 7.624 times higher"/>
   <result pre="symptoms (p=0.037) and allergy (p=0.026). Co morbidity of allergy in" exact="migraine" post="patients with chronic is 7.624 times higher than the"/>
   <result pre="showed that the presence of vertigo, cranial autonomic symptoms, concomitant" exact="allergy" post="were effective in the chronicity of migraine with requires"/>
   <result pre="autonomic symptoms, concomitant allergy were effective in the chronicity of" exact="migraine" post="with requires much more attention to migraine comorbidities associated"/>
   <result pre="the chronicity of migraine with requires much more attention to" exact="migraine" post="comorbidities associated rather than diagnostic peculiarities, not only for"/>
   <result pre="study (NCT03096834) demonstrated efficacy of erenumab 140 mg in episodic" exact="migraine" post="patients with 2-4 prior preventive treatment failures. The aim"/>
   <result pre="outcomes included ≥50%/≥75%/100% reduction from the DBTP baseline in monthly" exact="migraine" post="days (MMD) (responder rates), change from the DBTP baseline"/>
   <result pre="DBTP, double-blind treatment phase; HIT-6, Headache Impact Test; MMD, monthly" exact="migraine" post="days; MPFID-EA; Migraine Physical Function Impact Diary-everyday activities MPFID-PI,"/>
   <result pre="obtaining a proper management of headache. Results: Patients with chronic" exact="migraine" post="or MOH were 16% and 12%, respectively, at the"/>
   <result pre="hypothyroidism. To date, numerous studies suggested a bidirectional relationship between" exact="migraine" post="and hypothyroidism, though certain had contradictory results. Methods We"/>
   <result pre="= 76 / 351), 253 patients (59.3%) were diagnosed with" exact="migraine" post="without aura, 53 (12.4%) with TTH, 49 (11.5%) with"/>
   <result pre="migraine without aura, 53 (12.4%) with TTH, 49 (11.5%) with" exact="migraine" post="with aura, 29 (6.8%) with medication-overuse headache, 23 (5.4%)"/>
   <result pre="high prevalence of thyroid dysfunction in general (20.7%) and specifically" exact="hypothyroidism" post="(6.3%), needs further clarification in prospective longitudinal studies, highlights"/>
   <result pre="Allena( marta.allena@mondino.it) Background The biological mechanisms of the progression of" exact="migraine" post="from episodic to chronic are poorly understood. Medication overuse"/>
   <result pre="considered by many as one of the main determinants of" exact="migraine" post="progression. Recently, in a preliminary study, we have shown"/>
   <result pre="further investigated the asset of the endocannabinoid system (ES) in" exact="migraine" post="as a function of disease severity. Methods Using rt-PCR"/>
   <result pre="the degradation, in the PBMCs of 21 subjects with episodic" exact="migraine" post="(EM), 19 subjects with chronic migraine and MO (CM-MO)"/>
   <result pre="21 subjects with episodic migraine (EM), 19 subjects with chronic" exact="migraine" post="and MO (CM-MO) and an age- and sex-matched control"/>
   <result pre="group. Discussion These findings confirm the involvement of ES in" exact="migraine" post="disease showing that not only anandamide, but also 2-AG"/>
   <result pre="conflict of interest in relation to this study Background: Hemiplegic" exact="migraine" post="(HM) is a rare headache disorder, and few data"/>
   <result pre="connectivity changes within the salience network in patients with chronic" exact="migraine" post="Francesca Pistoia 1,2, Alessandra Splendiani 1,2, Mario Quarantelli 1,2,"/>
   <result pre="Italy Correspondence: Francesca Pistoia( francesca.pistoia@univaq.it) Background: Migraine is a common" exact="neurological disorder" post="whose pathogenesis is still unclear, especially when it occurs"/>
   <result pre="network (SN) and the default mode network (DMN) in episodic" exact="migraine" post="(EM) and chronic migraine (CM), in order to identify"/>
   <result pre="default mode network (DMN) in episodic migraine (EM) and chronic" exact="migraine" post="(CM), in order to identify any functional brain connectivity"/>
   <result pre="the Regional Headache Centre of L’Aquila with a diagnosis of" exact="migraine" post="were screened for the inclusion in the study. The"/>
   <result pre="cortical hubs deserves further investigation in order to better understand" exact="migraine" post="pathogenesis and to develop effective treatment strategies. References 1."/>
   <result pre="migraine. Curr Pain Headache Rep 2013;17:304. A30 Reduction in monthly" exact="migraine" post="days (MMDs) with fremanezumab and erenumab among patients with"/>
   <result pre="days (MMDs) with fremanezumab and erenumab among patients with chronic" exact="migraine" post="(CM) with 2 to 4 prior treatment failures: A"/>
   <result pre="of CGRP monoclonal antibodies fremanezumab and erenumab in reducing monthly" exact="migraine" post="days (MMDs) in chronic migraine (CM) patients with 2-4"/>
   <result pre="and erenumab in reducing monthly migraine days (MMDs) in chronic" exact="migraine" post="(CM) patients with 2-4 prior treatment failures. Methods: Randomized"/>
   <result pre="received consulting fees from Teva Pharmaceuticals. A31 Reduction in monthly" exact="migraine" post="days (MMDs) with fremanezumab and erenumab among patients with"/>
   <result pre="days (MMDs) with fremanezumab and erenumab among patients with episodic" exact="migraine" post="(EM) with 2-4 prior treatment failures: A Network Meta-Analysis"/>
   <result pre="meta-analysis (NMA) of fremanezumab and erenumab for reduction in monthly" exact="migraine" post="days (MMDs) in patients with episodic migraine (EM) who"/>
   <result pre="reduction in monthly migraine days (MMDs) in patients with episodic" exact="migraine" post="(EM) who failed 2-4 prior treatments. Methods: RCTs of"/>
   <result pre="headache days per month) who had failed 2-4 prior preventive" exact="migraine" post="treatments due to efficacy, safety, or tolerability. Reductions in"/>
   <result pre="responder rates between fremanezumab, erenumab and onabotulinumtoxinA among patients with" exact="migraine" post="with ≥3 prior treatment failures: A Network Meta-Analysis Oscar"/>
   <result pre="(RR) of CGRP monoclonal antibodies and other common treatments in" exact="migraine" post="patients with ≥3 prior treatment failures. Methods: A systematic"/>
   <result pre="and onabotulinumtoxinA (onaA) (2007-present). Adults with episodic (EM) or chronic" exact="migraine" post="(CM) and ≥3 prior treatment failures were included. 30%"/>
   <result pre="Effectiveness of botulinum toxin type-A(BTX-A) has been reported in chronic" exact="migraine" post="by probably inhibiting the release of CGRP in trigeminal"/>
   <result pre="administration of botulinum toxin type A (BTX-A) in patients with" exact="trigeminal neuralgia" post="Perez-Esteban, R; Baena-Palomino, P; Lamas-Perez R.; Munoz-Delgado, L; Jimenez-Hernandez,"/>
   <result pre="has been shown to be a choice of treatment for" exact="trigeminal neuralgia" post="(TN), and may be an efficient, safe and novel"/>
   <result pre="points for ADH-depression . Discussion: The administration of BTX-A for" exact="trigeminal neuralgia" post="is effective, and associated with a reduction in number"/>
   <result pre="Prophylactic effect of ultramicronized N-Palmitoyl Ethanol Amide (PEA) on pediatric" exact="migraine" post="Laura Papetti 1*, Giorgia Sforza 1,2*, Giulia Tullo 3,"/>
   <result pre="to evaluate the role of PEA in the management of" exact="migraine" post="in pediatric patients. OBJECTIVE: The aim of this open-label"/>
   <result pre="M and 75.5% F). All patients had a diagnosis of" exact="migraine" post="without aura (ICHD 3 criteria) and received umPEA (600"/>
   <result pre="University, Aalborg, Denmark Correspondence: Massimiliano Valeriani( massimiliano.valeria@OPBGMAIL.onmicrosoft.com) Abstract Background. Periodic" exact="migraine" post="variants are a group of disorders affecting patients with"/>
   <result pre="migraine variants are a group of disorders affecting patients with" exact="migraine" post="or with an increased risk of presenting it, and"/>
   <result pre="groups of patients, the vast majority presented with different periodic" exact="migraine" post="variants at different ages, thus suggesting an age dependent"/>
   <result pre="headache. A39 Dysphasia and other higher cortical dysfunctions during the" exact="migraine" post="aura - A systematic review of literature Igor Petrusic"/>
   <result pre="Visual and somatosensory disturbances are the most common symptoms of" exact="migraine" post="aura (MA). Yet, patients can experience also other disturbances"/>
   <result pre="from clear and need future investigations. A42 Consistent reductions in" exact="migraine" post="frequency with eptinezumab treatment in patients with migraine stratified"/>
   <result pre="reductions in migraine frequency with eptinezumab treatment in patients with" exact="migraine" post="stratified by disease characteristics: subgroup analysis of PROMISE-1 and"/>
   <result pre="rcady@alderbio.com) Background: In two phase 3 clinical trials of episodic" exact="migraine" post="(EM) (PROMISE-1; NCT02559895) and chronic migraine (CM) (PROMISE-2; NCT02974153),"/>
   <result pre="clinical trials of episodic migraine (EM) (PROMISE-1; NCT02559895) and chronic" exact="migraine" post="(CM) (PROMISE-2; NCT02974153), eptinezumab met the primary efficacy endpoint."/>
   <result pre="primary endpoint was the change from baseline in mean monthly" exact="migraine" post="days (MMDs) over Months 1-3. Here, mean MMDs were"/>
   <result pre="in patient subgroups defined by disease characteristics including: duration of" exact="migraine" post="(≤15/&amp;gt;15 years), baseline MMDs (≤9/&amp;gt;9 days, PROMISE-1; &amp;lt;17/≥17 days,"/>
   <result pre="in 100mg and 300mg, respectively: total, -0.7 (p=0.0001), -1.1 (p=0.0182);" exact="migraine" post="duration ≤15y, -0.4, -1.5 vs &amp;gt;15y, -1.3, -0.8; baseline"/>
   <result pre="vs &amp;gt;9d, -0.3, -1.5. PROMISE-2: total, -2.0 (p&amp;lt;0.0001), -2.6 (p&amp;lt;0.0001);" exact="migraine" post="duration ≤15y, -2.0, -2.3 vs &amp;gt;15y, -1.9, -2.8; baseline"/>
   <result pre="Bothell, WA, USA. A43 Content validity of the HIT-6 in" exact="migraine" post="patients: results of a systematic literature review Carrie R."/>
   <result pre="supportive qualitative evidence for HIT-6 content validity, 8 specific to" exact="migraine" post="(episodic and chronic) and 4 citing general headache patients."/>
   <result pre="supporting the relevance of content of each HIT-6 item to" exact="migraine" post="patients’ lives were found. Across interviews, limitations in daily"/>
   <result pre="a responder definition for the HIT-6 items in a chronic" exact="migraine" post="population Richard Lipton 1, Carrie R. Houts 2, Joe"/>
   <result pre="definitions for the individual HIT-6 items in patients with chronic" exact="migraine" post="(CM). Methods: Responder definitions for the HIT-6 items were"/>
   <result pre="responder threshold: patient global impression of change, ≥75% reduction in" exact="migraine" post="frequency, and EuroQOL 5-dimensions 5-level (EQ-5D-5L) visual analog scale."/>
   <result pre="Alder BioPharmaceuticals, Inc., Bothell, WA, USA. A45 Consistent reductions in" exact="migraine" post="frequency with eptinezumab treatment in patients with migraine stratified"/>
   <result pre="reductions in migraine frequency with eptinezumab treatment in patients with" exact="migraine" post="stratified by intrinsic factors: subgroup analyses of PROMISE-1 and"/>
   <result pre="rcady@alderbio.com) Background: In two phase 3 clinical trials of episodic" exact="migraine" post="(EM) (PROMISE-1; NCT02559895) and chronic migraine (CM) (PROMISE-2; NCT02974153),"/>
   <result pre="clinical trials of episodic migraine (EM) (PROMISE-1; NCT02559895) and chronic" exact="migraine" post="(CM) (PROMISE-2; NCT02974153), eptinezumab met the primary efficacy endpoint."/>
   <result pre="both studies was the change from baseline in mean monthly" exact="migraine" post="days (MMDs) over Months 1-3. Here, mean MMDs were"/>
   <result pre="all presented with chronic migraine, 9% fulfilled a diagnosis of" exact="migraine" post="with aura. Photo- and photophobia were present in 81%"/>
   <result pre="overuse. A47 Role of maternal stress and alexithymia in children’s" exact="migraine" post="severity and psychological profile Samuela Tarantino 1, Alessandra di"/>
   <result pre="explored the relationship between maternal stress, children’s psychological profile and" exact="migraine" post="severity. Aims of our study were to explore the"/>
   <result pre="and alexithymia did not show significant differences among the two" exact="migraine" post="frequency groups (p &amp;gt;0.05). However, in high frequency group,"/>
   <result pre="0.00). No relationships were found between TAS-20, CBCL, SAFA and" exact="migraine" post="frequency. Conclusions. Maternal stress has no relationship with children’s"/>
   <result pre="migraine frequency. Conclusions. Maternal stress has no relationship with children’s" exact="migraine" post="frequency. However, it shows a relationship with maternal perception"/>
   <result pre="and patients’ depressive symptoms, which in turn may impact on" exact="migraine" post="severity. A48 Is it useful to determine CGRP, VIP,"/>
   <result pre="VIP, and PACAP in migraine? A cross-sectional study in chronic" exact="migraine" post="patients Sara Pérez-Pereda 1, María Toriello-Suárez 1, Gonzalo Ocejo-Vinyals"/>
   <result pre="sperez@idival.org) Background: VIP, CRGP, and PACAP have important roles in" exact="migraine" post="pathogenesis but their diagnostic value is controversial. Objective: To"/>
   <result pre="compare these neuropeptides serum levels in a cohort of chronic" exact="migraine" post="(CM), episodic migraine (EM), and healthy controls (HC). Methods:"/>
   <result pre="serum levels in a cohort of chronic migraine (CM), episodic" exact="migraine" post="(EM), and healthy controls (HC). Methods: Peripheral blood samples"/>
   <result pre="IDIVAL. A49 Protective role of fruit and vegetable against pediatric" exact="migraine" post="headache: A case- control study Soodeh Razeghi Jahromi 1,2,"/>
   <result pre="Introduction: Diet is recognized as a possible potential factor in" exact="migraine" post="pathogenesis. As fruits and vegetables are considered as major"/>
   <result pre="the association between fruit and vegetable consumption and odds of" exact="migraine" post="in children Method: We conducted a case-control study in"/>
   <result pre="study in tertiary hospital, Tehran, Iran. One hundred children with" exact="migraine" post="as case group and 190 sex-matched healthy controls were"/>
   <result pre="healthy controls were recruited in this study. Definite diagnosis of" exact="migraine" post="was based on 2018 international classification of headache disorder"/>
   <result pre="fiber which was stratified into quartiles. Result: Children in the" exact="migraine" post="group had significantly higher BMI and age compared with"/>
   <result pre="noticed 50% and 70% reduction in odds of assigning to" exact="migraine" post="group by increasing the consumption of vegetable and fruit"/>
   <result pre="first tertile, respectively. Also a 72% reduction in odds of" exact="migraine" post="was observed by an incremented level of fiber intake"/>
   <result pre="role of dietary fruits and vegetables against the risk of" exact="migraine" post="in children which can be attributed to the probable"/>
   <result pre="prevalence of depression compared to those without EDS. A51 Hemiplegic" exact="migraine" post="with late-onset cerebellar signs as phenotypic variant of CANCA1A"/>
   <result pre="of Athens, Athens, Greece Correspondence: Mavridis Theodoros( mavridismdr@gmail.com) Βackground Hemiplegic" exact="migraine" post="(HM) is a rare and complex clinical entity which"/>
   <result pre="SCN1A). Although patients with mutations in CACNA1A may present with" exact="cerebellar ataxia," post="the presence of both clinical entities and moreover the"/>
   <result pre="pathological finding. Results The following genetic tests for mutations in" exact="spinocerebellar ataxia" post="related genes (SCA panel) were all negative. Finally, a"/>
   <result pre="Multi-sensory gain abnormalities in postural tachycardia syndrome exceed those of" exact="migraine" post="Melissa M. Cortez, Leah Millsap, K.C. Brennan Department of"/>
   <result pre="headaches might be expected to be strictly orthostatic, though comorbid" exact="migraine" post="headache is common. Given this observation, it is possible"/>
   <result pre="the two disorders interact pathophysiologically. Methods: 30 PoTS, 30 chronic" exact="migraine" post="(CM), and 30 non-headache (NH) control subjects completed a"/>
   <result pre="migraine (CM), and 30 non-headache (NH) control subjects completed a" exact="migraine" post="questionnaire, MIDAS/HIT6, and sensory/autonomic symptom assessment. Sensory testing included"/>
   <result pre="resource utilization (HRU) by patients treated with onabotulinumtoxinA for chronic" exact="migraine" post="(CM). Methods: The single-arm, open-label, multicenter, prospective study (NCT01516892)"/>
   <result pre="single pulse Transcranial Magnetic Stimulation (sTMS) in animal models of" exact="migraine" post="M Jones 2,3, S McMahon 2, R Abuukar Abdullahi"/>
   <result pre="is a non-invasive neuromodulation technique shown to be successful for" exact="migraine" post="treatment. Previous research has shown that acute sTMS treatment"/>
   <result pre="diameter of 11 mm and stimulating parameters similar to the" exact="migraine" post="treatment. Behavioural testing of paraorbital von Frey thresholds was"/>
   <result pre="from episodic PHD subtypes; 1000 patients (48,3%) were suffering from" exact="migraine" post="(720 (34,8%) episodic and 280 (13,5%) chronic), 761 (36,8%)"/>
   <result pre="MOH patients (OR=2.13 for anxiety, OR= 2.38 for depression). In" exact="migraine" post="patients HAM-A and HAM-D scores were higher than those"/>
   <result pre="suffering from cluster headache (OR=3.01, OR=2.30). On the other hand" exact="migraine" post="patients have 30% and 24.5% lower odds to score"/>
   <result pre="patients (OR=1.43, OR=1.32). Conclusion: Outpatients suffering from chronic PHDs, TTH," exact="migraine" post="or MOH need further evaluation for potential mood comorbidities"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6908502/results/search/disease/results.xml">
   <result pre="relieving factors, and interpretation of children's behavior during attacks of" exact="migraine" post="and tension-type headaches, the most frequent types of primary"/>
   <result pre="groups. Thirdly, children's responses to pharmacological and non-pharmacological treatment of" exact="migraine" post="are shown to be different in the pediatric population."/>
   <result pre="al. underlined the differences in the clinical presentation of hemiplegic" exact="migraine" post="between children and adults. On the issue of ictal"/>
   <result pre="reduction of arousability and lower NREM sleep instability associated with" exact="migraine" post="without aura. This subject deserves further investigation in the"/>
   <result pre="sensory information and pain catastrophizing, modulate the clinical presentation of" exact="migraine" post="and can be fundamental in its chronification. Although new"/>
   <result pre="as suggested by Brighina et al. The non-pharmacological interventions for" exact="migraine" post="treatment in children, reviewed by Andrasik et al., bear"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6911735/results/search/disease/results.xml">
   <result pre="with visual activities (screen time, reading, near work, driving, etc);" exact="asthenopia" post="(eye strain) and eye fatigue; problems with visual focus"/>
   <result pre="in patients with known complicating underlying neurological disease such as" exact="epilepsy" post="or stroke. Second-level selection was performed independently by 2"/>
   <result pre="ration Measurements used for SMD Concussion subtype Cognitive Concentration, remembering," exact="retrograde amnesia," post="anterograde amnesia, posttraumatic amnesia, cognitive problems, feeling slow ImPACT"/>
   <result pre="used for SMD Concussion subtype Cognitive Concentration, remembering, retrograde amnesia," exact="anterograde amnesia," post="posttraumatic amnesia, cognitive problems, feeling slow ImPACT - verbal"/>
   <result pre="the opportunity for refined classifications within a subtype, for example" exact="migraine" post="headache vs nonmigraine headache. The results of this large,"/>
   <result pre="4): 271- 280. 12036500 11. Seifert T The relationship of" exact="migraine" post="and other headache disorders to concussion. Handb Clin Neurol."/>
   <result pre="RJ , Collins MW , Kontos AP Family history of" exact="migraine" post="associated with posttraumatic migraine symptoms following sport-related concussion ."/>
   <result pre=", Kontos AP Family history of migraine associated with posttraumatic" exact="migraine" post="symptoms following sport-related concussion . J Head Trauma Rehabil."/>
   <result pre="Barnett SD , Nakase-Richardson R Incidence, characterization, and predictors of" exact="sleep apnea" post="in consecutive brain injury rehabilitation admissions . J Head"/>
   <result pre=", Geffen GM , Massavelli BM The effects of post-traumatic" exact="amnesia" post="on information processing following mild traumatic brain injury ."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6916280/results/search/disease/results.xml">
   <result pre="is properly cited. file:JBMR-34-2183.pdf Abstract ABSTRACT In adults with X‐linked" exact="hypophosphatemia" post="(XLH), excess FGF23 impairs renal phosphate reabsorption and suppresses"/>
   <result pre="reabsorption and suppresses production of 1,25‐dihydroxyvitamin D, resulting in chronic" exact="hypophosphatemia" post="and persistent osteomalacia. Osteomalacia is associated with poor bone"/>
   <result pre="efficacy of subcutaneous burosumab, 1.0 mg/kg administered every 4 weeks, in improving" exact="osteomalacia" post="in adults with XLH who have not been treated"/>
   <result pre="occurred. In conclusion, by normalizing phosphate homeostasis, burosumab significantly improved" exact="osteomalacia" post="in adults with XLH, which likely explains the improved"/>
   <result pre="on Osteomalacia in Adults With X‐linked Hypophosphatemia (XLH). Introduction X‐linked" exact="hypophosphatemia" post="(XLH) is a rare, lifelong disease caused by loss"/>
   <result pre="in increased circulating levels of FGF23 that lead to chronic" exact="hypophosphatemia" post="and impaired production of 1,25‐dihydroxyvitamin D (1,25(OH) 2D). 1,"/>
   <result pre="(1,25(OH) 2D). 1, 2 Low serum phosphorus levels result in" exact="rickets" post="and osteomalacia, the hallmarks of XLH in children and"/>
   <result pre="Previous studies have demonstrated improvement, albeit not complete healing of" exact="osteomalacia" post="with conventional therapy in adults. 6, 7, 8 Those"/>
   <result pre="the effect of treatment with burosumab on histomorphometric indices of" exact="osteomalacia" post="in adults with XLH. Subjects and Methods Study design"/>
   <result pre="single‐arm, multicenter trial investigating the efficacy of burosumab in improving" exact="osteomalacia" post="in adults with XLH. Subjects were treated with burosumab,"/>
   <result pre="14 Biopsies were qualitatively analyzed in real‐time to determine if" exact="osteomalacia" post="was present by an experienced histomorphometrist (FR). If the"/>
   <result pre="experienced histomorphometrist (FR). If the baseline biopsy did not reveal" exact="osteomalacia" post="in a given subject, they continued treatment but did"/>
   <result pre="antibodies, changes in echocardiograms (ECHO) and electrocardiograms (ECG), renal ultrasound" exact="nephrocalcinosis" post="scores, fasting serum calcium, plasma intact parathyroid hormone (iPTH),"/>
   <result pre="quality to conduct histomorphometric analysis, and therefore, the presence of" exact="osteomalacia" post="could not be confirmed (per the protocol subjects without"/>
   <result pre="not be confirmed (per the protocol subjects without demonstration of" exact="osteomalacia" post="at baseline did not undergo biopsy at week 48)."/>
   <result pre="in six (43%) subjects, active pseudofractures in four (29%) subjects," exact="osteoarthritis" post="in eight (57%) subjects, dental disease in 13 (93%)"/>
   <result pre="(ie, occurring in two or more subjects) being injection site" exact="urticaria" post="(three subjects), abdominal pain (two subjects), asthenia (two subjects),"/>
   <result pre="Any TEAE 14 (100.0) Related TEAE 10 (71.4) Injection site" exact="urticaria" post="3 (21.4) Abdominal pain 2 (14.3) Asthenia 2 (14.3)"/>
   <result pre="experienced serious AEs, a grade 3 paresthesia and grade 3" exact="migraine" post="headache; neither AE was considered related to burosumab, and"/>
   <result pre="arthralgia in the same subject that experienced the serious AE" exact="migraine" post="and a uterine hemorrhage in another subject. Of the"/>
   <result pre="interval and heart rate. Discussion In adults with XLH, chronic" exact="hypophosphatemia" post="leads to osteomalacia, fractures, pain, stiffness, decreased mobility, and"/>
   <result pre="approved for the treatment of XLH, was shown to reverse" exact="hypophosphatemia" post="and improve clinical outcomes in both children and adults"/>
   <result pre="in the mineralization defect in XLH that manifests clinically as" exact="rickets" post="in children and osteomalacia‐related fractures and bone pain in"/>
   <result pre="In the current study, all four key histomorphometric parameters of" exact="osteomalacia" post="in adults with XLH were markedly elevated at baseline,"/>
   <result pre="referred to as conventional therapy, has led to improvement in" exact="rickets" post="and growth in children with XLH, but there is"/>
   <result pre="therapy can improve, but not completely reverse, histomorphometric parameters of" exact="osteomalacia" post="in a prospective study in adults with XLH. In"/>
   <result pre="serum calcium or PTH concentrations, urine calcium excretion, nor renal" exact="nephrocalcinosis" post="scores and no incidents of hyperphosphatemia. Burosumab's safety profile"/>
   <result pre="Finally, it is possible that greater improvement in measures of" exact="osteomalacia" post="would occur with a treatment duration longer than 48 weeks."/>
   <result pre="iliac trabecular bone, the standard location for histomorphometric measures. However," exact="osteomalacia" post="in XLH also affects cortical bone, such as the"/>
   <result pre="pseudofractures and fractures occur. Although we did not quantify the" exact="osteomalacia" post="at these cortical sites, the significant healing of osteomalacia"/>
   <result pre="the osteomalacia at these cortical sites, the significant healing of" exact="osteomalacia" post="in the trabecular compartment, together with the dramatic healing"/>
   <result pre="controlled trial support the conclusion that substantial healing of cortical" exact="osteomalacia" post="also occurs with burosumab therapy. 12, 13 It is"/>
   <result pre="trial by Sullivan and colleagues 6 showed 50% healing of" exact="osteomalacia" post="after 4 years of conventional therapy in these patients. A"/>
   <result pre="of the long‐term complications of XLH in adults such as" exact="enthesopathy" post="and hearing loss. It remains to be determined if"/>
   <result pre="osteoid surface/bone surface, and mineralization lag time. The improvements in" exact="osteomalacia" post="coincided with increases in serum phosphorus and biochemical markers"/>
   <result pre="bone remodeling. Such improvements in phosphorus homeostasis and healing of" exact="osteomalacia" post="provide a physiologic basis for the efficacy of burosumab"/>
   <result pre=", Briot K , et al. Therapeutic management of hypophosphatemic" exact="rickets" post="from infancy to adulthood. Endocr Connect. 2014; 3( 1):"/>
   <result pre="U , et al. Outcome of adult patients with X‐linked" exact="hypophosphatemia" post="caused by PHEX gene mutations. J Inherit Metab Dis."/>
   <result pre="et al. Impaired quality of life in adults with X‐linked" exact="hypophosphatemia" post="and skeletal symptoms. Eur J Endocrinol. 2016; 174( 3):"/>
   <result pre="Siegel BA , Reid IR , Whyte MP . X‐linked" exact="hypophosphatemia" post="in adults: prevalence of skeletal radiographic and scintigraphic features"/>
   <result pre="and 1,25‐dihydroxyvitamin D3 therapy in symptomatic adults with X‐linked hypophosphatemic" exact="rickets" post=". J Clin Endocrinol Metab. 1992; 75( 3): 879–"/>
   <result pre="to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D‐resistant" exact="rickets" post=". N Engl J Med. 1980; 303( 18): 1023–"/>
   <result pre="JM , Friedman NE , Drezner MK . Healing of" exact="bone disease" post="in X‐linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus"/>
   <result pre="2): 305– 12. 19594303 10 Reuss‐Borst MA . [ Metabolic" exact="bone disease" post="osteomalacia]. Z Rheumatol. 2014; 73( 4): 316– 22. 24811356"/>
   <result pre="Johansson S , Raeder H , Bjerknes R . Hereditary" exact="hypophosphatemia" post="in Norway; a retrospective population‐based study of genotypes, phenotypes"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6918555/results/search/disease/results.xml">
   <result pre="University of Messina, Messina, Italy Correspondence: Stefania Arasi (stefania.arasi@opbg.net) IgE-mediated" exact="food allergy" post="(FA) has been emerging as a significant health issue"/>
   <result pre="of Messina, Messina, Italy Correspondence: Stefania Arasi (stefania.arasi@opbg.net) IgE-mediated food" exact="allergy" post="(FA) has been emerging as a significant health issue"/>
   <result pre="their family members. It represents a major cause of life-threatening" exact="hypersensitivity" post="reactions whose prevalence is increasing significantly. The diagnostic work-up"/>
   <result pre="of reaction in children with persistent cow’s milk, egg or" exact="peanut allergy" post="[3]. However, there are still several gaps to be"/>
   <result pre="reaction in children with persistent cow’s milk, egg or peanut" exact="allergy" post="[3]. However, there are still several gaps to be"/>
   <result pre="Alvaro-Lozano M, et al. EAACI Guidelines on allergen immunotherapy: IgE-mediated" exact="food allergy." post="Allergy. 2018; 73(4):799-815. 3. Nurmatov U, Dhami S, Arasi"/>
   <result pre="Pecora V, Fierro V, et al. Impact of omalizumab on" exact="food allergy" post="in patients treated for asthma: a real-life study. J"/>
   <result pre="V, Fierro V, et al. Impact of omalizumab on food" exact="allergy" post="in patients treated for asthma: a real-life study. J"/>
   <result pre="cycle of patients. A7 Lung ultrasound in infants with acute" exact="bronchiolitis" post="Carlotta Biagi, Anna Mingozzi, Luca Pierantoni, Marcello Lanari Pediatric"/>
   <result pre="Correspondence: Carlotta Biagi (carlottabiagi@yahoo.it) Background: The variable course of acute" exact="bronchiolitis" post="(AB) and the lack of current scoring systems that"/>
   <result pre="accuracy and reliability of LUS for the diagnosis of concomitant" exact="pneumonia" post="in infants with AB and to evaluate the correlation"/>
   <result pre="radiologist and pediatrician) who independently performed LUS. The diagnosis of" exact="pneumonia" post="was established by an expert clinician on the basis"/>
   <result pre="infants with AB were enrolled. A final diagnosis of concomitant" exact="pneumonia" post="was made in 27 patients. Sensitivity and specificity of"/>
   <result pre="patients. Sensitivity and specificity of LUS for the diagnosis of" exact="pneumonia" post="were 96.3% and 85.5% respectively, while CXR showed a"/>
   <result pre="This study shows the good accuracy of LUS in diagnosing" exact="pneumonia" post="in infants with AB. Added benefit of LUS included"/>
   <result pre="to predict the need of supplemental oxygen in infants with" exact="bronchiolitis" post="and to help clinician in the management of this"/>
   <result pre="Most frequently RSV may cause bronchiolitis, which could precipitate acute" exact="respiratory failure" post="requiring intensive care and ventilatory support. According to a"/>
   <result pre="a pediatric intensive care unit (PICU).[2] Co-morbidities, such as prematurity," exact="congenital heart disease," post="genetic abnormalities, chronic lung disease, sepsis or neuromuscular diseases,"/>
   <result pre="pediatric intensive care unit (PICU).[2] Co-morbidities, such as prematurity, congenital" exact="heart disease," post="genetic abnormalities, chronic lung disease, sepsis or neuromuscular diseases,"/>
   <result pre="Co-morbidities, such as prematurity, congenital heart disease, genetic abnormalities, chronic" exact="lung disease," post="sepsis or neuromuscular diseases, were important contributors for worse"/>
   <result pre="(CPAP) is changing the admission patterns and ventilation requirements for" exact="bronchiolitis" post="[4,5]. Non-invasive ventilation (NIV) seems to be the first"/>
   <result pre="electrical diaphragmatic activity [7]. In 11 children with severe RSV" exact="bronchiolitis" post="failing CPAP, non-invasive intermittent positive-pressure ventilation was provided using"/>
   <result pre="Schell DN, Egan JR. Humidified high-flow nasal cannula oxygen in" exact="bronchiolitis" post="reduces need for invasive ventilation but not intensive care"/>
   <result pre="V, et al. Improved clinical and economic outcomes in severe" exact="bronchiolitis" post="with pre-emptive nCPAP ventilatory strategy. Intensive Care Med. 2014;40:84–91."/>
   <result pre="sigh. The increased use of smartphones may result in dry" exact="eye disease," post="eye irritation and fatigue, burning sensation, conjunctival injection, decreased"/>
   <result pre="injection, decreased visual acuity, strain, and fatigue acute acquired comitant" exact="esotropia" post="[7,8]; addiction. Many adolescents use compulsively their smartphones to"/>
   <result pre="Children Hospital, Rome, Italy Correspondence: Elena Bozzola (elena.bozzola@opbg.net) Background Pediatric" exact="bacterial meningitis" post="is a real neurologic emergency. An early diagnosis and"/>
   <result pre="Hospital, Rome, Italy Correspondence: Elena Bozzola (elena.bozzola@opbg.net) Background Pediatric bacterial" exact="meningitis" post="is a real neurologic emergency. An early diagnosis and"/>
   <result pre="years literature to find out the possible way to prevent" exact="bacterial meningitis." post="Results In literature a number of risk factors of"/>
   <result pre="meningitis. Results In literature a number of risk factors of" exact="meningitis" post="are reported, including socioeconomic factors, age, genetic variation of"/>
   <result pre="has led to a significant decline in the frequency of" exact="bacterial meningitis" post="over the past years [4]. Anyway, prevention still remains"/>
   <result pre="led to a significant decline in the frequency of bacterial" exact="meningitis" post="over the past years [4]. Anyway, prevention still remains"/>
   <result pre="provide direct and indirect protection and reduce the incidence of" exact="bacterial meningitis." post="For example, in England, within three years, the vaccination"/>
   <result pre="is actually the only effective way to prevent some of" exact="bacterial meningitis." post="References 1. Posadas E, Fisher J. Pediatric bacterial meningitis:"/>
   <result pre="2:B3-9. 3. Lundbo LF, Benfield T. Risk factors for community-acquired" exact="bacterial meningitis." post="Infect Dis (Lond). 2017;49:433-444. 4. McIntyre PB, O'Brien KL,"/>
   <result pre="Greenwood B, van de Beek D. Effect of vaccines on" exact="bacterial meningitis" post="worldwide. Lancet. 2012;380:1703-1711. 5. Ramsay ME, Andrews NJ, Trotter"/>
   <result pre="B, van de Beek D. Effect of vaccines on bacterial" exact="meningitis" post="worldwide. Lancet. 2012;380:1703-1711. 5. Ramsay ME, Andrews NJ, Trotter"/>
   <result pre="Correspondence: Mauro Bozzola (mauro.bozzola@unipv.it) Celiac disease (CD) is an immune-mediated" exact="enteropathy" post="triggered by dietary gluten-containing cereals in genetically susceptible individuals"/>
   <result pre="disease. The pathogenesis of growth failure is probably due to" exact="malabsorption" post="or abnormality in the endocrine growth axis. A lack"/>
   <result pre="a potentially fatal complication of rheumatic diseases, particularly of systemic" exact="juvenile idiopathic arthritis" post="(sJIA). MAS is caused by excessive activation and proliferation"/>
   <result pre="fatal complication of rheumatic diseases, particularly of systemic juvenile idiopathic" exact="arthritis" post="(sJIA). MAS is caused by excessive activation and proliferation"/>
   <result pre="antibody, in patients with macrophage activation syndrome (MAS) complicating systemic" exact="juvenile idiopathic arthritis" post="(sJIA). Ann Rheum Dis. 2019; 78 (S2):178. A15 Congenital"/>
   <result pre="patients with macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic" exact="arthritis" post="(sJIA). Ann Rheum Dis. 2019; 78 (S2):178. A15 Congenital"/>
   <result pre="follow-up after surgery. We recorded 7 cases of post-operative significant" exact="pericardial effusion;" post="6 of them had a diagnosis of anomalous origin"/>
   <result pre="such as (Shiga toxin-producing Escherichia coli) STEC-HUS or atypical post-infectious" exact="glomerulonephritis" post="(PIGN) [2]. Materials and methods 201 PIGN patients (121"/>
   <result pre="not statistically significant. No differences observed in age of onset," exact="proteinuria" post="and serum C4 levels (Table1). Conclusions The role of"/>
   <result pre="other kidney diseases such as PIGN, a common form of" exact="glomerulonephritis" post="in paediatric age. Prognosis is usually good; however, a"/>
   <result pre="with atypical features, such as persistent low C3 and/or persistent" exact="proteinuria" post="and/or decline in renal function. In our experience, these"/>
   <result pre="Riedl M, Thorner P, Licht C. C3 Glomerulopathy and post-infectious" exact="glomerulonephritis" post="define a disease spectrum. Pediatr Nephrol. 2016;31:2079-86. Fig. 1"/>
   <result pre="patients. EIB affects from 40 to 90% of individuals with" exact="asthma" post="[1] and approximately from 8 to 10% of children"/>
   <result pre="children without asthma. Children with EIB typically experience chest tightness," exact="shortness" post="of breath, cough, wheeze, due to bronchoconstriction which generally"/>
   <result pre="10-15 minutes and resolves by 60 minutes. Patients with atopic" exact="asthma" post="may present EIB more likely when exercise includes exposure"/>
   <result pre="when exercise includes exposure to the relevant allergen or when" exact="asthma" post="is not optimally controlled. The diagnosis of EIB is"/>
   <result pre="chronic pediatric onset disease, particularly in patients with Type 1" exact="diabetes mellitus." post="It is necessary to start a structured care pathway"/>
   <result pre="CBCL. Eur Child Adolesc Psychiatr. 2015;24(suppl.1):S22 A25 Management of chronic" exact="lung disease" post="in children Salvatore Cazzato, Federica Zallocco, Alessia Omenetti Pediatrics"/>
   <result pre="Correspondence: Salvatore Cazzato (salvatore.cazzato@ospedaliriuniti.marche.it) Among chronic lung diseases, non-cystic fibrosis" exact="bronchiectasis" post="(NCFB) has recently received growing attention, mainly due to"/>
   <result pre="and the current poor outcomes. An inappropriate medical approach to" exact="bronchiectasis" post="may actually be associated with rapid decline in lung"/>
   <result pre="strategies have been extrapolated from those used for children with" exact="cystic fibrosis" post="or adults with NCFB. The proposed methods used to"/>
   <result pre="effectiveness or inhalation of other mucoactive agents in children with" exact="bronchiectasis" post="is lacking [11]. Finally, nutritional aspects is another concern"/>
   <result pre="et al. Changes in the incidence, prevalence and mortality of" exact="bronchiectasis" post="in the UK from 2004 to 2013: a population-based"/>
   <result pre="4) McCallum GB, Binks MJ. The epidemiology of chronic suppurative" exact="lung disease" post="and bronchiectasis in children and adolescents. Front pediatr. 2017;20:5-27."/>
   <result pre="Binks MJ. The epidemiology of chronic suppurative lung disease and" exact="bronchiectasis" post="in children and adolescents. Front pediatr. 2017;20:5-27. 5) Kapur"/>
   <result pre="Main E, Grillo L, Rand S. Airway clearance strategies in" exact="cystic fibrosis" post="and non-cystic fibrosis bronchiectasis. Sem Respir Crit Care Med."/>
   <result pre="2015;11:CD008351. 10) Lee E, Hong SJ. Pharmacotherapeutic strategies for treating" exact="bronchiectasis" post="in pediatric patients. Expert Opin Pharmacother. 2019;22:1-2. 11) Elkins"/>
   <result pre="controlled trial of long-term inhaled hypertonic saline in patients with" exact="cystic fibrosis." post="N Engl J Med. 2006;354:229-40. 12) Bastardo CM, Sonnappa"/>
   <result pre="Navarro A, Lopez PM, Jaffe A, et al. Non-cystic fibrosis" exact="bronchiectasis" post="in childhood: longitudinal growth and lung function. Thorax. 2009;64:246-51."/>
   <result pre="settlements of shelter and marine colonies for children suffering from" exact="rickets" post="and scrofula spread. At the beginning of the twentieth"/>
   <result pre="shelter and marine colonies for children suffering from rickets and" exact="scrofula" post="spread. At the beginning of the twentieth century the"/>
   <result pre="Pediatrics.Good adherence to recommendations in literature for the treatment of" exact="allergic rhinitis" post="was found: oral antihistamines are used by 607 (61%)"/>
   <result pre="adherence to recommendations in literature for the treatment of allergic" exact="rhinitis" post="was found: oral antihistamines are used by 607 (61%)"/>
   <result pre="by 607 (61%) of the interviewed in case of secretory" exact="allergic rhinitis" post="while 649 (65%) use spray nasal corticoids for the"/>
   <result pre="607 (61%) of the interviewed in case of secretory allergic" exact="rhinitis" post="while 649 (65%) use spray nasal corticoids for the"/>
   <result pre="nasal corticoids for the obstructive type.For the treatment of the" exact="asthma" post="attack ICS are not used by 54% of the"/>
   <result pre="of need (49%) or as a maintenance therapy. Both for" exact="asthma" post="and wheezing ,treatment time before control appeared affected by"/>
   <result pre="survey. A good management of the child affected by recurrent" exact="asthma" post="or wheezing is shown as well as the choice"/>
   <result pre="needs. An excessive use of corticosteroids for the treatment of" exact="asthma" post="was found, expecially for the acute asthma attack as"/>
   <result pre="the treatment of asthma was found, expecially for the acute" exact="asthma" post="attack as well as for the dosages used in"/>
   <result pre="the organization of specific training courses. A30 Controversies in the" exact="tuberculosis" post="screening in internationally adopted children Elena Chiappini, Barba Bortone,"/>
   <result pre="infection (LTBI) is about 15%. The published screening protocols for" exact="tuberculosis" post="in IAC are discordant and the use of tuberculin"/>
   <result pre="age. In Italy, the national guidelines for the diagnosis of" exact="tuberculosis" post="in immigrants, published in 2018, suggest the possible use"/>
   <result pre="care (with an emphasis on age-specific needs), national centralisation of" exact="sarcoma" post="care, international consortia. As a matter of fact, different"/>
   <result pre="efforts from international collaborations between pediatric and adult oncologists of" exact="sarcoma" post="groups have optioned in converging towards a common therapeutic"/>
   <result pre="details. First, the outcome of adolescents and young adults with" exact="rhabdomyosarcoma" post="is decidedly worse than that generally seen in childhood."/>
   <result pre="than that generally seen in childhood. It is supposed that" exact="rhabdomyosarcoma" post="patients, regardless of their age, would receive better treatment"/>
   <result pre="pediatric population has not paralleled the progress seen in adult" exact="sarcoma" post="patients. Increased international collaboration between pediatric and adult sarcoma"/>
   <result pre="adult sarcoma patients. Increased international collaboration between pediatric and adult" exact="sarcoma" post="groups is of critical importance to facilitate the transfer"/>
   <result pre="Streptococcus pneumoniae (52.25%), Haemophilus influenzae B (7.36%), RSV (6.29%) and" exact="influenza" post="virus (1.28%) [1, 2, 3]. The Italian Society of"/>
   <result pre="Theodoratou E, Bhutta ZA, et al. Global burden of childhood" exact="pneumonia" post="and diarrhoea. Lancet. 2013;381:1405-1416. 3) GBD 2016 Lower Respiratory"/>
   <result pre="Accessed 8 August 2019. 4. World Health organization. Management of" exact="substance abuse" post="unit. Global status report on alcohol and health, 2014."/>
   <result pre="manifestations in paediatric subjects too. Some oral complications, such as" exact="periodontal disease," post="may be a possible risk factor for poor metabolic"/>
   <result pre="authors reviewed the literature to classify oral conditions related to" exact="diabetes mellitus" post="in paediatric age. Studies that had low or no"/>
   <result pre="paediatric age. Studies that had low or no association between" exact="diabetes mellitus" post="and oral manifestations were included too. Results In paediatric"/>
   <result pre="and oral manifestations were included too. Results In paediatric subjects," exact="diabetes mellitus" post="is associated with different frequency to the following oral"/>
   <result pre="associated with different frequency to the following oral clinical manifestations:" exact="periodontal disease" post="(increase of Plaque Index, Gingival Index, Bleeding on Probing),"/>
   <result pre="disease (increase of Plaque Index, Gingival Index, Bleeding on Probing)," exact="dental caries" post="(increase of dmft /DMFT), salivary changes (decreased of salivary"/>
   <result pre="to the time of diagnosis and the glycaemic control of" exact="diabetes mellitus." post="Particular attention was paid to salivary changes in the"/>
   <result pre="changes in the diabetic subject and the two-way relationship between" exact="diabetes mellitus" post="/periodontal disease and diabetes mellitus /periapical pathology, in particular"/>
   <result pre="and the two-way relationship between diabetes mellitus /periodontal disease and" exact="diabetes mellitus" post="/periapical pathology, in particular for preventive and interceptive purposes."/>
   <result pre="purposes. Some studies present conflicting results on the association between" exact="diabetes mellitus" post="and dental caries. Conclusions The prevention and interception of"/>
   <result pre="present conflicting results on the association between diabetes mellitus and" exact="dental caries." post="Conclusions The prevention and interception of some oral complications"/>
   <result pre="Conclusions The prevention and interception of some oral complications of" exact="diabetes mellitus" post="are fundamental both for oral health, but also for"/>
   <result pre="2008;122:1119-1126. A41 Outcomes of conservative treatment in children with acute" exact="appendicitis" post="Carolina D’Anna 1, Letizia Zenzeri 1, Maria Concetta Lonardo"/>
   <result pre="&quot;Federico II,&quot; Naples, Italy Correspondence: Carolina D’Anna (dannacarol@alice.it) Introduction Acute" exact="appendicitis" post="(AA) is still the most common indication as surgical"/>
   <result pre="clinical and laboratory examination improve diagnostic accuracy of acute uncomplicated" exact="appendicitis" post="(AUA). As second aim we evaluated the efficacy of"/>
   <result pre="at twelve months of follow-up underwent surgical treatment for complicated" exact="appendicitis" post="and 3(50%) during the long-term follow-up didn’t received any"/>
   <result pre="diagnosis of AA and especially in order to distinguish if" exact="appendicitis" post="is complicated or not. We observed in our study"/>
   <result pre="not. We observed in our study that the severity of" exact="appendicitis" post="correlates with decreased submucosal integrity rather than with appendiceal"/>
   <result pre="SW, Holcomb GW, Ostile DJ. An evidence-based definition for perforated" exact="appendicitis" post="derived from a prospective randomized trial. J Pediatr Surg."/>
   <result pre="Ansaloni L. Early appendectomy vs. conservative management in complicated acute" exact="appendicitis" post="in children: A meta-analysis. J Pediatr Surg. 2019; pii:"/>
   <result pre="2019; pii: S0022-3468(19)30125-3. A42 A problem at the Emergency Department:" exact="hyperglycemia" post="in diabetic child Giuseppe d’Annunzio, Nicola Minuto, Mohamad Maghnie"/>
   <result pre="Giuseppe d’Annunzio (giuseppedannunzio@gaslini.org) Despite increasing knowledge about the disease pathogenesis," exact="diabetic ketoacidosis" post="(DKA) is frequently observed in newly-diagnosed Type 1 Diabetes"/>
   <result pre="adverse event requiring hospitalization, with a prevalence of 2.4%. Insulin" exact="allergy" post="could elicit immediate reactions, usually induced by an IgE-mediated"/>
   <result pre="behaviour, mostly in females, for weight loss as expression of" exact="eating disorder" post="including &quot;diabulimia&quot;, or other severe psychological disturbances. Other acute"/>
   <result pre="complications leading to hospitalization in long-standing patients include acute appendicitis," exact="pancreatitis" post="and kidney injuries. As regards neurological involvement acute chorea"/>
   <result pre="appendicitis, pancreatitis and kidney injuries. As regards neurological involvement acute" exact="chorea" post="and central venous thrombosis have been described. Patients with"/>
   <result pre="of cases. The infections include bacteria (49%), viruses (49%), and" exact="tuberculosis" post="(2%). DKA with tuberculous meningitis, herpes simplex type 2"/>
   <result pre="(49%), viruses (49%), and tuberculosis (2%). DKA with tuberculous meningitis," exact="herpes simplex" post="type 2 encephalitis and group B streptococcal meningitis have"/>
   <result pre="tuberculosis (2%). DKA with tuberculous meningitis, herpes simplex type 2" exact="encephalitis" post="and group B streptococcal meningitis have also been reported."/>
   <result pre="tuberculous meningitis, herpes simplex type 2 encephalitis and group B" exact="streptococcal meningitis" post="have also been reported. Ileo psoas abscesses, rhinocerebral mucormycosis"/>
   <result pre="meningitis, herpes simplex type 2 encephalitis and group B streptococcal" exact="meningitis" post="have also been reported. Ileo psoas abscesses, rhinocerebral mucormycosis"/>
   <result pre="gene therapy. For several diseases target of prenatal diagnosis, including" exact="cystic fibrosis," post="spinal muscular atrophy, thalassemia and others, promising precision medicine"/>
   <result pre="For several diseases target of prenatal diagnosis, including cystic fibrosis," exact="spinal muscular atrophy," post="thalassemia and others, promising precision medicine protocols are becoming"/>
   <result pre="target of prenatal diagnosis, including cystic fibrosis, spinal muscular atrophy," exact="thalassemia" post="and others, promising precision medicine protocols are becoming available,"/>
   <result pre="with about 60% of affected males reaching diagnostic criteria for" exact="autism" post="spectrum disorder [2]. Anyway fragile-X children maintain an adequate"/>
   <result pre="them shows neuropsychiatric disorders [3]. Female carriers can have a" exact="premature ovarian failure," post="while a late-onset ataxic syndrome with tremor has been"/>
   <result pre="&quot;normal&quot; bowel function and long term artificial feeding requirement (encephalopathy," exact="cerebral palsy," post="repeated aspiration pneumonia, etc). Percutaneous endoscopic gastrostomy (PEG) is"/>
   <result pre="and long term artificial feeding requirement (encephalopathy, cerebral palsy, repeated" exact="aspiration pneumonia," post="etc). Percutaneous endoscopic gastrostomy (PEG) is easily and safety"/>
   <result pre="Respiratory physiotherapy is a fondamental tool for the cure of" exact="cystic fibrosis." post="Viscous mucus secretions obstruct airways, leading to recurrent and"/>
   <result pre="likelihood of avascular necrosis of the femoral head and early" exact="osteoarthritis" post="of the hip and leads to better results [7,8]."/>
   <result pre="parents on reasons for antibiotic prescription. Guidelines development on acute" exact="otitis media" post="and sore throat followed in 2007, a monitoring system"/>
   <result pre="child, that can take place only after the process of" exact="infertility" post="grief. The child of the new conception scenarios is"/>
   <result pre="progressive bronchial wall damage and dilatation, known as bronchiectasis. In" exact="bronchiectasis" post="mucus is even more stuck, which make infections and"/>
   <result pre="onset of sputum production and eventually bronchorrea. As a consequence," exact="bronchiectasis" post="severity correlates with worse pulmonary function [2]. Bronchiectasis is"/>
   <result pre="middle lobe, the lingula and the inferior lobes, while, unlike" exact="cystic fibrosis," post="upper lobes involvement can be found in most severe"/>
   <result pre="most severe cases and later disease stage. [4]. In children," exact="bronchiectasis" post="involves firstly the middle lobe, since the middle lobe"/>
   <result pre="Chest Tomography is still the gold standard test to diagnose" exact="bronchiectasis" post="and assess its extent and severity. Recently, some studies"/>
   <result pre="Resonance Imaging is an accurate and reliable method to evaluate" exact="bronchiectasis" post="in PCD patients [5]. Treatment of bronchiectasis is mainly"/>
   <result pre="method to evaluate bronchiectasis in PCD patients [5]. Treatment of" exact="bronchiectasis" post="is mainly based on respiratory physiotherapy and airway clearance"/>
   <result pre="al. Evaluation of pulmonary disease using static lung volumes in" exact="primary ciliary dyskinesia." post="Thorax. 2012;67:993-9. 3. Hosie PH, Fitzgerald DA, Jaffe A,"/>
   <result pre="Jaffe A, Birman CS, Rutland J, Morgan LC. Presentation of" exact="primary ciliary dyskinesia" post="in children: 30 years’ experience. J Paediatr Child Health."/>
   <result pre="SL, Knowles MR, et al. High-resolution CT of patients with" exact="primary ciliary dyskinesia." post="Am J Roentgenol. 2007;188:1232-8. 5. Montella S, Santamaria F,"/>
   <result pre="Ciliary Dyskinesia Paediatr Respir Rev. 2016;18:39-45. A53 Lung microbiome and" exact="asthma" post="in children Maria E Di Cicco 1,2, Mauro Pistello"/>
   <result pre="also known to be linked to a higher risk of" exact="asthma" post="at 5 years in children born to asthmatic mothers."/>
   <result pre="mothers. Moreover, the phylum Proteobacteria is linked to severity of" exact="asthma" post="and bronchial hyperreactivity. The lung microbiome may also interact"/>
   <result pre="panleukopenia, the recurrence of pulmonary infections may evolve to chronic" exact="lung disease" post="by early adulthood, and the specific susceptibility to chronic"/>
   <result pre="heart system development, other than hematopoiesis, the syndrome may feature" exact="congenital heart disease" post="and neurological abnormalities [6-7]. Conventional treatments include Granulocyte-Colony Stimulating"/>
   <result pre="system development, other than hematopoiesis, the syndrome may feature congenital" exact="heart disease" post="and neurological abnormalities [6-7]. Conventional treatments include Granulocyte-Colony Stimulating"/>
   <result pre="investigated patients had abnormal cerebellar morphology. All patients had severe" exact="neutropenia" post="at onset (150±105 cells/mmc), monocytopenia was reported in 13/21"/>
   <result pre="phenotypes, and it should always be suspected in cases of" exact="severe congenital neutropenia." post="The diagnosis is confirmed by molecular testing, but functional"/>
   <result pre="suggested since early childhood to prevent the development of chronic" exact="lung disease." post="References Hernandez PA, Gorlin RJ, Lukens JN, Taniuchi S,"/>
   <result pre="outcome of WHIM syndrome in 18 patients: high risk of" exact="lung disease" post="and HPV-related malignancies. J Allergy Clin Immunol Pract. 2019;7:1568-1577."/>
   <result pre="following criteria: patient’s age and type of pathology, presence of" exact="food allergy" post="or intolerance and mode or route of administration (through"/>
   <result pre="criteria: patient’s age and type of pathology, presence of food" exact="allergy" post="or intolerance and mode or route of administration (through"/>
   <result pre="been associated with a later increased risk of overweight and" exact="obesity" post="[3]. Intake of simple sugars, above all those from"/>
   <result pre="Group. Lower protein content in infant formula reduces BMI and" exact="obesity" post="risk at school age: follow-up of a randomized trial."/>
   <result pre="Daniela Fava (galanti.fava@gmail.com) Case report A 3-month-old male with progressive" exact="obesity" post="was referred for investigations. On admission, he presented apparent"/>
   <result pre="hypothermia were reported; RBCs and albumin were transfused due to" exact="anemia" post="and hypoalbuminemia. Since his Status Epilepticus he presented dysphagia"/>
   <result pre="perform a gastrostomy for enteral feeding in order to prevent" exact="aspiration pneumonia," post="dehydration and malnutrition and to make it easier to"/>
   <result pre="JE, Novak I, Cheong JLY. early diagnosis and treatment of" exact="cerebral palsy" post="in children with a history of preterm birth. Clin"/>
   <result pre="of the epileptogenic zone in children who are eligible for" exact="epilepsy" post="surgery Thomas Foiadelli 1, Katrien Jansen 2, Lieven Lagae"/>
   <result pre="Thomas Foiadelli (t.foiadelli@smatteo.pv.it) Background One out of three children with" exact="epilepsy" post="is drug-resistant. Children with drug-resistant epilepsy must undergo timely"/>
   <result pre="of three children with epilepsy is drug-resistant. Children with drug-resistant" exact="epilepsy" post="must undergo timely and thorough investigations to assess eligibility"/>
   <result pre="must undergo timely and thorough investigations to assess eligibility for" exact="epilepsy" post="surgery. Subtraction ictal-SPECT co-registered to MRI (SISCOM) is a"/>
   <result pre="feasibility and efficacy in children who are candidate for resective" exact="epilepsy" post="surgery. Methods We retrospectively analysed all pediatric patients (≤16"/>
   <result pre="retrospectively analysed all pediatric patients (≤16 years old) with drug-resistant" exact="epilepsy" post="that had entered the screening protocol for epilepsy surgery"/>
   <result pre="with drug-resistant epilepsy that had entered the screening protocol for" exact="epilepsy" post="surgery in the University Hospital of Leuven (Belgium), from"/>
   <result pre="quality of information available to the decision-maker. A65 Non diabetic" exact="hyperglycemia" post="in pediatric age Adriana Franzese (franzese@unina.it) Department of Translational"/>
   <result pre="the treatment of granuloma, and exclude other diagnoses such as" exact="herpes simplex" post="virus infection and Langerhans cell histiocytosis. Conclusion. As a"/>
   <result pre="Maria Giuseppina Gregorio (mariagiuseppina.gregorio@atssardegna.it) The World Health Organization (WHO) defines" exact="obesity" post="as ‘globesity’: a chronic disease so widespread to be"/>
   <result pre="34% of them have bariatric complications. However, the identification of" exact="obesity" post="as disease is recent: in medieval Europe, fat was"/>
   <result pre="would define &quot;fat&quot;. The Greeks were the first to recognize" exact="obesity" post="as a health disorder. Hippocrates wrote &quot;corpulence is not"/>
   <result pre="secondary pathologies were already known. The Indian surgeon Susruta linked" exact="obesity" post="to the onset of cardiac diseases and diabetes, suggesting"/>
   <result pre="to the Intensive Care Unit during the period determined with" exact="bronchiolitis" post="or pneumonia diagnosis. For the statistical analysis, frequencies were"/>
   <result pre="Intensive Care Unit during the period determined with bronchiolitis or" exact="pneumonia" post="diagnosis. For the statistical analysis, frequencies were calculated with"/>
   <result pre="adults Roberto Ieraci (roberto.ieraci@aslroma1.it) Asl Roma 1, Rome, Italy Cervical" exact="cancer" post="is the fourth most common malignancy worldwide. HPV infection"/>
   <result pre="countries where HPV vaccination programmes have been introduced, decrease in" exact="cancer" post="rates is speculated. In Australia, the first country to"/>
   <result pre="patient centered health promotion care that will decrease risks of" exact="cancer" post="in the future [4]. Increasing vaccination rates for HPV"/>
   <result pre="Bambino Gesù, Rome, Italy Correspondence: Andrzej Krzysztofiak (andrzej.krzysztofiak@opbg.net) Background Trauma-related" exact="osteomyelitis" post="are uncommon in children, but potentially devastating. The diagnosis"/>
   <result pre="using standard culture techniques [1]. Among bacterial pathogens responsible of" exact="osteomyelitis" post="following trauma and/or surgical fixation, the most frequent is"/>
   <result pre="clinical and microbiological characteristics of our pediatric cases with post-traumatic" exact="osteomyelitis" post="of extremity fractures. Material and Methods We retrospectively analyzed"/>
   <result pre="analyzed the cases of 14 children [Table 1] who developed" exact="osteomyelitis" post="after surgical treatment of a fracture. The median age"/>
   <result pre="Glaudemans AW. Accuracy of diagnostic imaging modalities for peripheral post-traumatic" exact="osteomyelitis" post="- a systematic review of the recent literature. Eur"/>
   <result pre="Y. Epidemiological, clinical and microbiological characteristics of patients with post-traumatic" exact="osteomyelitis" post="of limb fractures in southwest China: A Hospital-based study."/>
   <result pre="Infect Dis J. 2018;37:1204-1210. 5. Peltola H, Pääkkönen, M. Acute" exact="osteomyelitis" post="in children. N Engl J Med. 2014;370:352–360. Table 1"/>
   <result pre="1 (abstract A76). Clinical and Microbiological characteristics of patients with" exact="osteomyelitis" post="after fracture N pat Age years Sex Days from"/>
   <result pre="described as a comorbid for psychiatric depression, attention deficit/hyperactivity disorder," exact="social phobia," post="anxiety and impulse control disorders, and personality disorders. In"/>
   <result pre="Psichiatr. 2019; 54: 24-30. A79 &quot;Life changing&quot; treatments in pediatric" exact="allergy" post="Amelia Licari (amelia.licari@unipv.it) Department of Pediatrics, Fondazione IRCCS Policlinico"/>
   <result pre="IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy Severe" exact="asthma" post="in childhood is a major public health problem and"/>
   <result pre="the fact that conventional treatment options for children with severe" exact="asthma" post="are extremely limited, there are now some &quot;revolutionary, and"/>
   <result pre="asthma. As our understanding of the underlying pathophysiology of the" exact="asthma" post="spectrum expands, a number of pathways have drawn attention"/>
   <result pre="has been applied to many different therapeutic areas, whose severe" exact="asthma" post="is one that had its greatest development in the"/>
   <result pre="is now recommended as add-on treatment for children with severe" exact="allergic asthma." post="Binding to free IgE, omalizumab reduces cell-bound IgE, down-regulates"/>
   <result pre="[3]. Overall, omalizumab was effective in reducing the rate of" exact="asthma" post="exacerbations, the number of hospitalizations for acute asthma attacks"/>
   <result pre="rate of asthma exacerbations, the number of hospitalizations for acute" exact="asthma" post="attacks and the related need of oral corticosteroids in"/>
   <result pre="corticosteroids in severe asthmatic children; these effects resulted in better" exact="asthma" post="control and improvement of quality of life of children"/>
   <result pre="targeted age group [4]. The approved biologics for pediatric severe" exact="asthma" post="have emerged as important and effective treatments to improve"/>
   <result pre="asthma have emerged as important and effective treatments to improve" exact="asthma" post="outcomes; they are expensive therapies and require careful selection"/>
   <result pre="Obesity is also associated with and increased mortality. Rarely, severe" exact="obesity" post="in children can be the result of a monogenic"/>
   <result pre="leptin or with MC4R agonist drugs. Other forms od severe" exact="obesity" post="are part of complex developmental syndromes caused by monogenic"/>
   <result pre="syndrome and others. However, the large majority of forms of" exact="obesity" post="are the result of a complex interaction between predisposing"/>
   <result pre="development of anti-obesity drugs. Finally, recent research have shown that" exact="obesity" post="and its complications are associated with epigenetic alterations. The"/>
   <result pre="genes seem to play a role in the development of" exact="obesity" post="by controlling processes such as adipogenesis, inflammation, appetite and"/>
   <result pre="Obesity is also associated with and increased mortality. Rarely, severe" exact="obesity" post="in children can be the result of a monogenic"/>
   <result pre="leptin or with MC4R agonist drugs. Other forms od severe" exact="obesity" post="are part of complex developmental syndromes caused by monogenic"/>
   <result pre="syndrome and others. However, the large majority of forms of" exact="obesity" post="are the result of a complex interaction between predisposing"/>
   <result pre="development of anti-obesity drugs. Finally, recent research have shown that" exact="obesity" post="and its complications are associated with epigenetic alterations. The"/>
   <result pre="genes seem to play a role in the development of" exact="obesity" post="by controlling processes such as adipogenesis, inflammation, appetite and"/>
   <result pre="including autonomous signs or automatisms. The main etiology is hypoxic-ischemic" exact="encephalopathy" post="(about 45%) with early crises and variable semiology, including"/>
   <result pre="favorable prognosis (neonatal benign familial epilepsy) or unfavorable (early infantile" exact="encephalopathy" post="with epilepsy, early myoclonic encephalopathy and partial migration in"/>
   <result pre="epilepsy) or unfavorable (early infantile encephalopathy with epilepsy, early myoclonic" exact="encephalopathy" post="and partial migration in childhood) [3]. Knowledge of neonatal"/>
   <result pre="the upper airways, due for example to the presence of" exact="allergic rhinitis," post="but also from the postural changes of the intraoral"/>
   <result pre="extra and intraoral aspect of the mouth breathing child. Therefore," exact="allergic rhinitis" post="is one of the main causes of malocclusions in"/>
   <result pre="and intraoral aspect of the mouth breathing child. Therefore, allergic" exact="rhinitis" post="is one of the main causes of malocclusions in"/>
   <result pre="risk. It is estimated that in Italy the prevalence of" exact="allergic rhinitis" post="for subjects in the age range from 6 to"/>
   <result pre="It is estimated that in Italy the prevalence of allergic" exact="rhinitis" post="for subjects in the age range from 6 to"/>
   <result pre="preventive dental examination. A83 Biologic therapy in pediatric chronic non-infectious" exact="uveitis" post="Ilaria Maccora, Gabriele Simonini SODc di Reumatologia, AOU ANNA"/>
   <result pre="21% are associated to Juvenile Idiopathic Arthritis (JIA). Chronic pediatric" exact="uveitis" post="can be a complex therapeutic challenge, that if not"/>
   <result pre="us recommendation for the diagnosis, screening, treatment and management of" exact="uveitis" post="associated to JIA. There is agreement for the first-line"/>
   <result pre="anti-TNFα both result in efficacy. In children with anti-TNFα resistant" exact="uveitis" post="Abatacept, Tocilizumab and Rituximab are other possible options. Abatacept"/>
   <result pre="versus second-line. Tocilizumab is anti-IL6 is an emerging treatment for" exact="uveitis" post="and cystoid macular oedema. Rituximab and canakinumab are progressively"/>
   <result pre="Jacobs J, Springer DA, Crothers D. Homeopatic treatment of acute" exact="otitis media" post="in children: a preliminary randomized placebo- control trial. Pediatr"/>
   <result pre="immune response. IVIG are effective in the resolution of fever," exact="hepatitis" post="and/or cholestasis also if triggered by infections [3]. Anti-TNF-α"/>
   <result pre="IVIG are effective in the resolution of fever, hepatitis and/or" exact="cholestasis" post="also if triggered by infections [3]. Anti-TNF-α drugs are"/>
   <result pre="Maggio MC, Ragusa SS, Corsello G. Early treatment of systemic" exact="juvenile idiopathic arthritis" post="with canakinumab and complete remission after 2 years of"/>
   <result pre="Ragusa SS, Corsello G. Early treatment of systemic juvenile idiopathic" exact="arthritis" post="with canakinumab and complete remission after 2 years of"/>
   <result pre="Alessandra Marchesi (alessandra.marchesi@opbg.net) Kawasaki disease (KD) is an acute, systemic" exact="vasculitis" post="[1,2]. According to the &quot;Revised International Chapel Hill Consensus"/>
   <result pre="disease: a statement for health professionals from the committee on" exact="rheumatic fever," post="endocarditis and Kawasaki disease, council on cardiovascular disease in"/>
   <result pre="statement for health professionals from the committee on rheumatic fever," exact="endocarditis" post="and Kawasaki disease, council on cardiovascular disease in the"/>
   <result pre="committee on rheumatic fever, endocarditis and Kawasaki disease, council on" exact="cardiovascular disease" post="in the young, American Heart Association. Pediatrics. 2004;114:1708-33. 2."/>
   <result pre="2012 Revised international chapel hill consensus conference nomenclature of vasculitides." exact="arthritis" post="rheum. 2013;65:1-11. 4. Marchesi A, Tarissi de Jacobis I,"/>
   <result pre="clinical manifestation of nephropathy, and an independent risk factor for" exact="retinopathy" post="and cardiovascular disease. My work with cohorts of childhood-onset"/>
   <result pre="of nephropathy, and an independent risk factor for retinopathy and" exact="cardiovascular disease." post="My work with cohorts of childhood-onset T1D (Oxford Regional"/>
   <result pre="(AIT) is a proven therapeutic option for the treatment of" exact="allergic rhinitis" post="and/or asthma. AIT is the only therapy that can"/>
   <result pre="is a proven therapeutic option for the treatment of allergic" exact="rhinitis" post="and/or asthma. AIT is the only therapy that can"/>
   <result pre="Padova, 35128, Italy Correspondence: Davide Massano (davide.massano@aopd.veneto.it) Background The word" exact="lymphadenopathy" post="(LAP) identifies a condition in which lymph nodes are"/>
   <result pre="al. Development of an algorithm for the management of cervical" exact="lymphadenopathy" post="in children: consensus of the Italian Society of Preventive"/>
   <result pre="gene therapy and stem-cell technologies to treat patients affected by" exact="junctional epidermolysis bullosa" post="(JEB). They developed a method to extract stem cells"/>
   <result pre="therapy and stem-cell technologies to treat patients affected by junctional" exact="epidermolysis bullosa" post="(JEB). They developed a method to extract stem cells"/>
   <result pre="chimeric antigen receptors), which recently leads to further improvement of" exact="leukemia" post="immunotherapy. Despite only 7 years have passed since CRISPR-cas9"/>
   <result pre="and Kymriah® for the treatment of children with refractory B-cell" exact="acute lymphoblastic leukemia." post="However, they are personalized therapies and thus too expensive"/>
   <result pre="Kymriah® for the treatment of children with refractory B-cell acute" exact="lymphoblastic leukemia." post="However, they are personalized therapies and thus too expensive"/>
   <result pre="F, Di Iorio E, Recchia A, et al. Correction of" exact="junctional epidermolysis bullosa" post="by transplantation of genetically modified epidermal stem cells. Nat"/>
   <result pre="Di Iorio E, Recchia A, et al. Correction of junctional" exact="epidermolysis bullosa" post="by transplantation of genetically modified epidermal stem cells. Nat"/>
   <result pre="317 and 57 were defined as having non-severe and severe" exact="viral disease," post="respectively. TRAIL levels were markedly increased in all viral"/>
   <result pre="(MAS). In childhood, this condition occurs most commonly in systemic" exact="juvenile idiopathic arthritis" post="(sJIA). Primary HLH and MAS share many similarities in"/>
   <result pre="childhood, this condition occurs most commonly in systemic juvenile idiopathic" exact="arthritis" post="(sJIA). Primary HLH and MAS share many similarities in"/>
   <result pre="and the availability of the novel biologic medications. Focusing on" exact="juvenile idiopathic arthritis" post="(JIA), the most common rheumatic disease in childhood and"/>
   <result pre="availability of the novel biologic medications. Focusing on juvenile idiopathic" exact="arthritis" post="(JIA), the most common rheumatic disease in childhood and"/>
   <result pre="in polyarticular JIA and anti interleukin-1 and interleukin-6 in systemic" exact="juvenile idiopathic arthritis." post="Intrarticular corticosteroid injections (IACI) revolutionized not only the treatment"/>
   <result pre="It can be used in the management of children with" exact="bronchiolitis" post="[5] [6] It has also demonstrated 100% accuracy in"/>
   <result pre="accuracy. [9] It is useful even during pulse checks during" exact="cardiac arrest" post="resuscitation [10] and for categorization of shock state and"/>
   <result pre="with thoracic or abdominal trauma. It allows to check hemothorax," exact="pericardial effusion" post="and tamponade, and to identify an intra-abdominal source of"/>
   <result pre="Ellington LE, et al. Lung ultrasound for the diagnosis of" exact="pneumonia" post="in children: a meta-analysis. Pediatrics 2015;135:714–722. 5. Supino MC,"/>
   <result pre="Bock C, Chiaretti A. Point-of-care lung ultrasound in infants with" exact="bronchiolitis" post="in the pediatric emergency department: a prospective study. Eur"/>
   <result pre="Crashing Infant (LUCI) Protocol Study Group. Lung ultrasound for diagnosing" exact="pneumothorax" post="in the critically ill neonate. J Pediatr 2016;175:74–78. 8."/>
   <result pre="Sodano A, Capasso L, Raimondi F. Lung ultrasound- guided emergency" exact="pneumothorax" post="needle aspiration in a very preterm infant. BMJ Case"/>
   <result pre="et al. Emergency department point-of-care ultrasound in out-of-hospital and in-ED" exact="cardiac arrest." post="Resuscitation 2016;109:33-39. 11. Whitson MR, Mayo PH. Ultrasonography in"/>
   <result pre="(WHO 2015). Iron-Deficiency Anemia represents the most common cause of" exact="anemia" post="in immigrant children, but hemoglobinopathies are also frequent. Thalassemias"/>
   <result pre="However, in carriers of both the hemoglobin E gene and" exact="beta-thalassemia" post="severe anemia may result. HbC disease is frequent in"/>
   <result pre="carriers of both the hemoglobin E gene and beta-thalassemia severe" exact="anemia" post="may result. HbC disease is frequent in people originary"/>
   <result pre="is frequent in people originary from West Atlantic Africa. The" exact="anemia" post="is mycrocitic, usually mild or moderate, with a slight"/>
   <result pre="collaboration. A101 The workflow in a home telemonitoring project for" exact="cystic fibrosis" post="patients: the role of the nurse Clarissa Paglia, Bella"/>
   <result pre="the Caucasian population. Classically, the CF is known as a" exact="respiratory disease," post="where it causes repeated infections and progressive bronchiectasis formations"/>
   <result pre="a respiratory disease, where it causes repeated infections and progressive" exact="bronchiectasis" post="formations until the development of respiratory failure. Respiratory exacerbations"/>
   <result pre="repeated infections and progressive bronchiectasis formations until the development of" exact="respiratory failure." post="Respiratory exacerbations are a critical event for the CF"/>
   <result pre="AIT vaccines in adults and in children both for respiratory" exact="allergy" post="and for venom hypersensitivity and recent data look promising"/>
   <result pre="and in children both for respiratory allergy and for venom" exact="hypersensitivity" post="and recent data look promising also for IgE-mediated food"/>
   <result pre="venom hypersensitivity and recent data look promising also for IgE-mediated" exact="food allergy." post="However AIT for many reason remains underused. The European"/>
   <result pre="it is important to begin AIT in childhood when bronchial" exact="asthma" post="and other allergic comorbidities (i.e rhinitis) are often less"/>
   <result pre="efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass" exact="allergy" post="immunotherapy tablet. J Allergy Clin Immunol. 2010;125:131-8.e1-7. 4. Pajno"/>
   <result pre="Alvaro-Lozano M et al. EAACI Guidelines on allergen immunotherapy: IgE-mediated" exact="food allergy." post="Allergy. 2018;73:799-815. 9. Bonertz A, Roberts GC, Hoefnagel M,"/>
   <result pre="IMMUNOTHERAPY Immunotherapy is effective only in IgE-mediated diseases such as" exact="allergic rhinitis," post="allergic asthma and stinging insect anaphylaxis. Successful therapy require"/>
   <result pre="is effective only in IgE-mediated diseases such as allergic rhinitis," exact="allergic asthma" post="and stinging insect anaphylaxis. Successful therapy require years to"/>
   <result pre="effective only in IgE-mediated diseases such as allergic rhinitis, allergic" exact="asthma" post="and stinging insect anaphylaxis. Successful therapy require years to"/>
   <result pre="factors for systemic reaction such as of uncontrolled or severe" exact="asthma" post="or high allergen exposure need to be considered. A103"/>
   <result pre="than one-third of the costs (32%). A105 Endocrine consequences in" exact="cancer" post="survivors Stefania Pedicelli (stefania.pedicelli@gmail.com) Endocrinology Unit, &quot;Bambino Gesù&quot; Children’s"/>
   <result pre="Italy The continuous improvement in treatment and care of childhood" exact="cancer" post="has led to increased long-term survival rates. This has"/>
   <result pre="density. Recent data show that 40% to 50% of childhood" exact="cancer" post="survivors will develop at least one endocrine disorder over"/>
   <result pre="second neoplasia are still debated, whereas the risk of primary" exact="cancer" post="relapse seems to be not increased. Particular attention has"/>
   <result pre="strategies to preserve fertility. In conclusion, the follow-up of childhood" exact="cancer" post="survivors requires a multidisciplinary approach, and, considering that endocrine"/>
   <result pre="in good health and to prevent the problem of overweight," exact="obesity" post="and numerous diseases of young and adult age. As"/>
   <result pre="of PM 10 and PM 2.5 and increased incidence of" exact="asthma" post="and exertion asthma symptoms. In this context the pediatrician"/>
   <result pre="and PM 2.5 and increased incidence of asthma and exertion" exact="asthma" post="symptoms. In this context the pediatrician plays a role"/>
   <result pre="Migliaccio C, Borriello A, Cucciolla V, et al. Von Hippel-Lindau-dependent" exact="polycythemia" post="is endemic on the island of Ischia: identification of"/>
   <result pre="and Wales were the ones with the highest rates of" exact="heart disease." post="Why would this be, he wondered, when heart disease"/>
   <result pre="of heart disease. Why would this be, he wondered, when" exact="heart disease" post="was supposed to be a condition of affluence of"/>
   <result pre="(1921-25)— often an indication of poor prenatal nutrition — and" exact="heart disease" post="in middle age (1968-78) [1]. Faced with an inadequate"/>
   <result pre="a proposal of ten good practices to help to prevent" exact="obesity" post="in the unique window of opportunity, the first 1000"/>
   <result pre="health efforts are needed to achieve the healthy objectives for" exact="obesity" post="and nutrition and to fight the childhood obesity epidemic"/>
   <result pre="objectives for obesity and nutrition and to fight the childhood" exact="obesity" post="epidemic [6]. References 1. Barker DJ, Osmond C. Infant"/>
   <result pre="Barker DJ, Osmond C. Infant mortality, childhood nutrition, and ischaemic" exact="heart disease" post="in England and Wales. Lancet. 1986;1:1077-81. 2. Barker DJ,"/>
   <result pre="B, Simmonds SJ. Weight in infancy and death from ischaemic" exact="heart disease." post="Lancet. 1989;2:577-80. 3. Barker DJ, Gluckman PD, Godfrey KM,"/>
   <result pre="KM, Harding JE, Owens JA, Robinson JS. Fetal nutrition and" exact="cardiovascular disease" post="in adult life. Lancet. 1993;341:938-41. 4. Pietrobelli A, Agosti"/>
   <result pre="for prematurity), is generally considered an ominous sign predictive of" exact="cerebral palsy" post="(CP)[4]. The integration of perinatal history, clinical evaluation, cerebral"/>
   <result pre="A recent study showed in term infants with hypoxic ischemic" exact="encephalopathy" post="a strict correlation between GMs and the site and"/>
   <result pre="points and correlation with long term neuropsychiatric disorders such as" exact="autism" post="and ADHD [6-10]. Moreover, the opportunity for the clinician"/>
   <result pre="months of life: General movements in infants later diagnosed with" exact="autism" post="spectrum disorder or Rett Syndrome. Res Autism Spectr Disord."/>
   <result pre="The most common type of Primary headaches among children are" exact="migraine" post="and tension type headache (TTH), however their differential diagnosis"/>
   <result pre="manage the pain in the likely primary headache in particular" exact="migraine" post="and TTH among patients admitted in Pediatric emergency department"/>
   <result pre="primary headache in children. Ibuprofen maybe more effective in the" exact="migraine" post="and TTH than paracetamol administered orally, but it needs"/>
   <result pre="2012. pp 26-41. A112 Clinical features of the newborn with" exact="neuromuscular disease" post="Carmelo Rachele (carmelo.rachele@virgilio.it) Pediatra di Famiglia FIMP (Federazione Italiana"/>
   <result pre="isolate the genes and to identify the encoded proteins. Duchenne" exact="muscular dystrophy," post="characterized by progressive atrophy and weakness of skeletal and"/>
   <result pre="suspicion, a diagnostic process to confirm the existence of a" exact="neuromuscular disease." post="A113 Acute Ataxia Umberto Raucci (umberto.raucci@opbg.net) Pediatric Emergency Department,"/>
   <result pre="is a relatively uncommon neurological emergency in childhood. Acute post-infectious" exact="cerebellar ataxia" post="is the first cause of acute ataxia in children,"/>
   <result pre="ataxia, and altered levels of consciousness up to coma. Autoimmune" exact="encephalitis" post="(AE) is a severe condition in which the immune"/>
   <result pre="LGI1, CASPR2, VGKC-complex antibodies, AMPA, and GABA. In some patients," exact="encephalopathy" post="can be part of a paraneoplastic phenomenon, although in"/>
   <result pre="who are antibody negative in which etiology remains unknown. Steroid-responsive" exact="encephalopathy" post="associated with autoimmune thyroiditis (Hashimoto encephalopathy) in children or"/>
   <result pre="negative in which etiology remains unknown. Steroid-responsive encephalopathy associated with" exact="autoimmune thyroiditis" post="(Hashimoto encephalopathy) in children or adolescents can begin abruptly"/>
   <result pre="in which etiology remains unknown. Steroid-responsive encephalopathy associated with autoimmune" exact="thyroiditis" post="(Hashimoto encephalopathy) in children or adolescents can begin abruptly"/>
   <result pre="headaches, or acute focal neurological dysfunction. Conclusions. Infectious and non-infectious" exact="encephalitis" post="share similar clinical signs and symptoms. However, neuro-psychiatric symptoms"/>
   <result pre="indeed due to collateral effects (type A reactions), others are" exact="hypersensitivity" post="reactions (type B), while only a few are true"/>
   <result pre="mediated signs and symptoms (urticaria, angioedema, anaphylaxis). Other type of" exact="hypersensitivity" post="reactions have been described (Type II-IV) and require specific"/>
   <result pre="S, Saretta F, Mori F, Blanca-Lopez N, et al. Drug" exact="hypersensitivity" post="in children: report from the pediatric task force of"/>
   <result pre="G. Language and motor skills in siblings of children with" exact="autism" post="spectrum disorder: A meta‐analytic review. Autism Res. 2017;10:1737-1750. 5."/>
   <result pre="It doesn't occur exclusively during the course of anorexia or" exact="bulimia nervosa," post="from which differ for the absence of concern about"/>
   <result pre="isn't better explained by another mental disease. When co-exist a" exact="mental disorder," post="the severity exceeds that routinely associated with the basal"/>
   <result pre="17.4% across eating disorders. [6] Psychiatric comorbidities, including anxiety disorders," exact="autism" post="spectrum disorder and attention deficit hyperactivity disorder (ADHD) are"/>
   <result pre="[6] Psychiatric comorbidities, including anxiety disorders, autism spectrum disorder and" exact="attention deficit hyperactivity disorder" post="(ADHD) are common among individuals with ARFID [7]. ARFID"/>
   <result pre="studies show risk for amenorrhea, bradycardia, prolonged QT interval and" exact="hypokalemia" post="till to neurological degeneration because of folate deficiency. It"/>
   <result pre="N. Severe avoidant/restrictive food intake disorder and coexisting stimulant treated" exact="attention deficit hyperactivity disorder." post="Int J Eat Disord. 2016; 49(11):1036-1039. 8. Toufexis MD,"/>
   <result pre="in pediatric patients. A120 Andrological pathologies in pediatric age: preventing" exact="infertility" post="Matteo Sulpasso (sulpasso.matteo@libero.it) Pederzoli Hospital, Peschiera del Garda (Verona),"/>
   <result pre="may cause serious repercussions on normal fertility and, sometimes, ease" exact="cancer" post="outbreak. Materials and methods Andrological screening should be inserted"/>
   <result pre="sexual health: precocious puberty, delayed puberty, sexually transmitted diseases, varicocele," exact="cryptorchidism" post="and testicular cancer are often preventable and more often"/>
   <result pre="precocious puberty, delayed puberty, sexually transmitted diseases, varicocele, cryptorchidism and" exact="testicular cancer" post="are often preventable and more often curable. Already at"/>
   <result pre="puberty, delayed puberty, sexually transmitted diseases, varicocele, cryptorchidism and testicular" exact="cancer" post="are often preventable and more often curable. Already at"/>
   <result pre="male genital diseases such as varicocele, cryptorchidism, increased incidence of" exact="testicular cancer," post="reduction in semen quality and increase of hypospadias are"/>
   <result pre="of testicular cancer, reduction in semen quality and increase of" exact="hypospadias" post="are the expression of one single phenomenon: testicular dysgenesis"/>
   <result pre="3 adolescents has an andrological disease. The first cause of" exact="male infertility" post="is varicocele. Varicocele occurs in the development age (paediatric-adolescent"/>
   <result pre="adolescents has an andrological disease. The first cause of male" exact="infertility" post="is varicocele. Varicocele occurs in the development age (paediatric-adolescent"/>
   <result pre="with testicular hypotrophy. Cryptorchidism is the second leading cause of" exact="male infertility." post="The risk of developing testicular cancer is 3 to"/>
   <result pre="second leading cause of male infertility. The risk of developing" exact="testicular cancer" post="is 3 to 4 times higher in a criptorchide"/>
   <result pre="leading cause of male infertility. The risk of developing testicular" exact="cancer" post="is 3 to 4 times higher in a criptorchide"/>
   <result pre="4 times higher in a criptorchide patient. Early treatment of" exact="cryptorchidism" post="reduces the risk not only of infertility but also"/>
   <result pre="Early treatment of cryptorchidism reduces the risk not only of" exact="infertility" post="but also of testicular cancer. Conclusions These studies and"/>
   <result pre="reduces the risk not only of infertility but also of" exact="testicular cancer." post="Conclusions These studies and physicians daily experience confirm the"/>
   <result pre="motor function and health-related quality of life in children with" exact="cerebral palsy" post="as reported by their physiotherapists. BMC Pediatr. 2014;14:192. 4."/>
   <result pre="Italy Correspondence: Rita Tanas (tanas.rita@gmail.com) Is there any development in" exact="obesity" post="treatment? Obesity prevalence keeps rising among poorest countries and"/>
   <result pre="out jointly by politics, industry, media, and schools, starting with" exact="obesity" post="stigma. Stigma – which nowadays is spreading and increasing"/>
   <result pre="among professionals too. Failure to achieve the expected results in" exact="obesity" post="treatment leads to disappointment and guilt in pediatricians, who"/>
   <result pre="al. An integrated framework for the prevention and treatment of" exact="obesity" post="and its related chronic diseases. Health Aff (Millwood). 2015;34:1456-63."/>
   <result pre="body image dissatisfaction , eating disorders 3. Increase of weight," exact="obesity" post="comorbidities and death rate among the population 4. Decreased"/>
   <result pre="with families and support good qualities and intentions 2. Accept" exact="obesity" post="as a disease, indeed a chronic disease, and actually"/>
   <result pre="task, including social and incurable ones. 3. Accept that once" exact="obesity" post="has been established, weight loss results can be small."/>
   <result pre="are harmful to the body such as smoking, drugs and" exact="alcohol abuse." post="Physical activity improves the learning abilities and adaptability of"/>
   <result pre="an important form of prevention of respiratory and cardiovascular diseases," exact="obesity" post="and metabolic disease. Regular physical activity with an adequate"/>
   <result pre="physical activity with an adequate workload reduces minute ventilation and" exact="lactic acidosis," post="improves maximum oxygen consumption (VO2max), strengthens the muscle groups"/>
   <result pre="flow outcomes. Acad Emerg Med. 2008;15:832–7. A127 The impact of" exact="rheumatic fever" post="in a Province of Central-North Italy Elena Tronconi 1,"/>
   <result pre="of Bologna, Bologna, Italy Correspondence: Elena Tronconi (elena.tronconi@studio.unibo.it) Background Acute" exact="rheumatic fever" post="(ARF) is a multisystem complication of group A streptococcal"/>
   <result pre="Carditis was present in 27 patients (79.4% of cases) while" exact="chorea" post="in 10 children (29.4%). In 4 patients the diagnosis"/>
   <result pre="It is important to consider the new HR criteria for" exact="arthritis" post="in order not to miss diagnosis. A careful clinical"/>
   <result pre="mandatory. References 1. Carapetis J, McDonald M, Wilson N. Acute" exact="rheumatic fever." post="Lancet. 2005;366:155-168. 2. Gewitz H, Baltimore R, Lloyd T,"/>
   <result pre="Revision of the Jones Criteria for the diagnosis of acute" exact="rheumatic fever" post="in the era of Doppler echocardiography: a scientific statement"/>
   <result pre="Altobelli E. Population-based study of incidence and clinical characteristics of" exact="rheumatic fever" post="in Abruzzo, central Italy, 2000-2009. J Pediatr. 2012;160:832-836.e1. 4."/>
   <result pre="University of Chieti-Pescara, Chieti, Italy Correspondence: Stefano Tumini (stefano.tumini@gmail.com) The" exact="diabetic ketoacidosis" post="is one of the most frequent endocrine diseases in"/>
   <result pre="among the T1DM onset cases [1]. The DKA is a" exact="metabolic disorder" post="caused by the total or partial insulin deficiency and"/>
   <result pre="Sharp SJ, Walter FM. Factors associated with the presence of" exact="diabetic ketoacidosis" post="at diagnosis of diabetes in children and young adults:"/>
   <result pre="vs. 0.48%). Important causes for increased mortality in DS are" exact="congenital heart disease," post="leukemia, testicular cancer and sepsis. In addition, respiratory tract"/>
   <result pre="0.48%). Important causes for increased mortality in DS are congenital" exact="heart disease," post="leukemia, testicular cancer and sepsis. In addition, respiratory tract"/>
   <result pre="for increased mortality in DS are congenital heart disease, leukemia," exact="testicular cancer" post="and sepsis. In addition, respiratory tract infection represents the"/>
   <result pre="increased mortality in DS are congenital heart disease, leukemia, testicular" exact="cancer" post="and sepsis. In addition, respiratory tract infection represents the"/>
   <result pre="rhinoviruses, parainfluenza viruses type 1, 2, 3 and 4 and" exact="influenza" post="viruses type A and B. The remaining 20% of"/>
   <result pre="8. Kaur R, Morris M, Pichichero ME. Epidemiology of acute" exact="otitis media" post="in the postpneumococcal conjugate vaccine era. Pediatrics. 2017;140: pii:"/>
   <result pre="one lives, especially in later generations, with increased incidence of" exact="obesity" post="and its serious consequences up to DM2 and metabolic"/>
   <result pre="of obesity and its serious consequences up to DM2 and" exact="metabolic syndrome." post="All this may depend on various endogenous and exogenous"/>
   <result pre="many children, who come from areas with iodine deficiency, where" exact="congenital hypothyroidism" post="also appears to be more frequent, once they take"/>
   <result pre="children, who come from areas with iodine deficiency, where congenital" exact="hypothyroidism" post="also appears to be more frequent, once they take"/>
   <result pre="take normal iodine amounts they run the risk of developing" exact="autoimmune thyroiditis." post="Moreover, the frequent finding of elevated TSH at arrival"/>
   <result pre="is an endemic, underdiagnosed, bacterial respiratory infection caused by Bordetella" exact="pertussis" post=". Despite a widespread vaccination program, pertussis continues to"/>
   <result pre="caused by Bordetella pertussis . Despite a widespread vaccination program," exact="pertussis" post="continues to be a common worldwide infection in paediatric"/>
   <result pre="US, Canada and Australia too. Infants are known to acquire" exact="pertussis" post="from adolescents’ and adults’ contacts that return susceptible to"/>
   <result pre="on age: in previously immunised or infected adolescents and adults" exact="pertussis" post="can be atypical and often asymptomatic, with the main"/>
   <result pre="rates [2]. The cause of deaths in infants is irreversible" exact="pulmonary hypertension" post="associated with aggregates of white blood cells in pulmonary"/>
   <result pre="medications provide symptomatic relief from pertussis-associated cough. Antibiotics eliminate Bordetella" exact="pertussis" post="from nasopharynx and reduce the risk of transmission; they"/>
   <result pre="with WHO, demonstrate that the best cost-effective intervention in newborns" exact="pertussis" post="prevention is the vaccination with dTap vaccine in the"/>
   <result pre="Infect Dis. 2016;16:414. 2) Cherry JD. The prevention of severe" exact="pertussis" post="and pertussis deaths in young infant. Expert Rev Vaccines."/>
   <result pre="2016;16:414. 2) Cherry JD. The prevention of severe pertussis and" exact="pertussis" post="deaths in young infant. Expert Rev Vaccines. 2019;18:205-208. 3)"/>
   <result pre="Sin J, NG ESW, Wang K. Efficacy and safety of" exact="pertussis" post="vaccination for pregnant women - a systematic review of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6921558/results/search/disease/results.xml">
   <result pre="22] and opioids [ 23] has also been described in" exact="cerebral palsy." post="Among neuropsychiatric disorders, neuromuscular diseases are considered at the"/>
   <result pre="are considered at high risk of specific anesthesiologic complications as" exact="malignant hyperthermia" post="or rhabdomyolysis, in particular after inhaled anesthetics’ administration ["/>
   <result pre="non-sevoflurane-based anesthesia (16.2 vs. 8.6%; p = 0.012) and affected by" exact="neuromuscular disease" post="(22.8 vs. 8.6%; p &amp;lt; 0.001) were significantly more frequently ventilated."/>
   <result pre="50 min and for respiratory complications ASA score, presence of a" exact="neuromuscular disease," post="anesthesia length superior to 50 min and season autumn-winter; they"/>
   <result pre="R Berkenbosch JW Dexmedetomidine for procedural sedation in children with" exact="autism" post="and other behavior disorders Paediatr Neurol 2009 41 88"/>
   <result pre="Kern C Minimum alveolar concentration for halothane in children with" exact="cerebral palsy" post="and severe mental retardation Anaesth 1997 52 1056 1060"/>
   <result pre="MC Akins RE Surgery and anesthesia for children who have" exact="cerebral palsy" post="Anesth Clin North Am 2005 23 733 743 10.1016/j.atc.2005.08.001"/>
   <result pre="Lerman J Perioperative management of the paediatric patient with coexisting" exact="neuromuscular disease" post="Br J Anaesth 2011 107 Suppl 1 i79 i89"/>
   <result pre="JA Finder JD Perioperative respiratory management of pediatric patients with" exact="neuromuscular disease" post="Paediatr Anaesth 2013 23 9 770 776 10.1111/pan.12214 23763308"/>
   <result pre="T Erhan OL Anaesthesia management in a child with metabolic" exact="myopathy" post="Eur Rev Med Pharmacol Sci 2014 18 22 3347"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6925508/results/search/disease/results.xml">
   <result pre="children are asthma, diabetes, obesity, migraine, epilepsy, developmental disabilities, and" exact="cancer" post="[ 3]. In recent years, the prevalence in Mexico"/>
   <result pre="of the 446 patients had an oncologic disease. Acute lymphocytic" exact="leukemia" post="was the most frequent cancer. Moreover, 7% ( n = 31)"/>
   <result pre="flow due to a congenital heart defect, 4.7% ( n = 21)" exact="nephrotic syndrome," post="4% ( n = 18) end-stage renal disease, 2.9% ( n = 13)"/>
   <result pre="(n = 3) HIV/AIDS, 0.7% (n = 3) organ transplant care, and 0.4% (n = 2)" exact="cystic fibrosis." post="There was no difference in diagnosis between the sexes."/>
   <result pre="these patients are treated in another service specialized in this" exact="endocrine disease." post="Among the patients, 62.3% ( n = 278) were hospitalized for"/>
   <result pre="The challenge of quality care for family caregivers in pediatric" exact="cancer" post="care Semin Oncol Nurs 2012 28 213 220 10.1016/j.soncn.2012.09.003"/>
   <result pre="the mental health and wellbeing of caregivers of children with" exact="autism" post="in mid-childhood J Autism Dev Disord 2018 48 1189"/>
   <result pre="C Affiliate stigma and depression in caregivers of children with" exact="autism" post="spectrum disorders in China: effects of self-esteem, shame and"/>
   <result pre="Fitzpatrick P Caregiver burden of parents of young children with" exact="cystic fibrosis" post="J Cyst Fibros 2018 17 125 131 10.1016/j.jcf.2017.08.016 29150357"/>
   <result pre="Possin P Frierdich S Bryne B Family resiliency in childhood" exact="cancer" post="Fam Relat 2002 51 103 111 10.1111/j.1741-3729.2002.00103.x 30. Nabors"/>
   <result pre="of connectedness: processes of resilience and growth in children with" exact="cancer" post="J Pediatr Psychol 2015 40 904 913 10.1093/jpepsy/jsv036 25968051"/>
   <result pre="impacting the mental health of the caregivers of children with" exact="asthma" post="in China: effects of family socioeconomic status, symptoms control,"/>
   <result pre="perceived by Indian mothers of children and young adults with" exact="cerebral palsy" post="who have limited self-mobility Phys Occup Ther Pediatr. 2017"/>
   <result pre="affecting the quality of life of caregivers of children with" exact="cerebral palsy" post="Disabil Rehabil 2016 38 2374 2382 10.3109/09638288.2015.1129451 26752264 37."/>
   <result pre="Mental health and parenting characteristics of caregivers of children with" exact="spina bifida" post="J Pediatr Urol 2015 11 65.e1 65.e7 10.1016/j.jpurol.2014.09.009 25802105"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6926624/results/search/disease/results.xml">
   <result pre="department abdominal pain vitamin D low income middle income migrants" exact="irritable bowel syndrome" post="(IBS) 1. Introduction The definition of pain as given"/>
   <result pre="prevailing opinion in pathophysiology emphasizes the inter-relationship between alterations in" exact="hypersensitivity" post="and changed motility, with many associated risk factors ["/>
   <result pre="and even uncommon infectious diseases (e.g. tuberculosis, human immunodeficiency virus," exact="histoplasmosis" post="and others) are frequent causes of AP in migrants"/>
   <result pre="Recent evidence supports the concept that functional AP, for instance," exact="irritable bowel syndrome" post="(IBS), might be attributed to vitamin D deficiency (VDD),"/>
   <result pre="abdominal pathologies, such as pancreatitis, cholecystitis, cholangitis, acute hepatitis, and" exact="bowel obstruction" post="(ileus); urological/renal disorders (including infection, lithiasis); gynecological, oncological, or"/>
   <result pre="of anxiety and depression are frequently connected with chronic functional" exact="constipation" post="provoked by disorders in intestinal motility. 25OHD serum concentrations"/>
   <result pre="D was shown to be superior to placebo in reducing" exact="migraine" post="days [ 41]. Moreover, in a prospective case-control study,"/>
   <result pre="Moreover, in a prospective case-control study, it was demonstrated that" exact="migraine" post="had severe VDD compared to the control group and"/>
   <result pre="days with headache was related to VDD among patients with" exact="migraine" post="[ 43]. Lastly, comparable additional data on migraines and"/>
   <result pre="302 312 10.1373/clinchem.2018.296491 30518662 9. Cervellin G. Lippi G. Abdominal" exact="migraine" post="in the differential diagnosis of acute abdominal pain Am."/>
   <result pre="B.U. Maranda L. Candela N. Vitamin D status in pediatric" exact="irritable bowel syndrome" post="PLoS ONE 2017 12 e0172183 28192499 17. El Amrousy"/>
   <result pre="C.M. De Carne M. Rinaldi C.M. Shahini E. Chronic functional" exact="constipation" post="is strongly linked to vitamin D deficiency World J."/>
   <result pre="trial of vitamin D 3 supplementation in adult patients with" exact="migraine" post="Curr. Med. Res. Opin. 2019 35 715 723 10.1080/03007995.2018.1519503"/>
   <result pre="Gambardella A. Bono F. Sarica A. Relationship between severity of" exact="migraine" post="and vitamin D deficiency: A case-control study Neurol. Sci."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6928139/results/search/disease/results.xml">
   <result pre="table-count: equation-count: ref-count: page-count: word-count: Introduction Tic disorders (TD), including" exact="transient tic disorder" post="(TTD), chronic motor or vocal tic disorder (CTD), and"/>
   <result pre="equation-count: ref-count: page-count: word-count: Introduction Tic disorders (TD), including transient" exact="tic disorder" post="(TTD), chronic motor or vocal tic disorder (CTD), and"/>
   <result pre="(TD), including transient tic disorder (TTD), chronic motor or vocal" exact="tic disorder" post="(CTD), and Tourette syndrome (TS), are common neuropsychiatric disorders"/>
   <result pre="in up to 25% of healthy children. The prevalence of" exact="chronic tic disorder" post="is about 1–3% and that for TS varies from"/>
   <result pre="up to 25% of healthy children. The prevalence of chronic" exact="tic disorder" post="is about 1–3% and that for TS varies from"/>
   <result pre="15-fold increased risk of developing Tourette syndrome/chronic motor or vocal" exact="tic disorder" post="in siblings of individuals with Tourette syndrome, a positive"/>
   <result pre="having an 86% concordance rate with chronic motor or vocal" exact="tic disorder" post="compared to 20% in dizygotic twins ( 6). Although"/>
   <result pre="with obsessive compulsive disorder (OCD), major depression, and migraine, especially" exact="migraine" post="with aura ( 7, 8). There is much literature"/>
   <result pre="complex and diversified as well. In current clinics, treatment of" exact="tic disorder" post="mainly depends on medicines ( 11). The conventional medicines"/>
   <result pre="with many common comorbidities, the most common of which is" exact="attention deficit hyperactivity disorder" post="(ADHD). Some studies have found that serum Zn and"/>
   <result pre="course. Antipsychotics are the oldest and most effective treatment for" exact="tic disorder." post="Although most randomized controlled trials of antipsychotic treatment of"/>
   <result pre="disorder. Although most randomized controlled trials of antipsychotic treatment of" exact="tic disorder" post="have shown superior efficacy over placebo, there are also"/>
   <result pre="in iron levels are associated with dopamine-related dyskinesias, such as" exact="restless legs syndrome" post="( 42). We selected serum iron which is relatively"/>
   <result pre="studies to pay attention to the relationship between copper and" exact="tic disorder." post="Our study showed that serum copper levels in the"/>
   <result pre="This study only reveal the relationship of trace element with" exact="tic disorder," post="it is still unclear whether supplementation of corresponding trace"/>
   <result pre=". Iron, dopamine, genetics, and hormones in the pathophysiology of" exact="restless legs syndrome." post="J Neurol. ( 2017) 264: 1634– 41. 10.1007/s00415-017-8431-1 28236139"/>
   <result pre="Allen R . Dopamine and iron in the pathophysiology of" exact="restless legs syndrome" post="(RLS). Sleep Med. ( 2004) 5: 385– 91. 10.1016/j.sleep.2004.01.012"/>
   <result pre="BH Zhang YF . Relationship between serum zinc levels and" exact="attention deficit hyperactivity disorder" post="in children . Zhongguo Dang Dai Er Ke Za"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6929435/results/search/disease/results.xml">
   <result pre="pmcid: 6929435 1066 doi: 10.1186/s10194-019-1066-0 : Review Article Mechanisms of" exact="migraine" post="as a chronic evolutive condition http://orcid.org/0000-0002-7008-6626 Andreou Anna P."/>
   <result pre="indicate if changes were made. Abstract Understanding the mechanisms of" exact="migraine" post="remains challenging as migraine is not a static disorder,"/>
   <result pre="made. Abstract Understanding the mechanisms of migraine remains challenging as" exact="migraine" post="is not a static disorder, and even in its"/>
   <result pre="not a static disorder, and even in its episodic form" exact="migraine" post="remains an &quot;evolutive&quot; chronic condition. Considerable progress has been"/>
   <result pre="and functional and anatomical changes during the progression of a" exact="migraine" post="attack or the transformation of episodic to chronic migraine."/>
   <result pre="of episodic to chronic migraine. Migraine is a life span" exact="neurological disorder" post="that follows an evolutive age-dependent change in its prevalence"/>
   <result pre="in its prevalence and even clinical presentations. As a disorder," exact="migraine" post="involves recurrent intense head pain and associated unpleasant symptoms."/>
   <result pre="and symptoms being involved during each phase. In some patients," exact="migraine" post="can be transformed into a chronic form with daily"/>
   <result pre="play an important role. Introduction Migraine is a recurrent, disabling" exact="neurological disorder," post="involving intense head pain and associated with other unpleasant"/>
   <result pre="life with a significant socioeconomic impact. The toll of chronic" exact="migraine" post="on individual and society is even bigger, as up"/>
   <result pre="3], with nearly half of them in need of a" exact="migraine" post="preventive treatment [ 4]. The World Health Organization ranks"/>
   <result pre="migraine preventive treatment [ 4]. The World Health Organization ranks" exact="migraine" post="as the most prevalent, disabling, long-term neurological condition when"/>
   <result pre="and functional and anatomical changes during the progression of a" exact="migraine" post="attack, or the transformation of episodic to chronic migraine."/>
   <result pre="to chronic migraine. However, understanding disease mechanisms remains challenging as" exact="migraine" post="is not a static disorder, and even in its"/>
   <result pre="not a static disorder, and even in its episodic form" exact="migraine" post="remains an &quot;evolutive&quot; chronic condition. Migraine as a life"/>
   <result pre="affecting children, adults and the elderly. The clinical presentation of" exact="migraine" post="shows an age-dependent change with shorter duration and also"/>
   <result pre="absence of autonomic signs in the elderly. The prevalence of" exact="migraine" post="in children varies, depending on the study and the"/>
   <result pre="differ between girls and boys [ 6, 7]. In adulthood," exact="migraine" post="is more prevalent in women than in men with"/>
   <result pre="A factor that may contribute to the increased prevalence of" exact="migraine" post="in women compared to men in the reproductive years"/>
   <result pre="11, 12], indicating further the influence of hormonal changes on" exact="migraine" post="occurrence. The prevalence of migraine in the elderly is"/>
   <result pre="influence of hormonal changes on migraine occurrence. The prevalence of" exact="migraine" post="in the elderly is about 3.5% with females affected"/>
   <result pre="often than males [ 13, 14]. The clinical manifestation of" exact="migraine" post="is different in childhood from that in adulthood. Pediatric"/>
   <result pre="migraine is different in childhood from that in adulthood. Pediatric" exact="migraine" post="is characterized by shorter attacks with the pain being"/>
   <result pre="be partially responsible for the changes in the prevalence of" exact="migraine" post="in adults and the elderly, another general feature seems"/>
   <result pre="hypothalamic areas to different autonomic control centres during aging in" exact="migraine" post="[ 18]. Readers interested in changes in migraine symptoms"/>
   <result pre="aging in migraine [ 18]. Readers interested in changes in" exact="migraine" post="symptoms during lifespan, as well as, in mechanisms that"/>
   <result pre="Straube and Andreou [ 18]. Genetic and epigenetic component of" exact="migraine" post="Genetic factors may determine susceptibility to migraine, while different"/>
   <result pre="different environmental factors can contribute to the development of a" exact="migraine" post="attack [ 19, 20]. Mainly through genome-wide association studies"/>
   <result pre="frequencies of single nucleotide polymorphisms (SNPs) over the genome in" exact="migraine" post="patients and controls [ 21], it is now understood"/>
   <result pre="will highlight which molecular pathways potentially could be involved in" exact="migraine" post="pathophysiology [ 20]. In the latest GWAS which included"/>
   <result pre="patients and over 300,000 controls, 44 SNPs were associated with" exact="migraine" post="without aura, implicating 38 distinct genomic loci [ 23]."/>
   <result pre="rather unexpected, hypothesis that metal ion homeostasis might contribute to" exact="migraine" post="susceptibility. Only a handful of loci was found to"/>
   <result pre="study highlighted that vascular dysfunction is of great importance in" exact="migraine" post="susceptibility with neuronal dysfunction playing a rather secondary role"/>
   <result pre="link associated SNPs to actual genes and pathways. GWAS in" exact="migraine" post="are yet to offer further knowledge on the functional"/>
   <result pre="genetic studies of hemiplegic migraine, a rare monogenic forms of" exact="migraine" post="[ 24] offered knowledge about specific genes that encode"/>
   <result pre="assays or in mutant murine. In brief, mutations involved in" exact="familial hemiplegic migraine" post="were found in the genes CACNA1A, ATP1A2 and SCN1A,"/>
   <result pre="in mutant murine. In brief, mutations involved in familial hemiplegic" exact="migraine" post="were found in the genes CACNA1A, ATP1A2 and SCN1A,"/>
   <result pre="increased susceptibility to cortical spreading depression, the underlying mechanism of" exact="migraine" post="aura [ 28, 29]. Interestingly, mice carrying the CACNA1A"/>
   <result pre="migraine, to date they failed to explain the pathophysiology of" exact="migraine" post="and evolutive mechanisms. However, it is important to mention"/>
   <result pre="may be able to explain better the mechanisms that transform" exact="migraine" post="into a chronic form in some individuals or achieve"/>
   <result pre="migraine into a chronic form in some individuals or achieve" exact="migraine" post="freedom altogether later in life. Is there a role"/>
   <result pre="in life. Is there a role for epigenetic mechanisms in" exact="migraine" post="susceptibility and chronification? Beyond genetic factors that could be"/>
   <result pre="and chronification? Beyond genetic factors that could be responsible for" exact="migraine" post="susceptibility and evolution to migraine chronification, epigenetic pathways through"/>
   <result pre="that could be responsible for migraine susceptibility and evolution to" exact="migraine" post="chronification, epigenetic pathways through changes in DNA expression could"/>
   <result pre="research and only a handful of studies are done in" exact="migraine" post="patients. Recently, the first genome-wide study of DNA methylation"/>
   <result pre="methylation levels in episodic migraineurs and patients suffering from chronic" exact="migraine" post="with medication overuse headache (MOH), before and after detox"/>
   <result pre="evolve over time, have been reported by several studies between" exact="migraine" post="patients and controls. The prevalence and volume of deep"/>
   <result pre="and volume of deep white matter lesions is increased in" exact="migraine" post="patients, with women with migraine with aura having the"/>
   <result pre="matter lesions is increased in migraine patients, with women with" exact="migraine" post="with aura having the highest prevalence [ 34– 36]."/>
   <result pre="ARIC MRI study [ 39], the authors showed that although" exact="migraine" post="has an increased insistence of white matter lesions, there"/>
   <result pre="no progression overtime. The authors suggest that the association between" exact="migraine" post="and white matter lesions is stable in older age"/>
   <result pre="of the GWAS on vascular factors that may contribute to" exact="migraine" post="susceptibility, may also suggest an increased susceptibility to white"/>
   <result pre="lesions. A number of studies showed cortical structural changes in" exact="migraine" post="patients (detail reviews can be found here [ 43–"/>
   <result pre="include, increased thickening in the somatosensory cortex of patients with" exact="migraine" post="that does not differ between patients with and without"/>
   <result pre="recent multi-centre 3 T MRI study utilising a large number of" exact="migraine" post="patients [ 53] demonstrated significant clusters of thinner cortex"/>
   <result pre="demonstrated significant clusters of thinner cortex in the patients with" exact="migraine" post="compared with control subjects [ 54]. Gray matter changes"/>
   <result pre="region of the thalamus and a reduced striatal volume in" exact="migraine" post="subjects with and without aura. Studies have shown broad"/>
   <result pre="Studies have shown broad microstructural alterations in the thalamus of" exact="migraine" post="patients that may underlie abnormal cortical excitability. These changes"/>
   <result pre="colleagues demonstrated that structural changes in the brain of episodic" exact="migraine" post="patients without aura evolve over the course of the"/>
   <result pre="migraine patients without aura evolve over the course of the" exact="migraine" post="cycle. Interictally, patients were shown to have a significantly"/>
   <result pre="[ 58]. Whether these changes are an important mechanism of" exact="migraine" post="pathology remains to be evaluated. If indeed these data"/>
   <result pre="correlate with headache frequency assessed in both episodic and chronic" exact="migraine" post="[ 60]. Recently, another study demonstrated alterations in the"/>
   <result pre="the hypothalamus being significantly decreased in both episodic and chronic" exact="migraine" post="patients, which in CM was positively correlated with headache"/>
   <result pre="of these changes. What causes these structural changes in the" exact="migraine" post="brain is not known. Some alterations may be due"/>
   <result pre="alterations may be due to a genetic susceptibility towards developing" exact="migraine" post="attacks. To this end, structural brain studies in paediatric"/>
   <result pre="migraine attacks. To this end, structural brain studies in paediatric" exact="migraine" post="patients, could shed more light in the cause of"/>
   <result pre="showed significant alterations in brain volume. Compared to controls, paediatric" exact="migraine" post="patients experienced a significant gray matter loss in several"/>
   <result pre="gyrus had an increased volume. In the paediatric population of" exact="migraine" post="these structural changes were not correlated with disease duration"/>
   <result pre="apparent diffusion coefficient (ADC) found no volumetric changes in paediatric" exact="migraine" post="patients, but demonstrated increased ADC in the region of"/>
   <result pre="data suggest that brain abnormalities do occur early on in" exact="migraine" post="patients and the absence of correlation with patient clinical"/>
   <result pre="in the migraineur’s brain, their importance in the biology of" exact="migraine" post="remains uncertain. Nevertheless, the existence of structural changes, suggest"/>
   <result pre="remains uncertain. Nevertheless, the existence of structural changes, suggest that" exact="migraine" post="induces progressive anatomical transformation in the brain that may"/>
   <result pre="evolutive role in disease progression and associated disability. The evolutive" exact="migraine" post="attack Migraine is cyclic disorders with a complex sequence"/>
   <result pre="of symptoms within every headache attack. In its episodic form," exact="migraine" post="is characterised by recurrent attacks involving different phases: (a)."/>
   <result pre="mood changes [ 66] (b). Transient neurological symptoms, known as" exact="migraine" post="aura (typically visual alterations), that occur just before the"/>
   <result pre="head, which can be exacerbated by movement and accompanied with" exact="hypersensitivity" post="to sensory stimuli (e.g. light and smells), nausea ["/>
   <result pre="common [ 70]. Significant advances have been made in characterising" exact="migraine" post="as a brain disorder and in identifying evolutive functional"/>
   <result pre="in different brain areas during the different phases of a" exact="migraine" post="attack (Fig. 1). However, despite the number of studies"/>
   <result pre="phase [ 71], the molecular changes that actually trigger a" exact="migraine" post="attack in the brain remain unknown. The lack of"/>
   <result pre="Emerging evidence, partly obtained through use of the newly designed" exact="migraine" post="treatments designed against the calcitonin gene-related peptide (CGRP) and"/>
   <result pre="highlights an important role of the trigeminal system in driving" exact="migraine" post="attacks. Fig. 1 Migraine is cyclic disorders with a"/>
   <result pre="of symptoms within every headache attack. In its episodic form," exact="migraine" post="is characterised by recurrent attacks involving different phases, with"/>
   <result pre="within every phase. Significant advances have been made in characterising" exact="migraine" post="as a brain disorder and in identifying evolutive functional"/>
   <result pre="in different brain areas during the different phases of a" exact="migraine" post="attack The premonitory phase and the triggering mechanisms of"/>
   <result pre="migraine attack The premonitory phase and the triggering mechanisms of" exact="migraine" post="Accumulating evidence exists as to why the trigger of"/>
   <result pre="migraine Accumulating evidence exists as to why the trigger of" exact="migraine" post="attacks should be sought in the hypothalamus. The hypothalamus"/>
   <result pre="hypothalamus, may be also responsible for the monthly, menstrual associated" exact="migraine" post="attacks, and the increased prevalence of migraine in women"/>
   <result pre="monthly, menstrual associated migraine attacks, and the increased prevalence of" exact="migraine" post="in women (~ 3:1) [ 76]. The premonitory symptoms of"/>
   <result pre="migraine in women (~ 3:1) [ 76]. The premonitory symptoms of" exact="migraine" post="are strongly associated with homeostatic functions regulated by the"/>
   <result pre="and feeding. The strongest, direct evidence for hypothalamic activation in" exact="migraine" post="patients arises from brain imaging studies. These studies demonstrated,"/>
   <result pre="of the hypothalamus during the very early stages of spontaneous" exact="migraine" post="attacks [ 77, 78] and during the premonitory phase"/>
   <result pre="and during the premonitory phase of nitroglycerin (nitric oxide-NO donor)-induced" exact="migraine" post="attacks [ 79]. A disturbance in homeostatic function is"/>
   <result pre="as sleep disturbances can trigger attacks in over 50% of" exact="migraine" post="sufferers. Additionally, patients with both episodic and chronic migraine"/>
   <result pre="of migraine sufferers. Additionally, patients with both episodic and chronic" exact="migraine" post="are more prone to have their attacks in the"/>
   <result pre="are also common in patients with sleep disorders, while post-operative" exact="migraine" post="attacks in patients are common following anaesthesia [ 81]."/>
   <result pre="called familiar advanced sleep phase syndrome, was strongly linked to" exact="migraine" post="both clinically and experimentally in mice engineered to carry"/>
   <result pre="to carry this mutation [ 83]. The increased comorbidity of" exact="migraine" post="in narcolepsy [ 84] and sleepwalking [ 85], also"/>
   <result pre="this mutation [ 83]. The increased comorbidity of migraine in" exact="narcolepsy" post="[ 84] and sleepwalking [ 85], also supports that"/>
   <result pre="narcolepsy [ 84] and sleepwalking [ 85], also supports that" exact="migraine" post="is an arousal-related disorder. Such evidence highlights that the"/>
   <result pre="been investigated. Although several neurochemical pathways may be involved in" exact="migraine" post="pathophysiology [ 86], of them, dopaminergic mechanisms appear to"/>
   <result pre="be susceptible to nitric oxide donors in animal models of" exact="migraine" post="[ 90, 91]. Of interest, an fMRI study of"/>
   <result pre="interest, an fMRI study of daily brain scans in a" exact="migraine" post="patient reported a strong association for both hypothalamic and"/>
   <result pre="attack [ 78]. The involvement of the occipital cortex in" exact="migraine" post="has been long recognised, in particular because of the"/>
   <result pre="hyperactive [ 92, 93]. A study of photophobia during spontaneous" exact="migraine" post="attacks using PET imaging also found that this migraine"/>
   <result pre="spontaneous migraine attacks using PET imaging also found that this" exact="migraine" post="symptom is linked with visual cortex hyperexcitability [ 94,"/>
   <result pre="94, 95]. It has been suggested that thalamo-cortical dysrhythmia in" exact="migraine" post="patients may be responsible for abnormal cortical responses ["/>
   <result pre="cortical responses [ 96]. Hence, a focal cortical treatment for" exact="migraine" post="without systemic side effects is an attractive treatment opportunity."/>
   <result pre="ascending trigemino-thalamic pathway [ 97] and is now an approved" exact="migraine" post="treatment with good efficacy in the acute and preventive"/>
   <result pre="with good efficacy in the acute and preventive treatment of" exact="migraine" post="[ 98– 100]. The migraine aura Migraine with aura"/>
   <result pre="acute and preventive treatment of migraine [ 98– 100]. The" exact="migraine" post="aura Migraine with aura symptoms are typically seen in"/>
   <result pre="fMRI studies that tried to capture or simulate aura in" exact="migraine" post="patients also pointed to a role for CSD as"/>
   <result pre="pointed to a role for CSD as a mechanism for" exact="migraine" post="aura [ 103, 104]. CSD is a wave of"/>
   <result pre="neuronal activity and blood flow changes [ 105], which in" exact="migraine" post="is believed to spread out from the occipital cortex."/>
   <result pre="It remains enigmatic how CSD is triggered in patients during" exact="migraine" post="aura. Potentially, if indeed cortex is hyperactive in patients,"/>
   <result pre="for the cortex and this has also been recorded in" exact="migraine" post="patients without aura [ 102]. The discussion of CSD-induced"/>
   <result pre="without aura [ 102]. The discussion of CSD-induced headache in" exact="migraine" post="is still a matter of debate, as not every"/>
   <result pre="migraine is still a matter of debate, as not every" exact="migraine" post="patient experiences migraine aura, while the occurrence of aura"/>
   <result pre="a matter of debate, as not every migraine patient experiences" exact="migraine" post="aura, while the occurrence of aura without a headache"/>
   <result pre="pathway [ 115]. The headache phase The headache phase of" exact="migraine" post="involves activation of the ascending trigeminothalamic pathway. Through early"/>
   <result pre="surgery, it became well established that the pain during a" exact="migraine" post="attack is perceived to be felt on intracranial structures,"/>
   <result pre="the thalamus and pain modulating/pain encoding cortical areas during spontaneous" exact="migraine" post="attacks, as well as, thalamo-cortical dysrhythmia which correlate with"/>
   <result pre="migraine attacks, as well as, thalamo-cortical dysrhythmia which correlate with" exact="migraine" post="symptoms [ 121, 122]. Recently, a dynamic functional connectivity"/>
   <result pre="[ 121, 122]. Recently, a dynamic functional connectivity study in" exact="migraine" post="patients between attacks demonstrated abnormal thalamo-cortical network dynamics, with"/>
   <result pre="connectivity networks [ 123]. The role of the thalamus in" exact="migraine" post="deserves higher attention given its involvement in the development"/>
   <result pre="its involvement in the development of associated symptoms, such as" exact="hypersensitivity" post="to visual stimuli [ 124], while thalamo-cortical activation may"/>
   <result pre="the development of non-cranial allodynia that is frequently seen in" exact="migraine" post="patients [ 126]. A complex of descending networks from"/>
   <result pre="and brainstem in both episodic [ 128, 129] and chronic" exact="migraine" post="patients [ 130]. A great limitation of brain imaging"/>
   <result pre="nucleus raphe magnus. Initially, these loci were considered as the" exact="migraine" post="generator, due to the persistent blood flow increased in"/>
   <result pre="of pain inhibition in migraineurs [ 53]. The puzzle of" exact="migraine" post="pathophysiology is still incomplete, as we are yet to"/>
   <result pre="(CSD) is thought to be the biological process of the" exact="migraine" post="aura. How activation of the hypothalamus may lead to"/>
   <result pre="brainstem, or the parasympathetic system, leading to the development of" exact="migraine" post="aura and activation of the ascending trigeminothalamic pathway An"/>
   <result pre="equally important pathway may be the trigeminal autonomic activation in" exact="migraine" post="driven by the hypothalamus. Although autonomic features in migraine"/>
   <result pre="in migraine driven by the hypothalamus. Although autonomic features in" exact="migraine" post="are not as prominent as in trigeminal autonomic cephalalgias,"/>
   <result pre="and the otic ganglia [ 133]. Sphenopalatine ganglion block in" exact="migraine" post="patients with autonomic features was found to relieve the"/>
   <result pre="modulation of the trigeminal autonomic reflex by the hypothalamus in" exact="migraine" post="may be of great importance. The trigeminal system and"/>
   <result pre="system and its role in sustaining the head pain in" exact="migraine" post="Despite the various evidence of increased blood flow changes"/>
   <result pre="of the ascending trigemino-thalamic pathway in a manner that a" exact="migraine" post="headache may develop in susceptible individuals remains to be"/>
   <result pre="importance in driving the headache; The referred pain patterns of" exact="migraine" post="headache are similar to the locations of referred pain"/>
   <result pre="vast innervation by trigeminal fibres. CGRP levels are increased during" exact="migraine" post="attacks. Blood samples from patients or animal models during"/>
   <result pre="fibres suggest that the origin of the CGRP found in" exact="migraine" post="patients is indeed from the trigeminal nerve [ 139–"/>
   <result pre="145– 147], such as CGRP and histamine, can trigger a" exact="migraine" post="attack [ 148, 149]. It is worth pointing out"/>
   <result pre="the pain is not vasodilation as originally thought, as the" exact="migraine" post="headache is not associated with cerebral or meningeal vasodilation"/>
   <result pre="not susceptible (or respond to a much lower degree) to" exact="migraine" post="headache following provocation with such chemicals, suggesting that the"/>
   <result pre="provocation with such chemicals, suggesting that the trigeminal system in" exact="migraine" post="patients is sensitized. Effective migraine treatments, like the hydrophilic"/>
   <result pre="that the trigeminal system in migraine patients is sensitized. Effective" exact="migraine" post="treatments, like the hydrophilic sumatriptan, the large monoclonal antibodies"/>
   <result pre="demonstrate an important role for the peripheral trigeminal system in" exact="migraine" post="headache. This evidence further suggests that treatments that can"/>
   <result pre="effective in suppressing migraine, but not necessarily the generator of" exact="migraine" post="attacks. The trigeminal system, as well as, the trigemino-thalamic"/>
   <result pre="the major excitatory neurotransmitter [ 120]. An ideal treatment for" exact="migraine" post="would block the glutamatergic transmission along these pathways, as"/>
   <result pre="more promising treatment approach [ 155, 156]. Vascular changes in" exact="migraine" post="Vascular changes in migraine were for a long time"/>
   <result pre="[ 155, 156]. Vascular changes in migraine Vascular changes in" exact="migraine" post="were for a long time considered the driver of"/>
   <result pre="migraine were for a long time considered the driver of" exact="migraine" post="pain. In 1940 Ray and Wolff reported that stimulation"/>
   <result pre="A 3 T magnetic resonance angiography (MRA) study during a spontaneous" exact="migraine" post="attack showed no significant changes of the diameter of"/>
   <result pre="the diameter of middle meningeal artery (MMA) during a spontaneous" exact="migraine" post="attack [ 158], however a larger study in cilostazol-induced"/>
   <result pre="migraine attack [ 158], however a larger study in cilostazol-induced" exact="migraine" post="attacks, found that the onset of migraine is associated"/>
   <result pre="study in cilostazol-induced migraine attacks, found that the onset of" exact="migraine" post="is associated with increase in MMA circumference specific to"/>
   <result pre="to the headache side [ 159]. In different studies in" exact="migraine" post="patients with unilateral headache, headache was associated with intracranial"/>
   <result pre="the temporal artery [ 161]. Spontaneous dilatation alone cannot explain" exact="migraine" post="pain, as arteries may dilate markedly, such as during"/>
   <result pre="such as during blood pressure decreases, without induction of a" exact="migraine" post="attack. In a nitroglycerin-triggered migraine study, peak dilation of"/>
   <result pre="decreases, without induction of a migraine attack. In a nitroglycerin-triggered" exact="migraine" post="study, peak dilation of the MCA occurred during the"/>
   <result pre="MCA occurred during the infusion phase of nitroglycerin. However, a" exact="migraine" post="attack fulfilling the International Headache Society diagnostic criteria occurred"/>
   <result pre="role of the cGMP pathway in the development of a" exact="migraine" post="attack, rather than the vasodilation itself. These evidences suggest"/>
   <result pre="mechanical dilatation is not adequate to activate nociceptors and cause" exact="migraine" post="headache [ 162], and indeed, migraine can be induced,"/>
   <result pre="activate nociceptors and cause migraine headache [ 162], and indeed," exact="migraine" post="can be induced, e.g. by sildenafil, without initial dilatation"/>
   <result pre="of genomic loci identified in GWAS to be associated with" exact="migraine" post="without aura are involved in pathways associated with vascular"/>
   <result pre="still be possible that blood vessels play a role in" exact="migraine" post="pathophysiology in the absence of vasodilation. The postdrome phase"/>
   <result pre="the absence of vasodilation. The postdrome phase About 80% of" exact="migraine" post="patients report at least one non-headache symptom following the"/>
   <result pre="headache, while the disability scores remain high [ 69]. The" exact="migraine" post="postdrome is the least studied and least understood phase"/>
   <result pre="the occipital cortex [ 78, 165]. The evolutive process of" exact="migraine" post="chronification Chronic migraine (CM) is a disabling, underdiagnosed and"/>
   <result pre="[ 78, 165]. The evolutive process of migraine chronification Chronic" exact="migraine" post="(CM) is a disabling, underdiagnosed and undertreated disorder, affecting"/>
   <result pre="general population [ 166, 167]. Progression from episodic to chronic" exact="migraine" post="is a clinical reality [ 168, 169]. Studies show"/>
   <result pre="168, 169]. Studies show that each year 2.5% of episodic" exact="migraine" post="patients progress into chronic migraine [ 170] which appears"/>
   <result pre="each year 2.5% of episodic migraine patients progress into chronic" exact="migraine" post="[ 170] which appears as a distinct entity in"/>
   <result pre="entity in the classification of the International Headache Society (chronic" exact="migraine" post="&amp;gt; 15 migraine days per month) [ 68]. The nosology"/>
   <result pre="the classification of the International Headache Society (chronic migraine &amp;gt; 15" exact="migraine" post="days per month) [ 68]. The nosology of CM"/>
   <result pre="risk factors have been identified to double the risk for" exact="migraine" post="chronification [ 172], including de novo increased migraine attack"/>
   <result pre="risk for migraine chronification [ 172], including de novo increased" exact="migraine" post="attack frequency and overuse of acute migraine medications ["/>
   <result pre="de novo increased migraine attack frequency and overuse of acute" exact="migraine" post="medications [ 173– 175], ineffective acute treatment that could"/>
   <result pre="and lifestyle factors such as stress, high caffeine intake and" exact="obesity" post="[ 173, 178]. Certainly, either genetic factors or the"/>
   <result pre="of patients. In a recent resting-state fMRI study in chronic" exact="migraine" post="patients without medication overuse it was shown that CM"/>
   <result pre="unknow. The physiological mechanisms that underlie the development of chronic" exact="migraine" post="from its episodic form are not understood. Cortical excitability"/>
   <result pre="not understood. Cortical excitability appears to be abnormal in chronic" exact="migraine" post="patients, but this could be a consequence of the"/>
   <result pre="chronic migraine. Inflammation and central sensitization in the pathophysiology of" exact="migraine" post="chronification The question whether inflammation could contribute in the"/>
   <result pre="the trigeminal system in a manner that could drive the" exact="migraine" post="headache and be implicated in the evolutive process of"/>
   <result pre="migraine headache and be implicated in the evolutive process of" exact="migraine" post="chronification remains relevant in migraine pathophysiology and treatment ["/>
   <result pre="in the evolutive process of migraine chronification remains relevant in" exact="migraine" post="pathophysiology and treatment [ 187]. Indeed, the broad use"/>
   <result pre="the involvement of some neuroimmune responses in the development of" exact="migraine" post="[ 188, 189], while steroid injections in the region"/>
   <result pre="nerve, are widely used as a preventive method in chronic" exact="migraine" post="[ 190, 191]. In animals, sustained CGRP release may"/>
   <result pre="and cells of immune system [ 193– 195]. During a" exact="migraine" post="attack that can last for up to 72 h, the"/>
   <result pre="to be involved in the initiation and progression of a" exact="migraine" post="attack [ 198]. Studies have demonstrated changes in plasma,"/>
   <result pre="changes in plasma, serum, or urine levels of TNF-α in" exact="migraine" post="patients during attacks and attack free intervals [ 199,"/>
   <result pre="and coworkers reported that mRNA expression of TNF-α increased following" exact="migraine" post="induction in animal models [ 201]. Elevated TNF-α serum"/>
   <result pre="outside of attacks, confirm a possible role of TNF-α in" exact="migraine" post="[ 202]. A direct pathogenic role of TNF-α has"/>
   <result pre="MC/UC. Considering the very high prevalence of migraine, several hundred-thousand" exact="migraine" post="patients must have received TNF-α antibody but there are"/>
   <result pre="antibody but there are no reports on any prevention of" exact="migraine" post="attacks, not even in case-reports. This suggests that preventing"/>
   <result pre="long-term activation of the TG, serving as a model of" exact="migraine" post="chronification [ 206] and activation of the trigeminal nucleus"/>
   <result pre="CGRP in nociceptive neurons and could participate in generating pain" exact="hypersensitivity" post="[ 208]. Looking further into in vivo inflammation, administration"/>
   <result pre="occur if indeed the trigeminal system is sustainably activated during" exact="migraine" post="attacks, could lead to the development of central sensitization."/>
   <result pre="intestinal peptide (VIP) are higher in chronic than in episodic" exact="migraine" post="[ 212– 214]. Additionally, in animal models it has"/>
   <result pre="neuronal basis for persistent pain and &quot;pain memory&quot; in chronic" exact="migraine" post="[ 220– 222]. Central sensitization is a glutamate-dependent process"/>
   <result pre="fibres innervating the dura matter [ 223]. Indeed, during a" exact="migraine" post="headache about 80% of migraine patients develop cutaneous allodynia,"/>
   <result pre="[ 223]. Indeed, during a migraine headache about 80% of" exact="migraine" post="patients develop cutaneous allodynia, characterised by increased skin sensitivity,"/>
   <result pre="thirds of the patients developing cutaneous allodynia report that untreated" exact="migraine" post="attacks will result in a spread of allodynia to"/>
   <result pre="development of central sensitization and the susceptibility in developing chronic" exact="migraine" post="could be a dysfunction in pain modulating systems. An"/>
   <result pre="of sensitization and could contribute to the development of chronic" exact="migraine" post="[ 230, 231]. What is interesting though, is that"/>
   <result pre="static and evolve continuously. During lifespan the clinical phenotype of" exact="migraine" post="changes. These changes may include transformation from episodic to"/>
   <result pre="changes. These changes may include transformation from episodic to chronic" exact="migraine" post="or even a disappearance of some or all migraine"/>
   <result pre="chronic migraine or even a disappearance of some or all" exact="migraine" post="symptoms all together. Genetic and epigenetic susceptibility may be"/>
   <result pre="light on how such genetic alterations may be responsible for" exact="migraine" post="pathophysiology or any evolutive mechanism. On the other hand,"/>
   <result pre="the other hand, anatomical changes in the brain of a" exact="migraine" post="patient exist even from early childhood, but they do"/>
   <result pre="causality dilemma of whether such changes are responsible for how" exact="migraine" post="evolves, or whether migraine mechanisms drive these anatomic changes,"/>
   <result pre="such changes are responsible for how migraine evolves, or whether" exact="migraine" post="mechanisms drive these anatomic changes, remains to be answered."/>
   <result pre="changes, remains to be answered. Even in its episodic form," exact="migraine" post="is an evolutive condition with different mechanisms involved in"/>
   <result pre="with different mechanisms involved in the evolutive process of a" exact="migraine" post="attack. These mechanisms include hypothalamic alterations during the premonitory"/>
   <result pre="phase, and potential cortical changes during the postdrome phase. How" exact="migraine" post="headache is triggered following hypothalamic activation remains unknown. A"/>
   <result pre="brain-initiated event. The mechanisms that underlie the development of chronic" exact="migraine" post="from its episodic form are not well understood. Several"/>
   <result pre="Several factors have been identified to increase the risk for" exact="migraine" post="chronification. Inflammation and central sensitization play a significant role"/>
   <result pre="the evolutive mechanisms of chronic migraine. The continuous changes in" exact="migraine" post="phenotype and pathophysiology during a migraine attack between episodic"/>
   <result pre="The continuous changes in migraine phenotype and pathophysiology during a" exact="migraine" post="attack between episodic and chronic migraine and during the"/>
   <result pre="and pathophysiology during a migraine attack between episodic and chronic" exact="migraine" post="and during the patient lifespan, make migraine, even in"/>
   <result pre="J Lipton RB The prevalence and disability burden of adult" exact="migraine" post="in England and their relationships to age, gender and"/>
   <result pre="Peres FM Silberstein SD Stiles MA Young WB Epidemiology of" exact="migraine" post="Atlas of migraine and other headaches 2005 2 London"/>
   <result pre="SD Stiles MA Young WB Epidemiology of migraine Atlas of" exact="migraine" post="and other headaches 2005 2 London and New York"/>
   <result pre="P Olesen J Prevalence and sex-ratio of the subtypes of" exact="migraine" post="Int J Epidemiol 1995 24 3 612 618 10.1093/ije/24.3.612"/>
   <result pre="Evers S et al. Regional variations in the prevalence of" exact="migraine" post="and tension-type headache applying the new IHS criteria: the"/>
   <result pre="15. Maytal J Young M Shechter A Lipton RB Pediatric" exact="migraine" post="and the international headache society (IHS) criteria Neurology. 1997"/>
   <result pre="Eidlitz-Markus T Gorali O Haimi-Cohen Y Zeharia A Symptoms of" exact="migraine" post="in the paediatric population by age group Cephalalgia. 2008"/>
   <result pre="AA Reider AC Goadsby PJ Cranial autonomic symptoms in pediatric" exact="migraine" post="are the rule, not the exception Neurology. 2013 81"/>
   <result pre="al. Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for" exact="migraine" post="Nat Genet 2016 48 8 856 866 10.1038/ng.3598 27322543"/>
   <result pre="of ATP1A2 encoding the Na+/K+ pump alpha2 subunit associated with" exact="familial hemiplegic migraine" post="type 2 Nat Genet 2003 33 2 192 196"/>
   <result pre="encoding the Na+/K+ pump alpha2 subunit associated with familial hemiplegic" exact="migraine" post="type 2 Nat Genet 2003 33 2 192 196"/>
   <result pre="al. Mutation in the neuronal voltage-gated sodium channel SCN1A in" exact="familial hemiplegic migraine" post="Lancet. 2005 366 9483 371 377 10.1016/S0140-6736(05)66786-4 16054936 28."/>
   <result pre="in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic" exact="migraine" post="Lancet. 2005 366 9483 371 377 10.1016/S0140-6736(05)66786-4 16054936 28."/>
   <result pre="S Broos LA Cesetti T et al. A Cacna1a knockin" exact="migraine" post="mouse model with increased susceptibility to cortical spreading depression"/>
   <result pre="al. Differential trigeminovascular nociceptive responses in the thalamus in the" exact="familial hemiplegic migraine" post="1 knock-in mouse: a Fos protein study Neurobiol Dis"/>
   <result pre="trigeminovascular nociceptive responses in the thalamus in the familial hemiplegic" exact="migraine" post="1 knock-in mouse: a Fos protein study Neurobiol Dis"/>
   <result pre="of calcitonin gene-related peptide in the trigeminal system of the" exact="familial hemiplegic migraine" post="1 knock-in mouse Cephalalgia. 2011 31 13 1368 1380"/>
   <result pre="gene-related peptide in the trigeminal system of the familial hemiplegic" exact="migraine" post="1 knock-in mouse Cephalalgia. 2011 31 13 1368 1380"/>
   <result pre="methylation profiling in whole blood reveals epigenetic signatures associated with" exact="migraine" post="BMC Genomics 2018 19 1 69 10.1186/s12864-018-4450-2 29357833 33."/>
   <result pre="et al. Epigenetic DNA methylation changes in episodic and chronic" exact="migraine" post="Neurol Sci 2018 39 Suppl 1 67 68 10.1007/s10072-018-3348-8"/>
   <result pre="al. Microstructural white matter changes preceding white matter hyperintensities in" exact="migraine" post="Neurology 2019 93 7 e688 e694 10.1212/WNL.0000000000007940 31296653 38."/>
   <result pre="Konishi J Moonen JM et al. Structural brain changes in" exact="migraine" post="JAMA. 2012 308 18 1889 1897 10.1001/jama.2012.14276 23150008 39."/>
   <result pre="Ba-Ssalamah A Schoder M et al. Virchow-Robin spaces in childhood" exact="migraine" post="Neuroradiology. 1999 41 4 283 287 10.1007/s002340050749 10344516 41."/>
   <result pre="Structural changes in the cerebrum, cerebellum and Corpus callosum in" exact="migraine" post="patients Clin Invest Med 2016 39 6 27495 10.25011/cim.v39i6.27495"/>
   <result pre="et al. Structural and functional reorganization of the brain in" exact="migraine" post="without aura Front Neurol 2019 10 442 10.3389/fneur.2019.00442 31133962"/>
   <result pre="Hadjikhani N Thickening in the somatosensory cortex of patients with" exact="migraine" post="Neurology. 2007 69 21 1990 1995 10.1212/01.wnl.0000291618.32247.2d 18025393 50."/>
   <result pre="T Bogdahn U May A Subtle grey matter changes between" exact="migraine" post="patients and healthy controls Cephalalgia. 2008 28 1 1"/>
   <result pre="magnetic resonance imaging resting-state connectivity in periaqueductal gray networks in" exact="migraine" post="Annals of Neurology 2011 70 5 838 845 10.1002/ana.22537"/>
   <result pre="Frakes DH Schwedt TJ Structural alterations of the brainstem in" exact="migraine" post="Neuroimage Clin 2017 13 223 227 10.1016/j.nicl.2016.10.023 28003961 58."/>
   <result pre="C et al. Evidence for brain morphometric changes during the" exact="migraine" post="cycle: a magnetic resonance-based morphometry study Cephalalgia. 2015 35"/>
   <result pre="Volumetric differences suggest involvement of cerebellum and brainstem in chronic" exact="migraine" post="Cephalalgia. 2016 36 4 301 308 10.1177/0333102415588328 26002699 60."/>
   <result pre="S Volume of hypothalamus as a diagnostic biomarker of chronic" exact="migraine" post="Front Neurol 2019 10 606 10.3389/fneur.2019.00606 31244765 63. Rocca"/>
   <result pre="Filippi M Structural brain MRI abnormalities in pediatric patients with" exact="migraine" post="J Neurol 2014 261 2 350 357 10.1007/s00415-013-7201-y 24305994"/>
   <result pre="of headache disorders 3rd edition beta-based field testing of vestibular" exact="migraine" post="in China: demographic, clinical characteristics, audiometric findings and diagnosis"/>
   <result pre="NJ Lipton RB Silberstein SD Olesen J Goadsby PJ The" exact="migraine" post="postdrome: an electronic diary study Neurology. 2016 87 3"/>
   <result pre="70. Kelman L The triggers or precipitants of the acute" exact="migraine" post="attack Cephalalgia. 2007 27 5 394 402 10.1111/j.1468-2982.2007.01303.x 17403039"/>
   <result pre="Charbit A Andreou A Akerman S Holland P Neurobiology of" exact="migraine" post="Neuroscience. 2009 161 2 327 341 10.1016/j.neuroscience.2009.03.019 19303917 72."/>
   <result pre="G Andreou AP Guglielmetti M Martelletti P Emerging drugs for" exact="migraine" post="treatment: an update Expert Opin Emerg Drugs 2018 23"/>
   <result pre="75. Alstadhaug KB Salvesen R Bekkelund SI Seasonal variation in" exact="migraine" post="Cephalalgia. 2005 25 10 811 816 10.1111/j.1468-2982.2005.01018.x 16162258 76."/>
   <result pre="Payoux P Chollet F Geraud G Hypothalamic activation in spontaneous" exact="migraine" post="attacks Headache. 2007 47 10 1418 1426 18052951 78."/>
   <result pre="10 1418 1426 18052951 78. Schulte LH May A The" exact="migraine" post="generator revisited: continuous scanning of the migraine cycle over"/>
   <result pre="May A The migraine generator revisited: continuous scanning of the" exact="migraine" post="cycle over 30 days and three spontaneous attacks Brain."/>
   <result pre="Goadsby PJ Brain activations in the premonitory phase of nitroglycerin-triggered" exact="migraine" post="attacks Brain. 2014 137 Pt 1 232 241 10.1093/brain/awt320"/>
   <result pre="hypothesis for multiple triggers of the pain and strain of" exact="migraine" post="J Comp Neurol 2005 493 1 9 14 10.1002/cne.20688"/>
   <result pre="Huang Y et al. Casein kinase idelta mutations in familial" exact="migraine" post="and advanced sleep phase Sci Transl Med 2013 5"/>
   <result pre="S Gencik M Epplen JT Ullrich B Increased frequency of" exact="migraine" post="in narcoleptic patients: a confirmatory study Cephalalgia. 2003 23"/>
   <result pre="Palmer JE Koehler PJ Vredeveld JW Visual cortex excitability in" exact="migraine" post="with and without aura Headache. 2001 41 6 565"/>
   <result pre="Y Geraud G A PET study of photophobia during spontaneous" exact="migraine" post="attacks Neurology. 2011 76 3 213 218 10.1212/WNL.0b013e3182074a57 21148120"/>
   <result pre="KC Turn down the lights!: an irritable occipital cortex in" exact="migraine" post="without aura Neurology. 2011 76 3 206 207 10.1212/WNL.0b013e3182074bfb"/>
   <result pre="Transcranial magnetic stimulation and potential cortical and trigeminothalamic mechanisms in" exact="migraine" post="Brain. 2016 139 Pt 7 2002 2014 10.1093/brain/aww118 27246325"/>
   <result pre="et al. Single-pulse transcranial magnetic stimulation for acute treatment of" exact="migraine" post="with aura: a randomised, double-blind, parallel-group, sham-controlled trial Lancet"/>
   <result pre="prospective, single arm, open label, observational study of sTMS for" exact="migraine" post="prevention (ESPOUSE study) Cephalalgia. 2018 38 6 1038 1048"/>
   <result pre="29504483 101. Rasmussen BK Olesen J Migraine with aura and" exact="migraine" post="without aura: an epidemiological study Cephalalgia. 1992 12 4"/>
   <result pre="Olesen J Regional cerebral blood flow and oxygen metabolism during" exact="migraine" post="with and without aura Cephalalgia. 1998 18 1 2"/>
   <result pre="K Vestergaard MB Schytz HW Amin FM et al. Heterogenous" exact="migraine" post="aura symptoms correlate with visual cortex functional magnetic resonance"/>
   <result pre="Schwartz D Bakker D Fischl B et al. Mechanisms of" exact="migraine" post="aura revealed by functional MRI in human visual cortex"/>
   <result pre="MA Intrinsic brain activity triggers trigeminal meningeal afferents in a" exact="migraine" post="model Nat Med 2002 8 2 136 142 10.1038/nm0202-136"/>
   <result pre="Activation of meningeal nociceptors by cortical spreading depression: implications for" exact="migraine" post="with aura J Neurosci 2010 30 26 8807 8814"/>
   <result pre="between spreading depression, neurogenic inflammation, and nociception that might cause" exact="migraine" post="headache? Ann Neurol 2001 49 1 7 13 10.1002/1531-8249(200101)49:1&amp;lt;7::AID-ANA4&amp;gt;3.0.CO;2-K"/>
   <result pre="cortical spreading depression- unraveling a new central mechanism involved in" exact="migraine" post="aura J Headache Pain 2013 14 16 10.1186/1129-2377-14-S1-I6 23565801"/>
   <result pre="receptors modulate trigeminovascular responses in ventroposteromedial nucleus of thalamus: a" exact="migraine" post="target? Neurobiol Dis 2006 23 3 491 501 10.1016/j.nbd.2006.04.003"/>
   <result pre="Goadsby PJ Therapeutic potential of novel glutamate receptor antagonists in" exact="migraine" post="Expert Opin Investig Drugs 2009 18 6 789 803"/>
   <result pre="E et al. Altered thalamic connectivity during spontaneous attacks of" exact="migraine" post="without aura: a resting-state fMRI study Cephalalgia. 2018 38"/>
   <result pre="L Li Z et al. Abnormal thalamocortical network dynamics in" exact="migraine" post="Neurology. 2019 92 23 e2706 e2e16 10.1212/WNL.0000000000007607 31076535 124."/>
   <result pre="S Holland PR Goadsby PJ Diencephalic and brainstem mechanisms in" exact="migraine" post="Nat Rev Neurosci 2011 12 10 570 584 10.1038/nrn3057"/>
   <result pre="Schayck RV et al. Brain stem activation in spontaneous human" exact="migraine" post="attacks Nat Med 1995 1 7 658 660 10.1038/nm0795-658"/>
   <result pre="RS et al. A positron emission tomographic study in spontaneous" exact="migraine" post="Arch Neurol 2005 62 8 1270 1275 10.1001/archneur.62.8.1270 16087768"/>
   <result pre="Frackowiak RS Weiner R Goadsby PJ Central neuromodulation in chronic" exact="migraine" post="patients with suboccipital stimulators: a PET study Brain. 2004"/>
   <result pre="A PET study exploring the laterality of brainstem activation in" exact="migraine" post="using glyceryl trinitrate Brain. 2005 128 Pt 4 932"/>
   <result pre="award: possible parasympathetic contributions to peripheral and central sensitization during" exact="migraine" post="Headache. 2003 43 7 704 714 10.1046/j.1526-4610.2003.03127.x 12890124 135."/>
   <result pre="Vasoactive peptide release in the extracerebral circulation of humans during" exact="migraine" post="headache Ann Neurol 1990 28 2 183 187 10.1002/ana.410280213"/>
   <result pre="integrity of the blood-brain barrier for 11C-dihydroergotamine during glyceryl trinitrate-induced" exact="migraine" post="Brain. 2016 139 Pt 7 1994 2001 10.1093/brain/aww096 27234268"/>
   <result pre="brainstem perfusion, but no blood-brain barrier disruption, during attacks of" exact="migraine" post="with aura Brain. 2017 140 6 1633 1642 10.1093/brain/awx089"/>
   <result pre="B Olesen J CGRP may play a causative role in" exact="migraine" post="Cephalalgia. 2002 22 1 54 61 10.1046/j.1468-2982.2002.00310.x 11993614 149."/>
   <result pre="11993614 149. Lassen LH Thomsen LL Olesen J Histamine induces" exact="migraine" post="via the H1-receptor. Support for the NO hypothesis of"/>
   <result pre="migraine via the H1-receptor. Support for the NO hypothesis of" exact="migraine" post="Neuroreport. 1995 6 11 1475 1479 10.1097/00001756-199507310-00003 7579128 150."/>
   <result pre="C et al. Prospective real-world analysis of OnabotulinumtoxinA in chronic" exact="migraine" post="post-National Institute for health and care excellence UK technology"/>
   <result pre="153. Dodick DW CGRP ligand and receptor monoclonal antibodies for" exact="migraine" post="prevention: evidence review and clinical implications Cephalalgia. 2019 39"/>
   <result pre="Yanagimachi N Takagi S The middle meningial artery during a" exact="migraine" post="attack: 3T magnetic resonance angiography study Intern Med 2009"/>
   <result pre="H Younis S Olinger ACR et al. Meningeal contribution to" exact="migraine" post="pain: a magnetic resonance angiography study Brain. 2019 142"/>
   <result pre="HK Nielsen TH Olesen J Tfelt-Hansen P Arterial responses during" exact="migraine" post="headache Lancet. 1990 336 8719 837 839 10.1016/0140-6736(90)92339-J 1976878"/>
   <result pre="162. Ashina M Vascular changes have a primary role in" exact="migraine" post="Cephalalgia. 2012 32 5 428 430 10.1177/0333102412438978 22523234 163."/>
   <result pre="130 144 10.1016/j.neuroscience.2016.06.012 27312704 165. Bose P Goadsby PJ The" exact="migraine" post="postdrome Curr Opin Neurol 2016 29 3 299 301"/>
   <result pre="KM Serrano D Reed ML Turkel CC et al. Chronic" exact="migraine" post="prevalence, disability, and sociodemographic factors: results from the American"/>
   <result pre="F D'Amico D Schieroni F Bussone G Neurobiology of chronic" exact="migraine" post="Neurol Sci 2003 24 Suppl 2 S94 S96 10.1007/s100720300051"/>
   <result pre="S94 S96 10.1007/s100720300051 12811602 169. Lipton RB Pan J Is" exact="migraine" post="a progressive brain disease? JAMA. 2004 291 4 493"/>
   <result pre="171. Mathew NT Reuveni U Perez F Transformed or evolutive" exact="migraine" post="Headache. 1987 27 2 102 106 10.1111/j.1526-4610.1987.hed2702102.x 3570762 172."/>
   <result pre="and predictors for chronicity of headache in patients with episodic" exact="migraine" post="Neurology. 2004 62 5 788 790 10.1212/01.WNL.0000113747.18760.D2 15007133 176."/>
   <result pre="ML Cady R Buse DC Ineffective acute treatment of episodic" exact="migraine" post="is associated with new-onset chronic migraine Neurology. 2015 84"/>
   <result pre="acute treatment of episodic migraine is associated with new-onset chronic" exact="migraine" post="Neurology. 2015 84 7 688 695 10.1212/WNL.0000000000001256 25609757 177."/>
   <result pre="al. Depression and risk of transformation of episodic to chronic" exact="migraine" post="J Headache Pain 2012 13 8 615 624 10.1007/s10194-012-0479-9"/>
   <result pre="ME Lipton RB Obesity is a risk factor for transformed" exact="migraine" post="but not chronic tension-type headache Neurology. 2006 67 2"/>
   <result pre="Quantitative MRI studies of chronic brain white matter hyperintensities in" exact="migraine" post="patients Headache. 2013 53 5 752 763 10.1111/head.12013 23278630"/>
   <result pre="L Ferraro S Grazzi L Bussone G Neuroimaging in chronic" exact="migraine" post="Neurol Sci 2010 31 Suppl 1 S19 S22 10.1007/s10072-010-0266-9"/>
   <result pre="tesla shows subtle cerebral grey matter abnormalities in patients with" exact="migraine" post="J Neurol Neurosurg Psychiatry 2006 77 5 686 689"/>
   <result pre="M Pinessi L Voxel-based morphometry reveals gray matter abnormalities in" exact="migraine" post="Headache. 2008 48 1 109 117 10.1111/j.1526-4610.2007.00723.x 18184293 184."/>
   <result pre="W Qi W et al. White matter lesions in chronic" exact="migraine" post="with medication overuse headache: a cross-sectional MRI study J"/>
   <result pre="24535135 185. Coppola G Schoenen J Cortical excitability in chronic" exact="migraine" post="Curr Pain Headache Rep 2012 16 1 93 100"/>
   <result pre="Moskowitz MA Neurogenic inflammation in the pathophysiology and treatment of" exact="migraine" post="Neurology. 1993 43 6 Suppl 3 S16 S20 8389008"/>
   <result pre="H Han W Wang J Li M Network meta-analysis of" exact="migraine" post="disorder treatment by NSAIDs and triptans J Headache Pain"/>
   <result pre="Mookadam M Greater occipital nerve block for acute treatment of" exact="migraine" post="headache: a large retrospective cohort study J Am Board"/>
   <result pre="of greater occipital nerve block on severity and frequency of" exact="migraine" post="headache Global J Health Sci 2014 6 6 209"/>
   <result pre="Wilkins 309 319 198. Pietrobon D Moskowitz MA Pathophysiology of" exact="migraine" post="Annu Rev Physiol 2013 75 365 391 10.1146/annurev-physiol-030212-183717 23190076"/>
   <result pre="Are TNF-alpha and IL-1 beta relevant in the pathogenesis of" exact="migraine" post="without aura? Acta Neurol (Napoli) 1991 13 2 205"/>
   <result pre="inflammatory potential of trigeminal ganglia in a mouse model of" exact="familial hemiplegic migraine" post="PLoS One 2013 8 1 e52394 10.1371/journal.pone.0052394 23326332 202."/>
   <result pre="of trigeminal ganglia in a mouse model of familial hemiplegic" exact="migraine" post="PLoS One 2013 8 1 e52394 10.1371/journal.pone.0052394 23326332 202."/>
   <result pre="Domingues RB Increased serum levels of brain-derived neurotropic factor during" exact="migraine" post="attacks: a pilot study J Headache Pain 2010 11"/>
   <result pre="C Pascual J Increased VIP levels in peripheral blood outside" exact="migraine" post="attacks as a potential biomarker of cranial parasympathetic activation"/>
   <result pre="as a potential biomarker of cranial parasympathetic activation in chronic" exact="migraine" post="Cephalalgia. 2015 35 4 310 316 10.1177/0333102414535111 24847167 213."/>
   <result pre="CGRP levels in peripheral blood as a biomarker for chronic" exact="migraine" post="Neurology. 2013 81 14 1191 1196 10.1212/WNL.0b013e3182a6cb72 23975872 215."/>
   <result pre="acid receptor activation; implications for the treatment of post-injury pain" exact="hypersensitivity" post="states Pain. 1991 44 3 293 299 10.1016/0304-3959(91)90100-C 1828878"/>
   <result pre="MF Yarnitsky D The development of cutaneous allodynia during a" exact="migraine" post="attack clinical evidence for the sequential recruitment of spinal"/>
   <result pre="the sequential recruitment of spinal and supraspinal nociceptive neurons in" exact="migraine" post="Brain. 2000 123 Pt 8 1703 1709 10.1093/brain/123.8.1703 10908199"/>
   <result pre="225. Selby G Lance JW Observations on 500 cases of" exact="migraine" post="and allied vascular headache J Neurol Neurosurg Psychiatry 1960"/>
   <result pre="J Neurochemistry of trigeminal activation in an animal model of" exact="migraine" post="Headache. 2006 46 Suppl 1 S39 S44 10.1111/j.1526-4610.2006.00489.x 16927963"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6935960/results/search/disease/results.xml">
   <result pre="common in Chiari Type 1 malformation (CM-1). The prevalence of" exact="migraine" post="headaches in CM-1 is similar to that of the"/>
   <result pre="is similar to that of the general population. However, when" exact="migraine" post="headaches occur with CM-1, they tend to have an"/>
   <result pre="CM-1 association. The exact role or impact of CM-1 in" exact="migraine" post="headaches has not been fully elucidated. Case Description: We"/>
   <result pre="occur simultaneously needs to be further elucidated. Chiari malformations Fatal" exact="migraine" post="Migraine Status migrainosus INTRODUCTION Fatalities directly due to a"/>
   <result pre="literature. Furthermore, few reports have focused on the association of" exact="migraine" post="with Chiari Type 1 malformations (CM-1) in adults and"/>
   <result pre="edition 2018, the 7 years old discussed here had 1.2" exact="migraine" post="with aura headaches secondary to Chiari malformation.[ 13] This"/>
   <result pre="patient exhibited as a SM patient, defined as a debilitating" exact="migraine" post="attack lasting more than 72 h.[ 7, 13] Of"/>
   <result pre="attack lasting more than 72 h.[ 7, 13] Of all" exact="migraine" post="sufferers, 23– 73% exhibit autonomic dysfunction which is characterized"/>
   <result pre="6] Although sudden death in an adult patient with intractable" exact="migraine" post="and CM-1 has been described, few if any of"/>
   <result pre="Guest IA Woolf AL Fatal infarction of the brain in" exact="migraine" post="Br Med J 1964 1 225 6 14074182 2"/>
   <result pre="2018 19 57 30046928 3 Kaplan Y Oksuz E Chronic" exact="migraine" post="associated with the Chiari Type 1 malformation Clin Neurol"/>
   <result pre="of cerebral cortex, thalamus and basal ganglia during spontaneously occurring" exact="migraine" post="headaches Headache 1989 29 282 9 2745066 5 Kurth"/>
   <result pre="Logroscino G Diener HC et al. Migraine and risk of" exact="cardiovascular disease" post="in men Arch Intern Med 2007 167 795 801"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6935986/results/search/disease/results.xml">
   <result pre="identical terms. Abstract A bstract Background: Many patients presenting with" exact="migraine" post="also complain of constipation. The relationship between these two"/>
   <result pre="was carried out to investigate the effect of treatment of" exact="constipation" post="with lactulose on the improvement of migraine headache in"/>
   <result pre="of treatment of constipation with lactulose on the improvement of" exact="migraine" post="headache in patients who referred to neurology clinics in"/>
   <result pre="Arak. Materials and Methods: A total of 50 patients with" exact="migraine" post="were selected based on the Headache International Society (HIS)"/>
   <result pre="disorders (FGIDs) (ROME III) scale so as to diagnose their" exact="migraine" post="and constipation. The patients were randomly divided into an"/>
   <result pre="10-mg propranonol daily). In contrast, only the standard treatment for" exact="migraine" post="was prescribed for the control group. The severity of"/>
   <result pre="scores ‑of the severity of disability and the severity of" exact="migraine" post="pain between the measurement times were significantly different for"/>
   <result pre="of this study showed that lactulose syrup could remove the" exact="constipation" post="with no significant side effects––can be used as an"/>
   <result pre="with migraine. However, future studies suggested for long-term consequences of" exact="constipation" post="control. K eywords: Constipation headache lactalosis migraine I ntroduction"/>
   <result pre="long-term consequences of constipation control. K eywords: Constipation headache lactalosis" exact="migraine" post="I ntroduction Migraine is one of the most common"/>
   <result pre="12% of the general population.[ 1] The prevalence of the" exact="migraine" post="in women is three times higher than that of"/>
   <result pre="loss of quality of life.[ 1] The molecular mechanism of" exact="migraine" post="has not yet been completely identified. It is believed"/>
   <result pre="not been explored yet in detail. It is likely that" exact="constipation" post="plays a key role in starting a headache, or"/>
   <result pre="key role in starting a headache, or that headache and" exact="constipation" post="have a common pathophysiology.[ 8] Constipation and migraines have"/>
   <result pre="quality of life. Studies have shown that the prevalence of" exact="constipation" post="in patients with primary headaches is higher than that"/>
   <result pre="this area, it cannot unconditionally be stated that treatment of" exact="constipation" post="can help improve migraine headaches. There are several drugs,"/>
   <result pre="unconditionally be stated that treatment of constipation can help improve" exact="migraine" post="headaches. There are several drugs, such as magnesium, lactulose,"/>
   <result pre="was carried out to investigate the effect of treatment of" exact="constipation" post="with lactulose on improving the symptoms of patients with"/>
   <result pre="The study was a single-blind study conducted on patients with" exact="migraine" post="suffering at least six months from the disease, having"/>
   <result pre="of Arak University of Medical Sciences so as to their" exact="migraine" post="being diagnosed by a neurologist and based on the"/>
   <result pre="neurologist and based on the HIS index.[ 1] Patients with" exact="migraine" post="who were also complaining of constipation were interviewed by"/>
   <result pre="index.[ 1] Patients with migraine who were also complaining of" exact="constipation" post="were interviewed by a trained researcher (nursing student) based"/>
   <result pre="was used for recognizing the constipation.[ 11 12] Patients with" exact="migraine" post="who simultaneously suffered from constipation, those who signed the"/>
   <result pre="1] In the control group, only the standard treatment for" exact="migraine" post="(10–25mg nortriptyline and 20–40mg propranonol daily) was prescribed. When"/>
   <result pre="(10–25mg nortriptyline and 20–40mg propranonol daily) was prescribed. When the" exact="constipation" post="of the patient was not treated with this dose,"/>
   <result pre="of 0.05. R esults A total of 50 patients with" exact="migraine" post="were selected for this study. The participants were divided"/>
   <result pre="= 0.001) [ Table 1]. Table 1 The severity of" exact="migraine" post="disability in the control and intervention groups Duration of"/>
   <result pre="= 0.001) [ Table 2]. Table 2 The severity of" exact="migraine" post="pain in the control and intervention groups Duration of"/>
   <result pre="**Repeated-measures test Although the mean score of the severity of" exact="constipation" post="was not found to be significant between the intervention"/>
   <result pre="= 0.70) [ Table 3]. Table 3 The severity of" exact="constipation" post="(score) in the control and intervention groups Duration of"/>
   <result pre="after treatment, and the difference was also statistically significant. Hence," exact="constipation" post="can help improve migraine and can reduce the severity"/>
   <result pre="difference was also statistically significant. Hence, constipation can help improve" exact="migraine" post="and can reduce the severity of pain and disability"/>
   <result pre="Inaloo et al.,[ 7] examining the relationship between headache and" exact="constipation" post="in 12-to-14-year-old children, found a strong correlation between constipation"/>
   <result pre="and constipation in 12-to-14-year-old children, found a strong correlation between" exact="constipation" post="and headache that can be due to such accompanying"/>
   <result pre="by Park et al.[ 8] to investigate the relationship between" exact="constipation" post="and headache, the results showed that the treatment of"/>
   <result pre="constipation and headache, the results showed that the treatment of" exact="constipation" post="led to relief of headache in all the participants"/>
   <result pre="relief of headache in all the participants and that reduced" exact="constipation" post="was accompanied by a significant reduction in the severity"/>
   <result pre="the findings of this study. In another study by Gupta," exact="migraine" post="was reported to cause constipation and to reduce the"/>
   <result pre="In another study by Gupta, migraine was reported to cause" exact="constipation" post="and to reduce the peristaltic movements of the intestine."/>
   <result pre="of the intestine. They also found that the removal of" exact="constipation" post="in the patients led to a reduction in their"/>
   <result pre="constipation in the patients led to a reduction in their" exact="migraine" post="attacks, which also confirms the findings of this study.["/>
   <result pre="there may be a relationship between the initial headache and" exact="constipation" post="will become stronger. In addition, Park et al.[ 8]"/>
   <result pre="become stronger. In addition, Park et al.[ 8] believe that" exact="constipation" post="plays an important role in causing headaches, and that"/>
   <result pre="constipation plays an important role in causing headaches, and that" exact="constipation" post="and headache may also have a common pathophysiology. Among"/>
   <result pre="is increased in the gastrointestinal mucosa of the patients with" exact="constipation" post="and is decreased in patients with migraine.[ 3 15]"/>
   <result pre="than those of the normal population.[ 16 17 18] Moreover," exact="constipation" post="is associated with stress, dehydration, low-fluid intake, and loss"/>
   <result pre="On the contrary, Valsalva maneuver, which occurs in patients with" exact="constipation" post="for their intestinal excision, can also lead to headaches.["/>
   <result pre="treated, the severity of headache––especially migraine––is also reduced. People with" exact="irritable bowel syndrome" post="(IBS) are usually diagnosed with constipation or diarrhea. Cole"/>
   <result pre="People with irritable bowel syndrome (IBS) are usually diagnosed with" exact="constipation" post="or diarrhea. Cole et al.[ 24] reported that people"/>
   <result pre="that people with IBS have a 40%–80% higher risk of" exact="migraine" post="than others. Cole et al.[ 23] and Machnes-Maayan et"/>
   <result pre="and Machnes-Maayan et al.[ 24] reported that the pathophysiology of" exact="migraine" post="and constipation are similar in some cases. Some studies"/>
   <result pre="et al.[ 24] reported that the pathophysiology of migraine and" exact="constipation" post="are similar in some cases. Some studies have also"/>
   <result pre="the results of this study, which indicates the relationship between" exact="constipation" post="and migraine, it is recommended that patients with migraine"/>
   <result pre="between constipation and migraine, it is recommended that patients with" exact="migraine" post="should be diagnosed with gastrointestinal dysfunctions, including constipation, and"/>
   <result pre="should be diagnosed with gastrointestinal dysfunctions, including constipation, and if" exact="constipation" post="is diagnosed, all the necessary actions should be taken"/>
   <result pre="this study showed that lactulose syrup––being able to remove the" exact="constipation" post="with no significant side effects––can be used as an"/>
   <result pre="with migraine. However, future studies suggested for long-term consequences of" exact="constipation" post="control. Ethical policy and institutional review board statement This"/>
   <result pre="F Use of melatonin versus valproic acid in prophylaxis of" exact="migraine" post="patients: a double-blind randomized clinical trial Restor Neurol Neurosci"/>
   <result pre="A Koçyiğit A Oxidative and antioxidative balance in patients of" exact="migraine" post="Eur Rev Med Pharm Sci 2010 14 877 82"/>
   <result pre="review of oral magnesium supplementation in the preventive treatment of" exact="migraine" post="Cephalalgia 2015 35 912 22 25533715 6 Ghasami K"/>
   <result pre="effect of iron tablets on women in productive age with" exact="iron deficiency anemia" post="and vascular headaches Pak J Med Sci 2012 28"/>
   <result pre="iron tablets on women in productive age with iron deficiency" exact="anemia" post="and vascular headaches Pak J Med Sci 2012 28"/>
   <result pre="SM Heydari M Heydari ST Comorbidity of headache and functional" exact="constipation" post="in children: a cross-sectional survey Turk J Gastroenterol 2014"/>
   <result pre="You MSJ You SJ The relationship between primary headache and" exact="constipation" post="in children and adolescents Korean J Pediatr 2015 58"/>
   <result pre="10 Malekzadeh F Ansari R Malekzadeh R Approach to chronic" exact="constipation" post="Govaresh 2014 19 7 13 11 Tack J Müller-Lissner"/>
   <result pre="Life Outcomes 2018 16 42 29523138 14 Gupta V Constipation-related" exact="migraine" post="is linked to the effect of the Valsalva maneuver"/>
   <result pre="B Whorwell PJ Keevil B et al. Rome III functional" exact="constipation" post="and irritable bowel syndrome with constipation are similar disorders"/>
   <result pre="PJ Keevil B et al. Rome III functional constipation and" exact="irritable bowel syndrome" post="with constipation are similar disorders within a spectrum of"/>
   <result pre="al. Rome III functional constipation and irritable bowel syndrome with" exact="constipation" post="are similar disorders within a spectrum of sensitization, regulated"/>
   <result pre="V Rantanen K Kallela M Farkkila M Valsalva maneuver as" exact="migraine" post="inducer: a case report of a woman with patent"/>
   <result pre="as migraine inducer: a case report of a woman with" exact="patent foramen ovale" post="and an ischemic stroke Headache 2009 49 146 7"/>
   <result pre="of a woman with patent foramen ovale and an ischemic" exact="stroke" post="Headache 2009 49 146 7 18549412 20 Keszthelyi D"/>
   <result pre="bowel syndrome: methods, mechanisms, and pathophysiology: methods to assess visceral" exact="hypersensitivity" post="in irritable bowel syndrome Am J Physiol Gastrointest Liver"/>
   <result pre="methods, mechanisms, and pathophysiology: methods to assess visceral hypersensitivity in" exact="irritable bowel syndrome" post="Am J Physiol Gastrointest Liver Physiol 2012 303 G141"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6936047/results/search/disease/results.xml">
   <result pre="Central London pmcid: 6936047 1558 doi: 10.1186/s12883-019-1558-1 : Review Ischemic" exact="stroke" post="in Morocco: a systematic review Kharbach Ahmed kharbach.a.lbrce@gmail.com 2"/>
   <result pre="and 3-month mortality rate and the genetic aspect of ischemic" exact="stroke" post="in Morocco. Methods The present work is a systematic"/>
   <result pre="acute and 3-month mortality and the genetic factors of ischemic" exact="stroke" post="in Morocco. Results Twenty-nine ( n = 29) studies were"/>
   <result pre="ages in 13 studies. High blood pressure, diabetes, smoking and" exact="heart disease" post="were the four identified main risk factors by the"/>
   <result pre="a reduced sample size and no confidence interval. Conclusions Ischemic" exact="stroke" post="is affecting more likely the young population with male"/>
   <result pre="the management of this neurologic deficit in Morocco. Keywords Ischemic" exact="stroke" post="Trial of ORG classification 10,172 in acute stroke treatment"/>
   <result pre="Keywords Ischemic stroke Trial of ORG classification 10,172 in acute" exact="stroke" post="treatment classification Prehospital delay Thrombolysis Morocco Background Stroke has"/>
   <result pre="social, psychological, and economic levels [ 3]. The incidence of" exact="stroke" post="continues to increase in developing countries, including the North"/>
   <result pre="point of view, previous studies have described multiple causes of" exact="stroke" post="[ 5]. According to the epidemiological survey conducted in"/>
   <result pre="in the two metropolitan Moroccan cities (Casablanca and Rabat), ischemic" exact="stroke" post="(IS) represented 70.9% of all types of stroke ["/>
   <result pre="Rabat), ischemic stroke (IS) represented 70.9% of all types of" exact="stroke" post="[ 6]. Multidisciplinary and fast approaches are highly required"/>
   <result pre="long-term evolution of this debilitating disease [ 11]. Since ischemic" exact="stroke" post="is largely preventable, it is important to study the"/>
   <result pre="this is the first systematic review of the literature on" exact="stroke" post="to be conducted in Morocco. In this respect, the"/>
   <result pre="classification 10,172 in Acute Stroke Treatment (TOAST) classification, prehospital delay," exact="stroke" post="management (thrombolysis), mortality rate at the acute phase and"/>
   <result pre="8 Mean age and sex ratio of patients with ischemic" exact="stroke" post="in Morocco Twenty-three studies focusing on IS in all"/>
   <result pre="between the two genders [ 29]. Risk factors for ischemic" exact="stroke" post="in Morocco according to the selected studies Studies included"/>
   <result pre="of interest. Indeed, high blood pressure (HBP), diabetes, smoking and" exact="heart disease" post="were the four main risk factors listed and are"/>
   <result pre="17, 20, 21, 23, 25– 28, 30, 33, 35, 42]," exact="atrial fibrillation" post="as associated heart disease was specified in 9 studies"/>
   <result pre="25– 28, 30, 33, 35, 42], atrial fibrillation as associated" exact="heart disease" post="was specified in 9 studies (2,5–22%), and smoking in"/>
   <result pre="risk factors, other risk factors have been reported such as" exact="dyslipidemia" post="in ( n = 16) studies (0–61.8%) [ 13, 15,"/>
   <result pre="18, 20, 23, 25– 28, 30, 33, 35– 37, 42]," exact="obesity" post="in ( n = 6) studies (10.7–26.1%) [ 13, 17,"/>
   <result pre="17, 18, 26, 30, 35], the notion of a previous" exact="stroke" post="was noted in ( n = 10) hospital series (5–26.6%)"/>
   <result pre="( n = 3) studies (6.6–12.2%) [ 30, 32, 33], and" exact="migraine" post="in a single study at 6.5% [ 30]. Concerning"/>
   <result pre="n = 4) studies (7.5–13.2%) [ 14, 22, 29, 31, 43]," exact="migraine" post="in ( n = 4) studies (1.5–24%) [ 14, 22,"/>
   <result pre="n = 4) studies (1.5–24%) [ 14, 22, 29, 31, 43]," exact="dyslipidemia" post="in ( n = 3) studies (0–15.3%) [ 22, 29,"/>
   <result pre="in ( n = 3) studies (5–8%) [ 22, 29, 31]," exact="obesity" post="only ( n = 1) by the study of Ibouajbane"/>
   <result pre="2.5%, respectively [ 22, 31], the first-degree family history of" exact="stroke" post="was reported in a single study by Allaoui et"/>
   <result pre="Tables 2 and 3). Table 2 Risk factors for ischemic" exact="stroke" post="in Morocco according to selected studies (First part) Studies"/>
   <result pre="27/17 – AF Atrial fibrillation, IS Ischemic Stroke, ISC Ischemic" exact="stroke" post="cases, Cl Controls, NS Not significant, YIS Young Ischemic"/>
   <result pre="Controls, NS Not significant, YIS Young Ischemic Stroke, ISTr Ischemic" exact="stroke" post="trombolysed, Ob Obesity, M Migraine, HBP High Blood Pressure,"/>
   <result pre="ratio, CI confidence interval Table 3 Risk factors for ischemic" exact="stroke" post="in Morocco according to selected studies (Part Two) Studies"/>
   <result pre="Smoking (%) OR 95% CI Previous stroke/ family history of" exact="stroke" post="(%) Alcoholism (%) OR 95% CI Oral contraception (%)"/>
   <result pre="Controls, IS Ischemic Stroke, YIS Young Ischemic Stroke, ISTr Ischemic" exact="stroke" post="trombolysed, Ob Obesity, M Migraine, HBP High Blood Pressure"/>
   <result pre="obtained using Fisher’s exact test Genetic risk factors for ischemic" exact="stroke" post="in Moroccan studies The present systematic review includes only"/>
   <result pre="published studies on the association between six genes and ischemic" exact="stroke" post="in Morocco Study Cases Controls Genes Mutations Genotypes Methods"/>
   <result pre="PCR 1.1 (0.59–2.04) 0.303 Ω T allele and atherothrombotic subtype" exact="stroke" post="2.1 (1.17–3.8) 0.012 Ω They, TP et al., 2013"/>
   <result pre="^the multivariate analysis (logistic regression) TOAST etiological classification of ischemic" exact="stroke" post="in Moroccan studies The most prominent etiology is atherosclerosis"/>
   <result pre="ischemic stroke in Moroccan studies The most prominent etiology is" exact="atherosclerosis" post="of large arteries according to ( n = 16) studies"/>
   <result pre="23, 25– 28, 30, 32, 33, 35, 40], lacunar ischemic" exact="stroke" post="was reported in ( n = 12) studies (0–39%) ["/>
   <result pre="pathologies involved in the ontogeny and the occurrence of ischemic" exact="stroke" post="conditions [ 25, 27, 28, 30, 35]. The first"/>
   <result pre="observed during pregnancy and especially during the sixth month, and" exact="thrombophlebitis" post="in another case [ 31]. The third by Chraa"/>
   <result pre="this study were dominated by systemic lupus (32%) associated with" exact="antiphospholipid syndrome" post="(80%), Behcet’s disease (16%), Takayasu’s disease (12%) [ 43]."/>
   <result pre="disease (16%), Takayasu’s disease (12%) [ 43]. With respect to" exact="atherosclerosis" post="of large arteries, it was reported in ( n"/>
   <result pre="in Table 5). Table 5 TOAST etiological classification of ischemic" exact="stroke" post="according to selected studies Studies Sample size Atherosclerosis of"/>
   <result pre="Occlusion of small vessels (Lacunar) (%) Other determinate causes of" exact="stroke" post="(%) Undetermined causes of stroke (%) Chraa, M., 2010"/>
   <result pre="(%) Other determinate causes of stroke (%) Undetermined causes of" exact="stroke" post="(%) Chraa, M., 2010 [ 30] 352 32,1 28,4"/>
   <result pre="43] 25 YIS – 4 – 72 24 YIS: Ischemic" exact="stroke" post="of young adult (15–45 years) Prehospital delay in patients with"/>
   <result pre="of young adult (15–45 years) Prehospital delay in patients with ischemic" exact="stroke" post="in Morocco Since the notion of time is crucial"/>
   <result pre="results are detailed in Table 6). Table 6 Mean prehospital" exact="stroke" post="delay (symptom onset to emergency department arrival) and percent"/>
   <result pre="patients with IS. The percentage of patients with thrombolyzed ischemic" exact="stroke" post="in Morocco Four studies conducted at the neurology department"/>
   <result pre="age could be explained by the high frequency of embolic" exact="heart disease," post="rheumatic heart disease and sexually transmitted infections (syphilis, and"/>
   <result pre="explained by the high frequency of embolic heart disease, rheumatic" exact="heart disease" post="and sexually transmitted infections (syphilis, and acquired immunodeficiency syndrome)"/>
   <result pre="population in our country due to the preponderance of rheumatic" exact="heart disease" post="[ 43]. Similarly, it may also be due to"/>
   <result pre="world, which indicated that men were most often victims of" exact="stroke" post="(between 55.9 and 75%) [ 11]. These findings are"/>
   <result pre="of Eastern Mediterranean countries, which has explored higher prevalence of" exact="stroke" post="between men compared to women with a sex ratio"/>
   <result pre="of studies reported a high sex ratio in patients with" exact="stroke" post="[ 52]. This is also confirmed by a recent"/>
   <result pre="the main risk factor for IS in Morocco, smoking and" exact="heart disease" post="represented the other identified risk factors. In the African"/>
   <result pre="the African context more than half of patients with ischemic" exact="stroke" post="had HBP [ 54]. This joins the results of"/>
   <result pre="main risk factors identified in MENA countries [ 50]. For" exact="atrial fibrillation," post="most of the studies included in the present review"/>
   <result pre="than the proportion recorded in the SITS-MENA register (8.8%), while" exact="atrial fibrillation" post="in non-MENA countries accounted for 19.4% [ 50]. The"/>
   <result pre="contributing thus to the increased prevalence of cardiovascular diseases and" exact="stroke" post="in Morocco [ 56]. Concerning the risk factors of"/>
   <result pre="oral contraceptives are associated with an increased relative risk of" exact="cerebral infarction" post="of 2.75 [ 59]. Genetically speaking, studies have suggested"/>
   <result pre="mutation increased the risk of IS in adulthood, particularly in" exact="atherosclerosis" post="of large arteries [ 60]. The study by Diakite"/>
   <result pre="the etiological classification of TOAST, the present work showed that" exact="atherosclerosis" post="of the major arteries is the most dominant etiology."/>
   <result pre="by the lack of knowledge of the early signs of" exact="cerebral infarction." post="Furthermore, this delay of consultation in the Moroccan population"/>
   <result pre="stroke, the shortage of medical transportation, health care staff and" exact="stroke" post="management units, as well as the economic cost of"/>
   <result pre="facilities and thrombolysis were reported as major obstacles to improve" exact="stroke" post="care and stroke management in Africa [ 66]. Concerning"/>
   <result pre="were reported as major obstacles to improve stroke care and" exact="stroke" post="management in Africa [ 66]. Concerning the management of"/>
   <result pre="rates could also be explained by the lack of ischemic" exact="stroke" post="studies evaluating mortality rates in Morocco [ 71]. Three-month"/>
   <result pre="services in rural areas, and the fact that half of" exact="stroke" post="patients are not treated in hospitals [ 77], which"/>
   <result pre="concerns Moroccan hospital facilities, which mostly receive patients with severe" exact="stroke" post="conditions displaying consciousness perturbations and severe hemiplegia [ 77],"/>
   <result pre="several genetic markers have been suggested as predisposing factors of" exact="cerebral infarction" post="in Morocco. The prehospital delays are very long, compared"/>
   <result pre="EMS Emergency medical service HBP High blood pressure IS Ischemic" exact="stroke" post="MENA Middle-East and North African NCDs Noncommunicable diseases PRISMA"/>
   <result pre="Recombinant tissue plasminogen activator SITS Safe implementation of treatments in" exact="stroke" post="TOAST Trial of ORG classification 10,172 in Acute Stroke"/>
   <result pre="ORG classification 10,172 in Acute Stroke Treatment YIS Young ischemic" exact="stroke" post="Publisher’s Note Springer Nature remains neutral with regard to"/>
   <result pre="J Mirzaei M Anderson L Leeder SR The epidemiology of" exact="stroke" post="in the Middle East and North Africa J Neurol"/>
   <result pre="Adeloye D An estimate of the incidence and prevalence of" exact="stroke" post="in Africa: a systematic review and meta-analysis PLoS One"/>
   <result pre="Y Dargham S Abu Raddad L Khattab AD Epidemiology of" exact="stroke" post="in the MENA region: a systematic review Int J"/>
   <result pre="Mourji F Faris MEA collab: Group GS Socioeconomic status and" exact="stroke" post="prevalence in Morocco: results from the Rabat-Casablanca study PLoS"/>
   <result pre="10. Johnston SC Mendis S Mathers CD Global variation in" exact="stroke" post="burden and mortality: estimates from monitoring, surveillance, and modelling"/>
   <result pre="Sirbou R Bakkali H Belyamani L Thrombolysis for acute ischemic" exact="stroke" post="by tenecteplase in the emergency department of a Moroccan"/>
   <result pre="e367 10.1016/j.jns.2015.08.1314 19. Bourazza A Hsaini Y Epidemiology study of" exact="stroke" post="about 1256 cases J Neurol Sci 2013 333 e248"/>
   <result pre="Intravenous thrombolysis with rt-PA in stroke: experience of the moroccan" exact="stroke" post="unit Pan Afr Med J 2016 24 207 10.11604/pamj.2016.24.207.8815"/>
   <result pre="S Correlation between MTHFR and clinical risk factors in ischemic" exact="stroke" post="2014 37. Diakite B Hamzi K Hmimech W Nadifi"/>
   <result pre="Nadifi S First study of C2491T FV mutation with ischaemic" exact="stroke" post="risk in Morocco J Genet 2015 94 2 313"/>
   <result pre="T-1131C APOA5 and ALOX5AP SG13S114 with the susceptibility of ischaemic" exact="stroke" post="in Morocco J Genet 2016 95 2 303 309"/>
   <result pre="Sellama N G894T endothelial nitric oxide synthase polymorphism and ischemic" exact="stroke" post="in Morocco Meta Gene 2014 2 349 357 10.1016/j.mgene.2014.04.003"/>
   <result pre="Slassi I Methylenehydrofolate reductase (C677T) polymorphism and large artery ischemic" exact="stroke" post="subtypes Acta Neurol Scand 2011 123 2 105 110"/>
   <result pre="effect of MTHFR C677T and F2 G20210A polymorphisms on ischemic" exact="stroke" post="Neurosci Bull 2013 29 6 725 730 10.1007/s12264-013-1381-4 24132798"/>
   <result pre="Bougacha N Bouslama K Hamzaoui S M'rad S Young ischemic" exact="stroke" post="in Tunisia: a multicentric study Int J Neurosci 2017"/>
   <result pre="10.1080/00207454.2016.1214131 27426935 49. Khan FY Risk factors of young ischemic" exact="stroke" post="in Qatar Clin Neurol Neurosurg 2007 109 9 770"/>
   <result pre="M Salameh P Rachidi S Hosseini H The epidemiology of" exact="stroke" post="in the Middle East Eur Stroke J 2016 1"/>
   <result pre="Med Suisse 2002 2 22170 54. Mensah GA Epidemiology of" exact="stroke" post="and high blood pressure in Africa Heart 2008 94"/>
   <result pre="chiffre. 2016. 59. Gillum LA Mamidipudi SK Johnston SC Ischemic" exact="stroke" post="risk with oral contraceptives: a meta-analysis JAMA 2000 284"/>
   <result pre="mutation increased the risk of ischemic stroke, especially in large-artery" exact="atherosclerosis" post="in adults: an updated meta-analysis from 38 researches Int"/>
   <result pre="Zhang L Relationship between T-1131C polymorphism of apolipoprotein A5 and" exact="cerebral infarction" post="in Chinese Han population in Hunan J Apoplexy Nerv"/>
   <result pre="AS Muñoz SN Response to symptoms and prehospital delay in" exact="stroke" post="patients. Is it time to reconsider stroke awareness campaigns?"/>
   <result pre="prehospital delay in stroke patients. Is it time to reconsider" exact="stroke" post="awareness campaigns? J Stroke Cerebrovasc Dis 2018 27 3"/>
   <result pre="S Huffman MD Presentation, evaluation, management, and outcomes of acute" exact="stroke" post="in low-and middle-income countries: a systematic review and meta-analysis"/>
   <result pre="Middle-East and North Africa: A 2-year prospective observational study of" exact="stroke" post="characteristics in the region—Results from the Safe Implementation of"/>
   <result pre="30860454 76. Graham GDJS Tissue plasminogen activator for acute ischemic" exact="stroke" post="in clinical practice: a meta-analysis of safety data Stroke"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6939407/results/search/disease/results.xml">
   <result pre="a solid evidence base for nonpharmacological interventions. Keywords tension﻿-type headache" exact="migraine" post="pain sleep quality of life coping fig-count: table-count: ref-count:"/>
   <result pre="headache more frequently after puberty. 3 Tension-type headache (TTH) and" exact="migraine" post="are considered different disorders with separate pathomechanisms that often"/>
   <result pre="varying relative importance over time, from predominant TTH to predominant" exact="migraine" post="and vice versa. 6, 8 In chronic forms in"/>
   <result pre="sensitization of the central nervous system in both TTH and" exact="migraine" post="9– 11 and further reinforced by lifestyle factors. Sensitization"/>
   <result pre="than other chronic or longer standing childhood illnesses, such as" exact="juvenile idiopathic arthritis" post="and cancer. 29 A child suffering from primary headache"/>
   <result pre="chronic or longer standing childhood illnesses, such as juvenile idiopathic" exact="arthritis" post="and cancer. 29 A child suffering from primary headache"/>
   <result pre="Participants were diagnosed with primary headache, tension-type headache (TTH) or" exact="migraine" post="Interventions Nonpharmacological interventions as standalone approaches or in combination"/>
   <result pre="and coping. Studies of mental illness, disability, and acute conditions," exact="anxiety disorder," post="attention deficit hyperactivity disorder and other psychiatric diagnoses, pharmacology,"/>
   <result pre="Studies of mental illness, disability, and acute conditions, anxiety disorder," exact="attention deficit hyperactivity disorder" post="and other psychiatric diagnoses, pharmacology, melatonin and solely or"/>
   <result pre="2 arms To examine the feasibility of telephone administered behavioural" exact="migraine" post="management vs drug therapy Migraine 2–6/M by ICHD-II. N=34,"/>
   <result pre="weekly learning tasks for 8 weeks T2: Triptan treatment at" exact="migraine" post="headache for 8 M. T1 demonstrated partial mastery of"/>
   <result pre="8 M. T1 demonstrated partial mastery of skills, clinically meaningful" exact="migraine" post="reduction and improvement of QOL. Sample sizes too small"/>
   <result pre="the clinical efficacy of the MIPAS-Family behavioral training program on" exact="migraine" post="iCNV habituation Migraine without aura by ICHD-II Right-handed. N=26,"/>
   <result pre="time. Group training and involvement of parents recommended. Significantly reduced" exact="migraine" post="frequency and intensity for both groups without between-group difference."/>
   <result pre="strengths and difficulties and satisfaction Frequent or chronic TTH and" exact="migraine" post="by ICHD-II N=78, 12–17 years and parents T: 40"/>
   <result pre="headache education plus amitriptyline on pain, disability and credibility Chronic" exact="migraine" post="by ICHD-II PedMIDAS ≥ 20 points N=135, 10–17 years"/>
   <result pre="participants in a previous trial needed less preventive medication Chronic" exact="migraine" post="by ICHD-II PedMIDAS ≥ 20 N=135, 10–17 years T1:"/>
   <result pre="46– 48, 51, 55 Medication Cottrell et al 53 used" exact="migraine" post="medication as an active control group and found an"/>
   <result pre="retrospective clinical study assessing the prevalence and occurrence of possible" exact="migraine" post="trigger factors in children and adolescents with migraine showed"/>
   <result pre="of possible migraine trigger factors in children and adolescents with" exact="migraine" post="showed that stress was the most frequently reported trigger"/>
   <result pre="control group, suggesting that better sleep quality led to altered" exact="migraine" post="patterns. Although this study did not directly measure the"/>
   <result pre="with stressful situations, adjust to aversive stimuli, and even prevent" exact="migraine" post="attacks. Gerber et al 54 found that parents were"/>
   <result pre="daily family routines. In terms of the feasibility of training" exact="migraine" post="management skills in a group setting for adolescents, Cottrell"/>
   <result pre="telephone-administered behavior treatment was associated with clinically significant improvements in" exact="migraine" post="that did not reach statistical significance due to small"/>
   <result pre="Sivaraman B , Graham C . Prevalence of headache and" exact="migraine" post="in children and adolescents: a systematic review of population-based"/>
   <result pre="et al. Symptoms of central sensitization and comorbidity for juvenile" exact="fibromyalgia" post="in childhood migraine: an observational study in a tertiary"/>
   <result pre="A , Squires A , Herrmann L . Meta-synthesis on" exact="migraine" post="management. Headache . 2018; 58( 1): 22– 44. doi:"/>
   <result pre="Child Health, Editorial Office. Clinical Answers: are nonpharmacological interventions for" exact="migraine" post="effective in children and adolescents? Evid-Based Child Health ."/>
   <result pre="behavioral therapy plus amitriptyline for children and adolescents with chronic" exact="migraine" post="reduces headache days to ≤4 per month . Headache"/>
   <result pre=", et al. Cognitive behavioral therapy plus amitriptyline for chronic" exact="migraine" post="in children and adolescents: a randomized clinical trial ."/>
   <result pre="F . Feasibility assessment of telephone-administered behavioral treatment for adolescent" exact="migraine" post=". Headache . 2007; 47( 9): 1293– 1302. doi:"/>
   <result pre=", Bickel JL , et al. Headstrong intervention for pediatric" exact="migraine" post="headache: a randomized clinical trial. J Headache Pain ."/>
   <result pre="contributes to normalization of contingent negative variation in children with" exact="migraine" post=". Cephalalgia . 2011; 31( 5): 562– 572. doi:"/>
   <result pre=", Galli F , Guidetti V . Sleep hygiene and" exact="migraine" post="in children and adolescents. Cephalalgia . 1999; 19: 57."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6945584/results/search/disease/results.xml">
   <result pre="cannot move. Unfortunately, multiple pediatric and adult neurological conditions, including" exact="cerebral palsy" post="(CP), amyotrophic lateral sclerosis (ALS), brainstem stroke, and spinal"/>
   <result pre="multiple pediatric and adult neurological conditions, including cerebral palsy (CP)," exact="amyotrophic lateral sclerosis" post="(ALS), brainstem stroke, and spinal cord injury (SCI), can"/>
   <result pre="are also increasing across other areas of neurorehabilitation such as" exact="stroke" post="[ 5, 6, 13]. While invasive BCI may be"/>
   <result pre="Pediatric Neurology • Spinal cord injury • Stroke and perinatal" exact="stroke" post="• Cerebral palsy • Critical care/emergency neurology • Neuromuscular"/>
   <result pre="• Paediatric rehabilitation • Pain management • Pulmonary, cardiac and" exact="cancer" post="rehabilitation • Rheumatology Legend: A priori dichotomization was based"/>
   <result pre="thoracic injury), ALS or similar (loss of all motor control)," exact="spinal muscular atrophy" post="(SMA) or severe muscular dystrophy (MD) or similar and"/>
   <result pre="of all motor control), spinal muscular atrophy (SMA) or severe" exact="muscular dystrophy" post="(MD) or similar and brainstem stroke (locked-in syndrome/quadriplegia). We"/>
   <result pre="(SMA) or severe muscular dystrophy (MD) or similar and brainstem" exact="stroke" post="(locked-in syndrome/quadriplegia). We specified that &quot;preserved cognition&quot; refers to"/>
   <result pre="(26%) reported that &amp;gt; 50% of their patients had a severe" exact="neurological disorder" post="(SND) (Fig. 4a), while 21 (17%) reported that &amp;gt; 50%"/>
   <result pre="(17%) reported that &amp;gt; 50% of their patients had a severe" exact="neurological disorder" post="with preserved cognition (SNDwPC) (Fig. 4b). Most physicians (64%)"/>
   <result pre="the following conditions may also benefit from BCI: sensory ganglionopathy," exact="multiple sclerosis" post="(advanced or quadriplegic), multiple system atrophy, limb malformation/amputation, severe"/>
   <result pre="benefit from BCI: sensory ganglionopathy, multiple sclerosis (advanced or quadriplegic)," exact="multiple system atrophy," post="limb malformation/amputation, severe traumatic or hypoxic brain injury, and"/>
   <result pre="n = 55) Severe hemiplegic CP ( n = 48) Hemiplegia resulting from adult" exact="stroke" post="( n = 58) Spinal cord injury (High cervical or thoracic"/>
   <result pre="all motor control) ( n = 51) Spinal muscular atrophy or Severe" exact="muscular dystrophy" post="or similar ( n = 57) Brainstem stroke (Locked-in syndrome/ quadriplegia)"/>
   <result pre="atrophy or Severe muscular dystrophy or similar ( n = 57) Brainstem" exact="stroke" post="(Locked-in syndrome/ quadriplegia) ( n = 65) Total Average Prevalence (95%"/>
   <result pre="[ 32]. Further, a survey of happiness in patients with" exact="locked-in syndrome" post="found unhappiness was most associated with limited mobility and"/>
   <result pre="that might benefit from BCI, including quadriplegic or severe hemiplegic" exact="cerebral palsy," post="severe hemiplegia from adult stroke, ALS or similar disorders,"/>
   <result pre="from adult stroke, ALS or similar disorders, SMA/severe MD, or" exact="locked-in syndrome." post="Our techniques were limited by the nature of the"/>
   <result pre="estimate who could potentially benefit from BCI, including patients with" exact="multiple sclerosis," post="multiple system atrophy, movement disorders, limb malformation, and severe"/>
   <result pre="could potentially benefit from BCI, including patients with multiple sclerosis," exact="multiple system atrophy," post="movement disorders, limb malformation, and severe traumatic or hypoxic"/>
   <result pre="be 10 living with ALS, 130 with CP, 70 with" exact="muscular dystrophy," post="and 980 with stroke [ 37]. Other studies suggest"/>
   <result pre="130 with CP, 70 with muscular dystrophy, and 980 with" exact="stroke" post="[ 37]. Other studies suggest that, per 100,000, the"/>
   <result pre="SCI Spinal cord injury SMA Spinal muscular atrophy SND Severe" exact="neurological disorder" post="SNDwPC Severe neurological disorder with preserved cognition Publisher’s Note"/>
   <result pre="SMA Spinal muscular atrophy SND Severe neurological disorder SNDwPC Severe" exact="neurological disorder" post="with preserved cognition Publisher’s Note Springer Nature remains neutral"/>
   <result pre="Vogel J et al. Reach and grasp by people with" exact="tetraplegia" post="using a neurally controlled robotic arm Nature. 2012 485"/>
   <result pre="interface with the P300 speller: Usability for disabled people with" exact="amyotrophic lateral sclerosis" post="Ann Phys Rehabil Med 2018 61 1 5 11"/>
   <result pre="A survey on self-assessed well-being in a cohort of chronic" exact="locked-in syndrome" post="patients: happy majority, miserable minority BMJ Open 2011 1"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6946135/results/search/disease/results.xml">
   <result pre="many neurological disorders with minimal side effects [ 6], including" exact="migraine" post="[ 7], stroke [ 8], Parkinson’s disease [ 9],"/>
   <result pre="with minimal side effects [ 6], including migraine [ 7]," exact="stroke" post="[ 8], Parkinson’s disease [ 9], pain disorders ["/>
   <result pre="is also seen in pediatric studies applying tDCS contralateral to" exact="stroke" post="lesions in an effort to augment motor learning of"/>
   <result pre="weeks after tDCS intervention have been seen in primary progressive" exact="aphasia" post="[ 11]; though those changes were seen at the"/>
   <result pre="therapy for a range of disorders including migraine, pain and" exact="stroke" post="[ 6– 8, 10, 12, 20, 41]. While these"/>
   <result pre="of the motor cortex is altered during headache-free intervals in" exact="migraine" post="with aura . Cereb Cortex. 2008; 18( 11): 2701–"/>
   <result pre="brain DC stimulation is associated with motor function improvement in" exact="stroke" post="patients . Restor Neurol Neurosci. 2007; 25( 2): 123–"/>
   <result pre="et al. Transcranial direct current stimulation for children with perinatal" exact="stroke" post="and hemiparesis. Neurology. 2016; 88( 3): 259– 67. 10.1212/WNL.0000000000003518"/>
   <result pre="developmental plasticity after perinatal stroke: Defining central therapeutic targets in" exact="cerebral palsy" post=". Vol. 48, Pediatric Neurology. 2013 p. 81– 94."/>
   <result pre="biomarkers after transcranial direct current stimulation in children with perinatal" exact="stroke" post=". Brain Stimul. 2018; 11( 1): 94– 103. 10.1016/j.brs.2017.09.007"/>
   <result pre="current stimulation (HD-tDCS) to enhance treatment outcomes in persons with" exact="aphasia" post=". NeuroRehabilitation. 2015; 36( 1): 115– 26. 10.3233/NRE-141199 25547776"/>
   <result pre="direct current stimulation therapy and predictors of its efficacy in" exact="fibromyalgia" post=". Arthritis Rheumatol. 2015; 67( 2): 576– 81. 10.1002/art.38945"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6949664/results/search/disease/results.xml">
   <result pre="pathway of genes involved in PHACE syndrome and/or in infantile" exact="hemangioma" post="formation. Funding Research to Prevent Blindness National Institutes of"/>
   <result pre="of Health T32GM007347 1. Introduction Oculofaciocardiodental (OFCD) syndrome and Lenz" exact="microphthalmia" post="due to mutation in BCOR (BCL-6 corepressor) are allelic,"/>
   <result pre="1]. Specific hypomorphic mutations (typically c.254C&amp;gt;T; p.Pro85Leu) present as Lenz" exact="microphthalmia" post="syndrome, a classic X-linked recessive neurodevelopmental and multiple congenital"/>
   <result pre="with pathogenic BCOR mutation derived from 66 families. No other" exact="hemangioma" post="was reported, though the literature review was restricted to"/>
   <result pre="one month of age, with removal of reproliferation secondary membranous" exact="cataract" post="from the right eye at 4 months. She also"/>
   <result pre="and then referred to the Vanderbilt University Medical Center (VUMC)" exact="glaucoma" post="service for consultation and management of increased intraocular pressure"/>
   <result pre="in the right eye ( Figure 1), and a scalp" exact="hemangioma" post="( Figure 2) were noted. Neuroimaging was not performed."/>
   <result pre="Neuroimaging was not performed. She was initially managed with topical" exact="glaucoma" post="medications which controlled the intraocular pressure in the right"/>
   <result pre="right eye. However, over the next couple of months, her" exact="glaucoma" post="remained uncontrolled in the left eye despite advancement to"/>
   <result pre="in both eyes since age 4.5 years with supplemental topical" exact="glaucoma" post="medications for both eyes. After a few years, when"/>
   <result pre="multifocal CHRPE diagnosis, she was referred to genetics by her" exact="glaucoma" post="specialist to be evaluated for possible Gardner syndrome, with"/>
   <result pre="gravida 2, para 2 female. Additional past medical history included" exact="migraine" post="headaches and recurrent otitis media, with pressure equalization (PE)"/>
   <result pre="female. Additional past medical history included migraine headaches and recurrent" exact="otitis media," post="with pressure equalization (PE) tube placement at 4 years"/>
   <result pre="Medical Center pediatric ophthalmology for bilateral congenital cataracts. She underwent" exact="cataract" post="extraction and anterior vitrectomy at age 5 and 6"/>
   <result pre="and 6 weeks. She required removal of reproliferation secondary membranous" exact="cataract" post="in both eyes 2 months later. An additional two"/>
   <result pre="An additional two months later, she was referred to the" exact="glaucoma" post="service for elevated IOP in the right eye (30 mm"/>
   <result pre="the right eye (30 mm Hg). Examination under anesthesia revealed a" exact="hemangioma" post="near her right eyebrow and a soft protuberance at"/>
   <result pre="her posterior scalp, IOPs in both eyes controlled on topical" exact="glaucoma" post="medications required only in the right eye, bilateral multiple"/>
   <result pre="Her early secondary glaucoma/ocular hypertension subsequently required the addition of" exact="glaucoma" post="medications to the left eye. Both eyes were then"/>
   <result pre="to the left eye. Both eyes were then controlled with" exact="glaucoma" post="medications until age 17 months at which time she"/>
   <result pre="later. Subsequently, the IOP has remained controlled bilaterally on topical" exact="glaucoma" post="medications. She also had an atrial septal defect confirmed"/>
   <result pre="controlled bilaterally on topical glaucoma medications. She also had an" exact="atrial septal defect" post="confirmed by ECHO at 1 month of age, and"/>
   <result pre="scalp measuring up to 3.9 × 2.3 cm axially, interpreted as a likely" exact="hemangioma" post="( Figure 5). There was an adjacent prominent intracranial"/>
   <result pre="had a heart murmur in childhood. Her sister had childhood" exact="rheumatoid arthritis" post="in the knee but was in remission. During regular"/>
   <result pre="a heart murmur in childhood. Her sister had childhood rheumatoid" exact="arthritis" post="in the knee but was in remission. During regular"/>
   <result pre="the knee but was in remission. During regular follow-up, her" exact="glaucoma" post="ophthalmologist (KMJ) noted that the ocular phenotype, including congenital"/>
   <result pre="previously published cases, we report two new cases of infantile" exact="hemangioma" post="in OFCD [ 4]. The precise characteristics of infantile"/>
   <result pre="rapid growth is the key characteristic that differentiates an infantile" exact="hemangioma" post="from other vascular birthmarks [ 11]. Due to this"/>
   <result pre="facial hemangioma, it establishes a &quot;definite diagnosis&quot; of PHACE. Congenital" exact="glaucoma" post="has been reported in PHACE syndrome, so despite its"/>
   <result pre="be present in BCOR-microphthalmia syndromes, although rare. In addition, ocular" exact="coloboma" post="can also be a feature of either PHACE or"/>
   <result pre="the only well documented tooth anomaly associated with PHACE is" exact="enamel hypoplasia," post="present in 28% of cases, but there has been"/>
   <result pre="major diagnostic criterion [ 10]. She also had a cardiac" exact="ventricular septal defect," post="another minor criterion for PHACE diagnosis. Thus, with a"/>
   <result pre="have shown to be important in PHACE and/or in infantile" exact="hemangioma" post="formation. Currently, the molecular basis of PHACE syndrome is"/>
   <result pre="of affected daughters with OFCD [ 19]. Given that infantile" exact="hemangioma" post="is a benign neoplasm that exceedingly rarely transforms to"/>
   <result pre="OFCD [ 19]. Given that infantile hemangioma is a benign" exact="neoplasm" post="that exceedingly rarely transforms to angiosarcoma, along with the"/>
   <result pre="as some hematologic malignancies (with one reported case of T-cell" exact="lymphoma" post="reported in a male with Lenz microphthalmia [ 4]),"/>
   <result pre="case of T-cell lymphoma reported in a male with Lenz" exact="microphthalmia" post="[ 4]), systematic investigation of BCOR and PHACE patients"/>
   <result pre="Thakker N. Corcoran C. M. et al. Oculofaciocardiodental and lenz" exact="microphthalmia" post="syndromes result from distinct classes of mutations in BCOR"/>
   <result pre="et al. BCOR analysis in patients with OFCD and lenz" exact="microphthalmia" post="syndromes, mental retardation with ocular anomalies, and cardiac laterality"/>
   <result pre="P. et al. Expanding the phenotype of the X-linked BCOR" exact="microphthalmia" post="syndromes Human Genetics 2019 138 8-9 1051 1069 10.1007/s00439-018-1896-x"/>
   <result pre="Y. Gregory-Evans K. An update on the genetics of ocular" exact="coloboma" post="Human Genetics 2019 138 8-9 865 880 10.1007/s00439-019-02019-3 31073883"/>
   <result pre="M. Massink M. P. et al. Somatic genomic alterations in" exact="retinoblastoma" post="beyond RB1 are rare and limited to copy number"/>
   <result pre="D. et al. RB1 gene inactivation by chromothripsis in human" exact="retinoblastoma" post="Oncotarget 2014 5 2 438 450 10.18632/oncotarget.1686 24509483 23"/>
   <result pre="surgical removal of congenital cataracts. Figure 2 Involuted frontal scalp" exact="hemangioma" post="(case 1). Figure 3 Dental phenotype (case 1). Figure"/>
   <result pre="(T1) image of the brain showing a 1.2 cm diameter extracranial" exact="hemangioma" post="on the right frontal scalp (red arrow). (b) Coronal"/>
   <result pre="arrow). (b) Coronal MRI (postcontrast T1W) image showing the larger" exact="hemangioma" post="on the right parietal scalp. (c) Axial MRI image"/>
   <result pre="(c) Axial MRI image (postcontrast T1W) showing both the smaller" exact="hemangioma" post="on the right frontal scalp and the larger hemangioma"/>
   <result pre="smaller hemangioma on the right frontal scalp and the larger" exact="hemangioma" post="on the right parietal scalp measured 2.9 × 2.3 cm axially. (d)"/>
   <result pre="axially. (d) Axial MRI image (SWI) showing both the smaller" exact="hemangioma" post="on the right frontal scalp and the larger hemangioma"/>
   <result pre="smaller hemangioma on the right frontal scalp and the larger" exact="hemangioma" post="on the right parietal scalp. (e) Head and neck"/>
   <result pre="MRA showing intracranial circulation and the large right parietal scalp" exact="hemangioma" post="(red arrow). (f) Head MRA showing intracranial circulation and"/>
   <result pre="4&quot; in Ragge et al. [ 4] (i) Left temporal" exact="hemangioma" post="(size not specified) Absent Absent (i) Large ASD (i)"/>
   <result pre="8&quot; in Ragge et al. [ 4] (i) Large forehead" exact="hemangioma" post="(size not specified) (ii) Large neck hemangioma Absent Absent"/>
   <result pre="(i) Large forehead hemangioma (size not specified) (ii) Large neck" exact="hemangioma" post="Absent Absent (i) Left ventricular noncompaction (ii) Small persistent"/>
   <result pre="Small persistent ductus arteriosus (i) Bilateral congenital cataracts (ii) Mild" exact="microphthalmia" post="Absent (i) Thyroglossal cyst (ii) Agenesis of both superius"/>
   <result pre="cyst (ii) Agenesis of both superius lateral incisors (iii) Cutaneous" exact="syndactyly" post="of second and third toes Currently reported case 1"/>
   <result pre="second and third toes Currently reported case 1 (i) Involuted" exact="hemangioma" post="of the forehead Unknown Unknown (i) VSD (i) Bilateral"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6951453/results/search/disease/results.xml">
   <result pre="22390738 12 Otsuki, M. et al Adherence feedback to improve" exact="asthma" post="outcomes among inner‐city children: a randomized trial . Pediatrics"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="migraine/PMC6957294/results/search/disease/results.xml">
   <result pre="the treatment of primary and secondary immunodeficiency diseases, Kawasaki disease," exact="idiopathic thrombocytopenic purpura," post="and neurological diseases, such as Guillain–Barré syndrome, chronic inflammatory"/>
   <result pre="idiopathic thrombocytopenic purpura, and neurological diseases, such as Guillain–Barré syndrome," exact="chronic inflammatory demyelinating polyneuropathy," post="myasthenia gravis, polymyositis, multiple sclerosis, autoimmune encephalitis, and epilepsy"/>
   <result pre="neurological diseases, such as Guillain–Barré syndrome, chronic inflammatory demyelinating polyneuropathy," exact="myasthenia gravis," post="polymyositis, multiple sclerosis, autoimmune encephalitis, and epilepsy [ 1,"/>
   <result pre="as Guillain–Barré syndrome, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, polymyositis," exact="multiple sclerosis," post="autoimmune encephalitis, and epilepsy [ 1, 2]. Regardless of"/>
   <result pre="demyelinating polyneuropathy, myasthenia gravis, polymyositis, multiple sclerosis, autoimmune encephalitis, and" exact="epilepsy" post="[ 1, 2]. Regardless of age, disease, and severity"/>
   <result pre="1, 3, 5, 13, 14]. Several previous studies suggested that" exact="migraine" post="may be a risk factor for aseptic meningitis associated"/>
   <result pre="studies suggested that migraine may be a risk factor for" exact="aseptic meningitis" post="associated with IVIG [ 4, 15, 16]. Other studies"/>
   <result pre="suggested that migraine may be a risk factor for aseptic" exact="meningitis" post="associated with IVIG [ 4, 15, 16]. Other studies"/>
   <result pre="AE onset. Underlying diseases were divided into five categories: epilepsy," exact="central nervous system disease" post="(encephalitis/encephalopathy, cerebellitis, acute disseminated encephalomyelitis, and clinically isolated syndrome),"/>
   <result pre="onset. Underlying diseases were divided into five categories: epilepsy, central" exact="nervous system disease" post="(encephalitis/encephalopathy, cerebellitis, acute disseminated encephalomyelitis, and clinically isolated syndrome),"/>
   <result pre="into five categories: epilepsy, central nervous system disease (encephalitis/encephalopathy, cerebellitis," exact="acute disseminated encephalomyelitis," post="and clinically isolated syndrome), peripheral nervous system disease (including"/>
   <result pre="disease (encephalitis/encephalopathy, cerebellitis, acute disseminated encephalomyelitis, and clinically isolated syndrome)," exact="peripheral nervous system disease" post="(including chronic inflammatory demyelinating polyneuropathy, Guillain-Barré syndrome, Miller–Fisher syndrome,"/>
   <result pre="(encephalitis/encephalopathy, cerebellitis, acute disseminated encephalomyelitis, and clinically isolated syndrome), peripheral" exact="nervous system disease" post="(including chronic inflammatory demyelinating polyneuropathy, Guillain-Barré syndrome, Miller–Fisher syndrome,"/>
   <result pre="encephalomyelitis, and clinically isolated syndrome), peripheral nervous system disease (including" exact="chronic inflammatory demyelinating polyneuropathy," post="Guillain-Barré syndrome, Miller–Fisher syndrome, and myelitis), myasthenia gravis, and"/>
   <result pre="chronic inflammatory demyelinating polyneuropathy, Guillain-Barré syndrome, Miller–Fisher syndrome, and myelitis)," exact="myasthenia gravis," post="and hypogammaglobulinemia. Three immunoglobulin preparations were used in this"/>
   <result pre="and 52.9% were male. The most common underlying disease was" exact="epilepsy" post="(66.3%). The median total dosage of IVIG was 1.08"/>
   <result pre="* Disease classification Epilepsy 69 19 * 50 * Central" exact="nervous system disease" post="† 12 5 7 Peripheral nervous system disease ‡"/>
   <result pre="* Central nervous system disease † 12 5 7 Peripheral" exact="nervous system disease" post="‡ 13 9 ** 4 ** Myasthenia gravis 8"/>
   <result pre="* * P &amp;lt; 0.01 ** P &amp;lt; 0.05 †Central" exact="nervous system disease" post="total number (number of adverse effects) = encephalitis/encephalopathy 8"/>
   <result pre="of adverse effects) = encephalitis/encephalopathy 8 (3), cerebellitis 2 (0)," exact="acute disseminated encephalomyelitis" post="1 (1) and clinically isolated syndrome 1 (1) ‡Peripheral"/>
   <result pre="effects) = encephalitis/encephalopathy 8 (3), cerebellitis 2 (0), acute disseminated" exact="encephalomyelitis" post="1 (1) and clinically isolated syndrome 1 (1) ‡Peripheral"/>
   <result pre="encephalomyelitis 1 (1) and clinically isolated syndrome 1 (1) ‡Peripheral" exact="nervous system disease" post="total number (number of adverse effects) = chronic inflammatory"/>
   <result pre="nervous system disease total number (number of adverse effects) =" exact="chronic inflammatory demyelinating polyneuropathy" post="7 (6), Guillain–Barré syndrome 3 (2), Miller–Fisher syndrome 1"/>
   <result pre="total number (number of adverse effects) = chronic inflammatory demyelinating" exact="polyneuropathy" post="7 (6), Guillain–Barré syndrome 3 (2), Miller–Fisher syndrome 1"/>
   <result pre="7 (6), Guillain–Barré syndrome 3 (2), Miller–Fisher syndrome 1 (0)," exact="myelitis" post="1 (0), and others 1 (0) BUN, blood urea"/>
   <result pre="2 0 Headache 15 6 12 11 3 1 Maculopapular" exact="rash" post="13 2 11 10 3 0 Vomiting 10 1"/>
   <result pre="AEs showed significant associations with older age, diseases such as" exact="epilepsy" post="and peripheral nervous system diseases, longer duration of IVIG"/>
   <result pre="g/kg for 2 – 5 days in cases of Guillain-Barré syndrome," exact="multiple sclerosis," post="myasthenia gravis, immune cytopenia, and immunoglobulin deficiency, and examined"/>
   <result pre="2 – 5 days in cases of Guillain-Barré syndrome, multiple sclerosis," exact="myasthenia gravis," post="immune cytopenia, and immunoglobulin deficiency, and examined changes in"/>
   <result pre="may have been underestimated because infants and some patients with" exact="epilepsy" post="or mental retardation would not have complained of subjective"/>
   <result pre="Sekul EA , Cupler EJ , Dalakas MC . Aseptic" exact="meningitis" post="associated with high-dose intravenous immunoglobulin therapy: frequency and risk"/>
   <result pre="score: Reliability and validation for pain assessment in children with" exact="cerebral palsy" post=". Scand J Pain. 2015; 9( 1): 57– 61."/>
  </snippets>
 </snippetsTree>
</projectSnippetsTree>
